<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="0" size="12" family="Times" color="#ffffff"/>
	<fontspec id="1" size="26" family="Times" color="#15539a"/>
	<fontspec id="2" size="14" family="Times" color="#000000"/>
	<fontspec id="3" size="11" family="Times" color="#005c58"/>
	<fontspec id="4" size="11" family="Times" color="#327eb1"/>
	<fontspec id="5" size="12" family="Times" color="#000000"/>
	<fontspec id="6" size="12" family="Times" color="#327eb1"/>
	<fontspec id="7" size="8" family="Times" color="#000000"/>
	<fontspec id="8" size="8" family="Times" color="#327eb1"/>
	<fontspec id="9" size="8" family="Times" color="#ffffff"/>
<text top="112" left="75" width="151" height="13" font="0">PRACTICE GUIDELINE</text>
<text top="146" left="91" width="528" height="24" font="1">2014 AHA/ACC Guideline for the Management</text>
<text top="181" left="91" width="451" height="24" font="1">of Patients With Valvular Heart Disease</text>
<text top="211" left="91" width="523" height="16" font="2">A Report of the American College of Cardiology/American Heart Association</text>
<text top="232" left="91" width="230" height="16" font="2">Task Force on Practice Guidelines</text>
<text top="259" left="91" width="506" height="16" font="2">Developed in Collaboration With the American Association for Thoracic Surgery,</text>
<text top="280" left="91" width="613" height="16" font="2">American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions,</text>
<text top="301" left="91" width="476" height="16" font="2">Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons</text>
<text top="358" left="78" width="46" height="12" font="3">Writing</text>
<text top="374" left="78" width="70" height="12" font="3">Committee</text>
<text top="391" left="78" width="59" height="12" font="3">Members</text>
<text top="391" left="137" width="8" height="12" font="4"><a href="e57.full.html#1">*</a></text>
<text top="358" left="190" width="264" height="15" font="5">Rick A. Nishimura, MD, MACC, FAHA,</text>
<text top="378" left="205" width="55" height="15" font="5">Co-Chair</text>
<text top="373" left="260" width="7" height="19" font="6"><a href="e57.full.html#1">y</a></text>
<text top="396" left="190" width="259" height="15" font="5">Catherine M. Otto, MD, FACC, FAHA,</text>
<text top="416" left="205" width="55" height="15" font="5">Co-Chair</text>
<text top="412" left="260" width="7" height="19" font="6"><a href="e57.full.html#1">y</a></text>
<text top="456" left="190" width="254" height="15" font="5">Robert O. Bonow, MD, MACC, FAHA</text>
<text top="453" left="444" width="7" height="19" font="6"><a href="e57.full.html#1">y</a></text>
<text top="476" left="190" width="199" height="15" font="5">Blase A. Carabello, MD, <a href="e57.full.html#1">FACC</a></text>
<text top="476" left="389" width="5" height="15" font="6"><a href="e57.full.html#1">*</a></text>
<text top="473" left="394" width="7" height="19" font="6"><a href="e57.full.html#1">y</a></text>
<text top="495" left="190" width="248" height="15" font="5">John P. Erwin III, MD, FACC, FAHA</text>
<text top="492" left="438" width="7" height="19" font="6"><a href="e57.full.html#1">z</a></text>
<text top="515" left="190" width="198" height="15" font="5">Robert A. Guyton, MD, FACC</text>
<text top="515" left="388" width="5" height="15" font="6"><a href="e57.full.html#1">*</a></text>
<text top="511" left="393" width="7" height="19" font="6"><a href="e57.full.html#1">x</a></text>
<text top="534" left="190" width="78" height="15" font="5">Patrick T. O</text>
<text top="531" left="268" width="171" height="19" font="5">’Gara, MD, FACC, <a href="e57.full.html#1">FAHA</a></text>
<text top="531" left="439" width="7" height="19" font="6"><a href="e57.full.html#1">y</a></text>
<text top="554" left="190" width="144" height="15" font="5">Carlos E. Ruiz, MD, P</text>
<text top="557" left="334" width="9" height="10" font="7">H</text>
<text top="554" left="343" width="63" height="15" font="5">D, <a href="e57.full.html#1">FACC</a></text>
<text top="550" left="405" width="7" height="19" font="6"><a href="e57.full.html#1">y</a></text>
<text top="573" left="190" width="196" height="15" font="5">Nikolaos J. Skubas, MD, FASE</text>
<text top="570" left="386" width="9" height="19" font="6"><a href="e57.full.html#1">{</a></text>
<text top="357" left="494" width="210" height="15" font="5">Paul Sorajja, MD, FACC, FAHA</text>
<text top="357" left="704" width="7" height="15" font="6"><a href="e57.full.html#1">#</a></text>
<text top="377" left="494" width="166" height="15" font="5">Thoralf M. Sundt III, <a href="e57.full.html#1">MD</a></text>
<text top="377" left="660" width="19" height="15" font="6"><a href="e57.full.html#1">* **</a></text>
<text top="373" left="680" width="13" height="19" font="6"><a href="e57.full.html#1">yy</a></text>
<text top="396" left="494" width="292" height="15" font="5">James D. Thomas, MD, FASE, FACC, FAHA</text>
<text top="393" left="786" width="13" height="19" font="6"><a href="e57.full.html#1">zz</a></text>
<text top="434" left="494" width="305" height="10" font="7">*Writing committee members are required to recuse themselves from</text>
<text top="447" left="494" width="162" height="10" font="7">voting on sections to which their speci</text>
<text top="445" left="656" width="143" height="14" font="7">ﬁc relationships with industry and</text>
<text top="461" left="494" width="118" height="10" font="7">other entities may apply; see</text>
<text top="461" left="615" width="49" height="10" font="8"><a href="e57.full.html#122">Appendix 1</a></text>
<text top="461" left="667" width="98" height="10" font="7">for recusal information.</text>
<text top="458" left="767" width="31" height="14" font="7"><a href="e57.full.html#122">yACC/</a></text>
<text top="474" left="494" width="87" height="10" font="7">AHA representative.</text>
<text top="472" left="583" width="216" height="14" font="7"><a href="e57.full.html#122">zACC/AH</a>A Task Force on Performance Measures</text>
<text top="488" left="494" width="29" height="10" font="7">liaison.</text>
<text top="485" left="526" width="273" height="14" font="7"><a href="e57.full.html#122">xACC/AH</a>A Task Force on Practice Guidelines liaison. <a href="e57.full.html#122">{Society</a></text>
<text top="501" left="494" width="305" height="10" font="7">of Cardiovascular Anesthesiologists representative. #Society for Cardio-</text>
<text top="515" left="494" width="305" height="10" font="7">vascular Angiography and Interventions representative. **American</text>
<text top="528" left="494" width="207" height="10" font="7">Association for Thoracic Surgery representative.</text>
<text top="526" left="705" width="94" height="14" font="7"><a href="e57.full.html#122">yy</a>Society of Thoracic</text>
<text top="542" left="494" width="108" height="10" font="7">Surgeons representative.</text>
<text top="539" left="606" width="192" height="14" font="7"><a href="e57.full.html#122">zz</a>American Society of Echocardiography</text>
<text top="555" left="494" width="60" height="10" font="7">representative.</text>
<text top="632" left="78" width="95" height="12" font="3">ACC/AHA Task</text>
<text top="649" left="78" width="99" height="12" font="3">Force Members</text>
<text top="632" left="190" width="262" height="15" font="5">Jeffrey L. Anderson, MD, FACC, FAHA,</text>
<text top="652" left="205" width="33" height="15" font="5">Chair</text>
<text top="671" left="190" width="272" height="15" font="5">Jonathan L. Halperin, MD, FACC, FAHA,</text>
<text top="691" left="205" width="67" height="15" font="5">Chair-Elect</text>
<text top="731" left="190" width="118" height="15" font="5">Nancy M. Albert, P</text>
<text top="734" left="308" width="9" height="10" font="7">H</text>
<text top="731" left="317" width="164" height="15" font="5">D, CCNS, CCRN, FAHA</text>
<text top="750" left="190" width="152" height="15" font="5">Biykem Bozkurt, MD, P</text>
<text top="753" left="342" width="9" height="10" font="7">H</text>
<text top="750" left="351" width="115" height="15" font="5">D, FACC, FAHA</text>
<text top="770" left="190" width="242" height="15" font="5">Ralph G. Brindis, MD, MPH, MACC</text>
<text top="789" left="190" width="243" height="15" font="5">Mark A. Creager, MD, FACC, FAH<a href="e57.full.html#1">A</a></text>
<text top="786" left="433" width="13" height="19" font="6"><a href="e57.full.html#1">xx</a></text>
<text top="808" left="190" width="119" height="15" font="5">Lesley H. Curtis, P</text>
<text top="812" left="309" width="9" height="10" font="7">H</text>
<text top="808" left="318" width="64" height="15" font="5">D, FAHA</text>
<text top="828" left="190" width="108" height="15" font="5">David DeMets, P</text>
<text top="831" left="298" width="9" height="10" font="7">H</text>
<text top="828" left="307" width="12" height="15" font="5">D</text>
<text top="632" left="494" width="198" height="15" font="5">Robert A. Guyton, MD, FACC</text>
<text top="628" left="692" width="13" height="19" font="6"><a href="e57.full.html#1">xx</a></text>
<text top="651" left="494" width="257" height="15" font="5">Judith S. Hochman, MD, FACC, FAHA</text>
<text top="671" left="494" width="246" height="15" font="5">Richard J. Kovacs, MD, FACC, FAHA</text>
<text top="690" left="494" width="205" height="15" font="5">E. Magnus Ohman, MD, FACC</text>
<text top="709" left="494" width="117" height="15" font="5">Susan J. Pressler, P</text>
<text top="713" left="611" width="9" height="10" font="7">H</text>
<text top="709" left="620" width="95" height="15" font="5">D, RN, FAHA</text>
<text top="729" left="494" width="239" height="15" font="5">Frank W. Sellke, MD, FACC, FAHA</text>
<text top="748" left="494" width="247" height="15" font="5">Win-Kuang Shen, MD, FACC, FAHA</text>
<text top="768" left="494" width="274" height="15" font="5">William G. Stevenson, MD, FACC, FAHA</text>
<text top="764" left="768" width="13" height="19" font="6"><a href="e57.full.html#1">xx</a></text>
<text top="787" left="494" width="240" height="15" font="5">Clyde W. Yancy, MD, FACC, FAH<a href="e57.full.html#1">A</a></text>
<text top="784" left="733" width="13" height="19" font="6"><a href="e57.full.html#1">xx</a></text>
<text top="822" left="494" width="238" height="14" font="7"><a href="e57.full.html#1">xx</a>Former Task Force member during the writing effort.</text>
<text top="977" left="75" width="339" height="10" font="7">This document was approved by the American College of Cardiology Board of</text>
<text top="991" left="64" width="350" height="10" font="7">Trustees and the American Heart Association Science Advisory and Coordinating</text>
<text top="1004" left="64" width="121" height="10" font="7">Committee in January 2014.</text>
<text top="1018" left="75" width="339" height="10" font="7">The American College of Cardiology requests that this document be cited as follows:</text>
<text top="1031" left="64" width="350" height="10" font="7">Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA,</text>
<text top="1044" left="64" width="8" height="10" font="7">O</text>
<text top="1042" left="73" width="341" height="14" font="7">’Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM III, Thomas JD. 2014 AHA/</text>
<text top="1058" left="64" width="350" height="10" font="7">ACC guideline for the management of patients with valvular heart disease: a report</text>
<text top="1071" left="64" width="350" height="10" font="7">of the American College of Cardiology/American Heart Association Task Force</text>
<text top="1085" left="64" width="229" height="10" font="7">on Practice Guidelines. J Am Coll Cardiol 2014;63:e57</text>
<text top="1082" left="293" width="23" height="14" font="7">–185.</text>
<text top="1098" left="75" width="203" height="11" font="7">This article has been copublished in Circulation.</text>
<text top="977" left="460" width="339" height="10" font="7">Copies: This document is available on the World Wide Web sites of the</text>
<text top="991" left="450" width="146" height="10" font="7">American College of Cardiology <a href="http://www.cardiosource.org">(</a></text>
<text top="991" left="595" width="92" height="10" font="8"><a href="http://www.cardiosource.org">www.cardiosource.org</a></text>
<text top="991" left="687" width="112" height="10" font="7">) and the American Heart</text>
<text top="1004" left="450" width="55" height="10" font="7">Association <a href="http://my.americanheart.org">(</a></text>
<text top="1004" left="504" width="90" height="10" font="8"><a href="http://my.americanheart.org">my.americanheart.org</a></text>
<text top="1004" left="595" width="205" height="10" font="7"><a href="http://my.americanheart.org">). </a>For copies of this document, please contact the</text>
<text top="1018" left="450" width="232" height="10" font="7">Elsevier Inc. Reprint Department via fax (212) 633</text>
<text top="1015" left="682" width="72" height="14" font="7">–3820 or e-mail</text>
<text top="1018" left="759" width="40" height="10" font="8"><a href="mailto:reprints@elsevier.com">reprints@</a></text>
<text top="1031" left="450" width="51" height="10" font="8"><a href="mailto:reprints@elsevier.com">elsevier.com</a></text>
<text top="1031" left="500" width="3" height="10" font="7">.</text>
<text top="1044" left="460" width="158" height="10" font="7">Permissions: Multiple copies, modi</text>
<text top="1042" left="619" width="181" height="14" font="7">ﬁcation, alteration, enhancement, and/or</text>
<text top="1058" left="450" width="350" height="10" font="7">distribution of this document are not permitted without the express permission of</text>
<text top="1071" left="450" width="350" height="10" font="7">the American College of Cardiology. Requests may be completed online via</text>
<text top="1085" left="450" width="75" height="10" font="7">the Elsevier site (</text>
<text top="1085" left="525" width="275" height="10" font="8"><a href="http://www.elsevier.com/authors/obtaining-permission-to-re-use-elsevier-material">http://www.elsevier.com/authors/obtaining-permission-to-re-use-</a></text>
<text top="1098" left="450" width="68" height="10" font="8"><a href="http://www.elsevier.com/authors/obtaining-permission-to-re-use-elsevier-material">elsevier-material</a></text>
<text top="1098" left="518" width="6" height="10" font="7"><a href="http://www.elsevier.com/authors/obtaining-permission-to-re-use-elsevier-material">).</a></text>
<text top="51" left="64" width="199" height="10" font="9">Journal of the American College of Cardiology</text>
<text top="60" left="64" width="440" height="14" font="9">Ó 2014 by the American Heart Association, Inc., and the American College of Cardiology Foundation</text>
<text top="75" left="64" width="110" height="10" font="9">Published by Elsevier Inc.</text>
<text top="51" left="705" width="95" height="10" font="9">Vol. 63, No. 22, 2014</text>
<text top="63" left="694" width="105" height="10" font="9">ISSN 0735-1097/$36.00</text>
<text top="75" left="613" width="186" height="10" font="9"><a href="http://dx.doi.org/10.1016/j.jacc.2014.02.536">http://dx.doi.org/10.1016/j.jacc.2014.02.536</a></text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="10" size="11" family="Times" color="#ffffff"/>
	<fontspec id="11" size="11" family="Times" color="#a70c2f"/>
	<fontspec id="12" size="11" family="Times" color="#000000"/>
	<fontspec id="13" size="10" family="Times" color="#005c58"/>
	<fontspec id="14" size="7" family="Times" color="#000000"/>
	<fontspec id="15" size="9" family="Times" color="#000000"/>
	<fontspec id="16" size="10" family="Times" color="#000000"/>
<text top="114" left="75" width="132" height="12" font="10">TABLE OF CONTENTS</text>
<text top="147" left="64" width="61" height="12" font="11">Preamble</text>
<text top="146" left="129" width="285" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e60</text>
<text top="182" left="64" width="12" height="12" font="11">1.</text>
<text top="182" left="93" width="78" height="12" font="11">Introduction</text>
<text top="181" left="178" width="236" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e62</text>
<text top="217" left="93" width="242" height="11" font="13">1.1. Methodology and Evidence Review</text>
<text top="216" left="342" width="72" height="13" font="12">. . . . . . . . .e62</text>
<text top="236" left="93" width="266" height="11" font="13">1.2. Organization of the Writing Committee</text>
<text top="235" left="367" width="47" height="13" font="12">. . . . .e62</text>
<text top="256" left="93" width="223" height="11" font="13">1.3. Document Review and Approval</text>
<text top="254" left="323" width="91" height="13" font="12">. . . . . . . . . . . .e62</text>
<text top="275" left="93" width="170" height="11" font="13">1.4. Scope of the Guideline</text>
<text top="274" left="268" width="146" height="13" font="12">. . . . . . . . . . . . . . . . . . . . .e62</text>
<text top="289" left="64" width="12" height="12" font="11">2.</text>
<text top="289" left="93" width="117" height="12" font="11">General Principles</text>
<text top="289" left="215" width="199" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . e63</text>
<text top="324" left="93" width="215" height="11" font="13">2.1. Evaluation of the Patient With</text>
<text top="340" left="123" width="94" height="11" font="13">Suspected VHD</text>
<text top="339" left="225" width="189" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . .e63</text>
<text top="359" left="93" width="47" height="11" font="13">2.2. De</text>
<text top="356" left="139" width="227" height="17" font="13">ﬁnitions of Severity of Valve Disease</text>
<text top="358" left="373" width="41" height="13" font="12">. . . .e64</text>
<text top="379" left="93" width="178" height="11" font="13">2.3. Diagnosis and Follow-Up</text>
<text top="378" left="274" width="140" height="13" font="12">. . . . . . . . . . . . . . . . . . . .e64</text>
<text top="397" left="123" width="138" height="13" font="12">2.3.1. Diagnostic Testing</text>
<text top="394" left="262" width="97" height="17" font="12">–Initial Diagnosis:</text>
<text top="413" left="161" width="93" height="13" font="12">Recommendation</text>
<text top="413" left="262" width="152" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . .e64</text>
<text top="429" left="123" width="251" height="14" font="12">2.3.2. Diagnostic TestingdChanging Signs or</text>
<text top="444" left="161" width="156" height="13" font="12">Symptoms: Recommendation</text>
<text top="444" left="323" width="91" height="13" font="12">. . . . . . . . . . . .e65</text>
<text top="460" left="123" width="258" height="14" font="12">2.3.3. Diagnostic TestingdRoutine Follow-Up:</text>
<text top="476" left="161" width="93" height="13" font="12">Recommendation</text>
<text top="476" left="262" width="152" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . .e65</text>
<text top="492" left="123" width="192" height="14" font="12">2.3.4. Diagnostic TestingdCardiac</text>
<text top="507" left="161" width="181" height="13" font="12">Catheterization: Recommendation</text>
<text top="507" left="348" width="66" height="13" font="12">. . . . . . . .e65</text>
<text top="523" left="123" width="242" height="14" font="12">2.3.5. Diagnostic TestingdExercise Testing:</text>
<text top="539" left="161" width="93" height="13" font="12">Recommendation</text>
<text top="538" left="262" width="152" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . .e65</text>
<text top="555" left="93" width="247" height="11" font="13">2.4. Basic Principles of Medical Therapy</text>
<text top="554" left="348" width="66" height="13" font="12">. . . . . . . .e66</text>
<text top="574" left="123" width="264" height="13" font="12">2.4.1. Secondary Prevention of Rheumatic Fever:</text>
<text top="589" left="161" width="93" height="13" font="12">Recommendation</text>
<text top="589" left="262" width="152" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . .e66</text>
<text top="605" left="123" width="221" height="13" font="12">2.4.2. IE Prophylaxis: Recommendations</text>
<text top="605" left="348" width="66" height="13" font="12">. . . . . . . .e67</text>
<text top="622" left="93" width="191" height="11" font="13">2.5. Evaluation of Surgical and</text>
<text top="637" left="123" width="115" height="11" font="13">Interventional Risk</text>
<text top="636" left="243" width="171" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . .e68</text>
<text top="657" left="93" width="309" height="11" font="13">2.6. The Heart Valve Team and Heart Valve Centers</text>
<text top="672" left="123" width="202" height="11" font="13">of Excellence: Recommendations</text>
<text top="671" left="330" width="84" height="13" font="12">. . . . . . . . . . .e69</text>
<text top="699" left="64" width="12" height="12" font="11">3.</text>
<text top="699" left="93" width="99" height="12" font="11">Aortic Stenosis</text>
<text top="698" left="197" width="217" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e71</text>
<text top="734" left="93" width="164" height="11" font="13">3.1. Stages of Valvular AS</text>
<text top="733" left="262" width="152" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . .e71</text>
<text top="753" left="93" width="124" height="11" font="13">3.2. Aortic Stenosis</text>
<text top="752" left="225" width="189" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . .e71</text>
<text top="772" left="123" width="175" height="13" font="12">3.2.1. Diagnosis and Follow-Up</text>
<text top="772" left="305" width="109" height="13" font="12">. . . . . . . . . . . . . . .e71</text>
<text top="788" left="161" width="31" height="8" font="14">3.2.1.1.</text>
<text top="788" left="200" width="173" height="9" font="14">DIAGNOSTIC TESTINGdINITIAL DIAGNOSIS:</text>
<text top="802" left="200" width="84" height="8" font="14">RECOMMENDATIONS</text>
<text top="798" left="287" width="127" height="13" font="12">. . . . . . . . . . . . . . . . . e71</text>
<text top="815" left="161" width="31" height="8" font="14">3.2.1.2.</text>
<text top="815" left="200" width="181" height="9" font="14">DIAGNOSTIC TESTINGdCHANGING SIGNS OR</text>
<text top="829" left="200" width="46" height="8" font="14">SYMPTOMS</text>
<text top="825" left="250" width="164" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . e73</text>
<text top="842" left="161" width="31" height="8" font="14">3.2.1.3.</text>
<text top="842" left="200" width="176" height="9" font="14">DIAGNOSTIC TESTINGdROUTINE FOLLOW-UP</text>
<text top="839" left="381" width="33" height="13" font="12">. . e73</text>
<text top="856" left="161" width="31" height="8" font="14">3.2.1.4.</text>
<text top="856" left="200" width="131" height="9" font="14">DIAGNOSTIC TESTINGdCARDIAC</text>
<text top="869" left="200" width="73" height="8" font="14">CATHETERIZATION</text>
<text top="866" left="281" width="133" height="13" font="12">. . . . . . . . . . . . . . . . . . e73</text>
<text top="883" left="161" width="31" height="8" font="14">3.2.1.5.</text>
<text top="883" left="200" width="173" height="9" font="14">DIAGNOSTIC TESTINGdEXERCISE TESTING:</text>
<text top="896" left="200" width="84" height="8" font="14">RECOMMENDATIONS</text>
<text top="893" left="287" width="127" height="13" font="12">. . . . . . . . . . . . . . . . . e74</text>
<text top="909" left="123" width="233" height="13" font="12">3.2.2. Medical Therapy: Recommendations</text>
<text top="908" left="360" width="54" height="13" font="12">. . . . . .e74</text>
<text top="924" left="123" width="164" height="13" font="12">3.2.3. Timing of Intervention:</text>
<text top="940" left="161" width="97" height="13" font="12">Recommendations</text>
<text top="940" left="262" width="152" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . .e75</text>
<text top="956" left="123" width="251" height="13" font="12">3.2.4. Choice of Intervention: Recommendation</text>
<text top="955" left="379" width="35" height="13" font="12">. . .e79</text>
<text top="983" left="64" width="12" height="12" font="11">4.</text>
<text top="983" left="93" width="130" height="12" font="11">Aortic Regurgitation</text>
<text top="982" left="227" width="187" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . e82</text>
<text top="1018" left="93" width="87" height="11" font="13">4.1. Acute AR</text>
<text top="1017" left="188" width="226" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e82</text>
<text top="1036" left="123" width="89" height="13" font="12">4.1.1. Diagnosis</text>
<text top="1036" left="219" width="195" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . . .e83</text>
<text top="1052" left="123" width="102" height="13" font="12">4.1.2. Intervention</text>
<text top="1052" left="231" width="183" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . .e83</text>
<text top="1068" left="93" width="161" height="11" font="13">4.2. Stages of Chronic AR</text>
<text top="1067" left="262" width="152" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . .e83</text>
<text top="1088" left="93" width="97" height="11" font="13">4.3. Chronic AR</text>
<text top="1087" left="194" width="220" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e83</text>
<text top="103" left="509" width="175" height="13" font="12">4.3.1. Diagnosis and Follow-Up</text>
<text top="103" left="690" width="109" height="13" font="12">. . . . . . . . . . . . . . .e83</text>
<text top="119" left="547" width="31" height="8" font="14">4.3.1.1.</text>
<text top="119" left="585" width="173" height="9" font="14">DIAGNOSTIC TESTINGdINITIAL DIAGNOSIS:</text>
<text top="133" left="585" width="83" height="8" font="14">RECOMMENDATIONS</text>
<text top="129" left="673" width="127" height="13" font="12">. . . . . . . . . . . . . . . . . e83</text>
<text top="146" left="547" width="31" height="8" font="14">4.3.1.2.</text>
<text top="146" left="585" width="181" height="9" font="14">DIAGNOSTIC TESTINGdCHANGING SIGNS OR</text>
<text top="160" left="585" width="46" height="8" font="14">SYMPTOMS</text>
<text top="156" left="636" width="164" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . e85</text>
<text top="173" left="547" width="31" height="8" font="14">4.3.1.3.</text>
<text top="173" left="585" width="176" height="9" font="14">DIAGNOSTIC TESTINGdROUTINE FOLLOW-UP</text>
<text top="170" left="766" width="33" height="13" font="12">. . e85</text>
<text top="187" left="547" width="31" height="8" font="14">4.3.1.4.</text>
<text top="187" left="585" width="131" height="9" font="14">DIAGNOSTIC TESTINGdCARDIAC</text>
<text top="200" left="585" width="73" height="8" font="14">CATHETERIZATION</text>
<text top="197" left="666" width="133" height="13" font="12">. . . . . . . . . . . . . . . . . . e85</text>
<text top="214" left="547" width="31" height="8" font="14">4.3.1.5.</text>
<text top="214" left="585" width="171" height="9" font="14">DIAGNOSTIC TESTINGdEXERCISE TESTING</text>
<text top="210" left="765" width="35" height="13" font="12">. . e85</text>
<text top="226" left="509" width="233" height="13" font="12">4.3.2. Medical Therapy: Recommendations</text>
<text top="226" left="746" width="54" height="13" font="12">. . . . . .e85</text>
<text top="242" left="509" width="164" height="13" font="12">4.3.3. Timing of Intervention:</text>
<text top="257" left="547" width="97" height="13" font="12">Recommendations</text>
<text top="257" left="647" width="152" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . .e86</text>
<text top="279" left="450" width="12" height="12" font="11">5.</text>
<text top="279" left="478" width="240" height="12" font="11">Bicuspid Aortic Valve and Aortopathy</text>
<text top="278" left="724" width="76" height="13" font="12">. . . . . . . . . e88</text>
<text top="317" left="478" width="160" height="11" font="13">5.1. Bicuspid Aortic Valve</text>
<text top="316" left="641" width="158" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . .e88</text>
<text top="335" left="509" width="175" height="13" font="12">5.1.1. Diagnosis and Follow-Up</text>
<text top="335" left="690" width="109" height="13" font="12">. . . . . . . . . . . . . . .e88</text>
<text top="352" left="547" width="31" height="8" font="14">5.1.1.1.</text>
<text top="352" left="585" width="173" height="9" font="14">DIAGNOSTIC TESTINGdINITIAL DIAGNOSIS:</text>
<text top="366" left="585" width="83" height="8" font="14">RECOMMENDATIONS</text>
<text top="362" left="673" width="127" height="13" font="12">. . . . . . . . . . . . . . . . . e88</text>
<text top="379" left="547" width="31" height="8" font="14">5.1.1.2.</text>
<text top="379" left="585" width="183" height="9" font="14">DIAGNOSTIC TESTINGdROUTINE FOLLOW-UP:</text>
<text top="392" left="585" width="78" height="8" font="14">RECOMMENDATION</text>
<text top="389" left="673" width="127" height="13" font="12">. . . . . . . . . . . . . . . . . e89</text>
<text top="405" left="509" width="128" height="13" font="12">5.1.2. Medical Therapy</text>
<text top="405" left="641" width="158" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . .e89</text>
<text top="421" left="509" width="207" height="13" font="12">5.1.3. Intervention: Recommendations</text>
<text top="420" left="721" width="78" height="13" font="12">. . . . . . . . . .e89</text>
<text top="442" left="450" width="12" height="12" font="11">6.</text>
<text top="442" left="478" width="98" height="12" font="11">Mitral Stenosis</text>
<text top="441" left="582" width="218" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e90</text>
<text top="480" left="478" width="113" height="11" font="13">6.1. Stages of MS</text>
<text top="479" left="598" width="202" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e90</text>
<text top="499" left="478" width="119" height="11" font="13">6.2. Rheumatic MS</text>
<text top="498" left="604" width="195" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . . .e90</text>
<text top="518" left="509" width="175" height="13" font="12">6.2.1. Diagnosis and Follow-Up</text>
<text top="518" left="690" width="109" height="13" font="12">. . . . . . . . . . . . . . .e90</text>
<text top="535" left="547" width="31" height="8" font="14">6.2.1.1.</text>
<text top="535" left="585" width="173" height="9" font="14">DIAGNOSTIC TESTINGdINITIAL DIAGNOSIS:</text>
<text top="548" left="585" width="83" height="8" font="14">RECOMMENDATIONS</text>
<text top="545" left="673" width="127" height="13" font="12">. . . . . . . . . . . . . . . . . e90</text>
<text top="562" left="547" width="31" height="8" font="14">6.2.1.2.</text>
<text top="562" left="585" width="181" height="9" font="14">DIAGNOSTIC TESTINGdCHANGING SIGNS OR</text>
<text top="575" left="585" width="46" height="8" font="14">SYMPTOMS</text>
<text top="572" left="636" width="164" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . e91</text>
<text top="589" left="547" width="31" height="8" font="14">6.2.1.3.</text>
<text top="589" left="585" width="176" height="9" font="14">DIAGNOSTIC TESTINGdROUTINE FOLLOW-UP</text>
<text top="585" left="766" width="33" height="13" font="12">. . e91</text>
<text top="602" left="547" width="31" height="8" font="14">6.2.1.4.</text>
<text top="602" left="585" width="131" height="9" font="14">DIAGNOSTIC TESTINGdCARDIAC</text>
<text top="615" left="585" width="73" height="8" font="14">CATHETERIZATION</text>
<text top="612" left="666" width="133" height="13" font="12">. . . . . . . . . . . . . . . . . . e92</text>
<text top="629" left="547" width="31" height="8" font="14">6.2.1.5.</text>
<text top="629" left="585" width="173" height="9" font="14">DIAGNOSTIC TESTINGdEXERCISE TESTING:</text>
<text top="642" left="585" width="78" height="8" font="14">RECOMMENDATION</text>
<text top="639" left="673" width="127" height="13" font="12">. . . . . . . . . . . . . . . . . e93</text>
<text top="655" left="509" width="233" height="13" font="12">6.2.2. Medical Therapy: Recommendations</text>
<text top="655" left="746" width="54" height="13" font="12">. . . . . .e93</text>
<text top="671" left="509" width="207" height="13" font="12">6.2.3. Intervention: Recommendations</text>
<text top="670" left="721" width="78" height="13" font="12">. . . . . . . . . .e94</text>
<text top="687" left="478" width="138" height="11" font="13">6.3. Nonrheumatic MS</text>
<text top="686" left="623" width="177" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . .e96</text>
<text top="711" left="450" width="12" height="12" font="11">7.</text>
<text top="711" left="478" width="129" height="12" font="11">Mitral Regurgitation</text>
<text top="711" left="613" width="187" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . e97</text>
<text top="749" left="478" width="90" height="11" font="13">7.1. Acute MR</text>
<text top="748" left="573" width="226" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e97</text>
<text top="768" left="509" width="175" height="13" font="12">7.1.1. Diagnosis and Follow-Up</text>
<text top="768" left="690" width="109" height="13" font="12">. . . . . . . . . . . . . . .e97</text>
<text top="784" left="509" width="128" height="13" font="12">7.1.2. Medical Therapy</text>
<text top="783" left="641" width="158" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . .e97</text>
<text top="799" left="509" width="102" height="13" font="12">7.1.3. Intervention</text>
<text top="799" left="616" width="183" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . .e98</text>
<text top="816" left="478" width="163" height="11" font="13">7.2. Stages of Chronic MR</text>
<text top="815" left="647" width="152" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . .e98</text>
<text top="835" left="478" width="151" height="11" font="13">7.3. Chronic Primary MR</text>
<text top="834" left="635" width="165" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . .e98</text>
<text top="854" left="509" width="175" height="13" font="12">7.3.1. Diagnosis and Follow-Up</text>
<text top="854" left="690" width="109" height="13" font="12">. . . . . . . . . . . . . . .e98</text>
<text top="871" left="547" width="31" height="8" font="14">7.3.1.1.</text>
<text top="871" left="585" width="173" height="9" font="14">DIAGNOSTIC TESTINGdINITIAL DIAGNOSIS:</text>
<text top="884" left="585" width="83" height="8" font="14">RECOMMENDATIONS</text>
<text top="880" left="673" width="127" height="13" font="12">. . . . . . . . . . . . . . . . . e98</text>
<text top="897" left="547" width="31" height="8" font="14">7.3.1.2.</text>
<text top="897" left="585" width="181" height="9" font="14">DIAGNOSTIC TESTINGdCHANGING SIGNS OR</text>
<text top="911" left="585" width="46" height="8" font="14">SYMPTOMS</text>
<text top="907" left="636" width="164" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . e101</text>
<text top="924" left="547" width="31" height="8" font="14">7.3.1.3.</text>
<text top="924" left="585" width="173" height="9" font="14">DIAGNOSTIC TESTINGdROUTINE FOLLOW-UP</text>
<text top="921" left="762" width="38" height="13" font="12">. . e101</text>
<text top="938" left="547" width="31" height="8" font="14">7.3.1.4.</text>
<text top="938" left="585" width="131" height="9" font="14">DIAGNOSTIC TESTINGdCARDIAC</text>
<text top="951" left="585" width="73" height="8" font="14">CATHETERIZATION</text>
<text top="948" left="666" width="133" height="13" font="12">. . . . . . . . . . . . . . . . . e101</text>
<text top="965" left="547" width="31" height="8" font="14">7.3.1.5.</text>
<text top="965" left="585" width="173" height="9" font="14">DIAGNOSTIC TESTINGdEXERCISE TESTING:</text>
<text top="978" left="585" width="83" height="8" font="14">RECOMMENDATIONS</text>
<text top="975" left="673" width="127" height="13" font="12">. . . . . . . . . . . . . . . . e102</text>
<text top="991" left="509" width="233" height="13" font="12">7.3.2. Medical Therapy: Recommendations</text>
<text top="990" left="746" width="54" height="13" font="12">. . . . e102</text>
<text top="1006" left="509" width="207" height="13" font="12">7.3.3. Intervention: Recommendations</text>
<text top="1006" left="721" width="78" height="13" font="12">. . . . . . . . e102</text>
<text top="1023" left="478" width="168" height="11" font="13">7.4. Chronic Secondary MR</text>
<text top="1022" left="654" width="146" height="13" font="12">. . . . . . . . . . . . . . . . . . . e106</text>
<text top="1041" left="509" width="178" height="13" font="12">7.4.1. Diagnosis and Follow-Up:</text>
<text top="1057" left="547" width="97" height="13" font="12">Recommendations</text>
<text top="1057" left="647" width="152" height="13" font="12">. . . . . . . . . . . . . . . . . . . . e106</text>
<text top="1073" left="509" width="233" height="13" font="12">7.4.2. Medical Therapy: Recommendations</text>
<text top="1072" left="746" width="54" height="13" font="12">. . . . e106</text>
<text top="1088" left="509" width="207" height="13" font="12">7.4.3. Intervention: Recommendations</text>
<text top="1088" left="721" width="78" height="13" font="12">. . . . . . . . e107</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e58</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="12" height="12" font="11">8.</text>
<text top="103" left="93" width="153" height="12" font="11">Tricuspid Valve Disease</text>
<text top="103" left="252" width="162" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . e107</text>
<text top="132" left="93" width="109" height="11" font="13">8.1. Stages of TR</text>
<text top="131" left="206" width="208" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . e107</text>
<text top="152" left="93" width="171" height="11" font="13">8.2. Tricuspid Regurgitation</text>
<text top="151" left="268" width="146" height="13" font="12">. . . . . . . . . . . . . . . . . . . e108</text>
<text top="170" left="123" width="178" height="13" font="12">8.2.1. Diagnosis and Follow-Up:</text>
<text top="186" left="161" width="97" height="13" font="12">Recommendations</text>
<text top="186" left="262" width="152" height="13" font="12">. . . . . . . . . . . . . . . . . . . . e108</text>
<text top="202" left="123" width="233" height="13" font="12">8.2.2. Medical Therapy: Recommendations</text>
<text top="201" left="360" width="54" height="13" font="12">. . . . e111</text>
<text top="217" left="123" width="207" height="13" font="12">8.2.3. Intervention: Recommendations</text>
<text top="217" left="336" width="78" height="13" font="12">. . . . . . . . e111</text>
<text top="234" left="93" width="205" height="11" font="13">8.3. Stages of Tricuspid Stenosis</text>
<text top="233" left="305" width="109" height="13" font="12">. . . . . . . . . . . . . e113</text>
<text top="253" left="93" width="142" height="11" font="13">8.4. Tricuspid Stenosis</text>
<text top="252" left="243" width="171" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . e113</text>
<text top="272" left="123" width="178" height="13" font="12">8.4.1. Diagnosis and Follow-Up:</text>
<text top="288" left="161" width="97" height="13" font="12">Recommendations</text>
<text top="287" left="262" width="152" height="13" font="12">. . . . . . . . . . . . . . . . . . . . e113</text>
<text top="303" left="123" width="128" height="13" font="12">8.4.2. Medical Therapy</text>
<text top="303" left="256" width="158" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . e113</text>
<text top="319" left="123" width="207" height="13" font="12">8.4.3. Intervention: Recommendations</text>
<text top="319" left="336" width="78" height="13" font="12">. . . . . . . . e113</text>
<text top="340" left="64" width="12" height="12" font="11">9.</text>
<text top="340" left="93" width="154" height="12" font="11">Pulmonic Valve Disease</text>
<text top="340" left="252" width="162" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . e114</text>
<text top="369" left="93" width="236" height="11" font="13">9.1. Stages of Pulmonic Regurgitation</text>
<text top="368" left="336" width="78" height="13" font="12">. . . . . . . . e114</text>
<text top="389" left="93" width="207" height="11" font="13">9.2. Stages of Pulmonic Stenosis</text>
<text top="387" left="305" width="109" height="13" font="12">. . . . . . . . . . . . . e114</text>
<text top="413" left="64" width="20" height="12" font="11">10.</text>
<text top="413" left="101" width="134" height="12" font="11">Mixed Valve Disease</text>
<text top="412" left="240" width="174" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . e114</text>
<text top="441" left="101" width="105" height="11" font="13">10.1. Mixed VHD</text>
<text top="440" left="208" width="206" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . e114</text>
<text top="460" left="139" width="181" height="13" font="12">10.1.1. Diagnosis and Follow-Up</text>
<text top="460" left="327" width="87" height="13" font="12">. . . . . . . . . . e114</text>
<text top="476" left="139" width="135" height="13" font="12">10.1.2. Medical Therapy</text>
<text top="476" left="277" width="137" height="13" font="12">. . . . . . . . . . . . . . . . . . e115</text>
<text top="492" left="139" width="167" height="13" font="12">10.1.3. Timing of Intervention</text>
<text top="491" left="314" width="100" height="13" font="12">. . . . . . . . . . . . e115</text>
<text top="507" left="139" width="165" height="13" font="12">10.1.4. Choice of Intervention</text>
<text top="507" left="308" width="106" height="13" font="12">. . . . . . . . . . . . . e115</text>
<text top="528" left="64" width="20" height="12" font="11">11.</text>
<text top="528" left="101" width="114" height="12" font="11">Prosthetic Valves</text>
<text top="528" left="221" width="193" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . e116</text>
<text top="557" left="101" width="206" height="11" font="13">11.1. Evaluation and Selection of</text>
<text top="573" left="139" width="107" height="11" font="13">Prosthetic Valves</text>
<text top="572" left="251" width="163" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . e116</text>
<text top="592" left="139" width="184" height="13" font="12">11.1.1. Diagnosis and Follow-Up:</text>
<text top="607" left="183" width="97" height="13" font="12">Recommendations</text>
<text top="607" left="283" width="131" height="13" font="12">. . . . . . . . . . . . . . . . . e116</text>
<text top="623" left="139" width="213" height="13" font="12">11.1.2. Intervention: Recommendations</text>
<text top="623" left="357" width="57" height="13" font="12">. . . . . e117</text>
<text top="640" left="101" width="201" height="11" font="13">11.2. Antithrombotic Therapy for</text>
<text top="655" left="139" width="107" height="11" font="13">Prosthetic Valves</text>
<text top="654" left="251" width="163" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . e119</text>
<text top="674" left="139" width="181" height="13" font="12">11.2.1. Diagnosis and Follow-Up</text>
<text top="674" left="327" width="87" height="13" font="12">. . . . . . . . . . e119</text>
<text top="690" left="139" width="234" height="13" font="12">11.2.2. Medical Therapy: Recommendations</text>
<text top="689" left="377" width="37" height="13" font="12">. . e120</text>
<text top="706" left="101" width="272" height="11" font="13">11.3. Bridging Therapy for Prosthetic Valves</text>
<text top="705" left="381" width="33" height="13" font="12">. e122</text>
<text top="725" left="139" width="181" height="13" font="12">11.3.1. Diagnosis and Follow-Up</text>
<text top="724" left="327" width="87" height="13" font="12">. . . . . . . . . . e122</text>
<text top="740" left="139" width="234" height="13" font="12">11.3.2. Medical Therapy: Recommendations</text>
<text top="740" left="377" width="37" height="13" font="12">. . e122</text>
<text top="757" left="101" width="275" height="11" font="13">11.4. Excessive Anticoagulation and Serious</text>
<text top="773" left="139" width="200" height="11" font="13">Bleeding With Prosthetic Valves:</text>
<text top="788" left="139" width="105" height="11" font="13">Recommendation</text>
<text top="787" left="251" width="163" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . e123</text>
<text top="808" left="101" width="214" height="11" font="13">11.5. Thromboembolic Events With</text>
<text top="823" left="139" width="107" height="11" font="13">Prosthetic Valves</text>
<text top="822" left="251" width="163" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . e124</text>
<text top="842" left="139" width="181" height="13" font="12">11.5.1. Diagnosis and Follow-Up</text>
<text top="842" left="327" width="87" height="13" font="12">. . . . . . . . . . e124</text>
<text top="858" left="139" width="135" height="13" font="12">11.5.2. Medical Therapy</text>
<text top="857" left="277" width="137" height="13" font="12">. . . . . . . . . . . . . . . . . . e124</text>
<text top="873" left="139" width="108" height="13" font="12">11.5.3. Intervention</text>
<text top="873" left="253" width="161" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . e125</text>
<text top="890" left="101" width="212" height="11" font="13">11.6. Prosthetic Valve Thrombosis</text>
<text top="889" left="319" width="95" height="13" font="12">. . . . . . . . . . . e125</text>
<text top="909" left="139" width="184" height="13" font="12">11.6.1. Diagnosis and Follow-Up:</text>
<text top="924" left="183" width="97" height="13" font="12">Recommendations</text>
<text top="924" left="283" width="131" height="13" font="12">. . . . . . . . . . . . . . . . . e125</text>
<text top="940" left="139" width="230" height="13" font="12">11.6.2. Medical Therapy: Recommendations</text>
<text top="940" left="372" width="42" height="13" font="12">. . . e126</text>
<text top="956" left="139" width="213" height="13" font="12">11.6.3. Intervention: Recommendations</text>
<text top="955" left="357" width="57" height="13" font="12">. . . . . e127</text>
<text top="972" left="101" width="196" height="11" font="13">11.7. Prosthetic Valve Stenosis</text>
<text top="971" left="301" width="113" height="13" font="12">. . . . . . . . . . . . . . e127</text>
<text top="991" left="139" width="181" height="13" font="12">11.7.1. Diagnosis and Follow-Up</text>
<text top="990" left="327" width="87" height="13" font="12">. . . . . . . . . . e127</text>
<text top="1006" left="139" width="135" height="13" font="12">11.7.2. Medical Therapy</text>
<text top="1006" left="277" width="137" height="13" font="12">. . . . . . . . . . . . . . . . . . e128</text>
<text top="1022" left="139" width="209" height="13" font="12">11.7.3. Intervention: Recommendation</text>
<text top="1022" left="351" width="63" height="13" font="12">. . . . . . e128</text>
<text top="1039" left="101" width="225" height="11" font="13">11.8. Prosthetic Valve Regurgitation</text>
<text top="1038" left="331" width="83" height="13" font="12">. . . . . . . . . e128</text>
<text top="1057" left="139" width="181" height="13" font="12">11.8.1. Diagnosis and Follow-Up</text>
<text top="1057" left="327" width="87" height="13" font="12">. . . . . . . . . . e128</text>
<text top="1073" left="139" width="135" height="13" font="12">11.8.2. Medical Therapy</text>
<text top="1073" left="277" width="137" height="13" font="12">. . . . . . . . . . . . . . . . . . e128</text>
<text top="1089" left="139" width="213" height="13" font="12">11.8.3. Intervention: Recommendations</text>
<text top="1088" left="357" width="57" height="13" font="12">. . . . . e128</text>
<text top="103" left="450" width="20" height="12" font="11">12.</text>
<text top="103" left="486" width="140" height="12" font="11">Infective Endocarditis</text>
<text top="103" left="631" width="168" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . e129</text>
<text top="138" left="486" width="113" height="11" font="13">12.1. IE: Overview</text>
<text top="137" left="606" width="193" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . e129</text>
<text top="158" left="486" width="171" height="11" font="13">12.2. Infective Endocarditis</text>
<text top="157" left="662" width="138" height="13" font="12">. . . . . . . . . . . . . . . . . . e129</text>
<text top="172" left="524" width="184" height="13" font="12">12.2.1. Diagnosis and Follow-Up:</text>
<text top="187" left="569" width="97" height="13" font="12">Recommendations</text>
<text top="187" left="669" width="131" height="13" font="12">. . . . . . . . . . . . . . . . . e130</text>
<text top="203" left="524" width="233" height="13" font="12">12.2.2. Medical Therapy: Recommendations</text>
<text top="203" left="762" width="37" height="13" font="12">. . e134</text>
<text top="219" left="524" width="213" height="13" font="12">12.2.3. Intervention: Recommendations</text>
<text top="219" left="743" width="57" height="13" font="12">. . . . . e135</text>
<text top="239" left="450" width="20" height="12" font="11">13.</text>
<text top="239" left="486" width="126" height="12" font="11">Pregnancy and VHD</text>
<text top="239" left="619" width="180" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . e139</text>
<text top="274" left="486" width="176" height="11" font="13">13.1. Native Valve Stenosis:</text>
<text top="290" left="524" width="112" height="11" font="13">Recommendations</text>
<text top="289" left="643" width="156" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . e139</text>
<text top="304" left="524" width="184" height="13" font="12">13.1.1. Diagnosis and Follow-Up:</text>
<text top="320" left="569" width="93" height="13" font="12">Recommendation</text>
<text top="319" left="669" width="131" height="13" font="12">. . . . . . . . . . . . . . . . . e140</text>
<text top="335" left="524" width="233" height="13" font="12">13.1.2. Medical Therapy: Recommendations</text>
<text top="335" left="762" width="37" height="13" font="12">. . e140</text>
<text top="351" left="524" width="213" height="13" font="12">13.1.3. Intervention: Recommendations</text>
<text top="351" left="743" width="57" height="13" font="12">. . . . . e141</text>
<text top="368" left="486" width="202" height="11" font="13">13.2. Native Valve Regurgitation</text>
<text top="367" left="692" width="107" height="13" font="12">. . . . . . . . . . . . . e143</text>
<text top="386" left="524" width="184" height="13" font="12">13.2.1. Diagnosis and Follow-Up:</text>
<text top="402" left="569" width="97" height="13" font="12">Recommendations</text>
<text top="402" left="669" width="131" height="13" font="12">. . . . . . . . . . . . . . . . . e143</text>
<text top="418" left="524" width="229" height="13" font="12">13.2.2. Medical Therapy: Recommendation</text>
<text top="417" left="756" width="43" height="13" font="12">. . . e144</text>
<text top="433" left="524" width="213" height="13" font="12">13.2.3. Intervention: Recommendations</text>
<text top="433" left="743" width="57" height="13" font="12">. . . . . e144</text>
<text top="450" left="486" width="228" height="11" font="13">13.3. Prosthetic Valves in Pregnancy</text>
<text top="449" left="723" width="76" height="13" font="12">. . . . . . . . e145</text>
<text top="468" left="524" width="184" height="13" font="12">13.3.1. Diagnosis and Follow-Up:</text>
<text top="484" left="569" width="97" height="13" font="12">Recommendations</text>
<text top="484" left="669" width="131" height="13" font="12">. . . . . . . . . . . . . . . . . e145</text>
<text top="500" left="524" width="233" height="13" font="12">13.3.2. Medical Therapy: Recommendations</text>
<text top="499" left="762" width="37" height="13" font="12">. . e146</text>
<text top="520" left="450" width="20" height="12" font="11">14.</text>
<text top="520" left="486" width="153" height="12" font="11">Surgical Considerations</text>
<text top="520" left="644" width="156" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . e149</text>
<text top="555" left="486" width="238" height="11" font="13">14.1. Evaluation of Coronary Anatomy:</text>
<text top="571" left="524" width="112" height="11" font="13">Recommendations</text>
<text top="570" left="643" width="156" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . e149</text>
<text top="590" left="486" width="188" height="11" font="13">14.2. Concomitant Procedures</text>
<text top="589" left="680" width="119" height="13" font="12">. . . . . . . . . . . . . . . e151</text>
<text top="609" left="524" width="165" height="13" font="12">14.2.1. Intervention for CAD:</text>
<text top="624" left="569" width="93" height="13" font="12">Recommendation</text>
<text top="624" left="669" width="131" height="13" font="12">. . . . . . . . . . . . . . . . . e151</text>
<text top="640" left="524" width="153" height="13" font="12">14.2.2. Intervention for AF:</text>
<text top="656" left="569" width="97" height="13" font="12">Recommendations</text>
<text top="656" left="669" width="131" height="13" font="12">. . . . . . . . . . . . . . . . . e151</text>
<text top="676" left="450" width="20" height="12" font="11">15.</text>
<text top="676" left="486" width="265" height="12" font="11">Noncardiac Surgery in Patients With VHD</text>
<text top="676" left="755" width="45" height="13" font="12">. . . e152</text>
<text top="711" left="486" width="185" height="11" font="13">15.1. Diagnosis and Follow-Up</text>
<text top="710" left="680" width="119" height="13" font="12">. . . . . . . . . . . . . . . e152</text>
<text top="730" left="486" width="137" height="11" font="13">15.2. Medical Therapy</text>
<text top="729" left="631" width="169" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . e153</text>
<text top="750" left="486" width="232" height="11" font="13">15.3. Intervention: Recommendations</text>
<text top="749" left="723" width="76" height="13" font="12">. . . . . . . . e153</text>
<text top="769" left="450" width="20" height="12" font="11">16.</text>
<text top="769" left="486" width="237" height="12" font="11">Evidence Gaps and Future Directions</text>
<text top="769" left="730" width="69" height="13" font="12">. . . . . . . e154</text>
<text top="803" left="486" width="224" height="13" font="13">16.1. Prevention of Valve Diseased</text>
<text top="819" left="524" width="48" height="11" font="13">Stage A</text>
<text top="818" left="575" width="224" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e155</text>
<text top="839" left="486" width="257" height="11" font="13">16.2. Medical Therapy to Treat or Prevent</text>
<text top="854" left="524" width="185" height="13" font="13">Disease ProgressiondStage B</text>
<text top="853" left="717" width="82" height="13" font="12">. . . . . . . . . e155</text>
<text top="874" left="486" width="236" height="13" font="13">16.3. Optimal Timing of Interventiond</text>
<text top="889" left="524" width="48" height="11" font="13">Stage C</text>
<text top="888" left="575" width="224" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e155</text>
<text top="909" left="486" width="239" height="13" font="13">16.4. Better Options for Interventiond</text>
<text top="925" left="524" width="48" height="11" font="13">Stage D</text>
<text top="923" left="581" width="218" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e155</text>
<text top="940" left="450" width="73" height="12" font="11">References</text>
<text top="939" left="527" width="273" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e156</text>
<text top="976" left="450" width="248" height="12" font="11">Appendix 1. Author Relationships With</text>
<text top="993" left="450" width="245" height="12" font="11">Industry and Other Entities (Relevant)</text>
<text top="992" left="699" width="100" height="13" font="12">. . . . . . . . . . . . e178</text>
<text top="1028" left="450" width="265" height="12" font="11">Appendix 2. Reviewer Relationships With</text>
<text top="1044" left="450" width="245" height="12" font="11">Industry and Other Entities (Relevant)</text>
<text top="1044" left="699" width="100" height="13" font="12">. . . . . . . . . . . . e179</text>
<text top="1079" left="450" width="168" height="12" font="11">Appendix 3. Abbreviations</text>
<text top="1079" left="625" width="174" height="13" font="12">. . . . . . . . . . . . . . . . . . . . . . . . e185</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e59</text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="17" size="14" family="Times" color="#a70c2f"/>
<text top="104" left="64" width="74" height="14" font="17">Preamble</text>
<text top="139" left="65" width="349" height="15" font="5">The medical profession should play a central role in</text>
<text top="157" left="64" width="350" height="15" font="5">evaluating evidence related to drugs, devices, and pro-</text>
<text top="175" left="64" width="350" height="15" font="5">cedures for detection, management, and prevention of</text>
<text top="192" left="64" width="350" height="15" font="5">disease. When properly applied, expert analysis of avail-</text>
<text top="210" left="64" width="132" height="15" font="5">able data on the bene</text>
<text top="207" left="197" width="217" height="19" font="5">ﬁts and risks of these therapies and</text>
<text top="228" left="64" width="350" height="15" font="5">procedures can improve the quality of care, optimize</text>
<text top="246" left="64" width="350" height="15" font="5">patient outcomes, and favorably affect costs by focusing</text>
<text top="264" left="64" width="350" height="15" font="5">resources on the most effective strategies. An organized</text>
<text top="282" left="64" width="350" height="15" font="5">and directed approach to a thorough review of evidence</text>
<text top="300" left="64" width="350" height="15" font="5">has resulted in the production of clinical practice guide-</text>
<text top="318" left="64" width="350" height="15" font="5">lines that assist clinicians in selecting the best manage-</text>
<text top="336" left="64" width="350" height="15" font="5">ment strategy for an individual patient. Moreover, clinical</text>
<text top="354" left="64" width="350" height="15" font="5">practice guidelines can provide a foundation for other</text>
<text top="372" left="64" width="349" height="15" font="5">applications, such as performance measures, appropriate</text>
<text top="390" left="64" width="350" height="15" font="5">use criteria, and both quality improvement and clinical</text>
<text top="408" left="64" width="139" height="15" font="5">decision support tools.</text>
<text top="426" left="79" width="335" height="15" font="5">The American College of Cardiology (ACC) and the</text>
<text top="444" left="64" width="350" height="15" font="5">American Heart Association (AHA) have jointly engaged</text>
<text top="461" left="64" width="350" height="15" font="5">in the production of guidelines in the area of cardiovascular</text>
<text top="479" left="64" width="350" height="15" font="5">disease since 1980. The ACC/AHA Task Force on</text>
<text top="497" left="64" width="350" height="15" font="5">Practice Guidelines (Task Force) directs this effort by</text>
<text top="515" left="64" width="350" height="15" font="5">developing, updating, and revising practice guidelines for</text>
<text top="533" left="64" width="234" height="15" font="5">cardiovascular diseases and procedures.</text>
<text top="551" left="79" width="335" height="15" font="5">Experts in the subject under consideration are selected</text>
<text top="569" left="64" width="335" height="15" font="5">from both ACC and AHA to examine subject-speci</text>
<text top="566" left="400" width="14" height="19" font="5">ﬁc</text>
<text top="587" left="64" width="350" height="15" font="5">data and write guidelines. Writing committees are specif-</text>
<text top="605" left="64" width="350" height="15" font="5">ically charged with performing a literature review; weighing</text>
<text top="623" left="64" width="350" height="15" font="5">the strength of evidence for or against particular tests,</text>
<text top="641" left="64" width="350" height="15" font="5">treatments, or procedures; and including estimates of ex-</text>
<text top="659" left="64" width="350" height="15" font="5">pected health outcomes where such data exist. Patient-</text>
<text top="677" left="64" width="29" height="15" font="5">speci</text>
<text top="673" left="93" width="320" height="19" font="5">ﬁc modiﬁers, comorbidities, and issues of patient</text>
<text top="695" left="64" width="138" height="15" font="5">preference that may in</text>
<text top="691" left="202" width="212" height="19" font="5">ﬂuence the choice of tests or ther-</text>
<text top="713" left="64" width="350" height="15" font="5">apies are considered, as well as frequency of follow-up</text>
<text top="731" left="64" width="350" height="15" font="5">and cost effectiveness. When available, information from</text>
<text top="748" left="64" width="350" height="15" font="5">studies on cost is considered; however, a review of data on</text>
<text top="766" left="64" width="11" height="15" font="5">ef</text>
<text top="763" left="75" width="339" height="19" font="5">ﬁcacy and outcomes constitutes the primary basis for</text>
<text top="784" left="64" width="274" height="15" font="5">preparing recommendations in this guideline.</text>
<text top="802" left="79" width="335" height="15" font="5">In analyzing the data and developing recommendations</text>
<text top="820" left="64" width="350" height="15" font="5">and supporting text, the writing committee uses evidence-</text>
<text top="838" left="64" width="321" height="15" font="5">based methodologies developed by the Task Force</text>
<text top="838" left="393" width="17" height="15" font="6"><a href="e57.full.html#100">(1)</a></text>
<text top="838" left="410" width="4" height="15" font="5">.</text>
<text top="856" left="64" width="350" height="15" font="5">The Class of Recommendation (COR) is an estimate of</text>
<text top="874" left="64" width="350" height="15" font="5">the size of the treatment effect, with consideration given</text>
<text top="892" left="64" width="119" height="15" font="5">to risks versus bene</text>
<text top="889" left="184" width="230" height="19" font="5">ﬁts, as well as evidence and/or agree-</text>
<text top="910" left="64" width="350" height="15" font="5">ment that a given treatment or procedure is or is</text>
<text top="928" left="64" width="350" height="15" font="5">not useful/effective or in some situations may cause harm.</text>
<text top="946" left="64" width="350" height="15" font="5">The Level of Evidence (LOE) is an estimate of the cer-</text>
<text top="964" left="64" width="350" height="15" font="5">tainty or precision of the treatment effect. The writing</text>
<text top="982" left="64" width="350" height="15" font="5">committee reviews and ranks evidence supporting each</text>
<text top="1000" left="64" width="350" height="15" font="5">recommendation, with the weight of evidence ranked</text>
<text top="1018" left="64" width="260" height="15" font="5">as LOE A, B, or C, according to speci</text>
<text top="1014" left="324" width="90" height="19" font="5">ﬁc deﬁnitions.</text>
<text top="1035" left="64" width="350" height="15" font="5">The schema for the COR and LOE is summarized</text>
<text top="1053" left="64" width="12" height="15" font="5">in</text>
<text top="1053" left="84" width="50" height="15" font="6"><a href="e57.full.html#5">Table 1</a></text>
<text top="1053" left="134" width="280" height="15" font="5">, which also provides suggested phrases for</text>
<text top="1071" left="64" width="350" height="15" font="5">writing recommendations within each COR. Studies are</text>
<text top="1089" left="64" width="35" height="15" font="5">identi</text>
<text top="1086" left="99" width="315" height="19" font="5">ﬁed as observational, retrospective, prospective, or</text>
<text top="103" left="450" width="350" height="15" font="5">randomized, as appropriate. For certain conditions for</text>
<text top="121" left="450" width="350" height="15" font="5">which inadequate data are available, recommendations are</text>
<text top="139" left="450" width="350" height="15" font="5">based on expert consensus and clinical experience and are</text>
<text top="157" left="450" width="350" height="15" font="5">ranked as LOE C. When recommendations at LOE C</text>
<text top="175" left="450" width="350" height="15" font="5">are supported by historical clinical data, appropriate ref-</text>
<text top="193" left="450" width="350" height="15" font="5">erences (including clinical reviews) are cited if available.</text>
<text top="211" left="450" width="350" height="15" font="5">For issues with sparse available data, a survey of current</text>
<text top="229" left="450" width="350" height="15" font="5">practice among the clinician members of the writing</text>
<text top="247" left="450" width="350" height="15" font="5">committee is the basis for LOE C recommendations and</text>
<text top="264" left="450" width="141" height="15" font="5">no references are cited.</text>
<text top="282" left="465" width="335" height="15" font="5">A new addition to this methodology is separation of</text>
<text top="300" left="450" width="350" height="15" font="5">the Class III recommendations to delineate whether the</text>
<text top="318" left="450" width="241" height="15" font="5">recommendation is determined to be of</text>
<text top="315" left="696" width="103" height="19" font="5">“no beneﬁt” or is</text>
<text top="336" left="450" width="90" height="15" font="5">associated with</text>
<text top="333" left="545" width="255" height="19" font="5">“harm” to the patient. In addition, in view</text>
<text top="354" left="450" width="350" height="15" font="5">of the increasing number of comparative effectiveness</text>
<text top="372" left="450" width="350" height="15" font="5">studies, comparator verbs and suggested phrases for writing</text>
<text top="390" left="450" width="350" height="15" font="5">recommendations for the comparative effectiveness of one</text>
<text top="408" left="450" width="350" height="15" font="5">treatment or strategy versus another are included for COR</text>
<text top="426" left="450" width="177" height="15" font="5">I and IIa, LOE A or B only.</text>
<text top="444" left="465" width="335" height="15" font="5">In view of the advances in medical therapy across the</text>
<text top="462" left="450" width="350" height="15" font="5">spectrum of cardiovascular diseases, the Task Force has</text>
<text top="480" left="450" width="350" height="15" font="5">designated the term guideline-directed medical therapy</text>
<text top="498" left="450" width="320" height="15" font="5">(GDMT) to represent optimal medical therapy as de</text>
<text top="494" left="769" width="30" height="19" font="5">ﬁned</text>
<text top="516" left="450" width="350" height="15" font="5">by ACC/AHA guideline (primarily Class I)-recommended</text>
<text top="533" left="450" width="350" height="15" font="5">therapies. This new term, GDMT, is used herein and</text>
<text top="551" left="450" width="204" height="15" font="5">throughout subsequent guidelines.</text>
<text top="569" left="465" width="335" height="15" font="5">Because the ACC/AHA practice guidelines address</text>
<text top="587" left="450" width="350" height="15" font="5">patient populations (and clinicians) residing in North</text>
<text top="605" left="450" width="350" height="15" font="5">America, drugs that are not currently available in North</text>
<text top="623" left="450" width="294" height="15" font="5">America are discussed in the text without a speci</text>
<text top="620" left="744" width="56" height="19" font="5">ﬁc COR.</text>
<text top="641" left="450" width="350" height="15" font="5">For studies performed in large numbers of subjects outside</text>
<text top="659" left="450" width="350" height="15" font="5">North America, each writing committee reviews the po-</text>
<text top="677" left="450" width="350" height="15" font="5">tential impact of different practice patterns and patient</text>
<text top="695" left="450" width="350" height="15" font="5">populations on the treatment effect and relevance to the</text>
<text top="713" left="450" width="350" height="15" font="5">ACC/AHA target population to determine whether the</text>
<text top="727" left="450" width="307" height="19" font="5">ﬁndings should inform a speciﬁc recommendation.</text>
<text top="749" left="465" width="335" height="15" font="5">The ACC/AHA practice guidelines are intended to</text>
<text top="767" left="450" width="350" height="15" font="5">assist clinicians in clinical decision making by describing</text>
<text top="785" left="450" width="350" height="15" font="5">a range of generally acceptable approaches to the diag-</text>
<text top="803" left="450" width="281" height="15" font="5">nosis, management, and prevention of speci</text>
<text top="799" left="731" width="69" height="19" font="5">ﬁc diseases</text>
<text top="820" left="450" width="269" height="15" font="5">or conditions. The guidelines attempt to de</text>
<text top="817" left="719" width="80" height="19" font="5">ﬁne practices</text>
<text top="838" left="450" width="350" height="15" font="5">that meet the needs of most patients in most circum-</text>
<text top="856" left="450" width="350" height="15" font="5">stances. The ultimate judgment about care of a particular</text>
<text top="874" left="450" width="350" height="15" font="5">patient must be made by the clinician and patient in</text>
<text top="892" left="450" width="350" height="15" font="5">light of all the circumstances presented by that patient.</text>
<text top="910" left="450" width="350" height="15" font="5">As a result, situations may arise in which deviations</text>
<text top="928" left="450" width="350" height="15" font="5">from these guidelines may be appropriate. Clinical de-</text>
<text top="946" left="450" width="350" height="15" font="5">cision making should involve consideration of the quality</text>
<text top="964" left="450" width="350" height="15" font="5">and availability of expertise in the area where care is</text>
<text top="981" left="450" width="350" height="15" font="5">provided. When these guidelines are used as the basis</text>
<text top="999" left="450" width="350" height="15" font="5">for regulatory or payer decisions, the goal should be</text>
<text top="1017" left="450" width="350" height="15" font="5">improvement in quality of care. The Task Force recog-</text>
<text top="1035" left="450" width="350" height="15" font="5">nizes that situations arise in which additional data are</text>
<text top="1053" left="450" width="350" height="15" font="5">needed to inform patient care more effectively; these</text>
<text top="1071" left="450" width="104" height="15" font="5">areas are identi</text>
<text top="1068" left="554" width="246" height="19" font="5">ﬁed within each respective guideline</text>
<text top="1089" left="450" width="112" height="15" font="5">when appropriate.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e60</text>
</page>
<page number="5" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="18" size="6" family="Times" color="#000000"/>
<text top="856" left="79" width="335" height="15" font="5">Prescribed courses of treatment in accordance with these</text>
<text top="874" left="64" width="350" height="15" font="5">recommendations are effective only if followed. Because</text>
<text top="892" left="64" width="350" height="15" font="5">lack of patient understanding and adherence may adversely</text>
<text top="910" left="64" width="350" height="15" font="5">affect outcomes, clinicians should make every effort to</text>
<text top="928" left="64" width="121" height="15" font="5">engage the patient</text>
<text top="924" left="185" width="229" height="19" font="5">’s active participation in prescribed</text>
<text top="946" left="64" width="350" height="15" font="5">medical regimens and lifestyles. In addition, patients</text>
<text top="964" left="64" width="229" height="15" font="5">should be informed of the risks, bene</text>
<text top="960" left="293" width="121" height="19" font="5">ﬁts, and alternatives</text>
<text top="981" left="64" width="350" height="15" font="5">to a particular treatment and should be involved in shared</text>
<text top="999" left="64" width="350" height="15" font="5">decision making whenever feasible, particularly for COR</text>
<text top="1017" left="64" width="178" height="15" font="5">IIa and IIb, for which the bene</text>
<text top="1014" left="243" width="171" height="19" font="5">ﬁt-to-risk ratio may be lower.</text>
<text top="1035" left="79" width="335" height="15" font="5">The Task Force makes every effort to avoid actual, po-</text>
<text top="1053" left="64" width="143" height="15" font="5">tential, or perceived con</text>
<text top="1050" left="207" width="206" height="19" font="5">ﬂicts of interest that may arise as a</text>
<text top="1071" left="64" width="350" height="15" font="5">result of relationships with industry and other entities</text>
<text top="1089" left="64" width="350" height="15" font="5">(RWI) among the members of the writing committee. All</text>
<text top="856" left="450" width="350" height="15" font="5">writing committee members and peer reviewers of the</text>
<text top="874" left="450" width="350" height="15" font="5">guideline are required to disclose all current healthcare-</text>
<text top="892" left="450" width="350" height="15" font="5">related relationships, including those existing 12 months</text>
<text top="910" left="450" width="225" height="15" font="5">before initiation of the writing effort.</text>
<text top="928" left="465" width="335" height="15" font="5">In December 2009, the ACC and AHA implemented</text>
<text top="946" left="450" width="350" height="15" font="5">a new RWI policy that requires the writing committee</text>
<text top="964" left="450" width="350" height="15" font="5">chair plus a minimum of 50% of the writing committee to</text>
<text top="982" left="450" width="151" height="15" font="5">have no relevant RWI (</text>
<text top="982" left="601" width="73" height="15" font="6"><a href="e57.full.html#122">Appendix 1</a></text>
<text top="982" left="680" width="119" height="15" font="5">includes the ACC/</text>
<text top="999" left="450" width="56" height="15" font="5">AHA de</text>
<text top="996" left="506" width="293" height="19" font="5">ﬁnition of relevance). The Task Force and all</text>
<text top="1017" left="450" width="350" height="15" font="5">writing committee members review their respective RWI</text>
<text top="1035" left="450" width="350" height="15" font="5">disclosures during each conference call and/or meeting of</text>
<text top="1053" left="450" width="350" height="15" font="5">the writing committee, and members provide updates to</text>
<text top="1071" left="450" width="350" height="15" font="5">their RWI as changes occur. All guideline recommenda-</text>
<text top="1089" left="450" width="113" height="15" font="5">tions require a con</text>
<text top="1086" left="563" width="237" height="19" font="5">ﬁdential vote by the writing committee</text>
<text top="103" left="64" width="139" height="11" font="13">Table 1. Applying Classi</text>
<text top="100" left="203" width="292" height="17" font="13">ﬁcation of Recommendations and Level of Evidence</text>
<text top="751" left="64" width="735" height="8" font="18">A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials.</text>
<text top="763" left="64" width="530" height="8" font="18">Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.</text>
<text top="775" left="64" width="264" height="8" font="18">*Data available from clinical trials or registries about the usefulness/ef</text>
<text top="773" left="329" width="471" height="11" font="18">ﬁcacy in different subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial infarction, history of</text>
<text top="787" left="64" width="130" height="8" font="18">heart failure, and prior aspirin use.</text>
<text top="797" left="64" width="735" height="11" font="18"><a href="e57.full.html#122">y</a>For comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments</text>
<text top="811" left="64" width="111" height="8" font="18">or strategies being evaluated.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e61</text>
</page>
<page number="6" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="19" size="12" family="Times" color="#005c58"/>
<text top="103" left="64" width="350" height="15" font="5">and require approval by a consensus of the voting mem-</text>
<text top="121" left="64" width="82" height="15" font="5">bers. Authors</text>
<text top="117" left="147" width="267" height="19" font="5">’ and peer reviewers’ RWI pertinent to this</text>
<text top="139" left="64" width="154" height="15" font="5">guideline are disclosed in</text>
<text top="139" left="224" width="83" height="15" font="6"><a href="e57.full.html#122">Appendixes 1</a></text>
<text top="139" left="313" width="22" height="15" font="5">and</text>
<text top="139" left="340" width="7" height="15" font="6"><a href="e57.full.html#122">2</a></text>
<text top="139" left="348" width="66" height="15" font="5"><a href="e57.full.html#122">. </a>Members</text>
<text top="157" left="64" width="350" height="15" font="5">may not draft or vote on any recommendations pertaining</text>
<text top="175" left="64" width="350" height="15" font="5">to their RWI. Members who recused themselves from</text>
<text top="192" left="64" width="350" height="15" font="5">voting are indicated in the list of writing committee</text>
<text top="210" left="64" width="115" height="15" font="5">members with speci</text>
<text top="207" left="179" width="159" height="19" font="5">ﬁc section recusals noted in</text>
<text top="210" left="342" width="69" height="15" font="6"><a href="e57.full.html#122">Appendix 1</a></text>
<text top="210" left="410" width="4" height="15" font="5">.</text>
<text top="228" left="64" width="350" height="15" font="5">In addition, to ensure complete transparency, writing</text>
<text top="246" left="64" width="125" height="15" font="5">committee members</text>
<text top="243" left="189" width="225" height="19" font="5">’ comprehensive disclosure informa-</text>
<text top="264" left="64" width="350" height="16" font="5">tiondincluding RWI not pertinent to this documentdis</text>
<text top="282" left="64" width="84" height="15" font="5">available as an</text>
<text top="282" left="153" width="109" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">online supplement</a></text>
<text top="282" left="262" width="4" height="15" font="5"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">.</a></text>
<text top="300" left="79" width="335" height="15" font="5">Comprehensive disclosure information for the Task</text>
<text top="318" left="64" width="180" height="15" font="5">Force is also available online at</text>
<text top="318" left="249" width="165" height="15" font="6"><a href="http://www.cardiosource.org/en/ACC/About-ACC/Who-We-Are/Leadership/Guidelines-and-Documents-Task-Forces.aspx">http://www.cardiosource.org/</a></text>
<text top="336" left="64" width="349" height="15" font="6"><a href="http://www.cardiosource.org/en/ACC/About-ACC/Who-We-Are/Leadership/Guidelines-and-Documents-Task-Forces.aspx">en/ACC/About-ACC/Who-We-Are/Leadership/Guidelines</a></text>
<text top="354" left="64" width="201" height="15" font="6"><a href="http://www.cardiosource.org/en/ACC/About-ACC/Who-We-Are/Leadership/Guidelines-and-Documents-Task-Forces.aspx">-and-Documents-Task-Forces.aspx</a></text>
<text top="354" left="265" width="149" height="15" font="5"><a href="http://www.cardiosource.org/en/ACC/About-ACC/Who-We-Are/Leadership/Guidelines-and-Documents-Task-Forces.aspx">. </a>The ACC and AHA</text>
<text top="372" left="64" width="350" height="15" font="5">exclusively sponsor the work of the writing committee with-</text>
<text top="390" left="64" width="350" height="15" font="5">out commercial support. Writing committee members vol-</text>
<text top="408" left="64" width="324" height="15" font="5">unteered their time for this activity. Guidelines are of</text>
<text top="404" left="387" width="27" height="19" font="5">ﬁcial</text>
<text top="426" left="64" width="200" height="15" font="5">policy of both the ACC and AHA.</text>
<text top="444" left="79" width="335" height="15" font="5">In an effort to maintain relevance at the point of care for</text>
<text top="461" left="64" width="350" height="15" font="5">clinicians, the Task Force continues to oversee an ongoing</text>
<text top="479" left="64" width="350" height="15" font="5">process improvement initiative. As a result, several changes</text>
<text top="497" left="64" width="350" height="15" font="5">to these guidelines will be apparent, including limited</text>
<text top="515" left="64" width="350" height="15" font="5">narrative text, a focus on summary and evidence tables</text>
<text top="533" left="64" width="350" height="15" font="5">(with references linked to abstracts in PubMed), and more</text>
<text top="551" left="64" width="350" height="15" font="5">liberal use of summary recommendation tables (with ref-</text>
<text top="569" left="64" width="342" height="15" font="5">erences that support LOE) to serve as a quick reference.</text>
<text top="587" left="79" width="335" height="15" font="5">In April 2011, the Institute of Medicine released 2 re-</text>
<text top="605" left="64" width="350" height="15" font="5">ports: Finding What Works in Health Care: Standards for</text>
<text top="624" left="64" width="350" height="15" font="5">Systematic Reviews and Clinical Practice Guidelines We Can</text>
<text top="642" left="64" width="31" height="15" font="5">Trust</text>
<text top="641" left="100" width="28" height="15" font="6"><a href="e57.full.html#100">(2,3)</a></text>
<text top="641" left="128" width="286" height="15" font="5">. It is noteworthy that the Institute of Medicine</text>
<text top="659" left="64" width="350" height="15" font="5">cited ACC/AHA practice guidelines as being compliant</text>
<text top="677" left="64" width="350" height="15" font="5">with many of the proposed standards. A thorough review</text>
<text top="695" left="64" width="350" height="15" font="5">of these reports and of our current methodology is under</text>
<text top="713" left="64" width="268" height="15" font="5">way, with further enhancements anticipated.</text>
<text top="731" left="79" width="335" height="15" font="5">The recommendations in this guideline are considered</text>
<text top="748" left="64" width="350" height="15" font="5">current until they are superseded by a focused update,</text>
<text top="766" left="64" width="350" height="15" font="5">the full-text guideline is revised, or until a published</text>
<text top="784" left="64" width="322" height="15" font="5">addendum declares it out of date and no longer of</text>
<text top="781" left="386" width="28" height="19" font="5">ﬁcial</text>
<text top="802" left="64" width="117" height="15" font="5">ACC/AHA policy.</text>
<text top="821" left="181" width="233" height="15" font="5">Jeffrey L. Anderson, MD, FACC, FAHA</text>
<text top="839" left="115" width="299" height="15" font="5">Chair, ACC/AHA Task Force on Practice Guidelines</text>
<text top="878" left="64" width="118" height="14" font="17">1. Introduction</text>
<text top="923" left="64" width="268" height="12" font="19">1.1. Methodology and Evidence Review</text>
<text top="946" left="65" width="349" height="15" font="5">The recommendations listed in this document are,</text>
<text top="964" left="64" width="350" height="15" font="5">whenever possible, evidence based. An extensive review</text>
<text top="981" left="64" width="350" height="15" font="5">was conducted on literature published through November</text>
<text top="999" left="64" width="350" height="15" font="5">2012, and other selected references through October</text>
<text top="1017" left="64" width="350" height="15" font="5">2013 were reviewed by the guideline writing committee.</text>
<text top="1035" left="64" width="350" height="15" font="5">Searches were extended to studies, reviews, and other ev-</text>
<text top="1053" left="64" width="350" height="15" font="5">idence conducted on human subjects and that were pub-</text>
<text top="1071" left="64" width="350" height="15" font="5">lished in English from PubMed, EMBASE, Cochrane,</text>
<text top="1089" left="64" width="350" height="15" font="5">Agency for Healthcare Research and Quality Reports, and</text>
<text top="103" left="450" width="350" height="15" font="5">other selected databases relevant to this guideline. Key</text>
<text top="121" left="450" width="350" height="15" font="5">search words included but were not limited to the</text>
<text top="139" left="450" width="350" height="15" font="5">following: valvular heart disease, aortic stenosis, aortic</text>
<text top="157" left="450" width="350" height="15" font="5">regurgitation, bicuspid aortic valve, mitral stenosis, mitral</text>
<text top="175" left="450" width="350" height="15" font="5">regurgitation, tricuspid stenosis, tricuspid regurgitation, pul-</text>
<text top="193" left="450" width="350" height="15" font="5">monic stenosis, pulmonic regurgitation, prosthetic valves,</text>
<text top="211" left="450" width="350" height="15" font="5">anticoagulation therapy, infective endocarditis, cardiac surgery,</text>
<text top="228" left="450" width="350" height="15" font="5">and transcatheter aortic valve replacement. Additionally, the</text>
<text top="246" left="450" width="350" height="15" font="5">committee reviewed documents related to the subject</text>
<text top="264" left="450" width="350" height="15" font="5">matter previously published by the ACC and AHA. The</text>
<text top="282" left="450" width="350" height="15" font="5">references selected and published in this document are</text>
<text top="300" left="450" width="213" height="15" font="5">representative and not all-inclusive.</text>
<text top="331" left="450" width="295" height="12" font="19">1.2. Organization of the Writing Committee</text>
<text top="354" left="451" width="349" height="15" font="5">The committee was composed of clinicians, who included</text>
<text top="372" left="450" width="350" height="15" font="5">cardiologists, interventionalists, surgeons, and anesthesi-</text>
<text top="390" left="450" width="350" height="15" font="5">ologists. The committee also included representatives from</text>
<text top="408" left="450" width="350" height="15" font="5">the American Association for Thoracic Surgery, American</text>
<text top="426" left="450" width="350" height="15" font="5">Society of Echocardiography (ASE), Society for Cardio-</text>
<text top="443" left="450" width="350" height="15" font="5">vascular Angiography and Interventions, Society of Car-</text>
<text top="461" left="450" width="350" height="15" font="5">diovascular Anesthesiologists, and Society of Thoracic</text>
<text top="479" left="450" width="100" height="15" font="5">Surgeons (STS).</text>
<text top="510" left="450" width="247" height="12" font="19">1.3. Document Review and Approval</text>
<text top="533" left="451" width="228" height="15" font="5">This document was reviewed by 2 of</text>
<text top="530" left="679" width="120" height="19" font="5">ﬁcial reviewers each</text>
<text top="551" left="450" width="350" height="15" font="5">nominated by both the ACC and the AHA, as well as 1</text>
<text top="569" left="450" width="350" height="15" font="5">reviewer each from the American Association for Thoracic</text>
<text top="587" left="450" width="350" height="15" font="5">Surgery, ASE, Society for Cardiovascular Angiography</text>
<text top="605" left="450" width="350" height="15" font="5">and Interventions, Society of Cardiovascular Anesthesiol-</text>
<text top="623" left="450" width="350" height="15" font="5">ogists, and STS and 39 individual content reviewers</text>
<text top="641" left="450" width="350" height="15" font="5">(which included representatives from the following ACC</text>
<text top="659" left="450" width="350" height="15" font="5">committees and councils: Adult Congenital and Pediatric</text>
<text top="677" left="450" width="350" height="15" font="5">Cardiology Section, Association of International Gover-</text>
<text top="695" left="450" width="350" height="15" font="5">nors, Council on Clinical Practice, Cardiovascular Section</text>
<text top="712" left="450" width="350" height="15" font="5">Leadership Council, Geriatric Cardiology Section Lead-</text>
<text top="730" left="450" width="350" height="15" font="5">ership Council, Heart Failure and Transplant Council,</text>
<text top="748" left="450" width="350" height="15" font="5">Interventional Council, Lifelong Learning Oversight</text>
<text top="766" left="450" width="350" height="15" font="5">Committee, Prevention of Cardiovascular Disease Com-</text>
<text top="784" left="450" width="251" height="15" font="5">mittee, and Surgeon Council). Reviewers</text>
<text top="781" left="701" width="98" height="19" font="5">’ RWI informa-</text>
<text top="802" left="450" width="350" height="15" font="5">tion was distributed to the writing committee and is</text>
<text top="820" left="450" width="175" height="15" font="5">published in this document <a href="e57.full.html#122">(</a></text>
<text top="820" left="625" width="71" height="15" font="6"><a href="e57.full.html#122">Appendix 2</a></text>
<text top="820" left="696" width="9" height="15" font="5">).</text>
<text top="838" left="465" width="335" height="15" font="5">This document was approved for publication by the</text>
<text top="856" left="450" width="350" height="15" font="5">governing bodies of the ACC and AHA and endorsed by</text>
<text top="874" left="450" width="350" height="15" font="5">the American Association for Thoracic Surgery, ASE,</text>
<text top="892" left="450" width="350" height="15" font="5">Society for Cardiovascular Angiography and Interventions,</text>
<text top="910" left="450" width="327" height="15" font="5">Society of Cardiovascular Anesthesiologists, and STS.</text>
<text top="941" left="450" width="188" height="12" font="19">1.4. Scope of the Guideline</text>
<text top="964" left="451" width="349" height="15" font="5">The focus of this guideline is the diagnosis and manage-</text>
<text top="981" left="450" width="350" height="15" font="5">ment of adult patients with valvular heart disease (VHD).</text>
<text top="999" left="450" width="350" height="15" font="5">A full revision of the original 1998 VHD guideline was</text>
<text top="1017" left="450" width="287" height="15" font="5">made in 2006, and an update was made in 2008</text>
<text top="1017" left="741" width="17" height="15" font="6"><a href="e57.full.html#100">(4)</a></text>
<text top="1017" left="758" width="41" height="15" font="5"><a href="e57.full.html#100">. </a>Some</text>
<text top="1035" left="450" width="350" height="15" font="5">recommendations from the earlier VHD guidelines have</text>
<text top="1053" left="450" width="350" height="15" font="5">been updated as warranted by new evidence or a better</text>
<text top="1071" left="450" width="350" height="15" font="5">understanding of earlier evidence, whereas others that</text>
<text top="1089" left="450" width="350" height="15" font="5">were inaccurate, irrelevant, or overlapping were deleted</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e62</text>
</page>
<page number="7" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="51" height="15" font="5">or modi</text>
<text top="99" left="115" width="298" height="19" font="5">ﬁed. Throughout, our goal was to provide the</text>
<text top="121" left="64" width="350" height="15" font="5">clinician with concise, evidence-based, contemporary rec-</text>
<text top="139" left="64" width="350" height="15" font="5">ommendations and the supporting documentation to</text>
<text top="157" left="64" width="120" height="15" font="5">encourage their use.</text>
<text top="175" left="79" width="335" height="15" font="5">This guideline was created in a different format from</text>
<text top="192" left="64" width="350" height="15" font="5">prior VHD guidelines to facilitate access to concise, rele-</text>
<text top="210" left="64" width="350" height="15" font="5">vant bytes of information at the point of care when clinical</text>
<text top="228" left="64" width="350" height="15" font="5">knowledge is needed the most. Thus, each COR is fol-</text>
<text top="246" left="64" width="350" height="15" font="5">lowed by a brief paragraph of supporting text and refer-</text>
<text top="264" left="64" width="350" height="15" font="5">ences. Where applicable, sections were divided into</text>
<text top="282" left="64" width="350" height="15" font="5">subsections of 1) diagnosis and follow-up, 2) medical</text>
<text top="300" left="64" width="350" height="15" font="5">therapy, and 3) intervention. The purpose of these sub-</text>
<text top="318" left="64" width="350" height="15" font="5">sections was to categorize the COR according to the</text>
<text top="336" left="64" width="350" height="15" font="5">clinical decision-making pathways that caregivers use in</text>
<text top="354" left="64" width="350" height="15" font="5">the management of patients with VHD. New recom-</text>
<text top="372" left="64" width="350" height="15" font="5">mendations for assessment of the severity of valve lesions</text>
<text top="390" left="64" width="350" height="15" font="5">have been proposed, based on current natural history</text>
<text top="408" left="64" width="184" height="15" font="5">studies of patients with VHD.</text>
<text top="426" left="79" width="335" height="15" font="5">The present document applies to adult patients with</text>
<text top="444" left="64" width="350" height="15" font="5">VHD. Management of patients with congenital heart</text>
<text top="461" left="64" width="350" height="15" font="5">disease and infants and children with valve disease are not</text>
<text top="479" left="64" width="350" height="15" font="5">addressed here. The document recommends a combination</text>
<text top="497" left="64" width="100" height="15" font="5">of lifestyle modi</text>
<text top="494" left="164" width="250" height="19" font="5">ﬁcations and medications that constitute</text>
<text top="515" left="64" width="350" height="15" font="5">GDMT. Both for GDMT and other recommended drug</text>
<text top="533" left="64" width="293" height="15" font="5">treatment regimens, the reader is advised to con</text>
<text top="530" left="357" width="57" height="19" font="5">ﬁrm dos-</text>
<text top="551" left="64" width="350" height="15" font="5">ages with product insert material and to carefully evaluate</text>
<text top="569" left="64" width="184" height="15" font="5">for contraindications and drug</text>
<text top="566" left="249" width="113" height="19" font="5">–drug interactions.</text>
<text top="569" left="367" width="47" height="15" font="6"><a href="e57.full.html#7">Table 2</a></text>
<text top="587" left="64" width="350" height="15" font="5">is a list of associated guidelines that may be of interest</text>
<text top="605" left="64" width="350" height="15" font="5">to the reader. The table is intended for use as a resource</text>
<text top="623" left="64" width="350" height="15" font="5">and obviates the need to repeat extant guideline</text>
<text top="641" left="64" width="110" height="15" font="5">recommendations.</text>
<text top="680" left="64" width="166" height="14" font="17">2. General Principles</text>
<text top="726" left="64" width="238" height="12" font="19">2.1. Evaluation of the Patient With</text>
<text top="743" left="64" width="105" height="12" font="19">Suspected VHD</text>
<text top="766" left="65" width="349" height="15" font="5">Patients with VHD may present with a heart murmur,</text>
<text top="784" left="64" width="145" height="15" font="5">symptoms, or incidental</text>
<text top="781" left="214" width="200" height="19" font="5">ﬁndings of valvular abnormalities</text>
<text top="802" left="64" width="350" height="15" font="5">on chest imaging or noninvasive testing. Irrespective of the</text>
<text top="820" left="64" width="350" height="15" font="5">presentation, all patients with known or suspected VHD</text>
<text top="838" left="64" width="350" height="15" font="5">should undergo an initial meticulous history and physical</text>
<text top="856" left="64" width="350" height="15" font="5">examination. A careful history is of great importance in the</text>
<text top="874" left="64" width="350" height="15" font="5">evaluation of patients with VHD, because decisions about</text>
<text top="892" left="64" width="350" height="15" font="5">treatment are based on the presence or absence of symp-</text>
<text top="910" left="64" width="350" height="15" font="5">toms. Due to the slow, progressive nature of many valve</text>
<text top="928" left="64" width="350" height="15" font="5">lesions, patients may not recognize symptoms because they</text>
<text top="946" left="64" width="350" height="15" font="5">may have gradually limited their daily activity levels. A</text>
<text top="964" left="64" width="350" height="15" font="5">detailed physical examination should be performed to di-</text>
<text top="981" left="64" width="350" height="15" font="5">agnose and assess the severity of valve lesions based on a</text>
<text top="999" left="64" width="106" height="15" font="5">compilation of all</text>
<text top="996" left="176" width="238" height="19" font="5">ﬁndings made by inspection, palpation,</text>
<text top="1017" left="64" width="350" height="15" font="5">and auscultation. The use of an electrocardiogram (ECG)</text>
<text top="1035" left="64" width="38" height="15" font="5">to con</text>
<text top="1032" left="102" width="312" height="19" font="5">ﬁrm heart rhythm and use of a chest x-ray to assess</text>
<text top="1053" left="64" width="350" height="15" font="5">the presence or absence of pulmonary congestion and</text>
<text top="1071" left="64" width="350" height="15" font="5">other lung pathology may be helpful in the initial assess-</text>
<text top="1089" left="64" width="350" height="15" font="5">ment of patients with known or suspected VHD. A</text>
<text top="659" left="450" width="350" height="15" font="5">comprehensive transthoracic echocardiogram (TTE) with</text>
<text top="677" left="450" width="7" height="15" font="5">2</text>
<text top="673" left="457" width="342" height="19" font="5">–dimensional (2D) imaging and Doppler interrogation</text>
<text top="695" left="450" width="227" height="15" font="5">should then be performed to correlate</text>
<text top="691" left="681" width="118" height="19" font="5">ﬁndings with initial</text>
<text top="713" left="450" width="350" height="15" font="5">impressions based on the initial clinical evaluation. The</text>
<text top="730" left="450" width="350" height="15" font="5">TTE will also be able to provide additional information,</text>
<text top="748" left="450" width="350" height="15" font="5">such as the effect of the valve lesion on the cardiac</text>
<text top="766" left="450" width="350" height="15" font="5">chambers and great vessels, and to assess for other</text>
<text top="784" left="450" width="350" height="15" font="5">concomitant valve lesions. Other ancillary testing such as</text>
<text top="802" left="450" width="350" height="15" font="5">transesophageal echocardiography (TEE), computed to-</text>
<text top="820" left="450" width="350" height="15" font="5">mography (CT) or cardiac magnetic resonance (CMR)</text>
<text top="838" left="450" width="350" height="15" font="5">imaging, stress testing, and diagnostic hemodynamic car-</text>
<text top="856" left="450" width="350" height="15" font="5">diac catheterization may be required to determine the</text>
<text top="874" left="450" width="350" height="15" font="5">optimal treatment for a patient with VHD. An evaluation</text>
<text top="892" left="450" width="350" height="15" font="5">of the possible surgical risk for each individual patient</text>
<text top="910" left="450" width="350" height="15" font="5">should be performed if intervention is contemplated, as</text>
<text top="928" left="450" width="350" height="15" font="5">well as other contributing factors such as the presence and</text>
<text top="946" left="450" width="350" height="15" font="5">extent of comorbidities and frailty. Follow-up of these</text>
<text top="964" left="450" width="350" height="15" font="5">patients is important and should consist of an annual</text>
<text top="982" left="450" width="350" height="15" font="5">history and physical examination in most stable patients.</text>
<text top="1000" left="450" width="350" height="15" font="5">An evaluation of the patient may be necessary sooner than</text>
<text top="1017" left="450" width="254" height="15" font="5">annually if there is a change in the patient</text>
<text top="1014" left="704" width="95" height="19" font="5">’s symptoms. In</text>
<text top="1035" left="450" width="350" height="15" font="5">some valve lesions, there may be unpredictable adverse</text>
<text top="1053" left="450" width="350" height="15" font="5">consequences on the left ventricle in the absence of</text>
<text top="1071" left="450" width="350" height="15" font="5">symptoms necessitating more frequent follow-up. The</text>
<text top="1089" left="450" width="350" height="15" font="5">frequency of repeat testing, such as echocardiography, will</text>
<text top="103" left="450" width="272" height="11" font="13">Table 2. Associated Guidelines and Statements</text>
<text top="141" left="450" width="20" height="9" font="7">Title</text>
<text top="141" left="654" width="58" height="9" font="7">Organization</text>
<text top="129" left="720" width="82" height="9" font="7">Publication Year/</text>
<text top="141" left="738" width="47" height="9" font="7">Reference</text>
<text top="159" left="450" width="179" height="9" font="7">Recommendations for Evaluation of the</text>
<text top="173" left="462" width="181" height="9" font="7">Severity of Native Valvular Regurgitation</text>
<text top="188" left="462" width="158" height="9" font="7">With Two-Dimensional and Doppler</text>
<text top="202" left="462" width="79" height="9" font="7">Echocardiography</text>
<text top="159" left="649" width="18" height="9" font="7">ASE</text>
<text top="159" left="741" width="24" height="9" font="7">2003</text>
<text top="159" left="769" width="12" height="9" font="8"><a href="e57.full.html#100">(5)</a></text>
<text top="219" left="450" width="155" height="9" font="7">Guidelines for the Management of</text>
<text top="233" left="462" width="169" height="9" font="7">Adults With Congenital Heart Disease</text>
<text top="219" left="649" width="42" height="9" font="7">ACC/AHA</text>
<text top="219" left="741" width="24" height="9" font="7">2008</text>
<text top="219" left="769" width="12" height="9" font="8"><a href="e57.full.html#100">(7)</a></text>
<text top="250" left="450" width="178" height="9" font="7">Echocardiographic Assessment of Valve</text>
<text top="264" left="462" width="171" height="9" font="7">Stenosis: EAE/ASE Recommendations</text>
<text top="278" left="462" width="87" height="9" font="7">for Clinical Practice</text>
<text top="250" left="649" width="40" height="9" font="7">EAE/ASE</text>
<text top="250" left="741" width="24" height="9" font="7">2009</text>
<text top="250" left="769" width="12" height="9" font="8"><a href="e57.full.html#100">(8)</a></text>
<text top="295" left="450" width="162" height="9" font="7">Recommendations for Evaluation of</text>
<text top="309" left="462" width="183" height="9" font="7">Prosthetic Valves With Echocardiography</text>
<text top="323" left="462" width="106" height="9" font="7">and Doppler Ultrasound</text>
<text top="295" left="649" width="18" height="9" font="7">ASE</text>
<text top="295" left="741" width="24" height="9" font="7">2009</text>
<text top="295" left="769" width="12" height="9" font="8"><a href="e57.full.html#100">(9)</a></text>
<text top="340" left="450" width="191" height="9" font="7">Guideline for the Diagnosis and Treatment</text>
<text top="354" left="462" width="144" height="9" font="7">of Hypertrophic Cardiomyopathy</text>
<text top="340" left="649" width="47" height="9" font="7">ACCF/AHA</text>
<text top="340" left="738" width="24" height="9" font="7">2011</text>
<text top="340" left="766" width="19" height="9" font="8"><a href="e57.full.html#100">(10)</a></text>
<text top="371" left="450" width="154" height="9" font="7">Guidelines on the Management of</text>
<text top="386" left="462" width="141" height="9" font="7">Cardiovascular Diseases During</text>
<text top="400" left="462" width="46" height="9" font="7">Pregnancy</text>
<text top="371" left="649" width="17" height="9" font="7">ESC</text>
<text top="371" left="738" width="24" height="9" font="7">2011</text>
<text top="371" left="766" width="19" height="9" font="8"><a href="e57.full.html#100">(11)</a></text>
<text top="417" left="450" width="186" height="9" font="7">Antithrombotic and Thrombolytic Therapy</text>
<text top="431" left="462" width="161" height="9" font="7">for Valvular Disease: Antithrombotic</text>
<text top="445" left="462" width="173" height="9" font="7">Therapy and Prevention of Thrombosis</text>
<text top="417" left="649" width="24" height="9" font="7">ACCP</text>
<text top="417" left="738" width="24" height="9" font="7">2012</text>
<text top="417" left="766" width="19" height="9" font="8"><a href="e57.full.html#100">(12)</a></text>
<text top="462" left="450" width="192" height="9" font="7">Guidelines on the Management of Valvular</text>
<text top="476" left="462" width="63" height="9" font="7">Heart Disease</text>
<text top="462" left="649" width="51" height="9" font="7">ESC/EACTS</text>
<text top="462" left="738" width="24" height="9" font="7">2012</text>
<text top="462" left="766" width="19" height="9" font="8"><a href="e57.full.html#100">(13)</a></text>
<text top="493" left="450" width="150" height="9" font="7">Guideline for the Management of</text>
<text top="507" left="462" width="58" height="9" font="7">Heart Failure</text>
<text top="493" left="649" width="47" height="9" font="7">ACCF/AHA</text>
<text top="493" left="738" width="24" height="9" font="7">2013</text>
<text top="493" left="766" width="19" height="9" font="8"><a href="e57.full.html#100">(14)</a></text>
<text top="524" left="450" width="150" height="9" font="7">Guideline for the Management of</text>
<text top="538" left="462" width="138" height="9" font="7">Patients With Atrial Fibrillation</text>
<text top="524" left="649" width="66" height="9" font="7">AHA/ACC/HRS</text>
<text top="524" left="738" width="24" height="9" font="7">2014</text>
<text top="524" left="766" width="19" height="9" font="8"><a href="e57.full.html#100">(15)</a></text>
<text top="558" left="457" width="342" height="8" font="18">ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foun-</text>
<text top="570" left="457" width="240" height="8" font="18">dation; ACCP, American College of Chest Physicians; AF, atrial</text>
<text top="568" left="701" width="98" height="11" font="18">ﬁbrillation; AHA, American</text>
<text top="582" left="457" width="342" height="8" font="18">Heart Association; ASE, American Society of Echocardiography; EACTS, European Association</text>
<text top="594" left="457" width="342" height="8" font="18">for Cardio-Thoracic Surgery; EAE, European Association of Echocardiography; ESC, European</text>
<text top="606" left="457" width="205" height="8" font="18">Society of Cardiology; and VHD, valvular heart disease.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e63</text>
</page>
<page number="8" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="20" size="7" family="Times" color="#a70c2f"/>
	<fontspec id="21" size="9" family="Times" color="#005c58"/>
	<fontspec id="22" size="9" family="Times" color="#327eb1"/>
<text top="103" left="64" width="350" height="15" font="5">be dependent on the severity of the valve lesion and its</text>
<text top="121" left="64" width="350" height="15" font="5">effect on the left or right ventricle, coupled with the</text>
<text top="139" left="64" width="252" height="15" font="5">known natural history of the valve lesion.</text>
<text top="188" left="64" width="50" height="12" font="19">2.2. De</text>
<text top="184" left="115" width="254" height="18" font="19">ﬁnitions of Severity of Valve Disease</text>
<text top="210" left="65" width="36" height="15" font="5">Classi</text>
<text top="207" left="101" width="313" height="19" font="5">ﬁcation of the severity of valve lesions should be</text>
<text top="228" left="64" width="277" height="15" font="5">based on multiple criteria, including the initial</text>
<text top="225" left="346" width="68" height="19" font="5">ﬁndings on</text>
<text top="246" left="64" width="350" height="15" font="5">the physical examination, which should then be correlated</text>
<text top="264" left="64" width="350" height="15" font="5">with data from a comprehensive TTE. Intervention should</text>
<text top="282" left="64" width="350" height="15" font="5">primarily be performed on patients with severe VHD in</text>
<text top="300" left="64" width="314" height="15" font="5">addition to other criteria outlined in this document.</text>
<text top="318" left="79" width="194" height="15" font="5">This document provides a classi</text>
<text top="315" left="274" width="140" height="19" font="5">ﬁcation of the progres-</text>
<text top="336" left="64" width="350" height="15" font="5">sion of VHD with 4 stages (A to D) similar to that pro-</text>
<text top="354" left="64" width="87" height="15" font="5">posed by the</text>
<text top="350" left="161" width="252" height="19" font="5">“2013 ACCF/AHA Guideline for the</text>
<text top="372" left="64" width="183" height="15" font="5">Management of Heart Failure.</text>
<text top="368" left="247" width="167" height="19" font="5">” Indication for intervention</text>
<text top="390" left="64" width="350" height="15" font="5">in patients with VHD is dependent on 1) the presence or</text>
<text top="408" left="64" width="350" height="15" font="5">absence of symptoms; 2) the severity of VHD; 3) the</text>
<text top="426" left="64" width="350" height="15" font="5">response of the left and/or right ventricle to the volume or</text>
<text top="444" left="64" width="350" height="15" font="5">pressure overload caused by VHD; 4) the effect on the</text>
<text top="461" left="64" width="350" height="15" font="5">pulmonary or systemic circulation; and 5) a change in heart</text>
<text top="479" left="64" width="350" height="15" font="5">rhythm. The stages take into consideration all of these</text>
<text top="497" left="64" width="118" height="15" font="5">important factors (</text>
<text top="497" left="183" width="49" height="15" font="6"><a href="e57.full.html#8">Table 3</a></text>
<text top="497" left="232" width="182" height="15" font="5"><a href="e57.full.html#8">). </a>The criteria for the stages</text>
<text top="515" left="64" width="281" height="15" font="5">of each individual valve lesion are listed in</text>
<text top="515" left="354" width="60" height="15" font="6"><a href="e57.full.html#15">Section 3</a></text>
<text top="533" left="64" width="5" height="15" font="5"><a href="e57.full.html#16">(</a></text>
<text top="533" left="69" width="47" height="15" font="6"><a href="e57.full.html#16">Table 8</a></text>
<text top="533" left="116" width="9" height="15" font="5"><a href="e57.full.html#16">),</a></text>
<text top="533" left="129" width="68" height="15" font="6"><a href="e57.full.html#15">Section 4.2</a></text>
<text top="533" left="202" width="5" height="15" font="5"><a href="e57.full.html#26">(</a></text>
<text top="533" left="207" width="54" height="15" font="6"><a href="e57.full.html#26">Table 11</a></text>
<text top="533" left="261" width="9" height="15" font="5">),</text>
<text top="533" left="274" width="68" height="15" font="6"><a href="e57.full.html#32">Section 6.1</a></text>
<text top="533" left="347" width="5" height="15" font="5"><a href="e57.full.html#35">(</a></text>
<text top="533" left="351" width="54" height="15" font="6"><a href="e57.full.html#35">Table 13</a></text>
<text top="533" left="405" width="9" height="15" font="5">),</text>
<text top="551" left="64" width="66" height="15" font="6"><a href="e57.full.html#42">Section 7.2</a></text>
<text top="551" left="134" width="5" height="15" font="5">(</text>
<text top="551" left="139" width="58" height="15" font="6"><a href="e57.full.html#43">Tables 15</a></text>
<text top="551" left="200" width="22" height="15" font="5">and</text>
<text top="551" left="226" width="15" height="15" font="6"><a href="e57.full.html#44">16</a></text>
<text top="551" left="241" width="34" height="15" font="5"><a href="e57.full.html#44">), </a>and</text>
<text top="551" left="278" width="66" height="15" font="6"><a href="e57.full.html#51">Section 8.1</a></text>
<text top="551" left="348" width="5" height="15" font="5">(</text>
<text top="551" left="353" width="53" height="15" font="6"><a href="e57.full.html#53">Table 19</a></text>
<text top="551" left="405" width="9" height="15" font="5">),</text>
<text top="569" left="64" width="64" height="15" font="6"><a href="e57.full.html#57">Section 8.3</a></text>
<text top="569" left="130" width="5" height="15" font="5">(</text>
<text top="569" left="135" width="50" height="15" font="6"><a href="e57.full.html#57">Table 20</a></text>
<text top="569" left="185" width="8" height="15" font="5"><a href="e57.full.html#57">),</a></text>
<text top="569" left="195" width="64" height="15" font="6"><a href="e57.full.html#58">Section 9.1</a></text>
<text top="569" left="261" width="5" height="15" font="5"><a href="e57.full.html#58">(</a></text>
<text top="569" left="266" width="50" height="15" font="6"><a href="e57.full.html#58">Table 21</a></text>
<text top="569" left="316" width="32" height="15" font="5"><a href="e57.full.html#58">), </a>and</text>
<text top="569" left="350" width="64" height="15" font="6"><a href="e57.full.html#58">Section 9.2</a></text>
<text top="587" left="64" width="5" height="15" font="5"><a href="e57.full.html#58">(</a></text>
<text top="587" left="69" width="52" height="15" font="6"><a href="e57.full.html#58">Table 22</a></text>
<text top="587" left="120" width="8" height="15" font="5">).</text>
<text top="605" left="79" width="335" height="15" font="5">The purpose of valvular intervention is to improve</text>
<text top="623" left="64" width="350" height="15" font="5">symptoms and/or prolong survival, as well as to minimize</text>
<text top="641" left="64" width="350" height="15" font="5">the risk of VHD-related complications such as asymp-</text>
<text top="659" left="64" width="350" height="15" font="5">tomatic irreversible ventricular dysfunction, pulmonary</text>
<text top="677" left="64" width="184" height="15" font="5">hypertension, stroke, and atrial</text>
<text top="673" left="252" width="161" height="19" font="5">ﬁbrillation (AF). Thus, the</text>
<text top="695" left="64" width="63" height="15" font="5">criteria for</text>
<text top="691" left="133" width="281" height="19" font="5">“severe” VHD are based on studies describing</text>
<text top="713" left="64" width="350" height="15" font="5">the natural history of patients with unoperated VHD, as</text>
<text top="731" left="64" width="350" height="15" font="5">well as observational studies relating the onset of symptoms</text>
<text top="748" left="64" width="350" height="15" font="5">to measurements of severity. In patients with stenotic le-</text>
<text top="766" left="64" width="241" height="15" font="5">sions, there is an additional category of</text>
<text top="763" left="311" width="103" height="19" font="5">“very severe” ste-</text>
<text top="784" left="64" width="350" height="15" font="5">nosis based on studies of the natural history showing that</text>
<text top="802" left="64" width="350" height="15" font="5">prognosis becomes poorer as the severity of stenosis</text>
<text top="820" left="64" width="56" height="15" font="5">increases.</text>
<text top="839" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="838" left="212" width="25" height="15" font="6"><a href="e57.full.html#100">(14)</a></text>
<text top="838" left="237" width="4" height="15" font="5"><a href="e57.full.html#100">.</a></text>
<text top="887" left="64" width="196" height="12" font="19">2.3. Diagnosis and Follow-Up</text>
<text top="910" left="65" width="349" height="15" font="5">Diagnostic testing is very important for the diagnosis and</text>
<text top="928" left="64" width="350" height="15" font="5">treatment of patients with VHD. TTE provides</text>
<text top="946" left="64" width="350" height="15" font="5">morphological and hemodynamic information for diag-</text>
<text top="964" left="64" width="350" height="15" font="5">nosis and quantitation of VHD, as well as for determining</text>
<text top="981" left="64" width="350" height="15" font="5">optimal timing for intervention. In selected patients,</text>
<text top="999" left="64" width="350" height="15" font="5">additional testing such as stress testing, TEE, cardiac</text>
<text top="1017" left="64" width="350" height="15" font="5">catheterization, and CT or CMR imaging might be</text>
<text top="1035" left="64" width="349" height="15" font="5">indicated. However, both the performance and interpre-</text>
<text top="1053" left="64" width="349" height="15" font="5">tation of these diagnostic tests require meticulous attention</text>
<text top="1071" left="64" width="350" height="15" font="5">to detail as well as expertise in cardiac imaging and eval-</text>
<text top="1089" left="64" width="152" height="15" font="5">uation of hemodynamics.</text>
<text top="419" left="450" width="164" height="15" font="5">2.3.1. Diagnostic Testing</text>
<text top="415" left="614" width="118" height="19" font="5">–Initial Diagnosis:</text>
<text top="437" left="450" width="112" height="15" font="5">Recommendation</text>
<text top="464" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="479" left="449" width="350" height="10" font="21">1. TTE is recommended in the initial evaluation of patients with</text>
<text top="495" left="467" width="178" height="10" font="21">known or suspected VHD to con</text>
<text top="492" left="645" width="154" height="16" font="21">ﬁrm the diagnosis, establish</text>
<text top="512" left="467" width="332" height="10" font="21">etiology, determine severity, assess hemodynamic conse-</text>
<text top="528" left="467" width="332" height="10" font="21">quences, determine prognosis, and evaluate for timing of</text>
<text top="545" left="467" width="63" height="10" font="21">intervention</text>
<text top="545" left="534" width="19" height="10" font="22"><a href="e57.full.html#100">(17</a></text>
<text top="542" left="553" width="25" height="16" font="22"><a href="e57.full.html#100">–32)</a></text>
<text top="545" left="577" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="569" left="465" width="335" height="15" font="5">TTE is now the standard diagnostic test in the initial</text>
<text top="587" left="450" width="350" height="15" font="5">evaluation of patients with known or suspected VHD.</text>
<text top="605" left="450" width="350" height="15" font="5">Echocardiographic imaging can accurately assess the</text>
<text top="623" left="450" width="350" height="15" font="5">morphology and motion of valves and can usually deter-</text>
<text top="641" left="450" width="350" height="15" font="5">mine the etiology of the VHD. TTE can also assess for</text>
<text top="659" left="450" width="350" height="15" font="5">concomitant disease in other valves and associated abnor-</text>
<text top="677" left="450" width="350" height="15" font="5">malities such as aortic dilation. Left ventricular (LV)</text>
<text top="695" left="450" width="350" height="15" font="5">chamber size and function can be reliably assessed. It is the</text>
<text top="712" left="450" width="350" height="15" font="5">LV linear dimensions from echocardiography, either from</text>
<text top="730" left="450" width="350" height="15" font="5">2D images or 2D-directed M-mode, that have been used</text>
<text top="748" left="450" width="350" height="15" font="5">in studies to determine timing of valve operation. Until</text>
<text top="766" left="450" width="350" height="15" font="5">further studies are available using LV volumes, the rec-</text>
<text top="784" left="450" width="350" height="15" font="5">ommendations in this guideline will refer to LV di-</text>
<text top="802" left="450" width="350" height="15" font="5">mensions. It is also important to understand the variability</text>
<text top="820" left="450" width="350" height="15" font="5">in measurements of LV dimensions so that decisions on</text>
<text top="838" left="450" width="350" height="15" font="5">intervention are based on sequential studies rather than a</text>
<text top="856" left="450" width="350" height="15" font="5">single study, especially in asymptomatic patients. A semi-</text>
<text top="874" left="450" width="350" height="15" font="5">quantitative assessment of right ventricular (RV) size and</text>
<text top="892" left="450" width="350" height="15" font="5">function is usually made by a visual subjective analysis.</text>
<text top="910" left="450" width="350" height="15" font="5">Doppler TTE is used for noninvasive determination of</text>
<text top="928" left="450" width="350" height="15" font="5">valve hemodynamics. In stenotic lesions, measurements of</text>
<text top="946" left="450" width="350" height="15" font="5">the peak velocity, as well as calculation of valve gradients</text>
<text top="964" left="450" width="350" height="15" font="5">and valve area, characterize the severity of the lesion. He-</text>
<text top="982" left="450" width="350" height="15" font="5">modynamic measurements can be performed at rest and</text>
<text top="999" left="450" width="350" height="15" font="5">during provocation. The quantitation of the severity of</text>
<text top="1017" left="450" width="350" height="15" font="5">valve regurgitation is based on multiple hemodynamic</text>
<text top="1035" left="450" width="350" height="15" font="5">parameters using color Doppler imaging of jet geometry,</text>
<text top="1053" left="450" width="350" height="15" font="5">continuous wave Doppler recordings of the regurgitant</text>
<text top="1068" left="450" width="350" height="19" font="5">ﬂow, and pulsed wave Doppler measures of transvalvular</text>
<text top="1089" left="450" width="43" height="15" font="5">volume</text>
<text top="1086" left="498" width="302" height="19" font="5">ﬂow rates and ﬂow reversals in the atria and great</text>
<text top="103" left="450" width="220" height="11" font="13">Table 3. Stages of Progression of VHD</text>
<text top="129" left="450" width="27" height="9" font="7">Stage</text>
<text top="129" left="507" width="12" height="9" font="7">De</text>
<text top="126" left="519" width="32" height="14" font="7">ﬁnition</text>
<text top="129" left="664" width="53" height="9" font="7">Description</text>
<text top="146" left="450" width="7" height="9" font="7">A</text>
<text top="146" left="482" width="31" height="9" font="7">At risk</text>
<text top="146" left="581" width="189" height="9" font="7">Patients with risk factors for development</text>
<text top="161" left="594" width="31" height="9" font="7">of VHD</text>
<text top="177" left="450" width="7" height="9" font="7">B</text>
<text top="177" left="482" width="54" height="9" font="7">Progressive</text>
<text top="177" left="581" width="218" height="9" font="7">Patients with progressive VHD (mild-to-moderate</text>
<text top="192" left="594" width="124" height="9" font="7">severity and asymptomatic)</text>
<text top="208" left="450" width="7" height="9" font="7">C</text>
<text top="208" left="482" width="67" height="9" font="7">Asymptomatic</text>
<text top="223" left="494" width="30" height="9" font="7">severe</text>
<text top="209" left="581" width="218" height="9" font="7">Asymptomatic patients who have the criteria for</text>
<text top="223" left="594" width="54" height="9" font="7">severe VHD:</text>
<text top="240" left="581" width="198" height="9" font="7">C1: Asymptomatic patients with severe VHD</text>
<text top="254" left="594" width="191" height="9" font="7">in whom the left or right ventricle remains</text>
<text top="268" left="594" width="60" height="9" font="7">compensated</text>
<text top="285" left="581" width="198" height="9" font="7">C2: Asymptomatic patients with severe VHD</text>
<text top="299" left="594" width="180" height="9" font="7">with decompensation of the left or right</text>
<text top="313" left="594" width="37" height="9" font="7">ventricle</text>
<text top="330" left="450" width="7" height="9" font="7">D</text>
<text top="330" left="482" width="304" height="9" font="7">Symptomatic severe Patients who have developed symptoms as a</text>
<text top="344" left="594" width="59" height="9" font="7">result of VHD</text>
<text top="364" left="457" width="139" height="8" font="18">VHD indicates valvular heart disease.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e64</text>
</page>
<page number="9" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">vessels. The hemodynamic effect of valve lesions on the</text>
<text top="121" left="64" width="350" height="15" font="5">pulmonary circulation can be determined using tricuspid</text>
<text top="139" left="64" width="350" height="15" font="5">regurgitation (TR) velocity to provide a noninvasive mea-</text>
<text top="157" left="64" width="350" height="15" font="5">surement of RV systolic pressure. TTE quantitation of</text>
<text top="175" left="64" width="350" height="15" font="5">valve stenosis and valve regurgitation has been validated</text>
<text top="192" left="64" width="350" height="15" font="5">against catheterization data, in animal models with direct</text>
<text top="210" left="64" width="350" height="15" font="5">measures of disease severity, and in prospective clinical</text>
<text top="228" left="64" width="350" height="15" font="5">studies using valve replacement and mortality as the pri-</text>
<text top="246" left="64" width="350" height="15" font="5">mary endpoint. On the basis of their value in predicting</text>
<text top="264" left="64" width="350" height="15" font="5">clinical outcomes, these echocardiographic parameters are</text>
<text top="282" left="64" width="350" height="15" font="5">now used to determine timing of valve intervention in</text>
<text top="300" left="64" width="205" height="15" font="5">conjunction with symptom status.</text>
<text top="319" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="318" left="212" width="20" height="15" font="6"><a href="e57.full.html#100">(17</a></text>
<text top="315" left="232" width="27" height="19" font="6"><a href="e57.full.html#100">–32)</a></text>
<text top="345" left="64" width="350" height="16" font="5">2.3.2. Diagnostic TestingdChanging Signs or Symptoms:</text>
<text top="363" left="64" width="107" height="15" font="5">Recommendation</text>
<text top="390" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="405" left="64" width="350" height="10" font="21">1. TTE is recommended in patients with known VHD with any</text>
<text top="421" left="82" width="237" height="10" font="21">change in symptoms or physical examination</text>
<text top="418" left="322" width="92" height="16" font="21">ﬁndings. (Level of</text>
<text top="438" left="82" width="65" height="12" font="21">Evidence: C)</text>
<text top="462" left="79" width="335" height="15" font="5">Patients with VHD should be instructed to always</text>
<text top="480" left="64" width="350" height="15" font="5">report any change in symptomatic status. Patients with</text>
<text top="498" left="64" width="350" height="15" font="5">known VHD who have a change in symptoms should</text>
<text top="516" left="64" width="349" height="15" font="5">undergo a repeat comprehensive TTE study to determine</text>
<text top="534" left="64" width="350" height="15" font="5">whether the etiology of the symptoms is due to a pro-</text>
<text top="552" left="64" width="350" height="15" font="5">gression in the valve lesion, deterioration of the ventricular</text>
<text top="570" left="64" width="350" height="15" font="5">response to the volume or pressure overload, or another</text>
<text top="588" left="64" width="350" height="15" font="5">etiology. New signs on physical examination also warrant a</text>
<text top="606" left="64" width="107" height="15" font="5">repeat TTE. The</text>
<text top="602" left="177" width="236" height="19" font="5">ﬁndings on TTE will be important in</text>
<text top="624" left="64" width="239" height="15" font="5">determining the timing of intervention.</text>
<text top="642" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="642" left="212" width="20" height="15" font="6"><a href="e57.full.html#101">(33</a></text>
<text top="638" left="232" width="27" height="19" font="6"><a href="e57.full.html#101">–40)</a></text>
<text top="668" left="64" width="307" height="16" font="5">2.3.3. Diagnostic TestingdRoutine Follow-Up:</text>
<text top="686" left="64" width="111" height="15" font="5">Recommendation</text>
<text top="714" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="728" left="64" width="350" height="10" font="21">1. Periodic monitoring with TTE is recommended in asymptom-</text>
<text top="745" left="82" width="332" height="10" font="21">atic patients with known VHD at intervals depending on valve</text>
<text top="761" left="82" width="332" height="10" font="21">lesion, severity, ventricular size, and ventricular function.</text>
<text top="778" left="82" width="116" height="12" font="21">(Level of Evidence: C)</text>
<text top="802" left="79" width="335" height="15" font="5">After initial evaluation of an asymptomatic patient with</text>
<text top="820" left="64" width="350" height="15" font="5">VHD, the clinician may decide to continue close follow-</text>
<text top="838" left="64" width="350" height="15" font="5">up. The purpose of close follow-up is to prevent the irre-</text>
<text top="856" left="64" width="350" height="15" font="5">versible consequences of severe VHD that primarily affect</text>
<text top="874" left="64" width="350" height="15" font="5">the status of the ventricles and pulmonary circulation and</text>
<text top="892" left="64" width="350" height="15" font="5">may also occur in the absence of symptoms. At a mini-</text>
<text top="910" left="64" width="350" height="15" font="5">mum, the follow-up should consist of a yearly history</text>
<text top="928" left="64" width="350" height="15" font="5">and physical examination. Periodic TTE monitoring also</text>
<text top="946" left="64" width="350" height="15" font="5">provides important prognostic information. The frequency</text>
<text top="964" left="64" width="350" height="15" font="5">of a repeat 2D and Doppler echocardiogram is based on</text>
<text top="981" left="64" width="350" height="15" font="5">the type and severity of the valve lesion, the known rate</text>
<text top="999" left="64" width="157" height="15" font="5">of progression of the speci</text>
<text top="996" left="222" width="192" height="19" font="5">ﬁc valve lesion, and the effect of</text>
<text top="1017" left="64" width="260" height="15" font="5">the valve lesion on the affected ventricle <a href="e57.full.html#10">(</a></text>
<text top="1017" left="324" width="48" height="15" font="6"><a href="e57.full.html#10">Table 4</a></text>
<text top="1017" left="372" width="42" height="15" font="5"><a href="e57.full.html#10">). </a>This</text>
<text top="1035" left="64" width="350" height="15" font="5">table does not refer to patients with stage D VHD, who</text>
<text top="1053" left="64" width="350" height="15" font="5">will usually undergo intervention, as will other select</text>
<text top="1071" left="64" width="242" height="15" font="5">patient populations with stage C VHD.</text>
<text top="1090" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="1089" left="212" width="57" height="15" font="6"><a href="e57.full.html#101">(22,29,32</a></text>
<text top="1086" left="269" width="68" height="19" font="6"><a href="e57.full.html#101">–35,37–41)</a></text>
<text top="103" left="450" width="335" height="16" font="5">2.3.4. Diagnostic TestingdCardiac Catheterization:</text>
<text top="121" left="450" width="112" height="15" font="5">Recommendation</text>
<text top="148" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="163" left="449" width="350" height="10" font="21">1. Cardiac catheterization for hemodynamic assessment is rec-</text>
<text top="179" left="467" width="332" height="10" font="21">ommended in symptomatic patients when noninvasive tests are</text>
<text top="196" left="467" width="306" height="10" font="21">inconclusive or when there is a discrepancy between the</text>
<text top="193" left="777" width="22" height="16" font="21">ﬁnd-</text>
<text top="212" left="467" width="332" height="10" font="21">ings on noninvasive testing and physical examination regarding</text>
<text top="229" left="467" width="262" height="12" font="21">severity of the valve lesion. (Level of Evidence: C)</text>
<text top="253" left="465" width="335" height="15" font="5">Although TTE (and in some instances TEE) is now</text>
<text top="271" left="450" width="350" height="15" font="5">able to provide the required anatomic and hemodynamic</text>
<text top="289" left="450" width="350" height="15" font="5">information in most patients with VHD, there is still a</text>
<text top="307" left="450" width="350" height="15" font="5">subset of patients in whom hemodynamic catheterization is</text>
<text top="325" left="450" width="350" height="15" font="5">necessary to ensure that the proper decision about treat-</text>
<text top="343" left="450" width="350" height="15" font="5">ment is made. TTE may provide erroneous or inadequate</text>
<text top="361" left="450" width="350" height="15" font="5">information in some patients. Severity of stenosis may be</text>
<text top="379" left="450" width="231" height="15" font="5">underestimated when imaging is dif</text>
<text top="375" left="681" width="119" height="19" font="5">ﬁcult or when the</text>
<text top="396" left="450" width="350" height="15" font="5">Doppler beam is not directed parallel to the valvular jet</text>
<text top="414" left="450" width="350" height="15" font="5">velocities. TTE quantitation of valve regurgitation shows</text>
<text top="432" left="450" width="350" height="15" font="5">considerable variability in measurement, and severity of</text>
<text top="450" left="450" width="350" height="15" font="5">disease may be overestimated or underestimated if image or</text>
<text top="468" left="450" width="350" height="15" font="5">Doppler data quality is suboptimal. If there are inconclu-</text>
<text top="486" left="450" width="350" height="15" font="5">sive, noninvasive data, particularly in the symptomatic</text>
<text top="504" left="450" width="350" height="15" font="5">patient, or if there is a discrepancy between the noninvasive</text>
<text top="522" left="450" width="101" height="15" font="5">tests and clinical</text>
<text top="519" left="556" width="243" height="19" font="5">ﬁndings, a hemodynamic cardiac cathe-</text>
<text top="540" left="450" width="350" height="15" font="5">terization is indicated. The measurements of valve gradients</text>
<text top="558" left="450" width="350" height="15" font="5">and cardiac output are important for assessing valve stenosis.</text>
<text top="576" left="450" width="350" height="15" font="5">Contrast angiography is still useful for a semiquantitative</text>
<text top="594" left="450" width="350" height="15" font="5">assessment of the severity of regurgitation in those instances</text>
<text top="612" left="450" width="350" height="15" font="5">in which the noninvasive results are discordant with the</text>
<text top="630" left="450" width="350" height="15" font="5">physical examination. A major advantage of cardiac cathe-</text>
<text top="648" left="450" width="350" height="15" font="5">terization is the measurement of intracardiac pressures and</text>
<text top="666" left="450" width="350" height="15" font="5">pulmonary vascular resistance, which may further aid in</text>
<text top="683" left="450" width="350" height="15" font="5">decision making about valve intervention. Diagnostic in-</text>
<text top="701" left="450" width="350" height="15" font="5">terventions that can be performed in the catheterization</text>
<text top="719" left="450" width="285" height="15" font="5">laboratory include the use of dobutamine in low-</text>
<text top="716" left="735" width="65" height="19" font="5">ﬂow states,</text>
<text top="737" left="450" width="350" height="15" font="5">pulmonary vasodilators in pulmonary hypertension, and</text>
<text top="755" left="450" width="350" height="15" font="5">exercise hemodynamics in patients with discrepant symp-</text>
<text top="773" left="450" width="350" height="15" font="5">toms. It must be emphasized that there is no longer a</text>
<text top="788" left="450" width="350" height="19" font="5">“routine” cardiac catheterization. Patients who come to the</text>
<text top="809" left="450" width="350" height="15" font="5">catheterization laboratory present complex diagnostic</text>
<text top="827" left="450" width="350" height="15" font="5">challenges because the noninvasive testing in these patients</text>
<text top="845" left="450" width="350" height="15" font="5">has not provided all pertinent information. Thus, hemo-</text>
<text top="863" left="450" width="350" height="15" font="5">dynamic catheterization needs to be done with meticulous</text>
<text top="881" left="450" width="350" height="15" font="5">attention to detail and performed by persons with knowl-</text>
<text top="899" left="450" width="306" height="15" font="5">edge and expertise in assessing patients with VHD.</text>
<text top="917" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="917" left="597" width="43" height="15" font="6"><a href="e57.full.html#101">(42,43)</a></text>
<text top="943" left="450" width="288" height="16" font="5">2.3.5. Diagnostic TestingdExercise Testing:</text>
<text top="961" left="450" width="112" height="15" font="5">Recommendation</text>
<text top="983" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="998" left="449" width="350" height="10" font="21">1. Exercise testing is reasonable in selected patients with</text>
<text top="1014" left="467" width="194" height="10" font="21">asymptomatic severe VHD to 1) con</text>
<text top="1011" left="661" width="138" height="16" font="21">ﬁrm the absence of symp-</text>
<text top="1030" left="467" width="332" height="10" font="21">toms, or 2) assess the hemodynamic response to exercise, or</text>
<text top="1047" left="467" width="123" height="10" font="21">3) determine prognosis</text>
<text top="1047" left="594" width="19" height="10" font="22"><a href="e57.full.html#101">(44</a></text>
<text top="1044" left="613" width="25" height="16" font="22"><a href="e57.full.html#101">–48)</a></text>
<text top="1047" left="638" width="121" height="12" font="21"><a href="e57.full.html#101">. </a>(Level of Evidence: B)</text>
<text top="1071" left="465" width="335" height="15" font="5">In a subset of patients, exercise stress testing will be of</text>
<text top="1089" left="450" width="350" height="15" font="5">additional value in determining optimal therapy. Because</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e65</text>
</page>
<page number="10" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="23" size="4" family="Times" color="#000000"/>
	<fontspec id="24" size="3" family="Times" color="#000000"/>
<text top="365" left="64" width="350" height="15" font="5">of the slow, insidious rate of progression of many</text>
<text top="383" left="64" width="350" height="15" font="5">valve lesions, patients may deny symptoms as they grad-</text>
<text top="401" left="64" width="350" height="15" font="5">ually limit their activity level over years to match the</text>
<text top="419" left="64" width="350" height="15" font="5">gradual limitation imposed by the valve lesion. In pa-</text>
<text top="437" left="64" width="349" height="15" font="5">tients with an equivocal history of symptoms, exercise</text>
<text top="455" left="64" width="350" height="15" font="5">testing helps identify those who are truly symptomatic.</text>
<text top="473" left="64" width="350" height="15" font="5">There may be patients in whom resting hemodynamics</text>
<text top="491" left="64" width="350" height="15" font="5">do not correlate with symptoms. In these patients, exer-</text>
<text top="509" left="64" width="350" height="15" font="5">cise hemodynamics may be helpful in determining the</text>
<text top="527" left="64" width="205" height="15" font="5">etiology of the symptoms, speci</text>
<text top="523" left="269" width="145" height="19" font="5">ﬁcally in patients with</text>
<text top="545" left="64" width="350" height="15" font="5">mitral VHD. Exercise stress testing is of prognostic value</text>
<text top="562" left="64" width="350" height="15" font="5">in patients with asymptomatic severe aortic stenosis</text>
<text top="580" left="64" width="350" height="15" font="5">(AS) and provides further information about timing of</text>
<text top="598" left="64" width="350" height="15" font="5">intervention. Exercise testing in patients with severe</text>
<text top="616" left="64" width="350" height="15" font="5">VHD should always be performed by trained operators</text>
<text top="634" left="64" width="350" height="15" font="5">with continuous monitoring of the ECG and blood</text>
<text top="652" left="64" width="87" height="15" font="5">pressure (BP).</text>
<text top="671" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="670" left="212" width="20" height="15" font="6"><a href="e57.full.html#101">(44</a></text>
<text top="667" left="232" width="27" height="19" font="6"><a href="e57.full.html#101">–48)</a></text>
<text top="708" left="64" width="274" height="12" font="19">2.4. Basic Principles of Medical Therapy</text>
<text top="730" left="65" width="349" height="15" font="5">All patients being evaluated for VHD should also undergo</text>
<text top="748" left="64" width="350" height="15" font="5">GDMT for other risk factors associated with cardiac dis-</text>
<text top="766" left="64" width="350" height="15" font="5">ease. These include hypertension, diabetes mellitus, and</text>
<text top="784" left="64" width="218" height="15" font="5">hyperlipidemia. The safety and ef</text>
<text top="781" left="283" width="131" height="19" font="5">ﬁcacy of an exercise</text>
<text top="802" left="64" width="350" height="15" font="5">program for patients with VHD has not been established,</text>
<text top="820" left="64" width="134" height="15" font="5">but patients will bene</text>
<text top="817" left="199" width="215" height="19" font="5">ﬁt from an exercise prescription in</text>
<text top="838" left="64" width="350" height="15" font="5">which a regular aerobic exercise program is followed to</text>
<text top="856" left="64" width="129" height="15" font="5">ensure cardiovascular</text>
<text top="853" left="202" width="212" height="19" font="5">ﬁtness. Although heavy isometric</text>
<text top="874" left="64" width="350" height="15" font="5">repetitive training will increase the afterload on the LV,</text>
<text top="892" left="64" width="350" height="15" font="5">resistive training with small free weights or repetitive iso-</text>
<text top="910" left="64" width="350" height="15" font="5">lated muscle training may be used to strengthen individual</text>
<text top="928" left="64" width="89" height="15" font="5">muscle groups.</text>
<text top="946" left="79" width="335" height="15" font="5">Most patients with LV systolic dysfunction and severe</text>
<text top="964" left="64" width="350" height="15" font="5">VHD should undergo intervention for the valve itself.</text>
<text top="981" left="64" width="350" height="15" font="5">However, if the decision has been made for medical</text>
<text top="999" left="64" width="350" height="15" font="5">therapy, these patients should receive the GDMT drug</text>
<text top="1017" left="64" width="350" height="15" font="5">therapy for LV systolic dysfunction, including angiotensin-</text>
<text top="1035" left="64" width="350" height="15" font="5">converting enzyme (ACE) inhibitors or angiotensin-</text>
<text top="1053" left="64" width="350" height="15" font="5">receptor blockers (ARBs) and beta-adrenergic blockers.</text>
<text top="1071" left="64" width="350" height="15" font="5">Care must be taken to not abruptly lower BP in patients</text>
<text top="1089" left="64" width="126" height="15" font="5">with stenotic lesions.</text>
<text top="365" left="465" width="335" height="15" font="5">Rheumatic fever prophylaxis and infective endocarditis</text>
<text top="383" left="450" width="350" height="15" font="5">(IE) prophylaxis should be given to appropriate groups</text>
<text top="401" left="450" width="173" height="15" font="5">of patients as outlined in</text>
<text top="401" left="633" width="90" height="15" font="6"><a href="e57.full.html#10">Sections 2.4.1</a></text>
<text top="401" left="733" width="22" height="15" font="5">and</text>
<text top="401" left="766" width="30" height="15" font="6"><a href="e57.full.html#11">2.4.2</a></text>
<text top="401" left="796" width="4" height="15" font="5"><a href="e57.full.html#11">.</a></text>
<text top="419" left="450" width="350" height="15" font="5">The maintenance of optimal oral health remains the</text>
<text top="437" left="450" width="350" height="15" font="5">most important component of an overall healthcare pro-</text>
<text top="455" left="450" width="160" height="15" font="5">gram in preventing IE. In</text>
<text top="452" left="610" width="190" height="19" font="5">ﬂuenza and pneumococcal vac-</text>
<text top="473" left="450" width="350" height="15" font="5">cinations should be given to appropriate patient groups</text>
<text top="491" left="450" width="71" height="15" font="5">with VHD.</text>
<text top="510" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="509" left="593" width="25" height="15" font="6"><a href="e57.full.html#101">(49)</a></text>
<text top="532" left="450" width="316" height="15" font="5">2.4.1. Secondary Prevention of Rheumatic Fever:</text>
<text top="550" left="450" width="112" height="15" font="5">Recommendation</text>
<text top="576" left="451" width="349" height="15" font="5">Rheumatic fever is an important cause of VHD. In the</text>
<text top="594" left="450" width="350" height="15" font="5">United States, acute rheumatic fever has been uncommon</text>
<text top="612" left="450" width="350" height="15" font="5">since the 1970s. However, there has been an increase in</text>
<text top="630" left="450" width="350" height="15" font="5">the number of cases of rheumatic fever since 1987. Un-</text>
<text top="648" left="450" width="350" height="15" font="5">derstanding of the causative organism, group A Strepto-</text>
<text top="666" left="450" width="350" height="15" font="5">coccus, has been enhanced by the development of kits that</text>
<text top="684" left="450" width="350" height="15" font="5">allow rapid detection of this organism. Prompt recognition</text>
<text top="702" left="450" width="350" height="15" font="5">and treatment of streptococcal pharyngitis constitute pri-</text>
<text top="719" left="450" width="350" height="15" font="5">mary prevention of rheumatic fever. For patients with</text>
<text top="737" left="450" width="350" height="15" font="5">previous episodes of well-documented rheumatic fever or</text>
<text top="755" left="450" width="350" height="15" font="5">in those with evidence of rheumatic heart disease, long-</text>
<text top="773" left="450" width="350" height="15" font="5">term antistreptococcal prophylaxis is indicated for sec-</text>
<text top="791" left="450" width="113" height="15" font="5">ondary prevention.</text>
<text top="810" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="809" left="593" width="25" height="15" font="6"><a href="e57.full.html#101">(50)</a></text>
<text top="836" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="851" left="450" width="350" height="10" font="21">1. Secondary prevention of rheumatic fever is indicated in patients</text>
<text top="868" left="468" width="189" height="10" font="21">with rheumatic heart disease, speci</text>
<text top="865" left="657" width="143" height="16" font="21">ﬁcally mitral stenosis (MS)</text>
<text top="884" left="468" width="4" height="10" font="21"><a href="e57.full.html#11">(</a></text>
<text top="884" left="472" width="45" height="10" font="22"><a href="e57.full.html#11">Tables 5</a></text>
<text top="884" left="522" width="19" height="10" font="21">and</text>
<text top="884" left="545" width="7" height="10" font="22"><a href="e57.full.html#11">6</a></text>
<text top="884" left="552" width="4" height="10" font="21"><a href="e57.full.html#11">)</a></text>
<text top="884" left="560" width="23" height="10" font="22"><a href="e57.full.html#101">(50)</a></text>
<text top="884" left="583" width="120" height="12" font="21">. (Level of Evidence: C)</text>
<text top="908" left="465" width="335" height="15" font="5">Recurrent rheumatic fever is associated with a wors-</text>
<text top="926" left="450" width="350" height="15" font="5">ening of rheumatic heart disease. However, infection</text>
<text top="944" left="450" width="350" height="15" font="5">with group A Streptococcus does not have to be symp-</text>
<text top="962" left="450" width="350" height="15" font="5">tomatic to trigger a recurrence, and rheumatic fever can</text>
<text top="980" left="450" width="350" height="15" font="5">recur even when the symptomatic infection is treated.</text>
<text top="998" left="450" width="350" height="15" font="5">Prevention of recurrent rheumatic fever requires long-</text>
<text top="1016" left="450" width="350" height="15" font="5">term antimicrobial prophylaxis rather than recognition</text>
<text top="1034" left="450" width="350" height="15" font="5">and treatment of acute episodes of group A Streptococcus</text>
<text top="1052" left="450" width="350" height="15" font="5">pharyngitis. The recommended treatment regimens and</text>
<text top="1070" left="450" width="292" height="15" font="5">duration of secondary prophylaxis are shown in</text>
<text top="1070" left="747" width="53" height="15" font="6"><a href="e57.full.html#11">Tables 5</a></text>
<text top="1088" left="450" width="22" height="15" font="5">and</text>
<text top="1088" left="477" width="7" height="15" font="6"><a href="e57.full.html#11">6</a></text>
<text top="1088" left="485" width="314" height="15" font="5">. In patients with documented VHD, the duration</text>
<text top="103" left="64" width="647" height="11" font="13">Table 4. Frequency of Echocardiograms in Asymptomatic Patients With VHD and Normal Left Ventricular Function</text>
<text top="129" left="64" width="27" height="9" font="7">Stage</text>
<text top="129" left="445" width="58" height="9" font="7">Valve Lesion</text>
<text top="152" left="64" width="27" height="9" font="7">Stage</text>
<text top="152" left="201" width="71" height="9" font="7">Aortic Stenosis</text>
<text top="152" left="273" width="6" height="9" font="8"><a href="e57.full.html#10">*</a></text>
<text top="152" left="384" width="94" height="9" font="7">Aortic Regurgitation</text>
<text top="152" left="544" width="71" height="9" font="7">Mitral Stenosis</text>
<text top="152" left="681" width="94" height="9" font="7">Mitral Regurgitation</text>
<text top="169" left="64" width="54" height="9" font="7">Progressive</text>
<text top="184" left="74" width="44" height="9" font="7">(stage B)</text>
<text top="170" left="149" width="33" height="9" font="7">Every 3</text>
<text top="167" left="182" width="19" height="14" font="7">–5 y</text>
<text top="184" left="161" width="69" height="9" font="7">(mild severity V</text>
<text top="188" left="230" width="14" height="6" font="23">max</text>
<text top="184" left="248" width="15" height="9" font="7">2.0</text>
<text top="181" left="263" width="45" height="14" font="7">–2.9 m/s)</text>
<text top="170" left="359" width="33" height="9" font="7">Every 3</text>
<text top="167" left="393" width="86" height="14" font="7">–5 y (mild severity)</text>
<text top="184" left="359" width="33" height="9" font="7">Every 1</text>
<text top="181" left="393" width="110" height="14" font="7">–2 y (moderate severity)</text>
<text top="170" left="530" width="33" height="9" font="7">Every 3</text>
<text top="167" left="563" width="19" height="14" font="7">–5 y</text>
<text top="184" left="540" width="23" height="9" font="7">(MVA</text>
<text top="181" left="566" width="40" height="14" font="7">&gt;1.5 cm</text>
<text top="181" left="607" width="5" height="6" font="23">2</text>
<text top="184" left="611" width="3" height="9" font="7">)</text>
<text top="170" left="657" width="33" height="9" font="7">Every 3</text>
<text top="167" left="690" width="86" height="14" font="7">–5 y (mild severity)</text>
<text top="184" left="657" width="33" height="9" font="7">Every 1</text>
<text top="181" left="690" width="110" height="14" font="7">–2 y (moderate severity)</text>
<text top="201" left="149" width="33" height="9" font="7">Every 1</text>
<text top="198" left="182" width="19" height="14" font="7">–2 y</text>
<text top="215" left="161" width="93" height="9" font="7">(moderate severity V</text>
<text top="219" left="254" width="14" height="6" font="23">max</text>
<text top="215" left="272" width="15" height="9" font="7">3.0</text>
<text top="212" left="286" width="45" height="14" font="7">–3.9 m/s)</text>
<text top="232" left="64" width="31" height="9" font="7">Severe</text>
<text top="246" left="77" width="44" height="9" font="7">(stage C)</text>
<text top="232" left="149" width="33" height="9" font="7">Every 6</text>
<text top="229" left="182" width="35" height="14" font="7">–12 mo</text>
<text top="246" left="161" width="9" height="9" font="7">(V</text>
<text top="250" left="170" width="14" height="6" font="23">max</text>
<text top="243" left="188" width="39" height="14" font="7">4 m/s)</text>
<text top="232" left="359" width="33" height="9" font="7">Every 6</text>
<text top="229" left="393" width="35" height="14" font="7">–12 mo</text>
<text top="246" left="359" width="126" height="9" font="7">Dilating LV: more frequently</text>
<text top="232" left="530" width="33" height="9" font="7">Every 1</text>
<text top="229" left="563" width="19" height="14" font="7">–2 y</text>
<text top="246" left="542" width="41" height="9" font="7">(MVA 1.0</text>
<text top="243" left="584" width="37" height="14" font="7">–1.5 cm</text>
<text top="244" left="621" width="5" height="6" font="23">2</text>
<text top="246" left="626" width="3" height="9" font="7">)</text>
<text top="260" left="533" width="72" height="9" font="7">Once every year</text>
<text top="274" left="542" width="23" height="9" font="7">(MVA</text>
<text top="271" left="569" width="40" height="14" font="7">&lt;1.0 cm</text>
<text top="272" left="609" width="5" height="6" font="23">2</text>
<text top="274" left="614" width="3" height="9" font="7">)</text>
<text top="232" left="657" width="33" height="9" font="7">Every 6</text>
<text top="229" left="690" width="35" height="14" font="7">–12 mo</text>
<text top="246" left="657" width="126" height="9" font="7">Dilating LV: more frequently</text>
<text top="294" left="64" width="476" height="8" font="18">Patients with mixed valve disease may require serial evaluations at intervals earlier than recommended for single valve lesions.</text>
<text top="306" left="64" width="107" height="8" font="18">*With normal stroke volume.</text>
<text top="318" left="73" width="318" height="8" font="18">LV indicates left ventricle; MVA, mitral valve area; VHD, valvular heart disease; and V</text>
<text top="322" left="390" width="13" height="5" font="24">max,</text>
<text top="318" left="407" width="69" height="8" font="18">maximum velocity.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e66</text>
</page>
<page number="11" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="25" size="5" family="Times" color="#005c58"/>
	<fontspec id="26" size="6" family="Times" color="#327eb1"/>
<text top="318" left="64" width="349" height="15" font="5">of rheumatic fever prophylaxis should be at least 10 years</text>
<text top="336" left="64" width="350" height="15" font="5">or until the patient is 40 years of age (whichever is</text>
<text top="354" left="64" width="47" height="15" font="5">longer).</text>
<text top="381" left="64" width="263" height="15" font="5">2.4.2. IE Prophylaxis: Recommendations</text>
<text top="406" left="65" width="349" height="15" font="5">Because of the lack of published evidence on the use of</text>
<text top="424" left="64" width="350" height="15" font="5">prophylactic antibiotics to prevent IE, the value of anti-</text>
<text top="442" left="64" width="350" height="15" font="5">biotic prophylaxis has been questioned by several national</text>
<text top="460" left="64" width="350" height="15" font="5">and international medical societies. Antibiotic prophylaxis</text>
<text top="478" left="64" width="350" height="15" font="5">is now indicated for only a subset of patients who are at</text>
<text top="496" left="64" width="350" height="15" font="5">high risk for developing IE and at highest risk for an</text>
<text top="514" left="64" width="350" height="15" font="5">adverse outcome if IE occurs. The maintenance of optimal</text>
<text top="532" left="64" width="350" height="15" font="5">oral health care remains the most effective intervention to</text>
<text top="550" left="64" width="180" height="15" font="5">prevent future valve infection.</text>
<text top="568" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="568" left="212" width="20" height="15" font="6"><a href="e57.full.html#101">(51</a></text>
<text top="564" left="232" width="27" height="19" font="6"><a href="e57.full.html#101">–53)</a></text>
<text top="595" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="610" left="63" width="351" height="10" font="21">1. Prophylaxis against IE is reasonable for the following patients</text>
<text top="626" left="81" width="333" height="10" font="21">at highest risk for adverse outcomes from IE before dental</text>
<text top="643" left="81" width="333" height="10" font="21">procedures that involve manipulation of gingival tissue, manip-</text>
<text top="659" left="81" width="332" height="10" font="21">ulation of the periapical region of teeth, or perforation of the oral</text>
<text top="676" left="81" width="41" height="10" font="21">mucosa</text>
<text top="676" left="126" width="19" height="10" font="22"><a href="e57.full.html#101">(54</a></text>
<text top="672" left="145" width="25" height="16" font="22"><a href="e57.full.html#101">–56)</a></text>
<text top="676" left="174" width="116" height="12" font="21">(Level of Evidence: B):</text>
<text top="689" left="82" width="226" height="16" font="21"> Patients with prosthetic cardiac valves;</text>
<text top="705" left="82" width="151" height="16" font="21"> Patients with previous IE;</text>
<text top="722" left="82" width="332" height="16" font="21"> Cardiac transplant recipients with valve regurgitation due to</text>
<text top="741" left="97" width="171" height="10" font="21">a structurally abnormal valve; or</text>
<text top="755" left="82" width="250" height="16" font="21"> Patients with congenital heart disease with:</text>
<text top="775" left="102" width="8" height="10" font="25">B</text>
<text top="774" left="115" width="299" height="10" font="21">Unrepaired cyanotic congenital heart disease, including</text>
<text top="791" left="115" width="162" height="10" font="21">palliative shunts and conduits;</text>
<text top="808" left="102" width="8" height="10" font="25">B</text>
<text top="807" left="115" width="299" height="10" font="21">Completely repaired congenital heart defect repaired with</text>
<text top="824" left="115" width="299" height="10" font="21">prosthetic material or device, whether placed by surgery</text>
<text top="840" left="115" width="189" height="10" font="21">or catheter intervention, during the</text>
<text top="837" left="308" width="106" height="16" font="21">ﬁrst 6 months after</text>
<text top="856" left="115" width="91" height="10" font="21">the procedure; or</text>
<text top="874" left="102" width="8" height="10" font="25">B</text>
<text top="873" left="115" width="299" height="10" font="21">Repaired congenital heart disease with residual defects</text>
<text top="889" left="115" width="299" height="10" font="21">at the site or adjacent to the site of a prosthetic patch or</text>
<text top="906" left="115" width="95" height="10" font="21">prosthetic device.</text>
<text top="933" left="79" width="135" height="15" font="5">The risk of IE is signi</text>
<text top="930" left="215" width="199" height="19" font="5">ﬁcantly higher in patients with a</text>
<text top="951" left="64" width="350" height="15" font="5">history of prosthetic valve replacement. Even in those</text>
<text top="969" left="64" width="316" height="15" font="5">patients at high risk for IE, the evidence for signi</text>
<text top="965" left="380" width="34" height="19" font="5">ﬁcant</text>
<text top="987" left="64" width="269" height="15" font="5">reduction in events with prophylaxis is con</text>
<text top="983" left="333" width="81" height="19" font="5">ﬂicting. This</text>
<text top="1005" left="64" width="350" height="15" font="5">lack of supporting evidence along with the risk of</text>
<text top="1023" left="64" width="350" height="15" font="5">anaphylaxis and increasing bacterial resistance to anti-</text>
<text top="1041" left="64" width="150" height="15" font="5">microbials led to a signi</text>
<text top="1037" left="215" width="199" height="19" font="5">ﬁcant revision in the AHA rec-</text>
<text top="1059" left="64" width="350" height="15" font="5">ommendations for prophylaxis so that only those patients</text>
<text top="1077" left="64" width="350" height="15" font="5">at the highest risk of developing IE (e.g., those with</text>
<text top="341" left="450" width="350" height="15" font="5">prosthetic valves) should be treated. Furthermore, evi-</text>
<text top="359" left="450" width="350" height="15" font="5">dence for prophylaxis has only been found to be</text>
<text top="377" left="450" width="350" height="15" font="5">reasonable in dental procedures that involve manipula-</text>
<text top="395" left="450" width="350" height="15" font="5">tion of gingival tissue, manipulation of the periapical</text>
<text top="413" left="450" width="350" height="15" font="5">region of teeth, or perforation of the oral mucosa. In the</text>
<text top="431" left="450" width="350" height="15" font="5">case of other prosthetic material (excluding surgically</text>
<text top="449" left="450" width="350" height="15" font="5">created palliative systemic-pulmonary shunts or conduits)</text>
<text top="467" left="450" width="350" height="15" font="5">such as annuloplasty rings, neochords, Amplatzer de-</text>
<text top="485" left="450" width="350" height="15" font="5">vices, and MitraClips, there have been only sporadic case</text>
<text top="503" left="450" width="350" height="15" font="5">reports of infected devices. Given the low infection rate</text>
<text top="521" left="450" width="219" height="15" font="5">and scarcity of data, there is no de</text>
<text top="517" left="669" width="130" height="19" font="5">ﬁnitive evidence that</text>
<text top="539" left="450" width="350" height="15" font="5">prophylaxis in these patients is warranted in the absence</text>
<text top="556" left="450" width="350" height="15" font="5">of the patient having other high risks of intracardiac</text>
<text top="574" left="450" width="58" height="15" font="5">infection.</text>
<text top="592" left="465" width="335" height="15" font="5">There are no randomized controlled trials (RCTs) or</text>
<text top="610" left="450" width="350" height="15" font="5">large observational cohort studies for prophylaxis in pati-</text>
<text top="628" left="450" width="350" height="15" font="5">ents with a previous episode of IE, but given the cumulative</text>
<text top="646" left="450" width="350" height="15" font="5">risks of mortality with repeated infection, the potentially</text>
<text top="664" left="450" width="350" height="15" font="5">disabling complications from repeated infections, and the</text>
<text top="682" left="450" width="350" height="15" font="5">relatively low risk of prophylaxis, prophylaxis for IE has</text>
<text top="700" left="450" width="350" height="15" font="5">been recommended in this high-risk group of patients. IE</text>
<text top="718" left="450" width="350" height="15" font="5">is substantially more common in heart transplant recipi-</text>
<text top="736" left="450" width="350" height="15" font="5">ents than in the general population. The risk of IE is</text>
<text top="754" left="450" width="85" height="15" font="5">highest in the</text>
<text top="750" left="541" width="259" height="19" font="5">ﬁrst 6 months after transplantation due to</text>
<text top="772" left="450" width="350" height="15" font="5">endothelium disruption, high-intensity immunosuppres-</text>
<text top="790" left="450" width="350" height="15" font="5">sive therapy, frequent central venous catheter access, and</text>
<text top="808" left="450" width="350" height="15" font="5">endomyocardial biopsies. If there is a structurally abnormal</text>
<text top="826" left="450" width="305" height="15" font="5">valve, IE prophylaxis should be continued inde</text>
<text top="822" left="755" width="45" height="19" font="5">ﬁnitely,</text>
<text top="843" left="450" width="315" height="15" font="5">given the high risk of IE in post-transplant patients.</text>
<text top="861" left="465" width="335" height="15" font="5">In patients in whom IE prophylaxis is reasonable, give</text>
<text top="879" left="450" width="350" height="15" font="5">prophylaxis before dental procedures that involve manip-</text>
<text top="897" left="450" width="350" height="15" font="5">ulation of gingival tissue or the periapical region of teeth</text>
<text top="915" left="450" width="350" height="15" font="5">or cause perforation of the oral mucosa. Bacteremia com-</text>
<text top="933" left="450" width="350" height="15" font="5">monly occurs during activities of daily living such as</text>
<text top="951" left="450" width="350" height="15" font="5">routine brushing of the teeth or chewing. Persons at risk</text>
<text top="969" left="450" width="350" height="15" font="5">for developing bacterial IE should establish and maintain</text>
<text top="987" left="450" width="350" height="15" font="5">the best possible oral health to reduce potential sources of</text>
<text top="1005" left="450" width="350" height="15" font="5">bacterial seeding. Optimal oral health is maintained</text>
<text top="1023" left="450" width="350" height="15" font="5">through regular professional dental care and the use of</text>
<text top="1041" left="450" width="350" height="15" font="5">appropriate dental products, such as manual, powered, and</text>
<text top="1059" left="450" width="190" height="15" font="5">ultrasonic toothbrushes; dental</text>
<text top="1055" left="648" width="151" height="19" font="5">ﬂoss; and other plaque-</text>
<text top="1077" left="450" width="350" height="15" font="5">removal devices. There is no evidence for IE prophylaxis</text>
<text top="103" left="64" width="289" height="11" font="13">Table 5. Secondary Prevention of Rheumatic Fever</text>
<text top="129" left="64" width="27" height="9" font="7">Agent</text>
<text top="129" left="324" width="35" height="9" font="7">Dosage</text>
<text top="146" left="64" width="103" height="9" font="7">Penicillin G benzathine</text>
<text top="146" left="268" width="140" height="9" font="7">1.2 million units IM every 4 <a href="e57.full.html#11">wk</a></text>
<text top="146" left="408" width="6" height="9" font="8"><a href="e57.full.html#11">*</a></text>
<text top="163" left="64" width="99" height="9" font="7">Penicillin V potassium</text>
<text top="163" left="268" width="83" height="9" font="7">250 mg orally BID</text>
<text top="180" left="64" width="54" height="9" font="7">Sulfadiazine</text>
<text top="180" left="268" width="91" height="9" font="7">1 g orally once daily</text>
<text top="197" left="64" width="193" height="9" font="7">Macrolide or azalide antibiotic (for patients</text>
<text top="211" left="77" width="167" height="9" font="7">allergic to penicillin and sulfadiazine)</text>
<text top="208" left="244" width="5" height="14" font="8"><a href="e57.full.html#11">y</a></text>
<text top="197" left="268" width="27" height="9" font="7">Varies</text>
<text top="231" left="64" width="278" height="8" font="18">*Administration every 3 wk is recommended in certain high-risk situations.</text>
<text top="241" left="64" width="350" height="11" font="18"><a href="e57.full.html#11">y</a>Macrolide antibiotics should not be used in persons taking other medications that inhibit cy-</text>
<text top="255" left="64" width="350" height="9" font="18">tochrome P450 3A, such as azole antifungal agents, HIV protease inhibitors, and some se-</text>
<text top="267" left="64" width="136" height="8" font="18">lective serotonin reuptake inhibitors.</text>
<text top="279" left="64" width="99" height="8" font="18">Adapted from Gerber et al.</text>
<text top="279" left="166" width="15" height="8" font="26"><a href="e57.full.html#101">(50)</a></text>
<text top="279" left="182" width="3" height="8" font="18"><a href="e57.full.html#101">.</a></text>
<text top="291" left="72" width="181" height="8" font="18">BID indicates twice daily; HIV, human immunode</text>
<text top="289" left="253" width="142" height="11" font="18">ﬁciency virus; and IM, intramuscularly.</text>
<text top="103" left="450" width="265" height="11" font="13">Table 6. Duration of Secondary Prophylaxis for</text>
<text top="119" left="450" width="95" height="11" font="13">Rheumatic Fever</text>
<text top="144" left="450" width="22" height="9" font="7">Type</text>
<text top="144" left="659" width="124" height="9" font="7">Duration After Last Attack</text>
<text top="162" left="450" width="132" height="9" font="7">Rheumatic fever with carditis</text>
<text top="176" left="462" width="120" height="9" font="7">and residual heart disease</text>
<text top="190" left="462" width="69" height="9" font="7">(persistent VHD</text>
<text top="190" left="532" width="6" height="9" font="8"><a href="e57.full.html#11">*</a></text>
<text top="190" left="537" width="3" height="9" font="7">)</text>
<text top="162" left="643" width="156" height="9" font="7">10 y or until patient is 40 y of age</text>
<text top="176" left="655" width="93" height="9" font="7">(whichever is longer)</text>
<text top="207" left="450" width="132" height="9" font="7">Rheumatic fever with carditis</text>
<text top="222" left="462" width="132" height="9" font="7">but no residual heart disease</text>
<text top="236" left="462" width="89" height="9" font="7">(no valvular <a href="e57.full.html#11">disease</a></text>
<text top="236" left="551" width="6" height="9" font="8"><a href="e57.full.html#11">*</a></text>
<text top="236" left="557" width="3" height="9" font="7">)</text>
<text top="207" left="643" width="156" height="9" font="7">10 y or until patient is 21 y of age</text>
<text top="222" left="655" width="93" height="9" font="7">(whichever is longer)</text>
<text top="253" left="450" width="146" height="9" font="7">Rheumatic fever without carditis</text>
<text top="253" left="643" width="150" height="9" font="7">5 y or until patient is 21 y of age</text>
<text top="267" left="655" width="93" height="9" font="7">(whichever is longer)</text>
<text top="287" left="450" width="150" height="8" font="18">*Clinical or echocardiographic evidence.</text>
<text top="299" left="450" width="99" height="8" font="18">Adapted from Gerber et al.</text>
<text top="299" left="552" width="15" height="8" font="26"><a href="e57.full.html#101">(50)</a></text>
<text top="299" left="567" width="3" height="8" font="18">.</text>
<text top="311" left="457" width="139" height="8" font="18">VHD indicates valvular heart disease.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e67</text>
</page>
<page number="12" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">in gastrointestinal procedures or genitourinary procedures</text>
<text top="121" left="64" width="223" height="15" font="5">absent known enterococcal infection.</text>
<text top="139" left="79" width="335" height="15" font="5">Multiple epidemiological studies show no increase in</text>
<text top="157" left="64" width="350" height="15" font="5">the rate of IE since adoption of the AHA and European</text>
<text top="175" left="64" width="350" height="15" font="5">Society of Cardiology guidelines recommending more</text>
<text top="192" left="64" width="350" height="15" font="5">restrictive use of IE prophylaxis. The NICE (National</text>
<text top="210" left="64" width="350" height="15" font="5">Institute for Health and Clinical Excellence, United</text>
<text top="228" left="64" width="350" height="15" font="5">Kingdom) guidelines took an even more radical departure</text>
<text top="246" left="64" width="350" height="15" font="5">from the previous prophylaxis standards in not recom-</text>
<text top="264" left="64" width="350" height="15" font="5">mending antibiotic prophylaxis for dental or nondental</text>
<text top="282" left="64" width="350" height="15" font="5">procedures (e.g., respiratory, gastrointestinal, and genito-</text>
<text top="300" left="64" width="350" height="15" font="5">urinary). Similarly, subsequent epidemiological studies</text>
<text top="318" left="64" width="350" height="15" font="5">performed in the wake of the NICE guideline revisions</text>
<text top="336" left="64" width="350" height="15" font="5">have demonstrated no increase in clinical cases or</text>
<text top="354" left="64" width="350" height="15" font="5">deaths from IE. For the recommended choice of antibi-</text>
<text top="372" left="64" width="350" height="15" font="5">otic regimen when IE prophylaxis is recommended, see</text>
<text top="390" left="64" width="349" height="15" font="6"><a href="http://www.heart.org/idc/groups/heart-public/@wcm/@hcm/documents/downloadable/ucm_307644.pdf">http://www.heart.org/idc/groups/heart-public/@wcm/@hcm/</a></text>
<text top="408" left="64" width="248" height="15" font="6"><a href="http://www.heart.org/idc/groups/heart-public/@wcm/@hcm/documents/downloadable/ucm_307644.pdf">documents/downloadable/ucm_307644.pdf</a></text>
<text top="408" left="312" width="4" height="15" font="5">.</text>
<text top="426" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="426" left="212" width="20" height="15" font="6"><a href="e57.full.html#101">(50</a></text>
<text top="422" left="232" width="27" height="19" font="6"><a href="e57.full.html#101">–59)</a></text>
<text top="462" left="64" width="88" height="8" font="20">CLASS III: No Bene</text>
<text top="459" left="152" width="10" height="13" font="20">ﬁt</text>
<text top="477" left="63" width="351" height="10" font="21">1. Prophylaxis against IE is not recommended in patients with</text>
<text top="493" left="81" width="333" height="10" font="21">VHD who are at risk of IE for nondental procedures (e.g., TEE,</text>
<text top="510" left="81" width="332" height="10" font="21">esophagogastroduodenoscopy, colonoscopy, or cystoscopy) in</text>
<text top="526" left="81" width="164" height="10" font="21">the absence of active infection</text>
<text top="526" left="250" width="23" height="10" font="22"><a href="e57.full.html#101">(60)</a></text>
<text top="526" left="273" width="121" height="12" font="21"><a href="e57.full.html#101">. </a>(Level of Evidence: B)</text>
<text top="550" left="79" width="335" height="15" font="5">The incidence of IE following most procedures in pa-</text>
<text top="568" left="64" width="350" height="15" font="5">tients with underlying cardiac disease is low, and there is a</text>
<text top="586" left="64" width="259" height="15" font="5">lack of controlled data supporting the bene</text>
<text top="583" left="324" width="90" height="19" font="5">ﬁt of antibiotic</text>
<text top="604" left="64" width="350" height="15" font="5">prophylaxis. Furthermore, the indiscriminate use of anti-</text>
<text top="622" left="64" width="350" height="15" font="5">biotics can be associated with the development of resistant</text>
<text top="640" left="64" width="154" height="15" font="5">organisms, Clostridium dif</text>
<text top="637" left="219" width="195" height="19" font="5">ﬁcile colitis, unnecessary expense,</text>
<text top="658" left="64" width="350" height="15" font="5">and drug toxicity. The risk of IE as a direct result of a</text>
<text top="673" left="64" width="350" height="19" font="5">ﬂexible endoscopic procedure is small. Transient bacter-</text>
<text top="694" left="64" width="350" height="15" font="5">emia may occur during or immediately after endoscopy;</text>
<text top="712" left="64" width="350" height="15" font="5">however, there are few reports of IE attributable to</text>
<text top="730" left="64" width="350" height="15" font="5">endoscopy. For most gastrointestinal endoscopic pro-</text>
<text top="748" left="64" width="350" height="15" font="5">cedures, the rate of bacteremia is 2% to 5%, and organisms</text>
<text top="766" left="64" width="90" height="15" font="5">typically identi</text>
<text top="762" left="154" width="260" height="19" font="5">ﬁed are unlikely to cause IE. The rate of</text>
<text top="784" left="64" width="350" height="15" font="5">bacteremia does not increase with mucosal biopsy, poly-</text>
<text top="801" left="64" width="350" height="15" font="5">pectomy, or sphincterotomy. There are no data to indicate</text>
<text top="819" left="64" width="350" height="15" font="5">that deep biopsy, such as that performed in the rectum or</text>
<text top="837" left="64" width="350" height="15" font="5">stomach, leads to a higher rate of bacteremia. The rate of</text>
<text top="855" left="64" width="350" height="15" font="5">transient bacteremia is more commonly seen in routine</text>
<text top="873" left="64" width="212" height="15" font="5">activities such as brushing teeth and</text>
<text top="870" left="280" width="134" height="19" font="5">ﬂossing (20% to 68%),</text>
<text top="891" left="64" width="350" height="15" font="5">using toothpicks (20% to 40%), and simply chewing food</text>
<text top="909" left="64" width="350" height="15" font="5">(7% to 51%). Some gastrointestinal procedures, such as</text>
<text top="927" left="64" width="350" height="15" font="5">esophageal dilation (as high as 45%), sclerotherapy (31%),</text>
<text top="945" left="64" width="350" height="15" font="5">and endoscopic retrograde cholangiopancreatography (6%</text>
<text top="963" left="64" width="350" height="15" font="5">to 18%) have higher rates of bacteremia than simple</text>
<text top="981" left="64" width="350" height="15" font="5">endoscopy. However, no studies indicate reduced rates of</text>
<text top="999" left="64" width="185" height="15" font="5">IE with antibiotic prophylaxis.</text>
<text top="1017" left="79" width="335" height="15" font="5">Surgery, instrumentation, or diagnostic procedures</text>
<text top="1035" left="64" width="350" height="15" font="5">that involve the genitourinary tract may cause bacteremia.</text>
<text top="1053" left="64" width="350" height="15" font="5">The rate of bacteremia following urinary tract procedures</text>
<text top="1070" left="64" width="350" height="15" font="5">is high in the presence of urinary tract infection. Sterili-</text>
<text top="1088" left="64" width="350" height="15" font="5">zation of the urinary tract with antimicrobial therapy in</text>
<text top="103" left="450" width="350" height="15" font="5">patients with bacteriuria should be attempted before elec-</text>
<text top="121" left="450" width="350" height="15" font="5">tive procedures, including lithotripsy. Results of a pre-</text>
<text top="139" left="450" width="350" height="15" font="5">procedure urine culture will allow the clinician to choose</text>
<text top="157" left="450" width="310" height="15" font="5">antibiotics appropriate for the recovered organisms.</text>
<text top="175" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="175" left="597" width="20" height="15" font="6"><a href="e57.full.html#101">(61</a></text>
<text top="171" left="617" width="27" height="19" font="6"><a href="e57.full.html#101">–73)</a></text>
<text top="205" left="450" width="211" height="12" font="19">2.5. Evaluation of Surgical and</text>
<text top="223" left="450" width="129" height="12" font="19">Interventional Risk</text>
<text top="246" left="451" width="349" height="15" font="5">The decision to intervene, as well as the type of inter-</text>
<text top="264" left="450" width="350" height="15" font="5">vention for a patient with severe VHD, should be based on</text>
<text top="282" left="450" width="105" height="15" font="5">an individual risk</text>
<text top="279" left="555" width="244" height="19" font="5">–beneﬁt analysis. The risk of the proce-</text>
<text top="300" left="450" width="350" height="15" font="5">dure and intermediate-term mortality must be weighed</text>
<text top="318" left="450" width="96" height="15" font="5">against the bene</text>
<text top="315" left="546" width="253" height="19" font="5">ﬁts of the procedure in altering the natural</text>
<text top="336" left="450" width="350" height="15" font="5">history of the disease and acknowledging the long-term</text>
<text top="354" left="450" width="350" height="15" font="5">consequences of the intervention. Operative mortality can</text>
<text top="372" left="450" width="350" height="15" font="5">be estimated from a number of different scoring systems</text>
<text top="390" left="450" width="350" height="15" font="5">by using a combination of risk factors such as the STS</text>
<text top="408" left="450" width="184" height="15" font="5">risk estimate or Euroscore <a href="http://www.euroscore.org/">(</a></text>
<text top="408" left="633" width="157" height="15" font="6"><a href="http://www.euroscore.org/">http://www.euroscore.org/</a></text>
<text top="408" left="791" width="9" height="15" font="5"><a href="http://www.euroscore.org/">).</a></text>
<text top="426" left="450" width="350" height="15" font="5">There are limitations to these scores, including that they</text>
<text top="444" left="450" width="350" height="15" font="5">derive only from surgical patients and that they do not</text>
<text top="461" left="450" width="246" height="15" font="5">take into consideration procedure-speci</text>
<text top="458" left="696" width="104" height="19" font="5">ﬁc impediments,</text>
<text top="479" left="450" width="350" height="15" font="5">major organ system compromise, comorbidities, or the</text>
<text top="497" left="450" width="350" height="15" font="5">frailty of the patient. A risk-assessment scheme com-</text>
<text top="515" left="450" width="224" height="15" font="5">bining these factors is presented in</text>
<text top="515" left="681" width="49" height="15" font="6"><a href="e57.full.html#13">Table 7</a></text>
<text top="515" left="730" width="69" height="15" font="5">. The STS</text>
<text top="533" left="450" width="350" height="15" font="5">risk estimate is an accepted tool to predict the risk of a</text>
<text top="551" left="450" width="350" height="15" font="5">surgical operation. In an analysis of aortic valve operations</text>
<text top="569" left="450" width="350" height="15" font="5">in the STS database from 2002 to 2010, 80% of patients</text>
<text top="587" left="450" width="271" height="15" font="5">had a predicted risk of mortality (PROM) of</text>
<text top="584" left="725" width="75" height="19" font="5">&lt;4% and an</text>
<text top="605" left="450" width="350" height="15" font="5">actual mean mortality rate of 1.4%. Fourteen percent had</text>
<text top="623" left="450" width="350" height="15" font="5">a PROM of 4% to 8% and an actual mean mortality rate</text>
<text top="641" left="450" width="271" height="15" font="5">of 5.1%, and 6% of patients had a PROM of</text>
<text top="637" left="724" width="75" height="19" font="5">&gt;8% and an</text>
<text top="659" left="450" width="350" height="15" font="5">actual mortality rate of 11.1%. Other factors such as the</text>
<text top="677" left="450" width="350" height="15" font="5">frailty of the patient, major organ system compromise,</text>
<text top="695" left="450" width="124" height="15" font="5">and procedure-speci</text>
<text top="691" left="574" width="225" height="19" font="5">ﬁc impediments must be taken into</text>
<text top="713" left="450" width="350" height="15" font="5">consideration. A number of mechanisms to evaluate</text>
<text top="730" left="450" width="350" height="15" font="5">frailty assess the ability to perform activities of daily living</text>
<text top="748" left="450" width="350" height="15" font="5">(independence in feeding, bathing, dressing, transferring,</text>
<text top="766" left="450" width="350" height="15" font="5">toileting, urinary continence, etc.) and measurements of</text>
<text top="784" left="450" width="350" height="15" font="5">gait speed, grip strength, and muscle mass. Published</text>
<text top="802" left="450" width="350" height="15" font="5">frailty scores are available, but a limited evaluation may</text>
<text top="820" left="450" width="350" height="15" font="5">use the following: no frailty (able to perform all activities</text>
<text top="838" left="450" width="198" height="15" font="5">of daily living and perform a 5</text>
<text top="835" left="648" width="151" height="19" font="5">–meter walk in &lt;6 sec-</text>
<text top="856" left="450" width="350" height="15" font="5">onds), mild degree of frailty (unable to perform 1 activity</text>
<text top="874" left="450" width="235" height="15" font="5">of daily living or unable to perform a 5</text>
<text top="871" left="685" width="114" height="19" font="5">–meter walk in &lt;6</text>
<text top="892" left="450" width="350" height="15" font="5">seconds), and moderate-to-severe degree of frailty (unable</text>
<text top="910" left="450" width="66" height="15" font="5">to perform</text>
<text top="906" left="520" width="279" height="19" font="5">2 activities of daily living). Further research</text>
<text top="928" left="450" width="350" height="15" font="5">is required to enhance the predictive accuracy of current</text>
<text top="946" left="450" width="350" height="15" font="5">risk scores, particularly in patients undergoing trans-</text>
<text top="964" left="450" width="286" height="15" font="5">catheter therapy. The overall risks versus bene</text>
<text top="960" left="736" width="64" height="19" font="5">ﬁts should</text>
<text top="982" left="450" width="350" height="15" font="5">then be discussed with the patient and family using a</text>
<text top="1000" left="450" width="198" height="15" font="5">shared decision-making process.</text>
<text top="1017" left="465" width="181" height="15" font="5">In addition to the risk classi</text>
<text top="1014" left="645" width="63" height="19" font="5">ﬁcation in</text>
<text top="1017" left="716" width="49" height="15" font="6"><a href="e57.full.html#13">Table 7</a></text>
<text top="1017" left="764" width="35" height="15" font="5">, it is</text>
<text top="1035" left="450" width="350" height="15" font="5">appropriate to defer any type of intervention in patients</text>
<text top="1053" left="450" width="106" height="15" font="5">who will not bene</text>
<text top="1050" left="556" width="244" height="19" font="5">ﬁt in terms of symptoms or improved life</text>
<text top="1071" left="450" width="350" height="15" font="5">span from the procedure. This group of patients in whom</text>
<text top="1089" left="450" width="350" height="15" font="5">surgical or transcatheter intervention for severe VHD is</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e68</text>
</page>
<page number="13" position="absolute" top="0" left="0" height="1160" width="864">
<text top="497" left="64" width="261" height="15" font="5">futile are those with 1) a life expectancy of</text>
<text top="494" left="330" width="84" height="19" font="5">&lt;1 year, even</text>
<text top="515" left="64" width="350" height="15" font="5">with a successful procedure, and 2) those who have a</text>
<text top="533" left="64" width="61" height="15" font="5">chance of</text>
<text top="530" left="133" width="281" height="19" font="5">“survival with beneﬁt” of &lt;25% at 2 years.</text>
<text top="551" left="64" width="117" height="15" font="5">Survival with bene</text>
<text top="548" left="182" width="232" height="19" font="5">ﬁt means survival with improvement</text>
<text top="569" left="64" width="350" height="15" font="5">by at least 1 New York Heart Association (NYHA) or</text>
<text top="587" left="64" width="350" height="15" font="5">Canadian Cardiovascular Society class in heart failure</text>
<text top="605" left="64" width="350" height="15" font="5">(HF) or angina symptoms, improvement in quality of life,</text>
<text top="623" left="64" width="350" height="15" font="5">or improvement in life expectancy. Those patients with</text>
<text top="641" left="64" width="241" height="15" font="5">severe frailty may fall into this category.</text>
<text top="659" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="659" left="212" width="38" height="15" font="6"><a href="e57.full.html#101">(41,74</a></text>
<text top="655" left="251" width="27" height="19" font="6"><a href="e57.full.html#101">–78)</a></text>
<text top="690" left="64" width="293" height="12" font="19">2.6. The Heart Valve Team and Heart Valve</text>
<text top="708" left="64" width="283" height="12" font="19">Centers of Excellence: Recommendations</text>
<text top="730" left="65" width="349" height="15" font="5">The number of patients presenting with VHD in devel-</text>
<text top="748" left="64" width="350" height="15" font="5">oped countries is growing, primarily due to the increasing</text>
<text top="766" left="64" width="350" height="15" font="5">age of the population. In addition, more patients with</text>
<text top="784" left="64" width="350" height="15" font="5">VHD are referred to cardiovascular specialists due to</text>
<text top="802" left="64" width="350" height="15" font="5">enhanced awareness of various treatments, as well as</text>
<text top="820" left="64" width="350" height="15" font="5">improved noninvasive imaging tests. When patients with</text>
<text top="838" left="64" width="350" height="15" font="5">VHD are referred for intervention in a timely manner,</text>
<text top="856" left="64" width="350" height="15" font="5">there is an improved outcome in preservation of ventricular</text>
<text top="874" left="64" width="350" height="15" font="5">function as well as enhanced survival. However, the man-</text>
<text top="892" left="64" width="350" height="15" font="5">agement of patients with VHD is becoming increasingly</text>
<text top="910" left="64" width="350" height="15" font="5">complex, due to the use of more sophisticated noninvasive</text>
<text top="928" left="64" width="350" height="15" font="5">imaging modalities and technological advances in thera-</text>
<text top="946" left="64" width="350" height="15" font="5">pies. These advances result in changing thresholds for valve</text>
<text top="964" left="64" width="350" height="15" font="5">interventions. There remain a number of patients who are</text>
<text top="981" left="64" width="350" height="15" font="5">referred for intervention too late in the course of their</text>
<text top="999" left="64" width="350" height="15" font="5">disease or not referred at all, either of which results in poor</text>
<text top="1017" left="64" width="350" height="15" font="5">long-term outcomes. Alternatively, intervention in the</text>
<text top="1035" left="64" width="350" height="15" font="5">asymptomatic patient requires expertise in evaluation and</text>
<text top="1053" left="64" width="350" height="15" font="5">noninvasive imaging assessment. The advent of trans-</text>
<text top="1071" left="64" width="350" height="15" font="5">catheter valve therapies has transformed the treatment of</text>
<text top="1089" left="64" width="350" height="15" font="5">elderly high-risk patients with severe VHD but imposes</text>
<text top="497" left="450" width="16" height="15" font="5">dif</text>
<text top="494" left="466" width="333" height="19" font="5">ﬁcult decision making in terms of risk–beneﬁt analysis.</text>
<text top="515" left="450" width="299" height="15" font="5">Patient care should be customized to the patient</text>
<text top="512" left="748" width="51" height="19" font="5">’s needs,</text>
<text top="533" left="450" width="148" height="15" font="5">values, and expectations.</text>
<text top="551" left="465" width="335" height="15" font="5">A competent practicing cardiologist should have the</text>
<text top="569" left="450" width="350" height="15" font="5">ability to diagnose and direct the treatment of most pati-</text>
<text top="587" left="450" width="350" height="15" font="5">ents with VHD. For instance, otherwise healthy patients</text>
<text top="605" left="450" width="350" height="15" font="5">with severe VHD who become symptomatic should nearly</text>
<text top="623" left="450" width="350" height="15" font="5">always be considered for intervention. However, more</text>
<text top="641" left="450" width="350" height="15" font="5">complex decision-making processes may be required in</text>
<text top="659" left="450" width="350" height="15" font="5">select patient populations, such as those who have</text>
<text top="677" left="450" width="350" height="15" font="5">asymptomatic severe VHD, those who are at high risk for</text>
<text top="695" left="450" width="233" height="15" font="5">intervention, or those who could bene</text>
<text top="691" left="683" width="116" height="19" font="5">ﬁt from specialized</text>
<text top="713" left="450" width="350" height="15" font="5">therapies such as valve repair or transcatheter valve</text>
<text top="731" left="450" width="76" height="15" font="5">intervention.</text>
<text top="748" left="465" width="335" height="15" font="5">The management of patients with complex severe VHD</text>
<text top="766" left="450" width="350" height="15" font="5">is best achieved by a Heart Valve Team composed pri-</text>
<text top="784" left="450" width="350" height="15" font="5">marily of a cardiologist and surgeon (including a structural</text>
<text top="802" left="450" width="350" height="15" font="5">valve interventionist if a catheter-based therapy is being</text>
<text top="820" left="450" width="350" height="15" font="5">considered). In selected cases, there may be a multidisci-</text>
<text top="838" left="450" width="350" height="15" font="5">plinary, collaborative group of caregivers, including cardi-</text>
<text top="856" left="450" width="350" height="15" font="5">ologists, structural valve interventionalists, cardiovascular</text>
<text top="874" left="450" width="350" height="15" font="5">imaging specialists, cardiovascular surgeons, anesthesiolo-</text>
<text top="892" left="450" width="350" height="15" font="5">gists, and nurses, all of whom have expertise in the man-</text>
<text top="910" left="450" width="350" height="15" font="5">agement and outcomes of patients with complex VHD.</text>
<text top="928" left="450" width="350" height="15" font="5">The Heart Valve Team should optimize patient selection</text>
<text top="946" left="450" width="350" height="15" font="5">for available procedures through a comprehensive under-</text>
<text top="964" left="450" width="125" height="15" font="5">standing of the risk</text>
<text top="960" left="575" width="225" height="19" font="5">–beneﬁt ratio of different treatment</text>
<text top="982" left="450" width="225" height="15" font="5">strategies. This is particularly bene</text>
<text top="978" left="675" width="125" height="19" font="5">ﬁcial in patients in</text>
<text top="1000" left="450" width="350" height="15" font="5">whom there are several options for treatment, such as the</text>
<text top="1018" left="450" width="350" height="15" font="5">elderly high-risk patient with severe symptomatic AS being</text>
<text top="1035" left="450" width="350" height="15" font="5">considered for transcatheter aortic valve replacement</text>
<text top="1053" left="450" width="350" height="15" font="5">(TAVR) or surgical aortic valve replacement (AVR). The</text>
<text top="1071" left="450" width="200" height="15" font="5">patient and family should be suf</text>
<text top="1068" left="650" width="150" height="19" font="5">ﬁciently educated by the</text>
<text top="1089" left="450" width="350" height="15" font="5">Heart Valve Team about all alternatives for treatment so</text>
<text top="103" left="64" width="588" height="11" font="13">Table 7. Risk Assessment Combining STS Risk Estimate, Frailty, Major Organ System Dysfunction, and</text>
<text top="119" left="64" width="91" height="11" font="13">Procedure-Speci</text>
<text top="116" left="155" width="90" height="17" font="13">ﬁc Impediments</text>
<text top="144" left="291" width="43" height="9" font="7">Low Risk</text>
<text top="157" left="256" width="114" height="9" font="7">(Must Meet ALL Criteria</text>
<text top="170" left="276" width="73" height="9" font="7">in This Column)</text>
<text top="144" left="406" width="83" height="9" font="7">Intermediate Risk</text>
<text top="157" left="411" width="74" height="9" font="7">(Any 1 Criterion</text>
<text top="170" left="411" width="73" height="9" font="7">in This Column)</text>
<text top="144" left="564" width="45" height="9" font="7">High Risk</text>
<text top="157" left="550" width="74" height="9" font="7">(Any 1 Criterion</text>
<text top="170" left="550" width="73" height="9" font="7">in This Column)</text>
<text top="144" left="696" width="73" height="9" font="7">Prohibitive Risk</text>
<text top="157" left="695" width="74" height="9" font="7">(Any 1 Criterion</text>
<text top="170" left="696" width="73" height="9" font="7">in This Column)</text>
<text top="187" left="64" width="48" height="9" font="7">STS <a href="e57.full.html#13">PROM</a></text>
<text top="187" left="112" width="6" height="9" font="8"><a href="e57.full.html#13">*</a></text>
<text top="185" left="256" width="22" height="14" font="7">&lt;4%</text>
<text top="201" left="268" width="20" height="9" font="7">AND</text>
<text top="187" left="387" width="14" height="9" font="7">4%</text>
<text top="185" left="401" width="19" height="14" font="7">–8%</text>
<text top="201" left="400" width="14" height="9" font="7">OR</text>
<text top="185" left="526" width="22" height="14" font="7">&gt;8%</text>
<text top="201" left="538" width="14" height="9" font="7">OR</text>
<text top="187" left="665" width="120" height="9" font="7">Predicted risk with surgery</text>
<text top="202" left="675" width="125" height="9" font="7">of death or major morbidity</text>
<text top="216" left="675" width="46" height="9" font="7">(all-cause)</text>
<text top="213" left="724" width="58" height="14" font="7">&gt;50% at 1 y</text>
<text top="230" left="675" width="14" height="9" font="7">OR</text>
<text top="219" left="64" width="27" height="9" font="7"><a href="e57.full.html#13">Frailty</a></text>
<text top="216" left="91" width="5" height="14" font="8"><a href="e57.full.html#13">y</a></text>
<text top="219" left="256" width="23" height="9" font="7">None</text>
<text top="233" left="268" width="20" height="9" font="7">AND</text>
<text top="219" left="387" width="63" height="9" font="7">1 Index (mild)</text>
<text top="233" left="400" width="14" height="9" font="7">OR</text>
<text top="216" left="526" width="49" height="14" font="7">2 Indices</text>
<text top="233" left="538" width="94" height="9" font="7">(moderate to severe)</text>
<text top="247" left="538" width="14" height="9" font="7">OR</text>
<text top="264" left="64" width="148" height="9" font="7">Major organ system compromise</text>
<text top="278" left="77" width="157" height="9" font="7">not to be improved postoperat<a href="e57.full.html#13">ively</a></text>
<text top="275" left="233" width="5" height="14" font="8"><a href="e57.full.html#13">z</a></text>
<text top="264" left="256" width="23" height="9" font="7">None</text>
<text top="278" left="268" width="20" height="9" font="7">AND</text>
<text top="264" left="387" width="71" height="9" font="7">1 Organ system</text>
<text top="278" left="400" width="14" height="9" font="7">OR</text>
<text top="264" left="526" width="101" height="9" font="7">No more than 2 organ</text>
<text top="278" left="538" width="36" height="9" font="7">systems</text>
<text top="292" left="538" width="14" height="9" font="7">OR</text>
<text top="261" left="665" width="84" height="14" font="7">3 Organ systems</text>
<text top="278" left="677" width="14" height="9" font="7">OR</text>
<text top="309" left="64" width="71" height="9" font="7">Procedure-speci</text>
<text top="306" left="135" width="10" height="14" font="7">ﬁc</text>
<text top="323" left="77" width="54" height="9" font="7">impediment</text>
<text top="320" left="131" width="5" height="14" font="8"><a href="e57.full.html#13">x</a></text>
<text top="309" left="256" width="23" height="9" font="7">None</text>
<text top="309" left="387" width="111" height="9" font="7">Possible procedure-speci</text>
<text top="306" left="498" width="10" height="14" font="7">ﬁc</text>
<text top="323" left="400" width="54" height="9" font="7">impediment</text>
<text top="309" left="526" width="111" height="9" font="7">Possible procedure-speci</text>
<text top="306" left="637" width="10" height="14" font="7">ﬁc</text>
<text top="323" left="538" width="54" height="9" font="7">impediment</text>
<text top="309" left="665" width="104" height="9" font="7">Severe procedure-speci</text>
<text top="306" left="769" width="10" height="14" font="7">ﬁc</text>
<text top="323" left="677" width="54" height="9" font="7">impediment</text>
<text top="343" left="64" width="735" height="8" font="18">*Use of the STS PROM to predict risk in a given institution with reasonable reliability is appropriate only if institutional outcomes are within 1 standard deviation of STS average observed/expected ratio</text>
<text top="355" left="64" width="111" height="8" font="18">for the procedure in question.</text>
<text top="365" left="64" width="735" height="11" font="18"><a href="e57.full.html#13">y</a>Seven frailty indices: Katz Activities of Daily Living (independence in feeding, bathing, dressing, transferring, toileting, and urinary continence) and independence in ambulation (no walking aid or assist</text>
<text top="379" left="64" width="100" height="8" font="18">required or 5-meter walk in</text>
<text top="377" left="167" width="360" height="11" font="18">&lt;6 s). Other scoring systems can be applied to calculate no, mild-, or moderate-to-severe frailty.</text>
<text top="389" left="64" width="735" height="11" font="18"><a href="e57.full.html#13">z</a>Examples of major organ system compromise: Cardiacdsevere LV systolic or diastolic dysfunction or RV dysfunction, ﬁxed pulmonary hypertension; CKD stage 3 or worse; pulmonary dysfunction with</text>
<text top="403" left="64" width="19" height="8" font="18">FEV1</text>
<text top="401" left="86" width="56" height="11" font="18">&lt;50% or DLCO</text>
<text top="406" left="142" width="4" height="5" font="24">2</text>
<text top="401" left="148" width="651" height="11" font="18">&lt;50% of predicted; CNS dysfunction (dementia, Alzheimer’s disease, Parkinson’s disease, CVA with persistent physical limitation); GI dysfunctiondCrohn’s disease, ulcerative</text>
<text top="415" left="64" width="179" height="8" font="18">colitis, nutritional impairment, or serum albumin</text>
<text top="413" left="247" width="502" height="11" font="18">&lt;3.0; cancerdactive malignancy; and liverdany history of cirrhosis, variceal bleeding, or elevated INR in the absence of VKA therapy.</text>
<text top="425" left="64" width="617" height="11" font="18"><a href="e57.full.html#13">x</a>Examples: tracheostomy present, heavily calciﬁed ascending aorta, chest malformation, arterial coronary graft adherent to posterior chest wall, or radiation damage.</text>
<text top="439" left="72" width="335" height="8" font="18">CKD indicates chronic kidney disease; CNS, central nervous system; CVA, stroke; DLCO</text>
<text top="442" left="406" width="4" height="5" font="24">2</text>
<text top="439" left="410" width="389" height="8" font="18">, diffusion capacity for carbon dioxide; FEV1, forced expiratory volume in 1 s; GI, gastrointestinal; INR,</text>
<text top="451" left="72" width="642" height="8" font="18">international normalized ratio; LV, left ventricular; PROM, predicted risk of mortality; RV, right ventricular; STS, Society of Thoracic Surgeons; and VKA, vitamin K antagonist.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e69</text>
</page>
<page number="14" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">that their expectations can be met as fully as possible using</text>
<text top="121" left="64" width="216" height="15" font="5">a shared decision-making approach.</text>
<text top="139" left="79" width="335" height="15" font="5">The optimal care of the patient with complex heart</text>
<text top="157" left="64" width="350" height="15" font="5">disease is best performed in centers that can provide all</text>
<text top="175" left="64" width="350" height="15" font="5">available options for diagnosis and management, including</text>
<text top="192" left="64" width="350" height="15" font="5">the expertise for complex aortic or mitral valve repair, aortic</text>
<text top="210" left="64" width="350" height="15" font="5">surgery, and transcatheter therapies. This has led to the</text>
<text top="228" left="64" width="350" height="15" font="5">development of Heart Valve Centers of Excellence. Heart</text>
<text top="246" left="64" width="350" height="15" font="5">Valve Centers of Excellence 1) are composed of experi-</text>
<text top="264" left="64" width="350" height="15" font="5">enced healthcare providers with expertise from multiple</text>
<text top="282" left="64" width="350" height="15" font="5">disciplines; 2) offer all available options for diagnosis and</text>
<text top="300" left="64" width="350" height="15" font="5">management, including complex valve repair, aortic sur-</text>
<text top="318" left="64" width="350" height="15" font="5">gery, and transcatheter therapies; 3) participate in regional</text>
<text top="336" left="64" width="350" height="15" font="5">or national outcome registries; 4) demonstrate adherence</text>
<text top="354" left="64" width="350" height="15" font="5">to national guidelines; 5) participate in continued evalua-</text>
<text top="372" left="64" width="350" height="15" font="5">tion and quality improvement processes to enhance patient</text>
<text top="390" left="64" width="350" height="15" font="5">outcomes; and 6) publicly report their available mortality</text>
<text top="408" left="64" width="350" height="15" font="5">and success rates. Decisions about intervention at the</text>
<text top="426" left="64" width="350" height="15" font="5">Heart Valve Centers of Excellence should be dependent on</text>
<text top="444" left="64" width="65" height="15" font="5">the centers</text>
<text top="440" left="129" width="285" height="19" font="5">’ publicly available mortality rates and operative</text>
<text top="461" left="64" width="350" height="15" font="5">outcomes. It is recognized that some Heart Valve Centers</text>
<text top="479" left="64" width="349" height="15" font="5">of Excellence may have expertise in select valve problems.</text>
<text top="507" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="522" left="63" width="351" height="10" font="21">1. Patients with severe VHD should be evaluated by a multidisci-</text>
<text top="538" left="81" width="332" height="10" font="21">plinary Heart Valve Team when intervention is considered.</text>
<text top="555" left="81" width="113" height="12" font="21">(Level of Evidence: C)</text>
<text top="579" left="79" width="335" height="15" font="5">Decisions about selection and timing of interventions</text>
<text top="597" left="64" width="350" height="15" font="5">for patients with severe VHD are best done through the</text>
<text top="615" left="64" width="350" height="15" font="5">Heart Valve Team. The Heart Valve Team is composed</text>
<text top="633" left="64" width="350" height="15" font="5">primarily of a cardiologist and surgeon (including a</text>
<text top="650" left="64" width="350" height="15" font="5">structural valve interventionist if a catheter-based therapy is</text>
<text top="668" left="64" width="350" height="15" font="5">being considered). In selected cases, there may be a</text>
<text top="686" left="64" width="103" height="15" font="5">multidisciplinary,</text>
<text top="686" left="184" width="74" height="15" font="5">collaborative</text>
<text top="686" left="274" width="35" height="15" font="5">group</text>
<text top="686" left="325" width="12" height="15" font="5">of</text>
<text top="686" left="353" width="61" height="15" font="5">caregivers,</text>
<text top="704" left="64" width="350" height="15" font="5">including cardiologists, structural valve interventionalists,</text>
<text top="722" left="64" width="350" height="15" font="5">cardiovascular imaging specialists, cardiovascular surgeons,</text>
<text top="740" left="64" width="350" height="15" font="5">anesthesiologists, and nurses, many of whom have exper-</text>
<text top="758" left="64" width="350" height="15" font="5">tise in the management and outcomes of patients with</text>
<text top="776" left="64" width="350" height="15" font="5">complex VHD. For patients with infections of the heart,</text>
<text top="794" left="64" width="350" height="15" font="5">infectious disease specialists should be involved. For</text>
<text top="812" left="64" width="350" height="15" font="5">pregnant women, high-risk obstetrics should be involved.</text>
<text top="830" left="64" width="289" height="15" font="5">The Heart Valve Team 1) reviews the patient</text>
<text top="826" left="353" width="61" height="19" font="5">’s medical</text>
<text top="848" left="64" width="350" height="15" font="5">condition and valve abnormality, 2) determines the</text>
<text top="866" left="64" width="350" height="15" font="5">possible interventions that are indicated, technically</text>
<text top="884" left="64" width="350" height="15" font="5">feasible, and reasonable, and 3) discusses the risks and</text>
<text top="902" left="64" width="350" height="15" font="5">outcomes of these interventions with the patient and</text>
<text top="920" left="64" width="350" height="15" font="5">family. This approach has been used for patients with</text>
<text top="937" left="64" width="350" height="15" font="5">complex coronary artery disease (CAD) and is supported</text>
<text top="955" left="64" width="350" height="15" font="5">by reports that patients with complex CAD referred spe-</text>
<text top="973" left="64" width="10" height="15" font="5">ci</text>
<text top="970" left="74" width="340" height="19" font="5">ﬁcally for percutaneous coronary intervention (PCI) or</text>
<text top="991" left="64" width="350" height="15" font="5">coronary artery bypass graft (CABG) surgery in concurrent</text>
<text top="1009" left="64" width="350" height="15" font="5">trial registries using a heart team approach have lower</text>
<text top="1027" left="64" width="350" height="15" font="5">mortality rates than those randomly assigned to PCI or</text>
<text top="1045" left="64" width="163" height="15" font="5">CABG in controlled trials.</text>
<text top="1064" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="1063" left="212" width="38" height="15" font="6"><a href="e57.full.html#101">(35,79</a></text>
<text top="1060" left="251" width="27" height="19" font="6"><a href="e57.full.html#101">–84)</a></text>
<text top="106" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="121" left="449" width="351" height="10" font="21">1. Consultation with or referral to a Heart Valve Center of Excellence</text>
<text top="137" left="467" width="333" height="10" font="21">is reasonable when discussing treatment options for 1) asymp-</text>
<text top="154" left="467" width="321" height="10" font="21">tomatic patients with severe VHD, 2) patients who may bene</text>
<text top="151" left="788" width="11" height="16" font="21">ﬁt</text>
<text top="170" left="467" width="333" height="10" font="21">from valve repair versus valve replacement, or 3) patients with</text>
<text top="187" left="467" width="332" height="10" font="21">multiple comorbidities for whom valve intervention is considered.</text>
<text top="204" left="467" width="110" height="12" font="21">(Level of Evidence: C)</text>
<text top="236" left="465" width="335" height="15" font="5">With the advent of newer surgical techniques and</text>
<text top="254" left="450" width="350" height="15" font="5">lower rates of operative mortality, it is reasonable to lower</text>
<text top="272" left="450" width="350" height="15" font="5">the threshold for valve intervention to prevent the adverse</text>
<text top="290" left="450" width="350" height="15" font="5">consequences of severe VHD, particularly in the asymp-</text>
<text top="308" left="450" width="350" height="15" font="5">tomatic patient with severe VHD. However, the overall</text>
<text top="326" left="450" width="28" height="15" font="5">bene</text>
<text top="323" left="478" width="321" height="19" font="5">ﬁt of operating on these patients requires that the</text>
<text top="344" left="450" width="350" height="15" font="5">patient be evaluated by those with expertise in assessment</text>
<text top="362" left="450" width="350" height="15" font="5">of VHD and that they undergo operation in a center</text>
<text top="380" left="450" width="350" height="15" font="5">with low operative mortality and excellent patient out-</text>
<text top="398" left="450" width="77" height="15" font="5">comes. If a</text>
<text top="395" left="536" width="264" height="19" font="5">“watchful waiting” approach is taken in</text>
<text top="416" left="450" width="350" height="15" font="5">asymptomatic patients with severe VHD, a Heart Valve</text>
<text top="434" left="450" width="205" height="15" font="5">Center of Excellence may be bene</text>
<text top="430" left="655" width="144" height="19" font="5">ﬁcial in ensuring proper</text>
<text top="452" left="450" width="63" height="15" font="5">follow-up.</text>
<text top="470" left="465" width="335" height="15" font="5">Surgical outcomes depend on the expertise and expe-</text>
<text top="488" left="450" width="350" height="15" font="5">rience of the surgeons, especially with highly specialized</text>
<text top="506" left="450" width="350" height="15" font="5">operations such as complex mitral valve repair and surgical</text>
<text top="523" left="450" width="350" height="15" font="5">treatment of aortic disease. It is well documented that</text>
<text top="541" left="450" width="350" height="15" font="5">operative risks and outcomes are better for patients un-</text>
<text top="559" left="450" width="350" height="15" font="5">dergoing mitral valve repair versus mitral valve replace-</text>
<text top="577" left="450" width="350" height="15" font="5">ment (MVR) in patients with primary mitral regurgitation</text>
<text top="595" left="450" width="350" height="15" font="5">(MR) and morphology suitable for repair. Although the</text>
<text top="613" left="450" width="350" height="15" font="5">rate of mitral valve repair has increased, a number of pa-</text>
<text top="631" left="450" width="350" height="15" font="5">tients with primary MR will still undergo MVR. The rate</text>
<text top="649" left="450" width="350" height="15" font="5">of successful mitral valve repair in patients with primary</text>
<text top="667" left="450" width="350" height="15" font="5">MR is dependent on the experience of the surgeon as well</text>
<text top="685" left="450" width="350" height="15" font="5">as the surgical volume. Optimal outcomes are best ach-</text>
<text top="703" left="450" width="350" height="15" font="5">ieved in Heart Valve Centers of Excellence dedicated to</text>
<text top="721" left="450" width="350" height="15" font="5">the management and treatment of patients with VHD</text>
<text top="739" left="450" width="350" height="15" font="5">and that offer all available treatment options, including</text>
<text top="757" left="450" width="350" height="15" font="5">complex valve repair, aortic surgery, and transcatheter</text>
<text top="775" left="450" width="350" height="15" font="5">therapies. At Heart Valve Centers of Excellence, health-</text>
<text top="793" left="450" width="350" height="15" font="5">care providers have experience and expertise from multiple</text>
<text top="810" left="450" width="350" height="15" font="5">disciplines, demonstrate adherence to national guidelines,</text>
<text top="828" left="450" width="350" height="15" font="5">participate in regional or national outcome registries, and</text>
<text top="846" left="450" width="350" height="15" font="5">publicly report their available mortality and success rates</text>
<text top="864" left="450" width="350" height="15" font="5">with a continued quality improvement program in place.</text>
<text top="882" left="450" width="350" height="15" font="5">Decisions on early operation in the asymptomatic pati-</text>
<text top="900" left="450" width="350" height="15" font="5">ent can then be made based on the reported data from</text>
<text top="918" left="450" width="60" height="15" font="5">the speci</text>
<text top="915" left="510" width="290" height="19" font="5">ﬁc Heart Valve Center of Excellence, in-</text>
<text top="936" left="450" width="350" height="15" font="5">cluding mortality and morbidity statistics as well as du-</text>
<text top="954" left="450" width="350" height="15" font="5">rable repair rates for patients with primary MR. Heart</text>
<text top="972" left="450" width="350" height="15" font="5">Valve Centers of Excellence have also been shown to in-</text>
<text top="990" left="450" width="350" height="15" font="5">crease the proportion of patients managed according to</text>
<text top="1008" left="450" width="350" height="15" font="5">GDMT, decrease unnecessary testing, optimize timing of</text>
<text top="1026" left="450" width="350" height="15" font="5">intervention, and best handle other problems such as</text>
<text top="1044" left="450" width="350" height="15" font="5">operations for complex multivalve disease, multiple reop-</text>
<text top="1062" left="450" width="350" height="15" font="5">erations, and complex IE. Heart Valve Centers of</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e70</text>
</page>
<page number="15" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">Excellence can play an important role in patient and</text>
<text top="121" left="64" width="350" height="15" font="5">clinician education to help ensure timely referral for</text>
<text top="139" left="64" width="276" height="15" font="5">evaluation and proper protocol for follow-up.</text>
<text top="157" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="157" left="212" width="38" height="15" font="6"><a href="e57.full.html#101">(35,85</a></text>
<text top="153" left="251" width="27" height="19" font="6"><a href="e57.full.html#101">–88)</a></text>
<text top="200" left="64" width="143" height="14" font="17">3. Aortic Stenosis</text>
<text top="242" left="65" width="21" height="15" font="5">See</text>
<text top="242" left="89" width="44" height="15" font="6"><a href="e57.full.html#16">Table 8</a></text>
<text top="242" left="136" width="184" height="15" font="5">for the stages of valvular AS and</text>
<text top="242" left="322" width="49" height="15" font="6"><a href="e57.full.html#20">Tables 9</a></text>
<text top="242" left="374" width="22" height="15" font="5">and</text>
<text top="242" left="399" width="15" height="15" font="6"><a href="e57.full.html#23">10</a></text>
<text top="260" left="64" width="350" height="15" font="5">for a summary of recommendations for choice and timing</text>
<text top="278" left="64" width="91" height="15" font="5">of intervention.</text>
<text top="320" left="64" width="181" height="12" font="19">3.1. Stages of Valvular AS</text>
<text top="342" left="65" width="349" height="15" font="5">Medical and interventional approaches to the management</text>
<text top="360" left="64" width="350" height="15" font="5">of patients with valvular AS depend on accurate diagnosis</text>
<text top="378" left="64" width="261" height="15" font="5">of the cause and stage of the disease process.</text>
<text top="378" left="329" width="45" height="15" font="6"><a href="e57.full.html#16">Table 8</a></text>
<text top="378" left="378" width="36" height="15" font="5">shows</text>
<text top="396" left="64" width="350" height="15" font="5">the stages of AS ranging from patients at risk of AS (stage</text>
<text top="414" left="64" width="350" height="15" font="5">A) or with progressive hemodynamic obstruction (stage B)</text>
<text top="432" left="64" width="350" height="15" font="5">to severe asymptomatic (stage C) and symptomatic AS</text>
<text top="450" left="64" width="211" height="15" font="5">(stage D). Each of these stages is de</text>
<text top="447" left="276" width="138" height="19" font="5">ﬁned by valve anatomy,</text>
<text top="468" left="64" width="350" height="15" font="5">valve hemodynamics, the consequences of valve obstruction</text>
<text top="486" left="64" width="350" height="15" font="5">on the left ventricle and vasculature, as well as by patient</text>
<text top="504" left="64" width="350" height="15" font="5">symptoms. Hemodynamic severity is best characterized by</text>
<text top="522" left="64" width="350" height="15" font="5">the transaortic maximum velocity (or mean pressure</text>
<text top="540" left="64" width="229" height="15" font="5">gradient) when the transaortic volume</text>
<text top="536" left="297" width="116" height="19" font="5">ﬂow rate is normal.</text>
<text top="558" left="64" width="350" height="15" font="5">However, some patients with AS have a low transaortic</text>
<text top="576" left="64" width="43" height="15" font="5">volume</text>
<text top="572" left="111" width="303" height="19" font="5">ﬂow rate due to either LV systolic dysfunction with</text>
<text top="594" left="64" width="350" height="15" font="5">a low LV ejection fraction (LVEF) or due to a small hy-</text>
<text top="611" left="64" width="350" height="15" font="5">pertrophied left ventricle with a low stroke volume. These</text>
<text top="629" left="64" width="350" height="15" font="5">categories of severe AS pose a diagnostic and management</text>
<text top="647" left="64" width="350" height="15" font="5">challenge distinctly different from the challenges faced by</text>
<text top="665" left="64" width="350" height="15" font="5">the majority of patients with AS, who have a high gradient</text>
<text top="683" left="64" width="350" height="15" font="5">and velocity when AS is severe. These special subgroups</text>
<text top="701" left="64" width="59" height="15" font="5">with low-</text>
<text top="698" left="123" width="290" height="19" font="5">ﬂow AS are designated D2 (with a low LVEF)</text>
<text top="719" left="64" width="194" height="15" font="5">and D3 (with a normal LVEF).</text>
<text top="737" left="79" width="44" height="15" font="5">The de</text>
<text top="734" left="123" width="291" height="19" font="5">ﬁnition of severe AS is based on natural history</text>
<text top="755" left="64" width="350" height="15" font="5">studies of patients with unoperated AS, which show that</text>
<text top="773" left="64" width="350" height="15" font="5">the prognosis is poor once there is a peak aortic valve ve-</text>
<text top="791" left="64" width="48" height="15" font="5">locity of</text>
<text top="787" left="117" width="297" height="19" font="5">&gt;4 m per second, corresponding to a mean aortic</text>
<text top="809" left="64" width="83" height="15" font="5">valve gradient</text>
<text top="805" left="152" width="262" height="19" font="5">&gt;40 mm Hg. In patients with low forward</text>
<text top="823" left="64" width="350" height="19" font="5">ﬂow, severe AS can be present with lower aortic valve</text>
<text top="845" left="64" width="350" height="15" font="5">velocities and lower aortic valve gradients. Thus, an aortic</text>
<text top="863" left="64" width="350" height="15" font="5">valve area should be calculated in these patients. The</text>
<text top="881" left="64" width="350" height="15" font="5">prognosis of patients with AS is poorer when the aortic</text>
<text top="898" left="64" width="69" height="15" font="5">valve area is</text>
<text top="895" left="137" width="52" height="19" font="5">&lt;1.0 cm</text>
<text top="895" left="189" width="6" height="10" font="14">2</text>
<text top="898" left="194" width="69" height="15" font="5">. At normal</text>
<text top="895" left="267" width="147" height="19" font="5">ﬂow rates, an aortic valve</text>
<text top="916" left="64" width="38" height="15" font="5">area of</text>
<text top="913" left="106" width="51" height="19" font="5">&lt;0.8 cm</text>
<text top="913" left="157" width="6" height="10" font="14">2</text>
<text top="916" left="165" width="248" height="15" font="5">correlates with a mean aortic valve gradient</text>
<text top="931" left="64" width="350" height="19" font="5">&gt;40 mm Hg. However, symptomatic patients who have a</text>
<text top="952" left="64" width="26" height="15" font="5">calci</text>
<text top="949" left="90" width="324" height="19" font="5">ﬁed aortic valve with reduced opening and an aortic</text>
<text top="970" left="64" width="158" height="15" font="5">valve area between 0.8 cm</text>
<text top="967" left="222" width="6" height="10" font="14">2</text>
<text top="970" left="233" width="69" height="15" font="5">and 1.0 cm</text>
<text top="967" left="302" width="6" height="10" font="14">2</text>
<text top="970" left="312" width="102" height="15" font="5">should be closely</text>
<text top="988" left="64" width="302" height="15" font="5">evaluated to determine whether they would bene</text>
<text top="985" left="366" width="48" height="19" font="5">ﬁt from</text>
<text top="1006" left="64" width="350" height="15" font="5">valve intervention. Meticulous attention to detail is required</text>
<text top="1024" left="64" width="350" height="15" font="5">when assessing aortic valve hemodynamics, either with</text>
<text top="1042" left="64" width="350" height="15" font="5">Doppler echocardiography or cardiac catheterization, and the</text>
<text top="1060" left="64" width="350" height="15" font="5">inherent variability of the measurements and calculations</text>
<text top="1078" left="64" width="330" height="15" font="5">should always be considered in clinical-decision making.</text>
<text top="103" left="450" width="136" height="12" font="19">3.2. Aortic Stenosis</text>
<text top="130" left="450" width="206" height="15" font="5">3.2.1. Diagnosis and Follow-Up</text>
<text top="156" left="451" width="349" height="15" font="5">The overall approach to the initial diagnosis of VHD is</text>
<text top="174" left="450" width="75" height="15" font="5">discussed in</text>
<text top="174" left="533" width="71" height="15" font="6"><a href="e57.full.html#8">Section 2.3</a></text>
<text top="174" left="605" width="195" height="15" font="5"><a href="e57.full.html#8">, </a>and additional considerations</text>
<text top="192" left="450" width="29" height="15" font="5">speci</text>
<text top="189" left="479" width="257" height="19" font="5">ﬁc to patients with AS are addressed here.</text>
<text top="223" left="450" width="332" height="11" font="7">3.2.1.1. DIAGNOSTIC TESTINGdINITIAL DIAGNOSIS: RECOMMENDATIONS</text>
<text top="246" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="261" left="449" width="350" height="10" font="21">1. TTE is indicated in patients with signs or symptoms of AS or a</text>
<text top="278" left="467" width="332" height="10" font="21">bicuspid aortic valve for accurate diagnosis of the cause of AS,</text>
<text top="294" left="467" width="332" height="10" font="21">hemodynamic severity, LV size, and systolic function, and for</text>
<text top="311" left="467" width="62" height="10" font="21">determining</text>
<text top="311" left="541" width="51" height="10" font="21">prognosis</text>
<text top="311" left="603" width="19" height="10" font="21">and</text>
<text top="311" left="633" width="33" height="10" font="21">timing</text>
<text top="311" left="677" width="10" height="10" font="21">of</text>
<text top="311" left="699" width="27" height="10" font="21">valve</text>
<text top="311" left="737" width="63" height="10" font="21">intervention</text>
<text top="327" left="467" width="58" height="10" font="22"><a href="e57.full.html#101">(24,25,89)</a></text>
<text top="327" left="526" width="121" height="12" font="21"><a href="e57.full.html#101">. </a>(Level of Evidence: B)</text>
<text top="360" left="465" width="160" height="15" font="5">Most patients with AS are</text>
<text top="357" left="629" width="170" height="19" font="5">ﬁrst diagnosed when cardiac</text>
<text top="378" left="450" width="350" height="15" font="5">auscultation reveals a systolic murmur or after a review of</text>
<text top="396" left="450" width="350" height="15" font="5">TTE requested for other indications. Physical examination</text>
<text top="411" left="450" width="350" height="19" font="5">ﬁndings are speciﬁc but not sensitive for evaluation of</text>
<text top="432" left="450" width="179" height="15" font="5">stenosis severity. The classic</text>
<text top="429" left="637" width="162" height="19" font="5">ﬁndings of a loud (grade</text>
<text top="447" left="450" width="350" height="19" font="5">3/6), late-peaking systolic murmur that radiates to the</text>
<text top="468" left="450" width="350" height="15" font="5">carotid arteries, a single or paradoxically split second heart</text>
<text top="486" left="450" width="350" height="15" font="5">sound, and a delayed and diminished carotid upstroke</text>
<text top="504" left="450" width="21" height="15" font="5">con</text>
<text top="500" left="471" width="328" height="19" font="5">ﬁrm the presence of severe AS. However, carotid up-</text>
<text top="522" left="450" width="350" height="15" font="5">stroke may be normal in elderly patients because of the</text>
<text top="540" left="450" width="350" height="15" font="5">effects of aging on the vasculature, and the murmur may be</text>
<text top="558" left="450" width="350" height="15" font="5">soft or may radiate to the apex. The only physical exami-</text>
<text top="576" left="450" width="38" height="15" font="5">nation</text>
<text top="572" left="492" width="308" height="19" font="5">ﬁnding that is reliable in excluding the possibility of</text>
<text top="593" left="450" width="297" height="15" font="5">severe AS is a normally split second heart sound.</text>
<text top="611" left="465" width="335" height="15" font="5">TTE is indicated when there is an unexplained systolic</text>
<text top="629" left="450" width="350" height="15" font="5">murmur, a single second heart sound, a history of a</text>
<text top="647" left="450" width="350" height="15" font="5">bicuspid aortic valve, or symptoms that might be due to</text>
<text top="665" left="450" width="323" height="15" font="5">AS. Echocardiographic imaging allows reliable identi</text>
<text top="662" left="773" width="26" height="19" font="5">ﬁca-</text>
<text top="683" left="450" width="189" height="15" font="5">tion of the number of valve lea</text>
<text top="680" left="639" width="160" height="19" font="5">ﬂets along with qualitative</text>
<text top="701" left="450" width="227" height="15" font="5">assessment of valve motion and lea</text>
<text top="698" left="677" width="123" height="19" font="5">ﬂet calciﬁcation. In</text>
<text top="719" left="450" width="350" height="15" font="5">nearly all patients, the hemodynamic severity of the ste-</text>
<text top="737" left="450" width="147" height="15" font="5">notic lesion can be de</text>
<text top="734" left="597" width="202" height="19" font="5">ﬁned with Doppler echocardio-</text>
<text top="755" left="450" width="350" height="15" font="5">graphic measurements of maximum transvalvular velocity,</text>
<text top="773" left="450" width="350" height="15" font="5">mean pressure gradient, and continuity equation valve area,</text>
<text top="791" left="450" width="350" height="15" font="5">as discussed in the European Association of Echocardi-</text>
<text top="809" left="450" width="350" height="15" font="5">ography (EAE)/ASE guidelines for evaluation of valve</text>
<text top="827" left="450" width="350" height="15" font="5">stenosis. Doppler evaluation of severity of AS has been well</text>
<text top="845" left="450" width="350" height="15" font="5">validated in experimental and human studies compared</text>
<text top="863" left="450" width="350" height="15" font="5">with direct measurements of intracardiac pressure and</text>
<text top="880" left="450" width="350" height="15" font="5">cardiac output. In addition, Doppler measures of severity</text>
<text top="898" left="450" width="350" height="15" font="5">of AS are potent predictors of clinical outcome. However,</text>
<text top="916" left="450" width="350" height="15" font="5">Doppler may underestimate or overestimate aortic velocity</text>
<text top="934" left="450" width="350" height="15" font="5">and disease severity in some patients, so clinical evaluation</text>
<text top="952" left="450" width="292" height="15" font="5">should include symptoms, physical examination</text>
<text top="949" left="748" width="52" height="19" font="5">ﬁndings,</text>
<text top="970" left="450" width="277" height="15" font="5">and results of other diagnostic testing as well.</text>
<text top="988" left="465" width="335" height="15" font="5">TTE is also useful for determining the LV response to</text>
<text top="1006" left="450" width="350" height="15" font="5">pressure overload. Systolic function is evaluated using 2D</text>
<text top="1024" left="450" width="26" height="15" font="5">or 3</text>
<text top="1021" left="476" width="324" height="19" font="5">–dimensional (3D) measurement of LVEF. LV dia-</text>
<text top="1042" left="450" width="350" height="15" font="5">stolic function can be evaluated using standard Doppler</text>
<text top="1060" left="450" width="350" height="15" font="5">approaches and an estimate of pulmonary systolic pressure</text>
<text top="1078" left="450" width="350" height="15" font="5">derived from the TR jet. In addition, TTE allows</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e71</text>
</page>
<page number="16" position="absolute" top="0" left="0" height="1160" width="864">
<text top="882" left="64" width="350" height="15" font="5">diagnosis and evaluation of concurrent valve lesions, with</text>
<text top="900" left="64" width="248" height="15" font="5">MR being common in patients with AS.</text>
<text top="919" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="918" left="212" width="106" height="15" font="6"><a href="e57.full.html#100">(8,19,24,25,27,89</a></text>
<text top="915" left="318" width="27" height="19" font="6"><a href="e57.full.html#100">–94)</a></text>
<text top="945" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="960" left="63" width="351" height="10" font="21">1. Low-dose dobutamine stress testing using echocardiographic or</text>
<text top="977" left="81" width="333" height="10" font="21">invasive hemodynamic measurements is reasonable in patients</text>
<text top="993" left="81" width="233" height="10" font="21">with stage D2 AS with all of the following</text>
<text top="993" left="320" width="19" height="10" font="22"><a href="e57.full.html#102">(95</a></text>
<text top="990" left="338" width="25" height="16" font="22"><a href="e57.full.html#102">–97)</a></text>
<text top="993" left="368" width="46" height="12" font="21">(Level of</text>
<text top="1010" left="81" width="68" height="12" font="21">Evidence: B):</text>
<text top="1026" left="81" width="42" height="10" font="21">a. Calci</text>
<text top="1023" left="123" width="250" height="16" font="21">ﬁed aortic valve with reduced systolic opening;</text>
<text top="1042" left="81" width="125" height="10" font="21">b. LVEF less than 50%;</text>
<text top="1059" left="81" width="172" height="10" font="21">c. Calculated valve area 1.0 cm</text>
<text top="1056" left="252" width="5" height="7" font="25">2</text>
<text top="1059" left="262" width="62" height="10" font="21">or less; and</text>
<text top="1075" left="81" width="333" height="10" font="21">d. Aortic velocity less than 4.0 m per second or mean pressure</text>
<text top="1092" left="97" width="159" height="10" font="21">gradient less than 40 mm Hg.</text>
<text top="882" left="465" width="335" height="15" font="5">Patients with severe AS and concurrent LV systolic</text>
<text top="900" left="450" width="350" height="15" font="5">dysfunction often present with a relatively low transvalvular</text>
<text top="918" left="450" width="350" height="15" font="5">velocity and pressure gradient (i.e., mean pressure</text>
<text top="936" left="450" width="49" height="15" font="5">gradient</text>
<text top="932" left="505" width="294" height="19" font="5">&lt;40 mm Hg) but with a small calculated valve</text>
<text top="954" left="450" width="350" height="15" font="5">area. In some of these patients, severe AS is present with</text>
<text top="972" left="450" width="350" height="15" font="5">LV systolic dysfunction due to afterload mismatch. In</text>
<text top="990" left="450" width="350" height="15" font="5">others, primary myocardial dysfunction is present with only</text>
<text top="1008" left="450" width="221" height="15" font="5">moderate AS and reduced aortic lea</text>
<text top="1004" left="670" width="129" height="19" font="5">ﬂet opening due to a</text>
<text top="1026" left="450" width="140" height="15" font="5">low transaortic volume</text>
<text top="1022" left="597" width="202" height="19" font="5">ﬂow rate. In these patients with</text>
<text top="1044" left="450" width="27" height="15" font="5">low-</text>
<text top="1040" left="477" width="322" height="19" font="5">ﬂow/low-gradient AS and LV systolic dysfunction</text>
<text top="1061" left="450" width="44" height="15" font="5">(LVEF</text>
<text top="1058" left="498" width="301" height="19" font="5">&lt;50%), it may be useful to measure aortic velocity</text>
<text top="1079" left="450" width="350" height="15" font="5">(or mean pressure gradient) and valve area during a</text>
<text top="103" left="64" width="175" height="11" font="13">Table 8. Stages of Valvular AS</text>
<text top="129" left="64" width="27" height="9" font="7">Stage</text>
<text top="129" left="134" width="12" height="9" font="7">De</text>
<text top="126" left="146" width="32" height="14" font="7">ﬁnition</text>
<text top="129" left="256" width="69" height="9" font="7">Valve Anatomy</text>
<text top="129" left="400" width="99" height="9" font="7">Valve Hemodynamics</text>
<text top="129" left="538" width="136" height="9" font="7">Hemodynamic Consequences</text>
<text top="129" left="716" width="49" height="9" font="7">Symptoms</text>
<text top="145" left="67" width="7" height="9" font="7">A</text>
<text top="145" left="98" width="60" height="9" font="7">At risk of AS</text>
<text top="145" left="221" width="104" height="14" font="7"> Bicuspid aortic valve</text>
<text top="162" left="232" width="88" height="9" font="7">(or other congenital</text>
<text top="176" left="232" width="68" height="9" font="7">valve anomaly)</text>
<text top="187" left="221" width="105" height="14" font="7"> Aortic valve sclerosis</text>
<text top="145" left="368" width="46" height="14" font="7"> Aortic V</text>
<text top="151" left="414" width="14" height="6" font="23">max</text>
<text top="144" left="432" width="36" height="14" font="7">&lt;2 m/s</text>
<text top="144" left="539" width="35" height="14" font="7"> None</text>
<text top="144" left="681" width="35" height="14" font="7"> None</text>
<text top="207" left="67" width="7" height="9" font="7">B</text>
<text top="207" left="98" width="70" height="9" font="7">Progressive AS</text>
<text top="206" left="221" width="119" height="14" font="7"> Mild-to-moderate leaﬂet</text>
<text top="224" left="232" width="20" height="9" font="7">calci</text>
<text top="221" left="252" width="94" height="14" font="7">ﬁcation of a bicuspid</text>
<text top="238" left="232" width="35" height="9" font="7">or trilea</text>
<text top="235" left="267" width="62" height="14" font="7">ﬂet valve with</text>
<text top="252" left="232" width="117" height="9" font="7">some reduction in systolic</text>
<text top="266" left="232" width="44" height="9" font="7">motion or</text>
<text top="278" left="220" width="127" height="14" font="7"> Rheumatic valve changes</text>
<text top="295" left="232" width="110" height="9" font="7">with commissural fusion</text>
<text top="207" left="368" width="87" height="14" font="7"> Mild AS: Aortic V</text>
<text top="213" left="455" width="14" height="6" font="23">max</text>
<text top="224" left="380" width="15" height="9" font="7">2.0</text>
<text top="221" left="394" width="83" height="14" font="7">–2.9 m/s or mean</text>
<text top="233" left="380" width="7" height="16" font="16">D</text>
<text top="238" left="387" width="6" height="9" font="7">P</text>
<text top="235" left="396" width="57" height="14" font="7">&lt;20 mm Hg</text>
<text top="249" left="368" width="101" height="14" font="7"> Moderate AS: Aortic</text>
<text top="266" left="380" width="6" height="9" font="7">V</text>
<text top="270" left="385" width="14" height="6" font="23">max</text>
<text top="266" left="403" width="15" height="9" font="7">3.0</text>
<text top="263" left="418" width="42" height="14" font="7">–3.9 m/s</text>
<text top="280" left="380" width="38" height="9" font="7">or mean</text>
<text top="276" left="421" width="7" height="16" font="16">D</text>
<text top="280" left="428" width="22" height="9" font="7">P 20</text>
<text top="277" left="450" width="17" height="14" font="7">–39</text>
<text top="295" left="380" width="33" height="9" font="7">mm Hg</text>
<text top="206" left="539" width="88" height="14" font="7"> Early LV diastolic</text>
<text top="224" left="550" width="73" height="9" font="7">dysfunction may</text>
<text top="238" left="550" width="48" height="9" font="7">be present</text>
<text top="249" left="539" width="69" height="14" font="7"> Normal LVEF</text>
<text top="206" left="681" width="35" height="14" font="7"> None</text>
<text top="312" left="67" width="130" height="9" font="7">C: Asymptomatic severe AS</text>
<text top="330" left="67" width="13" height="9" font="7">C1</text>
<text top="330" left="98" width="67" height="9" font="7">Asymptomatic</text>
<text top="344" left="111" width="47" height="9" font="7">severe AS</text>
<text top="329" left="221" width="130" height="14" font="7"> Severe leaﬂet calciﬁcation</text>
<text top="346" left="232" width="120" height="9" font="7">or congenital stenosis with</text>
<text top="360" left="232" width="92" height="9" font="7">severely reduced lea</text>
<text top="357" left="325" width="14" height="14" font="7">ﬂet</text>
<text top="374" left="232" width="35" height="9" font="7">opening</text>
<text top="329" left="368" width="46" height="14" font="7"> Aortic V</text>
<text top="336" left="414" width="14" height="6" font="23">max</text>
<text top="329" left="432" width="36" height="14" font="7">4 m/s</text>
<text top="346" left="380" width="38" height="9" font="7">or mean</text>
<text top="341" left="421" width="7" height="16" font="16">D</text>
<text top="346" left="428" width="6" height="9" font="7">P</text>
<text top="343" left="438" width="57" height="14" font="7">40 mm Hg</text>
<text top="357" left="368" width="123" height="14" font="7"> AVA typically is 1.0 cm</text>
<text top="358" left="491" width="5" height="6" font="23">2</text>
<text top="374" left="380" width="36" height="9" font="7">(or AVAi</text>
<text top="371" left="419" width="40" height="14" font="7">0.6 cm</text>
<text top="372" left="459" width="5" height="6" font="23">2</text>
<text top="374" left="464" width="14" height="9" font="7">/m</text>
<text top="372" left="478" width="5" height="6" font="23">2</text>
<text top="374" left="482" width="3" height="9" font="7">)</text>
<text top="386" left="368" width="132" height="14" font="7"> Very severe AS is an aortic</text>
<text top="403" left="380" width="6" height="9" font="7">V</text>
<text top="407" left="385" width="14" height="6" font="23">max</text>
<text top="400" left="403" width="78" height="14" font="7">5 m/s or mean</text>
<text top="412" left="380" width="7" height="16" font="16">D</text>
<text top="417" left="387" width="6" height="9" font="7">P</text>
<text top="414" left="396" width="57" height="14" font="7">60 mm Hg</text>
<text top="329" left="539" width="117" height="14" font="7"> LV diastolic dysfunction</text>
<text top="343" left="539" width="101" height="14" font="7"> Mild LV hypertrophy</text>
<text top="357" left="539" width="69" height="14" font="7"> Normal LVEF</text>
<text top="329" left="681" width="77" height="14" font="7"> None: Exercise</text>
<text top="346" left="693" width="93" height="9" font="7">testing is reasonable</text>
<text top="360" left="693" width="28" height="9" font="7">to con</text>
<text top="357" left="721" width="63" height="14" font="7">ﬁrm symptom</text>
<text top="374" left="693" width="27" height="9" font="7">status</text>
<text top="434" left="67" width="13" height="9" font="7">C2</text>
<text top="434" left="98" width="67" height="9" font="7">Asymptomatic</text>
<text top="448" left="111" width="70" height="9" font="7">severe AS with</text>
<text top="463" left="111" width="68" height="9" font="7">LV dysfunction</text>
<text top="433" left="221" width="130" height="14" font="7"> Severe leaﬂet calciﬁcation</text>
<text top="450" left="232" width="120" height="9" font="7">or congenital stenosis with</text>
<text top="465" left="232" width="92" height="9" font="7">severely reduced lea</text>
<text top="462" left="325" width="14" height="14" font="7">ﬂet</text>
<text top="479" left="232" width="35" height="9" font="7">opening</text>
<text top="433" left="368" width="46" height="14" font="7"> Aortic V</text>
<text top="440" left="414" width="14" height="6" font="23">max</text>
<text top="433" left="432" width="49" height="14" font="7">4 m/s or</text>
<text top="450" left="380" width="26" height="9" font="7">mean</text>
<text top="446" left="409" width="7" height="16" font="16">D</text>
<text top="450" left="416" width="6" height="9" font="7">P</text>
<text top="447" left="425" width="57" height="14" font="7">40 mm Hg</text>
<text top="462" left="368" width="112" height="14" font="7"> AVA typically 1.0 cm</text>
<text top="462" left="480" width="5" height="6" font="23">2</text>
<text top="479" left="380" width="36" height="9" font="7">(or AVAi</text>
<text top="476" left="419" width="40" height="14" font="7">0.6 cm</text>
<text top="477" left="459" width="5" height="6" font="23">2</text>
<text top="479" left="464" width="14" height="9" font="7">/m</text>
<text top="477" left="478" width="5" height="6" font="23">2</text>
<text top="479" left="482" width="3" height="9" font="7">)</text>
<text top="433" left="539" width="65" height="14" font="7"> LVEF &lt;50%</text>
<text top="433" left="681" width="35" height="14" font="7"> None</text>
<text top="496" left="67" width="125" height="9" font="7">D: Symptomatic severe AS</text>
<text top="514" left="67" width="13" height="9" font="7">D1</text>
<text top="514" left="98" width="61" height="9" font="7">Symptomatic</text>
<text top="528" left="111" width="56" height="9" font="7">severe high-</text>
<text top="542" left="111" width="54" height="9" font="7">gradient AS</text>
<text top="513" left="221" width="130" height="14" font="7"> Severe leaﬂet calciﬁcation</text>
<text top="530" left="232" width="120" height="9" font="7">or congenital stenosis with</text>
<text top="544" left="232" width="92" height="9" font="7">severely reduced lea</text>
<text top="541" left="325" width="14" height="14" font="7">ﬂet</text>
<text top="559" left="232" width="35" height="9" font="7">opening</text>
<text top="513" left="368" width="46" height="14" font="7"> Aortic V</text>
<text top="520" left="414" width="14" height="6" font="23">max</text>
<text top="513" left="432" width="49" height="14" font="7">4 m/s or</text>
<text top="530" left="380" width="26" height="9" font="7">mean</text>
<text top="526" left="409" width="7" height="16" font="16">D</text>
<text top="530" left="416" width="6" height="9" font="7">P</text>
<text top="527" left="425" width="57" height="14" font="7">40 mm Hg</text>
<text top="541" left="368" width="112" height="14" font="7"> AVA typically 1.0 cm</text>
<text top="542" left="480" width="5" height="6" font="23">2</text>
<text top="559" left="380" width="36" height="9" font="7">(or AVAi</text>
<text top="556" left="419" width="40" height="14" font="7">0.6 cm</text>
<text top="556" left="459" width="5" height="6" font="23">2</text>
<text top="559" left="464" width="14" height="9" font="7">/m</text>
<text top="556" left="478" width="5" height="6" font="23">2</text>
<text top="559" left="482" width="3" height="9" font="7">)</text>
<text top="573" left="380" width="103" height="9" font="7">but may be larger with</text>
<text top="587" left="380" width="60" height="9" font="7">mixed AS/AR</text>
<text top="513" left="539" width="117" height="14" font="7"> LV diastolic dysfunction</text>
<text top="527" left="539" width="78" height="14" font="7"> LV hypertrophy</text>
<text top="541" left="539" width="120" height="14" font="7"> Pulmonary hypertension</text>
<text top="559" left="550" width="70" height="9" font="7">may be present</text>
<text top="513" left="681" width="96" height="14" font="7"> Exertional dyspnea</text>
<text top="530" left="693" width="98" height="9" font="7">or decreased exercise</text>
<text top="544" left="693" width="41" height="9" font="7">tolerance</text>
<text top="556" left="681" width="89" height="14" font="7"> Exertional angina</text>
<text top="570" left="681" width="107" height="14" font="7"> Exertional syncope or</text>
<text top="587" left="693" width="51" height="9" font="7">presyncope</text>
<text top="604" left="67" width="13" height="9" font="7">D2</text>
<text top="604" left="98" width="95" height="9" font="7">Symptomatic severe</text>
<text top="619" left="111" width="18" height="9" font="7">low-</text>
<text top="616" left="129" width="82" height="14" font="7">ﬂow/low-gradient</text>
<text top="633" left="111" width="103" height="9" font="7">AS with reduced LVEF</text>
<text top="603" left="221" width="130" height="14" font="7"> Severe leaﬂet calciﬁcation</text>
<text top="621" left="232" width="114" height="9" font="7">with severely reduced lea</text>
<text top="618" left="347" width="14" height="14" font="7">ﬂet</text>
<text top="635" left="232" width="31" height="9" font="7">motion</text>
<text top="603" left="368" width="73" height="14" font="7"> AVA 1.0 cm</text>
<text top="604" left="441" width="5" height="6" font="23">2</text>
<text top="606" left="449" width="19" height="9" font="7">with</text>
<text top="621" left="380" width="68" height="9" font="7">resting aortic V</text>
<text top="625" left="447" width="14" height="6" font="23">max</text>
<text top="632" left="380" width="78" height="14" font="7">&lt;4 m/s or mean</text>
<text top="630" left="461" width="7" height="16" font="16">D</text>
<text top="635" left="468" width="6" height="9" font="7">P</text>
<text top="646" left="380" width="57" height="14" font="7">&lt;40 mm Hg</text>
<text top="660" left="368" width="96" height="14" font="7"> Dobutamine stress</text>
<text top="677" left="380" width="110" height="9" font="7">echocardiography shows</text>
<text top="692" left="380" width="18" height="9" font="7">AVA</text>
<text top="689" left="401" width="40" height="14" font="7">1.0 cm</text>
<text top="689" left="441" width="5" height="6" font="23">2</text>
<text top="692" left="449" width="28" height="9" font="7">with V</text>
<text top="696" left="477" width="14" height="6" font="23">max</text>
<text top="703" left="380" width="110" height="14" font="7">4 m/s at any ﬂow rate</text>
<text top="603" left="539" width="117" height="14" font="7"> LV diastolic dysfunction</text>
<text top="618" left="539" width="78" height="14" font="7"> LV hypertrophy</text>
<text top="632" left="539" width="65" height="14" font="7"> LVEF &lt;50%</text>
<text top="603" left="681" width="23" height="14" font="7"> HF</text>
<text top="618" left="681" width="42" height="14" font="7"> Angina</text>
<text top="632" left="681" width="112" height="14" font="7"> Syncope or presyncope</text>
<text top="723" left="67" width="13" height="9" font="7">D3</text>
<text top="723" left="98" width="95" height="9" font="7">Symptomatic severe</text>
<text top="737" left="111" width="73" height="9" font="7">low-gradient AS</text>
<text top="752" left="111" width="94" height="9" font="7">with normal LVEF or</text>
<text top="766" left="111" width="75" height="9" font="7">paradoxical low-</text>
<text top="763" left="186" width="19" height="14" font="7">ﬂow</text>
<text top="780" left="111" width="47" height="9" font="7">severe AS</text>
<text top="722" left="220" width="130" height="14" font="7"> Severe leaﬂet calciﬁcation</text>
<text top="739" left="232" width="114" height="9" font="7">with severely reduced lea</text>
<text top="736" left="347" width="14" height="14" font="7">ﬂet</text>
<text top="754" left="232" width="31" height="9" font="7">motion</text>
<text top="722" left="368" width="73" height="14" font="7"> AVA 1.0 cm</text>
<text top="723" left="441" width="5" height="6" font="23">2</text>
<text top="725" left="449" width="47" height="9" font="7">with aortic</text>
<text top="739" left="380" width="6" height="9" font="7">V</text>
<text top="743" left="385" width="14" height="6" font="23">max</text>
<text top="736" left="403" width="78" height="14" font="7">&lt;4 m/s or mean</text>
<text top="735" left="484" width="7" height="16" font="16">D</text>
<text top="739" left="491" width="6" height="9" font="7">P</text>
<text top="751" left="380" width="57" height="14" font="7">&lt;40 mm Hg</text>
<text top="765" left="368" width="112" height="14" font="7"> Indexed AVA 0.6 cm</text>
<text top="765" left="479" width="5" height="6" font="23">2</text>
<text top="768" left="484" width="14" height="9" font="7">/m</text>
<text top="765" left="498" width="5" height="6" font="23">2</text>
<text top="768" left="506" width="17" height="9" font="7">and</text>
<text top="779" left="368" width="159" height="14" font="7"> Stroke volume index &lt;35 mL/m</text>
<text top="780" left="527" width="5" height="6" font="23">2</text>
<text top="793" left="368" width="128" height="14" font="7"> Measured when patient is</text>
<text top="810" left="380" width="116" height="9" font="7">normotensive (systolic BP</text>
<text top="822" left="380" width="66" height="14" font="7">&lt;140 mm Hg)</text>
<text top="722" left="539" width="105" height="14" font="7"> Increased LV relative</text>
<text top="739" left="550" width="63" height="9" font="7">wall thickness</text>
<text top="751" left="539" width="94" height="14" font="7"> Small LV chamber</text>
<text top="768" left="550" width="105" height="9" font="7">with low stroke volume</text>
<text top="779" left="539" width="126" height="14" font="7"> Restrictive diastolic ﬁlling</text>
<text top="793" left="539" width="65" height="14" font="7"> LVEF 50%</text>
<text top="722" left="681" width="23" height="14" font="7"> HF</text>
<text top="736" left="681" width="42" height="14" font="7"> Angina</text>
<text top="751" left="681" width="115" height="14" font="7"> Syncope or presyncope</text>
<text top="842" left="72" width="728" height="8" font="18">AR indicates aortic regurgitation; AS, aortic stenosis; AVA, aortic valve area; AVAi, aortic valve area indexed to body surface area; BP, blood pressure; HF, heart failure; LV, left ventricular;</text>
<text top="854" left="72" width="141" height="8" font="18">LVEF, left ventricular ejection fraction;</text>
<text top="851" left="216" width="6" height="13" font="14">D</text>
<text top="854" left="222" width="102" height="8" font="18">P, pressure gradient; and V</text>
<text top="858" left="323" width="11" height="5" font="24">max</text>
<text top="854" left="335" width="97" height="8" font="18">, maximum aortic velocity.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e72</text>
</page>
<page number="17" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">baseline state and again during low-dose pharmacological</text>
<text top="121" left="64" width="350" height="15" font="5">(i.e., dobutamine infusion) stress testing to determine</text>
<text top="139" left="64" width="350" height="15" font="5">whether AS is severe or only moderate and to evaluate for</text>
<text top="157" left="64" width="79" height="15" font="5">contractile or</text>
<text top="153" left="148" width="75" height="19" font="5">ﬂow reserve.</text>
<text top="175" left="79" width="335" height="15" font="5">Dobutamine is infused in progressive stages, beginning at</text>
<text top="192" left="64" width="350" height="15" font="5">5 mcg/kg per minute and increasing in increments of 5 mcg/</text>
<text top="210" left="64" width="350" height="15" font="5">kg per minute to a maximum dose of 20 mcg/kg per minute</text>
<text top="228" left="64" width="350" height="15" font="5">with appropriate clinical and hemodynamic monitoring.</text>
<text top="246" left="64" width="350" height="15" font="5">Echocardiographic and Doppler data (or hemodynamic</text>
<text top="264" left="64" width="350" height="15" font="5">data) are recorded at each dose of dobutamine for mea-</text>
<text top="282" left="64" width="350" height="15" font="5">surement of aortic velocity, mean pressure gradient, valve</text>
<text top="300" left="64" width="350" height="15" font="5">area, and LVEF. Patients who do not have true anatomically</text>
<text top="318" left="64" width="350" height="15" font="5">severe AS will exhibit an increase in valve area with only a</text>
<text top="336" left="64" width="350" height="15" font="5">modest increase in transaortic velocity or gradient as trans-</text>
<text top="354" left="64" width="350" height="15" font="5">aortic stroke volume increases. In contrast, patients with</text>
<text top="372" left="64" width="156" height="15" font="5">severe AS have a relatively</text>
<text top="368" left="224" width="190" height="19" font="5">ﬁxed valve area even with an in-</text>
<text top="390" left="64" width="290" height="15" font="5">crease in LV contractility and transaortic volume</text>
<text top="386" left="358" width="56" height="19" font="5">ﬂow rate.</text>
<text top="408" left="64" width="91" height="15" font="5">The document</text>
<text top="404" left="162" width="252" height="19" font="5">“Echocardiographic Assessment of Valve</text>
<text top="426" left="64" width="350" height="15" font="5">Stenosis: EAE/ASE Recommendations for Clinical Prac-</text>
<text top="444" left="64" width="21" height="15" font="5">tice</text>
<text top="440" left="85" width="329" height="19" font="5">” deﬁnes severe AS on low-dose dobutamine stress</text>
<text top="461" left="64" width="183" height="15" font="5">testing as a maximum velocity</text>
<text top="458" left="253" width="161" height="19" font="5">4.0 m per second with a</text>
<text top="479" left="64" width="56" height="15" font="5">valve area</text>
<text top="476" left="123" width="51" height="19" font="5">1.0 cm</text>
<text top="476" left="175" width="6" height="10" font="14">2</text>
<text top="479" left="184" width="230" height="15" font="5">at any point during the test protocol. In</text>
<text top="497" left="64" width="349" height="15" font="5">addition to moderate AS and true severe AS, low-dose</text>
<text top="515" left="64" width="350" height="15" font="5">dobutamine stress testing helps identify a third group of</text>
<text top="533" left="64" width="309" height="15" font="5">patients who fail to show an increase in stroke volume</text>
<text top="530" left="376" width="38" height="19" font="5">20%</text>
<text top="551" left="64" width="186" height="15" font="5">with dobutamine, referred to as</text>
<text top="548" left="254" width="160" height="19" font="5">“lack of contractile reserve”</text>
<text top="569" left="64" width="12" height="15" font="5">or</text>
<text top="566" left="79" width="335" height="19" font="5">“lack of ﬂow reserve.” This subgroup of patients appears to</text>
<text top="587" left="64" width="350" height="15" font="5">have a very poor prognosis with either medical or surgical</text>
<text top="605" left="64" width="350" height="15" font="5">therapy. Low-dose dobutamine stress testing in patients</text>
<text top="623" left="64" width="350" height="15" font="5">with AS requires center experience in pharmacological stress</text>
<text top="641" left="64" width="350" height="15" font="5">testing as well as continuous hemodynamic and electrocar-</text>
<text top="659" left="64" width="334" height="15" font="5">diographic monitoring with a cardiologist in attendance.</text>
<text top="677" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="677" left="212" width="87" height="15" font="6"><a href="e57.full.html#100">(8,43,95,96,98</a></text>
<text top="673" left="299" width="35" height="19" font="6"><a href="e57.full.html#100">–101)</a></text>
<text top="695" left="79" width="18" height="15" font="5">See</text>
<text top="695" left="103" width="161" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 1</a></text>
<text top="695" left="271" width="143" height="15" font="5">for more information on</text>
<text top="713" left="64" width="188" height="15" font="5">outcomes in patients with low-</text>
<text top="709" left="252" width="161" height="19" font="5">ﬂow/low-gradient AS with</text>
<text top="731" left="64" width="87" height="15" font="5">reduced LVEF.</text>
<text top="766" left="64" width="299" height="11" font="7">3.2.1.2. DIAGNOSTIC TESTINGdCHANGING SIGNS OR SYMPTOMS</text>
<text top="780" left="65" width="349" height="15" font="5">In patients with known valvular AS, repeat TTE is</text>
<text top="798" left="64" width="350" height="15" font="5">appropriate when physical examination reveals a louder</text>
<text top="816" left="64" width="350" height="15" font="5">systolic murmur or a change in the second heart sound or</text>
<text top="834" left="64" width="350" height="15" font="5">when symptoms occur that might be due to AS because</text>
<text top="852" left="64" width="350" height="15" font="5">valve obstruction may have progressed since the last eval-</text>
<text top="870" left="64" width="350" height="15" font="5">uation. Repeat TTE is also appropriate in patients with AS</text>
<text top="888" left="64" width="350" height="15" font="5">who are exposed to increased hemodynamic demands</text>
<text top="906" left="64" width="350" height="15" font="5">either electively, such as noncardiac surgery or pregnancy,</text>
<text top="924" left="64" width="350" height="15" font="5">or acutely, such as with a systemic infection, anemia, or</text>
<text top="942" left="64" width="350" height="15" font="5">gastrointestinal bleeding. In these clinical settings,</text>
<text top="960" left="64" width="350" height="15" font="5">knowledge of the severity of valve obstruction and LV</text>
<text top="977" left="64" width="350" height="15" font="5">function is critical for optimizing loading conditions and</text>
<text top="995" left="64" width="224" height="15" font="5">maintaining a normal cardiac output.</text>
<text top="1014" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="1013" left="212" width="114" height="15" font="6"><a href="e57.full.html#101">(24,25,89,102,103)</a></text>
<text top="1049" left="64" width="243" height="11" font="7">3.2.1.3. DIAGNOSTIC TESTINGdROUTINE FOLLOW-UP</text>
<text top="1063" left="65" width="349" height="15" font="5">Timing of periodic clinical evaluation of patients with</text>
<text top="1081" left="64" width="350" height="15" font="5">severe asymptomatic AS depends on comorbidities and</text>
<text top="103" left="450" width="76" height="15" font="5">patient-speci</text>
<text top="99" left="526" width="273" height="19" font="5">ﬁc factors. TTE for re-evaluation of asymp-</text>
<text top="121" left="450" width="350" height="15" font="5">tomatic patients with AS with normal LV systolic function</text>
<text top="139" left="450" width="350" height="15" font="5">who have no change in signs or symptoms is performed at</text>
<text top="157" left="450" width="316" height="15" font="5">intervals of 6 months to 1 year when aortic velocity is</text>
<text top="153" left="769" width="30" height="19" font="5">4.0</text>
<text top="175" left="450" width="350" height="15" font="5">m per second (stage C), 1 to 2 years when aortic velocity is</text>
<text top="192" left="450" width="350" height="15" font="5">between 3.0 m per second and 3.9 m per second (stage B),</text>
<text top="210" left="450" width="350" height="15" font="5">and 3 to 5 years when aortic velocity is 2.0 m per second to</text>
<text top="228" left="450" width="115" height="15" font="5">2.9 m/s (stage B) (</text>
<text top="228" left="565" width="47" height="15" font="6"><a href="e57.full.html#10">Table 4</a></text>
<text top="228" left="611" width="9" height="15" font="5">).</text>
<text top="246" left="465" width="335" height="15" font="5">Valvular AS is a progressive disease, and an increase in</text>
<text top="264" left="450" width="350" height="15" font="5">hemodynamic severity is inevitable once even mild AS is</text>
<text top="282" left="450" width="350" height="15" font="5">present. The rate of progression of the stenotic lesion has</text>
<text top="300" left="450" width="350" height="15" font="5">been estimated in a variety of invasive and noninvasive</text>
<text top="318" left="450" width="299" height="15" font="5">studies. When severe AS is present (aortic velocity</text>
<text top="315" left="753" width="46" height="19" font="5">4.0 m</text>
<text top="336" left="450" width="350" height="15" font="5">per second), the rate of progression to symptoms is high,</text>
<text top="354" left="450" width="350" height="15" font="5">with an event-free survival of only 30% to 50% at 2 years.</text>
<text top="372" left="450" width="350" height="15" font="5">Therefore, patients with asymptomatic severe AS require</text>
<text top="390" left="450" width="350" height="15" font="5">frequent monitoring for progressive disease because</text>
<text top="408" left="450" width="350" height="15" font="5">symptom onset may be insidious and not recognized by the</text>
<text top="426" left="450" width="45" height="15" font="5">patient.</text>
<text top="444" left="465" width="335" height="15" font="5">Once even moderate AS is present (aortic velocity be-</text>
<text top="462" left="450" width="350" height="15" font="5">tween 3.0 m per second and 3.9 m per second), the average</text>
<text top="479" left="450" width="350" height="15" font="5">rate of progression is an increase in velocity of 0.3 m per</text>
<text top="497" left="450" width="350" height="15" font="5">second per year, an increase in mean pressure gradient of 7</text>
<text top="515" left="450" width="344" height="15" font="5">mm Hg per year, and a decrease in valve area of 0.1 cm</text>
<text top="512" left="794" width="6" height="10" font="14">2</text>
<text top="533" left="450" width="350" height="15" font="5">per year. There is marked individual variability in the rate</text>
<text top="551" left="450" width="350" height="15" font="5">of hemodynamic change. Progression of AS can be more</text>
<text top="569" left="450" width="331" height="15" font="5">rapid in older patients and in those with more severe lea</text>
<text top="566" left="780" width="19" height="19" font="5">ﬂet</text>
<text top="587" left="450" width="26" height="15" font="5">calci</text>
<text top="584" left="476" width="324" height="19" font="5">ﬁcation. Because it is not possible to predict the exact</text>
<text top="605" left="450" width="350" height="15" font="5">rate of progression in an individual patient, regular clinical</text>
<text top="623" left="450" width="350" height="15" font="5">and echocardiographic follow-up is mandatory in all pa-</text>
<text top="641" left="450" width="291" height="15" font="5">tients with asymptomatic mild-to-moderate AS.</text>
<text top="659" left="465" width="207" height="15" font="5">In patients with aortic sclerosis, de</text>
<text top="655" left="672" width="127" height="19" font="5">ﬁned as focal areas of</text>
<text top="677" left="450" width="63" height="15" font="5">valve calci</text>
<text top="673" left="513" width="287" height="19" font="5">ﬁcation and leaﬂet thickening with an aortic</text>
<text top="695" left="450" width="45" height="15" font="5">velocity</text>
<text top="691" left="500" width="300" height="19" font="5">&lt;2.5 m per second, progression to severe AS oc-</text>
<text top="712" left="450" width="350" height="15" font="5">curs in about 10% of patients within 5 years. Patients with</text>
<text top="730" left="450" width="350" height="15" font="5">bicuspid aortic valve disease are also at risk for progressive</text>
<text top="748" left="450" width="350" height="15" font="5">valve stenosis, with AS being the most common reason for</text>
<text top="766" left="450" width="350" height="15" font="5">intervention in patients with a bicuspid aortic valve</text>
<text top="784" left="450" width="5" height="15" font="5">(</text>
<text top="784" left="455" width="79" height="15" font="6"><a href="e57.full.html#32">Section 5.1.1</a></text>
<text top="784" left="534" width="9" height="15" font="5"><a href="e57.full.html#32">).</a></text>
<text top="803" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="802" left="597" width="46" height="15" font="6"><a href="e57.full.html#101">(28,104</a></text>
<text top="799" left="643" width="35" height="19" font="6"><a href="e57.full.html#101">–115)</a></text>
<text top="821" left="465" width="18" height="15" font="5">See</text>
<text top="821" left="489" width="161" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 2</a></text>
<text top="821" left="657" width="143" height="15" font="5">for more information on</text>
<text top="839" left="450" width="182" height="15" font="5">hemodynamic progression of AS.</text>
<text top="869" left="450" width="273" height="11" font="7">3.2.1.4. DIAGNOSTIC TESTINGdCARDIAC CATHETERIZATION</text>
<text top="884" left="451" width="349" height="15" font="5">Diagnostic TTE and Doppler data can be obtained in</text>
<text top="902" left="450" width="350" height="15" font="5">nearly all patients, but severity of AS may be under-</text>
<text top="919" left="450" width="350" height="15" font="5">estimated if image quality is poor or if a parallel intercept</text>
<text top="937" left="450" width="350" height="15" font="5">angle is not obtained between the ultrasound beam and</text>
<text top="955" left="450" width="350" height="15" font="5">aortic jet. CMR imaging shows promise for evaluation of</text>
<text top="973" left="450" width="350" height="15" font="5">severity of AS but is not widely available. Cardiac CT</text>
<text top="991" left="450" width="305" height="15" font="5">imaging is useful for quantitation of valve calci</text>
<text top="988" left="755" width="44" height="19" font="5">ﬁcation</text>
<text top="1009" left="450" width="73" height="15" font="5">(severe calci</text>
<text top="1006" left="523" width="276" height="19" font="5">ﬁcation is considered to be present with an</text>
<text top="1027" left="450" width="97" height="15" font="5">aortic valve calci</text>
<text top="1024" left="547" width="252" height="19" font="5">ﬁcation score &gt;1,000 Agatston units) and</text>
<text top="1045" left="450" width="350" height="15" font="5">in patients undergoing TAVR for measurement of annulus</text>
<text top="1063" left="450" width="52" height="15" font="5">area, lea</text>
<text top="1060" left="502" width="298" height="19" font="5">ﬂet length, and the annular to coronary ostial</text>
<text top="1081" left="450" width="350" height="15" font="5">distance. However, CT imaging is less useful for evaluation</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e73</text>
</page>
<page number="18" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">of severity of AS. When noninvasive data are non-</text>
<text top="121" left="64" width="350" height="15" font="5">diagnostic or if there is a discrepancy between clinical and</text>
<text top="139" left="64" width="350" height="15" font="5">echocardiographic evaluation, cardiac catheterization for</text>
<text top="157" left="64" width="350" height="15" font="5">determination of severity of AS is recommended. Trans-</text>
<text top="175" left="64" width="350" height="15" font="5">aortic pressure gradients should be recorded for measure-</text>
<text top="192" left="64" width="350" height="15" font="5">ment of mean transaortic gradient, based on simultaneous</text>
<text top="210" left="64" width="350" height="15" font="5">LV and aortic pressure measurements. Aortic valve area</text>
<text top="228" left="64" width="350" height="15" font="5">should be calculated with the Gorlin formula, using a Fick</text>
<text top="246" left="64" width="350" height="15" font="5">or thermodilution cardiac output measurement. See</text>
<text top="264" left="64" width="78" height="15" font="6"><a href="e57.full.html#93">Section 14.1</a></text>
<text top="264" left="149" width="264" height="15" font="5">for recommendations on coronary angiog-</text>
<text top="282" left="64" width="161" height="15" font="5">raphy in patients with AS.</text>
<text top="301" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="300" left="212" width="51" height="15" font="6"><a href="e57.full.html#101">(42,116)</a></text>
<text top="331" left="64" width="331" height="11" font="7">3.2.1.5. DIAGNOSTIC TESTINGdEXERCISE TESTING: RECOMMENDATIONS</text>
<text top="354" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="369" left="64" width="350" height="10" font="21">1. Exercise testing is reasonable to assess physiological changes</text>
<text top="386" left="82" width="143" height="10" font="21">with exercise and to con</text>
<text top="383" left="225" width="189" height="16" font="21">ﬁrm the absence of symptoms in</text>
<text top="402" left="82" width="198" height="10" font="21">asymptomatic patients with a calci</text>
<text top="399" left="280" width="134" height="16" font="21">ﬁed aortic valve and an</text>
<text top="419" left="82" width="332" height="10" font="21">aortic velocity 4.0 m per second or greater or mean pressure</text>
<text top="435" left="82" width="208" height="10" font="21">gradient 40 mm Hg or higher (stage C)</text>
<text top="435" left="293" width="83" height="10" font="22"><a href="e57.full.html#101">(25,46,47,117)</a></text>
<text top="435" left="376" width="38" height="12" font="21">. (Level</text>
<text top="452" left="82" width="79" height="12" font="21">of Evidence: B)</text>
<text top="476" left="79" width="335" height="15" font="5">When performed under the direct supervision of an</text>
<text top="494" left="64" width="350" height="15" font="5">experienced clinician, with close monitoring of BP and</text>
<text top="512" left="64" width="350" height="15" font="5">ECG, exercise testing in asymptomatic patients is relatively</text>
<text top="530" left="64" width="350" height="15" font="5">safe and may provide information that is not evident</text>
<text top="548" left="64" width="350" height="15" font="5">during the initial clinical evaluation, particularly when the</text>
<text top="566" left="64" width="41" height="15" font="5">patient</text>
<text top="562" left="106" width="308" height="19" font="5">’s functional capacity is unclear. Patients with</text>
<text top="584" left="64" width="350" height="15" font="5">symptoms provoked by exercise testing should be consid-</text>
<text top="602" left="64" width="350" height="15" font="5">ered symptomatic, even if the clinical history is equivocal.</text>
<text top="619" left="64" width="350" height="15" font="5">Although it can be challenging to separate normal exercise</text>
<text top="637" left="64" width="350" height="15" font="5">limitations from abnormal symptoms due to AS, particu-</text>
<text top="655" left="64" width="350" height="15" font="5">larly in elderly sedentary patients, exercise-induced angina,</text>
<text top="673" left="64" width="350" height="15" font="5">excessive dyspnea early in exercise, dizziness, or syncope</text>
<text top="691" left="64" width="350" height="15" font="5">are consistent with symptoms of AS. In 1 series, exercise</text>
<text top="709" left="64" width="350" height="15" font="5">testing brought out symptoms in 29% of patients who were</text>
<text top="727" left="64" width="350" height="15" font="5">considered asymptomatic before testing; in these patients,</text>
<text top="745" left="64" width="350" height="15" font="5">spontaneous symptoms developed over the next year in</text>
<text top="763" left="64" width="350" height="15" font="5">51% of patients, compared with only 11% of patients who</text>
<text top="781" left="64" width="227" height="15" font="5">had no symptoms on exercise testing.</text>
<text top="799" left="79" width="335" height="15" font="5">Exercise testing can also identify a limited exercise ca-</text>
<text top="817" left="64" width="350" height="15" font="5">pacity, abnormal BP response, or arrhythmia. An abnormal</text>
<text top="835" left="64" width="350" height="15" font="5">hemodynamic response (e.g., hypotension or failure to</text>
<text top="853" left="64" width="350" height="15" font="5">increase BP with exercise) in patients with severe AS is</text>
<text top="871" left="64" width="180" height="15" font="5">considered a poor prognostic</text>
<text top="867" left="252" width="162" height="19" font="5">ﬁnding. In another series,</text>
<text top="888" left="64" width="350" height="15" font="5">patients with AS who manifested symptoms, an abnormal</text>
<text top="906" left="64" width="85" height="15" font="5">BP response (</text>
<text top="903" left="150" width="264" height="19" font="5">&lt;20 mm Hg increase), or ST-segment ab-</text>
<text top="924" left="64" width="250" height="15" font="5">normalities with exercise had a signi</text>
<text top="921" left="314" width="100" height="19" font="5">ﬁcantly reduced</text>
<text top="942" left="64" width="350" height="15" font="5">symptom-free survival at 2 years (19% compared with 85%).</text>
<text top="960" left="64" width="350" height="15" font="5">However, electrocardiographic ST-segment depression is</text>
<text top="978" left="64" width="44" height="15" font="5">seen in</text>
<text top="975" left="116" width="298" height="19" font="5">&gt;80% of patients with AS with exercise and is</text>
<text top="996" left="64" width="51" height="15" font="5">nonspeci</text>
<text top="993" left="115" width="299" height="19" font="5">ﬁc for diagnosis of CAD. Ventricular tachycardia</text>
<text top="1014" left="64" width="350" height="15" font="5">was reported in early exercise studies but has not been</text>
<text top="1032" left="64" width="189" height="15" font="5">reported in contemporary series.</text>
<text top="1050" left="79" width="335" height="15" font="5">Some studies suggest additional value for measuring</text>
<text top="1068" left="64" width="350" height="15" font="5">changes in valve hemodynamics with exercise. In a series of</text>
<text top="1086" left="64" width="349" height="15" font="5">186 patients with moderate-to-severe AS, stress testing</text>
<text top="103" left="450" width="350" height="15" font="5">was normal in 73% of patients; however, adverse cardiac</text>
<text top="121" left="450" width="350" height="15" font="5">events occurred in 67 of these patients at a mean follow-up</text>
<text top="139" left="450" width="85" height="15" font="5">interval of 20</text>
<text top="135" left="535" width="265" height="19" font="5">14 months. Predictors of cardiac events,</text>
<text top="157" left="450" width="317" height="15" font="5">primarily symptom onset requiring AVR, were age</text>
<text top="153" left="773" width="27" height="19" font="5">&gt;65</text>
<text top="175" left="450" width="350" height="15" font="5">years, diabetes mellitus, LV hypertrophy, a resting mean</text>
<text top="193" left="450" width="103" height="15" font="5">pressure gradient</text>
<text top="189" left="560" width="240" height="19" font="5">&gt;35 mm Hg, and an increase of &gt;20</text>
<text top="211" left="450" width="350" height="15" font="5">mm Hg in mean pressure gradient with exercise. However,</text>
<text top="228" left="450" width="350" height="15" font="5">a prospective study of 123 patients with asymptomatic AS</text>
<text top="246" left="450" width="350" height="15" font="5">did not show additive value for exercise hemodynamics</text>
<text top="264" left="450" width="350" height="15" font="5">for predicting clinical outcome when baseline measures</text>
<text top="282" left="450" width="350" height="15" font="5">of hemodynamic severity and functional status were con-</text>
<text top="300" left="450" width="350" height="15" font="5">sidered. Recording hemodynamics with exercise is chal-</text>
<text top="318" left="450" width="350" height="15" font="5">lenging, and simpler parameters are adequate in most</text>
<text top="336" left="450" width="50" height="15" font="5">patients.</text>
<text top="355" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="354" left="598" width="102" height="15" font="6"><a href="e57.full.html#101">(25,28,46,47,117</a></text>
<text top="351" left="700" width="35" height="19" font="6"><a href="e57.full.html#101">–121)</a></text>
<text top="373" left="465" width="18" height="15" font="5">See</text>
<text top="373" left="489" width="161" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 3</a></text>
<text top="373" left="657" width="143" height="15" font="5">for more information on</text>
<text top="391" left="450" width="206" height="15" font="5">exercise testing in patients with AS.</text>
<text top="418" left="450" width="73" height="8" font="20">CLASS III: Harm</text>
<text top="433" left="449" width="351" height="10" font="21">1. Exercise testing should not be performed in symptomatic pa-</text>
<text top="450" left="467" width="332" height="10" font="21">tients with AS when the aortic velocity is 4.0 m per second or</text>
<text top="466" left="467" width="333" height="10" font="21">greater or mean pressure gradient is 40 mm Hg or higher</text>
<text top="483" left="467" width="50" height="10" font="21">(stage D)</text>
<text top="483" left="521" width="30" height="10" font="22"><a href="e57.full.html#103">(122)</a></text>
<text top="483" left="551" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="507" left="465" width="335" height="15" font="5">As reported in several prospective and retrospective</text>
<text top="525" left="450" width="350" height="15" font="5">studies, the risk of exercise testing is low in asymptomatic</text>
<text top="543" left="450" width="350" height="15" font="5">patients with AS. However, even in asymptomatic patients,</text>
<text top="561" left="450" width="350" height="15" font="5">complications include exertional hypotension in up to 10%</text>
<text top="579" left="450" width="350" height="15" font="5">of patients, exercise-induced symptoms, and ventricular</text>
<text top="597" left="450" width="350" height="15" font="5">premature beats. A retrospective study of 347 patients with</text>
<text top="615" left="450" width="350" height="15" font="5">AS who underwent cardiopulmonary exercise testing</text>
<text top="633" left="450" width="350" height="15" font="5">showed no deaths or major complications. Most of these</text>
<text top="650" left="450" width="350" height="15" font="5">patients had no (78%) or equivocal (16%) symptoms at</text>
<text top="668" left="450" width="350" height="15" font="5">baseline, with only 20 symptomatic patients (6%) with</text>
<text top="686" left="450" width="100" height="15" font="5">AS in this series</text>
<text top="686" left="554" width="32" height="15" font="6"><a href="e57.full.html#103">(123)</a></text>
<text top="686" left="587" width="4" height="15" font="5"><a href="e57.full.html#103">.</a></text>
<text top="704" left="465" width="335" height="15" font="5">Exercise testing should not be performed in symptom-</text>
<text top="722" left="450" width="350" height="15" font="5">atic patients with AS owing to a high risk of complications,</text>
<text top="740" left="450" width="350" height="15" font="5">including syncope, ventricular tachycardia, and death. In</text>
<text top="758" left="450" width="350" height="15" font="5">a prospective survey of 20 medical centers in Sweden that</text>
<text top="776" left="450" width="302" height="15" font="5">included 50,000 exercise tests done over an 18</text>
<text top="773" left="752" width="47" height="19" font="5">–month</text>
<text top="794" left="450" width="350" height="15" font="5">period, the complication rate was 18.4; morbidity rate, 5.2;</text>
<text top="812" left="450" width="350" height="15" font="5">and mortality rate, 0.4 per 10,000 tests. Although the</text>
<text top="830" left="450" width="350" height="15" font="5">number of patients with AS was not reported, 12 of the 92</text>
<text top="848" left="450" width="350" height="15" font="5">complications occurred in patients with AS: 8 had an ex-</text>
<text top="866" left="450" width="350" height="15" font="5">ercise decline in BP, 1 had asystole, and 3 had ventricular</text>
<text top="884" left="450" width="70" height="15" font="5">tachycardia.</text>
<text top="902" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="902" left="597" width="65" height="15" font="6"><a href="e57.full.html#101">(46,47,117</a></text>
<text top="898" left="662" width="87" height="19" font="6"><a href="e57.full.html#101">–120,122,123)</a></text>
<text top="936" left="450" width="277" height="15" font="5">3.2.2. Medical Therapy: Recommendations</text>
<text top="963" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="978" left="449" width="350" height="10" font="21">1. Hypertension in patients at risk for developing AS (stage A) and</text>
<text top="995" left="467" width="332" height="10" font="21">in patients with asymptomatic AS (stages B and C) should be</text>
<text top="1011" left="467" width="332" height="10" font="21">treated according to standard GDMT, started at a low dose, and</text>
<text top="1027" left="467" width="332" height="10" font="21">gradually titrated upward as needed with frequent clinical</text>
<text top="1044" left="467" width="56" height="10" font="21">monitoring</text>
<text top="1044" left="527" width="26" height="10" font="22"><a href="e57.full.html#103">(124</a></text>
<text top="1041" left="553" width="32" height="16" font="22"><a href="e57.full.html#103">–126)</a></text>
<text top="1044" left="585" width="121" height="12" font="21"><a href="e57.full.html#103">. </a>(Level of Evidence: B)</text>
<text top="1068" left="465" width="335" height="15" font="5">Hypertension is common in patients with AS, may be a</text>
<text top="1086" left="450" width="350" height="15" font="5">risk factor for AS, and adds to the total pressure overload</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e74</text>
</page>
<page number="19" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">on the left ventricle in combination with valve obstruction.</text>
<text top="121" left="64" width="350" height="15" font="5">Concern that antihypertensive medications might result in</text>
<text top="139" left="64" width="350" height="15" font="5">a fall in cardiac output has not been corroborated in studies</text>
<text top="157" left="64" width="350" height="15" font="5">of medical therapy, including 2 small RCTs, likely because</text>
<text top="175" left="64" width="127" height="15" font="5">AS does not result in</text>
<text top="171" left="196" width="218" height="19" font="5">“ﬁxed” valve obstruction until late in</text>
<text top="192" left="64" width="350" height="15" font="5">the disease process. In 1,616 patients with asymptomatic</text>
<text top="210" left="64" width="350" height="15" font="5">AS in the SEAS (Simvastatin Ezetimibe in Aortic Ste-</text>
<text top="228" left="64" width="171" height="15" font="5">nosis) study, hypertension (n</text>
<text top="225" left="235" width="179" height="19" font="5">¼1,340) was associated with a</text>
<text top="246" left="64" width="350" height="15" font="5">56% higher rate of ischemic cardiovascular events and a</text>
<text top="264" left="64" width="242" height="15" font="5">2-fold increased mortality rate (both p</text>
<text top="261" left="306" width="108" height="19" font="5">&lt;0.01) compared</text>
<text top="282" left="64" width="350" height="15" font="5">with normotensive patients with AS, although no impact</text>
<text top="300" left="64" width="350" height="15" font="5">on AVR was seen. Medical therapy for hypertension</text>
<text top="318" left="64" width="350" height="15" font="5">should follow standard guidelines, starting at a low dose</text>
<text top="336" left="64" width="350" height="15" font="5">and gradually titrating upward as needed to achieve BP</text>
<text top="354" left="64" width="286" height="15" font="5">control. There are no studies addressing speci</text>
<text top="351" left="350" width="64" height="19" font="5">ﬁc antihy-</text>
<text top="372" left="64" width="350" height="15" font="5">pertensive medications in patients with AS, but diuretics</text>
<text top="390" left="64" width="350" height="15" font="5">should be avoided if the LV chamber is small, because even</text>
<text top="408" left="64" width="350" height="15" font="5">smaller LV volumes may result in a fall in cardiac output.</text>
<text top="426" left="64" width="350" height="15" font="5">In theory, ACE inhibitors may be advantageous due to the</text>
<text top="444" left="64" width="87" height="15" font="5">potential bene</text>
<text top="440" left="151" width="263" height="19" font="5">ﬁcial effects on LV ﬁbrosis in addition to</text>
<text top="461" left="64" width="349" height="15" font="5">control of hypertension. Beta blockers are an appropriate</text>
<text top="479" left="64" width="249" height="15" font="5">choice in patients with concurrent CAD.</text>
<text top="498" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="497" left="212" width="27" height="15" font="6"><a href="e57.full.html#103">(124</a></text>
<text top="494" left="239" width="35" height="19" font="6"><a href="e57.full.html#103">–128)</a></text>
<text top="525" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="539" left="63" width="351" height="10" font="21">1. Vasodilator therapy may be reasonable if used with invasive</text>
<text top="556" left="81" width="333" height="10" font="21">hemodynamic monitoring in the acute management of patients</text>
<text top="572" left="81" width="333" height="10" font="21">with severe decompensated AS (stage D) with NYHA class IV</text>
<text top="589" left="81" width="192" height="12" font="21">HF symptoms. (Level of Evidence: C)</text>
<text top="613" left="79" width="335" height="15" font="5">In patients who present with severe AS and NYHA</text>
<text top="631" left="64" width="350" height="15" font="5">class IV HF, afterload reduction may be used in an effort to</text>
<text top="649" left="64" width="350" height="15" font="5">stabilize the patient before urgent AVR. Invasive moni-</text>
<text top="667" left="64" width="76" height="15" font="5">toring of LV</text>
<text top="663" left="145" width="269" height="19" font="5">ﬁlling pressures, cardiac output, and systemic</text>
<text top="685" left="64" width="350" height="15" font="5">vascular resistance is essential because of the tenuous he-</text>
<text top="703" left="64" width="350" height="15" font="5">modynamic status of these patients, in whom a sudden</text>
<text top="721" left="64" width="350" height="15" font="5">decline in systemic vascular resistance might result in an</text>
<text top="739" left="64" width="350" height="15" font="5">acute decline in cardiac output across the obstructed aortic</text>
<text top="757" left="64" width="235" height="15" font="5">valve. However, some patients do bene</text>
<text top="753" left="299" width="115" height="19" font="5">ﬁt with an increase</text>
<text top="775" left="64" width="350" height="15" font="5">in cardiac output as systemic vascular resistance is slowly</text>
<text top="792" left="64" width="350" height="15" font="5">adjusted downward due to the reduction in total LV</text>
<text top="810" left="64" width="350" height="15" font="5">afterload. AVR should be performed as soon as feasible in</text>
<text top="828" left="64" width="86" height="15" font="5">these patients.</text>
<text top="847" left="79" width="123" height="15" font="5">Supporting Reference:</text>
<text top="846" left="208" width="32" height="15" font="6"><a href="e57.full.html#103">(129)</a></text>
<text top="873" left="64" width="88" height="8" font="20">CLASS III: No Bene</text>
<text top="871" left="152" width="10" height="13" font="20">ﬁt</text>
<text top="888" left="63" width="351" height="10" font="21">1. Statin therapy is not indicated for prevention of hemodynamic</text>
<text top="905" left="81" width="320" height="10" font="21">progression of AS in patients with mild-to-moderate calci</text>
<text top="902" left="401" width="13" height="16" font="21">ﬁc</text>
<text top="921" left="81" width="184" height="10" font="21">valve disease (stages B to D)</text>
<text top="921" left="274" width="80" height="10" font="22"><a href="e57.full.html#102">(109,130,131)</a></text>
<text top="921" left="354" width="60" height="12" font="21"><a href="e57.full.html#102">. </a>(Level of</text>
<text top="938" left="81" width="65" height="12" font="21">Evidence: A)</text>
<text top="962" left="79" width="335" height="15" font="5">Despite experimental models and retrospective clinical</text>
<text top="980" left="64" width="350" height="15" font="5">studies that suggest that lipid-lowering therapy with a</text>
<text top="998" left="64" width="294" height="15" font="5">statin might prevent disease progression of calci</text>
<text top="995" left="358" width="56" height="19" font="5">ﬁc AS, 3</text>
<text top="1016" left="64" width="283" height="15" font="5">large well-designed RCTs failed to show a bene</text>
<text top="1012" left="348" width="66" height="19" font="5">ﬁt either in</text>
<text top="1034" left="64" width="350" height="15" font="5">terms of changes in hemodynamic severity or in clinical</text>
<text top="1052" left="64" width="350" height="15" font="5">outcomes in patients with mild-to-moderate valve</text>
<text top="1070" left="64" width="350" height="15" font="5">obstruction. Thus, at the time of publication, there are no</text>
<text top="1088" left="64" width="350" height="15" font="5">data to support the use of statins for prevention of</text>
<text top="103" left="450" width="350" height="15" font="5">progression of AS. However, concurrent CAD is common</text>
<text top="121" left="450" width="350" height="15" font="5">in patients with AS, and all patients should be screened</text>
<text top="139" left="450" width="350" height="15" font="5">and treated for hypercholesterolemia using GDMT for</text>
<text top="157" left="450" width="264" height="15" font="5">primary and secondary prevention of CAD.</text>
<text top="175" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="175" left="597" width="53" height="15" font="6"><a href="e57.full.html#102">(109,130</a></text>
<text top="171" left="651" width="35" height="19" font="6"><a href="e57.full.html#102">–133)</a></text>
<text top="193" left="465" width="18" height="15" font="5">See</text>
<text top="193" left="489" width="161" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 4</a></text>
<text top="193" left="657" width="143" height="15" font="5">for more information on</text>
<text top="211" left="450" width="350" height="15" font="5">clinical trials of lipid-lowering therapy to slow progression of</text>
<text top="229" left="450" width="289" height="15" font="5">AS (stage B) and prevent cardiovascular outcomes.</text>
<text top="255" left="450" width="318" height="15" font="5">3.2.3. Timing of Intervention: Recommendations</text>
<text top="281" left="451" width="21" height="15" font="5">See</text>
<text top="281" left="476" width="46" height="15" font="6"><a href="e57.full.html#20">Table 9</a></text>
<text top="281" left="526" width="273" height="15" font="5">for a summary of recommendations from this</text>
<text top="299" left="450" width="69" height="15" font="5">section and</text>
<text top="299" left="525" width="52" height="15" font="6"><a href="e57.full.html#21">Figure 1</a></text>
<text top="299" left="582" width="217" height="15" font="5">for indications for AVR in patients</text>
<text top="316" left="450" width="350" height="15" font="5">with AS. These recommendations for timing of interven-</text>
<text top="334" left="450" width="350" height="15" font="5">tion for AS apply to both surgical and transcatheter AVR.</text>
<text top="352" left="450" width="350" height="15" font="5">The integrative approach to assessing risk of surgical or</text>
<text top="370" left="450" width="200" height="15" font="5">transcatheter AVR is discussed in</text>
<text top="370" left="653" width="67" height="15" font="6"><a href="e57.full.html#12">Section 2.5</a></text>
<text top="370" left="720" width="65" height="15" font="5">. The speci</text>
<text top="367" left="785" width="14" height="19" font="5">ﬁc</text>
<text top="388" left="450" width="256" height="15" font="5">type of intervention for AS is discussed in</text>
<text top="388" left="711" width="79" height="15" font="6"><a href="e57.full.html#23">Section 3.2.4</a></text>
<text top="388" left="790" width="4" height="15" font="5"><a href="e57.full.html#23">.</a></text>
<text top="415" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="430" left="449" width="351" height="10" font="21">1. AVR is recommended in symptomatic patients with severe AS</text>
<text top="447" left="467" width="84" height="10" font="21">(stage D1) with</text>
<text top="447" left="555" width="83" height="10" font="22"><a href="e57.full.html#100">(9,91,134,135)</a></text>
<text top="447" left="642" width="117" height="12" font="21">(Level of Evidence: B):</text>
<text top="463" left="467" width="227" height="10" font="21">a. Decreased systolic opening of a calci</text>
<text top="460" left="693" width="106" height="16" font="21">ﬁed or congenitally</text>
<text top="480" left="482" width="135" height="10" font="21">stenotic aortic valve; and</text>
<text top="496" left="467" width="333" height="10" font="21">b. An aortic velocity 4.0 m per second or greater or mean</text>
<text top="513" left="482" width="230" height="10" font="21">pressure gradient 40 mm Hg or higher; and</text>
<text top="529" left="467" width="333" height="10" font="21">c. Symptoms of HF, syncope, exertional dyspnea, angina, or</text>
<text top="546" left="482" width="240" height="10" font="21">presyncope by history or on exercise testing.</text>
<text top="568" left="465" width="335" height="15" font="5">Hemodynamic progression eventually leading to symp-</text>
<text top="585" left="450" width="350" height="15" font="5">tom onset occurs in nearly all asymptomatic patients with</text>
<text top="603" left="450" width="350" height="15" font="5">AS. However, survival during the asymptomatic phase is</text>
<text top="621" left="450" width="350" height="15" font="5">similar to age-matched controls with a low risk of sudden</text>
<text top="639" left="450" width="45" height="15" font="5">death (</text>
<text top="636" left="495" width="304" height="19" font="5">&lt;1% per year) when patients are followed pro-</text>
<text top="657" left="450" width="350" height="15" font="5">spectively and promptly report symptom onset. The rate of</text>
<text top="675" left="450" width="350" height="15" font="5">symptom onset is strongly dependent on severity of AS,</text>
<text top="693" left="450" width="350" height="15" font="5">with an event-free survival rate of about 75% to 80% at 2</text>
<text top="711" left="450" width="215" height="15" font="5">years in those with a jet velocity</text>
<text top="708" left="673" width="127" height="19" font="5">&lt;3.0 m per second</text>
<text top="729" left="450" width="350" height="15" font="5">compared with only 30% to 50% in those with a jet</text>
<text top="747" left="450" width="45" height="15" font="5">velocity</text>
<text top="744" left="501" width="299" height="19" font="5">4.0 m per second. Patients with asymptomatic</text>
<text top="765" left="450" width="350" height="15" font="5">AS require periodic monitoring for development of</text>
<text top="783" left="450" width="350" height="15" font="5">symptoms and progressive disease, but routine AVR is not</text>
<text top="801" left="450" width="94" height="15" font="5">recommended <a href="e57.full.html#15">(</a></text>
<text top="801" left="544" width="68" height="15" font="6"><a href="e57.full.html#15">Section 3.1</a></text>
<text top="801" left="612" width="9" height="15" font="5">).</text>
<text top="819" left="465" width="335" height="15" font="5">However, once even mild symptoms caused by severe</text>
<text top="837" left="450" width="350" height="15" font="5">AS are present, outcomes are extremely poor unless</text>
<text top="855" left="450" width="20" height="15" font="5">out</text>
<text top="851" left="469" width="330" height="19" font="5">ﬂow obstruction is relieved. Typical initial symptoms</text>
<text top="872" left="450" width="350" height="15" font="5">are dyspnea on exertion or decreased exercise tolerance.</text>
<text top="890" left="450" width="350" height="15" font="5">The classical symptoms of syncope, angina, and HF are</text>
<text top="908" left="450" width="350" height="15" font="5">late manifestations of disease, most often seen in patients</text>
<text top="926" left="450" width="350" height="15" font="5">in whom early symptom onset was not recognized and</text>
<text top="944" left="450" width="350" height="15" font="5">intervention was inappropriately delayed. In patients with</text>
<text top="962" left="450" width="190" height="15" font="5">severe, symptomatic, and calci</text>
<text top="959" left="639" width="160" height="19" font="5">ﬁc AS, the only effective</text>
<text top="980" left="450" width="350" height="15" font="5">treatment is surgical or transcatheter AVR, resulting in</text>
<text top="998" left="450" width="350" height="15" font="5">improved survival rates, reduced symptoms, and improved</text>
<text top="1016" left="450" width="350" height="15" font="5">exercise capacity. In the absence of serious comorbid</text>
<text top="1034" left="450" width="350" height="15" font="5">conditions that limit life expectancy or quality of life, AVR</text>
<text top="1052" left="450" width="350" height="15" font="5">is indicated in virtually all symptomatic patients with severe</text>
<text top="1070" left="450" width="350" height="15" font="5">AS and should be performed promptly after onset of</text>
<text top="1088" left="450" width="350" height="15" font="5">symptoms. Age alone is not a contraindication to surgery,</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e75</text>
</page>
<page number="20" position="absolute" top="0" left="0" height="1160" width="864">
<text top="461" left="64" width="350" height="15" font="5">with several series showing outcomes similar to age-</text>
<text top="479" left="64" width="267" height="15" font="5">matched normal subjects in the very elderly.</text>
<text top="497" left="79" width="98" height="15" font="5">Severe AS is de</text>
<text top="493" left="178" width="236" height="19" font="5">ﬁned as an aortic velocity 4.0 m per</text>
<text top="514" left="64" width="204" height="15" font="5">second or mean pressure gradient</text>
<text top="511" left="274" width="140" height="19" font="5">40 mm Hg based on</text>
<text top="532" left="64" width="350" height="15" font="5">outcomes in a series of patients with AS of known he-</text>
<text top="550" left="64" width="350" height="15" font="5">modynamic severity. Although transaortic velocity and</text>
<text top="568" left="64" width="350" height="15" font="5">mean pressure gradient are redundant measures of AS</text>
<text top="586" left="64" width="350" height="16" font="5">severitydwith native valve AS there is a close linear cor-</text>
<text top="604" left="64" width="350" height="15" font="5">relation between velocity and mean pressure gradient</text>
<text top="622" left="64" width="350" height="16" font="5">whether measured by catheterization or Doppler methodsd</text>
<text top="640" left="64" width="350" height="15" font="5">both are included in this guideline so that either Doppler</text>
<text top="658" left="64" width="350" height="15" font="5">or invasive measurements can be used in decision making.</text>
<text top="676" left="64" width="350" height="15" font="5">There is substantial overlap in hemodynamic severity be-</text>
<text top="694" left="64" width="350" height="15" font="5">tween asymptomatic and symptomatic patients, and there</text>
<text top="712" left="64" width="350" height="15" font="5">is no single parameter that indicates the need for AVR.</text>
<text top="730" left="64" width="350" height="15" font="5">Instead, it is the combination of symptoms, valve anatomy,</text>
<text top="748" left="64" width="132" height="15" font="5">and hemodynamics (</text>
<text top="748" left="197" width="50" height="15" font="6"><a href="e57.full.html#16">Table 8</a></text>
<text top="748" left="247" width="167" height="15" font="5"><a href="e57.full.html#16">) </a>that provides convincing</text>
<text top="766" left="64" width="196" height="15" font="5">evidence that AVR will be bene</text>
<text top="762" left="260" width="154" height="19" font="5">ﬁcial in an individual pa-</text>
<text top="784" left="64" width="349" height="15" font="5">tient. Many patients with a high transaortic velocity/</text>
<text top="801" left="64" width="350" height="15" font="5">pressure gradient will remain asymptomatic for several</text>
<text top="819" left="64" width="350" height="15" font="5">years and do not require AVR until symptom onset.</text>
<text top="837" left="64" width="350" height="15" font="5">However, if symptoms are present, a high velocity/</text>
<text top="855" left="64" width="76" height="15" font="5">gradient con</text>
<text top="852" left="140" width="274" height="19" font="5">ﬁrms valve obstruction as the cause of symp-</text>
<text top="873" left="64" width="350" height="15" font="5">toms. With mixed stenosis and regurgitation, a high ve-</text>
<text top="891" left="64" width="350" height="15" font="5">locity/gradient indicates severe mixed aortic valve disease.</text>
<text top="909" left="64" width="350" height="15" font="5">Calculation of valve area is not necessary when a high</text>
<text top="927" left="64" width="299" height="15" font="5">velocity/gradient is present and the valve is calci</text>
<text top="924" left="364" width="50" height="19" font="5">ﬁed and</text>
<text top="945" left="64" width="272" height="15" font="5">immobile; most patients will have a valve area</text>
<text top="942" left="340" width="52" height="19" font="5">1.0 cm</text>
<text top="942" left="392" width="6" height="10" font="14">2</text>
<text top="945" left="402" width="12" height="15" font="5">or</text>
<text top="963" left="64" width="133" height="15" font="5">an indexed valve area</text>
<text top="959" left="203" width="55" height="19" font="5">0.6 cm</text>
<text top="960" left="258" width="6" height="10" font="14">2</text>
<text top="963" left="263" width="17" height="15" font="5">/m</text>
<text top="960" left="281" width="6" height="10" font="14">2</text>
<text top="963" left="286" width="127" height="15" font="5">, but some will have</text>
<text top="981" left="64" width="349" height="15" font="5">a larger valve area due to a large body size or coexisting</text>
<text top="999" left="64" width="349" height="15" font="5">aortic regurgitation (AR). Thus, the primary criterion</text>
<text top="1017" left="64" width="60" height="15" font="5">for the de</text>
<text top="1013" left="125" width="289" height="19" font="5">ﬁnition of severity of AS is based on aortic ve-</text>
<text top="1035" left="64" width="350" height="15" font="5">locity or mean pressure gradient. Calculations of valve area</text>
<text top="1053" left="64" width="350" height="15" font="5">may be supportive but are not necessary when a high ve-</text>
<text top="1070" left="64" width="350" height="15" font="5">locity or gradient is present. In contrast, valve area cal-</text>
<text top="1088" left="64" width="349" height="15" font="5">culations are essential for patients with AS and a low</text>
<text top="461" left="450" width="235" height="15" font="5">ejection fraction or stroke volume as de</text>
<text top="457" left="685" width="115" height="19" font="5">ﬁned for stages D2</text>
<text top="479" left="450" width="51" height="15" font="5">and D3.</text>
<text top="497" left="465" width="120" height="15" font="5">Supporting References:</text>
<text top="497" left="587" width="213" height="15" font="6"><a href="e57.full.html#101">(24,25,29,89,92,94,108,109,134,135,</a></text>
<text top="515" left="450" width="72" height="15" font="6"><a href="e57.full.html#101">139,140,143</a></text>
<text top="511" left="522" width="34" height="19" font="6"><a href="e57.full.html#101">–148)</a></text>
<text top="533" left="465" width="18" height="15" font="5">See</text>
<text top="533" left="488" width="221" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplements 5, 6, and 7</a></text>
<text top="533" left="713" width="86" height="15" font="5">for more infor-</text>
<text top="551" left="450" width="350" height="15" font="5">mation on clinical outcomes with asymptomatic AS (stages B</text>
<text top="569" left="450" width="350" height="15" font="5">and C) of known hemodynamic severity, incidence of sudden</text>
<text top="587" left="450" width="350" height="15" font="5">death in asymptomatic patients with AS (stages B and C), and</text>
<text top="605" left="450" width="350" height="15" font="5">clinical outcomes with symptomatic AS of known hemodynamic</text>
<text top="623" left="450" width="118" height="15" font="5">severity, respectively.</text>
<text top="648" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="663" left="449" width="351" height="10" font="21">2. AVR is recommended for asymptomatic patients with severe AS</text>
<text top="679" left="467" width="333" height="10" font="21">(stage C2) and an LVEF less than 50% with decreased systolic</text>
<text top="696" left="467" width="93" height="10" font="21">opening of a calci</text>
<text top="692" left="560" width="239" height="16" font="21">ﬁed aortic valve with an aortic velocity 4.0 m</text>
<text top="712" left="467" width="332" height="10" font="21">per second or greater or mean pressure gradient 40 mm Hg or</text>
<text top="728" left="467" width="33" height="10" font="21">higher</text>
<text top="728" left="504" width="55" height="10" font="22"><a href="e57.full.html#103">(136,137)</a></text>
<text top="728" left="558" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="753" left="465" width="335" height="15" font="5">In patients with a low LVEF and severe AS, survival is</text>
<text top="771" left="450" width="350" height="15" font="5">better in those who undergo AVR than in those treated</text>
<text top="789" left="450" width="350" height="15" font="5">medically. The depressed LVEF in many patients is caused</text>
<text top="807" left="450" width="350" height="15" font="5">by excessive afterload (afterload mismatch), and LV</text>
<text top="824" left="450" width="350" height="15" font="5">function improves after AVR in such patients. If LV</text>
<text top="842" left="450" width="350" height="15" font="5">dysfunction is not caused by afterload mismatch, survival is</text>
<text top="860" left="450" width="350" height="15" font="5">still improved, likely because of the reduced afterload with</text>
<text top="878" left="450" width="350" height="15" font="5">AVR, but improvement in LV function and resolution of</text>
<text top="896" left="450" width="276" height="15" font="5">symptoms might not be complete after AVR.</text>
<text top="915" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="914" left="597" width="125" height="15" font="6"><a href="e57.full.html#102">(98,136,141,142,149</a></text>
<text top="911" left="722" width="35" height="19" font="6"><a href="e57.full.html#102">–153)</a></text>
<text top="933" left="465" width="18" height="15" font="5">See</text>
<text top="933" left="489" width="161" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 1</a></text>
<text top="933" left="657" width="143" height="15" font="5">for more information on</text>
<text top="951" left="450" width="188" height="15" font="5">outcomes in patients with low-</text>
<text top="947" left="638" width="161" height="19" font="5">ﬂow/low-gradient AS with</text>
<text top="969" left="450" width="87" height="15" font="5">reduced LVEF.</text>
<text top="994" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="1009" left="449" width="351" height="10" font="21">3. AVR is indicated for patients with severe AS (stage C or D)</text>
<text top="1025" left="467" width="333" height="10" font="21">when undergoing cardiac surgery for other indications when</text>
<text top="1042" left="467" width="246" height="10" font="21">there is decreased systolic opening of a calci</text>
<text top="1038" left="713" width="86" height="16" font="21">ﬁed aortic valve</text>
<text top="1058" left="467" width="332" height="10" font="21">and an aortic velocity 4.0 m per second or greater or mean</text>
<text top="1074" left="467" width="216" height="10" font="21">pressure gradient 40 mm Hg or higher</text>
<text top="1074" left="689" width="55" height="10" font="22"><a href="e57.full.html#102">(108,138)</a></text>
<text top="1074" left="744" width="55" height="12" font="21">. (Level of</text>
<text top="1091" left="467" width="65" height="12" font="21">Evidence: B)</text>
<text top="103" left="64" width="398" height="11" font="13">Table 9. Summary of Recommendations for AS: Timing of Intervention</text>
<text top="129" left="64" width="86" height="9" font="7">Recommendations</text>
<text top="129" left="553" width="21" height="9" font="7">COR</text>
<text top="129" left="652" width="18" height="9" font="7">LOE</text>
<text top="129" left="730" width="52" height="9" font="7">References</text>
<text top="148" left="64" width="442" height="9" font="7">AVR is recommended for symptomatic patients with severe high-gradient AS who have symptoms</text>
<text top="162" left="77" width="194" height="9" font="7">by history or on exercise testing (stage D1)</text>
<text top="148" left="562" width="3" height="9" font="7">I</text>
<text top="148" left="658" width="6" height="9" font="7">B</text>
<text top="148" left="721" width="69" height="9" font="8"><a href="e57.full.html#100">(9,91,134,135)</a></text>
<text top="176" left="64" width="384" height="9" font="7">AVR is recommended for asymptomatic patients with severe AS (stage C2) and LVEF</text>
<text top="173" left="452" width="28" height="14" font="7">&lt;50%</text>
<text top="176" left="562" width="3" height="9" font="7">I</text>
<text top="176" left="658" width="6" height="9" font="7">B</text>
<text top="176" left="733" width="45" height="9" font="8"><a href="e57.full.html#103">(136,137)</a></text>
<text top="194" left="64" width="443" height="9" font="7">AVR is indicated for patients with severe AS (stage C or D) when undergoing other cardiac surgery</text>
<text top="194" left="562" width="3" height="9" font="7">I</text>
<text top="194" left="658" width="6" height="9" font="7">B</text>
<text top="194" left="733" width="45" height="9" font="8"><a href="e57.full.html#102">(108,138)</a></text>
<text top="213" left="64" width="409" height="9" font="7">AVR is reasonable for asymptomatic patients with very severe AS (stage C1, aortic velocity</text>
<text top="224" left="77" width="144" height="14" font="7">5.0 m/s) and low surgical risk</text>
<text top="213" left="558" width="11" height="9" font="7">IIa</text>
<text top="213" left="658" width="6" height="9" font="7">B</text>
<text top="213" left="733" width="45" height="9" font="8"><a href="e57.full.html#103">(139,140)</a></text>
<text top="241" left="64" width="429" height="9" font="7">AVR is reasonable in asymptomatic patients (stage C1) with severe AS and decreased exercise</text>
<text top="255" left="77" width="153" height="9" font="7">tolerance or an exercise fall in BP</text>
<text top="241" left="558" width="11" height="9" font="7">IIa</text>
<text top="241" left="658" width="6" height="9" font="7">B</text>
<text top="241" left="739" width="33" height="9" font="8"><a href="e57.full.html#101">(25,47)</a></text>
<text top="269" left="64" width="233" height="9" font="7">AVR is reasonable in symptomatic patients with low-</text>
<text top="266" left="297" width="208" height="14" font="7">ﬂow/low-gradient severe AS with reduced LVEF</text>
<text top="283" left="77" width="366" height="9" font="7">(stage D2) with a low-dose dobutamine stress study that shows an aortic velocity</text>
<text top="280" left="446" width="45" height="14" font="7">4.0 m/s</text>
<text top="297" left="77" width="123" height="9" font="7">(or mean pressure gradient</text>
<text top="294" left="203" width="185" height="14" font="7">40 mm Hg) with a valve area 1.0 cm</text>
<text top="295" left="388" width="5" height="6" font="23">2</text>
<text top="297" left="396" width="110" height="9" font="7">at any dobutamine dose</text>
<text top="269" left="558" width="11" height="9" font="7">IIa</text>
<text top="269" left="658" width="6" height="9" font="7">B</text>
<text top="269" left="726" width="60" height="9" font="8"><a href="e57.full.html#101">(43,141,142)</a></text>
<text top="311" left="64" width="262" height="9" font="7">AVR is reasonable in symptomatic patients who have low-</text>
<text top="308" left="326" width="176" height="14" font="7">ﬂow/low-gradient severe AS (stage D3)</text>
<text top="325" left="77" width="184" height="9" font="7">who are normotensive and have an LVEF</text>
<text top="322" left="265" width="232" height="14" font="7">50% if clinical, hemodynamic, and anatomic data</text>
<text top="340" left="77" width="288" height="9" font="7">support valve obstruction as the most likely cause of symptoms</text>
<text top="311" left="558" width="11" height="9" font="7">IIa</text>
<text top="311" left="658" width="6" height="9" font="7">C</text>
<text top="311" left="747" width="18" height="9" font="7">N/A</text>
<text top="354" left="64" width="351" height="9" font="7">AVR is reasonable for patients with moderate AS (stage B) (aortic velocity 3.0</text>
<text top="351" left="416" width="85" height="14" font="7">–3.9 m/s) who are</text>
<text top="368" left="77" width="148" height="9" font="7">undergoing other cardiac surgery</text>
<text top="354" left="558" width="11" height="9" font="7">IIa</text>
<text top="354" left="658" width="6" height="9" font="7">C</text>
<text top="354" left="747" width="18" height="9" font="7">N/A</text>
<text top="382" left="64" width="433" height="9" font="7">AVR may be considered for asymptomatic patients with severe AS (stage C1) and rapid disease</text>
<text top="396" left="77" width="148" height="9" font="7">progression and low surgical risk</text>
<text top="382" left="558" width="11" height="9" font="7">IIb</text>
<text top="382" left="658" width="6" height="9" font="7">C</text>
<text top="382" left="747" width="18" height="9" font="7">N/A</text>
<text top="416" left="72" width="728" height="8" font="18">AS indicates aortic stenosis; AVR, aortic valve replacement by either surgical or transcatheter approach; BP, blood pressure; COR, Class of Recommendation; LOE, Level of Evidence; LVEF,</text>
<text top="428" left="72" width="212" height="8" font="18">left ventricular ejection fraction; and N/A, not applicable.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e76</text>
</page>
<page number="21" position="absolute" top="0" left="0" height="1160" width="864">
<text top="834" left="79" width="335" height="15" font="5">Prospective clinical studies demonstrate that disease</text>
<text top="852" left="64" width="350" height="15" font="5">progression occurs in nearly all patients with severe</text>
<text top="870" left="64" width="350" height="15" font="5">asymptomatic AS. Symptom onset within 2 to 5 years is</text>
<text top="888" left="64" width="172" height="15" font="5">likely when aortic velocity is</text>
<text top="885" left="241" width="173" height="19" font="5">4.0 m per second or mean</text>
<text top="906" left="64" width="121" height="15" font="5">pressure gradient is</text>
<text top="903" left="192" width="222" height="19" font="5">40 mm Hg. The additive risk of</text>
<text top="924" left="64" width="350" height="15" font="5">AVR at the time of other cardiac surgery is less than the</text>
<text top="942" left="64" width="204" height="15" font="5">risk of reoperation within 5 years.</text>
<text top="960" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="960" left="212" width="111" height="15" font="6"><a href="e57.full.html#102">(108,138,154,155)</a></text>
<text top="992" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="1006" left="63" width="351" height="10" font="21">1. AVR is reasonable for asymptomatic patients with very severe</text>
<text top="1023" left="81" width="103" height="10" font="21">AS (stage C1) with</text>
<text top="1023" left="188" width="55" height="10" font="22"><a href="e57.full.html#103">(139,140)</a></text>
<text top="1023" left="247" width="117" height="12" font="21">(Level of Evidence: B):</text>
<text top="1039" left="81" width="214" height="10" font="21">a. Decreased systolic opening of a calci</text>
<text top="1036" left="295" width="54" height="16" font="21">ﬁed valve;</text>
<text top="1056" left="81" width="333" height="10" font="21">b. An aortic velocity 5.0 m per second or greater or mean</text>
<text top="1072" left="97" width="229" height="10" font="21">pressure gradient 60 mm Hg or higher; and</text>
<text top="1089" left="81" width="118" height="10" font="21">c. A low surgical risk.</text>
<text top="834" left="465" width="335" height="15" font="5">In patients with very severe AS and an aortic</text>
<text top="852" left="450" width="45" height="15" font="5">velocity</text>
<text top="849" left="498" width="301" height="19" font="5">5.0 m per second or mean pressure gradient 60</text>
<text top="870" left="450" width="350" height="15" font="5">mm Hg, the rate of symptom onset is approximately 50%</text>
<text top="888" left="450" width="350" height="15" font="5">at 2 years. Several observational studies have shown higher</text>
<text top="906" left="450" width="350" height="15" font="5">rates of symptom onset and major adverse cardiac events in</text>
<text top="924" left="450" width="350" height="15" font="5">patients with very severe, compared with severe, AS. In</text>
<text top="942" left="450" width="350" height="15" font="5">addition, a study comparing early surgery with surgery at</text>
<text top="960" left="450" width="250" height="15" font="5">symptom onset in 57 propensity score</text>
<text top="956" left="700" width="100" height="19" font="5">matched pairs</text>
<text top="978" left="450" width="350" height="15" font="5">showed a lower all-cause mortality risk with early surgery</text>
<text top="996" left="450" width="221" height="15" font="5">(hazard ratio [HR]: 0.135; 95% con</text>
<text top="992" left="671" width="128" height="19" font="5">ﬁdence interval [CI]:</text>
<text top="1014" left="450" width="120" height="15" font="5">0.030 to 0.597; p</text>
<text top="1010" left="570" width="229" height="19" font="5">¼0.008). Thus, it is reasonable to</text>
<text top="1031" left="450" width="350" height="15" font="5">consider elective AVR in patients with very severe</text>
<text top="1049" left="450" width="350" height="15" font="5">asymptomatic AS if surgical risk is low rather than waiting</text>
<text top="1067" left="450" width="281" height="15" font="5">for symptom onset. A low surgical risk is de</text>
<text top="1064" left="731" width="69" height="19" font="5">ﬁned as an</text>
<text top="1085" left="450" width="143" height="15" font="5">STS PROM score of</text>
<text top="1082" left="602" width="197" height="19" font="5">&lt;4.0 in the absence of other</text>
<text top="685" left="64" width="282" height="11" font="13">Figure 1. Indications for AVR in Patients With AS</text>
<text top="718" left="64" width="735" height="9" font="14">Arrows show the decision pathways that result in a recommendation for AVR. Periodic monitoring is indicated for all patients in whom AVR is not yet indicated, including those with</text>
<text top="731" left="64" width="534" height="9" font="14">asymptomatic AS (stage D or C) and those with low-gradient AS (stage D2 or D3) who do not meet the criteria for intervention.</text>
<text top="745" left="64" width="536" height="9" font="14">*AVR should be considered with stage D3 AS only if valve obstruction is the most likely cause of symptoms, stroke volume index is</text>
<text top="742" left="602" width="47" height="13" font="14">&lt;35 mL/m</text>
<text top="743" left="649" width="4" height="6" font="23">2</text>
<text top="745" left="653" width="65" height="9" font="14">, indexed AVA is</text>
<text top="742" left="721" width="37" height="13" font="14">0.6 cm</text>
<text top="743" left="758" width="4" height="6" font="23">2</text>
<text top="745" left="762" width="13" height="9" font="14">/m</text>
<text top="743" left="775" width="4" height="6" font="23">2</text>
<text top="745" left="779" width="21" height="9" font="14">, and</text>
<text top="758" left="64" width="270" height="9" font="14">data are recorded when the patient is normotensive (systolic BP</text>
<text top="756" left="338" width="64" height="13" font="14">&lt;140 mm Hg).</text>
<text top="772" left="72" width="728" height="9" font="14">AS indicates aortic stenosis; AVA; aortic valve area; AVR, aortic valve replacement by either surgical or transcatheter approach; BP, blood pressure; DSE, dobutamine stress</text>
<text top="785" left="72" width="359" height="9" font="14">echocardiography; ETT, exercise treadmill test; LVEF, left ventricular ejection fraction;</text>
<text top="781" left="434" width="7" height="15" font="15">D</text>
<text top="785" left="441" width="5" height="9" font="14">P</text>
<text top="789" left="446" width="18" height="6" font="23">mean</text>
<text top="785" left="464" width="136" height="9" font="14">, mean pressure gradient; and V</text>
<text top="789" left="600" width="13" height="6" font="23">max</text>
<text top="785" left="613" width="84" height="9" font="14">, maximum velocity.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e77</text>
</page>
<page number="22" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">comorbidities or advanced frailty. At Heart Valve Centers</text>
<text top="121" left="64" width="350" height="15" font="5">of Excellence, this corresponds to an operative mortality</text>
<text top="139" left="64" width="12" height="15" font="5">of</text>
<text top="135" left="81" width="51" height="19" font="5">&lt;1.5% (</text>
<text top="139" left="132" width="68" height="15" font="6"><a href="e57.full.html#12">Section 2.5</a></text>
<text top="139" left="199" width="215" height="15" font="5">). Patient age, avoidance of patient-</text>
<text top="157" left="64" width="350" height="15" font="5">prosthesis mismatch, anticoagulation issues, and patient</text>
<text top="175" left="64" width="350" height="15" font="5">preferences should be taken into account in a decision to</text>
<text top="192" left="64" width="297" height="15" font="5">proceed with AVR or continue watchful waiting.</text>
<text top="211" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="210" left="212" width="132" height="15" font="6"><a href="e57.full.html#103">(115,139,140,145,156</a></text>
<text top="207" left="344" width="35" height="19" font="6"><a href="e57.full.html#103">–158)</a></text>
<text top="238" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="253" left="63" width="351" height="10" font="21">2. AVR is reasonable in apparently asymptomatic patients with</text>
<text top="269" left="81" width="141" height="10" font="21">severe AS (stage C1) with</text>
<text top="269" left="227" width="41" height="10" font="22"><a href="e57.full.html#101">(25,47)</a></text>
<text top="269" left="271" width="117" height="12" font="21">(Level of Evidence: B):</text>
<text top="285" left="81" width="52" height="10" font="21">a. A calci</text>
<text top="282" left="133" width="88" height="16" font="21">ﬁed aortic valve;</text>
<text top="302" left="81" width="333" height="10" font="21">b. An aortic velocity of 4.0 m per second to 4.9 m per second or</text>
<text top="318" left="97" width="300" height="10" font="21">mean pressure gradient of 40 mm Hg to 59 mm Hg; and</text>
<text top="335" left="81" width="333" height="10" font="21">c. An exercise test demonstrating decreased exercise toler-</text>
<text top="351" left="97" width="150" height="10" font="21">ance or a fall in systolic BP.</text>
<text top="376" left="79" width="335" height="15" font="5">Exercise testing may be helpful in clarifying symptom</text>
<text top="393" left="64" width="350" height="15" font="5">status in patients with severe AS. When symptoms are</text>
<text top="411" left="64" width="350" height="15" font="5">provoked by exercise testing, the patient is considered</text>
<text top="429" left="64" width="350" height="15" font="5">symptomatic and meets a Class I recommendation for</text>
<text top="447" left="64" width="350" height="15" font="5">AVR. In patients without overt symptoms who</text>
<text top="465" left="64" width="350" height="15" font="5">demonstrate 1) a decrease in systolic BP below baseline</text>
<text top="483" left="64" width="350" height="15" font="5">or a failure of BP to increase by at least 20 mm Hg or 2)</text>
<text top="501" left="64" width="39" height="15" font="5">a signi</text>
<text top="498" left="104" width="310" height="19" font="5">ﬁcant decrease in exercise tolerance compared with</text>
<text top="519" left="64" width="350" height="15" font="5">age and sex normal standards, symptom onset within 1</text>
<text top="537" left="64" width="350" height="15" font="5">to 2 years is high (about 60% to 80%). Thus, it is</text>
<text top="555" left="64" width="350" height="15" font="5">reasonable to consider elective AVR in these patients</text>
<text top="573" left="64" width="350" height="15" font="5">when surgical risk is low, taking into account patient</text>
<text top="591" left="64" width="350" height="15" font="5">preferences and clinical factors such as age and comorbid</text>
<text top="609" left="64" width="68" height="15" font="5">conditions.</text>
<text top="627" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="627" left="212" width="110" height="15" font="6"><a href="e57.full.html#101">(25,46,47,117,119</a></text>
<text top="623" left="322" width="35" height="19" font="6"><a href="e57.full.html#101">–121)</a></text>
<text top="645" left="79" width="18" height="15" font="5">See</text>
<text top="645" left="104" width="161" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 3</a></text>
<text top="645" left="271" width="143" height="15" font="5">for more information on</text>
<text top="663" left="64" width="86" height="15" font="5">exercise testing.</text>
<text top="689" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="704" left="63" width="301" height="10" font="21">3. AVR is reasonable in symptomatic patients with low-</text>
<text top="701" left="364" width="50" height="16" font="21">ﬂow/low-</text>
<text top="721" left="81" width="332" height="10" font="21">gradient severe AS with reduced LVEF (stage D2) with a</text>
<text top="737" left="81" width="73" height="10" font="22"><a href="e57.full.html#101">(43,141,142)</a></text>
<text top="737" left="158" width="116" height="12" font="21">(Level of Evidence: B):</text>
<text top="754" left="81" width="42" height="10" font="21">a. Calci</text>
<text top="751" left="123" width="250" height="16" font="21">ﬁed aortic valve with reduced systolic opening;</text>
<text top="770" left="81" width="156" height="10" font="21">b. Resting valve area 1.0 cm</text>
<text top="768" left="237" width="5" height="7" font="25">2</text>
<text top="770" left="246" width="39" height="10" font="21">or less;</text>
<text top="786" left="81" width="333" height="10" font="21">c. Aortic velocity less than 4 m per second or mean pressure</text>
<text top="803" left="97" width="159" height="10" font="21">gradient less than 40 mm Hg;</text>
<text top="819" left="81" width="147" height="10" font="21">d. LVEF less than 50%; and</text>
<text top="836" left="81" width="333" height="10" font="21">e. A low-dose dobutamine stress study that shows an aortic</text>
<text top="852" left="97" width="317" height="10" font="21">velocity 4 m per second or greater or mean pressure gradient</text>
<text top="869" left="97" width="237" height="10" font="21">40 mm Hg or higher with a valve area 1.0 cm</text>
<text top="866" left="334" width="5" height="7" font="25">2</text>
<text top="869" left="343" width="71" height="10" font="21">or less at any</text>
<text top="885" left="97" width="94" height="10" font="21">dobutamine dose.</text>
<text top="909" left="79" width="335" height="15" font="5">Mean pressure gradient is a strong predictor of outcome</text>
<text top="927" left="64" width="350" height="15" font="5">after AVR, with better outcomes with higher gradients.</text>
<text top="945" left="64" width="350" height="15" font="5">Outcomes are poor with severe low-gradient AS but are</text>
<text top="963" left="64" width="350" height="15" font="5">still improved with AVR compared with medical therapy</text>
<text top="981" left="64" width="350" height="15" font="5">in those with a low LVEF, particularly when contractile</text>
<text top="999" left="64" width="222" height="15" font="5">reserve is present. The document</text>
<text top="996" left="297" width="117" height="19" font="5">“Echocardiographic</text>
<text top="1017" left="64" width="350" height="15" font="5">Assessment of Valve Stenosis: EAE/ASE Recommenda-</text>
<text top="1035" left="64" width="159" height="15" font="5">tions for Clinical Practice</text>
<text top="1032" left="224" width="190" height="19" font="5">” deﬁnes severe AS on dobut-</text>
<text top="1053" left="64" width="269" height="15" font="5">amine stress testing as a maximum velocity</text>
<text top="1050" left="340" width="74" height="19" font="5">&gt;4.0 m per</text>
<text top="1071" left="64" width="144" height="15" font="5">second with a valve area</text>
<text top="1067" left="213" width="53" height="19" font="5">1.0 cm</text>
<text top="1068" left="265" width="6" height="10" font="14">2</text>
<text top="1071" left="275" width="139" height="15" font="5">at any point during the</text>
<text top="1089" left="64" width="350" height="15" font="5">test protocol, with a maximum dobutamine dose of</text>
<text top="103" left="450" width="350" height="15" font="5">20 mcg/kg per minute. On the basis of outcome data</text>
<text top="121" left="450" width="350" height="15" font="5">in several prospective nonrandomized studies, AVR is</text>
<text top="139" left="450" width="350" height="15" font="5">reasonable in these patients. LVEF typically increases by</text>
<text top="157" left="450" width="350" height="15" font="5">10 LVEF units and may return to normal if afterload</text>
<text top="175" left="450" width="350" height="15" font="5">mismatch was the cause of LV systolic dysfunction. Some</text>
<text top="192" left="450" width="303" height="15" font="5">patients without contractile reserve may also bene</text>
<text top="189" left="752" width="47" height="19" font="5">ﬁt from</text>
<text top="210" left="450" width="350" height="15" font="5">AVR, but decisions in these high-risk patients must be</text>
<text top="228" left="450" width="350" height="15" font="5">individualized because there are no data indicating who</text>
<text top="246" left="450" width="243" height="15" font="5">will have a better outcome with surgery.</text>
<text top="265" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="264" left="597" width="174" height="15" font="6"><a href="e57.full.html#101">(43,99,137,141,142,150,151)</a></text>
<text top="283" left="465" width="18" height="15" font="5">See</text>
<text top="283" left="489" width="161" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 1</a></text>
<text top="283" left="657" width="143" height="15" font="5">for more information on</text>
<text top="301" left="450" width="188" height="15" font="5">outcomes in patients with low-</text>
<text top="297" left="638" width="161" height="19" font="5">ﬂow/low-gradient AS with</text>
<text top="319" left="450" width="87" height="15" font="5">reduced LVEF.</text>
<text top="345" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="360" left="449" width="301" height="10" font="21">4. AVR is reasonable in symptomatic patients with low-</text>
<text top="357" left="750" width="50" height="16" font="21">ﬂow/low-</text>
<text top="377" left="467" width="332" height="10" font="21">gradient severe AS (stage D3) with an LVEF 50% or greater, a</text>
<text top="393" left="467" width="25" height="10" font="21">calci</text>
<text top="390" left="492" width="308" height="16" font="21">ﬁed aortic valve with signiﬁcantly reduced leaﬂet motion,</text>
<text top="410" left="467" width="128" height="10" font="21">and a valve area 1.0 cm</text>
<text top="407" left="595" width="5" height="7" font="25">2</text>
<text top="410" left="604" width="195" height="10" font="21">or less only if clinical, hemodynamic,</text>
<text top="426" left="467" width="332" height="10" font="21">and anatomic data support valve obstruction as the most likely</text>
<text top="442" left="467" width="332" height="10" font="21">cause of symptoms and data recorded when the patient is</text>
<text top="459" left="467" width="144" height="10" font="21">normotensive (systolic BP</text>
<text top="456" left="618" width="182" height="16" font="21">&lt;140 mm Hg) indicate (Level of</text>
<text top="475" left="467" width="68" height="12" font="21">Evidence: C):</text>
<text top="492" left="467" width="333" height="10" font="21">a. An aortic velocity less than 4 m per second or mean pressure</text>
<text top="508" left="482" width="182" height="10" font="21">gradient less than 40 mm Hg; and</text>
<text top="525" left="467" width="242" height="10" font="21">b. A stroke volume index less than 35 mL/m</text>
<text top="522" left="708" width="5" height="7" font="25">2</text>
<text top="525" left="713" width="26" height="10" font="21">; and</text>
<text top="541" left="467" width="174" height="10" font="21">c. An indexed valve area 0.6 cm</text>
<text top="538" left="641" width="5" height="7" font="25">2</text>
<text top="541" left="646" width="17" height="10" font="21">/m</text>
<text top="538" left="663" width="5" height="7" font="25">2</text>
<text top="541" left="672" width="39" height="10" font="21">or less.</text>
<text top="567" left="465" width="335" height="15" font="5">Most patients with severe AS present with a high</text>
<text top="585" left="450" width="350" height="15" font="5">transvalvular gradient and velocity. However, a subset</text>
<text top="603" left="450" width="350" height="15" font="5">present with severe AS despite a low gradient and veloc-</text>
<text top="621" left="450" width="350" height="15" font="5">ity due either to concurrent LV systolic dysfunction</text>
<text top="638" left="450" width="44" height="15" font="5">(LVEF</text>
<text top="635" left="501" width="298" height="19" font="5">&lt;50%) or a low transaortic stroke volume with</text>
<text top="656" left="450" width="350" height="15" font="5">preserved LV systolic function. Studies suggest that low-</text>
<text top="671" left="450" width="350" height="19" font="5">ﬂow/low-gradient severe AS with preserved LVEF oc-</text>
<text top="692" left="450" width="350" height="15" font="5">curs in 5% to 25% of patients with severe AS. Some studies</text>
<text top="710" left="450" width="319" height="15" font="5">suggest that even asymptomatic patients with low-</text>
<text top="707" left="769" width="31" height="19" font="5">ﬂow/</text>
<text top="728" left="450" width="350" height="15" font="5">low-gradient severe AS with a normal LVEF have a</text>
<text top="746" left="450" width="208" height="15" font="5">poor prognosis and might bene</text>
<text top="743" left="658" width="142" height="19" font="5">ﬁt from AVR. Other</text>
<text top="764" left="450" width="350" height="15" font="5">studies suggest that many of these asymptomatic patients</text>
<text top="782" left="450" width="350" height="15" font="5">have only moderate AS with outcomes similar to other</text>
<text top="800" left="450" width="317" height="15" font="5">patients with moderate AS and normal transaortic</text>
<text top="797" left="774" width="26" height="19" font="5">ﬂow</text>
<text top="818" left="450" width="350" height="15" font="5">rates. However, both case-control and prospective studies</text>
<text top="836" left="450" width="350" height="15" font="5">suggest that outcomes are worse in symptomatic patients</text>
<text top="854" left="450" width="63" height="15" font="5">with low-</text>
<text top="850" left="513" width="287" height="19" font="5">ﬂow/low-gradient AS with a normal LVEF</text>
<text top="872" left="450" width="350" height="15" font="5">compared with patients with high-gradient severe AS.</text>
<text top="890" left="450" width="350" height="15" font="5">Although no RCTs have been done, a post hoc subset</text>
<text top="908" left="450" width="350" height="15" font="5">analysis of an RCT suggests that survival may be improved</text>
<text top="925" left="450" width="350" height="15" font="5">with TAVR or AVR versus medical management in the</text>
<text top="943" left="450" width="186" height="15" font="5">symptomatic patient with low-</text>
<text top="940" left="636" width="94" height="19" font="5">ﬂow severe AS.</text>
<text top="961" left="465" width="263" height="15" font="5">The clinical approach to patients with low-</text>
<text top="958" left="728" width="72" height="19" font="5">ﬂow AS re-</text>
<text top="979" left="450" width="319" height="15" font="5">lies on integration of multiple sources of data. Low-</text>
<text top="976" left="769" width="31" height="19" font="5">ﬂow/</text>
<text top="997" left="450" width="350" height="15" font="5">low-gradient severe AS with preserved LVEF should be</text>
<text top="1015" left="450" width="253" height="15" font="5">considered in patients with a severely calci</text>
<text top="1012" left="703" width="97" height="19" font="5">ﬁed aortic valve,</text>
<text top="1033" left="450" width="110" height="15" font="5">an aortic velocity</text>
<text top="1030" left="568" width="231" height="19" font="5">&lt;4.0 m per second (mean pressure</text>
<text top="1051" left="450" width="49" height="15" font="5">gradient</text>
<text top="1048" left="508" width="282" height="19" font="5">&lt;40 mm Hg), and a valve area 1.0 cm</text>
<text top="1048" left="790" width="6" height="10" font="14">2</text>
<text top="1051" left="796" width="4" height="15" font="5">.</text>
<text top="1069" left="450" width="149" height="15" font="5">However, even with low</text>
<text top="1065" left="605" width="195" height="19" font="5">ﬂow, severe AS is unlikely with</text>
<text top="1087" left="450" width="57" height="15" font="5">a velocity</text>
<text top="1083" left="513" width="287" height="19" font="5">&lt;3.0 m per second or mean pressure gradient</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e78</text>
</page>
<page number="23" position="absolute" top="0" left="0" height="1160" width="864">
<text top="99" left="64" width="350" height="19" font="5">&lt;20 mm Hg. Typically, there is a small left ventricle with</text>
<text top="121" left="64" width="350" height="15" font="5">thick walls, diastolic dysfunction, and a normal LVEF</text>
<text top="139" left="64" width="5" height="15" font="5">(</text>
<text top="135" left="69" width="345" height="19" font="5">50%). The ﬁrst diagnostic step is to ensure that data</text>
<text top="157" left="64" width="350" height="15" font="5">have been recorded and measured correctly. If the patient</text>
<text top="175" left="64" width="350" height="15" font="5">was hypertensive, repeat evaluation after control of BP</text>
<text top="192" left="64" width="350" height="15" font="5">should be considered. Next, the valve area should be</text>
<text top="210" left="64" width="350" height="15" font="5">indexed to body size because an apparent small valve area</text>
<text top="228" left="64" width="350" height="15" font="5">may be only moderate AS in a small patient; an aortic valve</text>
<text top="246" left="64" width="62" height="15" font="5">area index</text>
<text top="243" left="132" width="54" height="19" font="5">0.6 cm</text>
<text top="243" left="187" width="6" height="10" font="14">2</text>
<text top="246" left="192" width="17" height="15" font="5">/m</text>
<text top="243" left="209" width="6" height="10" font="14">2</text>
<text top="246" left="221" width="193" height="15" font="5">suggests severe AS. Transaortic</text>
<text top="264" left="64" width="324" height="15" font="5">stroke volume should be calculated from the LV out</text>
<text top="261" left="388" width="26" height="19" font="5">ﬂow</text>
<text top="282" left="64" width="350" height="15" font="5">tract diameter and Doppler velocity time integral; a stroke</text>
<text top="300" left="64" width="242" height="15" font="5">volume indexed to body surface area</text>
<text top="297" left="315" width="75" height="19" font="5">&lt;35 mL/m</text>
<text top="297" left="390" width="6" height="10" font="14">2</text>
<text top="300" left="405" width="9" height="15" font="5">is</text>
<text top="318" left="64" width="115" height="15" font="5">consistent with low</text>
<text top="315" left="183" width="231" height="19" font="5">ﬂow. If the degree of valve calciﬁcation</text>
<text top="336" left="64" width="350" height="15" font="5">cannot be adequately assessed on TTE, TEE, CT imag-</text>
<text top="354" left="64" width="39" height="15" font="5">ing, or</text>
<text top="350" left="108" width="306" height="19" font="5">ﬂuoroscopy may be considered. The patient should</text>
<text top="372" left="64" width="350" height="15" font="5">be evaluated for other potential causes of symptoms to</text>
<text top="390" left="64" width="350" height="15" font="5">ensure that symptoms are most likely due to valve</text>
<text top="408" left="64" width="350" height="15" font="5">obstruction. The risk of surgery and patient comorbidities</text>
<text top="426" left="64" width="206" height="15" font="5">should also be taken into account.</text>
<text top="444" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="444" left="212" width="65" height="15" font="6"><a href="e57.full.html#100">(8,146,159</a></text>
<text top="440" left="277" width="35" height="19" font="6"><a href="e57.full.html#100">–166)</a></text>
<text top="462" left="79" width="18" height="15" font="5">See</text>
<text top="462" left="103" width="161" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 8</a></text>
<text top="462" left="271" width="143" height="15" font="5">for more information on</text>
<text top="480" left="64" width="188" height="15" font="5">outcomes in patients with low-</text>
<text top="476" left="252" width="161" height="19" font="5">ﬂow/low-gradient AS with</text>
<text top="498" left="64" width="98" height="15" font="5">preserved LVEF.</text>
<text top="525" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="539" left="63" width="351" height="10" font="21">5. AVR is reasonable for patients with moderate AS (stage B) with</text>
<text top="556" left="81" width="332" height="10" font="21">an aortic velocity between 3.0 m per second and 3.9 m per</text>
<text top="572" left="81" width="332" height="10" font="21">second or mean pressure gradient between 20 mm Hg and 39</text>
<text top="589" left="81" width="333" height="10" font="21">mm Hg who are undergoing cardiac surgery for other in-</text>
<text top="605" left="81" width="168" height="12" font="21">dications. (Level of Evidence: C)</text>
<text top="630" left="79" width="31" height="15" font="5">Calci</text>
<text top="626" left="110" width="304" height="19" font="5">ﬁc AS is a progressive disease, and once moderate</text>
<text top="647" left="64" width="350" height="15" font="5">AS is present, the likelihood of symptom onset within 5</text>
<text top="665" left="64" width="77" height="15" font="5">years is signi</text>
<text top="662" left="141" width="273" height="19" font="5">ﬁcant. When the risk of progressive VHD is</text>
<text top="683" left="64" width="350" height="15" font="5">balanced against the risk of repeat surgery within 5 years, it</text>
<text top="701" left="64" width="350" height="15" font="5">is reasonable to perform AVR at the time of other cardiac</text>
<text top="719" left="64" width="217" height="15" font="5">surgery when moderate AS is present <a href="e57.full.html#27">(</a></text>
<text top="719" left="281" width="82" height="15" font="6"><a href="e57.full.html#27">Sections 4.3.3.</a></text>
<text top="719" left="367" width="21" height="15" font="5">and</text>
<text top="719" left="391" width="15" height="15" font="6"><a href="e57.full.html#58">10</a></text>
<text top="719" left="406" width="8" height="15" font="5"><a href="e57.full.html#58">).</a></text>
<text top="737" left="64" width="336" height="15" font="5">This decision must be individualized based on the speci</text>
<text top="734" left="400" width="14" height="19" font="5">ﬁc</text>
<text top="755" left="64" width="349" height="15" font="5">operative risk in each patient, clinical factors such as age and</text>
<text top="773" left="64" width="350" height="15" font="5">comorbid conditions, valve durability, and patient preferences.</text>
<text top="792" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="791" left="212" width="122" height="15" font="6"><a href="e57.full.html#101">(25,92,138,154,155)</a></text>
<text top="106" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="121" left="449" width="351" height="10" font="21">1. AVR may be considered for asymptomatic patients with severe</text>
<text top="137" left="467" width="332" height="10" font="21">AS (stage C1) with an aortic velocity 4.0 m per second or</text>
<text top="154" left="467" width="332" height="10" font="21">greater or mean pressure gradient 40 mm Hg or higher if the</text>
<text top="170" left="467" width="332" height="10" font="21">patient is at low surgical risk and serial testing shows an in-</text>
<text top="187" left="467" width="333" height="10" font="21">crease in aortic velocity 0.3 m per second or greater per year.</text>
<text top="204" left="467" width="113" height="12" font="21">(Level of Evidence: C)</text>
<text top="228" left="465" width="335" height="15" font="5">Predictors of rapid disease progression include older age,</text>
<text top="246" left="450" width="137" height="15" font="5">more severe valve calci</text>
<text top="242" left="587" width="213" height="19" font="5">ﬁcation, and a faster rate of hemo-</text>
<text top="263" left="450" width="350" height="15" font="5">dynamic progression on serial studies. In patients with</text>
<text top="281" left="450" width="350" height="15" font="5">severe AS and predictors of rapid disease progression,</text>
<text top="299" left="450" width="350" height="15" font="5">elective AVR may be considered if the surgical risk is low</text>
<text top="317" left="450" width="350" height="15" font="5">and after consideration of other clinical factors and patient</text>
<text top="335" left="450" width="70" height="15" font="5">preferences.</text>
<text top="354" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="353" left="597" width="85" height="15" font="6"><a href="e57.full.html#103">(115,167,168)</a></text>
<text top="380" left="450" width="315" height="15" font="5">3.2.4. Choice of Intervention: Recommendations</text>
<text top="405" left="451" width="21" height="15" font="5">See</text>
<text top="405" left="475" width="53" height="15" font="6"><a href="e57.full.html#23">Table 10</a></text>
<text top="405" left="531" width="268" height="15" font="5">for a summary of recommendations from this</text>
<text top="423" left="450" width="45" height="15" font="5">section.</text>
<text top="441" left="465" width="335" height="15" font="5">These recommendations for choice of intervention for</text>
<text top="459" left="450" width="350" height="15" font="5">AS apply to both surgical and transcatheter AVR; in-</text>
<text top="477" left="450" width="224" height="15" font="5">dications for AVR are discussed in</text>
<text top="477" left="682" width="82" height="15" font="6"><a href="e57.full.html#19">Section 3.2.3</a></text>
<text top="477" left="764" width="36" height="15" font="5"><a href="e57.full.html#19">. </a>The</text>
<text top="495" left="450" width="350" height="15" font="5">integrative approach to assessing risk of surgical or trans-</text>
<text top="513" left="450" width="179" height="15" font="5">catheter AVR is discussed in</text>
<text top="513" left="635" width="69" height="15" font="6"><a href="e57.full.html#12">Section 2.5</a></text>
<text top="513" left="704" width="96" height="15" font="5"><a href="e57.full.html#12">. </a>The choice of</text>
<text top="531" left="450" width="350" height="15" font="5">proceeding with surgical versus transcatheter AVR is based</text>
<text top="549" left="450" width="350" height="15" font="5">on multiple parameters, including the risk of operation,</text>
<text top="567" left="450" width="350" height="15" font="5">patient frailty, and comorbid conditions. Concomitant</text>
<text top="585" left="450" width="350" height="15" font="5">severe CAD may also affect the optimal intervention</text>
<text top="603" left="450" width="350" height="15" font="5">because severe multivessel coronary disease may best be</text>
<text top="621" left="450" width="172" height="15" font="5">served by AVR and CABG.</text>
<text top="648" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="663" left="449" width="351" height="10" font="21">1. Surgical AVR is recommended in patients who meet an indica-</text>
<text top="679" left="467" width="74" height="10" font="21">tion for AVR <a href="e57.full.html#19">(</a></text>
<text top="679" left="541" width="73" height="10" font="22"><a href="e57.full.html#19">Section 3.2.3</a></text>
<text top="679" left="614" width="186" height="10" font="21"><a href="e57.full.html#19">) </a>with low or intermediate surgical</text>
<text top="696" left="467" width="28" height="10" font="21">risk (</text>
<text top="696" left="495" width="61" height="10" font="22"><a href="e57.full.html#12">Section 2.5</a></text>
<text top="696" left="556" width="4" height="10" font="21">)</text>
<text top="696" left="565" width="48" height="10" font="22"><a href="e57.full.html#102">(74,148)</a></text>
<text top="696" left="613" width="120" height="12" font="21"><a href="e57.full.html#102">. </a>(Level of Evidence: A)</text>
<text top="720" left="465" width="215" height="15" font="5">AVR is indicated for survival bene</text>
<text top="717" left="680" width="120" height="19" font="5">ﬁt, improvement in</text>
<text top="738" left="450" width="350" height="15" font="5">symptoms, and improvement in LV systolic function in</text>
<text top="756" left="450" width="254" height="15" font="5">patients with severe symptomatic AS (</text>
<text top="756" left="704" width="87" height="15" font="6"><a href="e57.full.html#19">Section 3.2.3.</a></text>
<text top="756" left="791" width="9" height="15" font="5"><a href="e57.full.html#19">).</a></text>
<text top="774" left="450" width="350" height="15" font="5">Given the magnitude of the difference in outcomes be-</text>
<text top="792" left="450" width="350" height="15" font="5">tween those undergoing AVR and those who refuse AVR</text>
<text top="868" left="64" width="554" height="11" font="13">Table 10. Summary of Recommendations for AS: Choice of Surgical or Transcatheter Intervention</text>
<text top="893" left="64" width="86" height="9" font="7">Recommendations</text>
<text top="893" left="553" width="21" height="9" font="7">COR</text>
<text top="893" left="652" width="18" height="9" font="7">LOE</text>
<text top="893" left="730" width="52" height="9" font="7">References</text>
<text top="912" left="64" width="341" height="9" font="7">Surgical AVR is recommended in patients who meet an indication for AVR <a href="e57.full.html#19">(</a></text>
<text top="912" left="405" width="60" height="9" font="8"><a href="e57.full.html#19">Section 3.2.3</a></text>
<text top="912" left="465" width="3" height="9" font="7">)</text>
<text top="926" left="77" width="167" height="9" font="7">with low or intermediate surgical risk</text>
<text top="912" left="562" width="3" height="9" font="7">I</text>
<text top="912" left="658" width="6" height="9" font="7">A</text>
<text top="912" left="736" width="39" height="9" font="8"><a href="e57.full.html#102">(74,148)</a></text>
<text top="940" left="64" width="424" height="9" font="7">For patients in whom TAVR or high-risk surgical AVR is being considered, members of a Heart</text>
<text top="954" left="77" width="281" height="9" font="7">Valve Team should collaborate to provide optimal patient care</text>
<text top="940" left="562" width="3" height="9" font="7">I</text>
<text top="940" left="658" width="6" height="9" font="7">C</text>
<text top="940" left="747" width="18" height="9" font="7">N/A</text>
<text top="968" left="64" width="437" height="9" font="7">TAVR is recommended in patients who meet an indication for AVR for AS who have a prohibitive</text>
<text top="983" left="77" width="213" height="9" font="7">surgical risk and a predicted post-TAVR survival</text>
<text top="980" left="294" width="38" height="14" font="7">&gt;12 mo</text>
<text top="968" left="562" width="3" height="9" font="7">I</text>
<text top="968" left="658" width="6" height="9" font="7">B</text>
<text top="968" left="733" width="45" height="9" font="8"><a href="e57.full.html#104">(169,170)</a></text>
<text top="996" left="64" width="416" height="9" font="7">TAVR is a reasonable alternative to surgical AVR in patients who meet an indication for AVR</text>
<text top="1011" left="77" width="3" height="9" font="7">(</text>
<text top="1011" left="80" width="60" height="9" font="8"><a href="e57.full.html#19">Section 3.2.3</a></text>
<text top="1011" left="140" width="157" height="9" font="7"><a href="e57.full.html#19">) </a>and who have high surgical risk <a href="e57.full.html#12">(</a></text>
<text top="1011" left="296" width="51" height="9" font="8"><a href="e57.full.html#12">Section 2.5</a></text>
<text top="1011" left="347" width="3" height="9" font="7">)</text>
<text top="996" left="558" width="11" height="9" font="7">IIa</text>
<text top="996" left="658" width="6" height="9" font="7">B</text>
<text top="996" left="733" width="45" height="9" font="8"><a href="e57.full.html#104">(171,172)</a></text>
<text top="1025" left="64" width="430" height="9" font="7">Percutaneous aortic balloon dilation may be considered as a bridge to surgical or transcatheter</text>
<text top="1039" left="77" width="240" height="9" font="7">AVR in severely symptomatic patients with severe AS</text>
<text top="1025" left="558" width="11" height="9" font="7">IIb</text>
<text top="1025" left="658" width="6" height="9" font="7">C</text>
<text top="1025" left="747" width="18" height="9" font="7">N/A</text>
<text top="1053" left="64" width="404" height="9" font="7">TAVR is not recommended in patients in whom existing comorbidities would preclude the</text>
<text top="1067" left="77" width="66" height="9" font="7">expected bene</text>
<text top="1064" left="142" width="109" height="14" font="7">ﬁt from correction of AS</text>
<text top="1053" left="558" width="11" height="9" font="7">III:</text>
<text top="1067" left="546" width="38" height="9" font="7">No Bene</text>
<text top="1064" left="584" width="9" height="14" font="7">ﬁt</text>
<text top="1053" left="658" width="6" height="9" font="7">B</text>
<text top="1053" left="743" width="25" height="9" font="8"><a href="e57.full.html#104">(169)</a></text>
<text top="1090" left="72" width="705" height="8" font="18">AS indicates aortic stenosis; AVR, aortic valve replacement; COR, Class of Recommendation; LOE, Level of Evidence; N/A, not applicable; and TAVR, transcatheter aortic valve replacement.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e79</text>
</page>
<page number="24" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">in historical series, an RCT of AVR versus medical therapy</text>
<text top="121" left="64" width="350" height="15" font="5">would not be appropriate in patients with a low to inter-</text>
<text top="139" left="64" width="130" height="15" font="5">mediate surgical risk <a href="e57.full.html#12">(</a></text>
<text top="139" left="194" width="67" height="15" font="6"><a href="e57.full.html#12">Section 2.5</a></text>
<text top="139" left="261" width="153" height="15" font="5"><a href="e57.full.html#12">). </a>Outcomes after surgical</text>
<text top="157" left="64" width="350" height="15" font="5">AVR are excellent in patients who do not have a high</text>
<text top="175" left="64" width="350" height="15" font="5">procedural risk. Surgical series demonstrate improved</text>
<text top="192" left="64" width="350" height="15" font="5">symptoms after AVR, and most patients have an im-</text>
<text top="210" left="64" width="350" height="15" font="5">provement in exercise tolerance as documented in studies</text>
<text top="228" left="64" width="350" height="15" font="5">with pre- and post-AVR exercise stress testing. The spe-</text>
<text top="246" left="64" width="10" height="15" font="5">ci</text>
<text top="243" left="74" width="291" height="19" font="5">ﬁc choice of prosthetic valve type is discussed in</text>
<text top="246" left="370" width="44" height="15" font="6"><a href="e57.full.html#60">Section</a></text>
<text top="264" left="64" width="26" height="15" font="6"><a href="e57.full.html#60">11.1</a></text>
<text top="264" left="91" width="323" height="15" font="5">. Surgical AVR should be considered over TAVR in</text>
<text top="282" left="64" width="350" height="15" font="5">patients who are at higher surgical risk but have severe</text>
<text top="300" left="64" width="171" height="15" font="5">multivessel coronary disease.</text>
<text top="319" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="318" left="212" width="65" height="15" font="6"><a href="e57.full.html#102">(74,93,173</a></text>
<text top="315" left="277" width="35" height="19" font="6"><a href="e57.full.html#102">–176)</a></text>
<text top="345" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="360" left="63" width="351" height="10" font="21">2. For patients in whom TAVR or high-risk surgical AVR is being</text>
<text top="377" left="81" width="333" height="10" font="21">considered, a Heart Valve Team consisting of an integrated,</text>
<text top="393" left="81" width="333" height="10" font="21">multidisciplinary group of healthcare professionals with exper-</text>
<text top="410" left="81" width="333" height="10" font="21">tise in VHD, cardiac imaging, interventional cardiology, cardiac</text>
<text top="426" left="81" width="333" height="10" font="21">anesthesia, and cardiac surgery should collaborate to provide</text>
<text top="442" left="81" width="227" height="12" font="21">optimal patient care. (Level of Evidence: C)</text>
<text top="467" left="79" width="335" height="15" font="5">Decision making is complex in the patient at high sur-</text>
<text top="485" left="64" width="350" height="15" font="5">gical risk with severe symptomatic AS. The decision to</text>
<text top="502" left="64" width="349" height="15" font="5">perform surgical AVR, TAVR, or to forgo intervention</text>
<text top="520" left="64" width="350" height="15" font="5">requires input from a Heart Valve Team. The primary</text>
<text top="538" left="64" width="350" height="15" font="5">cardiologist is aware of coexisting conditions that affect risk</text>
<text top="556" left="64" width="204" height="15" font="5">and long-term survival, the patient</text>
<text top="553" left="269" width="145" height="19" font="5">’s disease course, and the</text>
<text top="574" left="64" width="41" height="15" font="5">patient</text>
<text top="571" left="106" width="308" height="19" font="5">’s preferences and values. Cardiac imaging special-</text>
<text top="592" left="64" width="350" height="15" font="5">ists who are knowledgeable about AS and TAVR provide</text>
<text top="610" left="64" width="350" height="15" font="5">evaluation of aortic valve anatomy and hemodynamic</text>
<text top="628" left="64" width="350" height="15" font="5">severity, vascular anatomy, aortic annulus size, and coro-</text>
<text top="646" left="64" width="350" height="15" font="5">nary anatomy, including the annular-ostial distance.</text>
<text top="664" left="64" width="349" height="15" font="5">Interventional cardiologists help determine the likelihood</text>
<text top="682" left="64" width="350" height="15" font="5">of a successful transcatheter procedure. The cardiac sur-</text>
<text top="700" left="64" width="350" height="15" font="5">geon can provide a realistic estimate of risk with a con-</text>
<text top="718" left="64" width="350" height="15" font="5">ventional surgical approach, at times in conjunction with a</text>
<text top="736" left="64" width="350" height="15" font="5">cardiac anesthesiologist. An expert in VHD, typically a</text>
<text top="754" left="64" width="350" height="15" font="5">cardiologist or cardiac surgeon with expertise in imaging</text>
<text top="772" left="64" width="350" height="15" font="5">and/or intervention, provides the continuity and integra-</text>
<text top="789" left="64" width="350" height="15" font="5">tion needed for the collaborative decision-making process.</text>
<text top="807" left="64" width="350" height="15" font="5">Nurses and other members of the team coordinate care and</text>
<text top="825" left="64" width="350" height="15" font="5">help with patient education. The cardiac surgeon and</text>
<text top="843" left="64" width="350" height="15" font="5">interventional cardiologist are the core of the Heart Valve</text>
<text top="861" left="64" width="341" height="15" font="5">Team for patients being considered for AVR or TAVR.</text>
<text top="880" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="879" left="212" width="51" height="15" font="6"><a href="e57.full.html#102">(79,177)</a></text>
<text top="906" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="921" left="63" width="351" height="10" font="21">3. TAVR is recommended in patients who meet an indication for</text>
<text top="938" left="81" width="30" height="10" font="21">AVR <a href="e57.full.html#19">(</a></text>
<text top="938" left="111" width="71" height="10" font="22"><a href="e57.full.html#19">Section 3.2.3</a></text>
<text top="938" left="182" width="232" height="10" font="21">) who have a prohibitive risk for surgical AVR</text>
<text top="954" left="81" width="4" height="10" font="21">(</text>
<text top="954" left="86" width="62" height="10" font="22"><a href="e57.full.html#12">Section 2.5</a></text>
<text top="954" left="148" width="266" height="10" font="21"><a href="e57.full.html#12">) </a>and a predicted post-TAVR survival greater than</text>
<text top="971" left="81" width="57" height="10" font="21">12 months</text>
<text top="971" left="143" width="55" height="10" font="22"><a href="e57.full.html#104">(169,170)</a></text>
<text top="971" left="197" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="995" left="79" width="335" height="15" font="5">TAVR has been studied in numerous observational</text>
<text top="1013" left="64" width="350" height="15" font="5">studies and multicenter registries that include large</text>
<text top="1031" left="64" width="350" height="15" font="5">numbers of high-risk patients with severe symptomatic</text>
<text top="1049" left="64" width="350" height="15" font="5">AS. These studies demonstrated the feasibility, excellent</text>
<text top="1067" left="64" width="350" height="15" font="5">hemodynamic results, and favorable outcomes of the pro-</text>
<text top="1085" left="64" width="349" height="15" font="5">cedure. In addition, TAVR was compared with standard</text>
<text top="103" left="450" width="350" height="15" font="5">therapy in a prospective RCT of patients with severe</text>
<text top="121" left="450" width="350" height="15" font="5">symptomatic AS who were deemed inoperable. Severe AS</text>
<text top="139" left="450" width="41" height="15" font="5">was de</text>
<text top="135" left="491" width="225" height="19" font="5">ﬁned as an aortic valve area &lt;0.8 cm</text>
<text top="136" left="716" width="6" height="10" font="14">2</text>
<text top="139" left="727" width="73" height="15" font="5">plus a mean</text>
<text top="157" left="450" width="106" height="15" font="5">pressure gradient</text>
<text top="153" left="564" width="235" height="19" font="5">40 mm Hg or a maximum aortic</text>
<text top="175" left="450" width="45" height="15" font="5">velocity</text>
<text top="171" left="499" width="300" height="19" font="5">4.0 m per second. All patients had NYHA class</text>
<text top="192" left="450" width="350" height="15" font="5">II to IV symptoms. Patients were considered to have a</text>
<text top="210" left="450" width="270" height="15" font="5">prohibitive surgical risk when predicted 30</text>
<text top="207" left="719" width="80" height="19" font="5">–day surgical</text>
<text top="228" left="450" width="187" height="15" font="5">morbidity and mortality were</text>
<text top="225" left="646" width="154" height="19" font="5">50% due to comorbid</text>
<text top="246" left="450" width="350" height="15" font="5">disease or a serious irreversible condition. Patients were</text>
<text top="264" left="450" width="350" height="15" font="5">excluded if they had a bicuspid aortic valve, acute myo-</text>
<text top="282" left="450" width="169" height="15" font="5">cardial infarction (MI), signi</text>
<text top="279" left="619" width="181" height="19" font="5">ﬁcant CAD, an LVEF &lt;20%,</text>
<text top="300" left="450" width="163" height="15" font="5">an aortic annulus diameter</text>
<text top="297" left="618" width="181" height="19" font="5">&lt;18 mm or &gt;25 mm, severe</text>
<text top="318" left="450" width="350" height="15" font="5">AR or MR, a transient ischemic attack within 6 months, or</text>
<text top="336" left="450" width="103" height="15" font="5">severe renal insuf</text>
<text top="333" left="553" width="246" height="19" font="5">ﬁciency. TAVR was performed by either</text>
<text top="354" left="450" width="350" height="15" font="5">the transfemoral or transapical approach using the SA-</text>
<text top="372" left="450" width="350" height="15" font="5">PIEN heart-valve system (Edwards Lifesciences LLC,</text>
<text top="390" left="450" width="350" height="15" font="5">Irvine, CA). Standard therapy included percutaneous</text>
<text top="408" left="450" width="184" height="15" font="5">aortic balloon dilation in 84%.</text>
<text top="426" left="465" width="335" height="15" font="5">All-cause death at 2 years was lower with TAVR</text>
<text top="444" left="450" width="350" height="15" font="5">(43.3%) compared with standard medical therapy (68%),</text>
<text top="461" left="450" width="350" height="15" font="5">with an HR for TAVR of 0.58 (95% CI: 0.36 to 0.92;</text>
<text top="479" left="450" width="8" height="15" font="5">p</text>
<text top="476" left="457" width="342" height="19" font="5">¼0.02). There was a reduction in repeat hospitalization</text>
<text top="497" left="450" width="216" height="15" font="5">with TAVR (55% versus 72.5%; p</text>
<text top="494" left="666" width="133" height="19" font="5">&lt;0.001). In addition,</text>
<text top="515" left="450" width="350" height="15" font="5">only 25.2% of survivors were in NYHA class III or IV 1</text>
<text top="533" left="450" width="350" height="15" font="5">year after TAVR, compared with 58% of patients receiving</text>
<text top="551" left="450" width="120" height="15" font="5">standard therapy (p</text>
<text top="548" left="570" width="230" height="19" font="5">&lt;0.001). However, the rate of major</text>
<text top="569" left="450" width="350" height="15" font="5">stroke at 30 days was higher with TAVR (5.05% versus</text>
<text top="587" left="450" width="45" height="15" font="5">1.0%; p</text>
<text top="584" left="495" width="304" height="19" font="5">¼0.06) and remained higher at 2 years with TAVR</text>
<text top="605" left="450" width="350" height="15" font="5">compared with standard therapy (13.8% versus 5.5%;</text>
<text top="623" left="450" width="8" height="15" font="5">p</text>
<text top="620" left="457" width="342" height="19" font="5">¼0.01). Major vascular complications occurred in 16.2%</text>
<text top="641" left="450" width="296" height="15" font="5">with TAVR versus 1.1% with standard therapy (p</text>
<text top="637" left="746" width="54" height="19" font="5">&lt;0.001).</text>
<text top="659" left="465" width="335" height="15" font="5">Thus, in high-risk patients with severe symptomatic</text>
<text top="677" left="450" width="350" height="15" font="5">AS who are unable to undergo surgical AVR due to a</text>
<text top="695" left="450" width="350" height="15" font="5">prohibitive surgical risk and who have an expected survival</text>
<text top="713" left="450" width="12" height="15" font="5">of</text>
<text top="709" left="467" width="332" height="19" font="5">&gt;1 year after intervention, TAVR is recommended to</text>
<text top="731" left="450" width="350" height="15" font="5">improve survival and reduce symptoms. This decision</text>
<text top="748" left="450" width="350" height="15" font="5">should be made only after discussion with the patient</text>
<text top="766" left="450" width="147" height="15" font="5">about the expected bene</text>
<text top="763" left="597" width="202" height="19" font="5">ﬁts and possible complications of</text>
<text top="784" left="450" width="350" height="15" font="5">TAVR and surgical AVR. Patients with severe AS are</text>
<text top="802" left="450" width="350" height="15" font="5">considered to have a prohibitive surgical risk if they have a</text>
<text top="820" left="450" width="350" height="15" font="5">predicted risk with surgery of death or major morbidity</text>
<text top="838" left="450" width="77" height="15" font="5">(all cause) of</text>
<text top="835" left="533" width="267" height="19" font="5">&gt;50% at 1 year; disease affecting 3 major</text>
<text top="856" left="450" width="350" height="15" font="5">organ systems that is not likely to improve postoperatively;</text>
<text top="874" left="450" width="350" height="15" font="5">or anatomic factors that preclude or increase the risk of</text>
<text top="892" left="450" width="229" height="15" font="5">cardiac surgery, such as a heavily calci</text>
<text top="889" left="679" width="120" height="19" font="5">ﬁed (e.g., porcelain)</text>
<text top="910" left="450" width="350" height="15" font="5">aorta, prior radiation, or an arterial bypass graft adherent</text>
<text top="928" left="450" width="104" height="15" font="5">to the chest wall.</text>
<text top="947" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="946" left="598" width="85" height="15" font="6"><a href="e57.full.html#104">(169,170,178)</a></text>
<text top="977" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="992" left="449" width="351" height="10" font="21">1. TAVR is a reasonable alternative to surgical AVR in patients</text>
<text top="1008" left="467" width="178" height="10" font="21">who meet an indication for AVR <a href="e57.full.html#19">(</a></text>
<text top="1008" left="645" width="72" height="10" font="22"><a href="e57.full.html#19">Section 3.2.3</a></text>
<text top="1008" left="717" width="82" height="10" font="21">) and who have</text>
<text top="1024" left="467" width="201" height="10" font="21">high surgical risk for surgical AVR <a href="e57.full.html#12">(</a></text>
<text top="1024" left="667" width="63" height="10" font="22"><a href="e57.full.html#12">Section 2.5</a></text>
<text top="1024" left="731" width="4" height="10" font="21"><a href="e57.full.html#12">)</a></text>
<text top="1024" left="741" width="55" height="10" font="22"><a href="e57.full.html#104">(171,172)</a></text>
<text top="1024" left="796" width="3" height="10" font="21">.</text>
<text top="1041" left="467" width="113" height="12" font="21">(Level of Evidence: B)</text>
<text top="1065" left="465" width="335" height="15" font="5">TAVR has been studied in numerous observational</text>
<text top="1083" left="450" width="350" height="15" font="5">studies and multicenter registries that include large</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e80</text>
</page>
<page number="25" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">numbers of high-risk patients with severe symptomatic</text>
<text top="121" left="64" width="350" height="15" font="5">AS. These studies demonstrated the feasibility, excellent</text>
<text top="139" left="64" width="350" height="15" font="5">hemodynamic results, and favorable outcomes of the</text>
<text top="157" left="64" width="350" height="15" font="5">procedure. In addition, TAVR was compared with stan-</text>
<text top="175" left="64" width="350" height="15" font="5">dard therapy in a prospective RCT of patients with severe</text>
<text top="192" left="64" width="350" height="15" font="5">symptomatic AS who were deemed high risk for surgery.</text>
<text top="210" left="64" width="150" height="15" font="5">Severe symptomatic calci</text>
<text top="207" left="214" width="200" height="19" font="5">ﬁc AS was deﬁned as aortic valve</text>
<text top="228" left="64" width="23" height="15" font="5">area</text>
<text top="225" left="91" width="51" height="19" font="5">&lt;0.8 cm</text>
<text top="225" left="142" width="6" height="10" font="14">2</text>
<text top="228" left="151" width="182" height="15" font="5">plus a mean transaortic gradient</text>
<text top="225" left="337" width="77" height="19" font="5">40 mm Hg</text>
<text top="246" left="64" width="100" height="15" font="5">or aortic velocity</text>
<text top="243" left="169" width="245" height="19" font="5">4.0 m per second with NYHA class II</text>
<text top="264" left="64" width="350" height="15" font="5">to IV symptoms. Patients were deemed at high surgical</text>
<text top="282" left="64" width="149" height="15" font="5">risk if risk of death was</text>
<text top="279" left="220" width="194" height="19" font="5">15% within 30 days after the</text>
<text top="300" left="64" width="157" height="15" font="5">procedure. An STS score</text>
<text top="297" left="228" width="186" height="19" font="5">10% was used for guidance,</text>
<text top="318" left="64" width="258" height="15" font="5">with an actual mean STS score of 11.8%</text>
<text top="315" left="322" width="92" height="19" font="5">3.3%. Exclu-</text>
<text top="336" left="64" width="350" height="15" font="5">sions included bicuspid aortic valve anatomy, acute MI,</text>
<text top="354" left="64" width="28" height="15" font="5">signi</text>
<text top="350" left="93" width="321" height="19" font="5">ﬁcant CAD, an LVEF &lt;20%, an aortic annulus</text>
<text top="372" left="64" width="52" height="15" font="5">diameter</text>
<text top="368" left="122" width="292" height="19" font="5">&lt;18 mm or &gt;25 mm, severe AR or MR, tran-</text>
<text top="390" left="64" width="350" height="15" font="5">sient ischemic attack within 6 months, or severe renal</text>
<text top="408" left="64" width="29" height="15" font="5">insuf</text>
<text top="404" left="93" width="320" height="19" font="5">ﬁciency. On an intention-to-treat analysis, all-cause</text>
<text top="426" left="64" width="350" height="15" font="5">death was similar in those randomized to TAVR</text>
<text top="444" left="64" width="13" height="15" font="5">(n</text>
<text top="440" left="77" width="337" height="19" font="5">¼348) compared with surgical AVR (n¼351) at 30</text>
<text top="461" left="64" width="171" height="15" font="5">days, 1 year, and 2 years (p</text>
<text top="458" left="235" width="178" height="19" font="5">¼0.001) for noninferiority of</text>
<text top="479" left="64" width="349" height="15" font="5">TAVR compared with surgical AVR. The composite</text>
<text top="497" left="64" width="350" height="15" font="5">endpoint of all-cause death or stroke at 2 years was 35%</text>
<text top="515" left="64" width="350" height="15" font="5">with surgical AVR compared with 33.9% with TAVR</text>
<text top="533" left="64" width="12" height="15" font="5">(p</text>
<text top="530" left="77" width="337" height="19" font="5">¼0.78). TAVR was performed by the transfemoral</text>
<text top="551" left="64" width="350" height="15" font="5">approach in 244 patients and the transapical approach in</text>
<text top="569" left="64" width="350" height="15" font="5">104 patients. Only limited data on long-term durability of</text>
<text top="587" left="64" width="350" height="15" font="5">bioprosthetic valves implanted by the transcatheter</text>
<text top="605" left="64" width="136" height="15" font="5">approach are available.</text>
<text top="623" left="79" width="335" height="15" font="5">Given the known long-term outcomes and valve dura-</text>
<text top="641" left="64" width="350" height="15" font="5">bility with surgical AVR, TAVR currently remains</text>
<text top="659" left="64" width="350" height="15" font="5">restricted to patients with prohibitive or high surgical risk.</text>
<text top="677" left="64" width="136" height="15" font="5">High surgical risk is de</text>
<text top="673" left="200" width="214" height="19" font="5">ﬁned as an STS PROM score of 8%</text>
<text top="695" left="64" width="350" height="15" font="5">to 15%, anatomic factors that increase surgical risk, or</text>
<text top="713" left="64" width="28" height="15" font="5">signi</text>
<text top="709" left="93" width="82" height="19" font="5">ﬁcant frailty (</text>
<text top="713" left="175" width="75" height="15" font="6"><a href="e57.full.html#95">Section 14.2</a></text>
<text top="713" left="250" width="9" height="15" font="5">).</text>
<text top="731" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="731" left="212" width="111" height="15" font="6"><a href="e57.full.html#104">(171,172,179,180)</a></text>
<text top="749" left="79" width="18" height="15" font="5">See</text>
<text top="749" left="103" width="161" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 9</a></text>
<text top="749" left="271" width="143" height="15" font="5">for more information on</text>
<text top="767" left="64" width="124" height="15" font="5">choice of intervention.</text>
<text top="794" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="809" left="63" width="351" height="10" font="21">1. Percutaneous aortic balloon dilation may be considered as a</text>
<text top="825" left="81" width="333" height="10" font="21">bridge to surgical AVR or TAVR in patients with severe symp-</text>
<text top="841" left="81" width="179" height="12" font="21">tomatic AS. (Level of Evidence: C)</text>
<text top="866" left="79" width="335" height="15" font="5">Percutaneous aortic balloon dilation has an important</text>
<text top="884" left="64" width="350" height="15" font="5">role in treating children, adolescents, and young adults with</text>
<text top="902" left="64" width="350" height="15" font="5">AS, but its role in treating older patients is very limited. The</text>
<text top="919" left="64" width="350" height="15" font="5">mechanism by which balloon dilation modestly reduces the</text>
<text top="937" left="64" width="335" height="15" font="5">severity of stenosis in older patients is by fracture of calci</text>
<text top="934" left="400" width="14" height="19" font="5">ﬁc</text>
<text top="955" left="64" width="174" height="15" font="5">deposits within the valve lea</text>
<text top="952" left="238" width="176" height="19" font="5">ﬂets and, to a minor degree,</text>
<text top="973" left="64" width="350" height="15" font="5">stretching of the annulus and separation of the calci-</text>
<text top="988" left="64" width="350" height="19" font="5">ﬁed or fused commissures. Immediate hemodynamic results</text>
<text top="1009" left="64" width="350" height="15" font="5">include a moderate reduction in the transvalvular pressure</text>
<text top="1027" left="64" width="350" height="15" font="5">gradient, but the postdilation valve area rarely exceeds</text>
<text top="1045" left="64" width="41" height="15" font="5">1.0 cm</text>
<text top="1042" left="105" width="6" height="10" font="14">2</text>
<text top="1045" left="111" width="303" height="15" font="5">. Despite the modest change in valve area, an early</text>
<text top="1063" left="64" width="350" height="15" font="5">symptomatic improvement usually occurs. However, serious</text>
<text top="1081" left="64" width="350" height="15" font="5">acute complications, including acute severe AR and</text>
<text top="103" left="450" width="350" height="15" font="5">restenosis and clinical deterioration, occur within 6 to 12</text>
<text top="121" left="450" width="350" height="15" font="5">months in most patients. Therefore, in patients with AS,</text>
<text top="139" left="450" width="350" height="15" font="5">percutaneous aortic balloon dilation is not a substitute for</text>
<text top="157" left="450" width="36" height="15" font="5">AVR.</text>
<text top="175" left="465" width="335" height="15" font="5">Some clinicians contend that despite the procedural</text>
<text top="192" left="450" width="350" height="15" font="5">morbidity and mortality and limited long-term results,</text>
<text top="210" left="450" width="350" height="15" font="5">percutaneous aortic balloon dilation can have a temporary</text>
<text top="228" left="450" width="350" height="15" font="5">role in the management of some symptomatic patients who</text>
<text top="246" left="450" width="350" height="15" font="5">are not initially candidates for surgical AVR or TAVR. For</text>
<text top="264" left="450" width="350" height="15" font="5">example, patients with severe AS and refractory pulmonary</text>
<text top="282" left="450" width="247" height="15" font="5">edema or cardiogenic shock might bene</text>
<text top="279" left="696" width="103" height="19" font="5">ﬁt from percuta-</text>
<text top="300" left="450" width="211" height="15" font="5">neous aortic balloon dilation as a</text>
<text top="297" left="668" width="132" height="19" font="5">“bridge” to AVR; an</text>
<text top="318" left="450" width="350" height="15" font="5">improved hemodynamic state may reduce the risks of</text>
<text top="336" left="450" width="350" height="15" font="5">TAVR or surgery. In some patients, the effects of percu-</text>
<text top="354" left="450" width="350" height="15" font="5">taneous aortic balloon dilation on symptoms and LV</text>
<text top="372" left="450" width="350" height="15" font="5">function may be diagnostically helpful as well, but many</text>
<text top="390" left="450" width="350" height="15" font="5">clinicians recommend proceeding directly to AVR in these</text>
<text top="408" left="450" width="350" height="15" font="5">cases. The indications for palliative percutaneous aortic</text>
<text top="426" left="450" width="350" height="15" font="5">balloon dilation in patients in whom AVR cannot be</text>
<text top="444" left="450" width="350" height="15" font="5">recommended because of serious comorbid conditions are</text>
<text top="462" left="450" width="350" height="15" font="5">even less well established, with no data to suggest improved</text>
<text top="479" left="450" width="350" height="15" font="5">longevity; however, some patients do report a decrease in</text>
<text top="497" left="450" width="350" height="15" font="5">symptoms. Most asymptomatic patients with severe AS</text>
<text top="515" left="450" width="350" height="15" font="5">who require urgent noncardiac surgery can undergo surgery</text>
<text top="533" left="450" width="350" height="15" font="5">at a reasonably low risk with anesthetic monitoring and</text>
<text top="551" left="450" width="74" height="15" font="5">attention to</text>
<text top="548" left="533" width="266" height="19" font="5">ﬂuid balance. Percutaneous aortic balloon</text>
<text top="569" left="450" width="350" height="15" font="5">dilation is not recommended for these patients. If preop-</text>
<text top="587" left="450" width="350" height="15" font="5">erative correction of AS is needed, they should be</text>
<text top="605" left="450" width="126" height="15" font="5">considered for AVR.</text>
<text top="624" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="623" left="597" width="80" height="15" font="6"><a href="e57.full.html#104">(171,172,181</a></text>
<text top="620" left="677" width="35" height="19" font="6"><a href="e57.full.html#104">–183)</a></text>
<text top="650" left="450" width="88" height="8" font="20">CLASS III: No Bene</text>
<text top="648" left="538" width="10" height="13" font="20">ﬁt</text>
<text top="665" left="449" width="351" height="10" font="21">1. TAVR is not recommended in patients in whom existing</text>
<text top="681" left="467" width="288" height="10" font="21">comorbidities would preclude the expected bene</text>
<text top="678" left="755" width="45" height="16" font="21">ﬁt from</text>
<text top="698" left="467" width="86" height="10" font="21">correction of AS</text>
<text top="698" left="557" width="30" height="10" font="22"><a href="e57.full.html#104">(169)</a></text>
<text top="698" left="587" width="121" height="12" font="21"><a href="e57.full.html#104">. </a>(Level of Evidence: B)</text>
<text top="722" left="465" width="258" height="15" font="5">The survival and symptom reduction bene</text>
<text top="719" left="723" width="77" height="19" font="5">ﬁt of TAVR</text>
<text top="740" left="450" width="350" height="15" font="5">is only seen in appropriately selected patients. Baseline</text>
<text top="758" left="450" width="350" height="15" font="5">clinical factors associated with a poor outcome after</text>
<text top="776" left="450" width="350" height="15" font="5">TAVR include advanced age, frailty, smoking or chronic</text>
<text top="794" left="450" width="350" height="15" font="5">obstructive pulmonary disease, pulmonary hypertension,</text>
<text top="812" left="450" width="350" height="15" font="5">liver disease, prior stroke, anemia, and other systemic</text>
<text top="830" left="450" width="350" height="15" font="5">conditions. The STS estimated surgical risk score pro-</text>
<text top="848" left="450" width="350" height="15" font="5">vides a useful measure of the extent of patient comor-</text>
<text top="866" left="450" width="337" height="15" font="5">bidities and may help identify which patients will bene</text>
<text top="862" left="787" width="13" height="19" font="5">ﬁt</text>
<text top="884" left="450" width="350" height="15" font="5">from TAVR. In patients with a prohibitive surgical risk</text>
<text top="902" left="450" width="350" height="15" font="5">for AVR in the PARTNER (Placement of Aortic</text>
<text top="919" left="450" width="273" height="15" font="5">Transcatheter Valve) study, the survival bene</text>
<text top="916" left="723" width="76" height="19" font="5">ﬁt of TAVR</text>
<text top="937" left="450" width="231" height="15" font="5">was seen in those with an STS score</text>
<text top="934" left="687" width="112" height="19" font="5">&lt;5% (n¼40, HR:</text>
<text top="955" left="450" width="179" height="15" font="5">0.37; 95% CI: 0.13 to 1.01; p</text>
<text top="952" left="629" width="171" height="19" font="5">¼0.04) and in those with an</text>
<text top="973" left="450" width="240" height="15" font="5">STS score between 5% and 14.9% (n</text>
<text top="970" left="690" width="109" height="19" font="5">¼227, HR: 0.58;</text>
<text top="991" left="450" width="142" height="15" font="5">95% CI: 0.41 to 0.8; p</text>
<text top="988" left="592" width="207" height="19" font="5">¼0.002) but not in those with an</text>
<text top="1009" left="450" width="65" height="15" font="5">STS score</text>
<text top="1006" left="522" width="277" height="19" font="5">15% (n¼90, HR: 0.77; 95% CI: 0.46 to</text>
<text top="1027" left="450" width="50" height="15" font="5">1.28; p</text>
<text top="1024" left="500" width="299" height="19" font="5">¼0.31). The relative prevalence of oxygen-</text>
<text top="1045" left="450" width="350" height="15" font="5">dependent lung disease was similar in all 3 groups.</text>
<text top="1063" left="450" width="350" height="15" font="5">However, the other reasons for inoperability were quite</text>
<text top="1081" left="450" width="350" height="15" font="5">different, with a porcelain aorta or prior chest radiation</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e81</text>
</page>
<page number="26" position="absolute" top="0" left="0" height="1160" width="864">
<text top="928" left="64" width="350" height="15" font="5">damage being most common in those with an STS score</text>
<text top="946" left="64" width="12" height="15" font="5">of</text>
<text top="942" left="81" width="333" height="19" font="5">&lt;5% and frailty being most common in those with an</text>
<text top="964" left="64" width="63" height="15" font="5">STS score</text>
<text top="960" left="132" width="281" height="19" font="5">15%. These data emphasize the importance</text>
<text top="981" left="64" width="176" height="15" font="5">of evaluating the likely bene</text>
<text top="978" left="241" width="173" height="19" font="5">ﬁt of TAVR, as well as the</text>
<text top="999" left="64" width="157" height="15" font="5">risks, in weighing the risk</text>
<text top="996" left="222" width="192" height="19" font="5">–beneﬁt ratio of intervention in</text>
<text top="1017" left="64" width="350" height="15" font="5">an individual patient. TAVR is not recommended in</text>
<text top="1035" left="64" width="218" height="15" font="5">patients with 1) a life expectancy of</text>
<text top="1032" left="287" width="127" height="19" font="5">&lt;1 year, even with a</text>
<text top="1053" left="64" width="350" height="15" font="5">successful procedure, and 2) those with a chance of</text>
<text top="1068" left="64" width="265" height="19" font="5">“survival with beneﬁt” of &lt;25% at 2 years.</text>
<text top="1090" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="1089" left="212" width="111" height="15" font="6"><a href="e57.full.html#103">(115,169,178,184)</a></text>
<text top="928" left="450" width="182" height="14" font="17">4. Aortic Regurgitation</text>
<text top="973" left="450" width="95" height="12" font="19">4.1. Acute AR</text>
<text top="996" left="451" width="349" height="15" font="5">Acute AR may result from abnormalities of the valve,</text>
<text top="1014" left="450" width="350" height="15" font="5">primarily IE, or abnormalities of the aorta, primarily aortic</text>
<text top="1032" left="450" width="350" height="15" font="5">dissection. Acute AR may also occur from iatrogenic</text>
<text top="1050" left="450" width="350" height="15" font="5">complications, such as following percutaneous aortic</text>
<text top="1068" left="450" width="350" height="15" font="5">balloon dilation or TAVR or following blunt chest trauma.</text>
<text top="1086" left="450" width="350" height="15" font="5">The acute volume overload on the left ventricle usually</text>
<text top="103" left="64" width="182" height="11" font="13">Table 11. Stages of Chronic AR</text>
<text top="129" left="64" width="27" height="9" font="7">Stage</text>
<text top="129" left="120" width="12" height="9" font="7">De</text>
<text top="126" left="132" width="32" height="14" font="7">ﬁnition</text>
<text top="129" left="230" width="69" height="9" font="7">Valve Anatomy</text>
<text top="129" left="382" width="99" height="9" font="7">Valve Hemodynamics</text>
<text top="129" left="531" width="136" height="9" font="7">Hemodynamic Consequences</text>
<text top="129" left="718" width="49" height="9" font="7">Symptoms</text>
<text top="145" left="67" width="7" height="9" font="7">A</text>
<text top="145" left="106" width="60" height="9" font="7">At risk of AR</text>
<text top="145" left="193" width="143" height="14" font="7"> Bicuspid aortic valve (or other</text>
<text top="162" left="204" width="117" height="9" font="7">congenital valve anomaly)</text>
<text top="173" left="193" width="105" height="14" font="7"> Aortic valve sclerosis</text>
<text top="187" left="193" width="143" height="14" font="7"> Diseases of the aortic sinuses</text>
<text top="204" left="204" width="84" height="9" font="7">or ascending aorta</text>
<text top="215" left="193" width="141" height="14" font="7"> History of rheumatic fever or</text>
<text top="233" left="204" width="105" height="9" font="7">known rheumatic heart</text>
<text top="247" left="204" width="34" height="9" font="7">disease</text>
<text top="258" left="193" width="20" height="14" font="7"> IE</text>
<text top="145" left="351" width="128" height="14" font="7"> AR severity: none or trace</text>
<text top="145" left="528" width="35" height="14" font="7"> None</text>
<text top="145" left="686" width="35" height="14" font="7"> None</text>
<text top="279" left="67" width="7" height="9" font="7">B</text>
<text top="279" left="106" width="71" height="9" font="7">Progressive AR</text>
<text top="278" left="193" width="143" height="14" font="7"> Mild-to-moderate calciﬁcation</text>
<text top="295" left="204" width="44" height="9" font="7">of a trilea</text>
<text top="292" left="248" width="81" height="14" font="7">ﬂet valve bicuspid</text>
<text top="309" left="204" width="132" height="9" font="7">aortic valve (or other congen-</text>
<text top="323" left="204" width="85" height="9" font="7">ital valve anomaly)</text>
<text top="334" left="193" width="108" height="14" font="7"> Dilated aortic sinuses</text>
<text top="348" left="193" width="127" height="14" font="7"> Rheumatic valve changes</text>
<text top="363" left="193" width="61" height="14" font="7"> Previous IE</text>
<text top="278" left="351" width="52" height="14" font="7"> Mild AR:</text>
<text top="292" left="369" width="119" height="14" font="7">Jet width &lt;25% of LVOT;</text>
<text top="306" left="369" width="119" height="14" font="7">Vena contracta &lt;0.3 cm;</text>
<text top="320" left="369" width="95" height="14" font="7">RVol &lt;30 mL/beat;</text>
<text top="334" left="369" width="52" height="14" font="7">RF &lt;30%;</text>
<text top="348" left="369" width="75" height="14" font="7">ERO &lt;0.10 cm</text>
<text top="349" left="444" width="5" height="6" font="23">2</text>
<text top="351" left="448" width="3" height="9" font="7">;</text>
<text top="363" left="369" width="108" height="14" font="7">Angiography grade 1þ</text>
<text top="377" left="351" width="76" height="14" font="7"> Moderate AR:</text>
<text top="391" left="369" width="136" height="14" font="7">Jet width 25%–64% of LVOT;</text>
<text top="405" left="369" width="131" height="14" font="7">Vena contracta 0.3–0.6 cm;</text>
<text top="419" left="369" width="104" height="14" font="7">RVol 30–59 mL/beat;</text>
<text top="434" left="369" width="70" height="14" font="7">RF 30%–49%;</text>
<text top="448" left="369" width="93" height="14" font="7">ERO 0.10–0.29 cm</text>
<text top="448" left="462" width="5" height="6" font="23">2</text>
<text top="451" left="466" width="3" height="9" font="7">;</text>
<text top="462" left="369" width="108" height="14" font="7">Angiography grade 2þ</text>
<text top="277" left="528" width="134" height="14" font="7"> Normal LV systolic function</text>
<text top="292" left="528" width="130" height="14" font="7"> Normal LV volume or mild</text>
<text top="309" left="539" width="47" height="9" font="7">LV dilation</text>
<text top="278" left="686" width="35" height="14" font="7"> None</text>
<text top="482" left="67" width="7" height="9" font="7">C</text>
<text top="482" left="106" width="67" height="9" font="7">Asymptomatic</text>
<text top="497" left="119" width="47" height="9" font="7">severe AR</text>
<text top="481" left="193" width="135" height="14" font="7"> Calciﬁc aortic valve disease</text>
<text top="496" left="193" width="117" height="14" font="7"> Bicuspid valve (or other</text>
<text top="513" left="204" width="106" height="9" font="7">congenital abnormality)</text>
<text top="524" left="193" width="121" height="14" font="7"> Dilated aortic sinuses or</text>
<text top="541" left="204" width="72" height="9" font="7">ascending aorta</text>
<text top="552" left="193" width="127" height="14" font="7"> Rheumatic valve changes</text>
<text top="567" left="193" width="119" height="14" font="7"> IE with abnormal leaﬂet</text>
<text top="584" left="204" width="97" height="9" font="7">closure or perforation</text>
<text top="481" left="351" width="63" height="14" font="7"> Severe AR:</text>
<text top="496" left="369" width="119" height="14" font="7">Jet width 65% of LVOT;</text>
<text top="510" left="369" width="119" height="14" font="7">Vena contracta &gt;0.6 cm;</text>
<text top="524" left="369" width="135" height="14" font="7">Holodiastolic ﬂow reversal in</text>
<text top="541" left="375" width="134" height="9" font="7">the proximal abdominal aorta</text>
<text top="552" left="369" width="95" height="14" font="7">RVol 60 mL/beat;</text>
<text top="567" left="369" width="52" height="14" font="7">RF 50%;</text>
<text top="581" left="369" width="69" height="14" font="7">ERO 0.3 cm</text>
<text top="581" left="438" width="5" height="6" font="23">2</text>
<text top="584" left="442" width="3" height="9" font="7">;</text>
<text top="595" left="369" width="140" height="14" font="7">Angiography grade 3þ to 4þ;</text>
<text top="609" left="369" width="114" height="14" font="7">In addition, diagnosis of</text>
<text top="626" left="375" width="120" height="9" font="7">chronic severe AR requires</text>
<text top="641" left="375" width="102" height="9" font="7">evidence of LV dilation</text>
<text top="482" left="527" width="84" height="9" font="7">C1: Normal LVEF (</text>
<text top="480" left="611" width="52" height="14" font="7">50%) and</text>
<text top="497" left="540" width="127" height="9" font="7">mild-to-moderate LV dilation</text>
<text top="511" left="540" width="32" height="9" font="7">(LVESD</text>
<text top="508" left="575" width="45" height="14" font="7">50 mm)</text>
<text top="525" left="527" width="113" height="9" font="7">C2: Abnormal LV systolic</text>
<text top="539" left="540" width="107" height="9" font="7">function with depressed</text>
<text top="554" left="540" width="28" height="9" font="7">LVEF (</text>
<text top="551" left="568" width="90" height="14" font="7">&lt;50%) or severe LV</text>
<text top="568" left="540" width="76" height="9" font="7">dilatation (LVESD</text>
<text top="565" left="619" width="52" height="14" font="7">&gt;50 mm or</text>
<text top="582" left="540" width="66" height="9" font="7">indexed LVESD</text>
<text top="579" left="608" width="55" height="14" font="7">&gt;25 mm/m</text>
<text top="580" left="663" width="5" height="6" font="23">2</text>
<text top="582" left="668" width="3" height="9" font="7">)</text>
<text top="481" left="686" width="77" height="14" font="7"> None; exercise</text>
<text top="499" left="698" width="41" height="9" font="7">testing is</text>
<text top="513" left="698" width="61" height="9" font="7">reasonable to</text>
<text top="527" left="698" width="16" height="9" font="7">con</text>
<text top="524" left="714" width="63" height="14" font="7">ﬁrm symptom</text>
<text top="541" left="698" width="27" height="9" font="7">status</text>
<text top="658" left="67" width="7" height="9" font="7">D</text>
<text top="658" left="106" width="61" height="9" font="7">Symptomatic</text>
<text top="672" left="119" width="47" height="9" font="7">severe AR</text>
<text top="657" left="193" width="107" height="14" font="7"> Calciﬁc valve disease</text>
<text top="671" left="193" width="117" height="14" font="7"> Bicuspid valve (or other</text>
<text top="688" left="204" width="106" height="9" font="7">congenital abnormality)</text>
<text top="700" left="193" width="121" height="14" font="7"> Dilated aortic sinuses or</text>
<text top="717" left="204" width="72" height="9" font="7">ascending aorta</text>
<text top="728" left="193" width="127" height="14" font="7"> Rheumatic valve changes</text>
<text top="742" left="193" width="129" height="14" font="7"> Previous IE with abnormal</text>
<text top="759" left="204" width="13" height="9" font="7">lea</text>
<text top="756" left="218" width="114" height="14" font="7">ﬂet closure or perforation</text>
<text top="657" left="351" width="63" height="14" font="7"> Severe AR:</text>
<text top="671" left="369" width="127" height="14" font="7">Doppler jet width 65% of</text>
<text top="688" left="375" width="25" height="9" font="7">LVOT;</text>
<text top="700" left="369" width="119" height="14" font="7">Vena contracta &gt;0.6 cm,</text>
<text top="714" left="369" width="135" height="14" font="7">Holodiastolic ﬂow reversal in</text>
<text top="731" left="375" width="136" height="9" font="7">the proximal abdominal aorta,</text>
<text top="742" left="369" width="95" height="14" font="7">RVol 60 mL/beat;</text>
<text top="757" left="369" width="52" height="14" font="7">RF 50%;</text>
<text top="771" left="369" width="69" height="14" font="7">ERO 0.3 cm</text>
<text top="771" left="438" width="5" height="6" font="23">2</text>
<text top="774" left="442" width="3" height="9" font="7">;</text>
<text top="785" left="369" width="140" height="14" font="7">Angiography grade 3þ to 4þ;</text>
<text top="799" left="369" width="114" height="14" font="7">In addition, diagnosis of</text>
<text top="816" left="375" width="120" height="9" font="7">chronic severe AR requires</text>
<text top="830" left="375" width="102" height="9" font="7">evidence of LV dilation</text>
<text top="657" left="528" width="142" height="14" font="7"> Symptomatic severe AR may</text>
<text top="674" left="539" width="117" height="9" font="7">occur with normal systolic</text>
<text top="688" left="539" width="64" height="9" font="7">function (LVEF</text>
<text top="685" left="607" width="60" height="14" font="7">50%), mild-</text>
<text top="703" left="539" width="123" height="9" font="7">to-moderate LV dysfunction</text>
<text top="717" left="539" width="48" height="9" font="7">(LVEF 40%</text>
<text top="714" left="588" width="76" height="14" font="7">–50%), or severe</text>
<text top="731" left="539" width="93" height="9" font="7">LV dysfunction (LVEF</text>
<text top="728" left="636" width="34" height="14" font="7">&lt;40%);</text>
<text top="742" left="528" width="111" height="14" font="7"> Moderate-to-severe LV</text>
<text top="759" left="539" width="83" height="9" font="7">dilation is present.</text>
<text top="657" left="686" width="105" height="14" font="7"> Exertional dyspnea or</text>
<text top="674" left="698" width="97" height="9" font="7">angina or more severe</text>
<text top="688" left="698" width="60" height="9" font="7">HF symptoms</text>
<text top="848" left="72" width="236" height="8" font="18">AR indicates aortic regurgitation; ERO, effective regurgitant ori</text>
<text top="846" left="308" width="492" height="11" font="18">ﬁce; HF, heart failure; IE, infective endocarditis; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular</text>
<text top="860" left="72" width="182" height="8" font="18">end-systolic dimension; LVOT, left ventricular out</text>
<text top="858" left="253" width="239" height="11" font="18">ﬂow tract; RF, regurgitant fraction; and RVol, regurgitant volume.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e82</text>
</page>
<page number="27" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">results in severe pulmonary congestion as well as a low</text>
<text top="121" left="64" width="350" height="15" font="5">forward cardiac output. Urgent diagnosis and rapid inter-</text>
<text top="139" left="64" width="152" height="15" font="5">vention can be lifesaving.</text>
<text top="175" left="64" width="105" height="15" font="5">4.1.1. Diagnosis</text>
<text top="201" left="65" width="171" height="15" font="5">TTE is indispensable in con</text>
<text top="197" left="236" width="178" height="19" font="5">ﬁrming the presence, severity,</text>
<text top="219" left="64" width="350" height="15" font="5">and etiology of AR, estimating the degree of pulmonary</text>
<text top="236" left="64" width="350" height="15" font="5">hypertension, and determining whether there is rapid</text>
<text top="254" left="64" width="350" height="15" font="5">equilibration of aortic and LV diastolic pressure. Short</text>
<text top="272" left="64" width="181" height="15" font="5">deceleration time on the mitral</text>
<text top="269" left="249" width="165" height="19" font="5">ﬂow velocity curve and early</text>
<text top="290" left="64" width="350" height="15" font="5">closure of the mitral valve on M-mode echocardiography are</text>
<text top="308" left="64" width="350" height="15" font="5">indicators of markedly elevated LV end-diastolic pressure. A</text>
<text top="326" left="64" width="108" height="15" font="5">short half-time of</text>
<text top="323" left="178" width="236" height="19" font="5">&lt;300 milliseconds on the AR velocity</text>
<text top="344" left="64" width="350" height="15" font="5">curve indicates rapid equilibration of the aortic and LV</text>
<text top="362" left="64" width="219" height="15" font="5">diastolic pressures. Assessing reversed</text>
<text top="359" left="285" width="129" height="19" font="5">ﬂow during diastole in</text>
<text top="380" left="64" width="320" height="15" font="5">the aortic arch in comparison with the forward systolic</text>
<text top="377" left="388" width="26" height="19" font="5">ﬂow</text>
<text top="398" left="64" width="350" height="15" font="5">provides a quick semiquantitative estimate of regurgitant</text>
<text top="416" left="64" width="49" height="15" font="5">fraction.</text>
<text top="434" left="79" width="335" height="15" font="5">Acute severe AR caused by aortic dissection is a surgical</text>
<text top="452" left="64" width="305" height="15" font="5">emergency that requires particularly prompt identi</text>
<text top="448" left="370" width="44" height="19" font="5">ﬁcation</text>
<text top="470" left="64" width="350" height="15" font="5">and management. However, the presence of new, even</text>
<text top="488" left="64" width="350" height="15" font="5">mild, AR, diagnosed by auscultation of a diastolic murmur</text>
<text top="506" left="64" width="12" height="15" font="5">or</text>
<text top="502" left="83" width="331" height="19" font="5">ﬁndings on echocardiography, may be a sign of acute</text>
<text top="523" left="64" width="249" height="15" font="5">aortic dissection. The sensitivity and speci</text>
<text top="520" left="313" width="101" height="19" font="5">ﬁcity of TTE for</text>
<text top="541" left="64" width="350" height="15" font="5">diagnosis of aortic dissection are only 60% to 80%, whereas</text>
<text top="559" left="64" width="304" height="15" font="5">TEE has a sensitivity of 98% to 100% and a speci</text>
<text top="556" left="368" width="46" height="19" font="5">ﬁcity of</text>
<text top="577" left="64" width="350" height="15" font="5">95% to 100%. CT imaging is also very accurate and may</text>
<text top="595" left="64" width="350" height="15" font="5">provide the most rapid approach to diagnosis at many</text>
<text top="613" left="64" width="350" height="15" font="5">centers. CMR imaging is useful with chronic aortic disease</text>
<text top="631" left="64" width="350" height="15" font="5">but is rarely used in unstable patients with suspected</text>
<text top="649" left="64" width="350" height="15" font="5">dissection. Angiography should be considered only when</text>
<text top="667" left="64" width="350" height="15" font="5">the diagnosis cannot be determined by noninvasive imag-</text>
<text top="685" left="64" width="350" height="15" font="5">ing and when patients have suspected or known CAD,</text>
<text top="703" left="64" width="231" height="15" font="5">especially those with previous CABG.</text>
<text top="739" left="64" width="121" height="15" font="5">4.1.2. Intervention</text>
<text top="765" left="65" width="349" height="15" font="5">In patients with acute severe AR resulting from IE or</text>
<text top="783" left="64" width="350" height="15" font="5">aortic dissection, surgery should not be delayed, especially</text>
<text top="801" left="64" width="350" height="15" font="5">if there is hypotension, pulmonary edema, or evidence of</text>
<text top="819" left="64" width="21" height="15" font="5">low</text>
<text top="815" left="93" width="38" height="19" font="5">ﬂow (</text>
<text top="819" left="131" width="67" height="15" font="6"><a href="e57.full.html#73">Section 12</a></text>
<text top="819" left="198" width="216" height="15" font="5"><a href="e57.full.html#73">). </a>Numerous studies have demon-</text>
<text top="837" left="64" width="350" height="15" font="5">strated improved in-hospital and long-term survival in</text>
<text top="855" left="64" width="350" height="15" font="5">such patients if they are treated with prompt AVR, as long</text>
<text top="873" left="64" width="350" height="15" font="5">as there are no complications (such as severe embolic ce-</text>
<text top="890" left="64" width="350" height="15" font="5">rebral damage) or comorbid conditions that make the</text>
<text top="908" left="64" width="350" height="15" font="5">prospect of recovery remote. In a prospectively enrolled</text>
<text top="926" left="64" width="279" height="15" font="5">multinational cohort of 1,552 patients with de</text>
<text top="923" left="343" width="71" height="19" font="5">ﬁnite native</text>
<text top="944" left="64" width="350" height="15" font="5">valve endocarditis (NVE), evidence of new AR was present</text>
<text top="962" left="64" width="350" height="15" font="5">in 37% of patients. HF (HR: 2.33; 95% CI: 1.65 to 3.28;</text>
<text top="980" left="64" width="8" height="15" font="5">p</text>
<text top="977" left="72" width="342" height="19" font="5">&lt;0.001) and pulmonary edema (HR: 1.51; 95% CI: 1.04</text>
<text top="998" left="64" width="68" height="15" font="5">to 2.18; p</text>
<text top="995" left="132" width="282" height="19" font="5">¼0.029) were associated with increased in-</text>
<text top="1016" left="64" width="350" height="15" font="5">hospital mortality. Early surgery was associated with</text>
<text top="1034" left="64" width="350" height="15" font="5">reduced in-hospital mortality (HR: 0.56; 95% CI: 0.38 to</text>
<text top="1052" left="64" width="42" height="15" font="5">0.82; p</text>
<text top="1048" left="107" width="307" height="19" font="5">¼0.003). The effect of early surgery on in-hospital</text>
<text top="1070" left="64" width="350" height="15" font="5">mortality was also assessed by propensity-based matching</text>
<text top="103" left="450" width="350" height="15" font="5">adjustment for survivor bias and by instrumental variable</text>
<text top="121" left="450" width="350" height="15" font="5">analysis. Compared with medical therapy, early surgery in</text>
<text top="139" left="450" width="350" height="15" font="5">the propensity-matched cohort after adjustment for survi-</text>
<text top="157" left="450" width="350" height="15" font="5">vor bias was associated with an absolute risk reduction</text>
<text top="175" left="450" width="64" height="15" font="5">of 5.9% (p</text>
<text top="171" left="514" width="204" height="19" font="5">&lt;0.001) for in-hospital mortality.</text>
<text top="193" left="465" width="335" height="15" font="5">Intra-aortic balloon counterpulsation is contraindicated</text>
<text top="211" left="450" width="350" height="15" font="5">in patients with acute severe AR. Augmentation of aortic</text>
<text top="229" left="450" width="350" height="15" font="5">diastolic pressure will worsen the severity of the acute</text>
<text top="246" left="450" width="272" height="15" font="5">regurgitant volume, thereby aggravating LV</text>
<text top="243" left="728" width="71" height="19" font="5">ﬁlling pres-</text>
<text top="264" left="450" width="246" height="15" font="5">sures and compromising forward output.</text>
<text top="282" left="465" width="335" height="15" font="5">Beta blockers are often used in treating aortic dissection.</text>
<text top="300" left="450" width="350" height="15" font="5">However, these agents should be used very cautiously, if</text>
<text top="318" left="450" width="350" height="15" font="5">at all, for other causes of acute AR because they will block</text>
<text top="336" left="450" width="350" height="15" font="5">the compensatory tachycardia and could precipitate a</text>
<text top="354" left="450" width="150" height="15" font="5">marked reduction in BP.</text>
<text top="373" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="372" left="597" width="27" height="15" font="6"><a href="e57.full.html#104">(185</a></text>
<text top="369" left="625" width="35" height="19" font="6"><a href="e57.full.html#104">–195)</a></text>
<text top="409" left="450" width="177" height="12" font="19">4.2. Stages of Chronic AR</text>
<text top="432" left="451" width="349" height="15" font="5">The most common causes of chronic AR in the United</text>
<text top="450" left="450" width="350" height="15" font="5">States and other developed countries are bicuspid aortic</text>
<text top="468" left="450" width="86" height="15" font="5">valve and calci</text>
<text top="465" left="536" width="263" height="19" font="5">ﬁc valve disease. In addition, AR frequently</text>
<text top="486" left="450" width="350" height="15" font="5">arises from primary diseases causing dilation of the</text>
<text top="504" left="450" width="350" height="15" font="5">ascending aorta or the sinuses of Valsalva. Another cause of</text>
<text top="522" left="450" width="350" height="15" font="5">AR is rheumatic heart disease (the leading cause in many</text>
<text top="540" left="450" width="350" height="15" font="5">developing countries). In the majority of patients with AR,</text>
<text top="558" left="450" width="350" height="15" font="5">the disease course is chronic and slowly progressive with</text>
<text top="576" left="450" width="350" height="15" font="5">increasing LV volume overload and LV adaptation via</text>
<text top="594" left="450" width="350" height="15" font="5">chamber dilation and hypertrophy. Management of pa-</text>
<text top="612" left="450" width="350" height="15" font="5">tients with AR depends on accurate diagnosis of the cause</text>
<text top="629" left="450" width="190" height="15" font="5">and stage of the disease process.</text>
<text top="629" left="644" width="53" height="15" font="6"><a href="e57.full.html#26">Table 11</a></text>
<text top="629" left="701" width="98" height="15" font="5">shows the stages</text>
<text top="647" left="450" width="350" height="15" font="5">of AR ranging from patients at risk of AR (stage A) or</text>
<text top="665" left="450" width="350" height="15" font="5">with progressive mild-to-moderate AR (stage B) to severe</text>
<text top="683" left="450" width="350" height="15" font="5">asymptomatic (stage C) and symptomatic AR (stage D).</text>
<text top="701" left="450" width="166" height="15" font="5">Each of these stages is de</text>
<text top="698" left="615" width="184" height="19" font="5">ﬁned by valve anatomy, valve</text>
<text top="719" left="450" width="350" height="15" font="5">hemodynamics, severity of LV dilation, and LV systolic</text>
<text top="737" left="450" width="250" height="15" font="5">function, as well as by patient symptoms.</text>
<text top="775" left="450" width="107" height="12" font="19">4.3. Chronic AR</text>
<text top="797" left="451" width="21" height="15" font="5">See</text>
<text top="797" left="476" width="51" height="15" font="6"><a href="e57.full.html#28">Figure 2</a></text>
<text top="797" left="532" width="246" height="15" font="5">for indications for AVR for chronic AR.</text>
<text top="824" left="450" width="206" height="15" font="5">4.3.1. Diagnosis and Follow-Up</text>
<text top="854" left="450" width="332" height="11" font="7">4.3.1.1. DIAGNOSTIC TESTINGdINITIAL DIAGNOSIS: RECOMMENDATIONS</text>
<text top="877" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="892" left="449" width="350" height="10" font="21">1. TTE is indicated in patients with signs or symptoms of AR</text>
<text top="908" left="467" width="332" height="10" font="21">(stages A to D) for accurate diagnosis of the cause of regurgi-</text>
<text top="925" left="467" width="332" height="10" font="21">tation, regurgitant severity, and LV size and systolic function,</text>
<text top="941" left="467" width="332" height="10" font="21">and for determining clinical outcome and timing of valve inter-</text>
<text top="958" left="467" width="39" height="10" font="21">vention</text>
<text top="958" left="510" width="43" height="10" font="22"><a href="e57.full.html#101">(32,196</a></text>
<text top="955" left="553" width="32" height="16" font="22"><a href="e57.full.html#101">–205)</a></text>
<text top="958" left="585" width="121" height="12" font="21"><a href="e57.full.html#101">. </a>(Level of Evidence: B)</text>
<text top="982" left="465" width="335" height="15" font="5">The clinical stages that characterize the severity of</text>
<text top="1000" left="450" width="80" height="15" font="5">chronic AR <a href="e57.full.html#26">(</a></text>
<text top="1000" left="529" width="54" height="15" font="6"><a href="e57.full.html#26">Table 11</a></text>
<text top="1000" left="583" width="45" height="15" font="5"><a href="e57.full.html#26">) </a>are de</text>
<text top="997" left="628" width="171" height="19" font="5">ﬁned by symptomatic status,</text>
<text top="1018" left="450" width="350" height="15" font="5">severity of regurgitation, and LV volume and systolic</text>
<text top="1036" left="450" width="350" height="15" font="5">function. TTE is an indispensable imaging test for evalu-</text>
<text top="1054" left="450" width="350" height="15" font="5">ating patients with chronic AR and guiding appropriate</text>
<text top="1072" left="450" width="350" height="15" font="5">management decisions. It provides diagnostic information</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e83</text>
</page>
<page number="28" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">about the etiology and mechanism of AR (including valve</text>
<text top="121" left="64" width="350" height="15" font="5">reparability), severity of regurgitation, morphology of the</text>
<text top="139" left="64" width="350" height="15" font="5">ascending aorta, and LV response to the increases in pre-</text>
<text top="157" left="64" width="350" height="15" font="5">load and afterload. Quantitative measures of regurgitant</text>
<text top="175" left="64" width="221" height="15" font="5">volume and effective regurgitant ori</text>
<text top="171" left="286" width="128" height="19" font="5">ﬁce area were strong</text>
<text top="192" left="64" width="350" height="15" font="5">predictors of clinical outcome in a prospective study of 251</text>
<text top="210" left="64" width="350" height="15" font="5">asymptomatic patients with isolated AR and normal LV</text>
<text top="228" left="64" width="250" height="15" font="5">function (stages B and C). This was con</text>
<text top="225" left="314" width="100" height="19" font="5">ﬁrmed in a sub-</text>
<text top="246" left="64" width="350" height="15" font="5">sequent study involving 294 patients. Observation of dia-</text>
<text top="264" left="64" width="31" height="15" font="5">stolic</text>
<text top="261" left="101" width="313" height="19" font="5">ﬂow reversal in the aortic arch or more distally can</text>
<text top="282" left="64" width="350" height="15" font="5">help identify patients with severe AR. Numerous studies</text>
<text top="300" left="64" width="126" height="15" font="5">involving a total of</text>
<text top="297" left="199" width="215" height="19" font="5">&gt;1,150 patients have consistently</text>
<text top="318" left="64" width="350" height="15" font="5">shown that measures of LV systolic function (LVEF or</text>
<text top="336" left="64" width="350" height="15" font="5">fractional shortening) and LV end-systolic dimension</text>
<text top="354" left="64" width="350" height="15" font="5">(LVESD) or volume are associated with development</text>
<text top="372" left="64" width="350" height="15" font="5">of HF symptoms or death in initially asymptomatic pa-</text>
<text top="390" left="64" width="350" height="15" font="5">tients (stages B and C1). Moreover, in symptomatic pa-</text>
<text top="408" left="64" width="350" height="15" font="5">tients undergoing AVR (stage D), preoperative LV systolic</text>
<text top="426" left="64" width="350" height="15" font="5">function and end-systolic dimension or volume are</text>
<text top="103" left="450" width="28" height="15" font="5">signi</text>
<text top="99" left="478" width="321" height="19" font="5">ﬁcant determinants of survival and functional results</text>
<text top="121" left="450" width="350" height="15" font="5">after surgery. Symptomatic patients (stage D) with normal</text>
<text top="139" left="450" width="110" height="15" font="5">LVEF have signi</text>
<text top="135" left="560" width="239" height="19" font="5">ﬁcantly better long-term postoperative</text>
<text top="157" left="450" width="313" height="15" font="5">survival than those with depressed systolic function.</text>
<text top="175" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="175" left="597" width="65" height="15" font="6"><a href="e57.full.html#100">(17,32,196</a></text>
<text top="171" left="662" width="35" height="19" font="6"><a href="e57.full.html#100">–220)</a></text>
<text top="193" left="465" width="18" height="15" font="5">See</text>
<text top="193" left="488" width="166" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 10</a></text>
<text top="193" left="659" width="140" height="15" font="5">for more information on</text>
<text top="211" left="450" width="230" height="15" font="5">the natural history of asymptomatic AR.</text>
<text top="247" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="262" left="449" width="351" height="10" font="21">2. TTE is indicated in patients with dilated aortic sinuses or</text>
<text top="278" left="467" width="332" height="10" font="21">ascending aorta or with a bicuspid aortic valve (stages A and B)</text>
<text top="294" left="467" width="243" height="10" font="21">to evaluate the presence and severity of AR</text>
<text top="294" left="715" width="30" height="10" font="22"><a href="e57.full.html#105">(221)</a></text>
<text top="294" left="745" width="54" height="12" font="21">. (Level of</text>
<text top="311" left="467" width="65" height="12" font="21">Evidence: B)</text>
<text top="335" left="465" width="335" height="15" font="5">A diastolic regurgitant murmur is not always audible</text>
<text top="353" left="450" width="350" height="15" font="5">in patients with mild or moderate AR. TTE is more</text>
<text top="371" left="450" width="350" height="15" font="5">sensitive than auscultation in detecting AR in patients</text>
<text top="389" left="450" width="350" height="15" font="5">at risk for development of AR. In a series of 100</text>
<text top="407" left="450" width="350" height="15" font="5">patients referred for echocardiographic evaluation of</text>
<text top="425" left="450" width="350" height="15" font="5">a systolic murmur, 28 had AR on echocardiography.</text>
<text top="1034" left="64" width="253" height="11" font="13">Figure 2. Indications for AVR for Chronic AR</text>
<text top="1066" left="72" width="620" height="9" font="14">AR indicates aortic regurgitation; AVR, aortic valve replacement (valve repair may be appropriate in selected patients); ERO, effective regurgitant ori</text>
<text top="1064" left="692" width="99" height="13" font="14">ﬁce; LV, left ventricular;</text>
<text top="1080" left="72" width="705" height="9" font="14">LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; RF, regurgitant fraction; and RVol,</text>
<text top="1093" left="72" width="81" height="9" font="14">regurgitant volume.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e84</text>
</page>
<page number="29" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="171" height="15" font="5">Auscultation had high speci</text>
<text top="99" left="235" width="179" height="19" font="5">ﬁcity (96%) for detecting AR</text>
<text top="121" left="64" width="350" height="15" font="5">but low sensitivity (21%), and diagnostic accuracy was</text>
<text top="139" left="64" width="61" height="15" font="5">only 75%.</text>
<text top="157" left="79" width="123" height="15" font="5">Supporting Reference:</text>
<text top="157" left="208" width="32" height="15" font="6"><a href="e57.full.html#105">(221)</a></text>
<text top="184" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="199" left="63" width="351" height="10" font="21">3. CMR is indicated in patients with moderate or severe AR</text>
<text top="215" left="81" width="333" height="10" font="21">(stages B, C, and D) and suboptimal echocardiographic images</text>
<text top="232" left="81" width="332" height="10" font="21">for the assessment of LV systolic function, systolic and dia-</text>
<text top="248" left="81" width="268" height="10" font="21">stolic volumes, and measurement of AR severity</text>
<text top="248" left="356" width="55" height="10" font="22"><a href="e57.full.html#105">(222,223)</a></text>
<text top="248" left="410" width="3" height="10" font="21">.</text>
<text top="265" left="81" width="113" height="12" font="21">(Level of Evidence: B)</text>
<text top="289" left="79" width="335" height="15" font="5">CMR imaging provides accurate measures of regurgitant</text>
<text top="307" left="64" width="350" height="15" font="5">volume and regurgitant fraction in patients with AR, as</text>
<text top="325" left="64" width="350" height="15" font="5">well as assessment of aortic morphology, LV volume, and</text>
<text top="343" left="64" width="350" height="15" font="5">LV systolic function. In addition to its value in patients</text>
<text top="361" left="64" width="350" height="15" font="5">with suboptimal echocardiographic data, CMR is useful</text>
<text top="379" left="64" width="350" height="15" font="5">for evaluating patients in whom there is discordance be-</text>
<text top="396" left="64" width="350" height="15" font="5">tween clinical assessment and severity of AR by echocar-</text>
<text top="414" left="64" width="350" height="15" font="5">diography. CMR measurement of regurgitant severity is</text>
<text top="432" left="64" width="303" height="15" font="5">less variable than echocardiographic measurement.</text>
<text top="451" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="450" left="212" width="27" height="15" font="6"><a href="e57.full.html#105">(222</a></text>
<text top="447" left="239" width="35" height="19" font="6"><a href="e57.full.html#105">–228)</a></text>
<text top="481" left="64" width="299" height="11" font="7">4.3.1.2. DIAGNOSTIC TESTINGdCHANGING SIGNS OR SYMPTOMS</text>
<text top="496" left="65" width="349" height="15" font="5">Symptoms are the most common indication for AVR in</text>
<text top="514" left="64" width="349" height="15" font="5">patients with AR. In patients with previous documentation</text>
<text top="532" left="64" width="350" height="15" font="5">of mild or moderate AR, new-onset dyspnea or angina may</text>
<text top="550" left="64" width="350" height="15" font="5">indicate that AR has progressed in severity. If AR remains</text>
<text top="568" left="64" width="350" height="15" font="5">mild, further investigation for other etiologies is indicated.</text>
<text top="586" left="64" width="350" height="15" font="5">In patients with previous documentation of severe AR,</text>
<text top="603" left="64" width="350" height="15" font="5">onset of symptoms is an indication for surgery and repeat</text>
<text top="621" left="64" width="350" height="15" font="5">TTE is indicated to determine the status of the aortic</text>
<text top="639" left="64" width="268" height="15" font="5">valve, aorta, and left ventricle preoperatively.</text>
<text top="658" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="657" left="212" width="129" height="15" font="6"><a href="e57.full.html#101">(31,214,220,229,230)</a></text>
<text top="688" left="64" width="243" height="11" font="7">4.3.1.3. DIAGNOSTIC TESTINGdROUTINE FOLLOW-UP</text>
<text top="703" left="65" width="349" height="15" font="5">Patients with asymptomatic severe AR with normal LV</text>
<text top="721" left="64" width="350" height="15" font="5">systolic function are at risk for progressive increases in LV</text>
<text top="739" left="64" width="350" height="15" font="5">end-diastolic and end-systolic volumes and reduction in</text>
<text top="757" left="64" width="350" height="15" font="5">systolic function. In a series of asymptomatic patients with</text>
<text top="775" left="64" width="350" height="15" font="5">AR and normal LV systolic function who underwent serial</text>
<text top="792" left="64" width="350" height="15" font="5">echocardiograms, predictors of death or symptoms in a</text>
<text top="810" left="64" width="350" height="15" font="5">multivariate analysis were age, initial end-systolic dimen-</text>
<text top="828" left="64" width="350" height="15" font="5">sion, and rate of change in end-systolic dimension and rest</text>
<text top="846" left="64" width="350" height="15" font="5">LVEF during serial studies. In asymptomatic patients who</text>
<text top="864" left="64" width="61" height="15" font="5">do not ful</text>
<text top="861" left="126" width="288" height="19" font="5">ﬁll the criteria for AVR, serial imaging is indi-</text>
<text top="882" left="64" width="350" height="15" font="5">cated to identify those who are progressing toward the</text>
<text top="900" left="64" width="135" height="15" font="5">threshold for surgery <a href="e57.full.html#10">(</a></text>
<text top="900" left="199" width="47" height="15" font="6"><a href="e57.full.html#10">Table 4</a></text>
<text top="900" left="246" width="9" height="15" font="5"><a href="e57.full.html#10">).</a></text>
<text top="919" left="79" width="123" height="15" font="5">Supporting Reference:</text>
<text top="918" left="208" width="25" height="15" font="6"><a href="e57.full.html#101">(32)</a></text>
<text top="949" left="64" width="273" height="11" font="7">4.3.1.4. DIAGNOSTIC TESTINGdCARDIAC CATHETERIZATION</text>
<text top="964" left="65" width="349" height="15" font="5">When there is discordance between clinical assessment and</text>
<text top="981" left="64" width="350" height="15" font="5">noninvasive tests about the severity of AR, additional</text>
<text top="999" left="64" width="350" height="15" font="5">testing is indicated. Under most circumstances, another</text>
<text top="1017" left="64" width="350" height="15" font="5">noninvasive test such as CMR is used when TTE and</text>
<text top="1035" left="64" width="42" height="15" font="5">clinical</text>
<text top="1032" left="115" width="299" height="19" font="5">ﬁndings are discordant. Invasive assessment is</text>
<text top="1053" left="64" width="350" height="15" font="5">indicated when CMR is not available or there are con-</text>
<text top="1071" left="64" width="350" height="15" font="5">traindications for CMR, such as implanted devices. In</text>
<text top="1089" left="64" width="350" height="15" font="5">symptomatic patients with equivocal echocardiographic</text>
<text top="103" left="450" width="350" height="15" font="5">evidence of severity of AR, cardiac catheterization is useful</text>
<text top="121" left="450" width="350" height="15" font="5">to assess hemodynamics, coronary artery anatomy, and</text>
<text top="139" left="450" width="91" height="15" font="5">severity of AR.</text>
<text top="157" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="157" left="597" width="53" height="15" font="6"><a href="e57.full.html#105">(222,224</a></text>
<text top="153" left="651" width="35" height="19" font="6"><a href="e57.full.html#105">–228)</a></text>
<text top="188" left="450" width="232" height="11" font="7">4.3.1.5. DIAGNOSTIC TESTINGdEXERCISE TESTING</text>
<text top="202" left="451" width="349" height="15" font="5">Exercise stress testing can be used to assess symptomatic</text>
<text top="220" left="450" width="350" height="15" font="5">status and functional capacity in patients with AR. Such</text>
<text top="238" left="450" width="145" height="15" font="5">testing is helpful in con</text>
<text top="235" left="595" width="205" height="19" font="5">ﬁrming patients’ reports that they</text>
<text top="256" left="450" width="350" height="15" font="5">have no symptoms with daily life activities and in assessing</text>
<text top="274" left="450" width="350" height="15" font="5">objective exercise capacity and symptom status in those</text>
<text top="292" left="450" width="156" height="15" font="5">with equivocal symptoms.</text>
<text top="319" left="450" width="277" height="15" font="5">4.3.2. Medical Therapy: Recommendations</text>
<text top="346" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="361" left="449" width="230" height="10" font="21">1. Treatment of hypertension (systolic BP</text>
<text top="358" left="685" width="115" height="16" font="21">&gt;140 mm Hg) is rec-</text>
<text top="377" left="467" width="332" height="10" font="21">ommended in patients with chronic AR (stages B and C), pref-</text>
<text top="394" left="467" width="332" height="10" font="21">erably with dihydropyridine calcium channel blockers or ACE</text>
<text top="410" left="467" width="85" height="10" font="21">inhibitors/ARBs</text>
<text top="410" left="556" width="55" height="10" font="22"><a href="e57.full.html#105">(204,209)</a></text>
<text top="410" left="611" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="435" left="465" width="335" height="15" font="5">Vasodilating drugs are effective in reducing systolic BP in</text>
<text top="452" left="450" width="350" height="15" font="5">patients with chronic AR. Beta blockers may be less effective</text>
<text top="470" left="450" width="350" height="15" font="5">because the reduction in heart rate is associated with an even</text>
<text top="488" left="450" width="350" height="15" font="5">higher stroke volume, which contributes to the elevated</text>
<text top="506" left="450" width="308" height="15" font="5">systolic pressure in patients with chronic severe AR.</text>
<text top="525" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="524" left="597" width="80" height="15" font="6"><a href="e57.full.html#105">(204,209,231</a></text>
<text top="521" left="677" width="35" height="19" font="6"><a href="e57.full.html#105">–233)</a></text>
<text top="552" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="566" left="449" width="351" height="10" font="21">1. Medical therapy with ACE inhibitors/ARBs and beta blockers</text>
<text top="583" left="467" width="333" height="10" font="21">is reasonable in patients with severe AR who have symptoms</text>
<text top="599" left="467" width="332" height="10" font="21">and/or LV dysfunction (stages C2 and D) when surgery is</text>
<text top="616" left="467" width="220" height="10" font="21">not performed because of comorbidities</text>
<text top="616" left="692" width="55" height="10" font="22"><a href="e57.full.html#105">(232,234)</a></text>
<text top="616" left="747" width="53" height="12" font="21"><a href="e57.full.html#105">. </a>(Level of</text>
<text top="632" left="467" width="65" height="12" font="21">Evidence: B)</text>
<text top="656" left="465" width="335" height="15" font="5">Vasodilating drugs improve hemodynamic abnormalities</text>
<text top="674" left="450" width="350" height="15" font="5">in patients with AR and improve forward cardiac output.</text>
<text top="692" left="450" width="350" height="15" font="5">However, 2 small RCTs yielding discordant results did not</text>
<text top="710" left="450" width="350" height="15" font="5">conclusively show that these drugs alter the natural history</text>
<text top="728" left="450" width="350" height="15" font="5">of asymptomatic patients with chronic severe AR and</text>
<text top="746" left="450" width="350" height="15" font="5">normal LV systolic function. Thus, vasodilator therapy is</text>
<text top="764" left="450" width="350" height="15" font="5">not recommended routinely in patients with chronic</text>
<text top="782" left="450" width="314" height="15" font="5">asymptomatic AR and normal LV systolic function.</text>
<text top="800" left="465" width="335" height="15" font="5">In symptomatic patients who are candidates for surgery,</text>
<text top="818" left="450" width="350" height="15" font="5">medical therapy is not a substitute for AVR. However,</text>
<text top="836" left="450" width="350" height="15" font="5">medical therapy is helpful for alleviating symptoms in pa-</text>
<text top="854" left="450" width="350" height="15" font="5">tients who are considered at very high risk for surgery</text>
<text top="872" left="450" width="350" height="15" font="5">because of concomitant comorbid medical conditions. In</text>
<text top="890" left="450" width="350" height="15" font="5">a cohort study of 2,266 patients with chronic AR, treat-</text>
<text top="908" left="450" width="350" height="15" font="5">ment with ACE inhibitors or ARBs was associated with a</text>
<text top="925" left="450" width="350" height="15" font="5">reduced composite endpoint of AVR, hospitalization for</text>
<text top="943" left="450" width="350" height="15" font="5">HF, and death from HF (HR: 0.68; 95% CI: 0.54 to 0.87;</text>
<text top="961" left="450" width="8" height="15" font="5">p</text>
<text top="958" left="457" width="342" height="19" font="5">&lt;0.01). In that study, 45% had evidence of LV systolic</text>
<text top="979" left="450" width="350" height="15" font="5">impairment. In another retrospective cohort study of 756</text>
<text top="997" left="450" width="350" height="15" font="5">patients with chronic AR, therapy with beta-adrenergic</text>
<text top="1015" left="450" width="350" height="15" font="5">blockers was associated with improved survival (HR:</text>
<text top="1033" left="450" width="173" height="15" font="5">0.74; 95% CI: 0.58 to 0.93; p</text>
<text top="1030" left="623" width="176" height="19" font="5">&lt;0.01). Also, 33% of patients</text>
<text top="1051" left="450" width="350" height="15" font="5">had associated CAD, 64% had hypertension, 20% had</text>
<text top="1069" left="450" width="64" height="15" font="5">renal insuf</text>
<text top="1066" left="514" width="285" height="19" font="5">ﬁciency, 70% had HF, and 25% had AF. Pa-</text>
<text top="1087" left="450" width="350" height="15" font="5">tients treated with beta blockers were more likely to also</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e85</text>
</page>
<page number="30" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="274" height="15" font="5">be taking ACE inhibitors (53% versus 40%; p</text>
<text top="99" left="338" width="76" height="19" font="5">&lt;0.001) and</text>
<text top="121" left="64" width="350" height="15" font="5">dihydropyridine calcium channel blockers (22% versus</text>
<text top="139" left="64" width="44" height="15" font="5">16%; p</text>
<text top="135" left="108" width="306" height="19" font="5">¼0.03). Importantly, more patients receiving beta</text>
<text top="157" left="64" width="350" height="15" font="5">blockers in that study underwent AVR (49% versus 29%;</text>
<text top="175" left="64" width="8" height="15" font="5">p</text>
<text top="171" left="72" width="342" height="19" font="5">&lt;0.001), but this was accounted for in the multivariate</text>
<text top="192" left="64" width="350" height="15" font="5">model. When patients were censored at the time of sur-</text>
<text top="210" left="64" width="350" height="15" font="5">gery, beta-blocker therapy remained associated with higher</text>
<text top="228" left="64" width="94" height="15" font="5">survival rates (p</text>
<text top="225" left="158" width="46" height="19" font="5">&lt;0.05).</text>
<text top="247" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="246" left="212" width="132" height="15" font="6"><a href="e57.full.html#105">(204,209,231,232,234</a></text>
<text top="243" left="344" width="35" height="19" font="6"><a href="e57.full.html#105">–239)</a></text>
<text top="265" left="79" width="18" height="15" font="5">See</text>
<text top="265" left="103" width="166" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 11</a></text>
<text top="265" left="274" width="140" height="15" font="5">for more information on</text>
<text top="283" left="64" width="154" height="15" font="5">vasodilator therapy in AR.</text>
<text top="306" left="64" width="318" height="15" font="5">4.3.3. Timing of Intervention: Recommendations</text>
<text top="331" left="65" width="21" height="15" font="5">See</text>
<text top="331" left="89" width="53" height="15" font="6"><a href="e57.full.html#30">Table 12</a></text>
<text top="331" left="146" width="268" height="15" font="5">for a summary of recommendations from this</text>
<text top="349" left="64" width="45" height="15" font="5">section.</text>
<text top="367" left="79" width="335" height="15" font="5">The vast majority of patients who require surgery for</text>
<text top="385" left="64" width="349" height="15" font="5">chronic severe AR will require AVR. Valve-sparing</text>
<text top="403" left="64" width="350" height="15" font="5">replacement of the aortic sinuses and ascending aorta is a</text>
<text top="421" left="64" width="350" height="15" font="5">possible strategy in patients with AR caused by aortic</text>
<text top="439" left="64" width="166" height="15" font="5">dilation in whom a trilea</text>
<text top="436" left="231" width="183" height="19" font="5">ﬂet or bicuspid valve is not</text>
<text top="457" left="64" width="187" height="15" font="5">thickened, deformed, or calci</text>
<text top="454" left="251" width="162" height="19" font="5">ﬁed. Despite advances in</text>
<text top="475" left="64" width="350" height="15" font="5">primary aortic valve repair, especially in young patients</text>
<text top="493" left="64" width="350" height="15" font="5">with bicuspid aortic valves, the experience at a few</text>
<text top="511" left="64" width="350" height="15" font="5">specialized centers has not yet been replicated at the gen-</text>
<text top="529" left="64" width="350" height="15" font="5">eral community level, and durability of aortic valve repair</text>
<text top="547" left="64" width="350" height="15" font="5">remains a major concern. Performance of aortic valve repair</text>
<text top="565" left="64" width="350" height="15" font="5">should be concentrated in those centers with proven</text>
<text top="583" left="64" width="160" height="15" font="5">expertise in the procedure.</text>
<text top="601" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="600" left="212" width="27" height="15" font="6"><a href="e57.full.html#106">(244</a></text>
<text top="597" left="239" width="35" height="19" font="6"><a href="e57.full.html#106">–247)</a></text>
<text top="628" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="643" left="63" width="351" height="10" font="21">1. AVR is indicated for symptomatic patients with severe AR</text>
<text top="660" left="81" width="249" height="10" font="21">regardless of LV systolic function (stage D)</text>
<text top="660" left="338" width="73" height="10" font="22"><a href="e57.full.html#101">(31,229,230)</a></text>
<text top="660" left="410" width="3" height="10" font="21">.</text>
<text top="676" left="81" width="113" height="12" font="21">(Level of Evidence: B)</text>
<text top="695" left="79" width="335" height="15" font="5">Symptoms are an important indication for AVR in pa-</text>
<text top="712" left="64" width="350" height="15" font="5">tients with chronic severe AR, and the most important</text>
<text top="730" left="64" width="350" height="15" font="5">aspect of the clinical evaluation is taking a careful, detailed</text>
<text top="748" left="64" width="350" height="15" font="5">history to elicit symptoms or diminution of exercise ca-</text>
<text top="766" left="64" width="350" height="15" font="5">pacity. Patients with chronic severe AR who develop</text>
<text top="784" left="64" width="350" height="15" font="5">symptoms have a high risk of death if AVR is not per-</text>
<text top="802" left="64" width="350" height="15" font="5">formed. In a series of 246 patients with severe AR followed</text>
<text top="820" left="64" width="350" height="15" font="5">without surgery, those who were NYHA class III or IV</text>
<text top="103" left="450" width="350" height="15" font="5">had a mortality rate of 24.6% per year; even NYHA class II</text>
<text top="121" left="450" width="350" height="15" font="5">symptoms were associated with increased mortality (6.3%</text>
<text top="139" left="450" width="350" height="15" font="5">per year). Numerous other studies indicate that survival</text>
<text top="157" left="450" width="350" height="15" font="5">and functional status after AVR are related to severity of</text>
<text top="175" left="450" width="350" height="15" font="5">preoperative symptoms assessed either subjectively or</text>
<text top="192" left="450" width="350" height="15" font="5">objectively with exercise testing, with worse outcomes in</text>
<text top="210" left="450" width="350" height="15" font="5">patients who undergo surgery after development of</text>
<text top="228" left="450" width="350" height="15" font="5">moderately severe (NYHA class III) symptoms or</text>
<text top="246" left="450" width="350" height="15" font="5">impaired exercise capacity. In a series of 289 patients</text>
<text top="264" left="450" width="350" height="15" font="5">followed after AVR, long-term postoperative survival was</text>
<text top="282" left="450" width="29" height="15" font="5">signi</text>
<text top="279" left="479" width="321" height="19" font="5">ﬁcantly higher in patients who were in NYHA class</text>
<text top="300" left="450" width="350" height="15" font="5">I or II at the time of surgery compared with those in</text>
<text top="318" left="450" width="168" height="15" font="5">NYHA class III or IV (10</text>
<text top="315" left="619" width="181" height="19" font="5">–year survival rates 78%7%</text>
<text top="336" left="450" width="68" height="15" font="5">versus 45%</text>
<text top="333" left="518" width="282" height="19" font="5">4%, respectively; p&lt;0.001). The importance</text>
<text top="354" left="450" width="350" height="15" font="5">of preoperative symptoms in the study was observed for</text>
<text top="372" left="450" width="350" height="15" font="5">both patients with normal LV systolic function and those</text>
<text top="390" left="450" width="350" height="15" font="5">with LV systolic dysfunction. Postoperative survival is</text>
<text top="408" left="450" width="29" height="15" font="5">signi</text>
<text top="404" left="479" width="321" height="19" font="5">ﬁcantly higher in symptomatic patients with normal</text>
<text top="426" left="450" width="350" height="15" font="5">LVEF compared with those with impaired systolic</text>
<text top="444" left="450" width="350" height="15" font="5">function, but even in symptomatic patients with severely</text>
<text top="462" left="450" width="350" height="15" font="5">depressed systolic function, surgery is recommended over</text>
<text top="479" left="450" width="350" height="15" font="5">medical therapy. In a postoperative series of 450 patients</text>
<text top="497" left="450" width="350" height="15" font="5">undergoing AVR from 1980 to 1995, patients with</text>
<text top="515" left="450" width="350" height="15" font="5">markedly low LVEF incurred high short- and long-term</text>
<text top="533" left="450" width="350" height="15" font="5">mortality after AVR. However, postoperative LV func-</text>
<text top="551" left="450" width="124" height="15" font="5">tion improved signi</text>
<text top="548" left="574" width="225" height="19" font="5">ﬁcantly, and most patients survived</text>
<text top="569" left="450" width="246" height="15" font="5">without recurrence of HF. This was con</text>
<text top="566" left="696" width="104" height="19" font="5">ﬁrmed in a series</text>
<text top="587" left="450" width="350" height="15" font="5">of 724 patients who underwent AVR from 1972 to</text>
<text top="605" left="450" width="305" height="15" font="5">1999, in which long-term survival was signi</text>
<text top="602" left="755" width="44" height="19" font="5">ﬁcantly</text>
<text top="623" left="450" width="350" height="15" font="5">reduced in the 88 patients with severe LV dysfunction</text>
<text top="641" left="450" width="45" height="15" font="5">(LVEF</text>
<text top="638" left="503" width="296" height="19" font="5">&lt;30%) compared with the 636 patients with</text>
<text top="659" left="450" width="350" height="15" font="5">either less severe LV dysfunction or normal LVEF (81%</text>
<text top="677" left="450" width="350" height="15" font="5">versus 92% at 1 year, 68% versus 81% at 5 years, 46%</text>
<text top="695" left="450" width="350" height="15" font="5">versus 62% at 10 years, 26% versus 41% at 15 years, and</text>
<text top="713" left="450" width="302" height="15" font="5">12% versus 24% at 20 years, respectively; p</text>
<text top="709" left="752" width="47" height="19" font="5">¼0.04).</text>
<text top="731" left="450" width="350" height="15" font="5">Among propensity-matched patients operated on in the</text>
<text top="749" left="450" width="350" height="15" font="5">latter time frame since 1985, these trends were no longer</text>
<text top="766" left="450" width="29" height="15" font="5">signi</text>
<text top="763" left="479" width="321" height="19" font="5">ﬁcant (survival at 1, 5, and 10 years after surgery was</text>
<text top="784" left="450" width="350" height="15" font="5">92%, 79%, and 51%, respectively for patients with severe</text>
<text top="802" left="450" width="350" height="15" font="5">LV dysfunction and 96%, 83%, and 55% for the others,</text>
<text top="820" left="450" width="87" height="15" font="5">respectively; p</text>
<text top="817" left="536" width="40" height="19" font="5">¼0.9).</text>
<text top="856" left="64" width="346" height="11" font="13">Table 12. Summary of Recommendations for AR Intervention</text>
<text top="881" left="64" width="86" height="9" font="7">Recommendations</text>
<text top="881" left="564" width="21" height="9" font="7">COR</text>
<text top="881" left="663" width="18" height="9" font="7">LOE</text>
<text top="881" left="740" width="52" height="9" font="7">References</text>
<text top="901" left="64" width="448" height="9" font="7">AVR is indicated for symptomatic patients with severe AR regardless of LV systolic function (stage D)</text>
<text top="901" left="573" width="3" height="9" font="7">I</text>
<text top="901" left="668" width="6" height="9" font="7">B</text>
<text top="901" left="736" width="60" height="9" font="8"><a href="e57.full.html#101">(31,229,230)</a></text>
<text top="919" left="64" width="426" height="9" font="7">AVR is indicated for asymptomatic patients with chronic severe AR and LV systolic dysfunction</text>
<text top="933" left="77" width="25" height="9" font="7">(LVEF</text>
<text top="930" left="105" width="81" height="14" font="7">&lt;50%) (stage C2)</text>
<text top="919" left="573" width="3" height="9" font="7">I</text>
<text top="919" left="668" width="6" height="9" font="7">B</text>
<text top="919" left="744" width="45" height="9" font="8"><a href="e57.full.html#105">(211,229,</a></text>
<text top="933" left="751" width="42" height="9" font="8"><a href="e57.full.html#105">240,241)</a></text>
<text top="947" left="64" width="417" height="9" font="7">AVR is indicated for patients with severe AR (stage C or D) while undergoing cardiac surgery</text>
<text top="961" left="77" width="90" height="9" font="7">for other indications</text>
<text top="947" left="573" width="3" height="9" font="7">I</text>
<text top="947" left="669" width="6" height="9" font="7">C</text>
<text top="947" left="757" width="18" height="9" font="7">N/A</text>
<text top="975" left="64" width="421" height="9" font="7">AVR is reasonable for asymptomatic patients with severe AR with normal LV systolic function</text>
<text top="989" left="77" width="25" height="9" font="7">(LVEF</text>
<text top="986" left="105" width="284" height="14" font="7">50%) but with severe LV dilation (LVESD &gt;50 mm, stage C2)</text>
<text top="975" left="569" width="11" height="9" font="7">IIa</text>
<text top="975" left="668" width="6" height="9" font="7">B</text>
<text top="975" left="733" width="66" height="9" font="8"><a href="e57.full.html#105">(225,242,243)</a></text>
<text top="1003" left="64" width="448" height="9" font="7">AVR is reasonable in patients with moderate AR (stage B) who are undergoing other cardiac surgery</text>
<text top="1003" left="569" width="11" height="9" font="7">IIa</text>
<text top="1003" left="669" width="6" height="9" font="7">C</text>
<text top="1003" left="757" width="18" height="9" font="7">N/A</text>
<text top="1022" left="64" width="445" height="9" font="7">AVR may be considered for asymptomatic patients with severe AR and normal LV systolic function</text>
<text top="1036" left="77" width="25" height="9" font="7">(LVEF</text>
<text top="1033" left="105" width="386" height="14" font="7">50%, stage C1) but with progressive severe LV dilation (LVEDD &gt;65 mm) if surgical</text>
<text top="1050" left="77" width="45" height="9" font="7">risk is low</text>
<text top="1050" left="122" width="6" height="9" font="8"><a href="e57.full.html#30">*</a></text>
<text top="1022" left="569" width="11" height="9" font="7">IIb</text>
<text top="1022" left="669" width="6" height="9" font="7">C</text>
<text top="1022" left="757" width="18" height="9" font="7">N/A</text>
<text top="1070" left="64" width="216" height="8" font="18">*Particularly in the setting of progressive LV enlargement.</text>
<text top="1082" left="72" width="728" height="8" font="18">AR indicates aortic regurgitation; AVR, aortic valve replacement; COR, Class of Recommendation; LOE, Level of Evidence; LV, left ventricular; LVEDD, left ventricular end-diastolic dimension; LVEF, left</text>
<text top="1094" left="72" width="373" height="8" font="18">ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; and N/A, not applicable.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e86</text>
</page>
<page number="31" position="absolute" top="0" left="0" height="1160" width="864">
<text top="104" left="79" width="114" height="15" font="5">Supporting References:</text>
<text top="103" left="195" width="43" height="15" font="6"><a href="e57.full.html#101">(31,211</a></text>
<text top="99" left="237" width="177" height="19" font="6"><a href="e57.full.html#101">–221,229,230,240,241,248,249)</a></text>
<text top="121" left="79" width="18" height="15" font="5">See</text>
<text top="121" left="103" width="166" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 12</a></text>
<text top="121" left="274" width="140" height="15" font="5">for more information on</text>
<text top="139" left="64" width="168" height="15" font="5">outcome after surgery for AR.</text>
<text top="166" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="181" left="63" width="351" height="10" font="21">2. AVR is indicated for asymptomatic patients with chronic severe</text>
<text top="197" left="81" width="197" height="10" font="21">AR and LV systolic dysfunction (LVEF</text>
<text top="194" left="282" width="132" height="16" font="21">&lt;50%) at rest (stage C2)</text>
<text top="214" left="81" width="313" height="10" font="21">if no other cause for systolic dysfunction is identi</text>
<text top="211" left="395" width="19" height="16" font="21">ﬁed</text>
<text top="230" left="81" width="104" height="10" font="22"><a href="e57.full.html#105">(211,229,240,241)</a></text>
<text top="230" left="186" width="121" height="12" font="21"><a href="e57.full.html#105">. </a>(Level of Evidence: B)</text>
<text top="254" left="79" width="335" height="15" font="5">After AVR, LV systolic function is an important</text>
<text top="272" left="64" width="350" height="15" font="5">determinant of survival and functional status for chronic</text>
<text top="290" left="64" width="350" height="15" font="5">severe AR. Optimal outcomes are obtained when surgery is</text>
<text top="308" left="64" width="350" height="15" font="5">performed before LVEF decreases below 50%. However,</text>
<text top="326" left="64" width="350" height="15" font="5">among patients with LV systolic dysfunction, LV function</text>
<text top="344" left="64" width="350" height="15" font="5">will improve in many after surgery, especially those with</text>
<text top="362" left="64" width="350" height="15" font="5">minimal or no symptoms, mild versus severe LV systolic</text>
<text top="380" left="64" width="350" height="15" font="5">dysfunction, and a brief duration of LV dysfunction. A</text>
<text top="398" left="64" width="350" height="15" font="5">series of 37 patients with severe AR who underwent AVR</text>
<text top="416" left="64" width="349" height="15" font="5">were studied, all of whom had preoperative LV dysfunction</text>
<text top="434" left="64" width="350" height="15" font="5">but preserved exercise capacity (including 8 asymptomatic</text>
<text top="452" left="64" width="350" height="15" font="5">patients). In the 10 patients in whom LV dysfunction had</text>
<text top="470" left="64" width="59" height="15" font="5">developed</text>
<text top="466" left="128" width="285" height="19" font="5">&lt;14 months preoperatively, there was a greater</text>
<text top="488" left="64" width="350" height="15" font="5">improvement in LV systolic function and regression of LV</text>
<text top="506" left="64" width="350" height="15" font="5">dilatation compared with those patients who had a longer</text>
<text top="523" left="64" width="350" height="15" font="5">duration of LV dysfunction. Patients with preserved ex-</text>
<text top="541" left="64" width="350" height="15" font="5">ercise capacity had higher survival rates, a shorter duration</text>
<text top="559" left="64" width="350" height="15" font="5">of LV dysfunction, and a persistent improvement in LV</text>
<text top="577" left="64" width="350" height="15" font="5">size and systolic function at late postoperative studies</text>
<text top="595" left="64" width="349" height="15" font="5">at 3 to 7 years. Thus, once LV systolic dysfunction</text>
<text top="613" left="64" width="44" height="15" font="5">(LVEF</text>
<text top="610" left="114" width="300" height="19" font="5">&lt;50%) is demonstrated, results are optimized by</text>
<text top="631" left="64" width="350" height="15" font="5">referring for surgery rather than waiting for onset of</text>
<text top="649" left="64" width="257" height="15" font="5">symptoms or more severe LV dysfunction.</text>
<text top="668" left="79" width="116" height="15" font="5">Supporting References:</text>
<text top="667" left="198" width="46" height="15" font="6"><a href="e57.full.html#100">(17,211</a></text>
<text top="664" left="244" width="170" height="19" font="6"><a href="e57.full.html#100">–220,229,240–242,249,250)</a></text>
<text top="697" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="712" left="63" width="351" height="10" font="21">3. AVR is indicated for patients with severe AR (stage C or D)</text>
<text top="728" left="81" width="332" height="12" font="21">while undergoing cardiac surgery for other indications. (Level of</text>
<text top="745" left="81" width="65" height="12" font="21">Evidence: C)</text>
<text top="769" left="79" width="335" height="15" font="5">Patients with chronic severe AR should undergo AVR if</text>
<text top="787" left="64" width="350" height="15" font="5">they are referred for other forms of cardiac surgery, such as</text>
<text top="805" left="64" width="350" height="15" font="5">CABG, mitral valve surgery, or replacement of the</text>
<text top="823" left="64" width="350" height="15" font="5">ascending aorta. This will prevent both the hemodynamic</text>
<text top="841" left="64" width="350" height="15" font="5">consequences of persistent AR during the perioperative</text>
<text top="859" left="64" width="350" height="15" font="5">period and the possible need for a second cardiac operation</text>
<text top="877" left="64" width="110" height="15" font="5">in the near future.</text>
<text top="910" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="925" left="63" width="351" height="10" font="21">1. AVR is reasonable for asymptomatic patients with severe AR</text>
<text top="942" left="81" width="197" height="10" font="21">with normal LV systolic function (LVEF</text>
<text top="938" left="282" width="132" height="16" font="21">‡50%) but with severe LV</text>
<text top="958" left="81" width="80" height="10" font="21">dilation (LVESD</text>
<text top="955" left="165" width="202" height="16" font="21">&gt;50 mm or indexed LVESD &gt;25 mm/m</text>
<text top="955" left="367" width="5" height="7" font="25">2</text>
<text top="958" left="372" width="42" height="10" font="21">) (stage</text>
<text top="974" left="81" width="19" height="10" font="21">C2)</text>
<text top="974" left="104" width="78" height="10" font="22"><a href="e57.full.html#105">(225,242,243)</a></text>
<text top="974" left="183" width="119" height="12" font="21"><a href="e57.full.html#105">. </a>(Level of Evidence: B)</text>
<text top="999" left="79" width="247" height="15" font="5">LVESD in patients with chronic AR re</text>
<text top="995" left="326" width="88" height="19" font="5">ﬂects both the</text>
<text top="1017" left="64" width="350" height="15" font="5">severity of the LV volume overload and the degree of LV</text>
<text top="1035" left="64" width="350" height="15" font="5">systolic shortening. An elevated end-systolic dimension</text>
<text top="1052" left="64" width="50" height="15" font="5">often re</text>
<text top="1049" left="114" width="300" height="19" font="5">ﬂects LV systolic dysfunction with a depressed</text>
<text top="1070" left="64" width="350" height="15" font="5">LVEF. If LVEF is normal, an increased LVESD indicates</text>
<text top="1088" left="64" width="41" height="15" font="5">a signi</text>
<text top="1085" left="105" width="308" height="19" font="5">ﬁcant degree of LV remodeling and is associated</text>
<text top="103" left="450" width="350" height="15" font="5">with subsequent development of symptoms and/or LV</text>
<text top="121" left="450" width="350" height="15" font="5">systolic dysfunction. In a series of 104 initially asymp-</text>
<text top="139" left="450" width="350" height="15" font="5">tomatic patients with normal LV systolic function followed</text>
<text top="157" left="450" width="202" height="15" font="5">for a mean of 8 years, an LVESD</text>
<text top="153" left="656" width="144" height="19" font="5">&gt;50 mm was associated</text>
<text top="175" left="450" width="350" height="15" font="5">with a risk of death, symptoms, and/or LV dysfunction of</text>
<text top="192" left="450" width="350" height="15" font="5">19% per year. In a second study of 101 similar patients</text>
<text top="210" left="450" width="350" height="15" font="5">followed for a mean of 5 years, this risk was 7% per year.</text>
<text top="228" left="450" width="350" height="15" font="5">In a third study of 75 similar patients followed for a mean</text>
<text top="246" left="450" width="350" height="15" font="5">of 10 years, the risk was 7.6% per year. Among patients</text>
<text top="264" left="450" width="350" height="15" font="5">undergoing AVR, a smaller LVESD is associated with</text>
<text top="282" left="450" width="350" height="15" font="5">both better survival and improvement in LV systolic</text>
<text top="300" left="450" width="350" height="15" font="5">function after surgery. Most studies used unadjusted LV</text>
<text top="318" left="450" width="350" height="15" font="5">dimension, with more recent data suggesting that indexing</text>
<text top="336" left="450" width="350" height="15" font="5">for body size may be appropriate, particularly in women or</text>
<text top="354" left="450" width="350" height="15" font="5">small patients. A study of 246 patients that adjusted end-</text>
<text top="372" left="450" width="350" height="15" font="5">systolic dimension for body size suggested that an end-</text>
<text top="390" left="450" width="110" height="15" font="5">systolic dimension</text>
<text top="386" left="566" width="73" height="19" font="5">25 mm/m</text>
<text top="387" left="639" width="6" height="10" font="14">2</text>
<text top="390" left="650" width="150" height="15" font="5">is associated with a poor</text>
<text top="408" left="450" width="350" height="15" font="5">outcome in asymptomatic patients. This has been con-</text>
<text top="422" left="450" width="350" height="19" font="5">ﬁrmed by a subsequent study of 294 asymptomatic patients</text>
<text top="443" left="450" width="218" height="15" font="5">in which an end-systolic dimension</text>
<text top="440" left="673" width="73" height="19" font="5">&gt;24 mm/m</text>
<text top="440" left="747" width="6" height="10" font="14">2</text>
<text top="443" left="758" width="42" height="15" font="5">was an</text>
<text top="461" left="450" width="350" height="15" font="5">independent predictor of LV systolic dysfunction, symp-</text>
<text top="479" left="450" width="350" height="15" font="5">toms, or death, and an earlier study of 32 patients in which</text>
<text top="497" left="450" width="163" height="15" font="5">an end-systolic dimension</text>
<text top="494" left="621" width="76" height="19" font="5">&gt;26 mm/m</text>
<text top="494" left="697" width="6" height="10" font="14">2</text>
<text top="497" left="711" width="89" height="15" font="5">was associated</text>
<text top="515" left="450" width="350" height="15" font="5">with persistent LV dilation after AVR. Other studies have</text>
<text top="533" left="450" width="350" height="15" font="5">suggested that end-systolic volume index is a more sensi-</text>
<text top="551" left="450" width="350" height="15" font="5">tive predictor of cardiac events than end-systolic dimension</text>
<text top="569" left="450" width="350" height="15" font="5">in asymptomatic patients, but values of end-systolic volume</text>
<text top="587" left="450" width="350" height="15" font="5">index identifying high-risk patients have varied between</text>
<text top="605" left="450" width="59" height="15" font="5">35 mL/m</text>
<text top="602" left="509" width="6" height="10" font="14">2</text>
<text top="605" left="520" width="87" height="15" font="5">and 45 mL/m</text>
<text top="602" left="607" width="6" height="10" font="14">2</text>
<text top="605" left="618" width="181" height="15" font="5">in 2 studies. Thus, more data</text>
<text top="623" left="450" width="350" height="15" font="5">are needed to determine threshold values of end-systolic</text>
<text top="641" left="450" width="350" height="15" font="5">volume index with which to make recommendations for</text>
<text top="659" left="450" width="202" height="15" font="5">surgery in asymptomatic patients.</text>
<text top="677" left="465" width="131" height="15" font="5">Supporting References:</text>
<text top="677" left="604" width="162" height="15" font="6"><a href="e57.full.html#100">(17,31,32,196,197,199,203</a></text>
<text top="673" left="766" width="34" height="19" font="6"><a href="e57.full.html#100">–205,</a></text>
<text top="695" left="450" width="49" height="15" font="6"><a href="e57.full.html#100">208,212</a></text>
<text top="691" left="499" width="196" height="19" font="6"><a href="e57.full.html#100">–216,218,242,243,249,251–254)</a></text>
<text top="713" left="465" width="18" height="15" font="5">See</text>
<text top="713" left="488" width="166" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 12</a></text>
<text top="713" left="659" width="140" height="15" font="5">for more information on</text>
<text top="731" left="450" width="180" height="15" font="5">AVR in asymptomatic patients.</text>
<text top="758" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="773" left="449" width="351" height="10" font="21">2. AVR is reasonable in patients with moderate AR (stage B) while</text>
<text top="789" left="467" width="333" height="10" font="21">undergoing surgery on the ascending aorta, CABG, or mitral</text>
<text top="805" left="467" width="190" height="12" font="21">valve surgery. (Level of Evidence: C)</text>
<text top="830" left="465" width="335" height="15" font="5">Because of the likelihood of progression of AR and the</text>
<text top="848" left="450" width="350" height="15" font="5">need for future AVR in patients with moderate AR, it is</text>
<text top="866" left="450" width="350" height="15" font="5">reasonable to replace the aortic valve in patients who have</text>
<text top="884" left="450" width="205" height="15" font="5">evidence of primary aortic valve lea</text>
<text top="880" left="655" width="144" height="19" font="5">ﬂet disease or signiﬁcant</text>
<text top="902" left="450" width="350" height="15" font="5">aortic dilation if they are referred for other forms of cardiac</text>
<text top="919" left="450" width="350" height="15" font="5">surgery, such as CABG, mitral valve surgery, or replace-</text>
<text top="937" left="450" width="173" height="15" font="5">ment of the ascending aorta.</text>
<text top="965" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="980" left="449" width="351" height="10" font="21">1. AVR may be considered for asymptomatic patients with severe</text>
<text top="996" left="467" width="261" height="10" font="21">AR and normal LV systolic function at rest (LVEF</text>
<text top="993" left="733" width="67" height="16" font="21">‡50%, stage</text>
<text top="1012" left="467" width="332" height="10" font="21">C1) but with progressive severe LV dilatation (LV end-diastolic</text>
<text top="1029" left="467" width="53" height="10" font="21">dimension</text>
<text top="1026" left="523" width="276" height="16" font="21">&gt;65 mm) if surgical risk is low. (Level of Evidence: C)</text>
<text top="1053" left="465" width="335" height="15" font="5">LV end-diastolic dimension is indicative of the severity</text>
<text top="1071" left="450" width="350" height="15" font="5">of LV volume overload in patients with chronic AR. It is</text>
<text top="1089" left="450" width="28" height="15" font="5">signi</text>
<text top="1086" left="478" width="321" height="19" font="5">ﬁcantly associated with development of symptoms</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e87</text>
</page>
<page number="32" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">and/or LV systolic dysfunction in asymptomatic patients</text>
<text top="121" left="64" width="350" height="15" font="5">but less so than LVESD. Similarly, end-diastolic volume</text>
<text top="139" left="64" width="350" height="15" font="5">index is less predictive than end-systolic volume index in</text>
<text top="157" left="64" width="350" height="15" font="5">asymptomatic patients. However, especially in young pa-</text>
<text top="175" left="64" width="349" height="15" font="5">tients with severe AR, progressive increases in end-</text>
<text top="192" left="64" width="350" height="15" font="5">diastolic dimension are associated with a subsequent need</text>
<text top="210" left="64" width="350" height="15" font="5">for surgery. In a series of 104 initially asymptomatic pa-</text>
<text top="228" left="64" width="350" height="15" font="5">tients with normal LV systolic function followed for a</text>
<text top="246" left="64" width="293" height="15" font="5">mean of 8 years, an LV end-diastolic dimension of</text>
<text top="243" left="361" width="53" height="19" font="5">70 mm</text>
<text top="264" left="64" width="350" height="15" font="5">was associated with a risk of death, symptoms, and/or</text>
<text top="282" left="64" width="350" height="15" font="5">LV dysfunction of 10% per year. In a second study of 101</text>
<text top="300" left="64" width="350" height="15" font="5">patients followed for a mean of 5 years, this risk was 6.3%</text>
<text top="318" left="64" width="350" height="15" font="5">per year; in a third study of 75 patients followed for a mean</text>
<text top="336" left="64" width="350" height="15" font="5">of 10 years, the risk was 5.8% per year. Marked increases</text>
<text top="354" left="64" width="166" height="15" font="5">in end-diastolic dimension (</text>
<text top="351" left="231" width="183" height="19" font="5">80 mm) have been associated</text>
<text top="372" left="64" width="350" height="15" font="5">with sudden death. The writing committee thought that</text>
<text top="390" left="64" width="350" height="15" font="5">AVR may be considered for the asymptomatic patient with</text>
<text top="408" left="64" width="350" height="15" font="5">severe AR, normal LV systolic function, and severe LV</text>
<text top="426" left="64" width="236" height="15" font="5">dilatation (LV end-diastolic dimension</text>
<text top="422" left="305" width="109" height="19" font="5">&gt;65 mm) if there</text>
<text top="444" left="64" width="350" height="15" font="5">is a low surgical risk and particularly if there is evidence</text>
<text top="461" left="64" width="158" height="15" font="5">of progressive LV dilation.</text>
<text top="479" left="79" width="335" height="15" font="5">New markers of severity of AR and its resultant LV</text>
<text top="497" left="64" width="350" height="15" font="5">volume overload are under investigation. These include</text>
<text top="515" left="64" width="350" height="15" font="5">measures of regurgitant fraction, regurgitant volume, and</text>
<text top="533" left="64" width="145" height="15" font="5">effective regurgitant ori</text>
<text top="530" left="209" width="205" height="19" font="5">ﬁce area; LV volume assessment</text>
<text top="551" left="64" width="350" height="15" font="5">with 3D echocardiography; noninvasive measures of LV</text>
<text top="569" left="64" width="350" height="15" font="5">end-systolic stress and systolic and diastolic strain rates;</text>
<text top="587" left="64" width="350" height="15" font="5">and biomarkers such as brain natriuretic peptide. Further</text>
<text top="605" left="64" width="350" height="15" font="5">experience with these new markers pertaining to patient</text>
<text top="623" left="64" width="169" height="15" font="5">outcomes is necessary before</text>
<text top="620" left="237" width="177" height="19" font="5">ﬁrm recommendations can be</text>
<text top="641" left="64" width="58" height="15" font="5">proposed.</text>
<text top="660" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="659" left="212" width="98" height="15" font="6"><a href="e57.full.html#101">(32,196,197,203</a></text>
<text top="655" left="310" width="35" height="19" font="6"><a href="e57.full.html#101">–207)</a></text>
<text top="697" left="64" width="315" height="14" font="17">5. Bicuspid Aortic Valve and Aortopathy</text>
<text top="739" left="65" width="349" height="15" font="5">Patients with a bicuspid aortic valve may also have an</text>
<text top="757" left="64" width="350" height="15" font="5">associated aortopathy consisting of aortic dilation, coarc-</text>
<text top="774" left="64" width="193" height="15" font="5">tation, or even aortic dissection.</text>
<text top="813" left="64" width="177" height="12" font="19">5.1. Bicuspid Aortic Valve</text>
<text top="840" left="64" width="206" height="15" font="5">5.1.1. Diagnosis and Follow-Up</text>
<text top="870" left="64" width="332" height="11" font="7">5.1.1.1. DIAGNOSTIC TESTINGdINITIAL DIAGNOSIS: RECOMMENDATIONS</text>
<text top="893" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="908" left="64" width="350" height="10" font="21">1. An initial TTE is indicated in patients with a known bicuspid</text>
<text top="924" left="82" width="332" height="10" font="21">aortic valve to evaluate valve morphology, to measure the</text>
<text top="941" left="82" width="332" height="10" font="21">severity of AS and AR, and to assess the shape and diameter of</text>
<text top="957" left="82" width="332" height="10" font="21">the aortic sinuses and ascending aorta for prediction of clinical</text>
<text top="974" left="82" width="266" height="10" font="21">outcome and to determine timing of intervention</text>
<text top="974" left="353" width="26" height="10" font="22"><a href="e57.full.html#106">(255</a></text>
<text top="971" left="379" width="32" height="16" font="22"><a href="e57.full.html#106">–260)</a></text>
<text top="974" left="410" width="3" height="10" font="21">.</text>
<text top="990" left="82" width="113" height="12" font="21">(Level of Evidence: B)</text>
<text top="1014" left="79" width="335" height="15" font="5">Most patients with a bicuspid aortic valve will develop AS</text>
<text top="1032" left="64" width="350" height="15" font="5">or AR over their lifetime. Standard echocardiographic ap-</text>
<text top="1050" left="64" width="350" height="15" font="5">proaches for measurement of stenosis and regurgitant</text>
<text top="1068" left="64" width="350" height="15" font="5">severity are key to optimal patient management as detailed in</text>
<text top="1086" left="64" width="232" height="15" font="5">the recommendations for AS and AR (</text>
<text top="1086" left="296" width="61" height="15" font="6"><a href="e57.full.html#15">Sections 3</a></text>
<text top="1086" left="360" width="22" height="15" font="5">and</text>
<text top="1086" left="386" width="7" height="15" font="6"><a href="e57.full.html#32">4</a></text>
<text top="1086" left="394" width="9" height="15" font="5"><a href="e57.full.html#32">).</a></text>
<text top="103" left="465" width="335" height="15" font="5">Bicuspid aortic valves are frequently associated with</text>
<text top="121" left="450" width="350" height="15" font="5">aortic dilation either at the level of the sinuses of Valsalva</text>
<text top="139" left="450" width="350" height="15" font="5">or, more frequently, in the ascending aorta. In some pa-</text>
<text top="157" left="450" width="350" height="15" font="5">tients, severe aneurysmal aortic dilation may develop. The</text>
<text top="175" left="450" width="350" height="15" font="5">incidence of aortic dilation is higher in patients with fusion</text>
<text top="192" left="450" width="350" height="15" font="5">of the right and noncoronary cusps than the more common</text>
<text top="210" left="450" width="350" height="15" font="5">phenotype of fusion of the right and left coronary cusps.</text>
<text top="228" left="450" width="350" height="15" font="5">In a series of 191 patients with bicuspid aortic valves un-</text>
<text top="246" left="450" width="350" height="15" font="5">dergoing echocardiography, those with fusion of the right</text>
<text top="264" left="450" width="350" height="15" font="5">or left coronary cusp and the noncoronary cusp had a</text>
<text top="282" left="450" width="350" height="15" font="5">greater prevalence of aortic dilation than those with the</text>
<text top="300" left="450" width="350" height="15" font="5">fusion of the right and left coronary cusps (68% versus</text>
<text top="318" left="450" width="122" height="15" font="5">40%). This was con</text>
<text top="315" left="572" width="227" height="19" font="5">ﬁrmed in a subsequent report of 167</text>
<text top="336" left="450" width="350" height="15" font="5">patients with bicuspid aortic valves studied with CT and</text>
<text top="354" left="450" width="350" height="15" font="5">echocardiography. Patients with fusion involving the</text>
<text top="372" left="450" width="350" height="15" font="5">noncoronary cusp are also more likely to have dilation of</text>
<text top="390" left="450" width="350" height="15" font="5">the ascending aorta, rather than the sinuses, which often</text>
<text top="408" left="450" width="183" height="15" font="5">extends to the transverse arch.</text>
<text top="426" left="465" width="335" height="15" font="5">In nearly all patients with a bicuspid aortic valve, TTE</text>
<text top="444" left="450" width="350" height="15" font="5">provides good quality images of the aortic sinuses with</text>
<text top="462" left="450" width="350" height="15" font="5">accurate diameter measurements. Further cephalad seg-</text>
<text top="479" left="450" width="350" height="15" font="5">ments of the ascending aorta can be imaged in many pa-</text>
<text top="497" left="450" width="350" height="15" font="5">tients by moving the transducer up 1 or 2 interspaces to</text>
<text top="515" left="450" width="350" height="15" font="5">view the arch from a suprasternal notch approach. The</text>
<text top="533" left="450" width="350" height="15" font="5">echocardiographic report should include aortic measure-</text>
<text top="551" left="450" width="350" height="15" font="5">ments at the aortic annulus, sinuses, sinotubular junction,</text>
<text top="569" left="450" width="350" height="15" font="5">and mid-ascending aorta, along with an indicator of the</text>
<text top="587" left="450" width="350" height="15" font="5">quality and completeness of aortic imaging in each patient</text>
<text top="605" left="450" width="350" height="15" font="5">with a bicuspid aortic valve. Doppler interrogation of the</text>
<text top="623" left="450" width="350" height="15" font="5">proximal descending aorta allows evaluation for aortic</text>
<text top="641" left="450" width="350" height="15" font="5">coarctation, which is associated with the presence of a</text>
<text top="659" left="450" width="125" height="15" font="5">bicuspid aortic valve.</text>
<text top="677" left="465" width="335" height="15" font="5">In 20% to 30% of patients with bicuspid valves, other</text>
<text top="695" left="450" width="350" height="15" font="5">family members also have bicuspid valve disease and/or an</text>
<text top="713" left="450" width="177" height="15" font="5">associated aortopathy. A speci</text>
<text top="709" left="627" width="173" height="19" font="5">ﬁc genetic cause has not been</text>
<text top="731" left="450" width="34" height="15" font="5">identi</text>
<text top="727" left="484" width="315" height="19" font="5">ﬁed, and the patterns of inheritance are variable, so it</text>
<text top="749" left="450" width="350" height="15" font="5">is important to take a family history and inform patients</text>
<text top="766" left="450" width="350" height="15" font="5">that other family members may be affected. Imaging of</text>
<text top="781" left="450" width="350" height="19" font="5">ﬁrst-degree relatives is clearly appropriate if the patient has</text>
<text top="802" left="450" width="350" height="15" font="5">an associated aortopathy or a family history of VHD or</text>
<text top="820" left="450" width="350" height="15" font="5">aortopathy. Many valve experts also recommend screening</text>
<text top="838" left="450" width="14" height="15" font="5">all</text>
<text top="835" left="471" width="328" height="19" font="5">ﬁrst-degree relatives of patients with bicuspid aortic</text>
<text top="856" left="450" width="350" height="15" font="5">valve, although we do not yet have data addressing the</text>
<text top="874" left="450" width="350" height="15" font="5">possible impact of screening on outcomes or the cost-</text>
<text top="892" left="450" width="180" height="15" font="5">effectiveness of this approach.</text>
<text top="911" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="910" left="597" width="27" height="15" font="6"><a href="e57.full.html#106">(255</a></text>
<text top="907" left="625" width="35" height="19" font="6"><a href="e57.full.html#106">–261)</a></text>
<text top="945" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="960" left="449" width="351" height="10" font="21">2. Aortic magnetic resonance angiography or CT angiography is</text>
<text top="977" left="467" width="332" height="10" font="21">indicated in patients with a bicuspid aortic valve when</text>
<text top="993" left="467" width="332" height="10" font="21">morphology of the aortic sinuses, sinotubular junction, or</text>
<text top="1009" left="467" width="332" height="10" font="21">ascending aorta cannot be assessed accurately or fully by</text>
<text top="1026" left="467" width="213" height="12" font="21">echocardiography. (Level of Evidence: C)</text>
<text top="1050" left="465" width="335" height="15" font="5">TTE can provide accurate assessment of the presence</text>
<text top="1068" left="450" width="350" height="15" font="5">and severity of aortic dilation in most patients. However, in</text>
<text top="1086" left="450" width="350" height="15" font="5">some patients, only the aortic sinuses can be visualized,</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e88</text>
</page>
<page number="33" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">because the ascending aorta is obscured by intervening lung</text>
<text top="121" left="64" width="350" height="15" font="5">tissue. When echocardiographic images do not provide</text>
<text top="139" left="64" width="350" height="15" font="5">adequate images of the ascending aorta to a distance</text>
<text top="153" left="64" width="350" height="19" font="5">4.0 cm from the valve plane, additional imaging is</text>
<text top="175" left="64" width="350" height="15" font="5">needed. TEE may be considered but requires sedation</text>
<text top="192" left="64" width="350" height="15" font="5">and still may miss segments of the mid-ascending aorta.</text>
<text top="210" left="64" width="350" height="15" font="5">Magnetic resonance angiography or chest CT angiography</text>
<text top="228" left="64" width="350" height="15" font="5">provide accurate diameter measurements when aligned</text>
<text top="246" left="64" width="350" height="15" font="5">perpendicular to the long axis of the aorta. Advantages of</text>
<text top="264" left="64" width="350" height="15" font="5">magnetic resonance angiography and CT angiography</text>
<text top="282" left="64" width="350" height="15" font="5">compared with TTE include higher spatial (but lower</text>
<text top="300" left="64" width="350" height="15" font="5">temporal) resolution and the ability to display a 3D</text>
<text top="318" left="64" width="350" height="15" font="5">reconstruction of the entire length of the aorta. Magnetic</text>
<text top="336" left="64" width="350" height="15" font="5">resonance angiography and CT angiography aortic di-</text>
<text top="354" left="64" width="349" height="15" font="5">ameters typically are 1 mm to 2 mm larger than echocar-</text>
<text top="372" left="64" width="350" height="15" font="5">diographic measurements because of inclusion of the aortic</text>
<text top="390" left="64" width="350" height="15" font="5">wall in the measurement and because echocardiographic</text>
<text top="408" left="64" width="350" height="15" font="5">measurements are made at end-diastole, whereas magnetic</text>
<text top="426" left="64" width="350" height="15" font="5">resonance angiography or CT angiography measurements</text>
<text top="444" left="64" width="350" height="15" font="5">may represent an average value. Magnetic resonance an-</text>
<text top="461" left="64" width="350" height="15" font="5">giography imaging is preferred over CT angiography im-</text>
<text top="479" left="64" width="350" height="15" font="5">aging, when possible, because of the absence of ionizing</text>
<text top="497" left="64" width="350" height="15" font="5">radiation exposure in patients who likely will have multiple</text>
<text top="515" left="64" width="210" height="15" font="5">imaging studies over their lifetime.</text>
<text top="534" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="533" left="212" width="27" height="15" font="6"><a href="e57.full.html#106">(261</a></text>
<text top="530" left="239" width="35" height="19" font="6"><a href="e57.full.html#106">–263)</a></text>
<text top="568" left="64" width="337" height="11" font="7">5.1.1.2. DIAGNOSTIC TESTINGdROUTINE FOLLOW-UP: RECOMMENDATION</text>
<text top="591" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="606" left="64" width="350" height="10" font="21">1. Serial evaluation of the size and morphology of the aortic si-</text>
<text top="623" left="82" width="332" height="10" font="21">nuses and ascending aorta by echocardiography, CMR, or CT</text>
<text top="639" left="82" width="332" height="10" font="21">angiography is recommended in patients with a bicuspid aortic</text>
<text top="656" left="82" width="332" height="10" font="21">valve and an aortic diameter greater than 4.0 cm, with the</text>
<text top="672" left="82" width="332" height="10" font="21">examination interval determined by the degree and rate of</text>
<text top="689" left="82" width="332" height="10" font="21">progression of aortic dilation and by family history. In patients</text>
<text top="705" left="82" width="332" height="10" font="21">with an aortic diameter greater than 4.5 cm, this evaluation</text>
<text top="721" left="82" width="275" height="12" font="21">should be performed annually. (Level of Evidence: C)</text>
<text top="743" left="79" width="335" height="15" font="5">Patients with bicuspid aortic valves who have docu-</text>
<text top="761" left="64" width="350" height="15" font="5">mented dilation of the sinuses of Valsalva or ascending</text>
<text top="779" left="64" width="350" height="15" font="5">aorta should have serial assessment of aortic morphology</text>
<text top="796" left="64" width="350" height="15" font="5">because the aortopathy may progress with time. In a se-</text>
<text top="814" left="64" width="350" height="15" font="5">ries of 68 patients with bicuspid aortic valves, the mean</text>
<text top="832" left="64" width="350" height="15" font="5">rate of diameter progression was 0.5 mm per year at the</text>
<text top="850" left="64" width="350" height="15" font="5">sinuses of Valsalva (95% CI: 0.3 to 0.7), 0.5 mm per year</text>
<text top="868" left="64" width="350" height="15" font="5">at the sinotubular junction (95% CI: 0.3 to 0.7), and 0.9</text>
<text top="886" left="64" width="350" height="15" font="5">mm per year at the proximal ascending aorta (95% CI:</text>
<text top="904" left="64" width="350" height="15" font="5">0.6 to 1.2). Others have reported mean rates of increase</text>
<text top="922" left="64" width="350" height="15" font="5">of up to 2 mm per year. Aortic imaging at least annually</text>
<text top="940" left="64" width="350" height="15" font="5">is prudent in patients with a bicuspid aortic valve and</text>
<text top="958" left="64" width="29" height="15" font="5">signi</text>
<text top="955" left="93" width="321" height="19" font="5">ﬁcant aortic dilation (&gt;4.5 cm), a rapid rate of</text>
<text top="976" left="64" width="350" height="15" font="5">change in aortic diameter, and in those with a family</text>
<text top="994" left="64" width="350" height="15" font="5">history of aortic dissection. In patients with milder</text>
<text top="1012" left="64" width="350" height="15" font="5">dilation that shows no change on sequential studies and a</text>
<text top="1030" left="64" width="350" height="15" font="5">negative family history, a longer interval between imaging</text>
<text top="1048" left="64" width="135" height="15" font="5">studies is appropriate.</text>
<text top="1066" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="1066" left="212" width="27" height="15" font="6"><a href="e57.full.html#106">(264</a></text>
<text top="1062" left="239" width="35" height="19" font="6"><a href="e57.full.html#106">–266)</a></text>
<text top="103" left="450" width="151" height="15" font="5">5.1.2. Medical Therapy</text>
<text top="128" left="451" width="349" height="15" font="5">There are no proven drug therapies that have been shown</text>
<text top="146" left="450" width="350" height="15" font="5">to reduce the rate of progression of aortic dilation in pa-</text>
<text top="164" left="450" width="350" height="15" font="5">tients with aortopathy associated with bicuspid aortic valve.</text>
<text top="182" left="450" width="350" height="15" font="5">In patients with hypertension, control of BP with any</text>
<text top="200" left="450" width="350" height="15" font="5">effective antihypertensive medication is warranted. Beta</text>
<text top="218" left="450" width="350" height="15" font="5">blockers and ARBs have conceptual advantages to reduce</text>
<text top="236" left="450" width="350" height="15" font="5">rate of progression but have not been shown to be bene-</text>
<text top="250" left="450" width="141" height="19" font="5">ﬁcial in clinical studies.</text>
<text top="286" left="450" width="248" height="15" font="5">5.1.3. Intervention: Recommendations</text>
<text top="313" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="328" left="449" width="350" height="10" font="21">1. Operative intervention to repair the aortic sinuses or replace the</text>
<text top="345" left="467" width="332" height="10" font="21">ascending aorta is indicated in patients with a bicuspid aortic</text>
<text top="361" left="467" width="332" height="10" font="21">valve if the diameter of the aortic sinuses or ascending aorta is</text>
<text top="378" left="467" width="107" height="10" font="21">greater than 5.5 cm</text>
<text top="378" left="578" width="80" height="10" font="22"><a href="e57.full.html#103">(113,267,268)</a></text>
<text top="378" left="658" width="120" height="12" font="21"><a href="e57.full.html#103">. </a>(Level of Evidence: B)</text>
<text top="402" left="465" width="335" height="15" font="5">In 2 large long-term retrospective cohort studies of pa-</text>
<text top="420" left="450" width="350" height="15" font="5">tients with bicuspid aortic valves, the incidence of aortic</text>
<text top="438" left="450" width="350" height="15" font="5">dissection was very low. In a study of 642 patients followed</text>
<text top="456" left="450" width="350" height="15" font="5">for a mean of 9 years, there were 5 dissections (3 ascending</text>
<text top="474" left="450" width="350" height="15" font="5">and 2 descending). In another bicuspid aortic valve study</text>
<text top="491" left="450" width="350" height="15" font="5">of 416 patients followed for a mean of 16 years, there were</text>
<text top="509" left="450" width="350" height="15" font="5">2 dissections. In the latter report, the calculated incidence</text>
<text top="527" left="450" width="350" height="15" font="5">of dissection was higher than the age-adjusted relative risk</text>
<text top="545" left="450" width="81" height="15" font="5">of the county</text>
<text top="542" left="531" width="269" height="19" font="5">’s general population (HR: 8.4; 95% CI: 2.1</text>
<text top="563" left="450" width="60" height="15" font="5">to 33.5; p</text>
<text top="560" left="510" width="289" height="19" font="5">¼0.003) but was only 3.1 (95% CI: 0.5 to 9.5)</text>
<text top="581" left="450" width="350" height="15" font="5">cases per 10,000 patient-years. In patients with bicuspid</text>
<text top="599" left="450" width="350" height="15" font="5">aortic valves, data are limited regarding the degree of aortic</text>
<text top="617" left="450" width="350" height="15" font="5">dilation at which the risk of dissection is high enough</text>
<text top="635" left="450" width="350" height="15" font="5">to warrant operative intervention in patients who do not</text>
<text top="653" left="450" width="16" height="15" font="5">ful</text>
<text top="650" left="466" width="334" height="19" font="5">ﬁll criteria for AVR on the basis of severe AS or AR.</text>
<text top="671" left="450" width="350" height="15" font="5">Previous ACC/AHA guidelines have recommended sur-</text>
<text top="689" left="450" width="250" height="15" font="5">gery when the degree of aortic dilation is</text>
<text top="685" left="705" width="95" height="19" font="5">&gt;5.0 cm at any</text>
<text top="707" left="450" width="350" height="15" font="5">level, including sinuses of Valsalva, sinotubular junction,</text>
<text top="725" left="450" width="350" height="15" font="5">or ascending aorta. The current writing committee con-</text>
<text top="743" left="450" width="350" height="15" font="5">siders the evidence supporting these previous recommen-</text>
<text top="760" left="450" width="350" height="15" font="5">dations very limited and anecdotal and endorses a more</text>
<text top="778" left="450" width="350" height="15" font="5">individualized approach. Surgery is recommended with</text>
<text top="796" left="450" width="350" height="15" font="5">aortic dilation of 5.1 cm to 5.5 cm only if there is a family</text>
<text top="814" left="450" width="350" height="15" font="5">history of aortic dissection or rapid progression of dilation.</text>
<text top="832" left="450" width="350" height="15" font="5">In all other patients, operation is indicated if there is</text>
<text top="850" left="450" width="350" height="15" font="5">more severe dilation (5.5 cm). The writing committee also</text>
<text top="868" left="450" width="350" height="15" font="5">does not recommend the application of formulas to adjust</text>
<text top="886" left="450" width="350" height="15" font="5">the aortic diameter for body size. Furthermore, prior rec-</text>
<text top="904" left="450" width="350" height="15" font="5">ommendations were frequently ambiguous with regard</text>
<text top="922" left="450" width="350" height="15" font="5">to the level to which they apply (sinus segment versus</text>
<text top="940" left="450" width="350" height="15" font="5">tubular ascending aorta) and did not acknowledge the</text>
<text top="958" left="450" width="350" height="15" font="5">normal difference in diameter at these levels, with the sinus</text>
<text top="976" left="450" width="350" height="15" font="5">segment 0.5 cm larger in diameter than the normal</text>
<text top="994" left="450" width="350" height="15" font="5">ascending aorta. In Heart Valve Centers of Excellence,</text>
<text top="1012" left="450" width="350" height="15" font="5">valve-sparing replacement of the aortic sinuses and</text>
<text top="1030" left="450" width="350" height="15" font="5">ascending aorta yields excellent results in patients who do</text>
<text top="1047" left="450" width="309" height="15" font="5">not have severely deformed or dysfunctional valves.</text>
<text top="1066" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="1065" left="597" width="106" height="15" font="6"><a href="e57.full.html#103">(113,244,245,266</a></text>
<text top="1062" left="703" width="35" height="19" font="6"><a href="e57.full.html#103">–273)</a></text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e89</text>
</page>
<page number="34" position="absolute" top="0" left="0" height="1160" width="864">
<text top="106" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="121" left="63" width="351" height="10" font="21">1. Operative intervention to repair the aortic sinuses or replace the</text>
<text top="137" left="81" width="333" height="10" font="21">ascending aorta is reasonable in patients with bicuspid aortic</text>
<text top="154" left="81" width="333" height="10" font="21">valves if the diameter of the aortic sinuses or ascending aorta is</text>
<text top="170" left="81" width="333" height="10" font="21">greater than 5.0 cm and a risk factor for dissection is present</text>
<text top="187" left="81" width="332" height="10" font="21">(family history of aortic dissection or if the rate of increase in</text>
<text top="203" left="81" width="59" height="10" font="21">diameter is</text>
<text top="200" left="145" width="216" height="16" font="21">‡0.5 cm per year). (Level of Evidence: C)</text>
<text top="228" left="79" width="335" height="15" font="5">In patients with bicuspid aortic valves, data are limited</text>
<text top="246" left="64" width="350" height="15" font="5">regarding the degree of aortic dilation at which the risk of</text>
<text top="263" left="64" width="349" height="15" font="5">dissection is high enough to warrant operative intervention</text>
<text top="281" left="64" width="156" height="15" font="5">in patients who do not ful</text>
<text top="278" left="221" width="193" height="19" font="5">ﬁll criteria for AVR on the basis</text>
<text top="299" left="64" width="350" height="15" font="5">of severe AS or AR. In patients at higher risk of dissection</text>
<text top="317" left="64" width="350" height="15" font="5">based on family history or evidence of rapid progression of</text>
<text top="335" left="64" width="94" height="15" font="5">aortic dilation (</text>
<text top="332" left="158" width="256" height="19" font="5">0.5 cm per year), surgical intervention is</text>
<text top="353" left="64" width="232" height="15" font="5">reasonable when the aortic diameter is</text>
<text top="350" left="301" width="57" height="19" font="5">&gt;5.0 cm.</text>
<text top="372" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="371" left="212" width="53" height="15" font="6"><a href="e57.full.html#106">(266,268</a></text>
<text top="368" left="265" width="61" height="19" font="6"><a href="e57.full.html#106">–270,274)</a></text>
<text top="398" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="413" left="63" width="351" height="10" font="21">2. Replacement of the ascending aorta is reasonable in patients</text>
<text top="430" left="81" width="332" height="10" font="21">with a bicuspid aortic valve who are undergoing aortic valve</text>
<text top="446" left="81" width="196" height="10" font="21">surgery because of severe AS or AR (</text>
<text top="446" left="278" width="77" height="10" font="22"><a href="e57.full.html#19">Sections 3.2.3</a></text>
<text top="446" left="359" width="19" height="10" font="21">and</text>
<text top="446" left="381" width="28" height="10" font="22"><a href="e57.full.html#30">4.3.3</a></text>
<text top="446" left="409" width="4" height="10" font="21">)</text>
<text top="463" left="81" width="332" height="10" font="21">if the diameter of the ascending aorta is greater than 4.5 cm.</text>
<text top="479" left="81" width="113" height="12" font="21">(Level of Evidence: C)</text>
<text top="503" left="79" width="335" height="15" font="5">In patients with bicuspid aortic valves, data are limited</text>
<text top="521" left="64" width="350" height="15" font="5">regarding the degree of aortic dilation at which the risk of</text>
<text top="539" left="64" width="350" height="15" font="5">dissection is high enough to warrant replacement of the</text>
<text top="557" left="64" width="350" height="15" font="5">ascending aorta at the time of AVR. The risk of progres-</text>
<text top="575" left="64" width="350" height="15" font="5">sive aortic dilation and dissection after AVR in patients</text>
<text top="593" left="64" width="350" height="15" font="5">with bicuspid aortic valves has been the subject of several</text>
<text top="611" left="64" width="125" height="15" font="5">studies, although de</text>
<text top="607" left="189" width="225" height="19" font="5">ﬁnitive data are lacking. In patients</text>
<text top="629" left="64" width="350" height="15" font="5">undergoing AVR because of severe AS or AR, replacement</text>
<text top="647" left="64" width="350" height="15" font="5">of the ascending aorta is reasonable when the aortic</text>
<text top="665" left="64" width="67" height="15" font="5">diameter is</text>
<text top="661" left="136" width="278" height="19" font="5">&gt;4.5 cm. Replacement of the sinuses of Val-</text>
<text top="683" left="64" width="350" height="15" font="5">salva is not necessary in all cases and should be individu-</text>
<text top="701" left="64" width="350" height="15" font="5">alized based on the displacement of the coronary ostia,</text>
<text top="719" left="64" width="350" height="15" font="5">because progressive dilation of the sinus segment after</text>
<text top="736" left="64" width="271" height="15" font="5">separate valve and graft repair is uncommon.</text>
<text top="755" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="754" left="212" width="53" height="15" font="6"><a href="e57.full.html#106">(266,268</a></text>
<text top="751" left="265" width="91" height="19" font="6"><a href="e57.full.html#106">–270,275–279)</a></text>
<text top="788" left="64" width="142" height="14" font="17">6. Mitral Stenosis</text>
<text top="833" left="64" width="124" height="12" font="19">6.1. Stages of MS</text>
<text top="856" left="65" width="349" height="15" font="5">Medical and interventional approaches to the management</text>
<text top="874" left="64" width="350" height="15" font="5">of patients with valvular MS depend on accurate diagnosis</text>
<text top="892" left="64" width="287" height="15" font="5">of the cause and stage of the disease process.</text>
<text top="892" left="358" width="56" height="15" font="6"><a href="e57.full.html#35">Table 13</a></text>
<text top="910" left="64" width="350" height="15" font="5">shows the stages of mitral valve disease ranging from pa-</text>
<text top="928" left="64" width="350" height="15" font="5">tients at risk of MS (stage A) or with progressive hemo-</text>
<text top="946" left="64" width="350" height="15" font="5">dynamic obstruction (stage B) to severe asymptomatic</text>
<text top="964" left="64" width="350" height="15" font="5">(stage C) and symptomatic MS (stage D). Each of these</text>
<text top="981" left="64" width="70" height="15" font="5">stages is de</text>
<text top="978" left="134" width="279" height="19" font="5">ﬁned by valve anatomy, valve hemodynamics,</text>
<text top="999" left="64" width="350" height="15" font="5">the consequences of valve obstruction on the left atrium</text>
<text top="1017" left="64" width="350" height="15" font="5">(LA) and pulmonary circulation, and patient symptoms.</text>
<text top="1035" left="64" width="350" height="15" font="5">The anatomic features of the stages of MS are based on a</text>
<text top="1053" left="64" width="350" height="15" font="5">rheumatic etiology for the disease. There are patients who</text>
<text top="1071" left="64" width="335" height="15" font="5">have a nonrheumatic etiology of MS due to senile calci</text>
<text top="1068" left="400" width="14" height="19" font="5">ﬁc</text>
<text top="1089" left="64" width="52" height="15" font="5">disease (</text>
<text top="1089" left="116" width="69" height="15" font="6"><a href="e57.full.html#40">Section 6.3</a></text>
<text top="1089" left="185" width="207" height="15" font="5"><a href="e57.full.html#40">) </a>in whom there is a heavily calci</text>
<text top="1086" left="392" width="22" height="19" font="5">ﬁed</text>
<text top="103" left="450" width="350" height="15" font="5">mitral annulus with extension of the calcium into the</text>
<text top="121" left="450" width="16" height="15" font="5">lea</text>
<text top="117" left="466" width="333" height="19" font="5">ﬂets. Hemodynamic severity is best characterized by the</text>
<text top="139" left="450" width="350" height="15" font="5">planimetered mitral valve area and the calculated mitral</text>
<text top="157" left="450" width="336" height="15" font="5">valve area from the diastolic pressure half-time. The de</text>
<text top="153" left="785" width="14" height="19" font="5">ﬁ-</text>
<text top="175" left="450" width="54" height="15" font="5">nition of</text>
<text top="171" left="511" width="289" height="19" font="5">“severe” MS is based on the severity at which</text>
<text top="193" left="450" width="350" height="15" font="5">symptoms occur as well as the severity at which interven-</text>
<text top="210" left="450" width="350" height="15" font="5">tion will improve symptoms. Thus, a mitral valve area</text>
<text top="225" left="450" width="52" height="19" font="5">1.5 cm</text>
<text top="225" left="502" width="6" height="10" font="14">2</text>
<text top="228" left="512" width="287" height="15" font="5">is considered severe. This usually corresponds to</text>
<text top="246" left="450" width="183" height="15" font="5">a transmitral mean gradient of</text>
<text top="243" left="638" width="162" height="19" font="5">&gt;5 mm Hg to 10 mm Hg</text>
<text top="264" left="450" width="350" height="15" font="5">at a normal heart rate. However, the mean pressure</text>
<text top="282" left="450" width="293" height="15" font="5">gradient is highly dependent on the transvalvular</text>
<text top="279" left="747" width="52" height="19" font="5">ﬂow and</text>
<text top="300" left="450" width="49" height="15" font="5">diastolic</text>
<text top="297" left="503" width="297" height="19" font="5">ﬁlling period and will vary greatly with changes in</text>
<text top="318" left="450" width="350" height="15" font="5">heart rate. The diastolic pressure half-time is dependent</text>
<text top="336" left="450" width="350" height="15" font="5">not only on the degree of mitral obstruction but also the</text>
<text top="354" left="450" width="350" height="15" font="5">compliance of the left ventricle and the LA and other</text>
<text top="372" left="450" width="350" height="15" font="5">measures of mitral valve area, such as the continuity</text>
<text top="390" left="450" width="350" height="15" font="5">equation or the proximal isovelocity surface area, may be</text>
<text top="408" left="450" width="158" height="15" font="5">used if discrepancies exist.</text>
<text top="426" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="426" left="597" width="27" height="15" font="6"><a href="e57.full.html#106">(280</a></text>
<text top="422" left="625" width="35" height="19" font="6"><a href="e57.full.html#106">–286)</a></text>
<text top="471" left="450" width="131" height="12" font="19">6.2. Rheumatic MS</text>
<text top="494" left="451" width="20" height="15" font="5">See</text>
<text top="494" left="473" width="47" height="15" font="6"><a href="e57.full.html#36">Figure 3</a></text>
<text top="494" left="522" width="278" height="15" font="5">for indications for intervention for rheumatic MS.</text>
<text top="520" left="450" width="206" height="15" font="5">6.2.1. Diagnosis and Follow-Up</text>
<text top="550" left="450" width="332" height="11" font="7">6.2.1.1. DIAGNOSTIC TESTINGdINITIAL DIAGNOSIS: RECOMMENDATIONS</text>
<text top="573" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="588" left="449" width="350" height="10" font="21">1. TTE is indicated in patients with signs or symptoms of MS to</text>
<text top="605" left="467" width="332" height="10" font="21">establish the diagnosis, quantify hemodynamic severity (mean</text>
<text top="621" left="467" width="332" height="10" font="21">pressure gradient, mitral valve area, and pulmonary artery</text>
<text top="637" left="467" width="332" height="10" font="21">pressure), assess concomitant valvular lesions, and demon-</text>
<text top="654" left="467" width="332" height="10" font="21">strate valve morphology (to determine suitability for mitral</text>
<text top="670" left="467" width="94" height="10" font="21">commissurotomy)</text>
<text top="670" left="566" width="36" height="10" font="22"><a href="e57.full.html#100">(8,287</a></text>
<text top="667" left="602" width="32" height="16" font="22"><a href="e57.full.html#100">–295)</a></text>
<text top="670" left="634" width="121" height="12" font="21"><a href="e57.full.html#100">. </a>(Level of Evidence: B)</text>
<text top="695" left="465" width="335" height="15" font="5">Suspicion for MS may arise from a childhood history of</text>
<text top="712" left="450" width="283" height="15" font="5">rheumatic fever or a characteristic auscultatory</text>
<text top="709" left="739" width="60" height="19" font="5">ﬁnding of</text>
<text top="730" left="450" width="350" height="15" font="5">an opening snap after the second heart sound and subse-</text>
<text top="748" left="450" width="350" height="15" font="5">quent apical diastolic murmur, but such patients often</text>
<text top="766" left="450" width="132" height="15" font="5">present with nonspeci</text>
<text top="763" left="582" width="217" height="19" font="5">ﬁc complaints of exertional dyspnea</text>
<text top="784" left="450" width="350" height="15" font="5">with an unrevealing physical examination. In the vast</text>
<text top="802" left="450" width="350" height="15" font="5">majority of cases, TTE can elucidate the anatomy and</text>
<text top="820" left="450" width="92" height="15" font="5">functional signi</text>
<text top="817" left="542" width="258" height="19" font="5">ﬁcance of MS but must be undertaken with</text>
<text top="838" left="450" width="350" height="15" font="5">great care. Use of 2D scanning from the parasternal long-</text>
<text top="856" left="450" width="350" height="15" font="5">axis window can identify the characteristic diastolic dom-</text>
<text top="874" left="450" width="350" height="15" font="5">ing of the mitral valve, whereas short-axis scanning will</text>
<text top="892" left="450" width="350" height="15" font="5">demonstrate commissural fusion and allow planimetry of</text>
<text top="910" left="450" width="78" height="15" font="5">the mitral ori</text>
<text top="906" left="528" width="272" height="19" font="5">ﬁce. This must be done carefully to obtain the</text>
<text top="928" left="450" width="69" height="15" font="5">smallest ori</text>
<text top="924" left="519" width="280" height="19" font="5">ﬁce in space and the largest opening in time.</text>
<text top="946" left="450" width="350" height="15" font="5">3D echocardiography (either TTE or TEE) may allow</text>
<text top="964" left="450" width="350" height="15" font="5">greater accuracy but is not yet routinely used. Doppler</text>
<text top="981" left="450" width="350" height="15" font="5">hemodynamics are typically obtained from the apical</text>
<text top="999" left="450" width="7" height="15" font="5">4</text>
<text top="996" left="457" width="342" height="19" font="5">–chamber or long-axis view and should include peak and</text>
<text top="1017" left="450" width="327" height="15" font="5">mean transvalvular gradient as calculated by the simpli</text>
<text top="1014" left="777" width="22" height="19" font="5">ﬁed</text>
<text top="1035" left="450" width="350" height="15" font="5">Bernoulli equation, averaged from 3 to 5 beats in sinus</text>
<text top="1053" left="450" width="350" height="15" font="5">rhythm and 5 to 10 beats in AF. Heart rate should always</text>
<text top="1071" left="450" width="350" height="15" font="5">be included in the report because it greatly affects trans-</text>
<text top="1089" left="450" width="350" height="15" font="5">valvular gradient due to the differential impact of</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e90</text>
</page>
<page number="35" position="absolute" top="0" left="0" height="1160" width="864">
<text top="507" left="64" width="67" height="15" font="5">tachycardia</text>
<text top="507" left="148" width="15" height="15" font="5">on</text>
<text top="507" left="181" width="49" height="15" font="5">diastolic</text>
<text top="507" left="247" width="36" height="15" font="5">versus</text>
<text top="507" left="300" width="43" height="15" font="5">systolic</text>
<text top="507" left="360" width="54" height="15" font="5">duration.</text>
<text top="525" left="64" width="307" height="15" font="5">Concomitant MR should be sought and quanti</text>
<text top="522" left="372" width="42" height="19" font="5">ﬁed as</text>
<text top="543" left="64" width="305" height="15" font="5">recommended, along with other valve lesions (</text>
<text top="543" left="370" width="44" height="15" font="6"><a href="e57.full.html#42">Section</a></text>
<text top="561" left="64" width="41" height="15" font="6"><a href="e57.full.html#42">7.3.1.1</a></text>
<text top="561" left="105" width="309" height="15" font="5">). RV systolic pressure is typically estimated by</text>
<text top="579" left="64" width="350" height="15" font="5">continuous wave Doppler of TR. Mitral valve morphology</text>
<text top="597" left="64" width="350" height="15" font="5">and feasibility for percutaneous mitral balloon commis-</text>
<text top="615" left="64" width="350" height="15" font="5">surotomy or surgical commissurotomy can be assessed in</text>
<text top="633" left="64" width="350" height="15" font="5">several ways, most commonly via the Wilkins score, which</text>
<text top="650" left="64" width="274" height="15" font="5">combines valve thickening, mobility, and calci</text>
<text top="647" left="339" width="75" height="19" font="5">ﬁcation with</text>
<text top="668" left="64" width="169" height="15" font="5">subvalvular scarring in a 16</text>
<text top="665" left="233" width="181" height="19" font="5">–point scale. Characterization</text>
<text top="686" left="64" width="132" height="15" font="5">of commissural calci</text>
<text top="683" left="196" width="218" height="19" font="5">ﬁcation is also useful. Additional</text>
<text top="704" left="64" width="350" height="15" font="5">echocardiographic tools for assessment of MS include the</text>
<text top="722" left="64" width="350" height="15" font="5">mitral pressure half-time, which is inversely related to</text>
<text top="740" left="64" width="350" height="15" font="5">mitral valve area. However, the mitral pressure half-time is</text>
<text top="758" left="64" width="350" height="15" font="5">also affected by left atrial and LV compliance. Thus, other</text>
<text top="776" left="64" width="350" height="15" font="5">methods for calculation of the mitral valve area, such as the</text>
<text top="794" left="64" width="350" height="15" font="5">continuity method and proximal isovelocity surface area</text>
<text top="812" left="64" width="350" height="15" font="5">method, could be used if necessary. Left atrial dimension,</text>
<text top="830" left="64" width="350" height="15" font="5">area, and volume index should be measured, with careful</text>
<text top="848" left="64" width="350" height="15" font="5">interrogation for possible left atrial thrombus (although full</text>
<text top="866" left="64" width="350" height="15" font="5">exclusion of thrombus requires TEE). As with any echo-</text>
<text top="884" left="64" width="350" height="15" font="5">cardiogram, full characterization of global and regional LV</text>
<text top="902" left="64" width="224" height="15" font="5">and RV function should be reported.</text>
<text top="920" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="920" left="212" width="38" height="15" font="6"><a href="e57.full.html#100">(8,287</a></text>
<text top="916" left="251" width="35" height="19" font="6"><a href="e57.full.html#100">–295)</a></text>
<text top="947" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="962" left="63" width="351" height="10" font="21">2. TEE should be performed in patients considered for percuta-</text>
<text top="978" left="81" width="333" height="10" font="21">neous mitral balloon commissurotomy to assess the presence</text>
<text top="995" left="81" width="333" height="10" font="21">or absence of left atrial thrombus and to further evaluate the</text>
<text top="1011" left="81" width="77" height="10" font="21">severity of MR</text>
<text top="1011" left="163" width="50" height="10" font="22"><a href="e57.full.html#107">(288,296</a></text>
<text top="1008" left="213" width="32" height="16" font="22"><a href="e57.full.html#107">–298)</a></text>
<text top="1011" left="245" width="121" height="12" font="21"><a href="e57.full.html#107">. </a>(Level of Evidence: B)</text>
<text top="1035" left="79" width="335" height="15" font="5">TEE offers excellent visualization of the mitral valve</text>
<text top="1053" left="64" width="350" height="15" font="5">and LA and is an alternative approach to assessment of</text>
<text top="1071" left="64" width="350" height="15" font="5">MS in patients with technically limited transthoracic</text>
<text top="1089" left="64" width="81" height="15" font="5">interrogation.</text>
<text top="1089" left="163" width="114" height="15" font="5">Three-dimensional</text>
<text top="1089" left="294" width="46" height="15" font="5">datasets</text>
<text top="1089" left="358" width="25" height="15" font="5">may</text>
<text top="1089" left="400" width="14" height="15" font="5">be</text>
<text top="507" left="450" width="350" height="15" font="5">acquired, from which optimal measurements of minimal</text>
<text top="525" left="450" width="16" height="15" font="5">ori</text>
<text top="522" left="466" width="333" height="19" font="5">ﬁce area can be obtained ofﬂine. However, in the vast</text>
<text top="543" left="450" width="350" height="15" font="5">majority of patients with MS, valve morphology and lesion</text>
<text top="561" left="450" width="350" height="15" font="5">severity can be obtained with TTE. A key exception is in</text>
<text top="579" left="450" width="350" height="15" font="5">patients being considered for percutaneous mitral balloon</text>
<text top="597" left="450" width="350" height="15" font="5">commissurotomy, in whom left atrial cavity and appendage</text>
<text top="615" left="450" width="350" height="15" font="5">thrombi must be excluded. Although TTE may identify</text>
<text top="633" left="450" width="350" height="15" font="5">risk factors for thrombus formation, several studies show</text>
<text top="651" left="450" width="350" height="15" font="5">that TTE has poor sensitivity for detecting such thrombi,</text>
<text top="668" left="450" width="350" height="15" font="5">thus mandating a TEE before percutaneous mitral balloon</text>
<text top="686" left="450" width="350" height="15" font="5">commissurotomy. Although TTE is generally accurate in</text>
<text top="704" left="450" width="350" height="15" font="5">grading MR, TEE may offer additional quantitation and</text>
<text top="722" left="450" width="117" height="15" font="5">assurance that MR</text>
<text top="719" left="573" width="226" height="19" font="5">&gt;2þ is not present, which generally</text>
<text top="740" left="450" width="338" height="15" font="5">precludes percutaneous mitral balloon commissurotomy.</text>
<text top="759" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="758" left="597" width="53" height="15" font="6"><a href="e57.full.html#107">(288,296</a></text>
<text top="755" left="651" width="35" height="19" font="6"><a href="e57.full.html#107">–298)</a></text>
<text top="791" left="450" width="299" height="11" font="7">6.2.1.2. DIAGNOSTIC TESTINGdCHANGING SIGNS OR SYMPTOMS</text>
<text top="806" left="451" width="349" height="15" font="5">Patients with an established diagnosis of MS may experi-</text>
<text top="824" left="450" width="350" height="15" font="5">ence a change in symptoms from progressive narrowing of</text>
<text top="842" left="450" width="350" height="15" font="5">the mitral valve, worsening of concomitant MR or other</text>
<text top="860" left="450" width="350" height="15" font="5">valve lesions, or a change in hemodynamic state due to</text>
<text top="878" left="450" width="350" height="15" font="5">such factors as AF, fever, anemia, hyperthyroidism, or</text>
<text top="896" left="450" width="350" height="15" font="5">postoperative state. In such cases, a TTE examination</text>
<text top="914" left="450" width="350" height="15" font="5">should be repeated to quantify the mitral valve gradient</text>
<text top="931" left="450" width="350" height="15" font="5">and area, as well as other parameters that may contribute</text>
<text top="949" left="450" width="156" height="15" font="5">to a change in symptoms.</text>
<text top="983" left="450" width="243" height="11" font="7">6.2.1.3. DIAGNOSTIC TESTINGdROUTINE FOLLOW-UP</text>
<text top="997" left="451" width="349" height="15" font="5">Rheumatic MS is a slowly progressive disease, character-</text>
<text top="1015" left="450" width="350" height="15" font="5">ized by a prolonged latent phase between the initial</text>
<text top="1033" left="450" width="350" height="15" font="5">rheumatic illness and the development of valve stenosis.</text>
<text top="1051" left="450" width="350" height="15" font="5">The latent phase is an interval typically measured in de-</text>
<text top="1069" left="450" width="350" height="15" font="5">cades in the developed world but considerably shorter pe-</text>
<text top="1087" left="450" width="350" height="15" font="5">riods in the developing world, likely due to recurrent</text>
<text top="103" left="64" width="137" height="11" font="13">Table 13. Stages of MS</text>
<text top="129" left="64" width="27" height="9" font="7">Stage</text>
<text top="129" left="117" width="12" height="9" font="7">De</text>
<text top="126" left="129" width="32" height="14" font="7">ﬁnition</text>
<text top="129" left="233" width="69" height="9" font="7">Valve Anatomy</text>
<text top="129" left="404" width="99" height="9" font="7">Valve Hemodynamics</text>
<text top="129" left="573" width="136" height="9" font="7">Hemodynamic Consequences</text>
<text top="129" left="744" width="48" height="9" font="7">Symptoms</text>
<text top="145" left="67" width="7" height="9" font="7">A</text>
<text top="145" left="102" width="62" height="9" font="7">At risk of MS</text>
<text top="145" left="186" width="329" height="14" font="7"> Mild valve doming during diastole  Normal transmitral ﬂow velocity</text>
<text top="145" left="557" width="35" height="14" font="7"> None</text>
<text top="145" left="737" width="35" height="14" font="7"> None</text>
<text top="165" left="67" width="7" height="9" font="7">B</text>
<text top="165" left="102" width="73" height="9" font="7">Progressive MS</text>
<text top="164" left="186" width="149" height="14" font="7"> Rheumatic valve changes with</text>
<text top="181" left="198" width="148" height="9" font="7">commissural fusion and diastolic</text>
<text top="195" left="198" width="119" height="9" font="7">doming of the mitral valve</text>
<text top="209" left="198" width="13" height="9" font="7">lea</text>
<text top="207" left="211" width="19" height="14" font="7">ﬂets</text>
<text top="221" left="186" width="139" height="14" font="7"> Planimetered MVA &gt;1.5 cm</text>
<text top="221" left="325" width="5" height="6" font="23">2</text>
<text top="164" left="361" width="173" height="14" font="7"> Increased transmitral ﬂow velocities</text>
<text top="178" left="361" width="75" height="14" font="7"> MVA &gt;1.5 cm</text>
<text top="179" left="436" width="5" height="6" font="23">2</text>
<text top="192" left="361" width="182" height="14" font="7"> Diastolic pressure half-time &lt;150 ms</text>
<text top="164" left="557" width="162" height="14" font="7"> Mild-to-moderate LA enlargement</text>
<text top="178" left="557" width="169" height="14" font="7"> Normal pulmonary pressure at rest</text>
<text top="164" left="737" width="35" height="14" font="7"> None</text>
<text top="241" left="67" width="7" height="9" font="7">C</text>
<text top="241" left="102" width="67" height="9" font="7">Asymptomatic</text>
<text top="255" left="115" width="49" height="9" font="7">severe MS</text>
<text top="240" left="186" width="149" height="14" font="7"> Rheumatic valve changes with</text>
<text top="257" left="198" width="148" height="9" font="7">commissural fusion and diastolic</text>
<text top="271" left="198" width="119" height="9" font="7">doming of the mitral valve</text>
<text top="286" left="198" width="13" height="9" font="7">lea</text>
<text top="283" left="211" width="19" height="14" font="7">ﬂets</text>
<text top="297" left="186" width="139" height="14" font="7"> Planimetered MVA 1.5 cm</text>
<text top="297" left="325" width="5" height="6" font="23">2</text>
<text top="311" left="186" width="78" height="14" font="7"> (MVA 1.0 cm</text>
<text top="312" left="265" width="5" height="6" font="23">2</text>
<text top="314" left="273" width="40" height="9" font="7">with very</text>
<text top="328" left="198" width="50" height="9" font="7">severe MS)</text>
<text top="240" left="361" width="75" height="14" font="7"> MVA 1.5 cm</text>
<text top="241" left="436" width="5" height="6" font="23">2</text>
<text top="254" left="361" width="78" height="14" font="7"> (MVA 1.0 cm</text>
<text top="255" left="439" width="5" height="6" font="23">2</text>
<text top="257" left="447" width="93" height="9" font="7">with very severe MS)</text>
<text top="268" left="361" width="182" height="14" font="7"> Diastolic pressure half-time 150 ms</text>
<text top="283" left="361" width="185" height="14" font="7"> (Diastolic pressure half-time 220 ms</text>
<text top="300" left="372" width="93" height="9" font="7">with very severe MS)</text>
<text top="240" left="557" width="117" height="14" font="7"> Severe LA enlargement</text>
<text top="254" left="557" width="138" height="14" font="7"> Elevated PASP &gt;30 mm Hg</text>
<text top="240" left="737" width="35" height="14" font="7"> None</text>
<text top="346" left="67" width="7" height="9" font="7">D</text>
<text top="346" left="102" width="61" height="9" font="7">Symptomatic</text>
<text top="360" left="115" width="49" height="9" font="7">severe MS</text>
<text top="345" left="186" width="149" height="14" font="7"> Rheumatic valve changes with</text>
<text top="362" left="198" width="148" height="9" font="7">commissural fusion and diastolic</text>
<text top="376" left="198" width="119" height="9" font="7">doming of the mitral valve</text>
<text top="390" left="198" width="13" height="9" font="7">lea</text>
<text top="387" left="211" width="19" height="14" font="7">ﬂets</text>
<text top="402" left="186" width="139" height="14" font="7"> Planimetered MVA 1.5 cm</text>
<text top="402" left="325" width="5" height="6" font="23">2</text>
<text top="345" left="361" width="75" height="14" font="7"> MVA 1.5 cm</text>
<text top="345" left="436" width="5" height="6" font="23">2</text>
<text top="359" left="361" width="78" height="14" font="7"> (MVA 1.0 cm</text>
<text top="360" left="439" width="5" height="6" font="23">2</text>
<text top="362" left="447" width="93" height="9" font="7">with very severe MS)</text>
<text top="373" left="361" width="182" height="14" font="7"> Diastolic pressure half-time 150 ms</text>
<text top="387" left="361" width="185" height="14" font="7"> (Diastolic pressure half-time 220 ms</text>
<text top="404" left="372" width="93" height="9" font="7">with very severe MS)</text>
<text top="345" left="557" width="117" height="14" font="7"> Severe LA enlargement</text>
<text top="359" left="557" width="138" height="14" font="7"> Elevated PASP &gt;30 mm Hg</text>
<text top="345" left="737" width="59" height="14" font="7"> Decreased</text>
<text top="362" left="749" width="36" height="9" font="7">exercise</text>
<text top="376" left="749" width="41" height="9" font="7">tolerance</text>
<text top="387" left="737" width="55" height="14" font="7"> Exertional</text>
<text top="404" left="749" width="37" height="9" font="7">dyspnea</text>
<text top="422" left="64" width="472" height="8" font="18">The transmitral mean pressure gradient should be obtained to further determine the hemodynamic effect of the MS and is usually</text>
<text top="420" left="538" width="262" height="11" font="18">&gt;5 mm Hg to 10 mm Hg in severe MS; however, due to the variability of</text>
<text top="434" left="64" width="207" height="8" font="18">the mean pressure gradient with heart rate and forward</text>
<text top="432" left="274" width="209" height="11" font="18">ﬂow, it has not been included in the criteria for severity.</text>
<text top="446" left="72" width="498" height="8" font="18">LA indicates left atrial; LV, left ventricular; MS, mitral stenosis; MVA, mitral valve area; and PASP, pulmonary artery systolic pressure.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e91</text>
</page>
<page number="36" position="absolute" top="0" left="0" height="1160" width="864">
<text top="746" left="64" width="350" height="15" font="5">carditis. Once mild stenosis has developed, further nar-</text>
<text top="764" left="64" width="350" height="15" font="5">rowing is typical, although the rate of progression is highly</text>
<text top="781" left="64" width="331" height="15" font="5">variable. In 103 patients with MS followed for 3.3</text>
<text top="778" left="395" width="19" height="19" font="5">2</text>
<text top="799" left="64" width="229" height="15" font="5">years, valve area decreased at 0.09 cm</text>
<text top="796" left="294" width="6" height="10" font="14">2</text>
<text top="799" left="304" width="109" height="15" font="5">per year, although</text>
<text top="817" left="64" width="91" height="15" font="5">there was signi</text>
<text top="814" left="155" width="259" height="19" font="5">ﬁcant interpatient variability. Larger valves</text>
<text top="835" left="64" width="350" height="15" font="5">decreased in area more rapidly, although the same absolute</text>
<text top="853" left="64" width="350" height="15" font="5">decrease would be expected to have greater impact in the</text>
<text top="871" left="64" width="350" height="15" font="5">more stenotic valves. Importantly, progressive enlargement</text>
<text top="889" left="64" width="350" height="15" font="5">in the right ventricle and rise in RV systolic pressure were</text>
<text top="907" left="64" width="350" height="15" font="5">observed, even in the absence of a decrease in mitral valve</text>
<text top="925" left="64" width="350" height="15" font="5">area. Accordingly, repeat TTE at intervals dictated by valve</text>
<text top="943" left="64" width="350" height="15" font="5">area is an important aspect of disease management, even in</text>
<text top="961" left="64" width="350" height="15" font="5">patients without symptoms. TTE should be performed to</text>
<text top="979" left="64" width="350" height="15" font="5">re-evaluate asymptomatic patients with MS and stable</text>
<text top="997" left="64" width="41" height="15" font="5">clinical</text>
<text top="993" left="108" width="306" height="19" font="5">ﬁndings to assess pulmonary artery pressure and valve</text>
<text top="1015" left="64" width="285" height="15" font="5">gradient (very severe MS with mitral valve area</text>
<text top="1011" left="355" width="53" height="19" font="5">&lt;1.0 cm</text>
<text top="1012" left="408" width="6" height="10" font="14">2</text>
<text top="1033" left="64" width="255" height="15" font="5">every year, severe MS with mitral valve area</text>
<text top="1029" left="323" width="52" height="19" font="5">1.5 cm</text>
<text top="1030" left="375" width="6" height="10" font="14">2</text>
<text top="1033" left="384" width="30" height="15" font="5">every</text>
<text top="1050" left="64" width="350" height="15" font="5">1 to 2 years; and progressive MS with mitral valve area</text>
<text top="1065" left="64" width="52" height="19" font="5">&gt;1.5 cm</text>
<text top="1065" left="116" width="6" height="10" font="14">2</text>
<text top="1068" left="125" width="114" height="15" font="5">every 3 to 5 years) (</text>
<text top="1068" left="239" width="45" height="15" font="6"><a href="e57.full.html#10">Table 4</a></text>
<text top="1068" left="284" width="9" height="15" font="5"><a href="e57.full.html#10">).</a></text>
<text top="1087" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="1086" left="212" width="27" height="15" font="6"><a href="e57.full.html#107">(299</a></text>
<text top="1083" left="239" width="35" height="19" font="6"><a href="e57.full.html#107">–301)</a></text>
<text top="746" left="450" width="273" height="11" font="7">6.2.1.4. DIAGNOSTIC TESTINGdCARDIAC CATHETERIZATION</text>
<text top="766" left="451" width="349" height="15" font="5">In the contemporary era, adequate assessment of MS and</text>
<text top="784" left="450" width="350" height="15" font="5">associated lesions can be obtained in the vast majority of</text>
<text top="802" left="450" width="350" height="15" font="5">patients by TTE, occasionally supplemented by TEE.</text>
<text top="820" left="450" width="350" height="15" font="5">However, in those few patients with nondiagnostic studies</text>
<text top="838" left="450" width="235" height="15" font="5">or whose clinical and echocardiographic</text>
<text top="835" left="688" width="112" height="19" font="5">ﬁndings conﬂict, it</text>
<text top="856" left="450" width="350" height="15" font="5">is essential to further characterize MS hemodynamics and</text>
<text top="874" left="450" width="350" height="15" font="5">catheterization as the next best approach. Catheterization</text>
<text top="892" left="450" width="350" height="15" font="5">is also the only method available to measure absolute</text>
<text top="910" left="450" width="350" height="15" font="5">pressures inside the heart, which may be important in</text>
<text top="928" left="450" width="350" height="15" font="5">clinical decision making. Such studies must be carried out</text>
<text top="946" left="450" width="350" height="15" font="5">by personnel experienced with catheterization laboratory</text>
<text top="964" left="450" width="350" height="15" font="5">hemodynamics with simultaneous pressure measurements</text>
<text top="981" left="450" width="350" height="15" font="5">in the left ventricle and LA, ideally via transseptal cathe-</text>
<text top="999" left="450" width="350" height="15" font="5">terization. Although a properly performed mean pulmo-</text>
<text top="1017" left="450" width="350" height="15" font="5">nary artery wedge pressure is an acceptable substitute for</text>
<text top="1035" left="450" width="350" height="15" font="5">mean LA pressure, the LV to pulmonary wedge gradient</text>
<text top="1053" left="450" width="350" height="15" font="5">will overestimate the true transmitral gradient due to phase</text>
<text top="1071" left="450" width="350" height="15" font="5">delay and delayed transmission of pressure changes. The</text>
<text top="1089" left="450" width="350" height="15" font="5">Gorlin equation is applied for calculation of mitral valve</text>
<text top="641" left="64" width="316" height="11" font="13">Figure 3. Indications for Intervention for Rheumatic MS</text>
<text top="673" left="72" width="75" height="9" font="14">AF indicates atrial</text>
<text top="671" left="150" width="639" height="13" font="14">ﬁbrillation; LA, left atrial; MR, mitral regurgitation; MS, mitral stenosis; MVA, mitral valve area; MVR, mitral valve surgery (repair or replacement); NYHA,</text>
<text top="687" left="72" width="562" height="9" font="14">New York Heart Association; PCWP, pulmonary capillary wedge pressure; PMBC, percutaneous mitral balloon commissurotomy; and T</text>
<text top="685" left="637" width="4" height="6" font="23">1</text>
<text top="687" left="640" width="5" height="9" font="14">/</text>
<text top="691" left="645" width="4" height="6" font="23">2</text>
<text top="687" left="649" width="85" height="9" font="14">, pressure half-time.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e92</text>
</page>
<page number="37" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">area, using cardiac output obtained via thermodilution</text>
<text top="121" left="64" width="148" height="15" font="5">(when there is no signi</text>
<text top="117" left="213" width="201" height="19" font="5">ﬁcant TR) or the Fick method.</text>
<text top="139" left="64" width="350" height="15" font="5">Ideally, measured oxygen consumption should be used in</text>
<text top="157" left="64" width="350" height="15" font="5">this calculation. Full right-heart pressures should be re-</text>
<text top="175" left="64" width="350" height="15" font="5">ported. In cases where exertional symptoms seem out of</text>
<text top="192" left="64" width="350" height="15" font="5">proportion to resting hemodynamic severity, data may be</text>
<text top="210" left="64" width="150" height="15" font="5">obtained during exercise.</text>
<text top="229" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="228" left="212" width="27" height="15" font="6"><a href="e57.full.html#107">(302</a></text>
<text top="225" left="239" width="35" height="19" font="6"><a href="e57.full.html#107">–304)</a></text>
<text top="259" left="64" width="325" height="11" font="7">6.2.1.5. DIAGNOSTIC TESTINGdEXERCISE TESTING: RECOMMENDATION</text>
<text top="283" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="298" left="64" width="350" height="10" font="21">1. Exercise testing with Doppler or invasive hemodynamic</text>
<text top="314" left="82" width="332" height="10" font="21">assessment is recommended to evaluate the response of the</text>
<text top="331" left="82" width="332" height="10" font="21">mean mitral gradient and pulmonary artery pressure in patients</text>
<text top="347" left="82" width="332" height="10" font="21">with MS when there is a discrepancy between resting Doppler</text>
<text top="363" left="82" width="97" height="10" font="21">echocardiographic</text>
<text top="360" left="185" width="229" height="16" font="21">ﬁndings and clinical symptoms or signs.</text>
<text top="380" left="82" width="113" height="12" font="21">(Level of Evidence: C)</text>
<text top="404" left="79" width="335" height="15" font="5">Exercise testing with hemodynamics yields a number of</text>
<text top="422" left="64" width="350" height="15" font="5">data points to help in the management of MS when a</text>
<text top="440" left="64" width="41" height="15" font="5">patient</text>
<text top="437" left="106" width="308" height="19" font="5">’s symptoms seem signiﬁcantly greater or less than</text>
<text top="458" left="64" width="350" height="15" font="5">would be expected from TTE. Results have been published</text>
<text top="476" left="64" width="350" height="15" font="5">using both exercise and dobutamine with Doppler echo-</text>
<text top="494" left="64" width="350" height="15" font="5">cardiography, although exercise is preferred in general as</text>
<text top="512" left="64" width="350" height="15" font="5">the more physiological test. Most experience is with</text>
<text top="530" left="64" width="350" height="15" font="5">treadmill exercise, with images and Doppler obtained</text>
<text top="548" left="64" width="350" height="15" font="5">immediately after stress, but bicycle exercise allows data</text>
<text top="566" left="64" width="350" height="15" font="5">acquisition at various stages of exercise. Bicycle or arm</text>
<text top="584" left="64" width="350" height="15" font="5">ergometry exercise testing during cardiac catheterization</text>
<text top="602" left="64" width="350" height="15" font="5">can also be performed for direct measurements of pulmo-</text>
<text top="619" left="64" width="350" height="15" font="5">nary artery wedge pressure and pulmonary pressures at rest</text>
<text top="637" left="64" width="350" height="15" font="5">and with exercise. Simple functional capacity is important</text>
<text top="655" left="64" width="162" height="15" font="5">to help quantify the patient</text>
<text top="652" left="227" width="187" height="19" font="5">’s symptoms and assess changes</text>
<text top="673" left="64" width="350" height="15" font="5">over time. Changes in valve gradient are also helpful, as is</text>
<text top="691" left="64" width="350" height="15" font="5">the presence of exercise-induced pulmonary hypertension.</text>
<text top="709" left="64" width="350" height="15" font="5">Although exercise-induced pulmonary hypertension does</text>
<text top="727" left="64" width="350" height="15" font="5">not have a formal place in these guidelines, a rise in RV</text>
<text top="745" left="64" width="116" height="15" font="5">systolic pressure to</text>
<text top="742" left="187" width="227" height="19" font="5">&gt;60 mm Hg to 70 mm Hg should</text>
<text top="763" left="64" width="342" height="15" font="5">prompt the clinician to carefully consider the patient</text>
<text top="760" left="406" width="8" height="19" font="5">’s</text>
<text top="781" left="64" width="350" height="15" font="5">symptoms. Most patients can continue to be followed</text>
<text top="799" left="64" width="350" height="15" font="5">without exercise testing by careful clinical assessment and</text>
<text top="817" left="64" width="316" height="15" font="5">periodic resting echocardiograms as indicated above.</text>
<text top="835" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="835" left="212" width="27" height="15" font="6"><a href="e57.full.html#107">(305</a></text>
<text top="831" left="239" width="35" height="19" font="6"><a href="e57.full.html#107">–308)</a></text>
<text top="861" left="64" width="277" height="15" font="5">6.2.2. Medical Therapy: Recommendations</text>
<text top="889" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="904" left="64" width="350" height="10" font="21">1. Anticoagulation (vitamin K antagonist [VKA] or heparin) is</text>
<text top="920" left="82" width="332" height="10" font="21">indicated in patients with 1) MS and AF (paroxysmal, persis-</text>
<text top="937" left="82" width="332" height="10" font="21">tent, or permanent), 2) MS and a prior embolic event, or 3) MS</text>
<text top="953" left="82" width="135" height="10" font="21">and a left atrial thrombus</text>
<text top="953" left="221" width="26" height="10" font="22"><a href="e57.full.html#107">(309</a></text>
<text top="950" left="246" width="32" height="16" font="22"><a href="e57.full.html#107">–315)</a></text>
<text top="953" left="278" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="977" left="79" width="335" height="15" font="5">In the presurgical era, patients with MS were at high</text>
<text top="995" left="64" width="350" height="15" font="5">risk for arterial embolization, which was further elevated in</text>
<text top="1013" left="64" width="350" height="15" font="5">those with AF and prior embolic events. Anticoagulation</text>
<text top="1031" left="64" width="350" height="15" font="5">with VKA has long been recommended for patients</text>
<text top="1049" left="64" width="350" height="15" font="5">with MS with AF or prior embolism and has been so</text>
<text top="1067" left="64" width="350" height="15" font="5">well accepted that patients with MS have generally</text>
<text top="1085" left="64" width="350" height="15" font="5">been excluded from AF trials examining the utility of</text>
<text top="103" left="450" width="350" height="15" font="5">anticoagulation. One exception to trials excluding patients</text>
<text top="121" left="450" width="350" height="15" font="5">with MS is the NASPEAF (National Study for Prevention</text>
<text top="139" left="450" width="350" height="15" font="5">of Embolism in Atrial Fibrillation) trial. Of the 495 high-</text>
<text top="157" left="450" width="350" height="15" font="5">risk patients in the cohort, 316 patients had MS. Of these</text>
<text top="175" left="450" width="350" height="15" font="5">316 patients, 95 had a prior embolization. Patients in the</text>
<text top="192" left="450" width="350" height="15" font="5">study were randomized to standard anticoagulation with</text>
<text top="210" left="450" width="350" height="15" font="5">VKA (international normalized ratio [INR] goal 2 to 3)</text>
<text top="228" left="450" width="350" height="15" font="5">versus the combination of an antiplatelet agent and VKA</text>
<text top="246" left="450" width="350" height="15" font="5">anticoagulation with a lower INR goal (0.10 to 2.5). The</text>
<text top="264" left="450" width="207" height="15" font="5">study demonstrated a highly signi</text>
<text top="261" left="657" width="143" height="19" font="5">ﬁcant increased risk for</text>
<text top="282" left="450" width="350" height="15" font="5">embolism among those patients with VHD with prior</text>
<text top="300" left="450" width="350" height="15" font="5">events versus those without (9.1% versus 2.3% over 3 years;</text>
<text top="318" left="450" width="8" height="15" font="5">p</text>
<text top="315" left="457" width="342" height="19" font="5">&lt;0.001). Further larger studies are required to determine</text>
<text top="336" left="450" width="350" height="15" font="5">if antiplatelet agents should be used in patients with AF</text>
<text top="354" left="450" width="350" height="15" font="5">and MS. Although no trial evidence exists for anti-</text>
<text top="372" left="450" width="350" height="15" font="5">coagulation when LA or left atrial appendage thrombi are</text>
<text top="390" left="450" width="350" height="15" font="5">incidentally found (generally by TEE), it is well docu-</text>
<text top="408" left="450" width="350" height="15" font="5">mented that even in sinus rhythm, such clots are predis-</text>
<text top="426" left="450" width="350" height="15" font="5">posed to embolize, and so anticoagulation with VKA is</text>
<text top="444" left="450" width="336" height="15" font="5">recommended. Anticoagulation should be given inde</text>
<text top="440" left="785" width="14" height="19" font="5">ﬁ-</text>
<text top="462" left="450" width="350" height="15" font="5">nitely to patients with these indications. It is controversial</text>
<text top="479" left="450" width="350" height="15" font="5">as to whether long-term anticoagulation should be given to</text>
<text top="497" left="450" width="350" height="15" font="5">patients with MS in normal sinus rhythm on the basis of</text>
<text top="515" left="450" width="350" height="15" font="5">left atrial enlargement or spontaneous contrast on TEE.</text>
<text top="533" left="450" width="44" height="15" font="5">The ef</text>
<text top="530" left="494" width="306" height="19" font="5">ﬁcacy of the novel oral anticoagulant agents in</text>
<text top="551" left="450" width="350" height="15" font="5">preventing embolic events has not been studied in patients</text>
<text top="569" left="450" width="58" height="15" font="5">with MS.</text>
<text top="588" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="587" left="597" width="27" height="15" font="6"><a href="e57.full.html#107">(309</a></text>
<text top="584" left="625" width="35" height="19" font="6"><a href="e57.full.html#107">–315)</a></text>
<text top="614" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="629" left="449" width="179" height="10" font="21">1. Heart rate control can be bene</text>
<text top="626" left="628" width="172" height="16" font="21">ﬁcial in patients with MS and AF</text>
<text top="646" left="467" width="275" height="12" font="21">and fast ventricular response. (Level of Evidence: C)</text>
<text top="670" left="465" width="335" height="15" font="5">Patients with MS are prone to developing atrial ar-</text>
<text top="688" left="450" width="350" height="15" font="5">rhythmias. Thirty percent to 40% of patients with severe</text>
<text top="706" left="450" width="178" height="15" font="5">MS will develop AF. Signi</text>
<text top="702" left="628" width="172" height="19" font="5">ﬁcant detrimental hemody-</text>
<text top="724" left="450" width="350" height="15" font="5">namic consequences may be associated with the acute</text>
<text top="742" left="450" width="350" height="15" font="5">development of AF, primarily from the rapid ventricular</text>
<text top="760" left="450" width="235" height="15" font="5">response, which shortens the diastolic</text>
<text top="756" left="692" width="108" height="19" font="5">ﬁlling period and</text>
<text top="778" left="450" width="350" height="15" font="5">increases left atrial pressure. The treatment of acute AF is</text>
<text top="795" left="450" width="350" height="15" font="5">anticoagulation and control of the heart rate response with</text>
<text top="813" left="450" width="350" height="15" font="5">negative dromotropic agents. If the rate cannot be</text>
<text top="831" left="450" width="350" height="15" font="5">adequately controlled with medications, cardioversion may</text>
<text top="849" left="450" width="350" height="15" font="5">be necessary to improve hemodynamics. In the stable pa-</text>
<text top="867" left="450" width="350" height="15" font="5">tient, the decision for rate control versus rhythm control is</text>
<text top="885" left="450" width="350" height="15" font="5">dependent on multiple factors, including the duration of</text>
<text top="903" left="450" width="350" height="15" font="5">AF, hemodynamic response to AF, left atrial size, prior</text>
<text top="921" left="450" width="350" height="15" font="5">episodes of AF, and a history of embolic events. It is more</text>
<text top="939" left="450" width="16" height="15" font="5">dif</text>
<text top="936" left="466" width="333" height="19" font="5">ﬁcult to achieve rhythm control in patients with MS</text>
<text top="957" left="450" width="287" height="15" font="5">because the rheumatic process itself may lead to</text>
<text top="953" left="741" width="59" height="19" font="5">ﬁbrosis of</text>
<text top="975" left="450" width="350" height="15" font="5">the intermodal and interatrial tracts and damage to the</text>
<text top="993" left="450" width="92" height="15" font="5">sinoatrial node.</text>
<text top="1011" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="1011" left="593" width="32" height="15" font="6"><a href="e57.full.html#107">(316)</a></text>
<text top="1038" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="1053" left="449" width="351" height="10" font="21">1. Heart rate control may be considered for patients with MS in</text>
<text top="1069" left="467" width="333" height="10" font="21">normal sinus rhythm and symptoms associated with exercise</text>
<text top="1086" left="467" width="55" height="10" font="22"><a href="e57.full.html#107">(317,318)</a></text>
<text top="1086" left="522" width="121" height="12" font="21"><a href="e57.full.html#107">. </a>(Level of Evidence: B)</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e93</text>
</page>
<page number="38" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="79" width="335" height="15" font="5">It is well known that the proportion of the cardiac cycle</text>
<text top="121" left="64" width="350" height="15" font="5">occupied by diastole decreases with increasing heart rate,</text>
<text top="139" left="64" width="176" height="15" font="5">thereby increasing the mean</text>
<text top="135" left="248" width="166" height="19" font="5">ﬂow rate across the mitral</text>
<text top="157" left="64" width="350" height="15" font="5">valve (assuming constant cardiac output) with a consequent</text>
<text top="175" left="64" width="350" height="15" font="5">rise in mean mitral gradient in MS in proportion to the</text>
<text top="192" left="64" width="79" height="15" font="5">square of the</text>
<text top="189" left="148" width="266" height="19" font="5">ﬂow rate. A study of normal volunteers un-</text>
<text top="210" left="64" width="350" height="15" font="5">dergoing bicycle exercise echocardiography demonstrated a</text>
<text top="228" left="64" width="350" height="15" font="5">reduction in the diastolic interval from 604 milliseconds</text>
<text top="246" left="64" width="350" height="15" font="5">to 219 milliseconds as the heart rate increased from 60</text>
<text top="264" left="64" width="350" height="15" font="5">beats per minute to 120 beats per minute indicating a 63%</text>
<text top="282" left="64" width="350" height="15" font="5">reduction in total diastolic time. Maintaining the same</text>
<text top="300" left="64" width="319" height="15" font="5">cardiac output would require a 38% increase in mean</text>
<text top="297" left="388" width="26" height="19" font="5">ﬂow</text>
<text top="318" left="64" width="350" height="15" font="5">rate during diastole, which, by squared relation of the</text>
<text top="336" left="64" width="350" height="15" font="5">Bernoulli equation, requires an increase in mean mitral</text>
<text top="354" left="64" width="350" height="15" font="5">gradient of approximately 90%. Thus, it is rational to think</text>
<text top="372" left="64" width="350" height="15" font="5">that limiting tachycardia with beta blockade might be</text>
<text top="390" left="64" width="28" height="15" font="5">bene</text>
<text top="386" left="92" width="322" height="19" font="5">ﬁcial in patients with MS in normal sinus rhythm.</text>
<text top="408" left="64" width="350" height="15" font="5">Nevertheless, the only RCT on the impact of beta blockade</text>
<text top="426" left="64" width="350" height="15" font="5">on exercise duration in MS failed to show this salutary</text>
<text top="444" left="64" width="350" height="15" font="5">effect. One study looked at 15 patients with an average</text>
<text top="461" left="64" width="122" height="15" font="5">mitral area of 1.0 cm</text>
<text top="458" left="186" width="6" height="10" font="14">2</text>
<text top="461" left="195" width="219" height="15" font="5">(NYHA class II and III) randomized</text>
<text top="479" left="64" width="350" height="15" font="5">in crossover fashion to atenolol or placebo. Although the</text>
<text top="497" left="64" width="171" height="15" font="5">exercise heart rate was signi</text>
<text top="494" left="235" width="178" height="19" font="5">ﬁcantly reduced and diastolic</text>
<text top="512" left="64" width="350" height="19" font="5">ﬁlling interval increased by 40%, there was no increase in</text>
<text top="533" left="64" width="213" height="15" font="5">functional capacity, and maximal O</text>
<text top="539" left="277" width="6" height="10" font="14">2</text>
<text top="533" left="287" width="127" height="15" font="5">consumption actually</text>
<text top="551" left="64" width="350" height="15" font="5">fell by 11%, with cardiac index falling by 20% when pa-</text>
<text top="569" left="64" width="350" height="15" font="5">tients were treated with beta blockade. One study had</text>
<text top="587" left="64" width="350" height="15" font="5">more neutral results in a trial of 17 patients with NYHA</text>
<text top="605" left="64" width="350" height="15" font="5">class I and II MS, and 7 patients had improvement in</text>
<text top="623" left="64" width="350" height="15" font="5">maximal oxygen consumption, whereas 4 had a deteriora-</text>
<text top="641" left="64" width="350" height="15" font="5">tion in symptoms. Overall, anaerobic threshold was</text>
<text top="659" left="64" width="350" height="15" font="5">reduced by 11% with atenolol therapy, so these studies do</text>
<text top="103" left="450" width="350" height="15" font="5">not support the general use of heart rate control in patients</text>
<text top="121" left="450" width="350" height="15" font="5">with MS and normal sinus rhythm. Nevertheless, in</text>
<text top="139" left="450" width="350" height="15" font="5">selected patients whose symptoms worsen markedly with</text>
<text top="157" left="450" width="350" height="15" font="5">exercise, a trial of beta blockade might be considered.</text>
<text top="175" left="450" width="350" height="15" font="5">Other negative chronotropic agents have not been evalu-</text>
<text top="192" left="450" width="156" height="15" font="5">ated in patients with MS.</text>
<text top="211" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="210" left="597" width="58" height="15" font="6"><a href="e57.full.html#107">(317,318)</a></text>
<text top="248" left="450" width="248" height="15" font="5">6.2.3. Intervention: Recommendations</text>
<text top="273" left="451" width="21" height="15" font="5">See</text>
<text top="273" left="475" width="53" height="15" font="6"><a href="e57.full.html#38">Table 14</a></text>
<text top="273" left="531" width="268" height="15" font="5">for a summary of recommendations from this</text>
<text top="291" left="450" width="45" height="15" font="5">section.</text>
<text top="321" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="336" left="449" width="351" height="10" font="21">1. Percutaneous mitral balloon commissurotomy is recommended</text>
<text top="353" left="467" width="332" height="10" font="21">for symptomatic patients with severe MS (mitral valve area</text>
<text top="366" left="467" width="47" height="16" font="21">£1.5 cm</text>
<text top="367" left="514" width="5" height="7" font="25">2</text>
<text top="369" left="519" width="281" height="10" font="21">, stage D) and favorable valve morphology in the</text>
<text top="386" left="467" width="332" height="10" font="21">absence of left atrial thrombus or moderate-to-severe MR</text>
<text top="402" left="467" width="26" height="10" font="22"><a href="e57.full.html#106">(280</a></text>
<text top="399" left="493" width="81" height="16" font="22"><a href="e57.full.html#106">–284,286,328)</a></text>
<text top="402" left="574" width="120" height="12" font="21"><a href="e57.full.html#106">. </a>(Level of Evidence: A)</text>
<text top="426" left="465" width="286" height="15" font="5">Several RCTs have established the safety and ef</text>
<text top="423" left="750" width="49" height="19" font="5">ﬁcacy of</text>
<text top="444" left="450" width="350" height="15" font="5">percutaneous balloon mitral commissurotomy compared</text>
<text top="462" left="450" width="350" height="15" font="5">with surgical closed or open commissurotomy. The tech-</text>
<text top="480" left="450" width="271" height="15" font="5">nique is generally performed by advancing</text>
<text top="477" left="729" width="71" height="19" font="5">1 balloon</text>
<text top="498" left="450" width="226" height="15" font="5">catheters across the mitral valve and in</text>
<text top="495" left="676" width="124" height="19" font="5">ﬂating them, thereby</text>
<text top="516" left="450" width="350" height="15" font="5">splitting the commissures. For the percutaneous approach</text>
<text top="534" left="450" width="350" height="15" font="5">to have optimal outcome, it is essential that the valve</text>
<text top="552" left="450" width="350" height="15" font="5">morphology be predictive of success, generally being mo-</text>
<text top="570" left="450" width="350" height="15" font="5">bile, relatively thin, and free of calcium. This is usually</text>
<text top="588" left="450" width="350" height="15" font="5">assessed by the Wilkins score, although other risk scores</text>
<text top="606" left="450" width="350" height="15" font="5">have also shown utility. Clinical factors such as age,</text>
<text top="624" left="450" width="350" height="15" font="5">NYHA class, and presence or absence of AF are also</text>
<text top="642" left="450" width="350" height="15" font="5">predictive of outcome. Percutaneous mitral balloon com-</text>
<text top="659" left="450" width="131" height="15" font="5">missurotomy should</text>
<text top="659" left="596" width="14" height="15" font="5">be</text>
<text top="659" left="624" width="62" height="15" font="5">performed</text>
<text top="659" left="701" width="14" height="15" font="5">by</text>
<text top="659" left="730" width="70" height="15" font="5">experienced</text>
<text top="701" left="64" width="349" height="11" font="13">Table 14. Summary of Recommendations for MS Intervention</text>
<text top="726" left="64" width="86" height="9" font="7">Recommendations</text>
<text top="726" left="567" width="21" height="9" font="7">COR</text>
<text top="726" left="666" width="18" height="9" font="7">LOE</text>
<text top="726" left="739" width="52" height="9" font="7">References</text>
<text top="745" left="64" width="321" height="9" font="7">PMBC is recommended for symptomatic patients with severe MS (MVA</text>
<text top="742" left="389" width="40" height="14" font="7">1.5 cm</text>
<text top="743" left="429" width="5" height="6" font="23">2</text>
<text top="745" left="433" width="64" height="9" font="7">, stage D) and</text>
<text top="759" left="77" width="285" height="9" font="7">favorable valve morphology in the absence of contraindications</text>
<text top="745" left="576" width="3" height="9" font="7">I</text>
<text top="745" left="672" width="6" height="9" font="7">A</text>
<text top="745" left="730" width="21" height="9" font="8"><a href="e57.full.html#106">(280</a></text>
<text top="742" left="752" width="48" height="14" font="8"><a href="e57.full.html#106">–284,286)</a></text>
<text top="773" left="64" width="434" height="9" font="7">Mitral valve surgery is indicated in severely symptomatic patients (NYHA class III/IV) with severe</text>
<text top="788" left="77" width="41" height="9" font="7">MS (MVA</text>
<text top="785" left="121" width="40" height="14" font="7">1.5 cm</text>
<text top="785" left="161" width="5" height="6" font="23">2</text>
<text top="788" left="166" width="324" height="9" font="7">, stage D) who are not high risk for surgery and who are not candidates</text>
<text top="802" left="77" width="124" height="9" font="7">for or failed previous PMBC</text>
<text top="773" left="576" width="3" height="9" font="7">I</text>
<text top="773" left="672" width="6" height="9" font="7">B</text>
<text top="773" left="741" width="21" height="9" font="8"><a href="e57.full.html#107">(319</a></text>
<text top="770" left="762" width="27" height="14" font="8"><a href="e57.full.html#107">–324)</a></text>
<text top="816" left="64" width="357" height="9" font="7">Concomitant mitral valve surgery is indicated for patients with severe MS (MVA</text>
<text top="813" left="425" width="40" height="14" font="7">1.5 cm</text>
<text top="813" left="465" width="5" height="6" font="23">2</text>
<text top="816" left="470" width="3" height="9" font="7">,</text>
<text top="830" left="77" width="211" height="9" font="7">stage C or D) undergoing other cardiac surgery</text>
<text top="816" left="576" width="3" height="9" font="7">I</text>
<text top="816" left="672" width="6" height="9" font="7">C</text>
<text top="816" left="756" width="18" height="9" font="7">N/A</text>
<text top="844" left="64" width="332" height="9" font="7">PMBC is reasonable for asymptomatic patients with very severe MS (MVA</text>
<text top="841" left="400" width="40" height="14" font="7">1.0 cm</text>
<text top="841" left="440" width="5" height="6" font="23">2</text>
<text top="844" left="445" width="43" height="9" font="7">, stage C)</text>
<text top="858" left="77" width="305" height="9" font="7">and favorable valve morphology in the absence of contraindications</text>
<text top="844" left="572" width="11" height="9" font="7">IIa</text>
<text top="844" left="672" width="6" height="9" font="7">C</text>
<text top="844" left="730" width="42" height="9" font="8"><a href="e57.full.html#107">(293,325</a></text>
<text top="841" left="773" width="27" height="14" font="8"><a href="e57.full.html#107">–327)</a></text>
<text top="872" left="64" width="414" height="9" font="7">Mitral valve surgery is reasonable for severely symptomatic patients (NYHA class III/IV) with</text>
<text top="886" left="77" width="73" height="9" font="7">severe MS (MVA</text>
<text top="883" left="153" width="40" height="14" font="7">1.5 cm</text>
<text top="884" left="194" width="5" height="6" font="23">2</text>
<text top="886" left="198" width="255" height="9" font="7">, stage D), provided there are other operative indications</text>
<text top="872" left="572" width="11" height="9" font="7">IIa</text>
<text top="872" left="672" width="6" height="9" font="7">C</text>
<text top="872" left="756" width="18" height="9" font="7">N/A</text>
<text top="900" left="64" width="337" height="9" font="7">PMBC may be considered for asymptomatic patients with severe MS (MVA</text>
<text top="897" left="404" width="40" height="14" font="7">1.5 cm</text>
<text top="898" left="444" width="5" height="6" font="23">2</text>
<text top="900" left="449" width="63" height="9" font="7">, stage C) and</text>
<text top="914" left="77" width="408" height="9" font="7">favorable valve morphology who have new onset of AF in the absence of contraindications</text>
<text top="900" left="572" width="11" height="9" font="7">IIb</text>
<text top="900" left="672" width="6" height="9" font="7">C</text>
<text top="900" left="756" width="18" height="9" font="7">N/A</text>
<text top="928" left="64" width="278" height="9" font="7">PMBC may be considered for symptomatic patients with MVA</text>
<text top="925" left="345" width="40" height="14" font="7">&gt;1.5 cm</text>
<text top="926" left="386" width="5" height="6" font="23">2</text>
<text top="928" left="394" width="98" height="9" font="7">if there is evidence of</text>
<text top="942" left="77" width="103" height="9" font="7">hemodynamically signi</text>
<text top="939" left="179" width="114" height="14" font="7">ﬁcant MS during exercise</text>
<text top="928" left="572" width="11" height="9" font="7">IIb</text>
<text top="928" left="672" width="6" height="9" font="7">C</text>
<text top="928" left="756" width="18" height="9" font="7">N/A</text>
<text top="956" left="64" width="430" height="9" font="7">PMBC may be considered for severely symptomatic patients (NYHA class III/IV) with severe MS</text>
<text top="970" left="77" width="23" height="9" font="7">(MVA</text>
<text top="967" left="103" width="40" height="14" font="7">1.5 cm</text>
<text top="968" left="143" width="5" height="6" font="23">2</text>
<text top="970" left="148" width="335" height="9" font="7">, stage D) who have suboptimal valve anatomy and are not candidates for</text>
<text top="985" left="77" width="151" height="9" font="7">surgery or at high risk for surgery</text>
<text top="956" left="572" width="11" height="9" font="7">IIb</text>
<text top="956" left="672" width="6" height="9" font="7">C</text>
<text top="956" left="756" width="18" height="9" font="7">N/A</text>
<text top="998" left="64" width="379" height="9" font="7">Concomitant mitral valve surgery may be considered for patients with moderate MS</text>
<text top="1013" left="77" width="41" height="9" font="7">(MVA 1.6</text>
<text top="1010" left="118" width="37" height="14" font="7">–2.0 cm</text>
<text top="1010" left="155" width="5" height="6" font="23">2</text>
<text top="1013" left="160" width="155" height="9" font="7">) undergoing other cardiac surgery</text>
<text top="998" left="572" width="11" height="9" font="7">IIb</text>
<text top="998" left="672" width="6" height="9" font="7">C</text>
<text top="998" left="756" width="18" height="9" font="7">N/A</text>
<text top="1027" left="64" width="440" height="9" font="7">Mitral valve surgery and excision of the left atrial appendage may be considered for patients with</text>
<text top="1041" left="77" width="73" height="9" font="7">severe MS (MVA</text>
<text top="1038" left="152" width="40" height="14" font="7">1.5 cm</text>
<text top="1038" left="192" width="5" height="6" font="23">2</text>
<text top="1041" left="197" width="325" height="9" font="7">, stages C and D) who have had recurrent embolic events while receiving</text>
<text top="1055" left="77" width="114" height="9" font="7">adequate anticoagulation</text>
<text top="1027" left="572" width="11" height="9" font="7">IIb</text>
<text top="1027" left="672" width="6" height="9" font="7">C</text>
<text top="1027" left="756" width="18" height="9" font="7">N/A</text>
<text top="1075" left="72" width="65" height="8" font="18">AF indicates atrial</text>
<text top="1073" left="139" width="660" height="11" font="18">ﬁbrillation; COR, Class of Recommendation; LOE, Level of Evidence; MS, mitral stenosis; MVA, mitral valve area; NYHA, New York Heart Association; and PMBC, percutaneous mitral</text>
<text top="1087" left="72" width="95" height="8" font="18">balloon commissurotomy.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e94</text>
</page>
<page number="39" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">operators with immediate availability of surgical backup</text>
<text top="121" left="64" width="350" height="15" font="5">for potential complications. Percutaneous mitral balloon</text>
<text top="139" left="64" width="350" height="15" font="5">commissurotomy is also useful in patients with restenosis</text>
<text top="157" left="64" width="350" height="15" font="5">following prior commissurotomy if restenosis is the con-</text>
<text top="175" left="64" width="256" height="15" font="5">sequence of refusion of both commissures.</text>
<text top="193" left="79" width="109" height="15" font="5">Supporting References:</text>
<text top="192" left="191" width="27" height="15" font="6"><a href="e57.full.html#106">(280</a></text>
<text top="189" left="218" width="196" height="19" font="6"><a href="e57.full.html#106">–284,286,292,294,325,328–331)</a></text>
<text top="211" left="79" width="18" height="15" font="5">See</text>
<text top="211" left="103" width="166" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 13</a></text>
<text top="211" left="274" width="140" height="15" font="5">for a summary of RCTs</text>
<text top="229" left="64" width="227" height="15" font="5">that have established the safety and ef</text>
<text top="225" left="291" width="123" height="19" font="5">ﬁcacy of percutaneous</text>
<text top="247" left="64" width="350" height="15" font="5">mitral balloon commissurotomy in comparison to surgical closed</text>
<text top="265" left="64" width="141" height="15" font="5">or open commissurotomy.</text>
<text top="291" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="306" left="63" width="49" height="10" font="21">2. Mitral</text>
<text top="306" left="124" width="27" height="10" font="21">valve</text>
<text top="306" left="162" width="39" height="10" font="21">surgery</text>
<text top="306" left="212" width="38" height="10" font="21">(repair,</text>
<text top="306" left="261" width="93" height="10" font="21">commissurotomy,</text>
<text top="306" left="365" width="10" height="10" font="21">or</text>
<text top="306" left="387" width="27" height="10" font="21">valve</text>
<text top="323" left="81" width="333" height="10" font="21">replacement) is indicated in severely symptomatic patients</text>
<text top="339" left="81" width="303" height="10" font="21">(NYHA class III to IV) with severe MS (mitral valve area</text>
<text top="336" left="389" width="25" height="16" font="21">£1.5</text>
<text top="356" left="81" width="16" height="10" font="21">cm</text>
<text top="353" left="97" width="5" height="7" font="25">2</text>
<text top="356" left="103" width="311" height="10" font="21">, stage D) who are not high risk for surgery and who are not</text>
<text top="372" left="81" width="333" height="10" font="21">candidates for or who have failed previous percutaneous mitral</text>
<text top="389" left="81" width="131" height="10" font="21">balloon commissurotomy</text>
<text top="389" left="217" width="26" height="10" font="22"><a href="e57.full.html#107">(319</a></text>
<text top="385" left="242" width="32" height="16" font="22"><a href="e57.full.html#107">–324)</a></text>
<text top="389" left="274" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="411" left="79" width="335" height="15" font="5">Mitral valve surgery is an established therapy for MS,</text>
<text top="429" left="64" width="350" height="15" font="5">predating percutaneous mitral balloon commissurotomy.</text>
<text top="447" left="64" width="350" height="15" font="5">Surgical options may involve commissurotomy (either</text>
<text top="465" left="64" width="350" height="15" font="5">closed, where the valve is opened blindly through the LA</text>
<text top="483" left="64" width="350" height="15" font="5">or left ventricle, or open, which allows more extensive</text>
<text top="501" left="64" width="350" height="15" font="5">surgery under direct visualization). MVR may be preferred</text>
<text top="519" left="64" width="350" height="15" font="5">in the presence of severe valvular thickening and sub-</text>
<text top="537" left="64" width="45" height="15" font="5">valvular</text>
<text top="533" left="114" width="300" height="19" font="5">ﬁbrosis with leaﬂet tethering. In addition to those</text>
<text top="555" left="64" width="350" height="15" font="5">who have suboptimal valve anatomy (or failed percutaneous</text>
<text top="573" left="64" width="349" height="15" font="5">mitral balloon commissurotomy), patients with moderate</text>
<text top="591" left="64" width="350" height="15" font="5">or severe TR may also have a better outcome with a sur-</text>
<text top="609" left="64" width="350" height="15" font="5">gical approach that includes tricuspid valve repair. Because</text>
<text top="627" left="64" width="350" height="15" font="5">the natural history of MS is one of slow progression over</text>
<text top="645" left="64" width="350" height="15" font="5">decades and MS does not have long-standing detrimental</text>
<text top="663" left="64" width="350" height="15" font="5">effects on the left ventricle, surgery should be delayed until</text>
<text top="680" left="64" width="350" height="15" font="5">the patient has severe limiting symptoms (NYHA class III</text>
<text top="698" left="64" width="41" height="15" font="5">to IV).</text>
<text top="717" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="716" left="212" width="53" height="15" font="6"><a href="e57.full.html#106">(283,319</a></text>
<text top="713" left="265" width="91" height="19" font="6"><a href="e57.full.html#106">–324,332–334)</a></text>
<text top="744" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="758" left="63" width="351" height="10" font="21">3. Concomitant mitral valve surgery is indicated for patients with</text>
<text top="775" left="81" width="146" height="10" font="21">severe MS (mitral valve area</text>
<text top="772" left="230" width="43" height="16" font="21">£1.5 cm</text>
<text top="772" left="273" width="5" height="7" font="25">2</text>
<text top="775" left="278" width="136" height="10" font="21">, stage C or D) undergoing</text>
<text top="791" left="81" width="312" height="12" font="21">cardiac surgery for other indications. (Level of Evidence: C)</text>
<text top="814" left="79" width="335" height="15" font="5">Studies of the natural history of moderate-to-severe MS</text>
<text top="832" left="64" width="350" height="15" font="5">demonstrate progressive decrement in valve area of 0.09</text>
<text top="850" left="64" width="18" height="15" font="5">cm</text>
<text top="847" left="82" width="6" height="10" font="14">2</text>
<text top="850" left="93" width="321" height="15" font="5">per year. For patients with other indications for open</text>
<text top="868" left="64" width="350" height="15" font="5">heart surgery, mitral intervention should be undertaken,</text>
<text top="886" left="64" width="350" height="15" font="5">particularly in those patients with valves amenable to open</text>
<text top="904" left="64" width="196" height="15" font="5">commissurotomy or valve repair.</text>
<text top="922" left="79" width="123" height="15" font="5">Supporting Reference:</text>
<text top="922" left="208" width="32" height="15" font="6"><a href="e57.full.html#107">(300)</a></text>
<text top="949" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="964" left="63" width="351" height="10" font="21">1. Percutaneous mitral balloon commissurotomy is reasonable for</text>
<text top="980" left="81" width="333" height="10" font="21">asymptomatic patients with very severe MS (mitral valve</text>
<text top="997" left="81" width="23" height="10" font="21">area</text>
<text top="994" left="108" width="45" height="16" font="21">£1.0 cm</text>
<text top="994" left="153" width="5" height="7" font="25">2</text>
<text top="997" left="158" width="256" height="10" font="21">, stage C) and favorable valve morphology in the</text>
<text top="1013" left="81" width="332" height="10" font="21">absence of left atrial thrombus or moderate-to-severe MR</text>
<text top="1030" left="81" width="50" height="10" font="22"><a href="e57.full.html#107">(293,325</a></text>
<text top="1026" left="132" width="32" height="16" font="22"><a href="e57.full.html#107">–327)</a></text>
<text top="1030" left="164" width="120" height="12" font="21"><a href="e57.full.html#107">. </a>(Level of Evidence: C)</text>
<text top="1052" left="79" width="335" height="15" font="5">Although it is a general rule in VHD not to intervene</text>
<text top="1070" left="64" width="350" height="15" font="5">before the onset of symptoms, there are patients who will</text>
<text top="1088" left="64" width="75" height="15" font="5">clearly bene</text>
<text top="1085" left="139" width="275" height="19" font="5">ﬁt from intervention while still ostensibly</text>
<text top="103" left="450" width="314" height="15" font="5">asymptomatic. Most patients with mitral valve area</text>
<text top="99" left="769" width="30" height="19" font="5">1.0</text>
<text top="121" left="450" width="18" height="15" font="5">cm</text>
<text top="118" left="468" width="6" height="10" font="14">2</text>
<text top="121" left="480" width="320" height="15" font="5">will manifest a true reduction in functional capacity</text>
<text top="139" left="450" width="350" height="15" font="5">even if the gradual onset is not obvious. In addition,</text>
<text top="157" left="450" width="350" height="15" font="5">numerous studies have demonstrated a greater likelihood of</text>
<text top="175" left="450" width="350" height="15" font="5">successful percutaneous mitral balloon commissurotomy</text>
<text top="192" left="450" width="258" height="15" font="5">when the valve is less thickened and calci</text>
<text top="189" left="708" width="91" height="19" font="5">ﬁed, indicating</text>
<text top="210" left="450" width="350" height="15" font="5">intervention before this state. Furthermore, it is preferable</text>
<text top="228" left="450" width="350" height="15" font="5">to intervene before the development of severe pulmonary</text>
<text top="246" left="450" width="350" height="15" font="5">hypertension, because those patients with near systemic</text>
<text top="264" left="450" width="350" height="15" font="5">pulmonary pressure show reduced RV function and</text>
<text top="282" left="450" width="350" height="15" font="5">persistent pulmonary hypertension following percutaneous</text>
<text top="300" left="450" width="253" height="15" font="5">mitral balloon commissurotomy or MVR.</text>
<text top="319" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="318" left="597" width="53" height="15" font="6"><a href="e57.full.html#107">(293,325</a></text>
<text top="315" left="651" width="35" height="19" font="6"><a href="e57.full.html#107">–327)</a></text>
<text top="348" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="362" left="449" width="351" height="10" font="21">2. Mitral valve surgery is reasonable for severely symptomatic</text>
<text top="379" left="467" width="332" height="10" font="21">patients (NYHA class III to IV) with severe MS (mitral valve</text>
<text top="395" left="467" width="23" height="10" font="21">area</text>
<text top="392" left="496" width="46" height="16" font="21">£1.5 cm</text>
<text top="393" left="542" width="5" height="7" font="25">2</text>
<text top="395" left="547" width="252" height="10" font="21">, stage D), provided there are other operative</text>
<text top="412" left="467" width="333" height="10" font="21">indications (e.g., aortic valve disease, CAD, TR, aortic aneu-</text>
<text top="428" left="467" width="150" height="12" font="21">rysm). (Level of Evidence: C)</text>
<text top="454" left="465" width="335" height="15" font="5">A situation may arise in which a patient who is other-</text>
<text top="472" left="450" width="350" height="15" font="5">wise a candidate for percutaneous mitral balloon com-</text>
<text top="490" left="450" width="350" height="15" font="5">missurotomy (favorable valve anatomy, no atrial thrombus</text>
<text top="508" left="450" width="44" height="15" font="5">or signi</text>
<text top="504" left="494" width="305" height="19" font="5">ﬁcant MR) has other cardiac conditions that should</text>
<text top="526" left="450" width="350" height="15" font="5">be addressed surgically. These patients should undergo a</text>
<text top="544" left="450" width="350" height="15" font="5">comprehensive operation to address all lesions, including</text>
<text top="562" left="450" width="350" height="15" font="5">MS. However, as percutaneous intervention has evolved,</text>
<text top="579" left="450" width="350" height="15" font="5">particularly that involving the coronary arteries and aortic</text>
<text top="597" left="450" width="350" height="15" font="5">valve, there will be circumstances in which an all-</text>
<text top="615" left="450" width="350" height="15" font="5">percutaneous approach will be favored. This decision</text>
<text top="633" left="450" width="350" height="15" font="5">should take into account the local expertise at the treating</text>
<text top="651" left="450" width="43" height="15" font="5">facility.</text>
<text top="681" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="696" left="449" width="351" height="10" font="21">1. Percutaneous mitral balloon commissurotomy may be consid-</text>
<text top="712" left="467" width="333" height="10" font="21">ered for asymptomatic patients with severe MS (mitral valve</text>
<text top="728" left="467" width="23" height="10" font="21">area</text>
<text top="725" left="496" width="46" height="16" font="21">£1.5 cm</text>
<text top="726" left="542" width="5" height="7" font="25">2</text>
<text top="728" left="547" width="252" height="10" font="21">, stage C) and valve morphology favorable for</text>
<text top="745" left="467" width="332" height="10" font="21">percutaneous mitral balloon commissurotomy in the absence of</text>
<text top="761" left="467" width="333" height="10" font="21">left atrial thrombus or moderate-to-severe MR who have new</text>
<text top="778" left="467" width="181" height="12" font="21">onset of AF. (Level of Evidence: C)</text>
<text top="804" left="465" width="335" height="15" font="5">Patients with mild and asymptomatic MS may develop</text>
<text top="822" left="450" width="350" height="15" font="5">AF as an isolated event that can be managed without</text>
<text top="840" left="450" width="350" height="15" font="5">mitral valve intervention for many years. However, in many</text>
<text top="858" left="450" width="350" height="15" font="5">patients, the onset of AF may be a harbinger of a more</text>
<text top="876" left="450" width="350" height="15" font="5">symptomatic phase of the disease. Percutaneous mitral</text>
<text top="894" left="450" width="350" height="15" font="5">balloon commissurotomy may be considered in such cases,</text>
<text top="912" left="450" width="195" height="15" font="5">particularly if rate control is dif</text>
<text top="908" left="644" width="155" height="19" font="5">ﬁcult to achieve or if the</text>
<text top="930" left="450" width="120" height="15" font="5">mitral valve area is</text>
<text top="926" left="578" width="56" height="19" font="5">1.5 cm</text>
<text top="926" left="634" width="6" height="10" font="14">2</text>
<text top="929" left="640" width="160" height="15" font="5">. Lowering the left atrial</text>
<text top="947" left="450" width="350" height="15" font="5">pressure by percutaneous mitral balloon commissurotomy</text>
<text top="965" left="450" width="350" height="15" font="5">may be useful if a rhythm control approach is taken for AF.</text>
<text top="994" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="1009" left="449" width="351" height="10" font="21">2. Percutaneous mitral balloon commissurotomy may be considered</text>
<text top="1025" left="467" width="332" height="10" font="21">for symptomatic patients with mitral valve area greater than</text>
<text top="1042" left="467" width="36" height="10" font="21">1.5 cm</text>
<text top="1039" left="503" width="5" height="7" font="25">2</text>
<text top="1042" left="512" width="236" height="10" font="21">if there is evidence of hemodynamically signi</text>
<text top="1039" left="748" width="51" height="16" font="21">ﬁcant MS</text>
<text top="1058" left="467" width="333" height="10" font="21">based on pulmonary artery wedge pressure greater than 25 mm</text>
<text top="1075" left="467" width="333" height="10" font="21">Hg or mean mitral valve gradient greater than 15 mm Hg during</text>
<text top="1091" left="467" width="165" height="12" font="21">exercise. (Level of Evidence: C)</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e95</text>
</page>
<page number="40" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="79" width="335" height="15" font="5">It is recognized that there are patients with genuine</text>
<text top="121" left="64" width="350" height="15" font="5">symptoms from MS, even with mitral valve area between</text>
<text top="139" left="64" width="43" height="15" font="5">1.6 cm</text>
<text top="136" left="108" width="6" height="10" font="14">2</text>
<text top="139" left="120" width="72" height="15" font="5">and 2.0 cm</text>
<text top="136" left="191" width="6" height="10" font="14">2</text>
<text top="139" left="197" width="113" height="15" font="5">, who would bene</text>
<text top="135" left="310" width="104" height="19" font="5">ﬁt from percuta-</text>
<text top="157" left="64" width="350" height="15" font="5">neous mitral balloon commissurotomy. This may occur for</text>
<text top="175" left="64" width="350" height="15" font="5">several reasons. First, given the vagaries of clinical imaging,</text>
<text top="192" left="64" width="350" height="15" font="5">it is possible that the valve is actually smaller than the re-</text>
<text top="210" left="64" width="350" height="15" font="5">ported area. Second, for a given valve area, the transmitral</text>
<text top="228" left="64" width="350" height="15" font="5">gradient will be higher in persons with a large body surface</text>
<text top="246" left="64" width="350" height="15" font="5">area or those with other reasons to have an elevated cardiac</text>
<text top="264" left="64" width="158" height="15" font="5">output (e.g., arteriovenous</text>
<text top="261" left="227" width="187" height="19" font="5">ﬁstulae). Third, there is a vari-</text>
<text top="282" left="64" width="350" height="15" font="5">able relation of pulmonary vascular resistance in compari-</text>
<text top="300" left="64" width="350" height="15" font="5">son to mitral valve area. Thus, patients may experience</text>
<text top="318" left="64" width="350" height="15" font="5">clinical improvement in such cases. This procedure may</text>
<text top="336" left="64" width="350" height="15" font="5">be performed for these indications in patients with valve</text>
<text top="354" left="64" width="350" height="15" font="5">morphology suitable for percutaneous mitral balloon</text>
<text top="372" left="64" width="106" height="15" font="5">commissurotomy.</text>
<text top="391" left="79" width="123" height="15" font="5">Supporting Reference:</text>
<text top="390" left="208" width="32" height="15" font="6"><a href="e57.full.html#108">(335)</a></text>
<text top="417" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="432" left="63" width="351" height="10" font="21">3. Percutaneous mitral balloon commissurotomy may be consid-</text>
<text top="448" left="81" width="333" height="10" font="21">ered for severely symptomatic patients (NYHA class III to IV)</text>
<text top="465" left="81" width="176" height="10" font="21">with severe MS (mitral valve area</text>
<text top="462" left="260" width="44" height="16" font="21">£1.5 cm</text>
<text top="462" left="304" width="5" height="7" font="25">2</text>
<text top="465" left="310" width="104" height="10" font="21">, stage D) who have</text>
<text top="481" left="81" width="333" height="10" font="21">a suboptimal valve anatomy and who are not candidates for</text>
<text top="498" left="81" width="298" height="12" font="21">surgery or at high risk for surgery. (Level of Evidence: C)</text>
<text top="523" left="79" width="335" height="15" font="5">Both the Wilkins score and the presence of commis-</text>
<text top="541" left="64" width="61" height="15" font="5">sural calci</text>
<text top="538" left="126" width="288" height="19" font="5">ﬁcation predict successful percutaneous mitral</text>
<text top="559" left="64" width="350" height="15" font="5">balloon commissurotomy. However in all such series,</text>
<text top="577" left="64" width="350" height="15" font="5">this predictive ability is not absolute, with 42% of pa-</text>
<text top="595" left="64" width="188" height="15" font="5">tients with a Wilkins score</text>
<text top="592" left="262" width="152" height="19" font="5">&gt;8 having an optimal</text>
<text top="613" left="64" width="280" height="15" font="5">outcome (25% increase in mitral valve area to</text>
<text top="610" left="349" width="54" height="19" font="5">&gt;1.5 cm</text>
<text top="610" left="403" width="6" height="10" font="14">2</text>
<text top="613" left="409" width="5" height="15" font="5">)</text>
<text top="631" left="64" width="350" height="15" font="5">and 38% of patients with commissural calcium having</text>
<text top="649" left="64" width="350" height="15" font="5">event-free survival at 1.8 years. Accordingly, severely</text>
<text top="667" left="64" width="350" height="15" font="5">symptomatic patients who are poor surgical candidates</text>
<text top="685" left="64" width="60" height="15" font="5">may bene</text>
<text top="681" left="124" width="290" height="19" font="5">ﬁt from percutaneous mitral balloon commis-</text>
<text top="703" left="64" width="350" height="15" font="5">surotomy even with suboptimal valve anatomy. Patients</text>
<text top="721" left="64" width="350" height="15" font="5">who refuse surgery may also be considered for percuta-</text>
<text top="739" left="64" width="350" height="15" font="5">neous mitral balloon commissurotomy after discussion</text>
<text top="757" left="64" width="350" height="15" font="5">about the potential complications associated with this</text>
<text top="775" left="64" width="350" height="15" font="5">procedure when performed in patients with suboptimal</text>
<text top="792" left="64" width="92" height="15" font="5">valve anatomy.</text>
<text top="811" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="810" left="212" width="27" height="15" font="6"><a href="e57.full.html#107">(292</a></text>
<text top="807" left="239" width="35" height="19" font="6"><a href="e57.full.html#107">–294)</a></text>
<text top="839" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="854" left="63" width="351" height="10" font="21">4. Concomitant mitral valve surgery may be considered for pa-</text>
<text top="871" left="81" width="264" height="10" font="21">tients with moderate MS (mitral valve area 1.6 cm</text>
<text top="868" left="345" width="5" height="7" font="25">2</text>
<text top="871" left="354" width="51" height="10" font="21">to 2.0 cm</text>
<text top="868" left="404" width="5" height="7" font="25">2</text>
<text top="871" left="409" width="4" height="10" font="21">)</text>
<text top="887" left="81" width="332" height="12" font="21">undergoing cardiac surgery for other indications. (Level of</text>
<text top="904" left="81" width="66" height="12" font="21">Evidence: C)</text>
<text top="928" left="79" width="335" height="15" font="5">Consideration of concomitant MVR at the time of other</text>
<text top="946" left="64" width="350" height="15" font="5">heart surgery must balance several factors, including the</text>
<text top="964" left="64" width="350" height="15" font="5">severity of MS (based on mitral valve area, mean pressure</text>
<text top="982" left="64" width="350" height="15" font="5">gradient, and pulmonary arterial pressure); rate of pro-</text>
<text top="1000" left="64" width="350" height="15" font="5">gression; history of AF; skill of the surgeon; and perceived</text>
<text top="1018" left="64" width="350" height="15" font="5">risk of repeat cardiac surgery if the MS progresses to a</text>
<text top="1036" left="64" width="350" height="15" font="5">symptomatic state. Consideration should also include the</text>
<text top="1054" left="64" width="350" height="15" font="5">suitability of the valve for subsequent percutaneous mitral</text>
<text top="1072" left="64" width="350" height="15" font="5">balloon commissurotomy (echocardiogram score and presence</text>
<text top="103" left="450" width="350" height="15" font="5">of MR), as this might be a preferable method for treating</text>
<text top="121" left="450" width="92" height="15" font="5">worsening MS.</text>
<text top="148" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="163" left="449" width="351" height="10" font="21">5. Mitral valve surgery and excision of the left atrial appendage</text>
<text top="179" left="467" width="333" height="10" font="21">may be considered for patients with severe MS (mitral valve</text>
<text top="196" left="467" width="23" height="10" font="21">area</text>
<text top="193" left="493" width="44" height="16" font="21">£1.5 cm</text>
<text top="193" left="536" width="5" height="7" font="25">2</text>
<text top="196" left="542" width="258" height="10" font="21">, stages C and D) who have had recurrent embolic</text>
<text top="212" left="467" width="333" height="12" font="21">events while receiving adequate anticoagulation. (Level of</text>
<text top="229" left="467" width="66" height="12" font="21">Evidence: C)</text>
<text top="253" left="465" width="335" height="15" font="5">A large prospective study of patients with MS shows an</text>
<text top="271" left="450" width="350" height="15" font="5">elevated risk of recurrent embolism among patients with</text>
<text top="289" left="450" width="350" height="15" font="5">prior embolic events irrespective of the presence or absence</text>
<text top="307" left="450" width="350" height="15" font="5">of AF. The risk is reduced, but not eliminated, by percu-</text>
<text top="325" left="450" width="350" height="15" font="5">taneous mitral balloon commissurotomy. Another study of</text>
<text top="343" left="450" width="350" height="15" font="5">205 patients who underwent mitral valve surgery, 58 with</text>
<text top="361" left="450" width="350" height="15" font="5">ligation of the left atrial appendage, demonstrated that lack</text>
<text top="379" left="450" width="120" height="15" font="5">of ligation was signi</text>
<text top="375" left="570" width="229" height="19" font="5">ﬁcantly associated with future embolic</text>
<text top="396" left="450" width="350" height="15" font="5">events (odds ratio [OR]: 6.7). This study also noted that in</text>
<text top="414" left="450" width="350" height="15" font="5">6 of the 58 ligation patients, communication of the left</text>
<text top="432" left="450" width="350" height="15" font="5">atrial appendage and LA cavity was still present. Residual</text>
<text top="450" left="450" width="350" height="15" font="5">communication between the left atrial appendage and LA</text>
<text top="468" left="450" width="350" height="15" font="5">cavity was noted in 60% of patients undergoing left atrial</text>
<text top="486" left="450" width="350" height="15" font="5">appendage ligation in a subsequent study, suggesting that</text>
<text top="504" left="450" width="350" height="15" font="5">left atrial appendage excision and not ligation may be the</text>
<text top="522" left="450" width="236" height="15" font="5">preferred approach in selected patients.</text>
<text top="541" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="540" left="597" width="58" height="15" font="6"><a href="e57.full.html#108">(336,337)</a></text>
<text top="559" left="465" width="18" height="15" font="5">See</text>
<text top="559" left="488" width="218" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplements 14 and 15</a></text>
<text top="559" left="712" width="87" height="15" font="5">for more infor-</text>
<text top="576" left="450" width="350" height="15" font="5">mation on the outcomes of percutaneous mitral balloon</text>
<text top="594" left="450" width="95" height="15" font="5">commissurotomy.</text>
<text top="637" left="450" width="153" height="12" font="19">6.3. Nonrheumatic MS</text>
<text top="660" left="451" width="349" height="15" font="5">Although the vast majority of MS in the world results</text>
<text top="678" left="450" width="252" height="15" font="5">from rheumatic heart disease, senile calci</text>
<text top="674" left="702" width="97" height="19" font="5">ﬁc MS is found</text>
<text top="696" left="450" width="350" height="15" font="5">with increasing frequency in the elderly population in</text>
<text top="713" left="450" width="221" height="15" font="5">North America. This is due to calci</text>
<text top="710" left="671" width="128" height="19" font="5">ﬁcation of the mitral</text>
<text top="731" left="450" width="110" height="15" font="5">annulus and calci</text>
<text top="728" left="560" width="239" height="19" font="5">ﬁcation that extends into the leaﬂets,</text>
<text top="749" left="450" width="350" height="15" font="5">which cause both a narrowing of the annulus and rigidity</text>
<text top="767" left="450" width="56" height="15" font="5">of the lea</text>
<text top="764" left="506" width="294" height="19" font="5">ﬂets without commissural fusion. Mitral annular</text>
<text top="785" left="450" width="27" height="15" font="5">calci</text>
<text top="782" left="477" width="323" height="19" font="5">ﬁcation has been associated with decreased renal</text>
<text top="803" left="450" width="97" height="15" font="5">function and in</text>
<text top="800" left="547" width="252" height="19" font="5">ﬂammatory markers like C-reactive pro-</text>
<text top="821" left="450" width="154" height="15" font="5">tein; however, senile calci</text>
<text top="818" left="604" width="195" height="19" font="5">ﬁc MS is common in the elderly</text>
<text top="839" left="450" width="350" height="15" font="5">population with normal renal function and is associated</text>
<text top="857" left="450" width="350" height="15" font="5">with senile AS. Data are relatively sparse on the natural</text>
<text top="875" left="450" width="128" height="15" font="5">history of senile calci</text>
<text top="871" left="578" width="222" height="19" font="5">ﬁc MS. A small study of 32 patients</text>
<text top="893" left="450" width="350" height="15" font="5">observed over a mean of 2.6 years demonstrated pro-</text>
<text top="911" left="450" width="350" height="15" font="5">gression in mean mitral valve gradient in only half of the</text>
<text top="929" left="450" width="350" height="15" font="5">subjects. However, in those with progression, the rate of</text>
<text top="947" left="450" width="350" height="15" font="5">change averaged 2 mm Hg per year and changed as</text>
<text top="965" left="450" width="350" height="15" font="5">rapidly as 9 mm Hg per year. More rapid progression</text>
<text top="983" left="450" width="350" height="15" font="5">was found in younger patients, but surprisingly this was</text>
<text top="1000" left="450" width="253" height="15" font="5">not predicted by a reduced glomerular</text>
<text top="997" left="712" width="88" height="19" font="5">ﬁltration rate.</text>
<text top="1018" left="450" width="350" height="15" font="5">Although the mean pressure gradient from Doppler</text>
<text top="1036" left="450" width="350" height="15" font="5">echocardiography is accurate, the use of a mitral valve</text>
<text top="1054" left="450" width="350" height="15" font="5">area from diastolic half-time is uncertain in this popula-</text>
<text top="1072" left="450" width="350" height="15" font="5">tion. Indications for intervention in patients with senile</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e96</text>
</page>
<page number="41" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="27" height="15" font="5">calci</text>
<text top="99" left="91" width="323" height="19" font="5">ﬁc MS are different from those for rheumatic MS</text>
<text top="121" left="64" width="281" height="15" font="5">for the following reasons. First, because calci</text>
<text top="117" left="345" width="69" height="19" font="5">ﬁcation in-</text>
<text top="139" left="64" width="268" height="15" font="5">volves the annulus and base of the lea</text>
<text top="135" left="332" width="82" height="19" font="5">ﬂets without</text>
<text top="157" left="64" width="350" height="15" font="5">commissural fusion, there is no role for percutaneous</text>
<text top="175" left="64" width="350" height="15" font="5">mitral balloon or surgical commissurotomy. Second, the</text>
<text top="192" left="64" width="228" height="15" font="5">presence of severe mitral annular calci</text>
<text top="189" left="292" width="122" height="19" font="5">ﬁcation can be quite</text>
<text top="210" left="64" width="350" height="15" font="5">challenging for the surgeon because it causes problems in</text>
<text top="228" left="64" width="350" height="15" font="5">securely attaching the prosthetic valve and narrowing of</text>
<text top="246" left="64" width="41" height="15" font="5">the ori</text>
<text top="243" left="106" width="308" height="19" font="5">ﬁce. Supra-annular insertion and other innovative</text>
<text top="264" left="64" width="349" height="15" font="5">techniques can be used, such as placement of a felt patch</text>
<text top="282" left="64" width="128" height="15" font="5">around the valve ori</text>
<text top="279" left="192" width="222" height="19" font="5">ﬁce to anchor the prosthesis; how-</text>
<text top="300" left="64" width="234" height="15" font="5">ever, this only works if the mitral ori</text>
<text top="297" left="299" width="115" height="19" font="5">ﬁce is adequate. If</text>
<text top="318" left="64" width="102" height="15" font="5">the annular calci</text>
<text top="315" left="167" width="247" height="19" font="5">ﬁcation narrows the oriﬁce, it has to be</text>
<text top="336" left="64" width="350" height="15" font="5">debrided. The other alternative is left atrial to ventricular</text>
<text top="354" left="64" width="335" height="15" font="5">bypass with a valved conduit in extreme cases of calci</text>
<text top="351" left="400" width="14" height="19" font="5">ﬁ-</text>
<text top="372" left="64" width="139" height="15" font="5">cation both of the lea</text>
<text top="368" left="203" width="211" height="19" font="5">ﬂet and the annulus. Finally, pa-</text>
<text top="390" left="64" width="98" height="15" font="5">tients with calci</text>
<text top="386" left="162" width="252" height="19" font="5">ﬁcation are often elderly and debilitated,</text>
<text top="408" left="64" width="350" height="15" font="5">have multiple comorbidities, and are at high risk for</text>
<text top="426" left="64" width="350" height="15" font="5">surgery. For these reasons, intervention should be delayed</text>
<text top="444" left="64" width="350" height="15" font="5">until symptoms are severely limiting and cannot be</text>
<text top="461" left="64" width="282" height="15" font="5">managed with diuresis and heart rate control.</text>
<text top="479" left="79" width="210" height="15" font="5">A subset of patients have mitral in</text>
<text top="476" left="290" width="124" height="19" font="5">ﬂow obstruction due</text>
<text top="497" left="64" width="350" height="15" font="5">to other causes, such as congenital malformations, tumors,</text>
<text top="515" left="64" width="350" height="15" font="5">or other masses. Congenital MS usually takes the form of a</text>
<text top="533" left="64" width="350" height="15" font="5">parachute mitral valve, where the mitral chordae are</text>
<text top="551" left="64" width="350" height="15" font="5">attached to a single or dominant papillary muscle and often</text>
<text top="569" left="64" width="350" height="15" font="5">form a component of the Shone complex, which can</text>
<text top="587" left="64" width="350" height="15" font="5">include supramitral rings, valvular or subvalvular AS, and</text>
<text top="605" left="64" width="350" height="15" font="5">aortic coarctation. For MS caused by tumors or other</text>
<text top="623" left="64" width="350" height="15" font="5">obstructive lesions, intervention is aimed at reducing or</text>
<text top="641" left="64" width="350" height="15" font="5">removing the mass, with efforts made to preserve the valve.</text>
<text top="660" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="659" left="212" width="27" height="15" font="6"><a href="e57.full.html#108">(338</a></text>
<text top="655" left="239" width="35" height="19" font="6"><a href="e57.full.html#108">–352)</a></text>
<text top="700" left="64" width="181" height="14" font="17">7. Mitral Regurgitation</text>
<text top="745" left="64" width="98" height="12" font="19">7.1. Acute MR</text>
<text top="768" left="65" width="349" height="15" font="5">Acute MR may be due to disruption of different parts of</text>
<text top="786" left="64" width="261" height="15" font="5">the mitral valve apparatus. IE may cause lea</text>
<text top="782" left="325" width="89" height="19" font="5">ﬂet perforation</text>
<text top="804" left="64" width="350" height="15" font="5">or chordal rupture. Spontaneous chordal rupture may occur</text>
<text top="822" left="64" width="350" height="15" font="5">in patients with degenerative mitral valve disease. Rupture</text>
<text top="840" left="64" width="350" height="15" font="5">of the papillary muscle occurs in patients who have an acute</text>
<text top="857" left="64" width="350" height="15" font="5">ST-segment elevation MI usually associated with an</text>
<text top="875" left="64" width="350" height="15" font="5">inferior infarction. The acute volume overload on the left</text>
<text top="893" left="64" width="350" height="15" font="5">ventricle and LA results in pulmonary congestion and low</text>
<text top="911" left="64" width="350" height="15" font="5">forward cardiac output. Diagnosis of the presence and</text>
<text top="929" left="64" width="350" height="15" font="5">etiology of acute MR and urgent intervention may be</text>
<text top="947" left="64" width="59" height="15" font="5">lifesaving.</text>
<text top="974" left="64" width="206" height="15" font="5">7.1.1. Diagnosis and Follow-Up</text>
<text top="999" left="65" width="349" height="15" font="5">TTE is useful in patients with severe acute primary MR for</text>
<text top="1017" left="64" width="350" height="15" font="5">evaluation of LV function, RV function, pulmonary artery</text>
<text top="1035" left="64" width="350" height="15" font="5">pressure, and mechanism of MR. The patient with severe</text>
<text top="1053" left="64" width="350" height="15" font="5">acute MR, which might occur from chordal rupture, usu-</text>
<text top="1071" left="64" width="350" height="15" font="5">ally experiences acute decompensation with hemodynamic</text>
<text top="1089" left="64" width="350" height="15" font="5">embarrassment. The sudden volume overload increases left</text>
<text top="103" left="450" width="350" height="15" font="5">atrial and pulmonary venous pressure, leading to pulmo-</text>
<text top="121" left="450" width="350" height="15" font="5">nary congestion and hypoxia, whereas decreased blood</text>
<text top="139" left="450" width="350" height="15" font="5">delivery to the aorta causes reduced cardiac output, hypo-</text>
<text top="157" left="450" width="350" height="15" font="5">tension, or even shock. The rapid systolic rise in LA</text>
<text top="175" left="450" width="350" height="15" font="5">pressure with a concomitant fall in LV systolic pressure</text>
<text top="193" left="450" width="350" height="15" font="5">limits the pressure gradient driving MR to early systole.</text>
<text top="210" left="450" width="350" height="15" font="5">Thus, the murmur may be short and unimpressive. Some</text>
<text top="228" left="450" width="350" height="15" font="5">patients with severe torrential MR have no murmur due to</text>
<text top="246" left="450" width="350" height="15" font="5">equalization of the LV and left atrial pressures. TTE can</text>
<text top="264" left="450" width="350" height="15" font="5">usually clarify the diagnosis by demonstrating the presence</text>
<text top="282" left="450" width="350" height="15" font="5">of severe MR, the mechanism causing MR, and a hyper-</text>
<text top="300" left="450" width="350" height="15" font="5">dynamic instead of a depressed left ventricle as would be</text>
<text top="318" left="450" width="350" height="15" font="5">present in many other causes of hemodynamic compro-</text>
<text top="336" left="450" width="350" height="15" font="5">mise. Likely mechanisms of acute MR detected by TTE</text>
<text top="354" left="450" width="350" height="15" font="5">include valve disruption or perforation from IE, chordal</text>
<text top="372" left="450" width="350" height="15" font="5">rupture, and/or papillary muscle rupture. If the diagnosis</text>
<text top="390" left="450" width="350" height="15" font="5">of IE as the cause of acute MR is made, therapy that in-</text>
<text top="408" left="450" width="350" height="15" font="5">cludes antibiotic administration and early surgery must be</text>
<text top="426" left="450" width="67" height="15" font="5">considered.</text>
<text top="444" left="465" width="84" height="15" font="5">It may be dif</text>
<text top="440" left="549" width="251" height="19" font="5">ﬁcult to diagnose severe acute MR with</text>
<text top="462" left="450" width="350" height="15" font="5">TTE due to narrow eccentric jets of MR, tachycardia, and</text>
<text top="480" left="450" width="350" height="15" font="5">early equalization of LV and LA pressures. In cases where</text>
<text top="497" left="450" width="350" height="15" font="5">TTE is nondiagnostic but the suspicion of severe acute</text>
<text top="515" left="450" width="350" height="15" font="5">MR persists, enhanced mitral valve imaging with TEE</text>
<text top="533" left="450" width="75" height="15" font="5">usually clari</text>
<text top="530" left="525" width="275" height="19" font="5">ﬁes the diagnosis. TEE can be especially</text>
<text top="551" left="450" width="350" height="15" font="5">helpful in detecting valvular vegetations and annular ab-</text>
<text top="569" left="450" width="350" height="15" font="5">scesses that may further accentuate the need for a more</text>
<text top="587" left="450" width="350" height="15" font="5">urgent surgical approach. In the presence of sudden acute</text>
<text top="605" left="450" width="350" height="15" font="5">and hemodynamic instability after MI with hyperdynamic</text>
<text top="623" left="450" width="350" height="15" font="5">LV function by TTE and no other cause for the deterio-</text>
<text top="641" left="450" width="350" height="15" font="5">ration, TEE should be performed as soon as possible,</text>
<text top="659" left="450" width="350" height="15" font="5">looking for severe MR due either to a papillary muscle or</text>
<text top="677" left="450" width="96" height="15" font="5">chordal rupture.</text>
<text top="703" left="450" width="151" height="15" font="5">7.1.2. Medical Therapy</text>
<text top="729" left="451" width="349" height="15" font="5">Vasodilator therapy can be useful to improve hemody-</text>
<text top="747" left="450" width="350" height="15" font="5">namic compensation in acute MR. The premise of use of</text>
<text top="765" left="450" width="350" height="15" font="5">vasodilators in acute MR is reduction of impedance of</text>
<text top="783" left="450" width="33" height="15" font="5">aortic</text>
<text top="779" left="488" width="311" height="19" font="5">ﬂow, thereby preferentially guiding ﬂow away from</text>
<text top="801" left="450" width="350" height="15" font="5">the left ventricle to the left atrial regurgitant pathway,</text>
<text top="819" left="450" width="350" height="15" font="5">decreasing MR while simultaneously increasing forward</text>
<text top="837" left="450" width="350" height="15" font="5">output. This is usually accomplished by infusion of an</text>
<text top="855" left="450" width="350" height="15" font="5">easily titratable agent such as sodium nitroprusside or</text>
<text top="873" left="450" width="350" height="15" font="5">nicardipine. Use of vasodilators is often limited by systemic</text>
<text top="890" left="450" width="350" height="15" font="5">hypotension that is exacerbated when peripheral resistance</text>
<text top="908" left="450" width="75" height="15" font="5">is decreased.</text>
<text top="926" left="465" width="335" height="15" font="5">Intra-aortic balloon counterpulsation can be helpful</text>
<text top="944" left="450" width="350" height="15" font="5">to treat acute severe MR. By lowering systolic aortic</text>
<text top="962" left="450" width="350" height="15" font="5">pressure, intra-aortic balloon counterpulsation decreases</text>
<text top="980" left="450" width="350" height="15" font="5">LV afterload, increasing forward output while decreasing</text>
<text top="998" left="450" width="350" height="15" font="5">regurgitant volume. Simultaneously, intra-aortic balloon</text>
<text top="1016" left="450" width="350" height="15" font="5">counterpulsation increases diastolic and mean aortic pres-</text>
<text top="1034" left="450" width="350" height="15" font="5">sure, thereby supporting the systemic circulation. In almost</text>
<text top="1052" left="450" width="350" height="15" font="5">every case, intra-aortic balloon counterpulsation is a</text>
<text top="1070" left="450" width="350" height="15" font="5">temporizing measure for achieving hemodynamic stability</text>
<text top="1088" left="450" width="47" height="15" font="5">until de</text>
<text top="1084" left="497" width="302" height="19" font="5">ﬁnitive mitral surgery can be performed. The use</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e97</text>
</page>
<page number="42" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">of a percutaneous circulatory assist device may also be</text>
<text top="121" left="64" width="350" height="15" font="5">effective to stabilize a patient with acute hemodynamic</text>
<text top="139" left="64" width="180" height="15" font="5">compromise before operation.</text>
<text top="157" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="157" left="212" width="58" height="15" font="6"><a href="e57.full.html#108">(353,354)</a></text>
<text top="183" left="64" width="121" height="15" font="5">7.1.3. Intervention</text>
<text top="209" left="65" width="349" height="15" font="5">Prompt mitral valve surgery is recommended for treatment</text>
<text top="227" left="64" width="350" height="15" font="5">of the symptomatic patient with acute severe primary MR.</text>
<text top="245" left="64" width="350" height="15" font="5">The severity of acute primary MR is variable, and some</text>
<text top="263" left="64" width="350" height="15" font="5">patients with more moderate amounts of MR may develop</text>
<text top="281" left="64" width="305" height="15" font="5">compensation as LV dilation allows for lower</text>
<text top="277" left="379" width="35" height="19" font="5">ﬁlling</text>
<text top="299" left="64" width="350" height="15" font="5">pressure and increased forward cardiac output. However,</text>
<text top="316" left="64" width="350" height="15" font="5">most patients with acute severe MR will require surgical</text>
<text top="334" left="64" width="350" height="15" font="5">correction for re-establishment of normal hemodynamics</text>
<text top="352" left="64" width="350" height="15" font="5">and for relief of symptoms. This is especially true for a</text>
<text top="370" left="64" width="350" height="15" font="5">complete papillary muscle rupture that causes torrential</text>
<text top="388" left="64" width="350" height="15" font="5">MR, which is poorly tolerated. Even if there is a partial</text>
<text top="406" left="64" width="350" height="15" font="5">papillary muscle rupture with hemodynamic stability, ur-</text>
<text top="424" left="64" width="350" height="15" font="5">gent surgery is indicated because this can suddenly progress</text>
<text top="442" left="64" width="350" height="15" font="5">to complete papillary muscle rupture. In cases of ruptured</text>
<text top="460" left="64" width="350" height="15" font="5">chordae tendineae, mitral repair is usually feasible and</text>
<text top="478" left="64" width="350" height="15" font="5">preferred over MVR, and the timing of surgery can be</text>
<text top="496" left="64" width="158" height="15" font="5">determined by the patient</text>
<text top="492" left="222" width="192" height="19" font="5">’s hemodynamic status. If IE is</text>
<text top="514" left="64" width="350" height="15" font="5">the cause of severe symptomatic MR, earlier surgery is</text>
<text top="532" left="64" width="350" height="15" font="5">generally preferred because of better outcomes over medical</text>
<text top="550" left="64" width="350" height="15" font="5">therapy. However, this strategy should also be tempered</text>
<text top="568" left="64" width="84" height="15" font="5">by the patient</text>
<text top="564" left="148" width="117" height="19" font="5">’s overall condition.</text>
<text top="586" left="79" width="123" height="15" font="5">Supporting Reference:</text>
<text top="586" left="208" width="32" height="15" font="6"><a href="e57.full.html#108">(355)</a></text>
<text top="636" left="64" width="180" height="12" font="19">7.2. Stages of Chronic MR</text>
<text top="659" left="65" width="349" height="15" font="5">In assessing the patient with chronic MR, it is critical to</text>
<text top="677" left="64" width="350" height="15" font="5">distinguish between chronic primary (degenerative) MR</text>
<text top="695" left="64" width="350" height="15" font="5">and chronic secondary (functional) MR, as these 2 condi-</text>
<text top="712" left="64" width="270" height="15" font="5">tions have more differences than similarities.</text>
<text top="730" left="79" width="264" height="15" font="5">In chronic primary MR, the pathology of</text>
<text top="727" left="350" width="64" height="19" font="5">1 of the</text>
<text top="748" left="64" width="194" height="15" font="5">components of the valve (lea</text>
<text top="745" left="258" width="156" height="19" font="5">ﬂets, chordae tendineae,</text>
<text top="766" left="64" width="350" height="15" font="5">papillary muscles, annulus) causes valve incompetence</text>
<text top="784" left="64" width="350" height="15" font="5">with systolic regurgitation of blood from the left ventricle</text>
<text top="802" left="64" width="69" height="15" font="5">to the LA <a href="e57.full.html#43">(</a></text>
<text top="802" left="133" width="53" height="15" font="6"><a href="e57.full.html#43">Table 15</a></text>
<text top="802" left="187" width="227" height="15" font="5">). The most common cause of chronic</text>
<text top="821" left="64" width="350" height="15" font="5">primary MR in developed countries is mitral valve</text>
<text top="838" left="64" width="350" height="15" font="5">prolapse, which has a wide spectrum of etiology and</text>
<text top="856" left="64" width="350" height="15" font="5">presentation. Younger populations present with severe</text>
<text top="874" left="64" width="350" height="15" font="5">myxomatous degeneration with gross redundancy of both</text>
<text top="892" left="64" width="157" height="15" font="5">anterior and posterior lea</text>
<text top="888" left="221" width="192" height="19" font="5">ﬂets and the chordal apparatus</text>
<text top="910" left="64" width="47" height="15" font="5">(Barlow</text>
<text top="906" left="111" width="302" height="19" font="5">’s valve). Alternatively, older populations present</text>
<text top="928" left="64" width="27" height="15" font="5">with</text>
<text top="924" left="97" width="317" height="19" font="5">ﬁbroelastic deﬁciency disease, in which lack of con-</text>
<text top="946" left="64" width="350" height="15" font="5">nective tissue leads to chordal rupture. The differentiation</text>
<text top="964" left="64" width="350" height="15" font="5">between these 2 etiologies has important implications for</text>
<text top="981" left="64" width="350" height="15" font="5">operative intervention. Other less common causes of</text>
<text top="999" left="64" width="350" height="15" font="5">chronic primary MR include IE, connective tissue disor-</text>
<text top="1017" left="64" width="350" height="15" font="5">ders, rheumatic heart disease, cleft mitral valve, and radi-</text>
<text top="1035" left="64" width="350" height="15" font="5">ation heart disease. If the subsequent volume overload of</text>
<text top="1053" left="64" width="350" height="15" font="5">chronic primary MR is prolonged and severe, it causes</text>
<text top="1071" left="64" width="350" height="15" font="5">myocardial damage, HF, and eventual death. Correction of</text>
<text top="1089" left="64" width="201" height="15" font="5">the MR is curative. Thus, MR is</text>
<text top="1086" left="271" width="79" height="19" font="5">“the disease.”</text>
<text top="103" left="465" width="335" height="15" font="5">In chronic secondary MR, the mitral valve is usually</text>
<text top="121" left="450" width="56" height="15" font="5">normal (</text>
<text top="121" left="506" width="58" height="15" font="6"><a href="e57.full.html#44">Table 16</a></text>
<text top="121" left="564" width="235" height="15" font="5">). Instead, severe LV dysfunction is</text>
<text top="139" left="450" width="350" height="15" font="5">caused either by CAD, related MI (ischemic chronic</text>
<text top="157" left="450" width="350" height="15" font="5">secondary MR), or idiopathic myocardial disease (non-</text>
<text top="175" left="450" width="350" height="15" font="5">ischemic chronic secondary MR). The abnormal and</text>
<text top="193" left="450" width="350" height="15" font="5">dilated left ventricle causes papillary muscle displacement,</text>
<text top="210" left="450" width="170" height="15" font="5">which in turn results in lea</text>
<text top="207" left="620" width="179" height="19" font="5">ﬂet tethering with associated</text>
<text top="228" left="450" width="350" height="15" font="5">annular dilation that prevents coaptation. Because MR is</text>
<text top="246" left="450" width="350" height="15" font="5">only 1 component of the disease (severe LV dysfunction,</text>
<text top="264" left="450" width="350" height="15" font="5">coronary disease, or idiopathic myocardial disease are the</text>
<text top="282" left="450" width="350" height="15" font="5">others), restoration of mitral valve competence is not by</text>
<text top="300" left="450" width="350" height="15" font="5">itself curative; thus, the best therapy for chronic secondary</text>
<text top="318" left="450" width="350" height="15" font="5">MR is much less clear than it is for chronic primary MR.</text>
<text top="336" left="450" width="293" height="15" font="5">The data are limited, and there is greater dif</text>
<text top="333" left="743" width="56" height="19" font="5">ﬁculty in</text>
<text top="354" left="450" width="14" height="15" font="5">de</text>
<text top="351" left="464" width="335" height="19" font="5">ﬁning the severity of MR in patients with secondary MR</text>
<text top="372" left="450" width="350" height="15" font="5">than in those with primary MR. In patients with secondary</text>
<text top="390" left="450" width="350" height="15" font="5">MR, adverse outcomes are associated with a smaller</text>
<text top="408" left="450" width="214" height="15" font="5">calculated effective regurgitant ori</text>
<text top="404" left="664" width="136" height="19" font="5">ﬁce compared to pri-</text>
<text top="426" left="450" width="350" height="15" font="5">mary MR due to multiple reasons. The MR will likely</text>
<text top="444" left="450" width="350" height="15" font="5">progress because of the associated progressive LV systolic</text>
<text top="462" left="450" width="350" height="15" font="5">dysfunction and adverse remodeling. In addition, there is</text>
<text top="480" left="450" width="282" height="15" font="5">an underestimation of effective regurgitant ori</text>
<text top="476" left="731" width="68" height="19" font="5">ﬁce area by</text>
<text top="497" left="450" width="170" height="15" font="5">the 2D echocardiography</text>
<text top="494" left="620" width="180" height="19" font="5">derived ﬂow convergence</text>
<text top="515" left="450" width="350" height="15" font="5">method due to the crescentic shape of the regurgitant</text>
<text top="533" left="450" width="17" height="15" font="5">ori</text>
<text top="530" left="466" width="333" height="19" font="5">ﬁce. There are the additional clinical effects of a</text>
<text top="551" left="450" width="350" height="15" font="5">smaller amount of regurgitation in the presence of</text>
<text top="569" left="450" width="350" height="15" font="5">compromised LV systolic function and baseline elevated</text>
<text top="584" left="450" width="99" height="19" font="5">ﬁlling pressures.</text>
<text top="635" left="450" width="166" height="12" font="19">7.3. Chronic Primary MR</text>
<text top="662" left="450" width="206" height="15" font="5">7.3.1. Diagnosis and Follow-Up</text>
<text top="692" left="450" width="332" height="11" font="7">7.3.1.1. DIAGNOSTIC TESTINGdINITIAL DIAGNOSIS: RECOMMENDATIONS</text>
<text top="715" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="730" left="449" width="350" height="10" font="21">1. TTE is indicated for baseline evaluation of LV size and function,</text>
<text top="746" left="467" width="332" height="10" font="21">RV function and left atrial size, pulmonary artery pressure, and</text>
<text top="763" left="467" width="332" height="10" font="21">mechanism and severity of primary MR (stages A to D) in any</text>
<text top="779" left="467" width="275" height="10" font="21">patient suspected of having chronic primary MR</text>
<text top="779" left="749" width="50" height="10" font="22"><a href="e57.full.html#100">(5,21,39,</a></text>
<text top="796" left="467" width="21" height="10" font="22"><a href="e57.full.html#100">356</a></text>
<text top="793" left="489" width="32" height="16" font="22"><a href="e57.full.html#100">–371)</a></text>
<text top="796" left="520" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="820" left="465" width="335" height="15" font="5">Images provided by TTE generate most of the diag-</text>
<text top="838" left="450" width="350" height="15" font="5">nostic data needed for clinical decision making in chronic</text>
<text top="856" left="450" width="350" height="15" font="5">primary MR. The outcome of the patient with chronic</text>
<text top="874" left="450" width="350" height="15" font="5">primary MR is determined by lesion severity and the</text>
<text top="892" left="450" width="350" height="15" font="5">presence or absence of negative prognostic features that</text>
<text top="910" left="450" width="350" height="15" font="5">include the presence of symptoms, onset of LV dysfunc-</text>
<text top="928" left="450" width="350" height="15" font="5">tion, and presence of pulmonary hypertension; usually only</text>
<text top="946" left="450" width="350" height="15" font="5">severe MR leads to these negative sequelae. Favorable</text>
<text top="964" left="450" width="350" height="15" font="5">loading conditions in MR (increased preload and usually</text>
<text top="981" left="450" width="350" height="15" font="5">normal afterload) increase ejection phase indexes of LV</text>
<text top="999" left="450" width="350" height="15" font="5">function, such as LVEF, but do not affect the extent of</text>
<text top="1017" left="450" width="122" height="15" font="5">shortening. Thus, a</text>
<text top="1014" left="578" width="221" height="19" font="5">“normal” LVEF in MR is approxi-</text>
<text top="1035" left="450" width="350" height="15" font="5">mately 70%. In turn, the onset of LV dysfunction is</text>
<text top="1053" left="450" width="350" height="15" font="5">inferred when LVEF declines toward 60% or when the left</text>
<text top="1071" left="450" width="192" height="15" font="5">ventricle is unable to contract to</text>
<text top="1068" left="647" width="153" height="19" font="5">&lt;40 mm diameter at end</text>
<text top="1089" left="450" width="350" height="15" font="5">systole. It is clear that properly obtained and validated</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="18" height="10" font="15">e98</text>
</page>
<page number="43" position="absolute" top="0" left="0" height="1160" width="864">
<text top="672" left="64" width="350" height="15" font="5">chamber volumes give more information about detri-</text>
<text top="690" left="64" width="350" height="15" font="5">mental cardiac remodeling than simple chamber di-</text>
<text top="708" left="64" width="350" height="15" font="5">mensions, as suggested by angiographically obtained</text>
<text top="726" left="64" width="350" height="15" font="5">volume data. These techniques have been replaced by</text>
<text top="744" left="64" width="350" height="15" font="5">newer noninvasive imaging techniques, which initially</text>
<text top="762" left="64" width="350" height="15" font="5">used chamber dimensions for measurement of LV size and</text>
<text top="780" left="64" width="350" height="15" font="5">function. Until more prognostic volumetric data are</text>
<text top="798" left="64" width="350" height="15" font="5">available, most current prognostic data rely on chamber</text>
<text top="816" left="64" width="350" height="15" font="5">dimensions. Pulmonary artery systolic pressure approach-</text>
<text top="834" left="64" width="350" height="15" font="5">ing 50 mm Hg also worsens prognosis. Thus, when the</text>
<text top="852" left="64" width="112" height="15" font="5">murmur of MR is</text>
<text top="848" left="182" width="232" height="19" font="5">ﬁrst discovered, the clinician needs to</text>
<text top="869" left="64" width="186" height="15" font="5">know the severity of the MR <a href="e57.full.html#43">(</a></text>
<text top="869" left="250" width="54" height="15" font="6"><a href="e57.full.html#43">Table 15</a></text>
<text top="869" left="305" width="109" height="15" font="5"><a href="e57.full.html#43">) </a>and the size and</text>
<text top="887" left="64" width="350" height="15" font="5">function of the left ventricle, pulmonary artery pressure,</text>
<text top="905" left="64" width="350" height="15" font="5">and valve pathoanatomy from which valve reparability</text>
<text top="923" left="64" width="350" height="15" font="5">can be predicted. Determination of the severity of MR</text>
<text top="941" left="64" width="350" height="15" font="5">should be made on the basis of measurements of effective</text>
<text top="959" left="64" width="16" height="15" font="5">ori</text>
<text top="956" left="81" width="333" height="19" font="5">ﬁce area, regurgitant volume, and regurgitant fraction</text>
<text top="977" left="64" width="350" height="15" font="5">using the proximal isovelocity surface area or quantitative</text>
<text top="995" left="64" width="50" height="15" font="5">Doppler</text>
<text top="992" left="121" width="293" height="19" font="5">ﬂow measurements. However, there are limita-</text>
<text top="1013" left="64" width="350" height="15" font="5">tions to this technique, and multiple Doppler parameters,</text>
<text top="1031" left="64" width="350" height="15" font="5">including color jet area, vena contracta, continuous wave</text>
<text top="1049" left="64" width="350" height="15" font="5">Doppler intensity, and transmitral jet velocity curve should</text>
<text top="1067" left="64" width="350" height="15" font="5">be used to correlate with the quantitative measurements.</text>
<text top="1085" left="64" width="120" height="15" font="5">Once 1 of the above</text>
<text top="1081" left="188" width="226" height="19" font="5">“triggers” is reached, indicating severe</text>
<text top="672" left="450" width="350" height="15" font="5">MR and LV dysfunction, the patient should be considered</text>
<text top="690" left="450" width="350" height="15" font="5">for mitral valve surgery. TTE serves to give this infor-</text>
<text top="708" left="450" width="350" height="15" font="5">mation in most cases and also generates baseline data that</text>
<text top="726" left="450" width="221" height="15" font="5">can be used to compare the patient</text>
<text top="723" left="671" width="129" height="19" font="5">’s progress on subse-</text>
<text top="744" left="450" width="350" height="15" font="5">quent examinations. Three-dimensional echocardiogra-</text>
<text top="762" left="450" width="350" height="15" font="5">phy, strain imaging, or CMR may add more accurate</text>
<text top="780" left="450" width="350" height="15" font="5">assessment of the LV response in the future. Symptom</text>
<text top="798" left="450" width="350" height="15" font="5">presence is a key determinant of outcome, yet symptom</text>
<text top="816" left="450" width="350" height="15" font="5">status is highly subjective. Studies have demonstrated a</text>
<text top="834" left="450" width="350" height="15" font="5">correlation between B-type natriuretic peptide and</text>
<text top="852" left="450" width="350" height="15" font="5">outcome in MR. Although the data are preliminary, the</text>
<text top="866" left="450" width="350" height="19" font="5">ﬁnding of a rising B-type natriuretic peptide could be</text>
<text top="888" left="450" width="350" height="15" font="5">helpful as another factor in deciding the optimal timing of</text>
<text top="905" left="450" width="88" height="15" font="5">mitral surgery.</text>
<text top="924" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="923" left="597" width="76" height="15" font="6"><a href="e57.full.html#100">(5,21,39,356</a></text>
<text top="920" left="673" width="35" height="19" font="6"><a href="e57.full.html#100">–371)</a></text>
<text top="956" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="971" left="449" width="351" height="10" font="21">2. CMR is indicated in patients with chronic primary MR to assess</text>
<text top="988" left="467" width="332" height="10" font="21">LV and RV volumes, function, or MR severity and when these</text>
<text top="1004" left="467" width="245" height="10" font="21">issues are not satisfactorily addressed by TTE</text>
<text top="1004" left="716" width="80" height="10" font="22"><a href="e57.full.html#108">(366,372,373)</a></text>
<text top="1004" left="796" width="3" height="10" font="21">.</text>
<text top="1021" left="467" width="113" height="12" font="21">(Level of Evidence: B)</text>
<text top="1049" left="465" width="335" height="15" font="5">In most cases, TTE provides the data needed for</text>
<text top="1067" left="450" width="350" height="15" font="5">adequate evaluation of the MR patient. However, in cases</text>
<text top="1085" left="450" width="350" height="15" font="5">where TTE image quality is poor, CMR may be of value in</text>
<text top="103" left="64" width="185" height="13" font="13">Table 15. Stages of Primary MR</text>
<text top="129" left="64" width="27" height="9" font="7">Grade</text>
<text top="129" left="136" width="12" height="9" font="7">De</text>
<text top="126" left="148" width="32" height="14" font="7">ﬁnition</text>
<text top="129" left="259" width="69" height="9" font="7">Valve Anatomy</text>
<text top="129" left="394" width="99" height="9" font="7">Valve Hemodynamics</text>
<text top="129" left="493" width="6" height="9" font="8"><a href="e57.full.html#43">*</a></text>
<text top="129" left="542" width="136" height="9" font="7">Hemodynamic Consequences</text>
<text top="129" left="724" width="48" height="9" font="7">Symptoms</text>
<text top="145" left="67" width="7" height="9" font="7">A</text>
<text top="145" left="98" width="63" height="9" font="7">At risk of MR</text>
<text top="145" left="224" width="128" height="14" font="7"> Mild mitral valve prolapse</text>
<text top="162" left="236" width="104" height="9" font="7">with normal coaptation</text>
<text top="173" left="224" width="126" height="14" font="7"> Mild valve thickening and</text>
<text top="190" left="236" width="13" height="9" font="7">lea</text>
<text top="187" left="250" width="14" height="14" font="7">ﬂet</text>
<text top="204" left="236" width="44" height="9" font="7">restriction</text>
<text top="145" left="370" width="146" height="14" font="7"> No MR jet or small central jet</text>
<text top="162" left="382" width="20" height="9" font="7">area</text>
<text top="159" left="405" width="96" height="14" font="7">&lt;20% LA on Doppler</text>
<text top="173" left="370" width="150" height="14" font="7"> Small vena contracta &lt;0.3 cm</text>
<text top="145" left="530" width="35" height="14" font="7"> None</text>
<text top="145" left="698" width="35" height="14" font="7"> None</text>
<text top="222" left="67" width="7" height="9" font="7">B</text>
<text top="222" left="98" width="74" height="9" font="7">Progressive MR</text>
<text top="221" left="224" width="139" height="14" font="7"> Severe mitral valve prolapse</text>
<text top="238" left="236" width="104" height="9" font="7">with normal coaptation</text>
<text top="249" left="224" width="127" height="14" font="7"> Rheumatic valve changes</text>
<text top="266" left="236" width="36" height="9" font="7">with lea</text>
<text top="263" left="272" width="82" height="14" font="7">ﬂet restriction and</text>
<text top="280" left="236" width="114" height="9" font="7">loss of central coaptation</text>
<text top="292" left="224" width="44" height="14" font="7"> Prior IE</text>
<text top="221" left="370" width="153" height="14" font="7"> Central jet MR 20%–40% LA or</text>
<text top="238" left="382" width="129" height="9" font="7">late systolic eccentric jet MR</text>
<text top="249" left="370" width="122" height="14" font="7"> Vena contracta &lt;0.7 cm</text>
<text top="263" left="370" width="141" height="14" font="7"> Regurgitant volume &lt;60 mL</text>
<text top="278" left="370" width="133" height="14" font="7"> Regurgitant fraction &lt;50%</text>
<text top="292" left="370" width="80" height="14" font="7"> ERO &lt;0.40 cm</text>
<text top="292" left="451" width="5" height="6" font="23">2</text>
<text top="306" left="370" width="127" height="14" font="7"> Angiographic grade 1–2þ</text>
<text top="221" left="530" width="105" height="14" font="7"> Mild LA enlargement</text>
<text top="235" left="530" width="98" height="14" font="7"> No LV enlargement</text>
<text top="249" left="530" width="137" height="14" font="7"> Normal pulmonary pressure</text>
<text top="221" left="698" width="35" height="14" font="7"> None</text>
<text top="326" left="67" width="7" height="9" font="7">C</text>
<text top="326" left="98" width="120" height="9" font="7">Asymptomatic severe MR</text>
<text top="325" left="224" width="139" height="14" font="7"> Severe mitral valve prolapse</text>
<text top="342" left="236" width="114" height="9" font="7">with loss of coaptation or</text>
<text top="354" left="236" width="47" height="14" font="7">ﬂail leaﬂet</text>
<text top="368" left="224" width="127" height="14" font="7"> Rheumatic valve changes</text>
<text top="385" left="236" width="36" height="9" font="7">with lea</text>
<text top="382" left="272" width="82" height="14" font="7">ﬂet restriction and</text>
<text top="399" left="236" width="114" height="9" font="7">loss of central coaptation</text>
<text top="411" left="224" width="44" height="14" font="7"> Prior IE</text>
<text top="425" left="224" width="130" height="14" font="7"> Thickening of leaﬂets with</text>
<text top="442" left="236" width="104" height="9" font="7">radiation heart disease</text>
<text top="325" left="370" width="135" height="14" font="7"> Central jet MR &gt;40% LA or</text>
<text top="343" left="382" width="128" height="9" font="7">holosystolic eccentric jet MR</text>
<text top="354" left="370" width="122" height="14" font="7"> Vena contracta 0.7 cm</text>
<text top="368" left="370" width="141" height="14" font="7"> Regurgitant volume 60 mL</text>
<text top="382" left="370" width="133" height="14" font="7"> Regurgitant fraction 50%</text>
<text top="396" left="370" width="80" height="14" font="7"> ERO 0.40 cm</text>
<text top="397" left="451" width="5" height="6" font="23">2</text>
<text top="410" left="370" width="127" height="14" font="7"> Angiographic grade 3–4þ</text>
<text top="325" left="530" width="99" height="14" font="7"> Moderate or severe</text>
<text top="342" left="541" width="71" height="9" font="7">LA enlargement</text>
<text top="354" left="530" width="82" height="14" font="7"> LV enlargement</text>
<text top="368" left="530" width="143" height="14" font="7"> Pulmonary hypertension may</text>
<text top="385" left="541" width="150" height="9" font="7">be present at rest or with exercise</text>
<text top="396" left="530" width="137" height="14" font="7"> C1: LVEF &gt;60% and LVESD</text>
<text top="411" left="541" width="42" height="14" font="7">&lt;40 mm</text>
<text top="425" left="530" width="137" height="14" font="7"> C2: LVEF 60% and LVESD</text>
<text top="439" left="541" width="42" height="14" font="7">40 mm</text>
<text top="325" left="698" width="35" height="14" font="7"> None</text>
<text top="459" left="67" width="7" height="9" font="7">D</text>
<text top="459" left="98" width="114" height="9" font="7">Symptomatic severe MR</text>
<text top="458" left="224" width="139" height="14" font="7"> Severe mitral valve prolapse</text>
<text top="475" left="236" width="114" height="9" font="7">with loss of coaptation or</text>
<text top="487" left="236" width="47" height="14" font="7">ﬂail leaﬂet</text>
<text top="501" left="224" width="127" height="14" font="7"> Rheumatic valve changes</text>
<text top="518" left="236" width="36" height="9" font="7">with lea</text>
<text top="515" left="272" width="82" height="14" font="7">ﬂet restriction and</text>
<text top="532" left="236" width="114" height="9" font="7">loss of central coaptation</text>
<text top="544" left="224" width="44" height="14" font="7"> Prior IE</text>
<text top="558" left="224" width="130" height="14" font="7"> Thickening of leaﬂets with</text>
<text top="575" left="236" width="104" height="9" font="7">radiation heart disease</text>
<text top="458" left="370" width="135" height="14" font="7"> Central jet MR &gt;40% LA or</text>
<text top="476" left="382" width="128" height="9" font="7">holosystolic eccentric jet MR</text>
<text top="487" left="370" width="122" height="14" font="7"> Vena contracta 0.7 cm</text>
<text top="501" left="370" width="141" height="14" font="7"> Regurgitant volume 60 mL</text>
<text top="515" left="370" width="133" height="14" font="7"> Regurgitant fraction 50%</text>
<text top="529" left="370" width="80" height="14" font="7"> ERO 0.40 cm</text>
<text top="530" left="451" width="5" height="6" font="23">2</text>
<text top="543" left="370" width="127" height="14" font="7"> Angiographic grade 3–4þ</text>
<text top="458" left="530" width="114" height="14" font="7"> Moderate or severe LA</text>
<text top="475" left="541" width="57" height="9" font="7">enlargement</text>
<text top="487" left="530" width="82" height="14" font="7"> LV enlargement</text>
<text top="501" left="530" width="157" height="14" font="7"> Pulmonary hypertension present</text>
<text top="458" left="698" width="98" height="14" font="7"> Decreased exercise</text>
<text top="475" left="709" width="41" height="9" font="7">tolerance</text>
<text top="487" left="698" width="96" height="14" font="7"> Exertional dyspnea</text>
<text top="593" left="64" width="735" height="8" font="18">*Several valve hemodynamic criteria are provided for assessment of MR severity, but not all criteria for each category will be present in each patient. Categorization of MR severity as mild, moderate, or</text>
<text top="604" left="64" width="415" height="8" font="18">severe depends on data quality and integration of these parameters in conjunction with other clinical evidence.</text>
<text top="616" left="72" width="138" height="8" font="18">ERO indicates effective regurgitant ori</text>
<text top="614" left="210" width="589" height="11" font="18">ﬁce; IE, infective endocarditis; LA, left atrium/atrial; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD; left ventricular end-systolic dimension; and</text>
<text top="628" left="72" width="90" height="8" font="18">MR, mitral regurgitation.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="781" width="18" height="10" font="15">e99</text>
</page>
<page number="44" position="absolute" top="0" left="0" height="1160" width="864">
<text top="646" left="64" width="350" height="15" font="5">MR evaluation. CMR produces highly accurate data on</text>
<text top="664" left="64" width="350" height="15" font="5">LV volumes, RV volumes, and LVEF, and an estimation</text>
<text top="682" left="64" width="350" height="15" font="5">of MR severity, but outcome data using CMR volumes</text>
<text top="700" left="64" width="350" height="15" font="5">is pending. CMR is less helpful in establishing mitral</text>
<text top="718" left="64" width="88" height="15" font="5">pathoanatomy.</text>
<text top="737" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="736" left="212" width="84" height="15" font="6"><a href="e57.full.html#108">(366,372,373)</a></text>
<text top="763" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="778" left="63" width="351" height="10" font="21">3. Intraoperative TEE is indicated to establish the anatomic basis</text>
<text top="795" left="81" width="333" height="10" font="21">for chronic primary MR (stages C and D) and to guide repair</text>
<text top="811" left="81" width="55" height="10" font="22"><a href="e57.full.html#108">(374,375)</a></text>
<text top="811" left="136" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="835" left="79" width="335" height="15" font="5">Intraoperative TEE is a standard imaging modality for</text>
<text top="853" left="64" width="350" height="15" font="5">the surgical therapy of MR. Before the operative incision,</text>
<text top="871" left="64" width="350" height="15" font="5">TEE may give the surgeon a better understanding of the</text>
<text top="889" left="64" width="350" height="15" font="5">valve anatomy and type of repair that will likely be per-</text>
<text top="907" left="64" width="350" height="15" font="5">formed, although this decision is ultimately made when</text>
<text top="925" left="64" width="350" height="15" font="5">the valve is inspected visually. Three-dimensional TEE</text>
<text top="943" left="64" width="350" height="15" font="5">may be helpful in further visualizing the abnormal mitral</text>
<text top="961" left="64" width="350" height="15" font="5">valve anatomy. Because anesthesia lessens afterload, pre-</text>
<text top="979" left="64" width="350" height="15" font="5">load, and mitral valve closing force, it is important that</text>
<text top="997" left="64" width="350" height="15" font="5">decisions about severity of MR not be re-evaluated under</text>
<text top="1015" left="64" width="56" height="15" font="5">these arti</text>
<text top="1011" left="120" width="294" height="19" font="5">ﬁcial conditions, in which MR severity could be</text>
<text top="1033" left="64" width="95" height="15" font="5">underestimated.</text>
<text top="1051" left="79" width="335" height="15" font="5">Intraoperative TEE is especially helpful in gauging the</text>
<text top="1069" left="64" width="350" height="15" font="5">adequacy of repair. Because even mild residual MR</text>
<text top="1087" left="64" width="350" height="15" font="5">after repair increases the likelihood of later repair failure</text>
<text top="646" left="450" width="350" height="15" font="5">necessitating reoperation, surgeons strive for near-perfect</text>
<text top="664" left="450" width="350" height="15" font="5">operative repair. If MR is detected in the operating room</text>
<text top="682" left="450" width="350" height="15" font="5">following repair, it is often an indication that the repair</text>
<text top="700" left="450" width="350" height="15" font="5">should be revised. This assessment should be made during</text>
<text top="718" left="450" width="350" height="15" font="5">conditions that approach those of normal physiology. The</text>
<text top="736" left="450" width="166" height="15" font="5">left ventricle should be well</text>
<text top="733" left="620" width="179" height="19" font="5">ﬁlled and systemic BP should</text>
<text top="754" left="450" width="350" height="15" font="5">be brought well into the normal range. A low preload with</text>
<text top="772" left="450" width="34" height="15" font="5">under</text>
<text top="769" left="484" width="315" height="19" font="5">ﬁlling of the left ventricle can lead to 1) systolic</text>
<text top="790" left="450" width="68" height="15" font="5">anterior lea</text>
<text top="787" left="517" width="282" height="19" font="5">ﬂet motion with outﬂow obstruction or 2) un-</text>
<text top="808" left="450" width="350" height="15" font="5">derestimation of degree of residual MR. Thus, information</text>
<text top="826" left="450" width="268" height="15" font="5">obtained by TEE when the ventricle is under</text>
<text top="822" left="718" width="81" height="19" font="5">ﬁlled can lead</text>
<text top="844" left="450" width="350" height="15" font="5">to an unneeded revision in the former case while over-</text>
<text top="862" left="450" width="350" height="15" font="5">looking a needed revision in the latter. Intraoperative TEE</text>
<text top="880" left="450" width="232" height="15" font="5">is also useful for diagnosing mitral in</text>
<text top="876" left="682" width="117" height="19" font="5">ﬂow obstruction or</text>
<text top="898" left="450" width="48" height="15" font="5">LV out</text>
<text top="894" left="498" width="302" height="19" font="5">ﬂow obstruction as a result of the mitral valve</text>
<text top="915" left="450" width="38" height="15" font="5">repair.</text>
<text top="934" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="933" left="597" width="58" height="15" font="6"><a href="e57.full.html#108">(374,375)</a></text>
<text top="964" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="979" left="449" width="351" height="10" font="21">4. TEE is indicated for evaluation of patients with chronic primary</text>
<text top="995" left="467" width="332" height="10" font="21">MR (stages B to D) in whom noninvasive imaging provides</text>
<text top="1011" left="467" width="332" height="10" font="21">nondiagnostic information about severity of MR, mechanism of</text>
<text top="1028" left="467" width="297" height="12" font="21">MR, and/or status of LV function. (Level of Evidence: C)</text>
<text top="1052" left="465" width="335" height="15" font="5">TEE is not recommended for routine evaluation and</text>
<text top="1070" left="450" width="350" height="15" font="5">follow-up of patients with chronic primary MR but is</text>
<text top="1088" left="450" width="113" height="15" font="5">indicated in speci</text>
<text top="1085" left="563" width="237" height="19" font="5">ﬁc situations. Because TEE provides</text>
<text top="103" left="64" width="200" height="13" font="13">Table 16. Stages of Secondary MR</text>
<text top="129" left="64" width="27" height="9" font="7">Grade</text>
<text top="129" left="118" width="12" height="9" font="7">De</text>
<text top="126" left="131" width="32" height="14" font="7">ﬁnition</text>
<text top="129" left="226" width="69" height="9" font="7">Valve Anatomy</text>
<text top="129" left="364" width="99" height="9" font="7">Valve Hemodynamics</text>
<text top="129" left="463" width="6" height="9" font="8"><a href="e57.full.html#44">*</a></text>
<text top="129" left="506" width="132" height="9" font="7">Associated Cardiac Findings</text>
<text top="129" left="704" width="48" height="9" font="7">Symptoms</text>
<text top="145" left="67" width="7" height="9" font="7">A</text>
<text top="145" left="103" width="63" height="9" font="7">At risk of MR</text>
<text top="145" left="189" width="143" height="14" font="7"> Normal valve leaﬂets, chords,</text>
<text top="162" left="201" width="110" height="9" font="7">and annulus in a patient</text>
<text top="176" left="201" width="110" height="9" font="7">with coronary disease or</text>
<text top="190" left="201" width="71" height="9" font="7">cardiomyopathy</text>
<text top="145" left="345" width="143" height="14" font="7"> No MR jet or small central jet</text>
<text top="162" left="357" width="20" height="9" font="7">area</text>
<text top="159" left="380" width="96" height="14" font="7">&lt;20% LA on Doppler</text>
<text top="173" left="345" width="107" height="14" font="7"> Small vena contracta</text>
<text top="187" left="357" width="46" height="14" font="7">&lt;0.30 cm</text>
<text top="145" left="501" width="135" height="14" font="7"> Normal or mildly dilated LV</text>
<text top="162" left="512" width="39" height="9" font="7">size with</text>
<text top="159" left="555" width="85" height="14" font="7">ﬁxed (infarction) or</text>
<text top="176" left="512" width="129" height="9" font="7">inducible (ischemia) regional</text>
<text top="190" left="512" width="117" height="9" font="7">wall motion abnormalities</text>
<text top="201" left="501" width="136" height="14" font="7"> Primary myocardial disease</text>
<text top="218" left="512" width="125" height="9" font="7">with LV dilation and systolic</text>
<text top="233" left="512" width="51" height="9" font="7">dysfunction</text>
<text top="145" left="656" width="133" height="14" font="7"> Symptoms due to coronary</text>
<text top="162" left="668" width="105" height="9" font="7">ischemia or HF may be</text>
<text top="176" left="668" width="106" height="9" font="7">present that respond to</text>
<text top="190" left="668" width="95" height="9" font="7">revascularization and</text>
<text top="204" left="668" width="127" height="9" font="7">appropriate medical therapy</text>
<text top="250" left="67" width="7" height="9" font="7">B</text>
<text top="250" left="103" width="73" height="9" font="7">Progressive MR</text>
<text top="249" left="189" width="143" height="14" font="7"> Regional wall motion abnor-</text>
<text top="266" left="201" width="124" height="9" font="7">malities with mild tethering</text>
<text top="280" left="201" width="55" height="9" font="7">of mitral lea</text>
<text top="278" left="256" width="14" height="14" font="7">ﬂet</text>
<text top="292" left="189" width="128" height="14" font="7"> Annular dilation with mild</text>
<text top="309" left="201" width="126" height="9" font="7">loss of central coaptation of</text>
<text top="323" left="201" width="61" height="9" font="7">the mitral lea</text>
<text top="320" left="262" width="19" height="14" font="7">ﬂets</text>
<text top="249" left="345" width="80" height="14" font="7"> ERO &lt;0.20 cm</text>
<text top="250" left="425" width="5" height="6" font="23">2</text>
<text top="249" left="430" width="5" height="14" font="8"><a href="e57.full.html#44">y</a></text>
<text top="263" left="345" width="141" height="14" font="7"> Regurgitant volume &lt;30 mL</text>
<text top="278" left="345" width="133" height="14" font="7"> Regurgitant fraction &lt;50%</text>
<text top="249" left="501" width="143" height="14" font="7"> Regional wall motion abnor-</text>
<text top="266" left="512" width="111" height="9" font="7">malities with reduced LV</text>
<text top="280" left="512" width="72" height="9" font="7">systolic function</text>
<text top="292" left="501" width="115" height="14" font="7"> LV dilation and systolic</text>
<text top="309" left="512" width="121" height="9" font="7">dysfunction due to primary</text>
<text top="323" left="512" width="86" height="9" font="7">myocardial disease</text>
<text top="249" left="656" width="133" height="14" font="7"> Symptoms due to coronary</text>
<text top="266" left="668" width="105" height="9" font="7">ischemia or HF may be</text>
<text top="280" left="668" width="106" height="9" font="7">present that respond to</text>
<text top="295" left="668" width="95" height="9" font="7">revascularization and</text>
<text top="309" left="668" width="127" height="9" font="7">appropriate medical therapy</text>
<text top="340" left="67" width="7" height="9" font="7">C</text>
<text top="340" left="103" width="67" height="9" font="7">Asymptomatic</text>
<text top="355" left="116" width="50" height="9" font="7">severe MR</text>
<text top="340" left="189" width="143" height="14" font="7"> Regional wall motion abnor-</text>
<text top="357" left="201" width="120" height="9" font="7">malities and/or LV dilation</text>
<text top="371" left="201" width="107" height="9" font="7">with severe tethering of</text>
<text top="385" left="201" width="43" height="9" font="7">mitral lea</text>
<text top="382" left="244" width="14" height="14" font="7">ﬂet</text>
<text top="396" left="189" width="137" height="14" font="7"> Annular dilation with severe</text>
<text top="414" left="201" width="126" height="9" font="7">loss of central coaptation of</text>
<text top="428" left="201" width="61" height="9" font="7">the mitral lea</text>
<text top="425" left="262" width="19" height="14" font="7">ﬂets</text>
<text top="340" left="345" width="80" height="14" font="7"> ERO 0.20 cm</text>
<text top="340" left="425" width="5" height="6" font="23">2</text>
<text top="339" left="430" width="5" height="14" font="8"><a href="e57.full.html#44">y</a></text>
<text top="354" left="345" width="141" height="14" font="7"> Regurgitant volume 30 mL</text>
<text top="368" left="345" width="133" height="14" font="7"> Regurgitant fraction 50%</text>
<text top="340" left="501" width="143" height="14" font="7"> Regional wall motion abnor-</text>
<text top="357" left="512" width="111" height="9" font="7">malities with reduced LV</text>
<text top="371" left="512" width="72" height="9" font="7">systolic function</text>
<text top="382" left="501" width="115" height="14" font="7"> LV dilation and systolic</text>
<text top="399" left="512" width="121" height="9" font="7">dysfunction due to primary</text>
<text top="413" left="512" width="86" height="9" font="7">myocardial disease</text>
<text top="340" left="656" width="133" height="14" font="7"> Symptoms due to coronary</text>
<text top="357" left="668" width="105" height="9" font="7">ischemia or HF may be</text>
<text top="371" left="668" width="106" height="9" font="7">present that respond to</text>
<text top="385" left="668" width="95" height="9" font="7">revascularization and</text>
<text top="399" left="668" width="127" height="9" font="7">appropriate medical therapy</text>
<text top="445" left="67" width="7" height="9" font="7">D</text>
<text top="445" left="103" width="61" height="9" font="7">Symptomatic</text>
<text top="459" left="116" width="50" height="9" font="7">severe MR</text>
<text top="444" left="189" width="143" height="14" font="7"> Regional wall motion abnor-</text>
<text top="461" left="201" width="120" height="9" font="7">malities and/or LV dilation</text>
<text top="476" left="201" width="107" height="9" font="7">with severe tethering of</text>
<text top="490" left="201" width="43" height="9" font="7">mitral lea</text>
<text top="487" left="244" width="14" height="14" font="7">ﬂet</text>
<text top="501" left="189" width="137" height="14" font="7"> Annular dilation with severe</text>
<text top="518" left="201" width="126" height="9" font="7">loss of central coaptation of</text>
<text top="532" left="201" width="61" height="9" font="7">the mitral lea</text>
<text top="529" left="262" width="19" height="14" font="7">ﬂets</text>
<text top="444" left="345" width="80" height="14" font="7"> ERO 0.20 cm</text>
<text top="445" left="425" width="5" height="6" font="23">2</text>
<text top="444" left="430" width="5" height="14" font="8"><a href="e57.full.html#44">y</a></text>
<text top="458" left="345" width="141" height="14" font="7"> Regurgitant volume 30 mL</text>
<text top="472" left="345" width="133" height="14" font="7"> Regurgitant fraction 50%</text>
<text top="444" left="501" width="143" height="14" font="7"> Regional wall motion abnor-</text>
<text top="461" left="512" width="111" height="9" font="7">malities with reduced LV</text>
<text top="475" left="512" width="72" height="9" font="7">systolic function</text>
<text top="487" left="501" width="115" height="14" font="7"> LV dilation and systolic</text>
<text top="504" left="512" width="121" height="9" font="7">dysfunction due to primary</text>
<text top="518" left="512" width="86" height="9" font="7">myocardial disease</text>
<text top="444" left="656" width="124" height="14" font="7"> HF symptoms due to MR</text>
<text top="461" left="668" width="127" height="9" font="7">persist even after revascular-</text>
<text top="475" left="668" width="106" height="9" font="7">ization and optimization</text>
<text top="490" left="668" width="83" height="9" font="7">of medical therapy</text>
<text top="501" left="656" width="139" height="14" font="7"> Decreased exercise tolerance</text>
<text top="515" left="656" width="96" height="14" font="7"> Exertional dyspnea</text>
<text top="550" left="64" width="735" height="8" font="18">*Several valve hemodynamic criteria are provided for assessment of MR severity, but not all criteria for each category will be present in each patient. Categorization of MR severity as mild, moderate, or</text>
<text top="562" left="64" width="415" height="8" font="18">severe depends on data quality and integration of these parameters in conjunction with other clinical evidence.</text>
<text top="572" left="64" width="705" height="11" font="18"><a href="e57.full.html#44">y</a>The measurement of the proximal isovelocity surface area by 2D TTE in patients with secondary MR underestimates the true ERO due to the crescentic shape of the proximal convergence.</text>
<text top="586" left="72" width="214" height="8" font="18">2D indicates 2-dimensional; ERO, effective regurgitant ori</text>
<text top="584" left="286" width="454" height="11" font="18">ﬁce; HF, heart failure; LA, left atrium; LV, left ventricular; MR, mitral regurgitation; and TTE, transthoracic echocardiogram.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e100</text>
</page>
<page number="45" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">excellent imaging of the mitral valve, it should be per-</text>
<text top="121" left="64" width="350" height="15" font="5">formed when TTE images are inadequate. TEE is espe-</text>
<text top="139" left="64" width="350" height="15" font="5">cially useful in cases of MR due to IE, where additional</text>
<text top="157" left="64" width="350" height="15" font="5">information about other potentially infected structures can</text>
<text top="175" left="64" width="350" height="15" font="5">be fully evaluated by that technique. TEE allows more</text>
<text top="192" left="64" width="350" height="15" font="5">precise quantitation of regurgitant severity and provides a</text>
<text top="210" left="64" width="350" height="15" font="5">better estimate of the likelihood of a successful surgical</text>
<text top="228" left="64" width="350" height="15" font="5">valve repair. Three-dimensional TEE may be helpful in</text>
<text top="246" left="64" width="350" height="15" font="5">further visualizing the abnormal mitral valve anatomy.</text>
<text top="264" left="64" width="350" height="15" font="5">Mitral valve repair is preferable to valve replacement</text>
<text top="282" left="64" width="350" height="15" font="5">because of lower operative mortality and avoidance of the</text>
<text top="300" left="64" width="350" height="15" font="5">complications inherent to prosthetic valves that accrue over</text>
<text top="318" left="64" width="350" height="15" font="5">time. Thus, if repair can be accomplished, it might be</text>
<text top="336" left="64" width="350" height="15" font="5">performed earlier in the course of disease. Alternatively,</text>
<text top="354" left="64" width="350" height="15" font="5">if replacement is likely, strategy shifts toward performing</text>
<text top="372" left="64" width="350" height="15" font="5">surgery later to avoid unwanted exposure time to</text>
<text top="390" left="64" width="195" height="15" font="5">prosthetic-related complications.</text>
<text top="416" left="64" width="299" height="11" font="7">7.3.1.2. DIAGNOSTIC TESTINGdCHANGING SIGNS OR SYMPTOMS</text>
<text top="431" left="65" width="349" height="15" font="5">TTE is indicated in patients with primary MR (stages B to</text>
<text top="449" left="64" width="350" height="15" font="5">D) to evaluate the mitral valve apparatus and LV function</text>
<text top="467" left="64" width="350" height="15" font="5">after a change in signs or symptoms. The onset of symp-</text>
<text top="485" left="64" width="350" height="15" font="5">toms (dyspnea on exertion, orthopnea, or declining exercise</text>
<text top="503" left="64" width="350" height="15" font="5">tolerance) is by itself a negative prognostic event even if</text>
<text top="520" left="64" width="350" height="15" font="5">LV function is preserved. Symptoms are the culmination of</text>
<text top="538" left="64" width="350" height="15" font="5">the pathophysiology of MR and may indicate changes in</text>
<text top="556" left="64" width="308" height="15" font="5">LV diastolic function, left atrial compliance, LV</text>
<text top="553" left="379" width="35" height="19" font="5">ﬁlling</text>
<text top="574" left="64" width="350" height="15" font="5">pressure and/or increases in pulmonary artery pressure,</text>
<text top="592" left="64" width="350" height="15" font="5">and decreases in RV function or the coexistence of TR.</text>
<text top="610" left="64" width="350" height="15" font="5">Therefore, symptoms add pathophysiological data not</text>
<text top="628" left="64" width="350" height="15" font="5">readily available from imaging. Further, there is no evi-</text>
<text top="646" left="64" width="350" height="15" font="5">dence that treatment with diuretics or other therapies that</text>
<text top="664" left="64" width="350" height="15" font="5">might relieve symptoms changes the prognostic effect of</text>
<text top="682" left="64" width="350" height="15" font="5">symptom onset. Once symptoms have occurred, the patient</text>
<text top="700" left="64" width="350" height="15" font="5">should be considered for mitral valve operation even if</text>
<text top="718" left="64" width="350" height="15" font="5">medication has led to improvement. Repeat TTE at the</text>
<text top="736" left="64" width="291" height="15" font="5">time of symptom onset is indicated to con</text>
<text top="732" left="355" width="58" height="19" font="5">ﬁrm that</text>
<text top="754" left="64" width="350" height="15" font="5">symptoms are likely due to MR or its effect on the left</text>
<text top="772" left="64" width="350" height="15" font="5">ventricle, which in turn supports surgical correction. The</text>
<text top="789" left="64" width="350" height="15" font="5">new onset of AF is also an indication for repeat TTE to</text>
<text top="807" left="64" width="350" height="15" font="5">look for changes in severity of MR and the status of the left</text>
<text top="825" left="64" width="54" height="15" font="5">ventricle.</text>
<text top="844" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="843" left="212" width="58" height="15" font="6"><a href="e57.full.html#108">(365,376)</a></text>
<text top="874" left="64" width="243" height="11" font="7">7.3.1.3. DIAGNOSTIC TESTINGdROUTINE FOLLOW-UP</text>
<text top="889" left="65" width="349" height="15" font="5">TTE should be performed on an annual or semiannual</text>
<text top="907" left="64" width="350" height="15" font="5">basis for surveillance of LV function (estimated by LVEF</text>
<text top="925" left="64" width="350" height="15" font="5">and end-systolic dimension) and pulmonary artery pressure</text>
<text top="943" left="64" width="350" height="15" font="5">in asymptomatic patients with severe primary MR (stage</text>
<text top="961" left="64" width="350" height="15" font="5">C1). Chronic severe MR is tolerated poorly, reaching a</text>
<text top="978" left="64" width="350" height="15" font="5">trigger for surgery at an average rate of about 8% per year.</text>
<text top="996" left="64" width="350" height="15" font="5">Because this progression varies from patient to patient and</text>
<text top="1014" left="64" width="350" height="15" font="5">because prognosis worsens if correction of MR is delayed</text>
<text top="1032" left="64" width="350" height="15" font="5">beyond the onset of these triggers, either referral to a Heart</text>
<text top="1050" left="64" width="350" height="15" font="5">Valve Center of Excellence for early repair or very careful</text>
<text top="1068" left="64" width="350" height="15" font="5">surveillance is mandatory. If a watchful waiting approach is</text>
<text top="1086" left="64" width="350" height="15" font="5">pursued, periodic TTE is critical to examine the patient for</text>
<text top="103" left="450" width="350" height="15" font="5">changes in LV function and pulmonary pressure in</text>
<text top="121" left="450" width="350" height="15" font="5">determining the proper timing of surgery. For patients</text>
<text top="139" left="450" width="350" height="15" font="5">approaching the above benchmarks, semiannual TTE is</text>
<text top="157" left="450" width="350" height="15" font="5">recommended. It should be noted that echocardiographic</text>
<text top="175" left="450" width="350" height="15" font="5">measurements are variable, and management decisions that</text>
<text top="193" left="450" width="252" height="15" font="5">rest on these measurements should be con</text>
<text top="189" left="702" width="98" height="19" font="5">ﬁrmed by repeat</text>
<text top="210" left="450" width="350" height="15" font="5">TTE if the patient is approaching or has reached the</text>
<text top="228" left="450" width="259" height="15" font="5">important triggers for surgery noted above.</text>
<text top="246" left="465" width="335" height="15" font="5">In patients with chronic primary MR that is less than</text>
<text top="264" left="450" width="350" height="15" font="5">severe (stages A and B), TTE is indicated periodically to</text>
<text top="282" left="450" width="350" height="15" font="5">evaluate for changes in MR severity. MR is a progressive</text>
<text top="300" left="450" width="350" height="15" font="5">disease. The LV volume overload induced by chronic</text>
<text top="319" left="450" width="350" height="15" font="5">primary MR causes eccentric cardiac remodeling with</text>
<text top="336" left="450" width="350" height="15" font="5">progressively increasing chamber volume, tending to</text>
<text top="354" left="450" width="94" height="15" font="5">reduce valve lea</text>
<text top="351" left="543" width="256" height="19" font="5">ﬂet coaptation. Advancing valve pathology</text>
<text top="372" left="450" width="350" height="15" font="5">leads to further worsening of MR. This process may</text>
<text top="390" left="450" width="350" height="15" font="5">develop slowly without dramatic changes in symptoms or</text>
<text top="408" left="450" width="350" height="15" font="5">physical examination. Thus, MR could become severe and</text>
<text top="426" left="450" width="350" height="15" font="5">even lead to LV dysfunction without the patient or clini-</text>
<text top="444" left="450" width="350" height="15" font="5">cian being aware of it. Accordingly, periodic repeat TTE to</text>
<text top="462" left="450" width="350" height="15" font="5">examine for changes in severity of MR and LV size and</text>
<text top="479" left="450" width="350" height="15" font="5">function when baseline disease is less than severe is</text>
<text top="497" left="450" width="350" height="15" font="5">advisable. For mild MR, follow-up every 3 to 5 years is</text>
<text top="515" left="450" width="350" height="15" font="5">adequate unless the results of the physical examination or</text>
<text top="533" left="450" width="350" height="15" font="5">symptoms change. For moderate MR, follow-up every 1 to</text>
<text top="551" left="450" width="350" height="15" font="5">2 years is recommended, again unless clinical status sug-</text>
<text top="569" left="450" width="181" height="15" font="5">gests a worsening in severity <a href="e57.full.html#10">(</a></text>
<text top="569" left="631" width="47" height="15" font="6"><a href="e57.full.html#10">Table 4</a></text>
<text top="569" left="678" width="9" height="15" font="5"><a href="e57.full.html#10">).</a></text>
<text top="588" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="587" left="593" width="25" height="15" font="6"><a href="e57.full.html#101">(39)</a></text>
<text top="623" left="450" width="273" height="11" font="7">7.3.1.4. DIAGNOSTIC TESTINGdCARDIAC CATHETERIZATION</text>
<text top="638" left="451" width="349" height="15" font="5">Left ventriculography and/or hemodynamic measurements</text>
<text top="656" left="450" width="350" height="15" font="5">are indicated when clinical assessment and/or noninvasive</text>
<text top="674" left="450" width="350" height="15" font="5">tests are inconclusive or discordant regarding 1) severity of</text>
<text top="692" left="450" width="350" height="15" font="5">MR, 2) LV function, or 3) the need for surgery. Imaging</text>
<text top="709" left="450" width="350" height="15" font="5">with these techniques is adequate for evaluation of MR in</text>
<text top="727" left="450" width="350" height="15" font="5">the majority of cases. However, invasive hemodynamic</text>
<text top="745" left="450" width="350" height="15" font="5">evaluation may be necessary in some cases, especially when</text>
<text top="763" left="450" width="350" height="15" font="5">there is a clinical discrepancy between symptomatic status</text>
<text top="781" left="450" width="202" height="15" font="5">and noninvasive testing. Elevated</text>
<text top="778" left="656" width="143" height="19" font="5">ﬁlling pressures support</text>
<text top="799" left="450" width="350" height="15" font="5">a cardiac cause for dyspnea and/or may indicate severely</text>
<text top="817" left="450" width="350" height="15" font="5">abnormal pathophysiology even when the patient claims to</text>
<text top="835" left="450" width="350" height="15" font="5">be asymptomatic. Conversely, a normal invasive hemody-</text>
<text top="853" left="450" width="350" height="15" font="5">namic examination in a symptomatic patient with what</text>
<text top="871" left="450" width="350" height="15" font="5">appears to be less than severe MR suggests a noncardiac</text>
<text top="889" left="450" width="350" height="15" font="5">cause for the symptoms. Hemodynamic evaluation can be</text>
<text top="907" left="450" width="350" height="15" font="5">especially helpful in patients with concomitant lung dis-</text>
<text top="925" left="450" width="350" height="15" font="5">ease. Normal left atrial (or wedge) pressure and a large</text>
<text top="943" left="450" width="350" height="15" font="5">transpulmonary gradient suggest pulmonary hypertension</text>
<text top="961" left="450" width="350" height="15" font="5">due to lung disease rather than mitral valve disease. Pa-</text>
<text top="979" left="450" width="350" height="15" font="5">tients usually complain of dyspnea with exertion, yet</text>
<text top="996" left="450" width="350" height="15" font="5">noninvasive evaluation is usually made at rest. Hemody-</text>
<text top="1014" left="450" width="350" height="15" font="5">namic measurement made during either handgrip or dy-</text>
<text top="1032" left="450" width="350" height="15" font="5">namic exercise may be very revealing. Increased load with</text>
<text top="1050" left="450" width="350" height="15" font="5">exercise may bring out severely disordered hemodynamics</text>
<text top="1068" left="450" width="137" height="15" font="5">explaining the patient</text>
<text top="1065" left="587" width="213" height="19" font="5">’s exercise-related symptoms. Left</text>
<text top="1086" left="450" width="333" height="15" font="5">ventriculography may also be of diagnostic bene</text>
<text top="1083" left="783" width="17" height="19" font="5">ﬁt.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e101</text>
</page>
<page number="46" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">Whereas echo-Doppler interrogation of the mitral valve</text>
<text top="121" left="64" width="54" height="15" font="5">measures</text>
<text top="117" left="122" width="292" height="19" font="5">ﬂow velocity, ventriculography uses the density of</text>
<text top="139" left="64" width="261" height="15" font="5">contrast to determine the amount of blood</text>
<text top="135" left="330" width="84" height="19" font="5">ﬂow from the</text>
<text top="157" left="64" width="350" height="15" font="5">left ventricle to LA. Although only semiquantitative, a</text>
<text top="175" left="64" width="290" height="15" font="5">carefully performed ventriculogram can add signi</text>
<text top="171" left="355" width="59" height="19" font="5">ﬁcantly to</text>
<text top="192" left="64" width="149" height="15" font="5">the diagnostic data pool.</text>
<text top="211" left="79" width="123" height="15" font="5">Supporting Reference:</text>
<text top="210" left="208" width="25" height="15" font="6"><a href="e57.full.html#101">(42)</a></text>
<text top="238" left="64" width="331" height="11" font="7">7.3.1.5. DIAGNOSTIC TESTINGdEXERCISE TESTING: RECOMMENDATIONS</text>
<text top="262" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="277" left="64" width="350" height="10" font="21">1. Exercise hemodynamics with either Doppler echocardiography</text>
<text top="293" left="82" width="332" height="10" font="21">or cardiac catheterization is reasonable in symptomatic pa-</text>
<text top="310" left="82" width="332" height="10" font="21">tients with chronic primary MR where there is a discrepancy</text>
<text top="326" left="82" width="332" height="10" font="21">between symptoms and the severity of MR at rest (stages B</text>
<text top="343" left="82" width="35" height="10" font="21">and C)</text>
<text top="343" left="121" width="55" height="10" font="22"><a href="e57.full.html#109">(377,378)</a></text>
<text top="343" left="176" width="121" height="12" font="21"><a href="e57.full.html#109">. </a>(Level of Evidence: B)</text>
<text top="367" left="79" width="335" height="15" font="5">The symptoms of chronic primary MR usually occur</text>
<text top="385" left="64" width="350" height="15" font="5">during exercise. Thus, evaluation during exercise may be</text>
<text top="403" left="64" width="350" height="15" font="5">very informative when resting TTE and symptomatic</text>
<text top="421" left="64" width="350" height="15" font="5">status are discordant or when the magnitude of LV and LA</text>
<text top="439" left="64" width="350" height="15" font="5">enlargement seem out of proportion to the severity of</text>
<text top="457" left="64" width="350" height="15" font="5">resting MR. In such cases, severity of MR and/or pul-</text>
<text top="474" left="64" width="350" height="15" font="5">monary artery pressure may increase during exercise, both</text>
<text top="492" left="64" width="350" height="15" font="5">helping to explain exercise-induced symptoms and indi-</text>
<text top="510" left="64" width="350" height="15" font="5">cating that mitral surgery may be in order. The change in</text>
<text top="528" left="64" width="350" height="15" font="5">pulmonary artery wedge pressure and LV diastolic pressure</text>
<text top="546" left="64" width="350" height="15" font="5">during exercise can be obtained during cardiac catheteri-</text>
<text top="564" left="64" width="350" height="15" font="5">zation, which may further aid in determining the etiology</text>
<text top="582" left="64" width="81" height="15" font="5">of symptoms.</text>
<text top="601" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="600" left="212" width="77" height="15" font="6"><a href="e57.full.html#101">(42,377,378)</a></text>
<text top="627" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="642" left="63" width="351" height="10" font="21">2. Exercise treadmill testing can be useful in patients with chronic</text>
<text top="659" left="81" width="332" height="10" font="21">primary MR to establish symptom status and exercise tolerance</text>
<text top="675" left="81" width="211" height="12" font="21">(stages B and C). (Level of Evidence: C)</text>
<text top="699" left="79" width="335" height="15" font="5">The onset of symptoms represents a key development in</text>
<text top="717" left="64" width="350" height="15" font="5">severe MR. However, some patients may not recognize</text>
<text top="735" left="64" width="349" height="15" font="5">their symptoms, may deny them, or may alter their lifestyle</text>
<text top="753" left="64" width="350" height="15" font="5">to remain asymptomatic. A formal treadmill exercise test</text>
<text top="771" left="64" width="350" height="15" font="5">can establish true exercise tolerance and can also form the</text>
<text top="789" left="64" width="350" height="15" font="5">baseline for future symptom assessment. Additional in-</text>
<text top="807" left="64" width="350" height="15" font="5">formation about a cardiac or noncardiac limitation can be</text>
<text top="825" left="64" width="350" height="15" font="5">obtained using oxygen consumption measurements during</text>
<text top="843" left="64" width="350" height="15" font="5">exercise. Exercise echocardiography may add additional</text>
<text top="861" left="64" width="350" height="15" font="5">prognostic value beyond conventional exercise treadmill</text>
<text top="879" left="64" width="350" height="15" font="5">testing in patients with asymptomatic moderate or severe</text>
<text top="897" left="64" width="129" height="15" font="5">chronic primary MR.</text>
<text top="915" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="915" left="212" width="27" height="15" font="6"><a href="e57.full.html#109">(378</a></text>
<text top="911" left="239" width="35" height="19" font="6"><a href="e57.full.html#109">–381)</a></text>
<text top="953" left="64" width="277" height="15" font="5">7.3.2. Medical Therapy: Recommendations</text>
<text top="981" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="996" left="64" width="350" height="10" font="21">1. Medical therapy for systolic dysfunction is reasonable in</text>
<text top="1012" left="82" width="332" height="10" font="21">symptomatic patients with chronic primary MR (stage D) and</text>
<text top="1028" left="82" width="297" height="10" font="21">LVEF less than 60% in whom surgery is not contemplated</text>
<text top="1028" left="382" width="26" height="10" font="22"><a href="e57.full.html#109">(382</a></text>
<text top="1025" left="408" width="6" height="16" font="22"><a href="e57.full.html#109">–</a></text>
<text top="1045" left="82" width="26" height="10" font="22"><a href="e57.full.html#109">386)</a></text>
<text top="1045" left="108" width="121" height="12" font="21"><a href="e57.full.html#109">. </a>(Level of Evidence: B)</text>
<text top="1070" left="79" width="335" height="15" font="5">Patients with MR and LV dysfunction experience</text>
<text top="1087" left="64" width="350" height="15" font="5">myocardial damage and HF. With onset of LV systolic</text>
<text top="103" left="450" width="350" height="15" font="5">dysfunction, surgery is usually indicated. However, in those</text>
<text top="121" left="450" width="350" height="15" font="5">patients in whom surgery is not performed or will be</text>
<text top="139" left="450" width="350" height="15" font="5">delayed, medical therapy for systolic dysfunction should be</text>
<text top="157" left="450" width="350" height="15" font="5">implemented. Although there are sparse data available</text>
<text top="175" left="450" width="29" height="15" font="5">speci</text>
<text top="171" left="479" width="320" height="19" font="5">ﬁc to patients with MR with LV dysfunction, it seems</text>
<text top="192" left="450" width="350" height="15" font="5">reasonable to treat such patients with the standard regimen</text>
<text top="210" left="450" width="350" height="15" font="5">for HF, including beta-adrenergic blockade, ACE in-</text>
<text top="228" left="450" width="350" height="15" font="5">hibitors or ARBs, and possibly aldosterone antagonists.</text>
<text top="246" left="450" width="350" height="15" font="5">Perhaps the best data exist for the use of beta blockers,</text>
<text top="264" left="450" width="350" height="15" font="5">which reverse LV dysfunction in experimental MR. Pa-</text>
<text top="282" left="450" width="350" height="15" font="5">tients who are receiving beta blockers may have better</text>
<text top="300" left="450" width="350" height="15" font="5">surgical outcomes and delayed onset of LV dysfunction</text>
<text top="318" left="450" width="350" height="15" font="5">compared with those not taking these medications. ACE</text>
<text top="336" left="450" width="350" height="15" font="5">inhibition has not been effective in experimental MR with</text>
<text top="354" left="450" width="350" height="15" font="5">LV dysfunction but has caused reverse remodeling in a</text>
<text top="372" left="450" width="350" height="15" font="5">study with a small number of patients. Because aldosterone</text>
<text top="390" left="450" width="350" height="15" font="5">antagonism is thought to work in part by inhibiting</text>
<text top="404" left="450" width="350" height="19" font="5">ﬁbrosis, its role in MR where little ﬁbrosis occurs is</text>
<text top="426" left="450" width="46" height="15" font="5">unclear.</text>
<text top="444" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="444" left="597" width="27" height="15" font="6"><a href="e57.full.html#109">(382</a></text>
<text top="440" left="625" width="35" height="19" font="6"><a href="e57.full.html#109">–386)</a></text>
<text top="473" left="450" width="88" height="8" font="20">CLASS III: No Bene</text>
<text top="470" left="538" width="10" height="13" font="20">ﬁt</text>
<text top="488" left="449" width="80" height="10" font="21">1. Vasodilator</text>
<text top="488" left="539" width="41" height="10" font="21">therapy</text>
<text top="488" left="591" width="9" height="10" font="21">is</text>
<text top="488" left="611" width="18" height="10" font="21">not</text>
<text top="488" left="640" width="50" height="10" font="21">indicated</text>
<text top="488" left="701" width="14" height="10" font="21">for</text>
<text top="488" left="726" width="73" height="10" font="21">normotensive</text>
<text top="504" left="467" width="333" height="10" font="21">asymptomatic patients with chronic primary MR (stages B</text>
<text top="521" left="467" width="220" height="10" font="21">and C1) and normal systolic LV function</text>
<text top="521" left="691" width="26" height="10" font="22"><a href="e57.full.html#109">(386</a></text>
<text top="518" left="716" width="32" height="16" font="22"><a href="e57.full.html#109">–391)</a></text>
<text top="521" left="748" width="51" height="12" font="21">. (Level of</text>
<text top="537" left="467" width="65" height="12" font="21">Evidence: B)</text>
<text top="562" left="465" width="335" height="15" font="5">Because vasodilator therapy appears to be effective in</text>
<text top="579" left="450" width="350" height="15" font="5">acute severe symptomatic MR, it seems reasonable to</text>
<text top="597" left="450" width="350" height="15" font="5">attempt afterload reduction in chronic asymptomatic MR</text>
<text top="615" left="450" width="350" height="15" font="5">with normal LV function in an effort to forestall the need</text>
<text top="633" left="450" width="350" height="15" font="5">for surgery. However, the results from the limited number</text>
<text top="651" left="450" width="350" height="15" font="5">of trials addressing this therapy have been disappointing,</text>
<text top="669" left="450" width="333" height="15" font="5">demonstrating little or no clinically important bene</text>
<text top="666" left="783" width="17" height="19" font="5">ﬁt.</text>
<text top="687" left="450" width="350" height="15" font="5">Conversely, because vasodilators decrease LV size and</text>
<text top="705" left="450" width="350" height="15" font="5">mitral closing force, they may increase mitral valve pro-</text>
<text top="723" left="450" width="350" height="15" font="5">lapse, worsening rather than decreasing severity of MR.</text>
<text top="741" left="450" width="350" height="15" font="5">The foregoing does not apply to patients with concomitant</text>
<text top="759" left="450" width="350" height="15" font="5">hypertension. Hypertension must be treated because of the</text>
<text top="777" left="450" width="350" height="15" font="5">well-known morbidity and mortality associated with that</text>
<text top="795" left="450" width="350" height="15" font="5">condition and because increased LV systolic pressure by</text>
<text top="813" left="450" width="350" height="15" font="5">itself increases the systolic transmitral gradient and worsens</text>
<text top="831" left="450" width="95" height="15" font="5">severity of MR.</text>
<text top="849" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="848" left="597" width="27" height="15" font="6"><a href="e57.full.html#109">(386</a></text>
<text top="845" left="625" width="35" height="19" font="6"><a href="e57.full.html#109">–391)</a></text>
<text top="883" left="450" width="248" height="15" font="5">7.3.3. Intervention: Recommendations</text>
<text top="908" left="451" width="21" height="15" font="5">See</text>
<text top="908" left="475" width="53" height="15" font="6"><a href="e57.full.html#47">Table 17</a></text>
<text top="908" left="531" width="268" height="15" font="5">for a summary of recommendations from this</text>
<text top="926" left="450" width="45" height="15" font="5">section.</text>
<text top="944" left="465" width="335" height="15" font="5">Intervention for patients with primary MR consists of</text>
<text top="962" left="450" width="350" height="15" font="5">either surgical mitral valve repair or MVR. Mitral valve</text>
<text top="980" left="450" width="350" height="15" font="5">repair is preferred over MVR if a successful and durable</text>
<text top="998" left="450" width="350" height="15" font="5">repair can be achieved. Repair success is dependent on the</text>
<text top="1016" left="450" width="350" height="15" font="5">mitral valve morphology as well as surgical expertise.</text>
<text top="1034" left="450" width="350" height="15" font="5">Percutaneous mitral valve repair provides a less invasive</text>
<text top="1052" left="450" width="350" height="15" font="5">alternative to surgery but is not approved for clinical use in</text>
<text top="1070" left="450" width="109" height="15" font="5">the United States.</text>
<text top="1088" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="1088" left="593" width="32" height="15" font="6"><a href="e57.full.html#110">(426)</a></text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e102</text>
</page>
<page number="47" position="absolute" top="0" left="0" height="1160" width="864">
<text top="650" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="665" left="63" width="351" height="10" font="21">1. Mitral valve surgery is recommended for symptomatic patients</text>
<text top="681" left="81" width="333" height="10" font="21">with chronic severe primary MR (stage D) and LVEF greater</text>
<text top="698" left="81" width="50" height="10" font="21">than 30%</text>
<text top="698" left="135" width="55" height="10" font="22"><a href="e57.full.html#108">(365,376)</a></text>
<text top="698" left="190" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="722" left="79" width="283" height="15" font="5">Primary MR is a mechanical problem of the lea</text>
<text top="719" left="362" width="52" height="19" font="5">ﬂets that</text>
<text top="740" left="64" width="350" height="16" font="5">has only a mechanical solutiondthat of mitral valve sur-</text>
<text top="758" left="64" width="350" height="15" font="5">gery. The onset of symptoms that results from severe MR</text>
<text top="776" left="64" width="350" height="15" font="5">worsens prognosis even when LV function appears to be</text>
<text top="794" left="64" width="350" height="15" font="5">normal, and negative prognosis extends even to mild</text>
<text top="812" left="64" width="350" height="15" font="5">symptoms. Thus, the onset of symptoms is an indication</text>
<text top="830" left="64" width="192" height="15" font="5">for prompt mitral valve surgery.</text>
<text top="848" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="848" left="212" width="58" height="15" font="6"><a href="e57.full.html#108">(365,376)</a></text>
<text top="875" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="890" left="63" width="351" height="10" font="21">2. Mitral valve surgery is recommended for asymptomatic patients</text>
<text top="906" left="81" width="332" height="10" font="21">with chronic severe primary MR and LV dysfunction (LVEF 30%</text>
<text top="923" left="81" width="113" height="10" font="21">to 60% and/or LVESD</text>
<text top="920" left="197" width="102" height="16" font="21">‡40 mm, stage C2)</text>
<text top="923" left="301" width="26" height="10" font="22"><a href="e57.full.html#108">(359</a></text>
<text top="920" left="327" width="84" height="16" font="22"><a href="e57.full.html#108">–362,392–394)</a></text>
<text top="923" left="410" width="3" height="10" font="21">.</text>
<text top="939" left="81" width="113" height="12" font="21">(Level of Evidence: B)</text>
<text top="964" left="79" width="335" height="15" font="5">The goal of therapy in MR is to correct it before the onset</text>
<text top="981" left="64" width="350" height="15" font="5">of LV systolic dysfunction and the subsequent adverse</text>
<text top="999" left="64" width="350" height="15" font="5">effect on patient outcomes. Ideally, mitral valve surgery</text>
<text top="1017" left="64" width="235" height="15" font="5">should be performed when the patient</text>
<text top="1014" left="300" width="114" height="19" font="5">’s left ventricle ap-</text>
<text top="1035" left="64" width="350" height="15" font="5">proaches but has not yet reached the parameters that indi-</text>
<text top="1053" left="64" width="198" height="15" font="5">cate systolic dysfunction (LVEF</text>
<text top="1050" left="268" width="146" height="19" font="5">60% or LVESD 40</text>
<text top="1071" left="64" width="350" height="15" font="5">mm). Because symptoms do not always coincide with LV</text>
<text top="1089" left="64" width="350" height="15" font="5">dysfunction, imaging surveillance is used to plan surgery</text>
<text top="647" left="450" width="350" height="15" font="5">before severe dysfunction has occurred. If moderate LV</text>
<text top="665" left="450" width="350" height="15" font="5">dysfunction is already present, prognosis is reduced</text>
<text top="683" left="450" width="350" height="15" font="5">following mitral valve operation. Thus, further delay (even</text>
<text top="701" left="450" width="350" height="15" font="5">though symptoms are absent) will lead to greater LV</text>
<text top="719" left="450" width="350" height="15" font="5">dysfunction and a still worse prognosis. Because the loading</text>
<text top="736" left="450" width="350" height="15" font="5">conditions in MR allow continued late ejection into a</text>
<text top="754" left="450" width="239" height="15" font="5">lower-impedance LA, a higher cutoff for</text>
<text top="751" left="692" width="108" height="19" font="5">“normal” LVEF is</text>
<text top="772" left="450" width="350" height="15" font="5">used in MR than in other types of heart disease. Although</text>
<text top="790" left="450" width="247" height="15" font="5">it is clearly inadvisable to allow patients</text>
<text top="787" left="696" width="103" height="19" font="5">’ LV function to</text>
<text top="808" left="450" width="305" height="15" font="5">deteriorate beyond the benchmarks of an LVEF</text>
<text top="805" left="762" width="38" height="19" font="5">60%</text>
<text top="826" left="450" width="96" height="15" font="5">and/or LVESD</text>
<text top="823" left="551" width="248" height="19" font="5">40 mm, some recovery of LV function</text>
<text top="844" left="450" width="341" height="15" font="5">can still occur even if these thresholds have been crossed.</text>
<text top="863" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="862" left="598" width="27" height="15" font="6"><a href="e57.full.html#108">(359</a></text>
<text top="859" left="625" width="91" height="19" font="6"><a href="e57.full.html#108">–362,392–394)</a></text>
<text top="892" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="907" left="449" width="351" height="10" font="21">3. Mitral valve repair is recommended in preference to MVR when</text>
<text top="923" left="467" width="333" height="10" font="21">surgical treatment is indicated for patients with chronic severe</text>
<text top="940" left="467" width="208" height="10" font="21">primary MR limited to the posterior lea</text>
<text top="937" left="675" width="17" height="16" font="21">ﬂet</text>
<text top="940" left="696" width="68" height="10" font="22"><a href="e57.full.html#102">(87,364,395</a></text>
<text top="937" left="764" width="32" height="16" font="22"><a href="e57.full.html#102">–409)</a></text>
<text top="940" left="796" width="3" height="10" font="21">.</text>
<text top="957" left="467" width="113" height="12" font="21">(Level of Evidence: B)</text>
<text top="981" left="465" width="335" height="15" font="5">Mitral competence is only 1 function of the mitral valve</text>
<text top="999" left="450" width="350" height="15" font="5">apparatus. The mitral valve apparatus is an integral part of</text>
<text top="1016" left="450" width="350" height="15" font="5">the left ventricle. It aids in LV contraction and helps</text>
<text top="1034" left="450" width="97" height="15" font="5">maintain the ef</text>
<text top="1031" left="546" width="253" height="19" font="5">ﬁcient prolate ellipsoid shape of the left</text>
<text top="1052" left="450" width="350" height="15" font="5">ventricle. Destruction of the mitral apparatus causes im-</text>
<text top="1070" left="450" width="350" height="15" font="5">mediate LV dysfunction. Mitral valve repair is favored over</text>
<text top="1088" left="450" width="122" height="15" font="5">MVR for 3 reasons:</text>
<text top="103" left="64" width="372" height="13" font="13">Table 17. Summary of Recommendations for Chronic Primary MR</text>
<text top="129" left="64" width="86" height="9" font="7">Recommendations</text>
<text top="129" left="570" width="21" height="9" font="7">COR</text>
<text top="129" left="669" width="18" height="9" font="7">LOE</text>
<text top="129" left="742" width="52" height="9" font="7">References</text>
<text top="148" left="64" width="455" height="9" font="7">MV surgery is recommended for symptomatic patients with chronic severe primary MR (stage D) and</text>
<text top="162" left="77" width="21" height="9" font="7">LVEF</text>
<text top="159" left="102" width="28" height="14" font="7">&gt;30%</text>
<text top="148" left="579" width="3" height="9" font="7">I</text>
<text top="148" left="675" width="6" height="9" font="7">B</text>
<text top="148" left="745" width="45" height="9" font="8"><a href="e57.full.html#108">(365,376)</a></text>
<text top="176" left="64" width="431" height="9" font="7">MV surgery is recommended for asymptomatic patients with chronic severe primary MR and LV</text>
<text top="190" left="77" width="103" height="9" font="7">dysfunction (LVEF 30%</text>
<text top="187" left="179" width="186" height="14" font="7">–60% and/or LVESD 40 mm, stage C2)</text>
<text top="176" left="579" width="3" height="9" font="7">I</text>
<text top="176" left="675" width="6" height="9" font="7">B</text>
<text top="176" left="744" width="21" height="9" font="8"><a href="e57.full.html#108">(359</a></text>
<text top="173" left="766" width="26" height="14" font="8"><a href="e57.full.html#108">–362,</a></text>
<text top="190" left="752" width="18" height="9" font="8"><a href="e57.full.html#108">392</a></text>
<text top="187" left="771" width="27" height="14" font="8"><a href="e57.full.html#108">–394)</a></text>
<text top="204" left="64" width="444" height="9" font="7">MV repair is recommended in preference to MVR when surgical treatment is indicated for patients</text>
<text top="218" left="77" width="267" height="9" font="7">with chronic severe primary MR limited to the posterior lea</text>
<text top="215" left="343" width="14" height="14" font="7">ﬂet</text>
<text top="204" left="579" width="3" height="9" font="7">I</text>
<text top="204" left="675" width="6" height="9" font="7">B</text>
<text top="204" left="744" width="39" height="9" font="8"><a href="e57.full.html#102">(87,364,</a></text>
<text top="218" left="752" width="18" height="9" font="8"><a href="e57.full.html#102">395</a></text>
<text top="215" left="770" width="27" height="14" font="8"><a href="e57.full.html#102">–409)</a></text>
<text top="232" left="64" width="444" height="9" font="7">MV repair is recommended in preference to MVR when surgical treatment is indicated for patients</text>
<text top="246" left="77" width="255" height="9" font="7">with chronic severe primary MR involving the anterior lea</text>
<text top="243" left="332" width="190" height="14" font="7">ﬂet or both leaﬂets when a successful and</text>
<text top="261" left="77" width="162" height="9" font="7">durable repair can be accomplished</text>
<text top="232" left="579" width="3" height="9" font="7">I</text>
<text top="232" left="675" width="6" height="9" font="7">B</text>
<text top="232" left="737" width="36" height="9" font="8"><a href="e57.full.html#102">(86,407</a></text>
<text top="229" left="773" width="27" height="14" font="8"><a href="e57.full.html#102">–413)</a></text>
<text top="274" left="64" width="427" height="9" font="7">Concomitant MV repair or replacement is indicated in patients with chronic severe primary MR</text>
<text top="289" left="77" width="215" height="9" font="7">undergoing cardiac surgery for other indications</text>
<text top="274" left="579" width="3" height="9" font="7">I</text>
<text top="274" left="675" width="6" height="9" font="7">B</text>
<text top="274" left="756" width="25" height="9" font="8"><a href="e57.full.html#109">(414)</a></text>
<text top="303" left="64" width="442" height="9" font="7">MV repair is reasonable in asymptomatic patients with chronic severe primary MR (stage C1) with</text>
<text top="317" left="77" width="125" height="9" font="7">preserved LV function (LVEF</text>
<text top="314" left="205" width="307" height="14" font="7">&gt;60% and LVESD &lt;40 mm) in whom the likelihood of a successful</text>
<text top="331" left="77" width="187" height="9" font="7">and durable repair without residual MR is</text>
<text top="328" left="267" width="238" height="14" font="7">&gt;95% with an expected mortality rate of &lt;1% when</text>
<text top="345" left="77" width="218" height="9" font="7">performed at a Heart Valve Center of Excellence</text>
<text top="303" left="575" width="11" height="9" font="7">IIa</text>
<text top="303" left="675" width="6" height="9" font="7">B</text>
<text top="303" left="746" width="33" height="9" font="8"><a href="e57.full.html#101">(39,86,</a></text>
<text top="317" left="752" width="18" height="9" font="8"><a href="e57.full.html#101">415</a></text>
<text top="314" left="770" width="27" height="14" font="8"><a href="e57.full.html#101">–419)</a></text>
<text top="359" left="64" width="440" height="9" font="7">MV repair is reasonable for asymptomatic patients with chronic severe nonrheumatic primary MR</text>
<text top="373" left="77" width="445" height="9" font="7">(stage C1) and preserved LV function in whom there is a high likelihood of a successful and durable</text>
<text top="387" left="77" width="439" height="9" font="7">repair with 1) new onset of AF or 2) resting pulmonary hypertension (PA systolic arterial pressure</text>
<text top="399" left="77" width="60" height="14" font="7">&gt;50 mm Hg)</text>
<text top="359" left="575" width="11" height="9" font="7">IIa</text>
<text top="359" left="675" width="6" height="9" font="7">B</text>
<text top="359" left="743" width="45" height="9" font="8"><a href="e57.full.html#108">(363,415,</a></text>
<text top="373" left="752" width="18" height="9" font="8"><a href="e57.full.html#108">420</a></text>
<text top="370" left="770" width="27" height="14" font="8"><a href="e57.full.html#108">–425)</a></text>
<text top="416" left="64" width="422" height="9" font="7">Concomitant MV repair is reasonable in patients with chronic moderate primary MR (stage B)</text>
<text top="430" left="77" width="215" height="9" font="7">undergoing cardiac surgery for other indications</text>
<text top="416" left="575" width="11" height="9" font="7">IIa</text>
<text top="416" left="675" width="6" height="9" font="7">C</text>
<text top="416" left="759" width="18" height="9" font="7">N/A</text>
<text top="444" left="64" width="417" height="9" font="7">MV surgery may be considered in symptomatic patients with chronic severe primary MR and</text>
<text top="458" left="77" width="21" height="9" font="7">LVEF</text>
<text top="455" left="102" width="73" height="14" font="7">30% (stage D)</text>
<text top="444" left="575" width="11" height="9" font="7">IIb</text>
<text top="444" left="675" width="6" height="9" font="7">C</text>
<text top="444" left="759" width="18" height="9" font="7">N/A</text>
<text top="472" left="64" width="457" height="9" font="7">MV repair may be considered in patients with rheumatic mitral valve disease when surgical treatment is</text>
<text top="486" left="77" width="445" height="9" font="7">indicated if a durable and successful repair is likely or if the reliability of long-term anticoagulation</text>
<text top="500" left="77" width="131" height="9" font="7">management is questionable</text>
<text top="472" left="575" width="11" height="9" font="7">IIb</text>
<text top="472" left="675" width="6" height="9" font="7">B</text>
<text top="472" left="738" width="60" height="9" font="8"><a href="e57.full.html#102">(86,406,413)</a></text>
<text top="514" left="64" width="457" height="9" font="7">Transcatheter MV repair may be considered for severely symptomatic patients (NYHA class III/IV) with</text>
<text top="528" left="77" width="445" height="9" font="7">chronic severe primary MR (stage D) who have a reasonable life expectancy but a prohibitive surgical</text>
<text top="542" left="77" width="165" height="9" font="7">risk because of severe comorbidities</text>
<text top="514" left="575" width="11" height="9" font="7">IIb</text>
<text top="514" left="675" width="6" height="9" font="7">B</text>
<text top="514" left="756" width="25" height="9" font="8"><a href="e57.full.html#110">(426)</a></text>
<text top="556" left="64" width="449" height="9" font="7">MVR should not be performed for treatment of isolated severe primary MR limited to less than one</text>
<text top="571" left="77" width="107" height="9" font="7">half of the posterior lea</text>
<text top="568" left="183" width="289" height="14" font="7">ﬂet unless MV repair has been attempted and was unsuccessful</text>
<text top="556" left="561" width="39" height="9" font="7">III: Harm</text>
<text top="556" left="675" width="6" height="9" font="7">B</text>
<text top="556" left="737" width="36" height="9" font="8"><a href="e57.full.html#102">(87,407</a></text>
<text top="553" left="773" width="27" height="14" font="8"><a href="e57.full.html#102">–409)</a></text>
<text top="590" left="72" width="66" height="8" font="18">AF indicates atrial</text>
<text top="588" left="141" width="659" height="11" font="18">ﬁbrillation; COR, Class of Recommendation; LOE, Level of Evidence; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; MR,</text>
<text top="602" left="72" width="567" height="8" font="18">mitral regurgitation; MV, mitral valve; MVR, mitral valve replacement; N/A, not applicable; NYHA, New York Heart Association; and PA, pulmonary artery.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e103</text>
</page>
<page number="48" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="82" width="331" height="15" font="5">1. Mitral valve repair is performed at a lower operative</text>
<text top="121" left="101" width="313" height="15" font="5">mortality rate than MVR. Although no RCTs exist,</text>
<text top="139" left="101" width="313" height="15" font="5">virtually every clinical report, including data from the</text>
<text top="157" left="101" width="285" height="15" font="5">STS database, indicates that operative risk (30</text>
<text top="153" left="386" width="28" height="19" font="5">–day</text>
<text top="175" left="101" width="288" height="15" font="5">mortality) for repair is about half that of MVR.</text>
<text top="192" left="82" width="332" height="15" font="5">2. LV function is better preserved following repair</text>
<text top="210" left="101" width="313" height="15" font="5">preserving the integrity of the mitral valve apparatus</text>
<text top="228" left="101" width="140" height="15" font="5">versus following MVR.</text>
<text top="246" left="82" width="332" height="15" font="5">3. Repair avoids the risks inherent to prosthetic heart</text>
<text top="264" left="101" width="313" height="15" font="5">valves, that is, thromboembolism or anticoagulant-</text>
<text top="282" left="101" width="313" height="15" font="5">induced hemorrhage for mechanical valves or struc-</text>
<text top="300" left="101" width="255" height="15" font="5">tural deterioration for bioprosthetic valves.</text>
<text top="327" left="79" width="335" height="15" font="5">Because the success of repair increases with surgical</text>
<text top="345" left="64" width="350" height="15" font="5">volume and expertise, repair (which is the preferred treat-</text>
<text top="363" left="64" width="350" height="15" font="5">ment) is more likely to be accomplished in centers with</text>
<text top="381" left="64" width="350" height="15" font="5">surgeons who have expertise in this type of surgery. Mitral</text>
<text top="399" left="64" width="317" height="15" font="5">valve repair over MVR is indicated even in patients</text>
<text top="395" left="387" width="27" height="19" font="5">&gt;65</text>
<text top="417" left="64" width="350" height="15" font="5">years of age. When in doubt, MVR is preferable to a poor</text>
<text top="435" left="64" width="350" height="15" font="5">repair. The results of a minimally invasive approach per-</text>
<text top="453" left="64" width="350" height="15" font="5">formed via minithoracotomy/port access using direct</text>
<text top="470" left="64" width="350" height="15" font="5">vision, thoracoscopic, or robotic assistance versus a con-</text>
<text top="488" left="64" width="350" height="15" font="5">ventional sternotomy approach may be similar when per-</text>
<text top="506" left="64" width="239" height="15" font="5">formed by highly experienced surgeons.</text>
<text top="524" left="79" width="335" height="15" font="5">Surgical repair of MR has been remarkably successful in</text>
<text top="542" left="64" width="243" height="15" font="5">the treatment of primary MR. When lea</text>
<text top="539" left="308" width="106" height="19" font="5">ﬂet dysfunction is</text>
<text top="560" left="64" width="17" height="15" font="5">suf</text>
<text top="557" left="82" width="332" height="19" font="5">ﬁciently limited so that only annuloplasty and repair of</text>
<text top="578" left="64" width="109" height="15" font="5">the posterior lea</text>
<text top="575" left="173" width="240" height="19" font="5">ﬂet are necessary, repair of isolated</text>
<text top="596" left="64" width="350" height="15" font="5">degenerative mitral disease has led to outcomes distinctly</text>
<text top="614" left="64" width="350" height="15" font="5">superior to biological or mechanical valve replacement: an</text>
<text top="632" left="64" width="130" height="15" font="5">operative mortality of</text>
<text top="628" left="199" width="214" height="19" font="5">&lt;1%; long-term survival equivalent</text>
<text top="650" left="64" width="350" height="15" font="5">to that of the age-matched general population; approxi-</text>
<text top="668" left="64" width="255" height="15" font="5">mately 95% freedom from reoperation; and</text>
<text top="664" left="323" width="91" height="19" font="5">&gt;80% freedom</text>
<text top="686" left="64" width="213" height="15" font="5">from recurrent moderate or severe (</text>
<text top="682" left="278" width="136" height="19" font="5">3þ) MR at 15 to 20</text>
<text top="704" left="64" width="350" height="15" font="5">years after operation. As much as one half of the posterior</text>
<text top="722" left="64" width="16" height="15" font="5">lea</text>
<text top="718" left="80" width="333" height="19" font="5">ﬂet may be excised, plicated, or resuspended. Posterior</text>
<text top="740" left="64" width="16" height="15" font="5">lea</text>
<text top="736" left="80" width="333" height="19" font="5">ﬂet repair has become sufﬁciently standardized so that</text>
<text top="757" left="64" width="350" height="15" font="5">valve repair rather than valve replacement is the standard of</text>
<text top="775" left="64" width="350" height="15" font="5">care in this situation. Execution of this procedure with a</text>
<text top="793" left="64" width="72" height="15" font="5">success rate</text>
<text top="790" left="145" width="269" height="19" font="5">90% should be the expectation of every</text>
<text top="811" left="64" width="328" height="15" font="5">cardiac surgeon who performs mitral valve procedures.</text>
<text top="830" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="829" left="212" width="72" height="15" font="6"><a href="e57.full.html#102">(87,364,395</a></text>
<text top="826" left="284" width="91" height="19" font="6"><a href="e57.full.html#102">–409,427–432)</a></text>
<text top="856" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="871" left="63" width="351" height="10" font="21">4. Mitral valve repair is recommended in preference to MVR when</text>
<text top="888" left="81" width="333" height="10" font="21">surgical treatment is indicated for patients with chronic severe</text>
<text top="904" left="81" width="192" height="10" font="21">primary MR involving the anterior lea</text>
<text top="901" left="274" width="140" height="16" font="21">ﬂet or both leaﬂets when a</text>
<text top="921" left="81" width="278" height="10" font="21">successful and durable repair can be accomplished</text>
<text top="921" left="365" width="43" height="10" font="22"><a href="e57.full.html#102">(86,407</a></text>
<text top="917" left="408" width="6" height="16" font="22"><a href="e57.full.html#102">–</a></text>
<text top="937" left="81" width="26" height="10" font="22"><a href="e57.full.html#102">413)</a></text>
<text top="937" left="107" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="961" left="79" width="335" height="15" font="5">Degenerative mitral valve disease consisting of more</text>
<text top="979" left="64" width="105" height="15" font="5">than posterior lea</text>
<text top="976" left="169" width="244" height="19" font="5">ﬂet disease requires a more complex and</text>
<text top="997" left="64" width="235" height="15" font="5">extensive repair. When the anterior lea</text>
<text top="994" left="300" width="114" height="19" font="5">ﬂet or both leaﬂets</text>
<text top="1015" left="64" width="350" height="15" font="5">require repair, durability of the repair is less certain, with a</text>
<text top="1033" left="64" width="350" height="15" font="5">freedom from reoperation of approximately 80% and a</text>
<text top="1051" left="64" width="350" height="15" font="5">freedom from recurrent moderate or severe MR of 60% at</text>
<text top="1069" left="64" width="350" height="15" font="5">15 to 20 years. These results are superior to the results of</text>
<text top="1087" left="64" width="350" height="15" font="5">MVR, even in elderly patients. Repair should also be</text>
<text top="103" left="450" width="350" height="15" font="5">attempted if possible with other causes of severe MR, such</text>
<text top="121" left="450" width="350" height="15" font="5">as papillary muscle rupture, IE, and cleft mitral valve. As</text>
<text top="139" left="450" width="350" height="15" font="5">the repair becomes more complex, however, results of very</text>
<text top="157" left="450" width="350" height="15" font="5">complex repair in younger patients may be matched by</text>
<text top="175" left="450" width="350" height="15" font="5">results of durable mechanical MVR with careful manage-</text>
<text top="192" left="450" width="147" height="15" font="5">ment of anticoagulation.</text>
<text top="210" left="465" width="335" height="15" font="5">More complex repair is not well standardized and is</text>
<text top="228" left="450" width="350" height="15" font="5">more surgically demanding. The Heart Valve Team should</text>
<text top="246" left="450" width="350" height="15" font="5">assign complex repairs to more experienced mitral valve</text>
<text top="264" left="450" width="350" height="15" font="5">surgeons with established outcomes, including acute suc-</text>
<text top="282" left="450" width="350" height="15" font="5">cess rate as well as long-term durability. The probability of</text>
<text top="300" left="450" width="350" height="15" font="5">mitral valve repair rather than MVR correlates with</text>
<text top="318" left="450" width="82" height="15" font="5">surgeon-speci</text>
<text top="315" left="531" width="268" height="19" font="5">ﬁc mitral volumes. In a 2007 analysis, hos-</text>
<text top="336" left="450" width="125" height="15" font="5">pitals that performed</text>
<text top="333" left="579" width="220" height="19" font="5">&lt;36 mitral operations per year had a</text>
<text top="354" left="450" width="309" height="15" font="5">48% repair rate, whereas hospitals that performed</text>
<text top="351" left="766" width="34" height="19" font="5">&gt;140</text>
<text top="372" left="450" width="350" height="15" font="5">mitral operations per year had a 77% repair rate. Hospital</text>
<text top="390" left="450" width="350" height="15" font="5">mortality was also 50% lower, on average, in the highest-</text>
<text top="408" left="450" width="350" height="15" font="5">volume hospitals. There was, however, considerable</text>
<text top="426" left="450" width="94" height="15" font="5">overlap in speci</text>
<text top="422" left="544" width="256" height="19" font="5">ﬁc hospital outcomes, with &gt;25% of low-</text>
<text top="444" left="450" width="350" height="15" font="5">volume hospitals outperforming the median high-volume</text>
<text top="462" left="450" width="350" height="15" font="5">hospitals. This overlap suggests that hospital or surgeon-</text>
<text top="479" left="450" width="29" height="15" font="5">speci</text>
<text top="476" left="479" width="320" height="19" font="5">ﬁc volumes should not be used as a surrogate for</text>
<text top="497" left="450" width="121" height="15" font="5">actual surgeon-speci</text>
<text top="494" left="571" width="178" height="19" font="5">ﬁc repair rates and outcomes.</text>
<text top="516" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="515" left="597" width="46" height="15" font="6"><a href="e57.full.html#102">(86,407</a></text>
<text top="512" left="643" width="35" height="19" font="6"><a href="e57.full.html#102">–413)</a></text>
<text top="543" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="557" left="449" width="351" height="10" font="21">5. Concomitant mitral valve repair or MVR is indicated in patients</text>
<text top="574" left="467" width="333" height="10" font="21">with chronic severe primary MR undergoing cardiac surgery for</text>
<text top="590" left="467" width="89" height="10" font="21">other indications</text>
<text top="590" left="560" width="30" height="10" font="22"><a href="e57.full.html#109">(414)</a></text>
<text top="590" left="590" width="121" height="12" font="21"><a href="e57.full.html#109">. </a>(Level of Evidence: B)</text>
<text top="615" left="465" width="335" height="15" font="5">During coronary revascularization and in cases of IE or</text>
<text top="633" left="450" width="350" height="15" font="5">other conditions where multiple valves may be involved, it</text>
<text top="650" left="450" width="350" height="15" font="5">is prudent to correct severe primary MR at the time of</text>
<text top="668" left="450" width="350" height="15" font="5">surgery. This is especially true when mitral repair can be</text>
<text top="686" left="450" width="350" height="15" font="5">performed in conjunction with AVR because operative risk</text>
<text top="704" left="450" width="283" height="15" font="5">is lower than that of double valve replacement.</text>
<text top="723" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="722" left="593" width="32" height="15" font="6"><a href="e57.full.html#109">(414)</a></text>
<text top="750" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="764" left="449" width="351" height="10" font="21">1. Mitral valve repair is reasonable in asymptomatic patients with</text>
<text top="781" left="467" width="333" height="10" font="21">chronic severe primary MR (stage C1) with preserved LV func-</text>
<text top="797" left="467" width="54" height="10" font="21">tion (LVEF</text>
<text top="794" left="525" width="275" height="16" font="21">&gt;60% and LVESD &lt;40 mm) in whom the likelihood of</text>
<text top="814" left="467" width="333" height="10" font="21">a successful and durable repair without residual MR is greater</text>
<text top="830" left="467" width="333" height="10" font="21">than 95% with an expected mortality rate of less than 1% when</text>
<text top="847" left="467" width="261" height="10" font="21">performed at a Heart Valve Center of Excellence</text>
<text top="847" left="733" width="61" height="10" font="22"><a href="e57.full.html#101">(39,86,415</a></text>
<text top="843" left="793" width="6" height="16" font="22"><a href="e57.full.html#101">–</a></text>
<text top="863" left="467" width="26" height="10" font="22"><a href="e57.full.html#101">419)</a></text>
<text top="863" left="493" width="121" height="12" font="21"><a href="e57.full.html#101">. </a>(Level of Evidence: B)</text>
<text top="887" left="465" width="335" height="15" font="5">The onset of symptoms, LV dysfunction, or pulmonary</text>
<text top="905" left="450" width="350" height="15" font="5">hypertension worsens the prognosis for MR. Careful</text>
<text top="923" left="450" width="350" height="15" font="5">intensive surveillance may result in timing of valve surgery</text>
<text top="941" left="450" width="350" height="15" font="5">before these negative sequelae occur. However, an attrac-</text>
<text top="959" left="450" width="350" height="15" font="5">tive alternative strategy for treating severe chronic primary</text>
<text top="977" left="450" width="350" height="15" font="5">MR is to perform early mitral repair before these triggers</text>
<text top="995" left="450" width="350" height="15" font="5">are reached. Early mitral repair avoids the need for</text>
<text top="1013" left="450" width="350" height="15" font="5">intensive surveillance and also obviates the possibility that</text>
<text top="1031" left="450" width="350" height="15" font="5">patients might become lost to follow-up or delay seeing</text>
<text top="1049" left="450" width="350" height="15" font="5">their clinician until advanced LV dysfunction has already</text>
<text top="1067" left="450" width="350" height="15" font="5">ensued. This strategy requires expertise in clinical evalua-</text>
<text top="1085" left="450" width="350" height="15" font="5">tion and cardiac imaging to ensure that MR is severe. For</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e104</text>
</page>
<page number="49" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">this strategy to be effective, a durable repair must be pro-</text>
<text top="121" left="64" width="350" height="15" font="5">vided. An unwanted valve replacement, exposing the pa-</text>
<text top="139" left="64" width="350" height="15" font="5">tient to the unneeded risks accrued from prosthetic valve</text>
<text top="157" left="64" width="350" height="15" font="5">replacement, or a repair that fails, necessitating reopera-</text>
<text top="175" left="64" width="350" height="15" font="5">tion, should be considered complications of this approach.</text>
<text top="192" left="64" width="350" height="15" font="5">Thus, there must be a high degree of certainty that a du-</text>
<text top="210" left="64" width="350" height="15" font="5">rable repair can be performed. In this regard, posterior</text>
<text top="228" left="64" width="16" height="15" font="5">lea</text>
<text top="225" left="80" width="333" height="19" font="5">ﬂet repair is usually more durable than anterior leaﬂet</text>
<text top="246" left="64" width="350" height="15" font="5">repair, especially in less experienced hands, and high sur-</text>
<text top="264" left="64" width="350" height="15" font="5">gical volume is also associated with better repair rates and</text>
<text top="282" left="64" width="350" height="15" font="5">more durable outcomes. These operations on the asymp-</text>
<text top="300" left="64" width="350" height="15" font="5">tomatic patient should be performed in Heart Valve</text>
<text top="318" left="64" width="350" height="15" font="5">Centers of Excellence by experienced surgeons with</text>
<text top="336" left="64" width="350" height="15" font="5">expertise in mitral valve repair. When performed by</text>
<text top="354" left="64" width="350" height="15" font="5">experienced surgeons in a Heart Valve Center of Excel-</text>
<text top="372" left="64" width="350" height="15" font="5">lence, there is a lower risk of patients developing HF and</text>
<text top="390" left="64" width="323" height="15" font="5">lower mortality rates in patients with severe MR from</text>
<text top="386" left="392" width="22" height="19" font="5">ﬂail</text>
<text top="408" left="64" width="16" height="15" font="5">lea</text>
<text top="404" left="80" width="334" height="19" font="5">ﬂets who undergo early operation as opposed to</text>
<text top="426" left="64" width="103" height="15" font="5">watchful waiting.</text>
<text top="444" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="444" left="212" width="65" height="15" font="6"><a href="e57.full.html#101">(39,86,415</a></text>
<text top="440" left="277" width="35" height="19" font="6"><a href="e57.full.html#101">–419)</a></text>
<text top="474" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="489" left="63" width="351" height="10" font="21">2. Mitral valve repair is reasonable for asymptomatic patients with</text>
<text top="506" left="81" width="332" height="10" font="21">chronic severe nonrheumatic primary MR (stage C1) and pre-</text>
<text top="522" left="81" width="134" height="10" font="21">served LV function (LVEF</text>
<text top="519" left="220" width="194" height="16" font="21">&gt;60% and LVESD &lt;40 mm) in whom</text>
<text top="539" left="81" width="333" height="10" font="21">there is a high likelihood of a successful and durable repair with</text>
<text top="555" left="81" width="332" height="10" font="21">1) new onset of AF or 2) resting pulmonary hypertension (pul-</text>
<text top="572" left="81" width="38" height="10" font="21">monary</text>
<text top="572" left="131" width="30" height="10" font="21">artery</text>
<text top="572" left="174" width="40" height="10" font="21">systolic</text>
<text top="572" left="226" width="37" height="10" font="21">arterial</text>
<text top="572" left="275" width="45" height="10" font="21">pressure</text>
<text top="568" left="331" width="83" height="16" font="21">&gt;50 mm Hg)</text>
<text top="588" left="81" width="75" height="10" font="22"><a href="e57.full.html#108">(363,415,420</a></text>
<text top="585" left="157" width="32" height="16" font="22"><a href="e57.full.html#108">–425)</a></text>
<text top="588" left="188" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="609" left="79" width="335" height="15" font="5">In nonrheumatic MR, the onset of AF is in part due to</text>
<text top="627" left="64" width="350" height="15" font="5">enlarging left atrial size, and its presence worsens surgical</text>
<text top="645" left="64" width="350" height="15" font="5">outcome. Furthermore, the longer AF is present, the more</text>
<text top="663" left="64" width="350" height="15" font="5">likely it is to persist. Thus, it may be reasonable to restore</text>
<text top="681" left="64" width="350" height="15" font="5">mitral competence by low-risk repair with the hope that</text>
<text top="699" left="64" width="350" height="15" font="5">the ensuing reduction in left atrial size will help restore and</text>
<text top="717" left="64" width="350" height="15" font="5">maintain sinus rhythm. However, restoration of sinus</text>
<text top="735" left="64" width="350" height="15" font="5">rhythm following valve surgery is uncertain, and concom-</text>
<text top="753" left="64" width="305" height="15" font="5">itant AF ablation surgery may be warranted (</text>
<text top="753" left="370" width="44" height="15" font="6"><a href="e57.full.html#95">Section</a></text>
<text top="771" left="64" width="37" height="15" font="6"><a href="e57.full.html#95">14.2.2</a></text>
<text top="771" left="102" width="312" height="15" font="5"><a href="e57.full.html#95">). </a>This strategy does not apply to rheumatic MR,</text>
<text top="789" left="64" width="127" height="15" font="5">where active atrial in</text>
<text top="785" left="192" width="222" height="19" font="5">ﬂammation may make restoration of</text>
<text top="807" left="64" width="350" height="15" font="5">sinus rhythm less likely and valve scarring reduces the</text>
<text top="825" left="64" width="350" height="15" font="5">likelihood of a successful repair. The presence of pulmo-</text>
<text top="843" left="64" width="350" height="15" font="5">nary arterial hypertension due to MR is associated with</text>
<text top="860" left="64" width="350" height="15" font="5">poorer outcome after valve surgery. Thus, it is reasonable to</text>
<text top="878" left="64" width="350" height="15" font="5">consider surgery in these patients if there is a high likeli-</text>
<text top="896" left="64" width="239" height="15" font="5">hood of a successful and durable repair.</text>
<text top="915" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="914" left="212" width="53" height="15" font="6"><a href="e57.full.html#108">(363,420</a></text>
<text top="911" left="265" width="35" height="19" font="6"><a href="e57.full.html#108">–425)</a></text>
<text top="945" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="960" left="63" width="351" height="10" font="21">3. Concomitant mitral valve repair is reasonable in patients with</text>
<text top="977" left="81" width="332" height="10" font="21">chronic moderate primary MR (stage B) when undergoing car-</text>
<text top="993" left="81" width="295" height="12" font="21">diac surgery for other indications. (Level of Evidence: C)</text>
<text top="1017" left="79" width="335" height="15" font="5">Because MR is a progressive lesion, it is reasonable to</text>
<text top="1035" left="64" width="350" height="15" font="5">address it at the time of other cardiac surgery. This is</text>
<text top="1053" left="64" width="350" height="15" font="5">especially true if the mitral valve can be repaired. However,</text>
<text top="1071" left="64" width="350" height="15" font="5">the added risk of mitral valve surgery must be weighed</text>
<text top="1089" left="64" width="350" height="15" font="5">against the potential for progression of MR. In such cases,</text>
<text top="103" left="450" width="307" height="15" font="5">increased operative mortality might not be justi</text>
<text top="99" left="757" width="42" height="19" font="5">ﬁed in</text>
<text top="121" left="450" width="140" height="15" font="5">treating moderate MR.</text>
<text top="139" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="139" left="593" width="32" height="15" font="6"><a href="e57.full.html#110">(433)</a></text>
<text top="173" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="188" left="449" width="351" height="10" font="21">1. Mitral valve surgery may be considered in symptomatic patients</text>
<text top="205" left="467" width="333" height="10" font="21">with chronic severe primary MR and LVEF less than or equal to</text>
<text top="221" left="467" width="197" height="12" font="21">30% (stage D). (Level of Evidence: C)</text>
<text top="248" left="465" width="335" height="15" font="5">Most patients with decompensated MR and an</text>
<text top="266" left="450" width="39" height="15" font="5">LVEF</text>
<text top="263" left="496" width="303" height="19" font="5">30% have secondary rather than primary MR.</text>
<text top="284" left="450" width="350" height="15" font="5">However in the rare cases where valve pathology indicates a</text>
<text top="302" left="450" width="350" height="15" font="5">clear primary cause in a patient with far-advanced LV</text>
<text top="320" left="450" width="214" height="15" font="5">dysfunction, surgery might be bene</text>
<text top="317" left="664" width="135" height="19" font="5">ﬁcial, especially in pa-</text>
<text top="338" left="450" width="350" height="15" font="5">tients without severe comorbidities. Repair seems reason-</text>
<text top="356" left="450" width="350" height="15" font="5">able in such patients because of the likelihood of continued</text>
<text top="374" left="450" width="350" height="15" font="5">deterioration in LV function if surgery is not performed.</text>
<text top="392" left="450" width="350" height="15" font="5">However, data regarding surgery in patients with primary</text>
<text top="410" left="450" width="207" height="15" font="5">MR and a low LVEF are lacking.</text>
<text top="437" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="452" left="449" width="351" height="10" font="21">2. Mitral valve repair may be considered in patients with rheumatic</text>
<text top="469" left="467" width="332" height="10" font="21">mitral valve disease when surgical treatment is indicated if a</text>
<text top="485" left="467" width="332" height="10" font="21">durable and successful repair is likely or when the reliability of</text>
<text top="501" left="467" width="50" height="10" font="21">long-term</text>
<text top="501" left="531" width="81" height="10" font="21">anticoagulation</text>
<text top="501" left="627" width="68" height="10" font="21">management</text>
<text top="501" left="709" width="9" height="10" font="21">is</text>
<text top="501" left="732" width="67" height="10" font="21">questionable</text>
<text top="518" left="467" width="73" height="10" font="22"><a href="e57.full.html#102">(86,406,413)</a></text>
<text top="518" left="539" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="542" left="465" width="335" height="15" font="5">Rheumatic mitral valve disease is less suitable for mitral</text>
<text top="560" left="450" width="350" height="15" font="5">repair than complex degenerative disease. Durability of the</text>
<text top="578" left="450" width="221" height="15" font="5">repair is limited by thickened or calci</text>
<text top="575" left="671" width="128" height="19" font="5">ﬁed leaﬂets, extensive</text>
<text top="596" left="450" width="350" height="15" font="5">subvalvular disease with chordal fusion and shortening, and</text>
<text top="614" left="450" width="350" height="15" font="5">progression of rheumatic disease. Freedom from reopera-</text>
<text top="632" left="450" width="350" height="15" font="5">tion at 20 years, even in experienced hands, is in the 50%</text>
<text top="650" left="450" width="350" height="15" font="5">to 60% range. In a large series from Korea, repair was</text>
<text top="668" left="450" width="350" height="15" font="5">accomplished in 22% of patients operated on for rheumatic</text>
<text top="686" left="450" width="350" height="15" font="5">disease. One third of these patients who underwent repair</text>
<text top="704" left="450" width="54" height="15" font="5">had signi</text>
<text top="700" left="504" width="295" height="19" font="5">ﬁcant stenosis or regurgitation at 10 years. Repair</text>
<text top="722" left="450" width="350" height="15" font="5">of rheumatic mitral valve disease should be limited to pa-</text>
<text top="739" left="450" width="350" height="15" font="5">tients with less advanced disease in whom a durable repair</text>
<text top="757" left="450" width="350" height="15" font="5">can be accomplished or to patients in whom a mechan-</text>
<text top="775" left="450" width="350" height="15" font="5">ical prosthesis cannot be used because of anticoagulation</text>
<text top="793" left="450" width="137" height="15" font="5">management concerns.</text>
<text top="812" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="811" left="598" width="58" height="15" font="6"><a href="e57.full.html#110">(434,435)</a></text>
<text top="838" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="853" left="449" width="351" height="10" font="21">3. Transcatheter mitral valve repair may be considered for severely</text>
<text top="870" left="467" width="333" height="10" font="21">symptomatic patients (NYHA class III to IV) with chronic severe</text>
<text top="886" left="467" width="333" height="10" font="21">primary MR (stage D) who have favorable anatomy for the repair</text>
<text top="903" left="467" width="332" height="10" font="21">procedure and a reasonable life expectancy but who have a</text>
<text top="919" left="467" width="332" height="10" font="21">prohibitive surgical risk because of severe comorbidities and</text>
<text top="935" left="467" width="332" height="10" font="21">remain severely symptomatic despite optimal GDMT for HF</text>
<text top="952" left="467" width="30" height="10" font="22"><a href="e57.full.html#110">(426)</a></text>
<text top="952" left="497" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="980" left="465" width="335" height="15" font="5">An RCT of percutaneous mitral valve repair using the</text>
<text top="998" left="450" width="350" height="15" font="5">MitraClip device versus surgical mitral repair was con-</text>
<text top="1015" left="450" width="350" height="15" font="5">ducted in the United States. The clip was found to be safe</text>
<text top="1033" left="450" width="350" height="15" font="5">but less effective than surgical repair because residual MR</text>
<text top="1051" left="450" width="350" height="15" font="5">was more prevalent in the percutaneous group. However,</text>
<text top="1069" left="450" width="350" height="15" font="5">the clip reduced severity of MR, improved symptoms, and</text>
<text top="1087" left="450" width="350" height="15" font="5">led to reverse LV remodeling. Percutaneous mitral valve</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e105</text>
</page>
<page number="50" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">repair should only be considered for patients with chronic</text>
<text top="121" left="64" width="350" height="15" font="5">primary MR who remain severely symptomatic with</text>
<text top="139" left="64" width="350" height="15" font="5">NYHA class III to IV HF symptoms despite optimal</text>
<text top="157" left="64" width="316" height="15" font="5">GDMT for HF and who are considered inoperable.</text>
<text top="175" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="175" left="212" width="84" height="15" font="6"><a href="e57.full.html#110">(426,436,437)</a></text>
<text top="202" left="64" width="73" height="8" font="20">CLASS III: Harm</text>
<text top="217" left="63" width="351" height="10" font="21">1. MVR should not be performed for the treatment of isolated se-</text>
<text top="233" left="81" width="333" height="10" font="21">vere primary MR limited to less than one half of the posterior</text>
<text top="250" left="81" width="16" height="10" font="21">lea</text>
<text top="246" left="97" width="317" height="16" font="21">ﬂet unless mitral valve repair has been attempted and was</text>
<text top="266" left="81" width="69" height="10" font="21">unsuccessful</text>
<text top="266" left="154" width="43" height="10" font="22"><a href="e57.full.html#102">(87,407</a></text>
<text top="263" left="197" width="32" height="16" font="22"><a href="e57.full.html#102">–409)</a></text>
<text top="266" left="229" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="290" left="79" width="335" height="15" font="5">Surgical repair of MR has been remarkably successful,</text>
<text top="308" left="64" width="350" height="15" font="5">particularly in the treatment of chronic primary MR.</text>
<text top="326" left="64" width="331" height="15" font="5">Repair of isolated degenerative mitral disease, when lea</text>
<text top="323" left="395" width="19" height="19" font="5">ﬂet</text>
<text top="344" left="64" width="109" height="15" font="5">dysfunction is suf</text>
<text top="341" left="174" width="240" height="19" font="5">ﬁciently limited that only annuloplasty</text>
<text top="362" left="64" width="180" height="15" font="5">and repair of the posterior lea</text>
<text top="359" left="245" width="169" height="19" font="5">ﬂet are necessary, has led to</text>
<text top="380" left="64" width="350" height="15" font="5">outcomes distinctly superior to biological or mechanical</text>
<text top="398" left="64" width="185" height="15" font="5">MVR: operative mortality of</text>
<text top="395" left="258" width="156" height="19" font="5">&lt;1%; long-term survival</text>
<text top="416" left="64" width="350" height="15" font="5">equivalent to that of age-matched general population;</text>
<text top="434" left="64" width="307" height="15" font="5">approximately 95% freedom from reoperation; and</text>
<text top="430" left="376" width="38" height="19" font="5">&gt;80%</text>
<text top="452" left="64" width="269" height="15" font="5">freedom from recurrent moderate or severe (</text>
<text top="448" left="333" width="81" height="19" font="5">3þ) MR at</text>
<text top="470" left="64" width="350" height="15" font="5">15 to 20 years after operation. As much as one half of the</text>
<text top="488" left="64" width="74" height="15" font="5">posterior lea</text>
<text top="484" left="138" width="276" height="19" font="5">ﬂet may be excised, plicated, or resuspended.</text>
<text top="506" left="64" width="74" height="15" font="5">Posterior lea</text>
<text top="502" left="138" width="276" height="19" font="5">ﬂet repair has become sufﬁciently standardized</text>
<text top="523" left="64" width="350" height="15" font="5">in this situation that repair rather than MVR is the stan-</text>
<text top="541" left="64" width="350" height="15" font="5">dard of care. Execution of this procedure with a success</text>
<text top="559" left="64" width="22" height="15" font="5">rate</text>
<text top="556" left="95" width="319" height="19" font="5">90% should be the expectation of every cardiac</text>
<text top="577" left="64" width="282" height="15" font="5">surgeon who performs mitral valve procedures.</text>
<text top="596" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="595" left="212" width="46" height="15" font="6"><a href="e57.full.html#102">(87,407</a></text>
<text top="592" left="258" width="35" height="19" font="6"><a href="e57.full.html#102">–409)</a></text>
<text top="614" left="79" width="17" height="15" font="5">See</text>
<text top="614" left="102" width="219" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplements 16 and 17</a></text>
<text top="614" left="327" width="87" height="15" font="5">for more infor-</text>
<text top="632" left="64" width="137" height="15" font="5">mation on intervention.</text>
<text top="675" left="64" width="185" height="12" font="19">7.4. Chronic Secondary MR</text>
<text top="702" left="64" width="333" height="15" font="5">7.4.1. Diagnosis and Follow-Up: Recommendations</text>
<text top="730" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="744" left="64" width="350" height="10" font="21">1. TTE is useful to establish the etiology of chronic secondary MR</text>
<text top="761" left="82" width="332" height="10" font="21">(stages B to D) and the extent and location of wall motion</text>
<text top="777" left="82" width="332" height="10" font="21">abnormalities and to assess global LV function, severity of MR,</text>
<text top="794" left="82" width="332" height="12" font="21">and magnitude of pulmonary hypertension. (Level of Evidence: C)</text>
<text top="818" left="79" width="335" height="15" font="5">In general, the presence of chronic secondary MR</text>
<text top="836" left="64" width="349" height="15" font="5">worsens the prognosis of patients with LV systolic</text>
<text top="854" left="64" width="350" height="15" font="5">dysfunction and symptoms of HF, and most patients with</text>
<text top="872" left="64" width="350" height="15" font="5">secondary MR have severe global LV dysfunction. How-</text>
<text top="890" left="64" width="350" height="15" font="5">ever, in some patients, a limited but strategically placed</text>
<text top="908" left="64" width="350" height="15" font="5">wall motion abnormality may also cause chronic secondary</text>
<text top="926" left="64" width="350" height="15" font="5">MR, and prognosis may be better in such patients. An</text>
<text top="944" left="64" width="350" height="15" font="5">initial TTE helps establish the cause of chronic secondary</text>
<text top="961" left="64" width="350" height="15" font="5">MR and also serves as a baseline for future comparisons. In</text>
<text top="979" left="64" width="350" height="15" font="5">patients with secondary MR, outcome studies have shown</text>
<text top="997" left="64" width="294" height="15" font="5">poorer prognosis with effective regurgitant ori</text>
<text top="994" left="359" width="55" height="19" font="5">ﬁce 20</text>
<text top="1015" left="64" width="24" height="15" font="5">mm</text>
<text top="1012" left="88" width="6" height="10" font="14">2</text>
<text top="1015" left="94" width="223" height="15" font="5">. It is recognized that there is dif</text>
<text top="1012" left="317" width="97" height="19" font="5">ﬁculty assessing</text>
<text top="1033" left="64" width="350" height="15" font="5">secondary MR in patients with reduced LV systolic func-</text>
<text top="1051" left="64" width="128" height="15" font="5">tion and low forward</text>
<text top="1048" left="197" width="29" height="19" font="5">ﬂow.</text>
<text top="1070" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="1069" left="212" width="58" height="15" font="6"><a href="e57.full.html#110">(438,439)</a></text>
<text top="106" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="121" left="449" width="351" height="10" font="21">2. Noninvasive imaging (stress nuclear/positron emission tomog-</text>
<text top="137" left="467" width="333" height="10" font="21">raphy, CMR, or stress echocardiography), cardiac CT angiog-</text>
<text top="154" left="467" width="32" height="10" font="21">raphy,</text>
<text top="154" left="514" width="10" height="10" font="21">or</text>
<text top="154" left="540" width="39" height="10" font="21">cardiac</text>
<text top="154" left="594" width="82" height="10" font="21">catheterization,</text>
<text top="154" left="692" width="47" height="10" font="21">including</text>
<text top="154" left="754" width="45" height="10" font="21">coronary</text>
<text top="170" left="467" width="332" height="10" font="21">arteriography, is useful to establish etiology of chronic sec-</text>
<text top="187" left="467" width="332" height="10" font="21">ondary MR (stages B to D) and/or to assess myocardial</text>
<text top="203" left="467" width="154" height="10" font="21">viability, which in turn may in</text>
<text top="200" left="621" width="179" height="16" font="21">ﬂuence management of functional</text>
<text top="220" left="467" width="138" height="12" font="21">MR. (Level of Evidence: C)</text>
<text top="248" left="465" width="335" height="15" font="5">Prognosis is poor for both ischemic and nonischemic</text>
<text top="266" left="450" width="350" height="15" font="5">MR, but ischemic MR lends itself to the possibility of</text>
<text top="284" left="450" width="350" height="15" font="5">revascularization and potential improvement in LV func-</text>
<text top="302" left="450" width="350" height="15" font="5">tion if CAD has led to large areas of hibernating viable</text>
<text top="320" left="450" width="350" height="15" font="5">myocardium. CT angiography is usually adequate to rule</text>
<text top="338" left="450" width="54" height="15" font="5">out signi</text>
<text top="334" left="504" width="296" height="19" font="5">ﬁcant CAD and thus rule out ischemic MR. If</text>
<text top="356" left="450" width="350" height="15" font="5">CAD is detected and noninvasive testing demonstrates</text>
<text top="374" left="450" width="350" height="15" font="5">areas of viability, coronary arteriography is pursued to</text>
<text top="392" left="450" width="53" height="15" font="5">better de</text>
<text top="388" left="503" width="288" height="19" font="5">ﬁne the anatomy for potential revascularization.</text>
<text top="410" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="409" left="593" width="32" height="15" font="6"><a href="e57.full.html#110">(440)</a></text>
<text top="436" left="450" width="277" height="15" font="5">7.4.2. Medical Therapy: Recommendations</text>
<text top="464" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="479" left="449" width="350" height="10" font="21">1. Patients with chronic secondary MR (stages B to D) and HF</text>
<text top="495" left="467" width="332" height="10" font="21">with reduced LVEF should receive standard GDMT therapy for</text>
<text top="511" left="467" width="332" height="10" font="21">HF, including ACE inhibitors, ARBs, beta blockers, and/or</text>
<text top="528" left="467" width="195" height="10" font="21">aldosterone antagonists as indicated</text>
<text top="528" left="666" width="50" height="10" font="22"><a href="e57.full.html#107">(310,441</a></text>
<text top="525" left="717" width="32" height="16" font="22"><a href="e57.full.html#107">–445)</a></text>
<text top="528" left="748" width="51" height="12" font="21">. (Level of</text>
<text top="545" left="467" width="65" height="12" font="21">Evidence: A)</text>
<text top="572" left="465" width="335" height="15" font="5">Chronic secondary MR usually develops as a result of</text>
<text top="590" left="450" width="350" height="15" font="5">severe LV dysfunction. Thus, standard GDMT for HF</text>
<text top="608" left="450" width="350" height="15" font="5">forms the mainstay of therapy. Diuretics, beta blockers,</text>
<text top="626" left="450" width="350" height="15" font="5">ACE inhibition or ARBs, and aldosterone antagonists</text>
<text top="644" left="450" width="350" height="15" font="5">help improve symptoms and/or prolong life in HF in</text>
<text top="662" left="450" width="350" height="15" font="5">general and probably do so even when HF is complicated</text>
<text top="680" left="450" width="160" height="15" font="5">by chronic secondary MR.</text>
<text top="699" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="698" left="597" width="53" height="15" font="6"><a href="e57.full.html#107">(310,441</a></text>
<text top="694" left="651" width="35" height="19" font="6"><a href="e57.full.html#107">–445)</a></text>
<text top="725" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="740" left="449" width="351" height="10" font="21">2. Cardiac resynchronization therapy with biventricular pacing is</text>
<text top="756" left="467" width="333" height="10" font="21">recommended for symptomatic patients with chronic severe</text>
<text top="773" left="467" width="333" height="10" font="21">secondary MR (stages B to D) who meet the indications for de-</text>
<text top="789" left="467" width="64" height="10" font="21">vice therapy</text>
<text top="789" left="534" width="55" height="10" font="22"><a href="e57.full.html#110">(446,447)</a></text>
<text top="789" left="589" width="120" height="12" font="21">. (Level of Evidence: A)</text>
<text top="818" left="465" width="335" height="15" font="5">Wall motion abnormalities are a common cause of</text>
<text top="836" left="450" width="350" height="15" font="5">chronic secondary MR, and their presence worsens the</text>
<text top="854" left="450" width="350" height="15" font="5">condition. The presence of conduction system abnormal-</text>
<text top="871" left="450" width="350" height="15" font="5">ities, especially left bundle-branch block, causes disordered</text>
<text top="889" left="450" width="350" height="15" font="5">LV contraction that exacerbates or is the primary cause of</text>
<text top="907" left="450" width="350" height="15" font="5">wall motion abnormalities. Electrical resynchronization</text>
<text top="925" left="450" width="350" height="15" font="5">may reduce or even eliminate wall motion abnormalities.</text>
<text top="943" left="450" width="350" height="15" font="5">Cardiac resynchronization therapy may also improve LV</text>
<text top="961" left="450" width="350" height="15" font="5">function and mitral valve closing force, which in turn leads</text>
<text top="979" left="450" width="350" height="15" font="5">to a reduction in chronic secondary MR in some cases.</text>
<text top="997" left="450" width="350" height="15" font="5">Thus, cardiac resynchronization therapy should be consid-</text>
<text top="1015" left="450" width="350" height="15" font="5">ered in symptomatic patients with chronic secondary MR</text>
<text top="1033" left="450" width="350" height="15" font="5">who meet the indications for device therapy as outlined in</text>
<text top="1051" left="450" width="314" height="15" font="5">the ACC/AHA guidelines for device-based therapy.</text>
<text top="1070" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="1069" left="597" width="58" height="15" font="6"><a href="e57.full.html#110">(446,447)</a></text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e106</text>
</page>
<page number="51" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="248" height="15" font="5">7.4.3. Intervention: Recommendations</text>
<text top="128" left="65" width="21" height="15" font="5">See</text>
<text top="128" left="91" width="54" height="15" font="6"><a href="e57.full.html#51">Table 18</a></text>
<text top="128" left="150" width="264" height="15" font="5">for a summary of recommendations for this</text>
<text top="146" left="64" width="68" height="15" font="5">section and</text>
<text top="146" left="138" width="51" height="15" font="6"><a href="e57.full.html#52">Figure 4</a></text>
<text top="146" left="194" width="211" height="15" font="5">for indications for surgery for MR.</text>
<text top="164" left="79" width="335" height="15" font="5">Chronic severe secondary MR adds volume overload to</text>
<text top="182" left="64" width="350" height="15" font="5">a decompensated left ventricle and worsens prognosis.</text>
<text top="200" left="64" width="350" height="15" font="5">However, there are only sparse data to indicate that cor-</text>
<text top="218" left="64" width="350" height="15" font="5">recting MR prolongs life or even improves symptoms over</text>
<text top="236" left="64" width="169" height="15" font="5">an extended time. The bene</text>
<text top="232" left="234" width="180" height="19" font="5">ﬁts of performing mitral valve</text>
<text top="254" left="64" width="350" height="15" font="5">repair over MVR are also unclear in this subset of patients.</text>
<text top="272" left="64" width="350" height="15" font="5">Percutaneous mitral valve repair provides a less invasive</text>
<text top="290" left="64" width="350" height="15" font="5">alternative to surgery but is not approved for clinical use in</text>
<text top="308" left="64" width="109" height="15" font="5">the United States.</text>
<text top="326" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="325" left="212" width="84" height="15" font="6"><a href="e57.full.html#110">(426,436,459)</a></text>
<text top="353" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="368" left="63" width="351" height="10" font="21">1. Mitral valve surgery is reasonable for patients with chronic se-</text>
<text top="384" left="81" width="333" height="10" font="21">vere secondary MR (stages C and D) who are undergoing CABG</text>
<text top="401" left="81" width="157" height="12" font="21">or AVR. (Level of Evidence: C)</text>
<text top="425" left="79" width="335" height="15" font="5">There is no proof that correction of chronic secondary</text>
<text top="443" left="64" width="350" height="15" font="5">MR at the time of AVR or CABG is effective in pro-</text>
<text top="461" left="64" width="350" height="15" font="5">longing life or relieving symptoms, but it seems wise to</text>
<text top="479" left="64" width="350" height="15" font="5">address the mitral valve during those operations. Although</text>
<text top="497" left="64" width="350" height="15" font="5">it may be hoped that the revascularization will recruit hi-</text>
<text top="515" left="64" width="350" height="15" font="5">bernating myocardium and reduce chronic secondary MR</text>
<text top="532" left="64" width="350" height="15" font="5">or that LV pressure reduction from relief of AS or volume</text>
<text top="550" left="64" width="350" height="15" font="5">reduction from relief of AR might improve chronic sec-</text>
<text top="568" left="64" width="350" height="15" font="5">ondary MR, such hopes may not be realized. Failing to</text>
<text top="586" left="64" width="350" height="15" font="5">correct chronic secondary MR may leave the patient with</text>
<text top="604" left="64" width="120" height="15" font="5">severe residual MR.</text>
<text top="631" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="646" left="63" width="351" height="10" font="21">1. Mitral valve repair or replacement may be considered for</text>
<text top="663" left="81" width="333" height="10" font="21">severely symptomatic patients (NYHA class III to IV) with</text>
<text top="679" left="81" width="332" height="10" font="21">chronic severe secondary MR (stage D) who have persistent</text>
<text top="696" left="81" width="210" height="10" font="21">symptoms despite optimal GDMT for HF</text>
<text top="696" left="295" width="50" height="10" font="22"><a href="e57.full.html#110">(439,448</a></text>
<text top="693" left="345" width="32" height="16" font="22"><a href="e57.full.html#110">–458)</a></text>
<text top="696" left="377" width="37" height="12" font="21"><a href="e57.full.html#110">. </a>(Level</text>
<text top="712" left="81" width="79" height="12" font="21">of Evidence: B)</text>
<text top="736" left="79" width="335" height="15" font="5">Although it is clear that chronic severe secondary</text>
<text top="754" left="64" width="350" height="15" font="5">MR adds to the burden of HF by imposing volume</text>
<text top="772" left="64" width="350" height="15" font="5">overload on an already compromised left ventricle and</text>
<text top="790" left="64" width="350" height="15" font="5">worsens prognosis, there is remarkably little evidence</text>
<text top="808" left="64" width="350" height="15" font="5">that correcting chronic severe secondary MR prolongs</text>
<text top="826" left="64" width="350" height="15" font="5">life or even improves symptoms for a prolonged period.</text>
<text top="844" left="64" width="350" height="15" font="5">This paradox may result from the fact that mitral surgery</text>
<text top="862" left="64" width="350" height="15" font="5">in ischemic MR does not prevent CAD from progress-</text>
<text top="880" left="64" width="350" height="15" font="5">ing, nor does it prevent the continued idiopathic myo-</text>
<text top="898" left="64" width="350" height="15" font="5">cardial deterioration in nonischemic chronic secondary</text>
<text top="103" left="450" width="350" height="15" font="5">MR. Furthermore, when chronic severe secondary MR</text>
<text top="121" left="450" width="350" height="15" font="5">is addressed surgically, it is not clear that repair, so</text>
<text top="139" left="450" width="350" height="15" font="5">valuable in treating primary MR, is even preferred over</text>
<text top="157" left="450" width="350" height="15" font="5">MVR in chronic severe secondary MR. Small RCTs</text>
<text top="175" left="450" width="350" height="15" font="5">have demonstrated that mitral valve surgery reduces</text>
<text top="192" left="450" width="350" height="15" font="5">chamber size and improves peak oxygen consumption in</text>
<text top="210" left="450" width="350" height="15" font="5">chronic severe secondary MR. Deciding which patients</text>
<text top="228" left="450" width="298" height="15" font="5">with chronic severe secondary MR will bene</text>
<text top="225" left="748" width="51" height="19" font="5">ﬁt from</text>
<text top="246" left="450" width="350" height="15" font="5">mitral surgery awaits the results of larger RCTs. Ischemic</text>
<text top="264" left="450" width="350" height="15" font="5">or dilated cardiomyopathy presents different challenges</text>
<text top="282" left="450" width="350" height="15" font="5">for mitral repair. Regurgitation is caused by annular</text>
<text top="300" left="450" width="350" height="15" font="5">dilation as well as apical and lateral displacement of the</text>
<text top="318" left="450" width="350" height="15" font="5">papillary muscles. New techniques have facilitated mitral</text>
<text top="336" left="450" width="350" height="15" font="5">repair in this situation, but durability of the repair is</text>
<text top="354" left="450" width="350" height="15" font="5">primarily dependent on regression or progression of</text>
<text top="372" left="450" width="350" height="15" font="5">ventricular dilation. If the heart continues to dilate, long-</text>
<text top="390" left="450" width="350" height="15" font="5">term durability of the repair is moot; the survival of the</text>
<text top="408" left="450" width="110" height="15" font="5">patient is limited.</text>
<text top="426" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="426" left="597" width="106" height="15" font="6"><a href="e57.full.html#110">(434,435,439,448</a></text>
<text top="422" left="703" width="35" height="19" font="6"><a href="e57.full.html#110">–458)</a></text>
<text top="453" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="468" left="449" width="351" height="10" font="21">2. Mitral valve repair may be considered for patients with chronic</text>
<text top="484" left="467" width="333" height="10" font="21">moderate secondary MR (stage B) who are undergoing other</text>
<text top="501" left="467" width="202" height="12" font="21">cardiac surgery. (Level of Evidence: C)</text>
<text top="525" left="465" width="335" height="15" font="5">Because MR tends to be a progressive disease, it may be</text>
<text top="543" left="450" width="350" height="15" font="5">helpful to address moderate MR when other cardiac sur-</text>
<text top="561" left="450" width="350" height="15" font="5">gery is being performed. Because adding MVR to other</text>
<text top="579" left="450" width="350" height="15" font="5">valve surgery increases surgical risk, it seems logical that</text>
<text top="597" left="450" width="350" height="15" font="5">repair would be preferred in such instances; however, there</text>
<text top="615" left="450" width="350" height="15" font="5">are sparse data available at the time of publication to</text>
<text top="633" left="450" width="127" height="15" font="5">support this concept.</text>
<text top="651" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="650" left="593" width="32" height="15" font="6"><a href="e57.full.html#110">(433)</a></text>
<text top="669" left="465" width="18" height="15" font="5">See</text>
<text top="669" left="488" width="166" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 18</a></text>
<text top="669" left="659" width="140" height="15" font="5">for more information on</text>
<text top="687" left="450" width="74" height="15" font="5">intervention.</text>
<text top="722" left="450" width="209" height="14" font="17">8. Tricuspid Valve Disease</text>
<text top="768" left="450" width="120" height="12" font="19">8.1. Stages of TR</text>
<text top="790" left="451" width="349" height="15" font="5">Trace-to-mild degrees of TR of no physiological conse-</text>
<text top="808" left="450" width="350" height="15" font="5">quence are commonly detected on TTE in subjects with</text>
<text top="826" left="450" width="350" height="15" font="5">anatomically normal valves. Primary disorders of the</text>
<text top="844" left="450" width="290" height="15" font="5">tricuspid apparatus that can lead to more signi</text>
<text top="841" left="740" width="59" height="19" font="5">ﬁcant de-</text>
<text top="862" left="450" width="350" height="15" font="5">grees of TR include rheumatic disease, prolapse, congenital</text>
<text top="880" left="450" width="99" height="15" font="5">disease (Ebstein</text>
<text top="877" left="549" width="250" height="19" font="5">’s), IE, radiation, carcinoid, blunt chest</text>
<text top="898" left="450" width="247" height="15" font="5">wall trauma, RV endomyocardial biopsy</text>
<text top="895" left="696" width="103" height="19" font="5">related trauma,</text>
<text top="940" left="64" width="430" height="11" font="13">Table 18. Summary of Recommendations for Chronic Severe Secondary MR</text>
<text top="965" left="64" width="86" height="9" font="7">Recommendations</text>
<text top="965" left="562" width="21" height="9" font="7">COR</text>
<text top="965" left="661" width="18" height="9" font="7">LOE</text>
<text top="965" left="738" width="52" height="9" font="7">References</text>
<text top="984" left="64" width="443" height="9" font="7">MV surgery is reasonable for patients with chronic severe secondary MR (stages C and D) who are</text>
<text top="999" left="77" width="113" height="9" font="7">undergoing CABG or AVR</text>
<text top="984" left="567" width="11" height="9" font="7">IIa</text>
<text top="984" left="667" width="6" height="9" font="7">C</text>
<text top="984" left="755" width="18" height="9" font="7">N/A</text>
<text top="1013" left="64" width="438" height="9" font="7">MV surgery may be considered for severely symptomatic patients (NYHA class III/IV) with chronic</text>
<text top="1027" left="77" width="140" height="9" font="7">severe secondary MR (stage D)</text>
<text top="1013" left="567" width="11" height="9" font="7">IIb</text>
<text top="1013" left="667" width="6" height="9" font="7">B</text>
<text top="1013" left="729" width="42" height="9" font="8"><a href="e57.full.html#110">(439,448</a></text>
<text top="1010" left="771" width="27" height="14" font="8"><a href="e57.full.html#110">–458)</a></text>
<text top="1041" left="64" width="442" height="9" font="7">MV repair may be considered for patients with chronic moderate secondary MR (stage B) who are</text>
<text top="1055" left="77" width="148" height="9" font="7">undergoing other cardiac surgery</text>
<text top="1041" left="567" width="11" height="9" font="7">IIb</text>
<text top="1041" left="667" width="6" height="9" font="7">C</text>
<text top="1041" left="755" width="18" height="9" font="7">N/A</text>
<text top="1075" left="72" width="728" height="8" font="18">AVR indicates aortic valve replacement; CABG, coronary artery bypass graft; COR, Class of Recommendation; LOE, Level of Evidence; MR, mitral regurgitation; MV, mitral valve; N/A, not applicable; and</text>
<text top="1087" left="72" width="132" height="8" font="18">NYHA, New York Heart Association.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e107</text>
</page>
<page number="52" position="absolute" top="0" left="0" height="1160" width="864">
<text top="760" left="64" width="350" height="15" font="5">and intra-annular RV pacemaker or implantable</text>
<text top="778" left="64" width="94" height="15" font="5">cardioverter-de</text>
<text top="774" left="159" width="255" height="19" font="5">ﬁbrillator leads. Approximately 80% of</text>
<text top="795" left="64" width="90" height="15" font="5">cases of signi</text>
<text top="792" left="154" width="260" height="19" font="5">ﬁcant TR are functional in nature and</text>
<text top="813" left="64" width="269" height="15" font="5">related to tricuspid annular dilation and lea</text>
<text top="810" left="334" width="80" height="19" font="5">ﬂet tethering</text>
<text top="831" left="64" width="350" height="15" font="5">in the setting of RV remodeling due to pressure and/or</text>
<text top="849" left="64" width="350" height="15" font="5">volume overload. The tricuspid annulus is a saddle-</text>
<text top="867" left="64" width="350" height="15" font="5">shaped ellipsoid that becomes planar and circular as it</text>
<text top="885" left="64" width="350" height="15" font="5">dilates in an anterior-posterior direction and will often</text>
<text top="903" left="64" width="253" height="15" font="5">not return to its normal size and con</text>
<text top="900" left="318" width="96" height="19" font="5">ﬁguration after</text>
<text top="921" left="64" width="144" height="15" font="5">relief of RV overload.</text>
<text top="921" left="216" width="58" height="15" font="6"><a href="e57.full.html#53">Table 19</a></text>
<text top="921" left="282" width="132" height="15" font="5">shows the stages (A</text>
<text top="939" left="64" width="296" height="15" font="5">through D) of primary and functional TR as de</text>
<text top="936" left="360" width="54" height="19" font="5">ﬁned for</text>
<text top="957" left="64" width="350" height="15" font="5">other valve lesions. Severe TR (stages C and D) is</text>
<text top="975" left="64" width="350" height="15" font="5">associated with poor prognosis independent of age, LV</text>
<text top="993" left="64" width="350" height="15" font="5">and RV function, and RV size. Patients with signs or</text>
<text top="1011" left="64" width="202" height="15" font="5">symptoms of right HF would</text>
<text top="1007" left="276" width="138" height="19" font="5">ﬁt into the stage D</text>
<text top="1029" left="64" width="350" height="15" font="5">category even if they do not meet other hemodynamic or</text>
<text top="1047" left="64" width="142" height="15" font="5">morphological criteria.</text>
<text top="1065" left="79" width="123" height="15" font="5">Supporting Reference:</text>
<text top="1064" left="208" width="32" height="15" font="6"><a href="e57.full.html#111">(460)</a></text>
<text top="760" left="450" width="190" height="12" font="19">8.2. Tricuspid Regurgitation</text>
<text top="783" left="451" width="21" height="15" font="5">See</text>
<text top="783" left="476" width="51" height="15" font="6"><a href="e57.full.html#54">Figure 5</a></text>
<text top="783" left="532" width="160" height="15" font="5">for indications for surgery.</text>
<text top="810" left="450" width="332" height="15" font="5">8.2.1. Diagnosis and Follow-Up: Recommendations</text>
<text top="837" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="852" left="449" width="350" height="10" font="21">1. TTE is indicated to evaluate severity of TR, determine etiology,</text>
<text top="868" left="467" width="332" height="10" font="21">measure sizes of right-sided chambers and inferior vena cava,</text>
<text top="885" left="467" width="332" height="10" font="21">assess RV systolic function, estimate pulmonary artery systolic</text>
<text top="901" left="467" width="332" height="10" font="21">pressure, and characterize any associated left-sided heart dis-</text>
<text top="918" left="467" width="145" height="12" font="21">ease. (Level of Evidence: C)</text>
<text top="939" left="465" width="335" height="15" font="5">Most TR is clinically silent. Advanced degrees of TR</text>
<text top="957" left="450" width="350" height="15" font="5">may be detected on physical examination by the appearance</text>
<text top="975" left="450" width="67" height="15" font="5">of elevated</text>
<text top="971" left="525" width="275" height="19" font="5">“c-V” waves in the jugular venous pulse, a</text>
<text top="993" left="450" width="350" height="15" font="5">systolic murmur at the lower sternal border that increases</text>
<text top="1011" left="450" width="350" height="15" font="5">in intensity with inspiration, and a pulsatile liver edge. In</text>
<text top="1028" left="450" width="169" height="15" font="5">many patients, characteristic</text>
<text top="1025" left="623" width="177" height="19" font="5">ﬁndings in the jugular venous</text>
<text top="1046" left="450" width="350" height="15" font="5">pulse are the only clues to the presence of advanced TR,</text>
<text top="1064" left="450" width="350" height="15" font="5">because a murmur may be inaudible even with severe</text>
<text top="627" left="64" width="227" height="11" font="13">Figure 4. Indications for Surgery for MR</text>
<text top="659" left="64" width="242" height="9" font="14">*Mitral valve repair is preferred over MVR when possible.</text>
<text top="673" left="72" width="74" height="9" font="14">AF indicates atrial</text>
<text top="670" left="148" width="651" height="13" font="14">ﬁbrillation; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; ERO, effective regurgitant oriﬁce; HF, heart failure; LV, left ventricular; LVEF,</text>
<text top="686" left="72" width="728" height="9" font="14">left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; MR, mitral regurgitation, MV, mitral valve; MVR, mitral valve replacement; NYHA, New York Heart</text>
<text top="700" left="72" width="511" height="9" font="14">Association; PASP, pulmonary artery systolic pressure; RF, regurgitant fraction; RVol, regurgitant volume; and Rx, therapy.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e108</text>
</page>
<page number="53" position="absolute" top="0" left="0" height="1160" width="864">
<text top="891" left="64" width="350" height="15" font="5">TR. Symptoms include fatigue from low cardiac output,</text>
<text top="909" left="64" width="350" height="15" font="5">abdominal fullness, edema, and palpitations, particularly if</text>
<text top="927" left="64" width="350" height="15" font="5">AF is also present. Progressive hepatic dysfunction may</text>
<text top="945" left="64" width="350" height="15" font="5">occur due to the elevated right atrial pressure, and thus</text>
<text top="963" left="64" width="350" height="15" font="5">assessment of liver function is useful in patients with</text>
<text top="981" left="64" width="150" height="15" font="5">advanced degrees of TR.</text>
<text top="999" left="79" width="313" height="15" font="5">TTE can distinguish primary from functional TR, de</text>
<text top="996" left="392" width="22" height="19" font="5">ﬁne</text>
<text top="1017" left="64" width="350" height="15" font="5">any associated left-sided valvular and/or myocardial disease,</text>
<text top="1035" left="64" width="350" height="15" font="5">and provide an estimate of pulmonary artery systolic pres-</text>
<text top="1053" left="64" width="240" height="15" font="5">sure. Characterization of severity of TR <a href="e57.full.html#53">(</a></text>
<text top="1053" left="304" width="52" height="15" font="6"><a href="e57.full.html#53">Table 19</a></text>
<text top="1053" left="356" width="58" height="15" font="5">) relies on</text>
<text top="1071" left="64" width="350" height="15" font="5">an integrative assessment of multiple parameters as recom-</text>
<text top="1089" left="64" width="350" height="15" font="5">mended by the ASE and EAE. In cases of functional TR,</text>
<text top="891" left="450" width="350" height="15" font="5">the tricuspid annular diameter should be measured in the</text>
<text top="909" left="450" width="47" height="15" font="5">apical 4</text>
<text top="906" left="497" width="303" height="19" font="5">–chamber view. There is a linear relationship be-</text>
<text top="927" left="450" width="350" height="15" font="5">tween annular diameter and tricuspid regurgitant volume. A</text>
<text top="945" left="450" width="107" height="15" font="5">diastolic diameter</text>
<text top="942" left="565" width="166" height="19" font="5">&gt;40 mm (or &gt;21 mm/m</text>
<text top="942" left="730" width="6" height="10" font="14">2</text>
<text top="945" left="736" width="64" height="15" font="5">) indicates</text>
<text top="963" left="450" width="28" height="15" font="5">signi</text>
<text top="960" left="477" width="322" height="19" font="5">ﬁcant annular dilation and an increased risk of persis-</text>
<text top="981" left="450" width="350" height="15" font="5">tent or progressive TR after isolated mitral valve surgery.</text>
<text top="999" left="450" width="265" height="15" font="5">With RV remodeling, tricuspid valve lea</text>
<text top="995" left="715" width="84" height="19" font="5">ﬂet tethering</text>
<text top="1017" left="450" width="350" height="15" font="5">height and area also contribute to functional TR and may</text>
<text top="1035" left="450" width="350" height="15" font="5">predict the need for repair techniques other than annulo-</text>
<text top="1053" left="450" width="350" height="15" font="5">plasty to achieve an effective and durable operative result.</text>
<text top="1071" left="450" width="350" height="15" font="5">Pulmonary artery systolic pressure is estimated from the</text>
<text top="1089" left="450" width="350" height="15" font="5">maximal tricuspid valve regurgitant velocity using the</text>
<text top="103" left="64" width="134" height="11" font="13">Table 19. Stages of TR</text>
<text top="141" left="64" width="27" height="9" font="7">Stage</text>
<text top="141" left="119" width="12" height="9" font="7">De</text>
<text top="138" left="131" width="32" height="14" font="7">ﬁnition</text>
<text top="129" left="249" width="25" height="9" font="7">Valve</text>
<text top="141" left="241" width="41" height="9" font="7">Anatomy</text>
<text top="129" left="403" width="25" height="9" font="7">Valve</text>
<text top="141" left="378" width="70" height="9" font="7">Hemodynamics</text>
<text top="141" left="448" width="6" height="9" font="8"><a href="e57.full.html#53">*</a></text>
<text top="129" left="538" width="65" height="9" font="7">Hemodynamic</text>
<text top="141" left="536" width="67" height="9" font="7">Consequences</text>
<text top="141" left="703" width="49" height="9" font="7">Symptoms</text>
<text top="158" left="67" width="7" height="9" font="7">A</text>
<text top="158" left="106" width="59" height="9" font="7">At risk of TR</text>
<text top="158" left="190" width="35" height="9" font="7">Primary</text>
<text top="166" left="190" width="115" height="14" font="7"> Mild rheumatic change</text>
<text top="180" left="190" width="72" height="14" font="7"> Mild prolapse</text>
<text top="194" left="190" width="95" height="14" font="7"> Other (e.g., IE with</text>
<text top="211" left="202" width="74" height="9" font="7">vegetation, early</text>
<text top="226" left="202" width="92" height="9" font="7">carcinoid deposition,</text>
<text top="240" left="202" width="42" height="9" font="7">radiation)</text>
<text top="251" left="190" width="84" height="14" font="7"> Intra-annular RV</text>
<text top="268" left="202" width="104" height="9" font="7">pacemaker or ICD lead</text>
<text top="279" left="190" width="112" height="14" font="7"> Postcardiac transplant</text>
<text top="297" left="202" width="69" height="9" font="7">(biopsy related)</text>
<text top="311" left="190" width="48" height="9" font="7">Functional</text>
<text top="318" left="190" width="44" height="14" font="7"> Normal</text>
<text top="332" left="190" width="107" height="14" font="7"> Early annular dilation</text>
<text top="157" left="348" width="77" height="14" font="7"> No or trace TR</text>
<text top="157" left="498" width="35" height="14" font="7"> None</text>
<text top="157" left="656" width="135" height="14" font="7"> None or in relation to other</text>
<text top="174" left="668" width="109" height="9" font="7">left heart or pulmonary/</text>
<text top="189" left="668" width="125" height="9" font="7">pulmonary vascular disease</text>
<text top="353" left="67" width="7" height="9" font="7">B</text>
<text top="353" left="106" width="70" height="9" font="7">Progressive TR</text>
<text top="353" left="190" width="35" height="9" font="7">Primary</text>
<text top="361" left="190" width="94" height="14" font="7"> Progressive leaﬂet</text>
<text top="378" left="202" width="111" height="9" font="7">deterioration/destruction</text>
<text top="389" left="190" width="97" height="14" font="7"> Moderate-to-severe</text>
<text top="406" left="202" width="75" height="9" font="7">prolapse, limited</text>
<text top="420" left="202" width="68" height="9" font="7">chordal rupture</text>
<text top="434" left="190" width="48" height="9" font="7">Functional</text>
<text top="442" left="190" width="107" height="14" font="7"> Early annular dilation</text>
<text top="456" left="190" width="129" height="14" font="7"> Moderate leaﬂet tethering</text>
<text top="353" left="348" width="36" height="9" font="7">Mild TR</text>
<text top="361" left="348" width="125" height="14" font="7"> Central jet area &lt;5.0 cm</text>
<text top="361" left="473" width="5" height="6" font="23">2</text>
<text top="375" left="348" width="124" height="14" font="7"> Vena contracta width not</text>
<text top="392" left="363" width="11" height="9" font="7">de</text>
<text top="389" left="374" width="22" height="14" font="7">ﬁned</text>
<text top="403" left="348" width="136" height="14" font="7"> CW jet density and contour:</text>
<text top="420" left="359" width="81" height="9" font="7">soft and parabolic</text>
<text top="432" left="348" width="127" height="14" font="7"> Hepatic vein ﬂow: systolic</text>
<text top="449" left="359" width="50" height="9" font="7">dominance</text>
<text top="463" left="348" width="60" height="9" font="7">Moderate TR</text>
<text top="470" left="348" width="126" height="14" font="7"> Central jet area 5–10 cm</text>
<text top="471" left="474" width="5" height="6" font="23">2</text>
<text top="485" left="348" width="124" height="14" font="7"> Vena contracta width not</text>
<text top="502" left="359" width="11" height="9" font="7">de</text>
<text top="499" left="370" width="90" height="14" font="7">ﬁned but &lt;0.70 cm</text>
<text top="513" left="348" width="136" height="14" font="7"> CW jet density and contour:</text>
<text top="530" left="359" width="105" height="9" font="7">dense, variable contour</text>
<text top="541" left="348" width="127" height="14" font="7"> Hepatic vein ﬂow: systolic</text>
<text top="559" left="359" width="36" height="9" font="7">blunting</text>
<text top="353" left="498" width="36" height="9" font="7">Mild TR</text>
<text top="361" left="498" width="116" height="14" font="7"> RV/RA/IVC size normal</text>
<text top="378" left="498" width="60" height="9" font="7">Moderate TR</text>
<text top="385" left="498" width="100" height="14" font="7"> No RV enlargement</text>
<text top="399" left="498" width="136" height="14" font="7"> No or mild RA enlargement</text>
<text top="414" left="498" width="143" height="14" font="7"> No or mild IVC enlargement</text>
<text top="431" left="510" width="116" height="9" font="7">with normal respirophasic</text>
<text top="445" left="510" width="38" height="9" font="7">variation</text>
<text top="456" left="498" width="102" height="14" font="7"> Normal RA pressure</text>
<text top="352" left="656" width="135" height="14" font="7"> None or in relation to other</text>
<text top="369" left="668" width="109" height="9" font="7">left heart or pulmonary/</text>
<text top="383" left="668" width="125" height="9" font="7">pulmonary vascular disease</text>
<text top="576" left="67" width="7" height="9" font="7">C</text>
<text top="576" left="106" width="70" height="9" font="7">Asymptomatic,</text>
<text top="590" left="118" width="46" height="9" font="7">severe TR</text>
<text top="576" left="190" width="35" height="9" font="7">Primary</text>
<text top="584" left="190" width="119" height="14" font="7"> Flail or grossly distorted</text>
<text top="601" left="202" width="13" height="9" font="7">lea</text>
<text top="598" left="215" width="19" height="14" font="7">ﬂets</text>
<text top="615" left="190" width="48" height="9" font="7">Functional</text>
<text top="623" left="190" width="115" height="14" font="7"> Severe annular dilation</text>
<text top="640" left="202" width="3" height="9" font="7">(</text>
<text top="637" left="205" width="105" height="14" font="7">&gt;40 mm or 21 mm/m</text>
<text top="637" left="310" width="5" height="6" font="23">2</text>
<text top="640" left="315" width="3" height="9" font="7">)</text>
<text top="651" left="190" width="120" height="14" font="7"> Marked leaﬂet tethering</text>
<text top="575" left="348" width="131" height="14" font="7"> Central jet area &gt;10.0 cm</text>
<text top="576" left="479" width="5" height="6" font="23">2</text>
<text top="589" left="348" width="106" height="14" font="7"> Vena contracta width</text>
<text top="603" left="359" width="40" height="14" font="7">&gt;0.7 cm</text>
<text top="618" left="348" width="136" height="14" font="7"> CW jet density and contour:</text>
<text top="635" left="359" width="122" height="9" font="7">dense, triangular with early</text>
<text top="649" left="359" width="22" height="9" font="7">peak</text>
<text top="660" left="348" width="127" height="14" font="7"> Hepatic vein ﬂow: systolic</text>
<text top="677" left="359" width="35" height="9" font="7">reversal</text>
<text top="575" left="498" width="117" height="14" font="7"> RV/RA/IVC dilated with</text>
<text top="592" left="510" width="126" height="9" font="7">decreased IVC respirophasic</text>
<text top="606" left="510" width="38" height="9" font="7">variation</text>
<text top="618" left="498" width="130" height="14" font="7"> Elevated RA pressure with</text>
<text top="632" left="510" width="47" height="14" font="7">“c-V” wave</text>
<text top="646" left="498" width="120" height="14" font="7"> Diastolic interventricular</text>
<text top="663" left="510" width="27" height="9" font="7">septal</text>
<text top="660" left="541" width="79" height="14" font="7">ﬂattening may be</text>
<text top="677" left="510" width="33" height="9" font="7">present</text>
<text top="575" left="656" width="137" height="14" font="7"> None, or in relation to other</text>
<text top="592" left="668" width="109" height="9" font="7">left heart or pulmonary/</text>
<text top="606" left="668" width="125" height="9" font="7">pulmonary vascular disease</text>
<text top="695" left="67" width="7" height="9" font="7">D</text>
<text top="695" left="106" width="61" height="9" font="7">Symptomatic</text>
<text top="709" left="118" width="46" height="9" font="7">severe TR</text>
<text top="695" left="190" width="35" height="9" font="7">Primary</text>
<text top="703" left="190" width="119" height="14" font="7"> Flail or grossly distorted</text>
<text top="720" left="202" width="13" height="9" font="7">lea</text>
<text top="717" left="215" width="19" height="14" font="7">ﬂets</text>
<text top="734" left="190" width="48" height="9" font="7">Functional</text>
<text top="741" left="190" width="115" height="14" font="7"> Severe annular dilation</text>
<text top="759" left="202" width="3" height="9" font="7">(</text>
<text top="756" left="205" width="113" height="14" font="7">&gt;40 mm or &gt;21 mm/m</text>
<text top="756" left="318" width="5" height="6" font="23">2</text>
<text top="758" left="323" width="3" height="9" font="7">)</text>
<text top="770" left="190" width="120" height="14" font="7"> Marked leaﬂet tethering</text>
<text top="694" left="348" width="131" height="14" font="7"> Central jet area &gt;10.0 cm</text>
<text top="694" left="479" width="5" height="6" font="23">2</text>
<text top="708" left="348" width="106" height="14" font="7"> Vena contracta width</text>
<text top="722" left="359" width="46" height="14" font="7">&gt;0.70 cm</text>
<text top="736" left="348" width="136" height="14" font="7"> CW jet density and contour:</text>
<text top="754" left="359" width="122" height="9" font="7">dense, triangular with early</text>
<text top="768" left="359" width="22" height="9" font="7">peak</text>
<text top="779" left="348" width="127" height="14" font="7"> Hepatic vein ﬂow: systolic</text>
<text top="796" left="359" width="35" height="9" font="7">reversal</text>
<text top="694" left="498" width="117" height="14" font="7"> RV/RA/IVC dilated with</text>
<text top="711" left="510" width="126" height="9" font="7">decreased IVC respirophasic</text>
<text top="725" left="510" width="38" height="9" font="7">variation</text>
<text top="736" left="498" width="130" height="14" font="7"> Elevated RA pressure with</text>
<text top="751" left="510" width="47" height="14" font="7">“c-V” wave</text>
<text top="765" left="498" width="120" height="14" font="7"> Diastolic interventricular</text>
<text top="782" left="510" width="27" height="9" font="7">septal</text>
<text top="779" left="541" width="42" height="14" font="7">ﬂattening</text>
<text top="793" left="498" width="142" height="14" font="7"> Reduced RV systolic function</text>
<text top="810" left="510" width="59" height="9" font="7">in late phase</text>
<text top="694" left="656" width="105" height="14" font="7"> Fatigue, palpitations,</text>
<text top="711" left="668" width="90" height="9" font="7">dyspnea, abdominal</text>
<text top="725" left="668" width="117" height="9" font="7">bloating, anorexia, edema</text>
<text top="828" left="64" width="735" height="8" font="18">*Several valve hemodynamic criteria are provided for assessment of severity of TR, but not all criteria for each category will necessarily be present in every patient. Categorization of severity of TR as</text>
<text top="840" left="64" width="396" height="8" font="18">mild, moderate, or severe also depends on image quality and integration of these parameters with clinical</text>
<text top="838" left="463" width="31" height="11" font="18">ﬁndings.</text>
<text top="852" left="72" width="237" height="8" font="18">CW indicates continuous wave; ICD, implantable cardioverter-de</text>
<text top="850" left="309" width="471" height="11" font="18">ﬁbrillator; IE, infective endocarditis; IVC, inferior vena cava; RA, right atrium; RV, right ventricle; and TR, tricuspid regurgitation.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e109</text>
</page>
<page number="54" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="27" size="7" family="Times" color="#327eb1"/>
<text top="671" left="64" width="31" height="15" font="5">modi</text>
<text top="668" left="95" width="319" height="19" font="5">ﬁed Bernoulli equation. The accuracy of this technique</text>
<text top="689" left="64" width="297" height="15" font="5">can be compromised in severe TR due to the dif</text>
<text top="686" left="361" width="53" height="19" font="5">ﬁculty in</text>
<text top="707" left="64" width="350" height="15" font="5">assessing right atrial pressure as well as potential inaccura-</text>
<text top="725" left="64" width="155" height="15" font="5">cies of applying the simpli</text>
<text top="722" left="219" width="195" height="19" font="5">ﬁed Bernoulli equation to lesions</text>
<text top="743" left="64" width="77" height="15" font="5">with laminar</text>
<text top="740" left="147" width="267" height="19" font="5">ﬂow. Assessment of RV systolic function is</text>
<text top="761" left="64" width="350" height="15" font="5">challenged by geometric and image acquisition constraints,</text>
<text top="779" left="64" width="350" height="15" font="5">as well as by variability in RV loading conditions. Normal RV</text>
<text top="797" left="64" width="128" height="15" font="5">systolic function is de</text>
<text top="794" left="192" width="222" height="19" font="5">ﬁned by several parameters, including</text>
<text top="815" left="64" width="236" height="15" font="5">tricuspid annular plane systolic excursion</text>
<text top="811" left="303" width="111" height="19" font="5">&gt;16 mm, tricuspid</text>
<text top="833" left="64" width="147" height="15" font="5">valve annular velocity (S</text>
<text top="829" left="211" width="204" height="19" font="5">’) &gt;10.0 cm per second, and RV</text>
<text top="851" left="64" width="95" height="15" font="5">end-systolic area</text>
<text top="847" left="163" width="58" height="19" font="5">&lt;20.0 cm</text>
<text top="848" left="221" width="6" height="10" font="14">2</text>
<text top="851" left="230" width="140" height="15" font="5">or fractional area change</text>
<text top="847" left="373" width="41" height="19" font="5">&gt;35%.</text>
<text top="869" left="64" width="350" height="15" font="5">TEE for tricuspid valve assessment can be considered when</text>
<text top="887" left="64" width="350" height="15" font="5">TTE images are inadequate, although visualization of the</text>
<text top="904" left="64" width="289" height="15" font="5">tricuspid valve with TEE can also be suboptimal.</text>
<text top="923" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="922" left="212" width="38" height="15" font="6"><a href="e57.full.html#100">(5,461</a></text>
<text top="919" left="251" width="91" height="19" font="6"><a href="e57.full.html#100">–469,469–471)</a></text>
<text top="947" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="962" left="63" width="351" height="10" font="21">1. Invasive measurement of pulmonary artery pressures and pul-</text>
<text top="978" left="81" width="332" height="10" font="21">monary vascular resistance can be useful in patients with TR</text>
<text top="995" left="81" width="333" height="10" font="21">when clinical and noninvasive data regarding their values are</text>
<text top="1011" left="81" width="176" height="12" font="21">discordant. (Level of Evidence: C)</text>
<text top="1035" left="79" width="335" height="15" font="5">When physical examination, ECG, and TTE data</text>
<text top="1053" left="64" width="350" height="15" font="5">regarding estimated pulmonary artery systolic pressure are</text>
<text top="1071" left="64" width="148" height="15" font="5">either discordant or insuf</text>
<text top="1068" left="213" width="201" height="19" font="5">ﬁcient, including when the TR jet</text>
<text top="1089" left="64" width="350" height="15" font="5">velocity signal is inadequate or may underestimate pulmonary</text>
<text top="671" left="450" width="350" height="15" font="5">artery systolic pressure, invasive measurement of pulmonary</text>
<text top="689" left="450" width="350" height="15" font="5">artery pressures and pulmonary vascular resistance can be</text>
<text top="707" left="450" width="350" height="15" font="5">helpful to guide clinical decision making in individual pa-</text>
<text top="725" left="450" width="350" height="15" font="5">tients. Invasive data are essential for accurate diagnosis of</text>
<text top="743" left="450" width="350" height="15" font="5">the cause of pulmonary hypertension and for the assessment</text>
<text top="761" left="450" width="350" height="15" font="5">of pulmonary vascular reactivity following vasodilator chal-</text>
<text top="779" left="450" width="350" height="15" font="5">lenge. Direct measurements of right atrial pressure may</text>
<text top="797" left="450" width="350" height="15" font="5">also be useful for clinical decision making. Right ven-</text>
<text top="815" left="450" width="350" height="15" font="5">triculography may further aid in the evaluation of the</text>
<text top="833" left="450" width="350" height="15" font="5">severity of TR and the status of the right ventricle. Ther-</text>
<text top="851" left="450" width="350" height="15" font="5">modilution cardiac output measurements may be inaccurate</text>
<text top="869" left="450" width="350" height="15" font="5">with severe TR, and thus a Fick cardiac output should be</text>
<text top="887" left="450" width="350" height="15" font="5">measured to apply to the calculation of pulmonary resistance.</text>
<text top="911" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="926" left="449" width="351" height="10" font="21">1. CMR or real-time 3D echocardiography may be considered for</text>
<text top="942" left="467" width="332" height="10" font="21">assessment of RV systolic function and systolic and diastolic</text>
<text top="959" left="467" width="332" height="10" font="21">volumes in patients with severe TR (stages C and D) and sub-</text>
<text top="975" left="467" width="269" height="12" font="21">optimal 2D echocardiograms. (Level of Evidence: C)</text>
<text top="999" left="465" width="335" height="15" font="5">Assessment of RV systolic function in patients with TR</text>
<text top="1017" left="450" width="350" height="15" font="5">is a critical component of preoperative planning, especial-</text>
<text top="1035" left="450" width="350" height="15" font="5">ly in the context of reoperative isolated tricuspid valve</text>
<text top="1053" left="450" width="350" height="15" font="5">repair or replacement years after left-sided valve surgery.</text>
<text top="1071" left="450" width="350" height="15" font="5">Impaired RV systolic function negatively impacts early</text>
<text top="1089" left="450" width="350" height="15" font="5">functional, late functional, and survival outcomes following</text>
<text top="577" left="64" width="185" height="11" font="13">Figure 5. Indications for Surgery</text>
<text top="609" left="64" width="22" height="9" font="14">*See</text>
<text top="609" left="89" width="37" height="9" font="27"><a href="e57.full.html#53">Table 19</a></text>
<text top="609" left="130" width="25" height="9" font="14">for de</text>
<text top="606" left="155" width="307" height="13" font="14">ﬁnition of stages. TA dilation is deﬁned by &gt;40 mm on TTE (&gt;21 mm/m</text>
<text top="607" left="461" width="4" height="6" font="23">2</text>
<text top="609" left="466" width="14" height="9" font="14">) or</text>
<text top="606" left="483" width="202" height="13" font="14">&gt;70 mm on direct intraoperative measurement.</text>
<text top="623" left="72" width="714" height="9" font="14">LV indicates left ventricular; PHTN, pulmonary hypertension; RV, right ventricular; TA, tricuspid annular; TR, tricuspid regurgitation; TTE, transthoracic echocardiogram; TV,</text>
<text top="636" left="72" width="225" height="9" font="14">tricuspid valve; and TVR, tricuspid valve replacement.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e110</text>
</page>
<page number="55" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">tricuspid valve surgery. Evaluation with TTE or TEE may</text>
<text top="121" left="64" width="350" height="15" font="5">be suboptimal in some patients, due to poor acoustic win-</text>
<text top="139" left="64" width="350" height="15" font="5">dows, the technical limitations of standard echocardio-</text>
<text top="157" left="64" width="350" height="15" font="5">graphic and Doppler techniques, and dynamic changes in</text>
<text top="175" left="64" width="350" height="15" font="5">RV loading conditions. Both CMR and real-time 3D</text>
<text top="192" left="64" width="350" height="15" font="5">echocardiography may provide more accurate assessment</text>
<text top="210" left="64" width="350" height="15" font="5">of RV volumes and systolic function, as well as annular</text>
<text top="228" left="64" width="186" height="15" font="5">dimension and the degree of lea</text>
<text top="225" left="250" width="164" height="19" font="5">ﬂet tethering. CMR may be</text>
<text top="246" left="64" width="350" height="15" font="5">the ideal modality in young asymptomatic patients with se-</text>
<text top="264" left="64" width="350" height="15" font="5">vere TR to assess initial and serial measurements of RV size</text>
<text top="282" left="64" width="350" height="15" font="5">and systolic function. In addition, echocardiographic strain</text>
<text top="300" left="64" width="350" height="15" font="5">imaging or CT scanning may be useful in assessing RV</text>
<text top="318" left="64" width="350" height="15" font="5">function. These imaging modalities are not widely used at</text>
<text top="336" left="64" width="350" height="15" font="5">the time of guideline publication, and outcome data are</text>
<text top="354" left="64" width="339" height="15" font="5">needed to determine the incremental utility of these tests.</text>
<text top="373" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="372" left="212" width="27" height="15" font="6"><a href="e57.full.html#111">(472</a></text>
<text top="368" left="239" width="35" height="19" font="6"><a href="e57.full.html#111">–481)</a></text>
<text top="396" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="411" left="63" width="351" height="10" font="21">2. Exercise testing may be considered for the assessment of ex-</text>
<text top="427" left="81" width="333" height="10" font="21">ercise capacity in patients with severe TR with no or minimal</text>
<text top="444" left="81" width="229" height="12" font="21">symptoms (stage C). (Level of Evidence: C)</text>
<text top="468" left="79" width="335" height="15" font="5">Patients with severe functional TR usually report</text>
<text top="486" left="64" width="350" height="15" font="5">symptoms referable to the responsible left-sided valve or</text>
<text top="504" left="64" width="350" height="15" font="5">myocardial abnormality. However, in some patients with</text>
<text top="522" left="64" width="350" height="15" font="5">primary TR, symptoms may not emerge until relatively late</text>
<text top="540" left="64" width="350" height="15" font="5">in the course of the disease. As is the case for left-sided</text>
<text top="558" left="64" width="350" height="15" font="5">valve lesions, treadmill or bicycle testing may uncover</text>
<text top="576" left="64" width="350" height="15" font="5">limitations to exercise not previously recognized by the</text>
<text top="594" left="64" width="350" height="15" font="5">patient and prompt earlier evaluation for surgery. Although</text>
<text top="612" left="64" width="350" height="15" font="5">some clinical experience has been reported for patients with</text>
<text top="630" left="64" width="46" height="15" font="5">Ebstein</text>
<text top="626" left="110" width="304" height="19" font="5">’s anomaly, the effect on clinical outcomes of any</text>
<text top="648" left="64" width="350" height="15" font="5">exercise-induced changes in RV size/function or pulmo-</text>
<text top="665" left="64" width="350" height="15" font="5">nary artery pressures in patients with severe TR (stage C)</text>
<text top="683" left="64" width="211" height="15" font="5">has not been prospectively studied.</text>
<text top="702" left="79" width="123" height="15" font="5">Supporting Reference:</text>
<text top="701" left="208" width="32" height="15" font="6"><a href="e57.full.html#111">(482)</a></text>
<text top="728" left="64" width="277" height="15" font="5">8.2.2. Medical Therapy: Recommendations</text>
<text top="755" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="770" left="64" width="350" height="10" font="21">1. Diuretics can be useful for patients with severe TR and signs of</text>
<text top="787" left="82" width="248" height="12" font="21">right-sided HF (stage D). (Level of Evidence: C)</text>
<text top="811" left="79" width="335" height="15" font="5">Patients with severe TR usually present with signs or</text>
<text top="829" left="64" width="350" height="15" font="5">symptoms of right HF, including peripheral edema and</text>
<text top="847" left="64" width="350" height="15" font="5">ascites. Diuretics can be used to decrease volume over-</text>
<text top="865" left="64" width="350" height="15" font="5">load in these patients. Loop diuretics are typically provided</text>
<text top="883" left="64" width="350" height="15" font="5">and may relieve systemic congestion, but their use can</text>
<text top="901" left="64" width="179" height="15" font="5">be limited by worsening low-</text>
<text top="897" left="243" width="170" height="19" font="5">ﬂow syndrome. Aldosterone</text>
<text top="919" left="64" width="226" height="15" font="5">antagonists may be of additive bene</text>
<text top="915" left="290" width="123" height="19" font="5">ﬁt, especially in the</text>
<text top="937" left="64" width="350" height="15" font="5">setting of hepatic congestion, which may promote sec-</text>
<text top="955" left="64" width="165" height="15" font="5">ondary hyperaldosteronism.</text>
<text top="982" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="997" left="63" width="351" height="10" font="21">1. Medical therapies to reduce elevated pulmonary artery pres-</text>
<text top="1013" left="81" width="333" height="10" font="21">sures and/or pulmonary vascular resistance might be consid-</text>
<text top="1030" left="81" width="332" height="10" font="21">ered in patients with severe functional TR (stages C and D).</text>
<text top="1046" left="81" width="113" height="12" font="21">(Level of Evidence: C)</text>
<text top="1070" left="79" width="335" height="15" font="5">Medical therapies for management of severe TR (stages</text>
<text top="1088" left="64" width="350" height="15" font="5">C and D) are limited. Attention should be focused on the</text>
<text top="103" left="450" width="350" height="15" font="5">causative lesion in patients with functional TR. Reduc-</text>
<text top="121" left="450" width="350" height="15" font="5">tion of pulmonary artery pressures and pulmonary vascu-</text>
<text top="139" left="450" width="153" height="15" font="5">lar resistance with speci</text>
<text top="135" left="603" width="197" height="19" font="5">ﬁc pulmonary vasodilators may</text>
<text top="157" left="450" width="350" height="15" font="5">be helpful to reduce RV afterload and functional TR in</text>
<text top="175" left="450" width="350" height="15" font="5">selected patients with pulmonary hypertension who dem-</text>
<text top="192" left="450" width="350" height="15" font="5">onstrate acute responsiveness during invasive testing.</text>
<text top="210" left="450" width="350" height="15" font="5">Medical treatment of conditions that elevate left-sided</text>
<text top="225" left="450" width="350" height="19" font="5">ﬁlling pressures, such as systemic hypertension, should be</text>
<text top="246" left="450" width="64" height="15" font="5">optimized.</text>
<text top="265" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="264" left="597" width="58" height="15" font="6"><a href="e57.full.html#111">(483,484)</a></text>
<text top="298" left="450" width="248" height="15" font="5">8.2.3. Intervention: Recommendations</text>
<text top="326" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="341" left="449" width="350" height="10" font="21">1. Tricuspid valve surgery is recommended for patients with se-</text>
<text top="358" left="467" width="332" height="10" font="21">vere TR (stages C and D) undergoing left-sided valve surgery.</text>
<text top="374" left="467" width="113" height="12" font="21">(Level of Evidence: C)</text>
<text top="398" left="465" width="335" height="15" font="5">The indications for surgical correction of TR are most</text>
<text top="416" left="450" width="350" height="15" font="5">often considered at the time of mitral or aortic valve sur-</text>
<text top="434" left="450" width="350" height="15" font="5">gery. Severe TR of either a primary or functional nature</text>
<text top="452" left="450" width="350" height="15" font="5">may not predictably improve after treatment of the left-</text>
<text top="470" left="450" width="350" height="15" font="5">sided valve lesion and reduction of RV afterload; as such,</text>
<text top="488" left="450" width="350" height="15" font="5">severe TR should be addressed as part of the index pro-</text>
<text top="506" left="450" width="350" height="15" font="5">cedure. Reoperation for severe, isolated TR after left-sided</text>
<text top="524" left="450" width="350" height="15" font="5">valve surgery is associated with a perioperative mortality</text>
<text top="542" left="450" width="350" height="15" font="5">rate of 10% to 25%. Tricuspid valve repair does not add</text>
<text top="560" left="450" width="350" height="15" font="5">appreciably to the risks of surgery and can be accomplished</text>
<text top="578" left="450" width="147" height="15" font="5">with a clinically insigni</text>
<text top="574" left="596" width="203" height="19" font="5">ﬁcant increase in ischemic time.</text>
<text top="596" left="450" width="146" height="15" font="5">There has been a signi</text>
<text top="592" left="596" width="204" height="19" font="5">ﬁcant increase in the number of</text>
<text top="614" left="450" width="350" height="15" font="5">tricuspid valve repairs performed for this indication over</text>
<text top="632" left="450" width="350" height="15" font="5">the past decade. Tricuspid valve repair is preferable to</text>
<text top="649" left="450" width="350" height="15" font="5">replacement. When replacement is necessary for primary,</text>
<text top="667" left="450" width="350" height="15" font="5">uncorrectable tricuspid valve disease, the choice of pros-</text>
<text top="685" left="450" width="350" height="15" font="5">thesis is individualized, with the usual trade-offs between</text>
<text top="703" left="450" width="350" height="15" font="5">thrombosis/anticoagulation with a mechanical valve and</text>
<text top="721" left="450" width="350" height="15" font="5">durability with a tissue valve. Meta-analysis has shown no</text>
<text top="739" left="450" width="350" height="15" font="5">difference in overall survival between mechanical and tissue</text>
<text top="757" left="450" width="350" height="15" font="5">valves for patients undergoing tricuspid valve replacement.</text>
<text top="775" left="450" width="117" height="15" font="5">The risks and bene</text>
<text top="772" left="567" width="233" height="19" font="5">ﬁts of tricuspid valve operation should</text>
<text top="793" left="450" width="350" height="15" font="5">be carefully considered in the presence of severe RV sys-</text>
<text top="811" left="450" width="350" height="15" font="5">tolic dysfunction or irreversible pulmonary hypertension,</text>
<text top="829" left="450" width="308" height="15" font="5">due to the possibility of RV failure after operation.</text>
<text top="847" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="847" left="597" width="27" height="15" font="6"><a href="e57.full.html#111">(485</a></text>
<text top="843" left="625" width="35" height="19" font="6"><a href="e57.full.html#111">–494)</a></text>
<text top="875" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="890" left="449" width="202" height="10" font="21">1. Tricuspid valve repair can be bene</text>
<text top="886" left="651" width="148" height="16" font="21">ﬁcial for patients with mild,</text>
<text top="906" left="467" width="332" height="10" font="21">moderate, or greater functional TR (stage B) at the time of left-</text>
<text top="922" left="467" width="332" height="10" font="21">sided valve surgery with either 1) tricuspid annular dilation or 2)</text>
<text top="939" left="467" width="154" height="10" font="21">prior evidence of right HF</text>
<text top="939" left="629" width="26" height="10" font="22"><a href="e57.full.html#111">(464</a></text>
<text top="936" left="655" width="84" height="16" font="22"><a href="e57.full.html#111">–466,495–501)</a></text>
<text top="939" left="739" width="61" height="12" font="21"><a href="e57.full.html#111">. </a>(Level of</text>
<text top="956" left="467" width="65" height="12" font="21">Evidence: B)</text>
<text top="980" left="465" width="335" height="15" font="5">Left uncorrected at the time of left-sided valve sur-</text>
<text top="998" left="450" width="350" height="15" font="5">gery, mild or moderate degrees of functional TR may</text>
<text top="1016" left="450" width="350" height="15" font="5">progress over time in approximately 25% of patients and</text>
<text top="1033" left="450" width="350" height="15" font="5">result in reduced long-term functional outcome and sur-</text>
<text top="1051" left="450" width="350" height="15" font="5">vival. Risk factors for persistence and/or progression of</text>
<text top="1069" left="450" width="237" height="15" font="5">TR include tricuspid annulus dilation (</text>
<text top="1066" left="687" width="113" height="19" font="5">&gt;40 mm diameter</text>
<text top="1087" left="450" width="81" height="15" font="5">or 21 mm/m</text>
<text top="1084" left="531" width="6" height="10" font="14">2</text>
<text top="1087" left="543" width="257" height="15" font="5">diameter indexed to body surface area on</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e111</text>
</page>
<page number="56" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="118" height="15" font="5">preoperative TTE;</text>
<text top="99" left="189" width="225" height="19" font="5">&gt;70 mm diameter on direct intra-</text>
<text top="121" left="64" width="350" height="15" font="5">operative measurement); degree of RV dysfunction/re-</text>
<text top="139" left="64" width="89" height="15" font="5">modeling; lea</text>
<text top="135" left="154" width="260" height="19" font="5">ﬂet tethering height; pulmonary artery</text>
<text top="157" left="64" width="350" height="15" font="5">hypertension; AF; nonmyxomatous etiology of MR; and</text>
<text top="175" left="64" width="350" height="15" font="5">intra-annular RV pacemaker or implantable cardioverter-</text>
<text top="192" left="64" width="14" height="15" font="5">de</text>
<text top="189" left="78" width="336" height="19" font="5">ﬁbrillator leads. The cut-off of &gt;70 mm diameter on</text>
<text top="210" left="64" width="350" height="15" font="5">direct intraoperative measurement originated from a sin-</text>
<text top="228" left="64" width="350" height="15" font="5">gle center, performed with the patient on cardiopulmonary</text>
<text top="246" left="64" width="350" height="15" font="5">bypass using a supple ruler, taken from the anteroseptal</text>
<text top="264" left="64" width="350" height="15" font="5">commissure to the anteroposterior commissure. Echocar-</text>
<text top="282" left="64" width="350" height="15" font="5">diography is usually performed on the beating heart and</text>
<text top="300" left="64" width="350" height="15" font="5">examines a different plane of the tricuspid annulus. Nu-</text>
<text top="318" left="64" width="350" height="15" font="5">merous observational studies and 1 prospective RCT attest</text>
<text top="336" left="64" width="68" height="15" font="5">to the bene</text>
<text top="333" left="133" width="281" height="19" font="5">ﬁt on several echocardiographic and functional</text>
<text top="354" left="64" width="350" height="15" font="5">parameters of tricuspid repair at the time of mitral valve</text>
<text top="372" left="64" width="349" height="15" font="5">surgery for mild-to-moderate TR (stage B) with tricuspid</text>
<text top="390" left="64" width="349" height="15" font="5">annulus dilation. When surgery is performed for isolated</text>
<text top="408" left="64" width="350" height="15" font="5">severe primary MR due to a degenerative etiology, less than</text>
<text top="426" left="64" width="350" height="15" font="5">moderate TR is unlikely to progress if left untreated. A</text>
<text top="444" left="64" width="350" height="15" font="5">prior recent history of right HF is also an indication for</text>
<text top="461" left="64" width="350" height="15" font="5">tricuspid valve repair at the time of left-sided valve surgery.</text>
<text top="479" left="64" width="94" height="15" font="5">A survival bene</text>
<text top="476" left="158" width="255" height="19" font="5">ﬁt with tricuspid repair in this setting has</text>
<text top="497" left="64" width="350" height="15" font="5">not been demonstrated. Management of indwelling pace-</text>
<text top="515" left="64" width="228" height="15" font="5">maker or implantable cardioverter-de</text>
<text top="512" left="292" width="122" height="19" font="5">ﬁbrillator leads may</text>
<text top="533" left="64" width="350" height="15" font="5">require their removal with epicardial placement in selected</text>
<text top="551" left="64" width="350" height="15" font="5">patients. Other approaches, such as sequestering the leads</text>
<text top="569" left="64" width="350" height="15" font="5">in a commissure or placing them in an extra-annular po-</text>
<text top="587" left="64" width="350" height="15" font="5">sition, may be used. Following repair with ring annulo-</text>
<text top="605" left="64" width="350" height="15" font="5">plasty, residual TR is present in approximately 10% of</text>
<text top="623" left="64" width="113" height="15" font="5">patients at 5 years.</text>
<text top="642" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="641" left="212" width="27" height="15" font="6"><a href="e57.full.html#111">(463</a></text>
<text top="637" left="239" width="91" height="19" font="6"><a href="e57.full.html#111">–466,495–504)</a></text>
<text top="668" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="683" left="63" width="224" height="10" font="21">2. Tricuspid valve surgery can be bene</text>
<text top="680" left="288" width="126" height="16" font="21">ﬁcial for patients with</text>
<text top="699" left="81" width="333" height="10" font="21">symptoms due to severe primary TR that are unresponsive to</text>
<text top="716" left="81" width="259" height="12" font="21">medical therapy (stage D). (Level of Evidence: C)</text>
<text top="740" left="79" width="335" height="15" font="5">Correction of symptomatic severe primary TR (stage D)</text>
<text top="758" left="64" width="350" height="15" font="5">in patients without left-sided valve disease is preferentially</text>
<text top="776" left="64" width="205" height="15" font="5">performed before onset of signi</text>
<text top="773" left="269" width="144" height="19" font="5">ﬁcant RV dysfunction.</text>
<text top="794" left="64" width="350" height="15" font="5">Replacement may be required because of the extent and</text>
<text top="812" left="64" width="349" height="15" font="5">severity of the underlying pathology (e.g., carcinoid, radi-</text>
<text top="830" left="64" width="84" height="15" font="5">ation, Ebstein</text>
<text top="826" left="148" width="266" height="19" font="5">’s anomaly). Reduction or elimination of the</text>
<text top="848" left="64" width="350" height="15" font="5">regurgitant volume load can alleviate systemic venous and</text>
<text top="866" left="64" width="350" height="15" font="5">hepatic congestion and decrease reliance on diuretics. Pa-</text>
<text top="884" left="64" width="337" height="15" font="5">tients with severe congestive hepatopathy may also bene</text>
<text top="880" left="401" width="13" height="19" font="5">ﬁt</text>
<text top="902" left="64" width="350" height="15" font="5">from surgery to prevent irreversible cirrhosis of the liver.</text>
<text top="919" left="64" width="350" height="15" font="5">Quality and duration of long-term survival are related to</text>
<text top="937" left="64" width="130" height="15" font="5">residual RV function.</text>
<text top="965" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="980" left="63" width="351" height="10" font="21">1. Tricuspid valve repair may be considered for patients with</text>
<text top="996" left="81" width="332" height="10" font="21">moderate functional TR (stage B) and pulmonary artery hy-</text>
<text top="1012" left="81" width="333" height="12" font="21">pertension at the time of left-sided valve surgery. (Level of</text>
<text top="1029" left="81" width="66" height="12" font="21">Evidence: C)</text>
<text top="1053" left="79" width="335" height="15" font="5">When pulmonary artery hypertension is caused pre-</text>
<text top="1071" left="64" width="350" height="15" font="5">dominantly by left-sided valve disease, effective surgery on</text>
<text top="1089" left="64" width="350" height="15" font="5">the left-sided valve lesions usually leads to a fall in RV</text>
<text top="103" left="450" width="350" height="15" font="5">afterload and improvement in functional TR, especially in</text>
<text top="121" left="450" width="115" height="15" font="5">the absence of signi</text>
<text top="117" left="565" width="234" height="19" font="5">ﬁcant (i.e., &gt;40 mm on TEE) tricuspid</text>
<text top="139" left="450" width="350" height="15" font="5">annulus dilation. This observation dates to the early years</text>
<text top="157" left="450" width="350" height="15" font="5">of mitral valve surgery. Prediction rules that account for the</text>
<text top="175" left="450" width="350" height="15" font="5">relative contributions of pulmonary hypertension and only</text>
<text top="192" left="450" width="350" height="15" font="5">mild-to-moderate degrees of tricuspid annulus enlarge-</text>
<text top="210" left="450" width="337" height="15" font="5">ment for the risk of progressive TR are lacking. The bene</text>
<text top="207" left="787" width="13" height="19" font="5">ﬁt</text>
<text top="228" left="450" width="350" height="15" font="5">of routine tricuspid valve repair in this context is less clear</text>
<text top="246" left="450" width="350" height="15" font="5">across broad populations but may be considered on an</text>
<text top="264" left="450" width="96" height="15" font="5">individual basis.</text>
<text top="283" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="282" left="598" width="85" height="15" font="6"><a href="e57.full.html#112">(503,505,506)</a></text>
<text top="311" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="326" left="449" width="351" height="10" font="21">2. Tricuspid valve surgery may be considered for asymptomatic or</text>
<text top="342" left="467" width="333" height="10" font="21">minimally symptomatic patients with severe primary TR (stage</text>
<text top="359" left="467" width="332" height="10" font="21">C) and progressive degrees of moderate or greater RV dilation</text>
<text top="375" left="467" width="262" height="12" font="21">and/or systolic dysfunction. (Level of Evidence: C)</text>
<text top="399" left="465" width="335" height="15" font="5">The optimal timing of tricuspid valve surgery for</text>
<text top="417" left="450" width="350" height="15" font="5">asymptomatic or minimally symptomatic, severe primary</text>
<text top="435" left="450" width="350" height="15" font="5">TR has not been established. Extrapolation from limited</text>
<text top="453" left="450" width="350" height="15" font="5">experiences reported for patients with stable carcinoid</text>
<text top="471" left="450" width="198" height="15" font="5">heart disease and patients with a</text>
<text top="468" left="653" width="147" height="19" font="5">ﬂail tricuspid leaﬂet and</text>
<text top="489" left="450" width="350" height="15" font="5">application of the management principles adopted for</text>
<text top="507" left="450" width="350" height="15" font="5">patients with severe MR suggest that serial assessments</text>
<text top="525" left="450" width="350" height="15" font="5">of RV size and function might trigger consideration of</text>
<text top="543" left="450" width="350" height="15" font="5">corrective surgery in selected patients with severe, primary</text>
<text top="561" left="450" width="350" height="15" font="5">TR when a pattern of continued deterioration can be</text>
<text top="579" left="450" width="350" height="15" font="5">established and the risks of surgery are considered ac-</text>
<text top="597" left="450" width="350" height="15" font="5">ceptable. In otherwise healthy patients without other</text>
<text top="615" left="450" width="350" height="15" font="5">comorbidities, such as the patient with severe TR due to</text>
<text top="633" left="450" width="319" height="15" font="5">trauma, the risk of tricuspid valve operation is low (</text>
<text top="629" left="769" width="30" height="19" font="5">&lt;1%</text>
<text top="651" left="450" width="350" height="15" font="5">to 2%) in the absence of RV dysfunction or pulmonary</text>
<text top="668" left="450" width="82" height="15" font="5">hypertension.</text>
<text top="687" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="686" left="597" width="58" height="15" font="6"><a href="e57.full.html#112">(507,508)</a></text>
<text top="715" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="730" left="449" width="351" height="10" font="21">3. Reoperation for isolated tricuspid valve repair or replacement</text>
<text top="746" left="467" width="332" height="10" font="21">may be considered for persistent symptoms due to severe TR</text>
<text top="763" left="467" width="332" height="10" font="21">(stage D) in patients who have undergone previous left-sided</text>
<text top="779" left="467" width="332" height="10" font="21">valve surgery and who do not have severe pulmonary hyper-</text>
<text top="796" left="467" width="93" height="10" font="21">tension or signi</text>
<text top="793" left="560" width="239" height="16" font="21">ﬁcant RV systolic dysfunction. (Level of</text>
<text top="812" left="467" width="66" height="12" font="21">Evidence: C)</text>
<text top="837" left="465" width="335" height="15" font="5">Isolated tricuspid valve surgery for severe TR has his-</text>
<text top="854" left="450" width="350" height="15" font="5">torically been performed relatively late in the natural his-</text>
<text top="872" left="450" width="350" height="15" font="5">tory of the disease and once patients have become</text>
<text top="890" left="450" width="350" height="15" font="5">symptomatic with signs of right HF. Unadjusted mortality</text>
<text top="908" left="450" width="350" height="15" font="5">rates for isolated tricuspid valve surgery have therefore</text>
<text top="926" left="450" width="350" height="15" font="5">exceeded those reported for isolated aortic or mitral valve</text>
<text top="944" left="450" width="350" height="15" font="5">surgery, and this trend has been even more pronounced</text>
<text top="962" left="450" width="350" height="15" font="5">following reoperative tricuspid surgery late after left-sided</text>
<text top="980" left="450" width="350" height="15" font="5">valve surgery. This high mortality is likely related to the</text>
<text top="998" left="450" width="350" height="15" font="5">advanced nature of RV failure encountered at the time of</text>
<text top="1016" left="450" width="350" height="15" font="5">the second procedure, residual pulmonary hypertension,</text>
<text top="1034" left="450" width="350" height="15" font="5">LV dysfunction, and other valve abnormalities. Two Heart</text>
<text top="1052" left="450" width="350" height="15" font="5">Valve Centers of Excellence have reported perioperative</text>
<text top="1070" left="450" width="350" height="15" font="5">mortality rates with tricuspid valve reoperation of 4.2%</text>
<text top="1088" left="450" width="350" height="15" font="5">and 13.2%, respectively. Thus, the hazards imposed by</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e112</text>
</page>
<page number="57" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="123" height="15" font="5">reoperation have in</text>
<text top="99" left="187" width="227" height="19" font="5">ﬂuenced decision making for repair</text>
<text top="121" left="64" width="350" height="15" font="5">of functional TR initially at the time of left-sided valve</text>
<text top="139" left="64" width="350" height="15" font="5">surgery. The sobering results seen with tricuspid valve</text>
<text top="157" left="64" width="350" height="15" font="5">repair at reoperation inject a note of caution into the</text>
<text top="175" left="64" width="350" height="15" font="5">recommendations for its performance and may encour-</text>
<text top="192" left="64" width="350" height="15" font="5">age replacement with an age-appropriate (mechanical or</text>
<text top="210" left="64" width="350" height="15" font="5">biological) prosthesis. The presence of either severe and</text>
<text top="228" left="64" width="289" height="15" font="5">uncorrectable pulmonary hypertension or signi</text>
<text top="225" left="354" width="60" height="19" font="5">ﬁcant RV</text>
<text top="246" left="64" width="350" height="15" font="5">dysfunction constitutes a relative contraindication to</text>
<text top="264" left="64" width="71" height="15" font="5">reoperation.</text>
<text top="283" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="282" left="212" width="27" height="15" font="6"><a href="e57.full.html#111">(485</a></text>
<text top="279" left="239" width="91" height="19" font="6"><a href="e57.full.html#111">–489,509–512)</a></text>
<text top="301" left="79" width="18" height="15" font="5">See</text>
<text top="301" left="103" width="166" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 19</a></text>
<text top="301" left="274" width="140" height="15" font="5">for more information on</text>
<text top="319" left="64" width="244" height="15" font="5">outcomes following tricuspid valve surgery.</text>
<text top="366" left="64" width="227" height="12" font="19">8.3. Stages of Tricuspid Stenosis</text>
<text top="388" left="65" width="21" height="15" font="5">See</text>
<text top="388" left="89" width="52" height="15" font="6"><a href="e57.full.html#57">Table 20</a></text>
<text top="388" left="144" width="270" height="15" font="5">for the stages of severe tricuspid stenosis (TS).</text>
<text top="436" left="64" width="156" height="12" font="19">8.4. Tricuspid Stenosis</text>
<text top="463" left="64" width="333" height="15" font="5">8.4.1. Diagnosis and Follow-Up: Recommendations</text>
<text top="491" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="505" left="64" width="350" height="10" font="21">1. TTE is indicated in patients with TS to assess the anatomy of</text>
<text top="522" left="82" width="332" height="10" font="21">the valve complex, evaluate severity of stenosis, and charac-</text>
<text top="538" left="82" width="332" height="10" font="21">terize any associated regurgitation and/or left-sided valve dis-</text>
<text top="555" left="82" width="145" height="12" font="21">ease. (Level of Evidence: C)</text>
<text top="579" left="79" width="335" height="15" font="5">Rheumatic disease is the most common etiology of TS.</text>
<text top="597" left="64" width="350" height="15" font="5">Its clinical manifestations are far overshadowed by those</text>
<text top="615" left="64" width="350" height="15" font="5">attributable to the associated left-sided (particularly mitral)</text>
<text top="633" left="64" width="350" height="15" font="5">valve disease. Because TS is often not detected during</text>
<text top="651" left="64" width="350" height="15" font="5">bedside examination, TTE is essential for diagnosis and</text>
<text top="669" left="64" width="350" height="15" font="5">characterization. TS is usually accompanied by TR of</text>
<text top="687" left="64" width="350" height="15" font="5">varying severity. When valve and/or chordal thickening</text>
<text top="705" left="64" width="53" height="15" font="5">and calci</text>
<text top="701" left="117" width="297" height="19" font="5">ﬁcation are evident, additional ﬁndings indicative</text>
<text top="723" left="64" width="268" height="15" font="5">of severe TS include mean pressure gradient</text>
<text top="719" left="337" width="76" height="19" font="5">&gt;5 mm Hg,</text>
<text top="740" left="64" width="107" height="15" font="5">pressure half-time</text>
<text top="737" left="176" width="232" height="19" font="5">190 milliseconds, valve area 1.0 cm</text>
<text top="737" left="408" width="6" height="10" font="14">2</text>
<text top="758" left="64" width="350" height="15" font="5">(continuity equation), and associated right atrial and</text>
<text top="776" left="64" width="350" height="15" font="5">inferior vena cava enlargement. It is recognized that as-</text>
<text top="794" left="64" width="350" height="15" font="5">sessment of TS severity with TTE is limited by several</text>
<text top="812" left="64" width="350" height="15" font="5">technical factors; thus, these values are less well validated</text>
<text top="830" left="64" width="171" height="15" font="5">than those reported for MS.</text>
<text top="849" left="79" width="123" height="15" font="5">Supporting Reference:</text>
<text top="848" left="208" width="17" height="15" font="6"><a href="e57.full.html#100">(8)</a></text>
<text top="875" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="890" left="63" width="351" height="10" font="21">1. Invasive hemodynamic assessment of severity of TS may be</text>
<text top="907" left="81" width="333" height="10" font="21">considered in symptomatic patients when clinical and nonin-</text>
<text top="923" left="81" width="261" height="12" font="21">vasive data are discordant. (Level of Evidence: C)</text>
<text top="103" left="465" width="335" height="15" font="5">Hemodynamic assessment of TS is rarely undertaken</text>
<text top="121" left="450" width="350" height="15" font="5">for patients with acquired disease but may be performed in</text>
<text top="139" left="450" width="350" height="15" font="5">selected patients at the time of invasive study for another</text>
<text top="157" left="450" width="350" height="15" font="5">indication, such as MS with pulmonary hypertension.</text>
<text top="175" left="450" width="350" height="15" font="5">Direct assessment of the absolute right atrial and RV di-</text>
<text top="192" left="450" width="350" height="15" font="5">astolic pressure may be useful in determining the contri-</text>
<text top="210" left="450" width="166" height="15" font="5">bution of TS to the patient</text>
<text top="207" left="616" width="129" height="19" font="5">’s signs or symptoms.</text>
<text top="237" left="450" width="151" height="15" font="5">8.4.2. Medical Therapy</text>
<text top="263" left="451" width="349" height="15" font="5">As for patients with severe TR, loop diuretics may be</text>
<text top="281" left="450" width="350" height="15" font="5">useful to relieve systemic and hepatic congestion in patients</text>
<text top="299" left="450" width="350" height="15" font="5">with severe, symptomatic TS, although their use may be</text>
<text top="316" left="450" width="168" height="15" font="5">limited by worsening low-</text>
<text top="313" left="618" width="181" height="19" font="5">ﬂow syndrome. Attention to</text>
<text top="334" left="450" width="350" height="15" font="5">left-sided valve disease and AF, when present, is also</text>
<text top="352" left="450" width="63" height="15" font="5">important.</text>
<text top="379" left="450" width="248" height="15" font="5">8.4.3. Intervention: Recommendations</text>
<text top="407" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="421" left="449" width="350" height="10" font="21">1. Tricuspid valve surgery is recommended for patients with se-</text>
<text top="438" left="467" width="332" height="10" font="21">vere TS at the time of operation for left-sided valve disease.</text>
<text top="455" left="467" width="113" height="12" font="21">(Level of Evidence: C)</text>
<text top="479" left="465" width="335" height="15" font="5">Surgery for severe TS is most often performed at the</text>
<text top="497" left="450" width="335" height="15" font="5">time of operation for left-sided valve disease, chie</text>
<text top="493" left="785" width="15" height="19" font="5">ﬂy</text>
<text top="514" left="450" width="350" height="15" font="5">rheumatic MS/MR. If repair is not adequate or feasible</text>
<text top="532" left="450" width="350" height="15" font="5">due to valve destruction or multiple levels of pathological</text>
<text top="550" left="450" width="350" height="15" font="5">involvement, replacement may be necessary. The choice of</text>
<text top="568" left="450" width="350" height="15" font="5">prosthesis should be individualized. Perioperative mortal-</text>
<text top="586" left="450" width="350" height="15" font="5">ity rates are higher for mitral plus tricuspid versus either</text>
<text top="604" left="450" width="247" height="15" font="5">isolated mitral or tricuspid surgery alone.</text>
<text top="623" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="622" left="593" width="32" height="15" font="6"><a href="e57.full.html#111">(489)</a></text>
<text top="649" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="664" left="449" width="351" height="10" font="21">2. Tricuspid valve surgery is recommended for patients with iso-</text>
<text top="681" left="467" width="278" height="12" font="21">lated, symptomatic severe TS. (Level of Evidence: C)</text>
<text top="705" left="465" width="335" height="15" font="5">Relief of severe stenosis should lower elevated right atrial</text>
<text top="723" left="450" width="350" height="15" font="5">and systemic venous pressures and alleviate associated</text>
<text top="741" left="450" width="350" height="15" font="5">symptoms. Tricuspid valve surgery is preferred over percu-</text>
<text top="759" left="450" width="350" height="15" font="5">taneous balloon tricuspid commissurotomy for treatment</text>
<text top="777" left="450" width="350" height="15" font="5">of symptomatic severe TS because most cases of severe</text>
<text top="795" left="450" width="350" height="15" font="5">TS are accompanied by TR (rheumatic, carcinoid, other),</text>
<text top="813" left="450" width="350" height="15" font="5">and percutaneous balloon tricuspid commissurotomy may</text>
<text top="831" left="450" width="350" height="15" font="5">either create or worsen regurgitation. There is also a rela-</text>
<text top="848" left="450" width="350" height="15" font="5">tive lack of long-term follow-up data on patients managed</text>
<text top="866" left="450" width="350" height="15" font="5">with percutaneous balloon tricuspid commissurotomy for</text>
<text top="884" left="450" width="350" height="15" font="5">this indication. Outcomes with surgery are dependent on</text>
<text top="902" left="450" width="79" height="15" font="5">RV function.</text>
<text top="921" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="920" left="597" width="58" height="15" font="6"><a href="e57.full.html#112">(513,514)</a></text>
<text top="970" left="64" width="175" height="11" font="13">Table 20. Stages of Severe TS</text>
<text top="995" left="64" width="27" height="9" font="7">Stage</text>
<text top="995" left="105" width="12" height="9" font="7">De</text>
<text top="992" left="117" width="32" height="14" font="7">ﬁnition</text>
<text top="995" left="200" width="69" height="9" font="7">Valve Anatomy</text>
<text top="995" left="324" width="99" height="9" font="7">Valve Hemodynamics</text>
<text top="995" left="439" width="136" height="9" font="7">Hemodynamic Consequences</text>
<text top="995" left="669" width="49" height="9" font="7">Symptoms</text>
<text top="1013" left="67" width="20" height="9" font="7">C, D</text>
<text top="1013" left="103" width="47" height="9" font="7">Severe TS</text>
<text top="1012" left="163" width="145" height="14" font="7"> Thickened, distorted, calciﬁed</text>
<text top="1029" left="174" width="13" height="9" font="7">lea</text>
<text top="1026" left="188" width="19" height="14" font="7">ﬂets</text>
<text top="1012" left="320" width="17" height="14" font="7"> T</text>
<text top="1012" left="340" width="5" height="6" font="23">1</text>
<text top="1015" left="344" width="5" height="9" font="7">/</text>
<text top="1019" left="348" width="5" height="6" font="23">2</text>
<text top="1012" left="356" width="44" height="14" font="7">190 ms</text>
<text top="1026" left="320" width="102" height="14" font="7"> Valve area 1.0 cm</text>
<text top="1026" left="422" width="5" height="6" font="23">2</text>
<text top="1012" left="439" width="104" height="14" font="7"> RA/IVC enlargement</text>
<text top="1012" left="587" width="209" height="14" font="7"> None or variable and dependent on severity</text>
<text top="1029" left="599" width="190" height="9" font="7">of associated valve disease and degree of</text>
<text top="1043" left="599" width="50" height="9" font="7">obstruction</text>
<text top="1061" left="64" width="339" height="8" font="18">The transtricuspid diastolic gradient is highly variable and is affected by heart rate, forward</text>
<text top="1058" left="406" width="394" height="11" font="18">ﬂow, and phases of the respiratory cycle. However, severe TS usually has mean pressure gradients &gt;5 to</text>
<text top="1073" left="64" width="123" height="8" font="18">10 mm Hg at heart rate 70 bpm.</text>
<text top="1085" left="72" width="280" height="8" font="18">bpm indicates beats per minute; IVC, inferior vena cava; RA, right atrium; T</text>
<text top="1083" left="355" width="4" height="5" font="24">1</text>
<text top="1085" left="358" width="4" height="8" font="18">/</text>
<text top="1088" left="362" width="4" height="5" font="24">2</text>
<text top="1085" left="366" width="178" height="8" font="18">, pressure half-time; and TS, tricuspid stenosis.</text>
<text top="1085" left="546" width="10" height="8" font="26"><a href="e57.full.html#100">(8)</a></text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e113</text>
</page>
<page number="58" position="absolute" top="0" left="0" height="1160" width="864">
<text top="275" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="290" left="63" width="351" height="10" font="21">1. Percutaneous balloon tricuspid commissurotomy might be</text>
<text top="307" left="81" width="332" height="10" font="21">considered in patients with isolated, symptomatic severe TS</text>
<text top="323" left="81" width="258" height="12" font="21">without accompanying TR. (Level of Evidence: C)</text>
<text top="347" left="79" width="335" height="15" font="5">Isolated, symptomatic severe TS without accompanying</text>
<text top="365" left="64" width="349" height="15" font="5">TR is an extremely rare condition for which percutaneous</text>
<text top="383" left="64" width="350" height="15" font="5">balloon tricuspid commissurotomy might be considered,</text>
<text top="401" left="64" width="350" height="15" font="5">recognizing its short-term limitations and the lack of long-</text>
<text top="419" left="64" width="118" height="15" font="5">term outcome data.</text>
<text top="438" left="79" width="18" height="15" font="5">See</text>
<text top="438" left="103" width="166" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 19</a></text>
<text top="438" left="274" width="140" height="15" font="5">for more information on</text>
<text top="456" left="64" width="244" height="15" font="5">outcomes following tricuspid valve surgery.</text>
<text top="493" left="64" width="211" height="14" font="17">9. Pulmonic Valve Disease</text>
<text top="538" left="64" width="262" height="12" font="19">9.1. Stages of Pulmonic Regurgitation</text>
<text top="561" left="65" width="21" height="15" font="5">See</text>
<text top="561" left="91" width="54" height="15" font="6"><a href="e57.full.html#58">Table 21</a></text>
<text top="561" left="150" width="264" height="15" font="5">for the stages of severe pulmonic regurgita-</text>
<text top="579" left="64" width="62" height="15" font="5">tion (PR).</text>
<text top="597" left="79" width="335" height="15" font="5">Mild-to-moderate PR seen on echocardiography is</text>
<text top="615" left="64" width="350" height="15" font="5">common and does not require further follow-up or inter-</text>
<text top="633" left="64" width="350" height="15" font="5">vention if asymptomatic with normal RV size and func-</text>
<text top="651" left="64" width="63" height="15" font="5">tion. Signi</text>
<text top="648" left="127" width="287" height="19" font="5">ﬁcant PR in patients is uncommon. Primary PR</text>
<text top="669" left="64" width="350" height="15" font="5">that follows in the wake of childhood surgery for tetralogy</text>
<text top="687" left="64" width="350" height="15" font="5">of Fallot or other congenital lesions may progress insidi-</text>
<text top="705" left="64" width="350" height="15" font="5">ously and reach severe proportions that threaten RV</text>
<text top="723" left="64" width="350" height="15" font="5">function without adequate clinical recognition. Its evalua-</text>
<text top="741" left="64" width="350" height="15" font="5">tion and management, including indications for valve</text>
<text top="759" left="64" width="308" height="15" font="5">replacement, are comprehensively reviewed in the</text>
<text top="755" left="379" width="35" height="19" font="5">“2008</text>
<text top="776" left="64" width="350" height="15" font="5">ACC/AHA Guidelines for the Management of Patients</text>
<text top="794" left="64" width="201" height="15" font="5">With Congenital Heart Disease.</text>
<text top="791" left="265" width="149" height="19" font="5">” The pulmonic valve is</text>
<text top="812" left="64" width="350" height="15" font="5">rarely involved by IE or rheumatic disease but is susceptible</text>
<text top="830" left="64" width="350" height="15" font="5">to carcinoid accretion because it also affects the tricuspid</text>
<text top="848" left="64" width="350" height="15" font="5">valve and results in varying degrees of stenosis and regur-</text>
<text top="866" left="64" width="350" height="15" font="5">gitation. Surgery is considered when symptoms or signs of</text>
<text top="884" left="64" width="350" height="15" font="5">RV dysfunction have intervened and PR is severe. Sec-</text>
<text top="903" left="64" width="350" height="15" font="5">ondary PR from long-standing pulmonary hypertension</text>
<text top="920" left="64" width="350" height="15" font="5">and annular dilation is encountered less frequently in the</text>
<text top="272" left="450" width="350" height="15" font="5">modern era. Treatment should focus on the cause(s) of</text>
<text top="290" left="450" width="217" height="15" font="5">elevated pulmonary artery pressures.</text>
<text top="309" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="308" left="593" width="32" height="15" font="6"><a href="e57.full.html#112">(516)</a></text>
<text top="348" left="450" width="229" height="12" font="19">9.2. Stages of Pulmonic Stenosis</text>
<text top="370" left="451" width="21" height="15" font="5">See</text>
<text top="370" left="476" width="54" height="15" font="6"><a href="e57.full.html#58">Table 22</a></text>
<text top="370" left="535" width="253" height="15" font="5">for the stages of severe pulmonic stenosis.</text>
<text top="388" left="465" width="335" height="15" font="5">Pulmonic stenosis is essentially a congenital disorder.</text>
<text top="406" left="450" width="350" height="15" font="5">Less common etiologies include carcinoid and obstructing</text>
<text top="424" left="450" width="350" height="15" font="5">vegetations or tumors. Assessment with TTE alone is</text>
<text top="442" left="450" width="63" height="15" font="5">usually suf</text>
<text top="439" left="513" width="286" height="19" font="5">ﬁcient for diagnosis and clinical decision mak-</text>
<text top="460" left="450" width="350" height="15" font="5">ing. Indications for percutaneous balloon pulmonic valve</text>
<text top="478" left="450" width="350" height="15" font="5">commissurotomy and valve replacement are contained in</text>
<text top="496" left="450" width="19" height="15" font="5">the</text>
<text top="493" left="473" width="326" height="19" font="5">“2008 ACC/AHA Guidelines for the Management of</text>
<text top="514" left="450" width="250" height="15" font="5">Patients With Congenital Heart Disease.</text>
<text top="511" left="700" width="5" height="19" font="5">”</text>
<text top="533" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="532" left="593" width="32" height="15" font="6"><a href="e57.full.html#112">(516)</a></text>
<text top="571" left="450" width="196" height="14" font="17">10. Mixed Valve Disease</text>
<text top="616" left="450" width="115" height="12" font="19">10.1. Mixed VHD</text>
<text top="643" left="450" width="214" height="15" font="5">10.1.1. Diagnosis and Follow-Up</text>
<text top="669" left="451" width="349" height="15" font="5">For the majority of patients with mixed valve disease, there</text>
<text top="687" left="450" width="350" height="15" font="5">is usually a predominant valve lesion (i.e., stenosis or</text>
<text top="705" left="450" width="350" height="15" font="5">regurgitation); further, the symptoms and pathophysiol-</text>
<text top="723" left="450" width="350" height="15" font="5">ogy resemble those of a pure dominant lesion. However,</text>
<text top="741" left="450" width="350" height="15" font="5">the presence of mixed valve disease poses limitations for</text>
<text top="758" left="450" width="350" height="15" font="5">noninvasive and invasive techniques used to determine</text>
<text top="776" left="450" width="350" height="15" font="5">severity. These limitations should be strongly considered in</text>
<text top="794" left="450" width="350" height="15" font="5">the evaluation of patients with mixed valve disease. For</text>
<text top="812" left="450" width="350" height="15" font="5">patients with mixed aortic disease and predominant AS, a</text>
<text top="830" left="450" width="350" height="15" font="5">high gradient and small valve area will be present. Pressure</text>
<text top="848" left="450" width="350" height="15" font="5">overload results in concentric LV myocardial hypertrophy,</text>
<text top="866" left="450" width="350" height="15" font="5">usually without chamber enlargement except in late stages</text>
<text top="884" left="450" width="350" height="15" font="5">of the disease. Symptoms may be present in patients with</text>
<text top="902" left="450" width="350" height="15" font="5">predominant AS with or without alterations in chamber</text>
<text top="920" left="450" width="350" height="15" font="5">morphology. Conversely, for patients with mixed aortic</text>
<text top="103" left="64" width="177" height="11" font="13">Table 21. Stages of Severe PR</text>
<text top="129" left="64" width="27" height="9" font="7">Stage</text>
<text top="129" left="112" width="12" height="9" font="7">De</text>
<text top="126" left="124" width="32" height="14" font="7">ﬁnition</text>
<text top="129" left="210" width="69" height="9" font="7">Valve Anatomy</text>
<text top="129" left="350" width="99" height="9" font="7">Valve Hemodynamics</text>
<text top="129" left="485" width="136" height="9" font="7">Hemodynamic Consequences</text>
<text top="129" left="695" width="49" height="9" font="7">Symptoms</text>
<text top="146" left="67" width="20" height="9" font="7">C, D</text>
<text top="146" left="110" width="48" height="9" font="7">Severe PR</text>
<text top="145" left="176" width="136" height="14" font="7"> Distorted or absent leaﬂets,</text>
<text top="162" left="188" width="70" height="9" font="7">annular dilation</text>
<text top="145" left="331" width="95" height="14" font="7"> Color jet ﬁlls RVOT</text>
<text top="159" left="331" width="136" height="14" font="7"> CW jet density and contour:</text>
<text top="177" left="343" width="64" height="9" font="7">dense laminar</text>
<text top="174" left="410" width="40" height="14" font="7">ﬂow with</text>
<text top="191" left="343" width="113" height="9" font="7">steep deceleration slope;</text>
<text top="205" left="343" width="106" height="9" font="7">may terminate abruptly</text>
<text top="145" left="486" width="129" height="14" font="7"> Paradoxical septal motion</text>
<text top="162" left="497" width="116" height="9" font="7">(volume overload pattern)</text>
<text top="174" left="486" width="84" height="14" font="7"> RV enlargement</text>
<text top="145" left="640" width="157" height="14" font="7"> None or variable and dependent</text>
<text top="162" left="651" width="144" height="9" font="7">on cause of PR and RV function</text>
<text top="223" left="72" width="414" height="8" font="18">CW indicates continuous wave; PR, pulmonic regurgitation; RV, right ventricular; and RVOT, right ventricular out</text>
<text top="220" left="486" width="36" height="11" font="18">ﬂow tract.</text>
<text top="223" left="525" width="20" height="8" font="26"><a href="e57.full.html#112">(515)</a></text>
<text top="965" left="64" width="265" height="11" font="13">Table 22. Stages of Severe Pulmonic Stenosis</text>
<text top="990" left="64" width="27" height="9" font="7">Stage</text>
<text top="990" left="105" width="12" height="9" font="7">De</text>
<text top="988" left="117" width="32" height="14" font="7">ﬁnition</text>
<text top="990" left="220" width="69" height="9" font="7">Valve Anatomy</text>
<text top="990" left="366" width="99" height="9" font="7">Valve Hemodynamics</text>
<text top="990" left="488" width="136" height="9" font="7">Hemodynamic Consequences</text>
<text top="990" left="695" width="49" height="9" font="7">Symptoms</text>
<text top="1008" left="67" width="20" height="9" font="7">C, D</text>
<text top="1008" left="103" width="47" height="9" font="7">Severe PS</text>
<text top="1007" left="162" width="184" height="14" font="7"> Thickened, distorted, possibly calciﬁed</text>
<text top="1024" left="174" width="13" height="9" font="7">lea</text>
<text top="1021" left="188" width="148" height="14" font="7">ﬂets with systolic doming and/or</text>
<text top="1039" left="174" width="81" height="9" font="7">reduced excursion</text>
<text top="1050" left="162" width="168" height="14" font="7"> Other anatomic abnormalities may</text>
<text top="1067" left="174" width="161" height="9" font="7">be present, such as narrowed RVOT</text>
<text top="1007" left="358" width="17" height="14" font="7"> V</text>
<text top="1014" left="375" width="14" height="6" font="23">max</text>
<text top="1007" left="393" width="64" height="14" font="7">&gt;4 m/s; peak</text>
<text top="1024" left="370" width="103" height="9" font="7">instantaneous gradient</text>
<text top="1036" left="370" width="57" height="14" font="7">&gt;64 mm Hg</text>
<text top="1007" left="485" width="30" height="14" font="7"> RVH</text>
<text top="1021" left="485" width="143" height="14" font="7"> Possible RV, RA enlargement</text>
<text top="1036" left="485" width="139" height="14" font="7"> Poststenotic enlargement of</text>
<text top="1053" left="496" width="39" height="9" font="7">main PA</text>
<text top="1007" left="640" width="157" height="14" font="7"> None or variable and dependent</text>
<text top="1024" left="651" width="114" height="9" font="7">on severity of obstruction</text>
<text top="1085" left="72" width="535" height="8" font="18">PA indicates pulmonary artery; PS, pulmonic stenosis; RA, right atrium; RV, right ventricle; RVH, right ventricular hypertrophy; RVOT, right ventricular out</text>
<text top="1082" left="607" width="39" height="11" font="18">ﬂow; and V</text>
<text top="1088" left="645" width="11" height="5" font="24">max</text>
<text top="1085" left="656" width="132" height="8" font="18">, maximal pulmonic valve jet velocity.</text>
<text top="1085" left="790" width="10" height="8" font="26"><a href="e57.full.html#100">(8)</a></text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e114</text>
</page>
<page number="59" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">disease and predominant AR, the aortic velocity and</text>
<text top="121" left="64" width="130" height="15" font="5">gradient may be signi</text>
<text top="117" left="194" width="220" height="19" font="5">ﬁcantly elevated due to regurgitation</text>
<text top="139" left="64" width="350" height="15" font="5">in the setting of AS, but the aortic valve area is relatively</text>
<text top="157" left="64" width="350" height="15" font="5">large. Patients with predominant AR will have both</text>
<text top="175" left="64" width="350" height="15" font="5">pressure and volume overload, resulting in marked in-</text>
<text top="192" left="64" width="350" height="15" font="5">creases in LV volume. In these patients, symptoms may be</text>
<text top="210" left="64" width="350" height="15" font="5">relatively latent due to preload recruitment with compen-</text>
<text top="228" left="64" width="350" height="15" font="5">satory hypertrophy. For patients with mixed mitral disease</text>
<text top="246" left="64" width="350" height="15" font="5">and predominant MS, a high transmitral gradient and</text>
<text top="264" left="64" width="350" height="15" font="5">small valve area will be present. Left atrial enlargement</text>
<text top="282" left="64" width="350" height="15" font="5">occurs with relative preservation of the LV chamber size.</text>
<text top="300" left="64" width="350" height="15" font="5">Conversely, in patients with mixed mitral disease and</text>
<text top="318" left="64" width="350" height="15" font="5">predominant MR, LV remodeling will occur in addition to</text>
<text top="336" left="64" width="350" height="15" font="5">left atrial enlargement. These patients frequently have high</text>
<text top="354" left="64" width="265" height="15" font="5">transmitral gradients due to the regurgitant</text>
<text top="351" left="335" width="79" height="19" font="5">ﬂow, but the</text>
<text top="372" left="64" width="200" height="15" font="5">valve area may be relatively large.</text>
<text top="390" left="79" width="335" height="15" font="5">For patients with mixed valve disease, there is a paucity</text>
<text top="408" left="64" width="350" height="15" font="5">of data on the natural history of such coexistent conditions.</text>
<text top="426" left="64" width="350" height="15" font="5">Consequently, the appropriate timing for serial evaluations</text>
<text top="444" left="64" width="350" height="15" font="5">of these patients remains uncertain. For patients with</text>
<text top="461" left="64" width="350" height="15" font="5">predominant lesions (i.e., stenosis or regurgitation), serial</text>
<text top="479" left="64" width="350" height="15" font="5">evaluations in accordance with recommendations for the</text>
<text top="497" left="64" width="350" height="15" font="5">predominant valve lesion are generally recommended.</text>
<text top="515" left="64" width="350" height="15" font="5">Nonetheless, it is important to recognize that the coexis-</text>
<text top="533" left="64" width="350" height="15" font="5">tence of stenosis and regurgitation may have pathological</text>
<text top="551" left="64" width="350" height="15" font="5">consequences that are incremental to the effects of either of</text>
<text top="569" left="64" width="350" height="15" font="5">these disease states alone. As a result, patients with mixed</text>
<text top="587" left="64" width="350" height="15" font="5">disease may require serial evaluations at intervals earlier</text>
<text top="605" left="64" width="260" height="15" font="5">than recommended for single valve lesions.</text>
<text top="624" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="623" left="212" width="27" height="15" font="6"><a href="e57.full.html#112">(517</a></text>
<text top="620" left="239" width="35" height="19" font="6"><a href="e57.full.html#112">–521)</a></text>
<text top="650" left="64" width="158" height="15" font="5">10.1.2. Medical Therapy</text>
<text top="675" left="65" width="349" height="15" font="5">Recommendations for medical therapy follow those for</text>
<text top="693" left="64" width="350" height="15" font="5">single valve disease when there is a predominant valve</text>
<text top="711" left="64" width="350" height="15" font="5">lesion and other management recommendations for</text>
<text top="729" left="64" width="350" height="15" font="5">concomitant LV dysfunction. There are no other recom-</text>
<text top="747" left="64" width="231" height="15" font="5">mendations for medical therapy speci</text>
<text top="744" left="295" width="119" height="19" font="5">ﬁc to patients with</text>
<text top="765" left="64" width="120" height="15" font="5">mixed valve disease.</text>
<text top="792" left="64" width="199" height="15" font="5">10.1.3. Timing of Intervention</text>
<text top="817" left="65" width="349" height="15" font="5">For patients with mixed valve disease and a predominant</text>
<text top="835" left="64" width="350" height="15" font="5">lesion, the need for intervention should generally follow</text>
<text top="853" left="64" width="350" height="15" font="5">recommendations for a pure dominant lesion. This con-</text>
<text top="871" left="64" width="350" height="15" font="5">sideration should be undertaken with attention to symp-</text>
<text top="889" left="64" width="350" height="15" font="5">toms, lesion severity, chamber remodeling, operative risk,</text>
<text top="907" left="64" width="349" height="15" font="5">and the expected surgical outcome. Timing of intervention</text>
<text top="925" left="64" width="350" height="15" font="5">must be individualized because coexistence of stenosis and</text>
<text top="943" left="64" width="350" height="15" font="5">regurgitation may have pathological consequences that</text>
<text top="961" left="64" width="350" height="15" font="5">are incremental to the effects of either lesion alone. For</text>
<text top="979" left="64" width="350" height="15" font="5">example, patients with mixed aortic disease will have</text>
<text top="997" left="64" width="350" height="15" font="5">increased afterload due to both the regurgitant volume and</text>
<text top="1015" left="64" width="350" height="15" font="5">the relatively small aortic valve area. Thus, patients with</text>
<text top="1032" left="64" width="350" height="15" font="5">dominant AR may develop symptoms and require sur-</text>
<text top="1050" left="64" width="350" height="15" font="5">gery before severe LV enlargement develops. For patients</text>
<text top="1068" left="64" width="350" height="15" font="5">with dominant AS, coexistent regurgitation may be poor-</text>
<text top="1086" left="64" width="350" height="15" font="5">ly tolerated by a ventricle that is noncompliant due to</text>
<text top="103" left="450" width="350" height="15" font="5">pressure hypertrophy. An elevated left atrial pressure re-</text>
<text top="121" left="450" width="350" height="15" font="5">sults from both MS and regurgitation in patients with</text>
<text top="139" left="450" width="350" height="15" font="5">mixed mitral disease. Thus, patients with mixed mitral</text>
<text top="157" left="450" width="350" height="15" font="5">disease may develop symptoms or pulmonary hypertension</text>
<text top="175" left="450" width="350" height="15" font="5">at earlier intervals than has been demonstrated in patients</text>
<text top="193" left="450" width="350" height="15" font="5">with pure stenosis or regurgitation. The alterations in</text>
<text top="211" left="450" width="350" height="15" font="5">loading conditions due to mixed valve disease may also lead</text>
<text top="229" left="450" width="350" height="15" font="5">to cardiac symptoms and chamber remodeling in patients</text>
<text top="246" left="450" width="350" height="15" font="5">when there is not a predominant lesion (i.e., mixed mod-</text>
<text top="264" left="450" width="350" height="15" font="5">erate valve disease). Patients with mixed moderate valve</text>
<text top="282" left="450" width="350" height="15" font="5">disease present a special management challenge, as there is</text>
<text top="300" left="450" width="350" height="15" font="5">a paucity of data to guide timing of intervention in these</text>
<text top="318" left="450" width="50" height="15" font="5">patients.</text>
<text top="336" left="465" width="335" height="15" font="5">For those patients with symptoms of uncertain origin,</text>
<text top="354" left="450" width="350" height="15" font="5">valve intervention may be considered when there are</text>
<text top="372" left="450" width="42" height="15" font="5">clinical</text>
<text top="369" left="498" width="301" height="19" font="5">ﬁndings or data supportive of signiﬁcant patho-</text>
<text top="390" left="450" width="350" height="15" font="5">logical consequences of the mixed valve lesion. Suppor-</text>
<text top="408" left="450" width="350" height="15" font="5">tive abnormalities include objective evidence of functional</text>
<text top="426" left="450" width="350" height="15" font="5">limitation (e.g., severely reduced peak myocardial oxygen</text>
<text top="444" left="450" width="350" height="15" font="5">consumption attributable to impaired cardiac output) and</text>
<text top="462" left="450" width="28" height="15" font="5">signi</text>
<text top="458" left="478" width="321" height="19" font="5">ﬁcantly elevated atrial or ventricular pressures. Exer-</text>
<text top="480" left="450" width="350" height="15" font="5">cise hemodynamic studies should be considered for those</text>
<text top="498" left="450" width="350" height="15" font="5">patients with symptoms that are out of proportion to he-</text>
<text top="516" left="450" width="70" height="15" font="5">modynamic</text>
<text top="512" left="527" width="273" height="19" font="5">ﬁndings at rest. For example, patients with</text>
<text top="533" left="450" width="350" height="15" font="5">mixed mitral disease and a relatively low mitral gradient</text>
<text top="551" left="450" width="350" height="15" font="5">may be particularly susceptible to developing functional MS</text>
<text top="569" left="450" width="135" height="15" font="5">at higher transvalvular</text>
<text top="566" left="591" width="209" height="19" font="5">ﬂow rates due to the concomitant</text>
<text top="587" left="450" width="350" height="15" font="5">regurgitant volume. In patients with mixed aortic disease,</text>
<text top="605" left="450" width="350" height="15" font="5">the pathological contribution of aortic regurgitant volume</text>
<text top="623" left="450" width="350" height="15" font="5">may lessen with exercise due to shortening of diastole.</text>
<text top="641" left="450" width="350" height="15" font="5">Given the potential limitations of noninvasive assessments,</text>
<text top="659" left="450" width="350" height="15" font="5">direct pressure measurement with cardiac catheterization</text>
<text top="677" left="450" width="242" height="15" font="5">may be needed for assessing ventricular</text>
<text top="674" left="697" width="102" height="19" font="5">ﬁlling abnormal-</text>
<text top="695" left="450" width="350" height="15" font="5">ities at rest and with exercise in patients with mixed valve</text>
<text top="713" left="450" width="350" height="15" font="5">disease. Because the indications for intervention have not</text>
<text top="731" left="450" width="350" height="15" font="5">been well studied in this patient population, the decision</text>
<text top="749" left="450" width="350" height="15" font="5">to pursue surgical therapy should be individualized, with</text>
<text top="767" left="450" width="350" height="15" font="5">consideration of patient symptoms, severity of hemody-</text>
<text top="785" left="450" width="246" height="15" font="5">namic abnormalities, and risk of surgery.</text>
<text top="803" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="802" left="597" width="27" height="15" font="6"><a href="e57.full.html#112">(517</a></text>
<text top="799" left="625" width="35" height="19" font="6"><a href="e57.full.html#112">–521)</a></text>
<text top="829" left="450" width="196" height="15" font="5">10.1.4. Choice of Intervention</text>
<text top="855" left="451" width="349" height="15" font="5">For patients with mixed valve disease, the appropriate</text>
<text top="873" left="450" width="350" height="15" font="5">interventional therapy is determined by guidelines for the</text>
<text top="891" left="450" width="350" height="15" font="5">predominant valve lesion with consideration of the severity</text>
<text top="909" left="450" width="350" height="15" font="5">of the concomitant valve disease. For example, in a patient</text>
<text top="926" left="450" width="350" height="15" font="5">with predominant AS, TAVR may be considered in pa-</text>
<text top="944" left="450" width="350" height="15" font="5">tients with moderate but not severe AR, whereas con-</text>
<text top="962" left="450" width="350" height="15" font="5">ventional AVR may be a therapeutic option regardless of</text>
<text top="980" left="450" width="350" height="15" font="5">severity of mixed valve disease. Similarly, percutaneous</text>
<text top="998" left="450" width="350" height="15" font="5">balloon mitral commissurotomy is a therapeutic option in</text>
<text top="1016" left="450" width="350" height="15" font="5">patients with MS and suitable anatomy if there is mild but</text>
<text top="1034" left="450" width="350" height="15" font="5">not moderate or severe regurgitation. Percutaneous aortic</text>
<text top="1052" left="450" width="350" height="15" font="5">balloon dilation should not be performed if there is</text>
<text top="1070" left="450" width="350" height="15" font="5">moderate or severe regurgitation due to the potential for</text>
<text top="1088" left="450" width="306" height="15" font="5">worsening of the regurgitation with the procedure.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e115</text>
</page>
<page number="60" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="171" height="14" font="17">11. Prosthetic Valves</text>
<text top="149" left="64" width="228" height="12" font="19">11.1. Evaluation and Selection of</text>
<text top="166" left="64" width="120" height="12" font="19">Prosthetic Valves</text>
<text top="194" left="64" width="340" height="15" font="5">11.1.1. Diagnosis and Follow-Up: Recommendations</text>
<text top="219" left="65" width="349" height="15" font="5">Patients who have undergone valve replacement are not</text>
<text top="237" left="64" width="350" height="15" font="5">cured but still have serious heart disease. Patients have</text>
<text top="255" left="64" width="350" height="15" font="5">exchanged native valve disease for prosthetic valve disease</text>
<text top="273" left="64" width="350" height="15" font="5">and must be followed with the same care as those with</text>
<text top="291" left="64" width="350" height="15" font="5">native valve disease. The clinical course of patients with</text>
<text top="309" left="64" width="178" height="15" font="5">prosthetic heart valves is in</text>
<text top="305" left="242" width="172" height="19" font="5">ﬂuenced by several factors,</text>
<text top="327" left="64" width="350" height="15" font="5">including LV dysfunction; progression of other valve</text>
<text top="345" left="64" width="350" height="15" font="5">disease; pulmonary hypertension; concurrent coronary,</text>
<text top="363" left="64" width="350" height="15" font="5">myocardial, or aortic disease; and complications of pros-</text>
<text top="381" left="64" width="350" height="15" font="5">thetic heart valves. The interval between routine follow-up</text>
<text top="399" left="64" width="181" height="15" font="5">visits depends on the patient</text>
<text top="395" left="245" width="169" height="19" font="5">’s valve type, residual heart</text>
<text top="416" left="64" width="350" height="15" font="5">disease, comorbid conditions, and other clinical factors.</text>
<text top="434" left="64" width="350" height="15" font="5">Management of anticoagulation should be supervised</text>
<text top="452" left="64" width="350" height="15" font="5">and monitored frequently by an experienced healthcare</text>
<text top="470" left="64" width="74" height="15" font="5">professional.</text>
<text top="488" left="79" width="335" height="15" font="5">The asymptomatic uncomplicated patient is usually</text>
<text top="506" left="64" width="55" height="15" font="5">seen at 1</text>
<text top="503" left="119" width="295" height="19" font="5">–year intervals for a cardiac history and physical</text>
<text top="524" left="64" width="350" height="15" font="5">examination. ECG and chest x-ray examinations are not</text>
<text top="542" left="64" width="350" height="15" font="5">routinely indicated but may be appropriate in individual</text>
<text top="560" left="64" width="350" height="15" font="5">patients. Additional tests that may be considered include</text>
<text top="578" left="64" width="350" height="15" font="5">hemoglobin and hematocrit in patients receiving chro-</text>
<text top="596" left="64" width="350" height="15" font="5">nic anticoagulation. No further echocardiographic testing</text>
<text top="614" left="64" width="350" height="15" font="5">is required after the initial postoperative evaluation in</text>
<text top="632" left="64" width="350" height="15" font="5">patients with mechanical valves who are stable and who</text>
<text top="650" left="64" width="350" height="15" font="5">have no symptoms or clinical evidence of prosthetic valve</text>
<text top="668" left="64" width="350" height="15" font="5">or ventricular dysfunction or dysfunction of other heart</text>
<text top="686" left="64" width="39" height="15" font="5">valves.</text>
<text top="715" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="729" left="63" width="351" height="10" font="21">1. An initial TTE study is recommended in patients after pros-</text>
<text top="746" left="81" width="332" height="10" font="21">thetic valve implantation for evaluation of valve hemodynamics</text>
<text top="762" left="81" width="26" height="10" font="22"><a href="e57.full.html#112">(522</a></text>
<text top="759" left="107" width="32" height="16" font="22"><a href="e57.full.html#112">–525)</a></text>
<text top="762" left="139" width="121" height="12" font="21"><a href="e57.full.html#112">. </a>(Level of Evidence: B)</text>
<text top="787" left="79" width="335" height="15" font="5">An echocardiographic examination performed 6 weeks</text>
<text top="805" left="64" width="350" height="15" font="5">to 3 months after valve implantation is an essential com-</text>
<text top="823" left="64" width="82" height="15" font="5">ponent of the</text>
<text top="819" left="152" width="262" height="19" font="5">ﬁrst postoperative visit because it allows for</text>
<text top="840" left="64" width="350" height="15" font="5">an assessment of the effects and results of surgery and</text>
<text top="858" left="64" width="350" height="15" font="5">serves as a baseline for comparison should complications or</text>
<text top="876" left="64" width="350" height="15" font="5">deterioration occur later. Doppler TTE provides accurate</text>
<text top="894" left="64" width="350" height="15" font="5">measurements of transvalvular velocities and pressure gra-</text>
<text top="912" left="64" width="350" height="15" font="5">dients as well as detection and quantitation of valvular and</text>
<text top="930" left="64" width="350" height="15" font="5">paravalvular regurgitation. Normal Doppler transvalvular</text>
<text top="948" left="64" width="350" height="15" font="5">velocities and gradients vary among different types and</text>
<text top="966" left="64" width="349" height="15" font="5">sizes of prosthetic valves but are also affected by patient-</text>
<text top="984" left="64" width="29" height="15" font="5">speci</text>
<text top="981" left="93" width="320" height="19" font="5">ﬁc factors, including body size and cardiac output.</text>
<text top="1002" left="64" width="350" height="15" font="5">The postoperative study, recorded when the patient is</text>
<text top="1020" left="64" width="350" height="15" font="5">asymptomatic and in a stable hemodynamic state, provides</text>
<text top="1038" left="64" width="118" height="15" font="5">the normal Doppler</text>
<text top="1034" left="186" width="228" height="19" font="5">ﬂow data for that valve in that patient.</text>
<text top="1056" left="64" width="233" height="15" font="5">In addition to imaging and Doppler</text>
<text top="1052" left="305" width="109" height="19" font="5">ﬂow data for the</text>
<text top="1074" left="64" width="350" height="15" font="5">prosthetic valve, TTE provides assessment of other valve</text>
<text top="103" left="450" width="350" height="15" font="5">disease(s), pulmonary hypertension, atrial size, LV and RV</text>
<text top="121" left="450" width="350" height="15" font="5">hypertrophy, LV and RV size and function, and pericardial</text>
<text top="139" left="450" width="45" height="15" font="5">disease.</text>
<text top="157" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="157" left="597" width="85" height="15" font="6"><a href="e57.full.html#107">(291,526,527)</a></text>
<text top="184" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="199" left="449" width="351" height="10" font="21">2. Repeat TTE is recommended in patients with prosthetic heart</text>
<text top="215" left="467" width="333" height="10" font="21">valves if there is a change in clinical symptoms or signs sug-</text>
<text top="232" left="467" width="255" height="12" font="21">gesting valve dysfunction. (Level of Evidence: C)</text>
<text top="256" left="465" width="335" height="15" font="5">Bioprosthetic valves are prone to tissue degeneration or</text>
<text top="274" left="450" width="350" height="15" font="5">pannus formation with development of valve regurgita-</text>
<text top="292" left="450" width="350" height="15" font="5">tion and/or stenosis. Bioprosthetic valve dysfunction typ-</text>
<text top="310" left="450" width="350" height="15" font="5">ically presents with the insidious onset of exertional</text>
<text top="328" left="450" width="350" height="15" font="5">dyspnea or with a louder systolic murmur (MR or AS) or</text>
<text top="346" left="450" width="350" height="15" font="5">a new diastolic murmur (AR or MS) on physical exami-</text>
<text top="364" left="450" width="350" height="15" font="5">nation. More abrupt and severe symptoms may occur</text>
<text top="382" left="450" width="350" height="15" font="5">with bioprosthetic valve endocarditis or with degenerative</text>
<text top="399" left="450" width="141" height="15" font="5">rupture of a valve cusp.</text>
<text top="417" left="465" width="335" height="15" font="5">Patients with mechanical valve dysfunction present</text>
<text top="435" left="450" width="350" height="15" font="5">with symptoms of HF, systemic thromboembolism,</text>
<text top="453" left="450" width="350" height="15" font="5">hemolysis, or a new murmur on auscultation. Mechani-</text>
<text top="471" left="450" width="350" height="15" font="5">cal valve dysfunction may be due to thrombosis, pannus</text>
<text top="489" left="450" width="350" height="15" font="5">formation, or IE. Signs or symptoms of mechanical valve</text>
<text top="507" left="450" width="350" height="15" font="5">dysfunction are often acute or subacute because of more</text>
<text top="525" left="450" width="154" height="15" font="5">abrupt impairment of lea</text>
<text top="522" left="604" width="195" height="19" font="5">ﬂet occluder opening or closing</text>
<text top="543" left="450" width="350" height="15" font="5">by thrombus or pannus. Acute or chronic paravalvular</text>
<text top="561" left="450" width="350" height="15" font="5">regurgitation may also be seen due to IE or suture</text>
<text top="579" left="450" width="68" height="15" font="5">dehiscence.</text>
<text top="597" left="465" width="335" height="15" font="5">TTE allows evaluation of valve dysfunction based on</text>
<text top="615" left="450" width="88" height="15" font="5">imaging of lea</text>
<text top="611" left="538" width="261" height="19" font="5">ﬂet structure and motion, vegetations, and</text>
<text top="633" left="450" width="350" height="15" font="5">thrombus and Doppler evaluation for prosthetic valve</text>
<text top="651" left="450" width="350" height="15" font="5">stenosis or regurgitation. Comparison with the baseline</text>
<text top="668" left="450" width="350" height="15" font="5">postoperative echocardiogram is particularly helpful for</text>
<text top="686" left="450" width="247" height="15" font="5">detection of prosthetic valve dysfunction.</text>
<text top="705" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="704" left="597" width="58" height="15" font="6"><a href="e57.full.html#112">(528,529)</a></text>
<text top="732" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="746" left="449" width="351" height="10" font="21">3. TEE is recommended when clinical symptoms or signs suggest</text>
<text top="763" left="467" width="269" height="12" font="21">prosthetic valve dysfunction. (Level of Evidence: C)</text>
<text top="787" left="465" width="335" height="15" font="5">TTE is the preferred approach for initial assessment of</text>
<text top="805" left="450" width="350" height="15" font="5">suspected prosthetic valve dysfunction because it allows</text>
<text top="823" left="450" width="350" height="15" font="5">correct alignment of the Doppler beam with transvalvular</text>
<text top="838" left="450" width="350" height="19" font="5">ﬂow for measurement of velocity, gradient, and valve area.</text>
<text top="859" left="450" width="350" height="15" font="5">TTE also allows quantitation of LV volumes and LVEF,</text>
<text top="877" left="450" width="350" height="15" font="5">an estimate of pulmonary pressures, and evaluation of right</text>
<text top="895" left="450" width="350" height="15" font="5">heart function. However, the left atrial side of a prosthetic</text>
<text top="913" left="450" width="350" height="15" font="5">mitral valve is obscured by acoustic shadowing from the</text>
<text top="931" left="450" width="350" height="15" font="5">TTE approach, resulting in a low sensitivity for detection</text>
<text top="949" left="450" width="350" height="15" font="5">of prosthetic MR and prosthetic mitral valve thrombus,</text>
<text top="967" left="450" width="350" height="15" font="5">pannus, or vegetation. TEE provides superior images of</text>
<text top="985" left="450" width="350" height="15" font="5">the left atrial side of the mitral prosthesis and is accurate</text>
<text top="1002" left="450" width="350" height="15" font="5">for diagnosis of prosthetic mitral valve dysfunction.</text>
<text top="1020" left="450" width="350" height="15" font="5">However, both TTE and TEE are needed for complete</text>
<text top="1038" left="450" width="350" height="15" font="5">evaluation in a patient with suspected prosthetic valve</text>
<text top="1056" left="450" width="350" height="15" font="5">dysfunction, particularly for those with prosthetic aortic</text>
<text top="1074" left="450" width="350" height="15" font="5">valves in whom the posterior aspect of the valve is</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e116</text>
</page>
<page number="61" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">shadowed on the TTE approach and the anterior aspect of</text>
<text top="121" left="64" width="350" height="15" font="5">the valve is shadowed on the TEE approach. With sus-</text>
<text top="139" left="64" width="202" height="15" font="5">pected mechanical valve stenosis,</text>
<text top="135" left="272" width="142" height="19" font="5">ﬂuoroscopy or CT im-</text>
<text top="157" left="64" width="350" height="15" font="5">aging of valve occluder motion is also helpful for detection</text>
<text top="175" left="64" width="286" height="15" font="5">of reduced motion due to pannus or thrombus.</text>
<text top="193" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="192" left="212" width="58" height="15" font="6"><a href="e57.full.html#112">(530,531)</a></text>
<text top="224" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="239" left="63" width="351" height="10" font="21">1. Annual TTE is reasonable in patients with a bioprosthetic valve</text>
<text top="256" left="81" width="47" height="10" font="21">after the</text>
<text top="252" left="134" width="280" height="16" font="21">ﬁrst 10 years, even in the absence of a change in</text>
<text top="272" left="81" width="195" height="12" font="21">clinical status. (Level of Evidence: C)</text>
<text top="296" left="79" width="335" height="15" font="5">The incidence of bioprosthetic valve dysfunction is low</text>
<text top="314" left="64" width="350" height="15" font="5">within 10 years of valve implantation but increases mark-</text>
<text top="332" left="64" width="350" height="15" font="5">edly after that point; as such, routine annual evaluation is</text>
<text top="350" left="64" width="350" height="15" font="5">a reasonable approach. Earlier evaluation may also be</text>
<text top="368" left="64" width="350" height="15" font="5">prudent in selected patients at increased risk of early bio-</text>
<text top="386" left="64" width="350" height="15" font="5">prosthetic valve degeneration, including those with renal</text>
<text top="404" left="64" width="350" height="15" font="5">impairment, diabetes mellitus, abnormal calcium meta-</text>
<text top="422" left="64" width="112" height="15" font="5">bolism, systemic in</text>
<text top="418" left="176" width="238" height="19" font="5">ﬂammatory disease, and in patients &lt;60</text>
<text top="440" left="64" width="350" height="15" font="5">years of age. Patients typically remain asymptomatic until</text>
<text top="458" left="64" width="350" height="15" font="5">valve dysfunction is severe enough to result in adverse</text>
<text top="476" left="64" width="350" height="15" font="5">hemodynamic consequences, such as LV dilation and</text>
<text top="494" left="64" width="350" height="15" font="5">systolic dysfunction, pulmonary hypertension, or AF. It</text>
<text top="512" left="64" width="350" height="15" font="5">may be challenging to distinguish a murmur due to pros-</text>
<text top="530" left="64" width="316" height="15" font="5">thetic MR or AS from the normal postoperative</text>
<text top="526" left="388" width="26" height="19" font="5">ﬂow</text>
<text top="547" left="64" width="350" height="15" font="5">murmur, and the diastolic murmurs of prosthetic AR and</text>
<text top="565" left="64" width="177" height="15" font="5">MS often are very soft and dif</text>
<text top="562" left="242" width="172" height="19" font="5">ﬁcult to hear on auscultation.</text>
<text top="583" left="64" width="350" height="15" font="5">Depending on the valve type and mechanism of regurgi-</text>
<text top="601" left="64" width="280" height="15" font="5">tation, some patients with asymptomatic signi</text>
<text top="598" left="344" width="70" height="19" font="5">ﬁcant pros-</text>
<text top="619" left="64" width="350" height="15" font="5">thetic valve regurgitation may require surgical intervention.</text>
<text top="637" left="64" width="350" height="15" font="5">For example, if prosthetic regurgitation is due to a bio-</text>
<text top="655" left="64" width="79" height="15" font="5">prosthetic lea</text>
<text top="652" left="144" width="270" height="19" font="5">ﬂet tear, more severe acute regurgitation may</text>
<text top="673" left="64" width="350" height="15" font="5">suddenly occur and cause clinical decompensation. Other</text>
<text top="691" left="64" width="350" height="15" font="5">asymptomatic patients with less severe prosthetic valve</text>
<text top="709" left="64" width="350" height="15" font="5">regurgitation or with stable valve anatomy can be moni-</text>
<text top="727" left="64" width="350" height="15" font="5">tored for evidence of progressive LV dilation and systolic</text>
<text top="745" left="64" width="350" height="15" font="5">dysfunction with the same criteria for timing of surgical</text>
<text top="763" left="64" width="350" height="15" font="5">intervention as those for native valve regurgitation. With</text>
<text top="781" left="64" width="350" height="15" font="5">prosthetic valve stenosis, echocardiographic diagnosis while</text>
<text top="799" left="64" width="350" height="15" font="5">the patient is asymptomatic alerts the clinician to the need</text>
<text top="816" left="64" width="350" height="15" font="5">for more frequent follow-up. Patients with asymptomatic</text>
<text top="834" left="64" width="350" height="15" font="5">prosthetic valve stenosis should be educated about symp-</text>
<text top="852" left="64" width="350" height="15" font="5">toms, the likely need for repeat valve intervention, and the</text>
<text top="870" left="64" width="302" height="15" font="5">importance of promptly reporting new symptoms.</text>
<text top="888" left="79" width="335" height="15" font="5">In patients with mechanical valve prostheses, routine</text>
<text top="906" left="64" width="350" height="15" font="5">annual echocardiographic evaluation is not needed if the</text>
<text top="924" left="64" width="350" height="15" font="5">postoperative baseline study is normal in the absence of</text>
<text top="942" left="64" width="350" height="15" font="5">signs or symptoms of valve dysfunction. However, many of</text>
<text top="960" left="64" width="350" height="15" font="5">these patients require TTE for other indications, such as</text>
<text top="978" left="64" width="350" height="15" font="5">residual LV systolic dysfunction, pulmonary hypertension,</text>
<text top="996" left="64" width="252" height="15" font="5">aortic disease, or concurrent valve disease.</text>
<text top="1014" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="1014" left="212" width="58" height="15" font="6"><a href="e57.full.html#112">(532,533)</a></text>
<text top="1044" left="64" width="255" height="15" font="5">11.1.2. Intervention: Recommendations</text>
<text top="1070" left="65" width="21" height="15" font="5">See</text>
<text top="1070" left="94" width="57" height="15" font="6"><a href="e57.full.html#62">Table 23</a></text>
<text top="1070" left="160" width="254" height="15" font="5">for a summary of recommendations for</text>
<text top="1088" left="64" width="139" height="15" font="5">prosthetic valve choice.</text>
<text top="106" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="121" left="449" width="351" height="10" font="21">1. The choice of valve intervention, that is, repair or replacement, as</text>
<text top="137" left="467" width="332" height="10" font="21">well as type of prosthetic heart valve, should be a shared decision-</text>
<text top="154" left="467" width="237" height="10" font="21">making process that accounts for the patient</text>
<text top="151" left="704" width="95" height="16" font="21">’s values and pref-</text>
<text top="170" left="467" width="333" height="10" font="21">erences, with full disclosure of the indications for and risks of</text>
<text top="187" left="467" width="333" height="10" font="21">anticoagulant therapy and the potential need for and risk of</text>
<text top="203" left="467" width="175" height="12" font="21">reoperation. (Level of Evidence: C)</text>
<text top="228" left="465" width="335" height="15" font="5">The choice of valve prosthesis in an individual patient is</text>
<text top="246" left="450" width="350" height="15" font="5">based on consideration of several factors, including valve</text>
<text top="263" left="450" width="273" height="15" font="5">durability, expected hemodynamics for a speci</text>
<text top="260" left="723" width="76" height="19" font="5">ﬁc valve type</text>
<text top="281" left="450" width="350" height="15" font="5">and size, surgical or interventional risk, the potential need</text>
<text top="299" left="450" width="350" height="15" font="5">for long-term anticoagulation, and patient preferences.</text>
<text top="317" left="450" width="32" height="15" font="5">Speci</text>
<text top="314" left="482" width="318" height="19" font="5">ﬁcally, the tradeoff between risk of reoperation for</text>
<text top="335" left="450" width="350" height="15" font="5">bioprosthetic valve degeneration and the risk associated</text>
<text top="353" left="450" width="350" height="15" font="5">with long-term anticoagulation should be discussed in</text>
<text top="371" left="450" width="350" height="15" font="5">detail with the patient. Surgical or interventional risk for an</text>
<text top="389" left="450" width="350" height="15" font="5">individual patient is estimated by using the STS PROM</text>
<text top="407" left="450" width="204" height="15" font="5">score with the online calculator (</text>
<text top="407" left="654" width="80" height="15" font="6"><a href="e57.full.html#23">Section 3.2.4</a></text>
<text top="407" left="734" width="66" height="15" font="5"><a href="e57.full.html#23">). </a>This in-</text>
<text top="425" left="450" width="350" height="15" font="5">formation is discussed with the patient and family to allow</text>
<text top="443" left="450" width="350" height="15" font="5">for shared decision making about the timing and type of</text>
<text top="461" left="450" width="350" height="15" font="5">intervention. In a patient with a small aortic annulus,</text>
<text top="479" left="450" width="350" height="15" font="5">patient-prosthesis mismatch of the implanted prosthetic</text>
<text top="497" left="450" width="350" height="15" font="5">aortic valve may be avoided or reduced by consulting tables</text>
<text top="515" left="450" width="350" height="15" font="5">of prosthetic valve hemodynamics for the valve types and</text>
<text top="532" left="450" width="350" height="15" font="5">sizes being considered. Aortic annular enlarging pro-</text>
<text top="550" left="450" width="350" height="15" font="5">cedures may be used when patient-prosthesis mismatch</text>
<text top="568" left="450" width="322" height="15" font="5">cannot be avoided with any available valve substitute.</text>
<text top="586" left="465" width="335" height="15" font="5">Bioprosthetic valves avoid the need for long-term anti-</text>
<text top="604" left="450" width="350" height="15" font="5">coagulation with VKA, such as warfarin, but have limited</text>
<text top="622" left="450" width="350" height="15" font="5">durability. The risk of need for reoperation with a bio-</text>
<text top="640" left="450" width="283" height="15" font="5">prosthetic valve is inversely related to the patient</text>
<text top="637" left="732" width="67" height="19" font="5">’s age at the</text>
<text top="658" left="450" width="350" height="15" font="5">time of implantation, with a rate of structural deterioration</text>
<text top="676" left="450" width="350" height="15" font="5">15 to 20 years after implantation of only 10% in patients 70</text>
<text top="694" left="450" width="350" height="15" font="5">years of age at the time of implantation compared with 90%</text>
<text top="712" left="450" width="350" height="15" font="5">in those 20 years of age at the time of implantation. Me-</text>
<text top="730" left="450" width="350" height="15" font="5">chanical valves are durable in patients of any age with a low</text>
<text top="748" left="450" width="350" height="15" font="5">risk of reoperation, and current VKA therapeutic manage-</text>
<text top="766" left="450" width="350" height="15" font="5">ment strategies are associated with a low risk of thrombo-</text>
<text top="784" left="450" width="350" height="15" font="5">embolism and bleeding. Some patients prefer to avoid repeat</text>
<text top="802" left="450" width="350" height="15" font="5">surgery and are willing to accept the risks and inconvenience</text>
<text top="819" left="450" width="350" height="15" font="5">of lifelong anticoagulant therapy. A mechanical valve might</text>
<text top="837" left="450" width="350" height="15" font="5">be prudent for patients in whom a second surgical procedure</text>
<text top="855" left="450" width="350" height="15" font="5">would be high risk; for example, those with prior radiation</text>
<text top="873" left="450" width="350" height="15" font="5">therapy or a porcelain aorta. Other patients are unwilling to</text>
<text top="891" left="450" width="350" height="15" font="5">consider long-term VKA therapy due to the inconvenience</text>
<text top="909" left="450" width="350" height="15" font="5">of monitoring, the attendant dietary and medication in-</text>
<text top="927" left="450" width="350" height="15" font="5">teractions, and the need to restrict participation in some</text>
<text top="945" left="450" width="350" height="15" font="5">types of athletic activity. In women who desire subsequent</text>
<text top="963" left="450" width="350" height="15" font="5">pregnancy, the issue of anticoagulation during pregnancy is a</text>
<text top="981" left="450" width="88" height="15" font="5">consideration <a href="e57.full.html#83">(</a></text>
<text top="981" left="538" width="63" height="15" font="6"><a href="e57.full.html#83">Section 13</a></text>
<text top="981" left="601" width="9" height="15" font="5">).</text>
<text top="999" left="465" width="335" height="15" font="5">In patients who are being treated with long-term VKA</text>
<text top="1017" left="450" width="350" height="15" font="5">anticoagulation before valve surgery, a mechanical valve</text>
<text top="1035" left="450" width="350" height="15" font="5">may be appropriate, given its greater durability compared</text>
<text top="1053" left="450" width="350" height="15" font="5">with a bioprosthetic valve and the need for continued VKA</text>
<text top="1071" left="450" width="350" height="15" font="5">anticoagulation even if a bioprosthetic valve is implanted.</text>
<text top="1089" left="450" width="350" height="15" font="5">However, if interruption of VKA therapy is necessary for</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e117</text>
</page>
<page number="62" position="absolute" top="0" left="0" height="1160" width="864">
<text top="355" left="64" width="350" height="15" font="5">noncardiac procedures, bridging therapy with other anti-</text>
<text top="373" left="64" width="350" height="15" font="5">coagulants may be needed if a mechanical valve is present,</text>
<text top="391" left="64" width="350" height="15" font="5">whereas stopping and restarting VKA therapy for other</text>
<text top="409" left="64" width="199" height="15" font="5">indications may be simpler. Speci</text>
<text top="406" left="264" width="150" height="19" font="5">ﬁc clinical circumstances,</text>
<text top="427" left="64" width="350" height="15" font="5">comorbid conditions, and patient preferences should be</text>
<text top="445" left="64" width="350" height="15" font="5">considered when deciding between a bioprosthetic and</text>
<text top="463" left="64" width="350" height="15" font="5">mechanical valve in patients receiving VKA therapy for</text>
<text top="481" left="64" width="291" height="15" font="5">indications other than the prosthetic valve itself.</text>
<text top="499" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="499" left="212" width="80" height="15" font="6"><a href="e57.full.html#112">(532,533,543</a></text>
<text top="495" left="292" width="35" height="19" font="6"><a href="e57.full.html#112">–545)</a></text>
<text top="525" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="539" left="63" width="351" height="10" font="21">2. A bioprosthesis is recommended in patients of any age for whom</text>
<text top="556" left="81" width="332" height="10" font="21">anticoagulant therapy is contraindicated, cannot be managed</text>
<text top="572" left="81" width="273" height="12" font="21">appropriately, or is not desired. (Level of Evidence: C)</text>
<text top="597" left="79" width="335" height="15" font="5">Anticoagulant therapy with VKA is necessary in all</text>
<text top="615" left="64" width="350" height="15" font="5">patients with a mechanical valve to prevent valve throm-</text>
<text top="633" left="64" width="350" height="15" font="5">bosis and thromboembolic events. If anticoagulation is</text>
<text top="650" left="64" width="350" height="15" font="5">contraindicated or if the patient refuses VKA therapy, an</text>
<text top="668" left="64" width="218" height="15" font="5">alternate valve choice is appropriate.</text>
<text top="694" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="709" left="63" width="351" height="10" font="21">1. A mechanical prosthesis is reasonable for AVR or MVR in pa-</text>
<text top="726" left="81" width="333" height="10" font="21">tients less than 60 years of age who do not have a contraindi-</text>
<text top="742" left="81" width="133" height="10" font="21">cation to anticoagulation</text>
<text top="742" left="218" width="26" height="10" font="22"><a href="e57.full.html#112">(534</a></text>
<text top="739" left="244" width="32" height="16" font="22"><a href="e57.full.html#112">–536)</a></text>
<text top="742" left="276" width="121" height="12" font="21"><a href="e57.full.html#112">. </a>(Level of Evidence: B)</text>
<text top="766" left="79" width="335" height="15" font="5">In a prospective randomized study of 575 patients un-</text>
<text top="784" left="64" width="350" height="15" font="5">dergoing older-generation mechanical versus bioprosthetic</text>
<text top="802" left="64" width="350" height="15" font="5">valve replacement, overall survival was similar at 15 years in</text>
<text top="820" left="64" width="211" height="15" font="5">both groups. However, in patients</text>
<text top="817" left="281" width="132" height="19" font="5">&lt;65 years of age un-</text>
<text top="838" left="64" width="350" height="15" font="5">dergoing AVR, primary valve failure occurred in 26% of</text>
<text top="856" left="64" width="350" height="15" font="5">those with a bioprosthetic valve compared with 0% of pa-</text>
<text top="874" left="64" width="287" height="15" font="5">tients with a mechanical valve. Similarly, in those</text>
<text top="870" left="355" width="59" height="19" font="5">&lt;65 years</text>
<text top="892" left="64" width="350" height="15" font="5">of age undergoing MVR, primary valve failure occurred in</text>
<text top="910" left="64" width="350" height="15" font="5">44% of patients with a bioprosthetic mitral valve compared</text>
<text top="928" left="64" width="258" height="15" font="5">with 4% with a mechanical mitral valve (p</text>
<text top="924" left="323" width="91" height="19" font="5">¼0.0001). In a</text>
<text top="946" left="64" width="95" height="15" font="5">propensity score</text>
<text top="942" left="159" width="254" height="19" font="5">matched comparison of 103 patients &lt;60</text>
<text top="964" left="64" width="350" height="15" font="5">years of age undergoing mechanical versus biological AVR,</text>
<text top="981" left="64" width="350" height="15" font="5">those with a mechanical valve had lower mortality rates (HR:</text>
<text top="999" left="64" width="207" height="15" font="5">0.243; 95% CI: 0.054 to 0.923; p</text>
<text top="996" left="271" width="143" height="19" font="5">¼0.038) despite similar</text>
<text top="1017" left="64" width="350" height="15" font="5">rates of valve-related complications. This is possibly related</text>
<text top="1035" left="64" width="262" height="15" font="5">to better valve hemodynamics and the bene</text>
<text top="1032" left="327" width="87" height="19" font="5">ﬁcial effects of</text>
<text top="1053" left="64" width="326" height="15" font="5">anticoagulant therapy in those with a mechanical valve.</text>
<text top="1071" left="79" width="98" height="15" font="5">Overall, patients</text>
<text top="1068" left="183" width="230" height="19" font="5">&lt;60 years of age at the time of valve</text>
<text top="1089" left="64" width="350" height="15" font="5">implantation have a higher incidence of primary structural</text>
<text top="355" left="450" width="350" height="15" font="5">deterioration and a reoperation rate as high as 40% for pa-</text>
<text top="373" left="450" width="350" height="15" font="5">tients 50 years of age, 55% for patients 40 years of age, 75%</text>
<text top="391" left="450" width="350" height="15" font="5">for patients 30 years of age, and 90% for patients 20 years</text>
<text top="409" left="450" width="350" height="15" font="5">of age. Anticoagulation with VKA has an acceptable risk</text>
<text top="427" left="450" width="167" height="15" font="5">of complications in patients</text>
<text top="424" left="622" width="177" height="19" font="5">&lt;60 years of age, particularly</text>
<text top="445" left="450" width="350" height="15" font="5">in compliant patients with appropriate monitoring of INR</text>
<text top="463" left="450" width="350" height="15" font="5">levels. Thus, the balance between valve durability versus</text>
<text top="481" left="450" width="350" height="15" font="5">risk of bleeding and thromboembolic events favors the</text>
<text top="499" left="450" width="241" height="15" font="5">choice of a mechanical valve in patients</text>
<text top="495" left="694" width="105" height="19" font="5">&lt;60 years of age.</text>
<text top="518" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="517" left="598" width="85" height="15" font="6"><a href="e57.full.html#112">(533,536,546)</a></text>
<text top="541" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="556" left="449" width="351" height="10" font="21">2. A bioprosthesis is reasonable in patients more than 70 years of</text>
<text top="572" left="467" width="19" height="10" font="21">age</text>
<text top="572" left="490" width="26" height="10" font="22"><a href="e57.full.html#112">(537</a></text>
<text top="569" left="516" width="32" height="16" font="22"><a href="e57.full.html#112">–540)</a></text>
<text top="572" left="548" width="121" height="12" font="21"><a href="e57.full.html#112">. </a>(Level of Evidence: B)</text>
<text top="597" left="465" width="64" height="15" font="5">In patients</text>
<text top="593" left="533" width="266" height="19" font="5">&gt;70 years of age at the time of bioprosthetic</text>
<text top="615" left="450" width="350" height="15" font="5">valve implantation, the likelihood of primary structural</text>
<text top="633" left="450" width="350" height="15" font="5">deterioration at 15 to 20 years is only about 10%. In</text>
<text top="650" left="450" width="350" height="15" font="5">addition, older patients are at higher risk of bleeding</text>
<text top="668" left="450" width="350" height="15" font="5">complications related to VKA therapy and more often</text>
<text top="686" left="450" width="350" height="15" font="5">require interruption of VKA therapy for noncardiac sur-</text>
<text top="704" left="450" width="350" height="15" font="5">gical and interventional procedures. In the United States,</text>
<text top="722" left="450" width="350" height="15" font="5">the expected number of remaining years of life at 70 years</text>
<text top="740" left="450" width="350" height="15" font="5">of age is 13.6 years for a man and 15.9 years for a woman;</text>
<text top="758" left="450" width="350" height="15" font="5">at 80 years of age the expected number of remaining years</text>
<text top="776" left="450" width="350" height="15" font="5">of life is 7.8 years for men and 9.3 years for women. Thus,</text>
<text top="794" left="450" width="319" height="15" font="5">it is reasonable to use a bioprosthetic valve in patients</text>
<text top="791" left="773" width="27" height="19" font="5">&gt;70</text>
<text top="812" left="450" width="350" height="15" font="5">years of age to avoid the risks of anticoagulation because</text>
<text top="830" left="450" width="350" height="15" font="5">the durability of the valve exceeds the expected years of life.</text>
<text top="848" left="450" width="350" height="15" font="5">Data from 41,227 patients in the Society for Cardiotho-</text>
<text top="866" left="450" width="350" height="15" font="5">racic Surgery in the Great Britain and Ireland National</text>
<text top="884" left="450" width="350" height="15" font="5">database between 2004 and 2009 show that the proportion</text>
<text top="902" left="450" width="67" height="15" font="5">of patients</text>
<text top="898" left="525" width="274" height="19" font="5">&gt;70 years of age who receive a biological</text>
<text top="920" left="450" width="350" height="15" font="5">prosthesis at the time of valve replacement has increased</text>
<text top="937" left="450" width="350" height="15" font="5">from 87% to 96%, with no evidence for an increase in</text>
<text top="955" left="450" width="89" height="15" font="5">adverse events.</text>
<text top="974" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="973" left="597" width="77" height="15" font="6"><a href="e57.full.html#101">(41,533,546)</a></text>
<text top="998" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="1012" left="449" width="351" height="10" font="21">3. Either a bioprosthetic or mechanical valve is reasonable in pa-</text>
<text top="1029" left="467" width="218" height="10" font="21">tients between 60 and 70 years of age</text>
<text top="1029" left="690" width="55" height="10" font="22"><a href="e57.full.html#112">(541,542)</a></text>
<text top="1029" left="745" width="55" height="12" font="21"><a href="e57.full.html#112">. </a>(Level of</text>
<text top="1046" left="467" width="65" height="12" font="21">Evidence: B)</text>
<text top="1070" left="465" width="335" height="15" font="5">Outcomes are similar with implantation of either a</text>
<text top="1088" left="450" width="350" height="15" font="5">bioprosthetic or mechanical valve for patients between 60</text>
<text top="103" left="64" width="394" height="11" font="13">Table 23. Summary of Recommendations for Prosthetic Valve Choice</text>
<text top="129" left="64" width="86" height="9" font="7">Recommendations</text>
<text top="129" left="558" width="21" height="9" font="7">COR</text>
<text top="129" left="657" width="18" height="9" font="7">LOE</text>
<text top="129" left="733" width="52" height="9" font="7">References</text>
<text top="148" left="64" width="408" height="9" font="7">Choice of valve intervention and prosthetic valve type should be a shared decision process</text>
<text top="148" left="567" width="3" height="9" font="7">I</text>
<text top="148" left="663" width="6" height="9" font="7">C</text>
<text top="148" left="750" width="18" height="9" font="7">N/A</text>
<text top="166" left="64" width="408" height="9" font="7">A bioprosthesis is recommended in patients of any age for whom anticoagulant therapy is</text>
<text top="180" left="77" width="306" height="9" font="7">contraindicated, cannot be managed appropriately, or is not desired</text>
<text top="166" left="567" width="3" height="9" font="7">I</text>
<text top="166" left="663" width="6" height="9" font="7">C</text>
<text top="166" left="750" width="18" height="9" font="7">N/A</text>
<text top="194" left="64" width="298" height="9" font="7">A mechanical prosthesis is reasonable for AVR or MVR in patients</text>
<text top="191" left="366" width="114" height="14" font="7">&lt;60 y of age who do not</text>
<text top="209" left="77" width="189" height="9" font="7">have a contraindication to anticoagulation</text>
<text top="194" left="563" width="11" height="9" font="7">IIa</text>
<text top="194" left="663" width="6" height="9" font="7">B</text>
<text top="194" left="735" width="22" height="9" font="8"><a href="e57.full.html#112">(534</a></text>
<text top="191" left="757" width="27" height="14" font="8"><a href="e57.full.html#112">–536)</a></text>
<text top="222" left="64" width="183" height="9" font="7">A bioprosthesis is reasonable in patients</text>
<text top="220" left="251" width="60" height="14" font="7">&gt;70 y of age</text>
<text top="222" left="563" width="11" height="9" font="7">IIa</text>
<text top="222" left="663" width="6" height="9" font="7">B</text>
<text top="222" left="735" width="22" height="9" font="8"><a href="e57.full.html#112">(537</a></text>
<text top="220" left="757" width="27" height="14" font="8"><a href="e57.full.html#112">–540)</a></text>
<text top="241" left="64" width="445" height="9" font="7">Either a bioprosthetic or mechanical valve is reasonable in patients between 60 y and 70 y of age</text>
<text top="241" left="563" width="11" height="9" font="7">IIa</text>
<text top="241" left="663" width="6" height="9" font="7">B</text>
<text top="241" left="736" width="45" height="9" font="8"><a href="e57.full.html#112">(541,542)</a></text>
<text top="259" left="64" width="439" height="9" font="7">Replacement of the aortic valve by a pulmonary autograft (the Ross procedure), when performed</text>
<text top="273" left="77" width="425" height="9" font="7">by an experienced surgeon, may be considered in young patients when VKA anticoagulation is</text>
<text top="288" left="77" width="136" height="9" font="7">contraindicated or undesirable</text>
<text top="259" left="563" width="11" height="9" font="7">IIb</text>
<text top="259" left="663" width="6" height="9" font="7">C</text>
<text top="259" left="750" width="18" height="9" font="7">N/A</text>
<text top="307" left="72" width="677" height="8" font="18">AVR indicates aortic valve replacement; COR, Class of Recommendation; LOE, Level of Evidence; MVR, mitral valve replacement; N/A, not applicable; and VKA, vitamin K antagonist.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e118</text>
</page>
<page number="63" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">and 70 years of age at the time of surgery. In the Edin-</text>
<text top="121" left="64" width="350" height="15" font="5">burgh Heart Valve Study of 533 patients (mean age</text>
<text top="139" left="64" width="26" height="15" font="5">54.4</text>
<text top="135" left="90" width="323" height="19" font="5">10.4 years) undergoing valve surgery, there was no</text>
<text top="157" left="64" width="350" height="15" font="5">difference in long-term survival between those random-</text>
<text top="175" left="64" width="350" height="15" font="5">ized to a Bjork-Shiley mechanical prosthesis or a porcine</text>
<text top="192" left="64" width="166" height="15" font="5">prosthesis (log-rank test: p</text>
<text top="189" left="230" width="184" height="19" font="5">¼0.39). In a prospective ran-</text>
<text top="210" left="64" width="350" height="15" font="5">domized Italian study of 310 patients between 55 and 70</text>
<text top="228" left="64" width="350" height="15" font="5">years of age, there was no difference in overall survival at</text>
<text top="246" left="64" width="350" height="15" font="5">13 years between those receiving a mechanical valve</text>
<text top="264" left="64" width="350" height="15" font="5">compared with those who received a bioprosthetic valve.</text>
<text top="282" left="64" width="350" height="15" font="5">The linearized rates of thromboembolism, bleeding, IE,</text>
<text top="300" left="64" width="350" height="15" font="5">and major adverse prosthesis-related events were no dif-</text>
<text top="318" left="64" width="350" height="15" font="5">ferent between the 2 valve types, but valve failures and</text>
<text top="336" left="64" width="350" height="15" font="5">reoperations were more frequent in the bioprosthetic</text>
<text top="354" left="64" width="350" height="15" font="5">valve group compared with the mechanical valve group</text>
<text top="372" left="64" width="12" height="15" font="5">(p</text>
<text top="368" left="77" width="230" height="19" font="5">¼0.0001 and p¼0.0003, respectively).</text>
<text top="390" left="79" width="335" height="15" font="5">Although the evidence supports the use of either a</text>
<text top="408" left="64" width="350" height="15" font="5">mechanical or bioprosthetic valve in patients 60 to 70 years</text>
<text top="426" left="64" width="350" height="15" font="5">of age, patient preferences should also be considered. Ac-</text>
<text top="444" left="64" width="350" height="15" font="5">cording to data on 41,227 patients in the Society for</text>
<text top="461" left="64" width="350" height="15" font="5">Cardiothoracic Surgery in the Great Britain and Ireland</text>
<text top="479" left="64" width="350" height="15" font="5">National database collected between 2004 and 2009, the</text>
<text top="497" left="64" width="350" height="15" font="5">proportion of patients 60 to 65 years of age who received a</text>
<text top="515" left="64" width="350" height="15" font="5">bioprosthesis at the time of valve replacement increased</text>
<text top="533" left="64" width="350" height="15" font="5">from 37% to 55%; in those 65 to 70 years of age, the</text>
<text top="551" left="64" width="240" height="15" font="5">proportion increased from 62% to 78%.</text>
<text top="570" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="569" left="212" width="111" height="15" font="6"><a href="e57.full.html#112">(532,533,543,546)</a></text>
<text top="602" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="617" left="63" width="351" height="10" font="21">1. Replacement of the aortic valve by a pulmonary autograft (the</text>
<text top="634" left="81" width="333" height="10" font="21">Ross procedure), when performed by an experienced surgeon,</text>
<text top="650" left="81" width="333" height="10" font="21">may be considered in young patients when VKA anticoagulation</text>
<text top="667" left="81" width="294" height="12" font="21">is contraindicated or undesirable. (Level of Evidence: C)</text>
<text top="691" left="79" width="335" height="15" font="5">Replacement of the aortic valve with a pulmonary</text>
<text top="709" left="64" width="350" height="15" font="5">autograft (the Ross procedure) is a complex operation</text>
<text top="727" left="64" width="350" height="15" font="5">intended to provide an autologous substitute for the pa-</text>
<text top="745" left="64" width="27" height="15" font="5">tient</text>
<text top="741" left="92" width="322" height="19" font="5">’s diseased aortic valve by relocating the pulmonic</text>
<text top="763" left="64" width="350" height="15" font="5">valve into the aortic position and subsequently replacing</text>
<text top="781" left="64" width="350" height="15" font="5">the pulmonic valve with a homograft. It is a surgical</text>
<text top="798" left="64" width="350" height="15" font="5">challenge and requires an experienced surgical team with</text>
<text top="816" left="64" width="350" height="15" font="5">exceptional surgical expertise. In the most experienced</text>
<text top="834" left="64" width="350" height="15" font="5">hands, hospital mortality can be similar to mortality for a</text>
<text top="852" left="64" width="350" height="15" font="5">simple bioprosthetic or mechanical valve replacement.</text>
<text top="870" left="64" width="350" height="15" font="5">Expansion of the Ross procedure to a broader group of</text>
<text top="888" left="64" width="316" height="15" font="5">surgeons with less focused experience has been dif</text>
<text top="885" left="380" width="34" height="19" font="5">ﬁcult.</text>
<text top="906" left="64" width="350" height="15" font="5">The failure mode of the Ross procedure is most often due</text>
<text top="924" left="64" width="350" height="15" font="5">to regurgitation of the pulmonary autograft (the neoaortic</text>
<text top="942" left="64" width="350" height="15" font="5">valve) in the second decade after the operation. Regurgi-</text>
<text top="960" left="64" width="167" height="15" font="5">tation typically is due to lea</text>
<text top="956" left="231" width="183" height="19" font="5">ﬂet prolapse if the autograft is</text>
<text top="978" left="64" width="350" height="15" font="5">implanted in the subcoronary position or to aortic sinus</text>
<text top="996" left="64" width="350" height="15" font="5">dilation if the autograft is implanted starting at the aortic</text>
<text top="1014" left="64" width="350" height="15" font="5">sinuses. Surgical reinforcement techniques have been used</text>
<text top="1032" left="64" width="350" height="15" font="5">to prevent dilation of the neoaortic sinuses. Some surgeons</text>
<text top="1050" left="64" width="350" height="15" font="5">have advocated placing the pulmonic valve within a Dacron</text>
<text top="1067" left="64" width="350" height="15" font="5">conduit. Still others have returned to placing the neoaortic</text>
<text top="1085" left="64" width="350" height="15" font="5">valve in a subcoronary position with a reinforced native</text>
<text top="103" left="450" width="350" height="15" font="5">aorta. The outcome of these new procedures, with data</text>
<text top="121" left="450" width="350" height="15" font="5">extending into the second decade after operation, is not yet</text>
<text top="139" left="450" width="54" height="15" font="5">available.</text>
<text top="157" left="465" width="81" height="15" font="5">In a small (n</text>
<text top="153" left="546" width="253" height="19" font="5">¼228) RCT comparing pulmonary auto-</text>
<text top="175" left="450" width="350" height="15" font="5">grafts with aortic valve allografts, the HR for death at 10</text>
<text top="193" left="450" width="109" height="15" font="5">years was 4.61 (p</text>
<text top="189" left="558" width="241" height="19" font="5">¼0.006) in those receiving an allograft</text>
<text top="210" left="450" width="350" height="15" font="5">compared with those with a pulmonary autograft AVR,</text>
<text top="228" left="450" width="350" height="15" font="5">with survival in the autograft group similar to an age-</text>
<text top="246" left="450" width="350" height="15" font="5">matched general population. Freedom from reoperation</text>
<text top="264" left="450" width="350" height="15" font="5">for the aortic sinuses and ascending aorta was 99% in the</text>
<text top="282" left="450" width="350" height="15" font="5">autograft group and 82% in the allograft group. Freedom</text>
<text top="300" left="450" width="350" height="15" font="5">from severe regurgitation of the neoaortic valve was 94%</text>
<text top="318" left="450" width="350" height="15" font="5">at 10 years. However, these outstanding results have not</text>
<text top="336" left="450" width="350" height="15" font="5">been generally replicated. In addition, an allograft valve is</text>
<text top="354" left="450" width="350" height="15" font="5">not the ideal comparator, given current outcomes with</text>
<text top="372" left="450" width="120" height="15" font="5">bioprosthetic valves.</text>
<text top="390" left="465" width="335" height="15" font="5">In addition to reoperation for neoaortic valve regurgi-</text>
<text top="408" left="450" width="350" height="15" font="5">tation, at least half of the new pulmonic homograft valve</text>
<text top="426" left="450" width="350" height="15" font="5">implants will require intervention during the second</text>
<text top="444" left="450" width="350" height="15" font="5">decade. This is obviously a concern for young patients who</text>
<text top="462" left="450" width="350" height="15" font="5">began with single valve disease and then face a lifetime of</text>
<text top="480" left="450" width="350" height="15" font="5">dealing with both pulmonic homograft and neoaortic valve</text>
<text top="497" left="450" width="81" height="15" font="5">disease. Calci</text>
<text top="494" left="531" width="269" height="19" font="5">ﬁcation of the homograft and adhesions be-</text>
<text top="515" left="450" width="336" height="15" font="5">tween the homograft and neoaorta may increase the dif</text>
<text top="512" left="785" width="14" height="19" font="5">ﬁ-</text>
<text top="533" left="450" width="121" height="15" font="5">culty of reoperation.</text>
<text top="551" left="465" width="335" height="15" font="5">The Ross procedure is an effective procedure in the</text>
<text top="569" left="450" width="350" height="15" font="5">hands of a small group of focused and experienced sur-</text>
<text top="587" left="450" width="350" height="15" font="5">geons. It is a risky procedure in the hands of surgeons who</text>
<text top="605" left="450" width="350" height="15" font="5">perform it only occasionally. The procedure should be</text>
<text top="623" left="450" width="350" height="15" font="5">reserved for patients in whom anticoagulation is either</text>
<text top="641" left="450" width="350" height="15" font="5">contraindicated or very undesirable, and it should be per-</text>
<text top="659" left="450" width="350" height="15" font="5">formed only by surgeons experienced in complex surgery</text>
<text top="677" left="450" width="333" height="15" font="5">involving the aortic valve, sinuses, and ascending aorta.</text>
<text top="695" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="695" left="597" width="27" height="15" font="6"><a href="e57.full.html#113">(547</a></text>
<text top="691" left="625" width="35" height="19" font="6"><a href="e57.full.html#113">–549)</a></text>
<text top="713" left="465" width="18" height="15" font="5">See</text>
<text top="713" left="488" width="166" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 20</a></text>
<text top="713" left="659" width="140" height="15" font="5">for more information on</text>
<text top="731" left="450" width="143" height="15" font="5">choice of valve prosthesis.</text>
<text top="762" left="450" width="223" height="12" font="19">11.2. Antithrombotic Therapy for</text>
<text top="780" left="450" width="120" height="12" font="19">Prosthetic Valves</text>
<text top="807" left="450" width="214" height="15" font="5">11.2.1. Diagnosis and Follow-Up</text>
<text top="833" left="451" width="349" height="15" font="5">Effective antithrombotic therapy in patients with me-</text>
<text top="851" left="450" width="350" height="15" font="5">chanical heart valves requires continuous effective VKA</text>
<text top="869" left="450" width="350" height="15" font="5">anticoagulation with an INR in the target range. It is</text>
<text top="887" left="450" width="350" height="15" font="5">preferable to specify a single INR target in each patient,</text>
<text top="904" left="450" width="350" height="15" font="5">recognizing that the acceptable range is 0.5 INR units on</text>
<text top="922" left="450" width="350" height="15" font="5">each side of this target; this is preferable because it avoids</text>
<text top="940" left="450" width="350" height="15" font="5">patients having INR values consistently near the upper or</text>
<text top="958" left="450" width="225" height="15" font="5">lower edge of the range. In addition,</text>
<text top="955" left="680" width="119" height="19" font="5">ﬂuctuations in INR</text>
<text top="976" left="450" width="350" height="15" font="5">are associated with increased incidence of complications in</text>
<text top="994" left="450" width="350" height="15" font="5">patients with prosthetic valves, so patients and caregivers</text>
<text top="1012" left="450" width="350" height="15" font="5">should strive to attain the single INR value. The effects of</text>
<text top="1030" left="450" width="258" height="15" font="5">VKA anticoagulation vary with the speci</text>
<text top="1027" left="708" width="91" height="19" font="5">ﬁc medication,</text>
<text top="1048" left="450" width="350" height="15" font="5">absorption of medication, effects of various foods and</text>
<text top="1066" left="450" width="350" height="15" font="5">medications, and changes in liver function. Most of the</text>
<text top="1084" left="450" width="350" height="15" font="5">published studies on VKA therapy used warfarin, although</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e119</text>
</page>
<page number="64" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="349" height="15" font="5">other coumarin agents are used on a worldwide basis. In</text>
<text top="121" left="64" width="350" height="15" font="5">clinical practice, a program of patient education and close</text>
<text top="139" left="64" width="350" height="15" font="5">surveillance by an experienced healthcare professional</text>
<text top="157" left="64" width="350" height="15" font="5">with periodic monitoring of the INR is necessary. Patient</text>
<text top="175" left="64" width="350" height="15" font="5">monitoring by hospital-based anticoagulation clinics re-</text>
<text top="192" left="64" width="350" height="15" font="5">sults in lower complication rates compared with standard</text>
<text top="210" left="64" width="350" height="15" font="5">care and is cost-effective due to lower rates of bleeding</text>
<text top="228" left="64" width="350" height="15" font="5">and hemorrhagic complications. Periodic direct patient</text>
<text top="246" left="64" width="350" height="15" font="5">contact and telephone encounters with the anticoagu-</text>
<text top="264" left="64" width="350" height="15" font="5">lation clinic pharmacists are equally effective in reducing</text>
<text top="282" left="64" width="350" height="15" font="5">complication rates. Self-monitoring with home INR</text>
<text top="300" left="64" width="350" height="15" font="5">measurement devices is another option for educated and</text>
<text top="318" left="64" width="114" height="15" font="5">motivated patients.</text>
<text top="337" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="336" left="212" width="27" height="15" font="6"><a href="e57.full.html#113">(550</a></text>
<text top="333" left="239" width="35" height="19" font="6"><a href="e57.full.html#113">–555)</a></text>
<text top="369" left="64" width="284" height="15" font="5">11.2.2. Medical Therapy: Recommendations</text>
<text top="397" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="412" left="64" width="350" height="10" font="21">1. Anticoagulation with a VKA and INR monitoring is recommended</text>
<text top="428" left="82" width="264" height="10" font="21">in patients with a mechanical prosthetic valve</text>
<text top="428" left="353" width="26" height="10" font="22"><a href="e57.full.html#113">(556</a></text>
<text top="425" left="379" width="32" height="16" font="22"><a href="e57.full.html#113">–558)</a></text>
<text top="428" left="410" width="3" height="10" font="21">.</text>
<text top="445" left="82" width="113" height="12" font="21">(Level of Evidence: A)</text>
<text top="469" left="79" width="335" height="15" font="5">All patients with mechanical valves require anticoagu-</text>
<text top="487" left="64" width="350" height="15" font="5">lant therapy. In addition to the thrombogenicity of the</text>
<text top="505" left="64" width="350" height="15" font="5">intravascular prosthetic material, mechanical valves im-</text>
<text top="523" left="64" width="91" height="15" font="5">pose abnormal</text>
<text top="519" left="161" width="252" height="19" font="5">ﬂow conditions, with zones of low ﬂow</text>
<text top="541" left="64" width="350" height="15" font="5">within their components, as well as areas of high-shear</text>
<text top="559" left="64" width="350" height="15" font="5">stress, which can cause platelet activation, leading to</text>
<text top="576" left="64" width="350" height="15" font="5">valve thrombosis and embolic events. Life-long therapy</text>
<text top="594" left="64" width="350" height="15" font="5">with an oral VKA at an INR goal appropriate for the co-</text>
<text top="612" left="64" width="350" height="15" font="5">morbidity of the patient and the type and position of the</text>
<text top="630" left="64" width="350" height="15" font="5">mechanical valve prosthesis is recommended to decrease</text>
<text top="648" left="64" width="349" height="15" font="5">the incidence of thromboembolism and the associated</text>
<text top="666" left="64" width="350" height="15" font="5">morbidity (e.g., ischemic stroke, cerebrovascular accident,</text>
<text top="684" left="64" width="350" height="15" font="5">and peripheral systemic embolism). Cumulative data show</text>
<text top="702" left="64" width="350" height="15" font="5">that anticoagulation with a VKA is protective against valve</text>
<text top="720" left="64" width="350" height="15" font="5">thrombosis (OR: 0.11; 95% CI: 0.07 to 0.2) and throm-</text>
<text top="738" left="64" width="318" height="15" font="5">boembolic events (OR: 0.21; 95% CI: 0.16 to 0.27).</text>
<text top="756" left="79" width="335" height="15" font="5">Many centers initiate heparin early after surgery for</text>
<text top="774" left="64" width="350" height="15" font="5">anticoagulation until the INR reaches the therapeutic</text>
<text top="792" left="64" width="350" height="15" font="5">range. Bridging anticoagulation is typically started once</text>
<text top="810" left="64" width="350" height="15" font="5">postoperative bleeding is no longer an issue. Some centers</text>
<text top="828" left="64" width="350" height="15" font="5">use subcutaneous low-molecular-weight heparin (LMWH)</text>
<text top="846" left="64" width="350" height="15" font="5">or unfractionated heparin (UFH), whereas other centers</text>
<text top="863" left="64" width="223" height="15" font="5">continue to prefer intravenous UFH.</text>
<text top="882" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="881" left="212" width="103" height="15" font="6"><a href="e57.full.html#100">(12,556,559,560)</a></text>
<text top="911" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="926" left="63" width="351" height="10" font="21">2. Anticoagulation with a VKA to achieve an INR of 2.5 is re-</text>
<text top="942" left="81" width="299" height="10" font="21">commended in patients with a mechanical AVR (bilea</text>
<text top="939" left="380" width="34" height="16" font="21">ﬂet or</text>
<text top="959" left="81" width="333" height="10" font="21">current-generation single tilting disc) and no risk factors for</text>
<text top="975" left="81" width="94" height="10" font="21">thromboembolism</text>
<text top="975" left="179" width="26" height="10" font="22"><a href="e57.full.html#113">(561</a></text>
<text top="972" left="205" width="32" height="16" font="22"><a href="e57.full.html#113">–563)</a></text>
<text top="975" left="237" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="999" left="79" width="335" height="15" font="5">The intensity of anticoagulation in a patient with a</text>
<text top="1017" left="64" width="350" height="15" font="5">mechanical aortic valve prosthesis should be optimized so</text>
<text top="1035" left="64" width="350" height="15" font="5">that protection from thromboembolism and valve throm-</text>
<text top="1053" left="64" width="350" height="15" font="5">bosis is achieved without excess risk of bleeding. The rate</text>
<text top="1071" left="64" width="259" height="15" font="5">of thromboembolism in patients with bilea</text>
<text top="1068" left="323" width="90" height="19" font="5">ﬂet mechanical</text>
<text top="1089" left="64" width="350" height="15" font="5">AVR on VKA and antiplatelet regimen is estimated to be</text>
<text top="103" left="450" width="350" height="15" font="5">0.53% per patient-year over the INR range of 2.0 to 4.5.</text>
<text top="121" left="450" width="350" height="15" font="5">In a large retrospective study, adverse events increased if</text>
<text top="139" left="450" width="79" height="15" font="5">the INR was</text>
<text top="135" left="535" width="265" height="19" font="5">&gt;4.0 in patients with mechanical AVR. In</text>
<text top="157" left="450" width="350" height="15" font="5">patients with the new-generation AVR without other risk</text>
<text top="175" left="450" width="350" height="15" font="5">factors for thromboembolism, the risk of thromboembolic</text>
<text top="192" left="450" width="350" height="15" font="5">events was similar, but the risk of hemorrhage was lower</text>
<text top="210" left="450" width="350" height="15" font="5">in the group with an INR of 2.0 to 3.0 versus the group</text>
<text top="228" left="450" width="172" height="15" font="5">with an INR of 3.0 to 4.5 (p</text>
<text top="225" left="622" width="178" height="19" font="5">&lt;0.01). In a study comparing</text>
<text top="246" left="450" width="350" height="15" font="5">an INR target of 1.5 to 2.5 with the conventional 2.0 to</text>
<text top="264" left="450" width="350" height="15" font="5">3.0 in 396 patients with low-risk mechanical aortic pros-</text>
<text top="282" left="450" width="350" height="15" font="5">thetic valves and no other risk factors, the lower INR</text>
<text top="300" left="450" width="350" height="15" font="5">target was noninferior, but the quality of the evidence was</text>
<text top="318" left="450" width="134" height="15" font="5">low. Thus, for bilea</text>
<text top="315" left="584" width="216" height="19" font="5">ﬂet and current-generation single</text>
<text top="336" left="450" width="350" height="15" font="5">tilting disc valve prostheses in the aortic position, an INR</text>
<text top="354" left="450" width="350" height="15" font="5">of 2.5 (between 2.0 and 3.0) provides a reasonable balance</text>
<text top="372" left="450" width="350" height="15" font="5">between optimal anticoagulation and a low risk of</text>
<text top="390" left="450" width="350" height="15" font="5">bleeding for mechanical aortic valves with a low throm-</text>
<text top="408" left="450" width="92" height="15" font="5">boembolic risk.</text>
<text top="426" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="426" left="593" width="25" height="15" font="6"><a href="e57.full.html#100">(12)</a></text>
<text top="454" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="469" left="449" width="351" height="10" font="21">3. Anticoagulation with a VKA is indicated to achieve an INR of 3.0</text>
<text top="486" left="467" width="332" height="10" font="21">in patients with a mechanical AVR and additional risk factors for</text>
<text top="502" left="467" width="332" height="10" font="21">thromboembolic events (AF, previous thromboembolism, LV</text>
<text top="519" left="467" width="293" height="10" font="21">dysfunction, or hypercoagulable conditions) or an</text>
<text top="519" left="771" width="29" height="10" font="21">older-</text>
<text top="535" left="467" width="290" height="10" font="21">generation mechanical AVR (such as ball-in-cage)</text>
<text top="535" left="766" width="30" height="10" font="22"><a href="e57.full.html#113">(564)</a></text>
<text top="535" left="796" width="3" height="10" font="21">.</text>
<text top="552" left="467" width="113" height="12" font="21">(Level of Evidence: B)</text>
<text top="576" left="465" width="335" height="15" font="5">In patients with an aortic mechanical prosthesis who</text>
<text top="594" left="450" width="350" height="15" font="5">are at higher risk of thromboembolic complications, INR</text>
<text top="612" left="450" width="350" height="15" font="5">should be maintained at 3.0 (range 2.5 to 3.5). These pa-</text>
<text top="630" left="450" width="350" height="15" font="5">tients include those with AF, previous thromboembolism,</text>
<text top="648" left="450" width="350" height="15" font="5">and a hypercoagulable state. Many would also include pa-</text>
<text top="665" left="450" width="350" height="15" font="5">tients with severe LV dysfunction in this higher-risk group.</text>
<text top="684" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="683" left="593" width="25" height="15" font="6"><a href="e57.full.html#100">(12)</a></text>
<text top="712" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="727" left="449" width="351" height="10" font="21">4. Anticoagulation with a VKA is indicated to achieve an INR of 3.0</text>
<text top="743" left="467" width="209" height="10" font="21">in patients with a mechanical MVR</text>
<text top="743" left="684" width="55" height="10" font="22"><a href="e57.full.html#113">(564,565)</a></text>
<text top="743" left="739" width="61" height="12" font="21"><a href="e57.full.html#113">. </a>(Level of</text>
<text top="760" left="467" width="65" height="12" font="21">Evidence: B)</text>
<text top="784" left="465" width="335" height="15" font="5">In patients with mechanical prostheses, the incidence of</text>
<text top="802" left="450" width="350" height="15" font="5">thromboembolism is higher for the mitral than the aortic</text>
<text top="820" left="450" width="350" height="15" font="5">position, and the rate of thromboembolism is lower in</text>
<text top="838" left="450" width="350" height="15" font="5">patients with a higher INR goal compared with those with</text>
<text top="856" left="450" width="350" height="15" font="5">a lower target INR. In the GELIA (German Experience</text>
<text top="874" left="450" width="350" height="15" font="5">With Low Intensity Anticoagulation) study of patients</text>
<text top="892" left="450" width="350" height="15" font="5">with a mechanical mitral prosthesis, a lower INR (2.0 to</text>
<text top="910" left="450" width="350" height="15" font="5">3.5) was associated with lower survival rates than a higher</text>
<text top="928" left="450" width="350" height="15" font="5">target INR range (2.5 to 4.5) in those with a second me-</text>
<text top="946" left="450" width="350" height="15" font="5">chanical valve. Patient compliance may be challenging with</text>
<text top="964" left="450" width="350" height="15" font="5">higher INR goals. In 1 study, patients with a target INR</text>
<text top="981" left="450" width="350" height="15" font="5">between 2.0 and 3.5 were within that range 74.5% of the</text>
<text top="999" left="450" width="350" height="15" font="5">time. In contrast, patients with a target INR of 3.0 to 4.5</text>
<text top="1017" left="450" width="350" height="15" font="5">were within range only 44.5% of the time. An INR target</text>
<text top="1035" left="450" width="350" height="15" font="5">of 3.0 (range 2.5 to 3.5) provides a reasonable balance</text>
<text top="1053" left="450" width="350" height="15" font="5">between the risks of under- or overanticoagulation in pa-</text>
<text top="1071" left="450" width="225" height="15" font="5">tients with a mechanical mitral valve.</text>
<text top="1090" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="1089" left="597" width="51" height="15" font="6"><a href="e57.full.html#100">(12,562)</a></text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e120</text>
</page>
<page number="65" position="absolute" top="0" left="0" height="1160" width="864">
<text top="106" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="121" left="63" width="351" height="10" font="21">5. Aspirin 75 mg to 100 mg daily is recommended in addition to</text>
<text top="137" left="81" width="333" height="10" font="21">anticoagulation with a VKA in patients with a mechanical valve</text>
<text top="154" left="81" width="55" height="10" font="21">prosthesis</text>
<text top="154" left="140" width="55" height="10" font="22"><a href="e57.full.html#113">(566,567)</a></text>
<text top="154" left="195" width="120" height="12" font="21"><a href="e57.full.html#113">. </a>(Level of Evidence: A)</text>
<text top="179" left="79" width="335" height="15" font="5">Aspirin is recommended for all patients with prosthetic</text>
<text top="197" left="64" width="350" height="15" font="5">heart valves, including those with mechanical prosthetic</text>
<text top="215" left="64" width="350" height="15" font="5">valves receiving VKA therapy. Even with the use of VKA,</text>
<text top="233" left="64" width="294" height="15" font="5">the risk of thromboemboli is 1% to 2% per year.</text>
<text top="251" left="79" width="335" height="15" font="5">The addition of aspirin 100 mg daily to oral VKA</text>
<text top="269" left="64" width="350" height="15" font="5">anticoagulation decreases the incidence of major embo-</text>
<text top="287" left="64" width="264" height="15" font="5">lism or death (1.9% versus 8.5% per year; p</text>
<text top="283" left="328" width="86" height="19" font="5">&lt;0.001), with</text>
<text top="305" left="64" width="350" height="15" font="5">the stroke rate decreasing to 1.3% per year versus 4.2%</text>
<text top="322" left="64" width="65" height="15" font="5">per year (p</text>
<text top="319" left="129" width="285" height="19" font="5">&lt;0.027) and overall mortality to 2.8% per year</text>
<text top="340" left="64" width="155" height="15" font="5">versus 7.4% per year (p</text>
<text top="337" left="220" width="194" height="19" font="5">&lt;0.01). The addition of low-</text>
<text top="358" left="64" width="350" height="15" font="5">dose aspirin (75 mg to 100 mg per day) to VKA ther-</text>
<text top="376" left="64" width="349" height="15" font="5">apy (INR 2.0 to 3.5) also decreases mortality due to other</text>
<text top="394" left="64" width="350" height="15" font="5">cardiovascular diseases. The combination of low-dose</text>
<text top="412" left="64" width="350" height="15" font="5">aspirin and VKA is associated with a slightly increased</text>
<text top="430" left="64" width="350" height="15" font="5">risk of minor bleeding such as epistaxis, bruising, and</text>
<text top="448" left="64" width="350" height="15" font="5">hematuria, but the risk of major bleeding does not differ</text>
<text top="466" left="64" width="29" height="15" font="5">signi</text>
<text top="463" left="93" width="321" height="19" font="5">ﬁcantly between those who received aspirin (8.5%)</text>
<text top="484" left="64" width="208" height="15" font="5">versus those who did not (6.6%; p</text>
<text top="481" left="272" width="142" height="19" font="5">¼0.43). The risk of GI</text>
<text top="502" left="64" width="350" height="15" font="5">irritation and hemorrhage with aspirin is dose dependent</text>
<text top="520" left="64" width="350" height="15" font="5">over the range of 100 mg to 1,000 mg per day, but the</text>
<text top="538" left="64" width="350" height="15" font="5">antiplatelet effects are independent of dose over this</text>
<text top="556" left="64" width="350" height="15" font="5">range. The addition of aspirin (75 mg to 100 mg per day)</text>
<text top="574" left="64" width="350" height="15" font="5">to VKA should be strongly considered unless there is</text>
<text top="592" left="64" width="350" height="15" font="5">a contraindication to the use of aspirin (i.e., bleeding or</text>
<text top="609" left="64" width="350" height="15" font="5">aspirin intolerance). This combination is particularly</text>
<text top="627" left="64" width="350" height="15" font="5">appropriate in patients who have had an embolus while</text>
<text top="645" left="64" width="350" height="15" font="5">on VKA therapy with a therapeutic INR, those with</text>
<text top="663" left="64" width="350" height="15" font="5">known vascular disease, and those who are known to be</text>
<text top="681" left="64" width="170" height="15" font="5">particularly hypercoagulable.</text>
<text top="700" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="699" left="212" width="46" height="15" font="6"><a href="e57.full.html#100">(12,568</a></text>
<text top="696" left="258" width="35" height="19" font="6"><a href="e57.full.html#100">–571)</a></text>
<text top="730" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="745" left="63" width="351" height="10" font="21">1. Aspirin 75 mg to 100 mg per day is reasonable in all patients</text>
<text top="761" left="81" width="220" height="10" font="21">with a bioprosthetic aortic or mitral valve</text>
<text top="761" left="305" width="26" height="10" font="22"><a href="e57.full.html#113">(572</a></text>
<text top="758" left="331" width="32" height="16" font="22"><a href="e57.full.html#113">–575)</a></text>
<text top="761" left="362" width="52" height="12" font="21">. (Level of</text>
<text top="778" left="81" width="65" height="12" font="21">Evidence: B)</text>
<text top="802" left="79" width="335" height="15" font="5">The risk of a clinical thromboembolism is on average</text>
<text top="820" left="64" width="350" height="15" font="5">0.7% per year in patients with biological valves in sinus</text>
<text top="838" left="64" width="74" height="15" font="5">rhythm; this</text>
<text top="835" left="142" width="272" height="19" font="5">ﬁgure is derived from several studies in which</text>
<text top="856" left="64" width="350" height="15" font="5">the majority of patients were not undergoing therapy with</text>
<text top="874" left="64" width="350" height="15" font="5">VKA. Among patients with bioprosthetic valves, those</text>
<text top="892" left="64" width="350" height="15" font="5">with mitral prostheses have a higher rate of thrombo-</text>
<text top="910" left="64" width="350" height="15" font="5">embolism than those with aortic prostheses in the long</text>
<text top="928" left="64" width="350" height="15" font="5">term (2.4% per patient-year versus 1.9% per patient-year,</text>
<text top="946" left="64" width="349" height="15" font="5">respectively). In a prospective study of bioprosthetic</text>
<text top="964" left="64" width="350" height="15" font="5">valves in patients with AVR who were in sinus rhythm</text>
<text top="981" left="64" width="350" height="15" font="5">and had no other indications for anticoagulation, the</text>
<text top="999" left="64" width="350" height="15" font="5">incidence of thromboembolic events, bleeding, and death</text>
<text top="1017" left="64" width="350" height="15" font="5">was similar between those who received aspirin or aspirin-</text>
<text top="1035" left="64" width="350" height="15" font="5">like antiplatelet agents only versus those who received</text>
<text top="1053" left="64" width="350" height="15" font="5">VKA. There are no studies examining the long-term effect</text>
<text top="1071" left="64" width="350" height="15" font="5">of antiplatelet agents in patients with bioprosthetic MVR</text>
<text top="1089" left="64" width="215" height="15" font="5">or mitral valve repair, but the bene</text>
<text top="1086" left="279" width="135" height="19" font="5">ﬁcial effects seen with</text>
<text top="103" left="450" width="350" height="15" font="5">bioprosthetic aortic valves are presumed to apply to mitral</text>
<text top="121" left="450" width="83" height="15" font="5">valves as well.</text>
<text top="139" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="139" left="593" width="25" height="15" font="6"><a href="e57.full.html#100">(12)</a></text>
<text top="164" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="179" left="449" width="273" height="10" font="21">2. Anticoagulation with a VKA is reasonable for the</text>
<text top="176" left="725" width="74" height="16" font="21">ﬁrst 3 months</text>
<text top="196" left="467" width="332" height="10" font="21">after bioprosthetic MVR or repair to achieve an INR of 2.5</text>
<text top="212" left="467" width="30" height="10" font="22"><a href="e57.full.html#113">(576)</a></text>
<text top="212" left="497" width="120" height="12" font="21">. (Level of Evidence: C)</text>
<text top="236" left="465" width="335" height="15" font="5">The risk of ischemic stroke after all types of mitral valve</text>
<text top="254" left="450" width="350" height="15" font="5">surgery is about 2% at 30 days, 3% at 180 days, and 8% at</text>
<text top="272" left="450" width="350" height="15" font="5">5 years. This is observed even with routine use of early</text>
<text top="290" left="450" width="350" height="15" font="5">heparin followed by VKA in patients with a mechanical</text>
<text top="308" left="450" width="350" height="15" font="5">valve or other indications for long-term anticoagulant ther-</text>
<text top="326" left="450" width="350" height="15" font="5">apy. The risk of ischemic stroke at 5 years is lower with</text>
<text top="344" left="450" width="163" height="15" font="5">mitral valve repair (6.1%</text>
<text top="341" left="614" width="186" height="19" font="5">0.9%) compared with bio-</text>
<text top="362" left="450" width="100" height="15" font="5">prosthetic (8.0%</text>
<text top="359" left="550" width="250" height="19" font="5">2.1%) and mechanical valve replacement</text>
<text top="380" left="450" width="42" height="15" font="5">(16.1%</text>
<text top="377" left="492" width="307" height="19" font="5">2.7%). In 1 study, patients with a bioprosthetic</text>
<text top="398" left="450" width="350" height="15" font="5">MVR who received anticoagulation had a lower rate of</text>
<text top="416" left="450" width="350" height="15" font="5">thromboembolism than those who did not receive therapy</text>
<text top="434" left="450" width="350" height="15" font="5">with VKA (2.5% per year with anticoagulation versus</text>
<text top="452" left="450" width="242" height="15" font="5">3.9% per year without anticoagulation; p</text>
<text top="448" left="691" width="108" height="19" font="5">¼0.05). However,</text>
<text top="470" left="450" width="350" height="15" font="5">another study showed that even with routine anticoagu-</text>
<text top="488" left="450" width="350" height="15" font="5">lation early after valve surgery, the incidence of ischemic</text>
<text top="506" left="450" width="107" height="15" font="5">stroke within the</text>
<text top="502" left="563" width="236" height="19" font="5">ﬁrst 30 postoperative days was higher</text>
<text top="523" left="450" width="304" height="15" font="5">after replacement with a biological prosthesis (4.6%</text>
<text top="520" left="754" width="45" height="19" font="5">1.5%;</text>
<text top="541" left="450" width="8" height="15" font="5">p</text>
<text top="538" left="457" width="342" height="19" font="5">&lt;0.0001) than after mitral valve repair (1.5%0.4%) or</text>
<text top="559" left="450" width="304" height="15" font="5">replacement with a mechanical prosthesis (1.3%</text>
<text top="556" left="754" width="45" height="19" font="5">0.8%;</text>
<text top="577" left="450" width="8" height="15" font="5">p</text>
<text top="574" left="457" width="342" height="19" font="5">&lt;0.001). Thus, anticoagulation with a target INR of 2.5</text>
<text top="595" left="450" width="350" height="15" font="5">(range 2.0 to 3.0) is reasonable early after bioprosthetic</text>
<text top="613" left="450" width="154" height="15" font="5">mitral valve implantation.</text>
<text top="631" left="465" width="335" height="15" font="5">Many centers start heparin as soon as the risk of surgical</text>
<text top="649" left="450" width="350" height="15" font="5">bleeding is acceptable (usually within 24 to 48 hours), with</text>
<text top="667" left="450" width="350" height="15" font="5">maintenance of a therapeutic partial thromboplastin time.</text>
<text top="685" left="450" width="350" height="15" font="5">After an overlap of heparin and VKA for 3 to 5 days,</text>
<text top="703" left="450" width="350" height="15" font="5">heparin may be discontinued when the INR reaches 2.5.</text>
<text top="721" left="450" width="350" height="15" font="5">After 3 months, the tissue valve can be treated like native</text>
<text top="739" left="450" width="350" height="15" font="5">valve disease, and VKA can be discontinued in more than</text>
<text top="757" left="450" width="350" height="15" font="5">two thirds of patients with biological valves. In the</text>
<text top="775" left="450" width="350" height="15" font="5">remaining patients with associated risk factors for throm-</text>
<text top="793" left="450" width="350" height="15" font="5">boembolism, such as AF, previous thromboembolism, or</text>
<text top="810" left="450" width="350" height="15" font="5">hypercoagulable condition, lifelong VKA therapy is indi-</text>
<text top="828" left="450" width="210" height="15" font="5">cated to achieve an INR of 2 to 3.</text>
<text top="847" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="846" left="597" width="27" height="15" font="6"><a href="e57.full.html#113">(572</a></text>
<text top="843" left="625" width="91" height="19" font="6"><a href="e57.full.html#113">–574,577–582)</a></text>
<text top="873" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="888" left="449" width="351" height="10" font="21">1. Anticoagulation, with a VKA, to achieve an INR of 2.5 may be</text>
<text top="905" left="467" width="94" height="10" font="21">reasonable for the</text>
<text top="902" left="564" width="199" height="16" font="21">ﬁrst 3 months after bioprosthetic AVR</text>
<text top="905" left="766" width="30" height="10" font="22"><a href="e57.full.html#113">(583)</a></text>
<text top="905" left="796" width="3" height="10" font="21">.</text>
<text top="922" left="467" width="113" height="12" font="21">(Level of Evidence: B)</text>
<text top="946" left="465" width="335" height="15" font="5">Patients with a bioprosthetic aortic valve are at a higher</text>
<text top="964" left="450" width="350" height="15" font="5">risk of ischemic stroke or peripheral embolism than the</text>
<text top="981" left="450" width="233" height="15" font="5">normal population, particularly in the</text>
<text top="978" left="689" width="110" height="19" font="5">ﬁrst 90 days after</text>
<text top="999" left="450" width="350" height="15" font="5">valve replacement. Anticoagulation early after valve im-</text>
<text top="1017" left="450" width="350" height="15" font="5">plantation is intended to decrease the risk of thrombo-</text>
<text top="1035" left="450" width="350" height="15" font="5">embolism until the prosthetic valve is fully endothelialized.</text>
<text top="1053" left="450" width="117" height="15" font="5">The potential bene</text>
<text top="1050" left="567" width="233" height="19" font="5">ﬁt of anticoagulation therapy must be</text>
<text top="1071" left="450" width="350" height="15" font="5">weighed against the risk for bleeding, particularly in pa-</text>
<text top="1089" left="450" width="350" height="15" font="5">tients who are at low risk for thromboembolism (e.g., those</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e121</text>
</page>
<page number="66" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">in sinus rhythm with normal LV function, no history of</text>
<text top="121" left="64" width="350" height="15" font="5">thromboembolism, or history of hypercoagulable condi-</text>
<text top="139" left="64" width="280" height="15" font="5">tions). Small RCTs have not established bene</text>
<text top="135" left="345" width="69" height="19" font="5">ﬁt for anti-</text>
<text top="157" left="64" width="350" height="15" font="5">coagulation after implantation of a bioprosthetic AVR;</text>
<text top="175" left="64" width="350" height="15" font="5">however, a large observational registry demonstrated ben-</text>
<text top="192" left="64" width="6" height="15" font="5">e</text>
<text top="189" left="70" width="343" height="19" font="5">ﬁt without a signiﬁcantly increased bleeding risk. In 4,075</text>
<text top="210" left="64" width="350" height="15" font="5">patients undergoing isolated bioprosthetic AVR with a</text>
<text top="228" left="64" width="350" height="15" font="5">median duration of follow-up of 6.57 person-years, the</text>
<text top="246" left="64" width="350" height="15" font="5">estimated rate of strokes per 100 person-years was 7.00</text>
<text top="264" left="64" width="350" height="15" font="5">(95% CI: 4.07 to 12.06) in patients not treated with VKA</text>
<text top="282" left="64" width="350" height="15" font="5">versus 2.69 (95% CI: 1.49 to 4.87) in those treated with</text>
<text top="300" left="64" width="350" height="15" font="5">VKA (HR: 2.46; 95% CI: 1.09 to 5.55). The lower event</text>
<text top="318" left="64" width="350" height="15" font="5">rates in those on VKA persisted at 6 months, with a car-</text>
<text top="336" left="64" width="350" height="15" font="5">diovascular death rate of 6.50 per 100 person-years (95%</text>
<text top="354" left="64" width="350" height="15" font="5">CI: 4.67 to 9.06) in those not on VKA therapy compared</text>
<text top="372" left="64" width="350" height="15" font="5">with 2.08 (95% CI: 0.99 to 4.36) in those on VKA therapy</text>
<text top="390" left="64" width="350" height="15" font="5">(adjusted internal rate of return: 3.51; 95% CI: 1.54 to</text>
<text top="408" left="64" width="350" height="15" font="5">8.03) for events within 90 to 179 days after surgery. Thus,</text>
<text top="426" left="64" width="350" height="15" font="5">anticoagulation with an INR target of 2.5 (range 2.0 to</text>
<text top="444" left="64" width="350" height="15" font="5">3.0) may be reasonable for at least 3 months, and perhaps</text>
<text top="461" left="64" width="280" height="15" font="5">as long as 6 months, after bioprosthetic AVR.</text>
<text top="480" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="479" left="212" width="80" height="15" font="6"><a href="e57.full.html#113">(572,574,583</a></text>
<text top="476" left="292" width="35" height="19" font="6"><a href="e57.full.html#113">–586)</a></text>
<text top="505" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="520" left="63" width="309" height="10" font="21">2. Clopidogrel 75 mg daily may be reasonable for the</text>
<text top="517" left="379" width="35" height="16" font="21">ﬁrst 6</text>
<text top="536" left="81" width="333" height="10" font="21">months after TAVR in addition to life-long aspirin 75 mg to 100</text>
<text top="553" left="81" width="165" height="12" font="21">mg daily. (Level of Evidence: C)</text>
<text top="577" left="79" width="335" height="15" font="5">During TAVR, a biological prosthesis mounted on a</text>
<text top="595" left="64" width="350" height="15" font="5">metallic expandable frame is inserted transcutaneously</text>
<text top="613" left="64" width="350" height="15" font="5">within the native aortic valve with stenosis. In prospective</text>
<text top="631" left="64" width="350" height="15" font="5">RCTs of balloon-expandable TAVR for treatment of AS,</text>
<text top="649" left="64" width="350" height="15" font="5">the research protocol included dual antiplatelet therapy</text>
<text top="667" left="64" width="230" height="15" font="5">with aspirin and clopidogrel for the</text>
<text top="663" left="302" width="112" height="19" font="5">ﬁrst 6 months to</text>
<text top="685" left="64" width="350" height="15" font="5">minimize the risk of thromboembolism. The current re-</text>
<text top="703" left="64" width="350" height="15" font="5">commendation is based on outcomes in these published</text>
<text top="721" left="64" width="350" height="15" font="5">studies, although the issue of antiplatelet therapy was not</text>
<text top="739" left="64" width="350" height="15" font="5">assessed. A small prospective, RCT, single-center study of</text>
<text top="756" left="64" width="350" height="15" font="5">79 patients receiving self-expanding TAVR did not show a</text>
<text top="774" left="64" width="350" height="15" font="5">difference in the composite of major adverse cardiac and</text>
<text top="792" left="64" width="158" height="15" font="5">cerebrovascular events, de</text>
<text top="789" left="222" width="192" height="19" font="5">ﬁned as death from any cause,</text>
<text top="810" left="64" width="350" height="15" font="5">MI, major stroke, urgent or emergency conversion to sur-</text>
<text top="828" left="64" width="350" height="15" font="5">gery, or life-threatening bleeding between aspirin and</text>
<text top="846" left="64" width="350" height="15" font="5">clopidogrel versus aspirin alone at both 30 days (13%</text>
<text top="864" left="64" width="89" height="15" font="5">versus 15%; p</text>
<text top="861" left="153" width="261" height="19" font="5">¼0.71) and 6 months (18% versus 15%;</text>
<text top="882" left="64" width="8" height="15" font="5">p</text>
<text top="879" left="72" width="46" height="19" font="5">¼0.85).</text>
<text top="901" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="900" left="212" width="103" height="15" font="6"><a href="e57.full.html#102">(79,170,587,588)</a></text>
<text top="927" left="64" width="73" height="8" font="20">CLASS III: Harm</text>
<text top="942" left="63" width="351" height="10" font="21">1. Anticoagulant therapy with oral direct thrombin inhibitors or</text>
<text top="959" left="81" width="333" height="10" font="21">anti-Xa agents should not be used in patients with mechanical</text>
<text top="975" left="81" width="89" height="10" font="21">valve prostheses</text>
<text top="975" left="174" width="26" height="10" font="22"><a href="e57.full.html#114">(589</a></text>
<text top="972" left="200" width="32" height="16" font="22"><a href="e57.full.html#114">–591)</a></text>
<text top="975" left="232" width="121" height="12" font="21"><a href="e57.full.html#114">. </a>(Level of Evidence: B)</text>
<text top="999" left="79" width="335" height="15" font="5">The U.S. Food and Drug Administration has approved</text>
<text top="1017" left="64" width="350" height="15" font="5">new anticoagulants that are direct thrombin inhibitors or</text>
<text top="1035" left="64" width="349" height="15" font="5">factor Xa inhibitors (dabigatran, apixaban, and rivarox-</text>
<text top="1053" left="64" width="350" height="15" font="5">aban) for anticoagulant prophylaxis in patients with AF not</text>
<text top="1071" left="64" width="350" height="15" font="5">caused by VHD. Several case reports have demonstrated</text>
<text top="1089" left="64" width="350" height="15" font="5">thrombosis on mechanical heart valves despite therapeutic</text>
<text top="103" left="450" width="350" height="15" font="5">dosing with dabigatran. The RE-ALIGN (Randomized,</text>
<text top="121" left="450" width="350" height="15" font="5">Phase II Study to Evaluate the Safety and Pharmacoki-</text>
<text top="139" left="450" width="350" height="15" font="5">netics of Oral Dabigatran Etexilate in Patients after Heart</text>
<text top="157" left="450" width="350" height="15" font="5">Valve Replacement) trial was stopped prematurely for</text>
<text top="175" left="450" width="350" height="15" font="5">excessive thrombotic complications in the dabigatran arm.</text>
<text top="192" left="450" width="327" height="15" font="5">After enrollment of 252 patients, ischemic or unspeci</text>
<text top="189" left="777" width="22" height="19" font="5">ﬁed</text>
<text top="210" left="450" width="350" height="15" font="5">stroke occurred in 9 patients (5%) randomized to dabiga-</text>
<text top="228" left="450" width="350" height="15" font="5">tran compared with no patients treated with warfarin. In</text>
<text top="246" left="450" width="350" height="15" font="5">the dabigatran group, 15 patients (9%) reached the com-</text>
<text top="264" left="450" width="350" height="15" font="5">posite endpoint of stroke, transient ischemic attack, sys-</text>
<text top="282" left="450" width="350" height="15" font="5">temic embolism, MI, or death compared with 4 patients</text>
<text top="300" left="450" width="350" height="15" font="5">(5%) in the warfarin group (HR in the dabigatran group:</text>
<text top="318" left="450" width="179" height="15" font="5">1.94; 95% CI: 0.64 to 5.86; p</text>
<text top="315" left="628" width="171" height="19" font="5">¼0.24). In addition, a major</text>
<text top="336" left="450" width="350" height="15" font="5">bleeding episode occurred in 7 patients (4%) in the dabi-</text>
<text top="354" left="450" width="350" height="15" font="5">gatran group and 2 patients (2%) in the warfarin group,</text>
<text top="372" left="450" width="350" height="15" font="5">and bleeding of any type occurred in 45 patients (27%) and</text>
<text top="390" left="450" width="350" height="15" font="5">10 patients (12%), respectively (HR: 2.45; 95% CI: 1.23 to</text>
<text top="408" left="450" width="44" height="15" font="5">4.86; p</text>
<text top="404" left="494" width="306" height="19" font="5">¼0.01). The Food and Drug Administration has</text>
<text top="426" left="450" width="80" height="15" font="5">issued a speci</text>
<text top="422" left="530" width="269" height="19" font="5">ﬁc contraindication for use of this product in</text>
<text top="444" left="450" width="350" height="15" font="5">patients with mechanical heart valves. These agents are also</text>
<text top="462" left="450" width="350" height="15" font="5">not recommended, due to lack of data on their safety and</text>
<text top="479" left="450" width="350" height="15" font="5">effectiveness, in patients with bioprosthetic valves who</text>
<text top="497" left="450" width="141" height="15" font="5">require anticoagulation.</text>
<text top="516" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="515" left="597" width="27" height="15" font="6"><a href="e57.full.html#114">(591</a></text>
<text top="512" left="625" width="35" height="19" font="6"><a href="e57.full.html#114">–594)</a></text>
<text top="573" left="450" width="302" height="12" font="19">11.3. Bridging Therapy for Prosthetic Valves</text>
<text top="600" left="450" width="214" height="15" font="5">11.3.1. Diagnosis and Follow-Up</text>
<text top="626" left="451" width="349" height="15" font="5">The management of patients with mechanical heart valves</text>
<text top="644" left="450" width="350" height="15" font="5">in whom interruption of anticoagulation therapy is needed</text>
<text top="662" left="450" width="350" height="15" font="5">for diagnostic or surgical procedures should take into ac-</text>
<text top="680" left="450" width="350" height="15" font="5">count the type of procedure, risk factors, and type, location,</text>
<text top="698" left="450" width="247" height="15" font="5">and number of heart valve prosthesis(es).</text>
<text top="724" left="450" width="284" height="15" font="5">11.3.2. Medical Therapy: Recommendations</text>
<text top="752" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="767" left="449" width="350" height="10" font="21">1. Continuation of VKA anticoagulation with a therapeutic INR is</text>
<text top="783" left="467" width="332" height="10" font="21">recommended in patients with mechanical heart valves under-</text>
<text top="800" left="467" width="332" height="10" font="21">going minor procedures (such as dental extractions or cataract</text>
<text top="816" left="467" width="332" height="12" font="21">removal) where bleeding is easily controlled. (Level of Evidence: C)</text>
<text top="840" left="465" width="335" height="15" font="5">Management of antithrombotic therapy must be indi-</text>
<text top="858" left="450" width="350" height="15" font="5">vidualized, but some generalizations apply. Antithrombotic</text>
<text top="876" left="450" width="350" height="15" font="5">therapy should not be stopped for procedures in which</text>
<text top="894" left="450" width="350" height="15" font="5">bleeding is unlikely or would be inconsequential if it oc-</text>
<text top="912" left="450" width="350" height="15" font="5">curred (i.e., surgery on the skin, dental cleaning, or simple</text>
<text top="930" left="450" width="350" height="15" font="5">treatment for dental caries). Eye surgery, particularly for</text>
<text top="948" left="450" width="350" height="15" font="5">cataracts or glaucoma, is usually associated with very little</text>
<text top="966" left="450" width="350" height="15" font="5">bleeding and thus is frequently performed without alter-</text>
<text top="984" left="450" width="213" height="15" font="5">ations to antithrombotic treatment.</text>
<text top="1011" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="1026" left="449" width="351" height="10" font="21">2. Temporary interruption of VKA anticoagulation, without bridging</text>
<text top="1042" left="467" width="332" height="10" font="21">agents while the INR is subtherapeutic, is recommended in</text>
<text top="1059" left="467" width="116" height="10" font="21">patients with a bilea</text>
<text top="1056" left="583" width="216" height="16" font="21">ﬂet mechanical AVR and no other risk</text>
<text top="1075" left="467" width="333" height="10" font="21">factors for thrombosis who are undergoing invasive or surgical</text>
<text top="1092" left="467" width="178" height="12" font="21">procedures. (Level of Evidence: C)</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e122</text>
</page>
<page number="67" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="79" width="335" height="15" font="5">The risk of increased bleeding during a procedure per-</text>
<text top="121" left="64" width="350" height="15" font="5">formed with a patient receiving antithrombotic therapy</text>
<text top="139" left="64" width="350" height="15" font="5">has to be weighed against the increased risk of a throm-</text>
<text top="157" left="64" width="350" height="15" font="5">boembolism caused by stopping the therapy. In patients</text>
<text top="175" left="64" width="72" height="15" font="5">with a bilea</text>
<text top="171" left="136" width="278" height="19" font="5">ﬂet mechanical aortic valve and no other risk</text>
<text top="192" left="64" width="350" height="15" font="5">factors for thromboembolism, the risk of stopping VKA</text>
<text top="210" left="64" width="350" height="15" font="5">is relatively slight if the drug is withheld for only a few</text>
<text top="228" left="64" width="350" height="15" font="5">days. In these low-risk patients, the inconvenience and</text>
<text top="246" left="64" width="350" height="15" font="5">expense of bridging anticoagulation can be avoided. When</text>
<text top="264" left="64" width="350" height="15" font="5">it is necessary to interrupt VKA therapy, VKA is stopped</text>
<text top="282" left="64" width="315" height="15" font="5">2 to 4 days before the procedure (so the INR falls to</text>
<text top="279" left="384" width="30" height="19" font="5">&lt;1.5</text>
<text top="300" left="64" width="350" height="15" font="5">for major surgical procedures) and restarted as soon as</text>
<text top="318" left="64" width="350" height="15" font="5">bleeding risk allows, typically 12 to 24 hours after surgery.</text>
<text top="337" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="336" left="212" width="58" height="15" font="6"><a href="e57.full.html#114">(595,596)</a></text>
<text top="372" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="387" left="63" width="351" height="10" font="21">3. Bridging anticoagulation with either intravenous UFH or sub-</text>
<text top="403" left="81" width="333" height="10" font="21">cutaneous LMWH is recommended during the time interval</text>
<text top="420" left="81" width="333" height="10" font="21">when the INR is subtherapeutic preoperatively in patients who</text>
<text top="436" left="81" width="333" height="10" font="21">are undergoing invasive or surgical procedures with a 1) me-</text>
<text top="453" left="81" width="333" height="10" font="21">chanical AVR and any thromboembolic risk factor, 2) older-</text>
<text top="469" left="81" width="332" height="12" font="21">generation mechanical AVR, or 3) mechanical MVR. (Level of</text>
<text top="486" left="81" width="65" height="12" font="21">Evidence: C)</text>
<text top="514" left="79" width="335" height="15" font="5">In patients at higher risk of thromboembolism during</text>
<text top="532" left="64" width="350" height="15" font="5">interruption of VKA anticoagulation, the risk of an adverse</text>
<text top="550" left="64" width="349" height="15" font="5">event can be minimized by anticoagulation with alternative</text>
<text top="568" left="64" width="350" height="15" font="5">agents that can be stopped right before and restarted right</text>
<text top="586" left="64" width="199" height="15" font="5">after the surgical procedure (e.g.,</text>
<text top="583" left="269" width="145" height="19" font="5">“bridging therapy”). Pa-</text>
<text top="604" left="64" width="350" height="15" font="5">tients at high risk of thrombosis include all patients with</text>
<text top="622" left="64" width="350" height="15" font="5">mechanical MVR or tricuspid valve replacements and</text>
<text top="640" left="64" width="350" height="15" font="5">patients with an AVR and any risk factors for thrombo-</text>
<text top="658" left="64" width="350" height="15" font="5">embolism. Such risk factors include AF, previous throm-</text>
<text top="676" left="64" width="350" height="15" font="5">boembolism, hypercoagulable condition, older-generation</text>
<text top="694" left="64" width="300" height="15" font="5">mechanical valves, LV systolic dysfunction (LVEF</text>
<text top="690" left="368" width="46" height="19" font="5">&lt;30%),</text>
<text top="712" left="64" width="12" height="15" font="5">or</text>
<text top="708" left="82" width="128" height="19" font="5">&gt;1 mechanical valve.</text>
<text top="730" left="79" width="335" height="15" font="5">When interruption of VKA therapy is needed, VKA is</text>
<text top="748" left="64" width="350" height="15" font="5">stopped 2 to 4 days before the procedure (so the INR falls</text>
<text top="766" left="64" width="12" height="15" font="5">to</text>
<text top="762" left="83" width="330" height="19" font="5">&lt;1.5 for major surgical procedures) and restarted as</text>
<text top="784" left="64" width="350" height="15" font="5">soon as bleeding risk allows, typically 12 to 24 hours after</text>
<text top="801" left="64" width="350" height="15" font="5">surgery. Bridging anticoagulation with intravenous UFH</text>
<text top="819" left="64" width="312" height="15" font="5">or subcutaneous LMWH is started when INR is</text>
<text top="816" left="384" width="30" height="19" font="5">&lt;2.0</text>
<text top="837" left="64" width="350" height="15" font="5">(usually about 48 hours before surgery) and stopped 4 to</text>
<text top="855" left="64" width="350" height="15" font="5">6 hours (for intravenous UFH) or 12 hours (for subcu-</text>
<text top="873" left="64" width="350" height="15" font="5">taneous LMWH) before the procedure. When LMWH is</text>
<text top="891" left="64" width="350" height="15" font="5">used, therapeutic weight-adjusted doses are given twice</text>
<text top="909" left="64" width="350" height="15" font="5">daily. One study of bridging therapy for interruption of</text>
<text top="927" left="64" width="350" height="15" font="5">VKA included 215 patients with mechanical valves. In the</text>
<text top="945" left="64" width="350" height="15" font="5">total group of 650 patients, the risk of thromboembolism</text>
<text top="963" left="64" width="350" height="15" font="5">(including possible events) was 0.62%, with 95% CI:</text>
<text top="981" left="64" width="350" height="15" font="5">0.17% to 1.57%. Major bleeding occurred in 0.95% (0.34%</text>
<text top="999" left="64" width="350" height="15" font="5">to 2.0%). Most studies using LMWH used enoxaparin for</text>
<text top="1017" left="64" width="350" height="15" font="5">therapy. The use of bridging heparin after surgery must be</text>
<text top="1035" left="64" width="350" height="15" font="5">individualized, depending on risk of bleeding and risk of</text>
<text top="1053" left="64" width="70" height="15" font="5">thrombosis.</text>
<text top="1071" left="79" width="335" height="15" font="5">The acceptable level of anticoagulation in patients un-</text>
<text top="1088" left="64" width="335" height="15" font="5">dergoing cardiac catheterization depends on the speci</text>
<text top="1085" left="400" width="14" height="19" font="5">ﬁc</text>
<text top="103" left="450" width="350" height="15" font="5">procedure being performed. For procedures with a low</text>
<text top="121" left="450" width="350" height="15" font="5">bleeding risk, such as coronary angiography from the</text>
<text top="139" left="450" width="212" height="15" font="5">radial approach, only slight modi</text>
<text top="135" left="662" width="138" height="19" font="5">ﬁcation in VKA dos-</text>
<text top="157" left="450" width="350" height="15" font="5">ing is needed. With interventional procedures at higher</text>
<text top="175" left="450" width="350" height="15" font="5">risk, many clinicians prefer to stop VKA anticoagulation</text>
<text top="193" left="450" width="350" height="15" font="5">and use bridging therapy as is done for other surgical</text>
<text top="211" left="450" width="69" height="15" font="5">procedures.</text>
<text top="229" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="228" left="597" width="27" height="15" font="6"><a href="e57.full.html#114">(597</a></text>
<text top="225" left="625" width="35" height="19" font="6"><a href="e57.full.html#114">–599)</a></text>
<text top="256" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="270" left="449" width="351" height="10" font="21">1. Administration of fresh frozen plasma or prothrombin complex</text>
<text top="287" left="467" width="333" height="10" font="21">concentrate is reasonable in patients with mechanical valves</text>
<text top="303" left="467" width="333" height="10" font="21">receiving VKA therapy who require emergency noncardiac sur-</text>
<text top="320" left="467" width="266" height="12" font="21">gery or invasive procedures. (Level of Evidence: C)</text>
<text top="344" left="465" width="335" height="15" font="5">Because VKA inhibits production of several proteins</text>
<text top="362" left="450" width="350" height="15" font="5">involved in the coagulation cascade, the anticoagulant ef-</text>
<text top="380" left="450" width="350" height="15" font="5">fect persists until adequate levels of these proteins are</text>
<text top="398" left="450" width="350" height="15" font="5">achieved after stopping warfarin therapy, a process that</text>
<text top="416" left="450" width="350" height="15" font="5">takes at least 48 to 72 hours. In patients with mechanical</text>
<text top="434" left="450" width="350" height="15" font="5">valves on long-term warfarin therapy who require emer-</text>
<text top="452" left="450" width="350" height="15" font="5">gency surgery or invasive procedures, anticoagulation can</text>
<text top="470" left="450" width="350" height="15" font="5">be reversed by administration of fresh frozen plasma or</text>
<text top="488" left="450" width="350" height="15" font="5">intravenous prothrombin complex concentrate. Adminis-</text>
<text top="505" left="450" width="350" height="15" font="5">tration of low-dose (1 mg to 2 mg) oral vitamin K may be</text>
<text top="523" left="450" width="350" height="15" font="5">added because the effect of fresh frozen plasma or pro-</text>
<text top="541" left="450" width="350" height="15" font="5">thrombin complex has a shorter half-life than the effects of</text>
<text top="559" left="450" width="350" height="15" font="5">VKA therapy. Higher doses of vitamin K are discouraged</text>
<text top="577" left="450" width="69" height="15" font="5">to avoid dif</text>
<text top="574" left="519" width="281" height="19" font="5">ﬁculty in achieving a therapeutic INR after the</text>
<text top="595" left="450" width="62" height="15" font="5">procedure.</text>
<text top="614" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="613" left="597" width="27" height="15" font="6"><a href="e57.full.html#114">(600</a></text>
<text top="610" left="625" width="35" height="19" font="6"><a href="e57.full.html#114">–602)</a></text>
<text top="632" left="465" width="18" height="15" font="5">See</text>
<text top="632" left="488" width="166" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 21</a></text>
<text top="632" left="659" width="140" height="15" font="5">for more information on</text>
<text top="650" left="450" width="98" height="15" font="5">bridging therapy.</text>
<text top="681" left="450" width="249" height="12" font="19">11.4. Excessive Anticoagulation and</text>
<text top="699" left="450" width="279" height="12" font="19">Serious Bleeding With Prosthetic Valves:</text>
<text top="717" left="450" width="117" height="12" font="19">Recommendation</text>
<text top="740" left="451" width="21" height="15" font="5">See</text>
<text top="740" left="476" width="51" height="15" font="6"><a href="e57.full.html#68">Figure 6</a></text>
<text top="740" left="532" width="241" height="15" font="5">for anticoagulation for prosthetic valves.</text>
<text top="767" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="782" left="449" width="351" height="10" font="21">1. Administration of fresh frozen plasma or prothrombin complex</text>
<text top="799" left="467" width="333" height="10" font="21">concentrate is reasonable in patients with mechanical valves</text>
<text top="815" left="467" width="332" height="10" font="21">and uncontrollable bleeding who require reversal of anti-</text>
<text top="832" left="467" width="61" height="10" font="21">coagulation</text>
<text top="832" left="532" width="55" height="10" font="22"><a href="e57.full.html#114">(601,602)</a></text>
<text top="832" left="587" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="856" left="465" width="187" height="15" font="5">Excessive anticoagulation (INR</text>
<text top="853" left="655" width="145" height="19" font="5">5) greatly increases the</text>
<text top="874" left="450" width="350" height="15" font="5">risk of hemorrhage. However, a rapid decrease in the INR</text>
<text top="892" left="450" width="350" height="15" font="5">that leads to INR falling below the therapeutic level in-</text>
<text top="910" left="450" width="350" height="15" font="5">creases the risk of thromboembolism. High-dose vitamin</text>
<text top="928" left="450" width="350" height="15" font="5">K should not be given routinely, because this may create</text>
<text top="946" left="450" width="350" height="15" font="5">a hypercoagulable condition. In most patients with an</text>
<text top="964" left="450" width="350" height="15" font="5">INR of 5 to 10, excessive anticoagulation can be managed</text>
<text top="981" left="450" width="350" height="15" font="5">by withholding VKA and monitoring the level of anti-</text>
<text top="999" left="450" width="350" height="15" font="5">coagulation with serial INR determinations. In patients</text>
<text top="1017" left="450" width="79" height="15" font="5">with an INR</text>
<text top="1014" left="535" width="265" height="19" font="5">&gt;10 who are not bleeding, it is prudent to</text>
<text top="1035" left="450" width="350" height="15" font="5">administer 1 mg to 2.5 mg of oral vitamin K1 (phytona-</text>
<text top="1053" left="450" width="350" height="15" font="5">dione) in addition to holding VKA therapy. When the</text>
<text top="1071" left="450" width="350" height="15" font="5">INR falls to a safe level, VKA therapy is restarted with the</text>
<text top="1089" left="450" width="91" height="15" font="5">dose adjusted</text>
<text top="1089" left="555" width="95" height="15" font="5">as needed to</text>
<text top="1089" left="666" width="53" height="15" font="5">maintain</text>
<text top="1089" left="733" width="66" height="15" font="5">therapeutic</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e123</text>
</page>
<page number="68" position="absolute" top="0" left="0" height="1160" width="864">
<text top="732" left="64" width="350" height="15" font="5">anticoagulation. In emergency situations, such as uncon-</text>
<text top="750" left="64" width="350" height="15" font="5">trollable bleeding, administration of fresh frozen plasma or</text>
<text top="768" left="64" width="350" height="15" font="5">prothrombin complex concentrate is reasonable because</text>
<text top="786" left="64" width="274" height="15" font="5">the onset of action of vitamin K is very slow.</text>
<text top="804" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="804" left="212" width="58" height="15" font="6"><a href="e57.full.html#114">(600,603)</a></text>
<text top="839" left="64" width="237" height="12" font="19">11.5. Thromboembolic Events With</text>
<text top="857" left="64" width="120" height="12" font="19">Prosthetic Valves</text>
<text top="884" left="64" width="214" height="15" font="5">11.5.1. Diagnosis and Follow-Up</text>
<text top="910" left="65" width="349" height="15" font="5">The annual risk of thromboembolic events in patients with</text>
<text top="928" left="64" width="350" height="15" font="5">a mechanical heart valve is 1% to 2% versus 0.7% with a</text>
<text top="946" left="64" width="350" height="15" font="5">bioprosthetic valve, even with appropriate antithrombotic</text>
<text top="964" left="64" width="350" height="15" font="5">therapy. Many complications are likely related to subop-</text>
<text top="981" left="64" width="350" height="15" font="5">timal anticoagulation; even in clinical trials, the time in</text>
<text top="999" left="64" width="350" height="15" font="5">therapeutic range for patients on VKA varies from only</text>
<text top="1017" left="64" width="350" height="15" font="5">60% to 70%. However, embolic events do occur even in</text>
<text top="1035" left="64" width="350" height="15" font="5">patients who are in the therapeutic range at every testing</text>
<text top="1053" left="64" width="350" height="15" font="5">interval. Annual follow-up in patients with prosthetic heart</text>
<text top="1071" left="64" width="350" height="15" font="5">valves should include review of the adequacy of anti-</text>
<text top="1089" left="64" width="350" height="15" font="5">coagulation and any issues related to compliance with</text>
<text top="732" left="450" width="350" height="15" font="5">medical therapy. Screening questions for symptoms that</text>
<text top="750" left="450" width="350" height="15" font="5">may be related to embolic events are especially important if</text>
<text top="768" left="450" width="350" height="15" font="5">anticoagulation has been suboptimal. Patients should be</text>
<text top="786" left="450" width="350" height="15" font="5">educated about symptoms related to embolic events and</text>
<text top="804" left="450" width="350" height="15" font="5">instructed to promptly report to a healthcare provider</text>
<text top="822" left="450" width="215" height="15" font="5">should symptoms occur. TTE is the</text>
<text top="818" left="669" width="131" height="19" font="5">ﬁrst step in evaluation</text>
<text top="840" left="450" width="350" height="15" font="5">of suspected prosthetic valve thromboembolism to evaluate</text>
<text top="858" left="450" width="350" height="15" font="5">valve hemodynamics in comparison to previous studies,</text>
<text top="875" left="450" width="350" height="15" font="5">and TEE often is needed, particularly for mitral prosthetic</text>
<text top="893" left="450" width="350" height="15" font="5">valves. However, the prosthetic valve should be considered</text>
<text top="911" left="450" width="350" height="15" font="5">the source of thromboembolism even if echocardiographic</text>
<text top="926" left="450" width="144" height="19" font="5">ﬁndings are unchanged.</text>
<text top="956" left="450" width="158" height="15" font="5">11.5.2. Medical Therapy</text>
<text top="982" left="451" width="349" height="15" font="5">In patients on VKA anticoagulation and aspirin 75 mg to</text>
<text top="999" left="450" width="319" height="15" font="5">100 mg daily for a mechanical valve who have a de</text>
<text top="996" left="769" width="31" height="19" font="5">ﬁnite</text>
<text top="1017" left="450" width="350" height="15" font="5">embolic episode, it is important to document the adequacy</text>
<text top="1035" left="450" width="350" height="15" font="5">of the anticoagulation, including the time within thera-</text>
<text top="1053" left="450" width="350" height="15" font="5">peutic range. If there have been periods in which the INR</text>
<text top="1071" left="450" width="350" height="15" font="5">has been documented to be subtherapeutic, appropriate</text>
<text top="1089" left="450" width="350" height="15" font="5">steps to ensure adequate anticoagulation should be taken.</text>
<text top="608" left="64" width="268" height="11" font="13">Figure 6. Anticoagulation for Prosthetic Valves</text>
<text top="641" left="64" width="563" height="9" font="14">Risk factors include AF, previous thromboembolism, LV dysfunction, hypercoagulable condition, and older-generation mechanical AVR.</text>
<text top="654" left="72" width="75" height="9" font="14">AF indicates atrial</text>
<text top="652" left="150" width="617" height="13" font="14">ﬁbrillation; ASA, aspirin; AVR, aortic valve replacement; INR, international normalized ratio; LMWH, low-molecular-weight heparin; MVR, mitral valve</text>
<text top="668" left="72" width="716" height="9" font="14">replacement; PO, by mouth; QD, every day; SC, subcutaneous; TAVR, transcatheter aortic valve replacement; UFH, unfractionated heparin; and VKA, vitamin K antagonist.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e124</text>
</page>
<page number="69" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">If embolic events have occurred despite a therapeutic INR</text>
<text top="121" left="64" width="350" height="15" font="5">when other contraindications are not present, a prudent</text>
<text top="139" left="64" width="232" height="15" font="5">approach to antithrombotic therapy is:</text>
<text top="162" left="82" width="332" height="19" font="5"> Increase the INR goal from 2.5 (range 2.0 to 3.0) to</text>
<text top="183" left="99" width="315" height="15" font="5">3.0 (range 2.5 to 3.5) for patients with an AVR; or,</text>
<text top="201" left="99" width="315" height="15" font="5">increase the INR goal from 3.0 (range 2.5 to 3.5) to</text>
<text top="219" left="99" width="298" height="15" font="5">4.0 (range 3.5 to 4.5) for patients with an MVR.</text>
<text top="246" left="64" width="350" height="15" font="5">In patients with a bioprosthetic valve with embolic events</text>
<text top="264" left="64" width="350" height="15" font="5">who are only on aspirin 75 mg to 100 mg daily, a possible</text>
<text top="282" left="64" width="350" height="15" font="5">approach includes consideration of anticoagulation with</text>
<text top="300" left="64" width="47" height="15" font="5">a VKA.</text>
<text top="327" left="64" width="129" height="15" font="5">11.5.3. Intervention</text>
<text top="352" left="65" width="349" height="15" font="5">Embolic events in patients with prosthetic heart valves</text>
<text top="370" left="64" width="349" height="15" font="5">should be managed by ensuring optimal anticoagulation</text>
<text top="388" left="64" width="350" height="15" font="5">and antiplatelet therapy. Measures to improve patient</text>
<text top="406" left="64" width="350" height="15" font="5">compliance, including patient education and more frequent</text>
<text top="424" left="64" width="350" height="15" font="5">monitoring, should be instituted. Studies show that pa-</text>
<text top="442" left="64" width="350" height="15" font="5">tients on anticoagulation with VKA who are managed by a</text>
<text top="460" left="64" width="350" height="15" font="5">dedicated pharmacist-led anticoagulation clinic have lower</text>
<text top="478" left="64" width="350" height="15" font="5">rates of bleeding and thromboembolism compared with</text>
<text top="496" left="64" width="243" height="15" font="5">conventional monitoring by a clinician</text>
<text top="492" left="307" width="107" height="19" font="5">’s ofﬁce. Surgical</text>
<text top="514" left="64" width="350" height="15" font="5">intervention is rarely needed for recurrent thromboembolic</text>
<text top="532" left="64" width="350" height="15" font="5">events but might be considered in some situations. In</text>
<text top="550" left="64" width="335" height="15" font="5">patients with degenerated bioprosthetic valves, calci</text>
<text top="546" left="400" width="14" height="19" font="5">ﬁc</text>
<text top="568" left="64" width="350" height="15" font="5">emboli may complicate thrombotic embolism, often in</text>
<text top="586" left="64" width="350" height="15" font="5">association with prosthetic valve stenosis and/or regurgi-</text>
<text top="603" left="64" width="350" height="15" font="5">tation. In patients with mechanical valves who have</text>
<text top="621" left="64" width="350" height="15" font="5">recurrent serious adverse effects of over- or underanti-</text>
<text top="639" left="64" width="350" height="15" font="5">coagulation despite all efforts to improve compliance,</text>
<text top="657" left="64" width="350" height="15" font="5">replacement of the mechanical valve with a bioprosthetic</text>
<text top="675" left="64" width="350" height="15" font="5">valve might be considered after a discussion of the potential</text>
<text top="693" left="64" width="87" height="15" font="5">risks and bene</text>
<text top="690" left="151" width="124" height="19" font="5">ﬁts of this approach.</text>
<text top="725" left="64" width="234" height="12" font="19">11.6. Prosthetic Valve Thrombosis</text>
<text top="748" left="65" width="21" height="15" font="5">See</text>
<text top="748" left="90" width="51" height="15" font="6"><a href="e57.full.html#70">Figure 7</a></text>
<text top="748" left="146" width="268" height="15" font="5">for evaluation and management of suspected</text>
<text top="766" left="64" width="104" height="15" font="5">valve thrombosis.</text>
<text top="792" left="64" width="340" height="15" font="5">11.6.1. Diagnosis and Follow-Up: Recommendations</text>
<text top="820" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="835" left="64" width="350" height="10" font="21">1. TTE is indicated in patients with suspected prosthetic valve</text>
<text top="851" left="82" width="332" height="10" font="21">thrombosis to assess hemodynamic severity and follow resolu-</text>
<text top="868" left="82" width="130" height="10" font="21">tion of valve dysfunction</text>
<text top="868" left="215" width="55" height="10" font="22"><a href="e57.full.html#114">(604,605)</a></text>
<text top="868" left="270" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="892" left="79" width="335" height="15" font="5">Obstruction of prosthetic heart valves may be caused by</text>
<text top="910" left="64" width="350" height="15" font="5">thrombus formation, pannus ingrowth, or a combination</text>
<text top="928" left="64" width="350" height="15" font="5">of both. Mechanical prosthetic heart valve thrombosis has a</text>
<text top="946" left="64" width="350" height="15" font="5">prevalence of only 0.3% to 1.3% per patient-year in</text>
<text top="964" left="64" width="349" height="15" font="5">developed countries but is as high as 6.1% per patient-year</text>
<text top="981" left="64" width="350" height="15" font="5">in developing countries. Bioprosthetic valve thrombosis is</text>
<text top="999" left="64" width="350" height="15" font="5">less common. Differentiation of valve dysfunction due to</text>
<text top="1017" left="64" width="98" height="15" font="5">thrombus versus</text>
<text top="1014" left="168" width="246" height="19" font="5">ﬁbrous tissue ingrowth (pannus) is chal-</text>
<text top="1035" left="64" width="350" height="15" font="5">lenging because the clinical presentations are similar.</text>
<text top="1053" left="64" width="350" height="15" font="5">Thrombus is more likely when there is a history of inad-</text>
<text top="1071" left="64" width="350" height="15" font="5">equate anticoagulation and with more acute onset of valve</text>
<text top="1089" left="64" width="230" height="15" font="5">dysfunction and symptoms. Although</text>
<text top="1086" left="301" width="113" height="19" font="5">ﬂuoroscopy or CT</text>
<text top="103" left="450" width="244" height="15" font="5">imaging can be used to evaluate the lea</text>
<text top="99" left="694" width="106" height="19" font="5">ﬂet motion of an</text>
<text top="121" left="450" width="350" height="15" font="5">obstructed mechanical prosthesis, the etiology and hemo-</text>
<text top="139" left="450" width="350" height="15" font="5">dynamic impact are best evaluated by echocardiography.</text>
<text top="157" left="450" width="350" height="15" font="5">TTE allows evaluation of valve hemodynamics and</text>
<text top="175" left="450" width="283" height="15" font="5">detection of valve stenosis or regurgitation. Lea</text>
<text top="171" left="733" width="67" height="19" font="5">ﬂet motion</text>
<text top="193" left="450" width="350" height="15" font="5">and thrombus may be visualized in some patients, but</text>
<text top="210" left="450" width="350" height="15" font="5">TEE is more sensitive for detection of valve thrombosis,</text>
<text top="228" left="450" width="350" height="15" font="5">especially of the mitral valve. Transthoracic imaging also</text>
<text top="246" left="450" width="350" height="15" font="5">allows measurement of LV size and systolic function, left</text>
<text top="264" left="450" width="350" height="15" font="5">atrial size, right heart function, and an estimation of pul-</text>
<text top="282" left="450" width="107" height="15" font="5">monary pressures.</text>
<text top="300" left="465" width="335" height="15" font="5">Clinical evaluation, including auscultation of dimin-</text>
<text top="318" left="450" width="350" height="15" font="5">ished or abolished clicks together with new systolic or</text>
<text top="336" left="450" width="153" height="15" font="5">diastolic murmurs, is the</text>
<text top="333" left="609" width="190" height="19" font="5">ﬁrst step in the routine assess-</text>
<text top="354" left="450" width="350" height="15" font="5">ment of patients with a prosthetic heart valve but is un-</text>
<text top="372" left="450" width="350" height="15" font="5">reliable for detection of valve thrombosis. TTE allows</text>
<text top="390" left="450" width="350" height="15" font="5">detection of prosthetic valve dysfunction and quantita-</text>
<text top="408" left="450" width="350" height="15" font="5">tion of stenosis and regurgitation but is inadequate for</text>
<text top="426" left="450" width="350" height="15" font="5">evaluation of the presence and size of thrombus or valve</text>
<text top="444" left="450" width="102" height="15" font="5">occluder motion.</text>
<text top="469" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="484" left="449" width="351" height="10" font="21">2. TEE is indicated in patients with suspected prosthetic</text>
<text top="501" left="467" width="333" height="10" font="21">valve thrombosis to assess thrombus size and valve motion</text>
<text top="517" left="467" width="26" height="10" font="22"><a href="e57.full.html#114">(605</a></text>
<text top="514" left="493" width="32" height="16" font="22"><a href="e57.full.html#114">–607)</a></text>
<text top="517" left="524" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="541" left="465" width="335" height="15" font="5">TEE allows direct imaging of mechanical valve</text>
<text top="559" left="450" width="350" height="15" font="5">thrombosis, particularly for thrombi on the left atrial</text>
<text top="577" left="450" width="350" height="15" font="5">side of the mitral valve, which is obscured by shadowing</text>
<text top="595" left="450" width="275" height="15" font="5">on TTE imaging. Compared with chronic</text>
<text top="592" left="732" width="67" height="19" font="5">ﬁbrous in-</text>
<text top="613" left="450" width="350" height="15" font="5">growth or pannus, thrombi tend to be larger, less dense,</text>
<text top="631" left="450" width="350" height="15" font="5">and more mobile than pannus on ultrasound imaging.</text>
<text top="649" left="450" width="279" height="15" font="5">Thrombus size, measured on TEE, is a signi</text>
<text top="645" left="729" width="70" height="19" font="5">ﬁcant inde-</text>
<text top="667" left="450" width="350" height="15" font="5">pendent predictor of outcome after thrombolysis of an</text>
<text top="685" left="450" width="350" height="15" font="5">obstructed prosthetic heart valve. Multivariate analysis</text>
<text top="703" left="450" width="350" height="15" font="5">of 107 patients with thrombosed heart valve prostheses</text>
<text top="721" left="450" width="350" height="15" font="5">revealed that prior history of stroke (OR: 4.55; 95%</text>
<text top="739" left="450" width="350" height="15" font="5">CI: 1.35 to 15.38) and thrombus area by TEE (OR: 2.41</text>
<text top="756" left="450" width="67" height="15" font="5">per 1.0 cm</text>
<text top="753" left="516" width="6" height="10" font="14">2</text>
<text top="756" left="522" width="278" height="15" font="5">; CI: 1.12 to 5.19) were independent predic-</text>
<text top="774" left="450" width="350" height="15" font="5">tors of complications after thrombolysis. A thrombus</text>
<text top="792" left="450" width="24" height="15" font="5">area</text>
<text top="789" left="480" width="55" height="19" font="5">&lt;0.8 cm</text>
<text top="789" left="534" width="6" height="10" font="14">2</text>
<text top="792" left="546" width="34" height="15" font="5">identi</text>
<text top="789" left="580" width="219" height="19" font="5">ﬁed patients at lower risk for com-</text>
<text top="810" left="450" width="350" height="15" font="5">plications from thrombolysis, irrespective of NYHA clas-</text>
<text top="828" left="450" width="9" height="15" font="5">si</text>
<text top="825" left="459" width="340" height="19" font="5">ﬁcation. TEE should be used to identify lower-risk</text>
<text top="846" left="450" width="154" height="15" font="5">patients for thrombolysis.</text>
<text top="865" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="864" left="597" width="27" height="15" font="6"><a href="e57.full.html#114">(605</a></text>
<text top="861" left="625" width="35" height="19" font="6"><a href="e57.full.html#114">–607)</a></text>
<text top="890" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="905" left="449" width="351" height="10" font="21">1. Fluoroscopy or CT is reasonable in patients with suspected valve</text>
<text top="921" left="467" width="295" height="12" font="21">thrombosis to assess valve motion. (Level of Evidence: C)</text>
<text top="945" left="465" width="335" height="15" font="5">Fluoroscopy and CT are alternative imaging techniques</text>
<text top="963" left="450" width="212" height="15" font="5">for evaluation of mechanical valve</text>
<text top="960" left="668" width="131" height="19" font="5">“leaﬂet” motion, par-</text>
<text top="981" left="450" width="350" height="15" font="5">ticularly in patients with prosthetic aortic valves, which</text>
<text top="999" left="450" width="39" height="15" font="5">are dif</text>
<text top="996" left="489" width="311" height="19" font="5">ﬁcult to image by either TTE or TEE. CT is best</text>
<text top="1017" left="450" width="350" height="15" font="5">suited for measurement of valve opening angles because</text>
<text top="1035" left="450" width="350" height="15" font="5">3D image acquisition allows postacquisition analysis from</text>
<text top="1053" left="450" width="350" height="15" font="5">multiple views. CT imaging may also allow visualization</text>
<text top="1071" left="450" width="350" height="15" font="5">of pannus or thrombus in patients with mechanical or</text>
<text top="1089" left="450" width="120" height="15" font="5">bioprosthetic valves.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e125</text>
</page>
<page number="70" position="absolute" top="0" left="0" height="1160" width="864">
<text top="801" left="64" width="284" height="15" font="5">11.6.2. Medical Therapy: Recommendations</text>
<text top="833" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="853" left="64" width="350" height="10" font="21">1. Fibrinolytic therapy is reasonable for patients with a throm-</text>
<text top="869" left="82" width="280" height="10" font="21">bosed left-sided prosthetic heart valve, recent onset (</text>
<text top="866" left="362" width="53" height="16" font="21">&lt;14 days)</text>
<text top="885" left="82" width="280" height="10" font="21">of NYHA class I to II symptoms, and a small thrombus (</text>
<text top="882" left="362" width="43" height="16" font="21">&lt;0.8 cm</text>
<text top="883" left="404" width="5" height="7" font="25">2</text>
<text top="885" left="409" width="4" height="10" font="21">)</text>
<text top="902" left="82" width="55" height="10" font="22"><a href="e57.full.html#114">(605,608)</a></text>
<text top="902" left="137" width="121" height="12" font="21"><a href="e57.full.html#114">. </a>(Level of Evidence: B)</text>
<text top="926" left="79" width="57" height="15" font="5">Although</text>
<text top="923" left="142" width="272" height="19" font="5">ﬁbrinolytic therapy of a left-sided obstructed</text>
<text top="944" left="64" width="350" height="15" font="5">prosthetic heart valve is associated with an overall rate of</text>
<text top="962" left="64" width="350" height="15" font="5">thromboembolism and bleeding of 17.8%, the degree of</text>
<text top="980" left="64" width="350" height="15" font="5">risk is directly related to thrombus size. When thrombus</text>
<text top="998" left="64" width="350" height="15" font="5">area is measured in the 2D TEE view showing the largest</text>
<text top="1016" left="64" width="225" height="15" font="5">thrombus size, an area of 0.8 cm</text>
<text top="1013" left="289" width="6" height="10" font="14">2</text>
<text top="1016" left="303" width="111" height="15" font="5">provides a useful</text>
<text top="1034" left="64" width="350" height="15" font="5">breakpoint for clinical decision making. A mobile throm-</text>
<text top="1052" left="64" width="92" height="15" font="5">bus or a length</text>
<text top="1048" left="161" width="253" height="19" font="5">&gt;5 mm to 10 mm is also associated with</text>
<text top="1070" left="64" width="350" height="15" font="5">increased embolic risk. Patients with a small thrombus</text>
<text top="1088" left="64" width="5" height="15" font="5">(</text>
<text top="1084" left="69" width="209" height="19" font="5">&lt;1.0 cm in diameter or 0.8 cm</text>
<text top="1085" left="278" width="6" height="10" font="14">2</text>
<text top="1088" left="291" width="123" height="15" font="5">in area) have fewer</text>
<text top="801" left="450" width="350" height="15" font="5">thrombolysis-related complications, whereas those with</text>
<text top="819" left="450" width="114" height="15" font="5">a large thrombus (</text>
<text top="816" left="564" width="178" height="19" font="5">&gt;1.0 cm diameter or 0.8 cm</text>
<text top="816" left="742" width="6" height="10" font="14">2</text>
<text top="819" left="753" width="46" height="15" font="5">in area)</text>
<text top="837" left="450" width="63" height="15" font="5">have a 2.4</text>
<text top="834" left="513" width="281" height="19" font="5">–fold higher rate of complications per 1.0 cm</text>
<text top="834" left="794" width="6" height="10" font="14">2</text>
<text top="855" left="450" width="350" height="15" font="5">increase in size. Factors that identify patients at risk for</text>
<text top="873" left="450" width="128" height="15" font="5">adverse outcomes of</text>
<text top="870" left="585" width="215" height="19" font="5">ﬁbrinolytic therapy include active</text>
<text top="891" left="450" width="350" height="15" font="5">internal bleeding, history of hemorrhagic stroke, recent</text>
<text top="909" left="450" width="350" height="15" font="5">cranial trauma or neoplasm, diabetic hemorrhagic reti-</text>
<text top="927" left="450" width="350" height="15" font="5">nopathy, large thrombi, mobile thrombi, systemic hy-</text>
<text top="945" left="450" width="75" height="15" font="5">pertension (</text>
<text top="941" left="525" width="274" height="19" font="5">&gt;200 mm Hg/120 mm Hg), hypotension or</text>
<text top="963" left="450" width="275" height="15" font="5">shock, and NYHA class III to IV symptoms.</text>
<text top="981" left="465" width="335" height="15" font="5">With mild symptoms due to aortic or mitral valve</text>
<text top="999" left="450" width="350" height="15" font="5">thrombosis with a small thrombus burden, it is prudent to</text>
<text top="1017" left="450" width="350" height="15" font="5">reassess after several days of intravenous UFH. If valve</text>
<text top="1035" left="450" width="119" height="15" font="5">thrombosis persists,</text>
<text top="1031" left="574" width="226" height="19" font="5">ﬁbrinolysis with a recombinant tissue</text>
<text top="1052" left="450" width="350" height="15" font="5">plasminogen activator dose of a 10 mg IV bolus followed</text>
<text top="1070" left="450" width="350" height="15" font="5">by 90 mg infused IV over 2 hours is reasonable. Heparin</text>
<text top="1088" left="450" width="350" height="15" font="5">and glycoprotein IIb/IIIa inhibitors are held, but aspirin</text>
<text top="685" left="64" width="461" height="11" font="13">Figure 7. Evaluation and Management of Suspected Prosthetic Valve Thrombosis</text>
<text top="717" left="64" width="169" height="9" font="14">*See text for dosage recommendations.</text>
<text top="730" left="72" width="695" height="9" font="14">CT indicates computed tomography; IV, intravenous; NYHA, New York Heart Association; Rx, therapy; TEE, transesophageal echocardiography; and TTE, transthoracic</text>
<text top="744" left="72" width="76" height="9" font="14">echocardiography.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e126</text>
</page>
<page number="71" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">can be continued. A lower tissue plasminogen activator</text>
<text top="121" left="64" width="350" height="15" font="5">dose of a 20 mg IV bolus followed by 10 mg per hour</text>
<text top="139" left="64" width="350" height="15" font="5">for 3 hours may be appropriate in some situations. Alter-</text>
<text top="157" left="64" width="350" height="15" font="5">natively, streptokinase may be used with a loading dose of</text>
<text top="175" left="64" width="350" height="15" font="5">500,000 IU in 20 minutes followed by 1,500,000 IU over</text>
<text top="192" left="64" width="350" height="15" font="5">10 hours. Urokinase is less effective than tissue plasmin-</text>
<text top="210" left="64" width="211" height="15" font="5">ogen activator or streptokinase. If</text>
<text top="207" left="282" width="132" height="19" font="5">ﬁbrinolytic therapy is</text>
<text top="228" left="64" width="350" height="15" font="5">successful, it is followed by intravenous UFH until VKA</text>
<text top="246" left="64" width="350" height="15" font="5">achieves an INR of 3.0 to 4.0 for aortic prosthetic valves</text>
<text top="264" left="64" width="350" height="15" font="5">and 3.5 to 4.5 for mitral prosthetic valves. A structured</text>
<text top="282" left="64" width="350" height="15" font="5">institutional protocol with indications, contraindications,</text>
<text top="300" left="64" width="68" height="15" font="5">and a speci</text>
<text top="297" left="132" width="281" height="19" font="5">ﬁc timeline for medication administration and</text>
<text top="318" left="64" width="221" height="15" font="5">patient monitoring is recommended.</text>
<text top="336" left="79" width="335" height="15" font="5">After treatment of the acute thrombotic event, it is</text>
<text top="354" left="64" width="350" height="15" font="5">important to always determine the adequacy of anti-</text>
<text top="372" left="64" width="350" height="15" font="5">coagulation before the event and ensure that there is</text>
<text top="390" left="64" width="349" height="15" font="5">meticulous follow-up after the event. The anticoagulation</text>
<text top="408" left="64" width="239" height="15" font="5">regimen can be increased as outlined in</text>
<text top="408" left="309" width="87" height="15" font="6"><a href="e57.full.html#68">Section 11.5.2</a></text>
<text top="408" left="395" width="4" height="15" font="5">.</text>
<text top="426" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="426" left="212" width="58" height="15" font="6"><a href="e57.full.html#114">(609,610)</a></text>
<text top="453" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="468" left="63" width="351" height="10" font="21">2. Fibrinolytic therapy is reasonable for thrombosed right-sided</text>
<text top="484" left="81" width="122" height="10" font="21">prosthetic heart valves</text>
<text top="484" left="207" width="55" height="10" font="22"><a href="e57.full.html#114">(611,612)</a></text>
<text top="484" left="262" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="509" left="79" width="335" height="15" font="5">In nonrandomized, retrospective cohorts of thrombosed</text>
<text top="526" left="64" width="313" height="15" font="5">mechanical or biological tricuspid valve prostheses,</text>
<text top="523" left="384" width="30" height="19" font="5">ﬁbri-</text>
<text top="544" left="64" width="349" height="15" font="5">nolysis was as successful in normalization of hemody-</text>
<text top="562" left="64" width="251" height="15" font="5">namics as surgical intervention. With</text>
<text top="559" left="326" width="87" height="19" font="5">ﬁbrinolysis of</text>
<text top="580" left="64" width="350" height="15" font="5">right-sided valve thrombosis, the resultant small pulmo-</text>
<text top="598" left="64" width="350" height="15" font="5">nary emboli appear to be well tolerated and systemic</text>
<text top="616" left="64" width="140" height="15" font="5">emboli are uncommon.</text>
<text top="635" left="79" width="18" height="15" font="5">See</text>
<text top="635" left="103" width="166" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 22</a></text>
<text top="635" left="274" width="140" height="15" font="5">for more information on</text>
<text top="649" left="64" width="110" height="19" font="5">ﬁbrinolytic therapy.</text>
<text top="685" left="64" width="255" height="15" font="5">11.6.3. Intervention: Recommendations</text>
<text top="712" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="727" left="64" width="350" height="10" font="21">1. Emergency surgery is recommended for patients with a throm-</text>
<text top="743" left="82" width="332" height="10" font="21">bosed left-sided prosthetic heart valve with NYHA class III to IV</text>
<text top="760" left="82" width="54" height="10" font="21">symptoms</text>
<text top="760" left="140" width="80" height="10" font="22"><a href="e57.full.html#114">(610,611,613)</a></text>
<text top="760" left="220" width="121" height="12" font="21"><a href="e57.full.html#114">. </a>(Level of Evidence: B)</text>
<text top="784" left="79" width="335" height="15" font="5">Prompt surgical treatment of a thrombosed prosthetic</text>
<text top="802" left="64" width="350" height="15" font="5">heart valve is an effective treatment to ameliorate clinical</text>
<text top="820" left="64" width="350" height="15" font="5">symptoms and restore normal hemodynamics, with a</text>
<text top="838" left="64" width="350" height="15" font="5">success rate close to 90% in patients who do not have a</text>
<text top="856" left="64" width="350" height="15" font="5">contraindication to surgical intervention. In contrast, a</text>
<text top="874" left="64" width="350" height="15" font="5">meta-analysis of 7 studies that included 690 episodes of</text>
<text top="892" left="64" width="350" height="15" font="5">left-sided prosthetic valve thrombosis showed a success</text>
<text top="910" left="64" width="350" height="15" font="5">rate for restoring normal valve function of only about</text>
<text top="928" left="64" width="184" height="15" font="5">70% in 244 cases treated with</text>
<text top="924" left="253" width="161" height="19" font="5">ﬁbrinolytic therapy. There</text>
<text top="946" left="64" width="350" height="15" font="5">was no difference in mortality between surgical and</text>
<text top="960" left="64" width="350" height="19" font="5">ﬁbrinolytic therapy for left-sided prosthetic valve</text>
<text top="981" left="64" width="350" height="15" font="5">thrombosis, but in addition to a higher success rate for</text>
<text top="999" left="64" width="350" height="15" font="5">restoring normal valve function, surgery was associated with</text>
<text top="1017" left="64" width="350" height="15" font="5">lower rates of thromboembolism (1.6% versus 16%), major</text>
<text top="1035" left="64" width="350" height="15" font="5">bleeding (1.4% versus 5%), and recurrent prosthetic valve</text>
<text top="1053" left="64" width="350" height="15" font="5">thrombosis (7.1% versus 25.4%). Although RCTs have</text>
<text top="1071" left="64" width="350" height="15" font="5">not been performed, the weight of the evidence favors</text>
<text top="1089" left="64" width="350" height="15" font="5">surgical intervention for left-sided prosthetic valve thrombosis</text>
<text top="103" left="450" width="350" height="15" font="5">unless the patient is asymptomatic and the thrombus</text>
<text top="121" left="450" width="97" height="15" font="5">burden is small.</text>
<text top="139" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="139" left="598" width="85" height="15" font="6"><a href="e57.full.html#114">(605,613,614)</a></text>
<text top="166" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="181" left="449" width="351" height="10" font="21">1. Emergency surgery is reasonable for patients with a throm-</text>
<text top="197" left="467" width="332" height="10" font="21">bosed left-sided prosthetic heart valve with a mobile or large</text>
<text top="214" left="467" width="58" height="10" font="21">thrombus (</text>
<text top="211" left="525" width="44" height="16" font="21">&gt;0.8 cm</text>
<text top="211" left="569" width="5" height="7" font="25">2</text>
<text top="214" left="574" width="4" height="10" font="21">)</text>
<text top="214" left="583" width="80" height="10" font="22"><a href="e57.full.html#114">(605,607,610)</a></text>
<text top="214" left="662" width="120" height="12" font="21">. (Level of Evidence: C)</text>
<text top="238" left="465" width="335" height="15" font="5">Prompt surgical treatment of a thrombosed prosthetic</text>
<text top="256" left="450" width="350" height="15" font="5">heart valve is associated with a relatively low rate of mor-</text>
<text top="274" left="450" width="350" height="15" font="5">tality. In a retrospective study of 106 surgeries for</text>
<text top="292" left="450" width="350" height="15" font="5">obstructed left-sided prosthetic heart valves, the mortality</text>
<text top="310" left="450" width="350" height="15" font="5">rate was 17.5% for patients with NYHA class IV symp-</text>
<text top="328" left="450" width="350" height="15" font="5">toms and 4.7% in those patients with NYHA class I to III</text>
<text top="346" left="450" width="350" height="15" font="5">symptoms. Mortality was similar for removing the</text>
<text top="364" left="450" width="350" height="15" font="5">thrombus or replacing the entire prosthetic valve. Patients</text>
<text top="382" left="450" width="350" height="15" font="5">with large, mobile clots that extend beyond the prosthesis</text>
<text top="399" left="450" width="277" height="15" font="5">are better suited for surgical intervention than</text>
<text top="396" left="731" width="68" height="19" font="5">ﬁbrinolysis,</text>
<text top="417" left="450" width="184" height="15" font="5">which is associated with signi</text>
<text top="414" left="634" width="165" height="19" font="5">ﬁcant risk of systemic em-</text>
<text top="435" left="450" width="350" height="15" font="5">bolism. In 1 report, in which patients with small throm-</text>
<text top="453" left="450" width="81" height="15" font="5">bus burden (</text>
<text top="450" left="531" width="55" height="19" font="5">&lt;0.8 cm</text>
<text top="450" left="587" width="6" height="10" font="14">2</text>
<text top="453" left="600" width="200" height="15" font="5">on TEE imaging) had minimal</text>
<text top="471" left="450" width="350" height="15" font="5">thrombolysis-related complications, those with large</text>
<text top="489" left="450" width="112" height="15" font="5">thrombus burden (</text>
<text top="486" left="562" width="52" height="19" font="5">0.8 cm</text>
<text top="486" left="614" width="6" height="10" font="14">2</text>
<text top="489" left="620" width="64" height="15" font="5">) had a 2.4</text>
<text top="486" left="684" width="115" height="19" font="5">–fold higher rate of</text>
<text top="507" left="450" width="151" height="15" font="5">complications per 1.0 cm</text>
<text top="504" left="601" width="6" height="10" font="14">2</text>
<text top="507" left="611" width="189" height="15" font="5">increase in size, making surgery</text>
<text top="525" left="450" width="350" height="15" font="5">the optimal intervention. In patients with recent hemor-</text>
<text top="543" left="450" width="350" height="15" font="5">rhagic stroke, surgery is a better choice because of the</text>
<text top="561" left="450" width="178" height="15" font="5">bleeding risks associated with</text>
<text top="557" left="633" width="68" height="19" font="5">ﬁbrinolysis.</text>
<text top="606" left="450" width="217" height="12" font="19">11.7. Prosthetic Valve Stenosis</text>
<text top="633" left="450" width="214" height="15" font="5">11.7.1. Diagnosis and Follow-Up</text>
<text top="659" left="451" width="349" height="15" font="5">Reoperation to replace a prosthetic heart valve is a serious</text>
<text top="677" left="450" width="350" height="15" font="5">clinical event. It is usually required for moderate-to-</text>
<text top="695" left="450" width="350" height="15" font="5">severe prosthetic dysfunction (structural and nonstruc-</text>
<text top="712" left="450" width="350" height="15" font="5">tural), dehiscence, and prosthetic valve endocarditis</text>
<text top="730" left="450" width="350" height="15" font="5">(PVE). Causes of prosthetic valve stenosis that might</text>
<text top="748" left="450" width="350" height="15" font="5">require reoperation with a mechanical valve include</text>
<text top="766" left="450" width="350" height="15" font="5">chronic thrombus or pannus impinging on normal leaf-</text>
<text top="784" left="450" width="330" height="15" font="5">let occluder motion; for a bioprosthetic valve, lea</text>
<text top="781" left="780" width="20" height="19" font="5">ﬂet</text>
<text top="799" left="450" width="350" height="19" font="5">ﬁbrosis and calciﬁcation are the most common causes.</text>
<text top="820" left="450" width="350" height="15" font="5">Reoperation may also be needed for recurrent thrombo-</text>
<text top="838" left="450" width="350" height="15" font="5">embolism, severe intravascular hemolysis, severe recurrent</text>
<text top="856" left="450" width="350" height="15" font="5">bleeding from anticoagulant therapy, and thrombosed</text>
<text top="874" left="450" width="102" height="15" font="5">prosthetic valves.</text>
<text top="892" left="465" width="335" height="15" font="5">In some patients, the size of the prosthetic valve that</text>
<text top="910" left="450" width="269" height="15" font="5">can be implanted results in inadequate blood</text>
<text top="906" left="724" width="76" height="19" font="5">ﬂow to meet</text>
<text top="928" left="450" width="350" height="15" font="5">the metabolic demands of the patient, even when the</text>
<text top="946" left="450" width="350" height="15" font="5">prosthetic valve itself is functioning normally. This situa-</text>
<text top="964" left="450" width="68" height="15" font="5">tion, called</text>
<text top="960" left="524" width="275" height="19" font="5">“patient-prosthesis mismatch” (deﬁned as an</text>
<text top="981" left="450" width="119" height="15" font="5">indexed effective ori</text>
<text top="978" left="569" width="111" height="19" font="5">ﬁce area 0.85 cm</text>
<text top="978" left="680" width="6" height="10" font="14">2</text>
<text top="981" left="686" width="17" height="15" font="5">/m</text>
<text top="978" left="703" width="6" height="10" font="14">2</text>
<text top="981" left="713" width="87" height="15" font="5">for aortic valve</text>
<text top="999" left="450" width="350" height="15" font="5">prostheses), is a predictor of a high transvalvular gradient,</text>
<text top="1017" left="450" width="350" height="15" font="5">persistent LV hypertrophy, and an increased rate of cardiac</text>
<text top="1035" left="450" width="350" height="15" font="5">events after AVR. The impact of a relatively small valve</text>
<text top="1053" left="450" width="350" height="15" font="5">area is most noticeable with severe patient-prosthesis</text>
<text top="1071" left="450" width="87" height="15" font="5">mismatch, de</text>
<text top="1068" left="537" width="229" height="19" font="5">ﬁned as an oriﬁce area &lt;0.65 cm</text>
<text top="1068" left="766" width="6" height="10" font="14">2</text>
<text top="1071" left="772" width="17" height="15" font="5">/m</text>
<text top="1068" left="790" width="6" height="10" font="14">2</text>
<text top="1071" left="796" width="4" height="15" font="5">.</text>
<text top="1089" left="450" width="350" height="15" font="5">Patient-prosthesis mismatch is especially detrimental in</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e127</text>
</page>
<page number="72" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">patients with reduced LVEF and may decrease the likeli-</text>
<text top="121" left="64" width="350" height="15" font="5">hood of resolution of symptoms and improvement in</text>
<text top="139" left="64" width="350" height="15" font="5">LVEF. Patient-prosthesis mismatch can be avoided or</text>
<text top="157" left="64" width="350" height="15" font="5">reduced by choosing a valve prosthesis that will have an</text>
<text top="175" left="64" width="135" height="15" font="5">adequate indexed ori</text>
<text top="171" left="199" width="215" height="19" font="5">ﬁce area, based on the patient’s</text>
<text top="192" left="64" width="350" height="15" font="5">body size and annular dimension. In some cases, annular</text>
<text top="210" left="64" width="350" height="15" font="5">enlargement or other approaches may be needed to</text>
<text top="228" left="64" width="350" height="15" font="5">allow implantation of an appropriately sized valve or</text>
<text top="246" left="64" width="259" height="15" font="5">avoidance of a prosthetic valve. With bilea</text>
<text top="243" left="323" width="91" height="19" font="5">ﬂet mechanical</text>
<text top="264" left="64" width="147" height="15" font="5">valves, patterns of blood</text>
<text top="261" left="217" width="197" height="19" font="5">ﬂow are complex and signiﬁcant</text>
<text top="282" left="64" width="350" height="15" font="5">pressure recovery may be present; this may result in a high</text>
<text top="300" left="64" width="350" height="15" font="5">velocity across the prosthesis that should not be mis-</text>
<text top="318" left="64" width="350" height="15" font="5">taken for prosthetic valve stenosis or patient-prosthesis</text>
<text top="336" left="64" width="62" height="15" font="5">mismatch.</text>
<text top="354" left="79" width="335" height="15" font="5">In patients with bioprosthetic valves who show evidence</text>
<text top="372" left="64" width="350" height="15" font="5">of prosthetic valve stenosis, TTE is used to monitor the</text>
<text top="390" left="64" width="163" height="15" font="5">appearance of the valve lea</text>
<text top="386" left="227" width="186" height="19" font="5">ﬂets, valve hemodynamics, LV</text>
<text top="408" left="64" width="350" height="15" font="5">size, and systolic function, and to estimate pulmonary</text>
<text top="426" left="64" width="350" height="15" font="5">pressures. Transthoracic imaging is usually adequate, with</text>
<text top="444" left="64" width="350" height="15" font="5">TEE imaging reserved for patients with poor-quality im-</text>
<text top="461" left="64" width="255" height="15" font="5">ages. In patients with mechanical valves,</text>
<text top="458" left="327" width="87" height="19" font="5">ﬂuoroscopy or</text>
<text top="479" left="64" width="350" height="15" font="5">CT imaging can be helpful for showing disc motion.</text>
<text top="497" left="64" width="350" height="15" font="5">CT may also visualize paravalvular pannus formation</text>
<text top="515" left="64" width="280" height="15" font="5">with either bioprosthetic or mechanical valves.</text>
<text top="534" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="533" left="212" width="137" height="15" font="6"><a href="e57.full.html#112">(527,528,544,615,616)</a></text>
<text top="560" left="64" width="158" height="15" font="5">11.7.2. Medical Therapy</text>
<text top="586" left="65" width="349" height="15" font="5">There are no medical therapies known to prevent bio-</text>
<text top="603" left="64" width="350" height="15" font="5">prosthetic valve degeneration other than those integrated</text>
<text top="621" left="64" width="350" height="15" font="5">into the valve design. Medical therapy is not effective for</text>
<text top="639" left="64" width="218" height="15" font="5">treatment of symptoms due to signi</text>
<text top="636" left="283" width="131" height="19" font="5">ﬁcant prosthetic valve</text>
<text top="657" left="64" width="350" height="15" font="5">stenosis, except with valve thrombosis, but standard</text>
<text top="675" left="64" width="350" height="15" font="5">medical therapy may help stabilize patients before surgical</text>
<text top="693" left="64" width="350" height="15" font="5">intervention and may be used for palliative care in patients</text>
<text top="711" left="64" width="193" height="15" font="5">who are not surgical candidates.</text>
<text top="738" left="64" width="249" height="15" font="5">11.7.3. Intervention: Recommendation</text>
<text top="765" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="780" left="64" width="350" height="10" font="21">1. Repeat valve replacement is indicated for severe symptomatic</text>
<text top="797" left="82" width="253" height="12" font="21">prosthetic valve stenosis. (Level of Evidence: C)</text>
<text top="821" left="79" width="335" height="15" font="5">The indications for surgical intervention for prosthetic</text>
<text top="839" left="64" width="350" height="15" font="5">valve stenosis are the same as those for native stenosis of</text>
<text top="857" left="64" width="350" height="15" font="5">the aortic or mitral valve. Surgery is primarily needed for</text>
<text top="875" left="64" width="350" height="15" font="5">bioprosthetic valve degeneration. In this situation, the</text>
<text top="893" left="64" width="350" height="15" font="5">choice of a new valve prosthesis depends on the same</text>
<text top="911" left="64" width="279" height="15" font="5">factors as those for patients undergoing a</text>
<text top="907" left="351" width="62" height="19" font="5">ﬁrst valve</text>
<text top="928" left="64" width="350" height="15" font="5">replacement. The use of transcatheter valve prostheses to</text>
<text top="946" left="64" width="250" height="15" font="5">treat bioprosthetic valve stenosis with a</text>
<text top="943" left="322" width="92" height="19" font="5">“valve-in-valve”</text>
<text top="964" left="64" width="298" height="15" font="5">approach is promising but not yet fully validated.</text>
<text top="982" left="79" width="335" height="15" font="5">Mechanical valve stenosis is rare and typically due to</text>
<text top="1000" left="64" width="350" height="15" font="5">valve thrombosis or pannus formation. If patient non-</text>
<text top="1018" left="64" width="350" height="15" font="5">compliance contributed to valve thrombosis, it is prudent</text>
<text top="1036" left="64" width="350" height="15" font="5">to consider a bioprosthetic valve at the time of reopera-</text>
<text top="1054" left="64" width="350" height="15" font="5">tion. With attention to optimal valve selection, a second</text>
<text top="1072" left="64" width="154" height="15" font="5">surgical procedure for signi</text>
<text top="1069" left="218" width="196" height="19" font="5">ﬁcant patient-prosthesis mismatch</text>
<text top="103" left="450" width="350" height="15" font="5">is rarely needed and should be considered only if a larger</text>
<text top="121" left="450" width="350" height="15" font="5">prosthetic valve or a valve type with better hemodynamics</text>
<text top="139" left="450" width="108" height="15" font="5">can be implanted.</text>
<text top="176" left="450" width="250" height="12" font="19">11.8. Prosthetic Valve Regurgitation</text>
<text top="206" left="450" width="214" height="15" font="5">11.8.1. Diagnosis and Follow-Up</text>
<text top="231" left="451" width="349" height="15" font="5">In patients with bioprosthetic valves who show evidence of</text>
<text top="249" left="450" width="350" height="15" font="5">prosthetic valve regurgitation, TTE is used to monitor the</text>
<text top="267" left="450" width="164" height="15" font="5">appearance of the valve lea</text>
<text top="264" left="613" width="186" height="19" font="5">ﬂets, valve hemodynamics, LV</text>
<text top="285" left="450" width="350" height="15" font="5">size, and systolic function, and to estimate pulmonary</text>
<text top="303" left="450" width="350" height="15" font="5">pressures. The initial approach is TTE for evaluation of</text>
<text top="321" left="450" width="350" height="15" font="5">antegrade valve velocities and pressure gradients. However,</text>
<text top="339" left="450" width="350" height="15" font="5">TEE is essential for evaluation of suspected or known</text>
<text top="357" left="450" width="350" height="15" font="5">prosthetic mitral valve regurgitation. On TTE imaging, the</text>
<text top="375" left="450" width="350" height="15" font="5">LA is shadowed by the valve prosthesis, obscuring evi-</text>
<text top="393" left="450" width="350" height="15" font="5">dence of prosthetic regurgitation. TEE imaging provides</text>
<text top="411" left="450" width="350" height="15" font="5">clear images of the left atrial side of the mitral prosthesis</text>
<text top="429" left="450" width="350" height="15" font="5">and is particularly useful for delineation of the site and</text>
<text top="446" left="450" width="350" height="15" font="5">severity of paravalvular regurgitation, evaluation of suit-</text>
<text top="464" left="450" width="350" height="15" font="5">ability for a percutaneous approach, and guidance during</text>
<text top="482" left="450" width="193" height="15" font="5">percutaneous closure procedures.</text>
<text top="509" left="450" width="158" height="15" font="5">11.8.2. Medical Therapy</text>
<text top="535" left="451" width="330" height="15" font="5">Bioprosthetic valve regurgitation is typically due to lea</text>
<text top="531" left="780" width="19" height="19" font="5">ﬂet</text>
<text top="553" left="450" width="146" height="15" font="5">degeneration and calci</text>
<text top="549" left="595" width="204" height="19" font="5">ﬁcation. There are no medical</text>
<text top="571" left="450" width="350" height="15" font="5">therapies known to prevent bioprosthetic valve degenera-</text>
<text top="589" left="450" width="350" height="15" font="5">tion other than those integrated into the valve design.</text>
<text top="606" left="450" width="350" height="15" font="5">Pathological regurgitation of a mechanical prosthetic valve</text>
<text top="624" left="450" width="350" height="15" font="5">is typically due to a paravalvular leak or pannus limiting</text>
<text top="642" left="450" width="350" height="15" font="5">normal occluder closure. Medical therapy is not effective</text>
<text top="660" left="450" width="251" height="15" font="5">for treatment of symptoms due to signi</text>
<text top="657" left="701" width="99" height="19" font="5">ﬁcant prosthetic</text>
<text top="678" left="450" width="350" height="15" font="5">valve regurgitation, but standard approaches may help</text>
<text top="696" left="450" width="350" height="15" font="5">stabilize patients before surgical intervention and may be</text>
<text top="714" left="450" width="350" height="15" font="5">used for palliative care in patients who are not surgical</text>
<text top="732" left="450" width="66" height="15" font="5">candidates.</text>
<text top="759" left="450" width="255" height="15" font="5">11.8.3. Intervention: Recommendations</text>
<text top="786" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="801" left="449" width="350" height="10" font="21">1. Surgery is recommended for operable patients with mechanical</text>
<text top="817" left="467" width="332" height="10" font="21">heart valves with intractable hemolysis or HF due to severe</text>
<text top="834" left="467" width="221" height="10" font="21">prosthetic or paraprosthetic regurgitation</text>
<text top="834" left="692" width="55" height="10" font="22"><a href="e57.full.html#114">(617,618)</a></text>
<text top="834" left="747" width="52" height="12" font="21">. (Level of</text>
<text top="851" left="467" width="65" height="12" font="21">Evidence: B)</text>
<text top="875" left="465" width="335" height="15" font="5">The indications for surgical intervention for prosthetic</text>
<text top="893" left="450" width="350" height="15" font="5">valve regurgitation include the same indications for native</text>
<text top="911" left="450" width="289" height="15" font="5">regurgitation of the aortic or mitral valve. Speci</text>
<text top="907" left="739" width="61" height="19" font="5">ﬁcally, in-</text>
<text top="928" left="450" width="350" height="15" font="5">dicators are evidence of LV systolic dysfunction, including</text>
<text top="946" left="450" width="350" height="15" font="5">a low LVEF or progressive LV dilation; the same cut-off</text>
<text top="964" left="450" width="171" height="15" font="5">points should be used as de</text>
<text top="961" left="621" width="179" height="19" font="5">ﬁned for native valve disease.</text>
<text top="982" left="450" width="350" height="15" font="5">Paravalvular regurgitation may also result in hemolytic</text>
<text top="1000" left="450" width="350" height="15" font="5">anemia; often this is mild and is managed medically but</text>
<text top="1018" left="450" width="350" height="15" font="5">may be refractory in some patients. Paravalvular regurgi-</text>
<text top="1036" left="450" width="350" height="15" font="5">tation may be treated by replacing the dysfunctional valve</text>
<text top="1054" left="450" width="338" height="15" font="5">with a new valve or by repairing the paravalvular defect.</text>
<text top="1073" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="1072" left="593" width="32" height="15" font="6"><a href="e57.full.html#114">(619)</a></text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e128</text>
</page>
<page number="73" position="absolute" top="0" left="0" height="1160" width="864">
<text top="106" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="121" left="63" width="351" height="10" font="21">1. Surgery is reasonable for operable patients with severe symp-</text>
<text top="137" left="81" width="332" height="12" font="21">tomatic or asymptomatic bioprosthetic regurgitation. (Level of</text>
<text top="154" left="81" width="61" height="12" font="21">Evidence C)</text>
<text top="178" left="79" width="335" height="15" font="5">Bioprosthetic valve degeneration results in regurgitation</text>
<text top="196" left="64" width="65" height="15" font="5">due to lea</text>
<text top="193" left="130" width="284" height="19" font="5">ﬂet calciﬁcation and noncoaptation or leaﬂet</text>
<text top="214" left="64" width="350" height="15" font="5">degeneration with a tear or perforation. Even in asymp-</text>
<text top="232" left="64" width="350" height="15" font="5">tomatic patients with severe bioprosthetic regurgitation,</text>
<text top="250" left="64" width="350" height="15" font="5">valve replacement is reasonable due to the risk of sudden</text>
<text top="268" left="64" width="207" height="15" font="5">clinical deterioration if further lea</text>
<text top="264" left="271" width="143" height="19" font="5">ﬂet tearing occurs. The</text>
<text top="286" left="64" width="350" height="15" font="5">choice of type of valve prosthesis in a patient undergoing</text>
<text top="304" left="64" width="350" height="15" font="5">reoperation depends on the same factors as those for pa-</text>
<text top="322" left="64" width="122" height="15" font="5">tients undergoing a</text>
<text top="318" left="193" width="220" height="19" font="5">ﬁrst valve replacement. The use of</text>
<text top="340" left="64" width="350" height="15" font="5">transcatheter valve prostheses to treat bioprosthetic valve</text>
<text top="358" left="64" width="125" height="15" font="5">regurgitation with a</text>
<text top="354" left="197" width="217" height="19" font="5">“valve-in-valve” approach is prom-</text>
<text top="376" left="64" width="350" height="15" font="5">ising but is not yet fully validated. Paravalvular regurgi-</text>
<text top="393" left="64" width="350" height="15" font="5">tation can also occur with a bioprosthetic valve. New</text>
<text top="411" left="64" width="350" height="15" font="5">paravalvular regurgitation may be due to IE or suture</text>
<text top="429" left="64" width="350" height="15" font="5">disruption from mechanical causes. Blood cultures should</text>
<text top="447" left="64" width="350" height="15" font="5">be obtained when new paravalvular regurgitation is</text>
<text top="465" left="64" width="54" height="15" font="5">detected.</text>
<text top="495" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="510" left="63" width="351" height="10" font="21">2. Percutaneous repair of paravalvular regurgitation is reasonable</text>
<text top="527" left="81" width="333" height="10" font="21">in patients with prosthetic heart valves and intractable hemo-</text>
<text top="543" left="81" width="332" height="10" font="21">lysis or NYHA class III/IV HF who are at high risk for surgery and</text>
<text top="560" left="81" width="333" height="10" font="21">have anatomic features suitable for catheter-based therapy</text>
<text top="576" left="81" width="333" height="10" font="21">when performed in centers with expertise in the procedure</text>
<text top="593" left="81" width="26" height="10" font="22"><a href="e57.full.html#114">(620</a></text>
<text top="589" left="107" width="32" height="16" font="22"><a href="e57.full.html#114">–622)</a></text>
<text top="593" left="139" width="118" height="12" font="21"><a href="e57.full.html#114">. </a>(Level of Evidence B)</text>
<text top="617" left="79" width="335" height="15" font="5">Surgery is a viable therapeutic option in many patients</text>
<text top="635" left="64" width="350" height="15" font="5">with symptomatic paravalvular prosthetic regurgitation.</text>
<text top="653" left="64" width="350" height="15" font="5">However, in some patients, surgery to replace a prosthetic</text>
<text top="671" left="64" width="95" height="15" font="5">valve with signi</text>
<text top="667" left="159" width="255" height="19" font="5">ﬁcant paravalvular regurgitation may carry</text>
<text top="689" left="64" width="28" height="15" font="5">signi</text>
<text top="685" left="93" width="321" height="19" font="5">ﬁcant operative risk due to the need for reoperation</text>
<text top="707" left="64" width="350" height="15" font="5">and patient comorbidity. Recent studies have demon-</text>
<text top="724" left="64" width="350" height="15" font="5">strated clinical success with percutaneous approaches, in</text>
<text top="742" left="64" width="350" height="15" font="5">which operators use complex catheter techniques and a</text>
<text top="760" left="64" width="350" height="15" font="5">variety of occluder devices to reduce paravalvular regurgi-</text>
<text top="778" left="64" width="350" height="15" font="5">tation. Procedural success rates with percutaneous closure,</text>
<text top="796" left="64" width="69" height="15" font="5">typically de</text>
<text top="793" left="133" width="281" height="19" font="5">ﬁned by no more than mild residual regurgi-</text>
<text top="814" left="64" width="350" height="15" font="5">tation and the absence of death and major complications,</text>
<text top="832" left="64" width="350" height="15" font="5">have been reported to be 80% to 85% in centers with</text>
<text top="850" left="64" width="350" height="15" font="5">expertise in the procedure. Major complications, none-</text>
<text top="868" left="64" width="350" height="15" font="5">theless, occur in 9% of patients, mainly due to vascular</text>
<text top="886" left="64" width="350" height="15" font="5">injury, cardiac perforation, and bleeding (procedural</text>
<text top="904" left="64" width="37" height="15" font="5">death,</text>
<text top="900" left="106" width="308" height="19" font="5">&lt;2%). The degree of residual regurgitation directly</text>
<text top="922" left="64" width="350" height="15" font="5">affects symptom improvement and survival free of adverse</text>
<text top="940" left="64" width="350" height="15" font="5">events. Treatment of HF symptoms is more successful</text>
<text top="958" left="64" width="350" height="15" font="5">than treatment of hemolysis. Due to the complexity of</text>
<text top="976" left="64" width="350" height="15" font="5">these procedures, consideration should be given to their</text>
<text top="994" left="64" width="350" height="15" font="5">performance in centers of expertise under the guidance of</text>
<text top="1011" left="64" width="149" height="15" font="5">a multidisciplinary team.</text>
<text top="1030" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="1029" left="212" width="27" height="15" font="6"><a href="e57.full.html#114">(620</a></text>
<text top="1026" left="239" width="35" height="19" font="6"><a href="e57.full.html#114">–629)</a></text>
<text top="1048" left="79" width="18" height="15" font="5">See</text>
<text top="1048" left="103" width="166" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 23</a></text>
<text top="1048" left="274" width="140" height="15" font="5">for more information on</text>
<text top="1066" left="64" width="157" height="15" font="5">paravalvular regurgitation.</text>
<text top="103" left="450" width="204" height="14" font="17">12. Infective Endocarditis</text>
<text top="146" left="451" width="18" height="15" font="5">See</text>
<text top="146" left="478" width="181" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 24</a></text>
<text top="146" left="668" width="131" height="15" font="5">for more information</text>
<text top="163" left="450" width="121" height="15" font="5">on surgical outcomes.</text>
<text top="187" left="450" width="125" height="12" font="19">12.1. IE: Overview</text>
<text top="210" left="451" width="349" height="15" font="5">IE has a high mortality rate, even with appropriate</text>
<text top="228" left="450" width="350" height="15" font="5">antibiotic therapy and surgical intervention, with an in-</text>
<text top="246" left="450" width="283" height="15" font="5">hospital mortality rate of 15% to 20% and a 1</text>
<text top="242" left="733" width="67" height="19" font="5">–year mor-</text>
<text top="264" left="450" width="350" height="15" font="5">tality rate approaching 40%. The overall incidence of IE is</text>
<text top="281" left="450" width="350" height="15" font="5">3 to 10 per 100,000 patient-years, with a higher prevalence</text>
<text top="299" left="450" width="350" height="15" font="5">in older patients. In underdeveloped countries, IE is most</text>
<text top="317" left="450" width="350" height="15" font="5">often associated with rheumatic heart disease. In developed</text>
<text top="335" left="450" width="350" height="15" font="5">countries, IE is increasingly associated with prosthetic</text>
<text top="353" left="450" width="350" height="15" font="5">valve and intracardiac devices, with a risk of IE 50 times</text>
<text top="371" left="450" width="350" height="15" font="5">higher in patients with a prosthetic valve compared with</text>
<text top="389" left="450" width="350" height="15" font="5">the general population. IE also may be associated with</text>
<text top="407" left="450" width="350" height="15" font="5">intravenous drug use, diabetes mellitus, or immunosup-</text>
<text top="425" left="450" width="350" height="15" font="5">pression. Despite differences in associated risk factors</text>
<text top="443" left="450" width="350" height="15" font="5">and clinical outcomes, there are few differences in the</text>
<text top="461" left="450" width="350" height="15" font="5">recommendations for diagnosis and treatment of NVE</text>
<text top="479" left="450" width="350" height="15" font="5">versus PVE. In this guideline, there is 1 set of recom-</text>
<text top="497" left="450" width="350" height="15" font="5">mendations for diagnosis and management of all types of</text>
<text top="515" left="450" width="350" height="15" font="5">IE. Recommendations for prevention of IE are included in</text>
<text top="533" left="450" width="57" height="15" font="6"><a href="e57.full.html#7">Section 2</a></text>
<text top="533" left="507" width="4" height="15" font="5">.</text>
<text top="551" left="465" width="335" height="15" font="5">Antimicrobial therapy is the cornerstone of therapy for</text>
<text top="568" left="450" width="82" height="15" font="5">IE. The speci</text>
<text top="565" left="531" width="268" height="19" font="5">ﬁc antimicrobial agents and duration of ther-</text>
<text top="586" left="450" width="288" height="15" font="5">apy should be guided by the susceptibility pro</text>
<text top="583" left="738" width="62" height="19" font="5">ﬁle of the</text>
<text top="604" left="450" width="350" height="15" font="5">causative organism. Temporal and geographic variability</text>
<text top="622" left="450" width="350" height="15" font="5">in causative organisms and antimicrobial susceptibility</text>
<text top="640" left="450" width="20" height="15" font="5">pro</text>
<text top="637" left="470" width="330" height="19" font="5">ﬁles mandate concomitant management with an in-</text>
<text top="658" left="450" width="252" height="15" font="5">fectious disease specialist. Details of speci</text>
<text top="655" left="702" width="98" height="19" font="5">ﬁc antimicrobial</text>
<text top="676" left="450" width="350" height="15" font="5">regimens have previously been published by the AHA,</text>
<text top="694" left="450" width="350" height="15" font="5">European Society of Cardiology, and British Society for</text>
<text top="712" left="450" width="350" height="15" font="5">Antimicrobial Chemotherapy and are not repeated in this</text>
<text top="730" left="450" width="58" height="15" font="5">guideline.</text>
<text top="748" left="465" width="335" height="15" font="5">In addition to antibiotic therapy, early surgical inter-</text>
<text top="766" left="450" width="350" height="15" font="5">vention is often needed for effective treatment of infec-</text>
<text top="784" left="450" width="300" height="15" font="5">tion and to manage the sequelae of valve lea</text>
<text top="780" left="750" width="50" height="19" font="5">ﬂet and</text>
<text top="802" left="450" width="350" height="15" font="5">paravalvular tissue destruction. Decisions about whether</text>
<text top="820" left="450" width="350" height="15" font="5">surgical intervention is needed and the optimal timing of</text>
<text top="838" left="450" width="350" height="15" font="5">intervention are complex. Most of the indications for</text>
<text top="855" left="450" width="350" height="15" font="5">surgical intervention are the same for NVE and PVE and</text>
<text top="873" left="450" width="350" height="15" font="5">are included in 1 recommendation for both when</text>
<text top="891" left="450" width="350" height="15" font="5">possible. Appropriate management of patients with IE</text>
<text top="909" left="450" width="350" height="15" font="5">requires a Heart Valve Team approach, initiated as soon</text>
<text top="927" left="450" width="207" height="15" font="5">as a diagnosis of probable or de</text>
<text top="924" left="657" width="143" height="19" font="5">ﬁnite IE is conﬁrmed,</text>
<text top="945" left="450" width="350" height="15" font="5">with specialists in cardiology, cardiothoracic surgery, and</text>
<text top="963" left="450" width="350" height="15" font="5">infectious disease all involved in patient care and decision</text>
<text top="981" left="450" width="49" height="15" font="5">making.</text>
<text top="1000" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="999" left="598" width="72" height="15" font="6"><a href="e57.full.html#101">(52,278,630</a></text>
<text top="996" left="670" width="35" height="19" font="6"><a href="e57.full.html#101">–635)</a></text>
<text top="1024" left="450" width="189" height="12" font="19">12.2. Infective Endocarditis</text>
<text top="1048" left="451" width="18" height="15" font="5">See</text>
<text top="1048" left="476" width="171" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 24</a></text>
<text top="1048" left="654" width="145" height="15" font="5">for more information on</text>
<text top="1066" left="450" width="99" height="15" font="5">surgical outcomes.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e129</text>
</page>
<page number="74" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="340" height="15" font="5">12.2.1. Diagnosis and Follow-Up: Recommendations</text>
<text top="128" left="65" width="21" height="15" font="5">See</text>
<text top="128" left="91" width="51" height="15" font="6"><a href="e57.full.html#74">Figure 8</a></text>
<text top="128" left="147" width="267" height="15" font="5">for recommendations for imaging studies in</text>
<text top="146" left="64" width="98" height="15" font="5">NVE and PVE.</text>
<text top="173" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="188" left="63" width="351" height="10" font="21">1. At least 2 sets of blood cultures should be obtained in patients</text>
<text top="205" left="81" width="333" height="10" font="21">at risk for IE (e.g., those with congenital or acquired VHD,</text>
<text top="221" left="81" width="332" height="10" font="21">previous IE, prosthetic heart valves, certain congenital or heri-</text>
<text top="238" left="81" width="202" height="10" font="21">table heart malformations, immunode</text>
<text top="234" left="283" width="131" height="16" font="21">ﬁciency states, or injec-</text>
<text top="254" left="81" width="332" height="10" font="21">tion drug users) who have unexplained fever for more than 48</text>
<text top="270" left="81" width="29" height="10" font="21">hours</text>
<text top="270" left="114" width="30" height="10" font="22"><a href="e57.full.html#115">(636)</a></text>
<text top="271" left="149" width="265" height="12" font="21">(Level of Evidence: B) or patients with newly diag-</text>
<text top="287" left="81" width="306" height="12" font="21">nosed left-sided valve regurgitation. (Level of Evidence: C)</text>
<text top="308" left="79" width="335" height="15" font="5">Blood cultures are positive in 90% of patients with IE.</text>
<text top="326" left="64" width="350" height="15" font="5">In patients with a chronic (or subacute) presentation, 3 sets</text>
<text top="344" left="64" width="209" height="15" font="5">of blood cultures should be drawn</text>
<text top="341" left="279" width="135" height="19" font="5">&gt;6 hours apart at pe-</text>
<text top="362" left="64" width="350" height="15" font="5">ripheral sites before initiation of antimicrobial therapy.</text>
<text top="380" left="64" width="350" height="15" font="5">However, this is not feasible or safe in patients with severe</text>
<text top="398" left="64" width="252" height="15" font="5">sepsis or septic shock. In this situation,</text>
<text top="395" left="323" width="90" height="19" font="5">2 cultures at</text>
<text top="416" left="64" width="350" height="15" font="5">separate times should allow for a secure microbiological</text>
<text top="434" left="64" width="350" height="15" font="5">diagnosis before initiation of antimicrobial therapy. More</text>
<text top="452" left="64" width="350" height="15" font="5">important than the time interval of the cultures is the</text>
<text top="470" left="64" width="350" height="15" font="5">observance of strict aseptic technique, avoiding sam-</text>
<text top="488" left="64" width="350" height="15" font="5">pling from intravascular lines, and ensuring adequate vol-</text>
<text top="506" left="64" width="350" height="15" font="5">ume of blood for culture sample. Routine incubation of</text>
<text top="523" left="64" width="109" height="15" font="5">blood cultures for</text>
<text top="520" left="179" width="235" height="19" font="5">&gt;7 days is no longer necessary in the</text>
<text top="541" left="64" width="350" height="15" font="5">era of continuous-monitoring blood culture systems and</text>
<text top="559" left="64" width="350" height="15" font="5">nonculture-based technology. In the 10% of patients with</text>
<text top="577" left="64" width="350" height="15" font="5">culture-negative endocarditis, serologic testing to identify</text>
<text top="595" left="64" width="202" height="15" font="5">the etiologic agent is appropriate.</text>
<text top="614" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="613" left="212" width="46" height="15" font="6"><a href="e57.full.html#101">(52,637</a></text>
<text top="610" left="258" width="35" height="19" font="6"><a href="e57.full.html#101">–641)</a></text>
<text top="106" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="121" left="449" width="68" height="10" font="21">2. The Modi</text>
<text top="118" left="517" width="283" height="16" font="21">ﬁed Duke Criteria should be used in evaluating a pa-</text>
<text top="137" left="467" width="128" height="10" font="21">tient with suspected IE (</text>
<text top="137" left="595" width="51" height="10" font="22"><a href="e57.full.html#75">Tables 24</a></text>
<text top="137" left="649" width="19" height="10" font="21">and</text>
<text top="137" left="671" width="14" height="10" font="22"><a href="e57.full.html#75">25</a></text>
<text top="137" left="685" width="4" height="10" font="21">)</text>
<text top="137" left="693" width="26" height="10" font="22"><a href="e57.full.html#115">(642</a></text>
<text top="134" left="718" width="32" height="16" font="22"><a href="e57.full.html#115">–645)</a></text>
<text top="137" left="750" width="50" height="12" font="21"><a href="e57.full.html#115">. </a>(Level of</text>
<text top="154" left="467" width="65" height="12" font="21">Evidence: B)</text>
<text top="180" left="465" width="64" height="15" font="5">The Modi</text>
<text top="176" left="529" width="124" height="19" font="5">ﬁed Duke Criteria (</text>
<text top="180" left="653" width="60" height="15" font="6"><a href="e57.full.html#75">Tables 24</a></text>
<text top="180" left="719" width="22" height="15" font="5">and</text>
<text top="180" left="747" width="15" height="15" font="6"><a href="e57.full.html#75">25</a></text>
<text top="180" left="762" width="37" height="15" font="5"><a href="e57.full.html#75">) </a>have</text>
<text top="198" left="450" width="350" height="15" font="5">been well validated in comparison to surgical or autopsy</text>
<text top="212" left="450" width="350" height="19" font="5">ﬁndings and in clinical outcomes in numerous studies in a</text>
<text top="234" left="450" width="350" height="15" font="5">wide spectrum of patients, including children, the elderly,</text>
<text top="251" left="450" width="350" height="15" font="5">prosthetic valve recipients, injection drug users, and non-</text>
<text top="269" left="450" width="350" height="15" font="5">drug users, as well as patients in both primary and tertiary</text>
<text top="287" left="450" width="350" height="15" font="5">care settings. Clinical judgment and infectious disease</text>
<text top="305" left="450" width="350" height="15" font="5">specialty guidance are essential when deciding on the type</text>
<text top="323" left="450" width="350" height="15" font="5">and duration of antibiotic therapy when these criteria</text>
<text top="341" left="450" width="350" height="15" font="5">suggest possible IE and in patients with unusual clinical</text>
<text top="359" left="450" width="350" height="15" font="5">presentations or culture-negative endocarditis. About three</text>
<text top="377" left="450" width="350" height="15" font="5">fourths of patients with IE are diagnosed within 30 days</text>
<text top="395" left="450" width="350" height="15" font="5">of the onset of infection, so classic clinical features, such</text>
<text top="413" left="450" width="350" height="15" font="5">as embolic or vasculitic skin lesions, renal disease due to</text>
<text top="431" left="450" width="350" height="15" font="5">immune complex deposition, and immunologic abnor-</text>
<text top="449" left="450" width="350" height="15" font="5">malities of IE, are often absent. In these cases, maintaining</text>
<text top="467" left="450" width="350" height="15" font="5">a high level of clinical suspicion to the possibility of IE in</text>
<text top="485" left="450" width="256" height="15" font="5">patients who are susceptible is paramount.</text>
<text top="503" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="503" left="597" width="53" height="15" font="6"><a href="e57.full.html#115">(644,646</a></text>
<text top="499" left="651" width="35" height="19" font="6"><a href="e57.full.html#115">–650)</a></text>
<text top="535" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="549" left="449" width="351" height="10" font="21">3. Patients with IE should be evaluated and managed with</text>
<text top="566" left="467" width="333" height="10" font="21">consultation of a multispecialty Heart Valve Team including an</text>
<text top="582" left="467" width="333" height="10" font="21">infectious disease specialist, cardiologist, and cardiac surgeon.</text>
<text top="599" left="467" width="332" height="10" font="21">In surgically managed patients, this team should also include a</text>
<text top="615" left="467" width="129" height="10" font="21">cardiac anesthesiologist</text>
<text top="615" left="600" width="30" height="10" font="22"><a href="e57.full.html#115">(651)</a></text>
<text top="615" left="630" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="1034" left="64" width="368" height="11" font="13">Figure 8. Recommendations for Imaging Studies in NVE and PVE</text>
<text top="1066" left="64" width="697" height="9" font="14">*Repeat TEE and/or TTE re-commended for re-evaluation of patients with IE and a change in clinical signs or symptoms and in patients at high risk of complications.</text>
<text top="1080" left="72" width="709" height="10" font="14">CT indicates computed tomography; IE, infective endocarditis; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; S. aureus, Staphylococcus aureus; TEE,</text>
<text top="1093" left="72" width="325" height="9" font="14">transesophageal echocardiography; and TTE, transthoracic echocardiography.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e130</text>
</page>
<page number="75" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="28" size="5" family="Times" color="#000000"/>
<text top="515" left="79" width="203" height="15" font="5">The diagnosis of IE can still be dif</text>
<text top="512" left="282" width="131" height="19" font="5">ﬁcult and is frequently</text>
<text top="533" left="64" width="350" height="15" font="5">delayed, which may cause progressive and potentially</text>
<text top="551" left="64" width="350" height="15" font="5">irreparable structural damage to the heart and other organ</text>
<text top="569" left="64" width="350" height="15" font="5">systems secondary to vascular-embolic and immunologically</text>
<text top="587" left="64" width="350" height="15" font="5">mediated events. The in-hospital mortality rate for patients</text>
<text top="605" left="64" width="257" height="15" font="5">with IE remains high (15% to 20%), with 1</text>
<text top="602" left="321" width="93" height="19" font="5">–year mortality,</text>
<text top="623" left="64" width="350" height="15" font="5">even in the current therapeutic era, approaching 40%.</text>
<text top="641" left="64" width="350" height="15" font="5">Additionally, stroke (16.9%), embolization other than</text>
<text top="659" left="64" width="350" height="15" font="5">stroke (22.6%), HF (32.3%), intracardiac abscess (14.4%),</text>
<text top="677" left="64" width="350" height="15" font="5">and the need for surgical therapy (48.2%) remain common.</text>
<text top="695" left="79" width="335" height="15" font="5">The optimal treatment and potential timing of invasive</text>
<text top="712" left="64" width="350" height="15" font="5">strategies in these patients can be quite challenging in the</text>
<text top="730" left="64" width="350" height="15" font="5">individual patient. Patients with suspected IE are most</text>
<text top="748" left="64" width="350" height="15" font="5">optimally managed in an environment that coordinates</text>
<text top="766" left="64" width="350" height="15" font="5">management of specialists well attuned to various organ</text>
<text top="784" left="64" width="350" height="15" font="5">systems, pathological processes, and potential treatment</text>
<text top="802" left="64" width="350" height="15" font="5">modalities involved. Cardiologists provide expertise in</text>
<text top="820" left="64" width="350" height="15" font="5">diagnosis, imaging, and clinical management; infectious</text>
<text top="838" left="64" width="285" height="15" font="5">disease specialists provide expertise in identi</text>
<text top="835" left="349" width="65" height="19" font="5">ﬁcation of</text>
<text top="856" left="64" width="350" height="15" font="5">the causative organism and the choice and duration of</text>
<text top="874" left="64" width="350" height="15" font="5">antimicrobial therapy; cardiac surgeons are essential for</text>
<text top="892" left="64" width="350" height="15" font="5">decisions about timing of surgical intervention as well</text>
<text top="910" left="64" width="350" height="15" font="5">as the procedure itself; and anesthesiologists are essential</text>
<text top="928" left="64" width="350" height="15" font="5">for peri- and intraoperative diagnosis and management.</text>
<text top="946" left="64" width="350" height="15" font="5">Because the urgent/emergency need for surgical interven-</text>
<text top="964" left="64" width="350" height="15" font="5">tion can arise rapidly, it is strongly recommended that</text>
<text top="982" left="64" width="350" height="15" font="5">these patients be cared for in centers with immediate access</text>
<text top="999" left="64" width="350" height="15" font="5">to cardiac surgery during the initial observation stages of</text>
<text top="1017" left="64" width="350" height="15" font="5">the disease. With the emerging use of telemedicine, it</text>
<text top="1035" left="64" width="350" height="15" font="5">may be reasonable to manage patients with lower-acuity</text>
<text top="1053" left="64" width="350" height="15" font="5">IE in a center without on-site multispecialty care by tele-</text>
<text top="1071" left="64" width="350" height="15" font="5">communication with a Heart Valve Team and infectious</text>
<text top="1089" left="64" width="350" height="15" font="5">disease specialists. Rapid transfer of the patient should also</text>
<text top="758" left="450" width="350" height="15" font="5">be available if the need arises. IE is a disease that is contin-</text>
<text top="776" left="450" width="350" height="15" font="5">ually changing with new high-risk patients, new diagnostic</text>
<text top="794" left="450" width="350" height="15" font="5">procedures, the involvement of new micro-organisms, and</text>
<text top="812" left="450" width="350" height="15" font="5">new therapeutic approaches. Despite knowledge of these</text>
<text top="830" left="450" width="350" height="15" font="5">changes and considerable improvements in diagnostic and</text>
<text top="848" left="450" width="350" height="15" font="5">therapeutic strategies, IE is still a potentially debilitating or</text>
<text top="866" left="450" width="350" height="15" font="5">fatal disease. Patients affected by the disease are often older</text>
<text top="884" left="450" width="258" height="15" font="5">and sicker, and the comorbidity rate is high.</text>
<text top="902" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="902" left="597" width="27" height="15" font="6"><a href="e57.full.html#115">(652</a></text>
<text top="898" left="625" width="35" height="19" font="6"><a href="e57.full.html#115">–654)</a></text>
<text top="929" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="944" left="449" width="351" height="10" font="21">4. TTE is recommended in patients with suspected IE to identify</text>
<text top="960" left="467" width="333" height="10" font="21">vegetations, characterize the hemodynamic severity of valvular</text>
<text top="977" left="467" width="333" height="10" font="21">lesions, assess ventricular function and pulmonary pressures,</text>
<text top="993" left="467" width="135" height="10" font="21">and detect complications</text>
<text top="993" left="605" width="26" height="10" font="22"><a href="e57.full.html#115">(655</a></text>
<text top="990" left="631" width="32" height="16" font="22"><a href="e57.full.html#115">–659)</a></text>
<text top="993" left="663" width="121" height="12" font="21"><a href="e57.full.html#115">. </a>(Level of Evidence: B)</text>
<text top="1017" left="465" width="335" height="15" font="5">The presence of valvular vegetation is a major criterion</text>
<text top="1035" left="450" width="350" height="15" font="5">in the diagnosis of IE. TTE has a sensitivity of between</text>
<text top="1053" left="450" width="169" height="15" font="5">50% and 90% and a speci</text>
<text top="1050" left="619" width="180" height="19" font="5">ﬁcity &gt;90% for detection of</text>
<text top="1071" left="450" width="350" height="15" font="5">vegetations in NVE. TTE has a sensitivity of only 36% to</text>
<text top="1089" left="450" width="350" height="15" font="5">69% in PVE, but TTE still has a role in these patients for</text>
<text top="103" left="64" width="300" height="11" font="13">Table 24. Diagnosis of IE According to the Proposed</text>
<text top="119" left="64" width="28" height="11" font="13">Modi</text>
<text top="116" left="92" width="99" height="17" font="13">ﬁed Duke Criteria</text>
<text top="144" left="64" width="12" height="9" font="7">De</text>
<text top="141" left="77" width="36" height="14" font="7">ﬁnite IE</text>
<text top="162" left="64" width="94" height="9" font="7">Pathological criteria</text>
<text top="183" left="64" width="324" height="14" font="7"> Microorganisms demonstrated by culture or histologic examination of</text>
<text top="200" left="76" width="292" height="9" font="7">a vegetation, a vegetation that has embolized, or an intracardiac</text>
<text top="214" left="76" width="97" height="9" font="7">abscess specimen; or</text>
<text top="226" left="64" width="322" height="14" font="7"> Pathological lesions: vegetation or intracardiac abscess conﬁrmed by</text>
<text top="243" left="76" width="236" height="9" font="7">histological examination showing active endocarditis</text>
<text top="261" left="64" width="70" height="9" font="7">Clinical criteria</text>
<text top="282" left="64" width="96" height="14" font="7"> 2 major criteria; or</text>
<text top="296" left="64" width="195" height="14" font="7"> 1 major criterion and 3 minor criteria; or</text>
<text top="310" left="64" width="82" height="14" font="7"> 5 minor criteria</text>
<text top="334" left="64" width="51" height="9" font="7">Possible IE</text>
<text top="351" left="64" width="201" height="14" font="7"> 1 major criterion and 1 minor criterion; or</text>
<text top="365" left="64" width="82" height="14" font="7"> 3 minor criteria</text>
<text top="384" left="64" width="41" height="9" font="7">Rejected</text>
<text top="406" left="64" width="251" height="14" font="7"> Firm alternate diagnosis explaining evidence of IE; or</text>
<text top="420" left="64" width="290" height="14" font="7"> Resolution of IE syndrome with antibiotic therapy for &lt;4 d; or</text>
<text top="434" left="64" width="316" height="14" font="7"> No pathological evidence of IE at surgery or autopsy, with antibiotic</text>
<text top="451" left="76" width="49" height="9" font="7">therapy for</text>
<text top="448" left="129" width="38" height="14" font="7">&lt;4 d; or</text>
<text top="462" left="64" width="251" height="14" font="7"> Does not meet criteria for possible IE as listed above</text>
<text top="485" left="72" width="128" height="8" font="18">IE indicates infective endocarditis.</text>
<text top="485" left="202" width="38" height="8" font="26"><a href="e57.full.html#115">(642,644)</a></text>
<text top="103" left="450" width="236" height="11" font="13">Table 25. Major and Minor Criteria in the</text>
<text top="119" left="450" width="28" height="11" font="13">Modi</text>
<text top="116" left="478" width="229" height="17" font="13">ﬁed Duke Criteria for the Diagnosis of IE</text>
<text top="144" left="450" width="64" height="9" font="7">Major Criteria</text>
<text top="162" left="450" width="142" height="9" font="7">1. Blood culture positive for IE</text>
<text top="184" left="450" width="334" height="9" font="7">Typical microorganisms consistent with IE from 2 separate blood cultures:</text>
<text top="195" left="462" width="265" height="14" font="7"> Viridans streptococci, Streptococcus bovis, HACEK group</text>
<text top="213" left="474" width="266" height="9" font="7">(Haemophilus spp., Actinobacillus actinomycetemcomitans,</text>
<text top="227" left="474" width="282" height="9" font="7">Cardiobacterium hominis, Eikenella spp., and Kingella kingae),</text>
<text top="241" left="474" width="268" height="9" font="7">Staphylococcus aureus; or community-acquired enterococci,</text>
<text top="255" left="474" width="167" height="9" font="7">in the absence of a primary focus; or</text>
<text top="269" left="450" width="339" height="9" font="7">Microorganisms consistent with IE from persistently positive blood cultures,</text>
<text top="284" left="450" width="11" height="9" font="7">de</text>
<text top="281" left="461" width="73" height="14" font="7">ﬁned as follows:</text>
<text top="295" left="462" width="310" height="14" font="7"> At least 2 positive cultures of blood samples drawn 12 h apart; or</text>
<text top="309" left="462" width="302" height="14" font="7"> All of 3 or a majority of 4 separate cultures of blood (with ﬁrst</text>
<text top="326" left="474" width="194" height="9" font="7">and last samples drawn at least 1 h apart)</text>
<text top="337" left="462" width="289" height="14" font="7"> Single positive blood culture for Coxiella burnetii or antiphase</text>
<text top="355" left="474" width="84" height="9" font="7">I IgG antibody titer</text>
<text top="352" left="561" width="35" height="14" font="7">&gt;1:800</text>
<text top="371" left="450" width="182" height="9" font="7">2. Evidence of endocardial involvement</text>
<text top="392" left="450" width="236" height="14" font="7"> Echocardiogram positive for IE deﬁned as follows:</text>
<text top="406" left="468" width="306" height="14" font="7"> Oscillating intracardiac mass on valve or supporting structures, in</text>
<text top="423" left="479" width="310" height="9" font="7">the path of regurgitant jets, or on implanted material in the absence</text>
<text top="438" left="479" width="177" height="9" font="7">of an alternative anatomic explanation;</text>
<text top="449" left="468" width="62" height="14" font="7"> Abscess; or</text>
<text top="463" left="468" width="202" height="14" font="7"> New partial dehiscence of prosthetic valve</text>
<text top="477" left="450" width="303" height="14" font="7"> New valvular regurgitation (worsening or changing of pre-existing</text>
<text top="494" left="462" width="71" height="9" font="7">murmur not suf</text>
<text top="491" left="532" width="30" height="14" font="7">ﬁcient)</text>
<text top="514" left="450" width="69" height="9" font="7">Minor Criteria</text>
<text top="532" left="450" width="319" height="9" font="7">1. Predisposition, predisposing heart condition, or injection drug use</text>
<text top="549" left="450" width="101" height="9" font="7">2. Fever, temperature</text>
<text top="546" left="554" width="18" height="14" font="7">&gt;38</text>
<text top="545" left="573" width="4" height="10" font="28"></text>
<text top="549" left="580" width="42" height="9" font="7">C (100.4</text>
<text top="545" left="623" width="4" height="10" font="28"></text>
<text top="549" left="630" width="9" height="9" font="7">F)</text>
<text top="565" left="450" width="339" height="9" font="7">3. Vascular phenomena, major arterial emboli, septic pulmonary infarcts,</text>
<text top="580" left="462" width="330" height="9" font="7">mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages,</text>
<text top="594" left="462" width="95" height="9" font="7">and Janeway lesions</text>
<text top="611" left="450" width="250" height="9" font="7">4. Immunologic phenomena: glomerulonephritis, Osler</text>
<text top="608" left="700" width="76" height="14" font="7">’s nodes, Roth’s</text>
<text top="625" left="462" width="135" height="9" font="7">spots, and rheumatoid factor</text>
<text top="642" left="450" width="324" height="9" font="7">5. Microbiological evidence: positive blood culture but does not meet</text>
<text top="656" left="462" width="151" height="9" font="7">a major criterion as noted <a href="e57.full.html#75">above</a></text>
<text top="656" left="613" width="6" height="9" font="8"><a href="e57.full.html#75">*</a></text>
<text top="656" left="622" width="151" height="9" font="7">or serological evidence of active</text>
<text top="670" left="462" width="197" height="9" font="7">infection with organism consistent with IE</text>
<text top="690" left="450" width="350" height="8" font="18">*Excludes single positive cultures for coagulase-negative staphylococci and organisms that do</text>
<text top="702" left="450" width="49" height="8" font="18">not cause IE.</text>
<text top="714" left="457" width="342" height="8" font="18">C indicates Celsius; F, Fahrenheit; IE, infective endocarditis; spp, species; TEE, trans-</text>
<text top="726" left="457" width="269" height="8" font="18">esophageal echocardiography; and TTE, transthoracic echocardiography.</text>
<text top="726" left="729" width="38" height="8" font="26"><a href="e57.full.html#115">(642,644)</a></text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e131</text>
</page>
<page number="76" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">detection and quantitation of valve dysfunction (even in the</text>
<text top="121" left="64" width="350" height="15" font="5">challenging situation of regurgitation in the mechanical</text>
<text top="139" left="64" width="350" height="15" font="5">prosthetic mitral valve, for which a proximal convergence</text>
<text top="157" left="64" width="350" height="15" font="5">zone may provide important evidence for a paravalvular</text>
<text top="175" left="64" width="350" height="15" font="5">leak), evaluation of ventricular size and systolic function,</text>
<text top="192" left="64" width="350" height="15" font="5">and estimation of pulmonary pressures. TTE exhibits su-</text>
<text top="210" left="64" width="350" height="15" font="5">perior imaging over TEE for the anterior aspect of a</text>
<text top="228" left="64" width="350" height="15" font="5">prosthetic aortic valve, which is commonly shadowed by</text>
<text top="246" left="64" width="350" height="15" font="5">the valve on TEE. TTE also allows measurement of aortic</text>
<text top="264" left="64" width="350" height="15" font="5">transvalvular velocity/gradient, which is not always possible</text>
<text top="282" left="64" width="228" height="15" font="5">on TEE. Although TTE will not de</text>
<text top="279" left="292" width="122" height="19" font="5">ﬁnitely exclude veg-</text>
<text top="300" left="64" width="350" height="15" font="5">etations or abscesses in IE, it can identify very high-risk</text>
<text top="318" left="64" width="350" height="15" font="5">patients and establish the diagnosis as well as guide early</text>
<text top="336" left="64" width="126" height="15" font="5">treatment decisions <a href="e57.full.html#74">(</a></text>
<text top="336" left="190" width="51" height="15" font="6"><a href="e57.full.html#74">Figure 8</a></text>
<text top="336" left="242" width="9" height="15" font="5"><a href="e57.full.html#74">).</a></text>
<text top="355" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="354" left="212" width="53" height="15" font="6"><a href="e57.full.html#115">(655,660</a></text>
<text top="351" left="265" width="35" height="19" font="6"><a href="e57.full.html#115">–664)</a></text>
<text top="390" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="405" left="63" width="351" height="10" font="21">5. TEE is recommended in all patients with known or suspected IE</text>
<text top="421" left="81" width="333" height="10" font="21">when TTE is nondiagnostic, when complications have developed</text>
<text top="438" left="81" width="333" height="10" font="21">or are clinically suspected, or when intracardiac device leads</text>
<text top="454" left="81" width="60" height="10" font="21">are present</text>
<text top="454" left="146" width="50" height="10" font="22"><a href="e57.full.html#115">(662,665</a></text>
<text top="451" left="196" width="32" height="16" font="22"><a href="e57.full.html#115">–672)</a></text>
<text top="454" left="228" width="121" height="12" font="21"><a href="e57.full.html#115">. </a>(Level of Evidence: B)</text>
<text top="479" left="79" width="335" height="15" font="5">The sensitivity of TEE in NVE ranges from 90% to</text>
<text top="497" left="64" width="350" height="15" font="5">100%, with sensitivity ranges slightly lower in PVE. The</text>
<text top="514" left="64" width="350" height="15" font="5">positive predictive value for TEE in both NVE and PVE</text>
<text top="532" left="64" width="350" height="15" font="5">is 90%. TEE is superior to TTE in the visualization</text>
<text top="550" left="64" width="350" height="15" font="5">of both vegetations and perivalvular complications, which</text>
<text top="568" left="64" width="350" height="15" font="5">can be anatomic or hemodynamic in nature. Examples of</text>
<text top="586" left="64" width="350" height="15" font="5">such complications include valve perforation, abscesses,</text>
<text top="604" left="64" width="350" height="15" font="5">and pericardial effusion. Hemodynamic complications</text>
<text top="622" left="64" width="195" height="15" font="5">may include valve regurgitation,</text>
<text top="619" left="265" width="148" height="19" font="5">ﬁstulae, and intracardiac</text>
<text top="640" left="64" width="350" height="15" font="5">thrombi. TEE is now considered the most reliable</text>
<text top="658" left="64" width="135" height="15" font="5">noninvasive test for de</text>
<text top="655" left="199" width="215" height="19" font="5">ﬁning this disease. However, it may</text>
<text top="676" left="64" width="350" height="15" font="5">not differentiate between active and healed vegetations and</text>
<text top="694" left="64" width="350" height="15" font="5">may not discriminate between thickened valves or valvular</text>
<text top="712" left="64" width="350" height="15" font="5">nodules and vegetations. TTE and TEE are complemen-</text>
<text top="730" left="64" width="350" height="15" font="5">tary for the comprehensive evaluation of hemodynamics</text>
<text top="748" left="64" width="350" height="15" font="5">and anatomy in patients with IE. Because TEE has a</text>
<text top="766" left="64" width="350" height="15" font="5">higher sensitivity in detecting anatomic complications, it</text>
<text top="784" left="64" width="350" height="15" font="5">should be used as an adjunct in patients with echocardio-</text>
<text top="801" left="64" width="350" height="15" font="5">graphic features of IE on TTE to rule out the presence of</text>
<text top="816" left="64" width="350" height="19" font="5">ﬁndings such as abscesses, which may alter the therapeutic</text>
<text top="837" left="64" width="350" height="15" font="5">approach to the management of the patient. TEE also</text>
<text top="855" left="64" width="350" height="15" font="5">serves a vital role in reassessment of patients with known</text>
<text top="873" left="64" width="350" height="15" font="5">IE with suspected clinical complications as well as a</text>
<text top="891" left="64" width="350" height="15" font="5">guiding tool in the intraoperative assessment and man-</text>
<text top="909" left="64" width="162" height="15" font="5">agement of the IE patient.</text>
<text top="927" left="79" width="335" height="15" font="5">The number, type, and timing of repeat examinations</text>
<text top="945" left="64" width="350" height="15" font="5">depend on the clinical presentation and course as well as the</text>
<text top="963" left="64" width="350" height="15" font="5">virulence of the microorganism. Vegetation size at diagnosis</text>
<text top="981" left="64" width="101" height="15" font="5">has clearly identi</text>
<text top="977" left="165" width="249" height="19" font="5">ﬁed a higher risk of death in prospective</text>
<text top="999" left="64" width="350" height="15" font="5">studies. Additionally, 1 study has shown that failure to</text>
<text top="1017" left="64" width="350" height="15" font="5">decrease vegetation size with antibiotic treatment was asso-</text>
<text top="1035" left="64" width="350" height="15" font="5">ciated with an increased risk of embolism. Another study</text>
<text top="1053" left="64" width="350" height="15" font="5">demonstrated that most vegetations (83.8%) remain constant</text>
<text top="1071" left="64" width="350" height="15" font="5">in size under therapy and that this does not worsen prog-</text>
<text top="1088" left="64" width="350" height="15" font="5">nosis. In this study, both increase of vegetation size under</text>
<text top="103" left="450" width="350" height="15" font="5">antibiotic therapy (observed in 10.5% of patients with IE)</text>
<text top="121" left="450" width="350" height="15" font="5">and reduction of vegetation size under therapy were associ-</text>
<text top="139" left="450" width="350" height="15" font="5">ated with an increased embolic risk. Thus, increasing vege-</text>
<text top="157" left="450" width="350" height="15" font="5">tation size under therapy must be considered a risk factor for</text>
<text top="175" left="450" width="350" height="15" font="5">new embolic events, whereas unchanged or reduced vege-</text>
<text top="193" left="450" width="247" height="15" font="5">tation size under therapy may be more dif</text>
<text top="189" left="696" width="104" height="19" font="5">ﬁcult to interpret.</text>
<text top="211" left="465" width="335" height="15" font="5">Compared with TTE, TEE is more sensitive for</text>
<text top="228" left="450" width="350" height="15" font="5">detection of vegetations and thrombi associated with de-</text>
<text top="246" left="450" width="350" height="15" font="5">vice leads. There are emerging data that intracardiac</text>
<text top="264" left="450" width="350" height="15" font="5">echocardiography may be an increasingly useful tool to</text>
<text top="282" left="450" width="350" height="15" font="5">diagnose vegetations that may be present on right-sided</text>
<text top="300" left="450" width="350" height="15" font="5">pacemaker leads. It has shown superior sensitivity over</text>
<text top="318" left="450" width="201" height="15" font="5">TEE in identifying these lesions.</text>
<text top="337" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="336" left="597" width="80" height="15" font="6"><a href="e57.full.html#115">(664,670,673</a></text>
<text top="333" left="677" width="35" height="19" font="6"><a href="e57.full.html#115">–681)</a></text>
<text top="364" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="379" left="449" width="351" height="10" font="21">6. TTE and/or TEE are recommended for re-evaluation of patients</text>
<text top="396" left="467" width="332" height="10" font="21">with IE who have a change in clinical signs or symptoms (e.g.,</text>
<text top="412" left="467" width="332" height="10" font="21">new murmur, embolism, persistent fever, HF, abscess, or</text>
<text top="429" left="467" width="332" height="10" font="21">atrioventricular heart block) and in patients at high risk of</text>
<text top="445" left="467" width="333" height="10" font="21">complications (e.g., extensive infected tissue/large vegetation</text>
<text top="461" left="467" width="332" height="10" font="21">on initial echocardiogram or staphylococcal, enterococcal,</text>
<text top="478" left="467" width="92" height="10" font="21">fungal infections)</text>
<text top="478" left="563" width="55" height="10" font="22"><a href="e57.full.html#116">(679,682)</a></text>
<text top="478" left="618" width="121" height="12" font="21"><a href="e57.full.html#116">. </a>(Level of Evidence: B)</text>
<text top="502" left="465" width="335" height="15" font="5">HF, perivalvular extension, and embolic events represent</text>
<text top="520" left="450" width="350" height="15" font="5">the 3 most frequent and severe complications of IE. They</text>
<text top="538" left="450" width="350" height="15" font="5">are also the 3 main indications for early surgery, which is</text>
<text top="556" left="450" width="350" height="15" font="5">performed in almost 50% of cases. If signs or symptoms</text>
<text top="574" left="450" width="350" height="15" font="5">consistent with any of these complications exist, there</text>
<text top="592" left="450" width="350" height="15" font="5">should be a very low threshold for repeat imaging in these</text>
<text top="610" left="450" width="350" height="15" font="5">patients. TEE may miss initial paravalvular abscesses,</text>
<text top="628" left="450" width="350" height="15" font="5">particularly when the study is performed early in the pa-</text>
<text top="646" left="450" width="27" height="15" font="5">tient</text>
<text top="642" left="477" width="322" height="19" font="5">’s illness. In such cases, the incipient abscess may be</text>
<text top="664" left="450" width="129" height="15" font="5">seen only as nonspeci</text>
<text top="660" left="579" width="221" height="19" font="5">ﬁc paravalvular thickening, which on</text>
<text top="682" left="450" width="350" height="15" font="5">repeat imaging across several days may become recogniz-</text>
<text top="699" left="450" width="350" height="15" font="5">able as it expands and cavitates. Similarly, paravalvular</text>
<text top="714" left="450" width="350" height="19" font="5">ﬁstulae and pseudoaneurysms develop over time, and</text>
<text top="735" left="450" width="350" height="15" font="5">negative early TEE images do not exclude the potential for</text>
<text top="753" left="450" width="350" height="15" font="5">their development. For patients who have IE that was</text>
<text top="771" left="450" width="350" height="15" font="5">diagnosed by clinical, microbiological, or surgical criteria</text>
<text top="789" left="450" width="350" height="15" font="5">but for whom results of initial TEE were false-negative,</text>
<text top="807" left="450" width="350" height="15" font="5">repeated TEE has often demonstrated vegetative IE.</text>
<text top="825" left="450" width="350" height="15" font="5">Thus, it appears that a single negative TEE study cannot</text>
<text top="843" left="450" width="350" height="15" font="5">rule out underlying IE and that a repeat TEE study should</text>
<text top="861" left="450" width="350" height="15" font="5">be performed when a suspicion of persistence of infection</text>
<text top="879" left="450" width="350" height="15" font="5">remains or if complications ensue. Conversely, in the</text>
<text top="897" left="450" width="350" height="15" font="5">absence of clinical deterioration or new signs/symptoms,</text>
<text top="915" left="450" width="350" height="15" font="5">routine follow-up echocardiography is probably of only</text>
<text top="933" left="450" width="132" height="15" font="5">limited clinical utility.</text>
<text top="951" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="951" left="597" width="98" height="15" font="6"><a href="e57.full.html#101">(52,630,665,683</a></text>
<text top="947" left="696" width="35" height="19" font="6"><a href="e57.full.html#101">–685)</a></text>
<text top="979" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="994" left="449" width="351" height="10" font="21">7. Intraoperative TEE is recommended for patients undergoing</text>
<text top="1010" left="467" width="102" height="10" font="21">valve surgery for IE</text>
<text top="1010" left="573" width="55" height="10" font="22"><a href="e57.full.html#116">(686,687)</a></text>
<text top="1010" left="628" width="121" height="12" font="21"><a href="e57.full.html#116">. </a>(Level of Evidence: B)</text>
<text top="1035" left="465" width="335" height="15" font="5">Intraoperative TEE during cardiac surgery plays an</text>
<text top="1053" left="450" width="350" height="15" font="5">important role in the evaluation and quality control of</text>
<text top="1071" left="450" width="350" height="15" font="5">a large variety of pathologies. Clinical and echocardio-</text>
<text top="1089" left="450" width="350" height="15" font="5">graphic characteristics may change during an episode of</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e132</text>
</page>
<page number="77" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="280" height="15" font="5">IE because of the prolonged active phase and</text>
<text top="99" left="350" width="64" height="19" font="5">ﬂuctuating</text>
<text top="121" left="64" width="350" height="15" font="5">course of this disease. Even if preoperative TEE has been</text>
<text top="139" left="64" width="350" height="15" font="5">performed, the possibility of vegetation change/emboli-</text>
<text top="157" left="64" width="350" height="15" font="5">zation or extension of the infectious process beyond the</text>
<text top="175" left="64" width="350" height="15" font="5">valve tissue may occur. In addition, other valves may</text>
<text top="192" left="64" width="350" height="15" font="5">become involved as the disease timeline progresses. In-</text>
<text top="210" left="64" width="350" height="15" font="5">traoperative TEE has been invaluable for baseline reas-</text>
<text top="228" left="64" width="350" height="15" font="5">sessment of anatomical/hemodynamic changes that may</text>
<text top="246" left="64" width="350" height="15" font="5">occur in the interval between the diagnostic echocardio-</text>
<text top="264" left="64" width="350" height="15" font="5">gram and the time of surgery. TEE is also an important</text>
<text top="282" left="64" width="350" height="15" font="5">monitoring tool for evaluation of operative complications</text>
<text top="300" left="64" width="350" height="15" font="5">such as air emboli and an important adjunct to ensure the</text>
<text top="318" left="64" width="229" height="15" font="5">quality of the intended surgical result.</text>
<text top="337" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="336" left="212" width="58" height="15" font="6"><a href="e57.full.html#116">(688,689)</a></text>
<text top="362" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="377" left="63" width="351" height="10" font="21">1. TEE is reasonable to diagnose possible IE in patients with</text>
<text top="393" left="81" width="333" height="12" font="21">Staphylococcal aureus (S. aureus) bacteremia without a known</text>
<text top="410" left="81" width="35" height="10" font="21">source</text>
<text top="410" left="121" width="26" height="10" font="22"><a href="e57.full.html#116">(690</a></text>
<text top="406" left="146" width="32" height="16" font="22"><a href="e57.full.html#116">–692)</a></text>
<text top="410" left="178" width="121" height="12" font="21"><a href="e57.full.html#116">. </a>(Level of Evidence: B)</text>
<text top="434" left="79" width="335" height="15" font="5">IE in patients with S. aureus bacteremia frequently in-</text>
<text top="452" left="64" width="350" height="15" font="5">volves normal cardiac valves and is seldom accompanied by</text>
<text top="470" left="64" width="350" height="15" font="5">the physical stigmata of IE, rendering the diagnosis of the</text>
<text top="488" left="64" width="61" height="15" font="5">disease dif</text>
<text top="484" left="126" width="288" height="19" font="5">ﬁcult. Reliance on physical examination ﬁndings</text>
<text top="505" left="64" width="350" height="15" font="5">and clinical stigmata is likely to result in underdiagnosis of</text>
<text top="524" left="64" width="350" height="15" font="5">S. aureus IE in a large number of cases. TEE is cost-</text>
<text top="541" left="64" width="350" height="15" font="5">effective to guide duration of therapy in patients with</text>
<text top="559" left="64" width="350" height="15" font="5">intravascular catheter-associated S. aureus bacteremia, pa-</text>
<text top="577" left="64" width="350" height="15" font="5">tients with intracardiac electronic devices, or other patients</text>
<text top="595" left="64" width="350" height="15" font="5">at higher risk for IE (including those with previous pros-</text>
<text top="613" left="64" width="292" height="15" font="5">thetic valve surgery) or associated complications.</text>
<text top="631" left="79" width="335" height="15" font="5">Despite early diagnosis and appropriate therapy, IE</text>
<text top="649" left="64" width="350" height="15" font="5">following S. aureus bacteremia is frequently associated with</text>
<text top="667" left="64" width="350" height="15" font="5">disabling and life-threatening sequelae. The overall mor-</text>
<text top="685" left="64" width="350" height="15" font="5">tality of S. aureus IE ranges from 19% to 65%. Other</text>
<text top="703" left="64" width="350" height="15" font="5">complications include HF (20% to 50%), paravalvular</text>
<text top="721" left="64" width="350" height="15" font="5">cardiac abscesses (30% to 40%), neurological manifesta-</text>
<text top="739" left="64" width="282" height="15" font="5">tions (30%), and systemic embolization (40%).</text>
<text top="757" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="757" left="212" width="111" height="15" font="6"><a href="e57.full.html#115">(652,677,693,694)</a></text>
<text top="784" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="799" left="63" width="351" height="10" font="21">2. TEE is reasonable to diagnose IE of a prosthetic valve in the</text>
<text top="815" left="81" width="332" height="10" font="21">presence of persistent fever without bacteremia or a new</text>
<text top="832" left="81" width="40" height="10" font="21">murmur</text>
<text top="832" left="125" width="55" height="10" font="22"><a href="e57.full.html#116">(695,696)</a></text>
<text top="832" left="180" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="856" left="79" width="335" height="15" font="5">When compared with NVE, PVE is characterized by</text>
<text top="874" left="64" width="350" height="15" font="5">a lower incidence of vegetations (especially in mechanical</text>
<text top="892" left="64" width="350" height="15" font="5">prostheses) and a higher incidence of annular abscess and</text>
<text top="910" left="64" width="350" height="15" font="5">other paravalvular complications. Because cardiac auscul-</text>
<text top="928" left="64" width="350" height="15" font="5">tation may also be less revealing in PVE and because</text>
<text top="946" left="64" width="350" height="15" font="5">ordinarily less virulent organisms may cause more anatomic</text>
<text top="964" left="64" width="350" height="15" font="5">destruction before culture or serological detection, it is</text>
<text top="981" left="64" width="350" height="15" font="5">important to use TEE early in these high-risk patients.</text>
<text top="999" left="64" width="350" height="15" font="5">TEE has a lower sensitivity in detecting prosthetic IE</text>
<text top="1017" left="64" width="350" height="15" font="5">when compared with TEE detection rates in NVE, so the</text>
<text top="1035" left="64" width="350" height="15" font="5">importance of comparing serial echocardiographic studies</text>
<text top="1053" left="64" width="232" height="15" font="5">is paramount to making the diagnosis.</text>
<text top="1072" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="1071" left="212" width="58" height="15" font="6"><a href="e57.full.html#116">(697,698)</a></text>
<text top="106" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="121" left="449" width="351" height="10" font="21">3. Cardiac CT is reasonable to evaluate morphology/anatomy in</text>
<text top="137" left="467" width="332" height="10" font="21">the setting of suspected paravalvular infections when the</text>
<text top="154" left="467" width="333" height="10" font="21">anatomy cannot be clearly delineated by echocardiography</text>
<text top="170" left="467" width="50" height="10" font="22"><a href="e57.full.html#116">(678,699</a></text>
<text top="167" left="517" width="32" height="16" font="22"><a href="e57.full.html#116">–701)</a></text>
<text top="170" left="549" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="195" left="465" width="212" height="15" font="5">Electrocardiographic-synchronized,</text>
<text top="195" left="691" width="108" height="15" font="5">multidetector-row</text>
<text top="213" left="450" width="350" height="15" font="5">CT is emerging as an important tool for noninvasive car-</text>
<text top="231" left="450" width="350" height="15" font="5">diac assessment and may be helpful in evaluating compli-</text>
<text top="248" left="450" width="350" height="15" font="5">cations of IE. CT may also be indicated in right-sided</text>
<text top="266" left="450" width="350" height="15" font="5">IE to demonstrate the presence of septic pulmonary in-</text>
<text top="284" left="450" width="350" height="15" font="5">farcts and abscesses. Although CT is less accurate than</text>
<text top="302" left="450" width="350" height="15" font="5">TTE and TEE for identifying valvular vegetation and</text>
<text top="320" left="450" width="350" height="15" font="5">valvular perforations, CT is useful for evaluating patients</text>
<text top="338" left="450" width="87" height="15" font="5">with equivocal</text>
<text top="335" left="542" width="257" height="19" font="5">ﬁndings on TEE and for evaluating com-</text>
<text top="356" left="450" width="350" height="15" font="5">plications in patients with suspected myocardial, pericar-</text>
<text top="374" left="450" width="350" height="15" font="5">dial, and coronary sinus extension of the infectious process.</text>
<text top="392" left="450" width="350" height="15" font="5">CT can also more sensitively detect paravalvular abscess</text>
<text top="410" left="450" width="350" height="15" font="5">involvement and evaluate extent and anatomic conse-</text>
<text top="428" left="450" width="350" height="15" font="5">quences of pseudoaneurysms and their relationship to</text>
<text top="446" left="450" width="350" height="15" font="5">adjacent structures. CT imaging is particularly useful in</text>
<text top="464" left="450" width="350" height="15" font="5">preoperative evaluation of patients with aortic valve IE to</text>
<text top="482" left="450" width="289" height="15" font="5">evaluate coronary artery and aortic involvement.</text>
<text top="500" left="465" width="335" height="15" font="5">In suspected PVE, cardiac CT is less affected by the</text>
<text top="518" left="450" width="350" height="15" font="5">shadowing of mechanical valves or bioprosthetic valve</text>
<text top="535" left="450" width="350" height="15" font="5">sewing rings than ultrasound. CT also allows evaluation of</text>
<text top="553" left="450" width="350" height="15" font="5">motion of mechanical valve occluders and provides visu-</text>
<text top="571" left="450" width="350" height="15" font="5">alization of thrombus or infective material limiting valve</text>
<text top="589" left="450" width="350" height="15" font="5">occluder motion. Additional imaging modalities such as</text>
<text top="607" left="450" width="94" height="15" font="5">cardiac valvular</text>
<text top="604" left="551" width="248" height="19" font="5">ﬂuoroscopy can be an adjunct to other</text>
<text top="625" left="450" width="350" height="15" font="5">clinical and imaging information to detect the presence of</text>
<text top="643" left="450" width="350" height="15" font="5">obstructive disease of mechanical prosthetic valves affected</text>
<text top="661" left="450" width="350" height="15" font="5">by IE. Normative values for the opening and closing angles</text>
<text top="679" left="450" width="350" height="15" font="5">are known for the common valves available for patient use.</text>
<text top="697" left="450" width="350" height="15" font="5">A combination of cineradiography and echocardiography</text>
<text top="715" left="450" width="350" height="15" font="5">makes it possible to provide an accurate and detailed</text>
<text top="733" left="450" width="350" height="15" font="5">determination of the degree and extent of valvular</text>
<text top="751" left="450" width="306" height="15" font="5">obstruction that may accompany mechanical PVE.</text>
<text top="769" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="769" left="597" width="53" height="15" font="6"><a href="e57.full.html#116">(699,702</a></text>
<text top="765" left="651" width="35" height="19" font="6"><a href="e57.full.html#116">–706)</a></text>
<text top="796" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="811" left="449" width="351" height="10" font="21">1. TEE might be considered to detect concomitant staphylococcal</text>
<text top="827" left="467" width="332" height="12" font="21">IE in nosocomial S. aureus bacteremia with a known portal of</text>
<text top="844" left="467" width="190" height="10" font="21">entry from an extracardiac source</text>
<text top="844" left="663" width="80" height="10" font="22"><a href="e57.full.html#115">(663,707,708)</a></text>
<text top="844" left="743" width="57" height="12" font="21"><a href="e57.full.html#115">. </a>(Level of</text>
<text top="860" left="467" width="65" height="12" font="21">Evidence: B)</text>
<text top="884" left="465" width="335" height="15" font="5">Because the frequency of IE among patients with</text>
<text top="903" left="450" width="350" height="15" font="5">S. aureus bacteremia is reported to be approximately 30%,</text>
<text top="920" left="450" width="350" height="15" font="5">with many cases not being clinically suspected, TEE</text>
<text top="938" left="450" width="350" height="15" font="5">should generally be pursued in the setting of S. aureus</text>
<text top="956" left="450" width="350" height="15" font="5">bacteremia to rule out IE. Even in S. aureus bacteremia</text>
<text top="974" left="450" width="350" height="15" font="5">from a known extracardiac source, such as an infected joint</text>
<text top="992" left="450" width="350" height="15" font="5">or joint prosthesis, TEE might be considered. given</text>
<text top="1010" left="450" width="350" height="15" font="5">known cases of seeding of valve tissue in this type of</text>
<text top="1028" left="450" width="350" height="15" font="5">setting. Possible exceptions are patients who have no un-</text>
<text top="1046" left="450" width="350" height="15" font="5">derlying cardiac predisposing conditions or clinical signs</text>
<text top="1064" left="450" width="350" height="15" font="5">of IE whose fever and bacteremia resolve within 72 hours</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e133</text>
</page>
<page number="78" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">after removal of a likely infected focus (such as intravascu-</text>
<text top="121" left="64" width="350" height="15" font="5">lar catheter removal). In the absence of 1) prolonged</text>
<text top="139" left="64" width="64" height="15" font="5">bacteremia</text>
<text top="135" left="135" width="279" height="19" font="5">&gt;4 days, 2) a permanent intracardiac device,</text>
<text top="157" left="64" width="350" height="15" font="5">3) hemodialysis dependency, and 4) spinal infection or</text>
<text top="175" left="64" width="350" height="15" font="5">nonvertebral osteomyelitis, the risk of IE is relatively low,</text>
<text top="192" left="64" width="242" height="15" font="5">and routine TEE may not be necessary.</text>
<text top="211" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="210" left="212" width="111" height="15" font="6"><a href="e57.full.html#115">(663,691,692,709)</a></text>
<text top="258" left="64" width="284" height="15" font="5">12.2.2. Medical Therapy: Recommendations</text>
<text top="284" left="65" width="18" height="15" font="5">See</text>
<text top="284" left="90" width="171" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 24</a></text>
<text top="284" left="269" width="145" height="15" font="5">for more information on</text>
<text top="302" left="64" width="99" height="15" font="5">surgical outcomes.</text>
<text top="329" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="344" left="64" width="350" height="10" font="21">1. Appropriate antibiotic therapy should be initiated and continued</text>
<text top="360" left="82" width="332" height="10" font="21">after blood cultures are obtained with guidance from antibiotic</text>
<text top="377" left="82" width="290" height="10" font="21">sensitivity data and infectious disease consultants</text>
<text top="377" left="380" width="30" height="10" font="22"><a href="e57.full.html#115">(636)</a></text>
<text top="377" left="410" width="3" height="10" font="21">.</text>
<text top="393" left="82" width="113" height="12" font="21">(Level of Evidence: B)</text>
<text top="417" left="79" width="335" height="15" font="5">Optimal treatment of IE is based on the appropriately</text>
<text top="435" left="64" width="350" height="15" font="5">timed initiation of antimicrobial therapy that is effective</text>
<text top="453" left="64" width="99" height="15" font="5">against the speci</text>
<text top="450" left="163" width="250" height="19" font="5">ﬁc infective organism involved. Empirical</text>
<text top="471" left="64" width="350" height="15" font="5">therapy may be necessary in patients with septic shock or</text>
<text top="489" left="64" width="350" height="15" font="5">who show high-risk signs on presentation; however, tar-</text>
<text top="507" left="64" width="350" height="15" font="5">geted antimicrobial therapy guided by minimum inhibitory</text>
<text top="525" left="64" width="350" height="15" font="5">concentration is the goal. The minimum inhibitory con-</text>
<text top="543" left="64" width="350" height="15" font="5">centration is used to determine the antibiotic dosage that</text>
<text top="561" left="64" width="350" height="15" font="5">the patient will receive and the type of antibiotic used and</text>
<text top="579" left="64" width="350" height="15" font="5">can lower the opportunity for microbial resistance to spe-</text>
<text top="597" left="64" width="10" height="15" font="5">ci</text>
<text top="593" left="74" width="340" height="19" font="5">ﬁc antimicrobial agents. Prompt use of antibiotics</text>
<text top="615" left="64" width="28" height="15" font="5">signi</text>
<text top="611" left="93" width="321" height="19" font="5">ﬁcantly reduces the incidence of emboli in patients</text>
<text top="633" left="64" width="350" height="15" font="5">with IE. Duration of therapy needs to be guided by those</text>
<text top="651" left="64" width="125" height="15" font="5">with expertise in the</text>
<text top="647" left="194" width="220" height="19" font="5">ﬁeld of antibiotic therapy. Although</text>
<text top="668" left="64" width="350" height="15" font="5">no RCTs have been performed with the use of antibiotic</text>
<text top="686" left="64" width="350" height="15" font="5">therapy in IE, the mortality rate before the antibiotic age</text>
<text top="704" left="64" width="350" height="15" font="5">neared 100%. Despite advances in knowledge of mecha-</text>
<text top="722" left="64" width="350" height="15" font="5">nism of therapeutic approaches to treating infections and</text>
<text top="740" left="64" width="87" height="15" font="5">despite a signi</text>
<text top="737" left="151" width="263" height="19" font="5">ﬁcant expansion of the antimicrobial arma-</text>
<text top="758" left="64" width="350" height="15" font="5">mentarium, the emergence of resistant organisms has led to</text>
<text top="776" left="64" width="350" height="15" font="5">continued complexity in the approach to patients with</text>
<text top="794" left="64" width="350" height="15" font="5">systemic infections. Antimicrobial therapy for NVE and</text>
<text top="812" left="64" width="290" height="15" font="5">PVE should be guided by the susceptibility pro</text>
<text top="809" left="354" width="59" height="19" font="5">ﬁle of the</text>
<text top="830" left="64" width="171" height="15" font="5">causative organism. Speci</text>
<text top="827" left="236" width="178" height="19" font="5">ﬁc antimicrobial regimens,</text>
<text top="848" left="64" width="350" height="15" font="5">depending on the causative microorganism, have been</text>
<text top="866" left="64" width="350" height="15" font="5">published by the British Society for Antimicrobial</text>
<text top="884" left="64" width="350" height="15" font="5">Chemotherapy and the AHA. Given the ever-changing</text>
<text top="902" left="64" width="350" height="15" font="5">spectrum of antimicrobial sensitivity, as well as regional</text>
<text top="920" left="64" width="83" height="15" font="5">and site-speci</text>
<text top="916" left="147" width="267" height="19" font="5">ﬁc differences in antimicrobial susceptibility</text>
<text top="937" left="64" width="20" height="15" font="5">pro</text>
<text top="934" left="84" width="330" height="19" font="5">ﬁles, concomitant management with the assistance of a</text>
<text top="955" left="64" width="350" height="15" font="5">consultant thoroughly familiar with these patterns is</text>
<text top="973" left="64" width="66" height="15" font="5">imperative.</text>
<text top="992" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="991" left="212" width="106" height="15" font="6"><a href="e57.full.html#115">(633,634,636,710</a></text>
<text top="988" left="318" width="35" height="19" font="6"><a href="e57.full.html#115">–713)</a></text>
<text top="1018" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="1033" left="63" width="351" height="10" font="21">1. It is reasonable to temporarily discontinue anticoagulation in</text>
<text top="1050" left="81" width="333" height="10" font="21">patients with IE who develop central nervous system symptoms</text>
<text top="1066" left="81" width="333" height="10" font="21">compatible with embolism or stroke regardless of the other in-</text>
<text top="1083" left="81" width="151" height="10" font="21">dications for anticoagulation</text>
<text top="1083" left="236" width="26" height="10" font="22"><a href="e57.full.html#116">(714</a></text>
<text top="1080" left="262" width="32" height="16" font="22"><a href="e57.full.html#116">–719)</a></text>
<text top="1083" left="294" width="120" height="12" font="21"><a href="e57.full.html#116">. </a>(Level of Evidence: B)</text>
<text top="103" left="465" width="335" height="15" font="5">There are several potential mechanisms of stroke in</text>
<text top="121" left="450" width="350" height="15" font="5">patients with IE, including hemorrhagic transformation of</text>
<text top="139" left="450" width="350" height="15" font="5">an ischemic infarct, septic erosion of an arteritic vessel</text>
<text top="157" left="450" width="350" height="15" font="5">without aneurysm formation, and rupture of a mycotic</text>
<text top="175" left="450" width="350" height="15" font="5">aneurysm. Approximately 15% to 35% of all patients with</text>
<text top="192" left="450" width="350" height="15" font="5">IE develop clinically evident systemic emboli. If more</text>
<text top="210" left="450" width="350" height="15" font="5">sensitive tests such as cerebral magnetic resonance imaging</text>
<text top="228" left="450" width="350" height="15" font="5">are used, a much higher proportion of patients with IE</text>
<text top="246" left="450" width="150" height="15" font="5">have evidence of emboli (</text>
<text top="243" left="600" width="199" height="19" font="5">30%). The most common cause</text>
<text top="264" left="450" width="350" height="15" font="5">of stroke in patients with IE in the modern antimicrobial</text>
<text top="282" left="450" width="350" height="15" font="5">era is a septic embolus resulting in ischemia, often followed</text>
<text top="300" left="450" width="350" height="15" font="5">by hemorrhagic transformation. Anticoagulant therapy</text>
<text top="318" left="450" width="350" height="15" font="5">may increase the risk of an embolic infarct converting to a</text>
<text top="336" left="450" width="350" height="15" font="5">hemorrhagic infarct. Hemorrhagic transformations can</text>
<text top="354" left="450" width="350" height="15" font="5">occur up to 11 days after an initial infarct. On the other</text>
<text top="372" left="450" width="350" height="15" font="5">hand, the longer anticoagulation is withheld, the higher</text>
<text top="390" left="450" width="350" height="15" font="5">the chance of recurrent embolization or valve dysfunction</text>
<text top="408" left="450" width="197" height="15" font="5">in patients with PVE. The bene</text>
<text top="404" left="647" width="152" height="19" font="5">ﬁcial or deleterious effect</text>
<text top="426" left="450" width="350" height="15" font="5">of anticoagulation in patients with IE is determined by</text>
<text top="444" left="450" width="350" height="15" font="5">a multitude of clinical, bacteriologic, radiological, and</text>
<text top="461" left="450" width="350" height="15" font="5">echocardiographic variables that may tilt the balance of the</text>
<text top="479" left="450" width="350" height="15" font="5">risk toward early recurrent stroke or intracranial hemor-</text>
<text top="497" left="450" width="350" height="15" font="5">rhage. Patients with IE and a cerebral embolism or stroke</text>
<text top="515" left="450" width="350" height="15" font="5">should be referred to a center with a multispecialty Heart</text>
<text top="533" left="450" width="193" height="15" font="5">Valve Team. A specialist in the</text>
<text top="530" left="648" width="152" height="19" font="5">ﬁeld of neurology and/or</text>
<text top="551" left="450" width="350" height="15" font="5">neuroradiology should be added to this team when the</text>
<text top="569" left="450" width="350" height="15" font="5">complication of stroke arises in IE. The risk of bleeding</text>
<text top="587" left="450" width="350" height="15" font="5">complications should be included in the assessment of</text>
<text top="605" left="450" width="319" height="15" font="5">patients with IE receiving anticoagulation treatment.</text>
<text top="624" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="623" left="597" width="46" height="15" font="6"><a href="e57.full.html#100">(12,720</a></text>
<text top="620" left="643" width="35" height="19" font="6"><a href="e57.full.html#100">–726)</a></text>
<text top="650" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="665" left="449" width="351" height="10" font="21">1. Temporary discontinuation of VKA anticoagulation might be</text>
<text top="681" left="467" width="333" height="10" font="21">considered in patients receiving VKA anticoagulation at the</text>
<text top="698" left="467" width="105" height="10" font="21">time of IE diagnosis</text>
<text top="698" left="576" width="50" height="10" font="22"><a href="e57.full.html#116">(715,727</a></text>
<text top="695" left="627" width="32" height="16" font="22"><a href="e57.full.html#116">–730)</a></text>
<text top="698" left="658" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="722" left="465" width="335" height="15" font="5">In patients with NVE, routine use of VKA is not rec-</text>
<text top="740" left="450" width="350" height="15" font="5">ommended unless a separate indication exists. There is no</text>
<text top="758" left="450" width="350" height="15" font="5">conclusive evidence that prophylactic use of VKA anti-</text>
<text top="776" left="450" width="350" height="15" font="5">coagulation reduces the incidence of emboli in patients</text>
<text top="794" left="450" width="27" height="15" font="5">with</text>
<text top="794" left="493" width="33" height="15" font="5">NVE</text>
<text top="794" left="542" width="25" height="15" font="5">who</text>
<text top="794" left="584" width="27" height="15" font="5">have</text>
<text top="794" left="627" width="15" height="15" font="5">no</text>
<text top="794" left="659" width="31" height="15" font="5">other</text>
<text top="794" left="707" width="60" height="15" font="5">indication</text>
<text top="794" left="783" width="17" height="15" font="5">for</text>
<text top="812" left="450" width="95" height="15" font="5">anticoagulation.</text>
<text top="830" left="465" width="335" height="15" font="5">Alternatively, for patients already receiving anti-</text>
<text top="848" left="450" width="350" height="15" font="5">coagulation with VKA or aspirin for other evidence-based</text>
<text top="866" left="450" width="350" height="15" font="5">indications at the time of diagnosis with IE, there is little</text>
<text top="884" left="450" width="213" height="15" font="5">information on the risks and bene</text>
<text top="880" left="663" width="137" height="19" font="5">ﬁts of continued anti-</text>
<text top="902" left="450" width="350" height="15" font="5">coagulation therapy. Continuing anticoagulant therapy</text>
<text top="919" left="450" width="350" height="15" font="5">in the face of IE potentially increases the risk of hemor-</text>
<text top="937" left="450" width="350" height="15" font="5">rhagic transformation of an embolic stroke or accentuation</text>
<text top="955" left="450" width="350" height="15" font="5">of bleeding from septic arteritis or mycotic aneurysms</text>
<text top="973" left="450" width="350" height="15" font="5">should they occur. The evidence and propensity of expert</text>
<text top="991" left="450" width="350" height="15" font="5">consensus would suggest that VKAs be discontinued at the</text>
<text top="1009" left="450" width="350" height="15" font="5">time of initial presentation with IE secondary to the</text>
<text top="1027" left="450" width="350" height="15" font="5">combined risk of bleeding from potentially urgent invasive</text>
<text top="1045" left="450" width="350" height="15" font="5">procedures and the risk of developing hemorrhagic stroke.</text>
<text top="1063" left="450" width="350" height="15" font="5">Early surgery is required in roughly 50% of patients with</text>
<text top="1081" left="450" width="350" height="15" font="5">PVE. Although there is no evidence regarding the use of</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e134</text>
</page>
<page number="79" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">bridging therapy with intravenous or subcutaneous anti-</text>
<text top="121" left="64" width="350" height="15" font="5">coagulant therapy while patients are off VKAs, studies</text>
<text top="139" left="64" width="350" height="15" font="5">indicate that there is increased risk of hemorrhagic stroke</text>
<text top="157" left="64" width="350" height="15" font="5">in patients on intravenous UFH during the acute phase</text>
<text top="175" left="64" width="350" height="15" font="5">of acute IE. It should be noted that the strength of this</text>
<text top="192" left="64" width="350" height="15" font="5">evidence is low, and some institutional practices continue</text>
<text top="210" left="64" width="350" height="15" font="5">VKA anticoagulation until an invasive procedure is</text>
<text top="228" left="64" width="86" height="15" font="5">deemed a de</text>
<text top="225" left="150" width="264" height="19" font="5">ﬁnitive necessity or until a neurological</text>
<text top="246" left="64" width="350" height="15" font="5">complication develops or is noted on imaging studies.</text>
<text top="264" left="64" width="350" height="15" font="5">Decisions about continued anticoagulation and antiplatelet</text>
<text top="282" left="64" width="341" height="15" font="5">therapy should ultimately be directed by the patient</text>
<text top="279" left="406" width="8" height="19" font="5">’s</text>
<text top="300" left="64" width="350" height="15" font="5">consulting cardiologist and cardiothoracic surgeon in con-</text>
<text top="318" left="64" width="298" height="15" font="5">sultation with a neurology specialist if neurological</text>
<text top="315" left="366" width="48" height="19" font="5">ﬁndings</text>
<text top="336" left="64" width="350" height="15" font="5">are clinically present or noted on imaging. Although there</text>
<text top="354" left="64" width="350" height="15" font="5">is no strong evidence base for screening neurological im-</text>
<text top="372" left="64" width="350" height="15" font="5">aging studies and their potential impact on management,</text>
<text top="390" left="64" width="350" height="15" font="5">the data are strong that subclinical neurological abnor-</text>
<text top="408" left="64" width="350" height="15" font="5">malities are common, occurring in 25% of patients with</text>
<text top="426" left="64" width="350" height="15" font="5">IE and S. aureus and up to 55% of critically ill patients with</text>
<text top="444" left="64" width="350" height="15" font="5">IE. In patients with valvular or nonvalvular indications</text>
<text top="461" left="64" width="350" height="15" font="5">for continued use of VKAs, strong consideration should</text>
<text top="479" left="64" width="350" height="15" font="5">be given to cerebral magnetic resonance imaging to eval-</text>
<text top="497" left="64" width="350" height="15" font="5">uate for subclinical cerebrovascular complications to help</text>
<text top="515" left="64" width="350" height="15" font="5">guide anticoagulation management. Novel oral anticoagu-</text>
<text top="533" left="64" width="210" height="15" font="5">lants have no indication for VHD.</text>
<text top="551" left="79" width="335" height="15" font="5">In patients with IE, routine antiplatelet therapy is not</text>
<text top="569" left="64" width="350" height="15" font="5">recommended unless a separate indication exists. There</text>
<text top="587" left="64" width="350" height="15" font="5">is no evidence that routine use of aspirin in the setting of</text>
<text top="605" left="64" width="350" height="15" font="5">IE reduces risk of embolic stroke in patients who are</text>
<text top="623" left="64" width="350" height="15" font="5">already receiving antibiotic therapy. However, large retro-</text>
<text top="641" left="64" width="349" height="15" font="5">spective studies have suggested that embolism associated</text>
<text top="659" left="64" width="350" height="15" font="5">with IE occurs less frequently among patients who have</text>
<text top="677" left="64" width="350" height="15" font="5">received continuous daily antiplatelet therapy for other</text>
<text top="695" left="64" width="232" height="15" font="5">indications before the diagnosis of IE.</text>
<text top="713" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="713" left="212" width="46" height="15" font="6"><a href="e57.full.html#100">(12,728</a></text>
<text top="709" left="258" width="35" height="19" font="6"><a href="e57.full.html#100">–735)</a></text>
<text top="743" left="64" width="73" height="8" font="20">CLASS III: Harm</text>
<text top="758" left="63" width="351" height="10" font="21">1. Patients with known VHD should not receive antibiotics before</text>
<text top="774" left="81" width="332" height="12" font="21">blood cultures are obtained for unexplained fever. (Level of</text>
<text top="791" left="81" width="65" height="12" font="21">Evidence: C)</text>
<text top="815" left="79" width="335" height="15" font="5">Two sets of blood cultures are the minimum for a secure</text>
<text top="833" left="64" width="317" height="15" font="5">microbiological diagnosis of IE. The leading cause of</text>
<text top="829" left="385" width="28" height="19" font="5">“cul-</text>
<text top="851" left="64" width="107" height="15" font="5">ture-negative IE,</text>
<text top="847" left="172" width="242" height="19" font="5">” which can be a signiﬁcant clinical</text>
<text top="869" left="64" width="350" height="15" font="5">conundrum, is the use of antibiotics before blood cultures</text>
<text top="887" left="64" width="350" height="15" font="5">are obtained. Negative blood cultures in the setting of IE can</text>
<text top="904" left="64" width="350" height="15" font="5">delay diagnosis by slowing other serological and polymerase</text>
<text top="922" left="64" width="308" height="15" font="5">chain reaction assessments; therefore, it can delay de</text>
<text top="919" left="373" width="41" height="19" font="5">ﬁnitive</text>
<text top="940" left="64" width="350" height="15" font="5">treatment of the patient as well as impair determination of</text>
<text top="958" left="64" width="266" height="15" font="5">antimicrobial treatment duration. The identi</text>
<text top="955" left="330" width="83" height="19" font="5">ﬁcation of the</text>
<text top="976" left="64" width="247" height="15" font="5">causative pathogen will improve the speci</text>
<text top="973" left="311" width="102" height="19" font="5">ﬁcity of the ther-</text>
<text top="994" left="64" width="200" height="15" font="5">apeutic regimen and may signi</text>
<text top="991" left="264" width="150" height="19" font="5">ﬁcantly improve patient</text>
<text top="1012" left="64" width="350" height="15" font="5">outcome. S. aureus is the most common pathogen respon-</text>
<text top="1030" left="64" width="350" height="15" font="5">sible for PVE but still accounts for only 23% of cases.</text>
<text top="1048" left="64" width="350" height="15" font="5">Antibiotic therapy is most effective if the identity and</text>
<text top="1066" left="64" width="306" height="15" font="5">sensitivities of the responsible organism are known.</text>
<text top="1085" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="1084" left="212" width="84" height="15" font="6"><a href="e57.full.html#117">(724,736,737)</a></text>
<text top="103" left="450" width="255" height="15" font="5">12.2.3. Intervention: Recommendations</text>
<text top="128" left="451" width="21" height="15" font="5">See</text>
<text top="128" left="475" width="50" height="15" font="6"><a href="e57.full.html#80">Figure 9</a></text>
<text top="128" left="529" width="225" height="15" font="5">for diagnosis and treatment of IE and</text>
<text top="128" left="758" width="42" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online</a></text>
<text top="146" left="450" width="132" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Data Supplement 24</a></text>
<text top="146" left="590" width="210" height="15" font="5">for more information on surgical</text>
<text top="164" left="450" width="60" height="15" font="5">outcomes.</text>
<text top="194" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="209" left="449" width="351" height="10" font="21">1. Decisions about timing of surgical intervention should be made</text>
<text top="226" left="467" width="332" height="10" font="21">by a multispecialty Heart Valve Team of cardiology, cardiotho-</text>
<text top="242" left="467" width="250" height="10" font="21">racic surgery, and infectious disease specialists</text>
<text top="242" left="720" width="30" height="10" font="22"><a href="e57.full.html#115">(651)</a></text>
<text top="242" left="750" width="50" height="12" font="21"><a href="e57.full.html#115">. </a>(Level of</text>
<text top="259" left="467" width="65" height="12" font="21">Evidence: B)</text>
<text top="283" left="465" width="335" height="15" font="5">The in-hospital mortality rate for IE is high, at 15% to</text>
<text top="301" left="450" width="72" height="15" font="5">20%, with 1</text>
<text top="297" left="522" width="277" height="19" font="5">–year mortality approaching 40%. Given those</text>
<text top="319" left="450" width="350" height="15" font="5">rates and the complexities and uncertainties about surgical</text>
<text top="337" left="450" width="350" height="15" font="5">timing/indications related to comorbid conditions in many</text>
<text top="355" left="450" width="350" height="15" font="5">of these patients, it is recommended that patients with IE</text>
<text top="372" left="450" width="350" height="15" font="5">be managed in an environment with ready access to spe-</text>
<text top="390" left="450" width="82" height="15" font="5">cialists in the</text>
<text top="387" left="538" width="262" height="19" font="5">ﬁelds of cardiology, cardiothoracic surgery,</text>
<text top="408" left="450" width="350" height="15" font="5">and infectious disease. Cardiothoracic surgical consultation</text>
<text top="426" left="450" width="350" height="15" font="5">should be obtained rapidly after the diagnosis of IE. A</text>
<text top="444" left="450" width="350" height="15" font="5">risk-scoring system using the STS database has been</text>
<text top="462" left="450" width="350" height="15" font="5">developed to predict risk of surgery in patients with IE to</text>
<text top="480" left="450" width="327" height="15" font="5">help better counsel patients and more objectively de</text>
<text top="477" left="777" width="22" height="19" font="5">ﬁne</text>
<text top="498" left="450" width="350" height="15" font="5">risks of surgery. One trial noted that even when surgery is</text>
<text top="516" left="450" width="350" height="15" font="5">indicated, women were less likely to undergo a surgical</text>
<text top="534" left="450" width="350" height="15" font="5">procedure than men (26% versus 47%) and that women</text>
<text top="552" left="450" width="169" height="15" font="5">had higher in-hospital and 1</text>
<text top="548" left="619" width="181" height="19" font="5">–year mortality rates than men</text>
<text top="570" left="450" width="350" height="15" font="5">despite similar comorbidities. To prevent subjective bias in</text>
<text top="588" left="450" width="350" height="15" font="5">decision making for patients, it is recommended that</text>
<text top="606" left="450" width="350" height="15" font="5">hospitals use system policies to ensure best practices in</text>
<text top="624" left="450" width="103" height="15" font="5">patients with IE.</text>
<text top="642" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="642" left="598" width="27" height="15" font="6"><a href="e57.full.html#117">(738</a></text>
<text top="638" left="625" width="35" height="19" font="6"><a href="e57.full.html#117">–740)</a></text>
<text top="672" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="687" left="449" width="351" height="10" font="21">2. Early surgery (during initial hospitalization before completion of</text>
<text top="703" left="467" width="333" height="10" font="21">a full therapeutic course of antibiotics) is indicated in patients</text>
<text top="720" left="467" width="332" height="10" font="21">with IE who present with valve dysfunction resulting in symp-</text>
<text top="736" left="467" width="58" height="10" font="21">toms of HF</text>
<text top="736" left="529" width="26" height="10" font="22"><a href="e57.full.html#117">(741</a></text>
<text top="733" left="555" width="32" height="16" font="22"><a href="e57.full.html#117">–746)</a></text>
<text top="736" left="587" width="121" height="12" font="21"><a href="e57.full.html#117">. </a>(Level of Evidence: B)</text>
<text top="760" left="465" width="335" height="15" font="5">Death may occur suddenly in patients with endocarditis-</text>
<text top="778" left="450" width="350" height="15" font="5">induced HF, particularly if the aortic valve is involved. The</text>
<text top="796" left="450" width="350" height="15" font="5">ICE-PCS (International Collaboration on Endocarditis-</text>
<text top="814" left="450" width="350" height="15" font="5">Prospective Cohort Study) has reported a 21% in-</text>
<text top="832" left="450" width="350" height="15" font="5">hospital mortality rate in patients with IE with HF</text>
<text top="850" left="450" width="350" height="15" font="5">treated with surgery versus a 45% mortality rate in those</text>
<text top="868" left="450" width="350" height="15" font="5">who were medically treated. One-year mortality in this</text>
<text top="886" left="450" width="350" height="15" font="5">study was 29.1% in patients undergoing valvular surgery</text>
<text top="904" left="450" width="350" height="15" font="5">versus 58.4% in those not undergoing surgery. In</text>
<text top="922" left="450" width="350" height="15" font="5">complicated left-heart NVE, 4 baseline features have</text>
<text top="940" left="450" width="237" height="15" font="5">been independently associated with 6</text>
<text top="936" left="687" width="113" height="19" font="5">–month mortality:</text>
<text top="958" left="450" width="350" height="15" font="5">abnormal mental status, moderate-to-severe HF, bacterial</text>
<text top="976" left="450" width="350" height="15" font="5">etiology other than Viridans streptococci, and medical ther-</text>
<text top="993" left="450" width="259" height="15" font="5">apy without valve surgery. This risk strati</text>
<text top="990" left="709" width="91" height="19" font="5">ﬁcation system</text>
<text top="1011" left="450" width="298" height="15" font="5">has been validated in a separate cohort, and similar</text>
<text top="1008" left="751" width="48" height="19" font="5">ﬁndings</text>
<text top="1029" left="450" width="350" height="15" font="5">have been reproduced in both retrospective propensity</text>
<text top="1047" left="450" width="350" height="15" font="5">studies and prospective studies. Prompt surgical consulta-</text>
<text top="1065" left="450" width="350" height="15" font="5">tion should be obtained in all cases of IE to assist with</text>
<text top="1083" left="450" width="350" height="15" font="5">assessment of the need for surgical treatment and to</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e135</text>
</page>
<page number="80" position="absolute" top="0" left="0" height="1160" width="864">
<text top="730" left="64" width="350" height="15" font="5">help judge the timing of surgery. Further prospective</text>
<text top="748" left="64" width="350" height="15" font="5">randomized studies with large study populations are</text>
<text top="766" left="64" width="350" height="15" font="5">necessary to more precisely evaluate the optimal timing</text>
<text top="784" left="64" width="200" height="15" font="5">of surgery in patients with NVE.</text>
<text top="802" left="79" width="335" height="15" font="5">Reinfection after prosthetic valve surgery (which occurs</text>
<text top="820" left="64" width="245" height="15" font="5">in 5% to 10% of patients, with a signi</text>
<text top="817" left="310" width="104" height="19" font="5">ﬁcant percentage</text>
<text top="838" left="64" width="350" height="15" font="5">of these being injectable drug users) is low relative to the</text>
<text top="856" left="64" width="350" height="15" font="5">risk of no surgery in patients with hemodynamic and</text>
<text top="874" left="64" width="350" height="15" font="5">microbial indications for surgery. Repair rather than</text>
<text top="892" left="64" width="350" height="15" font="5">replacement of a valve is always best; however, such re-</text>
<text top="910" left="64" width="350" height="15" font="5">pairs are possible in only a minority of cases, such as when</text>
<text top="928" left="64" width="34" height="15" font="5">a lea</text>
<text top="924" left="98" width="316" height="19" font="5">ﬂet perforation occurs without extensive leaﬂet</text>
<text top="946" left="64" width="350" height="15" font="5">destruction or annular involvement. PVE is clearly as-</text>
<text top="964" left="64" width="350" height="15" font="5">sociated with both higher mortality rates (especially if</text>
<text top="981" left="64" width="350" height="15" font="5">associated with a new murmur, HF, or severe valvular</text>
<text top="999" left="64" width="350" height="15" font="5">dysfunction or if the infectious microbe is staphylococ-</text>
<text top="1017" left="64" width="350" height="15" font="5">cal or fungal) and higher post-treatment HF-related</text>
<text top="1035" left="64" width="350" height="15" font="5">disability. Most surgical series report a surgical rate of</text>
<text top="1053" left="64" width="350" height="15" font="5">nearly 50% in patients with PVE. Up to 20% more would</text>
<text top="1071" left="64" width="28" height="15" font="5">bene</text>
<text top="1068" left="93" width="321" height="19" font="5">ﬁt from surgery if it were not for an already developed</text>
<text top="1089" left="64" width="350" height="15" font="5">catastrophic complication. Surgical debridement and</text>
<text top="730" left="450" width="350" height="15" font="5">replacement of the infected prosthetic valve lead to</text>
<text top="748" left="450" width="29" height="15" font="5">signi</text>
<text top="745" left="479" width="321" height="19" font="5">ﬁcantly lower mortality (23%) compared with med-</text>
<text top="766" left="450" width="350" height="15" font="5">ical therapy alone (56%). Improved outcome was seen for</text>
<text top="784" left="450" width="350" height="15" font="5">the surgical group even when controlling for severity of</text>
<text top="802" left="450" width="350" height="15" font="5">illness at time of diagnosis. In a series of 1,025 patients</text>
<text top="820" left="450" width="342" height="15" font="5">with PVE, early surgery did not reduce in-hospital or 1</text>
<text top="817" left="792" width="7" height="19" font="5">–</text>
<text top="838" left="450" width="350" height="15" font="5">year mortality when adjusted for the propensity to operate</text>
<text top="856" left="450" width="350" height="15" font="5">and the effect of survivor bias. However, subgroup analysis</text>
<text top="874" left="450" width="350" height="15" font="5">indicated that patients with the strongest indications for</text>
<text top="892" left="450" width="350" height="15" font="5">surgery (new left-sided valve regurgitation, paravalvular</text>
<text top="910" left="450" width="60" height="15" font="5">abscess or</text>
<text top="906" left="514" width="285" height="19" font="5">ﬁstula, prosthetic valve dehiscence, or HF) did</text>
<text top="928" left="450" width="99" height="15" font="5">have a lower 1</text>
<text top="924" left="549" width="250" height="19" font="5">–year mortality rate with early surgery</text>
<text top="946" left="450" width="144" height="15" font="5">(27.9% versus 50.0%; p</text>
<text top="942" left="594" width="54" height="19" font="5">¼0.007).</text>
<text top="964" left="465" width="88" height="15" font="5">PVE is classi</text>
<text top="960" left="552" width="247" height="19" font="5">ﬁed into “early-,” “intermediate-,” and</text>
<text top="978" left="450" width="350" height="19" font="5">“late-” onset PVE. Early-onset PVE is deﬁned as occur-</text>
<text top="1000" left="450" width="95" height="15" font="5">ring within the</text>
<text top="996" left="552" width="247" height="19" font="5">ﬁrst 60 days of surgery and is typically</text>
<text top="1017" left="450" width="162" height="15" font="5">associated with healthcare</text>
<text top="1014" left="612" width="188" height="19" font="5">acquired infection, with the</text>
<text top="1035" left="450" width="350" height="15" font="5">most common microbe during this time frame being</text>
<text top="1054" left="450" width="350" height="15" font="5">S. aureus. Intermediate-onset PVE occurs between 60 and</text>
<text top="1071" left="450" width="350" height="15" font="5">365 days after surgery and is associated with a mix of both</text>
<text top="1089" left="450" width="60" height="15" font="5">healthcare</text>
<text top="1086" left="510" width="289" height="19" font="5">acquired infection and community-acquired</text>
<text top="624" left="64" width="228" height="11" font="13">Figure 9. Diagnosis and Treatment of IE</text>
<text top="656" left="64" width="73" height="9" font="14">*Early surgery de</text>
<text top="654" left="137" width="408" height="13" font="14">ﬁned as during initial hospitalization before completion of a full therapeutic course of antibiotics.</text>
<text top="670" left="72" width="246" height="9" font="14">HF indicates heart failure; ICD, implantable cardioverter-de</text>
<text top="667" left="318" width="482" height="13" font="14">ﬁbrillator; IE, infective endocarditis; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; Rx, therapy;</text>
<text top="683" left="72" width="608" height="10" font="14">S. aureus, Staphylococcus aureus; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography; and VKA, vitamin K antagonist.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e136</text>
</page>
<page number="81" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">infection. The most common microbe implicated in</text>
<text top="121" left="64" width="350" height="15" font="5">intermediate-onset PVE is coagulase-negative Staphylo-</text>
<text top="139" left="64" width="350" height="15" font="5">coccus. Two thirds of all reported cases of PVE occur within</text>
<text top="157" left="64" width="19" height="15" font="5">the</text>
<text top="153" left="87" width="327" height="19" font="5">ﬁrst year of valve surgery. Late-onset PVE is deﬁned as</text>
<text top="175" left="64" width="56" height="15" font="5">occurring</text>
<text top="171" left="127" width="287" height="19" font="5">&gt;1 year after surgery. Although S. aureus and</text>
<text top="192" left="64" width="350" height="15" font="5">coagulase-negative Staphylococcus remain important infect-</text>
<text top="210" left="64" width="350" height="15" font="5">ing agents, the late-onset PVE microbial spectrum more</text>
<text top="228" left="64" width="188" height="15" font="5">closely resembles that of NVE.</text>
<text top="247" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="246" left="212" width="80" height="15" font="6"><a href="e57.full.html#115">(635,724,747</a></text>
<text top="243" left="292" width="35" height="19" font="6"><a href="e57.full.html#115">–751)</a></text>
<text top="274" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="288" left="63" width="351" height="10" font="21">3. Early surgery (during initial hospitalization before completion of</text>
<text top="305" left="81" width="333" height="10" font="21">a full therapeutic course of antibiotics) is indicated in patients</text>
<text top="321" left="81" width="333" height="12" font="21">with left-sided IE caused by S. aureus, fungal, or other highly</text>
<text top="338" left="81" width="105" height="10" font="21">resistant organisms</text>
<text top="338" left="190" width="50" height="10" font="22"><a href="e57.full.html#117">(746,752</a></text>
<text top="335" left="241" width="32" height="16" font="22"><a href="e57.full.html#117">–758)</a></text>
<text top="338" left="272" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="362" left="79" width="335" height="15" font="5">In the United States, 34% of NVE cases are due to</text>
<text top="381" left="64" width="350" height="15" font="5">S. aureus. Compared with patients with IE due to other</text>
<text top="398" left="64" width="306" height="15" font="5">organisms, patients with S. aureus IE were signi</text>
<text top="395" left="371" width="43" height="19" font="5">ﬁcantly</text>
<text top="416" left="64" width="350" height="15" font="5">more likely to die (20% versus 12%), experience an embolic</text>
<text top="434" left="64" width="350" height="15" font="5">event (60% versus 31%), have a central nervous system</text>
<text top="452" left="64" width="350" height="15" font="5">event (20% versus 13%), and not undergo surgery (26%</text>
<text top="470" left="64" width="350" height="15" font="5">versus 39%). Although mortality rates are lower in patients</text>
<text top="488" left="64" width="350" height="15" font="5">with methicillin-sensitive S. aureus, the rate of embolic</text>
<text top="506" left="64" width="350" height="15" font="5">events is even higher than that of methicillin-resistant</text>
<text top="524" left="64" width="350" height="15" font="5">S. aureus. Factors involved in the higher modern rates of</text>
<text top="542" left="64" width="350" height="15" font="5">S. aureus IE are a low prevalence of rheumatic heart disease</text>
<text top="559" left="64" width="349" height="15" font="5">(therefore an older, less immunocompetent population</text>
<text top="577" left="64" width="350" height="15" font="5">with underlying degenerative VHD), a larger population of</text>
<text top="595" left="64" width="350" height="15" font="5">hemodialysis patients, an increasing diabetic population,</text>
<text top="613" left="64" width="350" height="15" font="5">and a higher rate of prolonged use of an intravascular de-</text>
<text top="631" left="64" width="350" height="15" font="5">vice. In hospital-acquired IE, the mortality rate has been</text>
<text top="649" left="64" width="350" height="15" font="5">reported to be 2 times that of community-acquired IE,</text>
<text top="667" left="64" width="350" height="15" font="5">largely due to resistant staphylococcal and enterococcal</text>
<text top="685" left="64" width="350" height="15" font="5">species. Certain pathogens, such as Pseudomonas aerugi-</text>
<text top="704" left="64" width="350" height="15" font="5">nosa, Brucella, fungi, and gram-positive cocci (especially</text>
<text top="721" left="64" width="350" height="15" font="5">those that are resistant to beta-lactam antibiotics or van-</text>
<text top="739" left="64" width="173" height="15" font="5">comycin) are extremely dif</text>
<text top="735" left="237" width="176" height="19" font="5">ﬁcult to cure with medical</text>
<text top="757" left="64" width="350" height="15" font="5">therapy alone. Many of these organisms are also prone to</text>
<text top="775" left="64" width="47" height="15" font="5">abscess/</text>
<text top="771" left="111" width="302" height="19" font="5">ﬁstula formation and other cardiac tissue destruc-</text>
<text top="792" left="64" width="350" height="15" font="5">tion, which cannot be effectively treated with medical</text>
<text top="810" left="64" width="350" height="15" font="5">therapy alone. Despite high-quality imaging using 2D and</text>
<text top="828" left="64" width="189" height="15" font="5">even 3D TEE, false-negative</text>
<text top="825" left="262" width="152" height="19" font="5">ﬁndings for intracardiac</text>
<text top="846" left="64" width="350" height="15" font="5">abscess are as high as 60%. Similar to studies in S. aureus</text>
<text top="864" left="64" width="192" height="15" font="5">IE, the mortality rate is signi</text>
<text top="861" left="256" width="158" height="19" font="5">ﬁcantly lower in patients</text>
<text top="882" left="64" width="350" height="15" font="5">treated with antifungal agents combined with surgery</text>
<text top="900" left="64" width="350" height="15" font="5">compared with those treated with antifungal agents alone</text>
<text top="918" left="64" width="111" height="15" font="5">(42% versus 59%).</text>
<text top="936" left="79" width="335" height="15" font="5">An important distinction is made for injectable drug</text>
<text top="954" left="64" width="350" height="15" font="5">users. When Staphylococcus is the bacteria, death occurs</text>
<text top="972" left="64" width="12" height="15" font="5">in</text>
<text top="968" left="83" width="331" height="19" font="5">&lt;5% of patients with right-sided NVE; however, in</text>
<text top="990" left="64" width="350" height="15" font="5">left-sided NVE with the same organism, death ensues</text>
<text top="1008" left="64" width="350" height="15" font="5">in 20% to 30% of cases. In injectable drug users with</text>
<text top="1026" left="64" width="350" height="15" font="5">NVE, Enterococcus sp carries a mortality rate of 15% to</text>
<text top="1044" left="64" width="350" height="15" font="5">25%. Pseudomonas aeruginosa, Enterobacteriaceae, and</text>
<text top="1062" left="64" width="350" height="15" font="5">fungi, though rare, carry an overall mortality rate of</text>
<text top="1076" left="64" width="350" height="19" font="5">&gt;50% in this population. Coexisting conditions that</text>
<text top="103" left="450" width="350" height="15" font="5">increase mortality in injectable drug users include HF,</text>
<text top="121" left="450" width="350" height="15" font="5">neurological events, renal failure, and symptomatic HIV</text>
<text top="139" left="450" width="350" height="15" font="5">infection. Given the high nonsurgical cure rates of right-</text>
<text top="157" left="450" width="211" height="15" font="5">sided IE combined with the signi</text>
<text top="153" left="660" width="139" height="19" font="5">ﬁcant concern of rein-</text>
<text top="175" left="450" width="350" height="15" font="5">fection of prosthetic material in surgical intervention,</text>
<text top="193" left="450" width="350" height="15" font="5">an even more coordinated effort of surgical and nonsurgi-</text>
<text top="211" left="450" width="350" height="15" font="5">cal experts in management of NVE is necessary for</text>
<text top="229" left="450" width="127" height="15" font="5">injectable drug users.</text>
<text top="246" left="465" width="335" height="15" font="5">Staphylococcal PVE has been associated with a mor-</text>
<text top="264" left="450" width="254" height="15" font="5">tality rate as high as 70%. Given the dif</text>
<text top="261" left="704" width="96" height="19" font="5">ﬁculty in eradi-</text>
<text top="282" left="450" width="350" height="15" font="5">cating Staphylococcus spp when foreign and avascular</text>
<text top="300" left="450" width="350" height="15" font="5">material are involved in the infection, survival rates are</text>
<text top="318" left="450" width="29" height="15" font="5">signi</text>
<text top="315" left="480" width="320" height="19" font="5">ﬁcantly higher in patients who undergo surgical</text>
<text top="336" left="450" width="350" height="15" font="5">debridement and have the infected valve removed and</text>
<text top="354" left="450" width="350" height="15" font="5">replaced. Mortality rates remain higher in this group of</text>
<text top="372" left="450" width="350" height="15" font="5">patients whether treated surgically or not when compared</text>
<text top="390" left="450" width="350" height="15" font="5">with every other category of IE aside from fungal in-</text>
<text top="408" left="450" width="350" height="15" font="5">fections. Pseudomonas aeruginosa and multiresistant en-</text>
<text top="426" left="450" width="350" height="15" font="5">terococci, for which there is no synergistic bactericidal</text>
<text top="444" left="450" width="310" height="15" font="5">regimen, are also less amenable to medical therapy.</text>
<text top="462" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="462" left="597" width="132" height="15" font="6"><a href="e57.full.html#115">(652,724,747,753,759</a></text>
<text top="458" left="730" width="35" height="19" font="6"><a href="e57.full.html#115">–766)</a></text>
<text top="489" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="504" left="449" width="351" height="10" font="21">4. Early surgery (during initial hospitalization before completion of</text>
<text top="520" left="467" width="333" height="10" font="21">a full therapeutic course of antibiotics) is indicated in patients</text>
<text top="536" left="467" width="332" height="10" font="21">with IE complicated by heart block, annular or aortic abscess,</text>
<text top="553" left="467" width="187" height="10" font="21">or destructive penetrating lesions</text>
<text top="553" left="660" width="50" height="10" font="22"><a href="e57.full.html#117">(746,767</a></text>
<text top="550" left="711" width="32" height="16" font="22"><a href="e57.full.html#117">–771)</a></text>
<text top="553" left="742" width="57" height="12" font="21">. (Level of</text>
<text top="570" left="467" width="65" height="12" font="21">Evidence: B)</text>
<text top="594" left="465" width="335" height="15" font="5">Abscess of the native valves or paravalvular structures</text>
<text top="612" left="450" width="350" height="15" font="5">with or without extension to the cardiac conduction system</text>
<text top="630" left="450" width="350" height="15" font="5">is a life-threatening complication that cannot be cured</text>
<text top="647" left="450" width="350" height="15" font="5">with antibiotic therapy alone. Early recognition and</text>
<text top="665" left="450" width="350" height="15" font="5">institution of appropriate medical and surgical therapy is</text>
<text top="683" left="450" width="350" height="15" font="5">necessary for patient survival. Complete heart block in IE</text>
<text top="701" left="450" width="350" height="15" font="5">usually occurs secondary to extension of infection into the</text>
<text top="719" left="450" width="350" height="15" font="5">atrioventricular node. Heart block is most commonly</text>
<text top="737" left="450" width="350" height="15" font="5">associated with aortic valve IE, given the high prevalence</text>
<text top="755" left="450" width="350" height="15" font="5">of paravalvular extension and the proximity of the con-</text>
<text top="773" left="450" width="350" height="15" font="5">duction system to the valve (although it has also been re-</text>
<text top="791" left="450" width="350" height="15" font="5">ported in mitral and tricuspid valve IE) and is associated</text>
<text top="809" left="450" width="350" height="15" font="5">with an increased risk for sudden cardiac death and more</text>
<text top="827" left="450" width="350" height="15" font="5">severe anatomical destruction of cardiac tissues. Extensive</text>
<text top="845" left="450" width="350" height="15" font="5">perivalvular infections (to include annular/aortic abscesses</text>
<text top="863" left="450" width="241" height="15" font="5">and destructive penetrating lesions/</text>
<text top="859" left="691" width="108" height="19" font="5">ﬁstulae) respond</text>
<text top="881" left="450" width="350" height="15" font="5">poorly to medical therapy and are associated with a mor-</text>
<text top="899" left="450" width="74" height="15" font="5">tality rate of</text>
<text top="895" left="528" width="272" height="19" font="5">40%. Patients with paravalvular abscess are</text>
<text top="917" left="450" width="350" height="15" font="5">typically very ill by the time they are referred for surgery.</text>
<text top="934" left="450" width="350" height="15" font="5">Even so, the long-term results of surgery are very satis-</text>
<text top="952" left="450" width="288" height="15" font="5">factory, with an actuarial survival rate of 75%</text>
<text top="949" left="738" width="62" height="19" font="5">6% at 5</text>
<text top="970" left="450" width="350" height="15" font="5">years. Freedom from recurrent IE has been reported to be</text>
<text top="988" left="450" width="350" height="15" font="5">76% at 8 years. The 2 primary objectives of surgery are total</text>
<text top="1006" left="450" width="350" height="15" font="5">removal of infected tissues and reconstruction of functional</text>
<text top="1024" left="450" width="350" height="15" font="5">anatomy. Surgical series have shown that the surgical re-</text>
<text top="1042" left="450" width="213" height="15" font="5">sults are more related to a surgeon</text>
<text top="1039" left="663" width="136" height="19" font="5">’s ability to remove all</text>
<text top="1060" left="450" width="350" height="15" font="5">infected tissues than to the type of valve used for a</text>
<text top="1078" left="450" width="77" height="15" font="5">replacement.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e137</text>
</page>
<page number="82" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="79" width="335" height="15" font="5">Patients with PVE complicated by paravalvular invasion,</text>
<text top="121" left="64" width="242" height="15" font="5">as manifested by intracardiac abscesses,</text>
<text top="117" left="313" width="101" height="19" font="5">ﬁstulae, or heart</text>
<text top="139" left="64" width="350" height="15" font="5">block, experience high mortality rates and are rarely cured by</text>
<text top="157" left="64" width="350" height="15" font="5">medical treatment alone. By contrast, surgical series have</text>
<text top="175" left="64" width="350" height="15" font="5">reported surgical survival rates of 71% in this high-risk group.</text>
<text top="193" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="192" left="212" width="53" height="15" font="6"><a href="e57.full.html#117">(724,772</a></text>
<text top="189" left="265" width="35" height="19" font="6"><a href="e57.full.html#117">–775)</a></text>
<text top="227" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="242" left="63" width="351" height="10" font="21">5. Early surgery (during initial hospitalization before completion of</text>
<text top="259" left="81" width="332" height="10" font="21">a full therapeutic course of antibiotics) for IE is indicated in</text>
<text top="275" left="81" width="332" height="10" font="21">patients with evidence of persistent infection as manifested by</text>
<text top="291" left="81" width="333" height="10" font="21">persistent bacteremia or fevers lasting longer than 5 to 7 days</text>
<text top="308" left="81" width="271" height="10" font="21">after onset of appropriate antimicrobial therapy</text>
<text top="308" left="360" width="54" height="10" font="22"><a href="e57.full.html#117">(746,756,</a></text>
<text top="324" left="81" width="46" height="10" font="22"><a href="e57.full.html#117">757,776</a></text>
<text top="321" left="127" width="32" height="16" font="22"><a href="e57.full.html#117">–778)</a></text>
<text top="324" left="159" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="346" left="79" width="335" height="15" font="5">Blood cultures will typically become negative after 48</text>
<text top="364" left="64" width="350" height="15" font="5">hours of appropriate antimicrobial therapy; however, in</text>
<text top="382" left="64" width="350" height="15" font="5">methicillin-resistant S. aureus and other resistant organ-</text>
<text top="400" left="64" width="350" height="15" font="5">isms, it may take up to a week for cultures to become</text>
<text top="418" left="64" width="350" height="15" font="5">negative. An ongoing infection despite antibiotic therapy</text>
<text top="436" left="64" width="350" height="15" font="5">is common with aggressive micro-organisms, abscess for-</text>
<text top="454" left="64" width="350" height="15" font="5">mation, or large vegetations. In some patients, the only</text>
<text top="472" left="64" width="350" height="15" font="5">evidence of persistent infection is an elevated white blood</text>
<text top="490" left="64" width="350" height="15" font="5">cell count or fevers that persist longer than 5 to 7 days. In</text>
<text top="508" left="64" width="349" height="15" font="5">patients with persistent bacteremia despite appropriate</text>
<text top="526" left="64" width="350" height="15" font="5">susceptibility-based therapy, the clinician must consider</text>
<text top="544" left="64" width="350" height="15" font="5">surgical adjunctive therapy based on multispecialty input</text>
<text top="562" left="64" width="350" height="15" font="5">and guidance from serial TEE and other imaging data.</text>
<text top="580" left="64" width="350" height="15" font="5">Detection of abscess by TEE can be missed in the presence</text>
<text top="597" left="64" width="42" height="15" font="5">of calci</text>
<text top="594" left="106" width="308" height="19" font="5">ﬁcation in the posterior mitral annulus or because of</text>
<text top="615" left="64" width="350" height="15" font="5">echocardiography artifact from prosthetic material. CT</text>
<text top="633" left="64" width="350" height="15" font="5">imaging may be helpful in this situation. Early surgery has</text>
<text top="651" left="64" width="350" height="15" font="5">been shown to improve outcome in patients with an ab-</text>
<text top="669" left="64" width="350" height="15" font="5">scess. Additionally, patients with persistent sepsis are at</text>
<text top="687" left="64" width="350" height="15" font="5">high risk of developing multiorgan failure, and surgery may</text>
<text top="705" left="64" width="349" height="15" font="5">be needed in these patients to debride infected/necrotic</text>
<text top="723" left="64" width="350" height="15" font="5">tissues to effectively eradicate the infection. Predictors of</text>
<text top="741" left="64" width="350" height="15" font="5">in-hospital mortality in patients with PVE include older</text>
<text top="759" left="64" width="350" height="15" font="5">age, healthcare-associated infection, S. aureus infection,</text>
<text top="777" left="64" width="350" height="15" font="5">HF, stroke, intracardiac abscess, and persistent bacteremia.</text>
<text top="795" left="64" width="350" height="15" font="5">Some caution is advised in patients who develop recurrent</text>
<text top="813" left="64" width="350" height="15" font="5">fever after an initially successful response to antibiotics,</text>
<text top="831" left="64" width="350" height="15" font="5">because the fever could be explained by other reasons than</text>
<text top="849" left="64" width="134" height="15" font="5">the endocarditic valve.</text>
<text top="867" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="866" left="212" width="137" height="15" font="6"><a href="e57.full.html#117">(724,746,747,777,779)</a></text>
<text top="901" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="916" left="63" width="351" height="10" font="21">6. Surgery is recommended for patients with PVE and relapsing</text>
<text top="933" left="81" width="66" height="10" font="21">infection (de</text>
<text top="929" left="148" width="267" height="16" font="21">ﬁned as recurrence of bacteremia after a complete</text>
<text top="949" left="81" width="333" height="10" font="21">course of appropriate antibiotics and subsequently negative</text>
<text top="965" left="81" width="193" height="10" font="21">blood cultures) without other identi</text>
<text top="962" left="275" width="139" height="16" font="21">ﬁable source for portal of</text>
<text top="982" left="81" width="166" height="12" font="21">infection. (Level of Evidence: C)</text>
<text top="1004" left="79" width="335" height="15" font="5">TEE has a reduced sensitivity for detection of abscess in</text>
<text top="1022" left="64" width="350" height="15" font="5">patients with prosthetic valves. If there is suspicion by a</text>
<text top="1040" left="64" width="350" height="15" font="5">team of cardiologists, cardiothoracic surgeons, and infec-</text>
<text top="1058" left="64" width="350" height="15" font="5">tious disease specialists that relapsing infections may be</text>
<text top="1076" left="64" width="350" height="15" font="5">due to incomplete sterilization of valvular or paravalvular</text>
<text top="103" left="450" width="350" height="15" font="5">tissue secondary to a deep tissue infection, it is reasonable</text>
<text top="121" left="450" width="350" height="15" font="5">to consider surgery in this situation. In the absence of</text>
<text top="139" left="450" width="350" height="15" font="5">other indications for intervention, such as severe valve</text>
<text top="157" left="450" width="350" height="15" font="5">dysfunction or a resistant organism, the timing of surgi-</text>
<text top="175" left="450" width="226" height="15" font="5">cal intervention cannot be strictly de</text>
<text top="171" left="676" width="124" height="19" font="5">ﬁned in these situa-</text>
<text top="192" left="450" width="198" height="15" font="5">tions. Because the possibility of</text>
<text top="189" left="654" width="145" height="19" font="5">“reseeding” a prosthetic</text>
<text top="210" left="450" width="350" height="15" font="5">valve has been reported in the setting of infection from</text>
<text top="228" left="450" width="350" height="15" font="5">an origin separate from the heart, careful assessment for</text>
<text top="246" left="450" width="350" height="15" font="5">the possibility of reintroduction of an infectious microbe</text>
<text top="264" left="450" width="350" height="15" font="5">from another portal should be thoroughly ruled out in</text>
<text top="282" left="450" width="350" height="15" font="5">these instances before consideration of cardiac surgical</text>
<text top="300" left="450" width="87" height="15" font="5">reintervention.</text>
<text top="319" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="318" left="593" width="32" height="15" font="6"><a href="e57.full.html#117">(746)</a></text>
<text top="349" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="364" left="449" width="247" height="10" font="21">7. Complete removal of pacemaker or de</text>
<text top="361" left="696" width="104" height="16" font="21">ﬁbrillator systems,</text>
<text top="380" left="467" width="332" height="10" font="21">including all leads and the generator, is indicated as part of</text>
<text top="397" left="467" width="333" height="10" font="21">the early management plan in patients with IE with docu-</text>
<text top="413" left="467" width="216" height="10" font="21">mented infection of the device or leads</text>
<text top="413" left="688" width="26" height="10" font="22"><a href="e57.full.html#118">(780</a></text>
<text top="410" left="714" width="32" height="16" font="22"><a href="e57.full.html#118">–783)</a></text>
<text top="413" left="745" width="54" height="12" font="21">. (Level of</text>
<text top="430" left="467" width="66" height="12" font="21">Evidence: B)</text>
<text top="454" left="465" width="335" height="15" font="5">Complete device and lead removal is recommended</text>
<text top="472" left="450" width="350" height="15" font="5">for all patients with cardiac device infection, even if evi-</text>
<text top="490" left="450" width="350" height="15" font="5">dence for infection appears to be limited to the generator</text>
<text top="508" left="450" width="349" height="15" font="5">pocket site. A prospective cohort study using data from</text>
<text top="526" left="450" width="350" height="15" font="5">ICE-PCS showed that among patients with cardiac de-</text>
<text top="544" left="450" width="350" height="15" font="5">vice IE, the rates of both concomitant valve infection and</text>
<text top="562" left="450" width="350" height="15" font="5">mortality are high, particularly if there is valve dys-</text>
<text top="579" left="450" width="350" height="15" font="5">function. Optimal therapy for cardiac device IE combines</text>
<text top="597" left="450" width="350" height="15" font="5">complete device extraction and a prolonged course of</text>
<text top="615" left="450" width="350" height="15" font="5">parenteral antibiotics. A proportional hazards regression</text>
<text top="633" left="450" width="202" height="15" font="5">analysis showed a survival bene</text>
<text top="630" left="651" width="148" height="19" font="5">ﬁt at 1 year for device</text>
<text top="651" left="450" width="350" height="15" font="5">removal during the initial hospitalization; 28 of 141 pa-</text>
<text top="669" left="450" width="350" height="15" font="5">tients (19.9%) who underwent device removal during</text>
<text top="687" left="450" width="350" height="15" font="5">the index hospitalization had died at 1 year versus 13 of</text>
<text top="705" left="450" width="350" height="15" font="5">34 (38.2%) who did not undergo device removal (HR:</text>
<text top="723" left="450" width="177" height="15" font="5">0.42; 95% CI: 0.22 to 0.82).</text>
<text top="742" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="741" left="597" width="53" height="15" font="6"><a href="e57.full.html#116">(681,784</a></text>
<text top="738" left="651" width="35" height="19" font="6"><a href="e57.full.html#116">–786)</a></text>
<text top="773" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="788" left="449" width="247" height="10" font="21">1. Complete removal of pacemaker or de</text>
<text top="785" left="696" width="104" height="16" font="21">ﬁbrillator systems,</text>
<text top="804" left="467" width="333" height="10" font="21">including all leads and the generator, is reasonable in patients</text>
<text top="821" left="467" width="333" height="12" font="21">with valvular IE caused by S. aureus or fungi, even without</text>
<text top="837" left="467" width="208" height="10" font="21">evidence of device or lead infection</text>
<text top="837" left="683" width="26" height="10" font="22"><a href="e57.full.html#118">(780</a></text>
<text top="834" left="708" width="32" height="16" font="22"><a href="e57.full.html#118">–783)</a></text>
<text top="837" left="740" width="60" height="12" font="21"><a href="e57.full.html#118">. </a>(Level of</text>
<text top="854" left="467" width="66" height="12" font="21">Evidence: B)</text>
<text top="878" left="465" width="335" height="15" font="5">The likelihood of underlying cardiac device infection in</text>
<text top="896" left="450" width="350" height="15" font="5">a patient with S. aureus bacteremia is relatively high</text>
<text top="914" left="450" width="350" height="15" font="5">(approximately 30% to 40%) and is also likely in patients</text>
<text top="932" left="450" width="350" height="15" font="5">with fungal valvular IE. In patients with a normal pocket</text>
<text top="950" left="450" width="80" height="15" font="5">site, it is dif</text>
<text top="946" left="529" width="270" height="19" font="5">ﬁcult to determine if the device should be</text>
<text top="968" left="450" width="350" height="15" font="5">removed. If there is evidence of valvular endocarditis on</text>
<text top="986" left="450" width="350" height="15" font="5">TEE, then the device should be removed. If there is a lead</text>
<text top="1003" left="450" width="350" height="15" font="5">mass without a valve lesion, device removal has been</text>
<text top="1021" left="450" width="169" height="15" font="5">advocated by some based on</text>
<text top="1018" left="623" width="177" height="19" font="5">“lead endocarditis.” However,</text>
<text top="1039" left="450" width="302" height="15" font="5">the writing committee noted that the likelihood of</text>
<text top="1036" left="757" width="43" height="19" font="5">ﬁnding</text>
<text top="1057" left="450" width="350" height="15" font="5">a clot on a lead in noninfected patients can range from 1%</text>
<text top="1075" left="450" width="224" height="15" font="5">to 50% of patients undergoing TEE.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e138</text>
</page>
<page number="83" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="79" width="335" height="15" font="5">The likelihood of underlying cardiovascular implantable</text>
<text top="121" left="64" width="350" height="15" font="5">electronic device infection in someone with bacteremia due</text>
<text top="139" left="64" width="350" height="15" font="5">to gram-negative bacilli is much less. Therefore, if the</text>
<text top="157" left="64" width="350" height="15" font="5">pocket site appears normal, device removal is generally not</text>
<text top="175" left="64" width="268" height="15" font="5">required for an initial episode of bacteremia.</text>
<text top="193" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="192" left="212" width="84" height="15" font="6"><a href="e57.full.html#118">(781,785,787)</a></text>
<text top="230" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="245" left="63" width="247" height="10" font="21">2. Complete removal of pacemaker or de</text>
<text top="242" left="310" width="104" height="16" font="21">ﬁbrillator systems,</text>
<text top="262" left="81" width="333" height="10" font="21">including all leads and the generator, is reasonable in patients</text>
<text top="278" left="81" width="328" height="12" font="21">undergoing valve surgery for valvular IE. (Level of Evidence: C)</text>
<text top="302" left="79" width="335" height="15" font="5">In patients with an intracardiac lead who are undergoing</text>
<text top="320" left="64" width="350" height="15" font="5">prosthetic valve replacement for valvular IE, the device and</text>
<text top="338" left="64" width="350" height="15" font="5">lead might serve as a nidus for recurrent infection because</text>
<text top="356" left="64" width="350" height="15" font="5">infection of the leads may be present even without visible</text>
<text top="374" left="64" width="350" height="15" font="5">vegetations. Removal of the entire device and leads reduces</text>
<text top="392" left="64" width="134" height="15" font="5">the risk of reinfection.</text>
<text top="419" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="434" left="63" width="351" height="10" font="21">3. Early surgery (during initial hospitalization before completion of</text>
<text top="451" left="81" width="333" height="10" font="21">a full therapeutic course of antibiotics) is reasonable in patients</text>
<text top="467" left="81" width="333" height="10" font="21">with IE who present with recurrent emboli and persistent veg-</text>
<text top="484" left="81" width="246" height="10" font="21">etations despite appropriate antibiotic therapy</text>
<text top="484" left="331" width="80" height="10" font="22"><a href="e57.full.html#115">(655,788,789)</a></text>
<text top="484" left="410" width="3" height="10" font="21">.</text>
<text top="500" left="81" width="113" height="12" font="21">(Level of Evidence: B)</text>
<text top="524" left="79" width="335" height="15" font="5">Early surgery is associated with a reduction in the rate</text>
<text top="542" left="64" width="350" height="15" font="5">of embolic complications in patients who present with</text>
<text top="560" left="64" width="323" height="15" font="5">left-sided IE, severe VHD, and large vegetations (</text>
<text top="557" left="387" width="27" height="19" font="5">&gt;10</text>
<text top="578" left="64" width="350" height="15" font="5">mm). Embolic events are a frequent and life-threatening</text>
<text top="596" left="64" width="350" height="15" font="5">complication of IE. Embolism is associated with an in-</text>
<text top="614" left="64" width="350" height="15" font="5">creased morbidity and mortality in IE and occurs in 20%</text>
<text top="632" left="64" width="350" height="15" font="5">to 40% of patients with IE. Embolic incidence decreases</text>
<text top="650" left="64" width="350" height="15" font="5">to 9% to 21% after initiation of antibiotic treatment.</text>
<text top="668" left="64" width="350" height="15" font="5">Factors associated with a new embolic event are vegeta-</text>
<text top="686" left="64" width="55" height="15" font="5">tion size</text>
<text top="682" left="129" width="285" height="19" font="5">&gt;10 mm in length and marked vegetation</text>
<text top="704" left="64" width="350" height="15" font="5">mobility (especially when associated with the anterior</text>
<text top="722" left="64" width="16" height="15" font="5">lea</text>
<text top="718" left="80" width="333" height="19" font="5">ﬂet of the mitral valve). The risk of embolism is highest</text>
<text top="739" left="64" width="63" height="15" font="5">during the</text>
<text top="736" left="131" width="282" height="19" font="5">ﬁrst days after initiation of antibiotic treatment</text>
<text top="757" left="64" width="169" height="15" font="5">and decreases after 2 weeks.</text>
<text top="775" left="79" width="288" height="15" font="5">Patients with PVE who are most likely to bene</text>
<text top="772" left="367" width="47" height="19" font="5">ﬁt from</text>
<text top="793" left="64" width="350" height="15" font="5">medical therapy without surgery are those with non-</text>
<text top="812" left="64" width="350" height="15" font="5">Staphylococcal PVE without complications or prosthetic</text>
<text top="829" left="64" width="350" height="15" font="5">valve dysfunction, as well as those who remain clinically stable</text>
<text top="847" left="64" width="350" height="15" font="5">and who show clinical improvement on antibiotic treatment.</text>
<text top="865" left="64" width="226" height="15" font="5">Surgical intervention is especially bene</text>
<text top="862" left="290" width="124" height="19" font="5">ﬁcial in patients with</text>
<text top="884" left="64" width="350" height="15" font="5">Staphylococcal PVE and complicated PVE, of which recurrent</text>
<text top="901" left="64" width="137" height="15" font="5">embolization is identi</text>
<text top="898" left="201" width="213" height="19" font="5">ﬁed as a common type of major</text>
<text top="919" left="64" width="84" height="15" font="5">complication (</text>
<text top="915" left="149" width="221" height="19" font="5">&gt;20% of patients in all PVE studies).</text>
<text top="937" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="937" left="212" width="80" height="15" font="6"><a href="e57.full.html#116">(679,783,789</a></text>
<text top="933" left="292" width="35" height="19" font="6"><a href="e57.full.html#116">–791)</a></text>
<text top="964" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="979" left="63" width="351" height="10" font="21">1. Early surgery (during initial hospitalization before completion of</text>
<text top="995" left="81" width="332" height="10" font="21">a full therapeutic course of antibiotics) may be considered in</text>
<text top="1012" left="81" width="333" height="10" font="21">patients with NVE who exhibit mobile vegetations greater than</text>
<text top="1028" left="81" width="333" height="10" font="21">10 mm in length (with or without clinical evidence of embolic</text>
<text top="1045" left="81" width="71" height="10" font="21">phenomenon)</text>
<text top="1045" left="157" width="80" height="10" font="22"><a href="e57.full.html#115">(655,788,789)</a></text>
<text top="1045" left="236" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="1069" left="79" width="335" height="15" font="5">With NVE, large vegetation size is associated with</text>
<text top="1087" left="64" width="350" height="15" font="5">a markedly higher rate of embolic phenomenon. Embolic</text>
<text top="103" left="450" width="350" height="15" font="5">events are also known to be causally associated with</text>
<text top="121" left="450" width="350" height="15" font="5">higher rates of mortality in IE. In an RCT of surgical</text>
<text top="139" left="450" width="350" height="15" font="5">intervention in patients with severe left-sided valve</text>
<text top="157" left="450" width="178" height="15" font="5">dysfunction and vegetations</text>
<text top="153" left="635" width="164" height="19" font="5">&gt;10 mm in length (even</text>
<text top="175" left="450" width="350" height="15" font="5">in the absence of clinically apparent embolic events or</text>
<text top="192" left="450" width="165" height="15" font="5">HF), there was no signi</text>
<text top="189" left="615" width="184" height="19" font="5">ﬁcant difference in all-cause</text>
<text top="210" left="450" width="350" height="15" font="5">mortality at 6 months in the early-surgery versus the</text>
<text top="228" left="450" width="350" height="15" font="5">conventional-treatment groups (3% and 5%, respectively;</text>
<text top="246" left="450" width="8" height="15" font="5">p</text>
<text top="243" left="457" width="342" height="19" font="5">¼0.59); however, there was a marked reduction in the</text>
<text top="264" left="450" width="350" height="15" font="5">number of embolic events, 0% in the early-surgery group</text>
<text top="282" left="450" width="350" height="15" font="5">compared with 21% in the conventional-treatment</text>
<text top="300" left="450" width="55" height="15" font="5">group (p</text>
<text top="297" left="504" width="295" height="19" font="5">¼0.005). Additionally, 77% of the conventional</text>
<text top="318" left="450" width="350" height="15" font="5">group required surgery in the initial hospitalization or</text>
<text top="336" left="450" width="350" height="15" font="5">during the follow-up phase secondary to HF, paravalvular</text>
<text top="354" left="450" width="163" height="15" font="5">extension, and heart block.</text>
<text top="373" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="372" left="598" width="58" height="15" font="6"><a href="e57.full.html#115">(652,789)</a></text>
<text top="416" left="450" width="186" height="14" font="17">13. Pregnancy and VHD</text>
<text top="461" left="450" width="324" height="12" font="19">13.1. Native Valve Stenosis: Recommendations</text>
<text top="487" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="502" left="449" width="350" height="10" font="21">1. All patients with suspected valve stenosis should undergo a clin-</text>
<text top="519" left="467" width="323" height="12" font="21">ical evaluation and TTE before pregnancy. (Level of Evidence: C)</text>
<text top="543" left="465" width="335" height="15" font="5">Patients with severe valve stenosis tolerate the hemo-</text>
<text top="561" left="450" width="350" height="15" font="5">dynamic changes of pregnancy poorly. The increased car-</text>
<text top="579" left="450" width="350" height="15" font="5">diac output, increased heart rate, and decreased afterload</text>
<text top="597" left="450" width="350" height="15" font="5">that occur during pregnancy may all contribute to hemo-</text>
<text top="615" left="450" width="350" height="15" font="5">dynamic decompensation in the presence of severe valve</text>
<text top="633" left="450" width="350" height="15" font="5">stenosis. Thus, it is critical to identify patients who may</text>
<text top="650" left="450" width="350" height="15" font="5">have suspected valve stenosis before pregnancy, because</text>
<text top="668" left="450" width="22" height="15" font="5">this</text>
<text top="665" left="477" width="322" height="19" font="5">ﬁnding may have important implications for therapy</text>
<text top="686" left="450" width="350" height="15" font="5">before conception as well as management during preg-</text>
<text top="704" left="450" width="350" height="15" font="5">nancy and delivery. The most common etiology of AS in</text>
<text top="722" left="450" width="350" height="15" font="5">women of childbearing age in developed countries is a</text>
<text top="740" left="450" width="350" height="15" font="5">congenitally abnormal unicuspid or bicuspid valve, which</text>
<text top="758" left="450" width="350" height="15" font="5">can be associated with an aortopathy. In these patients, it</text>
<text top="776" left="450" width="350" height="15" font="5">is important to determine the size of the aorta before</text>
<text top="794" left="450" width="350" height="15" font="5">pregnancy, because those with a dilated aorta may be at</text>
<text top="812" left="450" width="350" height="15" font="5">increased risk for further dilation during pregnancy. A</text>
<text top="830" left="450" width="350" height="15" font="5">comprehensive TTE and Doppler echocardiogram should</text>
<text top="848" left="450" width="350" height="15" font="5">be performed before pregnancy to diagnose the presence</text>
<text top="866" left="450" width="350" height="15" font="5">of valve stenosis, severity of stenosis, and hemodynamic</text>
<text top="884" left="450" width="170" height="15" font="5">consequence of the stenosis.</text>
<text top="902" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="902" left="597" width="27" height="15" font="6"><a href="e57.full.html#118">(792</a></text>
<text top="898" left="625" width="35" height="19" font="6"><a href="e57.full.html#118">–794)</a></text>
<text top="929" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="944" left="449" width="351" height="10" font="21">2. All patients with severe valve stenosis (stages C and D) should</text>
<text top="960" left="467" width="332" height="10" font="21">undergo prepregnancy counseling by a cardiologist with exper-</text>
<text top="977" left="467" width="332" height="12" font="21">tise in managing patients with VHD during pregnancy. (Level of</text>
<text top="993" left="467" width="65" height="12" font="21">Evidence: C)</text>
<text top="1017" left="465" width="335" height="15" font="5">The management of patients with valve stenosis should</text>
<text top="1035" left="450" width="350" height="15" font="5">ideally begin before conception. A complete assessment of</text>
<text top="1053" left="450" width="350" height="15" font="5">functional capacity, severity of stenosis, and the status of</text>
<text top="1071" left="450" width="350" height="15" font="5">the left ventricle and pulmonary pressures are necessary to</text>
<text top="1089" left="450" width="350" height="15" font="5">determine the risk of pregnancy and delivery in patients</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e139</text>
</page>
<page number="84" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="242" height="15" font="5">with valve stenosis. The risks and bene</text>
<text top="99" left="307" width="107" height="19" font="5">ﬁts of proceeding</text>
<text top="121" left="64" width="350" height="15" font="5">with pregnancy must be fully discussed with the patient.</text>
<text top="139" left="64" width="350" height="15" font="5">Interventions before pregnancy, such as valve replacement,</text>
<text top="157" left="64" width="350" height="15" font="5">valve repair, or percutaneous aortic or mitral balloon dila-</text>
<text top="175" left="64" width="350" height="15" font="5">tion should be considered, particularly in those patients</text>
<text top="192" left="64" width="350" height="15" font="5">with severe stenosis, regardless of symptoms. Drugs with</text>
<text top="210" left="64" width="324" height="15" font="5">potential harmful effects on the fetus must be identi</text>
<text top="207" left="388" width="26" height="19" font="5">ﬁed.</text>
<text top="228" left="64" width="350" height="15" font="5">If pregnancy is contemplated, arrangements should be</text>
<text top="246" left="64" width="350" height="15" font="5">made for the patient to be monitored in a tertiary care</text>
<text top="264" left="64" width="350" height="15" font="5">center with a dedicated Heart Valve Team of cardiologists,</text>
<text top="282" left="64" width="350" height="15" font="5">surgeons, anesthesiologists, and obstetricians who have</text>
<text top="300" left="64" width="350" height="15" font="5">expertise in managing high-risk cardiac patients. Coun-</text>
<text top="318" left="64" width="350" height="15" font="5">seling regarding all these areas should be performed by a</text>
<text top="336" left="64" width="350" height="15" font="5">cardiologist with expertise in managing patients with</text>
<text top="354" left="64" width="151" height="15" font="5">VHD during pregnancy.</text>
<text top="373" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="372" left="212" width="27" height="15" font="6"><a href="e57.full.html#118">(792</a></text>
<text top="368" left="239" width="35" height="19" font="6"><a href="e57.full.html#118">–794)</a></text>
<text top="402" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="417" left="63" width="351" height="10" font="21">3. All patients referred for a valve operation before pregnancy</text>
<text top="433" left="81" width="333" height="10" font="21">should receive prepregnancy counseling by a cardiologist with</text>
<text top="450" left="81" width="333" height="10" font="21">expertise in managing patients with VHD during pregnancy</text>
<text top="466" left="81" width="142" height="10" font="21">about the risks and bene</text>
<text top="463" left="223" width="191" height="16" font="21">ﬁts of all options for operative in-</text>
<text top="483" left="81" width="333" height="10" font="21">terventions, including mechanical prosthesis, bioprosthesis,</text>
<text top="499" left="81" width="204" height="12" font="21">and valve repair. (Level of Evidence: C)</text>
<text top="523" left="79" width="335" height="15" font="5">All prosthetic valve types pose major problems during</text>
<text top="541" left="64" width="350" height="15" font="5">pregnancy. Patients with mechanical prostheses require</text>
<text top="559" left="64" width="350" height="15" font="5">continued anticoagulation throughout pregnancy to pre-</text>
<text top="577" left="64" width="350" height="15" font="5">vent valve thrombosis and systemic embolism. However,</text>
<text top="595" left="64" width="350" height="15" font="5">anticoagulation has risks for both the mother and the fetus.</text>
<text top="613" left="64" width="350" height="15" font="5">Bioprostheses have a limited life span, particularly in the</text>
<text top="631" left="64" width="350" height="15" font="5">younger patient, and controversy persists as to whether</text>
<text top="649" left="64" width="350" height="15" font="5">there is acceleration of valve degeneration during preg-</text>
<text top="667" left="64" width="350" height="15" font="5">nancy. Patients of childbearing age who undergo valve</text>
<text top="685" left="64" width="350" height="15" font="5">surgery should be informed of the maternal and fetal risks</text>
<text top="703" left="64" width="350" height="15" font="5">of anticoagulation, risk of mechanical valve thrombosis and</text>
<text top="721" left="64" width="349" height="15" font="5">embolism, and risk of bioprosthetic valve degeneration</text>
<text top="739" left="64" width="109" height="15" font="5">during pregnancy.</text>
<text top="757" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="757" left="212" width="58" height="15" font="6"><a href="e57.full.html#118">(793,795)</a></text>
<text top="787" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="802" left="63" width="351" height="10" font="21">4. Pregnant patients with severe valve stenosis (stages C and D)</text>
<text top="818" left="81" width="333" height="10" font="21">should be monitored in a tertiary care center with a dedicated</text>
<text top="835" left="81" width="333" height="10" font="21">Heart Valve Team of cardiologists, surgeons, anesthesiologists,</text>
<text top="851" left="81" width="332" height="10" font="21">and obstetricians with expertise in the management of high-risk</text>
<text top="868" left="81" width="301" height="12" font="21">cardiac patients during pregnancy. (Level of Evidence: C)</text>
<text top="892" left="79" width="335" height="15" font="5">Patients with severe stenosis are at high risk during</text>
<text top="910" left="64" width="350" height="15" font="5">pregnancy. The risk increases throughout pregnancy, given</text>
<text top="928" left="64" width="350" height="15" font="5">the continued hemodynamic changes, including increased</text>
<text top="946" left="64" width="350" height="15" font="5">intravascular volume, decreased afterload, and increased</text>
<text top="964" left="64" width="350" height="15" font="5">heart rate. Pulmonary edema, arrhythmias, and even</text>
<text top="981" left="64" width="350" height="15" font="5">maternal death may occur. The presence of severe valve</text>
<text top="999" left="64" width="350" height="15" font="5">stenosis is also associated with an increased risk to the</text>
<text top="1017" left="64" width="350" height="15" font="5">fetus. Management of pregnant patients with VHD re-</text>
<text top="1035" left="64" width="350" height="15" font="5">quires that clinicians have knowledge and experience in</text>
<text top="1053" left="64" width="350" height="15" font="5">caring for these patients. Cardiac diagnostics, hemody-</text>
<text top="1071" left="64" width="350" height="15" font="5">namic monitoring, and prevention of cardiovascular com-</text>
<text top="1089" left="64" width="350" height="15" font="5">plications require expertise beyond the standard obstetrical</text>
<text top="103" left="450" width="350" height="15" font="5">scope of practice. Timing and mode of delivery should be</text>
<text top="121" left="450" width="350" height="15" font="5">discussed jointly and carried out by the Heart Valve Team,</text>
<text top="139" left="450" width="350" height="15" font="5">with close hemodynamic monitoring during and up to 24</text>
<text top="157" left="450" width="119" height="15" font="5">hours after delivery.</text>
<text top="175" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="175" left="597" width="27" height="15" font="6"><a href="e57.full.html#118">(792</a></text>
<text top="171" left="625" width="35" height="19" font="6"><a href="e57.full.html#118">–794)</a></text>
<text top="212" left="450" width="334" height="15" font="5">13.1.1. Diagnosis and Follow-Up: Recommendation</text>
<text top="236" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="251" left="449" width="350" height="10" font="21">1. Exercise testing is reasonable in asymptomatic patients with severe</text>
<text top="267" left="467" width="94" height="10" font="21">AS (aortic velocity</text>
<text top="264" left="565" width="235" height="16" font="21">‡4.0 m per second or mean pressure gradient</text>
<text top="281" left="467" width="310" height="16" font="21">‡40 mm Hg, stage C) before pregnancy. (Level of Evidence: C)</text>
<text top="305" left="465" width="335" height="16" font="5">Patients with severe ASdparticularly those who are</text>
<text top="323" left="450" width="350" height="16" font="5">symptomaticdhave an increased risk of sudden clinical</text>
<text top="341" left="450" width="350" height="15" font="5">deterioration and even death during pregnancy. Exercise</text>
<text top="359" left="450" width="350" height="15" font="5">testing is reasonable in asymptomatic patients with severe</text>
<text top="377" left="450" width="350" height="15" font="5">AS before pregnancy to obtain an objective assessment of</text>
<text top="395" left="450" width="350" height="15" font="5">exercise tolerance. Patients with symptoms provoked by</text>
<text top="413" left="450" width="350" height="15" font="5">exercise testing should be considered symptomatic, espe-</text>
<text top="431" left="450" width="350" height="15" font="5">cially if the clinical history is equivocal. These patients</text>
<text top="449" left="450" width="350" height="15" font="5">should be treated for symptomatic severe AS and cautioned</text>
<text top="467" left="450" width="350" height="15" font="5">against pregnancy or should undergo an intervention such</text>
<text top="485" left="450" width="350" height="15" font="5">as AVR or percutaneous aortic balloon dilation before</text>
<text top="503" left="450" width="350" height="15" font="5">conception. Although there are no data on the prognostic</text>
<text top="520" left="450" width="80" height="15" font="5">value of other</text>
<text top="517" left="534" width="266" height="19" font="5">ﬁndings on exercise testing before pregnancy,</text>
<text top="538" left="450" width="350" height="15" font="5">high-risk parameters on exercise testing for nonpregnant</text>
<text top="556" left="450" width="350" height="15" font="5">patients include a limited exercise tolerance or a drop in BP.</text>
<text top="575" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="574" left="598" width="122" height="15" font="6"><a href="e57.full.html#101">(46,47,117,793,794)</a></text>
<text top="601" left="450" width="284" height="15" font="5">13.1.2. Medical Therapy: Recommendations</text>
<text top="628" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="643" left="449" width="350" height="10" font="21">1. Anticoagulation should be given to pregnant patients with MS</text>
<text top="660" left="467" width="281" height="12" font="21">and AF unless contraindicated. (Level of Evidence: C)</text>
<text top="684" left="465" width="335" height="15" font="5">Systemic embolization may occur in up to 10% to 20%</text>
<text top="702" left="450" width="350" height="15" font="5">of patients with MS, with the highest risk in patients</text>
<text top="720" left="450" width="350" height="15" font="5">with AF. One third of embolic events occur within the</text>
<text top="735" left="450" width="350" height="19" font="5">ﬁrst month of the onset of AF. Anticoagulation will result</text>
<text top="756" left="450" width="38" height="15" font="5">in a 4</text>
<text top="752" left="488" width="311" height="19" font="5">– to 15–fold decrease in the incidence of embolic</text>
<text top="774" left="450" width="350" height="15" font="5">events in nonpregnant patients. Pregnancy is associated</text>
<text top="792" left="450" width="350" height="15" font="5">with a hypercoagulable state and is expected to further</text>
<text top="810" left="450" width="350" height="15" font="5">increase the risk of thromboembolic events. Therefore, all</text>
<text top="828" left="450" width="350" height="15" font="5">patients with MS and AF should receive antithrombotic</text>
<text top="845" left="450" width="350" height="15" font="5">therapy. Warfarin is the most effective anticoagulant</text>
<text top="863" left="450" width="350" height="15" font="5">regimen in the second and third trimester. These patients</text>
<text top="881" left="450" width="350" height="15" font="5">should then be converted to continuous infusion of UFH</text>
<text top="899" left="450" width="350" height="15" font="5">before planned delivery. The optimal anticoagulation</text>
<text top="917" left="450" width="122" height="15" font="5">regimen during the</text>
<text top="914" left="579" width="220" height="19" font="5">ﬁrst trimester remains controversial</text>
<text top="935" left="450" width="350" height="15" font="5">and is discussed further in the prosthetic valve and preg-</text>
<text top="953" left="450" width="91" height="15" font="5">nancy section (</text>
<text top="953" left="541" width="87" height="15" font="6"><a href="e57.full.html#90">Section 13.3.2</a></text>
<text top="953" left="627" width="9" height="15" font="5">).</text>
<text top="972" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="971" left="597" width="111" height="15" font="6"><a href="e57.full.html#107">(310,316,796,797)</a></text>
<text top="998" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="1013" left="449" width="351" height="10" font="21">1. Use of beta blockers as required for rate control is reasonable</text>
<text top="1030" left="467" width="332" height="10" font="21">for pregnant patients with MS in the absence of contraindica-</text>
<text top="1046" left="467" width="202" height="12" font="21">tion if tolerated. (Level of Evidence: C)</text>
<text top="1070" left="465" width="335" height="15" font="5">In patients with MS, the shortening of the diastolic</text>
<text top="1085" left="450" width="350" height="19" font="5">ﬁlling period with the increased heart rate of pregnancy</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e140</text>
</page>
<page number="85" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">results in a rise in LA pressure due to obstruction at the</text>
<text top="121" left="64" width="350" height="15" font="5">mitral valve level. If stenosis is only mild to moderate, the</text>
<text top="139" left="64" width="350" height="15" font="5">increase in cardiac output further exacerbates the rise in</text>
<text top="157" left="64" width="350" height="15" font="5">LA pressure. If MS is severe, the normal rise in cardiac</text>
<text top="175" left="64" width="308" height="15" font="5">output may be blunted due to the short diastolic</text>
<text top="171" left="379" width="35" height="19" font="5">ﬁlling</text>
<text top="192" left="64" width="196" height="15" font="5">period across a small mitral ori</text>
<text top="189" left="260" width="153" height="19" font="5">ﬁce. Therapy targeted at</text>
<text top="210" left="64" width="266" height="15" font="5">reducing heart rate allows a longer diastolic</text>
<text top="207" left="336" width="78" height="19" font="5">ﬁlling period</text>
<text top="228" left="64" width="350" height="15" font="5">with an improvement in forward cardiac output and re-</text>
<text top="246" left="64" width="199" height="15" font="5">duction in LA pressure. After the</text>
<text top="243" left="267" width="147" height="19" font="5">ﬁrst trimester, restricting</text>
<text top="264" left="64" width="350" height="15" font="5">physical activity helps with heart rate control. In addition,</text>
<text top="282" left="64" width="350" height="15" font="5">beta-blocker medications are relatively safe for both the</text>
<text top="300" left="64" width="350" height="15" font="5">mother and the fetus. The use of beta blockers with beta-1</text>
<text top="318" left="64" width="350" height="15" font="5">selectivity is preferred because the beta-2 effects on uterine</text>
<text top="336" left="64" width="350" height="15" font="5">relaxation are avoided. Metoprolol has a lower incidence</text>
<text top="354" left="64" width="350" height="15" font="5">of fetal growth retardation than atenolol and is the pre-</text>
<text top="372" left="64" width="244" height="15" font="5">ferred beta blocker for use in pregnancy.</text>
<text top="391" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="390" left="212" width="53" height="15" font="6"><a href="e57.full.html#118">(794,798</a></text>
<text top="386" left="265" width="35" height="19" font="6"><a href="e57.full.html#118">–801)</a></text>
<text top="417" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="432" left="63" width="351" height="10" font="21">1. Use of diuretics may be reasonable for pregnant patients with</text>
<text top="448" left="81" width="291" height="12" font="21">MS and HF symptoms (stage D). (Level of Evidence: C)</text>
<text top="473" left="79" width="335" height="15" font="5">Diuretics may be helpful in reducing elevated LA</text>
<text top="491" left="64" width="350" height="15" font="5">pressure in patients with MS who become symptomatic.</text>
<text top="509" left="64" width="350" height="15" font="5">However, they should be used with caution due to the</text>
<text top="526" left="64" width="252" height="15" font="5">potential for reducing placental perfusion.</text>
<text top="545" left="79" width="123" height="15" font="5">Supporting Reference:</text>
<text top="544" left="208" width="32" height="15" font="6"><a href="e57.full.html#118">(793)</a></text>
<text top="572" left="64" width="73" height="8" font="20">CLASS III: Harm</text>
<text top="587" left="63" width="351" height="10" font="21">1. ACE inhibitors and ARBs should not be given to pregnant patients</text>
<text top="603" left="81" width="99" height="10" font="21">with valve stenosis</text>
<text top="603" left="184" width="26" height="10" font="22"><a href="e57.full.html#118">(802</a></text>
<text top="600" left="209" width="31" height="16" font="22"><a href="e57.full.html#118">–804)</a></text>
<text top="603" left="240" width="116" height="12" font="21">. (Level of Evidence: B)</text>
<text top="627" left="79" width="335" height="15" font="5">ACE inhibitors and ARBs are contraindicated during</text>
<text top="645" left="64" width="350" height="15" font="5">pregnancy due to fetal toxicity, including renal or tubular</text>
<text top="663" left="64" width="323" height="15" font="5">dysplasia, oligohydramnios, growth retardation, ossi</text>
<text top="660" left="388" width="26" height="19" font="5">ﬁca-</text>
<text top="681" left="64" width="350" height="15" font="5">tion disorders of the skull, lung hypoplasia, and intra-</text>
<text top="699" left="64" width="350" height="15" font="5">uterine fetal death. If a patient with valve stenosis is taking</text>
<text top="717" left="64" width="350" height="15" font="5">1 of these medications for any reason, it should be dis-</text>
<text top="735" left="64" width="350" height="15" font="5">continued or replaced with an alternate medication before</text>
<text top="753" left="64" width="69" height="15" font="5">conception.</text>
<text top="772" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="771" left="212" width="27" height="15" font="6"><a href="e57.full.html#118">(802</a></text>
<text top="767" left="239" width="35" height="19" font="6"><a href="e57.full.html#118">–804)</a></text>
<text top="797" left="64" width="255" height="15" font="5">13.1.3. Intervention: Recommendations</text>
<text top="826" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="841" left="64" width="350" height="10" font="21">1. Valve intervention is recommended before pregnancy for</text>
<text top="858" left="82" width="288" height="10" font="21">symptomatic patients with severe AS (aortic velocity</text>
<text top="855" left="375" width="39" height="16" font="21">‡4.0 m</text>
<text top="874" left="82" width="205" height="10" font="21">per second or mean pressure gradient</text>
<text top="871" left="291" width="123" height="16" font="21">‡40 mm Hg, stage D).</text>
<text top="891" left="82" width="113" height="12" font="21">(Level of Evidence: C)</text>
<text top="915" left="79" width="335" height="15" font="5">Patients with severe AS are at high risk for complica-</text>
<text top="933" left="64" width="350" height="15" font="5">tions during the hemodynamic stress of pregnancy. Early</text>
<text top="951" left="64" width="350" height="15" font="5">studies demonstrated a very poor outcome for patients</text>
<text top="969" left="64" width="350" height="15" font="5">with severe AS who become pregnant, with a maternal</text>
<text top="987" left="64" width="350" height="15" font="5">mortality rate of 17% and fetal and neonatal mortality rate</text>
<text top="1005" left="64" width="350" height="15" font="5">of 32%. Subsequent studies reported better outcomes, but</text>
<text top="1023" left="64" width="350" height="15" font="5">there is still a 3% to 10% risk of complication of HF and</text>
<text top="1041" left="64" width="350" height="15" font="5">up to a 25% risk of arrhythmia. In addition, sudden</text>
<text top="1058" left="64" width="350" height="15" font="5">deterioration and even death may occur, despite meticu-</text>
<text top="1076" left="64" width="350" height="15" font="5">lous medical care during pregnancy and delivery. Fetal</text>
<text top="103" left="450" width="350" height="15" font="5">complications, including preterm birth, intrauterine</text>
<text top="121" left="450" width="350" height="15" font="5">growth retardation, and low birth weight occur in up to</text>
<text top="139" left="450" width="350" height="15" font="5">25% of pregnant women with moderate and severe AS.</text>
<text top="157" left="450" width="350" height="15" font="5">The severity of stenosis and presence of symptoms are</text>
<text top="175" left="450" width="350" height="15" font="5">predictors of poor outcomes during pregnancy in patients</text>
<text top="193" left="450" width="350" height="15" font="5">with AS. Valve intervention is recommended for all pa-</text>
<text top="210" left="450" width="350" height="15" font="5">tients with severe symptomatic AS, regardless of whether</text>
<text top="228" left="450" width="350" height="15" font="5">or not pregnancy is being contemplated. Women with</text>
<text top="246" left="450" width="350" height="15" font="5">symptomatic severe AS who wish to become pregnant</text>
<text top="264" left="450" width="350" height="15" font="5">should have a valve intervention before conception to</text>
<text top="282" left="450" width="350" height="15" font="5">prevent the possible devastating consequences of progres-</text>
<text top="300" left="450" width="350" height="15" font="5">sive or sudden deterioration during pregnancy and delivery.</text>
<text top="318" left="450" width="350" height="15" font="5">Percutaneous aortic balloon dilation may be considered in</text>
<text top="336" left="450" width="134" height="15" font="5">patients with noncalci</text>
<text top="333" left="583" width="216" height="19" font="5">ﬁed bicuspid aortic valves, with the</text>
<text top="354" left="450" width="350" height="15" font="5">understanding that restenosis may occur within several</text>
<text top="372" left="450" width="350" height="15" font="5">years of the procedure. AVR may also be considered before</text>
<text top="390" left="450" width="350" height="15" font="5">pregnancy, after a detailed discussion with the patient</text>
<text top="408" left="450" width="158" height="15" font="5">about the risks and bene</text>
<text top="404" left="608" width="192" height="19" font="5">ﬁts of a bioprosthetic versus a</text>
<text top="426" left="450" width="104" height="15" font="5">mechanical valve.</text>
<text top="444" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="444" left="597" width="53" height="15" font="6"><a href="e57.full.html#118">(792,805</a></text>
<text top="440" left="651" width="35" height="19" font="6"><a href="e57.full.html#118">–810)</a></text>
<text top="471" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="486" left="449" width="351" height="10" font="21">2. Valve intervention is recommended before pregnancy for</text>
<text top="502" left="467" width="303" height="10" font="21">symptomatic patients with severe MS (mitral valve area</text>
<text top="499" left="775" width="25" height="16" font="21">£1.5</text>
<text top="519" left="467" width="16" height="10" font="21">cm</text>
<text top="516" left="483" width="5" height="7" font="25">2</text>
<text top="519" left="488" width="174" height="12" font="21">, stage D). (Level of Evidence: C)</text>
<text top="543" left="465" width="264" height="15" font="5">Patients with severe MS (mitral valve area</text>
<text top="539" left="734" width="54" height="19" font="5">1.5 cm</text>
<text top="540" left="789" width="6" height="10" font="14">2</text>
<text top="543" left="795" width="5" height="15" font="5">)</text>
<text top="561" left="450" width="350" height="15" font="5">are at increased risk for complications during pregnancy.</text>
<text top="579" left="450" width="350" height="15" font="5">The increased blood volume, heart rate, and cardiac</text>
<text top="597" left="450" width="350" height="15" font="5">output will more than double the transmitral gradient,</text>
<text top="615" left="450" width="29" height="15" font="5">signi</text>
<text top="611" left="479" width="321" height="19" font="5">ﬁcantly increasing LA pressure. Up to 74% of pa-</text>
<text top="633" left="450" width="350" height="15" font="5">tients with severe MS will have clinical deterioration</text>
<text top="650" left="450" width="350" height="15" font="5">during pregnancy, manifested primarily by HF symptoms</text>
<text top="668" left="450" width="350" height="15" font="5">and atrial arrhythmias. The predictors of poor outcome</text>
<text top="686" left="450" width="350" height="15" font="5">are severity of the stenosis and symptoms before preg-</text>
<text top="704" left="450" width="350" height="15" font="5">nancy. Maternal mortality is uncommon but does occur</text>
<text top="722" left="450" width="350" height="15" font="5">with severe symptoms and critical MS. Fetal outcome is</text>
<text top="740" left="450" width="350" height="15" font="5">also dependent on the severity of stenosis and symptoms.</text>
<text top="758" left="450" width="350" height="15" font="5">The rate of premature delivery is 14% in patients with</text>
<text top="776" left="450" width="350" height="15" font="5">mild MS and up to 33% in patients with severe MS. If</text>
<text top="794" left="450" width="350" height="15" font="5">severe symptoms develop, there is a 30% risk of fetal</text>
<text top="812" left="450" width="350" height="15" font="5">mortality. These complications can be minimized by</text>
<text top="830" left="450" width="350" height="15" font="5">relief of MS before pregnancy. When valve morphology</text>
<text top="848" left="450" width="350" height="15" font="5">is favorable, percutaneous mitral balloon commissur-</text>
<text top="866" left="450" width="350" height="15" font="5">otomy is the preferred intervention. In patients with</text>
<text top="884" left="450" width="27" height="15" font="5">calci</text>
<text top="880" left="477" width="322" height="19" font="5">ﬁed immobile valves and subvalvular fusion, the</text>
<text top="902" left="450" width="350" height="15" font="5">choice between therapeutic intervention using percuta-</text>
<text top="920" left="450" width="350" height="15" font="5">neous mitral balloon commissurotomy, surgical commis-</text>
<text top="937" left="450" width="350" height="15" font="5">surotomy, or MVR should be made based on institutional</text>
<text top="955" left="450" width="66" height="15" font="5">experience.</text>
<text top="974" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="973" left="597" width="53" height="15" font="6"><a href="e57.full.html#118">(792,809</a></text>
<text top="970" left="651" width="35" height="19" font="6"><a href="e57.full.html#118">–813)</a></text>
<text top="1001" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="1015" left="449" width="351" height="10" font="21">3. Percutaneous mitral balloon commissurotomy is recommended</text>
<text top="1032" left="467" width="333" height="10" font="21">before pregnancy for asymptomatic patients with severe MS</text>
<text top="1048" left="467" width="103" height="10" font="21">(mitral valve area</text>
<text top="1045" left="580" width="50" height="16" font="21">£1.5 cm</text>
<text top="1046" left="630" width="5" height="7" font="25">2</text>
<text top="1048" left="635" width="165" height="10" font="21">, stage C) who have valve</text>
<text top="1065" left="467" width="333" height="10" font="21">morphology favorable for percutaneous mitral balloon commis-</text>
<text top="1081" left="467" width="169" height="12" font="21">surotomy. (Level of Evidence: C)</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e141</text>
</page>
<page number="86" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="79" width="335" height="15" font="5">Percutaneous mitral balloon commissurotomy can be</text>
<text top="121" left="64" width="350" height="15" font="5">performed with a high rate of success and low rate of</text>
<text top="139" left="64" width="350" height="15" font="5">complications in patients with valve anatomy amenable to</text>
<text top="157" left="64" width="350" height="15" font="5">this procedure. There is a high rate of clinical deteriora-</text>
<text top="175" left="64" width="350" height="15" font="5">tion that occurs in patients with severe MS during the</text>
<text top="192" left="64" width="350" height="15" font="5">hemodynamic changes of pregnancy. There is also a high</text>
<text top="210" left="64" width="350" height="15" font="5">rate of compromised fetal outcome, including growth</text>
<text top="228" left="64" width="350" height="15" font="5">retardation, prematurity, and low birth weight, which</text>
<text top="246" left="64" width="350" height="15" font="5">has subsequent consequences on infant morbidity, infant</text>
<text top="264" left="64" width="350" height="15" font="5">mortality, and patient cardiovascular disease. If valve</text>
<text top="282" left="64" width="350" height="15" font="5">anatomy is suitable for commissurotomy, percutaneous</text>
<text top="300" left="64" width="350" height="15" font="5">mitral balloon commissurotomy should be performed in</text>
<text top="318" left="64" width="350" height="15" font="5">patients with severe MS before conception, even in the</text>
<text top="336" left="64" width="133" height="15" font="5">absence of symptoms.</text>
<text top="355" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="354" left="212" width="27" height="15" font="6"><a href="e57.full.html#118">(809</a></text>
<text top="351" left="239" width="35" height="19" font="6"><a href="e57.full.html#118">–814)</a></text>
<text top="381" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="396" left="63" width="351" height="10" font="21">1. Valve intervention is reasonable before pregnancy for asymp-</text>
<text top="412" left="81" width="265" height="10" font="21">tomatic patients with severe AS (aortic velocity</text>
<text top="409" left="352" width="62" height="16" font="21">‡4.0 m per</text>
<text top="429" left="81" width="173" height="10" font="21">second or mean pressure gradient</text>
<text top="426" left="257" width="157" height="16" font="21">‡40 mm Hg, stage C). (Level of</text>
<text top="446" left="81" width="63" height="12" font="21">Evidence: C)</text>
<text top="470" left="79" width="335" height="15" font="5">Most patients with mild-to-moderate AS can tolerate the</text>
<text top="488" left="64" width="350" height="15" font="5">hemodynamic changes of pregnancy without adverse car-</text>
<text top="505" left="64" width="350" height="15" font="5">diovascular events. However, patients with severe AS are at</text>
<text top="523" left="64" width="350" height="15" font="5">an increased risk for complications, with HF developing in</text>
<text top="541" left="64" width="350" height="15" font="5">10% to 44% of patients and arrhythmias in up to 25%, even if</text>
<text top="559" left="64" width="350" height="15" font="5">they were asymptomatic before pregnancy. Progressive as</text>
<text top="577" left="64" width="350" height="15" font="5">well as sudden deterioration may occur in patients with se-</text>
<text top="595" left="64" width="350" height="15" font="5">vere AS during pregnancy and delivery. There is also an</text>
<text top="613" left="64" width="350" height="15" font="5">increased incidence of hypertensive emergencies that occur</text>
<text top="631" left="64" width="350" height="15" font="5">during pregnancy in patients with severe AS, possibly related</text>
<text top="649" left="64" width="350" height="15" font="5">to poor placental perfusion. Fetal outcomes are also worse in</text>
<text top="667" left="64" width="350" height="15" font="5">patients with severe AS. These adverse outcomes can be</text>
<text top="685" left="64" width="350" height="15" font="5">minimized by relief of AS. Percutaneous aortic balloon</text>
<text top="703" left="64" width="327" height="15" font="5">dilation may be considered in patients with noncalci</text>
<text top="699" left="392" width="22" height="19" font="5">ﬁed</text>
<text top="721" left="64" width="350" height="15" font="5">congenital AS, with the understanding that restenosis may</text>
<text top="739" left="64" width="350" height="15" font="5">occur within several years of the procedure. When anatomy</text>
<text top="757" left="64" width="350" height="15" font="5">is not suitable for balloon aortic dilation, AVR may be</text>
<text top="775" left="64" width="350" height="15" font="5">considered before pregnancy, after a detailed discussion with</text>
<text top="792" left="64" width="220" height="15" font="5">the patient about the risks and bene</text>
<text top="789" left="285" width="129" height="19" font="5">ﬁts of a bioprosthetic</text>
<text top="810" left="64" width="153" height="15" font="5">versus a mechanical valve.</text>
<text top="829" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="828" left="212" width="27" height="15" font="6"><a href="e57.full.html#118">(805</a></text>
<text top="825" left="239" width="35" height="19" font="6"><a href="e57.full.html#118">–810)</a></text>
<text top="856" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="871" left="63" width="351" height="10" font="21">2. Percutaneous mitral balloon commissurotomy is reasonable for</text>
<text top="887" left="81" width="276" height="10" font="21">pregnant patients with severe MS (mitral valve area</text>
<text top="884" left="361" width="45" height="16" font="21">£1.5 cm</text>
<text top="885" left="405" width="5" height="7" font="25">2</text>
<text top="887" left="410" width="3" height="10" font="21">,</text>
<text top="903" left="81" width="332" height="10" font="21">stage D) with valve morphology favorable for percutaneous</text>
<text top="920" left="81" width="333" height="10" font="21">mitral balloon commissurotomy who remain symptomatic with</text>
<text top="936" left="81" width="333" height="10" font="21">NYHA class III to IV HF symptoms despite medical therapy</text>
<text top="953" left="81" width="50" height="10" font="22"><a href="e57.full.html#104">(157,815</a></text>
<text top="950" left="132" width="32" height="16" font="22"><a href="e57.full.html#104">–818)</a></text>
<text top="953" left="164" width="121" height="12" font="21"><a href="e57.full.html#104">. </a>(Level of Evidence: B)</text>
<text top="977" left="79" width="335" height="15" font="5">Patients with severe MS have a high probability of</text>
<text top="995" left="64" width="350" height="15" font="5">developing progressive symptoms during the hemody-</text>
<text top="1013" left="64" width="350" height="15" font="5">namic changes of pregnancy, particularly during the second</text>
<text top="1031" left="64" width="350" height="15" font="5">and third trimesters. Percutaneous mitral balloon com-</text>
<text top="1049" left="64" width="350" height="15" font="5">missurotomy has been performed successfully in pregnant</text>
<text top="1067" left="64" width="350" height="15" font="5">patients with severe MS, primarily in those who have an</text>
<text top="103" left="450" width="350" height="15" font="5">anatomy that is amenable to this intervention. Although</text>
<text top="121" left="450" width="350" height="15" font="5">the risk of complications is low, there is still a risk of severe</text>
<text top="139" left="450" width="350" height="15" font="5">MR requiring urgent MVR. This procedure should be</text>
<text top="157" left="450" width="350" height="15" font="5">reserved only for those patients who remain symptomatic</text>
<text top="175" left="450" width="350" height="15" font="5">with NYHA class III to IV HF symptoms after initial</text>
<text top="192" left="450" width="350" height="15" font="5">therapy with bed rest, beta blockade, and diuretics.</text>
<text top="210" left="450" width="350" height="15" font="5">Percutaneous mitral balloon commissurotomy should</text>
<text top="228" left="450" width="350" height="15" font="5">preferably be performed after 20 weeks of gestation, the</text>
<text top="246" left="450" width="350" height="15" font="5">period safest for the fetus. Percutaneous mitral balloon</text>
<text top="264" left="450" width="350" height="15" font="5">commissurotomy during pregnancy should only be per-</text>
<text top="282" left="450" width="350" height="15" font="5">formed by experienced operators who have a demonstrated</text>
<text top="300" left="450" width="350" height="15" font="5">low complication rate, minimizing radiation dose to the</text>
<text top="318" left="450" width="350" height="15" font="5">mother and fetus. The procedure should also be done with</text>
<text top="336" left="450" width="350" height="15" font="5">back-up cardiac surgery, anesthesiology, and high-risk</text>
<text top="354" left="450" width="161" height="15" font="5">obstetrics services in place.</text>
<text top="373" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="372" left="597" width="53" height="15" font="6"><a href="e57.full.html#104">(157,815</a></text>
<text top="368" left="651" width="35" height="19" font="6"><a href="e57.full.html#104">–818)</a></text>
<text top="402" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="417" left="449" width="351" height="10" font="21">3. Valve intervention is reasonable for pregnant patients with se-</text>
<text top="433" left="467" width="153" height="10" font="21">vere MS (mitral valve area</text>
<text top="430" left="627" width="48" height="16" font="21">£1.5 cm</text>
<text top="431" left="675" width="5" height="7" font="25">2</text>
<text top="433" left="680" width="120" height="10" font="21">, stage D) and valve</text>
<text top="450" left="467" width="333" height="10" font="21">morphology not favorable for percutaneous mitral balloon com-</text>
<text top="466" left="467" width="332" height="10" font="21">missurotomy only if there are refractory NYHA class IV HF</text>
<text top="483" left="467" width="174" height="12" font="21">symptoms. (Level of Evidence: C)</text>
<text top="507" left="465" width="335" height="15" font="5">Patients with severe MS and unfavorable valve</text>
<text top="525" left="450" width="168" height="15" font="5">morphology (i.e., severe lea</text>
<text top="522" left="617" width="182" height="19" font="5">ﬂet calciﬁcation, leaﬂet thick-</text>
<text top="543" left="450" width="350" height="15" font="5">ening, immobility, subvalvular fusion, and commissural</text>
<text top="561" left="450" width="26" height="15" font="5">calci</text>
<text top="557" left="476" width="324" height="19" font="5">ﬁcation) are at high risk for percutaneous mitral</text>
<text top="579" left="450" width="350" height="15" font="5">balloon commissurotomy. In these patients, the percuta-</text>
<text top="597" left="450" width="350" height="15" font="5">neous approach may be complicated by severe MR</text>
<text top="615" left="450" width="350" height="15" font="5">requiring emergency MVR. Although percutaneous</text>
<text top="633" left="450" width="350" height="15" font="5">balloon mitral commissurotomy remains an option, MVR</text>
<text top="650" left="450" width="350" height="15" font="5">under controlled surgical conditions is the safest approach</text>
<text top="668" left="450" width="350" height="15" font="5">in this subgroup of patients. However, valve operation</text>
<text top="686" left="450" width="350" height="15" font="5">during pregnancy is high risk, with a 30% to 40% fetal</text>
<text top="704" left="450" width="350" height="15" font="5">mortality rate and up to 9% maternal mortality rate. Sur-</text>
<text top="722" left="450" width="350" height="15" font="5">gery for MS during pregnancy should be reserved for those</text>
<text top="740" left="450" width="350" height="15" font="5">with refractory NYHA class IV HF symptoms that are not</text>
<text top="758" left="450" width="350" height="15" font="5">responsive to medical therapy. The operation needs to be</text>
<text top="776" left="450" width="350" height="15" font="5">carefully planned with a Heart Valve Team of cardiologists,</text>
<text top="794" left="450" width="350" height="15" font="5">cardiovascular anesthesiologists, surgeons, and obstetri-</text>
<text top="812" left="450" width="350" height="15" font="5">cians specializing in high-risk obstetrics to determine</text>
<text top="830" left="450" width="350" height="15" font="5">optimal timing and sequence of therapies. High pump</text>
<text top="844" left="450" width="350" height="19" font="5">ﬂows and normothermic perfusion should be used to</text>
<text top="866" left="450" width="350" height="15" font="5">protect the fetus during cardiopulmonary bypass, with the</text>
<text top="884" left="450" width="350" height="15" font="5">shortest pump time possible. Continued monitoring of the</text>
<text top="902" left="450" width="350" height="15" font="5">fetus should be performed. There is no ideal time during</text>
<text top="920" left="450" width="350" height="15" font="5">pregnancy to perform open heart surgery, so timing is</text>
<text top="937" left="450" width="350" height="15" font="5">based on the combination of the clinical status of the</text>
<text top="955" left="450" width="350" height="15" font="5">mother and the fetus. The period between the 20th and</text>
<text top="973" left="450" width="350" height="15" font="5">28th weeks of pregnancy appears to be safest for the fetus</text>
<text top="991" left="450" width="350" height="15" font="5">in terms of risk of malformation and premature delivery. If</text>
<text top="1009" left="450" width="350" height="15" font="5">the mother can carry the fetus to full maturity, a combined</text>
<text top="1027" left="450" width="350" height="15" font="5">cesarean section followed by cardiac surgery can be</text>
<text top="1045" left="450" width="51" height="15" font="5">planned.</text>
<text top="1064" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="1064" left="597" width="53" height="15" font="6"><a href="e57.full.html#118">(816,819</a></text>
<text top="1060" left="651" width="35" height="19" font="6"><a href="e57.full.html#118">–822)</a></text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e142</text>
</page>
<page number="87" position="absolute" top="0" left="0" height="1160" width="864">
<text top="106" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="121" left="63" width="351" height="10" font="21">4. Valve intervention is reasonable for pregnant patients with se-</text>
<text top="137" left="81" width="175" height="10" font="21">vere AS (mean pressure gradient</text>
<text top="134" left="261" width="153" height="16" font="21">‡40 mm Hg, stage D) only if</text>
<text top="154" left="81" width="332" height="10" font="21">there is hemodynamic deterioration or NYHA class III to IV HF</text>
<text top="170" left="81" width="54" height="10" font="21">symptoms</text>
<text top="170" left="140" width="50" height="10" font="22"><a href="e57.full.html#118">(805,823</a></text>
<text top="167" left="190" width="32" height="16" font="22"><a href="e57.full.html#118">–828)</a></text>
<text top="170" left="222" width="121" height="12" font="21"><a href="e57.full.html#118">. </a>(Level of Evidence: B)</text>
<text top="195" left="79" width="335" height="15" font="5">Patients with severe AS may develop progressive HF or</text>
<text top="213" left="64" width="350" height="15" font="5">sudden hemodynamic deterioration during the hemody-</text>
<text top="231" left="64" width="350" height="15" font="5">namic stress of pregnancy. Medical therapy is of limited</text>
<text top="248" left="64" width="11" height="15" font="5">ef</text>
<text top="245" left="75" width="339" height="19" font="5">ﬁcacy, as the AS is a ﬁxed mechanical obstruction. Both</text>
<text top="266" left="64" width="349" height="15" font="5">open heart surgery and percutaneous aortic balloon dilation</text>
<text top="284" left="64" width="350" height="15" font="5">are high-risk procedures during pregnancy for both the</text>
<text top="302" left="64" width="350" height="15" font="5">mother and the fetus and should only be performed</text>
<text top="320" left="64" width="350" height="15" font="5">if there is hemodynamic deterioration or severe NYHA</text>
<text top="338" left="64" width="349" height="15" font="5">class III to IV HF symptoms. The type of intervention</text>
<text top="356" left="64" width="350" height="15" font="5">(AVR or percutaneous aortic balloon dilation) will be</text>
<text top="374" left="64" width="350" height="15" font="5">dependent on the expertise of the center but the inter-</text>
<text top="392" left="64" width="350" height="15" font="5">vention should always be performed in a center with a</text>
<text top="410" left="64" width="350" height="15" font="5">multidisciplinary group of cardiologists, interventionalists,</text>
<text top="428" left="64" width="350" height="15" font="5">cardiac anesthesiologists, and obstetricians specializing in</text>
<text top="446" left="64" width="119" height="15" font="5">high-risk obstetrics.</text>
<text top="464" left="79" width="335" height="15" font="5">There have been reports of successful percutaneous</text>
<text top="482" left="64" width="350" height="15" font="5">aortic balloon dilation during pregnancy. This procedure</text>
<text top="500" left="64" width="274" height="15" font="5">has better results in patients with the noncalci</text>
<text top="496" left="338" width="76" height="19" font="5">ﬁed bicuspid</text>
<text top="518" left="64" width="350" height="15" font="5">aortic valve but may result in severe AR due to a tear in an</text>
<text top="535" left="64" width="161" height="15" font="5">aortic valve cusp. Limited</text>
<text top="532" left="232" width="181" height="19" font="5">ﬂuoroscopy time with appro-</text>
<text top="553" left="64" width="350" height="15" font="5">priate lead shielding of the fetus is necessary. Intervention</text>
<text top="571" left="64" width="350" height="15" font="5">is preferable after 20 weeks of gestation because it is safer</text>
<text top="589" left="64" width="350" height="15" font="5">for the fetus. Percutaneous aortic balloon dilation should</text>
<text top="607" left="64" width="350" height="15" font="5">only be performed by highly experienced operators in</text>
<text top="625" left="64" width="350" height="15" font="5">centers with a competent team of cardiologists and car-</text>
<text top="643" left="64" width="350" height="15" font="5">diovascular anesthesiologists, with back-up cardiac surgery</text>
<text top="661" left="64" width="247" height="15" font="5">and high-risk obstetrics services in place.</text>
<text top="679" left="79" width="268" height="15" font="5">AVR may also be considered. High pump</text>
<text top="676" left="354" width="60" height="19" font="5">ﬂows and</text>
<text top="697" left="64" width="350" height="15" font="5">normothermic perfusion should be used to protect the fetus</text>
<text top="715" left="64" width="350" height="15" font="5">during cardiopulmonary bypass, with the shortest pump</text>
<text top="733" left="64" width="350" height="15" font="5">time possible. Continued monitoring of the fetus should be</text>
<text top="751" left="64" width="350" height="15" font="5">performed. There is no ideal time during pregnancy to</text>
<text top="769" left="64" width="350" height="15" font="5">perform open heart surgery, so timing is based on the</text>
<text top="787" left="64" width="350" height="15" font="5">combination of the clinical status of the mother and the</text>
<text top="805" left="64" width="350" height="15" font="5">fetus. The period between the 20th and 28th weeks of</text>
<text top="822" left="64" width="350" height="15" font="5">pregnancy appears to be safest for the fetus in terms of risk</text>
<text top="840" left="64" width="350" height="15" font="5">of malformation and premature delivery. If the mother can</text>
<text top="858" left="64" width="350" height="15" font="5">carry the fetus to full maturity, a combined cesarean section</text>
<text top="876" left="64" width="277" height="15" font="5">followed by cardiac operation can be planned.</text>
<text top="894" left="79" width="335" height="15" font="5">Percutaneous aortic balloon dilation and AVR pro-</text>
<text top="912" left="64" width="350" height="15" font="5">cedures need to be carefully planned with a Heart Valve</text>
<text top="930" left="64" width="350" height="15" font="5">Team of cardiologists, cardiovascular anesthesiologists,</text>
<text top="948" left="64" width="350" height="15" font="5">surgeons, and obstetricians specializing in high-risk ob-</text>
<text top="966" left="64" width="350" height="15" font="5">stetrics to determine optimal timing and sequence of</text>
<text top="984" left="64" width="57" height="15" font="5">therapies.</text>
<text top="1003" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="1003" left="212" width="80" height="15" font="6"><a href="e57.full.html#118">(805,816,819</a></text>
<text top="999" left="292" width="35" height="19" font="6"><a href="e57.full.html#118">–828)</a></text>
<text top="1030" left="64" width="73" height="8" font="20">CLASS III: Harm</text>
<text top="1045" left="63" width="351" height="10" font="21">1. Valve operation should not be performed in pregnant patients</text>
<text top="1061" left="81" width="333" height="10" font="21">with valve stenosis in the absence of severe HF symptoms.</text>
<text top="1078" left="81" width="113" height="12" font="21">(Level of Evidence: C)</text>
<text top="103" left="465" width="335" height="15" font="5">Valve surgery during pregnancy is high risk, with a 30%</text>
<text top="121" left="450" width="350" height="15" font="5">to 40% fetal mortality rate and up to 9% maternal mortality</text>
<text top="139" left="450" width="350" height="15" font="5">rate reported. It should be reserved only for patients with</text>
<text top="157" left="450" width="350" height="15" font="5">severe, intractable symptoms unresponsive to bed rest and</text>
<text top="175" left="450" width="99" height="15" font="5">medical therapy.</text>
<text top="193" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="192" left="597" width="53" height="15" font="6"><a href="e57.full.html#118">(816,819</a></text>
<text top="189" left="651" width="35" height="19" font="6"><a href="e57.full.html#118">–822)</a></text>
<text top="239" left="450" width="224" height="12" font="19">13.2. Native Valve Regurgitation</text>
<text top="266" left="450" width="340" height="15" font="5">13.2.1. Diagnosis and Follow-Up: Recommendations</text>
<text top="294" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="309" left="449" width="350" height="10" font="21">1. All patients with suspected valve regurgitation should undergo a</text>
<text top="325" left="467" width="332" height="12" font="21">clinical evaluation and TTE before pregnancy. (Level of Evidence: C)</text>
<text top="349" left="465" width="335" height="15" font="5">Patients with valve regurgitation tolerate pregnancy</text>
<text top="367" left="450" width="350" height="15" font="5">better than do patients with valve stenosis because the</text>
<text top="385" left="450" width="350" height="15" font="5">decrease in afterload that occurs throughout pregnancy</text>
<text top="403" left="450" width="350" height="15" font="5">allows an appropriate increase in cardiac output without a</text>
<text top="421" left="450" width="104" height="15" font="5">rise in ventricular</text>
<text top="418" left="558" width="241" height="19" font="5">ﬁlling pressures. However, patients with</text>
<text top="439" left="450" width="350" height="15" font="5">severe regurgitation who are already symptom limited or</text>
<text top="457" left="450" width="350" height="15" font="5">have a reduced LVEF or pulmonary hypertension may</text>
<text top="475" left="450" width="350" height="15" font="5">develop HF symptoms because of the volume load of</text>
<text top="493" left="450" width="350" height="15" font="5">pregnancy. Clinical and TTE evaluation before pregnancy</text>
<text top="511" left="450" width="350" height="15" font="5">allow determination of the cause of regurgitation, quanti-</text>
<text top="529" left="450" width="350" height="15" font="5">tation of regurgitant severity, measurement of LVEF, and</text>
<text top="547" left="450" width="350" height="15" font="5">estimation of pulmonary pressures so that patients at high</text>
<text top="565" left="450" width="105" height="15" font="5">risk can be identi</text>
<text top="561" left="555" width="26" height="19" font="5">ﬁed.</text>
<text top="583" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="582" left="597" width="27" height="15" font="6"><a href="e57.full.html#118">(792</a></text>
<text top="579" left="625" width="117" height="19" font="6"><a href="e57.full.html#118">–794,810,829–834)</a></text>
<text top="610" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="625" left="449" width="351" height="10" font="21">2. All patients with severe valve regurgitation (stages C and D)</text>
<text top="641" left="467" width="333" height="10" font="21">should undergo prepregnancy counseling by a cardiologist with</text>
<text top="658" left="467" width="332" height="10" font="21">expertise in managing patients with VHD during pregnancy.</text>
<text top="674" left="467" width="113" height="12" font="21">(Level of Evidence: C)</text>
<text top="698" left="465" width="335" height="15" font="5">The management of patients with valve regurgitation</text>
<text top="716" left="450" width="350" height="15" font="5">should ideally begin before conception. A complete</text>
<text top="734" left="450" width="350" height="15" font="5">assessment of functional capacity, severity of regurgita-</text>
<text top="752" left="450" width="350" height="15" font="5">tion, pulmonary pressures, and LV size and function are</text>
<text top="770" left="450" width="350" height="15" font="5">necessary to determine the risk of pregnancy and delivery</text>
<text top="788" left="450" width="350" height="15" font="5">in patients with valve regurgitation. The risks and ben-</text>
<text top="806" left="450" width="6" height="15" font="5">e</text>
<text top="803" left="456" width="343" height="19" font="5">ﬁts of proceeding with pregnancy must be fully dis-</text>
<text top="824" left="450" width="350" height="15" font="5">cussed with the patient. Interventions before pregnancy</text>
<text top="842" left="450" width="350" height="15" font="5">may be considered in the patient with severe regurgita-</text>
<text top="860" left="450" width="350" height="15" font="5">tion who is at high risk for developing HF during</text>
<text top="878" left="450" width="350" height="15" font="5">pregnancy, particularly if the valve can be repaired</text>
<text top="896" left="450" width="350" height="15" font="5">instead of replaced. Drugs with potential harmful effects</text>
<text top="914" left="450" width="204" height="15" font="5">on the fetus must be identi</text>
<text top="910" left="654" width="145" height="19" font="5">ﬁed. If pregnancy is</text>
<text top="931" left="450" width="350" height="15" font="5">contemplated, arrangements should be made for the</text>
<text top="949" left="450" width="350" height="15" font="5">patient to be monitored in a tertiary care center with a</text>
<text top="967" left="450" width="350" height="15" font="5">dedicated Heart Valve Team of cardiologists, surgeons,</text>
<text top="985" left="450" width="350" height="15" font="5">anesthesiologists, and obstetricians with expertise in</text>
<text top="1003" left="450" width="60" height="15" font="5">managing</text>
<text top="1003" left="527" width="56" height="15" font="5">high-risk</text>
<text top="1003" left="600" width="43" height="15" font="5">cardiac</text>
<text top="1003" left="660" width="52" height="15" font="5">patients.</text>
<text top="1003" left="729" width="70" height="15" font="5">Counseling</text>
<text top="1021" left="450" width="350" height="15" font="5">regarding all these areas should be performed by a</text>
<text top="1039" left="450" width="350" height="15" font="5">cardiologist with expertise in managing patients with</text>
<text top="1057" left="450" width="153" height="15" font="5">VHD during pregnancy.</text>
<text top="1076" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="1075" left="598" width="27" height="15" font="6"><a href="e57.full.html#118">(792</a></text>
<text top="1072" left="625" width="87" height="19" font="6"><a href="e57.full.html#118">–794,810,834)</a></text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e143</text>
</page>
<page number="88" position="absolute" top="0" left="0" height="1160" width="864">
<text top="106" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="121" left="63" width="351" height="10" font="21">3. All patients referred for a valve operation before pregnancy</text>
<text top="137" left="81" width="333" height="10" font="21">should receive prepregnancy counseling by a cardiologist with</text>
<text top="154" left="81" width="333" height="10" font="21">expertise in managing patients with VHD during pregnancy</text>
<text top="170" left="81" width="154" height="10" font="21">regarding the risks and bene</text>
<text top="167" left="235" width="179" height="16" font="21">ﬁts of all options for operative in-</text>
<text top="187" left="81" width="333" height="10" font="21">terventions, including mechanical prosthesis, bioprosthesis,</text>
<text top="203" left="81" width="204" height="12" font="21">and valve repair. (Level of Evidence: C)</text>
<text top="228" left="79" width="335" height="15" font="5">When intervention is indicated, valve repair is preferred</text>
<text top="246" left="64" width="350" height="15" font="5">for the treatment of valve regurgitation in women of child-</text>
<text top="263" left="64" width="350" height="15" font="5">bearing age. However, not all valves can be adequately</text>
<text top="281" left="64" width="350" height="15" font="5">repaired, and the decision to proceed with implantation of a</text>
<text top="299" left="64" width="350" height="15" font="5">prosthetic valve is sometimes made at the time of operation.</text>
<text top="317" left="64" width="350" height="15" font="5">All prosthetic valve types pose major problems during</text>
<text top="335" left="64" width="350" height="15" font="5">pregnancy. Mechanical prostheses require continued anti-</text>
<text top="353" left="64" width="350" height="15" font="5">coagulation throughout pregnancy, with risks to both the</text>
<text top="371" left="64" width="350" height="15" font="5">mother and the fetus. Bioprostheses have a limited life span,</text>
<text top="389" left="64" width="350" height="15" font="5">particularly in the younger patient, and controversy persists</text>
<text top="407" left="64" width="350" height="15" font="5">as to whether there is acceleration of valve degeneration</text>
<text top="425" left="64" width="350" height="15" font="5">during pregnancy. All patients of childbearing age being</text>
<text top="443" left="64" width="350" height="15" font="5">considered for a valve operation should receive prepregnancy</text>
<text top="461" left="64" width="350" height="15" font="5">counseling by a cardiologist with expertise in managing</text>
<text top="479" left="64" width="350" height="15" font="5">patients with VHD during pregnancy to discuss the risks</text>
<text top="497" left="64" width="54" height="15" font="5">and bene</text>
<text top="493" left="118" width="201" height="19" font="5">ﬁts of available treatment options.</text>
<text top="515" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="515" left="212" width="111" height="15" font="6"><a href="e57.full.html#118">(793,795,810,834)</a></text>
<text top="543" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="558" left="63" width="351" height="10" font="21">4. Pregnant patients with severe regurgitation (stages C and D)</text>
<text top="574" left="81" width="333" height="10" font="21">should be monitored in a tertiary care center with a dedicated</text>
<text top="591" left="81" width="333" height="10" font="21">Heart Valve Team of cardiologists, surgeons, anesthesiologists,</text>
<text top="607" left="81" width="333" height="10" font="21">and obstetricians with expertise in managing high-risk cardiac</text>
<text top="624" left="81" width="163" height="12" font="21">patients. (Level of Evidence: C)</text>
<text top="648" left="79" width="335" height="15" font="5">Patients with severe regurgitation may be at high risk</text>
<text top="666" left="64" width="350" height="15" font="5">during pregnancy. The risk increases throughout pregnancy,</text>
<text top="684" left="64" width="350" height="15" font="5">given the continued physiological hemodynamic changes,</text>
<text top="702" left="64" width="350" height="15" font="5">including increased volume, decreased afterload, and</text>
<text top="720" left="64" width="350" height="15" font="5">increased heart rate. Pulmonary edema, arrhythmias, and</text>
<text top="738" left="64" width="350" height="15" font="5">even maternal death may occur. The presence of severe valve</text>
<text top="756" left="64" width="350" height="15" font="5">regurgitation is also associated with an increased risk to the</text>
<text top="774" left="64" width="350" height="15" font="5">fetus. Timing and mode of delivery should be discussed and</text>
<text top="792" left="64" width="350" height="15" font="5">carried out by the Heart Valve Team, with close hemody-</text>
<text top="810" left="64" width="350" height="15" font="5">namic monitoring during and up to 24 hours after delivery.</text>
<text top="827" left="64" width="350" height="15" font="5">Management at a tertiary care center with a dedicated Heart</text>
<text top="845" left="64" width="350" height="15" font="5">Valve Team of cardiologists, surgeons, anesthesiologists, and</text>
<text top="863" left="64" width="350" height="15" font="5">obstetricians who have expertise in the care of high-risk</text>
<text top="881" left="64" width="350" height="15" font="5">cardiac patients will ensure optimal maternal and fetal out-</text>
<text top="899" left="64" width="282" height="15" font="5">comes in women with severe valve regurgitation.</text>
<text top="918" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="917" left="212" width="27" height="15" font="6"><a href="e57.full.html#118">(792</a></text>
<text top="914" left="239" width="87" height="19" font="6"><a href="e57.full.html#118">–794,810,834)</a></text>
<text top="944" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="959" left="63" width="351" height="10" font="21">1. Exercise testing is reasonable in asymptomatic patients with</text>
<text top="976" left="81" width="332" height="12" font="21">severe valve regurgitation (stage C) before pregnancy. (Level of</text>
<text top="992" left="81" width="65" height="12" font="21">Evidence: C)</text>
<text top="1016" left="79" width="335" height="15" font="5">Asymptomatic patients with severe valve regurgitation</text>
<text top="1034" left="64" width="350" height="15" font="5">usually tolerate the hemodynamic changes of pregnancy,</text>
<text top="1052" left="64" width="350" height="15" font="5">unless there is concurrent ventricular systolic dysfunction</text>
<text top="1070" left="64" width="350" height="15" font="5">or pulmonary hypertension. Exercise testing may identify</text>
<text top="1088" left="64" width="350" height="15" font="5">apparently asymptomatic patients at higher risk of</text>
<text top="103" left="450" width="350" height="15" font="5">complications during pregnancy. Exercise parameters</text>
<text top="121" left="450" width="350" height="15" font="5">suggesting a higher risk include limited exercise tolerance,</text>
<text top="139" left="450" width="350" height="15" font="5">exercise-induced pulmonary hypertension, or abnormal</text>
<text top="157" left="450" width="350" height="15" font="5">symptoms. Patients with symptoms provoked by exercise</text>
<text top="175" left="450" width="257" height="15" font="5">testing should be considered symptomatic.</text>
<text top="193" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="192" left="597" width="85" height="15" font="6"><a href="e57.full.html#118">(793,810,834)</a></text>
<text top="223" left="450" width="279" height="15" font="5">13.2.2. Medical Therapy: Recommendation</text>
<text top="250" left="450" width="73" height="8" font="20">CLASS III: Harm</text>
<text top="265" left="449" width="350" height="10" font="21">1. ACE inhibitors and ARBs should not be given to pregnant pa-</text>
<text top="282" left="467" width="156" height="10" font="21">tients with valve regurgitation</text>
<text top="282" left="626" width="26" height="10" font="22"><a href="e57.full.html#118">(802</a></text>
<text top="279" left="652" width="32" height="16" font="22"><a href="e57.full.html#118">–804)</a></text>
<text top="282" left="684" width="116" height="12" font="21"><a href="e57.full.html#118">. </a>(Level of Evidence: B)</text>
<text top="306" left="465" width="335" height="15" font="5">ACE inhibitors and ARBs are contraindicated during</text>
<text top="324" left="450" width="350" height="15" font="5">pregnancy due to fetal toxicity, including renal or tubular</text>
<text top="342" left="450" width="323" height="15" font="5">dysplasia, oligohydramnios, growth retardation, ossi</text>
<text top="338" left="773" width="26" height="19" font="5">ﬁca-</text>
<text top="360" left="450" width="350" height="15" font="5">tion disorders of the skull, lung hypoplasia, and intra-</text>
<text top="378" left="450" width="350" height="15" font="5">uterine fetal death. If a patient with valvular regurgitation</text>
<text top="396" left="450" width="350" height="15" font="5">is taking 1 of these medications for any reason, it should be</text>
<text top="414" left="450" width="350" height="15" font="5">discontinued or replaced with an alternate medication</text>
<text top="432" left="450" width="111" height="15" font="5">before conception.</text>
<text top="450" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="449" left="597" width="27" height="15" font="6"><a href="e57.full.html#118">(802</a></text>
<text top="446" left="625" width="35" height="19" font="6"><a href="e57.full.html#118">–804)</a></text>
<text top="477" left="450" width="255" height="15" font="5">13.2.3. Intervention: Recommendations</text>
<text top="505" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="519" left="449" width="350" height="10" font="21">1. Valve repair or replacement is recommended before pregnancy for</text>
<text top="536" left="467" width="332" height="10" font="21">symptomatic women with severe valve regurgitation (stage D).</text>
<text top="553" left="467" width="109" height="12" font="21">(Level of Evidence: C)</text>
<text top="577" left="465" width="335" height="15" font="5">Symptomatic women with severe valve regurgitation are</text>
<text top="595" left="450" width="350" height="15" font="5">at high risk for developing HF during pregnancy. All pa-</text>
<text top="613" left="450" width="350" height="15" font="5">tients with symptomatic severe valve regurgitation should</text>
<text top="630" left="450" width="350" height="15" font="5">undergo surgery to repair or replace the valve, regardless of</text>
<text top="648" left="450" width="350" height="15" font="5">whether they wish to become pregnant. The operation will</text>
<text top="666" left="450" width="350" height="15" font="5">improve long-term outcomes and prevent progressive</text>
<text top="684" left="450" width="350" height="15" font="5">ventricular dysfunction from the long-standing volume</text>
<text top="702" left="450" width="350" height="15" font="5">overload. Although the ideal operation would be valve</text>
<text top="720" left="450" width="350" height="15" font="5">repair, not all valves can be successfully repaired. Potential</text>
<text top="738" left="450" width="350" height="15" font="5">problems associated with the different types of prosthetic</text>
<text top="756" left="450" width="350" height="15" font="5">valves during pregnancy must be discussed in detail with all</text>
<text top="774" left="450" width="150" height="15" font="5">women before operation.</text>
<text top="793" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="792" left="597" width="85" height="15" font="6"><a href="e57.full.html#118">(793,810,834)</a></text>
<text top="819" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="834" left="449" width="351" height="10" font="21">1. Valve operation for pregnant patients with severe valve regur-</text>
<text top="850" left="467" width="332" height="10" font="21">gitation is reasonable only if there are refractory NYHA class IV</text>
<text top="867" left="467" width="247" height="12" font="21">HF symptoms (stage D). (Level of Evidence: C)</text>
<text top="891" left="465" width="335" height="15" font="5">Valve operation during pregnancy is high risk for both</text>
<text top="909" left="450" width="350" height="15" font="5">the mother and the fetus, with a 30% to 40% fetal mor-</text>
<text top="927" left="450" width="350" height="15" font="5">tality rate and up to 9% maternal mortality rate reported.</text>
<text top="945" left="450" width="350" height="15" font="5">Thus, it should be reserved for the very rare patient with</text>
<text top="963" left="450" width="350" height="15" font="5">severe valve regurgitation who has severe refractory HF</text>
<text top="981" left="450" width="350" height="15" font="5">symptoms. The operation needs to be carefully planned</text>
<text top="999" left="450" width="350" height="15" font="5">with the multidisciplinary Heart Valve Team of cardiol-</text>
<text top="1017" left="450" width="350" height="15" font="5">ogists, cardiovascular anesthesiologists, surgeons, and</text>
<text top="1035" left="450" width="350" height="15" font="5">high-risk obstetricians to determine optimal timing and</text>
<text top="1053" left="450" width="224" height="15" font="5">sequence of therapies. High pump</text>
<text top="1049" left="683" width="116" height="19" font="5">ﬂows and normo-</text>
<text top="1071" left="450" width="350" height="15" font="5">thermic perfusion should be used to protect the fetus</text>
<text top="1089" left="450" width="350" height="15" font="5">during cardiopulmonary bypass, with the shortest pump</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e144</text>
</page>
<page number="89" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">time possible. Continuous monitoring of the fetus should</text>
<text top="121" left="64" width="350" height="15" font="5">be performed. There is no ideal time during pregnancy to</text>
<text top="139" left="64" width="350" height="15" font="5">perform open heart surgery, so timing is based on the</text>
<text top="157" left="64" width="350" height="15" font="5">combination of the clinical status of the mother and the</text>
<text top="175" left="64" width="350" height="15" font="5">fetus. The period between the 20th and 28th weeks of</text>
<text top="192" left="64" width="350" height="15" font="5">pregnancy appears to be safest for the fetus in terms of</text>
<text top="210" left="64" width="350" height="15" font="5">risk of malformation and premature delivery. If the</text>
<text top="228" left="64" width="350" height="15" font="5">mother can carry the fetus to full maturity, a combined</text>
<text top="246" left="64" width="350" height="15" font="5">cesarean section followed by cardiac operation can be</text>
<text top="264" left="64" width="51" height="15" font="5">planned.</text>
<text top="283" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="282" left="212" width="27" height="15" font="6"><a href="e57.full.html#119">(819</a></text>
<text top="279" left="239" width="35" height="19" font="6"><a href="e57.full.html#119">–822)</a></text>
<text top="311" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="326" left="63" width="351" height="10" font="21">1. Valve repair before pregnancy may be considered in the</text>
<text top="342" left="81" width="333" height="10" font="21">asymptomatic patient with severe MR (stage C) and a valve</text>
<text top="359" left="81" width="333" height="10" font="21">suitable for valve repair, but only after detailed discussion with</text>
<text top="375" left="81" width="201" height="10" font="21">the patient about the risks and bene</text>
<text top="372" left="282" width="132" height="16" font="21">ﬁts of the operation and</text>
<text top="392" left="81" width="303" height="12" font="21">its outcome on future pregnancies. (Level of Evidence: C)</text>
<text top="416" left="79" width="335" height="15" font="5">The threshold for valve operation for valve regurgitation</text>
<text top="434" left="64" width="350" height="15" font="5">should be higher in the asymptomatic patient who wants</text>
<text top="452" left="64" width="350" height="15" font="5">to become pregnant as opposed to conventional criteria in</text>
<text top="470" left="64" width="349" height="15" font="5">patients who are not likely to become pregnant. Although</text>
<text top="488" left="64" width="350" height="15" font="5">a successful mitral valve repair will result in a low-risk</text>
<text top="505" left="64" width="350" height="15" font="5">pregnancy and delivery, not all valves can be successfully</text>
<text top="523" left="64" width="350" height="15" font="5">repaired with complete certainty. If surgery is undertaken</text>
<text top="541" left="64" width="350" height="15" font="5">and valve repair is unsuccessful, the implantation of a</text>
<text top="559" left="64" width="350" height="15" font="5">mitral valve prosthesis increases the risks during preg-</text>
<text top="577" left="64" width="350" height="15" font="5">nancy, regardless of whether a mechanical or bioprosthetic</text>
<text top="595" left="64" width="350" height="15" font="5">valve is used. Most patients with asymptomatic severe MR</text>
<text top="613" left="64" width="350" height="15" font="5">tolerate pregnancy, and there is no evidence for accelera-</text>
<text top="631" left="64" width="350" height="15" font="5">tion of LV dysfunction during pregnancy. Thus, it may be</text>
<text top="649" left="64" width="350" height="15" font="5">prudent to manage these patients medically rather than</text>
<text top="667" left="64" width="350" height="15" font="5">recommending valve surgery before pregnancy. In patients</text>
<text top="685" left="64" width="350" height="15" font="5">with MR who are at higher risk for the development of</text>
<text top="703" left="64" width="350" height="15" font="5">HF during pregnancy, including those with depressed LV</text>
<text top="721" left="64" width="350" height="15" font="5">systolic function or pulmonary hypertension (pulmonary</text>
<text top="739" left="64" width="141" height="15" font="5">artery systolic pressure</text>
<text top="735" left="214" width="200" height="19" font="5">&gt;50 mm Hg), the decision to</text>
<text top="757" left="64" width="349" height="15" font="5">operate before pregnancy should take into consideration</text>
<text top="775" left="64" width="350" height="15" font="5">the mitral valve morphology, chance of successful repair in</text>
<text top="792" left="64" width="350" height="15" font="5">the institution, estimated surgical risk, and issues related</text>
<text top="810" left="64" width="350" height="15" font="5">to possible MVR. This may require referral to a Heart</text>
<text top="828" left="64" width="350" height="15" font="5">Valve Center of Excellence if the expected rate of a suc-</text>
<text top="846" left="64" width="350" height="15" font="5">cessful and durable valve repair at the institution does not</text>
<text top="864" left="64" width="74" height="15" font="5">exceed 95%.</text>
<text top="883" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="882" left="212" width="84" height="15" font="6"><a href="e57.full.html#118">(793,810,834)</a></text>
<text top="911" left="64" width="73" height="8" font="20">CLASS III: Harm</text>
<text top="926" left="63" width="351" height="10" font="21">1. Valve operations should not be performed in pregnant patients</text>
<text top="942" left="81" width="332" height="10" font="21">with valve regurgitation in the absence of severe intractable HF</text>
<text top="959" left="81" width="174" height="12" font="21">symptoms. (Level of Evidence: C)</text>
<text top="983" left="79" width="335" height="15" font="5">Valve surgery during pregnancy is high risk, with a 30%</text>
<text top="1001" left="64" width="350" height="15" font="5">to 40% fetal mortality rate and up to 9% maternal mortality</text>
<text top="1019" left="64" width="350" height="15" font="5">rate reported. It should be reserved only for patients with</text>
<text top="1037" left="64" width="350" height="15" font="5">severe, intractable symptoms unresponsive to bed rest and</text>
<text top="1055" left="64" width="99" height="15" font="5">medical therapy.</text>
<text top="1073" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="1073" left="212" width="27" height="15" font="6"><a href="e57.full.html#119">(819</a></text>
<text top="1069" left="239" width="35" height="19" font="6"><a href="e57.full.html#119">–822)</a></text>
<text top="103" left="450" width="253" height="12" font="19">13.3. Prosthetic Valves in Pregnancy</text>
<text top="130" left="450" width="340" height="15" font="5">13.3.1. Diagnosis and Follow-Up: Recommendations</text>
<text top="158" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="173" left="449" width="350" height="10" font="21">1. All patients with a prosthetic valve should undergo a clinical eval-</text>
<text top="189" left="467" width="325" height="12" font="21">uation and baseline TTE before pregnancy. (Level of Evidence: C)</text>
<text top="214" left="465" width="335" height="15" font="5">Major complications can occur during pregnancy in pa-</text>
<text top="231" left="450" width="350" height="15" font="5">tients with prosthetic valves. The increased hemodynamic</text>
<text top="249" left="450" width="350" height="15" font="5">burden of pregnancy can lead to HF if there is prosthetic</text>
<text top="267" left="450" width="350" height="15" font="5">valve thrombosis, stenosis, regurgitation, or patient-</text>
<text top="285" left="450" width="350" height="15" font="5">prosthesis mismatch. Clinical evaluation and baseline</text>
<text top="303" left="450" width="350" height="15" font="5">TTE allow determination of valve function and hemody-</text>
<text top="321" left="450" width="350" height="15" font="5">namics under normal loading conditions and help identify</text>
<text top="339" left="450" width="350" height="15" font="5">valve dysfunction that might require treatment before</text>
<text top="357" left="450" width="350" height="15" font="5">pregnancy. In addition, there is an increased risk of valve</text>
<text top="375" left="450" width="350" height="15" font="5">thrombosis in patients with a mechanical prosthesis due</text>
<text top="393" left="450" width="350" height="15" font="5">to the hypercoagulable state of pregnancy. The baseline</text>
<text top="411" left="450" width="350" height="15" font="5">TTE serves as the reference standard for the patient if</text>
<text top="429" left="450" width="284" height="15" font="5">valve thrombosis is suspected during pregnancy.</text>
<text top="447" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="447" left="597" width="58" height="15" font="6"><a href="e57.full.html#118">(793,795)</a></text>
<text top="474" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="489" left="449" width="351" height="10" font="21">2. All patients with a prosthetic valve should undergo prepreg-</text>
<text top="505" left="467" width="333" height="10" font="21">nancy counseling by a cardiologist with expertise in managing</text>
<text top="522" left="467" width="311" height="12" font="21">patients with VHD during pregnancy. (Level of Evidence: C)</text>
<text top="546" left="465" width="335" height="15" font="5">The management of the pregnant patient with a pros-</text>
<text top="564" left="450" width="127" height="15" font="5">thetic valve may signi</text>
<text top="561" left="577" width="223" height="19" font="5">ﬁcantly differ from that of the patient</text>
<text top="582" left="450" width="173" height="15" font="5">who is not pregnant, speci</text>
<text top="579" left="623" width="177" height="19" font="5">ﬁcally in relation to antith-</text>
<text top="600" left="450" width="350" height="15" font="5">rombotic therapy. There is a much higher risk of valve</text>
<text top="618" left="450" width="350" height="15" font="5">thrombosis for patients with a mechanical prosthesis due</text>
<text top="636" left="450" width="350" height="15" font="5">to the hypercoagulable state of pregnancy. Certain drugs</text>
<text top="654" left="450" width="350" height="15" font="5">are contraindicated during pregnancy. Prepregnancy coun-</text>
<text top="672" left="450" width="350" height="15" font="5">seling by a cardiologist with expertise in managing patients</text>
<text top="690" left="450" width="350" height="15" font="5">with VHD during pregnancy should be performed to</text>
<text top="707" left="450" width="350" height="15" font="5">determine the risk of pregnancy, discuss potential com-</text>
<text top="725" left="450" width="350" height="15" font="5">plications, and outline an approach for anticoagulation at</text>
<text top="743" left="450" width="141" height="15" font="5">the time of conception.</text>
<text top="762" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="761" left="597" width="58" height="15" font="6"><a href="e57.full.html#118">(793,795)</a></text>
<text top="789" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="804" left="449" width="351" height="10" font="21">3. TTE should be performed in all pregnant patients with a pros-</text>
<text top="820" left="467" width="332" height="12" font="21">thetic valve if not done before pregnancy. (Level of Evidence: C)</text>
<text top="844" left="465" width="335" height="15" font="5">Although it is preferable to perform a baseline echo-</text>
<text top="862" left="450" width="350" height="15" font="5">cardiogram before pregnancy in women with prosthetic</text>
<text top="880" left="450" width="350" height="15" font="5">heart valves, if a baseline study is not available during the</text>
<text top="898" left="450" width="350" height="15" font="5">time the patient has been clinically stable, TTE during</text>
<text top="916" left="450" width="350" height="15" font="5">pregnancy still provides evaluation of prosthetic valve</text>
<text top="934" left="450" width="350" height="15" font="5">function, as well as ventricular function and pulmonary</text>
<text top="952" left="450" width="350" height="15" font="5">pressures. Due to an increase in cardiac output that</text>
<text top="970" left="450" width="350" height="15" font="5">occurs during pregnancy, the mean pressure gradient</text>
<text top="988" left="450" width="318" height="15" font="5">across all prostheses will increase throughout the</text>
<text top="984" left="776" width="24" height="19" font="5">ﬁrst</text>
<text top="1006" left="450" width="350" height="15" font="5">and second trimesters and remain elevated in the third</text>
<text top="1024" left="450" width="350" height="15" font="5">trimester. Other hemodynamic parameters such as dia-</text>
<text top="1042" left="450" width="350" height="15" font="5">stolic half-time (for a mitral prosthesis) and dimen-</text>
<text top="1059" left="450" width="238" height="15" font="5">sionless index (the ratio of the LV out</text>
<text top="1056" left="688" width="111" height="19" font="5">ﬂow time velocity</text>
<text top="1077" left="450" width="350" height="15" font="5">divided by the peak aortic valve velocity for an aortic</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e145</text>
</page>
<page number="90" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">prosthesis) must be used to determine the function of the</text>
<text top="121" left="64" width="62" height="15" font="5">prosthesis.</text>
<text top="139" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="139" left="212" width="58" height="15" font="6"><a href="e57.full.html#118">(793,795)</a></text>
<text top="169" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="184" left="63" width="351" height="10" font="21">4. Repeat TTE should be performed in all pregnant patients with a</text>
<text top="200" left="81" width="332" height="12" font="21">prosthetic valve who develop symptoms. (Level of Evidence: C)</text>
<text top="224" left="79" width="335" height="15" font="5">If there are changes in clinical status with either the</text>
<text top="242" left="64" width="350" height="15" font="5">onset of symptoms of dyspnea or change in the clinical</text>
<text top="260" left="64" width="350" height="15" font="5">examination, a repeat echocardiogram is indicated to look</text>
<text top="278" left="64" width="350" height="15" font="5">for changes in ventricular function and in the hemody-</text>
<text top="296" left="64" width="350" height="15" font="5">namics of the prosthetic valve. Bioprosthetic valves are at</text>
<text top="314" left="64" width="350" height="15" font="5">risk for tissue degeneration; bioprosthetic valve stenosis</text>
<text top="332" left="64" width="350" height="15" font="5">typically develops slowly, but bioprosthetic regurgitation</text>
<text top="350" left="64" width="161" height="15" font="5">may be acute due to a lea</text>
<text top="347" left="226" width="188" height="19" font="5">ﬂet tear adjacent to an area of</text>
<text top="368" left="64" width="26" height="15" font="5">calci</text>
<text top="365" left="90" width="324" height="19" font="5">ﬁcation. Mechanical valves are prone to acute stenosis</text>
<text top="386" left="64" width="350" height="15" font="5">or regurgitation during pregnancy due to valve thrombosis</text>
<text top="404" left="64" width="350" height="15" font="5">limiting disc opening or closure. TTE should be performed</text>
<text top="422" left="64" width="313" height="15" font="5">initially because both aortic and mitral transvalvular</text>
<text top="418" left="383" width="31" height="19" font="5">ﬂows</text>
<text top="440" left="64" width="350" height="15" font="5">can be recorded from this approach. However, TEE is</text>
<text top="458" left="64" width="350" height="15" font="5">needed if prosthetic MR is suspected. Although radiation</text>
<text top="476" left="64" width="188" height="15" font="5">exposure should be minimized,</text>
<text top="472" left="257" width="156" height="19" font="5">ﬂuoroscopy of mechanical</text>
<text top="493" left="64" width="290" height="15" font="5">valves may be helpful in evaluating disc motion.</text>
<text top="512" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="511" left="212" width="58" height="15" font="6"><a href="e57.full.html#118">(793,795)</a></text>
<text top="541" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="556" left="63" width="351" height="10" font="21">5. TEE should be performed in all pregnant patients with a me-</text>
<text top="573" left="81" width="332" height="10" font="21">chanical prosthetic valve who have prosthetic valve obstruction</text>
<text top="589" left="81" width="287" height="12" font="21">or experience an embolic event. (Level of Evidence: C)</text>
<text top="613" left="79" width="335" height="15" font="5">If thrombotic obstruction is suspected or if an embolic</text>
<text top="631" left="64" width="350" height="15" font="5">event occurs in a pregnant patient with a mechanical</text>
<text top="649" left="64" width="350" height="15" font="5">prosthesis, TEE is indicated to look at valve function</text>
<text top="667" left="64" width="350" height="15" font="5">and disc motion and to determine the thrombus burden.</text>
<text top="685" left="64" width="350" height="15" font="5">Subsequent therapeutic decisions will depend on the</text>
<text top="703" left="64" width="350" height="15" font="5">clinical state of the patient, gestational age of the child,</text>
<text top="721" left="64" width="350" height="15" font="5">degree of valve dysfunction, and thrombus burden. TEE</text>
<text top="739" left="64" width="350" height="15" font="5">is especially important for detection of prosthetic mitral</text>
<text top="757" left="64" width="350" height="15" font="5">valve dysfunction, and an apparently normal trans-</text>
<text top="775" left="64" width="350" height="15" font="5">thoracic study should not dissuade clinicians from pro-</text>
<text top="793" left="64" width="350" height="15" font="5">ceeding with TEE. With a prosthetic aortic valve, both</text>
<text top="811" left="64" width="350" height="15" font="5">TTE and TEE are needed for a complete examination.</text>
<text top="829" left="64" width="350" height="15" font="5">Chest CT imaging can also diagnose prosthetic valve</text>
<text top="847" left="64" width="350" height="15" font="5">thrombosis and limitations of mechanical valve motion</text>
<text top="864" left="64" width="350" height="15" font="5">but should be avoided during pregnancy due to radiation</text>
<text top="882" left="64" width="57" height="15" font="5">exposure.</text>
<text top="901" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="900" left="212" width="106" height="15" font="6"><a href="e57.full.html#114">(605,793,795,835</a></text>
<text top="897" left="318" width="35" height="19" font="6"><a href="e57.full.html#114">–837)</a></text>
<text top="928" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="943" left="63" width="351" height="10" font="21">6. Pregnant patients with a mechanical prosthesis should be</text>
<text top="959" left="81" width="333" height="10" font="21">monitored in a tertiary care center with a dedicated Heart Valve</text>
<text top="975" left="81" width="333" height="10" font="21">Team of cardiologists, surgeons, anesthesiologists, and obste-</text>
<text top="992" left="81" width="333" height="10" font="21">tricians with expertise in the management of high-risk cardiac</text>
<text top="1008" left="81" width="163" height="12" font="21">patients. (Level of Evidence: C)</text>
<text top="1033" left="79" width="335" height="15" font="5">Women with mechanical valves are at high risk of</text>
<text top="1050" left="64" width="350" height="15" font="5">devastating complications during pregnancy. There is an</text>
<text top="1068" left="64" width="350" height="15" font="5">increased risk for thrombosis of mechanical valves due</text>
<text top="1086" left="64" width="350" height="15" font="5">to the hypercoagulable state of pregnancy, particularly</text>
<text top="103" left="450" width="350" height="15" font="5">those with a prosthetic valve in the mitral position. Anti-</text>
<text top="121" left="450" width="350" height="15" font="5">coagulation regimens to prevent valve thrombosis require</text>
<text top="139" left="450" width="276" height="15" font="5">in-depth knowledge of the risks and bene</text>
<text top="135" left="726" width="74" height="19" font="5">ﬁts of each</text>
<text top="157" left="450" width="350" height="15" font="5">approach. Valve thrombosis may result in acute, severe HF</text>
<text top="175" left="450" width="350" height="15" font="5">and/or embolic events, with a high-resultant maternal and</text>
<text top="192" left="450" width="350" height="15" font="5">fetal mortality. The occurrence of valve thrombosis during</text>
<text top="210" left="450" width="350" height="15" font="5">pregnancy constitutes a medical and sometimes surgical</text>
<text top="228" left="450" width="350" height="15" font="5">emergency. Integrated care by a Heart Valve Team of</text>
<text top="246" left="450" width="350" height="15" font="5">cardiologists, surgeons, anesthesiologists, and obstetricians</text>
<text top="264" left="450" width="350" height="15" font="5">with expertise in the management of high-risk cardiac</text>
<text top="282" left="450" width="112" height="15" font="5">patients is needed.</text>
<text top="301" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="300" left="597" width="58" height="15" font="6"><a href="e57.full.html#118">(793,795)</a></text>
<text top="327" left="450" width="284" height="15" font="5">13.3.2. Medical Therapy: Recommendations</text>
<text top="352" left="451" width="21" height="15" font="5">See</text>
<text top="352" left="475" width="57" height="15" font="6"><a href="e57.full.html#91">Figure 10</a></text>
<text top="352" left="536" width="264" height="15" font="5">for anticoagulation of pregnant patients with</text>
<text top="370" left="450" width="109" height="15" font="5">mechanical valves.</text>
<text top="398" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="412" left="449" width="351" height="10" font="21">1. Therapeutic anticoagulation with frequent monitoring is rec-</text>
<text top="429" left="467" width="332" height="10" font="21">ommended for all pregnant patients with a mechanical pros-</text>
<text top="445" left="467" width="32" height="10" font="21">thesis</text>
<text top="445" left="503" width="55" height="10" font="22"><a href="e57.full.html#119">(838,839)</a></text>
<text top="445" left="558" width="121" height="12" font="21"><a href="e57.full.html#119">. </a>(Level of Evidence: B)</text>
<text top="470" left="465" width="335" height="15" font="5">There is a high risk of valve thrombosis in patients with</text>
<text top="488" left="450" width="350" height="15" font="5">mechanical prostheses who are pregnant due to the hy-</text>
<text top="505" left="450" width="350" height="15" font="5">percoagulable state that occurs during pregnancy. All</text>
<text top="523" left="450" width="350" height="15" font="5">anticoagulant regimens carry an increased risk to the fetus,</text>
<text top="541" left="450" width="350" height="15" font="5">with fetal abnormalities, an increased risk of miscarriage,</text>
<text top="559" left="450" width="350" height="15" font="5">and hemorrhagic complications, including retroplacental</text>
<text top="577" left="450" width="350" height="15" font="5">bleeding, leading to premature birth and fetal death.</text>
<text top="595" left="450" width="350" height="15" font="5">However, without any anticoagulation, maternal mortality</text>
<text top="613" left="450" width="350" height="15" font="5">is high (up to 5%), and there is a high risk of thrombo-</text>
<text top="631" left="450" width="350" height="15" font="5">embolic events (up to 24%) and valve thrombosis. Because</text>
<text top="649" left="450" width="350" height="15" font="5">of the physiological effects of pregnancy, there are con-</text>
<text top="667" left="450" width="350" height="15" font="5">stantly changing requirements for antithrombotic regi-</text>
<text top="685" left="450" width="350" height="15" font="5">mens. Effective anticoagulation with frequent monitoring</text>
<text top="703" left="450" width="347" height="15" font="5">of its systemic effect is critical throughout the pregnancy.</text>
<text top="721" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="721" left="597" width="58" height="15" font="6"><a href="e57.full.html#119">(838,839)</a></text>
<text top="739" left="465" width="18" height="15" font="5">See</text>
<text top="739" left="488" width="166" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 25</a></text>
<text top="739" left="659" width="140" height="15" font="5">for more information on</text>
<text top="757" left="450" width="60" height="15" font="5">pregnancy.</text>
<text top="784" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="799" left="449" width="351" height="10" font="21">2. Warfarin is recommended in pregnant patients with a mechanical</text>
<text top="815" left="467" width="332" height="10" font="21">prosthesis to achieve a therapeutic INR in the second and third</text>
<text top="832" left="467" width="53" height="10" font="21">trimesters</text>
<text top="832" left="524" width="25" height="10" font="22"><a href="e57.full.html#119">(840</a></text>
<text top="828" left="549" width="31" height="16" font="22"><a href="e57.full.html#119">–845)</a></text>
<text top="832" left="580" width="119" height="12" font="21">. (Level of Evidence: B)</text>
<text top="856" left="465" width="335" height="15" font="5">Warfarin is the most effective anticoagulant for pre-</text>
<text top="874" left="450" width="350" height="15" font="5">venting maternal thromboembolic events during preg-</text>
<text top="892" left="450" width="350" height="15" font="5">nancy. Although warfarin has potential fetal teratogenic</text>
<text top="910" left="450" width="77" height="15" font="5">effects in the</text>
<text top="906" left="531" width="269" height="19" font="5">ﬁrst trimester, there is little teratogenic effect</text>
<text top="928" left="450" width="350" height="15" font="5">in the second and third trimesters. Use of UFH</text>
<text top="946" left="450" width="350" height="15" font="5">throughout pregnancy has the highest risk of thrombo-</text>
<text top="964" left="450" width="350" height="15" font="5">embolic events and maternal death in patients with a</text>
<text top="981" left="450" width="350" height="15" font="5">mechanical prosthesis, with reported instances of mas-</text>
<text top="999" left="450" width="350" height="15" font="5">sive thrombosis of prosthetic valves. Although there are</text>
<text top="1017" left="450" width="350" height="15" font="5">no RCTs comparing the different antithrombotic regi-</text>
<text top="1035" left="450" width="350" height="15" font="5">mens, the risk of thromboembolic events using warfarin</text>
<text top="1053" left="450" width="148" height="15" font="5">throughout pregnancy is</text>
<text top="1050" left="604" width="195" height="19" font="5">&lt;4%, compared with 33% with</text>
<text top="1071" left="450" width="350" height="15" font="5">the use of UFH throughout pregnancy. Use of UFH</text>
<text top="1089" left="450" width="350" height="15" font="5">throughout pregnancy is also associated with maternal</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e146</text>
</page>
<page number="91" position="absolute" top="0" left="0" height="1160" width="864">
<text top="759" left="64" width="350" height="15" font="5">complications of thrombocytopenia and osteoporosis.</text>
<text top="777" left="64" width="120" height="15" font="5">LMWH given at a</text>
<text top="774" left="190" width="224" height="19" font="5">ﬁxed dose has resulted in fatal valve</text>
<text top="795" left="64" width="350" height="15" font="5">thrombosis. When monitored with anti-Xa levels, LMWH</text>
<text top="813" left="64" width="350" height="15" font="5">has a lower rate of valve thrombosis compared with UFH.</text>
<text top="831" left="64" width="350" height="15" font="5">Even with meticulous monitoring of anti-Xa levels, there</text>
<text top="849" left="64" width="350" height="15" font="5">have been cases of valve thrombosis with LMWH used</text>
<text top="867" left="64" width="350" height="15" font="5">throughout pregnancy. There is no ideal anticoagulant</text>
<text top="885" left="64" width="350" height="15" font="5">regimen for pregnant women with mechanical valves.</text>
<text top="903" left="64" width="350" height="15" font="5">However, during the second and third trimesters of preg-</text>
<text top="921" left="64" width="102" height="15" font="5">nancy, the bene</text>
<text top="917" left="166" width="248" height="19" font="5">ﬁts of warfarin for the mother appear</text>
<text top="939" left="64" width="305" height="15" font="5">to outweigh the slightly increased risk to the fetus.</text>
<text top="957" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="957" left="212" width="53" height="15" font="6"><a href="e57.full.html#119">(838,840</a></text>
<text top="953" left="265" width="35" height="19" font="6"><a href="e57.full.html#119">–847)</a></text>
<text top="975" left="79" width="18" height="15" font="5">See</text>
<text top="975" left="103" width="170" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplements 25</a></text>
<text top="975" left="279" width="22" height="15" font="5">and</text>
<text top="975" left="306" width="15" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">26</a></text>
<text top="975" left="327" width="87" height="15" font="5">for more infor-</text>
<text top="993" left="64" width="123" height="15" font="5">mation on pregnancy.</text>
<text top="1020" left="64" width="37" height="8" font="20">CLASS I</text>
<text top="1035" left="63" width="351" height="10" font="21">3. Discontinuation of warfarin with initiation of intravenous UFH (with</text>
<text top="1051" left="81" width="242" height="10" font="21">an activated partial thromboplastin time [aPTT]</text>
<text top="1048" left="326" width="88" height="16" font="21">&gt;2 times control)</text>
<text top="1068" left="81" width="333" height="10" font="21">is recommended before planned vaginal delivery in pregnant</text>
<text top="1084" left="81" width="309" height="12" font="21">patients with a mechanical prosthesis. (Level of Evidence: C)</text>
<text top="759" left="465" width="335" height="15" font="5">Warfarin crosses the placental barrier and results in</text>
<text top="777" left="450" width="350" height="15" font="5">anticoagulation of the fetus as well as the mother. There is a</text>
<text top="795" left="450" width="350" height="15" font="5">higher risk of intracranial hemorrhage for the fetus if the</text>
<text top="813" left="450" width="350" height="15" font="5">mother is fully anticoagulated during vaginal delivery. It is</text>
<text top="831" left="450" width="350" height="15" font="5">recommended that the mother be hospitalized before plan-</text>
<text top="849" left="450" width="350" height="15" font="5">ned delivery with discontinuation of warfarin and initiation</text>
<text top="867" left="450" width="350" height="15" font="5">of intravenous continuous infusion of UFH to keep aPTT</text>
<text top="882" left="450" width="350" height="19" font="5">&gt;2 times control levels. Then heparin is stopped just before</text>
<text top="903" left="450" width="350" height="15" font="5">delivery. Patients with mechanical prostheses are at</text>
<text top="921" left="450" width="350" height="15" font="5">increased risk for premature labor, so careful planning with a</text>
<text top="939" left="450" width="350" height="15" font="5">Heart Valve Team of cardiologists, anesthesiologists, and</text>
<text top="957" left="450" width="350" height="15" font="5">obstetricians is required before anticipated delivery. Alter-</text>
<text top="975" left="450" width="350" height="15" font="5">native approaches to delivery include elective cesarean sec-</text>
<text top="993" left="450" width="238" height="15" font="5">tion after a shorter cessation of warfarin.</text>
<text top="1011" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="1010" left="597" width="58" height="15" font="6"><a href="e57.full.html#119">(848,849)</a></text>
<text top="1038" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="1053" left="449" width="351" height="10" font="21">4. Low-dose aspirin (75 mg to 100 mg) once per day is recommended</text>
<text top="1069" left="467" width="333" height="10" font="21">for pregnant patients in the second and third trimesters with either</text>
<text top="1085" left="467" width="325" height="12" font="21">a mechanical prosthesis or bioprosthesis. (Level of Evidence: C)</text>
<text top="685" left="64" width="414" height="11" font="13">Figure 10. Anticoagulation of Pregnant Patients With Mechanical Valves</text>
<text top="717" left="72" width="696" height="9" font="14">aPTT indicates activated partial thromboplastin time; ASA, aspirin; INR, international normalized ratio; LMWH, low-molecular-weight heparin; QD, once daily; and UFH,</text>
<text top="730" left="72" width="97" height="9" font="14">unfractionated heparin.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e147</text>
</page>
<page number="92" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="79" width="335" height="15" font="5">Although there are no data regarding the addition of</text>
<text top="121" left="64" width="350" height="15" font="5">aspirin to anticoagulation in pregnant patients with pros-</text>
<text top="139" left="64" width="350" height="15" font="5">thetic valves, the addition of aspirin is effective in lowering</text>
<text top="157" left="64" width="350" height="15" font="5">the thromboembolic risk in nonpregnant patients. Aspirin</text>
<text top="175" left="64" width="350" height="15" font="5">is safe in the second and third trimesters of pregnancy from</text>
<text top="192" left="64" width="147" height="15" font="5">the obstetric standpoint.</text>
<text top="211" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="210" left="212" width="84" height="15" font="6"><a href="e57.full.html#113">(567,568,850)</a></text>
<text top="238" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="253" left="63" width="201" height="10" font="21">1. Continuation of warfarin during the</text>
<text top="249" left="268" width="146" height="16" font="21">ﬁrst trimester is reasonable</text>
<text top="269" left="81" width="333" height="10" font="21">for pregnant patients with a mechanical prosthesis if the dose</text>
<text top="285" left="81" width="333" height="10" font="21">of warfarin to achieve a therapeutic INR is 5 mg per day or less</text>
<text top="302" left="81" width="316" height="10" font="21">after full discussion with the patient about risks and bene</text>
<text top="299" left="397" width="17" height="16" font="21">ﬁts</text>
<text top="318" left="81" width="154" height="10" font="22"><a href="e57.full.html#119">(838,839,844,845,848,851)</a></text>
<text top="318" left="235" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="346" left="79" width="299" height="15" font="5">The optimal anticoagulant used during the</text>
<text top="342" left="391" width="23" height="19" font="5">ﬁrst</text>
<text top="364" left="64" width="350" height="15" font="5">trimester in pregnant patients with mechanical prosthetic</text>
<text top="381" left="64" width="350" height="15" font="5">valves remains controversial. Oral anticoagulation with</text>
<text top="399" left="64" width="350" height="15" font="5">warfarin is the safest regimen for the mother, but there is</text>
<text top="417" left="64" width="350" height="15" font="5">an increased risk of embryopathy. Anticoagulation with</text>
<text top="435" left="64" width="350" height="15" font="5">UFH or LMWH has been recommended to avoid the risk</text>
<text top="453" left="64" width="350" height="15" font="5">of embryopathy, but it is not as effective as warfarin in</text>
<text top="471" left="64" width="350" height="15" font="5">preventing thromboembolic events. The risk of embryop-</text>
<text top="489" left="64" width="271" height="15" font="5">athy is dose dependent, with a low risk (</text>
<text top="486" left="336" width="78" height="19" font="5">&lt;3%) if the</text>
<text top="507" left="64" width="114" height="15" font="5">dose of warfarin is</text>
<text top="504" left="184" width="230" height="19" font="5">5 mg per day. The risk of abortion</text>
<text top="525" left="64" width="350" height="15" font="5">and fetal loss are increased with any anticoagulant regimen</text>
<text top="543" left="64" width="350" height="15" font="5">but may be similar in women exposed to oral anticoagu-</text>
<text top="561" left="64" width="158" height="15" font="5">lants versus heparin in the</text>
<text top="557" left="227" width="187" height="19" font="5">ﬁrst trimester, especially at low</text>
<text top="579" left="64" width="323" height="15" font="5">doses of warfarin. Continuation of warfarin during the</text>
<text top="575" left="391" width="23" height="19" font="5">ﬁrst</text>
<text top="597" left="64" width="350" height="15" font="5">trimester is reasonable after a full discussion with the pa-</text>
<text top="615" left="64" width="276" height="15" font="5">tient and family about the risks and bene</text>
<text top="611" left="340" width="74" height="19" font="5">ﬁts when a</text>
<text top="633" left="64" width="350" height="15" font="5">therapeutic INR can be maintained with a daily warfarin</text>
<text top="651" left="64" width="43" height="15" font="5">dose of</text>
<text top="647" left="113" width="47" height="19" font="5">5 mg.</text>
<text top="669" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="668" left="212" width="158" height="15" font="6"><a href="e57.full.html#119">(838,839,844,845,848,851</a></text>
<text top="665" left="370" width="35" height="19" font="6"><a href="e57.full.html#119">–854)</a></text>
<text top="687" left="79" width="18" height="15" font="5">See</text>
<text top="687" left="103" width="170" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplements 25</a></text>
<text top="686" left="279" width="22" height="15" font="5">and</text>
<text top="687" left="306" width="15" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">26</a></text>
<text top="687" left="327" width="87" height="15" font="5">for more infor-</text>
<text top="705" left="64" width="123" height="15" font="5">mation on pregnancy.</text>
<text top="736" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="751" left="63" width="351" height="10" font="21">2. Dose-adjusted LMWH at least 2 times per day (with a target</text>
<text top="767" left="81" width="332" height="10" font="21">anti-Xa level of 0.8 U/mL to 1.2 U/mL, 4 to 6 hours post-</text>
<text top="784" left="81" width="94" height="10" font="21">dose) during the</text>
<text top="781" left="181" width="233" height="16" font="21">ﬁrst trimester is reasonable for pregnant</text>
<text top="800" left="81" width="332" height="10" font="21">patients with a mechanical prosthesis if the dose of warfarin</text>
<text top="817" left="81" width="333" height="10" font="21">is greater than 5 mg per day to achieve a therapeutic INR</text>
<text top="833" left="81" width="26" height="10" font="22"><a href="e57.full.html#119">(840</a></text>
<text top="830" left="107" width="81" height="16" font="22"><a href="e57.full.html#119">–843,855,856)</a></text>
<text top="833" left="188" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="860" left="79" width="236" height="15" font="5">In patients whose dosage of warfarin is</text>
<text top="857" left="319" width="95" height="19" font="5">&gt;5 mg per day,</text>
<text top="878" left="64" width="169" height="15" font="5">the risk of embryopathy is</text>
<text top="875" left="241" width="173" height="19" font="5">&gt;8% (compared with &lt;3%</text>
<text top="896" left="64" width="152" height="15" font="5">with a warfarin dosage of</text>
<text top="893" left="220" width="194" height="19" font="5">5 mg per day). It is reasonable</text>
<text top="914" left="64" width="350" height="15" font="5">to consider heparin anticoagulation instead of warfarin</text>
<text top="932" left="64" width="65" height="15" font="5">during the</text>
<text top="929" left="136" width="278" height="19" font="5">ﬁrst trimester of pregnancy, because heparin</text>
<text top="950" left="64" width="350" height="15" font="5">does not cross the placental barrier and is not associated</text>
<text top="968" left="64" width="350" height="15" font="5">with fetal embryopathy. LMWH may be a better alter-</text>
<text top="986" left="64" width="350" height="15" font="5">native than UFH with potential advantages of better</text>
<text top="1004" left="64" width="350" height="15" font="5">subcutaneous absorption and bioavailability, longer half-</text>
<text top="1022" left="64" width="350" height="15" font="5">life, and a more predictable anticoagulation response.</text>
<text top="1040" left="64" width="350" height="15" font="5">Anti-Xa levels should be monitored because dosage re-</text>
<text top="1058" left="64" width="350" height="15" font="5">quirements may increase by as much as 50% over the</text>
<text top="1076" left="64" width="350" height="15" font="5">course of pregnancy. The target anti-Xa level should be</text>
<text top="103" left="450" width="350" height="15" font="5">0.8 U/mL to 1.2 U/mL, measured 4 to 6 hours after in-</text>
<text top="121" left="450" width="350" height="15" font="5">jection. With use of this meticulous dosing regimen, the</text>
<text top="139" left="450" width="350" height="15" font="5">incidence of valve thrombosis is lower than with UFH,</text>
<text top="157" left="450" width="350" height="15" font="5">but there are still reports of valve thrombosis, even with</text>
<text top="175" left="450" width="350" height="15" font="5">the newer-generation mechanical prostheses. The data</text>
<text top="193" left="450" width="350" height="15" font="5">for use of LMWH in pregnancy are incomplete, with</text>
<text top="210" left="450" width="350" height="15" font="5">unresolved questions to be addressed, including optimal</text>
<text top="228" left="450" width="350" height="15" font="5">anti-Xa levels, use of peak and trough levels, optimal</text>
<text top="246" left="450" width="350" height="15" font="5">timing of dosage, and compliance issues with dosing</text>
<text top="264" left="450" width="350" height="15" font="5">2 times a day and sometimes 3 times a day. If the patient</text>
<text top="282" left="450" width="319" height="15" font="5">chooses not to be on an oral anticoagulant in the</text>
<text top="279" left="776" width="23" height="19" font="5">ﬁrst</text>
<text top="300" left="450" width="350" height="15" font="5">trimester, dose-adjusted LMWH is a reasonable choice of</text>
<text top="318" left="450" width="96" height="15" font="5">anticoagulation.</text>
<text top="337" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="336" left="598" width="27" height="15" font="6"><a href="e57.full.html#119">(840</a></text>
<text top="333" left="625" width="117" height="19" font="6"><a href="e57.full.html#119">–843,846,855–857)</a></text>
<text top="355" left="465" width="18" height="15" font="5">See</text>
<text top="355" left="488" width="170" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplements 25</a></text>
<text top="354" left="664" width="22" height="15" font="5">and</text>
<text top="355" left="692" width="15" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">26</a></text>
<text top="355" left="712" width="87" height="15" font="5">for more infor-</text>
<text top="373" left="450" width="123" height="15" font="5">mation on pregnancy.</text>
<text top="404" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="418" left="449" width="351" height="10" font="21">3. Dose-adjusted continuous intravenous UFH (with an aPTT at</text>
<text top="435" left="467" width="168" height="10" font="21">least 2 times control) during the</text>
<text top="432" left="638" width="161" height="16" font="21">ﬁrst trimester is reasonable for</text>
<text top="451" left="467" width="332" height="10" font="21">pregnant patients with a mechanical prosthesis if the dose of</text>
<text top="468" left="467" width="333" height="10" font="21">warfarin is greater than 5 mg per day to achieve a therapeutic</text>
<text top="484" left="467" width="19" height="10" font="21">INR</text>
<text top="484" left="490" width="80" height="10" font="22"><a href="e57.full.html#119">(838,839,848)</a></text>
<text top="484" left="570" width="121" height="12" font="21"><a href="e57.full.html#119">. </a>(Level of Evidence: B)</text>
<text top="509" left="465" width="305" height="15" font="5">If the decision is made to use UFH during the</text>
<text top="505" left="776" width="23" height="19" font="5">ﬁrst</text>
<text top="526" left="450" width="350" height="15" font="5">trimester of pregnancy, it is reasonable that the patient</text>
<text top="544" left="450" width="350" height="15" font="5">receive a continuous infusion of heparin, with carefully</text>
<text top="562" left="450" width="350" height="15" font="5">monitoring of aPTT and a goal of at least 2 times control.</text>
<text top="580" left="450" width="350" height="15" font="5">Prior studies have shown that the use of subcutaneous</text>
<text top="598" left="450" width="350" height="15" font="5">UFH is associated with a high incidence of valve throm-</text>
<text top="616" left="450" width="350" height="15" font="5">bosis, especially with older-generation valve prostheses.</text>
<text top="634" left="450" width="350" height="15" font="5">Disadvantages of intravenous UFH include an increased</text>
<text top="652" left="450" width="304" height="15" font="5">risk of serious infection and a risk of osteoporosis.</text>
<text top="671" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="670" left="598" width="85" height="15" font="6"><a href="e57.full.html#119">(838,839,848)</a></text>
<text top="689" left="465" width="18" height="15" font="5">See</text>
<text top="689" left="488" width="170" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplements 25</a></text>
<text top="688" left="664" width="22" height="15" font="5">and</text>
<text top="689" left="692" width="15" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">26</a></text>
<text top="689" left="712" width="87" height="15" font="5">for more infor-</text>
<text top="706" left="450" width="123" height="15" font="5">mation on pregnancy.</text>
<text top="738" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="753" left="449" width="351" height="10" font="21">1. Dose-adjusted LMWH at least 2 times per day (with a target</text>
<text top="770" left="467" width="333" height="10" font="21">anti-Xa level of 0.8 U/mL to 1.2 U/mL, 4 to 6 hours postdose)</text>
<text top="786" left="467" width="55" height="10" font="21">during the</text>
<text top="783" left="527" width="273" height="16" font="21">ﬁrst trimester may be reasonable for pregnant pa-</text>
<text top="802" left="467" width="332" height="10" font="21">tients with a mechanical prosthesis if the dose of warfarin is 5</text>
<text top="819" left="467" width="246" height="10" font="21">mg per day or less to achieve a therapeutic INR</text>
<text top="819" left="716" width="26" height="10" font="22"><a href="e57.full.html#119">(840</a></text>
<text top="816" left="742" width="58" height="16" font="22"><a href="e57.full.html#119">–843,855–</a></text>
<text top="835" left="467" width="26" height="10" font="22"><a href="e57.full.html#119">857)</a></text>
<text top="835" left="493" width="121" height="12" font="21"><a href="e57.full.html#119">. </a>(Level of Evidence: B)</text>
<text top="860" left="465" width="305" height="15" font="5">The choice of type of anticoagulation during the</text>
<text top="856" left="776" width="23" height="19" font="5">ﬁrst</text>
<text top="878" left="450" width="350" height="15" font="5">trimester requires a detailed discussion with the patient</text>
<text top="896" left="450" width="146" height="15" font="5">about the risks and bene</text>
<text top="892" left="596" width="204" height="19" font="5">ﬁts of the different regimens. The</text>
<text top="914" left="450" width="171" height="15" font="5">use of warfarin during the</text>
<text top="910" left="629" width="170" height="19" font="5">ﬁrst trimester is associated</text>
<text top="931" left="450" width="350" height="15" font="5">with an increased risk of warfarin embryopathy, but the</text>
<text top="949" left="450" width="73" height="15" font="5">risk is low (</text>
<text top="946" left="522" width="277" height="19" font="5">&lt;3%) if the daily dose of warfarin is 5 mg.</text>
<text top="967" left="450" width="350" height="15" font="5">The use of heparin will avoid the risk of embryopathy</text>
<text top="985" left="450" width="350" height="15" font="5">but is associated with an increased risk of valve thrombo-</text>
<text top="1003" left="450" width="350" height="15" font="5">sis and embolic events. If the patient decides not to</text>
<text top="1021" left="450" width="181" height="15" font="5">continue warfarin during the</text>
<text top="1018" left="638" width="161" height="19" font="5">ﬁrst trimester, after a full</text>
<text top="1039" left="450" width="198" height="15" font="5">discussion of the risks and bene</text>
<text top="1036" left="648" width="152" height="19" font="5">ﬁts of the different regi-</text>
<text top="1057" left="450" width="350" height="15" font="5">mens, dose-adjusted LMWH appears to be the safest</text>
<text top="1075" left="450" width="350" height="15" font="5">choice in terms of prevention of thromboembolic events.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e148</text>
</page>
<page number="93" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">However, this does require meticulous monitoring of anti-</text>
<text top="121" left="64" width="350" height="15" font="5">Xa levels, as dosing requirements change throughout</text>
<text top="139" left="64" width="350" height="15" font="5">pregnancy. The recommended target is an anti-Xa level of</text>
<text top="157" left="64" width="350" height="15" font="5">0.8 U/mL to 1.2 U/mL at 4 to 6 hours postdose, given at</text>
<text top="175" left="64" width="118" height="15" font="5">least 2 times a day.</text>
<text top="193" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="192" left="212" width="27" height="15" font="6"><a href="e57.full.html#119">(840</a></text>
<text top="189" left="239" width="117" height="19" font="6"><a href="e57.full.html#119">–843,846,855–857)</a></text>
<text top="211" left="79" width="18" height="15" font="5">See</text>
<text top="211" left="103" width="170" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplements 25</a></text>
<text top="210" left="279" width="22" height="15" font="5">and</text>
<text top="211" left="306" width="15" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">26</a></text>
<text top="211" left="327" width="87" height="15" font="5">for more infor-</text>
<text top="229" left="64" width="123" height="15" font="5">mation on pregnancy.</text>
<text top="256" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="270" left="63" width="351" height="10" font="21">2. Dose-adjusted continuous infusion of UFH (with aPTT at least 2</text>
<text top="287" left="81" width="133" height="10" font="21">times control) during the</text>
<text top="284" left="218" width="196" height="16" font="21">ﬁrst trimester may be reasonable for</text>
<text top="303" left="81" width="332" height="10" font="21">pregnant patients with a mechanical prosthesis if the dose of</text>
<text top="320" left="81" width="333" height="10" font="21">warfarin is 5 mg per day or less to achieve a therapeutic INR</text>
<text top="336" left="81" width="80" height="10" font="22"><a href="e57.full.html#119">(838,839,848)</a></text>
<text top="336" left="161" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="361" left="79" width="229" height="15" font="5">If the patient on a dose of warfarin</text>
<text top="357" left="315" width="99" height="19" font="5">5 mg per day</text>
<text top="379" left="64" width="261" height="15" font="5">decides not to continue warfarin during the</text>
<text top="375" left="330" width="84" height="19" font="5">ﬁrst trimester,</text>
<text top="396" left="64" width="285" height="15" font="5">after a full discussion of the risks and bene</text>
<text top="393" left="349" width="65" height="19" font="5">ﬁts of the</text>
<text top="414" left="64" width="350" height="15" font="5">different regimens, dose-adjusted LMWH appears to be</text>
<text top="432" left="64" width="350" height="15" font="5">the safest choice in terms of prevention of thromboembolic</text>
<text top="450" left="64" width="322" height="15" font="5">events. If the decision is made to use UFH during the</text>
<text top="447" left="391" width="23" height="19" font="5">ﬁrst</text>
<text top="468" left="64" width="350" height="15" font="5">trimester of pregnancy, it is reasonable that the patient</text>
<text top="486" left="64" width="350" height="15" font="5">receive a continuous infusion of heparin, with careful</text>
<text top="504" left="64" width="350" height="15" font="5">monitoring of aPTT with a goal of at least 2 times control.</text>
<text top="522" left="64" width="350" height="15" font="5">Subcutaneous UFH is associated with a high incidence</text>
<text top="540" left="64" width="350" height="15" font="5">of valve thrombosis, especially with the older-generation</text>
<text top="558" left="64" width="350" height="15" font="5">valve prostheses. Intravenous UFH is associated with an</text>
<text top="576" left="64" width="350" height="15" font="5">increased risk of infection from the prolonged use of</text>
<text top="594" left="64" width="288" height="15" font="5">intravenous catheters and a risk of osteoporosis.</text>
<text top="612" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="612" left="212" width="84" height="15" font="6"><a href="e57.full.html#119">(838,839,848)</a></text>
<text top="630" left="79" width="18" height="15" font="5">See</text>
<text top="630" left="103" width="170" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplements 25</a></text>
<text top="630" left="279" width="22" height="15" font="5">and</text>
<text top="630" left="306" width="15" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">26</a></text>
<text top="630" left="327" width="87" height="15" font="5">for more infor-</text>
<text top="648" left="64" width="123" height="15" font="5">mation on pregnancy.</text>
<text top="675" left="64" width="73" height="8" font="20">CLASS III: Harm</text>
<text top="690" left="63" width="351" height="10" font="21">1. LMWH should not be administered to pregnant patients with</text>
<text top="706" left="81" width="333" height="10" font="21">mechanical prostheses unless anti-Xa levels are monitored 4 to</text>
<text top="723" left="81" width="148" height="10" font="21">6 hours after administration</text>
<text top="723" left="233" width="129" height="10" font="22"><a href="e57.full.html#119">(841,842,847,855,856)</a></text>
<text top="723" left="362" width="52" height="12" font="21">. (Level of</text>
<text top="739" left="81" width="65" height="12" font="21">Evidence: B)</text>
<text top="763" left="79" width="299" height="15" font="5">Initial studies using subcutaneous LMWH at a</text>
<text top="760" left="385" width="29" height="19" font="5">ﬁxed</text>
<text top="781" left="64" width="350" height="15" font="5">dose without monitoring of anti-Xa levels in pregnant</text>
<text top="799" left="64" width="350" height="15" font="5">patients with a mechanical prosthesis were associated</text>
<text top="817" left="64" width="350" height="15" font="5">with a high risk of valve thrombosis, leading to maternal</text>
<text top="835" left="64" width="350" height="15" font="5">deaths. Since the requirements of LMWH increase</text>
<text top="853" left="64" width="350" height="15" font="5">throughout pregnancy, there should be meticulous mon-</text>
<text top="871" left="64" width="349" height="15" font="5">itoring of anti-Xa levels 4 to 6 hours after administration</text>
<text top="889" left="64" width="350" height="15" font="5">if dose-adjusted administration of LMWH is to be used.</text>
<text top="908" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="907" left="212" width="137" height="15" font="6"><a href="e57.full.html#119">(841,842,847,855,856)</a></text>
<text top="949" left="64" width="219" height="14" font="17">14. Surgical Considerations</text>
<text top="994" left="64" width="264" height="12" font="19">14.1. Evaluation of Coronary Anatomy:</text>
<text top="1012" left="64" width="125" height="12" font="19">Recommendations</text>
<text top="1035" left="65" width="21" height="15" font="5">See</text>
<text top="1035" left="90" width="58" height="15" font="6"><a href="e57.full.html#94">Figure 11</a></text>
<text top="1035" left="153" width="261" height="15" font="5">for evaluation and management of CAD in</text>
<text top="1053" left="64" width="205" height="15" font="5">patients undergoing valve surgery.</text>
<text top="1071" left="79" width="335" height="15" font="5">Screening coronary angiography to assess associated</text>
<text top="1089" left="64" width="350" height="15" font="5">CAD should be considered in selected patients before</text>
<text top="103" left="450" width="350" height="15" font="5">cardiac surgery or transcatheter intervention for VHD.</text>
<text top="121" left="450" width="350" height="15" font="5">Invasive selective coronary angiography remains the gold</text>
<text top="139" left="450" width="126" height="15" font="5">standard. Fractional</text>
<text top="135" left="584" width="215" height="19" font="5">ﬂow reserve may better delineate</text>
<text top="157" left="450" width="142" height="15" font="5">the physiological signi</text>
<text top="153" left="592" width="208" height="19" font="5">ﬁcance of a coronary lesion, but</text>
<text top="175" left="450" width="350" height="15" font="5">there are no outcome data for its utility in patients</text>
<text top="192" left="450" width="350" height="15" font="5">undergoing valve surgery. Due to its high negative</text>
<text top="210" left="450" width="350" height="15" font="5">predictive value, coronary CT angiography to exclude</text>
<text top="228" left="450" width="350" height="15" font="5">CAD may be an option in patients with low or inter-</text>
<text top="246" left="450" width="316" height="15" font="5">mediate pretest probability of CAD. If signi</text>
<text top="243" left="766" width="34" height="19" font="5">ﬁcant</text>
<text top="264" left="450" width="350" height="15" font="5">epicardial CAD is present, concomitant CABG should</text>
<text top="282" left="450" width="350" height="15" font="5">be considered at the time of valve surgery. The presence</text>
<text top="300" left="450" width="350" height="15" font="5">of severe CAD may also be helpful in determining</text>
<text top="318" left="450" width="350" height="15" font="5">whether a surgical or transcatheter approach is optimal</text>
<text top="336" left="450" width="128" height="15" font="5">in patients with AS.</text>
<text top="362" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="377" left="449" width="351" height="10" font="21">1. Coronary angiography is indicated before valve intervention in</text>
<text top="393" left="467" width="332" height="10" font="21">patients with symptoms of angina, objective evidence of</text>
<text top="410" left="467" width="332" height="10" font="21">ischemia, decreased LV systolic function, history of CAD, or</text>
<text top="426" left="467" width="219" height="10" font="21">coronary risk factors (including men age</text>
<text top="423" left="691" width="109" height="16" font="21">&gt;40 years and post-</text>
<text top="442" left="467" width="229" height="12" font="21">menopausal women). (Level of Evidence: C)</text>
<text top="467" left="465" width="335" height="15" font="5">Knowledge of the coronary anatomy contributes to risk</text>
<text top="485" left="450" width="30" height="15" font="5">strati</text>
<text top="481" left="480" width="320" height="19" font="5">ﬁcation and determines if concomitant coronary</text>
<text top="502" left="450" width="350" height="15" font="5">revascularization is indicated. Coronary angiography can</text>
<text top="520" left="450" width="213" height="15" font="5">be avoided in young patients (men</text>
<text top="517" left="668" width="131" height="19" font="5">&lt;40 years of age and</text>
<text top="538" left="450" width="350" height="15" font="5">premenopausal women) with no atherosclerotic risk fac-</text>
<text top="556" left="450" width="350" height="15" font="5">tors and in patients in whom the risks outweigh the</text>
<text top="574" left="450" width="28" height="15" font="5">bene</text>
<text top="571" left="478" width="322" height="19" font="5">ﬁts, such as in patients with acute aortic dissection,</text>
<text top="592" left="450" width="350" height="15" font="5">large aortic valve vegetation, or occlusive prosthetic</text>
<text top="610" left="450" width="70" height="15" font="5">thrombosis.</text>
<text top="629" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="628" left="597" width="27" height="15" font="6"><a href="e57.full.html#119">(858</a></text>
<text top="625" left="625" width="35" height="19" font="6"><a href="e57.full.html#119">–871)</a></text>
<text top="658" left="450" width="37" height="8" font="20">CLASS I</text>
<text top="679" left="449" width="351" height="10" font="21">2. Coronary angiography should be performed as part of the eval-</text>
<text top="695" left="467" width="332" height="12" font="21">uation of patients with chronic severe secondary MR. (Level of</text>
<text top="712" left="467" width="65" height="12" font="21">Evidence: C)</text>
<text top="736" left="465" width="310" height="15" font="5">In patients with chronic secondary MR, the valve lea</text>
<text top="732" left="775" width="24" height="19" font="5">ﬂets</text>
<text top="754" left="450" width="350" height="15" font="5">and chordae are structurally normal and the MR results from</text>
<text top="772" left="450" width="350" height="15" font="5">the geometrical distortion of the mitral apparatus. This is</text>
<text top="790" left="450" width="350" height="15" font="5">due to multiple factors that can cause displacement of the</text>
<text top="808" left="450" width="220" height="15" font="5">papillary muscles, tethering of the lea</text>
<text top="804" left="670" width="130" height="19" font="5">ﬂets, annular dilation,</text>
<text top="825" left="450" width="350" height="15" font="5">and decreased closing forces from reduced contractility.</text>
<text top="843" left="450" width="350" height="15" font="5">Because CAD and accompanying myocardial ischemia may</text>
<text top="861" left="450" width="350" height="15" font="5">contribute to chronic secondary MR, the assessment of</text>
<text top="879" left="450" width="350" height="15" font="5">coronary anatomy status is necessary to complete the diag-</text>
<text top="897" left="450" width="323" height="15" font="5">nosis and allow evaluation of revascularization options.</text>
<text top="916" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="915" left="597" width="53" height="15" font="6"><a href="e57.full.html#107">(309,872</a></text>
<text top="912" left="651" width="35" height="19" font="6"><a href="e57.full.html#107">–875)</a></text>
<text top="945" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="960" left="449" width="351" height="10" font="21">1. Surgery without coronary angiography is reasonable for patients</text>
<text top="976" left="467" width="332" height="10" font="21">having emergency valve surgery for acute valve regurgitation,</text>
<text top="993" left="467" width="332" height="12" font="21">disease of the aortic sinuses or ascending aorta, or IE. (Level of</text>
<text top="1009" left="467" width="65" height="12" font="21">Evidence: C)</text>
<text top="1033" left="465" width="335" height="15" font="5">Assessment of coronary artery anatomy is rarely required</text>
<text top="1051" left="450" width="350" height="15" font="5">in patients undergoing emergency valve surgery for acute</text>
<text top="1069" left="450" width="350" height="15" font="5">AR, aortic dissection, or IE with hemodynamic instability.</text>
<text top="1088" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="1087" left="597" width="53" height="15" font="6"><a href="e57.full.html#104">(188,876</a></text>
<text top="1084" left="651" width="35" height="19" font="6"><a href="e57.full.html#104">–879)</a></text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e149</text>
</page>
<page number="94" position="absolute" top="0" left="0" height="1160" width="864">
<text top="716" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="731" left="63" width="351" height="10" font="21">2. CT coronary angiography is reasonable to exclude the presence</text>
<text top="747" left="81" width="38" height="10" font="21">of signi</text>
<text top="744" left="120" width="294" height="16" font="21">ﬁcant obstructive CAD in selected patients with a low/</text>
<text top="764" left="81" width="332" height="10" font="21">intermediate pretest probability of CAD. A positive coronary CT</text>
<text top="780" left="81" width="300" height="10" font="21">angiogram (the presence of any epicardial CAD) is con</text>
<text top="777" left="381" width="33" height="16" font="21">ﬁrmed</text>
<text top="797" left="81" width="203" height="10" font="21">with invasive coronary angiography</text>
<text top="797" left="294" width="26" height="10" font="22"><a href="e57.full.html#120">(880</a></text>
<text top="793" left="319" width="32" height="16" font="22"><a href="e57.full.html#120">–886)</a></text>
<text top="797" left="351" width="63" height="12" font="21">. (Level of</text>
<text top="813" left="81" width="65" height="12" font="21">Evidence: B)</text>
<text top="837" left="79" width="335" height="15" font="5">In select patients who are at low-to-intermediate pretest</text>
<text top="855" left="64" width="350" height="15" font="5">probability of CAD and who are being considered for</text>
<text top="873" left="64" width="350" height="15" font="5">angiography before valve surgery, coronary CT angiog-</text>
<text top="891" left="64" width="350" height="15" font="5">raphy is a reasonable alternative. This does not include</text>
<text top="909" left="64" width="350" height="15" font="5">patients who have active symptoms of angina, those with</text>
<text top="927" left="64" width="350" height="15" font="5">documented ischemia, or those with a prior history of</text>
<text top="945" left="64" width="350" height="15" font="5">CAD, all of whom should have selective coronary angi-</text>
<text top="963" left="64" width="350" height="15" font="5">ography. Several small studies have reported high diag-</text>
<text top="981" left="64" width="350" height="15" font="5">nostic accuracy of coronary CT angiography in select</text>
<text top="999" left="64" width="350" height="15" font="5">patients with VHD. One study of 98 consecutive patients</text>
<text top="1017" left="64" width="60" height="15" font="5">with signi</text>
<text top="1013" left="124" width="290" height="19" font="5">ﬁcant VHD and guideline-based indications for</text>
<text top="1035" left="64" width="350" height="15" font="5">coronary angiography underwent CT coronary angiog-</text>
<text top="1052" left="64" width="244" height="15" font="5">raphy if their coronary calcium score was</text>
<text top="1049" left="313" width="101" height="19" font="5">&lt;1,000. Invasive</text>
<text top="1070" left="64" width="350" height="15" font="5">coronary angiography was performed in patients with at</text>
<text top="1088" left="64" width="145" height="15" font="5">least 1 of the following:</text>
<text top="1085" left="215" width="199" height="19" font="5">&gt;50% stenosis, calcium artifacts,</text>
<text top="713" left="450" width="350" height="15" font="5">or motion artifacts. CT coronary angiography excluded the</text>
<text top="730" left="450" width="100" height="15" font="5">presence of signi</text>
<text top="727" left="550" width="250" height="19" font="5">ﬁcant CAD in 80.6% of patients without</text>
<text top="748" left="450" width="350" height="15" font="5">the need for invasive angiography. Conventional coronary</text>
<text top="766" left="450" width="350" height="15" font="5">angiography was required in 19.4% of patients because of</text>
<text top="781" left="450" width="350" height="19" font="5">&gt;50% stenosis in 13.3%, calcium artifact in 2%, and mo-</text>
<text top="802" left="450" width="350" height="15" font="5">tion artifact in 1%. In another study of 70 patients, 31 had</text>
<text top="820" left="450" width="350" height="15" font="5">AS (44%), 24 had MR (34%), 9 had AR (13%), and the</text>
<text top="838" left="450" width="350" height="15" font="5">remainder had other valvular or congenital lesions. On a</text>
<text top="856" left="450" width="350" height="15" font="5">per-patient basis, sensitivity was 100% (18 of 18 patients</text>
<text top="874" left="450" width="60" height="15" font="5">with signi</text>
<text top="871" left="510" width="290" height="19" font="5">ﬁcant CAD) and speciﬁcity was 92% (48 of 52</text>
<text top="892" left="450" width="138" height="15" font="5">patients without signi</text>
<text top="889" left="588" width="211" height="19" font="5">ﬁcant CAD). The corresponding</text>
<text top="910" left="450" width="350" height="15" font="5">negative likelihood ratio is 0.01, which means a negative</text>
<text top="928" left="450" width="350" height="15" font="5">test would be associated with a very low posttest probability</text>
<text top="946" left="450" width="350" height="15" font="5">of disease for patients with low and intermediate pretest</text>
<text top="964" left="450" width="350" height="15" font="5">probabilities. Assuming that all patients would have pre-</text>
<text top="982" left="450" width="350" height="15" font="5">viously been referred for invasive angiography, coronary</text>
<text top="999" left="450" width="350" height="15" font="5">CT angiography allowed the 48 patients (69%) in the study</text>
<text top="1017" left="450" width="150" height="15" font="5">cohort with negative CT</text>
<text top="1014" left="604" width="195" height="19" font="5">ﬁndings to avoid this procedure.</text>
<text top="1035" left="450" width="302" height="15" font="5">However, a positive coronary CT angiogram, de</text>
<text top="1032" left="751" width="48" height="19" font="5">ﬁned as</text>
<text top="1053" left="450" width="294" height="15" font="5">the presence of epicardial CAD, requires con</text>
<text top="1050" left="744" width="55" height="19" font="5">ﬁrmation</text>
<text top="1071" left="450" width="350" height="15" font="5">with invasive coronary angiography to establish the need</text>
<text top="1089" left="450" width="350" height="15" font="5">for and extent of CABG. The risk of radiation exposure</text>
<text top="627" left="64" width="484" height="11" font="13">Figure 11. Evaluation and Management of CAD in Patients Undergoing Valve Surgery</text>
<text top="659" left="72" width="721" height="9" font="14">CABG indicates coronary artery bypass graft; CAD, coronary artery disease; CT, computed tomography; IE, infective endocarditis; LV, left ventricular; and PCI, percutaneous</text>
<text top="672" left="72" width="90" height="9" font="14">coronary intervention.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e150</text>
</page>
<page number="95" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">and renal failure due to the contrast injection should be</text>
<text top="121" left="64" width="150" height="15" font="5">taken into consideration.</text>
<text top="139" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="139" left="212" width="27" height="15" font="6"><a href="e57.full.html#120">(880</a></text>
<text top="135" left="239" width="35" height="19" font="6"><a href="e57.full.html#120">–887)</a></text>
<text top="178" left="64" width="208" height="12" font="19">14.2. Concomitant Procedures</text>
<text top="202" left="64" width="312" height="15" font="5">14.2.1. Intervention for CAD: Recommendation</text>
<text top="228" left="65" width="316" height="15" font="5">In patients undergoing AVR who also have signi</text>
<text top="225" left="381" width="33" height="19" font="5">ﬁcant</text>
<text top="246" left="64" width="350" height="15" font="5">CAD, the combination of CABG and AVR reduces the</text>
<text top="264" left="64" width="350" height="15" font="5">rates of perioperative MI, perioperative mortality, late</text>
<text top="282" left="64" width="350" height="15" font="5">mortality, and morbidity when compared with patients not</text>
<text top="300" left="64" width="350" height="15" font="5">undergoing simultaneous CABG, even though the com-</text>
<text top="318" left="64" width="350" height="15" font="5">bined operation carries a small but real increased risk of</text>
<text top="336" left="64" width="350" height="15" font="5">mortality. The alternative in some patients of a hybrid</text>
<text top="354" left="64" width="350" height="15" font="5">approach of surgical valve replacement and PCI is attractive,</text>
<text top="371" left="64" width="350" height="15" font="5">but there are no data at this time to support this approach.</text>
<text top="390" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="389" left="212" width="58" height="15" font="6"><a href="e57.full.html#119">(859,888)</a></text>
<text top="417" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="432" left="63" width="351" height="10" font="21">1. CABG or PCI is reasonable in patients undergoing valve repair or</text>
<text top="448" left="81" width="123" height="10" font="21">replacement with signi</text>
<text top="445" left="205" width="209" height="16" font="21">ﬁcant CAD (‡70% reduction in luminal</text>
<text top="465" left="81" width="195" height="10" font="21">diameter in major coronary arteries or</text>
<text top="461" left="279" width="135" height="16" font="21">‡50% reduction in luminal</text>
<text top="481" left="81" width="332" height="12" font="21">diameter in the left main coronary artery). (Level of Evidence: C)</text>
<text top="505" left="79" width="335" height="15" font="5">Several studies have reported the outcomes of patients</text>
<text top="523" left="64" width="350" height="15" font="5">undergoing combined CABG and valve operation. Al-</text>
<text top="541" left="64" width="350" height="15" font="5">though combined myocardial revascularization and valve</text>
<text top="559" left="64" width="350" height="15" font="5">operation increases cross-clamp time and has the potential</text>
<text top="577" left="64" width="350" height="15" font="5">to increase perioperative MI and early postoperative mor-</text>
<text top="595" left="64" width="350" height="15" font="5">tality compared with patients without CAD undergoing</text>
<text top="613" left="64" width="350" height="15" font="5">isolated valve surgery, in several series, combined CABG</text>
<text top="631" left="64" width="350" height="15" font="5">had little or no adverse effect on operative mortality.</text>
<text top="649" left="64" width="350" height="15" font="5">Moreover, combined CABG and valve operation reduces</text>
<text top="667" left="64" width="350" height="15" font="5">the rates of perioperative MI, operative mortality and late</text>
<text top="685" left="64" width="350" height="15" font="5">mortality, and morbidity compared with patients with</text>
<text top="703" left="64" width="28" height="15" font="5">signi</text>
<text top="699" left="93" width="321" height="19" font="5">ﬁcant CAD who do not undergo revascularization at</text>
<text top="720" left="64" width="350" height="15" font="5">the time of valve operation. Incomplete revascularization</text>
<text top="738" left="64" width="350" height="15" font="5">is associated with greater postoperative LV systolic dys-</text>
<text top="756" left="64" width="350" height="15" font="5">function and reduced survival rates after surgery compared</text>
<text top="774" left="64" width="350" height="15" font="5">with patients who receive complete revascularization. For</text>
<text top="792" left="64" width="350" height="15" font="5">more than a decade, improved myocardial preservation</text>
<text top="810" left="64" width="350" height="15" font="5">techniques have been associated with reduced overall</text>
<text top="828" left="64" width="350" height="15" font="5">operative mortality, and it has become standard practice</text>
<text top="846" left="64" width="117" height="15" font="5">to bypass all signi</text>
<text top="843" left="182" width="232" height="19" font="5">ﬁcant coronary artery stenoses when</text>
<text top="864" left="64" width="350" height="15" font="5">possible in patients undergoing valve surgery. In patients</text>
<text top="882" left="64" width="73" height="15" font="5">with a signi</text>
<text top="879" left="137" width="277" height="19" font="5">ﬁcant stenosis of the left anterior descending</text>
<text top="900" left="64" width="350" height="15" font="5">artery, a left internal thoracic artery graft should be</text>
<text top="918" left="64" width="350" height="15" font="5">used if possible. No RCTs fully support the use of con-</text>
<text top="936" left="64" width="350" height="15" font="5">comitant coronary revascularization in all patients with</text>
<text top="954" left="64" width="293" height="15" font="5">asymptomatic CAD undergoing valve operation.</text>
<text top="972" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="972" left="212" width="27" height="15" font="6"><a href="e57.full.html#120">(889</a></text>
<text top="968" left="239" width="35" height="19" font="6"><a href="e57.full.html#120">–895)</a></text>
<text top="1007" left="64" width="303" height="15" font="5">14.2.2. Intervention for AF: Recommendations</text>
<text top="1035" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="1050" left="64" width="350" height="10" font="21">1. A concomitant maze procedure is reasonable at the time of</text>
<text top="1066" left="82" width="332" height="10" font="21">mitral valve repair or replacement for treatment of chronic,</text>
<text top="1082" left="82" width="191" height="12" font="21">persistent AF. (Level of Evidence: C)</text>
<text top="103" left="465" width="335" height="15" font="5">The addition of arrhythmia surgery to valve procedures</text>
<text top="121" left="450" width="350" height="15" font="5">has been advocated on the basis of evidence that persistent</text>
<text top="139" left="450" width="350" height="15" font="5">AF is an independent risk factor for cerebrovascular acci-</text>
<text top="157" left="450" width="350" height="15" font="5">dent and mortality following surgery for VHD. When AF</text>
<text top="175" left="450" width="125" height="15" font="5">has been present for</text>
<text top="171" left="580" width="219" height="19" font="5">&gt;1 year, stable sinus rhythm is un-</text>
<text top="192" left="450" width="350" height="15" font="5">likely with mitral repair alone. Arrhythmia procedures</text>
<text top="210" left="450" width="350" height="15" font="5">span a spectrum from pulmonary vein isolation to the full</text>
<text top="228" left="450" width="350" height="15" font="5">maze and a variety of intermediate procedures. The term</text>
<text top="243" left="450" width="350" height="19" font="5">“maze procedure” properly refers to a speciﬁc biatrial pro-</text>
<text top="264" left="450" width="124" height="15" font="5">cedure creating a de</text>
<text top="261" left="574" width="226" height="19" font="5">ﬁned set of conduction block lesions</text>
<text top="282" left="450" width="62" height="15" font="5">performed</text>
<text top="279" left="517" width="283" height="19" font="5">“cut and sew” (“maze III”) or with tissue abla-</text>
<text top="300" left="450" width="350" height="15" font="5">tion technologies including cryoablative or radio-</text>
<text top="318" left="450" width="71" height="15" font="5">frequency (</text>
<text top="315" left="520" width="279" height="19" font="5">“maze IV”). The requisite lesions or incisions</text>
<text top="336" left="450" width="350" height="15" font="5">include complete encirclement of the pulmonary veins en</text>
<text top="354" left="450" width="350" height="15" font="5">bloc, an incision or lesion to the mitral annulus from this</text>
<text top="372" left="450" width="350" height="15" font="5">encircling lesion, and a lesion to the stump of the ligated or</text>
<text top="390" left="450" width="350" height="15" font="5">amputated left atrial appendage on the LA. On the right</text>
<text top="408" left="450" width="350" height="15" font="5">atrium, an ablation line or incision extends in the tubular</text>
<text top="426" left="450" width="350" height="15" font="5">portion from superior vena cava to inferior vena cava and</text>
<text top="444" left="450" width="350" height="15" font="5">along the right atrial free wall from this lateral incision</text>
<text top="461" left="450" width="350" height="15" font="5">across the body of the right atrium to the tricuspid annulus.</text>
<text top="479" left="450" width="350" height="15" font="5">A separate incision or lesion extends across the right atrial</text>
<text top="497" left="450" width="350" height="15" font="5">appendage down to the tricuspid annulus. As originally</text>
<text top="515" left="450" width="350" height="15" font="5">described, the septum is opened into the fossa ovalis,</text>
<text top="533" left="450" width="350" height="15" font="5">although this lesion or incision is increasingly omitted in</text>
<text top="551" left="450" width="350" height="15" font="5">current practice. When performed in this manner, com-</text>
<text top="569" left="450" width="350" height="15" font="5">bined with mitral valve repair or replacement, RCTs have</text>
<text top="587" left="450" width="350" height="15" font="5">shown that the surgical maze procedure affords superior</text>
<text top="605" left="450" width="350" height="15" font="5">freedom from AF at discharge and at 1 year (with success</text>
<text top="623" left="450" width="350" height="15" font="5">rates ranging from 75% to 95% with ablation versus 10%</text>
<text top="641" left="450" width="350" height="15" font="5">to 40% without ablation). Combining the maze proce-</text>
<text top="659" left="450" width="350" height="15" font="5">dure with a mitral valve procedure adds little complexity</text>
<text top="677" left="450" width="350" height="15" font="5">because the LA is already open. As such, the procedure</text>
<text top="695" left="450" width="149" height="15" font="5">does not appear to signi</text>
<text top="691" left="599" width="200" height="19" font="5">ﬁcantly increase operative risk of</text>
<text top="713" left="450" width="350" height="15" font="5">mortality in properly selected patients. In RCTs, long-</text>
<text top="731" left="450" width="350" height="15" font="5">term survival and stroke risk have not been improved by</text>
<text top="748" left="450" width="193" height="15" font="5">addition of the maze procedure.</text>
<text top="766" left="465" width="335" height="15" font="5">Ligation or amputation of the left atrial appendage is</text>
<text top="784" left="450" width="350" height="15" font="5">commonly performed in patients with AF with or without</text>
<text top="802" left="450" width="350" height="15" font="5">such arrhythmia procedures with the aim of reducing the</text>
<text top="820" left="450" width="350" height="15" font="5">risk of thromboembolic events, although no RCTs have</text>
<text top="838" left="450" width="125" height="15" font="5">demonstrated a bene</text>
<text top="835" left="575" width="77" height="19" font="5">ﬁcial impact.</text>
<text top="857" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="856" left="597" width="53" height="15" font="6"><a href="e57.full.html#110">(420,896</a></text>
<text top="853" left="651" width="35" height="19" font="6"><a href="e57.full.html#110">–912)</a></text>
<text top="883" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="898" left="449" width="351" height="10" font="21">2. A full biatrial maze procedure, when technically feasible, is</text>
<text top="915" left="467" width="332" height="10" font="21">reasonable at the time of mitral valve surgery, compared with a</text>
<text top="931" left="467" width="332" height="10" font="21">lesser ablation procedure, in patients with chronic, persistent</text>
<text top="947" left="467" width="14" height="10" font="21">AF</text>
<text top="947" left="485" width="55" height="10" font="22"><a href="e57.full.html#120">(907,908)</a></text>
<text top="947" left="540" width="121" height="12" font="21"><a href="e57.full.html#120">. </a>(Level of Evidence: B)</text>
<text top="972" left="465" width="335" height="15" font="5">A large variety of less extensive procedures, commonly</text>
<text top="990" left="450" width="82" height="15" font="5">referred to as</text>
<text top="986" left="538" width="261" height="19" font="5">“mini-maze” procedures, have been devel-</text>
<text top="1008" left="450" width="350" height="15" font="5">oped and promulgated, ranging from pulmonary vein</text>
<text top="1026" left="450" width="350" height="15" font="5">isolation alone to single atrial procedures. The clinical</text>
<text top="1044" left="450" width="11" height="15" font="5">ef</text>
<text top="1040" left="461" width="339" height="19" font="5">ﬁcacy of these procedures falls below that of the full</text>
<text top="1061" left="450" width="350" height="15" font="5">maze procedure, although the full maze procedure may be</text>
<text top="1079" left="450" width="350" height="15" font="5">associated with more bradycardia requiring pacemaker</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e151</text>
</page>
<page number="96" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="265" height="15" font="5">implantation. Although the less extensive</text>
<text top="99" left="339" width="75" height="19" font="5">“mini-maze”</text>
<text top="121" left="64" width="228" height="15" font="5">procedure may be preferable in speci</text>
<text top="117" left="293" width="121" height="19" font="5">ﬁc circumstances in</text>
<text top="139" left="64" width="182" height="15" font="5">which one is willing to trade ef</text>
<text top="135" left="246" width="168" height="19" font="5">ﬁcacy for invasiveness, when</text>
<text top="157" left="64" width="350" height="15" font="5">feasible, the full maze is preferable. These less extensive</text>
<text top="175" left="64" width="350" height="15" font="5">procedures are more often advocated when the AF is</text>
<text top="192" left="64" width="350" height="15" font="5">paroxysmal, rather than persistent, and when combined</text>
<text top="210" left="64" width="322" height="15" font="5">with procedures other than those on the mitral valve.</text>
<text top="229" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="228" left="212" width="58" height="15" font="6"><a href="e57.full.html#120">(907,908)</a></text>
<text top="254" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="269" left="63" width="351" height="10" font="21">1. A concomitant maze procedure or pulmonary vein isolation may</text>
<text top="285" left="81" width="332" height="10" font="21">be considered at the time of mitral valve repair or replacement</text>
<text top="302" left="81" width="333" height="10" font="21">in patients with paroxysmal AF that is symptomatic or associ-</text>
<text top="318" left="81" width="332" height="12" font="21">ated with a history of embolism on anticoagulation. (Level of</text>
<text top="335" left="81" width="65" height="12" font="21">Evidence: C)</text>
<text top="364" left="79" width="335" height="15" font="5">RCTs have shown that the surgical maze procedure</text>
<text top="381" left="64" width="350" height="15" font="5">affords superior freedom from AF at discharge and at</text>
<text top="399" left="64" width="60" height="15" font="5">1 year, de</text>
<text top="396" left="124" width="290" height="19" font="5">ﬁned as sinus rhythm at last follow-up (75% to</text>
<text top="417" left="64" width="350" height="15" font="5">95% with ablation versus 10% to 40% without ablation).</text>
<text top="435" left="64" width="350" height="15" font="5">When the maze procedure is added to mitral valve</text>
<text top="453" left="64" width="350" height="15" font="5">procedures, it adds little complexity because the LA is</text>
<text top="471" left="64" width="350" height="15" font="5">already open. As such, this procedure does not appear to</text>
<text top="489" left="64" width="350" height="15" font="5">increase operative risk of mortality in properly selected</text>
<text top="507" left="64" width="350" height="15" font="5">patients. In RCTs, neither long-term survival nor stroke</text>
<text top="525" left="64" width="350" height="15" font="5">risk appears to be improved by addition of the procedure.</text>
<text top="543" left="64" width="350" height="15" font="5">Several nonrandomized studies, however, have suggested a</text>
<text top="561" left="64" width="350" height="15" font="5">reduction in stroke risk with the addition of the maze</text>
<text top="579" left="64" width="350" height="15" font="5">procedure to mitral valve repair or MVR even when a</text>
<text top="597" left="64" width="180" height="15" font="5">mechanical prosthesis is used.</text>
<text top="615" left="79" width="335" height="15" font="5">Other surgical approaches to prevention of recurrent</text>
<text top="633" left="64" width="350" height="15" font="5">AF, including less extensive procedures such as pulmo-</text>
<text top="651" left="64" width="350" height="15" font="5">nary vein isolation or a left-sided-only maze, have been</text>
<text top="668" left="64" width="350" height="15" font="5">less successful than the full maze procedure in conver-</text>
<text top="686" left="64" width="350" height="15" font="5">ting the patient to sinus rhythm. Although less effective,</text>
<text top="704" left="64" width="350" height="15" font="5">these less extensive procedures are also less invasive</text>
<text top="722" left="64" width="350" height="15" font="5">and, accordingly, are more often advocated when the</text>
<text top="740" left="64" width="350" height="15" font="5">AF is paroxysmal rather than persistent and when com-</text>
<text top="758" left="64" width="350" height="15" font="5">bined with procedures other than those on the mitral</text>
<text top="776" left="64" width="33" height="15" font="5">valve.</text>
<text top="795" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="794" left="212" width="53" height="15" font="6"><a href="e57.full.html#120">(898,900</a></text>
<text top="791" left="265" width="143" height="19" font="6"><a href="e57.full.html#120">–902,904–906,913,914)</a></text>
<text top="823" left="64" width="45" height="8" font="20">CLASS IIb</text>
<text top="838" left="63" width="351" height="10" font="21">2. Concomitant maze procedure or pulmonary vein isolation may</text>
<text top="854" left="81" width="333" height="10" font="21">be considered at the time of cardiac surgical procedures other</text>
<text top="871" left="81" width="333" height="10" font="21">than mitral valve surgery in patients with paroxysmal or</text>
<text top="887" left="81" width="333" height="10" font="21">persistent AF that is symptomatic or associated with a history</text>
<text top="903" left="81" width="271" height="12" font="21">of emboli on anticoagulation. (Level of Evidence: C)</text>
<text top="928" left="79" width="335" height="15" font="5">The addition of arrhythmia surgery to valve proce-</text>
<text top="946" left="64" width="350" height="15" font="5">dures other than mitral valve disease has been advocated</text>
<text top="964" left="64" width="350" height="15" font="5">on the basis of evidence that persistent AF is an inde-</text>
<text top="981" left="64" width="350" height="15" font="5">pendent risk factor for cerebrovascular accident and</text>
<text top="999" left="64" width="350" height="15" font="5">mortality following surgery for mitral VHD. Limited data</text>
<text top="1017" left="64" width="350" height="15" font="5">suggest an increased risk of HF and stroke after AVR</text>
<text top="1035" left="64" width="350" height="15" font="5">as well. When combined with aortic valve surgery, the</text>
<text top="1053" left="64" width="350" height="15" font="5">addition of the maze procedure has been shown in</text>
<text top="1071" left="64" width="350" height="15" font="5">observational studies to improve conversion to sinus</text>
<text top="1089" left="64" width="350" height="15" font="5">rhythm over aortic valve surgery alone. This occurs in the</text>
<text top="103" left="450" width="317" height="15" font="5">setting of chronic AF without a statistically signi</text>
<text top="99" left="766" width="33" height="19" font="5">ﬁcant</text>
<text top="121" left="450" width="350" height="15" font="5">increase in operative risk of mortality, although the po-</text>
<text top="139" left="450" width="350" height="15" font="5">tential impact of selection bias cannot be ignored. Limited</text>
<text top="157" left="450" width="350" height="15" font="5">evidence suggests pulmonary vein isolation is equivalent to</text>
<text top="175" left="450" width="244" height="15" font="5">maze in the presence of paroxysmal AF.</text>
<text top="193" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="192" left="597" width="111" height="15" font="6"><a href="e57.full.html#110">(420,896,897,915)</a></text>
<text top="220" left="450" width="88" height="8" font="20">CLASS III: No Bene</text>
<text top="217" left="538" width="10" height="13" font="20">ﬁt</text>
<text top="235" left="449" width="351" height="10" font="21">1. Catheter ablation for AF should not be performed in patients</text>
<text top="251" left="467" width="333" height="10" font="21">with severe MR when mitral repair or replacement is antici-</text>
<text top="268" left="467" width="332" height="10" font="21">pated, with preference for the combined maze procedure plus</text>
<text top="284" left="467" width="95" height="10" font="21">mitral valve repair</text>
<text top="284" left="566" width="30" height="10" font="22"><a href="e57.full.html#121">(916)</a></text>
<text top="284" left="596" width="121" height="12" font="21">. (Level of Evidence: B)</text>
<text top="308" left="465" width="335" height="15" font="5">A single randomized study of patients with rheumatic</text>
<text top="326" left="450" width="350" height="15" font="5">mitral valve disease compared catheter ablation with sur-</text>
<text top="344" left="450" width="350" height="15" font="5">gical maze and demonstrated superior conversion to sinus</text>
<text top="362" left="450" width="350" height="15" font="5">rhythm (82% versus 55%) in the surgical group. Accord-</text>
<text top="380" left="450" width="350" height="15" font="5">ingly, if surgical repair or replacement of the mitral valve</text>
<text top="398" left="450" width="350" height="15" font="5">is anticipated, catheter ablation should be deferred in favor</text>
<text top="416" left="450" width="101" height="15" font="5">of surgical maze.</text>
<text top="435" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="434" left="597" width="32" height="15" font="6"><a href="e57.full.html#121">(916)</a></text>
<text top="452" left="465" width="18" height="15" font="5">See</text>
<text top="452" left="488" width="166" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 27</a></text>
<text top="452" left="659" width="140" height="15" font="5">for more information on</text>
<text top="470" left="450" width="112" height="15" font="5">the maze procedure.</text>
<text top="519" left="450" width="350" height="14" font="17">15. Noncardiac Surgery in Patients With VHD</text>
<text top="564" left="450" width="205" height="12" font="19">15.1. Diagnosis and Follow-Up</text>
<text top="587" left="451" width="349" height="15" font="5">The risk of noncardiac surgery is increased in patients</text>
<text top="605" left="450" width="61" height="15" font="5">with signi</text>
<text top="601" left="511" width="288" height="19" font="5">ﬁcant VHD. AS is present in 1% to 2% of all</text>
<text top="623" left="450" width="47" height="15" font="5">patients</text>
<text top="619" left="504" width="296" height="19" font="5">&gt;65 years of age and 3% to 8% of all patients</text>
<text top="637" left="450" width="350" height="19" font="5">&gt;75 years of age. Severe AS is associated with an in-</text>
<text top="659" left="450" width="350" height="15" font="5">creased risk for noncardiac surgery, depending on the</text>
<text top="677" left="450" width="30" height="15" font="5">speci</text>
<text top="673" left="480" width="320" height="19" font="5">ﬁc degree of valve narrowing, LV systolic function,</text>
<text top="695" left="450" width="350" height="15" font="5">concurrent CAD, and other risk factors for surgery. The</text>
<text top="712" left="450" width="350" height="15" font="5">estimated rate of cardiac complications in patients with</text>
<text top="730" left="450" width="350" height="15" font="5">undiagnosed severe AS undergoing noncardiac surgery</text>
<text top="748" left="450" width="350" height="15" font="5">is 10% to 30%. Thus, TTE is appropriate in patients being</text>
<text top="766" left="450" width="350" height="15" font="5">evaluated for noncardiac surgery when a systolic murmur</text>
<text top="784" left="450" width="350" height="15" font="5">suggestive of AS is present for evaluation of stenosis</text>
<text top="802" left="450" width="350" height="15" font="5">severity and LV systolic function to allow optimization</text>
<text top="820" left="450" width="350" height="15" font="5">of perioperative management. Evaluation for concurrent</text>
<text top="838" left="450" width="350" height="15" font="5">CAD in patients with AS is problematic, and standard</text>
<text top="856" left="450" width="350" height="15" font="5">ECG exercise testing is not adequate. A stress echocar-</text>
<text top="874" left="450" width="350" height="15" font="5">diographic or nuclear imaging study may be helpful if</text>
<text top="892" left="450" width="350" height="15" font="5">resting LV systolic function is normal and AS is only mild</text>
<text top="910" left="450" width="350" height="15" font="5">to moderate in severity. With severe AS, coronary angi-</text>
<text top="928" left="450" width="350" height="15" font="5">ography may be necessary if risk factors or symptoms</text>
<text top="946" left="450" width="305" height="15" font="5">that might be due to coronary disease are present.</text>
<text top="964" left="465" width="335" height="15" font="5">MS may also be poorly tolerated with the altered he-</text>
<text top="982" left="450" width="350" height="15" font="5">modynamics of anesthesia and noncardiac surgery. Left-</text>
<text top="999" left="450" width="350" height="15" font="5">sided regurgitant lesions are better tolerated but still</text>
<text top="1017" left="450" width="350" height="15" font="5">convey increased risk, particularly if the anesthesiologist</text>
<text top="1035" left="450" width="350" height="15" font="5">and surgeon are unaware of the diagnosis or severity</text>
<text top="1053" left="450" width="350" height="15" font="5">of valve disease. Thus, whenever the clinical history or</text>
<text top="1071" left="450" width="350" height="15" font="5">physical examination suggests valve disease might be pre-</text>
<text top="1089" left="450" width="350" height="15" font="5">sent, TTE is helpful to detect valve dysfunction and</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e152</text>
</page>
<page number="97" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">quantitate the severity of stenosis and regurgitation. Other</text>
<text top="121" left="64" width="350" height="15" font="5">echocardiographic data useful in operative planning in-</text>
<text top="139" left="64" width="350" height="15" font="5">clude LV systolic function and an estimate of pulmonary</text>
<text top="157" left="64" width="138" height="15" font="5">artery systolic pressure.</text>
<text top="175" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="175" left="212" width="27" height="15" font="6"><a href="e57.full.html#121">(917</a></text>
<text top="171" left="239" width="35" height="19" font="6"><a href="e57.full.html#121">–923)</a></text>
<text top="223" left="64" width="151" height="12" font="19">15.2. Medical Therapy</text>
<text top="246" left="65" width="349" height="15" font="5">Anesthetic management of patients with VHD undergo-</text>
<text top="264" left="64" width="350" height="15" font="5">ing noncardiac surgery should take into account the un-</text>
<text top="282" left="64" width="350" height="15" font="5">derlying valvular abnormality, its effect on the systolic and</text>
<text top="300" left="64" width="350" height="15" font="5">diastolic function of the heart, and any comorbidities, such</text>
<text top="318" left="64" width="350" height="15" font="5">as CAD or pulmonary hypertension. In noncardiac surgical</text>
<text top="336" left="64" width="350" height="15" font="5">patients with AS, the reduced LV compliance that results</text>
<text top="354" left="64" width="311" height="15" font="5">from the chronic pressure overload makes ventricular</text>
<text top="350" left="379" width="35" height="19" font="5">ﬁlling</text>
<text top="372" left="64" width="350" height="15" font="5">dependent on preload and atrial contraction. In the patient</text>
<text top="390" left="64" width="311" height="15" font="5">with AS, arrhythmias are poorly tolerated. Speci</text>
<text top="386" left="376" width="38" height="19" font="5">ﬁcally,</text>
<text top="408" left="64" width="350" height="15" font="5">tachycardia should be particularly avoided, because the</text>
<text top="426" left="64" width="225" height="15" font="5">combination of a shortened diastolic</text>
<text top="422" left="295" width="119" height="19" font="5">ﬁlling period and a</text>
<text top="444" left="64" width="252" height="15" font="5">stiff left ventricle results in inadequate LV</text>
<text top="440" left="320" width="94" height="19" font="5">ﬁlling and a fall</text>
<text top="461" left="64" width="350" height="15" font="5">in cardiac output. If possible, sinus rhythm should be</text>
<text top="479" left="64" width="350" height="15" font="5">maintained and the ventricular rate controlled. A typical</text>
<text top="497" left="64" width="350" height="15" font="5">example is the patient with AS with acute onset supra-</text>
<text top="515" left="64" width="350" height="15" font="5">ventricular tachycardia or AF, in whom synchronized</text>
<text top="533" left="64" width="350" height="15" font="5">cardioversion should be applied immediately if the patient</text>
<text top="551" left="64" width="311" height="15" font="5">becomes hypotensive. The atrial contribution to LV</text>
<text top="548" left="379" width="35" height="19" font="5">ﬁlling</text>
<text top="569" left="64" width="86" height="15" font="5">is often signi</text>
<text top="566" left="150" width="264" height="19" font="5">ﬁcant, particularly with AS and diastolic</text>
<text top="587" left="64" width="350" height="15" font="5">dysfunction. Intravascular volume should be titrated at a</text>
<text top="605" left="64" width="350" height="15" font="5">level that ensures an adequate forward cardiac output</text>
<text top="623" left="64" width="350" height="15" font="5">without an excessive rise in left atrial pressure. This can be</text>
<text top="641" left="64" width="350" height="15" font="5">achieved by ensuring adequate volume replacement with</text>
<text top="659" left="64" width="350" height="15" font="5">guidance from central venous or pulmonary pressures or</text>
<text top="677" left="64" width="350" height="15" font="5">dynamic pulsatility indices, and monitoring LV chamber</text>
<text top="695" left="64" width="350" height="15" font="5">size with intraoperative TEE may be particularly useful. A</text>
<text top="713" left="64" width="350" height="15" font="5">drop in systemic vascular resistance may reduce diastolic</text>
<text top="730" left="64" width="158" height="15" font="5">BP and coronary blood</text>
<text top="727" left="233" width="181" height="19" font="5">ﬂow, leading to myocardial</text>
<text top="748" left="64" width="350" height="15" font="5">ischemia, and this may be particularly detrimental in the</text>
<text top="766" left="64" width="350" height="15" font="5">patient with coexisting CAD or peripheral artery disease.</text>
<text top="784" left="64" width="350" height="15" font="5">The anesthetic approach and anesthetic agents should be</text>
<text top="802" left="64" width="349" height="15" font="5">chosen to avoid systemic hypotension. Potential detri-</text>
<text top="820" left="64" width="350" height="15" font="5">mental effects of the anesthetic approach should be</text>
<text top="838" left="64" width="350" height="15" font="5">considered, such as acute increases in afterload-induced</text>
<text top="856" left="64" width="350" height="15" font="5">laryngoscopy, tracheal intubation, or surgical stimulation.</text>
<text top="874" left="64" width="350" height="15" font="5">Either phenylephrine or norepinephrine can be used to</text>
<text top="892" left="64" width="350" height="15" font="5">raise the BP; both were found to not adversely affect LV</text>
<text top="910" left="64" width="350" height="15" font="5">systolic and diastolic function. Instances of systemic hy-</text>
<text top="928" left="64" width="350" height="15" font="5">pertension should be treated preferentially with arterial</text>
<text top="946" left="64" width="350" height="15" font="5">dilators, such as short-acting calcium channel blockers</text>
<text top="964" left="64" width="350" height="15" font="5">instead of preload-reducing agents such as nitroglycerin.</text>
<text top="982" left="64" width="350" height="15" font="5">General anesthetics are well tolerated, and the choice of</text>
<text top="1000" left="64" width="349" height="15" font="5">anesthetic agents should be carefully titrated to maintain</text>
<text top="1017" left="64" width="350" height="15" font="5">normotension and sinus rhythm. It is equally important to</text>
<text top="1035" left="64" width="350" height="15" font="5">modify epidural or spinal anesthetic interventions so that</text>
<text top="1053" left="64" width="350" height="15" font="5">systemic pressure changes do not occur or occur gradually.</text>
<text top="1071" left="64" width="349" height="15" font="5">For example, only high-dilution neuraxial local anesthetic</text>
<text top="1089" left="64" width="313" height="15" font="5">agents in combination with opioids should be used.</text>
<text top="103" left="465" width="335" height="15" font="5">The patient with MS undergoing noncardiac surgery</text>
<text top="121" left="450" width="350" height="15" font="5">should be treated in a manner similar to the patient</text>
<text top="139" left="450" width="350" height="15" font="5">with AS, because the pathophysiology of the disease and</text>
<text top="157" left="450" width="350" height="15" font="5">its implications are similar. Maintenance of normal</text>
<text top="175" left="450" width="350" height="15" font="5">LV preload and sinus rhythm, and avoidance of tachy-</text>
<text top="193" left="450" width="350" height="15" font="5">cardia and systemic hypotension should be the targets in</text>
<text top="211" left="450" width="350" height="15" font="5">the perioperative period. Of particular concern is judicious</text>
<text top="229" left="450" width="68" height="15" font="5">intravenous</text>
<text top="225" left="523" width="277" height="19" font="5">ﬂuid administration so as to avoid increases in</text>
<text top="246" left="450" width="350" height="15" font="5">the left atrial pressure and pulmonary capillary pressure</text>
<text top="264" left="450" width="272" height="15" font="5">that may precipitate acute pulmonary edema.</text>
<text top="282" left="465" width="335" height="15" font="5">Patients with AR or MR present with chronic LV</text>
<text top="300" left="450" width="350" height="15" font="5">volume overload. In either disease, a decrease in systemic</text>
<text top="318" left="450" width="350" height="15" font="5">afterload will augment the systemic LV output and reduce</text>
<text top="336" left="450" width="350" height="15" font="5">the regurgitant volume. Patients with regurgitant valve</text>
<text top="354" left="450" width="350" height="15" font="5">lesions are better suited to receive a regional anesthetic,</text>
<text top="372" left="450" width="350" height="15" font="5">because the combination of neuraxial local anesthetics and</text>
<text top="390" left="450" width="350" height="15" font="5">opioids produces a favorable systemic vasodilation. How-</text>
<text top="408" left="450" width="350" height="15" font="5">ever, preload should be maintained, particularly in the</text>
<text top="426" left="450" width="350" height="15" font="5">chronic regurgitation lesions, because there is a larger LV</text>
<text top="444" left="450" width="350" height="15" font="5">volume and increase in diastolic compliance. Monitoring</text>
<text top="462" left="450" width="350" height="15" font="5">of central venous or pulmonary pressures and size and</text>
<text top="480" left="450" width="350" height="15" font="5">function of the left ventricle should be done with invasive</text>
<text top="498" left="450" width="183" height="15" font="5">catheters or echocardiography.</text>
<text top="516" left="465" width="72" height="15" font="5">Changes in</text>
<text top="512" left="545" width="254" height="19" font="5">ﬂuid balance continue to occur postop-</text>
<text top="533" left="450" width="350" height="15" font="5">eratively, so these intraoperative considerations are appli-</text>
<text top="551" left="450" width="93" height="15" font="5">cable in the 48</text>
<text top="548" left="543" width="257" height="19" font="5">– to 72–hour postoperative period as well</text>
<text top="569" left="450" width="147" height="15" font="5">as during the procedure.</text>
<text top="588" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="587" left="597" width="27" height="15" font="6"><a href="e57.full.html#121">(924</a></text>
<text top="584" left="625" width="35" height="19" font="6"><a href="e57.full.html#121">–929)</a></text>
<text top="636" left="450" width="257" height="12" font="19">15.3. Intervention: Recommendations</text>
<text top="659" left="451" width="349" height="15" font="5">When VHD is diagnosed in patients being considered</text>
<text top="677" left="450" width="214" height="15" font="5">for elective noncardiac surgery, the</text>
<text top="673" left="670" width="130" height="19" font="5">ﬁrst step is to review</text>
<text top="695" left="450" width="301" height="15" font="5">the standard criteria for intervention of the speci</text>
<text top="691" left="750" width="49" height="19" font="5">ﬁc valve</text>
<text top="712" left="450" width="350" height="15" font="5">lesion. If the patient meets standard criteria for interven-</text>
<text top="730" left="450" width="350" height="15" font="5">tion, it is usually prudent to defer the elective noncardiac</text>
<text top="748" left="450" width="316" height="15" font="5">procedure and proceed to valve intervention instead.</text>
<text top="766" left="465" width="132" height="15" font="5">In patients with signi</text>
<text top="763" left="597" width="203" height="19" font="5">ﬁcant asymptomatic valve disease</text>
<text top="784" left="450" width="350" height="15" font="5">who do not meet standard criteria for intervention, the risk</text>
<text top="802" left="450" width="350" height="15" font="5">of the noncardiac procedure can be minimized by 1) having</text>
<text top="820" left="450" width="350" height="15" font="5">an accurate diagnosis of the type and severity of valve</text>
<text top="838" left="450" width="350" height="15" font="5">dysfunction, 2) choosing an anesthetic approach appro-</text>
<text top="856" left="450" width="350" height="15" font="5">priate to the valve lesion, and 3) ensuring a higher level of</text>
<text top="874" left="450" width="157" height="15" font="5">intraoperative monitoring.</text>
<text top="892" left="465" width="335" height="15" font="5">In emergency situations, noncardiac surgery may be</text>
<text top="910" left="450" width="350" height="15" font="5">necessary in the presence of uncorrected severe valve dis-</text>
<text top="928" left="450" width="350" height="15" font="5">ease. In patients with severe AS or MS, volume shifts and</text>
<text top="946" left="450" width="350" height="15" font="5">rhythm disturbances associated with the surgical stress and</text>
<text top="964" left="450" width="350" height="15" font="5">cardiovascular side effects of the anesthetic medications</text>
<text top="981" left="450" width="350" height="15" font="5">may lead to hypovolemia and tachycardia and further</text>
<text top="999" left="450" width="350" height="15" font="5">hemodynamic compromise. Thus, patients with severe</text>
<text top="1017" left="450" width="350" height="15" font="5">left-sided valve stenosis requiring emergency noncardiac</text>
<text top="1035" left="450" width="350" height="15" font="5">surgery should be managed by a cardiovascular anesthesi-</text>
<text top="1053" left="450" width="350" height="15" font="5">ologist with invasive hemodynamic or TEE imaging</text>
<text top="1071" left="450" width="350" height="15" font="5">monitoring intraoperatively and remain in an intensive</text>
<text top="1089" left="450" width="326" height="15" font="5">monitoring setting for 48 to 72 hours postoperatively.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e153</text>
</page>
<page number="98" position="absolute" top="0" left="0" height="1160" width="864">
<text top="106" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="121" left="63" width="351" height="10" font="21">1. Moderate-risk elective noncardiac surgery with appropriate</text>
<text top="137" left="81" width="333" height="10" font="21">intraoperative and postoperative hemodynamic monitoring is</text>
<text top="154" left="81" width="332" height="10" font="21">reasonable to perform in patients with asymptomatic severe AS</text>
<text top="170" left="81" width="50" height="10" font="22"><a href="e57.full.html#121">(917,920</a></text>
<text top="167" left="132" width="32" height="16" font="22"><a href="e57.full.html#121">–922)</a></text>
<text top="170" left="164" width="121" height="12" font="21"><a href="e57.full.html#121">. </a>(Level of Evidence: B)</text>
<text top="195" left="79" width="335" height="15" font="5">The hemodynamic effects of anesthesia and surgery are</text>
<text top="213" left="64" width="350" height="15" font="5">poorly tolerated in patients with severe AS. AVR is rec-</text>
<text top="231" left="64" width="350" height="15" font="5">ommended in all patients with symptomatic severe AS and</text>
<text top="248" left="64" width="350" height="15" font="5">should be performed before other surgical interventions to</text>
<text top="266" left="64" width="350" height="15" font="5">avoid hemodynamic instability during, as well as after,</text>
<text top="284" left="64" width="116" height="15" font="5">noncardiac surgery.</text>
<text top="302" left="79" width="270" height="15" font="5">In patients with moderate-to-severe AS, 30</text>
<text top="299" left="349" width="65" height="19" font="5">–day mor-</text>
<text top="320" left="64" width="350" height="15" font="5">tality is higher for patients with AS (2.1%) compared</text>
<text top="338" left="64" width="135" height="15" font="5">with propensity score</text>
<text top="335" left="199" width="215" height="19" font="5">matched controls (1.0%) with a</text>
<text top="356" left="64" width="350" height="15" font="5">higher risk of postoperative MI in patients with AS.</text>
<text top="374" left="64" width="350" height="15" font="5">Predictors of adverse outcomes include severity of AS,</text>
<text top="392" left="64" width="350" height="15" font="5">high-risk surgery, cardiac symptoms, coexisting MR, and</text>
<text top="410" left="64" width="350" height="15" font="5">CAD. However, these comorbidities also increase the</text>
<text top="428" left="64" width="145" height="15" font="5">risk of AVR. The risk</text>
<text top="424" left="210" width="204" height="19" font="5">–beneﬁt ratio continues to favor</text>
<text top="446" left="64" width="350" height="15" font="5">managing patients with severe AS undergoing moderate-</text>
<text top="464" left="64" width="350" height="15" font="5">risk noncardiac surgery with hemodynamic monitoring</text>
<text top="482" left="64" width="350" height="15" font="5">and optimization of loading conditions rather than con-</text>
<text top="500" left="64" width="165" height="15" font="5">sidering prophylactic AVR.</text>
<text top="518" left="79" width="335" height="15" font="5">Adverse outcomes in the setting of aortic valve</text>
<text top="535" left="64" width="350" height="15" font="5">obstruction are due to the combination of the anesthetic</text>
<text top="553" left="64" width="350" height="15" font="5">procedure (general, regional, or monitored anesthesia care)</text>
<text top="571" left="64" width="350" height="15" font="5">and surgical stress. Systemic hypotension and tachycardia</text>
<text top="589" left="64" width="350" height="15" font="5">may result in decreased coronary perfusion pressure, de-</text>
<text top="607" left="64" width="350" height="15" font="5">velopment of arrhythmias or ischemia, myocardial injury,</text>
<text top="625" left="64" width="350" height="15" font="5">cardiac failure, and death. These complications can be</text>
<text top="643" left="64" width="350" height="15" font="5">avoided by periprocedural hemodynamic monitoring with</text>
<text top="661" left="64" width="349" height="15" font="5">a right-heart catheter or intraoperative TEE to allow</text>
<text top="679" left="64" width="350" height="15" font="5">continuous optimization of loading conditions. Intra- and</text>
<text top="697" left="64" width="350" height="15" font="5">postoperative monitoring of BP and intracardiac volume</text>
<text top="715" left="64" width="350" height="15" font="5">are implemented starting in the preoperative period and</text>
<text top="733" left="64" width="350" height="15" font="5">continuing until hemodynamics are stable, which may be</text>
<text top="751" left="64" width="350" height="15" font="5">as long as 24 to 48 hours after the procedure. Mainte-</text>
<text top="769" left="64" width="350" height="15" font="5">nance of normal coronary perfusion pressure with the</text>
<text top="787" left="64" width="350" height="15" font="5">administration of alpha-adrenergic agents, such as</text>
<text top="805" left="64" width="350" height="15" font="5">phenylephrine, may be helpful early in the procedure</text>
<text top="822" left="64" width="350" height="15" font="5">to avoid the detrimental consequences of myocardial</text>
<text top="840" left="64" width="90" height="15" font="5">hypoperfusion.</text>
<text top="859" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="858" left="212" width="53" height="15" font="6"><a href="e57.full.html#121">(917,920</a></text>
<text top="855" left="266" width="35" height="19" font="6"><a href="e57.full.html#121">–922)</a></text>
<text top="886" left="64" width="45" height="8" font="20">CLASS IIa</text>
<text top="901" left="63" width="351" height="10" font="21">2. Moderate-risk elective noncardiac surgery with appropriate</text>
<text top="917" left="81" width="333" height="10" font="21">intraoperative and postoperative hemodynamic monitoring is</text>
<text top="934" left="81" width="333" height="10" font="21">reasonable to perform in patients with asymptomatic severe</text>
<text top="950" left="81" width="139" height="12" font="21">MR. (Level of Evidence: C)</text>
<text top="975" left="79" width="335" height="15" font="5">In patients with severe MR undergoing noncardiac</text>
<text top="992" left="64" width="350" height="15" font="5">surgery, the overall hemodynamic goals are avoidance of</text>
<text top="1010" left="64" width="350" height="15" font="5">both increased afterload and bradycardia by choosing the</text>
<text top="1028" left="64" width="350" height="15" font="5">appropriate anesthetic scheme. Invasive hemodynamic</text>
<text top="1046" left="64" width="350" height="15" font="5">and/or TEE monitoring allows for continuous optimiza-</text>
<text top="1064" left="64" width="349" height="15" font="5">tion of loading conditions during and after the operative</text>
<text top="1082" left="64" width="350" height="15" font="5">procedure, with these patients admitted to an intensive</text>
<text top="103" left="450" width="350" height="15" font="5">monitoring setting for up to 24 to 48 hours after the</text>
<text top="121" left="450" width="62" height="15" font="5">procedure.</text>
<text top="139" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="139" left="593" width="32" height="15" font="6"><a href="e57.full.html#121">(930)</a></text>
<text top="167" left="450" width="45" height="8" font="20">CLASS IIa</text>
<text top="182" left="449" width="351" height="10" font="21">3. Moderate-risk elective noncardiac surgery with appropriate</text>
<text top="198" left="467" width="332" height="10" font="21">intraoperative and postoperative hemodynamic monitoring is</text>
<text top="215" left="467" width="333" height="10" font="21">reasonable to perform in patients with asymptomatic severe AR</text>
<text top="231" left="467" width="219" height="12" font="21">and a normal LVEF. (Level of Evidence: C)</text>
<text top="255" left="465" width="335" height="15" font="5">Patients with severe AR are prone to hemodynamic</text>
<text top="273" left="450" width="350" height="15" font="5">instability because of the detrimental effects of increased</text>
<text top="291" left="450" width="350" height="15" font="5">volume on myocardial wall stress. The perioperative stress</text>
<text top="309" left="450" width="350" height="15" font="5">associated with noncardiac surgery may lead to hypoten-</text>
<text top="327" left="450" width="350" height="15" font="5">sion, arrhythmias, HF, or even death. It is especially</text>
<text top="345" left="450" width="350" height="15" font="5">important to avoid bradycardia when AR is present due to</text>
<text top="363" left="450" width="350" height="15" font="5">the increase in total diastolic time. These patients should</text>
<text top="381" left="450" width="350" height="15" font="5">be monitored with invasive systemic arterial and venous</text>
<text top="399" left="450" width="350" height="15" font="5">catheters and/or TEE and admitted postoperatively to an</text>
<text top="417" left="450" width="350" height="15" font="5">intensive monitoring setting. Patients with severe AR and</text>
<text top="435" left="450" width="274" height="15" font="5">a decreased LVEF, elevated serum creatinine</text>
<text top="431" left="730" width="70" height="19" font="5">&gt;2 mg/dL,</text>
<text top="453" left="450" width="350" height="15" font="5">or who are undergoing intermediate- to high-risk</text>
<text top="471" left="450" width="350" height="15" font="5">noncardiac surgery have the highest risk of cardiopulmo-</text>
<text top="489" left="450" width="181" height="15" font="5">nary complications and death.</text>
<text top="507" left="465" width="123" height="15" font="5">Supporting Reference:</text>
<text top="506" left="593" width="32" height="15" font="6"><a href="e57.full.html#121">(931)</a></text>
<text top="534" left="450" width="45" height="8" font="20">CLASS IIb</text>
<text top="549" left="449" width="351" height="10" font="21">1. Moderate-risk elective noncardiac surgery in patients with appro-</text>
<text top="565" left="467" width="332" height="10" font="21">priate intraoperative and postoperative hemodynamic monitoring</text>
<text top="581" left="467" width="332" height="10" font="21">may be reasonable to perform in asymptomatic patients with se-</text>
<text top="598" left="467" width="333" height="10" font="21">vere MS if valve morphology is not favorable for percutaneous</text>
<text top="614" left="467" width="275" height="12" font="21">balloon mitral commissurotomy. (Level of Evidence: C)</text>
<text top="639" left="465" width="335" height="15" font="5">Patients with asymptomatic severe MS and valve anat-</text>
<text top="657" left="450" width="350" height="15" font="5">omy favorable for percutaneous balloon mitral commis-</text>
<text top="675" left="450" width="350" height="15" font="5">surotomy who are undergoing elective noncardiac surgery</text>
<text top="692" left="450" width="350" height="15" font="5">should be evaluated and treated pursuant to the recom-</text>
<text top="710" left="450" width="125" height="15" font="5">mendations for MS (</text>
<text top="710" left="575" width="78" height="15" font="6">Section 6.2.3</text>
<text top="710" left="653" width="146" height="15" font="5">). If valve anatomy is not</text>
<text top="728" left="450" width="350" height="15" font="5">favorable or if there are other contraindications to percu-</text>
<text top="746" left="450" width="350" height="15" font="5">taneous balloon mitral commissurotomy, elective noncar-</text>
<text top="764" left="450" width="350" height="15" font="5">diac surgery may be considered with invasive hemodynamic</text>
<text top="782" left="450" width="350" height="15" font="5">monitoring to optimize loading conditions. Preload should</text>
<text top="800" left="450" width="350" height="15" font="5">be maintained high enough to allow an adequate forward</text>
<text top="818" left="450" width="350" height="15" font="5">cardiac output across the stenotic mitral valve but low</text>
<text top="836" left="450" width="350" height="15" font="5">enough to avoid pulmonary edema. Maintaining preload in</text>
<text top="854" left="450" width="350" height="15" font="5">this narrow range can be challenging and requires mea-</text>
<text top="872" left="450" width="350" height="15" font="5">surement of cardiac output and pulmonary wedge pressure.</text>
<text top="890" left="450" width="350" height="15" font="5">Tachycardia should be avoided due to the shortened dia-</text>
<text top="908" left="450" width="60" height="15" font="5">stolic LV</text>
<text top="904" left="518" width="281" height="19" font="5">ﬁlling time across the stenotic mitral valve,</text>
<text top="926" left="450" width="272" height="15" font="5">resulting in an increase in left atrial pressure.</text>
<text top="944" left="465" width="128" height="15" font="5">Supporting References:</text>
<text top="944" left="597" width="58" height="15" font="6"><a href="e57.full.html#121">(924,932)</a></text>
<text top="962" left="465" width="18" height="15" font="5">See</text>
<text top="962" left="488" width="166" height="15" font="6"><a href="http://jaccjacc.cardiosource.com/DataSupp/2014%20VHD%20Guideline%20Data%20Supplements.pdf">Online Data Supplement 28</a></text>
<text top="962" left="659" width="140" height="15" font="5">for more information on</text>
<text top="980" left="450" width="108" height="15" font="5">noncardiac surgery.</text>
<text top="1023" left="450" width="322" height="14" font="17">16. Evidence Gaps and Future Directions</text>
<text top="1064" left="451" width="349" height="15" font="5">Current recommendations for evaluation and manage-</text>
<text top="1082" left="450" width="350" height="15" font="5">ment of VHD are largely based on clinical experience</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e154</text>
</page>
<page number="99" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="15" font="5">and observational studies, with few prospective RCTs.</text>
<text top="121" left="64" width="350" height="15" font="5">We recommend that research on valve disease span the</text>
<text top="139" left="64" width="350" height="15" font="5">spectrum from basic science to prospective randomized</text>
<text top="157" left="64" width="350" height="15" font="5">trials and that studies focus on each stage of the disease</text>
<text top="175" left="64" width="350" height="15" font="5">process from the patient at risk to the patient with end-</text>
<text top="192" left="64" width="79" height="15" font="5">stage disease.</text>
<text top="223" left="64" width="301" height="15" font="19">16.1. Prevention of Valve DiseasedStage A</text>
<text top="246" left="65" width="349" height="15" font="5">On a worldwide basis, rheumatic fever remains the primary</text>
<text top="264" left="64" width="350" height="15" font="5">cause of VHD; global health systems outcomes studies</text>
<text top="282" left="64" width="350" height="15" font="5">are needed to identify impediments to successful primary</text>
<text top="300" left="64" width="350" height="15" font="5">and secondary prevention of rheumatic heart disease.</text>
<text top="318" left="64" width="350" height="15" font="5">Other approaches to prevention (such as vaccine develop-</text>
<text top="336" left="64" width="350" height="15" font="5">ment) and delaying disease progression once valve damage</text>
<text top="354" left="64" width="350" height="15" font="5">is present should also be explored. Disease prevention</text>
<text top="372" left="64" width="350" height="15" font="5">in patients at risk of other types of valve disease is needed.</text>
<text top="390" left="64" width="196" height="15" font="5">Some subgroups at risk of calci</text>
<text top="386" left="261" width="153" height="19" font="5">ﬁc AS can be identiﬁed,</text>
<text top="408" left="64" width="350" height="15" font="5">such as those with a congenital bicuspid aortic valve or</text>
<text top="426" left="64" width="350" height="15" font="5">elevated lipoprotein(a) levels. However, there are no known</text>
<text top="444" left="64" width="350" height="15" font="5">therapies to prevent valve dysfunction in these patients.</text>
<text top="461" left="64" width="350" height="15" font="5">Basic science studies on the genetic and pathobiological</text>
<text top="479" left="64" width="350" height="15" font="5">causes of valve dysfunction will provide insight into</text>
<text top="497" left="64" width="350" height="15" font="5">mechanisms of disease initiation and progression that</text>
<text top="515" left="64" width="236" height="15" font="5">might be amenable to medical therapy.</text>
<text top="534" left="79" width="128" height="15" font="5">Supporting References:</text>
<text top="533" left="212" width="27" height="15" font="6"><a href="e57.full.html#121">(933</a></text>
<text top="530" left="239" width="35" height="19" font="6"><a href="e57.full.html#121">–938)</a></text>
<text top="564" left="64" width="285" height="12" font="19">16.2. Medical Therapy to Treat or Prevent</text>
<text top="582" left="64" width="207" height="15" font="19">Disease ProgressiondStage B</text>
<text top="605" left="65" width="335" height="15" font="5">In patients with early VHD, including those with calci</text>
<text top="601" left="400" width="14" height="19" font="5">ﬁc</text>
<text top="623" left="64" width="350" height="15" font="5">or myxomatous disease, there are currently no therapies to</text>
<text top="641" left="64" width="268" height="15" font="5">prevent disease progression in the valve lea</text>
<text top="637" left="332" width="82" height="19" font="5">ﬂets. Instead,</text>
<text top="659" left="64" width="350" height="15" font="5">our recommendations are all directed toward patient mon-</text>
<text top="677" left="64" width="350" height="15" font="5">itoring with the intent to intervene once severe disease is</text>
<text top="695" left="64" width="350" height="15" font="5">present that results in symptoms or abnormal cardiovas-</text>
<text top="712" left="64" width="350" height="15" font="5">cular function. Again, basic science studies are needed to</text>
<text top="730" left="64" width="350" height="15" font="5">identify potential targets for prevention of progressive</text>
<text top="748" left="64" width="350" height="15" font="5">VHD that then can be translated into prospective clinical</text>
<text top="766" left="64" width="350" height="15" font="5">trials. Additional studies are needed for therapies that</text>
<text top="784" left="64" width="350" height="15" font="5">might prevent the adverse consequences of VHD, such as</text>
<text top="802" left="64" width="275" height="15" font="5">LV dysfunction and pulmonary hypertension.</text>
<text top="821" left="79" width="123" height="15" font="5">Supporting Reference:</text>
<text top="820" left="208" width="32" height="15" font="6"><a href="e57.full.html#121">(939)</a></text>
<text top="851" left="64" width="315" height="15" font="19">16.3. Optimal Timing of InterventiondStage C</text>
<text top="874" left="65" width="349" height="15" font="5">Current approaches to identifying the optimal timing of</text>
<text top="892" left="64" width="350" height="15" font="5">intervention in patients with progressive valve disease are</text>
<text top="910" left="64" width="350" height="15" font="5">suboptimal. Symptom onset is a subjective measure and</text>
<text top="928" left="64" width="350" height="15" font="5">may occur too late in the disease course for optimal long-</text>
<text top="946" left="64" width="350" height="15" font="5">term outcomes. Despite the availability of sophisticated</text>
<text top="964" left="64" width="350" height="15" font="5">approaches for measurement of LV volumes, systolic</text>
<text top="981" left="64" width="350" height="15" font="5">function, diastolic function, and other measures of myo-</text>
<text top="999" left="64" width="350" height="15" font="5">cardial performance, recommendations rely only on simple</text>
<text top="1017" left="64" width="350" height="15" font="5">linear dimensions used in published series with data that</text>
<text top="1035" left="64" width="69" height="15" font="5">may not re</text>
<text top="1032" left="133" width="281" height="19" font="5">ﬂect contemporary clinical outcomes. We ur-</text>
<text top="1053" left="64" width="350" height="15" font="5">gently need studies evaluating the value of newer measures</text>
<text top="1071" left="64" width="350" height="15" font="5">of LV size, function, and myocardial structure in predict-</text>
<text top="1089" left="64" width="350" height="15" font="5">ing outcomes after valve intervention. However, LV</text>
<text top="103" left="450" width="350" height="15" font="5">enlargement and dysfunction are late consequences of valve</text>
<text top="121" left="450" width="350" height="15" font="5">dysfunction; as more durable approaches to restoring</text>
<text top="139" left="450" width="350" height="15" font="5">normal valve function are developed, the balance of ben-</text>
<text top="157" left="450" width="6" height="15" font="5">e</text>
<text top="153" left="456" width="343" height="19" font="5">ﬁtrisk for intervention will shift to earlier in the disease.</text>
<text top="175" left="450" width="350" height="15" font="5">Studies examining the role of earlier markers of myocar-</text>
<text top="193" left="450" width="350" height="15" font="5">dial dysfunction such as strain and strain-rate imaging,</text>
<text top="210" left="450" width="350" height="15" font="5">diastolic dysfunction, serum markers, and other novel ap-</text>
<text top="228" left="450" width="92" height="15" font="5">proaches to de</text>
<text top="225" left="542" width="258" height="19" font="5">ﬁning the optimal timing of intervention</text>
<text top="246" left="450" width="96" height="15" font="5">also are needed.</text>
<text top="264" left="465" width="335" height="15" font="5">Few studies have included adequate numbers of older</text>
<text top="282" left="450" width="122" height="15" font="5">adults to make speci</text>
<text top="279" left="572" width="228" height="19" font="5">ﬁc recommendations for this group of</text>
<text top="300" left="450" width="350" height="15" font="5">patients in whom particular concerns, such as cognitive</text>
<text top="318" left="450" width="350" height="15" font="5">function, frailty, and mobility challenges, may change the</text>
<text top="336" left="450" width="121" height="15" font="5">decision algorithms.</text>
<text top="354" left="465" width="335" height="15" font="5">Given the relatively low risk of intervention in other-</text>
<text top="372" left="450" width="350" height="15" font="5">wise healthy patients and the improved options for valve</text>
<text top="390" left="450" width="350" height="15" font="5">repair or replacement, RCTs of intervention for severe</text>
<text top="408" left="450" width="335" height="15" font="5">asymptomatic VHD are needed. Examples of speci</text>
<text top="404" left="785" width="14" height="19" font="5">ﬁc</text>
<text top="426" left="450" width="350" height="15" font="5">conditions where clinical equipoise exists are asymptom-</text>
<text top="444" left="450" width="350" height="15" font="5">atic severe AS in otherwise healthy patients, asymptom-</text>
<text top="462" left="450" width="350" height="15" font="5">atic severe AR with normal LV systolic function, and</text>
<text top="479" left="450" width="350" height="15" font="5">severe primary MR with normal LV function and a high</text>
<text top="497" left="450" width="350" height="15" font="5">likelihood of valve repair. Data from large, carefully</text>
<text top="515" left="450" width="282" height="15" font="5">designed registries are also needed for de</text>
<text top="512" left="732" width="68" height="19" font="5">ﬁning and</text>
<text top="533" left="450" width="155" height="15" font="5">improving quality of care.</text>
<text top="564" left="450" width="319" height="15" font="19">16.4. Better Options for InterventiondStage D</text>
<text top="587" left="451" width="349" height="15" font="5">We need better options for valve repair and replacement.</text>
<text top="605" left="450" width="350" height="15" font="5">The timing of intervention is based on the balance between</text>
<text top="623" left="450" width="350" height="15" font="5">outcomes with native valve disease and the risk and long-</text>
<text top="641" left="450" width="350" height="15" font="5">term durability of the valve after intervention. As valve</text>
<text top="659" left="450" width="350" height="15" font="5">repair and replacement options improve, the balance will</text>
<text top="677" left="450" width="350" height="15" font="5">shift toward earlier intervention. We need a valve substi-</text>
<text top="695" left="450" width="350" height="15" font="5">tute that can be safely and reliably implanted, is non-</text>
<text top="712" left="450" width="350" height="15" font="5">thrombogenic, has hemodynamics similar to a normal</text>
<text top="730" left="450" width="350" height="15" font="5">native valve, and is durable. Transcatheter valve procedures</text>
<text top="748" left="450" width="350" height="15" font="5">offer the promise of safe implantation and excellent he-</text>
<text top="766" left="450" width="350" height="15" font="5">modynamics, but long-term durability is not yet known. In</text>
<text top="784" left="450" width="350" height="15" font="5">patients who require mechanical valve replacement, we</text>
<text top="802" left="450" width="350" height="15" font="5">need oral therapy that provides effective anticoagulation</text>
<text top="820" left="450" width="350" height="15" font="5">with a low risk of complications and no negative impact on</text>
<text top="838" left="450" width="84" height="15" font="5">quality of life.</text>
<text top="856" left="465" width="335" height="15" font="5">Moderate-to-severe VHD is present in 2.5% of the U.S.</text>
<text top="874" left="450" width="350" height="15" font="5">population and increases in prevalence with age. The dis-</text>
<text top="892" left="450" width="350" height="15" font="5">ease affects between 4% and 9% of those 65 to 75 years of</text>
<text top="910" left="450" width="180" height="15" font="5">age and 12% to 13% of those</text>
<text top="906" left="635" width="164" height="19" font="5">&gt;75 years of age. Many of</text>
<text top="928" left="450" width="350" height="15" font="5">these patients require surgical or interventional procedures.</text>
<text top="946" left="450" width="350" height="15" font="5">However, even with intervention, overall survival is lower</text>
<text top="964" left="450" width="350" height="15" font="5">than expected, and the risk of adverse outcomes due to</text>
<text top="982" left="450" width="350" height="15" font="5">VHD is high, both because of limited options for restoring</text>
<text top="999" left="450" width="350" height="15" font="5">normal valve function and failure to intervene at the</text>
<text top="1017" left="450" width="350" height="15" font="5">optimal time point in the disease course. We urgently need</text>
<text top="1035" left="450" width="350" height="15" font="5">research on almost every aspect of VHD to ensure that</text>
<text top="1053" left="450" width="350" height="15" font="5">patients who already have VHD receive optimal therapy</text>
<text top="1071" left="450" width="350" height="15" font="5">and to prevent VHD in those at risk. Approaches to</text>
<text top="1089" left="450" width="350" height="15" font="5">improving outcomes in patients with VHD include</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e155</text>
</page>
<page number="100" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="29" size="8" family="Times" color="#15539a"/>
<text top="103" left="64" width="350" height="15" font="5">1) national and international registries and RCTs, 2)</text>
<text top="121" left="64" width="350" height="15" font="5">continuous evaluation of outcomes data at each Heart</text>
<text top="139" left="64" width="350" height="15" font="5">Valve Center of Excellence, and 3) a focus on patient-</text>
<text top="157" left="64" width="350" height="15" font="5">centric care with involvement of the patient in the</text>
<text top="175" left="64" width="151" height="15" font="5">decision-making process.</text>
<text top="215" left="64" width="163" height="14" font="17">Presidents and Staff</text>
<text top="257" left="65" width="189" height="15" font="5">American College of Cardiology</text>
<text top="274" left="64" width="285" height="15" font="5">John Gordon Harold, MD, MACC, President</text>
<text top="292" left="64" width="238" height="15" font="5">Shalom Jacobovitz, Chief Executive Of</text>
<text top="289" left="302" width="25" height="19" font="5">ﬁcer</text>
<text top="310" left="64" width="350" height="15" font="5">William J. Oetgen, MD, MBA, FACC, Executive Vice</text>
<text top="328" left="79" width="260" height="15" font="5">President, Science, Education, and Quality</text>
<text top="346" left="64" width="350" height="15" font="5">Charlene L. May, Senior Director, Science and Clinical</text>
<text top="364" left="79" width="37" height="15" font="5">Policy</text>
<text top="398" left="64" width="350" height="15" font="5">American College of Cardiology/American Heart Association</text>
<text top="415" left="64" width="58" height="15" font="5">Lisa Brad</text>
<text top="411" left="122" width="292" height="19" font="5">ﬁeld, CAE, Director, Science and Clinical Policy</text>
<text top="433" left="64" width="350" height="15" font="5">Emily Cottrell, MA, Specialist, Science and Clinical Policy</text>
<text top="466" left="64" width="167" height="15" font="5">American Heart Association</text>
<text top="484" left="64" width="289" height="15" font="5">Mariell Jessup, MD, FACC, FAHA, President</text>
<text top="501" left="64" width="210" height="15" font="5">Nancy Brown, Chief Executive Of</text>
<text top="498" left="275" width="25" height="19" font="5">ﬁcer</text>
<text top="519" left="64" width="350" height="15" font="5">Rose Marie Robertson, MD, FAHA, Chief Science</text>
<text top="537" left="64" width="17" height="15" font="5">Of</text>
<text top="534" left="82" width="26" height="19" font="5">ﬁcer</text>
<text top="555" left="64" width="350" height="15" font="5">Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior</text>
<text top="573" left="79" width="113" height="15" font="5">Vice President, Of</text>
<text top="570" left="192" width="158" height="19" font="5">ﬁce of Science Operations</text>
<text top="591" left="64" width="350" height="15" font="5">Marco Di Buono, PhD, Vice President of Science and</text>
<text top="609" left="79" width="53" height="15" font="5">Research</text>
<text top="627" left="64" width="257" height="15" font="5">Jody Hundley, Production Manager, Scienti</text>
<text top="624" left="321" width="93" height="19" font="5">ﬁc Publications,</text>
<text top="645" left="79" width="17" height="15" font="5">Of</text>
<text top="642" left="96" width="156" height="19" font="5">ﬁce of Science Operations</text>
<text top="696" left="64" width="66" height="9" font="29">REFERENCES</text>
<text top="721" left="75" width="339" height="12" font="15">1. ACCF/AHA Task Force on Practice Guidelines. Methodology</text>
<text top="735" left="90" width="324" height="12" font="15">Manual and Policies From the ACCF/AHA Task Force on Practice</text>
<text top="748" left="90" width="324" height="12" font="15">Guidelines. American College of Cardiology Foundation and</text>
<text top="762" left="90" width="162" height="12" font="15">American Heart Association, Inc.</text>
<text top="762" left="256" width="77" height="12" font="22"><a href="http://cardiosource.org/">cardiosource.org</a></text>
<text top="762" left="333" width="81" height="12" font="15"><a href="http://cardiosource.org/">. </a>2010. Available</text>
<text top="775" left="90" width="12" height="12" font="15">at:</text>
<text top="775" left="110" width="304" height="12" font="22"><a href="http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf">http://assets.cardiosource.com/Methodology_Manual_for_ACC_</a></text>
<text top="789" left="90" width="155" height="12" font="22"><a href="http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf">AHA_Writing_Committees.pdf</a></text>
<text top="789" left="252" width="18" height="12" font="15">and</text>
<text top="789" left="276" width="138" height="12" font="22"><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">http://my.americanheart.org/</a></text>
<text top="802" left="90" width="324" height="12" font="22"><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/</a></text>
<text top="816" left="90" width="82" height="12" font="22"><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">ucm_319826.pdf</a></text>
<text top="816" left="172" width="146" height="12" font="15"><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">. </a>Accessed February 19, 2014.</text>
<text top="829" left="75" width="9" height="12" font="15">2.</text>
<text top="829" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref1">Institute of Medicine and Committee on Standards for Developing</a></text>
<text top="843" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref1">Trustworthy Clinical Practice Guidelines. Clinical Practice Guide-</a></text>
<text top="856" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref1">lines We Can Trust. Washington, DC: The National Academies</a></text>
<text top="869" left="90" width="55" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref1">Press; 2013</a></text>
<text top="869" left="145" width="3" height="12" font="15">.</text>
<text top="883" left="75" width="9" height="12" font="15">3.</text>
<text top="883" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref2">Committee on Standards for Systematic Reviews of Comparative</a></text>
<text top="896" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref2">Effectiveness Research, Institute of Medicine. Finding What Works</a></text>
<text top="910" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref2">in Health Care: Standards for Systematic Reviews. Washington,</a></text>
<text top="923" left="90" width="205" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref2">DC: The National Academies Press, 2011</a></text>
<text top="923" left="295" width="3" height="12" font="15">.</text>
<text top="937" left="75" width="9" height="12" font="15">4.</text>
<text top="937" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref3">Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update</a></text>
<text top="950" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref3">incorporated into the ACC/AHA 2006 guidelines for the man-</a></text>
<text top="964" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref3">agement of patients with valvular heart disease: a report of the</a></text>
<text top="977" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref3">American College of Cardiology/American Heart Association Task</a></text>
<text top="990" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref3">Force on Practice Guidelines (Writing Committee to revise the 1998</a></text>
<text top="1004" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref3">guidelines for the management of patients with valvular heart dis-</a></text>
<text top="1017" left="90" width="177" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref3">ease). J Am Coll Cardiol 2008;52:e1</a></text>
<text top="1015" left="267" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref3">–142</a></text>
<text top="1017" left="291" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref3">.</a></text>
<text top="1031" left="75" width="9" height="12" font="15">5.</text>
<text top="1031" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref4">Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommenda-</a></text>
<text top="1044" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref4">tions for evaluation of the severity of native valvular regurgitation</a></text>
<text top="1058" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref4">with two-dimensional and Doppler echocardiography. J Am Soc</a></text>
<text top="1071" left="90" width="128" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref4">Echocardiogr 2003;16:777</a></text>
<text top="1068" left="217" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref4">–802</a></text>
<text top="1071" left="241" width="3" height="12" font="15">.</text>
<text top="1085" left="75" width="96" height="12" font="15">6. Deleted in press.</text>
<text top="103" left="460" width="9" height="12" font="15">7.</text>
<text top="103" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref6">Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008</a></text>
<text top="116" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref6">guidelines for the management of adults with congenital heart dis-</a></text>
<text top="130" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref6">ease: a report of the American College of Cardiology/American</a></text>
<text top="143" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref6">Heart Association Task Force on Practice Guidelines (Writing</a></text>
<text top="157" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref6">Committee to Develop Guidelines on the Management of Adults</a></text>
<text top="170" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref6">With Congenital Heart Disease). Developed in Collaboration With</a></text>
<text top="184" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref6">the American Society of Echocardiography, Heart Rhythm Society,</a></text>
<text top="197" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref6">International Society for Adult Congenital Heart Disease, Society</a></text>
<text top="210" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref6">for Cardiovascular Angiography and Interventions, and Society of</a></text>
<text top="224" left="475" width="256" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref6">Thoracic Surgeons. J Am Coll Cardiol 2008;52:e143</a></text>
<text top="221" left="731" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref6">–263</a></text>
<text top="224" left="755" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref6">.</a></text>
<text top="237" left="460" width="9" height="12" font="15">8.</text>
<text top="237" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref7">Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic</a></text>
<text top="251" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref7">assessment of valve stenosis: EAE/ASE recommendations for clin-</a></text>
<text top="264" left="475" width="209" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref7">ical practice. Eur J Echocardiogr 2009;10:1</a></text>
<text top="261" left="684" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref7">–25</a></text>
<text top="264" left="702" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref7">.</a></text>
<text top="278" left="460" width="9" height="12" font="15">9.</text>
<text top="278" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref8">Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations</a></text>
<text top="291" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref8">for evaluation of prosthetic valves with echocardiography and</a></text>
<text top="305" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref8">Doppler ultrasound: a report from the American Society of Echo-</a></text>
<text top="318" left="475" width="61" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref8">cardiography</a></text>
<text top="315" left="536" width="263" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref8">’s Guidelines and Standards Committee and the Task</a></text>
<text top="331" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref8">Force on Prosthetic Valves, developed in conjunction with the</a></text>
<text top="345" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref8">American College of Cardiology Cardiovascular Imaging Commit-</a></text>
<text top="358" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref8">tee, Cardiac Imaging Committee of the American Heart Associa-</a></text>
<text top="372" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref8">tion, the European Association of Echocardiography, a registered</a></text>
<text top="385" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref8">branch of the European Society of Cardiology, the Japanese Society</a></text>
<text top="399" left="475" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref8">of Echocardiography and the Canadian Society of Echocardiogra-</a></text>
<text top="412" left="475" width="203" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref8">phy. J Am Soc Echocardiogr 2009;22:975</a></text>
<text top="409" left="678" width="30" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref8">–1014</a></text>
<text top="412" left="708" width="3" height="12" font="15">.</text>
<text top="426" left="455" width="15" height="12" font="15">10.</text>
<text top="426" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref9">Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA</a></text>
<text top="439" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref9">guideline for the diagnosis and treatment of hypertrophic cardio-</a></text>
<text top="453" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref9">myopathy: a report of the American College of Cardiology Foun-</a></text>
<text top="466" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref9">dation/American Heart Association Task Force on Practice</a></text>
<text top="479" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref9">Guidelines. Developed in collaboration with the American Associ-</a></text>
<text top="493" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref9">ation for Thoracic Surgery, American Society of Echocardiography,</a></text>
<text top="506" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref9">American Society of Nuclear Cardiology, Heart Failure Society of</a></text>
<text top="520" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref9">America, Heart Rhythm Society, Society for Cardiovascular Angi-</a></text>
<text top="533" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref9">ography and Interventions, and Society of Thoracic Surgeons. J Am</a></text>
<text top="547" left="476" width="129" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref9">Coll Cardiol 2011;58:e212</a></text>
<text top="544" left="605" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref9">–60</a></text>
<text top="547" left="623" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref9">.</a></text>
<text top="560" left="455" width="15" height="12" font="15">11.</text>
<text top="560" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref10">Regitz-Zagrosek V, Blomstrom LC, Borghi C, et al. ESC guide-</a></text>
<text top="574" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref10">lines on the management of cardiovascular diseases during preg-</a></text>
<text top="587" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref10">nancy: the Task Force on the Management of Cardiovascular</a></text>
<text top="600" left="476" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref10">Diseases during Pregnancy of the European Society of Cardiology</a></text>
<text top="614" left="476" width="165" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref10">(ESC). Eur Heart J 2011;32:3147</a></text>
<text top="611" left="641" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref10">–97</a></text>
<text top="614" left="659" width="3" height="12" font="15">.</text>
<text top="627" left="455" width="15" height="12" font="15">12.</text>
<text top="627" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref11">Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and</a></text>
<text top="641" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref11">thrombolytic therapy for valvular disease: antithrombotic therapy</a></text>
<text top="654" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref11">and prevention of thrombosis, 9th ed: American College of Chest</a></text>
<text top="668" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref11">Physicians Evidence-Based Clinical Practice Guidelines. Chest</a></text>
<text top="681" left="476" width="77" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref11">2012;141:e576S</a></text>
<text top="678" left="553" width="30" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref11">–600S</a></text>
<text top="681" left="583" width="3" height="12" font="15">.</text>
<text top="695" left="455" width="15" height="12" font="15">13.</text>
<text top="695" left="476" width="83" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref12">Vahanian A, Al</a></text>
<text top="692" left="559" width="241" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref12">ﬁeri O, Andreotti F, et al. Guidelines on the</a></text>
<text top="708" left="476" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref12">management of valvular heart disease (version 2012). Eur Heart J</a></text>
<text top="722" left="476" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref12">2012;33:2451</a></text>
<text top="719" left="542" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref12">–96</a></text>
<text top="722" left="560" width="3" height="12" font="15">.</text>
<text top="735" left="455" width="15" height="12" font="15">14.</text>
<text top="735" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref13">Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guide-</a></text>
<text top="748" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref13">line for the management of heart failure: a report of the American</a></text>
<text top="762" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref13">College of Cardiology Foundation/American Heart Association</a></text>
<text top="775" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref13">Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:</a></text>
<text top="789" left="476" width="23" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref13">e147</a></text>
<text top="786" left="498" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref13">–239</a></text>
<text top="789" left="522" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref13">.</a></text>
<text top="802" left="455" width="344" height="12" font="15">15. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS</text>
<text top="816" left="476" width="254" height="12" font="15">guideline for the management of patients with atrial</text>
<text top="813" left="734" width="65" height="16" font="15">ﬁbrillation: A</text>
<text top="829" left="476" width="324" height="12" font="15">report of the American College of Cardiology/American Heart</text>
<text top="843" left="476" width="324" height="12" font="15">Association Task Force on Practice Guidelines. Developed in</text>
<text top="856" left="476" width="324" height="12" font="15">Collaboration With the Society of Thoracic Surgeons. J Am Coll</text>
<text top="869" left="476" width="216" height="12" font="15">Cardiol 2014 Mar 28 [Epub ahead of print];</text>
<text top="869" left="695" width="104" height="12" font="22"><a href="http://dx.doi.org/10.1016/j.jacc.2014.03.022">http://dx.doi.org/10.1</a></text>
<text top="883" left="476" width="108" height="12" font="22"><a href="http://dx.doi.org/10.1016/j.jacc.2014.03.022">016/j.jacc.2014.03.022</a></text>
<text top="883" left="584" width="3" height="12" font="15"><a href="http://dx.doi.org/10.1016/j.jacc.2014.03.022">.</a></text>
<text top="896" left="455" width="102" height="12" font="15">16. Deleted in press.</text>
<text top="910" left="455" width="15" height="12" font="15">17.</text>
<text top="910" left="476" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref16">Carabello BA, Williams H, Gash AK, et al. Hemodynamic pre-</a></text>
<text top="923" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref16">dictors of outcome in patients undergoing valve replacement. Cir-</a></text>
<text top="937" left="476" width="107" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref16">culation 1986;74:1309</a></text>
<text top="934" left="583" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref16">–16</a></text>
<text top="937" left="601" width="3" height="12" font="15">.</text>
<text top="950" left="455" width="15" height="12" font="15">18.</text>
<text top="950" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref17">Currie PJ, Seward JB, Chan KL, et al. Continuous wave Doppler</a></text>
<text top="964" left="476" width="318" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref17">determination of right ventricular pressure: a simultaneous Doppler</a></text>
<text top="961" left="794" width="6" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref17">–</a></text>
<text top="977" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref17">catheterization study in 127 patients. J Am Coll Cardiol 1985;6:</a></text>
<text top="990" left="476" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref17">750</a></text>
<text top="988" left="494" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref17">–6</a></text>
<text top="990" left="506" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref17">.</a></text>
<text top="1004" left="455" width="15" height="12" font="15">19.</text>
<text top="1004" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref18">Currie PJ, Seward JB, Reeder GS, et al. Continuous-wave Doppler</a></text>
<text top="1017" left="476" width="230" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref18">echocardiographic assessment of severity of calci</a></text>
<text top="1015" left="706" width="93" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref18">ﬁc aortic stenosis: a</a></text>
<text top="1031" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref18">simultaneous Doppler-catheter correlative study in 100 adult pa-</a></text>
<text top="1044" left="476" width="156" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref18">tients. Circulation 1985;71:1162</a></text>
<text top="1042" left="632" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref18">–9</a></text>
<text top="1044" left="644" width="3" height="12" font="15">.</text>
<text top="1058" left="455" width="15" height="12" font="15">20.</text>
<text top="1058" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref19">Dujardin KS, Seward JB, Orszulak TA, et al. Outcome after surgery</a></text>
<text top="1071" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref19">for mitral regurgitation. Determinants of postoperative morbidity</a></text>
<text top="1085" left="476" width="210" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref19">and mortality. J Heart Valve Dis 1997;6:17</a></text>
<text top="1082" left="686" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref19">–21</a></text>
<text top="1085" left="704" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref19">.</a></text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e156</text>
</page>
<page number="101" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="70" width="15" height="12" font="15">21.</text>
<text top="103" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref20">Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al.</a></text>
<text top="116" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref20">Quantitative determinants of the outcome of asymptomatic mitral</a></text>
<text top="130" left="90" width="209" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref20">regurgitation. N Engl J Med 2005;352:875</a></text>
<text top="127" left="299" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref20">–83</a></text>
<text top="130" left="317" width="3" height="12" font="15">.</text>
<text top="143" left="70" width="15" height="12" font="15">22.</text>
<text top="143" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref21">Enriquez-Sarano M, Tajik AJ, Schaff HV, et al. Echocardiographic</a></text>
<text top="157" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref21">prediction of left ventricular function after correction of mitral</a></text>
<text top="170" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref21">regurgitation: results and clinical implications. J Am Coll Cardiol</a></text>
<text top="183" left="90" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref21">1994;24:1536</a></text>
<text top="181" left="156" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref21">–43</a></text>
<text top="183" left="174" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref21">.</a></text>
<text top="197" left="70" width="15" height="12" font="15">23.</text>
<text top="197" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref22">Nishimura RA, Rihal CS, Tajik AJ, et al. Accurate measurement of</a></text>
<text top="210" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref22">the transmitral gradient in patients with mitral stenosis: a simulta-</a></text>
<text top="224" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref22">neous catheterization and Doppler echocardiographic study. J Am</a></text>
<text top="237" left="90" width="124" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref22">Coll Cardiol 1994;24:152</a></text>
<text top="235" left="214" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref22">–8</a></text>
<text top="237" left="226" width="3" height="12" font="15">.</text>
<text top="251" left="70" width="15" height="12" font="15">24.</text>
<text top="251" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref23">Oh JK, Taliercio CP, Holmes DRJ, et al. Prediction of the severity</a></text>
<text top="264" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref23">of aortic stenosis by Doppler aortic valve area determination: pro-</a></text>
<text top="278" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref23">spective Doppler-catheterization correlation in 100 patients. J Am</a></text>
<text top="291" left="90" width="130" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref23">Coll Cardiol 1988;11:1227</a></text>
<text top="288" left="220" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref23">–34</a></text>
<text top="291" left="238" width="3" height="12" font="15">.</text>
<text top="305" left="70" width="15" height="12" font="15">25.</text>
<text top="305" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref24">Otto CM, Burwash IG, Legget ME, et al. Prospective study of</a></text>
<text top="318" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref24">asymptomatic valvular aortic stenosis. Clinical, echocardiographic,</a></text>
<text top="331" left="90" width="297" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref24">and exercise predictors of outcome. Circulation 1997;95:2262</a></text>
<text top="329" left="387" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref24">–70</a></text>
<text top="331" left="405" width="3" height="12" font="15">.</text>
<text top="345" left="70" width="15" height="12" font="15">26.</text>
<text top="345" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref25">Otto CM, Nishimura RA, Davis KB, et al. Doppler echocardio-</a></text>
<text top="358" left="91" width="35" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref25">graphic</a></text>
<text top="356" left="130" width="284" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref25">ﬁndings in adults with severe symptomatic valvular aortic</a></text>
<text top="372" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref25">stenosis. Balloon Valvuloplasty Registry Echocardiographers. Am J</a></text>
<text top="385" left="91" width="106" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref25">Cardiol 1991;68:1477</a></text>
<text top="382" left="196" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref25">–84</a></text>
<text top="385" left="214" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref25">.</a></text>
<text top="399" left="70" width="15" height="12" font="15">27.</text>
<text top="399" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref26">Otto CM, Pearlman AS, Comess KA, et al. Determination of the</a></text>
<text top="412" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref26">stenotic aortic valve area in adults using Doppler echocardiography.</a></text>
<text top="426" left="91" width="148" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref26">J Am Coll Cardiol 1986;7:509</a></text>
<text top="423" left="239" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref26">–17</a></text>
<text top="426" left="257" width="3" height="12" font="15">.</text>
<text top="439" left="70" width="15" height="12" font="15">28.</text>
<text top="439" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref27">Otto CM, Pearlman AS, Gardner CL. Hemodynamic progression</a></text>
<text top="452" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref27">of aortic stenosis in adults assessed by Doppler echocardiography.</a></text>
<text top="466" left="91" width="154" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref27">J Am Coll Cardiol 1989;13:545</a></text>
<text top="463" left="245" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref27">–50</a></text>
<text top="466" left="262" width="3" height="12" font="15">.</text>
<text top="479" left="70" width="15" height="12" font="15">29.</text>
<text top="479" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref28">Pellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622</a></text>
<text top="493" left="91" width="243" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref28">adults with asymptomatic, hemodynamically signi</a></text>
<text top="490" left="334" width="80" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref28">ﬁcant aortic ste-</a></text>
<text top="506" left="91" width="297" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref28">nosis during prolonged follow-up. Circulation 2005;111:3290</a></text>
<text top="504" left="387" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref28">–5</a></text>
<text top="506" left="399" width="3" height="12" font="15">.</text>
<text top="520" left="70" width="15" height="12" font="15">30.</text>
<text top="520" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref29">Zile MR, Gaasch WH, Carroll JD, et al. Chronic mitral regurgi-</a></text>
<text top="533" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref29">tation: predictive value of preoperative echocardiographic indexes of</a></text>
<text top="547" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref29">left ventricular function and wall stress. J Am Coll Cardiol 1984;3:</a></text>
<text top="560" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref29">235</a></text>
<text top="557" left="108" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref29">–42</a></text>
<text top="560" left="126" width="3" height="12" font="15">.</text>
<text top="574" left="70" width="15" height="12" font="15">31.</text>
<text top="574" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref30">Dujardin KS, Enriquez-Sarano M, Schaff HV, et al. Mortality and</a></text>
<text top="587" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref30">morbidity of aortic regurgitation in clinical practice. A long-term</a></text>
<text top="600" left="91" width="205" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref30">follow-up study. Circulation 1999;99:1851</a></text>
<text top="598" left="296" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref30">–7</a></text>
<text top="600" left="308" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref30">.</a></text>
<text top="614" left="70" width="15" height="12" font="15">32.</text>
<text top="614" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref31">Bonow RO, Lakatos E, Maron BJ, et al. Serial long-term assess-</a></text>
<text top="627" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref31">ment of the natural history of asymptomatic patients with chronic</a></text>
<text top="641" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref31">aortic regurgitation and normal left ventricular systolic function.</a></text>
<text top="654" left="91" width="123" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref31">Circulation 1991;84:1625</a></text>
<text top="652" left="214" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref31">–35</a></text>
<text top="654" left="232" width="3" height="12" font="15">.</text>
<text top="668" left="70" width="15" height="12" font="15">33.</text>
<text top="668" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref32">Enriquez-Sarano M, Basmadjian AJ, Rossi A, et al. Progression of</a></text>
<text top="681" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref32">mitral regurgitation: a prospective Doppler echocardiographic study.</a></text>
<text top="695" left="91" width="160" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref32">J Am Coll Cardiol 1999;34:1137</a></text>
<text top="692" left="251" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref32">–44</a></text>
<text top="695" left="268" width="3" height="12" font="15">.</text>
<text top="708" left="70" width="15" height="12" font="15">34.</text>
<text top="708" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref33">Gaasch WH, John RM, Aurigemma GP. Managing asymptomatic</a></text>
<text top="721" left="91" width="303" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref33">patients with chronic mitral regurgitation. Chest 1995;108:842</a></text>
<text top="719" left="394" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref33">–7</a></text>
<text top="721" left="406" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref33">.</a></text>
<text top="735" left="70" width="15" height="12" font="15">35.</text>
<text top="735" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref34">Lancellotti P, Rosenhek R, Pibarot P, et al. ESC Working Group</a></text>
<text top="748" left="91" width="200" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref34">on Valvular Heart Disease position paper</a></text>
<text top="746" left="291" width="123" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref34">–heart valve clinics: orga-</a></text>
<text top="762" left="91" width="297" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref34">nization, structure, and experiences. Eur Heart J 2013;34:1597</a></text>
<text top="759" left="387" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref34">–606</a></text>
<text top="762" left="411" width="3" height="12" font="15">.</text>
<text top="775" left="70" width="15" height="12" font="15">36.</text>
<text top="775" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref35">Otto CM. Doppler Echocardiographic evaluation of aortic and</a></text>
<text top="789" left="90" width="228" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref35">mitral stenoses. Echocardiography 1999;16:675</a></text>
<text top="786" left="318" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref35">–6</a></text>
<text top="789" left="330" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref35">.</a></text>
<text top="802" left="70" width="15" height="12" font="15">37.</text>
<text top="802" left="91" width="297" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref36">Otto CM. Timing of aortic valve surgery. Heart 2000;84:211</a></text>
<text top="799" left="388" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref36">–8</a></text>
<text top="802" left="400" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref36">.</a></text>
<text top="816" left="70" width="15" height="12" font="15">38.</text>
<text top="816" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref37">Otto CM, Salerno CT. Timing of surgery in asymptomatic mitral</a></text>
<text top="829" left="91" width="209" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref37">regurgitation. N Engl J Med 2005;352:928</a></text>
<text top="826" left="299" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref37">–9</a></text>
<text top="829" left="311" width="3" height="12" font="15">.</text>
<text top="843" left="70" width="15" height="12" font="15">39.</text>
<text top="843" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref38">Rosenhek R, Rader F, Klaar U, et al. Outcome of watchful waiting</a></text>
<text top="856" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref38">in asymptomatic severe mitral regurgitation. Circulation 2006;113:</a></text>
<text top="869" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref38">2238</a></text>
<text top="867" left="114" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref38">–44</a></text>
<text top="869" left="132" width="3" height="12" font="15">.</text>
<text top="883" left="70" width="15" height="12" font="15">40.</text>
<text top="883" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref39">Carabello BA, Crawford FA Jr. Valvular heart disease. N Engl J</a></text>
<text top="896" left="91" width="86" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref39">Med 1997;337:32</a></text>
<text top="894" left="177" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref39">–41</a></text>
<text top="896" left="195" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref39">.</a></text>
<text top="910" left="70" width="15" height="12" font="15">41.</text>
<text top="910" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref40">Rosenhek R, Iung B, Tornos P, et al. ESC Working Group on</a></text>
<text top="923" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref40">Valvular Heart Disease position paper: assessing the risk of in-</a></text>
<text top="937" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref40">terventions in patients with valvular heart disease. Eur Heart J 2012;</a></text>
<text top="950" left="91" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref40">33:822</a></text>
<text top="947" left="123" width="73" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref40">–8, 828a, 828b</a></text>
<text top="950" left="196" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref40">.</a></text>
<text top="964" left="70" width="15" height="12" font="15">42.</text>
<text top="964" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref41">Nishimura RA, Carabello BA. Hemodynamics in the cardiac</a></text>
<text top="977" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref41">catheterization laboratory of the 21st century. Circulation 2012;125:</a></text>
<text top="990" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref41">2138</a></text>
<text top="988" left="114" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref41">–50</a></text>
<text top="990" left="132" width="3" height="12" font="15">.</text>
<text top="1004" left="70" width="15" height="12" font="15">43.</text>
<text top="1004" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref42">Nishimura RA, Grantham JA, Connolly HM, et al. Low-output,</a></text>
<text top="1017" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref42">low-gradient aortic stenosis in patients with depressed left ventric-</a></text>
<text top="1031" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref42">ular systolic function: the clinical utility of the dobutamine challenge</a></text>
<text top="1044" left="91" width="283" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref42">in the catheterization laboratory. Circulation 2002;106:809</a></text>
<text top="1042" left="374" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref42">–13</a></text>
<text top="1044" left="392" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref42">.</a></text>
<text top="1058" left="70" width="15" height="12" font="15">44.</text>
<text top="1058" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref43">Aviles RJ, Nishimura RA, Pellikka PA, et al. Utility of stress</a></text>
<text top="1071" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref43">Doppler echocardiography in patients undergoing percutaneous</a></text>
<text top="1085" left="91" width="303" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref43">mitral balloon valvotomy. J Am Soc Echocardiogr 2001;14:676</a></text>
<text top="1082" left="393" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref43">–81</a></text>
<text top="1085" left="411" width="3" height="12" font="15">.</text>
<text top="103" left="455" width="15" height="12" font="15">45.</text>
<text top="103" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref44">Otto CM, Pearlman AS, Kraft CD, et al. Physiologic changes with</a></text>
<text top="116" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref44">maximal exercise in asymptomatic valvular aortic stenosis assessed by</a></text>
<text top="130" left="476" width="294" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref44">Doppler echocardiography. J Am Coll Cardiol 1992;20:1160</a></text>
<text top="127" left="770" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref44">–7</a></text>
<text top="130" left="782" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref44">.</a></text>
<text top="143" left="455" width="15" height="12" font="15">46.</text>
<text top="143" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref45">Lancellotti P, Lebois F, Simon M, et al. Prognostic importance of</a></text>
<text top="157" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref45">quantitative exercise Doppler echocardiography in asymptomatic</a></text>
<text top="170" left="476" width="241" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref45">valvular aortic stenosis. Circulation 2005;112:I377</a></text>
<text top="167" left="717" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref45">–82</a></text>
<text top="170" left="735" width="3" height="12" font="15">.</text>
<text top="184" left="455" width="15" height="12" font="15">47.</text>
<text top="184" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref46">Marechaux S, Hachicha Z, Bellouin A, et al. Usefulness of exercise-</a></text>
<text top="197" left="476" width="181" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref46">stress echocardiography for risk strati</a></text>
<text top="194" left="657" width="143" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref46">ﬁcation of true asymptomatic</a></text>
<text top="210" left="476" width="294" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref46">patients with aortic valve stenosis. Eur Heart J 2010;31:1390</a></text>
<text top="208" left="770" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref46">–7</a></text>
<text top="210" left="782" width="3" height="12" font="15">.</text>
<text top="224" left="455" width="15" height="12" font="15">48.</text>
<text top="224" left="476" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref47">Messika-Zeitoun D, Johnson BD, Nkomo V, et al. Cardiopulmo-</a></text>
<text top="237" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref47">nary exercise testing determination of functional capacity in mitral</a></text>
<text top="251" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref47">regurgitation: physiologic and outcome implications. J Am Coll</a></text>
<text top="264" left="476" width="106" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref47">Cardiol 2006;47:2521</a></text>
<text top="261" left="581" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref47">–7</a></text>
<text top="264" left="593" width="3" height="12" font="15">.</text>
<text top="278" left="455" width="15" height="12" font="15">49.</text>
<text top="278" left="476" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref48">Pina IL, Apstein CS, Balady GJ, et al. Exercise and heart failure: a</a></text>
<text top="291" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref48">statement from the American Heart Association Committee on</a></text>
<text top="305" left="476" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref48">Exercise, Rehabilitation, and Prevention. Circulation 2003;107:</a></text>
<text top="318" left="476" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref48">1210</a></text>
<text top="315" left="500" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref48">–25</a></text>
<text top="318" left="518" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref48">.</a></text>
<text top="331" left="455" width="15" height="12" font="15">50.</text>
<text top="331" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref49">Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of</a></text>
<text top="345" left="476" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref49">rheumatic fever and diagnosis and treatment of acute Strepto-</a></text>
<text top="358" left="476" width="146" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref49">coccal pharyngitis: a scienti</a></text>
<text top="356" left="623" width="177" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref49">ﬁc statement from the American</a></text>
<text top="372" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref49">Heart Association Rheumatic Fever, Endocarditis, and Kawasaki</a></text>
<text top="385" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref49">Disease Committee of the Council on Cardiovascular Disease in</a></text>
<text top="399" left="476" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref49">the Young, the Interdisciplinary Council on Functional Genomics</a></text>
<text top="412" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref49">and Translational Biology, and the Interdisciplinary Council</a></text>
<text top="426" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref49">on Quality of Care and Outcomes Research. Circulation 2009;</a></text>
<text top="439" left="476" width="46" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref49">119:1541</a></text>
<text top="436" left="522" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref49">–51</a></text>
<text top="439" left="541" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref49">.</a></text>
<text top="452" left="455" width="15" height="12" font="15">51.</text>
<text top="452" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref50">Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective</a></text>
<text top="466" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref50">endocarditis: guidelines from the American Heart Association: a</a></text>
<text top="479" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref50">guideline from the American Heart Association Rheumatic Fever,</a></text>
<text top="493" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref50">Endocarditis, and Kawasaki Disease Committee, Council on Car-</a></text>
<text top="506" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref50">diovascular Disease in the Young, and the Council on Clinical</a></text>
<text top="520" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref50">Cardiology, Council on Cardiovascular Surgery and Anesthesia, and</a></text>
<text top="533" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref50">the Quality of Care and Outcomes Research Interdisciplinary</a></text>
<text top="547" left="476" width="215" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref50">Working Group. Circulation 2007;116:1736</a></text>
<text top="544" left="691" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref50">–54</a></text>
<text top="547" left="709" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref50">.</a></text>
<text top="560" left="455" width="15" height="12" font="15">52.</text>
<text top="560" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref51">Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention,</a></text>
<text top="574" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref51">diagnosis, and treatment of infective endocarditis (new version</a></text>
<text top="587" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref51">2009): the Task Force on the Prevention, Diagnosis, and Treatment</a></text>
<text top="600" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref51">of Infective Endocarditis of the European Society of Cardiology</a></text>
<text top="614" left="476" width="165" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref51">(ESC). Eur Heart J 2009;30:2369</a></text>
<text top="611" left="641" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref51">–413</a></text>
<text top="614" left="665" width="3" height="12" font="15">.</text>
<text top="627" left="455" width="15" height="12" font="15">53.</text>
<text top="627" left="476" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref52">Gopalakrishnan PP, Shukla SK, Tak T. Infective endocarditis:</a></text>
<text top="641" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref52">rationale for revised guidelines for antibiotic prophylaxis. Clin Med</a></text>
<text top="654" left="476" width="69" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref52">Res 2009;7:63</a></text>
<text top="652" left="545" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref52">–8</a></text>
<text top="654" left="557" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref52">.</a></text>
<text top="668" left="455" width="15" height="12" font="15">54.</text>
<text top="668" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref53">Horstkotte D. Contribution for choosing the optimal prophylaxis of</a></text>
<text top="681" left="476" width="214" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref53">bacterial endocarditis. Eur Heart J 1987:379</a></text>
<text top="678" left="690" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref53">–81</a></text>
<text top="681" left="708" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref53">.</a></text>
<text top="695" left="455" width="15" height="12" font="15">55.</text>
<text top="695" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref54">Strom BL, Abrutyn E, Berlin JA, et al. Dental and cardiac risk</a></text>
<text top="708" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref54">factors for infective endocarditis. A population-based, case-control</a></text>
<text top="721" left="476" width="184" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref54">study. Ann Intern Med 1998;129:761</a></text>
<text top="719" left="660" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref54">–9</a></text>
<text top="721" left="672" width="3" height="12" font="15">.</text>
<text top="735" left="455" width="15" height="12" font="15">56.</text>
<text top="735" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref55">Duval X, Alla F, Hoen B, et al. Estimated risk of endocarditis in</a></text>
<text top="748" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref55">adults with predisposing cardiac conditions undergoing dental pro-</a></text>
<text top="762" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref55">cedures with or without antibiotic prophylaxis. Clin Infect Dis 2006;</a></text>
<text top="775" left="476" width="38" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref55">42:e102</a></text>
<text top="773" left="514" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref55">–7</a></text>
<text top="775" left="526" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref55">.</a></text>
<text top="789" left="455" width="15" height="12" font="15">57.</text>
<text top="789" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref56">Oliver R, Roberts GJ, Hooper L, et al. Antibiotics for the pro-</a></text>
<text top="802" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref56">phylaxis of bacterial endocarditis in dentistry. Cochrane Database</a></text>
<text top="816" left="476" width="127" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref56">Syst Rev 2008;CD003813</a></text>
<text top="816" left="603" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref56">.</a></text>
<text top="829" left="455" width="15" height="12" font="15">58.</text>
<text top="829" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref57">Desimone DC, Tleyjeh IM, Correa de Sa DD, et al. Incidence of</a></text>
<text top="843" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref57">infective endocarditis caused by viridans group streptococci before</a></text>
<text top="856" left="476" width="317" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref57">and after publication of the 2007 American Heart Association</a></text>
<text top="853" left="793" width="6" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref57">’s</a></text>
<text top="869" left="476" width="288" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref57">endocarditis prevention guidelines. Circulation 2012;126:60</a></text>
<text top="867" left="764" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref57">–4</a></text>
<text top="869" left="775" width="3" height="12" font="15">.</text>
<text top="883" left="455" width="344" height="12" font="15">59. Prevention of infective (bacterial) endocarditis. Wallet card. 2008.</text>
<text top="896" left="476" width="70" height="12" font="15">Available at:</text>
<text top="896" left="556" width="244" height="12" font="22"><a href="http://www.heart.org/idc/groups/heart-public/@wcm/@hcm/documents/downloadable/ucm_307684.pdf">http://www.heart.org/idc/groups/heart-public/@</a></text>
<text top="910" left="476" width="268" height="12" font="22"><a href="http://www.heart.org/idc/groups/heart-public/@wcm/@hcm/documents/downloadable/ucm_307684.pdf">wcm/@hcm/documents/downloadable/ucm_307684.pdf</a></text>
<text top="910" left="744" width="55" height="12" font="15">. Accessed</text>
<text top="923" left="476" width="92" height="12" font="15">February 24, 2014.</text>
<text top="937" left="455" width="15" height="12" font="15">60.</text>
<text top="937" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref58">Guarner-Argente C, Shah P, Buchner A, et al. Use of antimicrobials</a></text>
<text top="950" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref58">for EUS-guided FNA of pancreatic cysts: a retrospective, compar-</a></text>
<text top="964" left="476" width="224" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref58">ative analysis. Gastrointest Endosc 2011;74:81</a></text>
<text top="961" left="700" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref58">–6</a></text>
<text top="964" left="712" width="3" height="12" font="15">.</text>
<text top="977" left="455" width="15" height="12" font="15">61.</text>
<text top="977" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref59">Shull HJ Jr., Greene BM, Allen SD, et al. Bacteremia with upper</a></text>
<text top="990" left="476" width="278" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref59">gastrointestinal endoscopy. Ann Intern Med 1975;83:212</a></text>
<text top="988" left="754" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref59">–4</a></text>
<text top="990" left="766" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref59">.</a></text>
<text top="1004" left="455" width="15" height="12" font="15">62.</text>
<text top="1004" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref60">Botoman VA, Surawicz CM. Bacteremia with gastrointestinal</a></text>
<text top="1017" left="476" width="276" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref60">endoscopic procedures. Gastrointest Endosc 1986;32:342</a></text>
<text top="1015" left="752" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref60">–6</a></text>
<text top="1017" left="764" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref60">.</a></text>
<text top="1031" left="455" width="15" height="12" font="15">63.</text>
<text top="1031" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref61">Low DE, Shoenut JP, Kennedy JK, et al. Prospective assessment of</a></text>
<text top="1044" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref61">risk of bacteremia with colonoscopy and polypectomy. Dig Dis Sci</a></text>
<text top="1058" left="476" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref61">1987;32:1239</a></text>
<text top="1055" left="542" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref61">–43</a></text>
<text top="1058" left="560" width="3" height="12" font="15">.</text>
<text top="1071" left="455" width="15" height="12" font="15">64.</text>
<text top="1071" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref62">Low DE, Shoenut JP, Kennedy JK, et al. Risk of bacteremia with</a></text>
<text top="1085" left="476" width="254" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref62">endoscopic sphincterotomy. Can J Surg 1987;30:421</a></text>
<text top="1082" left="730" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref62">–3</a></text>
<text top="1085" left="742" width="3" height="12" font="15">.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e157</text>
</page>
<page number="102" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="70" width="15" height="12" font="15">65.</text>
<text top="103" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref63">Raines DR, Branche WC, Anderson DL, et al. The occurrence</a></text>
<text top="116" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref63">of bacteremia after esophageal dilation. Gastrointest Endosc 1975;</a></text>
<text top="130" left="90" width="27" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref63">22:86</a></text>
<text top="127" left="117" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref63">–7</a></text>
<text top="130" left="129" width="3" height="12" font="15">.</text>
<text top="143" left="70" width="15" height="12" font="15">66.</text>
<text top="143" left="90" width="74" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref64">Welsh JD, Grif</a></text>
<text top="140" left="165" width="249" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref64">ﬁths WJ, McKee J, et al. Bacteremia associated with</a></text>
<text top="157" left="90" width="263" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref64">esophageal dilatation. J Clin Gastroenterol 1983;5:109</a></text>
<text top="154" left="353" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref64">–12</a></text>
<text top="157" left="371" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref64">.</a></text>
<text top="170" left="70" width="15" height="12" font="15">67.</text>
<text top="170" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref65">Yin TP, Ellis R, Dellipiani AW. The incidence of bacteremia after</a></text>
<text top="183" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref65">outpatient Hurst bougienage in the management of benign oeso-</a></text>
<text top="197" left="90" width="206" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref65">phageal strictures. Endoscopy 1983;31:265</a></text>
<text top="194" left="296" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref65">–7</a></text>
<text top="197" left="308" width="3" height="12" font="15">.</text>
<text top="210" left="70" width="15" height="12" font="15">68.</text>
<text top="210" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref66">Sugrue D, Blake S, Troy P, et al. Antibiotic prophylaxis against</a></text>
<text top="224" left="91" width="202" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref66">infective endocarditis after normal delivery</a></text>
<text top="221" left="293" width="121" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref66">–is it necessary? Br Heart</a></text>
<text top="237" left="91" width="68" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref66">J 1980;44:499</a></text>
<text top="235" left="158" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref66">–502</a></text>
<text top="237" left="182" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref66">.</a></text>
<text top="251" left="70" width="15" height="12" font="15">69.</text>
<text top="251" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref67">Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial</a></text>
<text top="264" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref67">endocarditis. Recommendations by the American Heart Associa-</a></text>
<text top="278" left="91" width="143" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref67">tion. Circulation 1997;96:358</a></text>
<text top="275" left="234" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref67">–66</a></text>
<text top="278" left="251" width="3" height="12" font="15">.</text>
<text top="291" left="70" width="15" height="12" font="15">70.</text>
<text top="291" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref68">Nelson DB. Infectious disease complications of GI endoscopy: part</a></text>
<text top="305" left="91" width="286" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref68">I, endogenous infections. Gastrointest Endosc 2003;57:546</a></text>
<text top="302" left="377" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref68">–56</a></text>
<text top="305" left="395" width="3" height="12" font="15">.</text>
<text top="318" left="70" width="15" height="12" font="15">71.</text>
<text top="318" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref69">Wright TI, Baddour LM, Berbari EF, et al. Antibiotic prophylaxis</a></text>
<text top="331" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref69">in dermatologic surgery: advisory statement 2008. J Am Acad</a></text>
<text top="345" left="91" width="109" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref69">Dermatol 2008;59:464</a></text>
<text top="342" left="200" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref69">–73</a></text>
<text top="345" left="218" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref69">.</a></text>
<text top="358" left="70" width="15" height="12" font="15">72.</text>
<text top="358" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref70">Wolf JS Jr., Bennett CJ, Dmochowski RR, et al. Best practice policy</a></text>
<text top="372" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref70">statement on urologic surgery antimicrobial prophylaxis. J Urol</a></text>
<text top="385" left="91" width="72" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref70">2008;179:1379</a></text>
<text top="382" left="162" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref70">–90</a></text>
<text top="385" left="180" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref70">.</a></text>
<text top="399" left="70" width="15" height="12" font="15">73.</text>
<text top="399" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref71">Banerjee S, Shen B, Baron TH, et al. Antibiotic prophylaxis for GI</a></text>
<text top="412" left="91" width="218" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref71">endoscopy. Gastrointest Endosc 2008;67:791</a></text>
<text top="409" left="308" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref71">–8</a></text>
<text top="412" left="320" width="3" height="12" font="15">.</text>
<text top="426" left="70" width="15" height="12" font="15">74.</text>
<text top="426" left="91" width="10" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref72">O</a></text>
<text top="423" left="100" width="314" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref72">’Brien SM, Shahian DM, Filardo G, et al. The Society of</a></text>
<text top="439" left="91" width="295" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref72">Thoracic Surgeons 2008 cardiac surgery risk models: part 2</a></text>
<text top="436" left="385" width="29" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref72">–-iso-</a></text>
<text top="452" left="91" width="244" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref72">lated valve surgery. Ann Thorac Surg 2009;88:S23</a></text>
<text top="450" left="335" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref72">–42</a></text>
<text top="452" left="353" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref72">.</a></text>
<text top="466" left="70" width="15" height="12" font="15">75.</text>
<text top="466" left="91" width="87" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref73">Shahian DM, O</a></text>
<text top="463" left="177" width="237" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref73">’Brien SM, Filardo G, et al. The Society of</a></text>
<text top="479" left="91" width="290" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref73">Thoracic Surgeons 2008 cardiac surgery risk models: part 3</a></text>
<text top="477" left="380" width="34" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref73">–-valve</a></text>
<text top="493" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref73">plus coronary artery bypass grafting surgery. Ann Thorac Surg 2009;</a></text>
<text top="506" left="91" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref73">88:S43</a></text>
<text top="504" left="124" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref73">–62</a></text>
<text top="506" left="142" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref73">.</a></text>
<text top="520" left="70" width="15" height="12" font="15">76.</text>
<text top="520" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref74">Dewey TM, Brown D, Ryan WH, et al. Reliability of risk algo-</a></text>
<text top="533" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref74">rithms in predicting early and late operative outcomes in high-risk</a></text>
<text top="547" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref74">patients undergoing aortic valve replacement. J Thorac Cardiovasc</a></text>
<text top="560" left="91" width="92" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref74">Surg 2008;135:180</a></text>
<text top="557" left="182" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref74">–7</a></text>
<text top="560" left="194" width="3" height="12" font="15">.</text>
<text top="574" left="70" width="15" height="12" font="15">77.</text>
<text top="574" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref75">Lee DH, Buth KJ, Martin BJ, et al. Frail patients are at increased</a></text>
<text top="587" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref75">risk for mortality and prolonged institutional care after cardiac sur-</a></text>
<text top="600" left="91" width="150" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref75">gery. Circulation 2010;121:973</a></text>
<text top="598" left="240" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref75">–8</a></text>
<text top="600" left="252" width="3" height="12" font="15">.</text>
<text top="614" left="70" width="15" height="12" font="15">78.</text>
<text top="614" left="91" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref76">Thourani VH, Chowdhury R, Gunter RL, et al. The impact</a></text>
<text top="627" left="91" width="38" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref76">of speci</a></text>
<text top="625" left="129" width="285" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref76">ﬁc preoperative organ dysfunction in patients undergoing</a></text>
<text top="641" left="91" width="271" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref76">aortic valve replacement. Ann Thorac Surg 2013;95:838</a></text>
<text top="638" left="362" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref76">–45</a></text>
<text top="641" left="379" width="3" height="12" font="15">.</text>
<text top="654" left="70" width="15" height="12" font="15">79.</text>
<text top="654" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref77">Holmes DR Jr., Mack MJ, Kaul S, et al. 2012 ACCF/AATS/</a></text>
<text top="668" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref77">SCAI/STS expert consensus document on transcatheter aortic valve</a></text>
<text top="681" left="90" width="225" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref77">replacement. J Am Coll Cardiol 2012;59:1200</a></text>
<text top="678" left="315" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref77">–54</a></text>
<text top="681" left="333" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref77">.</a></text>
<text top="695" left="70" width="15" height="12" font="15">80.</text>
<text top="695" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref78">Holmes DR Jr., Mohr F, Hamm CW, et al. Venn diagrams in</a></text>
<text top="708" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref78">cardiovascular disease: the Heart Team concept. Ann Thorac Surg</a></text>
<text top="721" left="90" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref78">2013;95:389</a></text>
<text top="719" left="150" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref78">–91</a></text>
<text top="721" left="168" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref78">.</a></text>
<text top="735" left="70" width="15" height="12" font="15">81.</text>
<text top="735" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref79">Holmes DR Jr., Rich JB, Zoghbi WA, et al. The heart team of</a></text>
<text top="748" left="90" width="250" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref79">cardiovascular care. J Am Coll Cardiol 2013;61:903</a></text>
<text top="746" left="340" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref79">–7</a></text>
<text top="748" left="352" width="3" height="12" font="15">.</text>
<text top="762" left="70" width="15" height="12" font="15">82.</text>
<text top="762" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref80">King SBI, Barnhart HX, Kosinski AS, et al. Angioplasty or surgery</a></text>
<text top="775" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref80">for multivessel coronary artery disease: comparison of eligible registry</a></text>
<text top="789" left="90" width="246" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref80">and randomized patients in the EAST trial and in</a></text>
<text top="786" left="337" width="77" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref80">ﬂuence of treat-</a></text>
<text top="802" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref80">ment selection on outcomes. Emory Angioplasty versus Surgery</a></text>
<text top="816" left="90" width="230" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref80">Trial Investigators. Am J Cardiol 1997;79:1453</a></text>
<text top="813" left="320" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref80">–9</a></text>
<text top="816" left="332" width="3" height="12" font="15">.</text>
<text top="829" left="70" width="15" height="12" font="15">83.</text>
<text top="829" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref81">Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/</a></text>
<text top="843" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref81">SCAI guideline for percutaneous coronary intervention. A report of</a></text>
<text top="856" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref81">the American College of Cardiology Foundation/American Heart</a></text>
<text top="869" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref81">Association Task Force on Practice Guidelines and the Society for</a></text>
<text top="883" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref81">Cardiovascular Angiography and Interventions. J Am Coll Cardiol</a></text>
<text top="896" left="90" width="59" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref81">2011;58:e44</a></text>
<text top="894" left="149" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref81">–122</a></text>
<text top="896" left="173" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref81">.</a></text>
<text top="910" left="70" width="15" height="12" font="15">84.</text>
<text top="910" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref82">Feit F, Brooks MM, Sopko G, et al. Long-term clinical outcome in</a></text>
<text top="923" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref82">the Bypass Angioplasty Revascularization Investigation Registry:</a></text>
<text top="937" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref82">comparison with the randomized trial. BARI Investigators. Circu-</a></text>
<text top="950" left="90" width="102" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref82">lation 2000;101:2795</a></text>
<text top="947" left="193" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref82">–802</a></text>
<text top="950" left="217" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref82">.</a></text>
<text top="964" left="70" width="15" height="12" font="15">85.</text>
<text top="964" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref83">Chambers C, Lloyd G, Rimmington HM. Multidisciplinary valve</a></text>
<text top="977" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref83">clinics with devolved surveillence: a two year audit. Br J Cardiol</a></text>
<text top="990" left="90" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref83">2011;18:231</a></text>
<text top="988" left="150" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref83">–2</a></text>
<text top="990" left="162" width="3" height="12" font="15">.</text>
<text top="1004" left="70" width="15" height="12" font="15">86.</text>
<text top="1004" left="90" width="105" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref84">Bolling SF, Li S, O</a></text>
<text top="1001" left="195" width="219" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref84">’Brien SM, et al. Predictors of mitral valve</a></text>
<text top="1017" left="90" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref84">repair: clinical and surgeon factors. Ann Thorac Surg 2010;90:</a></text>
<text top="1031" left="90" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref84">1904</a></text>
<text top="1028" left="114" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref84">–11</a></text>
<text top="1031" left="132" width="3" height="12" font="15">.</text>
<text top="1044" left="70" width="15" height="12" font="15">87.</text>
<text top="1044" left="90" width="136" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref85">Gammie JS, Sheng S, Grif</a></text>
<text top="1042" left="227" width="187" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref85">ﬁth BP, et al. Trends in mitral valve</a></text>
<text top="1058" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref85">surgery in the United States: results from the Society of Thoracic</a></text>
<text top="1071" left="90" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref85">Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg 2009;</a></text>
<text top="1085" left="90" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref85">87:1431</a></text>
<text top="1082" left="129" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref85">–7</a></text>
<text top="1085" left="141" width="3" height="12" font="15">.</text>
<text top="103" left="455" width="15" height="12" font="15">88.</text>
<text top="103" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref86">Castillo JG, Anyanwu AC, Fuster V, et al. A near 100% repair rate</a></text>
<text top="116" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref86">for mitral valve prolapse is achievable in a reference center: impli-</a></text>
<text top="130" left="476" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref86">cations for future guidelines. J Thorac Cardiovasc Surg 2012;144:</a></text>
<text top="143" left="476" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref86">308</a></text>
<text top="140" left="494" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref86">–12</a></text>
<text top="143" left="512" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref86">.</a></text>
<text top="157" left="455" width="15" height="12" font="15">89.</text>
<text top="157" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref87">Galan A, Zoghbi WA, Quinones MA. Determination of severity of</a></text>
<text top="170" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref87">valvular aortic stenosis by Doppler echocardiography and relation of</a></text>
<text top="181" left="476" width="324" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref87">ﬁndings to clinical outcome and agreement with hemodynamic</a></text>
<text top="197" left="476" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref87">measurements determined at cardiac catheterization. Am J Cardiol</a></text>
<text top="210" left="476" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref87">1991;67:1007</a></text>
<text top="208" left="542" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref87">–12</a></text>
<text top="210" left="560" width="3" height="12" font="15">.</text>
<text top="224" left="455" width="15" height="12" font="15">90.</text>
<text top="224" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref88">Zoghbi WA, Farmer KL, Soto JG, et al. Accurate noninvasive</a></text>
<text top="237" left="476" width="30" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref88">quanti</a></text>
<text top="235" left="506" width="294" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref88">ﬁcation of stenotic aortic valve area by Doppler echocardi-</a></text>
<text top="251" left="476" width="162" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref88">ography. Circulation 1986;73:452</a></text>
<text top="248" left="638" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref88">–9</a></text>
<text top="251" left="650" width="3" height="12" font="15">.</text>
<text top="264" left="455" width="15" height="12" font="15">91.</text>
<text top="264" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref89">Otto CM, Pearlman AS. Doppler echocardiography in adults with</a></text>
<text top="278" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref89">symptomatic aortic stenosis. Diagnostic utility and cost-effective-</a></text>
<text top="291" left="476" width="187" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref89">ness. Arch Intern Med 1988;148:2553</a></text>
<text top="288" left="663" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref89">–60</a></text>
<text top="291" left="680" width="3" height="12" font="15">.</text>
<text top="305" left="455" width="15" height="12" font="15">92.</text>
<text top="305" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref90">Rosenhek R, Klaar U, Schemper M, et al. Mild and moderate aortic</a></text>
<text top="318" left="476" width="184" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref90">stenosis. Natural history and risk strati</a></text>
<text top="315" left="660" width="140" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref90">ﬁcation by echocardiography.</a></text>
<text top="331" left="476" width="121" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref90">Eur Heart J 2004;25:199</a></text>
<text top="329" left="597" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref90">–205</a></text>
<text top="331" left="621" width="3" height="12" font="15">.</text>
<text top="345" left="455" width="15" height="12" font="15">93.</text>
<text top="345" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref91">Rosenhek R. Arotic stenosis: disease severity, progression, timing of</a></text>
<text top="358" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref91">intervention and role in monitoring transcatheter valve implanation.</a></text>
<text top="372" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref91">In: Otto CM, editor. The Practice of Clinical Echocardiography.</a></text>
<text top="385" left="476" width="226" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref91">Philadelphia, PA: Elsevier/Saunders; 2012:425</a></text>
<text top="382" left="701" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref91">–49</a></text>
<text top="385" left="719" width="3" height="12" font="15">.</text>
<text top="399" left="455" width="15" height="12" font="15">94.</text>
<text top="399" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref92">Stewart RA, Kerr AJ, Whalley GA, et al. Left ventricular systolic and</a></text>
<text top="412" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref92">diastolic function assessed by tissue Doppler imaging and outcome in</a></text>
<text top="426" left="476" width="269" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref92">asymptomatic aortic stenosis. Eur Heart J 2010;31:2216</a></text>
<text top="423" left="745" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref92">–22</a></text>
<text top="426" left="762" width="3" height="12" font="15">.</text>
<text top="439" left="455" width="15" height="12" font="15">95.</text>
<text top="439" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref93">Lin SS, Roger VL, Pascoe R, et al. Dobutamine stress Doppler</a></text>
<text top="452" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref93">hemodynamics in patients with aortic stenosis: feasibility, safety, and</a></text>
<text top="466" left="476" width="235" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref93">surgical correlations. Am Heart J 1998;136:1010</a></text>
<text top="463" left="711" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref93">–6</a></text>
<text top="466" left="723" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref93">.</a></text>
<text top="479" left="455" width="15" height="12" font="15">96.</text>
<text top="479" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref94">Monin JL, Monchi M, Gest V, et al. Aortic stenosis with severe left</a></text>
<text top="493" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref94">ventricular dysfunction and low transvalvular pressure gradients: risk</a></text>
<text top="506" left="476" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref94">strati</a></text>
<text top="504" left="500" width="300" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref94">ﬁcation by low-dose dobutamine echocardiography. J Am Coll</a></text>
<text top="520" left="476" width="106" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref94">Cardiol 2001;37:2101</a></text>
<text top="517" left="581" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref94">–7</a></text>
<text top="520" left="593" width="3" height="12" font="15">.</text>
<text top="533" left="455" width="15" height="12" font="15">97.</text>
<text top="533" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref95">Clavel MA, Fuchs C, Burwash IG, et al. Predictors of outcomes in</a></text>
<text top="547" left="476" width="22" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref95">low-</a></text>
<text top="544" left="498" width="302" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref95">ﬂow, low-gradient aortic stenosis: results of the multicenter</a></text>
<text top="560" left="476" width="208" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref95">TOPAS Study. Circulation 2008;118:S234</a></text>
<text top="557" left="684" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref95">–42</a></text>
<text top="560" left="702" width="3" height="12" font="15">.</text>
<text top="574" left="455" width="15" height="12" font="15">98.</text>
<text top="574" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref96">Clavel MA, Webb JG, Rodes-Cabau J, et al. Comparison between</a></text>
<text top="587" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref96">transcatheter and surgical prosthetic valve implantation in patients</a></text>
<text top="600" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref96">with severe aortic stenosis and reduced left ventricular ejection</a></text>
<text top="614" left="476" width="172" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref96">fraction. Circulation 2010;122:1928</a></text>
<text top="611" left="648" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref96">–36</a></text>
<text top="614" left="666" width="3" height="12" font="15">.</text>
<text top="627" left="455" width="15" height="12" font="15">99.</text>
<text top="627" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref97">deFilippi CR, Willett DL, Brickner ME, et al. Usefulness of</a></text>
<text top="641" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref97">dobutamine echocardiography in distinguishing severe from non-</a></text>
<text top="654" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref97">severe valvular aortic stenosis in patients with depressed left ven-</a></text>
<text top="668" left="476" width="324" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref97">tricular function and low transvalvular gradients. Am J Cardiol 1995;</a></text>
<text top="681" left="476" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref97">75:191</a></text>
<text top="678" left="509" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref97">–4</a></text>
<text top="681" left="521" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref97">.</a></text>
<text top="695" left="450" width="21" height="12" font="15">100.</text>
<text top="695" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref98">Blais C, Burwash IG, Mundigler G, et al. Projected valve area at</a></text>
<text top="708" left="477" width="34" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref98">normal</a></text>
<text top="705" left="516" width="284" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref98">ﬂow rate improves the assessment of stenosis severity in</a></text>
<text top="721" left="477" width="87" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref98">patients with low-</a></text>
<text top="719" left="563" width="236" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref98">ﬂow, low-gradient aortic stenosis: the multicenter</a></text>
<text top="735" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref98">TOPAS (Truly or Pseudo-Severe Aortic Stenosis) study. Circula-</a></text>
<text top="748" left="477" width="89" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref98">tion 2006;113:711</a></text>
<text top="746" left="565" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref98">–21</a></text>
<text top="748" left="583" width="3" height="12" font="15">.</text>
<text top="762" left="450" width="21" height="12" font="15">101.</text>
<text top="762" left="477" width="158" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref99">Pibarot P, Dumesnil JG. Low-</a></text>
<text top="759" left="635" width="165" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref99">ﬂow, low-gradient aortic stenosis</a></text>
<text top="775" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref99">with normal and depressed left ventricular ejection fraction. J Am</a></text>
<text top="789" left="477" width="130" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref99">Coll Cardiol 2012;60:1845</a></text>
<text top="786" left="607" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref99">–53</a></text>
<text top="789" left="625" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref99">.</a></text>
<text top="802" left="450" width="21" height="12" font="15">102.</text>
<text top="802" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref100">Nistri S, Faggiano P, Olivotto I, et al. Hemodynamic progression</a></text>
<text top="816" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref100">and outcome of asymptomatic aortic stenosis in primary care. Am J</a></text>
<text top="829" left="477" width="106" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref100">Cardiol 2012;109:718</a></text>
<text top="826" left="582" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref100">–23</a></text>
<text top="829" left="600" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref100">.</a></text>
<text top="843" left="450" width="21" height="12" font="15">103.</text>
<text top="843" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref101">Kurtz CE, Otto CM. Aortic stenosis: clinical aspects of diagnosis</a></text>
<text top="856" left="477" width="298" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref101">and management, with 10 illustrative case reports from a 25</a></text>
<text top="853" left="775" width="25" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref101">–year</a></text>
<text top="869" left="477" width="224" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref101">experience. Medicine (Baltimore) 2010;89:349</a></text>
<text top="867" left="700" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref101">–79</a></text>
<text top="869" left="718" width="3" height="12" font="15">.</text>
<text top="883" left="450" width="21" height="12" font="15">104.</text>
<text top="883" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref102">Brener SJ, Duffy CI, Thomas JD, et al. Progression of aortic ste-</a></text>
<text top="896" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref102">nosis in 394 patients: relation to changes in myocardial and mitral</a></text>
<text top="910" left="477" width="243" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref102">valve dysfunction. J Am Coll Cardiol 1995;25:305</a></text>
<text top="907" left="720" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref102">–10</a></text>
<text top="910" left="738" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref102">.</a></text>
<text top="923" left="450" width="21" height="12" font="15">105.</text>
<text top="923" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref103">Roger VL, Tajik AJ, Bailey KR, et al. Progression of aortic stenosis</a></text>
<text top="937" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref103">in adults: new appraisal using Doppler echocardiography. Am Heart</a></text>
<text top="950" left="477" width="73" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref103">J 1990;119:331</a></text>
<text top="947" left="550" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref103">–8</a></text>
<text top="950" left="562" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref103">.</a></text>
<text top="964" left="450" width="21" height="12" font="15">106.</text>
<text top="964" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref104">Bahler RC, Desser DR, Finkelhor RS, et al. Factors leading to pro-</a></text>
<text top="977" left="477" width="295" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref104">gression of valvular aortic stenosis. Am J Cardiol 1999;84:1044</a></text>
<text top="974" left="772" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref104">–8</a></text>
<text top="977" left="783" width="3" height="12" font="15">.</text>
<text top="990" left="450" width="21" height="12" font="15">107.</text>
<text top="990" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref105">Palta S, Pai AM, Gill KS, et al. New insights into the progression of</a></text>
<text top="1004" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref105">aortic stenosis: implications for secondary prevention. Circulation</a></text>
<text top="1017" left="477" width="72" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref105">2000;101:2497</a></text>
<text top="1015" left="548" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref105">–502</a></text>
<text top="1017" left="572" width="3" height="12" font="15">.</text>
<text top="1031" left="450" width="21" height="12" font="15">108.</text>
<text top="1031" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref106">Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in</a></text>
<text top="1044" left="477" width="308" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref106">severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611</a></text>
<text top="1042" left="785" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref106">–7</a></text>
<text top="1044" left="797" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref106">.</a></text>
<text top="1058" left="450" width="21" height="12" font="15">109.</text>
<text top="1058" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref107">Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering</a></text>
<text top="1071" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref107">with simvastatin and ezetimibe in aortic stenosis. N Engl J Med</a></text>
<text top="1085" left="477" width="72" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref107">2008;359:1343</a></text>
<text top="1082" left="548" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref107">–56</a></text>
<text top="1085" left="566" width="3" height="12" font="15">.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e158</text>
</page>
<page number="103" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="21" height="12" font="15">110.</text>
<text top="103" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref108">Cosmi JE, Kort S, Tunick PA, et al. The risk of the development of</a></text>
<text top="116" left="91" width="155" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref108">aortic stenosis in patients with</a></text>
<text top="113" left="252" width="162" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref108">“benign” aortic valve thickening.</a></text>
<text top="130" left="91" width="160" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref108">Arch Intern Med 2002;162:2345</a></text>
<text top="127" left="251" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref108">–7</a></text>
<text top="130" left="263" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref108">.</a></text>
<text top="143" left="64" width="21" height="12" font="15">111.</text>
<text top="143" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref109">Novaro GM, Katz R, Aviles RJ, et al. Clinical factors, but not</a></text>
<text top="157" left="91" width="229" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref109">C-reactive protein, predict progression of calci</a></text>
<text top="154" left="320" width="94" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref109">ﬁc aortic-valve dis-</a></text>
<text top="170" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref109">ease: the Cardiovascular Health Study. J Am Coll Cardiol 2007;50:</a></text>
<text top="183" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref109">1992</a></text>
<text top="181" left="115" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref109">–8</a></text>
<text top="183" left="127" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref109">.</a></text>
<text top="197" left="64" width="21" height="12" font="15">112.</text>
<text top="197" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref110">Owens DS, Katz R, Takasu J, et al. Incidence and progression of</a></text>
<text top="210" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref110">aortic valve calcium in the Multi-ethnic Study of Atherosclerosis</a></text>
<text top="224" left="91" width="185" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref110">(MESA). Am J Cardiol 2010;105:701</a></text>
<text top="221" left="276" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref110">–8</a></text>
<text top="224" left="288" width="3" height="12" font="15">.</text>
<text top="237" left="64" width="21" height="12" font="15">113.</text>
<text top="237" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref111">Tzemos N, Therrien J, Yip J, et al. Outcomes in adults with bicuspid</a></text>
<text top="251" left="91" width="173" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref111">aortic valves. JAMA 2008;300:1317</a></text>
<text top="248" left="264" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref111">–25</a></text>
<text top="251" left="282" width="3" height="12" font="15">.</text>
<text top="264" left="64" width="21" height="12" font="15">114.</text>
<text top="264" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref112">Michelena HI, Desjardins VA, Avierinos JF, et al. Natural history of</a></text>
<text top="278" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref112">asymptomatic patients with normally functioning or minimally</a></text>
<text top="291" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref112">dysfunctional bicuspid aortic valve in the community. Circulation</a></text>
<text top="305" left="91" width="72" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref112">2008;117:2776</a></text>
<text top="302" left="163" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref112">–84</a></text>
<text top="305" left="181" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref112">.</a></text>
<text top="318" left="64" width="21" height="12" font="15">115.</text>
<text top="318" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref113">Lindman BR, Bonow RO, Otto CM. Current management of</a></text>
<text top="331" left="91" width="21" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref113">calci</a></text>
<text top="329" left="112" width="219" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref113">ﬁc aortic stenosis. Circ Res 2013;113:223–37</a></text>
<text top="331" left="331" width="3" height="12" font="15">.</text>
<text top="345" left="64" width="21" height="12" font="15">116.</text>
<text top="345" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref114">Shavelle DM. Evaluation of valvular heart disease by cardiac</a></text>
<text top="358" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref114">catherization and angiography. In: Otto CM, Bonow RO, editors.</a></text>
<text top="372" left="91" width="258" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref114">Valvular Heart Disease. A Companion to Braunwald</a></text>
<text top="369" left="350" width="64" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref114">’s Heart Dis-</a></text>
<text top="385" left="91" width="231" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref114">ease. Philadelphia, PA: Elsevier/Saunders; 2013</a></text>
<text top="385" left="322" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref114">.</a></text>
<text top="399" left="64" width="21" height="12" font="15">117.</text>
<text top="399" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref115">Das P, Rimington H, Chambers J. Exercise testing to stratify risk in</a></text>
<text top="412" left="91" width="201" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref115">aortic stenosis. Eur Heart J 2005;26:1309</a></text>
<text top="409" left="292" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref115">–13</a></text>
<text top="412" left="310" width="3" height="12" font="15">.</text>
<text top="426" left="64" width="21" height="12" font="15">118.</text>
<text top="426" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref116">Amato MC, Moffa PJ, Werner KE, et al. Treatment decision in</a></text>
<text top="439" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref116">asymptomatic aortic valve stenosis: role of exercise testing. Heart</a></text>
<text top="452" left="91" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref116">2001;86:381</a></text>
<text top="450" left="151" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref116">–6</a></text>
<text top="452" left="163" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref116">.</a></text>
<text top="466" left="64" width="21" height="12" font="15">119.</text>
<text top="466" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref117">Alborino D, Hoffmann JL, Fournet PC, et al. Value of exercise</a></text>
<text top="479" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref117">testing to evaluate the indication for surgery in asymptomatic</a></text>
<text top="493" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref117">patients with valvular aortic stenosis. J Heart Valve Dis 2002;11:</a></text>
<text top="506" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref117">204</a></text>
<text top="504" left="110" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref117">–9</a></text>
<text top="506" left="122" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref117">.</a></text>
<text top="520" left="64" width="21" height="12" font="15">120.</text>
<text top="520" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref118">Takeda S, Rimington H, Chambers J. Prediction of symptom-onset</a></text>
<text top="533" left="91" width="249" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref118">in aortic stenosis: a comparison of pressure drop/</a></text>
<text top="530" left="341" width="74" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref118">ﬂow slope and</a></text>
<text top="547" left="91" width="285" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref118">haemodynamic measures at rest. Int J Cardiol 2001;81:131</a></text>
<text top="544" left="376" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref118">–7</a></text>
<text top="547" left="388" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref118">.</a></text>
<text top="560" left="64" width="21" height="12" font="15">121.</text>
<text top="560" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref119">Skalski J, Allison TG, Miller TD. The safety of cardiopulmonary</a></text>
<text top="574" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref119">exercise testing in a population with high-risk cardiovascular dis-</a></text>
<text top="587" left="91" width="159" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref119">eases. Circulation 2012;126:2465</a></text>
<text top="584" left="251" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref119">–72</a></text>
<text top="587" left="268" width="3" height="12" font="15">.</text>
<text top="600" left="64" width="21" height="12" font="15">122.</text>
<text top="600" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref120">Atterhog JH, Jonsson B, Samuelsson R. Exercise testing: a pro-</a></text>
<text top="614" left="91" width="299" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref120">spective study of complication rates. Am Heart J 1979;98:572</a></text>
<text top="611" left="390" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref120">–9</a></text>
<text top="614" left="402" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref120">.</a></text>
<text top="627" left="64" width="21" height="12" font="15">123.</text>
<text top="627" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref121">Dhoble A, Sarano ME, Kopecky SL, et al. Safety of symptom-</a></text>
<text top="641" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref121">limited cardiopulmonary exercise testing in patients with aortic</a></text>
<text top="654" left="91" width="166" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref121">stenosis. Am J Med 2012;125:704</a></text>
<text top="652" left="257" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref121">–8</a></text>
<text top="654" left="269" width="3" height="12" font="15">.</text>
<text top="668" left="64" width="21" height="12" font="15">124.</text>
<text top="668" left="91" width="10" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref122">O</a></text>
<text top="665" left="101" width="313" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref122">’Brien KD, Zhao XQ, Shavelle DM, et al. Hemodynamic effects</a></text>
<text top="681" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref122">of the angiotensin-converting enzyme inhibitor, ramipril, in patients</a></text>
<text top="695" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref122">with mild to moderate aortic stenosis and preserved left ventricular</a></text>
<text top="708" left="91" width="182" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref122">function. J Investig Med 2004;52:185</a></text>
<text top="705" left="273" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref122">–91</a></text>
<text top="708" left="291" width="3" height="12" font="15">.</text>
<text top="721" left="64" width="21" height="12" font="15">125.</text>
<text top="721" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref123">Chockalingam A, Venkatesan S, Subramaniam T, et al. Safety and</a></text>
<text top="735" left="91" width="9" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref123">ef</a></text>
<text top="732" left="100" width="314" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref123">ﬁcacy of angiotensin-converting enzyme inhibitors in symptomatic</a></text>
<text top="748" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref123">severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot</a></text>
<text top="762" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref123">Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am Heart J</a></text>
<text top="775" left="91" width="68" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref123">2004;147:E19</a></text>
<text top="775" left="159" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref123">.</a></text>
<text top="789" left="64" width="21" height="12" font="15">126.</text>
<text top="789" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref124">Nadir MA, Wei L, Elder DH, et al. Impact of renin-angiotensin</a></text>
<text top="802" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref124">system blockade therapy on outcome in aortic stenosis. J Am Coll</a></text>
<text top="816" left="91" width="99" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref124">Cardiol 2011;58:570</a></text>
<text top="813" left="191" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref124">–6</a></text>
<text top="816" left="202" width="3" height="12" font="15">.</text>
<text top="829" left="64" width="21" height="12" font="15">127.</text>
<text top="829" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref125">Rieck AE, Cramariuc D, Boman K, et al. Hypertension in aortic</a></text>
<text top="843" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref125">stenosis: implications for left ventricular structure and cardiovascular</a></text>
<text top="856" left="91" width="159" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref125">events. Hypertension 2012;60:90</a></text>
<text top="853" left="250" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref125">–7</a></text>
<text top="856" left="262" width="3" height="12" font="15">.</text>
<text top="869" left="64" width="21" height="12" font="15">128.</text>
<text top="869" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref126">Briand M, Dumesnil JG, Kadem L, et al. Reduced systemic arterial</a></text>
<text top="883" left="91" width="124" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref126">compliance impacts signi</a></text>
<text top="880" left="215" width="199" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref126">ﬁcantly on left ventricular afterload and</a></text>
<text top="896" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref126">function in aortic stenosis: implications for diagnosis and treatment.</a></text>
<text top="910" left="91" width="154" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref126">J Am Coll Cardiol 2005;46:291</a></text>
<text top="907" left="245" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref126">–8</a></text>
<text top="910" left="257" width="3" height="12" font="15">.</text>
<text top="923" left="64" width="21" height="12" font="15">129.</text>
<text top="923" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref127">Khot UN, Novaro GM, Popovic ZB, et al. Nitroprusside in criti-</a></text>
<text top="937" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref127">cally ill patients with left ventricular dysfunction and aortic stenosis.</a></text>
<text top="950" left="91" width="147" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref127">N Engl J Med 2003;348:1756</a></text>
<text top="947" left="238" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref127">–63</a></text>
<text top="950" left="256" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref127">.</a></text>
<text top="964" left="64" width="21" height="12" font="15">130.</text>
<text top="964" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref128">Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of</a></text>
<text top="977" left="91" width="190" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref128">intensive lipid-lowering therapy in calci</a></text>
<text top="974" left="281" width="133" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref128">ﬁc aortic stenosis. N Engl J</a></text>
<text top="990" left="91" width="98" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref128">Med 2005;352:2389</a></text>
<text top="988" left="189" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref128">–97</a></text>
<text top="990" left="207" width="3" height="12" font="15">.</text>
<text top="1004" left="64" width="21" height="12" font="15">131.</text>
<text top="1004" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref129">Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with</a></text>
<text top="1017" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref129">rosuvastatin on progression of aortic stenosis: results of the aortic</a></text>
<text top="1031" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref129">stenosis progression observation: measuring effects of rosuvastatin</a></text>
<text top="1044" left="91" width="249" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref129">(ASTRONOMER) trial. Circulation 2010;121:306</a></text>
<text top="1042" left="340" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref129">–14</a></text>
<text top="1044" left="358" width="3" height="12" font="15">.</text>
<text top="1058" left="64" width="21" height="12" font="15">132.</text>
<text top="1058" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref130">Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting</a></text>
<text top="1071" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref130">aortic valve endothelium to slow the progression of aortic stenosis.</a></text>
<text top="1085" left="91" width="154" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref130">J Am Coll Cardiol 2007;49:554</a></text>
<text top="1082" left="245" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref130">–61</a></text>
<text top="1085" left="263" width="3" height="12" font="15">.</text>
<text top="103" left="450" width="21" height="12" font="15">133.</text>
<text top="103" left="477" width="253" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref131">Rajamannan NM, Evans FJ, Aikawa E, et al. Calci</a></text>
<text top="100" left="730" width="70" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref131">ﬁc aortic valve</a></text>
<text top="116" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref131">disease: not simply a degenerative process: a review and agenda for</a></text>
<text top="130" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref131">research from the National Heart and Lung and Blood Institute</a></text>
<text top="143" left="477" width="282" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref131">Aortic Stenosis Working Group. Executive summary: calci</a></text>
<text top="140" left="758" width="41" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref131">ﬁc aortic</a></text>
<text top="157" left="477" width="260" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref131">valve disease-2011 update. Circulation 2011;124:1783</a></text>
<text top="154" left="737" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref131">–91</a></text>
<text top="157" left="755" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref131">.</a></text>
<text top="170" left="450" width="21" height="12" font="15">134.</text>
<text top="170" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref132">Turina J, Hess O, Sepulcri F, et al. Spontaneous course of aortic</a></text>
<text top="184" left="477" width="182" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref132">valve disease. Eur Heart J 1987;8:471</a></text>
<text top="181" left="658" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref132">–83</a></text>
<text top="184" left="676" width="3" height="12" font="15">.</text>
<text top="197" left="450" width="21" height="12" font="15">135.</text>
<text top="197" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref133">Kelly TA, Rothbart RM, Cooper CM, et al. Comparison of outcome</a></text>
<text top="210" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref133">of asymptomatic to symptomatic patients older than 20 years of age</a></text>
<text top="224" left="477" width="266" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref133">with valvular aortic stenosis. Am J Cardiol 1988;61:123</a></text>
<text top="221" left="742" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref133">–30</a></text>
<text top="224" left="760" width="3" height="12" font="15">.</text>
<text top="237" left="450" width="21" height="12" font="15">136.</text>
<text top="237" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref134">Connolly HM, Oh JK, Orszulak TA, et al. Aortic valve replacement</a></text>
<text top="251" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref134">for aortic stenosis with severe left ventricular dysfunction. Prognostic</a></text>
<text top="264" left="477" width="177" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref134">indicators. Circulation 1997;95:2395</a></text>
<text top="262" left="653" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref134">–400</a></text>
<text top="264" left="677" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref134">.</a></text>
<text top="278" left="450" width="21" height="12" font="15">137.</text>
<text top="278" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref135">Tribouilloy C, Levy F, Rusinaru D, et al. Outcome after aortic valve</a></text>
<text top="291" left="477" width="100" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref135">replacement for low-</a></text>
<text top="288" left="577" width="222" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref135">ﬂow/low-gradient aortic stenosis without con-</a></text>
<text top="305" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref135">tractile reserve on dobutamine stress echocardiography. J Am Coll</a></text>
<text top="318" left="477" width="106" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref135">Cardiol 2009;53:1865</a></text>
<text top="315" left="582" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref135">–73</a></text>
<text top="318" left="600" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref135">.</a></text>
<text top="331" left="450" width="21" height="12" font="15">138.</text>
<text top="331" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref136">Smith WT, Ferguson TB Jr., Ryan T, et al. Should coronary artery</a></text>
<text top="345" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref136">bypass graft surgery patients with mild or moderate aortic stenosis</a></text>
<text top="358" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref136">undergo concomitant aortic valve replacement? A decision analysis</a></text>
<text top="372" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref136">approach to the surgical dilemma. J Am Coll Cardiol 2004;44:</a></text>
<text top="385" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref136">1241</a></text>
<text top="382" left="501" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref136">–7</a></text>
<text top="385" left="513" width="3" height="12" font="15">.</text>
<text top="399" left="450" width="21" height="12" font="15">139.</text>
<text top="399" left="477" width="271" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref137">Lancellotti P, Donal E, Magne J, et al. Risk strati</a></text>
<text top="396" left="747" width="52" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref137">ﬁcation in</a></text>
<text top="412" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref137">asymptomatic moderate to severe aortic stenosis: the importance</a></text>
<text top="426" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref137">of the valvular, arterial and ventricular interplay. Heart 2010;96:</a></text>
<text top="439" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref137">1364</a></text>
<text top="436" left="501" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref137">–71</a></text>
<text top="439" left="519" width="3" height="12" font="15">.</text>
<text top="452" left="450" width="21" height="12" font="15">140.</text>
<text top="452" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref138">Rosenhek R, Zilberszac R, Schemper M, et al. Natural history of</a></text>
<text top="466" left="477" width="252" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref138">very severe aortic stenosis. Circulation 2010;121:151</a></text>
<text top="463" left="729" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref138">–6</a></text>
<text top="466" left="741" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref138">.</a></text>
<text top="479" left="450" width="21" height="12" font="15">141.</text>
<text top="479" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref139">Monin JL, Quere JP, Monchi M, et al. Low-gradient aortic ste-</a></text>
<text top="493" left="477" width="132" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref139">nosis: operative risk strati</a></text>
<text top="490" left="609" width="191" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref139">ﬁcation and predictors for long-term</a></text>
<text top="506" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref139">outcome: a multicenter study using dobutamine stress hemody-</a></text>
<text top="520" left="477" width="163" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref139">namics. Circulation 2003;108:319</a></text>
<text top="517" left="640" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref139">–24</a></text>
<text top="520" left="658" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref139">.</a></text>
<text top="533" left="450" width="21" height="12" font="15">142.</text>
<text top="533" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref140">Fougeres E, Tribouilloy C, Monchi M, et al. Outcomes of pseudo-</a></text>
<text top="547" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref140">severe aortic stenosis under conservative treatment. Eur Heart J</a></text>
<text top="560" left="477" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref140">2012;33:2426</a></text>
<text top="557" left="542" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref140">–33</a></text>
<text top="560" left="560" width="3" height="12" font="15">.</text>
<text top="574" left="450" width="21" height="12" font="15">143.</text>
<text top="574" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref141">Pellikka PA, Nishimura RA, Bailey KR, et al. The natural history of</a></text>
<text top="587" left="477" width="243" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref141">adults with asymptomatic, hemodynamically signi</a></text>
<text top="584" left="719" width="80" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref141">ﬁcant aortic ste-</a></text>
<text top="600" left="477" width="191" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref141">nosis. J Am Coll Cardiol 1990;15:1012</a></text>
<text top="598" left="667" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref141">–7</a></text>
<text top="600" left="679" width="3" height="12" font="15">.</text>
<text top="614" left="450" width="21" height="12" font="15">144.</text>
<text top="614" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref142">Kennedy KD, Nishimura RA, Holmes DR Jr., et al. Natural</a></text>
<text top="627" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref142">history of moderate aortic stenosis. J Am Coll Cardiol 1991;17:</a></text>
<text top="641" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref142">313</a></text>
<text top="638" left="495" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref142">–9</a></text>
<text top="641" left="507" width="3" height="12" font="15">.</text>
<text top="654" left="450" width="21" height="12" font="15">145.</text>
<text top="654" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref143">Kang DH, Park SJ, Rim JH, et al. Early surgery versus conventional</a></text>
<text top="668" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref143">treatment in asymptomatic very severe aortic stenosis. Circulation</a></text>
<text top="681" left="477" width="72" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref143">2010;121:1502</a></text>
<text top="678" left="548" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref143">–9</a></text>
<text top="681" left="560" width="3" height="12" font="15">.</text>
<text top="695" left="450" width="21" height="12" font="15">146.</text>
<text top="695" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref144">Jander N, Minners J, Holme I, et al. Outcome of patients with low-</a></text>
<text top="708" left="477" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref144">gradient</a></text>
<text top="705" left="522" width="277" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref144">“severe” aortic stenosis and preserved ejection fraction.</a></text>
<text top="721" left="477" width="123" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref144">Circulation 2011;123:887</a></text>
<text top="719" left="600" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref144">–95</a></text>
<text top="721" left="618" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref144">.</a></text>
<text top="735" left="450" width="21" height="12" font="15">147.</text>
<text top="735" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref145">Saito T, Muro T, Takeda H, et al. Prognostic value of aortic valve</a></text>
<text top="748" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref145">area index in asymptomatic patients with severe aortic stenosis. Am J</a></text>
<text top="762" left="477" width="100" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref145">Cardiol 2012;110:93</a></text>
<text top="759" left="576" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref145">–7</a></text>
<text top="762" left="588" width="3" height="12" font="15">.</text>
<text top="775" left="450" width="21" height="12" font="15">148.</text>
<text top="775" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref146">Horstkotte D, Loogen F. The natural history of aortic valve stenosis.</a></text>
<text top="789" left="477" width="153" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref146">Eur Heart J 1988;9 Suppl E:57</a></text>
<text top="786" left="630" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref146">–64</a></text>
<text top="789" left="647" width="3" height="12" font="15">.</text>
<text top="802" left="450" width="21" height="12" font="15">149.</text>
<text top="802" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref147">Pereira JJ, Lauer MS, Bashir M, et al. Survival after aortic valve</a></text>
<text top="816" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref147">replacement for severe aortic stenosis with low transvalvular gradi-</a></text>
<text top="829" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref147">ents and severe left ventricular dysfunction. J Am Coll Cardiol 2002;</a></text>
<text top="843" left="477" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref147">39:1356</a></text>
<text top="840" left="515" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref147">–63</a></text>
<text top="843" left="533" width="3" height="12" font="15">.</text>
<text top="856" left="450" width="21" height="12" font="15">150.</text>
<text top="856" left="477" width="193" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref148">Quere JP, Monin JL, Levy F, et al. In</a></text>
<text top="853" left="669" width="130" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref148">ﬂuence of preoperative left</a></text>
<text top="869" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref148">ventricular contractile reserve on postoperative ejection fraction in</a></text>
<text top="883" left="477" width="268" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref148">low-gradient aortic stenosis. Circulation 2006;113:1738</a></text>
<text top="880" left="744" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref148">–44</a></text>
<text top="883" left="762" width="3" height="12" font="15">.</text>
<text top="896" left="450" width="21" height="12" font="15">151.</text>
<text top="896" left="477" width="242" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref149">Pai RG, Varadarajan P, Razzouk A. Survival bene</a></text>
<text top="894" left="719" width="81" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref149">ﬁt of aortic valve</a></text>
<text top="910" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref149">replacement in patients with severe aortic stenosis with low ejection</a></text>
<text top="923" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref149">fraction and low gradient with normal ejection fraction. Ann Thorac</a></text>
<text top="937" left="477" width="92" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref149">Surg 2008;86:1781</a></text>
<text top="934" left="568" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref149">–9</a></text>
<text top="937" left="580" width="3" height="12" font="15">.</text>
<text top="950" left="450" width="21" height="12" font="15">152.</text>
<text top="950" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref150">Levy F, Laurent M, Monin JL, et al. Aortic valve replacement for</a></text>
<text top="964" left="477" width="22" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref150">low-</a></text>
<text top="961" left="498" width="301" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref150">ﬂow/low-gradient aortic stenosis operative risk stratiﬁcation and</a></text>
<text top="977" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref150">long-term outcome: a European multicenter study. J Am Coll</a></text>
<text top="990" left="477" width="106" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref150">Cardiol 2008;51:1466</a></text>
<text top="988" left="582" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref150">–72</a></text>
<text top="990" left="600" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref150">.</a></text>
<text top="1004" left="450" width="21" height="12" font="15">153.</text>
<text top="1004" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref151">Gotzmann M, Lindstaedt M, Bojara W, et al. Clinical outcome of</a></text>
<text top="1017" left="477" width="299" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref151">transcatheter aortic valve implantation in patients with low-</a></text>
<text top="1015" left="776" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref151">ﬂow,</a></text>
<text top="1031" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref151">low gradient aortic stenosis. Catheter Cardiovasc Interv 2012;79:</a></text>
<text top="1044" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref151">693</a></text>
<text top="1042" left="495" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref151">–701</a></text>
<text top="1044" left="519" width="3" height="12" font="15">.</text>
<text top="1058" left="450" width="21" height="12" font="15">154.</text>
<text top="1058" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref152">Pereira JJ, Balaban K, Lauer MS, et al. Aortic valve replacement in</a></text>
<text top="1071" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref152">patients with mild or moderate aortic stenosis and coronary bypass</a></text>
<text top="1085" left="477" width="163" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref152">surgery. Am J Med 2005;118:735</a></text>
<text top="1082" left="640" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref152">–42</a></text>
<text top="1085" left="658" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref152">.</a></text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e159</text>
</page>
<page number="104" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="21" height="12" font="15">155.</text>
<text top="103" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref153">Gillinov AM, Garcia MJ. When is concomitant aortic valve</a></text>
<text top="116" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref153">replacement indicated in patients with mild to moderate stenosis</a></text>
<text top="130" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref153">undergoing coronary revascularization? Curr Cardiol Rep 2005;7:</a></text>
<text top="143" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref153">101</a></text>
<text top="140" left="109" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref153">–4</a></text>
<text top="143" left="121" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref153">.</a></text>
<text top="157" left="64" width="21" height="12" font="15">156.</text>
<text top="157" left="91" width="274" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref154">Bhattacharyya S, Hayward C, Pepper J, et al. Risk strati</a></text>
<text top="154" left="365" width="49" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref154">ﬁcation in</a></text>
<text top="170" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref154">asymptomatic severe aortic stenosis: a critical appraisal. Eur Heart J</a></text>
<text top="183" left="91" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref154">2012;33:2377</a></text>
<text top="181" left="157" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref154">–87</a></text>
<text top="183" left="175" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref154">.</a></text>
<text top="197" left="64" width="21" height="12" font="15">157.</text>
<text top="197" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref155">Abouzied AM, Al Abbady M, Al Gendy MF, et al. Percutaneous</a></text>
<text top="210" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref155">balloon mitral commissurotomy during pregnancy. Angiology 2001;</a></text>
<text top="224" left="91" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref155">52:205</a></text>
<text top="221" left="124" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref155">–9</a></text>
<text top="224" left="136" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref155">.</a></text>
<text top="237" left="64" width="21" height="12" font="15">158.</text>
<text top="237" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref156">McCann GP, Steadman CD, Ray SG, et al. Managing the asymp-</a></text>
<text top="251" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref156">tomatic patient with severe aortic stenosis: randomised controlled</a></text>
<text top="264" left="91" width="259" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref156">trials of early surgery are overdue. Heart 2011;97:1119</a></text>
<text top="261" left="350" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref156">–21</a></text>
<text top="264" left="367" width="3" height="12" font="15">.</text>
<text top="278" left="64" width="21" height="12" font="15">159.</text>
<text top="278" left="91" width="300" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref157">Hachicha Z, Dumesnil JG, Bogaty P, et al. Paradoxical low-</a></text>
<text top="275" left="391" width="23" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref157">ﬂow,</a></text>
<text top="291" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref157">low-gradient severe aortic stenosis despite preserved ejection frac-</a></text>
<text top="305" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref157">tion is associated with higher afterload and reduced survival. Cir-</a></text>
<text top="318" left="91" width="113" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref157">culation 2007;115:2856</a></text>
<text top="315" left="204" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref157">–64</a></text>
<text top="318" left="222" width="3" height="12" font="15">.</text>
<text top="331" left="64" width="21" height="12" font="15">160.</text>
<text top="331" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref158">Tarantini G, Covolo E, Razzolini R, et al. Valve replacement for</a></text>
<text top="345" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref158">severe aortic stenosis with low transvalvular gradient and left ven-</a></text>
<text top="358" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref158">tricular ejection fraction exceeding 0.50. Ann Thorac Surg 2011;91:</a></text>
<text top="372" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref158">1808</a></text>
<text top="369" left="115" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref158">–15</a></text>
<text top="372" left="133" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref158">.</a></text>
<text top="385" left="64" width="21" height="12" font="15">161.</text>
<text top="385" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref159">Clavel MA, Dumesnil JG, Capoulade R, et al. Outcome of patients</a></text>
<text top="399" left="91" width="234" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref159">with aortic stenosis, small valve area, and low-</a></text>
<text top="396" left="325" width="89" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref159">ﬂow, low-gradient</a></text>
<text top="412" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref159">despite preserved left ventricular ejection fraction. J Am Coll Cardiol</a></text>
<text top="426" left="91" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref159">2012;60:1259</a></text>
<text top="423" left="157" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref159">–67</a></text>
<text top="426" left="175" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref159">.</a></text>
<text top="439" left="64" width="21" height="12" font="15">162.</text>
<text top="439" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref160">Lancellotti P, Magne J, Donal E, et al. Clinical outcome in</a></text>
<text top="452" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref160">asymptomatic severe aortic stenosis: insights from the new proposed</a></text>
<text top="466" left="91" width="139" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref160">aortic stenosis grading classi</a></text>
<text top="463" left="230" width="184" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref160">ﬁcation. J Am Coll Cardiol 2012;59:</a></text>
<text top="479" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref160">235</a></text>
<text top="477" left="109" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref160">–43</a></text>
<text top="479" left="127" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref160">.</a></text>
<text top="493" left="64" width="21" height="12" font="15">163.</text>
<text top="493" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref161">Herrmann HC, Pibarot P, Hueter I, et al. Predictors of mortality</a></text>
<text top="506" left="91" width="174" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref161">and outcomes of therapy in low-</a></text>
<text top="504" left="265" width="149" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref161">ﬂow severe aortic stenosis: a</a></text>
<text top="520" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref161">Placement of Aortic Transcatheter Valves (PARTNER) Trial</a></text>
<text top="533" left="91" width="172" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref161">analysis. Circulation 2013;127:2316</a></text>
<text top="530" left="263" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref161">–26</a></text>
<text top="533" left="281" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref161">.</a></text>
<text top="547" left="64" width="21" height="12" font="15">164.</text>
<text top="547" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref162">Mehrotra P, Jansen K, Flynn AW, et al. Differential left ventricular</a></text>
<text top="560" left="91" width="271" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref162">remodelling and longitudinal function distinguishes low</a></text>
<text top="557" left="366" width="48" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref162">ﬂow from</a></text>
<text top="574" left="91" width="38" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref162">normal-</a></text>
<text top="571" left="130" width="285" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref162">ﬂow preserved ejection fraction low-gradient severe aortic</a></text>
<text top="587" left="91" width="171" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref162">stenosis. Eur Heart J 2013;34:1906</a></text>
<text top="584" left="262" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref162">–14</a></text>
<text top="587" left="280" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref162">.</a></text>
<text top="600" left="64" width="21" height="12" font="15">165.</text>
<text top="600" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref163">Ozkan M, Gunduz S, Biteker M, et al. Comparison of different</a></text>
<text top="614" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref163">TEE-guided thrombolytic regimens for prosthetic valve thrombosis:</a></text>
<text top="627" left="91" width="260" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref163">the TROIA trial. J Am Coll Cardiol Img 2013;6:206</a></text>
<text top="625" left="351" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref163">–16</a></text>
<text top="627" left="369" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref163">.</a></text>
<text top="641" left="64" width="21" height="12" font="15">166.</text>
<text top="641" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref164">Lauten J, Rost C, Breithardt OA, et al. Invasive hemodynamic</a></text>
<text top="654" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref164">characteristics of low gradient severe aortic stenosis despite preserved</a></text>
<text top="668" left="91" width="244" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref164">ejection fraction. J Am Coll Cardiol 2013;61:1799</a></text>
<text top="665" left="335" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref164">–808</a></text>
<text top="668" left="359" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref164">.</a></text>
<text top="681" left="64" width="21" height="12" font="15">167.</text>
<text top="681" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref165">Chan V, Lam BK, Rubens FD, et al. Long-term evaluation of</a></text>
<text top="695" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref165">biological versus mechanical prosthesis use at reoperative aortic valve</a></text>
<text top="708" left="91" width="258" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref165">replacement. J Thorac Cardiovasc Surg 2012;144:146</a></text>
<text top="705" left="349" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref165">–51</a></text>
<text top="708" left="367" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref165">.</a></text>
<text top="721" left="64" width="21" height="12" font="15">168.</text>
<text top="721" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref166">Eleid MF, Sorajja P, Michelena HI, et al. Flow-gradient patterns in</a></text>
<text top="735" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref166">severe aortic stenosis with preserved ejection fraction: clinical</a></text>
<text top="748" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref166">characteristics and predictors of survival. Circulation 2013;128:</a></text>
<text top="762" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref166">1781</a></text>
<text top="759" left="115" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref166">–9</a></text>
<text top="762" left="127" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref166">.</a></text>
<text top="775" left="64" width="21" height="12" font="15">169.</text>
<text top="775" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref167">Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes</a></text>
<text top="789" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref167">after transcatheter or surgical aortic-valve replacement. N Engl J</a></text>
<text top="802" left="91" width="98" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref167">Med 2012;366:1686</a></text>
<text top="799" left="189" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref167">–95</a></text>
<text top="802" left="207" width="3" height="12" font="15">.</text>
<text top="816" left="64" width="21" height="12" font="15">170.</text>
<text top="816" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref168">Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve</a></text>
<text top="829" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref168">implantation for aortic stenosis in patients who cannot undergo</a></text>
<text top="843" left="91" width="188" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref168">surgery. N Engl J Med 2010;363:1597</a></text>
<text top="840" left="279" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref168">–607</a></text>
<text top="843" left="302" width="3" height="12" font="15">.</text>
<text top="856" left="64" width="21" height="12" font="15">171.</text>
<text top="856" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref169">Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-</a></text>
<text top="869" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref169">valve replacement for inoperable severe aortic stenosis. N Engl J</a></text>
<text top="883" left="91" width="98" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref169">Med 2012;366:1696</a></text>
<text top="880" left="189" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref169">–704</a></text>
<text top="883" left="213" width="3" height="12" font="15">.</text>
<text top="896" left="64" width="21" height="12" font="15">172.</text>
<text top="896" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref170">Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical</a></text>
<text top="910" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref170">aortic-valve replacement in high-risk patients. N Engl J Med 2011;</a></text>
<text top="923" left="91" width="45" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref170">364:2187</a></text>
<text top="921" left="136" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref170">–98</a></text>
<text top="923" left="154" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref170">.</a></text>
<text top="937" left="64" width="21" height="12" font="15">173.</text>
<text top="937" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref171">Murphy ES, Lawson RM, Starr A, et al. Severe aortic stenosis</a></text>
<text top="950" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref171">in patients 60 years of age or older: left ventricular function</a></text>
<text top="964" left="91" width="35" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref171">and 10</a></text>
<text top="961" left="126" width="288" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref171">–year survival after valve replacement. Circulation 1981;64:</a></text>
<text top="977" left="91" width="26" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref171">II184</a></text>
<text top="974" left="117" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref171">–8</a></text>
<text top="977" left="129" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref171">.</a></text>
<text top="990" left="64" width="21" height="12" font="15">174.</text>
<text top="990" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref172">Kvidal P, Bergstrom R, Horte LG, et al. Observed and relative</a></text>
<text top="1004" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref172">survival after aortic valve replacement. J Am Coll Cardiol 2000;35:</a></text>
<text top="1017" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref172">747</a></text>
<text top="1015" left="109" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref172">–56</a></text>
<text top="1017" left="127" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref172">.</a></text>
<text top="1031" left="64" width="21" height="12" font="15">175.</text>
<text top="1031" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref173">Schwarz F, Baumann P, Manthey J, et al. The effect of aortic valve</a></text>
<text top="1044" left="91" width="243" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref173">replacement on survival. Circulation 1982;66:1105</a></text>
<text top="1042" left="334" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref173">–10</a></text>
<text top="1044" left="352" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref173">.</a></text>
<text top="1058" left="64" width="21" height="12" font="15">176.</text>
<text top="1058" left="91" width="212" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref174">Freeman RV, Otto CM. Spectrum of calci</a></text>
<text top="1055" left="303" width="111" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref174">ﬁc aortic valve disease:</a></text>
<text top="1071" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref174">pathogenesis, disease progression, and treatment strategies. Circu-</a></text>
<text top="1085" left="91" width="102" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref174">lation 2005;111:3316</a></text>
<text top="1082" left="194" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref174">–26</a></text>
<text top="1085" left="211" width="3" height="12" font="15">.</text>
<text top="103" left="450" width="21" height="12" font="15">177.</text>
<text top="103" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref175">Naber CK, Prendergast B, Thomas M, et al. An interdisciplinary</a></text>
<text top="116" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref175">debate initiated by the European Society of Cardiology Working</a></text>
<text top="130" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref175">Group on Valvular Heart Disease. EuroIntervention 2012;7:</a></text>
<text top="143" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref175">1257</a></text>
<text top="140" left="501" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref175">–74</a></text>
<text top="143" left="520" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref175">.</a></text>
<text top="157" left="450" width="21" height="12" font="15">178.</text>
<text top="157" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref176">Genereux P, Head SJ, Wood DA, et al. Transcatheter aortic valve</a></text>
<text top="170" left="477" width="78" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref176">implantation 10</a></text>
<text top="167" left="555" width="245" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref176">–year anniversary: review of current evidence and</a></text>
<text top="184" left="477" width="229" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref176">clinical implications. Eur Heart J 2012;33:2388</a></text>
<text top="181" left="706" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref176">–98</a></text>
<text top="184" left="724" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref176">.</a></text>
<text top="197" left="450" width="21" height="12" font="15">179.</text>
<text top="197" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref177">Eltchaninoff H, Prat A, Gilard M, et al. Transcatheter aortic</a></text>
<text top="210" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref177">valve implantation: early results of the FRANCE (FRench Aortic</a></text>
<text top="224" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref177">National CoreValve and Edwards) registry. Eur Heart J 2011;32:</a></text>
<text top="237" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref177">191</a></text>
<text top="235" left="495" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref177">–7</a></text>
<text top="237" left="508" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref177">.</a></text>
<text top="251" left="450" width="21" height="12" font="15">180.</text>
<text top="251" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref178">Rodes-Cabau J, Webb JG, Cheung A, et al. Long-term outcomes</a></text>
<text top="264" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref178">after transcatheter aortic valve implantation: insights on prognostic</a></text>
<text top="278" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref178">factors and valve durability from the Canadian multicenter experi-</a></text>
<text top="291" left="477" width="188" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref178">ence. J Am Coll Cardiol 2012;60:1864</a></text>
<text top="288" left="665" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref178">–75</a></text>
<text top="291" left="683" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref178">.</a></text>
<text top="305" left="450" width="21" height="12" font="15">181.</text>
<text top="305" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref179">Nishimura RA, Holmes DR Jr., Reeder GS. Percutaneous balloon</a></text>
<text top="318" left="477" width="209" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref179">valvuloplasty. Mayo Clin Proc 1990;65:198</a></text>
<text top="315" left="686" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref179">–220</a></text>
<text top="318" left="710" width="3" height="12" font="15">.</text>
<text top="331" left="450" width="21" height="12" font="15">182.</text>
<text top="331" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref180">Lieberman EB, Bashore TM, Hermiller JB, et al. Balloon aortic</a></text>
<text top="345" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref180">valvuloplasty in adults: failure of procedure to improve long-term</a></text>
<text top="358" left="477" width="203" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref180">survival. J Am Coll Cardiol 1995;26:1522</a></text>
<text top="356" left="679" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref180">–8</a></text>
<text top="358" left="691" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref180">.</a></text>
<text top="372" left="450" width="21" height="12" font="15">183.</text>
<text top="372" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref181">Otto CM, Mickel MC, Kennedy JW, et al. Three-year outcome</a></text>
<text top="385" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref181">after balloon aortic valvuloplasty. Insights into prognosis of valvular</a></text>
<text top="399" left="477" width="191" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref181">aortic stenosis. Circulation 1994;89:642</a></text>
<text top="396" left="668" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref181">–50</a></text>
<text top="399" left="686" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref181">.</a></text>
<text top="412" left="450" width="21" height="12" font="15">184.</text>
<text top="412" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref182">Genereux P, Head SJ, Wood DA, et al. Transcatheter aortic valve</a></text>
<text top="426" left="477" width="79" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref182">implantation: 10</a></text>
<text top="423" left="556" width="243" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref182">–year anniversary part II: clinical implications. Eur</a></text>
<text top="439" left="477" width="105" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref182">Heart J 2012;33:2399</a></text>
<text top="436" left="582" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref182">–402</a></text>
<text top="439" left="605" width="3" height="12" font="15">.</text>
<text top="452" left="450" width="21" height="12" font="15">185.</text>
<text top="452" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref183">Botvinick EH, Schiller NB, Wickramasekaran R, et al. Echocar-</a></text>
<text top="466" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref183">diographic demonstration of early mitral valve closure in severe</a></text>
<text top="479" left="477" width="55" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref183">aortic insuf</a></text>
<text top="477" left="532" width="268" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref183">ﬁciency. Its clinical implications. Circulation 1975;51:</a></text>
<text top="493" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref183">836</a></text>
<text top="490" left="495" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref183">–47</a></text>
<text top="493" left="512" width="3" height="12" font="15">.</text>
<text top="506" left="450" width="21" height="12" font="15">186.</text>
<text top="506" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref184">DeMaria AN, King JF, Salel AF, et al. Echography and phonog-</a></text>
<text top="520" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref184">raphy of acute aortic regurgitation in bacterial endocarditis. Ann</a></text>
<text top="533" left="477" width="120" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref184">Intern Med 1975;82:329</a></text>
<text top="530" left="597" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref184">–35</a></text>
<text top="533" left="615" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref184">.</a></text>
<text top="547" left="450" width="21" height="12" font="15">187.</text>
<text top="547" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref185">Cigarroa JE, Isselbacher EM, DeSanctis RW, et al. Diagnostic</a></text>
<text top="560" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref185">imaging in the evaluation of suspected aortic dissection. Old stan-</a></text>
<text top="574" left="477" width="262" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref185">dards and new directions. N Engl J Med 1993;328:35</a></text>
<text top="571" left="739" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref185">–43</a></text>
<text top="574" left="757" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref185">.</a></text>
<text top="587" left="450" width="21" height="12" font="15">188.</text>
<text top="587" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref186">Nienaber CA, von Kodolitsch Y, Nicolas V, et al. The diagnosis of</a></text>
<text top="600" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref186">thoracic aortic dissection by noninvasive imaging procedures.</a></text>
<text top="614" left="477" width="129" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref186">N Engl J Med 1993;328:1</a></text>
<text top="611" left="605" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref186">–9</a></text>
<text top="614" left="617" width="3" height="12" font="15">.</text>
<text top="627" left="450" width="21" height="12" font="15">189.</text>
<text top="627" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref187">Smith MD, Cassidy JM, Souther S, et al. Transesophageal echo-</a></text>
<text top="641" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref187">cardiography in the diagnosis of traumatic rupture of the aorta.</a></text>
<text top="654" left="477" width="141" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref187">N Engl J Med 1995;332:356</a></text>
<text top="652" left="617" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref187">–62</a></text>
<text top="654" left="635" width="3" height="12" font="15">.</text>
<text top="668" left="450" width="21" height="12" font="15">190.</text>
<text top="668" left="477" width="34" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref188">McGif</a></text>
<text top="665" left="511" width="289" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref188">ﬁn DC, Galbraith AJ, McLachlan GJ, et al. Aortic valve</a></text>
<text top="681" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref188">infection. Risk factors for death and recurrent endocarditis after</a></text>
<text top="695" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref188">aortic valve replacement. J Thorac Cardiovasc Surg 1992;104:</a></text>
<text top="708" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref188">511</a></text>
<text top="705" left="495" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref188">–20</a></text>
<text top="708" left="514" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref188">.</a></text>
<text top="721" left="450" width="21" height="12" font="15">191.</text>
<text top="721" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref189">Aranki SF, Santini F, Adams DH, et al. Aortic valve endocarditis.</a></text>
<text top="735" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref189">Determinants of early survival and late morbidity. Circulation 1994;</a></text>
<text top="748" left="477" width="42" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref189">90:II175</a></text>
<text top="746" left="518" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref189">–82</a></text>
<text top="748" left="536" width="3" height="12" font="15">.</text>
<text top="762" left="450" width="21" height="12" font="15">192.</text>
<text top="762" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref190">Cormier B, Vahanian A. Echocardiography and indications for</a></text>
<text top="775" left="477" width="199" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref190">surgery. Eur Heart J 1995;16 Suppl B:68</a></text>
<text top="773" left="676" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref190">–71</a></text>
<text top="775" left="694" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref190">.</a></text>
<text top="789" left="450" width="21" height="12" font="15">193.</text>
<text top="789" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref191">Chu VH, Cabell CH, Benjamin DK Jr., et al. Early predictors of</a></text>
<text top="802" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref191">in-hospital death in infective endocarditis. Circulation 2004;109:</a></text>
<text top="816" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref191">1745</a></text>
<text top="813" left="501" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref191">–9</a></text>
<text top="816" left="513" width="3" height="12" font="15">.</text>
<text top="829" left="450" width="21" height="12" font="15">194.</text>
<text top="829" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref192">Lalani T, Cabell CH, Benjamin DK, et al. Analysis of the impact of</a></text>
<text top="843" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref192">early surgery on in-hospital mortality of native valve endocarditis:</a></text>
<text top="856" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref192">use of propensity score and instrumental variable methods to adjust</a></text>
<text top="869" left="477" width="267" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref192">for treatment-selection bias. Circulation 2010;121:1005</a></text>
<text top="867" left="744" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref192">–13</a></text>
<text top="869" left="762" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref192">.</a></text>
<text top="883" left="450" width="21" height="12" font="15">195.</text>
<text top="883" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref193">Trost JC, Hillis LD. Intra-aortic balloon counterpulsation. Am J</a></text>
<text top="896" left="477" width="106" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref193">Cardiol 2006;97:1391</a></text>
<text top="894" left="582" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref193">–8</a></text>
<text top="896" left="594" width="3" height="12" font="15">.</text>
<text top="910" left="450" width="21" height="12" font="15">196.</text>
<text top="910" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref194">Detaint D, Messika-Zeitoun D, Maalouf J, et al. Quantitative</a></text>
<text top="923" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref194">echocardiographic determinants of clinical outcome in asymptom-</a></text>
<text top="937" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref194">atic patients with aortic regurgitation: a prospective study. J Am Coll</a></text>
<text top="950" left="477" width="105" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref194">Cardiol Img 2008;1:1</a></text>
<text top="947" left="582" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref194">–11</a></text>
<text top="950" left="600" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref194">.</a></text>
<text top="964" left="450" width="21" height="12" font="15">197.</text>
<text top="964" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref195">Pizarro R, Bazzino OO, Oberti PF, et al. Prospective validation of</a></text>
<text top="977" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref195">the prognostic usefulness of B-type natriuretic peptide in asymp-</a></text>
<text top="990" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref195">tomatic patients with chronic severe aortic regurgitation. J Am Coll</a></text>
<text top="1004" left="477" width="106" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref195">Cardiol 2011;58:1705</a></text>
<text top="1001" left="582" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref195">–14</a></text>
<text top="1004" left="600" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref195">.</a></text>
<text top="1017" left="450" width="21" height="12" font="15">198.</text>
<text top="1017" left="477" width="274" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref196">Teague SM, Heinsimer JA, Anderson JL, et al. Quanti</a></text>
<text top="1015" left="750" width="49" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref196">ﬁcation of</a></text>
<text top="1031" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref196">aortic regurgitation utilizing continuous wave Doppler ultrasound.</a></text>
<text top="1044" left="477" width="148" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref196">J Am Coll Cardiol 1986;8:592</a></text>
<text top="1042" left="625" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref196">–9</a></text>
<text top="1044" left="637" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref196">.</a></text>
<text top="1058" left="450" width="21" height="12" font="15">199.</text>
<text top="1058" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref197">Bonow RO, Rosing DR, McIntosh CL, et al. The natural history of</a></text>
<text top="1071" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref197">asymptomatic patients with aortic regurgitation and normal left</a></text>
<text top="1085" left="477" width="218" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref197">ventricular function. Circulation 1983;68:509</a></text>
<text top="1082" left="694" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref197">–17</a></text>
<text top="1085" left="712" width="3" height="12" font="15">.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e160</text>
</page>
<page number="105" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="21" height="12" font="15">200.</text>
<text top="103" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref198">Scognamiglio R, Fasoli G, Dalla VS. Progression of myocardial</a></text>
<text top="116" left="91" width="312" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref198">dysfunction in asymptomatic patients with severe aortic insuf</a></text>
<text top="113" left="403" width="11" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref198">ﬁ-</a></text>
<text top="130" left="91" width="155" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref198">ciency. Clin Cardiol 1986;9:151</a></text>
<text top="127" left="246" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref198">–6</a></text>
<text top="130" left="258" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref198">.</a></text>
<text top="143" left="64" width="21" height="12" font="15">201.</text>
<text top="143" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref199">Siemienczuk D, Greenberg B, Morris C, et al. Chronic aortic</a></text>
<text top="157" left="91" width="23" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref199">insuf</a></text>
<text top="154" left="114" width="300" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref199">ﬁciency: factors associated with progression to aortic valve</a></text>
<text top="170" left="91" width="216" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref199">replacement. Ann Intern Med 1989;110:587</a></text>
<text top="167" left="307" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref199">–92</a></text>
<text top="170" left="325" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref199">.</a></text>
<text top="183" left="64" width="21" height="12" font="15">202.</text>
<text top="183" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref200">Tornos MP, Olona M, Permanyer-Miralda G, et al. Clinical</a></text>
<text top="197" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref200">outcome of severe asymptomatic chronic aortic regurgitation: a</a></text>
<text top="210" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref200">long-term prospective follow-up study. Am Heart J 1995;130:</a></text>
<text top="224" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref200">333</a></text>
<text top="221" left="109" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref200">–9</a></text>
<text top="224" left="121" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref200">.</a></text>
<text top="237" left="64" width="21" height="12" font="15">203.</text>
<text top="237" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref201">Ishii K, Hirota Y, Suwa M, et al. Natural history and left ven-</a></text>
<text top="251" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref201">tricular response in chronic aortic regurgitation. Am J Cardiol</a></text>
<text top="264" left="91" width="61" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref201">1996;78:357</a></text>
<text top="261" left="152" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref201">–61</a></text>
<text top="264" left="170" width="3" height="12" font="15">.</text>
<text top="278" left="64" width="21" height="12" font="15">204.</text>
<text top="278" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref202">Scognamiglio R, Rahimtoola SH, Fasoli G, et al. Nifedipine in</a></text>
<text top="291" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref202">asymptomatic patients with severe aortic regurgitation and normal</a></text>
<text top="305" left="91" width="261" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref202">left ventricular function. N Engl J Med 1994;331:689</a></text>
<text top="302" left="352" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref202">–94</a></text>
<text top="305" left="369" width="3" height="12" font="15">.</text>
<text top="318" left="64" width="21" height="12" font="15">205.</text>
<text top="318" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref203">Borer JS, Hochreiter C, Herrold EM, et al. Prediction of indications</a></text>
<text top="331" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref203">for valve replacement among asymptomatic or minimally symp-</a></text>
<text top="345" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref203">tomatic patients with chronic aortic regurgitation and normal left</a></text>
<text top="358" left="91" width="237" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref203">ventricular performance. Circulation 1998;97:525</a></text>
<text top="356" left="328" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref203">–34</a></text>
<text top="358" left="346" width="3" height="12" font="15">.</text>
<text top="372" left="64" width="21" height="12" font="15">206.</text>
<text top="372" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref204">Tamborini G, Galli CA, Maltagliati A, et al. Comparison of</a></text>
<text top="385" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref204">feasibility and accuracy of transthoracic echocardiography versus</a></text>
<text top="399" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref204">computed tomography in patients with known ascending aortic</a></text>
<text top="412" left="91" width="182" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref204">aneurysm. Am J Cardiol 2006;98:966</a></text>
<text top="409" left="273" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref204">–9</a></text>
<text top="412" left="285" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref204">.</a></text>
<text top="426" left="64" width="21" height="12" font="15">207.</text>
<text top="426" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref205">Kabirdas D, Scridon C, Brenes JC, et al. Accuracy of transthoracic</a></text>
<text top="439" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref205">echocardiography for the measurement of the ascending aorta:</a></text>
<text top="452" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref205">comparison with transesophageal echocardiography. Clin Cardiol</a></text>
<text top="466" left="91" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref205">2010;33:502</a></text>
<text top="463" left="151" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref205">–7</a></text>
<text top="466" left="163" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref205">.</a></text>
<text top="479" left="64" width="21" height="12" font="15">208.</text>
<text top="479" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref206">Tarasoutchi F, Grinberg M, Spina GS, et al. Ten-year clinical</a></text>
<text top="493" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref206">laboratory follow-up after application of a symptom-based thera-</a></text>
<text top="506" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref206">peutic strategy to patients with severe chronic aortic regurgitation</a></text>
<text top="520" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref206">of predominant rheumatic etiology. J Am Coll Cardiol 2003;41:</a></text>
<text top="533" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref206">1316</a></text>
<text top="530" left="115" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref206">–24</a></text>
<text top="533" left="134" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref206">.</a></text>
<text top="547" left="64" width="21" height="12" font="15">209.</text>
<text top="547" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref207">Evangelista A, Tornos P, Sambola A, et al. Long-term vasodilator</a></text>
<text top="560" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref207">therapy in patients with severe aortic regurgitation. N Engl J Med</a></text>
<text top="574" left="91" width="72" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref207">2005;353:1342</a></text>
<text top="571" left="163" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref207">–9</a></text>
<text top="574" left="175" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref207">.</a></text>
<text top="587" left="64" width="21" height="12" font="15">210.</text>
<text top="587" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref208">Olsen NT, Sogaard P, Larsson HB, et al. Speckle-tracking echo-</a></text>
<text top="600" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref208">cardiography for predicting outcome in chronic aortic regurgitation</a></text>
<text top="614" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref208">during conservative management and after surgery. J Am Coll</a></text>
<text top="627" left="91" width="117" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref208">Cardiol Img 2011;4:223</a></text>
<text top="625" left="208" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref208">–30</a></text>
<text top="627" left="226" width="3" height="12" font="15">.</text>
<text top="641" left="64" width="21" height="12" font="15">211.</text>
<text top="641" left="91" width="254" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref209">Forman R, Firth BG, Barnard MS. Prognostic signi</a></text>
<text top="638" left="345" width="70" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref209">ﬁcance of pre-</a></text>
<text top="654" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref209">operative left ventricular ejection fraction and valve lesion in patients</a></text>
<text top="668" left="91" width="277" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref209">with aortic valve replacement. Am J Cardiol 1980;45:1120</a></text>
<text top="665" left="368" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref209">–5</a></text>
<text top="668" left="379" width="3" height="12" font="15">.</text>
<text top="681" left="64" width="21" height="12" font="15">212.</text>
<text top="681" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref210">Henry WL, Bonow RO, Borer JS, et al. Observations on the</a></text>
<text top="695" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref210">optimum time for operative intervention for aortic regurgitation.</a></text>
<text top="708" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref210">I. Evaluation of the results of aortic valve replacement in symp-</a></text>
<text top="721" left="91" width="201" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref210">tomatic patients. Circulation 1980;61:471</a></text>
<text top="719" left="292" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref210">–83</a></text>
<text top="721" left="310" width="3" height="12" font="15">.</text>
<text top="735" left="64" width="21" height="12" font="15">213.</text>
<text top="735" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref211">Cunha CL, Giuliani ER, Fuster V, et al. Preoperative M-mode</a></text>
<text top="748" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref211">echocardiography as a predictor of surgical results in chronic aortic</a></text>
<text top="762" left="91" width="23" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref211">insuf</a></text>
<text top="759" left="114" width="248" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref211">ﬁciency. J Thorac Cardiovasc Surg 1980;79:256–65</a></text>
<text top="762" left="363" width="3" height="12" font="15">.</text>
<text top="775" left="64" width="21" height="12" font="15">214.</text>
<text top="775" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref212">Bonow RO, Picone AL, McIntosh CL, et al. Survival and func-</a></text>
<text top="789" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref212">tional results after valve replacement for aortic regurgitation from</a></text>
<text top="802" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref212">1976 to 1983: impact of preoperative left ventricular function.</a></text>
<text top="816" left="91" width="123" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref212">Circulation 1985;72:1244</a></text>
<text top="813" left="214" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref212">–56</a></text>
<text top="816" left="232" width="3" height="12" font="15">.</text>
<text top="829" left="64" width="21" height="12" font="15">215.</text>
<text top="829" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref213">Daniel WG, Hood WP Jr., Siart A, et al. Chronic aortic regurgi-</a></text>
<text top="843" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref213">tation: reassessment of the prognostic value of preoperative left</a></text>
<text top="856" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref213">ventricular end-systolic dimension and fractional shortening. Cir-</a></text>
<text top="869" left="91" width="101" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref213">culation 1985;71:669</a></text>
<text top="867" left="192" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref213">–80</a></text>
<text top="869" left="210" width="3" height="12" font="15">.</text>
<text top="883" left="64" width="21" height="12" font="15">216.</text>
<text top="883" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref214">Sheiban I, Trevi GP, Casarotto D, et al. Aortic valve replacement in</a></text>
<text top="896" left="91" width="306" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref214">patients with aortic incompetence. Preoperative parameters in</a></text>
<text top="894" left="397" width="17" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref214">ﬂu-</a></text>
<text top="910" left="91" width="277" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref214">encing long-term results. Z Kardiol 1986;75 Suppl 2:146</a></text>
<text top="907" left="368" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref214">–54</a></text>
<text top="910" left="386" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref214">.</a></text>
<text top="923" left="64" width="21" height="12" font="15">217.</text>
<text top="923" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref215">Taniguchi K, Nakano S, Hirose H, et al. Preoperative left ventric-</a></text>
<text top="937" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref215">ular function: minimal requirement for successful late results of valve</a></text>
<text top="950" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref215">replacement for aortic regurgitation. J Am Coll Cardiol 1987;10:</a></text>
<text top="964" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref215">510</a></text>
<text top="961" left="109" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref215">–8</a></text>
<text top="964" left="121" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref215">.</a></text>
<text top="977" left="64" width="21" height="12" font="15">218.</text>
<text top="977" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref216">Michel PL, Iung B, Abou JS, et al. The effect of left ventricular</a></text>
<text top="990" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref216">systolic function on long term survival in mitral and aortic regur-</a></text>
<text top="1004" left="91" width="236" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref216">gitation. J Heart Valve Dis 1995;4 Suppl 2:S160</a></text>
<text top="1001" left="327" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref216">–8</a></text>
<text top="1004" left="339" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref216">.</a></text>
<text top="1017" left="64" width="21" height="12" font="15">219.</text>
<text top="1017" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref217">Klodas E, Enriquez-Sarano M, Tajik AJ, et al. Aortic regurgitation</a></text>
<text top="1031" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref217">complicated by extreme left ventricular dilation: long-term outcome</a></text>
<text top="1044" left="91" width="273" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref217">after surgical correction. J Am Coll Cardiol 1996;27:670</a></text>
<text top="1042" left="365" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref217">–7</a></text>
<text top="1044" left="376" width="3" height="12" font="15">.</text>
<text top="1058" left="64" width="21" height="12" font="15">220.</text>
<text top="1058" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref218">Turina J, Milincic J, Seifert B, et al. Valve replacement in chronic</a></text>
<text top="1071" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref218">aortic regurgitation. True predictors of survival after extended</a></text>
<text top="1085" left="91" width="179" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref218">follow-up. Circulation 1998;98:II100</a></text>
<text top="1082" left="270" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref218">–6</a></text>
<text top="1085" left="282" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref218">.</a></text>
<text top="103" left="450" width="21" height="12" font="15">221.</text>
<text top="103" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref219">Attenhofer JCH, Turina J, Mayer K, et al. Echocardiography in the</a></text>
<text top="116" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref219">evaluation of systolic murmurs of unknown cause. Am J Med 2000:</a></text>
<text top="130" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref219">614</a></text>
<text top="127" left="495" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref219">–20</a></text>
<text top="130" left="513" width="3" height="12" font="15">.</text>
<text top="143" left="450" width="21" height="12" font="15">222.</text>
<text top="143" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref220">Gelfand EV, Hughes S, Hauser TH, et al. Severity of mitral</a></text>
<text top="157" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref220">and aortic regurgitation as assessed by cardiovascular magnetic</a></text>
<text top="170" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref220">resonance: optimizing correlation with Doppler echocardiography.</a></text>
<text top="183" left="477" width="184" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref220">J Cardiovasc Magn Reson 2006;8:503</a></text>
<text top="181" left="660" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref220">–7</a></text>
<text top="183" left="672" width="3" height="12" font="15">.</text>
<text top="197" left="450" width="21" height="12" font="15">223.</text>
<text top="197" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref221">Cawley PJ, Hamilton-Craig C, Owens DS, et al. Prospective</a></text>
<text top="210" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref221">comparison of valve regurgitation quantitation by cardiac magnetic</a></text>
<text top="224" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref221">resonance imaging and transthoracic echocardiography. Circ Car-</a></text>
<text top="237" left="477" width="130" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref221">diovasc Imaging 2013;6:48</a></text>
<text top="235" left="606" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref221">–57</a></text>
<text top="237" left="624" width="3" height="12" font="15">.</text>
<text top="251" left="450" width="21" height="12" font="15">224.</text>
<text top="251" left="477" width="149" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref222">Dulce MC, Mostbeck GH, O</a></text>
<text top="248" left="626" width="174" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref222">’Sullivan M, et al. Severity of aortic</a></text>
<text top="264" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref222">regurgitation: interstudy reproducibility of measurements with</a></text>
<text top="278" left="477" width="294" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref222">velocity-encoded cine MR imaging. Radiology 1992;185:235</a></text>
<text top="275" left="770" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref222">–40</a></text>
<text top="278" left="788" width="3" height="12" font="15">.</text>
<text top="291" left="450" width="21" height="12" font="15">225.</text>
<text top="291" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref223">Van Rossum AC, Visser FC, Sprenger M, et al. Evaluation of</a></text>
<text top="305" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref223">magnetic resonance imaging for determination of left ventricular</a></text>
<text top="318" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref223">ejection fraction and comparison with angiography. Am J Cardiol</a></text>
<text top="331" left="477" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref223">1988;62:628</a></text>
<text top="329" left="536" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref223">–33</a></text>
<text top="331" left="554" width="3" height="12" font="15">.</text>
<text top="345" left="450" width="21" height="12" font="15">226.</text>
<text top="345" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref224">Buser PT, Auffermann W, Holt WW, et al. Noninvasive evaluation</a></text>
<text top="358" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref224">of global left ventricular function with use of cine nuclear magnetic</a></text>
<text top="372" left="477" width="214" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref224">resonance. J Am Coll Cardiol 1989;13:1294</a></text>
<text top="369" left="690" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref224">–300</a></text>
<text top="372" left="714" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref224">.</a></text>
<text top="385" left="450" width="21" height="12" font="15">227.</text>
<text top="385" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref225">Cranney GB, Lotan CS, Dean L, et al. Left ventricular volume</a></text>
<text top="399" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref225">measurement using cardiac axis nuclear magnetic resonance imag-</a></text>
<text top="412" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref225">ing. Validation by calibrated ventricular angiography. Circulation</a></text>
<text top="426" left="477" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref225">1990;82:154</a></text>
<text top="423" left="536" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref225">–63</a></text>
<text top="426" left="554" width="3" height="12" font="15">.</text>
<text top="439" left="450" width="21" height="12" font="15">228.</text>
<text top="439" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref226">Benjelloun H, Cranney GB, Kirk KA, et al. Interstudy reproduc-</a></text>
<text top="453" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref226">ibility of biplane cine nuclear magnetic resonance measurements of</a></text>
<text top="466" left="477" width="255" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref226">left ventricular function. Am J Cardiol 1991;67:1413</a></text>
<text top="463" left="732" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref226">–20</a></text>
<text top="466" left="750" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref226">.</a></text>
<text top="479" left="450" width="21" height="12" font="15">229.</text>
<text top="479" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref227">Greves J, Rahimtoola SH, McAnulty JH, et al. Preoperative criteria</a></text>
<text top="493" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref227">predictive of late survival following valve replacement for severe</a></text>
<text top="506" left="477" width="226" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref227">aortic regurgitation. Am Heart J 1981;101:300</a></text>
<text top="504" left="702" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref227">–8</a></text>
<text top="506" left="714" width="3" height="12" font="15">.</text>
<text top="520" left="450" width="21" height="12" font="15">230.</text>
<text top="520" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref228">Klodas E, Enriquez-Sarano M, Tajik AJ, et al. Optimizing timing</a></text>
<text top="533" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref228">of surgical correction in patients with severe aortic regurgitation: role</a></text>
<text top="547" left="477" width="223" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref228">of symptoms. J Am Coll Cardiol 1997;30:746</a></text>
<text top="544" left="699" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref228">–52</a></text>
<text top="547" left="717" width="3" height="12" font="15">.</text>
<text top="560" left="450" width="21" height="12" font="15">231.</text>
<text top="560" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref229">Fioretti P, Benussi B, Scardi S, et al. Afterload reduction with</a></text>
<text top="574" left="477" width="119" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref229">nifedipine in aortic insuf</a></text>
<text top="571" left="595" width="196" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref229">ﬁciency. Am J Cardiol 1982;49:1728–32</a></text>
<text top="574" left="791" width="3" height="12" font="15">.</text>
<text top="587" left="450" width="21" height="12" font="15">232.</text>
<text top="587" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref230">Sondergaard L, Aldershvile J, Hildebrandt P, et al. Vasodilatation</a></text>
<text top="600" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref230">with felodipine in chronic asymptomatic aortic regurgitation. Am</a></text>
<text top="614" left="477" width="105" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref230">Heart J 2000;139:667</a></text>
<text top="611" left="582" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref230">–74</a></text>
<text top="614" left="600" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref230">.</a></text>
<text top="627" left="450" width="21" height="12" font="15">233.</text>
<text top="627" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref231">Lin M, Chiang HT, Lin SL, et al. Vasodilator therapy in chronic</a></text>
<text top="641" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref231">asymptomatic aortic regurgitation: enalapril versus hydralazine</a></text>
<text top="654" left="477" width="202" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref231">therapy. J Am Coll Cardiol 1994;24:1046</a></text>
<text top="652" left="679" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref231">–53</a></text>
<text top="654" left="697" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref231">.</a></text>
<text top="668" left="450" width="21" height="12" font="15">234.</text>
<text top="668" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref232">Elder DH, Wei L, Szwejkowski BR, et al. The impact of</a></text>
<text top="681" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref232">renin-angiotensin-aldosterone system blockade on heart failure</a></text>
<text top="695" left="477" width="223" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref232">outcomes and mortality in patients identi</a></text>
<text top="692" left="699" width="100" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref232">ﬁed to have aortic</a></text>
<text top="708" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref232">regurgitation: a large population cohort study. J Am Coll Cardiol</a></text>
<text top="721" left="477" width="67" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref232">2011;58:2084</a></text>
<text top="719" left="544" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref232">–91</a></text>
<text top="721" left="562" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref232">.</a></text>
<text top="735" left="450" width="21" height="12" font="15">235.</text>
<text top="735" left="477" width="253" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref233">Greenberg BH, DeMots H, Murphy E, et al. Bene</a></text>
<text top="732" left="729" width="70" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref233">ﬁcial effects of</a></text>
<text top="748" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref233">hydralazine on rest and exercise hemodynamics in patients with</a></text>
<text top="762" left="477" width="125" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref233">chronic severe aortic insuf</a></text>
<text top="759" left="602" width="172" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref233">ﬁciency. Circulation 1980;62:49–55</a></text>
<text top="762" left="773" width="3" height="12" font="15">.</text>
<text top="775" left="450" width="21" height="12" font="15">236.</text>
<text top="775" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref234">Shen WF, Roubin GS, Hirasawa K, et al. Noninvasive assessment</a></text>
<text top="789" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref234">of acute effects of nifedipine on rest and exercise hemodynamics and</a></text>
<text top="802" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref234">cardiac function in patients with aortic regurgitation. J Am Coll</a></text>
<text top="816" left="477" width="94" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref234">Cardiol 1984;4:902</a></text>
<text top="813" left="570" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref234">–7</a></text>
<text top="816" left="582" width="3" height="12" font="15">.</text>
<text top="829" left="450" width="21" height="12" font="15">237.</text>
<text top="829" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref235">Scognamiglio R, Fasoli G, Visintin L, et al. Effects of unloading</a></text>
<text top="843" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref235">and positive inotropic interventions on left ventricular function in</a></text>
<text top="856" left="477" width="259" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref235">asymptomatic patients with chronic severe aortic insuf</a></text>
<text top="853" left="736" width="64" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref235">ﬁciency. Clin</a></text>
<text top="869" left="477" width="100" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref235">Cardiol 1987;10:804</a></text>
<text top="867" left="576" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref235">–10</a></text>
<text top="869" left="594" width="3" height="12" font="15">.</text>
<text top="883" left="450" width="21" height="12" font="15">238.</text>
<text top="883" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref236">Rothlisberger C, Sareli P, Wisenbaugh T. Comparison of single-</a></text>
<text top="896" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref236">dose nifedipine and captopril for chronic severe aortic regurgita-</a></text>
<text top="910" left="477" width="156" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref236">tion. Am J Cardiol 1993;72:799</a></text>
<text top="907" left="632" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref236">–804</a></text>
<text top="910" left="656" width="3" height="12" font="15">.</text>
<text top="923" left="450" width="21" height="12" font="15">239.</text>
<text top="923" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref237">Sampat U, Varadarajan P, Turk R, et al. Effect of beta-blocker</a></text>
<text top="937" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref237">therapy on survival in patients with severe aortic regurgitation re-</a></text>
<text top="950" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref237">sults from a cohort of 756 patients. J Am Coll Cardiol 2009;54:</a></text>
<text top="964" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref237">452</a></text>
<text top="961" left="495" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref237">–7</a></text>
<text top="964" left="507" width="3" height="12" font="15">.</text>
<text top="977" left="450" width="21" height="12" font="15">240.</text>
<text top="977" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref238">Chaliki HP, Mohty D, Avierinos JF, et al. Outcomes after aortic</a></text>
<text top="990" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref238">valve replacement in patients with severe aortic regurgitation and</a></text>
<text top="1004" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref238">markedly reduced left ventricular function. Circulation 2002;106:</a></text>
<text top="1017" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref238">2687</a></text>
<text top="1015" left="501" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref238">–93</a></text>
<text top="1017" left="518" width="3" height="12" font="15">.</text>
<text top="1031" left="450" width="21" height="12" font="15">241.</text>
<text top="1031" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref239">Bhudia SK, McCarthy PM, Kumpati GS, et al. Improved outcomes</a></text>
<text top="1044" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref239">after aortic valve surgery for chronic aortic regurgitation with severe</a></text>
<text top="1058" left="477" width="296" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref239">left ventricular dysfunction. J Am Coll Cardiol 2007;49:1465</a></text>
<text top="1055" left="772" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref239">–71</a></text>
<text top="1058" left="790" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref239">.</a></text>
<text top="1071" left="450" width="21" height="12" font="15">242.</text>
<text top="1071" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref240">Bonow RO, Dodd JT, Maron BJ, et al. Long-term serial changes in</a></text>
<text top="1085" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref240">left ventricular function and reversal of ventricular dilatation after</a></text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e161</text>
</page>
<page number="106" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref240">valve replacement for chronic aortic regurgitation. Circulation 1988;</a></text>
<text top="116" left="91" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref240">78:1108</a></text>
<text top="113" left="130" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref240">–20</a></text>
<text top="116" left="148" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref240">.</a></text>
<text top="130" left="64" width="21" height="12" font="15">243.</text>
<text top="130" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref241">Gaasch WH, Carroll JD, Levine HJ, et al. Chronic aortic regurgi-</a></text>
<text top="143" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref241">tation: prognostic value of left ventricular end-systolic dimension</a></text>
<text top="157" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref241">and end-diastolic radius/thickness ratio. J Am Coll Cardiol 1983;1:</a></text>
<text top="170" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref241">775</a></text>
<text top="167" left="109" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref241">–82</a></text>
<text top="170" left="127" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref241">.</a></text>
<text top="183" left="64" width="21" height="12" font="15">244.</text>
<text top="183" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref242">David TE, Armstrong S, Ivanov J, et al. Aortic valve sparing op-</a></text>
<text top="197" left="91" width="254" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref242">erations: an update. Ann Thorac Surg 1999;67:1840</a></text>
<text top="194" left="345" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref242">–2</a></text>
<text top="197" left="356" width="3" height="12" font="15">.</text>
<text top="210" left="64" width="21" height="12" font="15">245.</text>
<text top="210" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref243">Kallenbach K, Hagl C, Walles T, et al. Results of valve-sparing</a></text>
<text top="224" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref243">aortic root reconstruction in 158 consecutive patients. Ann Thorac</a></text>
<text top="237" left="91" width="92" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref243">Surg 2002;74:2026</a></text>
<text top="235" left="183" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref243">–32</a></text>
<text top="237" left="201" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref243">.</a></text>
<text top="251" left="64" width="21" height="12" font="15">246.</text>
<text top="251" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref244">Pettersson GB, Crucean AC, Savage R, et al. Toward predictable</a></text>
<text top="264" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref244">repair of regurgitant aortic valves: a systematic morphology-directed</a></text>
<text top="278" left="91" width="308" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref244">approach to bicommissural repair. J Am Coll Cardiol 2008;52:40</a></text>
<text top="275" left="399" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref244">–9</a></text>
<text top="278" left="411" width="3" height="12" font="15">.</text>
<text top="291" left="64" width="21" height="12" font="15">247.</text>
<text top="291" left="91" width="256" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref245">Aicher D, Kunihara T, Abou IO, et al. Valve con</a></text>
<text top="288" left="347" width="67" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref245">ﬁguration de-</a></text>
<text top="305" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref245">termines long-term results after repair of the bicuspid aortic valve.</a></text>
<text top="318" left="91" width="123" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref245">Circulation 2011;123:178</a></text>
<text top="315" left="214" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref245">–85</a></text>
<text top="318" left="232" width="3" height="12" font="15">.</text>
<text top="331" left="64" width="21" height="12" font="15">248.</text>
<text top="331" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref246">Bonow RO, Borer JS, Rosing DR, et al. Preoperative exercise ca-</a></text>
<text top="345" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref246">pacity in symptomatic patients with aortic regurgitation as a pre-</a></text>
<text top="358" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref246">dictor of postoperative left ventricular function and long-term</a></text>
<text top="372" left="91" width="175" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref246">prognosis. Circulation 1980;62:1280</a></text>
<text top="369" left="267" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref246">–90</a></text>
<text top="372" left="284" width="3" height="12" font="15">.</text>
<text top="385" left="64" width="21" height="12" font="15">249.</text>
<text top="385" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref247">Tornos P, Sambola A, Permanyer-Miralda G, et al. Long-term</a></text>
<text top="399" left="91" width="272" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref247">outcome of surgically treated aortic regurgitation: in</a></text>
<text top="396" left="363" width="51" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref247">ﬂuence of</a></text>
<text top="412" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref247">guideline adherence toward early surgery. J Am Coll Cardiol 2006;</a></text>
<text top="426" left="91" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref247">47:1012</a></text>
<text top="423" left="130" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref247">–7</a></text>
<text top="426" left="142" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref247">.</a></text>
<text top="439" left="64" width="21" height="12" font="15">250.</text>
<text top="439" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref248">Bonow RO, Rosing DR, Maron BJ, et al. Reversal of left ventricular</a></text>
<text top="452" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref248">dysfunction after aortic valve replacement for chronic aortic regur-</a></text>
<text top="466" left="91" width="57" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref248">gitation: in</a></text>
<text top="463" left="148" width="266" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref248">ﬂuence of duration of preoperative left ventricular</a></text>
<text top="479" left="91" width="179" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref248">dysfunction. Circulation 1984;70:570</a></text>
<text top="477" left="271" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref248">–9</a></text>
<text top="479" left="282" width="3" height="12" font="15">.</text>
<text top="493" left="64" width="21" height="12" font="15">251.</text>
<text top="493" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref249">Kumpuris AG, Quinones MA, Waggoner AD, et al. Importance of</a></text>
<text top="506" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref249">preoperative hypertrophy, wall stress and end-systolic dimension as</a></text>
<text top="520" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref249">echocardiographic predictors of normalization of left ventricular</a></text>
<text top="533" left="91" width="263" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref249">dilatation after valve replacement in chronic aortic insuf</a></text>
<text top="530" left="354" width="60" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref249">ﬁciency. Am</a></text>
<text top="547" left="91" width="113" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref249">J Cardiol 1982;49:1091</a></text>
<text top="544" left="204" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref249">–100</a></text>
<text top="547" left="228" width="3" height="12" font="15">.</text>
<text top="560" left="64" width="21" height="12" font="15">252.</text>
<text top="560" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref250">Fioretti P, Roelandt J, Bos RJ, et al. Echocardiography in chronic</a></text>
<text top="574" left="91" width="54" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref250">aortic insuf</a></text>
<text top="571" left="145" width="269" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref250">ﬁciency. Is valve replacement too late when left ventric-</a></text>
<text top="587" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref250">ular end-systolic dimension reaches 55 mm? Circulation 1983;67:</a></text>
<text top="600" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref250">216</a></text>
<text top="598" left="109" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref250">–21</a></text>
<text top="600" left="127" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref250">.</a></text>
<text top="614" left="64" width="21" height="12" font="15">253.</text>
<text top="614" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref251">Stone PH, Clark RD, Goldschlager N, et al. Determinants of</a></text>
<text top="627" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref251">prognosis of patients with aortic regurgitation who undergo aortic</a></text>
<text top="641" left="91" width="245" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref251">valve replacement. J Am Coll Cardiol 1984;3:1118</a></text>
<text top="638" left="337" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref251">–26</a></text>
<text top="641" left="355" width="3" height="12" font="15">.</text>
<text top="654" left="64" width="21" height="12" font="15">254.</text>
<text top="654" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref252">Cormier B, Vahanian A, Luxereau P, et al. Should asymptomatic or</a></text>
<text top="668" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref252">mildly symptomatic aortic regurgitation be operated on? Z Kardiol</a></text>
<text top="681" left="91" width="99" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref252">1986;75 suppl 2:141</a></text>
<text top="678" left="190" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref252">–5</a></text>
<text top="681" left="202" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref252">.</a></text>
<text top="695" left="64" width="21" height="12" font="15">255.</text>
<text top="695" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref253">Pachulski RT, Weinberg AL, Chan KL. Aortic aneurysm in pa-</a></text>
<text top="708" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref253">tients with functionally normal or minimally stenotic bicuspid aortic</a></text>
<text top="721" left="91" width="160" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref253">valve. Am J Cardiol 1991;67:781</a></text>
<text top="719" left="251" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref253">–2</a></text>
<text top="721" left="263" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref253">.</a></text>
<text top="735" left="64" width="21" height="12" font="15">256.</text>
<text top="735" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref254">Hahn RT, Roman MJ, Mogtader AH, et al. Association of aortic</a></text>
<text top="748" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref254">dilation with regurgitant, stenotic and functionally normal bicuspid</a></text>
<text top="762" left="91" width="219" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref254">aortic valves. J Am Coll Cardiol 1992;19:283</a></text>
<text top="759" left="310" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref254">–8</a></text>
<text top="762" left="322" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref254">.</a></text>
<text top="775" left="64" width="21" height="12" font="15">257.</text>
<text top="775" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref255">Nistri S, Sorbo MD, Marin M, et al. Aortic root dilatation in young</a></text>
<text top="789" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref255">men with normally functioning bicuspid aortic valves. Heart 1999;</a></text>
<text top="802" left="91" width="27" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref255">82:19</a></text>
<text top="799" left="118" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref255">–22</a></text>
<text top="802" left="136" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref255">.</a></text>
<text top="816" left="64" width="21" height="12" font="15">258.</text>
<text top="816" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref256">Keane MG, Wiegers SE, Plappert T, et al. Bicuspid aortic valves are</a></text>
<text top="829" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref256">associated with aortic dilatation out of proportion to coexistent</a></text>
<text top="843" left="91" width="209" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref256">valvular lesions. Circulation 2000;102:III35</a></text>
<text top="840" left="300" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref256">–9</a></text>
<text top="843" left="312" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref256">.</a></text>
<text top="856" left="64" width="21" height="12" font="15">259.</text>
<text top="856" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref257">Novaro GM, Tiong IY, Pearce GL, et al. Features and predictors of</a></text>
<text top="869" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref257">ascending aortic dilatation in association with a congenital bicuspid</a></text>
<text top="883" left="91" width="184" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref257">aortic valve. Am J Cardiol 2003;92:99</a></text>
<text top="880" left="275" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref257">–101</a></text>
<text top="883" left="299" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref257">.</a></text>
<text top="896" left="64" width="21" height="12" font="15">260.</text>
<text top="896" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref258">Schaefer BM, Lewin MB, Stout KK, et al. The bicuspid aortic valve:</a></text>
<text top="910" left="91" width="153" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref258">an integrated phenotypic classi</a></text>
<text top="907" left="244" width="170" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref258">ﬁcation of leaﬂet morphology and</a></text>
<text top="923" left="91" width="184" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref258">aortic root shape. Heart 2008;94:1634</a></text>
<text top="921" left="276" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref258">–8</a></text>
<text top="923" left="287" width="3" height="12" font="15">.</text>
<text top="937" left="64" width="21" height="12" font="15">261.</text>
<text top="937" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref259">Kang JW, Song HG, Yang DH, et al. Association between bicuspid</a></text>
<text top="950" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref259">aortic valve phenotype and patterns of valvular dysfunction and</a></text>
<text top="964" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref259">bicuspid aortopathy: comprehensive evaluation using MDCT and</a></text>
<text top="977" left="91" width="262" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref259">echocardiography. J Am Coll Cardiol Img 2013;6:150</a></text>
<text top="974" left="353" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref259">–61</a></text>
<text top="977" left="371" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref259">.</a></text>
<text top="990" left="64" width="21" height="12" font="15">262.</text>
<text top="990" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref260">Pietro DA, Voelkel AG, Ray BJ, et al. Reproducibility of echocar-</a></text>
<text top="1004" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref260">diography. A study evaluating the variability of serial echocardio-</a></text>
<text top="1017" left="91" width="199" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref260">graphic measurements. Chest 1981;79:29</a></text>
<text top="1015" left="290" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref260">–32</a></text>
<text top="1017" left="308" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref260">.</a></text>
<text top="1031" left="64" width="21" height="12" font="15">263.</text>
<text top="1031" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref261">Hartnell GG. Imaging of aortic aneurysms and dissection: CT and</a></text>
<text top="1044" left="91" width="175" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref261">MRI. J Thorac Imaging 2001;16:35</a></text>
<text top="1042" left="266" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref261">–46</a></text>
<text top="1044" left="283" width="3" height="12" font="15">.</text>
<text top="1058" left="64" width="21" height="12" font="15">264.</text>
<text top="1058" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref262">Ferencik M, Pape LA. Changes in size of ascending aorta and aortic</a></text>
<text top="1071" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref262">valve function with time in patients with congenitally bicuspid aortic</a></text>
<text top="1085" left="91" width="158" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref262">valves. Am J Cardiol 2003;92:43</a></text>
<text top="1082" left="249" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref262">–6</a></text>
<text top="1085" left="261" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref262">.</a></text>
<text top="103" left="450" width="21" height="12" font="15">265.</text>
<text top="103" left="477" width="88" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref263">Novaro GM, Grif</a></text>
<text top="100" left="564" width="235" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref263">ﬁn BP. Congenital bicuspid aortic valve and rate</a></text>
<text top="116" left="477" width="276" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref263">of ascending aortic dilatation. Am J Cardiol 2004;93:525</a></text>
<text top="114" left="753" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref263">–6</a></text>
<text top="116" left="764" width="3" height="12" font="15">.</text>
<text top="130" left="450" width="21" height="12" font="15">266.</text>
<text top="130" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref264">Davies RR, Kaple RK, Mandapati D, et al. Natural history of</a></text>
<text top="143" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref264">ascending aortic aneurysms in the setting of an unreplaced bicuspid</a></text>
<text top="157" left="477" width="216" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref264">aortic valve. Ann Thorac Surg 2007;83:1338</a></text>
<text top="154" left="692" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref264">–44</a></text>
<text top="157" left="710" width="3" height="12" font="15">.</text>
<text top="170" left="450" width="21" height="12" font="15">267.</text>
<text top="170" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref265">Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic</a></text>
<text top="184" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref265">complications in patients with bicuspid aortic valves. JAMA 2011;</a></text>
<text top="197" left="477" width="45" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref265">306:1104</a></text>
<text top="194" left="521" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref265">–12</a></text>
<text top="197" left="539" width="3" height="12" font="15">.</text>
<text top="210" left="450" width="21" height="12" font="15">268.</text>
<text top="210" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref266">Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or</a></text>
<text top="224" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref266">dissection rates for thoracic aortic aneurysms: simple prediction</a></text>
<text top="237" left="477" width="214" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref266">based on size. Ann Thorac Surg 2002;73:17</a></text>
<text top="235" left="691" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref266">–27</a></text>
<text top="237" left="709" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref266">.</a></text>
<text top="251" left="450" width="21" height="12" font="15">269.</text>
<text top="251" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref267">Ergin MA, Spielvogel D, Apaydin A, et al. Surgical treatment of the</a></text>
<text top="264" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref267">dilated ascending aorta: when and how? Ann Thorac Surg 1999;67:</a></text>
<text top="278" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref267">1834</a></text>
<text top="275" left="501" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref267">–9</a></text>
<text top="278" left="513" width="3" height="12" font="15">.</text>
<text top="291" left="450" width="21" height="12" font="15">270.</text>
<text top="291" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref268">Svensson LG, Kim KH, Lytle BW, et al. Relationship of aortic</a></text>
<text top="305" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref268">cross-sectional area to height ratio and the risk of aortic dissection in</a></text>
<text top="318" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref268">patients with bicuspid aortic valves. J Thorac Cardiovasc Surg 2003;</a></text>
<text top="331" left="477" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref268">126:892</a></text>
<text top="329" left="516" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref268">–3</a></text>
<text top="331" left="527" width="3" height="12" font="15">.</text>
<text top="345" left="450" width="21" height="12" font="15">271.</text>
<text top="345" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref269">Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006</a></text>
<text top="358" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref269">guidelines for the management of patients with valvular heart</a></text>
<text top="372" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref269">disease: a report of the American College of Cardiology/American</a></text>
<text top="385" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref269">Heart Association Task Force on Practice Guidelines (writing</a></text>
<text top="399" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref269">committee to revise the 1998 Guidelines for the Management of</a></text>
<text top="412" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref269">Patients With Valvular Heart Disease). Circulation 2006;114:</a></text>
<text top="426" left="477" width="17" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref269">e84</a></text>
<text top="423" left="494" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref269">–231</a></text>
<text top="426" left="519" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref269">.</a></text>
<text top="439" left="450" width="21" height="12" font="15">272.</text>
<text top="439" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref270">Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/</a></text>
<text top="452" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref270">AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the</a></text>
<text top="466" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref270">diagnosis and management of patients with thoracic aortic disease:</a></text>
<text top="479" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref270">a report of the American College of Cardiology Foundation/</a></text>
<text top="493" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref270">American Heart Association Task Force on Practice Guidelines,</a></text>
<text top="506" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref270">American Association for Thoracic Surgery, American College of</a></text>
<text top="520" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref270">Radiology, American Stroke Association, Society of Cardiovascular</a></text>
<text top="533" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref270">Anesthesiologists, Society for Cardiovascular Angiography and</a></text>
<text top="547" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref270">Interventions, Society of Interventional Radiology, Society of</a></text>
<text top="560" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref270">Thoracic Surgeons, and Society for Vascular Medicine. Circulation</a></text>
<text top="574" left="477" width="71" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref270">2010;121:e266</a></text>
<text top="571" left="547" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref270">–369</a></text>
<text top="574" left="571" width="3" height="12" font="15">.</text>
<text top="587" left="450" width="21" height="12" font="15">273.</text>
<text top="587" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref271">Zehr KJ, Orszulak TA, Mullany CJ, et al. Surgery for aneurysms</a></text>
<text top="600" left="477" width="120" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref271">of the aortic root: a 30</a></text>
<text top="598" left="597" width="202" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref271">–year experience. Circulation 2004;110:</a></text>
<text top="614" left="477" width="25" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref271">1364</a></text>
<text top="611" left="501" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref271">–71</a></text>
<text top="614" left="520" width="3" height="12" font="15">.</text>
<text top="627" left="450" width="21" height="12" font="15">274.</text>
<text top="627" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref272">Svensson LG, Adams DH, Bonow RO, et al. Aortic valve and</a></text>
<text top="641" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref272">ascending aorta guidelines for management and quality measures.</a></text>
<text top="654" left="477" width="144" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref272">Ann Thorac Surg 2013;95:S1</a></text>
<text top="652" left="620" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref272">–66</a></text>
<text top="654" left="638" width="3" height="12" font="15">.</text>
<text top="668" left="450" width="21" height="12" font="15">275.</text>
<text top="668" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref273">Russo CF, Mazzetti S, Garatti A, et al. Aortic complications after</a></text>
<text top="681" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref273">bicuspid aortic valve replacement: long-term results. Ann Thorac</a></text>
<text top="695" left="477" width="98" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref273">Surg 2002;74:S1773</a></text>
<text top="692" left="575" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref273">–6</a></text>
<text top="695" left="587" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref273">.</a></text>
<text top="708" left="450" width="21" height="12" font="15">276.</text>
<text top="708" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref274">Yasuda H, Nakatani S, Stugaard M, et al. Failure to prevent pro-</a></text>
<text top="721" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref274">gressive dilation of ascending aorta by aortic valve replacement in</a></text>
<text top="735" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref274">patients with bicuspid aortic valve: comparison with tricuspid aortic</a></text>
<text top="748" left="477" width="203" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref274">valve. Circulation 2003;108 Suppl 1:II291</a></text>
<text top="746" left="680" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref274">–4</a></text>
<text top="748" left="692" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref274">.</a></text>
<text top="762" left="450" width="21" height="12" font="15">277.</text>
<text top="762" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref275">Borger MA, Preston M, Ivanov J, et al. Should the ascending aorta</a></text>
<text top="775" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref275">be replaced more frequently in patients with bicuspid aortic valve</a></text>
<text top="789" left="477" width="235" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref275">disease? J Thorac Cardiovasc Surg 2004;128:677</a></text>
<text top="786" left="711" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref275">–83</a></text>
<text top="789" left="729" width="3" height="12" font="15">.</text>
<text top="802" left="450" width="21" height="12" font="15">278.</text>
<text top="802" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref276">Svensson LG, Kim KH, Blackstone EH, et al. Bicuspid aortic valve</a></text>
<text top="816" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref276">surgery with proactive ascending aorta repair. J Thorac Cardiovasc</a></text>
<text top="829" left="477" width="92" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref276">Surg 2011;142:622</a></text>
<text top="826" left="568" width="37" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref276">–9, 629</a></text>
<text top="829" left="605" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref276">.</a></text>
<text top="843" left="450" width="21" height="12" font="15">279.</text>
<text top="843" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref277">Park CB, Greason KL, Suri RM, et al. Fate of nonreplaced sinuses</a></text>
<text top="856" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref277">of Valsalva in bicuspid aortic valve disease. J Thorac Cardiovasc Surg</a></text>
<text top="869" left="477" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref277">2011;142:278</a></text>
<text top="867" left="542" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref277">–84</a></text>
<text top="869" left="560" width="3" height="12" font="15">.</text>
<text top="883" left="450" width="21" height="12" font="15">280.</text>
<text top="883" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref278">Arora R, Nair M, Kalra GS, et al. Immediate and long-term results</a></text>
<text top="896" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref278">of balloon and surgical closed mitral valvotomy: a randomized</a></text>
<text top="910" left="477" width="226" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref278">comparative study. Am Heart J 1993;125:1091</a></text>
<text top="907" left="703" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref278">–4</a></text>
<text top="910" left="715" width="3" height="12" font="15">.</text>
<text top="923" left="450" width="21" height="12" font="15">281.</text>
<text top="923" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref279">Turi ZG, Reyes VP, Raju BS, et al. Percutaneous balloon versus</a></text>
<text top="937" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref279">surgical closed commissurotomy for mitral stenosis. A prospective,</a></text>
<text top="950" left="477" width="209" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref279">randomized trial. Circulation 1991;83:1179</a></text>
<text top="947" left="686" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref279">–85</a></text>
<text top="950" left="704" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref279">.</a></text>
<text top="964" left="450" width="21" height="12" font="15">282.</text>
<text top="964" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref280">Patel JJ, Shama D, Mitha AS, et al. Balloon valvuloplasty versus</a></text>
<text top="977" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref280">closed commissurotomy for pliable mitral stenosis: a prospective</a></text>
<text top="990" left="477" width="263" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref280">hemodynamic study. J Am Coll Cardiol 1991;18:1318</a></text>
<text top="988" left="740" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref280">–22</a></text>
<text top="990" left="758" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref280">.</a></text>
<text top="1004" left="450" width="21" height="12" font="15">283.</text>
<text top="1004" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref281">Ben FM, Ayari M, Maatouk F, et al. Percutaneous balloon versus</a></text>
<text top="1017" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref281">surgical closed and open mitral commissurotomy: seven-year</a></text>
<text top="1031" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref281">follow-up results of a randomized trial. Circulation 1998;97:</a></text>
<text top="1044" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref281">245</a></text>
<text top="1042" left="495" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref281">–50</a></text>
<text top="1044" left="513" width="3" height="12" font="15">.</text>
<text top="1058" left="450" width="21" height="12" font="15">284.</text>
<text top="1058" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref282">Cotrufo M, Renzulli A, Ismeno G, et al. Percutaneous mitral</a></text>
<text top="1071" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref282">commissurotomy versus open mitral commissurotomy: a compara-</a></text>
<text top="1085" left="477" width="235" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref282">tive study. Eur J Cardiothorac Surg 1999;15:646</a></text>
<text top="1082" left="712" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref282">–51</a></text>
<text top="1085" left="730" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref282">.</a></text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e162</text>
</page>
<page number="107" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="21" height="12" font="15">285.</text>
<text top="103" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref283">Hugenholtz PG, Ryan TJ, Stein SW, et al. The spectrum of pure</a></text>
<text top="116" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref283">mitral stenosis. Hemodynamic studies in relation to clinical</a></text>
<text top="130" left="91" width="179" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref283">disability. Am J Cardiol 1962;10:773</a></text>
<text top="127" left="270" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref283">–84</a></text>
<text top="130" left="288" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref283">.</a></text>
<text top="143" left="64" width="21" height="12" font="15">286.</text>
<text top="143" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref284">Reyes VP, Raju BS, Wynne J, et al. Percutaneous balloon valvulo-</a></text>
<text top="157" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref284">plasty compared with open surgical commissurotomy for mitral</a></text>
<text top="170" left="91" width="184" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref284">stenosis. N Engl J Med 1994;331:961</a></text>
<text top="167" left="275" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref284">–7</a></text>
<text top="170" left="287" width="3" height="12" font="15">.</text>
<text top="183" left="64" width="21" height="12" font="15">287.</text>
<text top="183" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref285">Sugeng L, Weinert L, Lammertin G, et al. Accuracy of mitral valve</a></text>
<text top="197" left="91" width="282" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref285">area measurements using transthoracic rapid freehand 3</a></text>
<text top="194" left="373" width="41" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref285">–dimen-</a></text>
<text top="210" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref285">sional scanning: comparison with noninvasive and invasive methods.</a></text>
<text top="224" left="91" width="185" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref285">J Am Soc Echocardiogr 2003;16:1292</a></text>
<text top="221" left="276" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref285">–300</a></text>
<text top="224" left="300" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref285">.</a></text>
<text top="237" left="64" width="21" height="12" font="15">288.</text>
<text top="237" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref286">Schlosshan D, Aggarwal G, Mathur G, et al. Real-time 3D trans-</a></text>
<text top="251" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref286">esophageal echocardiography for the evaluation of rheumatic mitral</a></text>
<text top="264" left="91" width="215" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref286">stenosis. J Am Coll Cardiol Img 2011;4:580</a></text>
<text top="261" left="306" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref286">–8</a></text>
<text top="264" left="318" width="3" height="12" font="15">.</text>
<text top="278" left="64" width="21" height="12" font="15">289.</text>
<text top="278" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref287">Leavitt JI, Coats MH, Falk RH. Effects of exercise on transmitral</a></text>
<text top="291" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref287">gradient and pulmonary artery pressure in patients with mitral ste-</a></text>
<text top="305" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref287">nosis or a prosthetic mitral valve: a Doppler echocardiographic</a></text>
<text top="318" left="91" width="192" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref287">study. J Am Coll Cardiol 1991;17:1520</a></text>
<text top="315" left="283" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref287">–6</a></text>
<text top="318" left="295" width="3" height="12" font="15">.</text>
<text top="331" left="64" width="21" height="12" font="15">290.</text>
<text top="331" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref288">Chung CS, Karamanoglu M, Kovacs SJ. Duration of diastole and its</a></text>
<text top="345" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref288">phases as a function of heart rate during supine bicycle exercise. Am</a></text>
<text top="358" left="91" width="223" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref288">J Physiol Heart Circ Physiol 2004;287:H2003</a></text>
<text top="356" left="314" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref288">–8</a></text>
<text top="358" left="326" width="3" height="12" font="15">.</text>
<text top="372" left="64" width="21" height="12" font="15">291.</text>
<text top="372" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref289">Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations</a></text>
<text top="385" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref289">for evaluation of prosthetic valves with echocardiography and</a></text>
<text top="399" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref289">Doppler ultrasound: a report from the American Society of</a></text>
<text top="412" left="91" width="88" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref289">Echocardiography</a></text>
<text top="409" left="179" width="235" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref289">’s Guidelines and Standards Committee and the</a></text>
<text top="426" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref289">Task Force on Prosthetic Valves. J Am Soc Echocardiogr 2009;22:</a></text>
<text top="439" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref289">975</a></text>
<text top="436" left="109" width="30" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref289">–1014</a></text>
<text top="439" left="140" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref289">.</a></text>
<text top="452" left="64" width="21" height="12" font="15">292.</text>
<text top="452" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref290">Wilkins GT, Weyman AE, Abascal VM, et al. Percutaneous</a></text>
<text top="466" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref290">balloon dilatation of the mitral valve: an analysis of echocardio-</a></text>
<text top="479" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref290">graphic variables related to outcome and the mechanism of dilata-</a></text>
<text top="493" left="91" width="141" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref290">tion. Br Heart J 1988;60:299</a></text>
<text top="490" left="232" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref290">–308</a></text>
<text top="493" left="256" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref290">.</a></text>
<text top="506" left="64" width="21" height="12" font="15">293.</text>
<text top="506" left="91" width="141" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref291">Abascal VM, Wilkins GT, O</a></text>
<text top="504" left="232" width="182" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref291">’Shea JP, et al. Prediction of successful</a></text>
<text top="520" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref291">outcome in 130 patients undergoing percutaneous balloon mitral</a></text>
<text top="533" left="91" width="172" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref291">valvotomy. Circulation 1990;82:448</a></text>
<text top="530" left="263" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref291">–56</a></text>
<text top="533" left="281" width="3" height="12" font="15">.</text>
<text top="547" left="64" width="21" height="12" font="15">294.</text>
<text top="547" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref292">Cannan CR, Nishimura RA, Reeder GS, et al. Echocardiographic</a></text>
<text top="560" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref292">assessment of commissural calcium: a simple predictor of outcome</a></text>
<text top="574" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref292">after percutaneous mitral balloon valvotomy. J Am Coll Cardiol</a></text>
<text top="587" left="91" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref292">1997;29:175</a></text>
<text top="584" left="151" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref292">–80</a></text>
<text top="587" left="169" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref292">.</a></text>
<text top="600" left="64" width="21" height="12" font="15">295.</text>
<text top="600" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref293">Thomas JD, Wilkins GT, Choong CY, et al. Inaccuracy of mitral</a></text>
<text top="614" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref293">pressure half-time immediately after percutaneous mitral valvotomy.</a></text>
<text top="627" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref293">Dependence on transmitral gradient and left atrial and ventricular</a></text>
<text top="641" left="91" width="178" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref293">compliance. Circulation 1988;78:980</a></text>
<text top="638" left="269" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref293">–93</a></text>
<text top="641" left="287" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref293">.</a></text>
<text top="654" left="64" width="21" height="12" font="15">296.</text>
<text top="654" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref294">Ellis K, Ziada KM, Vivekananthan D, et al. Transthoracic echo-</a></text>
<text top="668" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref294">cardiographic predictors of left atrial appendage thrombus. Am J</a></text>
<text top="681" left="91" width="99" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref294">Cardiol 2006;97:421</a></text>
<text top="678" left="191" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref294">–5</a></text>
<text top="681" left="203" width="3" height="12" font="15">.</text>
<text top="695" left="64" width="21" height="12" font="15">297.</text>
<text top="695" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref295">Kronzon I, Tunick PA, Glassman E, et al. Transesophageal echo-</a></text>
<text top="708" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref295">cardiography to detect atrial clots in candidates for percutaneous</a></text>
<text top="721" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref295">transseptal mitral balloon valvuloplasty. J Am Coll Cardiol 1990;16:</a></text>
<text top="735" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref295">1320</a></text>
<text top="732" left="115" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref295">–2</a></text>
<text top="735" left="127" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref295">.</a></text>
<text top="748" left="64" width="21" height="12" font="15">298.</text>
<text top="748" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref296">Tessier P, Mercier LA, Burelle D, et al. Results of percutaneous</a></text>
<text top="762" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref296">mitral commissurotomy in patients with a left atrial appendage</a></text>
<text top="775" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref296">thrombus detected by transesophageal echocardiography. J Am Soc</a></text>
<text top="789" left="91" width="122" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref296">Echocardiogr 1994;7:394</a></text>
<text top="786" left="213" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref296">–9</a></text>
<text top="789" left="224" width="3" height="12" font="15">.</text>
<text top="802" left="64" width="21" height="12" font="15">299.</text>
<text top="802" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref297">Horstkotte D, Niehues R, Strauer BE. Pathomorphological aspects,</a></text>
<text top="816" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref297">aetiology and natural history of acquired mitral valve stenosis. Eur</a></text>
<text top="829" left="91" width="136" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref297">Heart J 1991;12 Suppl B:55</a></text>
<text top="826" left="227" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref297">–60</a></text>
<text top="829" left="245" width="3" height="12" font="15">.</text>
<text top="843" left="64" width="21" height="12" font="15">300.</text>
<text top="843" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref298">Sagie A, Freitas N, Padial LR, et al. Doppler echocardiographic</a></text>
<text top="856" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref298">assessment of long-term progression of mitral stenosis in 103 pa-</a></text>
<text top="869" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref298">tients: valve area and right heart disease. J Am Coll Cardiol 1996;28:</a></text>
<text top="883" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref298">472</a></text>
<text top="880" left="109" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref298">–9</a></text>
<text top="883" left="121" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref298">.</a></text>
<text top="896" left="64" width="21" height="12" font="15">301.</text>
<text top="896" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref299">Rinkevich D, Lessick J, Mutlak D, et al. Natural history of moderate</a></text>
<text top="910" left="91" width="234" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref299">mitral valve stenosis. Isr Med Assoc J 2003;5:15</a></text>
<text top="907" left="325" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref299">–8</a></text>
<text top="910" left="337" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref299">.</a></text>
<text top="923" left="64" width="21" height="12" font="15">302.</text>
<text top="923" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref300">Suh WM, Kern MJ. Addressing the hemodynamic dilemma of</a></text>
<text top="937" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref300">combined mitral and aortic stenosis. Catheter Cardiovasc Interv</a></text>
<text top="950" left="91" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref300">2008;71:944</a></text>
<text top="947" left="151" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref300">–9</a></text>
<text top="950" left="163" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref300">.</a></text>
<text top="964" left="64" width="21" height="12" font="15">303.</text>
<text top="964" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref301">Gorlin R, Gorlin SG. Hydraulic formula for calculation of the area</a></text>
<text top="977" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref301">of the stenotic mitral valve, other cardiac valves, and central circu-</a></text>
<text top="990" left="91" width="189" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref301">latory shunts. I. Am Heart J 1951;41:1</a></text>
<text top="988" left="280" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref301">–29</a></text>
<text top="990" left="298" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref301">.</a></text>
<text top="1004" left="64" width="21" height="12" font="15">304.</text>
<text top="1004" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref302">Gorlin WB, Gorlin R. A generalized formulation of the Gorlin</a></text>
<text top="1017" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref302">formula for calculating the area of the stenotic mitral valve and other</a></text>
<text top="1031" left="91" width="266" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref302">stenotic cardiac valves. J Am Coll Cardiol 1990;15:246</a></text>
<text top="1028" left="357" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref302">–7</a></text>
<text top="1031" left="369" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref302">.</a></text>
<text top="1044" left="64" width="21" height="12" font="15">305.</text>
<text top="1044" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref303">Reis G, Motta MS, Barbosa MM, et al. Dobutamine stress echo-</a></text>
<text top="1058" left="91" width="273" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref303">cardiography for noninvasive assessment and risk strati</a></text>
<text top="1055" left="364" width="50" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref303">ﬁcation of</a></text>
<text top="1071" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref303">patients with rheumatic mitral stenosis. J Am Coll Cardiol 2004;43:</a></text>
<text top="1085" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref303">393</a></text>
<text top="1082" left="109" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref303">–401</a></text>
<text top="1085" left="133" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref303">.</a></text>
<text top="103" left="450" width="21" height="12" font="15">306.</text>
<text top="103" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref304">Cheriex EC, Pieters FA, Janssen JH, et al. Value of exercise</a></text>
<text top="116" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref304">Doppler-echocardiography in patients with mitral stenosis. Int J</a></text>
<text top="130" left="477" width="100" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref304">Cardiol 1994;45:219</a></text>
<text top="127" left="576" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref304">–26</a></text>
<text top="130" left="594" width="3" height="12" font="15">.</text>
<text top="143" left="450" width="21" height="12" font="15">307.</text>
<text top="143" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref305">Grimaldi A, Olivotto I, Figini F, et al. Dynamic assessment of</a></text>
<text top="154" left="477" width="323" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref305">’valvular reserve capacity’ in patients with rheumatic mitral stenosis.</a></text>
<text top="170" left="477" width="221" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref305">Eur Heart J Cardiovasc Imaging 2012;13:476</a></text>
<text top="167" left="697" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref305">–82</a></text>
<text top="170" left="715" width="3" height="12" font="15">.</text>
<text top="183" left="450" width="21" height="12" font="15">308.</text>
<text top="183" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref306">Cheitlin MD. Stress echocardiography in mitral stenosis: when is it</a></text>
<text top="197" left="477" width="190" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref306">useful? J Am Coll Cardiol 2004;43:402</a></text>
<text top="194" left="667" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref306">–4</a></text>
<text top="197" left="679" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref306">.</a></text>
<text top="210" left="450" width="21" height="12" font="15">309.</text>
<text top="210" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref307">Wilson JK, Greenwood WF. The natural history of mitral stenosis.</a></text>
<text top="224" left="477" width="150" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref307">Can Med Assoc J 1954;71:323</a></text>
<text top="221" left="627" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref307">–31</a></text>
<text top="224" left="645" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref307">.</a></text>
<text top="237" left="450" width="21" height="12" font="15">310.</text>
<text top="237" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref308">Rowe JC, Bland EF, Sprague HB, et al. The course of mitral ste-</a></text>
<text top="251" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref308">nosis without surgery: ten- and twenty-year perspectives. Ann Intern</a></text>
<text top="264" left="477" width="87" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref308">Med 1960;52:741</a></text>
<text top="261" left="563" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref308">–9</a></text>
<text top="264" left="575" width="3" height="12" font="15">.</text>
<text top="278" left="450" width="21" height="12" font="15">311.</text>
<text top="278" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref309">Olesen KH. The natural history of 271 patients with mitral stenosis</a></text>
<text top="291" left="477" width="240" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref309">under medical treatment. Br Heart J 1962;24:349</a></text>
<text top="288" left="716" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref309">–57</a></text>
<text top="291" left="734" width="3" height="12" font="15">.</text>
<text top="305" left="450" width="21" height="12" font="15">312.</text>
<text top="305" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref310">Szekely P. Systemic embolism and anticoagulant prophylaxis in</a></text>
<text top="318" left="477" width="229" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref310">rheumatic heart disease. Br Med J 1964;1:1209</a></text>
<text top="315" left="706" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref310">–12</a></text>
<text top="318" left="723" width="3" height="12" font="15">.</text>
<text top="331" left="450" width="21" height="12" font="15">313.</text>
<text top="331" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref311">Perez-Gomez F, Alegria E, Berjon J, et al. Comparative effects of</a></text>
<text top="345" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref311">antiplatelet, anticoagulant, or combined therapy in patients with</a></text>
<text top="358" left="477" width="142" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref311">valvular and nonvalvular atrial</a></text>
<text top="356" left="622" width="178" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref311">ﬁbrillation: a randomized multicenter</a></text>
<text top="372" left="477" width="192" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref311">study. J Am Coll Cardiol 2004;44:1557</a></text>
<text top="369" left="669" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref311">–66</a></text>
<text top="372" left="687" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref311">.</a></text>
<text top="385" left="450" width="21" height="12" font="15">314.</text>
<text top="385" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref312">Omran H, Rang B, Schmidt H, et al. Incidence of left atrial thrombi</a></text>
<text top="399" left="477" width="280" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref312">in patients in sinus rhythm and with a recent neurologic de</a></text>
<text top="396" left="757" width="43" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref312">ﬁcit. Am</a></text>
<text top="412" left="477" width="105" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref312">Heart J 2000;140:658</a></text>
<text top="409" left="582" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref312">–62</a></text>
<text top="412" left="600" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref312">.</a></text>
<text top="426" left="450" width="21" height="12" font="15">315.</text>
<text top="426" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref313">Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in</a></text>
<text top="439" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref313">atrial</a></text>
<text top="436" left="504" width="295" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref313">ﬁbrillation: American College of Chest Physicians Evidence-</a></text>
<text top="452" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref313">Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:</a></text>
<text top="466" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref313">546S</a></text>
<text top="463" left="501" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref313">–92S</a></text>
<text top="466" left="525" width="3" height="12" font="15">.</text>
<text top="479" left="450" width="21" height="12" font="15">316.</text>
<text top="479" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref314">Wood P. An appreciation of mitral stenosis. I. Clinical features. Br</a></text>
<text top="493" left="477" width="94" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref314">Med J 1954;1:1051</a></text>
<text top="490" left="571" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref314">–63</a></text>
<text top="493" left="589" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref314">.</a></text>
<text top="506" left="450" width="21" height="12" font="15">317.</text>
<text top="506" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref315">Stoll BC, Ashcom TL, Johns JP, et al. Effects of atenolol on rest</a></text>
<text top="520" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref315">and exercise hemodynamics in patients with mitral stenosis. Am J</a></text>
<text top="533" left="477" width="100" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref315">Cardiol 1995;75:482</a></text>
<text top="530" left="576" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref315">–4</a></text>
<text top="533" left="588" width="3" height="12" font="15">.</text>
<text top="547" left="450" width="21" height="12" font="15">318.</text>
<text top="547" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref316">Monmeneu Menadas JV, Marin OF, Reyes GF, et al. Beta-</a></text>
<text top="560" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref316">blockade and exercise capacity in patients with mitral stenosis in</a></text>
<text top="574" left="477" width="220" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref316">sinus rhythm. J Heart Valve Dis 2002;11:199</a></text>
<text top="571" left="697" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref316">–203</a></text>
<text top="574" left="720" width="3" height="12" font="15">.</text>
<text top="587" left="450" width="21" height="12" font="15">319.</text>
<text top="587" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref317">Ellis LB, Singh JB, Morales DD, et al. Fifteen-to twenty-year study</a></text>
<text top="600" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref317">of one thousand patients undergoing closed mitral valvuloplasty.</a></text>
<text top="614" left="477" width="117" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref317">Circulation 1973;48:357</a></text>
<text top="611" left="594" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref317">–64</a></text>
<text top="614" left="612" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref317">.</a></text>
<text top="627" left="450" width="21" height="12" font="15">320.</text>
<text top="627" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref318">John S, Bashi VV, Jairaj PS, et al. Closed mitral valvotomy: early</a></text>
<text top="641" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref318">results and long-term follow-up of 3724 consecutive patients. Cir-</a></text>
<text top="654" left="477" width="101" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref318">culation 1983;68:891</a></text>
<text top="652" left="578" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref318">–6</a></text>
<text top="654" left="590" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref318">.</a></text>
<text top="668" left="450" width="21" height="12" font="15">321.</text>
<text top="668" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref319">Finnegan JO, Gray DC, MacVaugh H III, et al. The open approach</a></text>
<text top="681" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref319">to mitral commissurotomy. J Thorac Cardiovasc Surg 1974;67:</a></text>
<text top="695" left="477" width="12" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref319">75</a></text>
<text top="692" left="489" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref319">–82</a></text>
<text top="695" left="507" width="3" height="12" font="15">.</text>
<text top="708" left="450" width="21" height="12" font="15">322.</text>
<text top="708" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref320">Mullin MJ, Engelman RM, Isom OW, et al. Experience with open</a></text>
<text top="721" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref320">mitral commissurotomy in 100 consecutive patients. Surgery 1974;</a></text>
<text top="735" left="477" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref320">76:974</a></text>
<text top="732" left="510" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref320">–82</a></text>
<text top="735" left="527" width="3" height="12" font="15">.</text>
<text top="748" left="450" width="21" height="12" font="15">323.</text>
<text top="748" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref321">Halseth WL, Elliott DP, Walker EL, et al. Open mitral commis-</a></text>
<text top="762" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref321">surotomy. A modern re-evaluation. J Thorac Cardiovasc Surg 1980;</a></text>
<text top="775" left="477" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref321">80:842</a></text>
<text top="773" left="510" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref321">–8</a></text>
<text top="775" left="521" width="3" height="12" font="15">.</text>
<text top="789" left="450" width="21" height="12" font="15">324.</text>
<text top="789" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref322">Gross RI, Cunningham JN Jr., Snively SL, et al. Long-term results</a></text>
<text top="802" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref322">of open radical mitral commissurotomy: ten year follow-up study of</a></text>
<text top="816" left="477" width="196" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref322">202 patients. Am J Cardiol 1981;47:821</a></text>
<text top="813" left="672" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref322">–5</a></text>
<text top="816" left="684" width="3" height="12" font="15">.</text>
<text top="829" left="450" width="21" height="12" font="15">325.</text>
<text top="829" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref323">Iung B, Cormier B, Ducimetiere P, et al. Functional results 5 years</a></text>
<text top="843" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref323">after successful percutaneous mitral commissurotomy in a series of</a></text>
<text top="856" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref323">528 patients and analysis of predictive factors. J Am Coll Cardiol</a></text>
<text top="869" left="477" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref323">1996;27:407</a></text>
<text top="867" left="536" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref323">–14</a></text>
<text top="869" left="554" width="3" height="12" font="15">.</text>
<text top="883" left="450" width="21" height="12" font="15">326.</text>
<text top="883" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref324">Arat N, Altay H, Korkmaz S, et al. The effect of baseline pulmonary</a></text>
<text top="896" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref324">artery pressure on right ventricular functions after mitral balloon</a></text>
<text top="910" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref324">valvuloplasty for rheumatic mitral stenosis: a tissue Doppler imaging</a></text>
<text top="923" left="477" width="214" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref324">study. Turk Kardiyol Dern Ars 2008;36:223</a></text>
<text top="921" left="691" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref324">–30</a></text>
<text top="923" left="709" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref324">.</a></text>
<text top="937" left="450" width="21" height="12" font="15">327.</text>
<text top="937" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref325">Vincens JJ, Temizer D, Post JR, et al. Long-term outcome of car-</a></text>
<text top="950" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref325">diac surgery in patients with mitral stenosis and severe pulmonary</a></text>
<text top="964" left="477" width="194" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref325">hypertension. Circulation 1995;92:II137</a></text>
<text top="961" left="671" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref325">–42</a></text>
<text top="964" left="688" width="3" height="12" font="15">.</text>
<text top="977" left="450" width="21" height="12" font="15">328.</text>
<text top="977" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref326">Bouleti C, Iung B, Laouenan C, et al. Late results of percutaneous</a></text>
<text top="990" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref326">mitral commissurotomy up to 20 years: development and validation</a></text>
<text top="1004" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref326">of a risk score predicting late functional results from a series of 912</a></text>
<text top="1017" left="477" width="173" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref326">patients. Circulation 2012;125:2119</a></text>
<text top="1015" left="650" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref326">–27</a></text>
<text top="1017" left="668" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref326">.</a></text>
<text top="1031" left="450" width="21" height="12" font="15">329.</text>
<text top="1031" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref327">Bhat A, Harikrishnan S, Tharakan JM, et al. Comparison of</a></text>
<text top="1044" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref327">percutaneous transmitral commissurotomy with Inoue balloon</a></text>
<text top="1058" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref327">technique and metallic commissurotomy: immediate and short-term</a></text>
<text top="1071" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref327">follow-up results of a randomized study. Am Heart J 2002;144:</a></text>
<text top="1085" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref327">1074</a></text>
<text top="1082" left="500" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref327">–80</a></text>
<text top="1085" left="518" width="3" height="12" font="15">.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e163</text>
</page>
<page number="108" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="21" height="12" font="15">330.</text>
<text top="103" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref328">Eltchaninoff H, Tron C, Cribier A. Effectiveness of percutaneous</a></text>
<text top="116" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref328">mechanical mitral commissurotomy using the metallic commissur-</a></text>
<text top="130" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref328">otome in patients with restenosis after balloon or previous surgical</a></text>
<text top="143" left="91" width="218" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref328">commissurotomy. Am J Cardiol 2003;91:425</a></text>
<text top="140" left="309" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref328">–8</a></text>
<text top="143" left="321" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref328">.</a></text>
<text top="157" left="64" width="21" height="12" font="15">331.</text>
<text top="157" left="91" width="280" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref329">Bouleti C, Iung B, Himbert D, et al. Long-term ef</a></text>
<text top="154" left="371" width="43" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref329">ﬁcacy of</a></text>
<text top="170" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref329">percutaneous mitral commissurotomy for restenosis after previous</a></text>
<text top="183" left="91" width="218" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref329">mitral commissurotomy. Heart 2013;99:1336</a></text>
<text top="181" left="309" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref329">–41</a></text>
<text top="183" left="327" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref329">.</a></text>
<text top="197" left="64" width="21" height="12" font="15">332.</text>
<text top="197" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref330">Chioin R, Razzolini R, Stritoni P, et al. Natural and post-surgical</a></text>
<text top="210" left="91" width="268" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref330">history of mitral stenosis and mitral stenosis and insuf</a></text>
<text top="208" left="359" width="55" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref330">ﬁciency: an</a></text>
<text top="224" left="91" width="224" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref330">observational study. Acta Cardiol 1985;40:447</a></text>
<text top="221" left="315" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref330">–60</a></text>
<text top="224" left="333" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref330">.</a></text>
<text top="237" left="64" width="21" height="12" font="15">333.</text>
<text top="237" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref331">Song H, Kang DH, Kim JH, et al. Percutaneous mitral valvuloplasty</a></text>
<text top="251" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref331">versus surgical treatment in mitral stenosis with severe tricuspid</a></text>
<text top="264" left="91" width="196" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref331">regurgitation. Circulation 2007;116:I246</a></text>
<text top="261" left="287" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref331">–50</a></text>
<text top="264" left="305" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref331">.</a></text>
<text top="278" left="64" width="21" height="12" font="15">334.</text>
<text top="278" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref332">Dahl JC, Winchell P, Borden CW. Mitral stenosis. A long term</a></text>
<text top="291" left="91" width="268" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref332">postoperative follow-up. Arch Intern Med 1967;119:92</a></text>
<text top="288" left="359" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref332">–7</a></text>
<text top="291" left="370" width="3" height="12" font="15">.</text>
<text top="305" left="64" width="21" height="12" font="15">335.</text>
<text top="305" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref333">Otto CM, Davis KB, Reid CL, et al. Relation between pulmonary</a></text>
<text top="318" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref333">artery pressure and mitral stenosis severity in patients undergoing</a></text>
<text top="331" left="91" width="289" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref333">balloon mitral commissurotomy. Am J Cardiol 1993;71:874</a></text>
<text top="329" left="380" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref333">–8</a></text>
<text top="331" left="392" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref333">.</a></text>
<text top="345" left="64" width="21" height="12" font="15">336.</text>
<text top="345" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref334">Chiang CW, Lo SK, Ko YS, et al. Predictors of systemic embolism</a></text>
<text top="358" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref334">in patients with mitral stenosis. A prospective study. Ann Intern</a></text>
<text top="372" left="91" width="93" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref334">Med 1998;128:885</a></text>
<text top="369" left="183" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref334">–9</a></text>
<text top="372" left="195" width="3" height="12" font="15">.</text>
<text top="385" left="64" width="21" height="12" font="15">337.</text>
<text top="385" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref335">Kanderian AS, Gillinov AM, Pettersson GB, et al. Success of sur-</a></text>
<text top="399" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref335">gical left atrial appendage closure: assessment by transesophageal</a></text>
<text top="412" left="91" width="244" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref335">echocardiography. J Am Coll Cardiol 2008;52:924</a></text>
<text top="409" left="335" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref335">–9</a></text>
<text top="412" left="347" width="3" height="12" font="15">.</text>
<text top="426" left="64" width="21" height="12" font="15">338.</text>
<text top="426" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref336">Akram MR, Chan T, McAuliffe S, et al. Non-rheumatic annular</a></text>
<text top="439" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref336">mitral stenosis: prevalence and characteristics. Eur J Echocardiogr</a></text>
<text top="452" left="91" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref336">2009;10:103</a></text>
<text top="450" left="151" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref336">–5</a></text>
<text top="452" left="163" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref336">.</a></text>
<text top="466" left="64" width="21" height="12" font="15">339.</text>
<text top="466" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref337">Schaverien MV, Freedom RM, McCrindle BW. Independent</a></text>
<text top="479" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref337">factors associated with outcomes of parachute mitral valve in 84</a></text>
<text top="493" left="91" width="173" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref337">patients. Circulation 2004;109:2309</a></text>
<text top="490" left="264" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref337">–13</a></text>
<text top="493" left="282" width="3" height="12" font="15">.</text>
<text top="506" left="64" width="21" height="12" font="15">340.</text>
<text top="506" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref338">Shone JD, Sellers RD, Anderson RC, et al. The developmental</a></text>
<text top="520" left="91" width="52" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref338">complex of</a></text>
<text top="517" left="146" width="268" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref338">“parachute mitral valve,” supravalvular ring of left atrium,</a></text>
<text top="533" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref338">subaortic stenosis, and coarctation of aorta. Am J Cardiol 1963;11:</a></text>
<text top="547" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref338">714</a></text>
<text top="544" left="109" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref338">–25</a></text>
<text top="547" left="127" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref338">.</a></text>
<text top="560" left="64" width="21" height="12" font="15">341.</text>
<text top="560" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref339">Asselbergs FW, Mozaffarian D, Katz R, et al. Association of renal</a></text>
<text top="574" left="91" width="123" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref339">function with cardiac calci</a></text>
<text top="571" left="215" width="200" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref339">ﬁcations in older adults: the cardiovascular</a></text>
<text top="587" left="91" width="249" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref339">health study. Nephrol Dial Transplant 2009;24:834</a></text>
<text top="584" left="340" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref339">–40</a></text>
<text top="587" left="358" width="3" height="12" font="15">.</text>
<text top="600" left="64" width="21" height="12" font="15">342.</text>
<text top="600" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref340">Ix JH, Shlipak MG, Katz R, et al. Kidney function and aortic valve</a></text>
<text top="614" left="91" width="124" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref340">and mitral annular calci</a></text>
<text top="611" left="216" width="198" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref340">ﬁcation in the Multi-Ethnic Study of</a></text>
<text top="627" left="91" width="275" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref340">Atherosclerosis (MESA). Am J Kidney Dis 2007;50:412</a></text>
<text top="625" left="366" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref340">–20</a></text>
<text top="627" left="384" width="3" height="12" font="15">.</text>
<text top="641" left="64" width="21" height="12" font="15">343.</text>
<text top="641" left="91" width="288" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref341">Rao AK, Djamali A, Korcarz CE, et al. Mitral annular calci</a></text>
<text top="638" left="379" width="35" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref341">ﬁcation</a></text>
<text top="654" left="91" width="268" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref341">is associated with reduced left ventricular function and in</a></text>
<text top="652" left="359" width="54" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref341">ﬂammation</a></text>
<text top="668" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref341">in patients with chronic kidney disease. J Am Soc Echocardiogr</a></text>
<text top="681" left="91" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref341">2008;21:747</a></text>
<text top="678" left="151" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref341">–50</a></text>
<text top="681" left="169" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref341">.</a></text>
<text top="695" left="64" width="21" height="12" font="15">344.</text>
<text top="695" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref342">Pressman GS, Agarwal A, Braitman LE, et al. Mitral annular cal-</a></text>
<text top="708" left="91" width="278" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref342">cium causing mitral stenosis. Am J Cardiol 2010;105:389</a></text>
<text top="705" left="369" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref342">–91</a></text>
<text top="708" left="387" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref342">.</a></text>
<text top="721" left="64" width="21" height="12" font="15">345.</text>
<text top="721" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref343">Jesri A, Braitman LE, Pressman GS. Severe mitral annular calci-</a></text>
<text top="732" left="91" width="323" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref343">ﬁcation predicts chronic kidney disease. Int J Cardiol 2008;128:</a></text>
<text top="748" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref343">193</a></text>
<text top="746" left="109" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref343">–6</a></text>
<text top="748" left="122" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref343">.</a></text>
<text top="762" left="64" width="21" height="12" font="15">346.</text>
<text top="762" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref344">Nataf P, Pavie A, Jault F, et al. Intraatrial insertion of a mitral</a></text>
<text top="775" left="91" width="162" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref344">prosthesis in a destroyed or calci</a></text>
<text top="773" left="253" width="161" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref344">ﬁed mitral annulus. Ann Thorac</a></text>
<text top="789" left="91" width="86" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref344">Surg 1994;58:163</a></text>
<text top="786" left="177" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref344">–7</a></text>
<text top="789" left="189" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref344">.</a></text>
<text top="802" left="64" width="21" height="12" font="15">347.</text>
<text top="802" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref345">Kato Y, Hattori K, Bito Y, et al. Simple supra-annular prosthesis</a></text>
<text top="816" left="91" width="312" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref345">insertion for dialysis patients with extensive mitral annular calci</a></text>
<text top="813" left="403" width="11" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref345">ﬁ-</a></text>
<text top="829" left="91" width="186" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref345">cation. J Heart Valve Dis 2011;20:180</a></text>
<text top="826" left="277" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref345">–3</a></text>
<text top="829" left="289" width="3" height="12" font="15">.</text>
<text top="843" left="64" width="21" height="12" font="15">348.</text>
<text top="843" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref346">McEnany MT. Mitral valve replacement in the presence of severe</a></text>
<text top="856" left="91" width="122" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref346">valvular and annular calci</a></text>
<text top="853" left="213" width="175" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref346">ﬁcation. J Card Surg 1993;8:117–24</a></text>
<text top="856" left="388" width="3" height="12" font="15">.</text>
<text top="869" left="64" width="21" height="12" font="15">349.</text>
<text top="869" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref347">Lin PY, Kan CD, Luo CY, et al. Mitral valve replacement in the</a></text>
<text top="883" left="91" width="216" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref347">presence of massive posterior annular calci</a></text>
<text top="880" left="307" width="107" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref347">ﬁcation. J Card Surg</a></text>
<text top="896" left="91" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref347">1999;14:266</a></text>
<text top="894" left="151" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref347">–9</a></text>
<text top="896" left="163" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref347">.</a></text>
<text top="910" left="64" width="21" height="12" font="15">350.</text>
<text top="910" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref348">Hussain ST, Idrees J, Brozzi NA, et al. Use of annulus washer after</a></text>
<text top="923" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref348">debridement: A new mitral valve replacement technique for patients</a></text>
<text top="937" left="91" width="153" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref348">with severe mitral annular calci</a></text>
<text top="934" left="244" width="170" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref348">ﬁcation. J Thorac Cardiovasc Surg</a></text>
<text top="950" left="91" width="72" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref348">2013;145:1672</a></text>
<text top="947" left="163" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref348">–4</a></text>
<text top="950" left="175" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref348">.</a></text>
<text top="964" left="64" width="21" height="12" font="15">351.</text>
<text top="964" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref349">Stellin G, Padalino MA, Vida VL, et al. Surgical repair of</a></text>
<text top="977" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref349">congenital mitral valve malformations in infancy and childhood: a</a></text>
<text top="990" left="91" width="78" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref349">single-center 36</a></text>
<text top="988" left="169" width="245" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref349">–year experience. J Thorac Cardiovasc Surg 2010;</a></text>
<text top="1004" left="91" width="45" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref349">140:1238</a></text>
<text top="1001" left="136" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref349">–44</a></text>
<text top="1004" left="154" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref349">.</a></text>
<text top="1017" left="64" width="21" height="12" font="15">352.</text>
<text top="1017" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref350">Hakim FA, Kendall CB, Alharthi M, et al. Parachute mitral</a></text>
<text top="1031" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref350">valve in adults-a systematic overview. Echocardiography 2010;27:</a></text>
<text top="1044" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref350">581</a></text>
<text top="1042" left="109" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref350">–6</a></text>
<text top="1044" left="121" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref350">.</a></text>
<text top="1058" left="64" width="21" height="12" font="15">353.</text>
<text top="1058" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref351">Yoran C, Yellin EL, Becker RM, et al. Mechanism of reduction of</a></text>
<text top="1071" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref351">mitral regurgitation with vasodilator therapy. Am J Cardiol 1979;43:</a></text>
<text top="1085" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref351">773</a></text>
<text top="1082" left="109" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref351">–7</a></text>
<text top="1085" left="121" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref351">.</a></text>
<text top="103" left="450" width="21" height="12" font="15">354.</text>
<text top="103" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref352">Horstkotte D, Schulte HD, Niehues R, et al. Diagnostic and</a></text>
<text top="116" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref352">therapeutic considerations in acute, severe mitral regurgitation:</a></text>
<text top="130" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref352">experience in 42 consecutive patients entering the intensive care unit</a></text>
<text top="143" left="477" width="262" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref352">with pulmonary edema. J Heart Valve Dis 1993;2:512</a></text>
<text top="140" left="738" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref352">–22</a></text>
<text top="143" left="756" width="3" height="12" font="15">.</text>
<text top="157" left="450" width="21" height="12" font="15">355.</text>
<text top="157" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref353">Nanjappa MC, Ananthakrishna R, Hemanna Setty SK, et al. Acute</a></text>
<text top="170" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref353">severe mitral regurgitation following balloon mitral valvotomy:</a></text>
<text top="184" left="477" width="178" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref353">echocardiographic features, operative</a></text>
<text top="181" left="659" width="140" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref353">ﬁndings, and outcome in 50</a></text>
<text top="197" left="477" width="263" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref353">surgical cases. Catheter Cardiovasc Interv 2013;81:603</a></text>
<text top="194" left="740" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref353">–8</a></text>
<text top="197" left="752" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref353">.</a></text>
<text top="210" left="450" width="21" height="12" font="15">356.</text>
<text top="210" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref354">Recusani F, Bargiggia GS, Yoganathan AP, et al. A new method for</a></text>
<text top="224" left="477" width="30" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref354">quanti</a></text>
<text top="221" left="507" width="293" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref354">ﬁcation of regurgitant ﬂow rate using color Doppler ﬂow</a></text>
<text top="237" left="477" width="76" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref354">imaging of the</a></text>
<text top="235" left="559" width="240" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref354">ﬂow convergence region proximal to a discrete</a></text>
<text top="251" left="477" width="13" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref354">ori</a></text>
<text top="248" left="490" width="255" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref354">ﬁce. An in vitro study. Circulation 1991;83:594–604</a></text>
<text top="251" left="744" width="3" height="12" font="15">.</text>
<text top="264" left="450" width="21" height="12" font="15">357.</text>
<text top="264" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref355">Bargiggia GS, Tronconi L, Sahn DJ, et al. A new method for</a></text>
<text top="278" left="477" width="252" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref355">quantitation of mitral regurgitation based on color</a></text>
<text top="275" left="734" width="66" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref355">ﬂow Doppler</a></text>
<text top="291" left="477" width="53" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref355">imaging of</a></text>
<text top="288" left="535" width="265" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref355">ﬂow convergence proximal to regurgitant oriﬁce. Cir-</a></text>
<text top="305" left="477" width="107" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref355">culation 1991;84:1481</a></text>
<text top="302" left="584" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref355">–9</a></text>
<text top="305" left="596" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref355">.</a></text>
<text top="318" left="450" width="21" height="12" font="15">358.</text>
<text top="318" left="477" width="275" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref356">Rivera JM, Vandervoort PM, Thoreau DH, et al. Quanti</a></text>
<text top="315" left="751" width="48" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref356">ﬁcation of</a></text>
<text top="331" left="477" width="184" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref356">mitral regurgitation with the proximal</a></text>
<text top="329" left="664" width="135" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref356">ﬂow convergence method: a</a></text>
<text top="345" left="477" width="202" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref356">clinical study. Am Heart J 1992;124:1289</a></text>
<text top="342" left="679" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref356">–96</a></text>
<text top="345" left="697" width="3" height="12" font="15">.</text>
<text top="358" left="450" width="21" height="12" font="15">359.</text>
<text top="358" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref357">Crawford MH, Souchek J, Oprian CA, et al. Determinants of</a></text>
<text top="372" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref357">survival and left ventricular performance after mitral valve replace-</a></text>
<text top="385" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref357">ment. Department of Veterans Affairs Cooperative Study on</a></text>
<text top="399" left="477" width="241" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref357">Valvular Heart Disease. Circulation 1990;81:1173</a></text>
<text top="396" left="718" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref357">–81</a></text>
<text top="399" left="736" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref357">.</a></text>
<text top="412" left="450" width="21" height="12" font="15">360.</text>
<text top="412" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref358">Enriquez-Sarano M, Tajik AJ, Schaff HV, et al. Echocardiographic</a></text>
<text top="426" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref358">prediction of survival after surgical correction of organic mitral</a></text>
<text top="439" left="477" width="185" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref358">regurgitation. Circulation 1994;90:830</a></text>
<text top="436" left="662" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref358">–7</a></text>
<text top="439" left="674" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref358">.</a></text>
<text top="452" left="450" width="21" height="12" font="15">361.</text>
<text top="452" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref359">Tribouilloy C, Grigioni F, Avierinos JF, et al. Survival implication</a></text>
<text top="466" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref359">of left ventricular end-systolic diameter in mitral regurgitation due to</a></text>
<text top="477" left="477" width="323" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref359">ﬂail leaﬂets a long-term follow-up multicenter study. J Am Coll</a></text>
<text top="493" left="477" width="106" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref359">Cardiol 2009;54:1961</a></text>
<text top="490" left="582" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref359">–8</a></text>
<text top="493" left="594" width="3" height="12" font="15">.</text>
<text top="506" left="450" width="21" height="12" font="15">362.</text>
<text top="506" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref360">Grigioni F, Tribouilloy C, Avierinos JF, et al. Outcomes in mitral</a></text>
<text top="520" left="477" width="94" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref360">regurgitation due to</a></text>
<text top="517" left="573" width="226" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref360">ﬂail leaﬂets a multicenter European study. J Am</a></text>
<text top="533" left="477" width="142" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref360">Coll Cardiol Img 2008;1:133</a></text>
<text top="530" left="618" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref360">–41</a></text>
<text top="533" left="636" width="3" height="12" font="15">.</text>
<text top="547" left="450" width="21" height="12" font="15">363.</text>
<text top="547" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref361">Ghoreishi M, Evans CF, deFilippi CR, et al. Pulmonary hyper-</a></text>
<text top="560" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref361">tension adversely affects short- and long-term survival after mitral</a></text>
<text top="574" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref361">valve operation for mitral regurgitation: implications for timing of</a></text>
<text top="587" left="477" width="240" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref361">surgery. J Thorac Cardiovasc Surg 2011;142:1439</a></text>
<text top="584" left="717" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref361">–52</a></text>
<text top="587" left="735" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref361">.</a></text>
<text top="600" left="450" width="21" height="12" font="15">364.</text>
<text top="600" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref362">Rozich JD, Carabello BA, Usher BW, et al. Mitral valve replace-</a></text>
<text top="614" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref362">ment with and without chordal preservation in patients with chronic</a></text>
<text top="627" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref362">mitral regurgitation. Mechanisms for differences in postoperative</a></text>
<text top="641" left="477" width="230" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref362">ejection performance. Circulation 1992;86:1718</a></text>
<text top="638" left="706" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref362">–26</a></text>
<text top="641" left="724" width="3" height="12" font="15">.</text>
<text top="654" left="450" width="21" height="12" font="15">365.</text>
<text top="654" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref363">Tribouilloy CM, Enriquez-Sarano M, Schaff HV, et al. Impact of</a></text>
<text top="668" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref363">preoperative symptoms on survival after surgical correction of</a></text>
<text top="681" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref363">organic mitral regurgitation: rationale for optimizing surgical in-</a></text>
<text top="695" left="477" width="166" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref363">dications. Circulation 1999;99:400</a></text>
<text top="692" left="643" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref363">–5</a></text>
<text top="695" left="655" width="3" height="12" font="15">.</text>
<text top="708" left="450" width="21" height="12" font="15">366.</text>
<text top="708" left="477" width="7" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref364">P</a></text>
<text top="705" left="484" width="316" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref364">ﬂugfelder PW, Sechtem UP, White RD, et al. Noninvasive eval-</a></text>
<text top="721" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref364">uation of mitral regurgitation by analysis of left atrial signal loss in</a></text>
<text top="735" left="477" width="257" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref364">cine magnetic resonance. Am Heart J 1989;117:1113</a></text>
<text top="732" left="734" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref364">–9</a></text>
<text top="735" left="746" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref364">.</a></text>
<text top="748" left="450" width="21" height="12" font="15">367.</text>
<text top="748" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref365">Pu M, Prior DL, Fan X, et al. Calculation of mitral regurgitant</a></text>
<text top="762" left="477" width="13" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref365">ori</a></text>
<text top="759" left="490" width="310" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref365">ﬁce area with use of a simpliﬁed proximal convergence method:</a></text>
<text top="775" left="477" width="306" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref365">initial clinical application. J Am Soc Echocardiogr 2001;14:180</a></text>
<text top="773" left="783" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref365">–5</a></text>
<text top="775" left="794" width="3" height="12" font="15">.</text>
<text top="789" left="450" width="21" height="12" font="15">368.</text>
<text top="789" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref366">Pu M, Vandervoort PM, Greenberg NL, et al. Impact of wall</a></text>
<text top="802" left="477" width="232" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref366">constraint on velocity distribution in proximal</a></text>
<text top="799" left="715" width="85" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref366">ﬂow convergence</a></text>
<text top="816" left="477" width="233" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref366">zone. Implications for color Doppler quanti</a></text>
<text top="813" left="710" width="90" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref366">ﬁcation of mitral</a></text>
<text top="829" left="477" width="222" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref366">regurgitation. J Am Coll Cardiol 1996;27:706</a></text>
<text top="826" left="699" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref366">–13</a></text>
<text top="829" left="717" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref366">.</a></text>
<text top="843" left="450" width="21" height="12" font="15">369.</text>
<text top="843" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref367">Lang RM, Badano LP, Tsang W, et al. EAE/ASE recommenda-</a></text>
<text top="856" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref367">tions for image acquisition and display using three-dimensional</a></text>
<text top="869" left="477" width="257" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref367">echocardiography. J Am Soc Echocardiogr 2012;25:3</a></text>
<text top="867" left="733" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref367">–46</a></text>
<text top="869" left="751" width="3" height="12" font="15">.</text>
<text top="883" left="450" width="21" height="12" font="15">370.</text>
<text top="883" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref368">Witkowski TG, Thomas JD, Debonnaire PJ, et al. Global longi-</a></text>
<text top="896" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref368">tudinal strain predicts left ventricular dysfunction after mitral valve</a></text>
<text top="910" left="477" width="249" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref368">repair. Eur Heart J Cardiovasc Imaging 2013;14:69</a></text>
<text top="907" left="725" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref368">–76</a></text>
<text top="910" left="743" width="3" height="12" font="15">.</text>
<text top="923" left="450" width="21" height="12" font="15">371.</text>
<text top="923" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref369">Magne J, Mahjoub H, Pierard LA, et al. Prognostic importance of</a></text>
<text top="937" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref369">brain natriuretic peptide and left ventricular longitudinal function in</a></text>
<text top="950" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref369">asymptomatic degenerative mitral regurgitation. Heart 2012;98:</a></text>
<text top="964" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref369">584</a></text>
<text top="961" left="495" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref369">–91</a></text>
<text top="964" left="512" width="3" height="12" font="15">.</text>
<text top="977" left="450" width="21" height="12" font="15">372.</text>
<text top="977" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref370">Ozdogan O, Yuksel A, Gurgun C, et al. Evaluation of the severity of</a></text>
<text top="990" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref370">mitral regurgitation by the use of signal void in magnetic resonance</a></text>
<text top="1004" left="477" width="201" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref370">imaging. Echocardiography 2009;26:1127</a></text>
<text top="1001" left="678" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref370">–35</a></text>
<text top="1004" left="696" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref370">.</a></text>
<text top="1017" left="450" width="21" height="12" font="15">373.</text>
<text top="1017" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref371">Myerson SG, Francis JM, Neubauer S. Direct and indirect quan-</a></text>
<text top="1031" left="477" width="7" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref371">ti</a></text>
<text top="1028" left="484" width="316" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref371">ﬁcation of mitral regurgitation with cardiovascular magnetic reso-</a></text>
<text top="1044" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref371">nance, and the effect of heart rate variability. MAGMA 2010;23:</a></text>
<text top="1058" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref371">243</a></text>
<text top="1055" left="495" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref371">–9</a></text>
<text top="1058" left="507" width="3" height="12" font="15">.</text>
<text top="1071" left="450" width="21" height="12" font="15">374.</text>
<text top="1071" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref372">Dahm M, Iversen S, Schmid FX, et al. Intraoperative evaluation of</a></text>
<text top="1085" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref372">reconstruction of the atrioventricular valves by transesophageal</a></text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e164</text>
</page>
<page number="109" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref372">echocardiography. Thorac Cardiovasc Surg 1987;35 Spec No 2:</a></text>
<text top="116" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref372">140</a></text>
<text top="113" left="109" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref372">–2</a></text>
<text top="116" left="121" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref372">.</a></text>
<text top="130" left="64" width="21" height="12" font="15">375.</text>
<text top="130" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref373">Saiki Y, Kasegawa H, Kawase M, et al. Intraoperative TEE during</a></text>
<text top="143" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref373">mitral valve repair: does it predict early and late postoperative mitral</a></text>
<text top="157" left="91" width="246" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref373">valve dysfunction? Ann Thorac Surg 1998;66:1277</a></text>
<text top="154" left="337" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref373">–81</a></text>
<text top="157" left="355" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref373">.</a></text>
<text top="170" left="64" width="21" height="12" font="15">376.</text>
<text top="170" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref374">Gillinov AM, Mihaljevic T, Blackstone EH, et al. Should patients</a></text>
<text top="183" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref374">with severe degenerative mitral regurgitation delay surgery until</a></text>
<text top="197" left="91" width="246" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref374">symptoms develop? Ann Thorac Surg 2010;90:481</a></text>
<text top="194" left="337" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref374">–8</a></text>
<text top="197" left="349" width="3" height="12" font="15">.</text>
<text top="210" left="64" width="21" height="12" font="15">377.</text>
<text top="210" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref375">Tischler MD, Cooper KA, Rowen M, et al. Mitral valve replace-</a></text>
<text top="224" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref375">ment versus mitral valve repair. A Doppler and quantitative stress</a></text>
<text top="237" left="91" width="239" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref375">echocardiographic study. Circulation 1994;89:132</a></text>
<text top="235" left="330" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref375">–7</a></text>
<text top="237" left="342" width="3" height="12" font="15">.</text>
<text top="251" left="64" width="21" height="12" font="15">378.</text>
<text top="251" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref376">Magne J, Lancellotti P, Pierard LA. Exercise-induced changes</a></text>
<text top="264" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref376">in degenerative mitral regurgitation. J Am Coll Cardiol 2010;56:</a></text>
<text top="278" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref376">300</a></text>
<text top="275" left="110" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref376">–9</a></text>
<text top="278" left="122" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref376">.</a></text>
<text top="291" left="64" width="21" height="12" font="15">379.</text>
<text top="291" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref377">Magne J, Lancellotti P, Pierard LA. Exercise pulmonary hyper-</a></text>
<text top="305" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref377">tension in asymptomatic degenerative mitral regurgitation. Circu-</a></text>
<text top="318" left="91" width="91" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref377">lation 2010;122:33</a></text>
<text top="315" left="182" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref377">–41</a></text>
<text top="318" left="200" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref377">.</a></text>
<text top="331" left="64" width="21" height="12" font="15">380.</text>
<text top="331" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref378">Magne J, Mahjoub H, Dulgheru R, et al. Left ventricular con-</a></text>
<text top="345" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref378">tractile reserve in asymptomatic primary mitral regurgitation. Eur</a></text>
<text top="358" left="91" width="64" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref378">Heart J 2013</a></text>
<text top="358" left="156" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref378">.</a></text>
<text top="372" left="64" width="21" height="12" font="15">381.</text>
<text top="372" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref379">Donal E, Mascle S, Brunet A, et al. Prediction of left ventricular</a></text>
<text top="385" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref379">ejection fraction 6 months after surgical correction of organic mitral</a></text>
<text top="399" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref379">regurgitation: the value of exercise echocardiography and deforma-</a></text>
<text top="412" left="91" width="289" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref379">tion imaging. Eur Heart J Cardiovasc Imaging 2012;13:922</a></text>
<text top="409" left="380" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref379">–30</a></text>
<text top="412" left="398" width="3" height="12" font="15">.</text>
<text top="426" left="64" width="21" height="12" font="15">382.</text>
<text top="426" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref380">Tsutsui H, Spinale FG, Nagatsu M, et al. Effects of chronic beta-</a></text>
<text top="439" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref380">adrenergic blockade on the left ventricular and cardiocyte abnor-</a></text>
<text top="452" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref380">malities of chronic canine mitral regurgitation. J Clin Invest 1994;</a></text>
<text top="466" left="91" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref380">93:2639</a></text>
<text top="463" left="130" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref380">–48</a></text>
<text top="466" left="148" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref380">.</a></text>
<text top="479" left="64" width="21" height="12" font="15">383.</text>
<text top="479" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref381">Varadarajan P, Joshi N, Appel D, et al. Effect of Beta-blocker</a></text>
<text top="493" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref381">therapy on survival in patients with severe mitral regurgitation and</a></text>
<text top="506" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref381">normal left ventricular ejection fraction. Am J Cardiol 2008;102:</a></text>
<text top="520" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref381">611</a></text>
<text top="517" left="109" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref381">–5</a></text>
<text top="520" left="121" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref381">.</a></text>
<text top="533" left="64" width="21" height="12" font="15">384.</text>
<text top="533" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref382">Ahmed MI, Aban I, Lloyd SG, et al. A randomized controlled</a></text>
<text top="547" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref382">phase IIb trial of beta(1)-receptor blockade for chronic degenerative</a></text>
<text top="560" left="91" width="254" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref382">mitral regurgitation. J Am Coll Cardiol 2012;60:833</a></text>
<text top="557" left="346" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref382">–8</a></text>
<text top="560" left="357" width="3" height="12" font="15">.</text>
<text top="574" left="64" width="21" height="12" font="15">385.</text>
<text top="574" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref383">Nemoto S, Hamawaki M, De Freitas G, et al. Differential effects of</a></text>
<text top="587" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref383">the angiotensin-converting enzyme inhibitor lisinopril versus the</a></text>
<text top="600" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref383">beta-adrenergic receptor blocker atenolol on hemodynamics and left</a></text>
<text top="614" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref383">ventricular contractile function in experimental mitral regurgitation.</a></text>
<text top="627" left="91" width="154" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref383">J Am Coll Cardiol 2002;40:149</a></text>
<text top="625" left="245" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref383">–54</a></text>
<text top="627" left="263" width="3" height="12" font="15">.</text>
<text top="641" left="64" width="21" height="12" font="15">386.</text>
<text top="641" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref384">Schon HR. Hemodynamic and morphologic changes after long-</a></text>
<text top="654" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref384">term angiotensin converting enzyme inhibition in patients with</a></text>
<text top="668" left="91" width="296" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref384">chronic valvular regurgitation. J Hypertens Suppl 1994;12:S95</a></text>
<text top="665" left="387" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref384">–104</a></text>
<text top="668" left="411" width="3" height="12" font="15">.</text>
<text top="681" left="64" width="21" height="12" font="15">387.</text>
<text top="681" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref385">Tischler MD, Rowan M, LeWinter MM. Effect of enalapril ther-</a></text>
<text top="695" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref385">apy on left ventricular mass and volumes in asymptomatic chronic,</a></text>
<text top="708" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref385">severe mitral regurgitation secondary to mitral valve prolapse. Am J</a></text>
<text top="721" left="91" width="99" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref385">Cardiol 1998;82:242</a></text>
<text top="719" left="191" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref385">–5</a></text>
<text top="721" left="203" width="3" height="12" font="15">.</text>
<text top="735" left="64" width="21" height="12" font="15">388.</text>
<text top="735" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref386">Wisenbaugh T, Sinovich V, Dullabh A, et al. Six month pilot study</a></text>
<text top="748" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref386">of captopril for mildly symptomatic, severe isolated mitral and iso-</a></text>
<text top="762" left="91" width="270" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref386">lated aortic regurgitation. J Heart Valve Dis 1994;3:197</a></text>
<text top="759" left="361" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref386">–204</a></text>
<text top="762" left="385" width="3" height="12" font="15">.</text>
<text top="775" left="64" width="21" height="12" font="15">389.</text>
<text top="775" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref387">Dujardin KS, Enriquez-Sarano M, Bailey KR, et al. Effect of los-</a></text>
<text top="789" left="91" width="224" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref387">artan on degree of mitral regurgitation quanti</a></text>
<text top="786" left="315" width="99" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref387">ﬁed by echocardiog-</a></text>
<text top="802" left="91" width="163" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref387">raphy. Am J Cardiol 2001;87:570</a></text>
<text top="799" left="254" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref387">–6</a></text>
<text top="802" left="266" width="3" height="12" font="15">.</text>
<text top="816" left="64" width="21" height="12" font="15">390.</text>
<text top="816" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref388">Harris KM, Aeppli DM, Carey CF. Effects of angiotensin-</a></text>
<text top="829" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref388">converting enzyme inhibition on mitral regurgitation severity, left</a></text>
<text top="843" left="91" width="320" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref388">ventricular size, and functional capacity. Am Heart J 2005;150:1106</a></text>
<text top="843" left="411" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref388">.</a></text>
<text top="856" left="64" width="21" height="12" font="15">391.</text>
<text top="856" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref389">Kizilbash AM, Willett DL, Brickner ME, et al. Effects of afterload</a></text>
<text top="869" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref389">reduction on vena contracta width in mitral regurgitation. J Am Coll</a></text>
<text top="883" left="91" width="99" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref389">Cardiol 1998;32:427</a></text>
<text top="880" left="191" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref389">–31</a></text>
<text top="883" left="208" width="3" height="12" font="15">.</text>
<text top="896" left="64" width="21" height="12" font="15">392.</text>
<text top="896" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref390">Grigioni F, Enriquez-Sarano M, Ling LH, et al. Sudden death in</a></text>
<text top="910" left="91" width="127" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref390">mitral regurgitation due to</a></text>
<text top="907" left="222" width="192" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref390">ﬂail leaﬂet. J Am Coll Cardiol 1999;34:</a></text>
<text top="923" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref390">2078</a></text>
<text top="921" left="115" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref390">–85</a></text>
<text top="923" left="133" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref390">.</a></text>
<text top="937" left="64" width="21" height="12" font="15">393.</text>
<text top="937" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref391">Schuler G, Peterson KL, Johnson A, et al. Temporal response of left</a></text>
<text top="950" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref391">ventricular performance to mitral valve surgery. Circulation 1979;59:</a></text>
<text top="964" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref391">1218</a></text>
<text top="961" left="115" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref391">–31</a></text>
<text top="964" left="133" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref391">.</a></text>
<text top="977" left="64" width="21" height="12" font="15">394.</text>
<text top="977" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref392">Starling MR. Effects of valve surgery on left ventricular contractile</a></text>
<text top="990" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref392">function in patients with long-term mitral regurgitation. Circulation</a></text>
<text top="1004" left="91" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref392">1995;92:811</a></text>
<text top="1001" left="151" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref392">–8</a></text>
<text top="1004" left="163" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref392">.</a></text>
<text top="1017" left="64" width="21" height="12" font="15">395.</text>
<text top="1017" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref393">Rushmer RF. Initial phase of ventricular systole: asynchronous</a></text>
<text top="1031" left="91" width="195" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref393">contraction. Am J Physiol 1956;184:188</a></text>
<text top="1028" left="286" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref393">–94</a></text>
<text top="1031" left="304" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref393">.</a></text>
<text top="1044" left="64" width="21" height="12" font="15">396.</text>
<text top="1044" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref394">Hansen DE, Sarris GE, Niczyporuk MA, et al. Physiologic role of</a></text>
<text top="1058" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref394">the mitral apparatus in left ventricular regional mechanics, contrac-</a></text>
<text top="1071" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref394">tion synergy, and global systolic performance. J Thorac Cardiovasc</a></text>
<text top="1085" left="91" width="85" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref394">Surg 1989;97:521</a></text>
<text top="1082" left="176" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref394">–33</a></text>
<text top="1085" left="194" width="3" height="12" font="15">.</text>
<text top="103" left="450" width="21" height="12" font="15">397.</text>
<text top="103" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref395">Sarris GE, Cahill PD, Hansen DE, et al. Restoration of left ven-</a></text>
<text top="116" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref395">tricular systolic performance after reattachment of the mitral chordae</a></text>
<text top="130" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref395">tendineae. The importance of valvular-ventricular interaction.</a></text>
<text top="143" left="477" width="188" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref395">J Thorac Cardiovasc Surg 1988;95:969</a></text>
<text top="140" left="664" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref395">–79</a></text>
<text top="143" left="682" width="3" height="12" font="15">.</text>
<text top="157" left="450" width="21" height="12" font="15">398.</text>
<text top="157" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref396">Goldman ME, Mora F, Guarino T, et al. Mitral valvuloplasty is</a></text>
<text top="170" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref396">superior to valve replacement for preservation of left ventricular</a></text>
<text top="183" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref396">function: an intraoperative two-dimensional echocardiographic</a></text>
<text top="197" left="477" width="186" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref396">study. J Am Coll Cardiol 1987;10:568</a></text>
<text top="194" left="663" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref396">–75</a></text>
<text top="197" left="681" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref396">.</a></text>
<text top="210" left="450" width="21" height="12" font="15">399.</text>
<text top="210" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref397">David TE, Burns RJ, Bacchus CM, et al. Mitral valve replacement</a></text>
<text top="224" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref397">for mitral regurgitation with and without preservation of chordae</a></text>
<text top="237" left="477" width="240" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref397">tendineae. J Thorac Cardiovasc Surg 1984;88:718</a></text>
<text top="235" left="717" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref397">–25</a></text>
<text top="237" left="735" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref397">.</a></text>
<text top="251" left="450" width="21" height="12" font="15">400.</text>
<text top="251" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref398">Hennein HA, Swain JA, McIntosh CL, et al. Comparative</a></text>
<text top="264" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref398">assessment of chordal preservation versus chordal resection dur-</a></text>
<text top="278" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref398">ing mitral valve replacement. J Thorac Cardiovasc Surg 1990;99:</a></text>
<text top="291" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref398">828</a></text>
<text top="288" left="495" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref398">–36</a></text>
<text top="291" left="514" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref398">.</a></text>
<text top="305" left="450" width="21" height="12" font="15">401.</text>
<text top="305" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref399">Cohn LH. Surgery for mitral regurgitation. JAMA 1988;260:</a></text>
<text top="318" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref399">2883</a></text>
<text top="315" left="501" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref399">–7</a></text>
<text top="318" left="513" width="3" height="12" font="15">.</text>
<text top="331" left="450" width="21" height="12" font="15">402.</text>
<text top="331" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref400">Cosgrove DM, Chavez AM, Lytle BW, et al. Results of mitral valve</a></text>
<text top="345" left="477" width="190" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref400">reconstruction. Circulation 1986;74:I82</a></text>
<text top="342" left="667" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref400">–7</a></text>
<text top="345" left="679" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref400">.</a></text>
<text top="358" left="450" width="235" height="12" font="15">403. STS online risk calculator. Available at:</text>
<text top="358" left="690" width="109" height="12" font="22"><a href="http://riskcalc.sts.org/STSWebRiskCalc273/de.aspx">http://riskcalc.sts.org/</a></text>
<text top="372" left="477" width="150" height="12" font="22"><a href="http://riskcalc.sts.org/STSWebRiskCalc273/de.aspx">STSWebRiskCalc273/de.aspx</a></text>
<text top="372" left="627" width="173" height="12" font="15"><a href="http://riskcalc.sts.org/STSWebRiskCalc273/de.aspx">. </a>2013. Accessed on February 20,</text>
<text top="385" left="477" width="28" height="12" font="15">2014.</text>
<text top="399" left="450" width="21" height="12" font="15">404.</text>
<text top="399" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref401">David TE, Uden DE, Strauss HD. The importance of the mitral</a></text>
<text top="412" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref401">apparatus in left ventricular function after correction of mitral</a></text>
<text top="426" left="477" width="188" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref401">regurgitation. Circulation 1983;68:II76</a></text>
<text top="423" left="665" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref401">–82</a></text>
<text top="426" left="683" width="3" height="12" font="15">.</text>
<text top="439" left="450" width="21" height="12" font="15">405.</text>
<text top="439" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref402">Horskotte D, Schulte HD, Bircks W, et al. The effect of chordal</a></text>
<text top="452" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref402">preservation on late outcome after mitral valve replacement: a ran-</a></text>
<text top="466" left="477" width="221" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref402">domized study. J Heart Valve Dis 1993;2:150</a></text>
<text top="463" left="698" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref402">–8</a></text>
<text top="466" left="710" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref402">.</a></text>
<text top="479" left="450" width="21" height="12" font="15">406.</text>
<text top="479" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref403">Vassileva CM, Mishkel G, McNeely C, et al. Long-term survival of</a></text>
<text top="493" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref403">patients undergoing mitral valve repair and replacement: a longitu-</a></text>
<text top="506" left="477" width="226" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref403">dinal analysis of Medicare fee-for-service bene</a></text>
<text top="504" left="703" width="97" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref403">ﬁciaries. Circulation</a></text>
<text top="520" left="477" width="72" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref403">2013;127:1870</a></text>
<text top="517" left="548" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref403">–6</a></text>
<text top="520" left="560" width="3" height="12" font="15">.</text>
<text top="533" left="450" width="21" height="12" font="15">407.</text>
<text top="533" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref404">Braunberger E, Deloche A, Berrebi A, et al. Very long-term re-</a></text>
<text top="547" left="477" width="286" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref404">sults (more than 20 years) of valve repair with carpentier</a></text>
<text top="544" left="763" width="37" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref404">’s tech-</a></text>
<text top="560" left="477" width="220" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref404">niques in nonrheumatic mitral valve insuf</a></text>
<text top="557" left="697" width="102" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref404">ﬁciency. Circulation</a></text>
<text top="574" left="477" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref404">2001;104:I8</a></text>
<text top="571" left="537" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref404">–11</a></text>
<text top="574" left="555" width="3" height="12" font="15">.</text>
<text top="587" left="450" width="21" height="12" font="15">408.</text>
<text top="587" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref405">David TE, Ivanov J, Armstrong S, et al. A comparison of outcomes</a></text>
<text top="600" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref405">of mitral valve repair for degenerative disease with posterior, anterior,</a></text>
<text top="614" left="477" width="43" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref405">and bilea</a></text>
<text top="611" left="520" width="274" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref405">ﬂet prolapse. J Thorac Cardiovasc Surg 2005;130:1242–9</a></text>
<text top="614" left="794" width="3" height="12" font="15">.</text>
<text top="627" left="450" width="21" height="12" font="15">409.</text>
<text top="627" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref406">McClure RS, Athanasopoulos LV, McGurk S, et al. One thousand</a></text>
<text top="641" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref406">minimally invasive mitral valve operations: early outcomes, late</a></text>
<text top="654" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref406">outcomes, and echocardiographic follow-up. J Thorac Cardiovasc</a></text>
<text top="668" left="477" width="98" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref406">Surg 2013;145:1199</a></text>
<text top="665" left="574" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref406">–206</a></text>
<text top="668" left="598" width="3" height="12" font="15">.</text>
<text top="681" left="450" width="21" height="12" font="15">410.</text>
<text top="681" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref407">Chikwe J, Goldstone AB, Passage J, et al. A propensity score-</a></text>
<text top="695" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref407">adjusted retrospective comparison of early and mid-term results of</a></text>
<text top="708" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref407">mitral valve repair versus replacement in octogenarians. Eur Heart J</a></text>
<text top="721" left="477" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref407">2011;32:618</a></text>
<text top="719" left="536" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref407">–26</a></text>
<text top="721" left="554" width="3" height="12" font="15">.</text>
<text top="735" left="450" width="21" height="12" font="15">411.</text>
<text top="735" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref408">Badhwar V, Peterson ED, Jacobs JP, et al. Longitudinal outcome of</a></text>
<text top="748" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref408">isolated mitral repair in older patients: results from 14,604 pro-</a></text>
<text top="762" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref408">cedures performed from 1991 to 2007. Ann Thorac Surg 2012;94:</a></text>
<text top="775" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref408">1870</a></text>
<text top="773" left="500" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref408">–7</a></text>
<text top="775" left="512" width="3" height="12" font="15">.</text>
<text top="789" left="450" width="21" height="12" font="15">412.</text>
<text top="789" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref409">Grossi EA, Galloway AC, Miller JS, et al. Valve repair versus</a></text>
<text top="802" left="477" width="133" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref409">replacement for mitral insuf</a></text>
<text top="799" left="609" width="190" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref409">ﬁciency: when is a mechanical valve still</a></text>
<text top="816" left="477" width="246" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref409">indicated? J Thorac Cardiovasc Surg 1998;115:389</a></text>
<text top="813" left="722" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref409">–94</a></text>
<text top="816" left="740" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref409">.</a></text>
<text top="829" left="450" width="21" height="12" font="15">413.</text>
<text top="829" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref410">Chauvaud S, Fuzellier JF, Berrebi A, et al. Long-term (29 years)</a></text>
<text top="843" left="477" width="312" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref410">results of reconstructive surgery in rheumatic mitral valve insuf</a></text>
<text top="840" left="788" width="11" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref410">ﬁ-</a></text>
<text top="856" left="477" width="158" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref410">ciency. Circulation 2001;104:I12</a></text>
<text top="853" left="634" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref410">–5</a></text>
<text top="856" left="646" width="3" height="12" font="15">.</text>
<text top="869" left="450" width="21" height="12" font="15">414.</text>
<text top="869" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref411">Gillinov AM, Blackstone EH, Cosgrove DM III, et al. Mitral valve</a></text>
<text top="883" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref411">repair with aortic valve replacement is superior to double valve</a></text>
<text top="896" left="477" width="264" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref411">replacement. J Thorac Cardiovasc Surg 2003;125:1372</a></text>
<text top="894" left="741" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref411">–87</a></text>
<text top="896" left="758" width="3" height="12" font="15">.</text>
<text top="910" left="450" width="21" height="12" font="15">415.</text>
<text top="910" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref412">Kang DH, Kim JH, Rim JH, et al. Comparison of early surgery</a></text>
<text top="923" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref412">versus conventional treatment in asymptomatic severe mitral</a></text>
<text top="937" left="477" width="191" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref412">regurgitation. Circulation 2009;119:797</a></text>
<text top="934" left="668" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref412">–804</a></text>
<text top="937" left="692" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref412">.</a></text>
<text top="950" left="450" width="21" height="12" font="15">416.</text>
<text top="950" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref413">Gillinov AM, Blackstone EH, Nowicki ER, et al. Valve repair</a></text>
<text top="964" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref413">versus valve replacement for degenerative mitral valve disease.</a></text>
<text top="977" left="477" width="194" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref413">J Thorac Cardiovasc Surg 2008;135:885</a></text>
<text top="974" left="670" width="43" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref413">–93, 893</a></text>
<text top="977" left="713" width="3" height="12" font="15">.</text>
<text top="990" left="450" width="21" height="12" font="15">417.</text>
<text top="990" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref414">Duran CM, Gometza B, Saad E. Valve repair in rheumatic mitral</a></text>
<text top="1004" left="477" width="262" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref414">disease: an unsolved problem. J Card Surg 1994;9:282</a></text>
<text top="1001" left="739" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref414">–5</a></text>
<text top="1004" left="751" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref414">.</a></text>
<text top="1017" left="450" width="21" height="12" font="15">418.</text>
<text top="1017" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref415">Suri RM, Vanoverschelde JL, Grigioni F, et al. Association between</a></text>
<text top="1031" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref415">early surgical intervention vs watchful waiting and outcomes for</a></text>
<text top="1044" left="477" width="130" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref415">mitral regurgitation due to</a></text>
<text top="1042" left="612" width="188" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref415">ﬂail mitral valve leaﬂets. JAMA 2013;</a></text>
<text top="1058" left="477" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref415">310:609</a></text>
<text top="1055" left="515" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref415">–16</a></text>
<text top="1058" left="533" width="3" height="12" font="15">.</text>
<text top="1071" left="450" width="21" height="12" font="15">419.</text>
<text top="1071" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref416">Suri RM, Schaff HV, Dearani JA, et al. Recovery of left ven-</a></text>
<text top="1085" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref416">tricular function after surgical correction of mitral regurgitation</a></text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e165</text>
</page>
<page number="110" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="91" width="67" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref416">caused by lea</a></text>
<text top="100" left="159" width="255" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref416">ﬂet prolapse. J Thorac Cardiovasc Surg 2009;137:</a></text>
<text top="116" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref416">1071</a></text>
<text top="113" left="115" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref416">–6</a></text>
<text top="116" left="128" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref416">.</a></text>
<text top="130" left="64" width="21" height="12" font="15">420.</text>
<text top="130" left="91" width="216" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref417">Ngaage DL, Schaff HV, Mullany CJ, et al. In</a></text>
<text top="127" left="308" width="106" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref417">ﬂuence of preoperative</a></text>
<text top="143" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref417">atrial</a></text>
<text top="140" left="121" width="293" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref417">ﬁbrillation on late results of mitral repair: is concomitant</a></text>
<text top="157" left="91" width="62" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref417">ablation justi</a></text>
<text top="154" left="153" width="193" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref417">ﬁed? Ann Thorac Surg 2007;84:434–42</a></text>
<text top="157" left="346" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref417">.</a></text>
<text top="170" left="64" width="21" height="12" font="15">421.</text>
<text top="170" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref418">Raine D, Dark J, Bourke JP. Effect of mitral valve repair/replace-</a></text>
<text top="183" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref418">ment surgery on atrial arrhythmia behavior. J Heart Valve Dis 2004;</a></text>
<text top="197" left="91" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref418">13:615</a></text>
<text top="194" left="124" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref418">–21</a></text>
<text top="197" left="142" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref418">.</a></text>
<text top="210" left="64" width="21" height="12" font="15">422.</text>
<text top="210" left="91" width="201" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref419">Cox JL. The surgical treatment of atrial</a></text>
<text top="208" left="297" width="117" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref419">ﬁbrillation. IV. Surgical</a></text>
<text top="224" left="91" width="247" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref419">technique. J Thorac Cardiovasc Surg 1991;101:584</a></text>
<text top="221" left="338" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref419">–92</a></text>
<text top="224" left="356" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref419">.</a></text>
<text top="237" left="64" width="21" height="12" font="15">423.</text>
<text top="237" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref420">Kobayashi J, Kosakai Y, Isobe F, et al. Rationale of the Cox maze</a></text>
<text top="251" left="91" width="92" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref420">procedure for atrial</a></text>
<text top="248" left="188" width="226" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref420">ﬁbrillation during redo mitral valve operations.</a></text>
<text top="264" left="91" width="200" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref420">J Thorac Cardiovasc Surg 1996;112:1216</a></text>
<text top="261" left="291" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref420">–21</a></text>
<text top="264" left="309" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref420">.</a></text>
<text top="278" left="64" width="21" height="12" font="15">424.</text>
<text top="278" left="91" width="294" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref421">Kawaguchi AT, Kosakai Y, Sasako Y, et al. Risks and bene</a></text>
<text top="275" left="386" width="28" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref421">ﬁts of</a></text>
<text top="291" left="91" width="184" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref421">combined maze procedure for atrial</a></text>
<text top="288" left="282" width="132" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref421">ﬁbrillation associated with</a></text>
<text top="305" left="91" width="260" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref421">organic heart disease. J Am Coll Cardiol 1996;28:985</a></text>
<text top="302" left="351" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref421">–90</a></text>
<text top="305" left="369" width="3" height="12" font="15">.</text>
<text top="318" left="64" width="21" height="12" font="15">425.</text>
<text top="318" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref422">Olasinska-Wisniewska A, Mularek-Kubzdela T, Grajek S, et al.</a></text>
<text top="331" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref422">Impact of atrial remodeling on heart rhythm after radiofrequency</a></text>
<text top="345" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref422">ablation and mitral valve operations. Ann Thorac Surg 2012;93:</a></text>
<text top="358" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref422">1449</a></text>
<text top="356" left="115" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref422">–55</a></text>
<text top="358" left="133" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref422">.</a></text>
<text top="372" left="64" width="21" height="12" font="15">426.</text>
<text top="372" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref423">Feldman T, Foster E, Glower DD, et al. Percutaneous repair or</a></text>
<text top="385" left="91" width="296" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref423">surgery for mitral regurgitation. N Engl J Med 2011;364:1395</a></text>
<text top="382" left="387" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref423">–406</a></text>
<text top="385" left="411" width="3" height="12" font="15">.</text>
<text top="399" left="64" width="21" height="12" font="15">427.</text>
<text top="399" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref424">Suri RM, Burkhart HM, Daly RC, et al. Robotic mitral valve repair</a></text>
<text top="412" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref424">for all prolapse subsets using techniques identical to open valvulo-</a></text>
<text top="426" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref424">plasty: establishing the benchmark against which percutaneous in-</a></text>
<text top="439" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref424">terventions should be judged. J Thorac Cardiovasc Surg 2011;142:</a></text>
<text top="452" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref424">970</a></text>
<text top="450" left="109" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref424">–9</a></text>
<text top="452" left="121" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref424">.</a></text>
<text top="466" left="64" width="21" height="12" font="15">428.</text>
<text top="466" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref425">Holzhey DM, Seeburger J, Misfeld M, et al. Learning minimally</a></text>
<text top="479" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref425">invasive mitral valve surgery: a cumulative sum sequential probability</a></text>
<text top="493" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref425">analysis of 3895 operations from a single high-volume center. Cir-</a></text>
<text top="506" left="91" width="107" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref425">culation 2013;128:483</a></text>
<text top="504" left="198" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref425">–91</a></text>
<text top="506" left="216" width="3" height="12" font="15">.</text>
<text top="520" left="64" width="21" height="12" font="15">429.</text>
<text top="520" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref426">Mihaljevic T, Jarrett CM, Gillinov AM, et al. Robotic repair of</a></text>
<text top="533" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref426">posterior mitral valve prolapse versus conventional approaches: po-</a></text>
<text top="547" left="91" width="265" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref426">tential realized. J Thorac Cardiovasc Surg 2011;141:72</a></text>
<text top="544" left="356" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref426">–80</a></text>
<text top="547" left="374" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref426">.</a></text>
<text top="560" left="64" width="21" height="12" font="15">430.</text>
<text top="560" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref427">Arcidi JM Jr., Rodriguez E, Elbeery JR, et al. Fifteen-year experi-</a></text>
<text top="574" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref427">ence with minimally invasive approach for reoperations involving the</a></text>
<text top="587" left="91" width="262" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref427">mitral valve. J Thorac Cardiovasc Surg 2012;143:1062</a></text>
<text top="584" left="353" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref427">–8</a></text>
<text top="587" left="365" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref427">.</a></text>
<text top="600" left="64" width="21" height="12" font="15">431.</text>
<text top="600" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref428">Suri RM, Schaff HV, Meyer SR, et al. Thoracoscopic versus open</a></text>
<text top="614" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref428">mitral valve repair: a propensity score analysis of early outcomes.</a></text>
<text top="627" left="91" width="155" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref428">Ann Thorac Surg 2009;88:1185</a></text>
<text top="625" left="246" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref428">–90</a></text>
<text top="627" left="264" width="3" height="12" font="15">.</text>
<text top="641" left="64" width="21" height="12" font="15">432.</text>
<text top="641" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref429">Suri RM, Schaff HV, Dearani JA, et al. Survival advantage and</a></text>
<text top="654" left="91" width="199" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref429">improved durability of mitral repair for lea</a></text>
<text top="652" left="290" width="124" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref429">ﬂet prolapse subsets in the</a></text>
<text top="668" left="91" width="208" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref429">current era. Ann Thorac Surg 2006;82:819</a></text>
<text top="665" left="299" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref429">–26</a></text>
<text top="668" left="317" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref429">.</a></text>
<text top="681" left="64" width="21" height="12" font="15">433.</text>
<text top="681" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref430">Suri RM, Aviernos JF, Dearani JA, et al. Management of less-than-</a></text>
<text top="695" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref430">severe mitral regurgitation: should guidelines recommend earlier</a></text>
<text top="708" left="91" width="288" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref430">surgical intervention? Eur J Cardiothorac Surg 2011;40:496</a></text>
<text top="705" left="379" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref430">–502</a></text>
<text top="708" left="403" width="3" height="12" font="15">.</text>
<text top="721" left="64" width="21" height="12" font="15">434.</text>
<text top="721" left="91" width="73" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref431">Gammie JS, O</a></text>
<text top="719" left="165" width="249" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref431">’Brien SM, Grifﬁth BP, et al. Inﬂuence of hospital</a></text>
<text top="735" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref431">procedural volume on care process and mortality for patients un-</a></text>
<text top="748" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref431">dergoing elective surgery for mitral regurgitation. Circulation 2007;</a></text>
<text top="762" left="91" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref431">115:881</a></text>
<text top="759" left="130" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref431">–7</a></text>
<text top="762" left="142" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref431">.</a></text>
<text top="775" left="64" width="21" height="12" font="15">435.</text>
<text top="775" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref432">Kim GS, Lee CH, Kim JB, et al. Echocardiographic evaluation of</a></text>
<text top="789" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref432">mitral durability following valve repair in rheumatic mitral valve</a></text>
<text top="802" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref432">disease: Impact of Maze procedure. J Thorac Cardiovasc Surg</a></text>
<text top="816" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref432">2012</a></text>
<text top="816" left="115" width="3" height="12" font="15">.</text>
<text top="829" left="64" width="21" height="12" font="15">436.</text>
<text top="829" left="91" width="317" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref433">Whitlow PL, Feldman T, Pedersen WR, et al. Acute and 12</a></text>
<text top="826" left="408" width="6" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref433">–</a></text>
<text top="843" left="91" width="251" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref433">month results with catheter-based mitral valve lea</a></text>
<text top="840" left="342" width="72" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref433">ﬂet repair: the</a></text>
<text top="856" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref433">EVEREST II (Endovascular Valve Edge-to-Edge Repair) High</a></text>
<text top="869" left="91" width="214" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref433">Risk Study. J Am Coll Cardiol 2012;59:130</a></text>
<text top="867" left="305" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref433">–9</a></text>
<text top="869" left="317" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref433">.</a></text>
<text top="883" left="64" width="350" height="12" font="15">437. Lim DS, Reynolds MR, Feldman T, et al. Improved functional</text>
<text top="896" left="91" width="323" height="12" font="15">status and quality of life in prohibitive surgical risk patients with</text>
<text top="910" left="91" width="323" height="12" font="15">degenerative mitral regurgitation following transcatheter mitral valve</text>
<text top="923" left="91" width="323" height="12" font="15">repair with the MitraClip(R) system. J Am Coll Cardiol 2013:</text>
<text top="937" left="91" width="323" height="12" font="15">published online before print October 24, 2013, doi:10 1016/j jacc</text>
<text top="950" left="91" width="220" height="12" font="15">2013 10 021 Accessed on February 20, 2014.</text>
<text top="964" left="64" width="21" height="12" font="15">438.</text>
<text top="964" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref434">Kwan J, Shiota T, Agler DA, et al. Geometric differences of the</a></text>
<text top="977" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref434">mitral apparatus between ischemic and dilated cardiomyopathy with</a></text>
<text top="990" left="91" width="23" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref434">signi</a></text>
<text top="988" left="114" width="300" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref434">ﬁcant mitral regurgitation: real-time three-dimensional echo-</a></text>
<text top="1004" left="91" width="226" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref434">cardiography study. Circulation 2003;107:1135</a></text>
<text top="1001" left="317" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref434">–40</a></text>
<text top="1004" left="335" width="3" height="12" font="15">.</text>
<text top="1017" left="64" width="21" height="12" font="15">439.</text>
<text top="1017" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref435">Grigioni F, Enriquez-Sarano M, Zehr KJ, et al. Ischemic mitral</a></text>
<text top="1031" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref435">regurgitation: long-term outcome and prognostic implications with</a></text>
<text top="1044" left="91" width="291" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref435">quantitative Doppler assessment. Circulation 2001;103:1759</a></text>
<text top="1042" left="382" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref435">–64</a></text>
<text top="1044" left="400" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref435">.</a></text>
<text top="1058" left="64" width="21" height="12" font="15">440.</text>
<text top="1058" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref436">Kang DH, Kim MJ, Kang SJ, et al. Mitral valve repair versus</a></text>
<text top="1071" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref436">revascularization alone in the treatment of ischemic mitral regurgi-</a></text>
<text top="1085" left="91" width="162" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref436">tation. Circulation 2006;114:I499</a></text>
<text top="1082" left="253" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref436">–503</a></text>
<text top="1085" left="277" width="3" height="12" font="15">.</text>
<text top="103" left="450" width="21" height="12" font="15">441.</text>
<text top="103" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref437">Effect of enalapril on mortality and the development of heart failure</a></text>
<text top="116" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref437">in asymptomatic patients with reduced left ventricular ejection</a></text>
<text top="130" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref437">fractions. The SOLVD Investigattors. N Engl J Med 1992;327:</a></text>
<text top="143" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref437">685</a></text>
<text top="140" left="495" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref437">–91</a></text>
<text top="143" left="513" width="3" height="12" font="15">.</text>
<text top="157" left="450" width="21" height="12" font="15">442.</text>
<text top="157" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref438">Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan</a></text>
<text top="170" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref438">in patients with chronic heart failure and reduced left-ventricular</a></text>
<text top="184" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref438">systolic function intolerant to angiotensin-converting-enzyme</a></text>
<text top="197" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref438">inhibitors: the CHARM-Alternative trial. Lancet 2003;362:</a></text>
<text top="210" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref438">772</a></text>
<text top="208" left="495" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref438">–6</a></text>
<text top="210" left="508" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref438">.</a></text>
<text top="224" left="450" width="21" height="12" font="15">443.</text>
<text top="224" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref439">Eriksson SV, Eneroth P, Kjekshus J, et al. Neuroendocrine activa-</a></text>
<text top="237" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref439">tion in relation to left ventricular function in chronic severe</a></text>
<text top="251" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref439">congestive heart failure: a subgroup analysis from the Cooperative</a></text>
<text top="264" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref439">North Scandinavian Enalapril Survival Study (CONSENSUS). Clin</a></text>
<text top="278" left="477" width="100" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref439">Cardiol 1994;17:603</a></text>
<text top="275" left="576" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref439">–6</a></text>
<text top="278" left="588" width="3" height="12" font="15">.</text>
<text top="291" left="450" width="21" height="12" font="15">444.</text>
<text top="291" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref440">Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on</a></text>
<text top="305" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref440">morbidity and mortality in patients with severe heart failure. Ran-</a></text>
<text top="318" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref440">domized Aldactone Evaluation Study Investigators. N Engl J Med</a></text>
<text top="331" left="477" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref440">1999;341:709</a></text>
<text top="329" left="542" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref440">–17</a></text>
<text top="331" left="560" width="3" height="12" font="15">.</text>
<text top="345" left="450" width="21" height="12" font="15">445.</text>
<text top="345" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref441">Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating car-</a></text>
<text top="358" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref441">vedilol in patients with severe chronic heart failure: results from the</a></text>
<text top="372" left="477" width="221" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref441">COPERNICUS Study. JAMA 2003;289:712</a></text>
<text top="369" left="698" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref441">–8</a></text>
<text top="372" left="710" width="3" height="12" font="15">.</text>
<text top="385" left="450" width="21" height="12" font="15">446.</text>
<text top="385" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref442">St John Sutton MG, Plappert T, Abraham WT, et al. Effect of</a></text>
<text top="399" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref442">cardiac resynchronization therapy on left ventricular size and func-</a></text>
<text top="412" left="477" width="269" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref442">tion in chronic heart failure. Circulation 2003;107:1985</a></text>
<text top="409" left="746" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref442">–90</a></text>
<text top="412" left="764" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref442">.</a></text>
<text top="426" left="450" width="21" height="12" font="15">447.</text>
<text top="426" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref443">van Bommel RJ, Marsan NA, Delgado V, et al. Cardiac resynch-</a></text>
<text top="439" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref443">ronization therapy as a therapeutic option in patients with moderate-</a></text>
<text top="452" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref443">severe functional mitral regurgitation and high operative risk.</a></text>
<text top="466" left="477" width="123" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref443">Circulation 2011;124:912</a></text>
<text top="463" left="600" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref443">–9</a></text>
<text top="466" left="612" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref443">.</a></text>
<text top="479" left="450" width="21" height="12" font="15">448.</text>
<text top="479" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref444">Lancellotti P, Gerard PL, Pierard LA. Long-term outcome of pa-</a></text>
<text top="493" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref444">tients with heart failure and dynamic functional mitral regurgitation.</a></text>
<text top="506" left="477" width="127" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref444">Eur Heart J 2005;26:1528</a></text>
<text top="504" left="604" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref444">–32</a></text>
<text top="506" left="622" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref444">.</a></text>
<text top="520" left="450" width="21" height="12" font="15">449.</text>
<text top="520" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref445">Trichon BH, Felker GM, Shaw LK, et al. Relation of frequency and</a></text>
<text top="533" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref445">severity of mitral regurgitation to survival among patients with left</a></text>
<text top="547" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref445">ventricular systolic dysfunction and heart failure. Am J Cardiol</a></text>
<text top="560" left="477" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref445">2003;91:538</a></text>
<text top="557" left="536" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref445">–43</a></text>
<text top="560" left="554" width="3" height="12" font="15">.</text>
<text top="574" left="450" width="21" height="12" font="15">450.</text>
<text top="574" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref446">Rossi A, Dini FL, Faggiano P, et al. Independent prognostic value</a></text>
<text top="587" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref446">of functional mitral regurgitation in patients with heart failure. A</a></text>
<text top="600" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref446">quantitative analysis of 1256 patients with ischaemic and non-</a></text>
<text top="614" left="477" width="266" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref446">ischaemic dilated cardiomyopathy. Heart 2011;97:1675</a></text>
<text top="611" left="742" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref446">–80</a></text>
<text top="614" left="760" width="3" height="12" font="15">.</text>
<text top="627" left="450" width="21" height="12" font="15">451.</text>
<text top="627" left="477" width="296" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref447">Fattouch K, Guccione F, Sampognaro R, et al. POINT: Ef</a></text>
<text top="625" left="773" width="27" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref447">ﬁcacy</a></text>
<text top="641" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref447">of adding mitral valve restrictive annuloplasty to coronary artery</a></text>
<text top="654" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref447">bypass grafting in patients with moderate ischemic mitral valve</a></text>
<text top="668" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref447">regurgitation: a randomized trial. J Thorac Cardiovasc Surg 2009;</a></text>
<text top="681" left="477" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref447">138:278</a></text>
<text top="678" left="516" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref447">–85</a></text>
<text top="681" left="534" width="3" height="12" font="15">.</text>
<text top="695" left="450" width="21" height="12" font="15">452.</text>
<text top="695" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref448">Mihaljevic T, Lam BK, Rajeswaran J, et al. Impact of mitral valve</a></text>
<text top="708" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref448">annuloplasty combined with revascularization in patients with</a></text>
<text top="721" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref448">functional ischemic mitral regurgitation. J Am Coll Cardiol 2007;</a></text>
<text top="735" left="477" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref448">49:2191</a></text>
<text top="732" left="515" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref448">–201</a></text>
<text top="735" left="539" width="3" height="12" font="15">.</text>
<text top="748" left="450" width="21" height="12" font="15">453.</text>
<text top="748" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref449">Wu AH, Aaronson KD, Bolling SF, et al. Impact of mitral valve</a></text>
<text top="762" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref449">annuloplasty on mortality risk in patients with mitral regurgitation</a></text>
<text top="775" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref449">and left ventricular systolic dysfunction. J Am Coll Cardiol 2005;45:</a></text>
<text top="789" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref449">381</a></text>
<text top="786" left="495" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref449">–7</a></text>
<text top="789" left="507" width="3" height="12" font="15">.</text>
<text top="802" left="450" width="21" height="12" font="15">454.</text>
<text top="802" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref450">Harris KM, Sundt TM III, Aeppli D, et al. Can late survival of</a></text>
<text top="816" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref450">patients with moderate ischemic mitral regurgitation be impacted by</a></text>
<text top="829" left="477" width="283" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref450">intervention on the valve? Ann Thorac Surg 2002;74:1468</a></text>
<text top="826" left="760" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref450">–75</a></text>
<text top="829" left="778" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref450">.</a></text>
<text top="843" left="450" width="21" height="12" font="15">455.</text>
<text top="843" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref451">Benedetto U, Melina G, Roscitano A, et al. Does combined mitral</a></text>
<text top="856" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref451">valve surgery improve survival when compared to revascularization</a></text>
<text top="869" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref451">alone in patients with ischemic mitral regurgitation? A meta-</a></text>
<text top="883" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref451">analysis on 2479 patients. J Cardiovasc Med (Hagerstown) 2009;</a></text>
<text top="896" left="477" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref451">10:109</a></text>
<text top="894" left="510" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref451">–14</a></text>
<text top="896" left="528" width="3" height="12" font="15">.</text>
<text top="910" left="450" width="21" height="12" font="15">456.</text>
<text top="910" left="477" width="208" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref452">Deja MA, Grayburn PA, Sun B, et al. In</a></text>
<text top="907" left="685" width="115" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref452">ﬂuence of mitral regur-</a></text>
<text top="923" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref452">gitation repair on survival in the surgical treatment for ischemic</a></text>
<text top="937" left="477" width="216" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref452">heart failure trial. Circulation 2012;125:2639</a></text>
<text top="934" left="693" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref452">–48</a></text>
<text top="937" left="711" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref452">.</a></text>
<text top="950" left="450" width="21" height="12" font="15">457.</text>
<text top="950" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref453">Cohn LH, Rizzo RJ, Adams DH, et al. The effect of pathophysi-</a></text>
<text top="964" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref453">ology on the surgical treatment of ischemic mitral regurgitation:</a></text>
<text top="977" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref453">operative and late risks of repair versus replacement. Eur J Car-</a></text>
<text top="990" left="477" width="129" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref453">diothorac Surg 1995;9:568</a></text>
<text top="988" left="605" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref453">–74</a></text>
<text top="990" left="623" width="3" height="12" font="15">.</text>
<text top="1004" left="450" width="21" height="12" font="15">458.</text>
<text top="1004" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref454">Chan KM, Punjabi PP, Flather M, et al. Coronary artery bypass</a></text>
<text top="1017" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref454">surgery with or without mitral valve annuloplasty in moderate</a></text>
<text top="1031" left="477" width="197" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref454">functional ischemic mitral regurgitation:</a></text>
<text top="1028" left="679" width="121" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref454">ﬁnal results of the Ran-</a></text>
<text top="1044" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref454">domized Ischemic Mitral Evaluation (RIME) trial. Circulation</a></text>
<text top="1058" left="477" width="72" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref454">2012;126:2502</a></text>
<text top="1055" left="548" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref454">–10</a></text>
<text top="1058" left="566" width="3" height="12" font="15">.</text>
<text top="1071" left="450" width="21" height="12" font="15">459.</text>
<text top="1071" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref455">Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve</a></text>
<text top="1085" left="477" width="214" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref455">interventions in the real world: early and 1</a></text>
<text top="1082" left="691" width="108" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref455">–year results from the</a></text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e166</text>
</page>
<page number="111" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref455">ACCESS-EU, a prospective, multicenter, nonrandomized post-</a></text>
<text top="116" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref455">approval study of the MitraClip therapy in Europe. J Am Coll</a></text>
<text top="130" left="91" width="105" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref455">Cardiol 2013;62:1052</a></text>
<text top="127" left="197" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref455">–61</a></text>
<text top="130" left="214" width="3" height="12" font="15">.</text>
<text top="143" left="64" width="21" height="12" font="15">460.</text>
<text top="143" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref456">Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation</a></text>
<text top="157" left="91" width="264" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref456">on long-term survival. J Am Coll Cardiol 2004;43:405</a></text>
<text top="154" left="355" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref456">–9</a></text>
<text top="157" left="367" width="3" height="12" font="15">.</text>
<text top="170" left="64" width="21" height="12" font="15">461.</text>
<text top="170" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref457">Lancellotti P, Moura L, Pierard LA, et al. European Association of</a></text>
<text top="183" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref457">Echocardiography recommendations for the assessment of valvular</a></text>
<text top="197" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref457">regurgitation. Part 2: mitral and tricuspid regurgitation (native valve</a></text>
<text top="210" left="91" width="201" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref457">disease). Eur J Echocardiogr 2010;11:307</a></text>
<text top="208" left="292" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref457">–32</a></text>
<text top="210" left="310" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref457">.</a></text>
<text top="224" left="64" width="21" height="12" font="15">462.</text>
<text top="224" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref458">Sugimoto T, Okada M, Ozaki N, et al. Long-term evaluation of</a></text>
<text top="237" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref458">treatment for functional tricuspid regurgitation with regurgitant</a></text>
<text top="251" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref458">volume: characteristic differences based on primary cardiac lesion.</a></text>
<text top="264" left="91" width="194" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref458">J Thorac Cardiovasc Surg 1999;117:463</a></text>
<text top="261" left="285" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref458">–71</a></text>
<text top="264" left="303" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref458">.</a></text>
<text top="278" left="64" width="21" height="12" font="15">463.</text>
<text top="278" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref459">Chopra HK, Nanda NC, Fan P, et al. Can two-dimensional</a></text>
<text top="291" left="91" width="183" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref459">echocardiography and Doppler color</a></text>
<text top="288" left="281" width="133" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref459">ﬂow mapping identify the</a></text>
<text top="305" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref459">need for tricuspid valve repair? J Am Coll Cardiol 1989;14:</a></text>
<text top="318" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref459">1266</a></text>
<text top="315" left="115" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref459">–74</a></text>
<text top="318" left="133" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref459">.</a></text>
<text top="331" left="64" width="21" height="12" font="15">464.</text>
<text top="331" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref460">Dreyfus GD, Corbi PJ, Chan KM, et al. Secondary tricuspid</a></text>
<text top="345" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref460">regurgitation or dilatation: which should be the criteria for surgical</a></text>
<text top="358" left="91" width="185" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref460">repair? Ann Thorac Surg 2005;79:127</a></text>
<text top="356" left="276" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref460">–32</a></text>
<text top="358" left="294" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref460">.</a></text>
<text top="372" left="64" width="21" height="12" font="15">465.</text>
<text top="372" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref461">Van de Veire NR, Braun J, Delgado V, et al. Tricuspid annulo-</a></text>
<text top="385" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref461">plasty prevents right ventricular dilatation and progression of</a></text>
<text top="399" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref461">tricuspid regurgitation in patients with tricuspid annular dilatation</a></text>
<text top="412" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref461">undergoing mitral valve repair. J Thorac Cardiovasc Surg 2011;141:</a></text>
<text top="426" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref461">1431</a></text>
<text top="423" left="115" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref461">–9</a></text>
<text top="426" left="127" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref461">.</a></text>
<text top="439" left="64" width="21" height="12" font="15">466.</text>
<text top="439" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref462">Benedetto U, Melina G, Angeloni E, et al. Prophylactic tricuspid</a></text>
<text top="452" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref462">annuloplasty in patients with dilated tricuspid annulus undergoing</a></text>
<text top="466" left="91" width="294" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref462">mitral valve surgery. J Thorac Cardiovasc Surg 2012;143:632</a></text>
<text top="463" left="385" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref462">–8</a></text>
<text top="466" left="397" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref462">.</a></text>
<text top="479" left="64" width="21" height="12" font="15">467.</text>
<text top="479" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref463">Fukuda S, Gillinov AM, McCarthy PM, et al. Determinants of</a></text>
<text top="493" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref463">recurrent or residual functional tricuspid regurgitation after tricuspid</a></text>
<text top="506" left="91" width="194" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref463">annuloplasty. Circulation 2006;114:I582</a></text>
<text top="504" left="285" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref463">–7</a></text>
<text top="506" left="297" width="3" height="12" font="15">.</text>
<text top="520" left="64" width="21" height="12" font="15">468.</text>
<text top="520" left="91" width="308" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref464">Dreyfus GD, Raja SG, John Chan KM. Tricuspid lea</a></text>
<text top="517" left="399" width="15" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref464">ﬂet</a></text>
<text top="533" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref464">augmentation to address severe tethering in functional tricuspid</a></text>
<text top="547" left="91" width="250" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref464">regurgitation. Eur J Cardiothorac Surg 2008;34:908</a></text>
<text top="544" left="341" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref464">–10</a></text>
<text top="547" left="359" width="3" height="12" font="15">.</text>
<text top="560" left="64" width="21" height="12" font="15">469.</text>
<text top="560" left="91" width="123" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref465">Rudski LG, Lai WW, A</a></text>
<text top="557" left="215" width="200" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref465">ﬁlalo J, et al. Guidelines for the echocar-</a></text>
<text top="574" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref465">diographic assessment of the right heart in adults: a report from the</a></text>
<text top="587" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref465">American Society of Echocardiography. J Am Soc Echocardiogr</a></text>
<text top="600" left="91" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref465">2010;23:685</a></text>
<text top="598" left="151" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref465">–713</a></text>
<text top="600" left="175" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref465">.</a></text>
<text top="614" left="64" width="21" height="12" font="15">470.</text>
<text top="614" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref466">Ling LF, Obuchowski NA, Rodriguez L, et al. Accuracy and</a></text>
<text top="627" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref466">interobserver concordance of echocardiographic assessment of right</a></text>
<text top="641" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref466">ventricular size and systolic function: a quality control exercise. J Am</a></text>
<text top="654" left="91" width="149" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref466">Soc Echocardiogr 2012;25:709</a></text>
<text top="652" left="240" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref466">–13</a></text>
<text top="654" left="258" width="3" height="12" font="15">.</text>
<text top="668" left="64" width="21" height="12" font="15">471.</text>
<text top="668" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref467">Geske JB, Scantlebury DC, Thomas JD, et al. Hemodynamic</a></text>
<text top="681" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref467">evaluation of severe tricuspid regurgitation. J Am Coll Cardiol 2013;</a></text>
<text top="695" left="91" width="38" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref467">62:e441</a></text>
<text top="695" left="129" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref467">.</a></text>
<text top="708" left="64" width="21" height="12" font="15">472.</text>
<text top="708" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref468">Beygui F, Furber A, Delepine S, et al. Routine breath-hold gradient</a></text>
<text top="721" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref468">echo MRI-derived right ventricular mass, volumes and function:</a></text>
<text top="735" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref468">accuracy, reproducibility and coherence study. Int J Cardiovasc</a></text>
<text top="748" left="91" width="103" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref468">Imaging 2004;20:509</a></text>
<text top="746" left="195" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref468">–16</a></text>
<text top="748" left="212" width="3" height="12" font="15">.</text>
<text top="762" left="64" width="21" height="12" font="15">473.</text>
<text top="762" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref469">Maceira AM, Prasad SK, Khan M, et al. Reference right ventricular</a></text>
<text top="775" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref469">systolic and diastolic function normalized to age, gender and body</a></text>
<text top="789" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref469">surface area from steady-state free precession cardiovascular mag-</a></text>
<text top="802" left="91" width="207" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref469">netic resonance. Eur Heart J 2006;27:2879</a></text>
<text top="799" left="299" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref469">–88</a></text>
<text top="802" left="316" width="3" height="12" font="15">.</text>
<text top="816" left="64" width="21" height="12" font="15">474.</text>
<text top="816" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref470">Caudron J, Fares J, Vivier PH, et al. Diagnostic accuracy and</a></text>
<text top="829" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref470">variability of three semi-quantitative methods for assessing right</a></text>
<text top="843" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref470">ventricular systolic function from cardiac MRI in patients with ac-</a></text>
<text top="856" left="91" width="225" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref470">quired heart disease. Eur Radiol 2011;21:2111</a></text>
<text top="853" left="316" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref470">–20</a></text>
<text top="856" left="333" width="3" height="12" font="15">.</text>
<text top="869" left="64" width="21" height="12" font="15">475.</text>
<text top="869" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref471">van der Zwaan HB, Geleijnse ML, McGhie JS, et al. Right ven-</a></text>
<text top="883" left="91" width="67" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref471">tricular quanti</a></text>
<text top="880" left="158" width="256" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref471">ﬁcation in clinical practice: two-dimensional vs. three-</a></text>
<text top="896" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref471">dimensional echocardiography compared with cardiac magnetic</a></text>
<text top="910" left="91" width="253" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref471">resonance imaging. Eur J Echocardiogr 2011;12:656</a></text>
<text top="907" left="344" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref471">–64</a></text>
<text top="910" left="362" width="3" height="12" font="15">.</text>
<text top="923" left="64" width="21" height="12" font="15">476.</text>
<text top="923" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref472">Pavlicek M, Wahl A, Rutz T, et al. Right ventricular systolic</a></text>
<text top="937" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref472">function assessment: rank of echocardiographic methods vs. car-</a></text>
<text top="950" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref472">diac magnetic resonance imaging. Eur J Echocardiogr 2011;12:</a></text>
<text top="964" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref472">871</a></text>
<text top="961" left="109" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref472">–80</a></text>
<text top="964" left="127" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref472">.</a></text>
<text top="977" left="64" width="21" height="12" font="15">477.</text>
<text top="977" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref473">Speiser U, Hirschberger M, Pilz G, et al. Tricuspid annular plane</a></text>
<text top="990" left="91" width="272" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref473">systolic excursion assessed using MRI for semi-quanti</a></text>
<text top="988" left="363" width="51" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref473">ﬁcation of</a></text>
<text top="1004" left="91" width="288" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref473">right ventricular ejection fraction. Br J Radiol 2012;85:e716</a></text>
<text top="1001" left="379" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref473">–21</a></text>
<text top="1004" left="397" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref473">.</a></text>
<text top="1017" left="64" width="21" height="12" font="15">478.</text>
<text top="1017" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref474">Anwar AM, Geleijnse ML, Ten Cate FJ, et al. Assessment of</a></text>
<text top="1031" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref474">tricuspid valve annulus size, shape and function using real-time</a></text>
<text top="1044" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref474">three-dimensional echocardiography. Interact Cardiovasc Thorac</a></text>
<text top="1058" left="91" width="80" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref474">Surg 2006;5:683</a></text>
<text top="1055" left="171" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref474">–7</a></text>
<text top="1058" left="183" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref474">.</a></text>
<text top="1071" left="64" width="21" height="12" font="15">479.</text>
<text top="1071" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref475">Nesser HJ, Tkalec W, Patel AR, et al. Quantitation of right ventricular</a></text>
<text top="1085" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref475">volumes and ejection fraction by three-dimensional echocardiography</a></text>
<text top="103" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref475">in patients: comparison with magnetic resonance imaging and radio-</a></text>
<text top="116" left="477" width="265" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref475">nuclide ventriculography. Echocardiography 2006;23:666</a></text>
<text top="114" left="742" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref475">–80</a></text>
<text top="116" left="759" width="3" height="12" font="15">.</text>
<text top="130" left="450" width="21" height="12" font="15">480.</text>
<text top="130" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref476">Anwar AM, Soliman OI, Nemes A, et al. Value of assessment of</a></text>
<text top="143" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref476">tricuspid annulus: real-time three-dimensional echocardiography</a></text>
<text top="157" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref476">and magnetic resonance imaging. Int J Cardiovasc Imaging 2007;23:</a></text>
<text top="170" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref476">701</a></text>
<text top="167" left="495" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref476">–5</a></text>
<text top="170" left="507" width="3" height="12" font="15">.</text>
<text top="183" left="450" width="21" height="12" font="15">481.</text>
<text top="183" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref477">Puwanant S, Park M, Popovic ZB, et al. Ventricular geometry,</a></text>
<text top="197" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref477">strain, and rotational mechanics in pulmonary hypertension. Cir-</a></text>
<text top="210" left="477" width="107" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref477">culation 2010;121:259</a></text>
<text top="208" left="584" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref477">–66</a></text>
<text top="210" left="602" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref477">.</a></text>
<text top="224" left="450" width="21" height="12" font="15">482.</text>
<text top="224" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref478">Kuhn A, De Pasquale MG, Muller J, et al. Tricuspid valve surgery</a></text>
<text top="237" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref478">improves cardiac output and exercise performance in patients with</a></text>
<text top="251" left="477" width="37" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref478">Ebstein</a></text>
<text top="248" left="513" width="201" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref478">’s anomaly. Int J Cardiol 2013;166:494–8</a></text>
<text top="251" left="714" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref478">.</a></text>
<text top="264" left="450" width="21" height="12" font="15">483.</text>
<text top="264" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref479">McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA</a></text>
<text top="278" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref479">2009 expert consensus document on pulmonary hypertension: a</a></text>
<text top="291" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref479">report of the American College of Cardiology Foundation Task</a></text>
<text top="305" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref479">Force on Expert Consensus Documents and the American Heart</a></text>
<text top="318" left="477" width="191" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref479">Association. Circulation 2009;119:2250</a></text>
<text top="315" left="668" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref479">–94</a></text>
<text top="318" left="686" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref479">.</a></text>
<text top="331" left="450" width="21" height="12" font="15">484.</text>
<text top="331" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref480">Antoniou T, Koletsis EN, Prokakis C, et al. Hemodynamic effects</a></text>
<text top="345" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref480">of combination therapy with inhaled nitric oxide and iloprost in</a></text>
<text top="358" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref480">patients with pulmonary hypertension and right ventricular</a></text>
<text top="372" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref480">dysfunction after high-risk cardiac surgery. J Cardiothorac Vasc</a></text>
<text top="385" left="477" width="98" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref480">Anesth 2013;27:459</a></text>
<text top="383" left="575" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref480">–66</a></text>
<text top="385" left="593" width="3" height="12" font="15">.</text>
<text top="399" left="450" width="21" height="12" font="15">485.</text>
<text top="399" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref481">Staab ME, Nishimura RA, Dearani JA. Isolated tricuspid valve</a></text>
<text top="412" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref481">surgery for severe tricuspid regurgitation following prior left heart</a></text>
<text top="426" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref481">valve surgery: analysis of outcome in 34 patients. J Heart Valve Dis</a></text>
<text top="439" left="477" width="54" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref481">1999;8:567</a></text>
<text top="436" left="530" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref481">–74</a></text>
<text top="439" left="548" width="3" height="12" font="15">.</text>
<text top="453" left="450" width="21" height="12" font="15">486.</text>
<text top="453" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref482">Mangoni AA, DiSalvo TG, Vlahakes GJ, et al. Outcome following</a></text>
<text top="466" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref482">isolated tricuspid valve replacement. Eur J Cardiothorac Surg 2001;</a></text>
<text top="479" left="477" width="27" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref482">19:68</a></text>
<text top="477" left="503" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref482">–73</a></text>
<text top="479" left="521" width="3" height="12" font="15">.</text>
<text top="493" left="450" width="21" height="12" font="15">487.</text>
<text top="493" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref483">Kwon DA, Park JS, Chang HJ, et al. Prediction of outcome in</a></text>
<text top="506" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref483">patients undergoing surgery for severe tricuspid regurgitation</a></text>
<text top="520" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref483">following mitral valve surgery and role of tricuspid annular systolic</a></text>
<text top="533" left="477" width="172" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref483">velocity. Am J Cardiol 2006;98:659</a></text>
<text top="530" left="649" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref483">–61</a></text>
<text top="533" left="667" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref483">.</a></text>
<text top="547" left="450" width="21" height="12" font="15">488.</text>
<text top="547" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref484">Kim YJ, Kwon DA, Kim HK, et al. Determinants of surgical</a></text>
<text top="560" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref484">outcome in patients with isolated tricuspid regurgitation. Circulation</a></text>
<text top="574" left="477" width="71" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref484">2009;120:1672</a></text>
<text top="571" left="548" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref484">–8</a></text>
<text top="574" left="560" width="3" height="12" font="15">.</text>
<text top="587" left="450" width="21" height="12" font="15">489.</text>
<text top="587" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref485">Lee R, Li S, Rankin JS, et al. Fifteen-year outcome trends for valve</a></text>
<text top="600" left="477" width="281" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref485">surgery in North America. Ann Thorac Surg 2011;91:677</a></text>
<text top="598" left="758" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref485">–84</a></text>
<text top="600" left="775" width="3" height="12" font="15">.</text>
<text top="614" left="450" width="21" height="12" font="15">490.</text>
<text top="614" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref486">Vassileva CM, Shabosky J, Boley T, et al. Tricuspid valve surgery:</a></text>
<text top="627" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref486">the past 10 years from the Nationwide Inpatient Sample (NIS)</a></text>
<text top="641" left="477" width="246" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref486">database. J Thorac Cardiovasc Surg 2012;143:1043</a></text>
<text top="638" left="723" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref486">–9</a></text>
<text top="641" left="735" width="3" height="12" font="15">.</text>
<text top="654" left="450" width="21" height="12" font="15">491.</text>
<text top="654" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref487">Rogers JH, Bolling SF. The tricuspid valve: current perspective and</a></text>
<text top="668" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref487">evolving management of tricuspid regurgitation. Circulation 2009;</a></text>
<text top="681" left="477" width="45" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref487">119:2718</a></text>
<text top="678" left="521" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref487">–25</a></text>
<text top="681" left="539" width="3" height="12" font="15">.</text>
<text top="695" left="450" width="21" height="12" font="15">492.</text>
<text top="695" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref488">Chikwe J, Anyanwu AC. Surgical strategies for functional tricuspid</a></text>
<text top="708" left="477" width="276" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref488">regurgitation. Semin Thorac Cardiovasc Surg 2010;22:90</a></text>
<text top="705" left="753" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref488">–6</a></text>
<text top="708" left="765" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref488">.</a></text>
<text top="721" left="450" width="21" height="12" font="15">493.</text>
<text top="721" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref489">Mahesh B, Wells F, Nashef S, et al. Role of concomitant tricuspid</a></text>
<text top="735" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref489">surgery in moderate functional tricuspid regurgitation in patients un-</a></text>
<text top="748" left="477" width="308" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref489">dergoing left heart valve surgery. Eur J Cardiothorac Surg 2013;43:2</a></text>
<text top="746" left="785" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref489">–8</a></text>
<text top="748" left="797" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref489">.</a></text>
<text top="762" left="450" width="21" height="12" font="15">494.</text>
<text top="762" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref490">Kunadian B, Vijayalakshmi K, Balasubramanian S, et al. Should the</a></text>
<text top="775" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref490">tricuspid valve be replaced with a mechanical or biological valve?</a></text>
<text top="789" left="477" width="215" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref490">Interact Cardiovasc Thorac Surg 2007;6:551</a></text>
<text top="786" left="691" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref490">–7</a></text>
<text top="789" left="703" width="3" height="12" font="15">.</text>
<text top="802" left="450" width="21" height="12" font="15">495.</text>
<text top="802" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref491">Chan V, Burwash IG, Lam BK, et al. Clinical and echocardiographic</a></text>
<text top="816" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref491">impact of functional tricuspid regurgitation repair at the time of</a></text>
<text top="829" left="477" width="276" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref491">mitral valve replacement. Ann Thorac Surg 2009;88:1209</a></text>
<text top="826" left="753" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref491">–15</a></text>
<text top="829" left="770" width="3" height="12" font="15">.</text>
<text top="843" left="450" width="21" height="12" font="15">496.</text>
<text top="843" left="477" width="22" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref492">Cala</a></text>
<text top="840" left="498" width="301" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref492">ﬁore AM, Gallina S, Iaco AL, et al. Mitral valve surgery for</a></text>
<text top="856" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref492">functional mitral regurgitation: should moderate-or-more tricuspid</a></text>
<text top="869" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref492">regurgitation be treated? a propensity score analysis. Ann Thorac</a></text>
<text top="883" left="477" width="86" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref492">Surg 2009;87:698</a></text>
<text top="880" left="562" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref492">–703</a></text>
<text top="883" left="586" width="3" height="12" font="15">.</text>
<text top="896" left="450" width="21" height="12" font="15">497.</text>
<text top="896" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref493">Di Mauro M, Bivona A, Iaco AL, et al. Mitral valve surgery for</a></text>
<text top="910" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref493">functional mitral regurgitation: prognostic role of tricuspid regur-</a></text>
<text top="923" left="477" width="226" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref493">gitation. Eur J Cardiothorac Surg 2009;35:635</a></text>
<text top="921" left="702" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref493">–9</a></text>
<text top="923" left="714" width="3" height="12" font="15">.</text>
<text top="937" left="450" width="21" height="12" font="15">498.</text>
<text top="937" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref494">Yilmaz O, Suri RM, Dearani JA, et al. Functional tricuspid</a></text>
<text top="950" left="477" width="308" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref494">regurgitation at the time of mitral valve repair for degenerative lea</a></text>
<text top="947" left="784" width="15" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref494">ﬂet</a></text>
<text top="964" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref494">prolapse: the case for a selective approach. J Thorac Cardiovasc Surg</a></text>
<text top="977" left="477" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref494">2011;142:608</a></text>
<text top="974" left="542" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref494">–13</a></text>
<text top="977" left="560" width="3" height="12" font="15">.</text>
<text top="990" left="450" width="21" height="12" font="15">499.</text>
<text top="990" left="477" width="22" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref495">Cala</a></text>
<text top="988" left="498" width="301" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref495">ﬁore AM, Iaco AL, Romeo A, et al. Echocardiographic-based</a></text>
<text top="1004" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref495">treatment of functional tricuspid regurgitation. J Thorac Cardiovasc</a></text>
<text top="1017" left="477" width="92" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref495">Surg 2011;142:308</a></text>
<text top="1015" left="568" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref495">–13</a></text>
<text top="1017" left="586" width="3" height="12" font="15">.</text>
<text top="1031" left="450" width="21" height="12" font="15">500.</text>
<text top="1031" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref496">Navia JL, Brozzi NA, Klein AL, et al. Moderate tricuspid regur-</a></text>
<text top="1044" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref496">gitation with left-sided degenerative heart valve disease: to repair or</a></text>
<text top="1058" left="477" width="212" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref496">not to repair? Ann Thorac Surg 2012;93:59</a></text>
<text top="1055" left="689" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref496">–67</a></text>
<text top="1058" left="707" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref496">.</a></text>
<text top="1071" left="450" width="21" height="12" font="15">501.</text>
<text top="1071" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref497">Kim JB, Yoo DG, Kim GS, et al. Mild-to-moderate functional</a></text>
<text top="1085" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref497">tricuspid regurgitation in patients undergoing valve replacement for</a></text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e167</text>
</page>
<page number="112" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="91" width="154" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref497">rheumatic mitral disease: the in</a></text>
<text top="100" left="245" width="169" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref497">ﬂuence of tricuspid valve repair on</a></text>
<text top="116" left="91" width="286" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref497">clinical and echocardiographic outcomes. Heart 2012;98:24</a></text>
<text top="113" left="377" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref497">–30</a></text>
<text top="116" left="395" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref497">.</a></text>
<text top="130" left="64" width="21" height="12" font="15">502.</text>
<text top="130" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref498">McCarthy PM, Bhudia SK, Rajeswaran J, et al. Tricuspid valve</a></text>
<text top="143" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref498">repair: durability and risk factors for failure. J Thorac Cardiovasc</a></text>
<text top="157" left="91" width="92" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref498">Surg 2004;127:674</a></text>
<text top="154" left="183" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref498">–85</a></text>
<text top="157" left="201" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref498">.</a></text>
<text top="170" left="64" width="21" height="12" font="15">503.</text>
<text top="170" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref499">Braunwald NS, Ross J Jr., Morrow AG. Conservative management</a></text>
<text top="183" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref499">of tricuspid regurgitation in patients undergoing mitral valve</a></text>
<text top="197" left="91" width="180" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref499">replacement. Circulation 1967;35:I63</a></text>
<text top="194" left="271" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref499">–9</a></text>
<text top="197" left="283" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref499">.</a></text>
<text top="210" left="64" width="21" height="12" font="15">504.</text>
<text top="210" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref500">Shiran A, Sagie A. Tricuspid regurgitation in mitral valve disease</a></text>
<text top="224" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref500">incidence, prognostic implications, mechanism, and management.</a></text>
<text top="237" left="91" width="154" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref500">J Am Coll Cardiol 2009;53:401</a></text>
<text top="235" left="245" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref500">–8</a></text>
<text top="237" left="257" width="3" height="12" font="15">.</text>
<text top="251" left="64" width="21" height="12" font="15">505.</text>
<text top="251" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref501">Menzel T, Kramm T, Wagner S, et al. Improvement of tricuspid</a></text>
<text top="264" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref501">regurgitation after pulmonary thromboendarterectomy. Ann Thorac</a></text>
<text top="278" left="91" width="86" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref501">Surg 2002;73:756</a></text>
<text top="275" left="177" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref501">–61</a></text>
<text top="278" left="195" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref501">.</a></text>
<text top="291" left="64" width="21" height="12" font="15">506.</text>
<text top="291" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref502">Sadeghi HM, Kimura BJ, Raisinghani A, et al. Does lowering</a></text>
<text top="305" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref502">pulmonary arterial pressure eliminate severe functional tricuspid</a></text>
<text top="318" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref502">regurgitation? Insights from pulmonary thromboendarterectomy.</a></text>
<text top="331" left="91" width="154" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref502">J Am Coll Cardiol 2004;44:126</a></text>
<text top="329" left="245" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref502">–32</a></text>
<text top="331" left="263" width="3" height="12" font="15">.</text>
<text top="345" left="64" width="21" height="12" font="15">507.</text>
<text top="345" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref503">Moller JE, Pellikka PA, Bernheim AM, et al. Prognosis of carcinoid</a></text>
<text top="358" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref503">heart disease: analysis of 200 cases over two decades. Circulation</a></text>
<text top="372" left="91" width="72" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref503">2005;112:3320</a></text>
<text top="369" left="163" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref503">–7</a></text>
<text top="372" left="175" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref503">.</a></text>
<text top="385" left="64" width="21" height="12" font="15">508.</text>
<text top="385" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref504">Messika-Zeitoun D, Thomson H, Bellamy M, et al. Medical and</a></text>
<text top="399" left="91" width="260" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref504">surgical outcome of tricuspid regurgitation caused by</a></text>
<text top="396" left="356" width="58" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref504">ﬂail leaﬂets.</a></text>
<text top="412" left="91" width="194" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref504">J Thorac Cardiovasc Surg 2004;128:296</a></text>
<text top="409" left="285" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref504">–302</a></text>
<text top="412" left="309" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref504">.</a></text>
<text top="426" left="64" width="21" height="12" font="15">509.</text>
<text top="426" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref505">Kuwaki K, Morishita K, Tsukamoto M, et al. Tricuspid valve</a></text>
<text top="439" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref505">surgery for functional tricuspid valve regurgitation associated</a></text>
<text top="452" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref505">with left-sided valvular disease. Eur J Cardiothorac Surg 2001;</a></text>
<text top="466" left="91" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref505">20:577</a></text>
<text top="463" left="125" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref505">–82</a></text>
<text top="466" left="143" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref505">.</a></text>
<text top="479" left="64" width="21" height="12" font="15">510.</text>
<text top="479" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref506">Kwak JJ, Kim YJ, Kim MK, et al. Development of tricuspid</a></text>
<text top="493" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref506">regurgitation late after left-sided valve surgery: a single-center</a></text>
<text top="506" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref506">experience with long-term echocardiographic examinations. Am</a></text>
<text top="520" left="91" width="105" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref506">Heart J 2008;155:732</a></text>
<text top="517" left="196" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref506">–7</a></text>
<text top="520" left="208" width="3" height="12" font="15">.</text>
<text top="533" left="64" width="21" height="12" font="15">511.</text>
<text top="533" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref507">Pfannmuller B, Misfeld M, Borger MA, et al. Isolated reoperative</a></text>
<text top="547" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref507">minimally invasive tricuspid valve operations. Ann Thorac Surg</a></text>
<text top="560" left="91" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref507">2012;94:2005</a></text>
<text top="557" left="157" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref507">–10</a></text>
<text top="560" left="175" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref507">.</a></text>
<text top="574" left="64" width="21" height="12" font="15">512.</text>
<text top="574" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref508">Jeganathan R, Armstrong S, Al-Alao B, et al. The risk and out-</a></text>
<text top="587" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref508">comes of reoperative tricuspid valve surgery. Ann Thorac Surg 2013;</a></text>
<text top="600" left="91" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref508">95:119</a></text>
<text top="598" left="124" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref508">–24</a></text>
<text top="600" left="142" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref508">.</a></text>
<text top="614" left="64" width="21" height="12" font="15">513.</text>
<text top="614" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref509">Orbe LC, Sobrino N, Arcas R, et al. Initial outcome of percutaneous</a></text>
<text top="627" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref509">balloon valvuloplasty in rheumatic tricuspid valve stenosis. Am J</a></text>
<text top="641" left="91" width="99" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref509">Cardiol 1993;71:353</a></text>
<text top="638" left="191" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref509">–4</a></text>
<text top="641" left="203" width="3" height="12" font="15">.</text>
<text top="654" left="64" width="21" height="12" font="15">514.</text>
<text top="654" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref510">Yeter E, Ozlem K, Kilic H, et al. Tricuspid balloon valvuloplasty to</a></text>
<text top="668" left="91" width="264" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref510">treat tricuspid stenosis. J Heart Valve Dis 2010;19:159</a></text>
<text top="665" left="355" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref510">–60</a></text>
<text top="668" left="373" width="3" height="12" font="15">.</text>
<text top="681" left="64" width="21" height="12" font="15">515.</text>
<text top="681" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref511">Lancellotti P, Tribouilloy C, Hagendorff A, et al. European Asso-</a></text>
<text top="695" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref511">ciation of Echocardiography recommendations for the assessment of</a></text>
<text top="708" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref511">valvular regurgitation. Part 1: aortic and pulmonary regurgitation</a></text>
<text top="721" left="91" width="264" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref511">(native valve disease). Eur J Echocardiogr 2010;11:223</a></text>
<text top="719" left="355" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref511">–44</a></text>
<text top="721" left="373" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref511">.</a></text>
<text top="735" left="64" width="21" height="12" font="15">516.</text>
<text top="735" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref512">Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008</a></text>
<text top="748" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref512">guidelines for the management of adults with congenital heart disease:</a></text>
<text top="762" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref512">a report of the American College of Cardiology/American Heart</a></text>
<text top="775" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref512">Association Task Force on Practice Guidelines (Writing Committee</a></text>
<text top="789" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref512">to Develop Guidelines on the Management of Adults With</a></text>
<text top="802" left="91" width="286" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref512">Congenital Heart Disease). J Am Coll Cardiol 2008;52:e143</a></text>
<text top="799" left="376" width="23" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref512">–263</a></text>
<text top="802" left="400" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref512">.</a></text>
<text top="816" left="64" width="21" height="12" font="15">517.</text>
<text top="816" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref513">Catovic S, Popovic ZB, Tasic N, et al. Impact of concomitant aortic</a></text>
<text top="829" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref513">regurgitation on long-term outcome after surgical aortic valve</a></text>
<text top="843" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref513">replacement in patients with severe aortic stenosis. J Cardiothorac</a></text>
<text top="856" left="91" width="74" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref513">Surg 2011;6:51</a></text>
<text top="856" left="165" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref513">.</a></text>
<text top="869" left="64" width="21" height="12" font="15">518.</text>
<text top="869" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref514">Hwang MH, Hammermeister KE, Oprian C, et al. Preoperative</a></text>
<text top="883" left="91" width="27" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref514">identi</a></text>
<text top="880" left="119" width="295" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref514">ﬁcation of patients likely to have left ventricular dysfunction</a></text>
<text top="896" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref514">after aortic valve replacement. Participants in the Veterans</a></text>
<text top="910" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref514">Administration Cooperative Study on Valvular Heart Disease.</a></text>
<text top="923" left="91" width="116" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref514">Circulation 1989;80:I65</a></text>
<text top="921" left="207" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref514">–76</a></text>
<text top="923" left="225" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref514">.</a></text>
<text top="937" left="64" width="21" height="12" font="15">519.</text>
<text top="937" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref515">Zilberszac R, Gabriel H, Schemper M, et al. Outcome of combined</a></text>
<text top="950" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref515">stenotic and regurgitant aortic valve disease. J Am Coll Cardiol</a></text>
<text top="964" left="91" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref515">2013;61:1489</a></text>
<text top="961" left="157" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref515">–95</a></text>
<text top="964" left="175" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref515">.</a></text>
<text top="977" left="64" width="21" height="12" font="15">520.</text>
<text top="977" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref516">Unger P, Rosenhek R, Dedobbeleer C, et al. Management of</a></text>
<text top="990" left="91" width="201" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref516">multiple valve disease. Heart 2011;97:272</a></text>
<text top="988" left="292" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref516">–7</a></text>
<text top="990" left="304" width="3" height="12" font="15">.</text>
<text top="1004" left="64" width="21" height="12" font="15">521.</text>
<text top="1004" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref517">Topal AE, Eren MN, Celik Y. Left ventricle and left atrium</a></text>
<text top="1017" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref517">remodeling after mitral valve replacement in case of mixed mitral</a></text>
<text top="1031" left="91" width="285" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref517">valve disease of rheumatic origin. J Card Surg 2010;25:367</a></text>
<text top="1028" left="376" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref517">–72</a></text>
<text top="1031" left="394" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref517">.</a></text>
<text top="1044" left="64" width="21" height="12" font="15">522.</text>
<text top="1044" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref518">Burstow DJ, Nishimura RA, Bailey KR, et al. Continuous wave</a></text>
<text top="1058" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref518">Doppler echocardiographic measurement of prosthetic valve gradi-</a></text>
<text top="1071" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref518">ents. A simultaneous Doppler-catheter correlative study. Circulation</a></text>
<text top="1085" left="91" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref518">1989;80:504</a></text>
<text top="1082" left="151" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref518">–14</a></text>
<text top="1085" left="169" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref518">.</a></text>
<text top="103" left="450" width="21" height="12" font="15">523.</text>
<text top="103" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref519">Baumgartner H, Khan S, DeRobertis M, et al. Effect of prosthetic</a></text>
<text top="116" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref519">aortic valve design on the Doppler-catheter gradient correlation: an</a></text>
<text top="130" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref519">in vitro study of normal St. Jude, Medtronic-Hall, Starr-Edwards</a></text>
<text top="143" left="477" width="257" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref519">and Hancock valves. J Am Coll Cardiol 1992;19:324</a></text>
<text top="140" left="733" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref519">–32</a></text>
<text top="143" left="751" width="3" height="12" font="15">.</text>
<text top="157" left="450" width="21" height="12" font="15">524.</text>
<text top="157" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref520">Vandervoort PM, Greenberg NL, Powell KA, et al. Pressure re-</a></text>
<text top="170" left="477" width="71" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref520">covery in bilea</a></text>
<text top="167" left="547" width="252" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref520">ﬂet heart valve prostheses. Localized high velocities</a></text>
<text top="184" left="477" width="190" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref520">and gradients in central and side ori</a></text>
<text top="181" left="667" width="133" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref520">ﬁces with implications for</a></text>
<text top="197" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref520">Doppler-catheter gradient relation in aortic and mitral position.</a></text>
<text top="210" left="477" width="123" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref520">Circulation 1995;92:3464</a></text>
<text top="208" left="600" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref520">–72</a></text>
<text top="210" left="618" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref520">.</a></text>
<text top="224" left="450" width="21" height="12" font="15">525.</text>
<text top="224" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref521">Dumesnil JG, Honos GN, Lemieux M, et al. Validation and</a></text>
<text top="237" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref521">applications of indexed aortic prosthetic valve areas calculated</a></text>
<text top="251" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref521">by Doppler echocardiography. J Am Coll Cardiol 1990;16:</a></text>
<text top="264" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref521">637</a></text>
<text top="261" left="495" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref521">–43</a></text>
<text top="264" left="513" width="3" height="12" font="15">.</text>
<text top="278" left="450" width="21" height="12" font="15">526.</text>
<text top="278" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref522">Rosenhek R, Binder T, Maurer G, et al. Normal values for Doppler</a></text>
<text top="291" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref522">echocardiographic assessment of heart valve prostheses. J Am Soc</a></text>
<text top="305" left="477" width="134" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref522">Echocardiogr 2003;16:1116</a></text>
<text top="302" left="610" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref522">–27</a></text>
<text top="305" left="628" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref522">.</a></text>
<text top="318" left="450" width="21" height="12" font="15">527.</text>
<text top="318" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref523">Pibarot P, Dumesnil JG. Doppler echocardiographic evaluation of</a></text>
<text top="331" left="477" width="210" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref523">prosthetic valve function. Heart 2012;98:69</a></text>
<text top="329" left="686" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref523">–78</a></text>
<text top="331" left="704" width="3" height="12" font="15">.</text>
<text top="345" left="450" width="21" height="12" font="15">528.</text>
<text top="345" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref524">Bach DS. Echo/Doppler evaluation of hemodynamics after aortic</a></text>
<text top="358" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref524">valve replacement: principles of interrogation and evaluation of high</a></text>
<text top="372" left="477" width="222" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref524">gradients. J Am Coll Cardiol Img 2010;3:296</a></text>
<text top="369" left="699" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref524">–304</a></text>
<text top="372" left="722" width="3" height="12" font="15">.</text>
<text top="385" left="450" width="21" height="12" font="15">529.</text>
<text top="385" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref525">Habets J, Budde RP, Symersky P, et al. Diagnostic evaluation of</a></text>
<text top="399" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref525">left-sided prosthetic heart valve dysfunction. Nat Rev Cardiol 2011;</a></text>
<text top="412" left="477" width="27" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref525">8:466</a></text>
<text top="409" left="503" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref525">–78</a></text>
<text top="412" left="521" width="3" height="12" font="15">.</text>
<text top="426" left="450" width="21" height="12" font="15">530.</text>
<text top="426" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref526">van den Brink RB. Evaluation of prosthetic heart valves by</a></text>
<text top="439" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref526">transesophageal echocardiography: problems, pitfalls, and timing</a></text>
<text top="452" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref526">of echocardiography. Semin Cardiothorac Vasc Anesth 2006;10:</a></text>
<text top="466" left="477" width="12" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref526">89</a></text>
<text top="463" left="489" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref526">–100</a></text>
<text top="466" left="513" width="3" height="12" font="15">.</text>
<text top="479" left="450" width="21" height="12" font="15">531.</text>
<text top="479" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref527">Vitarelli A, Conde Y, Cimino E, et al. Assessment of severity of</a></text>
<text top="493" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref527">mechanical prosthetic mitral regurgitation by transoesophageal</a></text>
<text top="506" left="477" width="181" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref527">echocardiography. Heart 2004;90:539</a></text>
<text top="504" left="658" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref527">–44</a></text>
<text top="506" left="676" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref527">.</a></text>
<text top="520" left="450" width="21" height="12" font="15">532.</text>
<text top="520" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref528">van Geldorp MW, Eric Jamieson WR, Kappetein AP, et al.</a></text>
<text top="533" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref528">Patient outcome after aortic valve replacement with a mechanical</a></text>
<text top="547" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref528">or biological prosthesis: weighing lifetime anticoagulant-related</a></text>
<text top="560" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref528">event risk against reoperation risk. J Thorac Cardiovasc Surg</a></text>
<text top="574" left="477" width="67" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref528">2009;137:881</a></text>
<text top="571" left="544" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref528">–5</a></text>
<text top="574" left="556" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref528">.</a></text>
<text top="587" left="450" width="21" height="12" font="15">533.</text>
<text top="587" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref529">Rahimtoola SH. Choice of prosthetic heart valve in adults an up-</a></text>
<text top="600" left="477" width="187" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref529">date. J Am Coll Cardiol 2010;55:2413</a></text>
<text top="598" left="663" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref529">–26</a></text>
<text top="600" left="681" width="3" height="12" font="15">.</text>
<text top="614" left="450" width="21" height="12" font="15">534.</text>
<text top="614" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref530">Hammermeister K, Sethi GK, Henderson WG, et al. Outcomes 15</a></text>
<text top="627" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref530">years after valve replacement with a mechanical versus a bio-</a></text>
<text top="641" left="477" width="79" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref530">prosthetic valve:</a></text>
<text top="638" left="561" width="239" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref530">ﬁnal report of the Veterans Affairs randomized</a></text>
<text top="654" left="477" width="186" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref530">trial. J Am Coll Cardiol 2000;36:1152</a></text>
<text top="652" left="662" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref530">–8</a></text>
<text top="654" left="674" width="3" height="12" font="15">.</text>
<text top="668" left="450" width="21" height="12" font="15">535.</text>
<text top="668" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref531">Badhwar V, Ofenloch JC, Rovin JD, et al. Noninferiority of closely</a></text>
<text top="681" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref531">monitored mechanical valves to bioprostheses overshadowed by early</a></text>
<text top="695" left="477" width="70" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref531">mortality bene</a></text>
<text top="692" left="547" width="253" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref531">ﬁt in younger patients. Ann Thorac Surg 2012;93:</a></text>
<text top="708" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref531">748</a></text>
<text top="705" left="495" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref531">–53</a></text>
<text top="708" left="512" width="3" height="12" font="15">.</text>
<text top="721" left="450" width="21" height="12" font="15">536.</text>
<text top="721" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref532">Weber A, Noureddine H, Englberger L, et al. Ten-year comparison</a></text>
<text top="735" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref532">of pericardial tissue valves versus mechanical prostheses for aortic</a></text>
<text top="748" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref532">valve replacement in patients younger than 60 years of age. J Thorac</a></text>
<text top="762" left="477" width="154" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref532">Cardiovasc Surg 2012;144:1075</a></text>
<text top="759" left="630" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref532">–83</a></text>
<text top="762" left="648" width="3" height="12" font="15">.</text>
<text top="775" left="450" width="21" height="12" font="15">537.</text>
<text top="775" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref533">Banbury MK, Cosgrove DM III, Thomas JD, et al. Hemodynamic</a></text>
<text top="789" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref533">stability during 17 years of the Carpentier-Edwards aortic pericar-</a></text>
<text top="802" left="477" width="245" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref533">dial bioprosthesis. Ann Thorac Surg 2002;73:1460</a></text>
<text top="799" left="722" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref533">–5</a></text>
<text top="802" left="734" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref533">.</a></text>
<text top="816" left="450" width="21" height="12" font="15">538.</text>
<text top="816" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref534">Dellgren G, David TE, Raanani E, et al. Late hemodynamic and</a></text>
<text top="829" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref534">clinical outcomes of aortic valve replacement with the Carpentier-</a></text>
<text top="843" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref534">Edwards Perimount pericardial bioprosthesis. J Thorac Cardiovasc</a></text>
<text top="856" left="477" width="92" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref534">Surg 2002;124:146</a></text>
<text top="853" left="568" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref534">–54</a></text>
<text top="856" left="586" width="3" height="12" font="15">.</text>
<text top="869" left="450" width="21" height="12" font="15">539.</text>
<text top="869" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref535">Borger MA, Ivanov J, Armstrong S, et al. Twenty-year results of the</a></text>
<text top="883" left="477" width="272" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref535">Hancock II bioprosthesis. J Heart Valve Dis 2006;15:49</a></text>
<text top="880" left="749" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref535">–55</a></text>
<text top="883" left="767" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref535">.</a></text>
<text top="896" left="450" width="21" height="12" font="15">540.</text>
<text top="896" left="477" width="165" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref536">Myken PS, Bech-Hansen O. A 20</a></text>
<text top="894" left="642" width="158" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref536">–year experience of 1712 patients</a></text>
<text top="910" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref536">with the Biocor porcine bioprosthesis. J Thorac Cardiovasc Surg</a></text>
<text top="923" left="477" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref536">2009;137:76</a></text>
<text top="921" left="536" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref536">–81</a></text>
<text top="923" left="554" width="3" height="12" font="15">.</text>
<text top="937" left="450" width="21" height="12" font="15">541.</text>
<text top="937" left="477" width="106" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref537">Oxenham H, Bloom</a></text>
<text top="934" left="583" width="217" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref537">ﬁeld P, Wheatley DJ, et al. Twenty year</a></text>
<text top="950" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref537">comparison of a Bjork-Shiley mechanical heart valve with porcine</a></text>
<text top="964" left="477" width="162" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref537">bioprostheses. Heart 2003;89:715</a></text>
<text top="961" left="638" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref537">–21</a></text>
<text top="964" left="656" width="3" height="12" font="15">.</text>
<text top="977" left="450" width="21" height="12" font="15">542.</text>
<text top="977" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref538">Stassano P, Di Tommaso L, Monaco M, et al. Aortic valve</a></text>
<text top="990" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref538">replacement: a prospective randomized evaluation of mechanical</a></text>
<text top="1004" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref538">versus biological valves in patients ages 55 to 70 years. J Am Coll</a></text>
<text top="1017" left="477" width="106" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref538">Cardiol 2009;54:1862</a></text>
<text top="1015" left="582" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref538">–8</a></text>
<text top="1017" left="594" width="3" height="12" font="15">.</text>
<text top="1031" left="450" width="21" height="12" font="15">543.</text>
<text top="1031" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref539">Pibarot P, Dumesnil JG. Prosthetic heart valves: selection of the</a></text>
<text top="1044" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref539">optimal prosthesis and long-term management. Circulation 2009;</a></text>
<text top="1058" left="477" width="45" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref539">119:1034</a></text>
<text top="1055" left="521" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref539">–48</a></text>
<text top="1058" left="539" width="3" height="12" font="15">.</text>
<text top="1071" left="450" width="21" height="12" font="15">544.</text>
<text top="1071" left="477" width="285" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref540">Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: de</a></text>
<text top="1068" left="762" width="38" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref540">ﬁnition,</a></text>
<text top="1085" left="477" width="252" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref540">clinical impact, and prevention. Heart 2006;92:1022</a></text>
<text top="1082" left="729" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref540">–9</a></text>
<text top="1085" left="741" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref540">.</a></text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e168</text>
</page>
<page number="113" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="21" height="12" font="15">545.</text>
<text top="103" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref541">Mohammadi S, Tchana-Sato V, Kalavrouziotis D, et al. Long-term</a></text>
<text top="116" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref541">clinical and echocardiographic follow-up of the Freestyle stentless</a></text>
<text top="130" left="91" width="229" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref541">aortic bioprosthesis. Circulation 2012;126:S198</a></text>
<text top="127" left="320" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref541">–204</a></text>
<text top="130" left="343" width="3" height="12" font="15">.</text>
<text top="143" left="64" width="21" height="12" font="15">546.</text>
<text top="143" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref542">Dunning J, Gao H, Chambers J, et al. Aortic valve surgery: marked</a></text>
<text top="157" left="91" width="147" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref542">increases in volume and signi</a></text>
<text top="154" left="238" width="176" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref542">ﬁcant decreases in mechanical valve</a></text>
<text top="170" left="91" width="15" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref542">use</a></text>
<text top="167" left="106" width="308" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref542">–an analysis of 41,227 patients over 5 years from the Society for</a></text>
<text top="183" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref542">Cardiothoracic Surgery in Great Britain and Ireland National</a></text>
<text top="197" left="91" width="241" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref542">database. J Thorac Cardiovasc Surg 2011;142:776</a></text>
<text top="194" left="332" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref542">–82</a></text>
<text top="197" left="350" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref542">.</a></text>
<text top="210" left="64" width="21" height="12" font="15">547.</text>
<text top="210" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref543">El-Hamamsy I, Eryigit Z, Stevens LM, et al. Long-term outcomes</a></text>
<text top="224" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref543">after autograft versus homograft aortic root replacement in adults</a></text>
<text top="237" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref543">with aortic valve disease: a randomised controlled trial. Lancet 2010;</a></text>
<text top="251" left="91" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref543">376:524</a></text>
<text top="248" left="130" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref543">–31</a></text>
<text top="251" left="148" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref543">.</a></text>
<text top="264" left="64" width="21" height="12" font="15">548.</text>
<text top="264" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref544">Charitos EI, Takkenberg JJ, Hanke T, et al. Reoperations on the</a></text>
<text top="278" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref544">pulmonary autograft and pulmonary homograft after the Ross pro-</a></text>
<text top="291" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref544">cedure: An update on the German Dutch Ross Registry. J Thorac</a></text>
<text top="305" left="91" width="148" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref544">Cardiovasc Surg 2012;144:813</a></text>
<text top="302" left="239" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref544">–21</a></text>
<text top="305" left="257" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref544">.</a></text>
<text top="318" left="64" width="21" height="12" font="15">549.</text>
<text top="318" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref545">Mokhles MM, Rizopoulos D, Andrinopoulou ER, et al. Autograft</a></text>
<text top="331" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref545">and pulmonary allograft performance in the second post-operative</a></text>
<text top="345" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref545">decade after the Ross procedure: insights from the Rotterdam</a></text>
<text top="358" left="91" width="258" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref545">Prospective Cohort Study. Eur Heart J 2012;33:2213</a></text>
<text top="356" left="349" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref545">–24</a></text>
<text top="358" left="367" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref545">.</a></text>
<text top="372" left="64" width="21" height="12" font="15">550.</text>
<text top="372" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref546">Aziz F, Corder M, Wolffe J, et al. Anticoagulation monitoring by an</a></text>
<text top="385" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref546">anticoagulation service is more cost-effective than routine physician</a></text>
<text top="399" left="91" width="152" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref546">care. J Vasc Surg 2011;54:1404</a></text>
<text top="396" left="242" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref546">–7</a></text>
<text top="399" left="254" width="3" height="12" font="15">.</text>
<text top="412" left="64" width="21" height="12" font="15">551.</text>
<text top="412" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref547">Lalonde L, Martineau J, Blais N, et al. Is long-term pharmacist-</a></text>
<text top="426" left="91" width="166" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref547">managed anticoagulation service ef</a></text>
<text top="423" left="257" width="157" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref547">ﬁcient? A pragmatic randomized</a></text>
<text top="439" left="91" width="205" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref547">controlled trial. Am Heart J 2008;156:148</a></text>
<text top="436" left="296" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref547">–54</a></text>
<text top="439" left="314" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref547">.</a></text>
<text top="452" left="64" width="21" height="12" font="15">552.</text>
<text top="452" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref548">Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation</a></text>
<text top="466" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref548">clinic with usual medical care: anticoagulation control, patient outcomes,</a></text>
<text top="479" left="91" width="251" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref548">and health care costs. Arch Intern Med 1998;158:1641</a></text>
<text top="477" left="342" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref548">–7</a></text>
<text top="479" left="354" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref548">.</a></text>
<text top="493" left="64" width="21" height="12" font="15">553.</text>
<text top="493" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref549">Witt DM, Sadler MA, Shanahan RL, et al. Effect of a centralized</a></text>
<text top="506" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref549">clinical pharmacy anticoagulation service on the outcomes of anti-</a></text>
<text top="520" left="91" width="204" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref549">coagulation therapy. Chest 2005;127:1515</a></text>
<text top="517" left="295" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref549">–22</a></text>
<text top="520" left="313" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref549">.</a></text>
<text top="533" left="64" width="21" height="12" font="15">554.</text>
<text top="533" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref550">Locke C, Ravnan SL, Patel R, et al. Reduction in warfarin adverse</a></text>
<text top="547" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref550">events requiring patient hospitalization after implementation of a</a></text>
<text top="560" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref550">pharmacist-managed anticoagulation service. Pharmacotherapy</a></text>
<text top="574" left="91" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref550">2005;25:685</a></text>
<text top="571" left="151" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref550">–9</a></text>
<text top="574" left="163" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref550">.</a></text>
<text top="587" left="64" width="21" height="12" font="15">555.</text>
<text top="587" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref551">Wittkowsky AK, Nutescu EA, Blackburn J, et al. Outcomes of oral</a></text>
<text top="600" left="91" width="252" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref551">anticoagulant therapy managed by telephone vs in-of</a></text>
<text top="598" left="343" width="71" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref551">ﬁce visits in an</a></text>
<text top="614" left="91" width="248" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref551">anticoagulation clinic setting. Chest 2006;130:1385</a></text>
<text top="611" left="339" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref551">–9</a></text>
<text top="614" left="351" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref551">.</a></text>
<text top="627" left="64" width="21" height="12" font="15">556.</text>
<text top="627" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref552">Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and</a></text>
<text top="641" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref552">bleeding complications in patients with mechanical heart valve</a></text>
<text top="654" left="91" width="173" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref552">prostheses. Circulation 1994;89:635</a></text>
<text top="652" left="264" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref552">–41</a></text>
<text top="654" left="282" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref552">.</a></text>
<text top="668" left="64" width="21" height="12" font="15">557.</text>
<text top="668" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref553">Stein PD, Alpert JS, Bussey HI, et al. Antithrombotic therapy in</a></text>
<text top="681" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref553">patients with mechanical and biological prosthetic heart valves.</a></text>
<text top="695" left="91" width="104" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref553">Chest 2001;119:220S</a></text>
<text top="692" left="195" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref553">–7S</a></text>
<text top="695" left="214" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref553">.</a></text>
<text top="708" left="64" width="21" height="12" font="15">558.</text>
<text top="708" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref554">Schlitt A, von Bardeleben RS, Ehrlich A, et al. Clopidogrel and</a></text>
<text top="721" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref554">aspirin in the prevention of thromboembolic complications after</a></text>
<text top="735" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref554">mechanical aortic valve replacement (CAPTA). Thromb Res 2003;</a></text>
<text top="748" left="91" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref554">109:131</a></text>
<text top="746" left="130" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref554">–5</a></text>
<text top="748" left="142" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref554">.</a></text>
<text top="762" left="64" width="21" height="12" font="15">559.</text>
<text top="762" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref555">Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral</a></text>
<text top="775" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref555">anticoagulant therapy in patients with mechanical heart valves.</a></text>
<text top="789" left="91" width="135" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref555">N Engl J Med 1995;333:11</a></text>
<text top="786" left="226" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref555">–7</a></text>
<text top="789" left="238" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref555">.</a></text>
<text top="802" left="64" width="21" height="12" font="15">560.</text>
<text top="802" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref556">Sun JC, Davidson MJ, Lamy A, et al. Antithrombotic management</a></text>
<text top="816" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref556">of patients with prosthetic heart valves: current evidence and future</a></text>
<text top="829" left="91" width="139" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref556">trends. Lancet 2009;374:565</a></text>
<text top="826" left="230" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref556">–76</a></text>
<text top="829" left="247" width="3" height="12" font="15">.</text>
<text top="843" left="64" width="21" height="12" font="15">561.</text>
<text top="843" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref557">Torella M, Torella D, Chiodini P, et al. LOWERing the INtensity</a></text>
<text top="856" left="91" width="251" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref557">of oral anticoaGulant Therapy in patients with bilea</a></text>
<text top="853" left="342" width="72" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref557">ﬂet mechanical</a></text>
<text top="869" left="91" width="194" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref557">aortic valve replacement: results from the</a></text>
<text top="867" left="289" width="125" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref557">“LOWERING-IT” Trial.</a></text>
<text top="883" left="91" width="127" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref557">Am Heart J 2010;160:171</a></text>
<text top="880" left="218" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref557">–8</a></text>
<text top="883" left="230" width="3" height="12" font="15">.</text>
<text top="896" left="64" width="21" height="12" font="15">562.</text>
<text top="896" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref558">Hering D, Piper C, Bergemann R, et al. Thromboembolic and</a></text>
<text top="910" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref558">bleeding complications following St. Jude Medical valve replace-</a></text>
<text top="923" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref558">ment: results of the German Experience With Low-Intensity</a></text>
<text top="937" left="91" width="206" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref558">Anticoagulation Study. Chest 2005;127:53</a></text>
<text top="934" left="297" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref558">–9</a></text>
<text top="937" left="309" width="3" height="12" font="15">.</text>
<text top="950" left="64" width="21" height="12" font="15">563.</text>
<text top="950" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref559">Acar J, Iung B, Boissel JP, et al. AREVA: multicenter randomized</a></text>
<text top="964" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref559">comparison of low-dose versus standard-dose anticoagulation in</a></text>
<text top="977" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref559">patients with mechanical prosthetic heart valves. Circulation 1996;</a></text>
<text top="990" left="91" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref559">94:2107</a></text>
<text top="988" left="130" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref559">–12</a></text>
<text top="990" left="148" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref559">.</a></text>
<text top="1004" left="64" width="21" height="12" font="15">564.</text>
<text top="1004" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref560">Horstkotte D, Scharf RE, Schultheiss HP. Intracardiac thrombosis:</a></text>
<text top="1017" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref560">patient-related and device-related factors. J Heart Valve Dis 1995;4:</a></text>
<text top="1031" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref560">114</a></text>
<text top="1028" left="109" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref560">–20</a></text>
<text top="1031" left="127" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref560">.</a></text>
<text top="1044" left="64" width="21" height="12" font="15">565.</text>
<text top="1044" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref561">Pruefer D, Dahm M, Dohmen G. Intensity of oral anticoagulation</a></text>
<text top="1058" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref561">after implantation of St. Jude Medical mitral or multiple valve</a></text>
<text top="1071" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref561">replacement: lessons learned from GELIA (GELIA 5). Eur Heart J</a></text>
<text top="1085" left="91" width="58" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref561">2001;3:Q43</a></text>
<text top="1085" left="149" width="3" height="12" font="15">.</text>
<text top="103" left="450" width="21" height="12" font="15">566.</text>
<text top="103" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref562">Meschengieser SS, Fondevila CG, Frontroth J, et al. Low-intensity</a></text>
<text top="116" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref562">oral anticoagulation plus low-dose aspirin versus high-intensity</a></text>
<text top="130" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref562">oral anticoagulation alone: a randomized trial in patients with me-</a></text>
<text top="143" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref562">chanical prosthetic heart valves. J Thorac Cardiovasc Surg 1997;113:</a></text>
<text top="157" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref562">910</a></text>
<text top="154" left="495" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref562">–6</a></text>
<text top="157" left="507" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref562">.</a></text>
<text top="170" left="450" width="21" height="12" font="15">567.</text>
<text top="170" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref563">Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin</a></text>
<text top="184" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref563">with placebo in patients treated with warfarin after heart-valve</a></text>
<text top="197" left="477" width="205" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref563">replacement. N Engl J Med 1993;329:524</a></text>
<text top="194" left="682" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref563">–9</a></text>
<text top="197" left="694" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref563">.</a></text>
<text top="210" left="450" width="21" height="12" font="15">568.</text>
<text top="210" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref564">Little SH, Massel DR. Antiplatelet and anticoagulation for patients</a></text>
<text top="224" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref564">with prosthetic heart valves. Cochrane Database Syst Rev 2003:</a></text>
<text top="237" left="477" width="54" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref564">CD003464</a></text>
<text top="237" left="531" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref564">.</a></text>
<text top="251" left="450" width="21" height="12" font="15">569.</text>
<text top="251" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref565">Laffort P, Roudaut R, Roques X, et al. Early and long-term (one-</a></text>
<text top="264" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref565">year) effects of the association of aspirin and oral anticoagulant on</a></text>
<text top="278" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref565">thrombi and morbidity after replacement of the mitral valve with the</a></text>
<text top="291" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref565">St. Jude medical prosthesis: a clinical and transesophageal echocar-</a></text>
<text top="305" left="477" width="240" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref565">diographic study. J Am Coll Cardiol 2000;35:739</a></text>
<text top="302" left="717" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref565">–46</a></text>
<text top="305" left="735" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref565">.</a></text>
<text top="318" left="450" width="21" height="12" font="15">570.</text>
<text top="318" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref566">Pengo V, Palareti G, Cucchini U, et al. Low-intensity oral antico-</a></text>
<text top="331" left="477" width="204" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref566">agulant plus low-dose aspirin during the</a></text>
<text top="329" left="687" width="113" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref566">ﬁrst six months versus</a></text>
<text top="345" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref566">standard-intensity oral anticoagulant therapy after mechanical heart</a></text>
<text top="358" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref566">valve replacement: a pilot study of low-intensity warfarin and aspirin</a></text>
<text top="372" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref566">in cardiac prostheses (LIWACAP). Clin Appl Thromb Hemost</a></text>
<text top="385" left="477" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref566">2007;13:241</a></text>
<text top="383" left="536" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref566">–8</a></text>
<text top="385" left="548" width="3" height="12" font="15">.</text>
<text top="399" left="450" width="21" height="12" font="15">571.</text>
<text top="399" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref567">Altman R, Boullon F, Rouvier J, et al. Aspirin and prophylaxis of</a></text>
<text top="412" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref567">thromboembolic complications in patients with substitute heart</a></text>
<text top="426" left="477" width="222" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref567">valves. J Thorac Cardiovasc Surg 1976;72:127</a></text>
<text top="423" left="699" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref567">–9</a></text>
<text top="426" left="710" width="3" height="12" font="15">.</text>
<text top="439" left="450" width="21" height="12" font="15">572.</text>
<text top="439" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref568">Heras M, Chesebro JH, Fuster V, et al. High risk of thromboemboli</a></text>
<text top="453" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref568">early after bioprosthetic cardiac valve replacement. J Am Coll Car-</a></text>
<text top="466" left="477" width="88" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref568">diol 1995;25:1111</a></text>
<text top="463" left="564" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref568">–9</a></text>
<text top="466" left="576" width="3" height="12" font="15">.</text>
<text top="479" left="450" width="21" height="12" font="15">573.</text>
<text top="479" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref569">Colli A, Mestres CA, Castella M, et al. Comparing warfarin to</a></text>
<text top="493" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref569">aspirin (WoA) after aortic valve replacement with the St. Jude</a></text>
<text top="506" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref569">Medical Epic heart valve bioprosthesis: results of the WoA Epic</a></text>
<text top="520" left="477" width="202" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref569">pilot trial. J Heart Valve Dis 2007;16:667</a></text>
<text top="517" left="678" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref569">–71</a></text>
<text top="520" left="696" width="3" height="12" font="15">.</text>
<text top="533" left="450" width="21" height="12" font="15">574.</text>
<text top="533" left="477" width="265" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref570">Aramendi JI, Mestres CA, Martinez-Leon J, et al. Tri</a></text>
<text top="530" left="742" width="58" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref570">ﬂusal versus</a></text>
<text top="547" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref570">oral anticoagulation for primary prevention of thromboembolism</a></text>
<text top="560" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref570">after bioprosthetic valve replacement (trac): prospective, ran-</a></text>
<text top="574" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref570">domized, co-operative trial. Eur J Cardiothorac Surg 2005;27:</a></text>
<text top="587" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref570">854</a></text>
<text top="584" left="495" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref570">–60</a></text>
<text top="587" left="513" width="3" height="12" font="15">.</text>
<text top="600" left="450" width="21" height="12" font="15">575.</text>
<text top="600" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref571">Nunez L, Gil AM, Larrea JL, et al. Prevention of thromboembolism</a></text>
<text top="614" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref571">using aspirin after mitral valve replacement with porcine bio-</a></text>
<text top="627" left="477" width="197" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref571">prosthesis. Ann Thorac Surg 1984;37:84</a></text>
<text top="625" left="674" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref571">–7</a></text>
<text top="627" left="686" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref571">.</a></text>
<text top="641" left="450" width="21" height="12" font="15">576.</text>
<text top="641" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref572">Russo A, Grigioni F, Avierinos JF, et al. Thromboembolic com-</a></text>
<text top="654" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref572">plications after surgical correction of mitral regurgitation incidence,</a></text>
<text top="668" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref572">predictors, and clinical implications. J Am Coll Cardiol 2008;51:</a></text>
<text top="681" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref572">1203</a></text>
<text top="678" left="500" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref572">–11</a></text>
<text top="681" left="518" width="3" height="12" font="15">.</text>
<text top="695" left="450" width="21" height="12" font="15">577.</text>
<text top="695" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref573">Ionescu MI, Smith DR, Hasan SS, et al. Clinical durability of the</a></text>
<text top="708" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref573">pericardial xenograft valve: ten years experience with mitral</a></text>
<text top="721" left="477" width="214" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref573">replacement. Ann Thorac Surg 1982;34:265</a></text>
<text top="719" left="690" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref573">–77</a></text>
<text top="721" left="708" width="3" height="12" font="15">.</text>
<text top="735" left="450" width="21" height="12" font="15">578.</text>
<text top="735" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref574">Orszulak TA, Schaff HV, Pluth JR, et al. The risk of stroke in the</a></text>
<text top="748" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref574">early postoperative period following mitral valve replacement. Eur J</a></text>
<text top="762" left="477" width="146" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref574">Cardiothorac Surg 1995;9:615</a></text>
<text top="759" left="623" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref574">–9</a></text>
<text top="762" left="635" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref574">.</a></text>
<text top="775" left="450" width="21" height="12" font="15">579.</text>
<text top="775" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref575">Turpie AG, Gunstensen J, Hirsh J, et al. Randomised comparison</a></text>
<text top="789" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref575">of two intensities of oral anticoagulant therapy after tissue heart valve</a></text>
<text top="802" left="477" width="161" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref575">replacement. Lancet 1988;1:1242</a></text>
<text top="799" left="637" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref575">–5</a></text>
<text top="802" left="649" width="3" height="12" font="15">.</text>
<text top="816" left="450" width="21" height="12" font="15">580.</text>
<text top="816" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref576">Moinuddeen K, Quin J, Shaw R, et al. Anticoagulation is unnec-</a></text>
<text top="829" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref576">essary after biological aortic valve replacement. Circulation 1998;98:</a></text>
<text top="843" left="477" width="21" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref576">II95</a></text>
<text top="840" left="497" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref576">–8</a></text>
<text top="843" left="509" width="3" height="12" font="15">.</text>
<text top="856" left="450" width="21" height="12" font="15">581.</text>
<text top="856" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref577">Blair KL, Hatton AC, White WD, et al. Comparison of anti-</a></text>
<text top="869" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref577">coagulation regimens after Carpentier-Edwards aortic or mitral valve</a></text>
<text top="883" left="477" width="190" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref577">replacement. Circulation 1994;90:II214</a></text>
<text top="880" left="667" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref577">–9</a></text>
<text top="883" left="679" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref577">.</a></text>
<text top="896" left="450" width="21" height="12" font="15">582.</text>
<text top="896" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref578">Suri RM, Thourani VH, He X, et al. Variation in warfarin</a></text>
<text top="910" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref578">thromboprophylaxis after mitral valve repair: does equipoise exist</a></text>
<text top="923" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref578">and is a randomized trial warranted? Ann Thorac Surg 2013;95:</a></text>
<text top="937" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref578">1991</a></text>
<text top="934" left="501" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref578">–8</a></text>
<text top="937" left="512" width="3" height="12" font="15">.</text>
<text top="950" left="450" width="21" height="12" font="15">583.</text>
<text top="950" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref579">Merie C, Kober L, Skov OP, et al. Association of warfarin therapy</a></text>
<text top="964" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref579">duration after bioprosthetic aortic valve replacement with risk of</a></text>
<text top="977" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref579">mortality, thromboembolic complications, and bleeding. JAMA</a></text>
<text top="990" left="477" width="72" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref579">2012;308:2118</a></text>
<text top="988" left="548" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref579">–25</a></text>
<text top="990" left="566" width="3" height="12" font="15">.</text>
<text top="1004" left="450" width="21" height="12" font="15">584.</text>
<text top="1004" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref580">Sundt TM, Zehr KJ, Dearani JA, et al. Is early anticoagulation with</a></text>
<text top="1017" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref580">warfarin necessary after bioprosthetic aortic valve replacement?</a></text>
<text top="1031" left="477" width="200" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref580">J Thorac Cardiovasc Surg 2005;129:1024</a></text>
<text top="1028" left="676" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref580">–31</a></text>
<text top="1031" left="694" width="3" height="12" font="15">.</text>
<text top="1044" left="450" width="21" height="12" font="15">585.</text>
<text top="1044" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref581">ElBardissi AW, DiBardino DJ, Chen FY, et al. Is early antith-</a></text>
<text top="1058" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref581">rombotic therapy necessary in patients with bioprosthetic aortic</a></text>
<text top="1071" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref581">valves in normal sinus rhythm? J Thorac Cardiovasc Surg 2010;139:</a></text>
<text top="1085" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref581">1137</a></text>
<text top="1082" left="501" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref581">–45</a></text>
<text top="1085" left="518" width="3" height="12" font="15">.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e169</text>
</page>
<page number="114" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="21" height="12" font="15">586.</text>
<text top="103" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref582">Mehta SR, Weitz JI. Warfarin after bioprosthetic aortic valve im-</a></text>
<text top="116" left="91" width="164" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref582">plantation. JAMA 2012;308:2147</a></text>
<text top="113" left="255" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref582">–8</a></text>
<text top="116" left="267" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref582">.</a></text>
<text top="130" left="64" width="21" height="12" font="15">587.</text>
<text top="130" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref583">Ussia GP, Scarabelli M, Mule M, et al. Dual antiplatelet therapy</a></text>
<text top="143" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref583">versus aspirin alone in patients undergoing transcatheter aortic valve</a></text>
<text top="157" left="91" width="209" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref583">implantation. Am J Cardiol 2011;108:1772</a></text>
<text top="154" left="300" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref583">–6</a></text>
<text top="157" left="312" width="3" height="12" font="15">.</text>
<text top="170" left="64" width="21" height="12" font="15">588.</text>
<text top="170" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref584">Tamburino C, Capodanno D, Ramondo A, et al. Incidence and</a></text>
<text top="183" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref584">predictors of early and late mortality after transcatheter aortic valve</a></text>
<text top="197" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref584">implantation in 663 patients with severe aortic stenosis. Circulation</a></text>
<text top="210" left="91" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref584">2011;123:299</a></text>
<text top="208" left="157" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref584">–308</a></text>
<text top="210" left="181" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref584">.</a></text>
<text top="224" left="64" width="350" height="12" font="15">589. FDA Drug Safety Communication: Pradaxa (dabigatran etexilate</text>
<text top="237" left="91" width="323" height="12" font="15">mesylate) should not be used in patients with mechanical pros-</text>
<text top="251" left="91" width="220" height="12" font="15">thetic heart valves. FDA. 2012. Available at:</text>
<text top="251" left="315" width="99" height="12" font="22"><a href="http://www.fda.gov/Drugs/DrugSafety/ucm332912.htm">http://www.fda.gov/</a></text>
<text top="264" left="91" width="174" height="12" font="22"><a href="http://www.fda.gov/Drugs/DrugSafety/ucm332912.htm">Drugs/DrugSafety/ucm332912.htm</a></text>
<text top="264" left="265" width="148" height="12" font="15">. Accessed February 20, 2014.</text>
<text top="278" left="64" width="21" height="12" font="15">590.</text>
<text top="278" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref586">Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison</a></text>
<text top="291" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref586">of dabigatran etexilate with warfarin in patients with mechanical</a></text>
<text top="305" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref586">heart valves: THE Randomized, phase II study to evaluate the</a></text>
<text top="318" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref586">safety and pharmacokinetics of oral dabigatran etexilate in patients</a></text>
<text top="331" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref586">after heart valve replacement (RE-ALIGN). Am Heart J 2012;</a></text>
<text top="345" left="91" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref586">163:931</a></text>
<text top="342" left="131" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref586">–7</a></text>
<text top="345" left="143" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref586">.</a></text>
<text top="358" left="64" width="21" height="12" font="15">591.</text>
<text top="358" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref587">Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran</a></text>
<text top="372" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref587">versus warfarin in patients with mechanical heart valves. N Engl J</a></text>
<text top="385" left="91" width="98" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref587">Med 2013;369:1206</a></text>
<text top="382" left="189" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref587">–14</a></text>
<text top="385" left="207" width="3" height="12" font="15">.</text>
<text top="399" left="64" width="21" height="12" font="15">592.</text>
<text top="399" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref588">Chu JW, Chen VH, Bunton R. Thrombosis of a mechanical heart</a></text>
<text top="412" left="91" width="273" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref588">valve despite dabigatran. Ann Intern Med 2012;157:304</a></text>
<text top="412" left="364" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref588">.</a></text>
<text top="426" left="64" width="21" height="12" font="15">593.</text>
<text top="426" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref589">Price J, Hynes M, Labinaz M, et al. Mechanical valve thrombosis</a></text>
<text top="439" left="91" width="242" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref589">with dabigatran. J Am Coll Cardiol 2012;60:1710</a></text>
<text top="436" left="333" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref589">–1</a></text>
<text top="439" left="345" width="3" height="12" font="15">.</text>
<text top="452" left="64" width="21" height="12" font="15">594.</text>
<text top="452" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref590">Stewart RA, Astell H, Young L, et al. Thrombosis on a Mechanical</a></text>
<text top="466" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref590">Aortic Valve whilst Anti-coagulated With Dabigatran. Heart Lung</a></text>
<text top="479" left="91" width="78" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref590">Circ 2012;21:53</a></text>
<text top="477" left="169" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref590">–5</a></text>
<text top="479" left="181" width="3" height="12" font="15">.</text>
<text top="493" left="64" width="21" height="12" font="15">595.</text>
<text top="493" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref591">Kearon C, Hirsh J. Management of anticoagulation before and after</a></text>
<text top="506" left="91" width="226" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref591">elective surgery. N Engl J Med 1997;336:1506</a></text>
<text top="504" left="317" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref591">–11</a></text>
<text top="506" left="335" width="3" height="12" font="15">.</text>
<text top="520" left="64" width="21" height="12" font="15">596.</text>
<text top="520" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref592">Tinker JH, Tarhan S. Discontinuing anticoagulant therapy in sur-</a></text>
<text top="533" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref592">gical patients with cardiac valve prostheses. Observations in 180</a></text>
<text top="547" left="91" width="159" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref592">operations. JAMA 1978;239:738</a></text>
<text top="544" left="250" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref592">–9</a></text>
<text top="547" left="262" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref592">.</a></text>
<text top="560" left="64" width="21" height="12" font="15">597.</text>
<text top="560" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref593">Pengo V, Cucchini U, Denas G, et al. Standardized low-molecular-</a></text>
<text top="574" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref593">weight heparin bridging regimen in outpatients on oral anticoagu-</a></text>
<text top="587" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref593">lants undergoing invasive procedure or surgery: an inception cohort</a></text>
<text top="600" left="91" width="226" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref593">management study. Circulation 2009;119:2920</a></text>
<text top="598" left="317" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref593">–7</a></text>
<text top="600" left="329" width="3" height="12" font="15">.</text>
<text top="614" left="64" width="21" height="12" font="15">598.</text>
<text top="614" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref594">Poldermans D, Bax JJ, Boersma E, et al. Guidelines for pre-</a></text>
<text top="627" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref594">operative cardiac risk assessment and perioperative cardiac man-</a></text>
<text top="641" left="91" width="286" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref594">agement in non-cardiac surgery. Eur Heart J 2009;30:2769</a></text>
<text top="638" left="377" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref594">–812</a></text>
<text top="641" left="401" width="3" height="12" font="15">.</text>
<text top="654" left="64" width="21" height="12" font="15">599.</text>
<text top="654" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref595">Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative</a></text>
<text top="668" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref595">management of antithrombotic therapy: Antithrombotic Therapy</a></text>
<text top="681" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref595">and Prevention of Thrombosis, 9th ed: American College of Chest</a></text>
<text top="695" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref595">Physicians Evidence-Based Clinical Practice Guidelines. Erratum</a></text>
<text top="708" left="91" width="279" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref595">in: Chest. 2012 Apr; 141(4):1129. Chest 2012;141:e326S</a></text>
<text top="705" left="370" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref595">–50S</a></text>
<text top="708" left="395" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref595">.</a></text>
<text top="721" left="64" width="21" height="12" font="15">600.</text>
<text top="721" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref596">Pernod G, Godier A, Gozalo C, et al. French clinical practice</a></text>
<text top="735" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref596">guidelines on the management of patients on vitamin K antagonists</a></text>
<text top="748" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref596">in at-risk situations (overdose, risk of bleeding, and active bleeding).</a></text>
<text top="762" left="91" width="136" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref596">Thromb Res 2010;126:e167</a></text>
<text top="759" left="227" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref596">–74</a></text>
<text top="762" left="245" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref596">.</a></text>
<text top="775" left="64" width="21" height="12" font="15">601.</text>
<text top="775" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref597">Weibert RT, Le DT, Kayser SR, et al. Correction of excessive</a></text>
<text top="789" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref597">anticoagulation with low-dose oral vitamin K1. Ann Intern Med</a></text>
<text top="802" left="91" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref597">1997;126:959</a></text>
<text top="799" left="157" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref597">–62</a></text>
<text top="802" left="175" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref597">.</a></text>
<text top="816" left="64" width="21" height="12" font="15">602.</text>
<text top="816" left="91" width="275" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref598">Yiu KH, Siu CW, Jim MH, et al. Comparison of the ef</a></text>
<text top="813" left="366" width="48" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref598">ﬁcacy and</a></text>
<text top="829" left="91" width="47" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref598">safety pro</a></text>
<text top="826" left="138" width="276" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref598">ﬁles of intravenous vitamin K and fresh frozen plasma as</a></text>
<text top="843" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref598">treatment of warfarin-related over-anticoagulation in patients with</a></text>
<text top="856" left="91" width="249" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref598">mechanical heart valves. Am J Cardiol 2006;97:409</a></text>
<text top="853" left="340" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref598">–11</a></text>
<text top="856" left="358" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref598">.</a></text>
<text top="869" left="64" width="21" height="12" font="15">603.</text>
<text top="869" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref599">Genewein U, Haeberli A, Straub PW, et al. Rebound after cessation</a></text>
<text top="883" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref599">of oral anticoagulant therapy: the biochemical evidence. Br J Hae-</a></text>
<text top="896" left="91" width="91" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref599">matol 1996;92:479</a></text>
<text top="894" left="182" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref599">–85</a></text>
<text top="896" left="200" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref599">.</a></text>
<text top="910" left="64" width="21" height="12" font="15">604.</text>
<text top="910" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref600">Barbetseas J, Nagueh SF, Pitsavos C, et al. Differentiating thrombus</a></text>
<text top="923" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref600">from pannus formation in obstructed mechanical prosthetic valves:</a></text>
<text top="937" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref600">an evaluation of clinical, transthoracic and transesophageal echo-</a></text>
<text top="950" left="91" width="287" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref600">cardiographic parameters. J Am Coll Cardiol 1998;32:1410</a></text>
<text top="947" left="377" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref600">–7</a></text>
<text top="950" left="389" width="3" height="12" font="15">.</text>
<text top="964" left="64" width="21" height="12" font="15">605.</text>
<text top="964" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref601">Tong AT, Roudaut R, Ozkan M, et al. Transesophageal echocar-</a></text>
<text top="977" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref601">diography improves risk assessment of thrombolysis of prosthetic</a></text>
<text top="990" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref601">valve thrombosis: results of the international PRO-TEE registry.</a></text>
<text top="1004" left="91" width="148" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref601">J Am Coll Cardiol 2004;43:77</a></text>
<text top="1001" left="239" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref601">–84</a></text>
<text top="1004" left="257" width="3" height="12" font="15">.</text>
<text top="1017" left="64" width="21" height="12" font="15">606.</text>
<text top="1017" left="91" width="110" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref602">Roudaut R, Serri K, La</a></text>
<text top="1015" left="201" width="213" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref602">ﬁtte S. Thrombosis of prosthetic heart valves:</a></text>
<text top="1031" left="91" width="292" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref602">diagnosis and therapeutic considerations. Heart 2007;93:137</a></text>
<text top="1028" left="383" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref602">–42</a></text>
<text top="1031" left="401" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref602">.</a></text>
<text top="1044" left="64" width="21" height="12" font="15">607.</text>
<text top="1044" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref603">Deviri E, Sareli P, Wisenbaugh T, et al. Obstruction of mechanical</a></text>
<text top="1058" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref603">heart valve prostheses: clinical aspects and surgical management.</a></text>
<text top="1071" left="91" width="154" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref603">J Am Coll Cardiol 1991;17:646</a></text>
<text top="1068" left="245" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref603">–50</a></text>
<text top="1071" left="263" width="3" height="12" font="15">.</text>
<text top="103" left="450" width="21" height="12" font="15">608.</text>
<text top="103" left="477" width="71" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref604">Roudaut R, La</a></text>
<text top="100" left="548" width="252" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref604">ﬁtte S, Roudaut MF, et al. Fibrinolysis of mechanical</a></text>
<text top="116" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref604">prosthetic valve thrombosis: a single-center study of 127 cases. J Am</a></text>
<text top="130" left="477" width="124" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref604">Coll Cardiol 2003;41:653</a></text>
<text top="127" left="601" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref604">–8</a></text>
<text top="130" left="613" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref604">.</a></text>
<text top="143" left="450" width="21" height="12" font="15">609.</text>
<text top="143" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref605">Lengyel M, Fuster V, Keltai M, et al. Guidelines for management of</a></text>
<text top="157" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref605">left-sided prosthetic valve thrombosis: a role for thrombolytic ther-</a></text>
<text top="170" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref605">apy. Consensus Conference on Prosthetic Valve Thrombosis. J Am</a></text>
<text top="183" left="477" width="130" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref605">Coll Cardiol 1997;30:1521</a></text>
<text top="181" left="607" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref605">–6</a></text>
<text top="183" left="619" width="3" height="12" font="15">.</text>
<text top="197" left="450" width="21" height="12" font="15">610.</text>
<text top="197" left="477" width="70" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref606">Roudaut R, La</a></text>
<text top="194" left="547" width="253" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref606">ﬁtte S, Roudaut MF, et al. Management of prosthetic</a></text>
<text top="210" left="477" width="111" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref606">heart valve obstruction:</a></text>
<text top="208" left="591" width="208" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref606">ﬁbrinolysis versus surgery. Early results and</a></text>
<text top="224" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref606">long-term follow-up in a single-centre study of 263 cases. Arch</a></text>
<text top="237" left="477" width="143" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref606">Cardiovasc Dis 2009;102:269</a></text>
<text top="235" left="619" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref606">–77</a></text>
<text top="237" left="637" width="3" height="12" font="15">.</text>
<text top="251" left="450" width="21" height="12" font="15">611.</text>
<text top="251" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref607">Keuleers S, Herijgers P, Herregods MC, et al. Comparison of</a></text>
<text top="264" left="477" width="150" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref607">thrombolysis versus surgery as a</a></text>
<text top="261" left="629" width="170" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref607">ﬁrst line therapy for prosthetic heart</a></text>
<text top="278" left="477" width="222" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref607">valve thrombosis. Am J Cardiol 2011;107:275</a></text>
<text top="275" left="699" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref607">–9</a></text>
<text top="278" left="711" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref607">.</a></text>
<text top="291" left="450" width="21" height="12" font="15">612.</text>
<text top="291" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref608">Caceres-Loriga FM, Perez-Lopez H, Morlans-Hernandez K, et al.</a></text>
<text top="305" left="477" width="82" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref608">Thrombolysis as</a></text>
<text top="302" left="567" width="233" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref608">ﬁrst choice therapy in prosthetic heart valve</a></text>
<text top="318" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref608">thrombosis. A study of 68 patients. J Thromb Thrombolysis 2006;</a></text>
<text top="331" left="477" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref608">21:185</a></text>
<text top="329" left="510" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref608">–90</a></text>
<text top="331" left="527" width="3" height="12" font="15">.</text>
<text top="345" left="450" width="21" height="12" font="15">613.</text>
<text top="345" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref609">Karthikeyan G, Senguttuvan NB, Joseph J, et al. Urgent surgery</a></text>
<text top="358" left="477" width="73" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref609">compared with</a></text>
<text top="356" left="554" width="245" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref609">ﬁbrinolytic therapy for the treatment of left-sided</a></text>
<text top="372" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref609">prosthetic heart valve thrombosis: a systematic review and meta-</a></text>
<text top="385" left="477" width="286" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref609">analysis of observational studies. Eur Heart J 2013;34:1557</a></text>
<text top="383" left="762" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref609">–66</a></text>
<text top="385" left="780" width="3" height="12" font="15">.</text>
<text top="399" left="450" width="21" height="12" font="15">614.</text>
<text top="399" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref610">Karthikeyan G, Math RS, Mathew N, et al. Accelerated infusion of</a></text>
<text top="412" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref610">streptokinase for the treatment of left-sided prosthetic valve</a></text>
<text top="426" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref610">thrombosis: a randomized controlled trial. Circulation 2009;120:</a></text>
<text top="439" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref610">1108</a></text>
<text top="436" left="501" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref610">–14</a></text>
<text top="439" left="518" width="3" height="12" font="15">.</text>
<text top="452" left="450" width="21" height="12" font="15">615.</text>
<text top="452" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref611">Bleiziffer S, Eichinger WB, Hettich I, et al. Prediction of valve</a></text>
<text top="466" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref611">prosthesis-patient mismatch prior to aortic valve replacement: which</a></text>
<text top="479" left="477" width="189" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref611">is the best method? Heart 2007;93:615</a></text>
<text top="477" left="666" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref611">–20</a></text>
<text top="479" left="684" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref611">.</a></text>
<text top="493" left="450" width="21" height="12" font="15">616.</text>
<text top="493" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref612">Head SJ, Mokhles MM, Osnabrugge RL, et al. The impact of</a></text>
<text top="506" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref612">prosthesis-patient mismatch on long-term survival after aortic valve</a></text>
<text top="520" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref612">replacement: a systematic review and meta-analysis of 34 observa-</a></text>
<text top="533" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref612">tional studies comprising 27 186 patients with 133 141 patient-</a></text>
<text top="547" left="477" width="157" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref612">years. Eur Heart J 2012;33:1518</a></text>
<text top="544" left="634" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref612">–29</a></text>
<text top="547" left="652" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref612">.</a></text>
<text top="560" left="450" width="21" height="12" font="15">617.</text>
<text top="560" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref613">Miller DL, Morris JJ, Schaff HV, et al. Reoperation for aortic valve</a></text>
<text top="574" left="477" width="136" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref613">periprosthetic leakage: identi</a></text>
<text top="571" left="613" width="187" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref613">ﬁcation of patients at risk and results of</a></text>
<text top="587" left="477" width="196" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref613">operation. J Heart Valve Dis 1995;4:160</a></text>
<text top="584" left="673" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref613">–5</a></text>
<text top="587" left="685" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref613">.</a></text>
<text top="600" left="450" width="21" height="12" font="15">618.</text>
<text top="600" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref614">Akins CW, Bitondo JM, Hilgenberg AD, et al. Early and late re-</a></text>
<text top="614" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref614">sults of the surgical correction of cardiac prosthetic paravalvular</a></text>
<text top="627" left="477" width="180" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref614">leaks. J Heart Valve Dis 2005;14:792</a></text>
<text top="625" left="657" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref614">–9</a></text>
<text top="627" left="669" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref614">.</a></text>
<text top="641" left="450" width="21" height="12" font="15">619.</text>
<text top="641" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref615">Genoni M, Franzen D, Vogt P, et al. Paravalvular leakage after</a></text>
<text top="654" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref615">mitral valve replacement: improved long-term survival with</a></text>
<text top="668" left="477" width="269" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref615">aggressive surgery? Eur J Cardiothorac Surg 2000;17:14</a></text>
<text top="665" left="746" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref615">–9</a></text>
<text top="668" left="758" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref615">.</a></text>
<text top="681" left="450" width="21" height="12" font="15">620.</text>
<text top="681" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref616">Sorajja P, Cabalka AK, Hagler DJ, et al. Percutaneous repair of</a></text>
<text top="695" left="477" width="239" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref616">paravalvular prosthetic regurgitation: acute and 30</a></text>
<text top="692" left="716" width="84" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref616">–day outcomes in</a></text>
<text top="708" left="477" width="233" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref616">115 patients. Circ Cardiovasc Interv 2011;4:314</a></text>
<text top="705" left="709" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref616">–21</a></text>
<text top="708" left="727" width="3" height="12" font="15">.</text>
<text top="721" left="450" width="21" height="12" font="15">621.</text>
<text top="721" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref617">Ruiz CE, Jelnin V, Kronzon I, et al. Clinical outcomes in patients</a></text>
<text top="735" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref617">undergoing percutaneous closure of periprosthetic paravalvular leaks.</a></text>
<text top="748" left="477" width="160" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref617">J Am Coll Cardiol 2011;58:2210</a></text>
<text top="746" left="637" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref617">–7</a></text>
<text top="748" left="649" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref617">.</a></text>
<text top="762" left="450" width="21" height="12" font="15">622.</text>
<text top="762" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref618">Sorajja P, Cabalka AK, Hagler DJ, et al. Long-term follow-up of</a></text>
<text top="775" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref618">percutaneous repair of paravalvular prosthetic regurgitation. J Am</a></text>
<text top="789" left="477" width="130" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref618">Coll Cardiol 2011;58:2218</a></text>
<text top="786" left="607" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref618">–24</a></text>
<text top="789" left="625" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref618">.</a></text>
<text top="802" left="450" width="21" height="12" font="15">623.</text>
<text top="802" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref619">Hourihan M, Perry SB, Mandell VS, et al. Transcatheter umbrella</a></text>
<text top="816" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref619">closure of valvular and paravalvular leaks. J Am Coll Cardiol 1992;</a></text>
<text top="829" left="477" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref619">20:1371</a></text>
<text top="826" left="515" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref619">–7</a></text>
<text top="829" left="527" width="3" height="12" font="15">.</text>
<text top="843" left="450" width="21" height="12" font="15">624.</text>
<text top="843" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref620">Moore JD, Lashus AG, Prieto LR, et al. Transcatheter coil occlu-</a></text>
<text top="856" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref620">sion of perivalvular mitral leaks associated with severe hemolysis.</a></text>
<text top="869" left="477" width="188" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref620">Catheter Cardiovasc Interv 2000;49:64</a></text>
<text top="867" left="664" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref620">–7</a></text>
<text top="869" left="676" width="3" height="12" font="15">.</text>
<text top="883" left="450" width="21" height="12" font="15">625.</text>
<text top="883" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref621">Eisenhauer AC, Piemonte TC, Watson PS. Closure of prosthetic</a></text>
<text top="896" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref621">paravalvular mitral regurgitation with the Gianturco-Grifka vascular</a></text>
<text top="910" left="477" width="278" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref621">occlusion device. Catheter Cardiovasc Interv 2001;54:234</a></text>
<text top="907" left="754" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref621">–8</a></text>
<text top="910" left="766" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref621">.</a></text>
<text top="923" left="450" width="21" height="12" font="15">626.</text>
<text top="923" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref622">Moscucci M, Deeb GM, Bach D, et al. Coil embolization of a</a></text>
<text top="937" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref622">periprosthetic mitral valve leak associated with severe hemolytic</a></text>
<text top="950" left="477" width="166" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref622">anemia. Circulation 2001;104:E85</a></text>
<text top="947" left="643" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref622">–6</a></text>
<text top="950" left="655" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref622">.</a></text>
<text top="964" left="450" width="21" height="12" font="15">627.</text>
<text top="964" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref623">Webb JG, Pate GE, Munt BI. Percutaneous closure of an aortic</a></text>
<text top="977" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref623">prosthetic paravalvular leak with an Amplatzer duct occluder.</a></text>
<text top="990" left="477" width="188" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref623">Catheter Cardiovasc Interv 2005;65:69</a></text>
<text top="988" left="664" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref623">–72</a></text>
<text top="990" left="682" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref623">.</a></text>
<text top="1004" left="450" width="21" height="12" font="15">628.</text>
<text top="1004" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref624">Garcia-Borbolla FR, Sancho JM, Calle PG, et al. Percutaneous</a></text>
<text top="1017" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref624">treatment of mitral valve periprosthetic leakage. An alternative to</a></text>
<text top="1031" left="477" width="234" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref624">high-risk surgery? Rev Esp Cardiol 2009;62:438</a></text>
<text top="1028" left="710" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref624">–41</a></text>
<text top="1031" left="728" width="3" height="12" font="15">.</text>
<text top="1044" left="450" width="21" height="12" font="15">629.</text>
<text top="1044" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref625">Nietlispach F, Johnson M, Moss RR, et al. Transcatheter closure of</a></text>
<text top="1058" left="477" width="205" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref625">paravalvular defects using a purpose-speci</a></text>
<text top="1055" left="682" width="118" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref625">ﬁc occluder. J Am Coll</a></text>
<text top="1071" left="477" width="117" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref625">Cardiol Intv 2010;3:759</a></text>
<text top="1068" left="594" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref625">–65</a></text>
<text top="1071" left="612" width="3" height="12" font="15">.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e170</text>
</page>
<page number="115" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="21" height="12" font="15">630.</text>
<text top="103" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref626">Cabell CH, Jollis JG, Peterson GE, et al. Changing patient char-</a></text>
<text top="116" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref626">acteristics and the effect on mortality in endocarditis. Arch Intern</a></text>
<text top="130" left="91" width="87" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref626">Med 2002;162:90</a></text>
<text top="127" left="177" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref626">–4</a></text>
<text top="130" left="189" width="3" height="12" font="15">.</text>
<text top="143" left="64" width="21" height="12" font="15">631.</text>
<text top="143" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref627">Tleyjeh IM, Abdel-Latif A, Rahbi H, et al. A systematic review of</a></text>
<text top="157" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref627">population-based studies of infective endocarditis. Chest 2007;132:</a></text>
<text top="170" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref627">1025</a></text>
<text top="167" left="115" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref627">–35</a></text>
<text top="170" left="133" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref627">.</a></text>
<text top="183" left="64" width="21" height="12" font="15">632.</text>
<text top="183" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref628">Klug D, Lacroix D, Savoye C, et al. Systemic infection related to</a></text>
<text top="197" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref628">endocarditis on pacemaker leads: clinical presentation and man-</a></text>
<text top="210" left="91" width="171" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref628">agement. Circulation 1997;95:2098</a></text>
<text top="208" left="261" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref628">–107</a></text>
<text top="210" left="285" width="3" height="12" font="15">.</text>
<text top="224" left="64" width="21" height="12" font="15">633.</text>
<text top="224" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref629">Gould FK, Denning DW, Elliott TS, et al. Guidelines for the</a></text>
<text top="237" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref629">diagnosis and antibiotic treatment of endocarditis in adults: a report</a></text>
<text top="251" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref629">of the Working Party of the British Society for Antimicrobial</a></text>
<text top="264" left="91" width="263" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref629">Chemotherapy. J Antimicrob Chemother 2012;67:269</a></text>
<text top="261" left="354" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref629">–89</a></text>
<text top="264" left="372" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref629">.</a></text>
<text top="278" left="64" width="21" height="12" font="15">634.</text>
<text top="278" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref630">Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis:</a></text>
<text top="291" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref630">diagnosis, antimicrobial therapy, and management of complications:</a></text>
<text top="305" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref630">a statement for healthcare professionals from the Committee on</a></text>
<text top="318" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref630">Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on</a></text>
<text top="331" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref630">Cardiovascular Disease in the Young, and the Councils on Clinical</a></text>
<text top="345" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref630">Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia,</a></text>
<text top="358" left="91" width="272" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref630">American Heart Association. Circulation 2005;111:e394</a></text>
<text top="356" left="363" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref630">–434</a></text>
<text top="358" left="387" width="3" height="12" font="15">.</text>
<text top="372" left="64" width="21" height="12" font="15">635.</text>
<text top="372" left="91" width="252" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref631">Lalani T, Chu VH, Park LP, et al. In-hospital and 1</a></text>
<text top="369" left="343" width="71" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref631">–year mortality</a></text>
<text top="385" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref631">in patients undergoing early surgery for prosthetic valve endocarditis.</a></text>
<text top="399" left="91" width="169" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref631">JAMA Intern Med 2013;173:1495</a></text>
<text top="396" left="260" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref631">–504</a></text>
<text top="399" left="284" width="3" height="12" font="15">.</text>
<text top="412" left="64" width="21" height="12" font="15">636.</text>
<text top="412" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref632">Lopez J, Sevilla T, Vilacosta I, et al. Prognostic role of persistent</a></text>
<text top="426" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref632">positive blood cultures after initiation of antibiotic therapy in left-</a></text>
<text top="439" left="91" width="264" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref632">sided infective endocarditis. Eur Heart J 2013;34:1749</a></text>
<text top="436" left="355" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref632">–54</a></text>
<text top="439" left="373" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref632">.</a></text>
<text top="452" left="64" width="21" height="12" font="15">637.</text>
<text top="452" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref633">Capp R, Chang Y, Brown DF. Effective antibiotic treatment pre-</a></text>
<text top="466" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref633">scribed by emergency physicians in patients admitted to the inten-</a></text>
<text top="479" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref633">sive care unit with severe sepsis or septic shock: where is the gap?</a></text>
<text top="493" left="91" width="131" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref633">J Emerg Med 2011;41:573</a></text>
<text top="490" left="222" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref633">–80</a></text>
<text top="493" left="240" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref633">.</a></text>
<text top="506" left="64" width="21" height="12" font="15">638.</text>
<text top="506" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref634">Garza D, Becan-McBride K. Phlebotomy Handbook. Stamford,</a></text>
<text top="520" left="91" width="147" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref634">CT: Appleton &amp; Lange; 1998</a></text>
<text top="520" left="238" width="3" height="12" font="15">.</text>
<text top="533" left="64" width="21" height="12" font="15">639.</text>
<text top="533" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref635">Baron EJ, Scott JD, Tompkins LS. Prolonged incubation and</a></text>
<text top="547" left="91" width="312" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref635">extensive subculturing do not increase recovery of clinically signi</a></text>
<text top="544" left="403" width="11" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref635">ﬁ-</a></text>
<text top="560" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref635">cant microorganisms from standard automated blood cultures. Clin</a></text>
<text top="574" left="91" width="118" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref635">Infect Dis 2005;41:1677</a></text>
<text top="571" left="209" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref635">–80</a></text>
<text top="574" left="227" width="3" height="12" font="15">.</text>
<text top="587" left="64" width="21" height="12" font="15">640.</text>
<text top="587" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref636">Houpikian P, Raoult D. Blood culture-negative endocarditis in a</a></text>
<text top="600" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref636">reference center: etiologic diagnosis of 348 cases. Medicine (Balti-</a></text>
<text top="614" left="91" width="92" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref636">more) 2005;84:162</a></text>
<text top="611" left="183" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref636">–73</a></text>
<text top="614" left="201" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref636">.</a></text>
<text top="627" left="64" width="21" height="12" font="15">641.</text>
<text top="627" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref637">Steckelberg JM, Wilson WR. Risk factors for infective endocarditis.</a></text>
<text top="641" left="91" width="175" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref637">Infect Dis Clin North Am 1993;7:9</a></text>
<text top="638" left="266" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref637">–19</a></text>
<text top="641" left="284" width="3" height="12" font="15">.</text>
<text top="654" left="64" width="21" height="12" font="15">642.</text>
<text top="654" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref638">Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of</a></text>
<text top="668" left="91" width="217" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref638">infective endocarditis: utilization of speci</a></text>
<text top="665" left="308" width="106" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref638">ﬁc echocardiographic</a></text>
<text top="678" left="91" width="309" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref638">ﬁndings. Duke Endocarditis Service. Am J Med 1994;96:200–9</a></text>
<text top="681" left="400" width="3" height="12" font="15">.</text>
<text top="695" left="64" width="21" height="12" font="15">643.</text>
<text top="695" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref639">Kupferwasser LI, Darius H, Muller AM, et al. Diagnosis of culture-</a></text>
<text top="708" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref639">negative endocarditis: the role of the Duke criteria and the impact of</a></text>
<text top="721" left="91" width="296" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref639">transesophageal echocardiography. Am Heart J 2001;142:146</a></text>
<text top="719" left="387" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref639">–52</a></text>
<text top="721" left="405" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref639">.</a></text>
<text top="735" left="64" width="21" height="12" font="15">644.</text>
<text top="735" left="91" width="248" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref640">Li JS, Sexton DJ, Mick N, et al. Proposed modi</a></text>
<text top="732" left="339" width="75" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref640">ﬁcations to the</a></text>
<text top="748" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref640">Duke criteria for the diagnosis of infective endocarditis. Clin Infect</a></text>
<text top="762" left="91" width="81" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref640">Dis 2000;30:633</a></text>
<text top="759" left="172" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref640">–8</a></text>
<text top="762" left="184" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref640">.</a></text>
<text top="775" left="64" width="21" height="12" font="15">645.</text>
<text top="775" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref641">Perez-Vazquez A, Farinas MC, Garcia-Palomo JD, et al. Evalua-</a></text>
<text top="789" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref641">tion of the Duke criteria in 93 episodes of prosthetic valve endo-</a></text>
<text top="802" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref641">carditis: could sensitivity be improved? Arch Intern Med 2000;160:</a></text>
<text top="816" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref641">1185</a></text>
<text top="813" left="115" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref641">–91</a></text>
<text top="816" left="133" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref641">.</a></text>
<text top="829" left="64" width="21" height="12" font="15">646.</text>
<text top="829" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref642">Lukes AS, Bright DK, Durack DT. Diagnosis of infective endo-</a></text>
<text top="843" left="91" width="216" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref642">carditis. Infect Dis Clin North Am 1993;7:1</a></text>
<text top="840" left="307" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref642">–8</a></text>
<text top="843" left="319" width="3" height="12" font="15">.</text>
<text top="856" left="64" width="21" height="12" font="15">647.</text>
<text top="856" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref643">Dodds GA, Sexton DJ, Durack DT, et al. Negative predictive value</a></text>
<text top="869" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref643">of the Duke criteria for infective endocarditis. Am J Cardiol 1996;</a></text>
<text top="883" left="91" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref643">77:403</a></text>
<text top="880" left="124" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref643">–7</a></text>
<text top="883" left="136" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref643">.</a></text>
<text top="896" left="64" width="21" height="12" font="15">648.</text>
<text top="896" left="91" width="317" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref644">Bayer AS. Diagnostic criteria for identifying cases of endocarditis</a></text>
<text top="894" left="408" width="6" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref644">–</a></text>
<text top="910" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref644">revisiting the Duke criteria two years later. Clin Infect Dis 1996;23:</a></text>
<text top="923" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref644">303</a></text>
<text top="921" left="109" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref644">–4</a></text>
<text top="923" left="121" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref644">.</a></text>
<text top="937" left="64" width="21" height="12" font="15">649.</text>
<text top="937" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref645">Prendergast BD. Diagnostic criteria and problems in infective</a></text>
<text top="950" left="91" width="156" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref645">endocarditis. Heart 2004;90:611</a></text>
<text top="947" left="247" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref645">–3</a></text>
<text top="950" left="259" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref645">.</a></text>
<text top="964" left="64" width="21" height="12" font="15">650.</text>
<text top="964" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref646">Tsutsumi T. Clinical use of the Duke criteria in patients with sus-</a></text>
<text top="977" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref646">pected infective endocarditis and negative transesophageal echocar-</a></text>
<text top="990" left="91" width="217" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref646">diograms. Infect Dis Clin Pract 2012;20:315</a></text>
<text top="988" left="308" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref646">–8</a></text>
<text top="990" left="320" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref646">.</a></text>
<text top="1004" left="64" width="21" height="12" font="15">651.</text>
<text top="1004" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref647">Botelho-Nevers E, Thuny F, Casalta JP, et al. Dramatic reduction</a></text>
<text top="1017" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref647">in infective endocarditis-related mortality with a management-based</a></text>
<text top="1031" left="91" width="210" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref647">approach. Arch Intern Med 2009;169:1290</a></text>
<text top="1028" left="301" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref647">–8</a></text>
<text top="1031" left="313" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref647">.</a></text>
<text top="1044" left="64" width="21" height="12" font="15">652.</text>
<text top="1044" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref648">Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation,</a></text>
<text top="1058" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref648">etiology, and outcome of infective endocarditis in the 21st century:</a></text>
<text top="1071" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref648">the International Collaboration on Endocarditis-Prospective Cohort</a></text>
<text top="1085" left="91" width="188" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref648">Study. Arch Intern Med 2009;169:463</a></text>
<text top="1082" left="279" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref648">–73</a></text>
<text top="1085" left="297" width="3" height="12" font="15">.</text>
<text top="103" left="450" width="21" height="12" font="15">653.</text>
<text top="103" left="477" width="79" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref649">Haldar SM, O</a></text>
<text top="100" left="555" width="244" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref649">’Gara PT. Infective endocarditis: diagnosis and</a></text>
<text top="116" left="477" width="280" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref649">management. Nat Clin Pract Cardiovasc Med 2006;3:310</a></text>
<text top="114" left="757" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref649">–7</a></text>
<text top="116" left="769" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref649">.</a></text>
<text top="130" left="450" width="21" height="12" font="15">654.</text>
<text top="130" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref650">Bashore TM, Cabell C, Fowler V Jr. Update on infective endo-</a></text>
<text top="143" left="477" width="197" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref650">carditis. Curr Probl Cardiol 2006;31:274</a></text>
<text top="140" left="674" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref650">–352</a></text>
<text top="143" left="698" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref650">.</a></text>
<text top="157" left="450" width="21" height="12" font="15">655.</text>
<text top="157" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref651">Mugge A, Daniel WG, Frank G, et al. Echocardiography in</a></text>
<text top="170" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref651">infective endocarditis: reassessment of prognostic implications of</a></text>
<text top="184" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref651">vegetation size determined by the transthoracic and the trans-</a></text>
<text top="197" left="477" width="259" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref651">esophageal approach. J Am Coll Cardiol 1989;14:631</a></text>
<text top="194" left="736" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref651">–8</a></text>
<text top="197" left="748" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref651">.</a></text>
<text top="210" left="450" width="21" height="12" font="15">656.</text>
<text top="210" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref652">Burger AJ, Peart B, Jabi H, et al. The role of two-dimensional</a></text>
<text top="224" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref652">echocardiology in the diagnosis of infective endocarditis [cor-</a></text>
<text top="237" left="477" width="153" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref652">rected]. Angiology 1991;42:552</a></text>
<text top="235" left="629" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref652">–60</a></text>
<text top="237" left="647" width="3" height="12" font="15">.</text>
<text top="251" left="450" width="21" height="12" font="15">657.</text>
<text top="251" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref653">Irani WN, Grayburn PA, Afridi I. A negative transthoracic echo-</a></text>
<text top="264" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref653">cardiogram obviates the need for transesophageal echocardiography</a></text>
<text top="278" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref653">in patients with suspected native valve active infective endocarditis.</a></text>
<text top="291" left="477" width="130" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref653">Am J Cardiol 1996;78:101</a></text>
<text top="288" left="606" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref653">–3</a></text>
<text top="291" left="618" width="3" height="12" font="15">.</text>
<text top="305" left="450" width="21" height="12" font="15">658.</text>
<text top="305" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref654">Liu YW, Tsai WC, Hsu CH, et al. Judicious use of transthoracic</a></text>
<text top="318" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref654">echocardiography in infective endocarditis screening. Can J Cardiol</a></text>
<text top="331" left="477" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref654">2009;25:703</a></text>
<text top="329" left="536" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref654">–5</a></text>
<text top="331" left="548" width="3" height="12" font="15">.</text>
<text top="345" left="450" width="21" height="12" font="15">659.</text>
<text top="345" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref655">Kemp WE Jr., Citrin B, Byrd BF III. Echocardiography in infective</a></text>
<text top="358" left="477" width="191" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref655">endocarditis. South Med J 1999;92:744</a></text>
<text top="356" left="668" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref655">–54</a></text>
<text top="358" left="685" width="3" height="12" font="15">.</text>
<text top="372" left="450" width="21" height="12" font="15">660.</text>
<text top="372" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref656">Rubenson DS, Tucker CR, Stinson EB, et al. The use of echo-</a></text>
<text top="385" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref656">cardiography in diagnosing culture-negative endocarditis. Circula-</a></text>
<text top="399" left="477" width="83" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref656">tion 1981;64:641</a></text>
<text top="396" left="559" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref656">–6</a></text>
<text top="399" left="571" width="3" height="12" font="15">.</text>
<text top="412" left="450" width="21" height="12" font="15">661.</text>
<text top="412" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref657">Shapiro SM, Young E, De Guzman S, et al. Transesophageal</a></text>
<text top="426" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref657">echocardiography in diagnosis of infective endocarditis. Chest 1994;</a></text>
<text top="439" left="477" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref657">105:377</a></text>
<text top="436" left="515" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref657">–82</a></text>
<text top="439" left="533" width="3" height="12" font="15">.</text>
<text top="452" left="450" width="21" height="12" font="15">662.</text>
<text top="452" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref658">Erbel R, Rohmann S, Drexler M, et al. Improved diagnostic value</a></text>
<text top="466" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref658">of echocardiography in patients with infective endocarditis by</a></text>
<text top="479" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref658">transoesophageal approach. A prospective study. Eur Heart J 1988;</a></text>
<text top="493" left="477" width="21" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref658">9:43</a></text>
<text top="490" left="498" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref658">–53</a></text>
<text top="493" left="516" width="3" height="12" font="15">.</text>
<text top="506" left="450" width="21" height="12" font="15">663.</text>
<text top="506" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref659">Rasmussen RV, Host U, Arpi M, et al. Prevalence of infective</a></text>
<text top="520" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref659">endocarditis in patients with Staphylococcus aureus bacteraemia: the</a></text>
<text top="533" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref659">value of screening with echocardiography. Eur J Echocardiogr 2011;</a></text>
<text top="547" left="477" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref659">12:414</a></text>
<text top="544" left="510" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref659">–20</a></text>
<text top="547" left="527" width="3" height="12" font="15">.</text>
<text top="560" left="450" width="21" height="12" font="15">664.</text>
<text top="560" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref660">Reynolds HR, Jagen MA, Tunick PA, et al. Sensitivity of trans-</a></text>
<text top="574" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref660">thoracic versus transesophageal echocardiography for the detection</a></text>
<text top="587" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref660">of native valve vegetations in the modern era. J Am Soc Echo-</a></text>
<text top="600" left="477" width="96" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref660">cardiogr 2003;16:67</a></text>
<text top="598" left="573" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref660">–70</a></text>
<text top="600" left="591" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref660">.</a></text>
<text top="614" left="450" width="21" height="12" font="15">665.</text>
<text top="614" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref661">Daniel WG, Mugge A, Martin RP, et al. Improvement in the</a></text>
<text top="627" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref661">diagnosis of abscesses associated with endocarditis by trans-</a></text>
<text top="641" left="477" width="286" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref661">esophageal echocardiography. N Engl J Med 1991;324:795</a></text>
<text top="638" left="762" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref661">–800</a></text>
<text top="641" left="786" width="3" height="12" font="15">.</text>
<text top="654" left="450" width="21" height="12" font="15">666.</text>
<text top="654" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref662">Sochowski RA, Chan KL. Implication of negative results on a</a></text>
<text top="668" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref662">monoplane transesophageal echocardiographic study in patients with</a></text>
<text top="681" left="477" width="303" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref662">suspected infective endocarditis. J Am Coll Cardiol 1993;21:216</a></text>
<text top="678" left="779" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref662">–21</a></text>
<text top="681" left="797" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref662">.</a></text>
<text top="695" left="450" width="21" height="12" font="15">667.</text>
<text top="695" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref663">Shively BK, Gurule FT, Roldan CA, et al. Diagnostic value of</a></text>
<text top="708" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref663">transesophageal compared with transthoracic echocardiography in</a></text>
<text top="721" left="477" width="262" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref663">infective endocarditis. J Am Coll Cardiol 1991;18:391</a></text>
<text top="719" left="739" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref663">–7</a></text>
<text top="721" left="751" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref663">.</a></text>
<text top="735" left="450" width="21" height="12" font="15">668.</text>
<text top="735" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref664">Pedersen WR, Walker M, Olson JD, et al. Value of transesophageal</a></text>
<text top="748" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref664">echocardiography as an adjunct to transthoracic echocardiography in</a></text>
<text top="762" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref664">evaluation of native and prosthetic valve endocarditis. Chest 1991;</a></text>
<text top="775" left="477" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref664">100:351</a></text>
<text top="773" left="515" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref664">–6</a></text>
<text top="775" left="527" width="3" height="12" font="15">.</text>
<text top="789" left="450" width="21" height="12" font="15">669.</text>
<text top="789" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref665">Ronderos RE, Portis M, Stoermann W, et al. Are all echocardio-</a></text>
<text top="802" left="477" width="35" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref665">graphic</a></text>
<text top="799" left="520" width="280" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref665">ﬁndings equally predictive for diagnosis in prosthetic</a></text>
<text top="816" left="477" width="244" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref665">endocarditis? J Am Soc Echocardiogr 2004;17:664</a></text>
<text top="813" left="721" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref665">–9</a></text>
<text top="816" left="733" width="3" height="12" font="15">.</text>
<text top="829" left="450" width="21" height="12" font="15">670.</text>
<text top="829" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref666">Roe MT, Abramson MA, Li J, et al. Clinical information de-</a></text>
<text top="843" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref666">termines the impact of transesophageal echocardiography on the</a></text>
<text top="856" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref666">diagnosis of infective endocarditis by the duke criteria. Am Heart J</a></text>
<text top="869" left="477" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref666">2000;139:945</a></text>
<text top="867" left="542" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref666">–51</a></text>
<text top="869" left="560" width="3" height="12" font="15">.</text>
<text top="883" left="450" width="21" height="12" font="15">671.</text>
<text top="883" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref667">Karalis DG, Bansal RC, Hauck AJ, et al. Transesophageal echo-</a></text>
<text top="896" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref667">cardiographic recognition of subaortic complications in aortic valve</a></text>
<text top="910" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref667">endocarditis. Clinical and surgical implications. Circulation 1992;</a></text>
<text top="923" left="477" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref667">86:353</a></text>
<text top="921" left="510" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref667">–62</a></text>
<text top="923" left="527" width="3" height="12" font="15">.</text>
<text top="937" left="450" width="21" height="12" font="15">672.</text>
<text top="937" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref668">El-Ahdab F, Benjamin DK Jr., Wang A, et al. Risk of endocarditis</a></text>
<text top="950" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref668">among patients with prosthetic valves and Staphylococcus aureus</a></text>
<text top="964" left="477" width="181" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref668">bacteremia. Am J Med 2005;118:225</a></text>
<text top="961" left="657" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref668">–9</a></text>
<text top="964" left="669" width="3" height="12" font="15">.</text>
<text top="977" left="450" width="21" height="12" font="15">673.</text>
<text top="977" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref669">Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/</a></text>
<text top="990" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref669">ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appro-</a></text>
<text top="1004" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref669">priate use criteria for echocardiography. A report of the American</a></text>
<text top="1017" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref669">College of Cardiology Foundation Appropriate Use Criteria Task</a></text>
<text top="1031" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref669">Force, American Society of Echocardiography, American Heart</a></text>
<text top="1044" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref669">Association, American Society of Nuclear Cardiology, Heart Failure</a></text>
<text top="1058" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref669">Society of America, Heart Rhythm Society, Society for Cardiovas-</a></text>
<text top="1071" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref669">cular Angiography and Interventions, Society of Critical Care</a></text>
<text top="1085" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref669">Medicine, Society of Cardiovascular Computed Tomography, and</a></text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e171</text>
</page>
<page number="116" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref669">Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol</a></text>
<text top="116" left="91" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref669">2011;57:1126</a></text>
<text top="113" left="157" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref669">–66</a></text>
<text top="116" left="175" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref669">.</a></text>
<text top="130" left="64" width="21" height="12" font="15">674.</text>
<text top="130" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref670">Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/</a></text>
<text top="143" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref670">ASE 2003 guideline update for the clinical application of echocar-</a></text>
<text top="157" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref670">diography: summary article: a report of the American College of</a></text>
<text top="170" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref670">Cardiology/American Heart Association Task Force on Practice</a></text>
<text top="183" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref670">Guidelines (ACC/AHA/ASE Committee to Update the 1997</a></text>
<text top="197" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref670">Guidelines for the Clinical Application of Echocardiography).</a></text>
<text top="210" left="91" width="129" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref670">Circulation 2003;108:1146</a></text>
<text top="208" left="220" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref670">–62</a></text>
<text top="210" left="238" width="3" height="12" font="15">.</text>
<text top="224" left="64" width="21" height="12" font="15">675.</text>
<text top="224" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref671">Vilacosta I, Graupner C, San Roman JA, et al. Risk of embolization</a></text>
<text top="237" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref671">after institution of antibiotic therapy for infective endocarditis. J Am</a></text>
<text top="251" left="91" width="130" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref671">Coll Cardiol 2002;39:1489</a></text>
<text top="248" left="221" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref671">–95</a></text>
<text top="251" left="239" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref671">.</a></text>
<text top="264" left="64" width="21" height="12" font="15">676.</text>
<text top="264" left="91" width="252" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref672">Hoen B, Alla F, Selton-Suty C, et al. Changing pro</a></text>
<text top="261" left="343" width="71" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref672">ﬁle of infective</a></text>
<text top="278" left="91" width="125" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref672">endocarditis: results of a 1</a></text>
<text top="275" left="216" width="198" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref672">–year survey in France. JAMA 2002;288:</a></text>
<text top="291" left="91" width="12" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref672">75</a></text>
<text top="288" left="103" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref672">–81</a></text>
<text top="291" left="121" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref672">.</a></text>
<text top="305" left="64" width="21" height="12" font="15">677.</text>
<text top="305" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref673">Rosen AB, Fowler VG Jr., Corey GR, et al. Cost-effectiveness of</a></text>
<text top="318" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref673">transesophageal echocardiography to determine the duration of</a></text>
<text top="331" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref673">therapy for intravascular catheter-associated Staphylococcus aureus</a></text>
<text top="345" left="91" width="210" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref673">bacteremia. Ann Intern Med 1999;130:810</a></text>
<text top="342" left="300" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref673">–20</a></text>
<text top="345" left="318" width="3" height="12" font="15">.</text>
<text top="358" left="64" width="21" height="12" font="15">678.</text>
<text top="358" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref674">Fagman E, Perrotta S, Bech-Hanssen O, et al. ECG-gated</a></text>
<text top="372" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref674">computed tomography: a new role for patients with suspected aortic</a></text>
<text top="385" left="91" width="265" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref674">prosthetic valve endocarditis. Eur Radiol 2012;22:2407</a></text>
<text top="382" left="356" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref674">–14</a></text>
<text top="385" left="374" width="3" height="12" font="15">.</text>
<text top="399" left="64" width="21" height="12" font="15">679.</text>
<text top="399" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref675">Rohmann S, Erbel R, Darius H, et al. Prediction of rapid versus</a></text>
<text top="412" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref675">prolonged healing of infective endocarditis by monitoring vegetation</a></text>
<text top="426" left="91" width="197" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref675">size. J Am Soc Echocardiogr 1991;4:465</a></text>
<text top="423" left="288" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref675">–74</a></text>
<text top="426" left="306" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref675">.</a></text>
<text top="439" left="64" width="21" height="12" font="15">680.</text>
<text top="439" left="91" width="138" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref676">Massoure PL, Reuter S, La</a></text>
<text top="436" left="229" width="185" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref676">ﬁtte S, et al. Pacemaker endocarditis:</a></text>
<text top="452" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref676">clinical features and management of 60 consecutive cases. Pacing</a></text>
<text top="466" left="91" width="151" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref676">Clin Electrophysiol 2007;30:12</a></text>
<text top="463" left="242" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref676">–9</a></text>
<text top="466" left="254" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref676">.</a></text>
<text top="479" left="64" width="21" height="12" font="15">681.</text>
<text top="479" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref677">Narducci ML, Pelargonio G, Russo E, et al. Usefulness of intra-</a></text>
<text top="493" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref677">cardiac echocardiography for the diagnosis of cardiovascular</a></text>
<text top="506" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref677">implantable electronic device-related endocarditis. J Am Coll Car-</a></text>
<text top="520" left="91" width="88" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref677">diol 2013;61:1398</a></text>
<text top="517" left="179" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref677">–405</a></text>
<text top="520" left="203" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref677">.</a></text>
<text top="533" left="64" width="21" height="12" font="15">682.</text>
<text top="533" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref678">Mylonakis E, Calderwood SB. Infective endocarditis in adults.</a></text>
<text top="547" left="91" width="147" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref678">N Engl J Med 2001;345:1318</a></text>
<text top="544" left="238" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref678">–30</a></text>
<text top="547" left="256" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref678">.</a></text>
<text top="560" left="64" width="21" height="12" font="15">683.</text>
<text top="560" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref679">Lengyel M. The impact of transesophageal echocardiography on</a></text>
<text top="574" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref679">the management of prosthetic valve endocarditis: experience of 31</a></text>
<text top="587" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref679">cases and review of the literature. J Heart Valve Dis 1997;6:</a></text>
<text top="600" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref679">204</a></text>
<text top="598" left="109" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref679">–11</a></text>
<text top="600" left="127" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref679">.</a></text>
<text top="614" left="64" width="21" height="12" font="15">684.</text>
<text top="614" left="91" width="300" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref680">Bayer AS. Infective endocarditis. Clin Infect Dis 1993;17:313</a></text>
<text top="611" left="391" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref680">–20</a></text>
<text top="614" left="409" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref680">.</a></text>
<text top="627" left="64" width="21" height="12" font="15">685.</text>
<text top="627" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref681">Ghatak A, Pullatt R, Vyse S, et al. Appropriateness criteria are an</a></text>
<text top="641" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref681">imprecise measure for repeat echocardiograms. Echocardiography</a></text>
<text top="654" left="91" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref681">2011;28:131</a></text>
<text top="652" left="151" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref681">–5</a></text>
<text top="654" left="163" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref681">.</a></text>
<text top="668" left="64" width="21" height="12" font="15">686.</text>
<text top="668" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref682">Shapira Y, Weisenberg DE, Vaturi M, et al. The impact of intra-</a></text>
<text top="681" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref682">operative transesophageal echocardiography in infective endocardi-</a></text>
<text top="695" left="91" width="155" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref682">tis. Isr Med Assoc J 2007;9:299</a></text>
<text top="692" left="246" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref682">–302</a></text>
<text top="695" left="270" width="3" height="12" font="15">.</text>
<text top="708" left="64" width="21" height="12" font="15">687.</text>
<text top="708" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref683">Yao F, Han L, Xu ZY, et al. Surgical treatment of multivalvular</a></text>
<text top="721" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref683">endocarditis: twenty-one-year single center experience. J Thorac</a></text>
<text top="735" left="91" width="154" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref683">Cardiovasc Surg 2009;137:1475</a></text>
<text top="732" left="245" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref683">–80</a></text>
<text top="735" left="263" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref683">.</a></text>
<text top="748" left="64" width="21" height="12" font="15">688.</text>
<text top="748" left="91" width="173" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref684">Eltzschig HK, Rosenberger P, Lof</a></text>
<text top="746" left="264" width="150" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref684">ﬂer M, et al. Impact of intra-</a></text>
<text top="762" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref684">operative transesophageal echocardiography on surgical decisions in</a></text>
<text top="775" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref684">12,566 patients undergoing cardiac surgery. Ann Thorac Surg 2008;</a></text>
<text top="789" left="91" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref684">85:845</a></text>
<text top="786" left="124" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref684">–52</a></text>
<text top="789" left="142" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref684">.</a></text>
<text top="802" left="64" width="21" height="12" font="15">689.</text>
<text top="802" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref685">Silva F, Arruda R, Nobre A, et al. Impact of intraoperative trans-</a></text>
<text top="816" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref685">esophageal echocardiography in cardiac surgery: retrospective anal-</a></text>
<text top="829" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref685">ysis of a series of 850 examinations. Rev Port Cardiol 2010;29:</a></text>
<text top="843" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref685">1363</a></text>
<text top="840" left="115" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref685">–82</a></text>
<text top="843" left="133" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref685">.</a></text>
<text top="856" left="64" width="21" height="12" font="15">690.</text>
<text top="856" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref686">Watanakunakorn C. Staphylococcus aureus endocarditis at a com-</a></text>
<text top="869" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref686">munity teaching hospital, 1980 to 1991. An analysis of 106 cases.</a></text>
<text top="883" left="91" width="160" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref686">Arch Intern Med 1994;154:2330</a></text>
<text top="880" left="251" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref686">–5</a></text>
<text top="883" left="263" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref686">.</a></text>
<text top="896" left="64" width="21" height="12" font="15">691.</text>
<text top="896" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref687">Abraham J, Mansour C, Veledar E, et al. Staphylococcus aureus</a></text>
<text top="910" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref687">bacteremia and endocarditis: the Grady Memorial Hospital experi-</a></text>
<text top="923" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref687">ence with methicillin-sensitive S aureus and methicillin-resistant S</a></text>
<text top="937" left="91" width="219" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref687">aureus bacteremia. Am Heart J 2004;147:536</a></text>
<text top="934" left="310" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref687">–9</a></text>
<text top="937" left="322" width="3" height="12" font="15">.</text>
<text top="950" left="64" width="21" height="12" font="15">692.</text>
<text top="950" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref688">Kaasch AJ, Fowler VG Jr., Rieg S, et al. Use of a simple criteria set</a></text>
<text top="964" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref688">for guiding echocardiography in nosocomial Staphylococcus aureus</a></text>
<text top="977" left="91" width="184" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref688">bacteremia. Clin Infect Dis 2011;53:1</a></text>
<text top="974" left="275" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref688">–9</a></text>
<text top="977" left="287" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref688">.</a></text>
<text top="990" left="64" width="21" height="12" font="15">693.</text>
<text top="990" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref689">Petti CA, Fowler VG Jr. Staphylococcus aureus bacteremia and</a></text>
<text top="1004" left="91" width="189" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref689">endocarditis. Cardiol Clin 2003;21:219</a></text>
<text top="1001" left="280" width="36" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref689">–33. vii</a></text>
<text top="1004" left="316" width="3" height="12" font="15">.</text>
<text top="1017" left="64" width="21" height="12" font="15">694.</text>
<text top="1017" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref690">Fowler VG Jr., Sanders LL, Kong LK, et al. Infective endocarditis</a></text>
<text top="1031" left="91" width="254" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref690">due to Staphylococcus aureus: 59 prospectively identi</a></text>
<text top="1028" left="345" width="69" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref690">ﬁed cases with</a></text>
<text top="1044" left="91" width="191" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref690">follow-up. Clin Infect Dis 1999;28:106</a></text>
<text top="1042" left="282" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref690">–14</a></text>
<text top="1044" left="300" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref690">.</a></text>
<text top="1058" left="64" width="21" height="12" font="15">695.</text>
<text top="1058" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref691">San Martin J, Sarria C, de las Cuevas C, et al. Relevance of clinical</a></text>
<text top="1071" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref691">presentation and period of diagnosis in prosthetic valve endocarditis.</a></text>
<text top="1085" left="91" width="150" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref691">J Heart Valve Dis 2010;19:131</a></text>
<text top="1082" left="241" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref691">–8</a></text>
<text top="1085" left="253" width="3" height="12" font="15">.</text>
<text top="103" left="450" width="21" height="12" font="15">696.</text>
<text top="103" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref692">Knudsen JB, Fuursted K, Petersen E, et al. Failure of clinical fea-</a></text>
<text top="116" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref692">tures of low probability endocarditis. The early echo remains</a></text>
<text top="130" left="477" width="203" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref692">essential. Scand Cardiovasc J 2011;45:133</a></text>
<text top="127" left="679" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref692">–8</a></text>
<text top="130" left="691" width="3" height="12" font="15">.</text>
<text top="143" left="450" width="21" height="12" font="15">697.</text>
<text top="143" left="477" width="186" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref693">Lamas CC, Eykyn SJ. Suggested modi</a></text>
<text top="140" left="663" width="137" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref693">ﬁcations to the Duke criteria</a></text>
<text top="157" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref693">for the clinical diagnosis of native valve and prosthetic valve endo-</a></text>
<text top="170" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref693">carditis: analysis of 118 pathologically proven cases. Clin Infect Dis</a></text>
<text top="184" left="477" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref693">1997;25:713</a></text>
<text top="181" left="536" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref693">–9</a></text>
<text top="184" left="548" width="3" height="12" font="15">.</text>
<text top="197" left="450" width="21" height="12" font="15">698.</text>
<text top="197" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref694">Piper C, Korfer R, Horstkotte D. Prosthetic valve endocarditis.</a></text>
<text top="210" left="477" width="91" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref694">Heart 2001;85:590</a></text>
<text top="208" left="568" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref694">–3</a></text>
<text top="210" left="580" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref694">.</a></text>
<text top="224" left="450" width="21" height="12" font="15">699.</text>
<text top="224" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref695">Feuchtner GM, Stolzmann P, Dichtl W, et al. Multislice computed</a></text>
<text top="237" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref695">tomography in infective endocarditis: comparison with trans-</a></text>
<text top="251" left="477" width="226" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref695">esophageal echocardiography and intraoperative</a></text>
<text top="248" left="706" width="94" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref695">ﬁndings. J Am Coll</a></text>
<text top="264" left="477" width="100" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref695">Cardiol 2009;53:436</a></text>
<text top="261" left="576" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref695">–44</a></text>
<text top="264" left="594" width="3" height="12" font="15">.</text>
<text top="278" left="450" width="21" height="12" font="15">700.</text>
<text top="278" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref696">Gahide G, Bommart S, Demaria R, et al. Preoperative evaluation in</a></text>
<text top="291" left="477" width="91" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref696">aortic endocarditis:</a></text>
<text top="288" left="571" width="228" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref696">ﬁndings on cardiac CT. AJR Am J Roentgenol</a></text>
<text top="305" left="477" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref696">2010;194:574</a></text>
<text top="302" left="542" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref696">–8</a></text>
<text top="305" left="554" width="3" height="12" font="15">.</text>
<text top="318" left="450" width="21" height="12" font="15">701.</text>
<text top="318" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref697">Lentini S, Monaco F, Tancredi F, et al. Aortic valve infective</a></text>
<text top="331" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref697">endocarditis: could multi-detector CT scan be proposed for routine</a></text>
<text top="345" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref697">screening of concomitant coronary artery disease before surgery?</a></text>
<text top="358" left="477" width="155" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref697">Ann Thorac Surg 2009;87:1585</a></text>
<text top="356" left="632" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref697">–7</a></text>
<text top="358" left="644" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref697">.</a></text>
<text top="372" left="450" width="350" height="12" font="15">702. Schoepf U, White R, Woodard P, et al. ACR Appropriateness</text>
<text top="385" left="477" width="37" height="12" font="15">Criteria</text>
<text top="383" left="513" width="286" height="16" font="15">Ò suspected infective endocarditis. Agency for Healthcare</text>
<text top="399" left="477" width="217" height="12" font="15">Research and Quality. 2011. Available at:</text>
<text top="399" left="701" width="98" height="12" font="22"><a href="http://guideline.gov/content.aspx?f=rss%26id=32600">http://guideline.gov/</a></text>
<text top="412" left="477" width="67" height="12" font="22"><a href="http://guideline.gov/content.aspx?f=rss%26id=32600">content.aspx?f</a></text>
<text top="409" left="544" width="80" height="16" font="22"><a href="http://guideline.gov/content.aspx?f=rss%26id=32600">¼rss&amp;id¼32600</a></text>
<text top="412" left="624" width="146" height="12" font="15"><a href="http://guideline.gov/content.aspx?f=rss%26id=32600">. </a>Accessed February 20, 2014.</text>
<text top="426" left="450" width="21" height="12" font="15">703.</text>
<text top="426" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref699">Kung VW, Jarral OA, Shipolini AR, et al. Is it safe to perform</a></text>
<text top="439" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref699">coronary angiography during acute endocarditis? Interact Cardiovasc</a></text>
<text top="452" left="477" width="124" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref699">Thorac Surg 2011;13:158</a></text>
<text top="450" left="601" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref699">–67</a></text>
<text top="452" left="618" width="3" height="12" font="15">.</text>
<text top="466" left="450" width="21" height="12" font="15">704.</text>
<text top="466" left="477" width="212" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref700">Cianciulli TE, Lax JA, Beck MA, et al. Cine</a></text>
<text top="463" left="688" width="111" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref700">ﬂuoroscopic assessment</a></text>
<text top="479" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref700">of mechanical disc prostheses: its value as a complementary method</a></text>
<text top="493" left="477" width="254" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref700">to echocardiography. J Heart Valve Dis 2005;14:664</a></text>
<text top="490" left="730" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref700">–73</a></text>
<text top="493" left="748" width="3" height="12" font="15">.</text>
<text top="506" left="450" width="21" height="12" font="15">705.</text>
<text top="506" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref701">Aoyagi S, Nishimi M, Kawano H, et al. Obstruction of St Jude</a></text>
<text top="520" left="477" width="205" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref701">Medical valves in the aortic position: signi</a></text>
<text top="517" left="681" width="118" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref701">ﬁcance of a combination</a></text>
<text top="533" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref701">of cineradiography and echocardiography. J Thorac Cardiovasc Surg</a></text>
<text top="547" left="477" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref701">2000;120:142</a></text>
<text top="544" left="542" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref701">–7</a></text>
<text top="547" left="554" width="3" height="12" font="15">.</text>
<text top="560" left="450" width="21" height="12" font="15">706.</text>
<text top="560" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref702">Vogel W, Stoll HP, Bay W, et al. Cineradiography for determi-</a></text>
<text top="574" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref702">nation of normal and abnormal function in mechanical heart valves.</a></text>
<text top="587" left="477" width="130" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref702">Am J Cardiol 1993;71:225</a></text>
<text top="584" left="606" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref702">–32</a></text>
<text top="587" left="624" width="3" height="12" font="15">.</text>
<text top="600" left="450" width="21" height="12" font="15">707.</text>
<text top="600" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref703">Fowler VG Jr., Li J, Corey GR, et al. Role of echocardiog-</a></text>
<text top="614" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref703">raphy in evaluation of patients with Staphylococcus aureus</a></text>
<text top="627" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref703">bacteremia: experience in 103 patients. J Am Coll Cardiol 1997;30:</a></text>
<text top="641" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref703">1072</a></text>
<text top="638" left="501" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref703">–8</a></text>
<text top="641" left="513" width="3" height="12" font="15">.</text>
<text top="654" left="450" width="21" height="12" font="15">708.</text>
<text top="654" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref704">Sullenberger AL, Avedissian LS, Kent SM. Importance of trans-</a></text>
<text top="668" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref704">esophageal echocardiography in the evaluation of Staphylococcus</a></text>
<text top="681" left="477" width="236" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref704">aureus bacteremia. J Heart Valve Dis 2005;14:23</a></text>
<text top="678" left="713" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref704">–8</a></text>
<text top="681" left="725" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref704">.</a></text>
<text top="695" left="450" width="21" height="12" font="15">709.</text>
<text top="695" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref705">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by</a></text>
<text top="708" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref705">the infectious diseases society of america for the treatment of</a></text>
<text top="721" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref705">methicillin-resistant Staphylococcus aureus infections in adults and</a></text>
<text top="735" left="477" width="182" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref705">children. Clin Infect Dis 2011;52:e18</a></text>
<text top="732" left="659" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref705">–55</a></text>
<text top="735" left="677" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref705">.</a></text>
<text top="748" left="450" width="21" height="12" font="15">710.</text>
<text top="748" left="477" width="88" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref706">Partridge DG, O</a></text>
<text top="746" left="564" width="235" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref706">’Brien E, Chapman AL. Outpatient parenteral</a></text>
<text top="762" left="477" width="321" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref706">antibiotic therapy for infective endocarditis: a review of 4 years</a></text>
<text top="759" left="797" width="2" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref706">’</a></text>
<text top="775" left="477" width="272" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref706">experience at a UK centre. Postgrad Med J 2012;88:377</a></text>
<text top="773" left="749" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref706">–81</a></text>
<text top="775" left="766" width="3" height="12" font="15">.</text>
<text top="789" left="450" width="21" height="12" font="15">711.</text>
<text top="789" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref707">Leekha S, Terrell CL, Edson RS. General principles of antimi-</a></text>
<text top="802" left="477" width="220" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref707">crobial therapy. Mayo Clin Proc 2011;86:156</a></text>
<text top="799" left="696" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref707">–67</a></text>
<text top="802" left="714" width="3" height="12" font="15">.</text>
<text top="816" left="450" width="21" height="12" font="15">712.</text>
<text top="816" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref708">DiNubile MJ. Short-course antibiotic therapy for right-sided</a></text>
<text top="829" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref708">endocarditis caused by Staphylococcus aureus in injection drug</a></text>
<text top="843" left="477" width="182" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref708">users. Ann Intern Med 1994;121:873</a></text>
<text top="840" left="658" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref708">–6</a></text>
<text top="843" left="670" width="3" height="12" font="15">.</text>
<text top="856" left="450" width="21" height="12" font="15">713.</text>
<text top="856" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref709">Marti-Carvajal A. Antibiotic therapy for treatment of infective</a></text>
<text top="869" left="477" width="231" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref709">endocarditis. Cochrane Database Syst Rev 2012</a></text>
<text top="869" left="708" width="3" height="12" font="15">.</text>
<text top="883" left="450" width="21" height="12" font="15">714.</text>
<text top="883" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref710">Masuda J, Yutani C, Waki R, et al. Histopathological analysis of the</a></text>
<text top="896" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref710">mechanisms of intracranial hemorrhage complicating infective</a></text>
<text top="910" left="477" width="159" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref710">endocarditis. Stroke 1992;23:843</a></text>
<text top="907" left="635" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref710">–50</a></text>
<text top="910" left="653" width="3" height="12" font="15">.</text>
<text top="923" left="450" width="21" height="12" font="15">715.</text>
<text top="923" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref711">Tornos P, Almirante B, Mirabet S, et al. Infective endocarditis due</a></text>
<text top="937" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref711">to Staphylococcus aureus: deleterious effect of anticoagulant therapy.</a></text>
<text top="950" left="477" width="154" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref711">Arch Intern Med 1999;159:473</a></text>
<text top="947" left="631" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref711">–5</a></text>
<text top="950" left="643" width="3" height="12" font="15">.</text>
<text top="964" left="450" width="21" height="12" font="15">716.</text>
<text top="964" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref712">Carpenter JL, McAllister CK. Anticoagulation in prosthetic valve</a></text>
<text top="977" left="477" width="197" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref712">endocarditis. South Med J 1983;76:1372</a></text>
<text top="974" left="674" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref712">–5</a></text>
<text top="977" left="686" width="3" height="12" font="15">.</text>
<text top="990" left="450" width="21" height="12" font="15">717.</text>
<text top="990" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref713">Lieberman A, Hass WK, Pinto R, et al. Intracranial hemorrhage</a></text>
<text top="1004" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref713">and infarction in anticoagulated patients with prosthetic heart valves.</a></text>
<text top="1017" left="477" width="82" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref713">Stroke 1978;9:18</a></text>
<text top="1015" left="559" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref713">–24</a></text>
<text top="1017" left="577" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref713">.</a></text>
<text top="1031" left="450" width="21" height="12" font="15">718.</text>
<text top="1031" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref714">Wilson WR, Geraci JE, Danielson GK, et al. Anticoagulant therapy</a></text>
<text top="1044" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref714">and central nervous system complications in patients with prosthetic</a></text>
<text top="1058" left="477" width="215" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref714">valve endocarditis. Circulation 1978;57:1004</a></text>
<text top="1055" left="691" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref714">–7</a></text>
<text top="1058" left="703" width="3" height="12" font="15">.</text>
<text top="1071" left="450" width="21" height="12" font="15">719.</text>
<text top="1071" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref715">Ananthasubramaniam K, Beattie JN, Rosman HS, et al. How safely</a></text>
<text top="1085" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref715">and for how long can warfarin therapy be withheld in prosthetic</a></text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e172</text>
</page>
<page number="117" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref715">heart valve patients hospitalized with a major hemorrhage? Chest</a></text>
<text top="116" left="91" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref715">2001;119:478</a></text>
<text top="113" left="157" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref715">–84</a></text>
<text top="116" left="175" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref715">.</a></text>
<text top="130" left="64" width="21" height="12" font="15">720.</text>
<text top="130" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref716">Snygg-Martin U, Gustafsson L, Rosengren L, et al. Cerebrovas-</a></text>
<text top="143" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref716">cular complications in patients with left-sided infective endo-</a></text>
<text top="157" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref716">carditis are common: a prospective study using magnetic resonance</a></text>
<text top="170" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref716">imaging and neurochemical brain damage markers. Clin Infect Dis</a></text>
<text top="183" left="91" width="55" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref716">2008;47:23</a></text>
<text top="181" left="146" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref716">–30</a></text>
<text top="183" left="164" width="3" height="12" font="15">.</text>
<text top="197" left="64" width="21" height="12" font="15">721.</text>
<text top="197" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref717">Tunkel AR, Kaye D. Neurologic complications of infective endo-</a></text>
<text top="210" left="91" width="163" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref717">carditis. Neurol Clin 1993;11:419</a></text>
<text top="208" left="254" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref717">–40</a></text>
<text top="210" left="272" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref717">.</a></text>
<text top="224" left="64" width="21" height="12" font="15">722.</text>
<text top="224" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref718">Immediate anticoagulation of embolic stroke: brain hemorrhage and</a></text>
<text top="237" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref718">management options. Cerebral Embolism Study Group. Stroke</a></text>
<text top="251" left="91" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref718">1984;15:779</a></text>
<text top="248" left="151" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref718">–89</a></text>
<text top="251" left="169" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref718">.</a></text>
<text top="264" left="64" width="21" height="12" font="15">723.</text>
<text top="264" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref719">Kamalakannan D, Muhammed B, Gardin J. Anticoagulation in</a></text>
<text top="278" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref719">infective endocarditis. A survey of infectious disease specialists and</a></text>
<text top="291" left="91" width="232" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref719">cardiologists. Infect Dis Clin Pract 2005;13:122</a></text>
<text top="288" left="323" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref719">–6</a></text>
<text top="291" left="335" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref719">.</a></text>
<text top="305" left="64" width="21" height="12" font="15">724.</text>
<text top="305" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref720">Nagpal A, Sohail M, Steckelberg JM. Prosthetic valve endocarditis:</a></text>
<text top="318" left="91" width="200" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref720">state of the heart. Clin Invest 2012;2:803</a></text>
<text top="315" left="291" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref720">–17</a></text>
<text top="318" left="309" width="3" height="12" font="15">.</text>
<text top="331" left="64" width="21" height="12" font="15">725.</text>
<text top="331" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref721">Thuny F, Avierinos JF, Tribouilloy C, et al. Impact of cerebrovas-</a></text>
<text top="345" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref721">cular complications on mortality and neurologic outcome during</a></text>
<text top="358" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref721">infective endocarditis: a prospective multicentre study. Eur Heart J</a></text>
<text top="372" left="91" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref721">2007;28:1155</a></text>
<text top="369" left="157" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref721">–61</a></text>
<text top="372" left="175" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref721">.</a></text>
<text top="385" left="64" width="21" height="12" font="15">726.</text>
<text top="385" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref722">Duval X, Iung B, Klein I, et al. Effect of early cerebral magnetic</a></text>
<text top="399" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref722">resonance imaging on clinical decisions in infective endocarditis: a</a></text>
<text top="412" left="91" width="241" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref722">prospective study. Ann Intern Med 2010;152:497</a></text>
<text top="409" left="331" width="61" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref722">–504. W175</a></text>
<text top="412" left="393" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref722">.</a></text>
<text top="426" left="64" width="21" height="12" font="15">727.</text>
<text top="426" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref723">Pruitt AA, Rubin RH, Karchmer AW, et al. Neurologic compli-</a></text>
<text top="439" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref723">cations of bacterial endocarditis. Medicine (Baltimore) 1978;57:</a></text>
<text top="452" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref723">329</a></text>
<text top="450" left="109" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref723">–43</a></text>
<text top="452" left="127" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref723">.</a></text>
<text top="466" left="64" width="21" height="12" font="15">728.</text>
<text top="466" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref724">Chan KL, Tam J, Dumesnil JG, et al. Effect of long-term aspirin</a></text>
<text top="479" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref724">use on embolic events in infective endocarditis. Clin Infect Dis</a></text>
<text top="493" left="91" width="54" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref724">2008;46:37</a></text>
<text top="490" left="145" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref724">–41</a></text>
<text top="493" left="163" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref724">.</a></text>
<text top="506" left="64" width="21" height="12" font="15">729.</text>
<text top="506" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref725">Fang MC, Go AS, Chang Y, et al. Death and disability from</a></text>
<text top="520" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref725">warfarin-associated intracranial and extracranial hemorrhages. Am J</a></text>
<text top="533" left="91" width="93" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref725">Med 2007;120:700</a></text>
<text top="530" left="183" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref725">–5</a></text>
<text top="533" left="195" width="3" height="12" font="15">.</text>
<text top="547" left="64" width="21" height="12" font="15">730.</text>
<text top="547" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref726">Rasmussen RV, Snygg-Martin U, Olaison L, et al. Major cerebral</a></text>
<text top="560" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref726">events in Staphylococcus aureus infective endocarditis: is anticoag-</a></text>
<text top="574" left="91" width="215" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref726">ulant therapy safe? Cardiology 2009;114:284</a></text>
<text top="571" left="306" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref726">–91</a></text>
<text top="574" left="324" width="3" height="12" font="15">.</text>
<text top="587" left="64" width="21" height="12" font="15">731.</text>
<text top="587" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref727">Sonneville R, Mirabel M, Hajage D, et al. Neurologic complications</a></text>
<text top="600" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref727">and outcomes of infective endocarditis in critically ill patients: the</a></text>
<text top="614" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref727">ENDOcardite en REAnimation prospective multicenter study. Crit</a></text>
<text top="627" left="91" width="119" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref727">Care Med 2011;39:1474</a></text>
<text top="625" left="210" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref727">–81</a></text>
<text top="627" left="228" width="3" height="12" font="15">.</text>
<text top="641" left="64" width="21" height="12" font="15">732.</text>
<text top="641" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref728">Chan KL, Dumesnil JG, Cujec B, et al. A randomized trial of</a></text>
<text top="654" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref728">aspirin on the risk of embolic events in patients with infective</a></text>
<text top="668" left="91" width="219" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref728">endocarditis. J Am Coll Cardiol 2003;42:775</a></text>
<text top="665" left="310" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref728">–80</a></text>
<text top="668" left="328" width="3" height="12" font="15">.</text>
<text top="681" left="64" width="21" height="12" font="15">733.</text>
<text top="681" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref729">Anavekar NS, Tleyjeh IM, Anavekar NS, et al. Impact of prior</a></text>
<text top="695" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref729">antiplatelet therapy on risk of embolism in infective endocarditis.</a></text>
<text top="708" left="91" width="144" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref729">Clin Infect Dis 2007;44:1180</a></text>
<text top="705" left="235" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref729">–6</a></text>
<text top="708" left="246" width="3" height="12" font="15">.</text>
<text top="721" left="64" width="21" height="12" font="15">734.</text>
<text top="721" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref730">Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous sys-</a></text>
<text top="735" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref730">tem bleeding during antithrombotic therapy: recent data and ideas.</a></text>
<text top="748" left="91" width="100" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref730">Stroke 2005;36:1588</a></text>
<text top="746" left="191" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref730">–93</a></text>
<text top="748" left="209" width="3" height="12" font="15">.</text>
<text top="762" left="64" width="21" height="12" font="15">735.</text>
<text top="762" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref731">He J, Whelton PK, Vu B, et al. Aspirin and risk of hemorrhagic</a></text>
<text top="775" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref731">stroke: a meta-analysis of randomized controlled trials. JAMA 1998;</a></text>
<text top="789" left="91" width="45" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref731">280:1930</a></text>
<text top="786" left="136" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref731">–5</a></text>
<text top="789" left="148" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref731">.</a></text>
<text top="802" left="64" width="21" height="12" font="15">736.</text>
<text top="802" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref732">Werner M, Andersson R, Olaison L, et al. A clinical study of culture-</a></text>
<text top="816" left="91" width="270" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref732">negative endocarditis. Medicine (Baltimore) 2003;82:263</a></text>
<text top="813" left="361" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref732">–73</a></text>
<text top="816" left="378" width="3" height="12" font="15">.</text>
<text top="829" left="64" width="21" height="12" font="15">737.</text>
<text top="829" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref733">Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis</a></text>
<text top="843" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref733">Campaign: international guidelines for management of severe sepsis</a></text>
<text top="856" left="91" width="254" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref733">and septic shock: 2008. Crit Care Med 2008;36:296</a></text>
<text top="853" left="345" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref733">–327</a></text>
<text top="856" left="369" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref733">.</a></text>
<text top="869" left="64" width="21" height="12" font="15">738.</text>
<text top="869" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref734">Thuny F, Grisoli D, Collart F, et al. Management of infective</a></text>
<text top="883" left="91" width="302" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref734">endocarditis: challenges and perspectives. Lancet 2012;379:965</a></text>
<text top="880" left="393" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref734">–75</a></text>
<text top="883" left="411" width="3" height="12" font="15">.</text>
<text top="896" left="64" width="21" height="12" font="15">739.</text>
<text top="896" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref735">Gaca JG, Sheng S, Daneshmand MA, et al. Outcomes for endo-</a></text>
<text top="910" left="91" width="208" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref735">carditis surgery in North America: a simpli</a></text>
<text top="907" left="299" width="115" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref735">ﬁed risk scoring system.</a></text>
<text top="923" left="91" width="188" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref735">J Thorac Cardiovasc Surg 2011;141:98</a></text>
<text top="921" left="279" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref735">–106</a></text>
<text top="923" left="303" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref735">.</a></text>
<text top="937" left="64" width="21" height="12" font="15">740.</text>
<text top="937" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref736">Sambola A, Fernandez-Hidalgo N, Almirante B, et al. Sex differ-</a></text>
<text top="950" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref736">ences in native-valve infective endocarditis in a single tertiary-care</a></text>
<text top="964" left="91" width="174" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref736">hospital. Am J Cardiol 2010;106:92</a></text>
<text top="961" left="265" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref736">–8</a></text>
<text top="964" left="277" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref736">.</a></text>
<text top="977" left="64" width="21" height="12" font="15">741.</text>
<text top="977" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref737">Jault F, Gandjbakhch I, Rama A, et al. Active native valve endo-</a></text>
<text top="990" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref737">carditis: determinants of operative death and late mortality. Ann</a></text>
<text top="1004" left="91" width="130" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref737">Thorac Surg 1997;63:1737</a></text>
<text top="1001" left="221" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref737">–41</a></text>
<text top="1004" left="239" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref737">.</a></text>
<text top="1017" left="64" width="21" height="12" font="15">742.</text>
<text top="1017" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref738">Hasbun R, Vikram HR, Barakat LA, et al. Complicated left-sided</a></text>
<text top="1031" left="91" width="219" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref738">native valve endocarditis in adults: risk classi</a></text>
<text top="1028" left="310" width="104" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref738">ﬁcation for mortality.</a></text>
<text top="1044" left="91" width="109" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref738">JAMA 2003;289:1933</a></text>
<text top="1042" left="200" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref738">–40</a></text>
<text top="1044" left="218" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref738">.</a></text>
<text top="1058" left="64" width="21" height="12" font="15">743.</text>
<text top="1058" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref739">Kiefer T, Park L, Tribouilloy C, et al. Association between valvular</a></text>
<text top="1071" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref739">surgery and mortality among patients with infective endocarditis</a></text>
<text top="1085" left="91" width="249" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref739">complicated by heart failure. JAMA 2011;306:2239</a></text>
<text top="1082" left="340" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref739">–47</a></text>
<text top="1085" left="358" width="3" height="12" font="15">.</text>
<text top="103" left="450" width="21" height="12" font="15">744.</text>
<text top="103" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref740">Tornos P, Sanz E, Permanyer-Miralda G, et al. Late prosthetic</a></text>
<text top="116" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref740">valve endocarditis. Immediate and long-term prognosis. Chest 1992;</a></text>
<text top="130" left="477" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref740">101:37</a></text>
<text top="127" left="510" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref740">–41</a></text>
<text top="130" left="527" width="3" height="12" font="15">.</text>
<text top="143" left="450" width="21" height="12" font="15">745.</text>
<text top="143" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref741">Gordon SM, Serkey JM, Longworth DL, et al. Early onset pros-</a></text>
<text top="157" left="477" width="317" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref741">thetic valve endocarditis: the Cleveland Clinic experience 1992</a></text>
<text top="154" left="794" width="6" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref741">–</a></text>
<text top="170" left="477" width="186" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref741">1997. Ann Thorac Surg 2000;69:1388</a></text>
<text top="167" left="663" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref741">–92</a></text>
<text top="170" left="681" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref741">.</a></text>
<text top="184" left="450" width="21" height="12" font="15">746.</text>
<text top="184" left="477" width="308" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref742">Wang A, Athan E, Pappas PA, et al. Contemporary clinical pro</a></text>
<text top="181" left="785" width="14" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref742">ﬁle</a></text>
<text top="197" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref742">and outcome of prosthetic valve endocarditis. JAMA 2007;297:</a></text>
<text top="210" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref742">1354</a></text>
<text top="208" left="501" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref742">–61</a></text>
<text top="210" left="519" width="3" height="12" font="15">.</text>
<text top="224" left="450" width="21" height="12" font="15">747.</text>
<text top="224" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref743">Prendergast BD, Tornos P. Surgery for infective endocarditis: who</a></text>
<text top="237" left="477" width="185" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref743">and when? Circulation 2010;121:1141</a></text>
<text top="235" left="661" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref743">–52</a></text>
<text top="237" left="679" width="3" height="12" font="15">.</text>
<text top="251" left="450" width="21" height="12" font="15">748.</text>
<text top="251" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref744">Funakoshi S, Kaji S, Yamamuro A, et al. Impact of early surgery</a></text>
<text top="264" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref744">in the active phase on long-term outcomes in left-sided native</a></text>
<text top="278" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref744">valve infective endocarditis. J Thorac Cardiovasc Surg 2011;142:</a></text>
<text top="291" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref744">836</a></text>
<text top="288" left="495" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref744">–42</a></text>
<text top="291" left="513" width="3" height="12" font="15">.</text>
<text top="305" left="450" width="21" height="12" font="15">749.</text>
<text top="305" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref745">Bauernschmitt R, Jakob HG, Vahl CF, et al. Operation for infective</a></text>
<text top="318" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref745">endocarditis: results after implantation of mechanical valves. Ann</a></text>
<text top="331" left="477" width="124" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref745">Thorac Surg 1998;65:359</a></text>
<text top="329" left="601" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref745">–64</a></text>
<text top="331" left="619" width="3" height="12" font="15">.</text>
<text top="345" left="450" width="21" height="12" font="15">750.</text>
<text top="345" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref746">Musci M, Siniawski H, Pasic M, et al. Surgical therapy in patients</a></text>
<text top="358" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref746">with active infective endocarditis: seven-year single centre experience</a></text>
<text top="372" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref746">in a subgroup of 255 patients treated with the Shelhigh stentless</a></text>
<text top="385" left="477" width="251" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref746">bioprosthesis. Eur J Cardiothorac Surg 2008;34:410</a></text>
<text top="382" left="727" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref746">–7</a></text>
<text top="385" left="739" width="3" height="12" font="15">.</text>
<text top="399" left="450" width="21" height="12" font="15">751.</text>
<text top="399" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref747">Yu VL, Fang GD, Keys TF, et al. Prosthetic valve endocarditis:</a></text>
<text top="412" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref747">superiority of surgical valve replacement versus medical therapy only.</a></text>
<text top="426" left="477" width="155" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref747">Ann Thorac Surg 1994;58:1073</a></text>
<text top="423" left="632" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref747">–7</a></text>
<text top="426" left="644" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref747">.</a></text>
<text top="439" left="450" width="21" height="12" font="15">752.</text>
<text top="439" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref748">Remadi JP, Habib G, Nadji G, et al. Predictors of death and impact</a></text>
<text top="452" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref748">of surgery in Staphylococcus aureus infective endocarditis. Ann</a></text>
<text top="466" left="477" width="130" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref748">Thorac Surg 2007;83:1295</a></text>
<text top="463" left="607" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref748">–302</a></text>
<text top="466" left="630" width="3" height="12" font="15">.</text>
<text top="479" left="450" width="21" height="12" font="15">753.</text>
<text top="479" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref749">Hill EE, Herijgers P, Claus P, et al. Infective endocarditis: changing</a></text>
<text top="493" left="477" width="165" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref749">epidemiology and predictors of 6</a></text>
<text top="490" left="642" width="158" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref749">–month mortality: a prospective</a></text>
<text top="506" left="477" width="188" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref749">cohort study. Eur Heart J 2007;28:196</a></text>
<text top="504" left="664" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref749">–203</a></text>
<text top="506" left="688" width="3" height="12" font="15">.</text>
<text top="520" left="450" width="21" height="12" font="15">754.</text>
<text top="520" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref750">Aksoy O, Sexton DJ, Wang A, et al. Early surgery in patients with</a></text>
<text top="533" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref750">infective endocarditis: a propensity score analysis. Clin Infect Dis</a></text>
<text top="547" left="477" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref750">2007;44:364</a></text>
<text top="544" left="536" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref750">–72</a></text>
<text top="547" left="554" width="3" height="12" font="15">.</text>
<text top="560" left="450" width="21" height="12" font="15">755.</text>
<text top="560" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref751">Ellis ME, Al-Abdely H, Sandridge A, et al. Fungal endocarditis:</a></text>
<text top="574" left="477" width="181" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref751">evidence in the world literature, 1965</a></text>
<text top="571" left="658" width="142" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref751">–1995. Clin Infect Dis 2001;</a></text>
<text top="587" left="477" width="27" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref751">32:50</a></text>
<text top="584" left="503" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref751">–62</a></text>
<text top="587" left="521" width="3" height="12" font="15">.</text>
<text top="600" left="450" width="21" height="12" font="15">756.</text>
<text top="600" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref752">Wolff M, Witchitz S, Chastang C, et al. Prosthetic valve endo-</a></text>
<text top="614" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref752">carditis in the ICU. Prognostic factors of overall survival in a series</a></text>
<text top="627" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref752">of 122 cases and consequences for treatment decision. Chest 1995;</a></text>
<text top="641" left="477" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref752">108:688</a></text>
<text top="638" left="515" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref752">–94</a></text>
<text top="641" left="533" width="3" height="12" font="15">.</text>
<text top="654" left="450" width="21" height="12" font="15">757.</text>
<text top="654" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref753">Chirouze C, Cabell CH, Fowler VG Jr., et al. Prognostic factors in</a></text>
<text top="668" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref753">61 cases of Staphylococcus aureus prosthetic valve infective endo-</a></text>
<text top="681" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref753">carditis from the International Collaboration on Endocarditis</a></text>
<text top="695" left="477" width="230" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref753">merged database. Clin Infect Dis 2004;38:1323</a></text>
<text top="692" left="706" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref753">–7</a></text>
<text top="695" left="718" width="3" height="12" font="15">.</text>
<text top="708" left="450" width="21" height="12" font="15">758.</text>
<text top="708" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref754">Melgar GR, Nasser RM, Gordon SM, et al. Fungal prosthetic valve</a></text>
<text top="721" left="477" width="164" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref754">endocarditis in 16 patients. An 11</a></text>
<text top="719" left="641" width="159" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref754">–year experience in a tertiary care</a></text>
<text top="735" left="477" width="206" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref754">hospital. Medicine (Baltimore) 1997;76:94</a></text>
<text top="732" left="682" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref754">–103</a></text>
<text top="735" left="706" width="3" height="12" font="15">.</text>
<text top="748" left="450" width="21" height="12" font="15">759.</text>
<text top="748" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref755">Fowler VG Jr., Miro JM, Hoen B, et al. Staphylococcus aureus</a></text>
<text top="762" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref755">endocarditis: a consequence of medical progress. JAMA 2005;293:</a></text>
<text top="775" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref755">3012</a></text>
<text top="773" left="501" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref755">–21</a></text>
<text top="775" left="518" width="3" height="12" font="15">.</text>
<text top="789" left="450" width="21" height="12" font="15">760.</text>
<text top="789" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref756">Miro JM, Anguera I, Cabell CH, et al. Staphylococcus aureus native</a></text>
<text top="802" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref756">valve infective endocarditis: report of 566 episodes from the Inter-</a></text>
<text top="816" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref756">national Collaboration on Endocarditis Merged Database. Clin</a></text>
<text top="829" left="477" width="112" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref756">Infect Dis 2005;41:507</a></text>
<text top="826" left="589" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref756">–14</a></text>
<text top="829" left="607" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref756">.</a></text>
<text top="843" left="450" width="21" height="12" font="15">761.</text>
<text top="843" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref757">Hill EE, Peetermans WE, Vanderschueren S, et al. Methicillin-</a></text>
<text top="856" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref757">resistant versus methicillin-sensitive Staphylococcus aureus infective</a></text>
<text top="869" left="477" width="283" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref757">endocarditis. Eur J Clin Microbiol Infect Dis 2008;27:445</a></text>
<text top="867" left="760" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref757">–50</a></text>
<text top="869" left="778" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref757">.</a></text>
<text top="883" left="450" width="21" height="12" font="15">762.</text>
<text top="883" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref758">Attaran S, Chukwuemeka A, Punjabi PP, et al. Do all patients with</a></text>
<text top="896" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref758">prosthetic valve endocarditis need surgery? Interact Cardiovasc</a></text>
<text top="910" left="477" width="130" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref758">Thorac Surg 2012;15:1057</a></text>
<text top="907" left="607" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref758">–61</a></text>
<text top="910" left="624" width="3" height="12" font="15">.</text>
<text top="923" left="450" width="21" height="12" font="15">763.</text>
<text top="923" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref759">Cowgill LD, Addonizio VP, Hopeman AR, et al. A practical</a></text>
<text top="937" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref759">approach to prosthetic valve endocarditis. Ann Thorac Surg 1987;</a></text>
<text top="950" left="477" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref759">43:450</a></text>
<text top="947" left="510" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref759">–7</a></text>
<text top="950" left="521" width="3" height="12" font="15">.</text>
<text top="964" left="450" width="21" height="12" font="15">764.</text>
<text top="964" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref760">Ribera E, Gomez-Jimenez J, Cortes E, et al. Effectiveness of</a></text>
<text top="977" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref760">cloxacillin with and without gentamicin in short-term therapy for</a></text>
<text top="990" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref760">right-sided Staphylococcus aureus endocarditis. A randomized,</a></text>
<text top="1004" left="477" width="229" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref760">controlled trial. Ann Intern Med 1996;125:969</a></text>
<text top="1001" left="706" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref760">–74</a></text>
<text top="1004" left="723" width="3" height="12" font="15">.</text>
<text top="1017" left="450" width="21" height="12" font="15">765.</text>
<text top="1017" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref761">Rabkin DG, Mokadam NA, Miller DW, et al. Long-term outcome</a></text>
<text top="1031" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref761">for the surgical treatment of infective endocarditis with a focus on</a></text>
<text top="1044" left="477" width="258" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref761">intravenous drug users. Ann Thorac Surg 2012;93:51</a></text>
<text top="1042" left="734" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref761">–7</a></text>
<text top="1044" left="746" width="3" height="12" font="15">.</text>
<text top="1058" left="450" width="21" height="12" font="15">766.</text>
<text top="1058" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref762">Hubbell G, Cheitlin MD, Rapaport E. Presentation, management,</a></text>
<text top="1071" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref762">and follow-up evaluation of infective endocarditis in drug addicts.</a></text>
<text top="1085" left="477" width="122" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref762">Am Heart J 1981;102:85</a></text>
<text top="1082" left="598" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref762">–94</a></text>
<text top="1085" left="616" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref762">.</a></text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e173</text>
</page>
<page number="118" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="21" height="12" font="15">767.</text>
<text top="103" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref763">Wang K, Gobel F, Gleason DF, et al. Complete heart block</a></text>
<text top="116" left="91" width="290" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref763">complicating bacterial endocarditis. Circulation 1972;46:939</a></text>
<text top="113" left="381" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref763">–47</a></text>
<text top="116" left="399" width="3" height="12" font="15">.</text>
<text top="130" left="64" width="21" height="12" font="15">768.</text>
<text top="130" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref764">Middlemost S, Wisenbaugh T, Meyerowitz C, et al. A case for early</a></text>
<text top="143" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref764">surgery in native left-sided endocarditis complicated by heart failure:</a></text>
<text top="157" left="91" width="268" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref764">results in 203 patients. J Am Coll Cardiol 1991;18:663</a></text>
<text top="154" left="358" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref764">–7</a></text>
<text top="157" left="370" width="3" height="12" font="15">.</text>
<text top="170" left="64" width="21" height="12" font="15">769.</text>
<text top="170" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref765">Chan KL. Early clinical course and long-term outcome of patients</a></text>
<text top="183" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref765">with infective endocarditis complicated by perivalvular abscess.</a></text>
<text top="197" left="91" width="97" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref765">CMAJ 2002;167:19</a></text>
<text top="194" left="188" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref765">–24</a></text>
<text top="197" left="206" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref765">.</a></text>
<text top="210" left="64" width="21" height="12" font="15">770.</text>
<text top="210" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref766">Jault F, Gandjbakhch I, Chastre JC, et al. Prosthetic valve endo-</a></text>
<text top="224" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref766">carditis with ring abscesses. Surgical management and long-term</a></text>
<text top="237" left="91" width="237" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref766">results. J Thorac Cardiovasc Surg 1993;105:1106</a></text>
<text top="235" left="328" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref766">–13</a></text>
<text top="237" left="346" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref766">.</a></text>
<text top="251" left="64" width="21" height="12" font="15">771.</text>
<text top="251" left="91" width="256" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref767">Anguera I, Miro JM, Vilacosta I, et al. Aorto-cavitary</a></text>
<text top="248" left="350" width="64" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref767">ﬁstulous tract</a></text>
<text top="264" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref767">formation in infective endocarditis: clinical and echocardiographic</a></text>
<text top="278" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref767">features of 76 cases and risk factors for mortality. Eur Heart J 2005;</a></text>
<text top="291" left="91" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref767">26:288</a></text>
<text top="288" left="124" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref767">–97</a></text>
<text top="291" left="142" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref767">.</a></text>
<text top="305" left="64" width="21" height="12" font="15">772.</text>
<text top="305" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref768">Habib G, Avierinos JF, Thuny F. Aortic valve endocarditis: is there</a></text>
<text top="318" left="91" width="284" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref768">an optimal surgical timing? Curr Opin Cardiol 2007;22:77</a></text>
<text top="315" left="375" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref768">–83</a></text>
<text top="318" left="393" width="3" height="12" font="15">.</text>
<text top="331" left="64" width="21" height="12" font="15">773.</text>
<text top="331" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref769">Spiliopoulos K, Haschemi A, Fink G, et al. Infective endocarditis</a></text>
<text top="345" left="91" width="298" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref769">complicated by paravalvular abscess: a surgical challenge. An 11</a></text>
<text top="342" left="389" width="25" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref769">–year</a></text>
<text top="358" left="91" width="276" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref769">single center experience. Heart Surg Forum 2010;13:E67</a></text>
<text top="356" left="367" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref769">–73</a></text>
<text top="358" left="385" width="3" height="12" font="15">.</text>
<text top="372" left="64" width="21" height="12" font="15">774.</text>
<text top="372" left="91" width="6" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref770">d</a></text>
<text top="369" left="97" width="317" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref770">’Udekem Y, David TE, Feindel CM, et al. Long-term results of</a></text>
<text top="385" left="91" width="302" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref770">operation for paravalvular abscess. Ann Thorac Surg 1996;62:48</a></text>
<text top="382" left="393" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref770">–53</a></text>
<text top="385" left="411" width="3" height="12" font="15">.</text>
<text top="399" left="64" width="21" height="12" font="15">775.</text>
<text top="399" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref771">Alonso-Valle H, Farinas-Alvarez C, Garcia-Palomo JD, et al.</a></text>
<text top="412" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref771">Clinical course and predictors of death in prosthetic valve endocarditis</a></text>
<text top="426" left="91" width="43" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref771">over a 20</a></text>
<text top="423" left="134" width="273" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref771">–year period. J Thorac Cardiovasc Surg 2010;139:887–93</a></text>
<text top="426" left="408" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref771">.</a></text>
<text top="439" left="64" width="21" height="12" font="15">776.</text>
<text top="439" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref772">Klieverik LM, Yacoub MH, Edwards S, et al. Surgical treatment of</a></text>
<text top="452" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref772">active native aortic valve endocarditis with allografts and mechanical</a></text>
<text top="466" left="91" width="211" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref772">prostheses. Ann Thorac Surg 2009;88:1814</a></text>
<text top="463" left="302" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref772">–21</a></text>
<text top="466" left="320" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref772">.</a></text>
<text top="479" left="64" width="21" height="12" font="15">777.</text>
<text top="479" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref773">Hill EE, Herijgers P, Claus P, et al. Abscess in infective endo-</a></text>
<text top="493" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref773">carditis: the value of transesophageal echocardiography and</a></text>
<text top="506" left="91" width="63" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref773">outcome: a 5</a></text>
<text top="504" left="154" width="200" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref773">–year study. Am Heart J 2007;154:923–8</a></text>
<text top="506" left="354" width="3" height="12" font="15">.</text>
<text top="520" left="64" width="21" height="12" font="15">778.</text>
<text top="520" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref774">Manne MB, Shrestha NK, Lytle BW, et al. Outcomes after surgical</a></text>
<text top="533" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref774">treatment of native and prosthetic valve infective endocarditis. Ann</a></text>
<text top="547" left="91" width="124" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref774">Thorac Surg 2012;93:489</a></text>
<text top="544" left="215" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref774">–93</a></text>
<text top="547" left="233" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref774">.</a></text>
<text top="560" left="64" width="21" height="12" font="15">779.</text>
<text top="560" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref775">Head SJ, Mokhles MM, Osnabrugge RL, et al. Surgery in current</a></text>
<text top="574" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref775">therapy for infective endocarditis. Vasc Health Risk Manag 2011;7:</a></text>
<text top="587" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref775">255</a></text>
<text top="584" left="109" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref775">–63</a></text>
<text top="587" left="127" width="3" height="12" font="15">.</text>
<text top="600" left="64" width="21" height="12" font="15">780.</text>
<text top="600" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref776">Sohail MR, Uslan DZ, Khan AH, et al. Infective endocarditis</a></text>
<text top="614" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref776">complicating permanent pacemaker and implantable cardioverter-</a></text>
<text top="627" left="91" width="11" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref776">de</a></text>
<text top="625" left="102" width="251" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref776">ﬁbrillator infection. Mayo Clin Proc 2008;83:46–53</a></text>
<text top="627" left="353" width="3" height="12" font="15">.</text>
<text top="641" left="64" width="21" height="12" font="15">781.</text>
<text top="641" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref777">Athan E, Chu VH, Tattevin P, et al. Clinical characteristics and</a></text>
<text top="654" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref777">outcome of infective endocarditis involving implantable cardiac</a></text>
<text top="668" left="91" width="149" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref777">devices. JAMA 2012;307:1727</a></text>
<text top="665" left="240" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref777">–35</a></text>
<text top="668" left="258" width="3" height="12" font="15">.</text>
<text top="681" left="64" width="21" height="12" font="15">782.</text>
<text top="681" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref778">Rundstrom H, Kennergren C, Andersson R, et al. Pacemaker</a></text>
<text top="695" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref778">endocarditis during 18 years in Goteborg. Scand J Infect Dis 2004;</a></text>
<text top="708" left="91" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref778">36:674</a></text>
<text top="705" left="124" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref778">–9</a></text>
<text top="708" left="136" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref778">.</a></text>
<text top="721" left="64" width="21" height="12" font="15">783.</text>
<text top="721" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref779">Ho HH, Siu CW, Yiu KH, et al. Prosthetic valve endocarditis in a</a></text>
<text top="735" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref779">multicenter registry of Chinese patients. Asian Cardiovasc Thorac</a></text>
<text top="748" left="91" width="85" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref779">Ann 2010;18:430</a></text>
<text top="746" left="176" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref779">–4</a></text>
<text top="748" left="188" width="3" height="12" font="15">.</text>
<text top="762" left="64" width="21" height="12" font="15">784.</text>
<text top="762" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref780">Baddour LM, Epstein AE, Erickson CC, et al. Update on cardio-</a></text>
<text top="775" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref780">vascular implantable electronic device infections and their manage-</a></text>
<text top="789" left="91" width="71" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref780">ment: a scienti</a></text>
<text top="786" left="162" width="252" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref780">ﬁc statement from the American Heart Association.</a></text>
<text top="802" left="91" width="123" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref780">Circulation 2010;121:458</a></text>
<text top="799" left="214" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref780">–77</a></text>
<text top="802" left="232" width="3" height="12" font="15">.</text>
<text top="816" left="64" width="21" height="12" font="15">785.</text>
<text top="816" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref781">Baddour LM, Cha YM, Wilson WR. Clinical practice. Infections of</a></text>
<text top="829" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref781">cardiovascular implantable electronic devices. N Engl J Med 2012;</a></text>
<text top="843" left="91" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref781">367:842</a></text>
<text top="840" left="130" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref781">–9</a></text>
<text top="843" left="142" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref781">.</a></text>
<text top="856" left="64" width="21" height="12" font="15">786.</text>
<text top="856" left="91" width="78" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref782">Viganego F, O</a></text>
<text top="853" left="169" width="245" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref782">’Donoghue S, Eldadah Z, et al. Effect of early</a></text>
<text top="869" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref782">diagnosis and treatment with percutaneous lead extraction on sur-</a></text>
<text top="883" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref782">vival in patients with cardiac device infections. Am J Cardiol 2012;</a></text>
<text top="896" left="91" width="45" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref782">109:1466</a></text>
<text top="894" left="136" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref782">–71</a></text>
<text top="896" left="154" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref782">.</a></text>
<text top="910" left="64" width="21" height="12" font="15">787.</text>
<text top="910" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref783">Madhavan M, Sohail MR, Friedman PA, et al. Outcomes in pa-</a></text>
<text top="923" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref783">tients with cardiovascular implantable electronic devices and</a></text>
<text top="937" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref783">bacteremia caused by Gram-positive cocci other than Staphylo-</a></text>
<text top="950" left="91" width="274" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref783">coccus aureus. Circ Arrhythm Electrophysiol 2010;3:639</a></text>
<text top="947" left="365" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref783">–45</a></text>
<text top="950" left="383" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref783">.</a></text>
<text top="964" left="64" width="21" height="12" font="15">788.</text>
<text top="964" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref784">Thuny F, Di Salvo G, Belliard O, et al. Risk of embolism and death</a></text>
<text top="977" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref784">in infective endocarditis: prognostic value of echocardiography: a</a></text>
<text top="990" left="91" width="264" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref784">prospective multicenter study. Circulation 2005;112:69</a></text>
<text top="988" left="355" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref784">–75</a></text>
<text top="990" left="373" width="3" height="12" font="15">.</text>
<text top="1004" left="64" width="21" height="12" font="15">789.</text>
<text top="1004" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref785">Kang DH, Kim YJ, Kim SH, et al. Early surgery versus conven-</a></text>
<text top="1017" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref785">tional treatment for infective endocarditis. N Engl J Med 2012;</a></text>
<text top="1031" left="91" width="46" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref785">366:2466</a></text>
<text top="1028" left="137" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref785">–73</a></text>
<text top="1031" left="155" width="3" height="12" font="15">.</text>
<text top="1044" left="64" width="21" height="12" font="15">790.</text>
<text top="1044" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref786">Habib G. Embolic risk in subacute bacterial endocarditis: de-</a></text>
<text top="1058" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref786">terminants and role of transesophageal echocardiography. Curr</a></text>
<text top="1071" left="91" width="130" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref786">Infect Dis Rep 2005;7:264</a></text>
<text top="1068" left="221" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref786">–71</a></text>
<text top="1071" left="239" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref786">.</a></text>
<text top="103" left="450" width="21" height="12" font="15">791.</text>
<text top="103" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref787">Truninger K, Attenhofer Jost CH, Seifert B, et al. Long term follow</a></text>
<text top="116" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref787">up of prosthetic valve endocarditis: what characteristics identify</a></text>
<text top="130" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref787">patients who were treated successfully with antibiotics alone? Heart</a></text>
<text top="143" left="477" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref787">1999;82:714</a></text>
<text top="140" left="536" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref787">–20</a></text>
<text top="143" left="554" width="3" height="12" font="15">.</text>
<text top="157" left="450" width="21" height="12" font="15">792.</text>
<text top="157" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref788">Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study</a></text>
<text top="170" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref788">of pregnancy outcomes in women with heart disease. Circulation</a></text>
<text top="184" left="477" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref788">2001;104:515</a></text>
<text top="181" left="542" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref788">–21</a></text>
<text top="184" left="560" width="3" height="12" font="15">.</text>
<text top="197" left="450" width="21" height="12" font="15">793.</text>
<text top="197" left="477" width="67" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref789">Taylor J. The</a></text>
<text top="194" left="548" width="252" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref789">ﬁrst ESC guidelines on the management of cardio-</a></text>
<text top="210" left="477" width="299" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref789">vascular diseases during pregnancy. Eur Heart J 2011;32:3055</a></text>
<text top="208" left="776" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref789">–6</a></text>
<text top="210" left="788" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref789">.</a></text>
<text top="224" left="450" width="21" height="12" font="15">794.</text>
<text top="224" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref790">Elkayam U, Bitar F. Valvular heart disease and pregnancy part I:</a></text>
<text top="237" left="477" width="221" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref790">native valves. J Am Coll Cardiol 2005;46:223</a></text>
<text top="235" left="697" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref790">–30</a></text>
<text top="237" left="715" width="3" height="12" font="15">.</text>
<text top="251" left="450" width="21" height="12" font="15">795.</text>
<text top="251" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref791">Elkayam U, Bitar F. Valvular heart disease and pregnancy: part II:</a></text>
<text top="264" left="477" width="239" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref791">prosthetic valves. J Am Coll Cardiol 2005;46:403</a></text>
<text top="262" left="716" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref791">–10</a></text>
<text top="264" left="734" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref791">.</a></text>
<text top="278" left="450" width="21" height="12" font="15">796.</text>
<text top="278" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref792">Adams GF, Merrett JD, Hutchinson WM, et al. Cerebral embolism</a></text>
<text top="291" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref792">and mitral stenosis: survival with and without anticoagulants.</a></text>
<text top="305" left="477" width="211" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref792">J Neurol Neurosurg Psychiatry 1974;37:378</a></text>
<text top="302" left="688" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref792">–83</a></text>
<text top="305" left="705" width="3" height="12" font="15">.</text>
<text top="318" left="450" width="21" height="12" font="15">797.</text>
<text top="318" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref793">Daley R, Mattingly TW, Holt CL, et al. Systemic arterial embolism</a></text>
<text top="331" left="477" width="254" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref793">in rheumatic heart disease. Am Heart J 1951;42:566</a></text>
<text top="329" left="730" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref793">–81</a></text>
<text top="331" left="748" width="3" height="12" font="15">.</text>
<text top="345" left="450" width="21" height="12" font="15">798.</text>
<text top="345" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref794">al Kasab SM, Sabag T, al Zaibag M, et al. Beta-adrenergic receptor</a></text>
<text top="358" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref794">blockade in the management of pregnant women with mitral ste-</a></text>
<text top="372" left="477" width="200" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref794">nosis. Am J Obstet Gynecol 1990;163:37</a></text>
<text top="369" left="677" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref794">–40</a></text>
<text top="372" left="695" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref794">.</a></text>
<text top="385" left="450" width="21" height="12" font="15">799.</text>
<text top="385" left="477" width="289" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref795">Nakhjavan FK, Katz MR, Maranhao V, et al. Analysis of in</a></text>
<text top="382" left="766" width="34" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref795">ﬂuence</a></text>
<text top="399" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref795">of catecholamine and tachycardia during supine exercise in patients</a></text>
<text top="412" left="477" width="302" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref795">with mitral stenosis and sinus rhythm. Br Heart J 1969;31:753</a></text>
<text top="409" left="779" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref795">–61</a></text>
<text top="412" left="797" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref795">.</a></text>
<text top="426" left="450" width="21" height="12" font="15">800.</text>
<text top="426" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref796">Bhatia ML, Shrivastava S, Roy SB. Immediate haemodynamic</a></text>
<text top="439" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref796">effects of a beta adrenergic blocking agent-propranolol-in mitral</a></text>
<text top="452" left="477" width="49" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref796">stenosis at</a></text>
<text top="450" left="530" width="216" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref796">ﬁxed heart rates. Br Heart J 1972;34:638–44</a></text>
<text top="452" left="746" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref796">.</a></text>
<text top="466" left="450" width="21" height="12" font="15">801.</text>
<text top="466" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref797">Lydakis C, Lip GY, Beevers M, et al. Atenolol and fetal growth in preg-</a></text>
<text top="479" left="477" width="299" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref797">nancies complicated by hypertension. Am J Hypertens 1999;12:541</a></text>
<text top="477" left="776" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref797">–7</a></text>
<text top="479" left="787" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref797">.</a></text>
<text top="493" left="450" width="21" height="12" font="15">802.</text>
<text top="493" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref798">Schaefer C. Angiotensin II-receptor-antagonists: further evidence of</a></text>
<text top="506" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref798">fetotoxicity but not teratogenicity. Birth Defects Res A Clin Mol</a></text>
<text top="520" left="477" width="98" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref798">Teratol 2003;67:591</a></text>
<text top="517" left="575" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref798">–4</a></text>
<text top="520" left="587" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref798">.</a></text>
<text top="533" left="450" width="21" height="12" font="15">803.</text>
<text top="533" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref799">Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major</a></text>
<text top="547" left="477" width="147" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref799">congenital malformations after</a></text>
<text top="544" left="627" width="172" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref799">ﬁrst-trimester exposure to ACE in-</a></text>
<text top="560" left="477" width="190" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref799">hibitors. N Engl J Med 2006;354:2443</a></text>
<text top="557" left="667" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref799">–51</a></text>
<text top="560" left="684" width="3" height="12" font="15">.</text>
<text top="574" left="450" width="21" height="12" font="15">804.</text>
<text top="574" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref800">Shotan A, Widerhorn J, Hurst A, et al. Risks of angiotensin-</a></text>
<text top="587" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref800">converting enzyme inhibition during pregnancy: experimental and</a></text>
<text top="600" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref800">clinical evidence, potential mechanisms, and recommendations for</a></text>
<text top="614" left="477" width="139" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref800">use. Am J Med 1994;96:451</a></text>
<text top="611" left="615" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref800">–6</a></text>
<text top="614" left="627" width="3" height="12" font="15">.</text>
<text top="627" left="450" width="21" height="12" font="15">805.</text>
<text top="627" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref801">Tzemos N, Silversides CK, Colman JM, et al. Late cardiac out-</a></text>
<text top="641" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref801">comes after pregnancy in women with congenital aortic stenosis. Am</a></text>
<text top="654" left="477" width="105" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref801">Heart J 2009;157:474</a></text>
<text top="652" left="582" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref801">–80</a></text>
<text top="654" left="600" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref801">.</a></text>
<text top="668" left="450" width="21" height="12" font="15">806.</text>
<text top="668" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref802">Arias F, Pineda J. Aortic stenosis and pregnancy. J Reprod Med</a></text>
<text top="681" left="477" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref802">1978;20:229</a></text>
<text top="678" left="536" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref802">–32</a></text>
<text top="681" left="554" width="3" height="12" font="15">.</text>
<text top="695" left="450" width="21" height="12" font="15">807.</text>
<text top="695" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref803">Silversides CK, Colman JM, Sermer M, et al. Early and</a></text>
<text top="708" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref803">intermediate-term outcomes of pregnancy with congenital aortic</a></text>
<text top="721" left="477" width="179" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref803">stenosis. Am J Cardiol 2003;91:1386</a></text>
<text top="719" left="656" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref803">–9</a></text>
<text top="721" left="668" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref803">.</a></text>
<text top="735" left="450" width="21" height="12" font="15">808.</text>
<text top="735" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref804">Yap SC, Drenthen W, Pieper PG, et al. Risk of complications</a></text>
<text top="748" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref804">during pregnancy in women with congenital aortic stenosis. Int J</a></text>
<text top="762" left="477" width="106" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref804">Cardiol 2008;126:240</a></text>
<text top="759" left="582" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref804">–6</a></text>
<text top="762" left="594" width="3" height="12" font="15">.</text>
<text top="775" left="450" width="21" height="12" font="15">809.</text>
<text top="775" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref805">Hameed A, Karaalp IS, Tummala PP, et al. The effect of valvular</a></text>
<text top="789" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref805">heart disease on maternal and fetal outcome of pregnancy. J Am Coll</a></text>
<text top="802" left="477" width="100" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref805">Cardiol 2001;37:893</a></text>
<text top="799" left="576" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref805">–9</a></text>
<text top="802" left="588" width="3" height="12" font="15">.</text>
<text top="816" left="450" width="21" height="12" font="15">810.</text>
<text top="816" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref806">Lesniak-Sobelga A, Tracz W, KostKiewicz M, et al. Clinical and</a></text>
<text top="829" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref806">echocardiographic assessment of pregnant women with valvular</a></text>
<text top="843" left="477" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref806">heart diseases</a></text>
<text top="840" left="542" width="257" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref806">–maternal and fetal outcome. Int J Cardiol 2004;94:</a></text>
<text top="856" left="477" width="12" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref806">15</a></text>
<text top="853" left="489" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref806">–23</a></text>
<text top="856" left="507" width="3" height="12" font="15">.</text>
<text top="869" left="450" width="21" height="12" font="15">811.</text>
<text top="869" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref807">Barbosa PJ, Lopes AA, Feitosa GS, et al. Prognostic factors of</a></text>
<text top="883" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref807">rheumatic mitral stenosis during pregnancy and puerperium. Arq</a></text>
<text top="896" left="477" width="124" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref807">Bras Cardiol 2000;75:215</a></text>
<text top="894" left="601" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref807">–24</a></text>
<text top="896" left="619" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref807">.</a></text>
<text top="910" left="450" width="21" height="12" font="15">812.</text>
<text top="910" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref808">Bhatla N, Lal S, Behera G, et al. Cardiac disease in pregnancy. Int J</a></text>
<text top="923" left="477" width="145" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref808">Gynaecol Obstet 2003;82:153</a></text>
<text top="921" left="621" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref808">–9</a></text>
<text top="923" left="633" width="3" height="12" font="15">.</text>
<text top="937" left="450" width="21" height="12" font="15">813.</text>
<text top="937" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref809">Bryg RJ, Gordon PR, Kudesia VS, et al. Effect of pregnancy on</a></text>
<text top="950" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref809">pressure gradient in mitral stenosis. Am J Cardiol 1989;63:</a></text>
<text top="964" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref809">384</a></text>
<text top="961" left="495" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref809">–6</a></text>
<text top="964" left="507" width="3" height="12" font="15">.</text>
<text top="977" left="450" width="21" height="12" font="15">814.</text>
<text top="977" left="477" width="313" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref810">Palacios IF, Sanchez PL, Harrell LC, et al. Which patients bene</a></text>
<text top="974" left="789" width="10" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref810">ﬁt</a></text>
<text top="990" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref810">from percutaneous mitral balloon valvuloplasty? Prevalvuloplasty and</a></text>
<text top="1004" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref810">postvalvuloplasty variables that predict long-term outcome. Circu-</a></text>
<text top="1017" left="477" width="102" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref810">lation 2002;105:1465</a></text>
<text top="1015" left="579" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref810">–71</a></text>
<text top="1017" left="597" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref810">.</a></text>
<text top="1031" left="450" width="21" height="12" font="15">815.</text>
<text top="1031" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref811">Ben FM, Gamra H, Betbout F, et al. Percutaneous balloon mitral</a></text>
<text top="1044" left="477" width="267" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref811">commissurotomy during pregnancy. Heart 1997;77:564</a></text>
<text top="1042" left="744" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref811">–7</a></text>
<text top="1044" left="756" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref811">.</a></text>
<text top="1058" left="450" width="21" height="12" font="15">816.</text>
<text top="1058" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref812">de Souza JA, Martinez EE Jr., Ambrose JA, et al. Percutaneous</a></text>
<text top="1071" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref812">balloon mitral valvuloplasty in comparison with open mitral valve</a></text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e174</text>
</page>
<page number="119" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref812">commissurotomy for mitral stenosis during pregnancy. J Am Coll</a></text>
<text top="116" left="91" width="99" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref812">Cardiol 2001;37:900</a></text>
<text top="113" left="191" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref812">–3</a></text>
<text top="116" left="202" width="3" height="12" font="15">.</text>
<text top="130" left="64" width="21" height="12" font="15">817.</text>
<text top="130" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref813">Glantz JC, Pomerantz RM, Cunningham MJ, et al. Percutaneous</a></text>
<text top="143" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref813">balloon valvuloplasty for severe mitral stenosis during pregnancy: a</a></text>
<text top="157" left="91" width="308" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref813">review of therapeutic options. Obstet Gynecol Surv 1993;48:503</a></text>
<text top="154" left="399" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref813">–8</a></text>
<text top="157" left="411" width="3" height="12" font="15">.</text>
<text top="170" left="64" width="21" height="12" font="15">818.</text>
<text top="170" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref814">Iung B, Cormier B, Elias J, et al. Usefulness of percutaneous balloon</a></text>
<text top="183" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref814">commissurotomy for mitral stenosis during pregnancy. Am J Cardiol</a></text>
<text top="197" left="91" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref814">1994;73:398</a></text>
<text top="194" left="151" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref814">–400</a></text>
<text top="197" left="175" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref814">.</a></text>
<text top="210" left="64" width="21" height="12" font="15">819.</text>
<text top="210" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref815">Weiss BM, von Segesser LK, Alon E, et al. Outcome of cardio-</a></text>
<text top="224" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref815">vascular surgery and pregnancy: a systematic review of the period</a></text>
<text top="237" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref815">1984</a></text>
<text top="235" left="115" width="236" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref815">–1996. Am J Obstet Gynecol 1998;179:1643–53</a></text>
<text top="237" left="351" width="3" height="12" font="15">.</text>
<text top="251" left="64" width="21" height="12" font="15">820.</text>
<text top="251" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref816">Becker RM. Intracardiac surgery in pregnant women. Ann Thorac</a></text>
<text top="264" left="91" width="86" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref816">Surg 1983;36:453</a></text>
<text top="261" left="177" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref816">–8</a></text>
<text top="264" left="189" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref816">.</a></text>
<text top="278" left="64" width="21" height="12" font="15">821.</text>
<text top="278" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref817">Chambers CE, Clark SL. Cardiac surgery during pregnancy. Clin</a></text>
<text top="291" left="91" width="140" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref817">Obstet Gynecol 1994;37:316</a></text>
<text top="288" left="231" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref817">–23</a></text>
<text top="291" left="249" width="3" height="12" font="15">.</text>
<text top="305" left="64" width="21" height="12" font="15">822.</text>
<text top="305" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref818">Parry AJ, Westaby S. Cardiopulmonary bypass during pregnancy.</a></text>
<text top="318" left="91" width="155" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref818">Ann Thorac Surg 1996;61:1865</a></text>
<text top="315" left="246" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref818">–9</a></text>
<text top="318" left="258" width="3" height="12" font="15">.</text>
<text top="331" left="64" width="21" height="12" font="15">823.</text>
<text top="331" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref819">Banning AP, Pearson JF, Hall RJ. Role of balloon dilatation of the</a></text>
<text top="345" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref819">aortic valve in pregnant patients with severe aortic stenosis. Br Heart</a></text>
<text top="358" left="91" width="68" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref819">J 1993;70:544</a></text>
<text top="356" left="159" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref819">–5</a></text>
<text top="358" left="170" width="3" height="12" font="15">.</text>
<text top="372" left="64" width="21" height="12" font="15">824.</text>
<text top="372" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref820">Easterling TR, Chadwick HS, Otto CM, et al. Aortic stenosis in</a></text>
<text top="385" left="91" width="195" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref820">pregnancy. Obstet Gynecol 1988;72:113</a></text>
<text top="382" left="286" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref820">–8</a></text>
<text top="385" left="298" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref820">.</a></text>
<text top="399" left="64" width="21" height="12" font="15">825.</text>
<text top="399" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref821">Lao TT, Adelman AG, Sermer M, et al. Balloon valvuloplasty for</a></text>
<text top="412" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref821">congenital aortic stenosis in pregnancy. Br J Obstet Gynaecol 1993;</a></text>
<text top="426" left="91" width="45" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref821">100:1141</a></text>
<text top="423" left="136" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref821">–2</a></text>
<text top="426" left="148" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref821">.</a></text>
<text top="439" left="64" width="21" height="12" font="15">826.</text>
<text top="439" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref822">McIvor RA. Percutaneous balloon aortic valvuloplasty during</a></text>
<text top="452" left="91" width="169" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref822">pregnancy. Int J Cardiol 1991;32:1</a></text>
<text top="450" left="260" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref822">–3</a></text>
<text top="452" left="272" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref822">.</a></text>
<text top="466" left="64" width="21" height="12" font="15">827.</text>
<text top="466" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref823">Myerson SG, Mitchell AR, Ormerod OJ, et al. What is the role of</a></text>
<text top="479" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref823">balloon dilatation for severe aortic stenosis during pregnancy?</a></text>
<text top="493" left="91" width="150" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref823">J Heart Valve Dis 2005;14:147</a></text>
<text top="490" left="241" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref823">–50</a></text>
<text top="493" left="259" width="3" height="12" font="15">.</text>
<text top="506" left="64" width="21" height="12" font="15">828.</text>
<text top="506" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref824">Tumelero RT, Duda NT, Tognon AP, et al. Percutaneous balloon</a></text>
<text top="520" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref824">aortic valvuloplasty in a pregnant adolescent. Arq Bras Cardiol 2004;</a></text>
<text top="533" left="91" width="27" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref824">82:98</a></text>
<text top="530" left="118" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref824">–7</a></text>
<text top="533" left="130" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref824">.</a></text>
<text top="547" left="64" width="21" height="12" font="15">829.</text>
<text top="547" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref825">Borges VT, Matsubara BB, Magalhaes CG, et al. Effect of physi-</a></text>
<text top="560" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref825">ological overload on pregnancy in women with mitral regurgitation.</a></text>
<text top="574" left="91" width="151" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref825">Clinics (Sao Paulo) 2011;66:47</a></text>
<text top="571" left="242" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref825">–50</a></text>
<text top="574" left="260" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref825">.</a></text>
<text top="587" left="64" width="21" height="12" font="15">830.</text>
<text top="587" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref826">Campos O, Andrade JL, Bocanegra J, et al. Physiologic multi-</a></text>
<text top="600" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref826">valvular regurgitation during pregnancy: a longitudinal Doppler</a></text>
<text top="614" left="91" width="248" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref826">echocardiographic study. Int J Cardiol 1993;40:265</a></text>
<text top="611" left="339" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref826">–72</a></text>
<text top="614" left="357" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref826">.</a></text>
<text top="627" left="64" width="21" height="12" font="15">831.</text>
<text top="627" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref827">Chia YT, Yeoh SC, Lim MC, et al. Pregnancy outcome and mitral</a></text>
<text top="641" left="91" width="293" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref827">valve prolapse. Asia Oceania J Obstet Gynaecol 1994;20:383</a></text>
<text top="638" left="384" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref827">–8</a></text>
<text top="641" left="396" width="3" height="12" font="15">.</text>
<text top="654" left="64" width="21" height="12" font="15">832.</text>
<text top="654" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref828">Jana N, Vasishta K, Khunnu B, et al. Pregnancy in association with</a></text>
<text top="668" left="91" width="308" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref828">mitral valve prolapse. Asia Oceania J Obstet Gynaecol 1993;19:61</a></text>
<text top="665" left="399" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref828">–5</a></text>
<text top="668" left="411" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref828">.</a></text>
<text top="681" left="64" width="21" height="12" font="15">833.</text>
<text top="681" left="91" width="117" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref829">Marcus FI, Ewy GA, O</a></text>
<text top="678" left="208" width="206" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref829">’Rourke RA, et al. The effect of pregnancy</a></text>
<text top="695" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref829">on the murmurs of mitral and aortic regurgitation. Circulation 1970;</a></text>
<text top="708" left="91" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref829">41:795</a></text>
<text top="705" left="124" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref829">–805</a></text>
<text top="708" left="148" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref829">.</a></text>
<text top="721" left="64" width="21" height="12" font="15">834.</text>
<text top="721" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref830">Sugishita Y, Ito I, Kubo T. Pregnancy in cardiac patients: possible</a></text>
<text top="735" left="91" width="9" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref830">in</a></text>
<text top="732" left="101" width="314" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref830">ﬂuence of volume overload by pregnancy on pulmonary circula-</a></text>
<text top="748" left="91" width="138" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref830">tion. Jpn Circ J 1986;50:376</a></text>
<text top="746" left="229" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref830">–83</a></text>
<text top="748" left="247" width="3" height="12" font="15">.</text>
<text top="762" left="64" width="21" height="12" font="15">835.</text>
<text top="762" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref831">Gueret P, Vignon P, Fournier P, et al. Transesophageal echocardiog-</a></text>
<text top="775" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref831">raphy for the diagnosis and management of nonobstructive thrombosis</a></text>
<text top="789" left="91" width="287" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref831">of mechanical mitral valve prosthesis. Circulation 1995;91:103</a></text>
<text top="786" left="378" width="17" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref831">–10</a></text>
<text top="789" left="395" width="3" height="12" font="15">.</text>
<text top="802" left="64" width="21" height="12" font="15">836.</text>
<text top="802" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref832">Daniel WG, Mugge A, Grote J, et al. Comparison of transthoracic</a></text>
<text top="816" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref832">and transesophageal echocardiography for detection of abnormalities</a></text>
<text top="829" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref832">of prosthetic and bioprosthetic valves in the mitral and aortic po-</a></text>
<text top="843" left="91" width="167" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref832">sitions. Am J Cardiol 1993;71:210</a></text>
<text top="840" left="258" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref832">–5</a></text>
<text top="843" left="270" width="3" height="12" font="15">.</text>
<text top="856" left="64" width="21" height="12" font="15">837.</text>
<text top="856" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref833">Dzavik V, Cohen G, Chan KL. Role of transesophageal echocar-</a></text>
<text top="869" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref833">diography in the diagnosis and management of prosthetic valve</a></text>
<text top="883" left="91" width="220" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref833">thrombosis. J Am Coll Cardiol 1991;18:1829</a></text>
<text top="880" left="311" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref833">–33</a></text>
<text top="883" left="329" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref833">.</a></text>
<text top="896" left="64" width="21" height="12" font="15">838.</text>
<text top="896" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref834">Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant</a></text>
<text top="910" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref834">women with mechanical heart valves: a systematic review of the</a></text>
<text top="923" left="91" width="203" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref834">literature. Arch Intern Med 2000;160:191</a></text>
<text top="921" left="294" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref834">–6</a></text>
<text top="923" left="306" width="3" height="12" font="15">.</text>
<text top="937" left="64" width="21" height="12" font="15">839.</text>
<text top="937" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref835">Meschengieser SS, Fondevila CG, Santarelli MT, et al. Anti-</a></text>
<text top="950" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref835">coagulation in pregnant women with mechanical heart valve pros-</a></text>
<text top="964" left="91" width="121" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref835">theses. Heart 1999;82:23</a></text>
<text top="961" left="212" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref835">–6</a></text>
<text top="964" left="224" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref835">.</a></text>
<text top="977" left="64" width="21" height="12" font="15">840.</text>
<text top="977" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref836">Abildgaard U, Sandset PM, Hammerstrom J, et al. Management of</a></text>
<text top="990" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref836">pregnant women with mechanical heart valve prosthesis: thrombo-</a></text>
<text top="1004" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref836">prophylaxis with low molecular weight heparin. Thromb Res 2009;</a></text>
<text top="1017" left="91" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref836">124:262</a></text>
<text top="1015" left="130" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref836">–7</a></text>
<text top="1017" left="142" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref836">.</a></text>
<text top="1031" left="64" width="21" height="12" font="15">841.</text>
<text top="1031" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref837">McLintock C, McCowan LM, North RA. Maternal complications</a></text>
<text top="1044" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref837">and pregnancy outcome in women with mechanical prosthetic heart</a></text>
<text top="1058" left="91" width="258" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref837">valves treated with enoxaparin. BJOG 2009;116:1585</a></text>
<text top="1055" left="349" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref837">–92</a></text>
<text top="1058" left="367" width="3" height="12" font="15">.</text>
<text top="1071" left="64" width="21" height="12" font="15">842.</text>
<text top="1071" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref838">Oran B, Lee-Parritz A, Ansell J. Low molecular weight heparin for</a></text>
<text top="1085" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref838">the prophylaxis of thromboembolism in women with prosthetic</a></text>
<text top="103" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref838">mechanical heart valves during pregnancy. Thromb Haemost 2004;</a></text>
<text top="116" left="477" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref838">92:747</a></text>
<text top="114" left="510" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref838">–51</a></text>
<text top="116" left="527" width="3" height="12" font="15">.</text>
<text top="130" left="450" width="21" height="12" font="15">843.</text>
<text top="130" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref839">Quinn J, Von Klemperer K, Brooks R, et al. Use of high intensity</a></text>
<text top="143" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref839">adjusted dose low molecular weight heparin in women with me-</a></text>
<text top="157" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref839">chanical heart valves during pregnancy: a single-center experience.</a></text>
<text top="170" left="477" width="141" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref839">Haematologica 2009;94:1608</a></text>
<text top="167" left="618" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref839">–12</a></text>
<text top="170" left="636" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref839">.</a></text>
<text top="184" left="450" width="21" height="12" font="15">844.</text>
<text top="184" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref840">Sillesen M, Hjortdal V, Vejlstrup N, et al. Pregnancy with prosthetic</a></text>
<text top="197" left="477" width="110" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref840">heart valves - 30 years</a></text>
<text top="194" left="587" width="213" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref840">’ nationwide experience in Denmark. Eur J</a></text>
<text top="210" left="477" width="152" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref840">Cardiothorac Surg 2011;40:448</a></text>
<text top="208" left="629" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref840">–54</a></text>
<text top="210" left="647" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref840">.</a></text>
<text top="224" left="450" width="21" height="12" font="15">845.</text>
<text top="224" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref841">De Santo LS, Romano G, Della Corte A, et al. Mechanical aortic</a></text>
<text top="237" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref841">valve replacement in young women planning on pregnancy: maternal</a></text>
<text top="251" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref841">and fetal outcomes under low oral anticoagulation, a pilot observa-</a></text>
<text top="264" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref841">tional study on a comprehensive pre-operative counseling protocol.</a></text>
<text top="278" left="477" width="160" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref841">J Am Coll Cardiol 2012;59:1110</a></text>
<text top="275" left="637" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref841">–5</a></text>
<text top="278" left="649" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref841">.</a></text>
<text top="291" left="450" width="21" height="12" font="15">846.</text>
<text top="291" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref842">McLintock C. Anticoagulant therapy in pregnant women with</a></text>
<text top="305" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref842">mechanical prosthetic heart valves: no easy option. Thromb Res</a></text>
<text top="318" left="477" width="108" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref842">2011;127 Suppl 3:S56</a></text>
<text top="315" left="584" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref842">–60</a></text>
<text top="318" left="602" width="3" height="12" font="15">.</text>
<text top="331" left="450" width="21" height="12" font="15">847.</text>
<text top="331" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref843">Ginsberg JS, Chan WS, Bates SM, et al. Anticoagulation of preg-</a></text>
<text top="345" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref843">nant women with mechanical heart valves. Arch Intern Med 2003;</a></text>
<text top="358" left="477" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref843">163:694</a></text>
<text top="356" left="515" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref843">–8</a></text>
<text top="358" left="527" width="3" height="12" font="15">.</text>
<text top="372" left="450" width="21" height="12" font="15">848.</text>
<text top="372" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref844">Salazar E, Izaguirre R, Verdejo J, et al. Failure of adjusted doses of</a></text>
<text top="385" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref844">subcutaneous heparin to prevent thromboembolic phenomena in</a></text>
<text top="399" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref844">pregnant patients with mechanical cardiac valve prostheses. J Am</a></text>
<text top="412" left="477" width="130" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref844">Coll Cardiol 1996;27:1698</a></text>
<text top="409" left="607" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref844">–703</a></text>
<text top="412" left="630" width="3" height="12" font="15">.</text>
<text top="426" left="450" width="21" height="12" font="15">849.</text>
<text top="426" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref845">Thorp JA, Poskin MF, McKenzie DR, et al. Perinatal factors</a></text>
<text top="439" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref845">predicting severe intracranial hemorrhage. Am J Perinatol 1997;14:</a></text>
<text top="452" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref845">631</a></text>
<text top="450" left="495" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref845">–6</a></text>
<text top="452" left="507" width="3" height="12" font="15">.</text>
<text top="466" left="450" width="21" height="12" font="15">850.</text>
<text top="466" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref846">CLASP: a randomised trial of low-dose aspirin for the prevention</a></text>
<text top="479" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref846">and treatment of pre-eclampsia among 9364 pregnant women.</a></text>
<text top="493" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref846">CLASP (Collaborative Low-dose Aspirin Study in Pregnancy)</a></text>
<text top="506" left="477" width="208" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref846">Collaborative Group. Lancet 1994;343:619</a></text>
<text top="504" left="684" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref846">–29</a></text>
<text top="506" left="702" width="3" height="12" font="15">.</text>
<text top="520" left="450" width="21" height="12" font="15">851.</text>
<text top="520" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref847">Vitale N, De Feo M, Cotrufo M. Anticoagulation for prosthetic</a></text>
<text top="533" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref847">heart valves during pregnancy: the importance of warfarin daily dose.</a></text>
<text top="547" left="477" width="182" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref847">Eur J Cardiothorac Surg 2002;22:656</a></text>
<text top="547" left="659" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref847">.</a></text>
<text top="560" left="450" width="21" height="12" font="15">852.</text>
<text top="560" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref848">Sbarouni E, Oakley CM. Outcome of pregnancy in women with</a></text>
<text top="574" left="477" width="197" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref848">valve prostheses. Br Heart J 1994;71:196</a></text>
<text top="571" left="674" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref848">–201</a></text>
<text top="574" left="698" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref848">.</a></text>
<text top="587" left="450" width="21" height="12" font="15">853.</text>
<text top="587" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref849">Al-Lawati AA, Venkitraman M, Al-Delaime T, et al. Pregnancy</a></text>
<text top="600" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref849">and mechanical heart valves replacement; dilemma of anti-</a></text>
<text top="614" left="477" width="243" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref849">coagulation. Eur J Cardiothorac Surg 2002;22:223</a></text>
<text top="611" left="720" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref849">–7</a></text>
<text top="614" left="732" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref849">.</a></text>
<text top="627" left="450" width="21" height="12" font="15">854.</text>
<text top="627" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref850">Sadler L, McCowan L, White H, et al. Pregnancy outcomes and</a></text>
<text top="641" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref850">cardiac complications in women with mechanical, bioprosthetic and</a></text>
<text top="654" left="477" width="188" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref850">homograft valves. BJOG 2000;107:245</a></text>
<text top="652" left="665" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref850">–53</a></text>
<text top="654" left="683" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref850">.</a></text>
<text top="668" left="450" width="21" height="12" font="15">855.</text>
<text top="668" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref851">Rowan JA, McCowan LM, Raudkivi PJ, et al. Enoxaparin treat-</a></text>
<text top="681" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref851">ment in women with mechanical heart valves during pregnancy. Am</a></text>
<text top="695" left="477" width="153" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref851">J Obstet Gynecol 2001;185:633</a></text>
<text top="692" left="630" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref851">–7</a></text>
<text top="695" left="642" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref851">.</a></text>
<text top="708" left="450" width="21" height="12" font="15">856.</text>
<text top="708" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref852">James AH, Brancazio LR, Gehrig TR, et al. Low-molecular-weight</a></text>
<text top="721" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref852">heparin for thromboprophylaxis in pregnant women with mechan-</a></text>
<text top="735" left="477" width="291" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref852">ical heart valves. J Matern Fetal Neonatal Med 2006;19:543</a></text>
<text top="732" left="767" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref852">–9</a></text>
<text top="735" left="779" width="3" height="12" font="15">.</text>
<text top="748" left="450" width="21" height="12" font="15">857.</text>
<text top="748" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref853">Yinon Y, Siu SC, Warshafsky C, et al. Use of low molecular weight</a></text>
<text top="762" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref853">heparin in pregnant women with mechanical heart valves. Am J</a></text>
<text top="775" left="477" width="111" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref853">Cardiol 2009;104:1259</a></text>
<text top="773" left="588" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref853">–63</a></text>
<text top="775" left="606" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref853">.</a></text>
<text top="789" left="450" width="21" height="12" font="15">858.</text>
<text top="789" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref854">Graboys TB, Cohn PF. The prevalence of angina pectoris and</a></text>
<text top="802" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref854">abnormal coronary arteriograms in severe aortic valvular disease. Am</a></text>
<text top="816" left="477" width="99" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref854">Heart J 1977;93:683</a></text>
<text top="813" left="576" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref854">–6</a></text>
<text top="816" left="588" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref854">.</a></text>
<text top="829" left="450" width="21" height="12" font="15">859.</text>
<text top="829" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref855">Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial</a></text>
<text top="843" left="477" width="212" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref855">revascularization. Eur Heart J 2010;31:2501</a></text>
<text top="840" left="689" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref855">–55</a></text>
<text top="843" left="707" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref855">.</a></text>
<text top="856" left="450" width="21" height="12" font="15">860.</text>
<text top="856" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref856">Kannel WB, McGee D, Gordon T. A general cardiovascular risk</a></text>
<text top="869" left="477" width="16" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref856">pro</a></text>
<text top="867" left="493" width="282" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref856">ﬁle: the Framingham Study. Am J Cardiol 1976;38:46–51</a></text>
<text top="869" left="774" width="3" height="12" font="15">.</text>
<text top="883" left="450" width="21" height="12" font="15">861.</text>
<text top="883" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref857">Diamond GA, Forrester JS. Analysis of probability as an aid in the</a></text>
<text top="896" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref857">clinical diagnosis of coronary-artery disease. N Engl J Med 1979;</a></text>
<text top="910" left="477" width="45" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref857">300:1350</a></text>
<text top="907" left="521" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref857">–8</a></text>
<text top="910" left="533" width="3" height="12" font="15">.</text>
<text top="923" left="450" width="21" height="12" font="15">862.</text>
<text top="923" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref858">Ramsdale DR, Bennett DH, Bray CL, et al. Angina, coronary risk</a></text>
<text top="937" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref858">factors and coronary artery disease in patients with valvular disease.</a></text>
<text top="950" left="477" width="217" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref858">A prospective study. Eur Heart J 1984;5:716</a></text>
<text top="947" left="693" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref858">–26</a></text>
<text top="950" left="711" width="3" height="12" font="15">.</text>
<text top="964" left="450" width="21" height="12" font="15">863.</text>
<text top="964" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref859">Fuster V, Gotto AM, Libby P, et al. 27th Bethesda Conference:</a></text>
<text top="977" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref859">matching the intensity of risk factor management with the hazard</a></text>
<text top="990" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref859">for coronary disease events. Task Force 1. Pathogenesis of coronary</a></text>
<text top="1004" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref859">disease: the biologic role of risk factors. J Am Coll Cardiol 1996;27:</a></text>
<text top="1017" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref859">964</a></text>
<text top="1015" left="495" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref859">–76</a></text>
<text top="1017" left="512" width="3" height="12" font="15">.</text>
<text top="1031" left="450" width="21" height="12" font="15">864.</text>
<text top="1031" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref860">Grundy SM, Pasternak R, Greenland P, et al. Assessment of car-</a></text>
<text top="1044" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref860">diovascular risk by use of multiple-risk-factor assessment equations:</a></text>
<text top="1058" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref860">a statement for healthcare professionals from the American Heart</a></text>
<text top="1071" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref860">Association and the American College of Cardiology. Circulation</a></text>
<text top="1085" left="477" width="72" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref860">1999;100:1481</a></text>
<text top="1082" left="548" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref860">–92</a></text>
<text top="1085" left="566" width="3" height="12" font="15">.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e175</text>
</page>
<page number="120" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="21" height="12" font="15">865.</text>
<text top="103" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref861">Hancock EW. Aortic stenosis, angina pectoris, and coronary artery</a></text>
<text top="116" left="91" width="161" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref861">disease. Am Heart J 1977;93:382</a></text>
<text top="113" left="252" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref861">–93</a></text>
<text top="116" left="270" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref861">.</a></text>
<text top="130" left="64" width="21" height="12" font="15">866.</text>
<text top="130" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref862">Lombard JT, Selzer A. Valvular aortic stenosis. A clinical and he-</a></text>
<text top="143" left="91" width="75" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref862">modynamic pro</a></text>
<text top="140" left="166" width="239" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref862">ﬁle of patients. Ann Intern Med 1987;106:292–8</a></text>
<text top="143" left="406" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref862">.</a></text>
<text top="157" left="64" width="21" height="12" font="15">867.</text>
<text top="157" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref863">Dangas G, Khan S, Curry BH, et al. Angina pectoris in severe aortic</a></text>
<text top="170" left="91" width="148" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref863">stenosis. Cardiology 1999;92:1</a></text>
<text top="167" left="239" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref863">–3</a></text>
<text top="170" left="251" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref863">.</a></text>
<text top="183" left="64" width="21" height="12" font="15">868.</text>
<text top="183" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref864">Basta LL, Raines D, Najjar S, et al. Clinical, haemodynamic, and</a></text>
<text top="197" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref864">coronary angiographic correlates of angina pectoris in patients with</a></text>
<text top="210" left="91" width="244" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref864">severe aortic valve disease. Br Heart J 1975;37:150</a></text>
<text top="208" left="335" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref864">–7</a></text>
<text top="210" left="347" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref864">.</a></text>
<text top="224" left="64" width="21" height="12" font="15">869.</text>
<text top="224" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref865">Lacy J, Goodin R, McMartin D, et al. Coronary atherosclerosis in</a></text>
<text top="237" left="91" width="257" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref865">valvular heart disease. Ann Thorac Surg 1977;23:429</a></text>
<text top="235" left="348" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref865">–35</a></text>
<text top="237" left="366" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref865">.</a></text>
<text top="251" left="64" width="21" height="12" font="15">870.</text>
<text top="251" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref866">Saltups A. Coronary arteriography in isolated aortic and mitral valve</a></text>
<text top="264" left="91" width="186" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref866">disease. Aust N Z J Med 1982;12:494</a></text>
<text top="261" left="277" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref866">–7</a></text>
<text top="264" left="289" width="3" height="12" font="15">.</text>
<text top="278" left="64" width="21" height="12" font="15">871.</text>
<text top="278" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref867">Mattina CJ, Green SJ, Tortolani AJ, et al. Frequency of angio-</a></text>
<text top="291" left="91" width="77" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref867">graphically signi</a></text>
<text top="288" left="168" width="246" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref867">ﬁcant coronary arterial narrowing in mitral stenosis.</a></text>
<text top="305" left="91" width="130" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref867">Am J Cardiol 1986;57:802</a></text>
<text top="302" left="221" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref867">–5</a></text>
<text top="305" left="233" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref867">.</a></text>
<text top="318" left="64" width="21" height="12" font="15">872.</text>
<text top="318" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref868">Gahl K, Sutton R, Pearson M, et al. Mitral regurgitation in coronary</a></text>
<text top="331" left="91" width="176" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref868">heart disease. Br Heart J 1977;39:13</a></text>
<text top="329" left="267" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref868">–8</a></text>
<text top="331" left="279" width="3" height="12" font="15">.</text>
<text top="345" left="64" width="21" height="12" font="15">873.</text>
<text top="345" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref869">Enriquez-Sarano M, Klodas E, Garratt KN, et al. Secular trends in</a></text>
<text top="358" left="91" width="114" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref869">coronary atherosclerosis</a></text>
<text top="356" left="205" width="209" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref869">–analysis in patients with valvular regurgi-</a></text>
<text top="372" left="91" width="176" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref869">tation. N Engl J Med 1996;335:316</a></text>
<text top="369" left="266" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref869">–22</a></text>
<text top="372" left="284" width="3" height="12" font="15">.</text>
<text top="385" left="64" width="21" height="12" font="15">874.</text>
<text top="385" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref870">Breisblatt WM, Cerqueira M, Francis CK, et al. Left ventricular</a></text>
<text top="399" left="91" width="217" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref870">function in ischemic mitral regurgitation</a></text>
<text top="396" left="308" width="106" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref870">–a precatheterization</a></text>
<text top="412" left="91" width="183" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref870">assessment. Am Heart J 1988;115:77</a></text>
<text top="409" left="274" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref870">–82</a></text>
<text top="412" left="293" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref870">.</a></text>
<text top="426" left="64" width="21" height="12" font="15">875.</text>
<text top="426" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref871">Lin SS, Lauer MS, Asher CR, et al. Prediction of coronary artery</a></text>
<text top="439" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref871">disease in patients undergoing operations for mitral valve degener-</a></text>
<text top="452" left="91" width="225" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref871">ation. J Thorac Cardiovasc Surg 2001;121:894</a></text>
<text top="450" left="316" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref871">–901</a></text>
<text top="452" left="339" width="3" height="12" font="15">.</text>
<text top="466" left="64" width="21" height="12" font="15">876.</text>
<text top="466" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref872">Kern MJ, Serota H, Callicoat P, et al. Use of coronary arteriography</a></text>
<text top="479" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref872">in the preoperative management of patients undergoing urgent</a></text>
<text top="493" left="91" width="263" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref872">repair of the thoracic aorta. Am Heart J 1990;119:143</a></text>
<text top="490" left="354" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref872">–8</a></text>
<text top="493" left="366" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref872">.</a></text>
<text top="506" left="64" width="21" height="12" font="15">877.</text>
<text top="506" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref873">Israel DH, Sharma SK, Ambrose JA, et al. Cardiac catheterization</a></text>
<text top="520" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref873">and selective coronary angiography in ascending aortic aneurysm or</a></text>
<text top="533" left="91" width="239" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref873">dissection. Cathet Cardiovasc Diagn 1994;32:232</a></text>
<text top="530" left="330" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref873">–7</a></text>
<text top="533" left="342" width="3" height="12" font="15">.</text>
<text top="547" left="64" width="21" height="12" font="15">878.</text>
<text top="547" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref874">Rizzo RJ, Aranki SF, Aklog L, et al. Rapid noninvasive diagnosis</a></text>
<text top="560" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref874">and surgical repair of acute ascending aortic dissection. Improved</a></text>
<text top="574" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref874">survival with less angiography. J Thorac Cardiovasc Surg 1994;108:</a></text>
<text top="587" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref874">567</a></text>
<text top="584" left="109" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref874">–74</a></text>
<text top="587" left="127" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref874">.</a></text>
<text top="600" left="64" width="21" height="12" font="15">879.</text>
<text top="600" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref875">Penn MS, Smedira N, Lytle B, et al. Does coronary angiography</a></text>
<text top="614" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref875">before emergency aortic surgery affect in-hospital mortality? J Am</a></text>
<text top="627" left="91" width="124" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref875">Coll Cardiol 2000;35:889</a></text>
<text top="625" left="215" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref875">–94</a></text>
<text top="627" left="233" width="3" height="12" font="15">.</text>
<text top="641" left="64" width="21" height="12" font="15">880.</text>
<text top="641" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref876">Mark DB, Berman DS, Budoff MJ, et al. ACCF/ACR/AHA/</a></text>
<text top="654" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref876">NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on</a></text>
<text top="668" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref876">coronary computed tomographic angiography: a report of the</a></text>
<text top="681" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref876">American College of Cardiology Foundation Task Force on Expert</a></text>
<text top="695" left="91" width="277" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref876">Consensus Documents. J Am Coll Cardiol 2010;55:2663</a></text>
<text top="692" left="368" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref876">–99</a></text>
<text top="695" left="386" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref876">.</a></text>
<text top="708" left="64" width="21" height="12" font="15">881.</text>
<text top="708" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref877">Gilard M, Cornily JC, Pennec PY, et al. Accuracy of multislice</a></text>
<text top="721" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref877">computed tomography in the preoperative assessment of coronary</a></text>
<text top="735" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref877">disease in patients with aortic valve stenosis. J Am Coll Cardiol</a></text>
<text top="748" left="91" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref877">2006;47:2020</a></text>
<text top="746" left="157" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref877">–4</a></text>
<text top="748" left="169" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref877">.</a></text>
<text top="762" left="64" width="21" height="12" font="15">882.</text>
<text top="762" left="91" width="279" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref878">Manghat NE, Morgan-Hughes GJ, Broadley AJ, et al. 16</a></text>
<text top="759" left="370" width="44" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref878">–detector</a></text>
<text top="775" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref878">row computed tomographic coronary angiography in patients un-</a></text>
<text top="789" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref878">dergoing evaluation for aortic valve replacement: comparison with</a></text>
<text top="802" left="91" width="227" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref878">catheter angiography. Clin Radiol 2006;61:749</a></text>
<text top="799" left="318" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref878">–57</a></text>
<text top="802" left="335" width="3" height="12" font="15">.</text>
<text top="816" left="64" width="21" height="12" font="15">883.</text>
<text top="816" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref879">Meijboom WB, Mollet NR, Van Mieghem CA, et al. Pre-operative</a></text>
<text top="829" left="91" width="297" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref879">computed tomography coronary angiography to detect signi</a></text>
<text top="826" left="388" width="26" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref879">ﬁcant</a></text>
<text top="843" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref879">coronary artery disease in patients referred for cardiac valve surgery.</a></text>
<text top="856" left="91" width="160" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref879">J Am Coll Cardiol 2006;48:1658</a></text>
<text top="853" left="251" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref879">–65</a></text>
<text top="856" left="269" width="3" height="12" font="15">.</text>
<text top="869" left="64" width="21" height="12" font="15">884.</text>
<text top="869" left="91" width="111" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref880">Reant P, Brunot S, La</a></text>
<text top="867" left="202" width="212" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref880">ﬁtte S, et al. Predictive value of noninvasive</a></text>
<text top="883" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref880">coronary angiography with multidetector computed tomography to</a></text>
<text top="896" left="91" width="58" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref880">detect signi</a></text>
<text top="894" left="149" width="265" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref880">ﬁcant coronary stenosis before valve surgery. Am J</a></text>
<text top="910" left="91" width="105" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref880">Cardiol 2006;97:1506</a></text>
<text top="907" left="197" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref880">–10</a></text>
<text top="910" left="214" width="3" height="12" font="15">.</text>
<text top="923" left="64" width="21" height="12" font="15">885.</text>
<text top="923" left="91" width="247" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref881">Scheffel H, Leschka S, Plass A, et al. Accuracy of 64</a></text>
<text top="921" left="338" width="76" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref881">–slice computed</a></text>
<text top="937" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref881">tomography for the preoperative detection of coronary artery disease</a></text>
<text top="950" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref881">in patients with chronic aortic regurgitation. Am J Cardiol 2007;</a></text>
<text top="964" left="91" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref881">100:701</a></text>
<text top="961" left="130" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref881">–6</a></text>
<text top="964" left="142" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref881">.</a></text>
<text top="977" left="64" width="21" height="12" font="15">886.</text>
<text top="977" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref882">Galas A, Hryniewiecki T, Kepka C, et al. May dual-source</a></text>
<text top="990" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref882">computed tomography angiography replace invasive coronary angi-</a></text>
<text top="1004" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref882">ography in the evaluation of patients referred for valvular disease</a></text>
<text top="1017" left="91" width="161" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref882">surgery? Kardiol Pol 2012;70:877</a></text>
<text top="1015" left="252" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref882">–82</a></text>
<text top="1017" left="270" width="3" height="12" font="15">.</text>
<text top="1031" left="64" width="21" height="12" font="15">887.</text>
<text top="1031" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref883">Morris MF, Suri RM, Akhtar NJ, et al. Computed tomography as</a></text>
<text top="1044" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref883">an alternative to catheter angiography prior to robotic mitral valve</a></text>
<text top="1058" left="91" width="189" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref883">repair. Ann Thorac Surg 2013;95:1354</a></text>
<text top="1055" left="280" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref883">–9</a></text>
<text top="1058" left="292" width="3" height="12" font="15">.</text>
<text top="1071" left="64" width="21" height="12" font="15">888.</text>
<text top="1071" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref884">Byrne JG, Leacche M, Vaughan DE, et al. Hybrid cardiovascular</a></text>
<text top="1085" left="91" width="230" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref884">procedures. J Am Coll Cardiol Intv 2008;1:459</a></text>
<text top="1082" left="321" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref884">–68</a></text>
<text top="1085" left="339" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref884">.</a></text>
<text top="103" left="450" width="21" height="12" font="15">889.</text>
<text top="103" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref885">Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical</a></text>
<text top="116" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref885">and medical group survival in patients with left main coronary</a></text>
<text top="130" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref885">artery disease. Long-term CASS experience. Circulation 1995;91:</a></text>
<text top="143" left="477" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref885">2325</a></text>
<text top="140" left="501" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref885">–34</a></text>
<text top="143" left="519" width="3" height="12" font="15">.</text>
<text top="157" left="450" width="21" height="12" font="15">890.</text>
<text top="157" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref886">Chaitman BR, Fisher LD, Bourassa MG, et al. Effect of coronary</a></text>
<text top="170" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref886">bypass surgery on survival patterns in subsets of patients with left</a></text>
<text top="184" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref886">main coronary artery disease. Report of the Collaborative Study in</a></text>
<text top="197" left="477" width="298" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref886">Coronary Artery Surgery (CASS). Am J Cardiol 1981;48:765</a></text>
<text top="194" left="775" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref886">–77</a></text>
<text top="197" left="793" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref886">.</a></text>
<text top="210" left="450" width="21" height="12" font="15">891.</text>
<text top="210" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref887">Dzavik V, Ghali WA, Norris C, et al. Long-term survival in 11,661</a></text>
<text top="224" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref887">patients with multivessel coronary artery disease in the era of</a></text>
<text top="237" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref887">stenting: a report from the Alberta Provincial Project for Outcome</a></text>
<text top="251" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref887">Assessment in Coronary Heart Disease (APPROACH) In-</a></text>
<text top="264" left="477" width="184" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref887">vestigators. Am Heart J 2001;142:119</a></text>
<text top="262" left="660" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref887">–26</a></text>
<text top="264" left="678" width="3" height="12" font="15">.</text>
<text top="278" left="450" width="21" height="12" font="15">892.</text>
<text top="278" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref888">Takaro T, Hultgren HN, Lipton MJ, et al. The VA cooperative</a></text>
<text top="291" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref888">randomized study of surgery for coronary arterial occlusive disease II.</a></text>
<text top="305" left="477" width="100" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref888">Subgroup with signi</a></text>
<text top="302" left="577" width="223" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref888">ﬁcant left main lesions. Circulation 1976;54:</a></text>
<text top="318" left="477" width="31" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref888">III107</a></text>
<text top="315" left="508" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref888">–17</a></text>
<text top="318" left="526" width="3" height="12" font="15">.</text>
<text top="331" left="450" width="21" height="12" font="15">893.</text>
<text top="331" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref889">Takaro T, Peduzzi P, Detre KM, et al. Survival in subgroups of</a></text>
<text top="345" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref889">patients with left main coronary artery disease. Veterans Adminis-</a></text>
<text top="358" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref889">tration Cooperative Study of Surgery for Coronary Arterial Occlu-</a></text>
<text top="372" left="477" width="176" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref889">sive Disease. Circulation 1982;66:14</a></text>
<text top="369" left="652" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref889">–22</a></text>
<text top="372" left="670" width="3" height="12" font="15">.</text>
<text top="385" left="450" width="21" height="12" font="15">894.</text>
<text top="385" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref890">Taylor HA, Deumite NJ, Chaitman BR, et al. Asymptomatic left</a></text>
<text top="399" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref890">main coronary artery disease in the Coronary Artery Surgery Study</a></text>
<text top="412" left="477" width="207" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref890">(CASS) registry. Circulation 1989;79:1171</a></text>
<text top="409" left="684" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref890">–9</a></text>
<text top="412" left="696" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref890">.</a></text>
<text top="426" left="450" width="21" height="12" font="15">895.</text>
<text top="426" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref891">Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass</a></text>
<text top="439" left="477" width="198" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref891">graft surgery on survival: overview of 10</a></text>
<text top="436" left="675" width="125" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref891">–year results from rando-</a></text>
<text top="452" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref891">mised trials by the Coronary Artery Bypass Graft Surgery Trialists</a></text>
<text top="466" left="477" width="175" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref891">Collaboration. Lancet 1994;344:563</a></text>
<text top="463" left="651" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref891">–70</a></text>
<text top="466" left="669" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref891">.</a></text>
<text top="479" left="450" width="21" height="12" font="15">896.</text>
<text top="479" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref892">Eguchi K, Ohtaki E, Matsumura T, et al. Pre-operative atrial</a></text>
<text top="490" left="477" width="323" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref892">ﬁbrillation as the key determinant of outcome of mitral valve</a></text>
<text top="506" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref892">repair for degenerative mitral regurgitation. Eur Heart J 2005;26:</a></text>
<text top="520" left="477" width="25" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref892">1866</a></text>
<text top="517" left="501" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref892">–72</a></text>
<text top="520" left="520" width="3" height="12" font="15">.</text>
<text top="533" left="450" width="21" height="12" font="15">897.</text>
<text top="533" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref893">Alexiou C, Doukas G, Oc M, et al. The effect of preoperative</a></text>
<text top="547" left="477" width="25" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref893">atrial</a></text>
<text top="544" left="508" width="291" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref893">ﬁbrillation on survival following mitral valve repair for</a></text>
<text top="560" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref893">degenerative mitral regurgitation. Eur J Cardiothorac Surg 2007;</a></text>
<text top="574" left="477" width="34" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref893">31:586</a></text>
<text top="571" left="511" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref893">–91</a></text>
<text top="574" left="529" width="3" height="12" font="15">.</text>
<text top="587" left="450" width="21" height="12" font="15">898.</text>
<text top="587" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref894">Chua YL, Schaff HV, Orszulak TA, et al. Outcome of mitral valve</a></text>
<text top="600" left="477" width="205" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref894">repair in patients with preoperative atrial</a></text>
<text top="598" left="687" width="113" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref894">ﬁbrillation. Should the</a></text>
<text top="614" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref894">maze procedure be combined with mitral valvuloplasty? J Thorac</a></text>
<text top="627" left="477" width="148" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref894">Cardiovasc Surg 1994;107:408</a></text>
<text top="625" left="624" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref894">–15</a></text>
<text top="627" left="642" width="3" height="12" font="15">.</text>
<text top="641" left="450" width="21" height="12" font="15">899.</text>
<text top="641" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref895">Obadia JF, el Farra M, Bastien OH, et al. Outcome of atrial</a></text>
<text top="652" left="477" width="323" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref895">ﬁbrillation after mitral valve repair. J Thorac Cardiovasc Surg 1997;</a></text>
<text top="668" left="477" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref895">114:179</a></text>
<text top="665" left="515" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref895">–85</a></text>
<text top="668" left="533" width="3" height="12" font="15">.</text>
<text top="681" left="450" width="21" height="12" font="15">900.</text>
<text top="681" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref896">Jessurun ER, van Hemel NM, Kelder JC, et al. Mitral valve surgery</a></text>
<text top="695" left="477" width="45" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref896">and atrial</a></text>
<text top="692" left="525" width="274" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref896">ﬁbrillation: is atrial ﬁbrillation surgery also needed? Eur J</a></text>
<text top="708" left="477" width="152" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref896">Cardiothorac Surg 2000;17:530</a></text>
<text top="705" left="629" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref896">–7</a></text>
<text top="708" left="641" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref896">.</a></text>
<text top="721" left="450" width="21" height="12" font="15">901.</text>
<text top="721" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref897">Akpinar B, Guden M, Sagbas E, et al. Combined radiofrequency</a></text>
<text top="735" left="477" width="25" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref897">modi</a></text>
<text top="732" left="501" width="298" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref897">ﬁed maze and mitral valve procedure through a port access</a></text>
<text top="748" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref897">approach: early and mid-term results. Eur J Cardiothorac Surg 2003;</a></text>
<text top="762" left="477" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref897">24:223</a></text>
<text top="759" left="510" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref897">–30</a></text>
<text top="762" left="527" width="3" height="12" font="15">.</text>
<text top="775" left="450" width="21" height="12" font="15">902.</text>
<text top="775" left="477" width="214" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref898">Deneke T, Khargi K, Grewe PH, et al. Ef</a></text>
<text top="773" left="691" width="109" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref898">ﬁcacy of an additional</a></text>
<text top="789" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref898">MAZE procedure using cooled-tip radiofrequency ablation in pa-</a></text>
<text top="802" left="477" width="124" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref898">tients with chronic atrial</a></text>
<text top="799" left="607" width="193" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref898">ﬁbrillation and mitral valve disease. A</a></text>
<text top="816" left="477" width="267" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref898">randomized, prospective trial. Eur Heart J 2002;23:558</a></text>
<text top="813" left="744" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref898">–66</a></text>
<text top="816" left="761" width="3" height="12" font="15">.</text>
<text top="829" left="450" width="21" height="12" font="15">903.</text>
<text top="829" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref899">Jessurun ER, van Hemel NM, Defauw JJ, et al. A randomized study</a></text>
<text top="843" left="477" width="181" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref899">of combining maze surgery for atrial</a></text>
<text top="840" left="663" width="137" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref899">ﬁbrillation with mitral valve</a></text>
<text top="856" left="477" width="224" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref899">surgery. J Cardiovasc Surg (Torino) 2003;44:9</a></text>
<text top="853" left="700" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref899">–18</a></text>
<text top="856" left="718" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref899">.</a></text>
<text top="869" left="450" width="21" height="12" font="15">904.</text>
<text top="869" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref900">Abreu Filho CA, Lisboa LA, Dallan LA, et al. Effectiveness of the</a></text>
<text top="883" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref900">maze procedure using cooled-tip radiofrequency ablation in patients</a></text>
<text top="896" left="477" width="102" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref900">with permanent atrial</a></text>
<text top="894" left="582" width="217" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref900">ﬁbrillation and rheumatic mitral valve disease.</a></text>
<text top="910" left="477" width="122" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref900">Circulation 2005;112:I20</a></text>
<text top="907" left="598" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref900">–5</a></text>
<text top="910" left="610" width="3" height="12" font="15">.</text>
<text top="923" left="450" width="21" height="12" font="15">905.</text>
<text top="923" left="477" width="161" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref901">Von Oppell UO, Masani N, O</a></text>
<text top="921" left="637" width="162" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref901">’Callaghan P, et al. Mitral valve</a></text>
<text top="937" left="477" width="153" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref901">surgery plus concomitant atrial</a></text>
<text top="934" left="635" width="165" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref901">ﬁbrillation ablation is superior to</a></text>
<text top="950" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref901">mitral valve surgery alone with an intensive rhythm control strategy.</a></text>
<text top="964" left="477" width="182" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref901">Eur J Cardiothorac Surg 2009;35:641</a></text>
<text top="961" left="659" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref901">–50</a></text>
<text top="964" left="677" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref901">.</a></text>
<text top="977" left="450" width="21" height="12" font="15">906.</text>
<text top="977" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref902">Cheng DC, Ad N, Martin J, et al. Surgical Ablation for Atrial</a></text>
<text top="990" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref902">Fibrillation in Cardiac Surgery: A Meta-Analysis and Systematic</a></text>
<text top="1004" left="477" width="185" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref902">Review. Innovations (Phila) 2010;5:84</a></text>
<text top="1001" left="662" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref902">–96</a></text>
<text top="1004" left="680" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref902">.</a></text>
<text top="1017" left="450" width="21" height="12" font="15">907.</text>
<text top="1017" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref903">Doukas G, Samani NJ, Alexiou C, et al. Left atrial radiofrequency</a></text>
<text top="1031" left="477" width="267" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref903">ablation during mitral valve surgery for continuous atrial</a></text>
<text top="1028" left="747" width="53" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref903">ﬁbrillation:</a></text>
<text top="1044" left="477" width="255" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref903">a randomized controlled trial. JAMA 2005;294:2323</a></text>
<text top="1042" left="732" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref903">–9</a></text>
<text top="1044" left="744" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref903">.</a></text>
<text top="1058" left="450" width="21" height="12" font="15">908.</text>
<text top="1058" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref904">Blomstrom-Lundqvist C, Johansson B, Berglin E, et al.</a></text>
<text top="1071" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref904">A randomized double-blind study of epicardial left atrial cryoa-</a></text>
<text top="1085" left="477" width="130" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref904">blation for permanent atrial</a></text>
<text top="1082" left="609" width="190" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref904">ﬁbrillation in patients undergoing mitral</a></text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e176</text>
</page>
<page number="121" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref904">valve surgery: the SWEDish Multicentre Atrial Fibrillation study</a></text>
<text top="116" left="91" width="206" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref904">(SWEDMAF). Eur Heart J 2007;28:2902</a></text>
<text top="113" left="297" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref904">–8</a></text>
<text top="116" left="309" width="3" height="12" font="15">.</text>
<text top="130" left="64" width="21" height="12" font="15">909.</text>
<text top="130" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref905">Kim R, Baumgartner N, Clements J. Routine left atrial appendage</a></text>
<text top="143" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref905">ligation during cardiac surgery may prevent postoperative atrial</a></text>
<text top="154" left="91" width="323" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref905">ﬁbrillation-related cerebrovascular accident. J Thorac Cardiovasc</a></text>
<text top="170" left="91" width="92" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref905">Surg 2013;145:582</a></text>
<text top="167" left="183" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref905">–9</a></text>
<text top="170" left="195" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref905">.</a></text>
<text top="183" left="64" width="21" height="12" font="15">910.</text>
<text top="183" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref906">Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS</a></text>
<text top="197" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref906">expert consensus statement on catheter and surgical ablation of atrial</a></text>
<text top="208" left="91" width="323" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref906">ﬁbrillation: recommendations for patient selection, procedural</a></text>
<text top="224" left="91" width="253" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref906">techniques, patient management and follow-up, de</a></text>
<text top="221" left="344" width="70" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref906">ﬁnitions, end-</a></text>
<text top="237" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref906">points, and research trial design: a report of the Heart Rhythm</a></text>
<text top="251" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref906">Society (HRS) Task Force on Catheter and Surgical Ablation of</a></text>
<text top="264" left="91" width="220" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref906">Atrial Fibrillation. Heart Rhythm 2012;9:632</a></text>
<text top="261" left="311" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref906">–96</a></text>
<text top="264" left="329" width="3" height="12" font="15">.</text>
<text top="278" left="64" width="21" height="12" font="15">911.</text>
<text top="278" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref907">Lee R, Jivan A, Kruse J, et al. Late neurologic events after surgery</a></text>
<text top="291" left="91" width="42" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref907">for atrial</a></text>
<text top="288" left="137" width="277" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref907">ﬁbrillation: rare but relevant. Ann Thorac Surg 2013;95:</a></text>
<text top="305" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref907">126</a></text>
<text top="302" left="109" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref907">–31</a></text>
<text top="305" left="128" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref907">.</a></text>
<text top="318" left="64" width="21" height="12" font="15">912.</text>
<text top="318" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref908">Lee R, McCarthy PM, Wang EC, et al. Midterm survival in pa-</a></text>
<text top="331" left="91" width="104" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref908">tients treated for atrial</a></text>
<text top="329" left="198" width="216" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref908">ﬁbrillation: a propensity-matched comparison</a></text>
<text top="345" left="91" width="188" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref908">to patients without a history of atrial</a></text>
<text top="342" left="284" width="130" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref908">ﬁbrillation. J Thorac Car-</a></text>
<text top="358" left="91" width="136" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref908">diovasc Surg 2012;143:1341</a></text>
<text top="356" left="227" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref908">–51</a></text>
<text top="358" left="245" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref908">.</a></text>
<text top="372" left="64" width="21" height="12" font="15">913.</text>
<text top="372" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref909">Bando K, Kobayashi J, Hirata M, et al. Early and late stroke after</a></text>
<text top="385" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref909">mitral valve replacement with a mechanical prosthesis: risk factor</a></text>
<text top="399" left="91" width="77" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref909">analysis of a 24</a></text>
<text top="396" left="168" width="246" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref909">–year experience. J Thorac Cardiovasc Surg 2003;</a></text>
<text top="412" left="91" width="39" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref909">126:358</a></text>
<text top="409" left="130" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref909">–64</a></text>
<text top="412" left="148" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref909">.</a></text>
<text top="426" left="64" width="21" height="12" font="15">914.</text>
<text top="426" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref910">Bum KJ, Suk MJ, Yun SC, et al. Long-term outcomes of me-</a></text>
<text top="439" left="91" width="231" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref910">chanical valve replacement in patients with atrial</a></text>
<text top="436" left="326" width="88" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref910">ﬁbrillation: impact</a></text>
<text top="452" left="91" width="244" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref910">of the maze procedure. Circulation 2012;125:2071</a></text>
<text top="450" left="335" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref910">–80</a></text>
<text top="452" left="353" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref910">.</a></text>
<text top="466" left="64" width="21" height="12" font="15">915.</text>
<text top="466" left="91" width="212" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref911">Malaisrie SC, Lee R, Kruse J, et al. Atrial</a></text>
<text top="463" left="308" width="106" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref911">ﬁbrillation ablation in</a></text>
<text top="479" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref911">patients undergoing aortic valve replacement. J Heart Valve Dis</a></text>
<text top="493" left="91" width="60" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref911">2012;21:350</a></text>
<text top="490" left="151" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref911">–7</a></text>
<text top="493" left="163" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref911">.</a></text>
<text top="506" left="64" width="21" height="12" font="15">916.</text>
<text top="506" left="91" width="181" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref912">Liu X, Tan HW, Wang XH, et al. Ef</a></text>
<text top="504" left="272" width="142" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref912">ﬁcacy of catheter ablation and</a></text>
<text top="520" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref912">surgical CryoMaze procedure in patients with long-lasting persistent</a></text>
<text top="533" left="91" width="24" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref912">atrial</a></text>
<text top="530" left="120" width="294" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref912">ﬁbrillation and rheumatic heart disease: a randomized trial.</a></text>
<text top="547" left="91" width="127" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref912">Eur Heart J 2010;31:2633</a></text>
<text top="544" left="218" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref912">–41</a></text>
<text top="547" left="236" width="3" height="12" font="15">.</text>
<text top="560" left="64" width="21" height="12" font="15">917.</text>
<text top="560" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref913">Agarwal S, Rajamanickam A, Bajaj NS, et al. Impact of aortic</a></text>
<text top="574" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref913">stenosis on postoperative outcomes after noncardiac surgeries. Circ</a></text>
<text top="587" left="91" width="190" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref913">Cardiovasc Qual Outcomes 2013;6:193</a></text>
<text top="584" left="281" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref913">–200</a></text>
<text top="587" left="305" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref913">.</a></text>
<text top="600" left="64" width="21" height="12" font="15">918.</text>
<text top="600" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref914">Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index</a></text>
<text top="614" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref914">of cardiac risk in noncardiac surgical procedures. N Engl J Med</a></text>
<text top="627" left="91" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref914">1977;297:845</a></text>
<text top="625" left="157" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref914">–50</a></text>
<text top="627" left="175" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref914">.</a></text>
<text top="641" left="64" width="21" height="12" font="15">919.</text>
<text top="641" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref915">Goldman L. Aortic stenosis in noncardiac surgery: underappreciated</a></text>
<text top="654" left="91" width="235" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref915">in more ways than one? Am J Med 2004;116:60</a></text>
<text top="652" left="326" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref915">–2</a></text>
<text top="654" left="338" width="3" height="12" font="15">.</text>
<text top="668" left="64" width="21" height="12" font="15">920.</text>
<text top="668" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref916">Zahid M, Sonel AF, Saba S, et al. Perioperative risk of noncardiac</a></text>
<text top="681" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref916">surgery associated with aortic stenosis. Am J Cardiol 2005;96:</a></text>
<text top="695" left="91" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref916">436</a></text>
<text top="692" left="110" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref916">–8</a></text>
<text top="695" left="122" width="3" height="12" font="15">.</text>
<text top="708" left="64" width="21" height="12" font="15">921.</text>
<text top="708" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref917">Torsher LC, Shub C, Rettke SR, et al. Risk of patients with severe</a></text>
<text top="721" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref917">aortic stenosis undergoing noncardiac surgery. Am J Cardiol 1998;</a></text>
<text top="735" left="91" width="33" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref917">81:448</a></text>
<text top="732" left="124" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref917">–52</a></text>
<text top="735" left="142" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref917">.</a></text>
<text top="748" left="64" width="21" height="12" font="15">922.</text>
<text top="748" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref918">Calleja AM, Dommaraju S, Gaddam R, et al. Cardiac risk in pa-</a></text>
<text top="762" left="91" width="54" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref918">tients aged</a></text>
<text top="759" left="151" width="263" height="16" font="22">&gt;<a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref918">75 years with asymptomatic, severe aortic stenosis</a></text>
<text top="775" left="91" width="296" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref918">undergoing noncardiac surgery. Am J Cardiol 2010;105:1159</a></text>
<text top="773" left="387" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref918">–63</a></text>
<text top="775" left="405" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref918">.</a></text>
<text top="789" left="64" width="21" height="12" font="15">923.</text>
<text top="789" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref919">Leibowitz D, Rivkin G, Schiffman J, et al. Effect of severe aortic</a></text>
<text top="802" left="91" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref919">stenosis on the outcome in elderly patients undergoing repair of hip</a></text>
<text top="816" left="91" width="166" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref919">fracture. Gerontology 2009;55:303</a></text>
<text top="813" left="258" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref919">–6</a></text>
<text top="816" left="270" width="3" height="12" font="15">.</text>
<text top="103" left="450" width="21" height="12" font="15">924.</text>
<text top="103" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref920">Mittnacht AJ, Fanshawe M, Konstadt S. Anesthetic considerations</a></text>
<text top="116" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref920">in the patient with valvular heart disease undergoing noncardiac</a></text>
<text top="130" left="477" width="260" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref920">surgery. Semin Cardiothorac Vasc Anesth 2008;12:33</a></text>
<text top="127" left="737" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref920">–59</a></text>
<text top="130" left="755" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref920">.</a></text>
<text top="143" left="450" width="21" height="12" font="15">925.</text>
<text top="143" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref921">Christ M, Sharkova Y, Geldner G, et al. Preoperative and periop-</a></text>
<text top="157" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref921">erative care for patients with suspected or established aortic stenosis</a></text>
<text top="170" left="477" width="232" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref921">facing noncardiac surgery. Chest 2005;128:2944</a></text>
<text top="167" left="709" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref921">–53</a></text>
<text top="170" left="727" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref921">.</a></text>
<text top="183" left="450" width="21" height="12" font="15">926.</text>
<text top="183" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref922">Goertz AW, Lindner KH, Seefelder C, et al. Effect of phenyl-</a></text>
<text top="197" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref922">ephrine bolus administration on global left ventricular function in</a></text>
<text top="210" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref922">patients with coronary artery disease and patients with valvular aortic</a></text>
<text top="224" left="477" width="179" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref922">stenosis. Anesthesiology 1993;78:834</a></text>
<text top="221" left="656" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref922">–41</a></text>
<text top="224" left="674" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref922">.</a></text>
<text top="237" left="450" width="21" height="12" font="15">927.</text>
<text top="237" left="477" width="234" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref923">Goertz AW, Lindner KH, Schutz W, et al. In</a></text>
<text top="235" left="711" width="89" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref923">ﬂuence of phenyl-</a></text>
<text top="251" left="477" width="229" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref923">ephrine bolus administration on left ventricular</a></text>
<text top="248" left="710" width="90" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref923">ﬁlling dynamics in</a></text>
<text top="264" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref923">patients with coronary artery disease and patients with valvular aortic</a></text>
<text top="278" left="477" width="173" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref923">stenosis. Anesthesiology 1994;81:49</a></text>
<text top="275" left="650" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref923">–58</a></text>
<text top="278" left="668" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref923">.</a></text>
<text top="291" left="450" width="21" height="12" font="15">928.</text>
<text top="291" left="477" width="10" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref924">O</a></text>
<text top="288" left="486" width="313" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref924">’Keefe JH Jr., Shub C, Rettke SR. Risk of noncardiac surgical</a></text>
<text top="305" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref924">procedures in patients with aortic stenosis. Mayo Clin Proc 1989;64:</a></text>
<text top="318" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref924">400</a></text>
<text top="315" left="495" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref924">–5</a></text>
<text top="318" left="507" width="3" height="12" font="15">.</text>
<text top="331" left="450" width="21" height="12" font="15">929.</text>
<text top="331" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref925">Ho MC, Beathe JC, Sharrock NE. Hypotensive epidural anesthesia</a></text>
<text top="345" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref925">in patients with aortic stenosis undergoing total hip replacement.</a></text>
<text top="358" left="477" width="173" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref925">Reg Anesth Pain Med 2008;33:129</a></text>
<text top="356" left="650" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref925">–33</a></text>
<text top="358" left="668" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref925">.</a></text>
<text top="372" left="450" width="21" height="12" font="15">930.</text>
<text top="372" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref926">Lai HC, Lai HC, Lee WL, et al. Mitral regurgitation complicates</a></text>
<text top="385" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref926">postoperative outcome of noncardiac surgery. Am Heart J 2007;153:</a></text>
<text top="399" left="477" width="18" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref926">712</a></text>
<text top="396" left="495" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref926">–7</a></text>
<text top="399" left="507" width="3" height="12" font="15">.</text>
<text top="412" left="450" width="21" height="12" font="15">931.</text>
<text top="412" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref927">Lai HC, Lai HC, Lee WL, et al. Impact of chronic advanced aortic</a></text>
<text top="426" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref927">regurgitation on the perioperative outcome of noncardiac surgery.</a></text>
<text top="439" left="477" width="183" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref927">Acta Anaesthesiol Scand 2010;54:580</a></text>
<text top="436" left="660" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref927">–8</a></text>
<text top="439" left="672" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref927">.</a></text>
<text top="452" left="450" width="21" height="12" font="15">932.</text>
<text top="452" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref928">Frogel J, Galusca D. Anesthetic considerations for patients with</a></text>
<text top="466" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref928">advanced valvular heart disease undergoing noncardiac surgery.</a></text>
<text top="479" left="477" width="138" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref928">Anesthesiol Clin 2010;28:67</a></text>
<text top="477" left="615" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref928">–85</a></text>
<text top="479" left="633" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref928">.</a></text>
<text top="493" left="450" width="21" height="12" font="15">933.</text>
<text top="493" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref929">Carapetis JR. Rheumatic heart disease in developing countries.</a></text>
<text top="506" left="477" width="141" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref929">N Engl J Med 2007;357:439</a></text>
<text top="504" left="617" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref929">–41</a></text>
<text top="506" left="635" width="3" height="12" font="15">.</text>
<text top="520" left="450" width="21" height="12" font="15">934.</text>
<text top="520" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref930">Soler-Soler J, Galve E. Worldwide perspective of valve disease.</a></text>
<text top="533" left="477" width="91" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref930">Heart 2000;83:721</a></text>
<text top="530" left="568" width="12" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref930">–5</a></text>
<text top="533" left="580" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref930">.</a></text>
<text top="547" left="450" width="21" height="12" font="15">935.</text>
<text top="547" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref931">Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart</a></text>
<text top="560" left="477" width="279" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref931">diseases: a population-based study. Lancet 2006;368:1005</a></text>
<text top="557" left="755" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref931">–11</a></text>
<text top="560" left="773" width="3" height="12" font="15">.</text>
<text top="574" left="450" width="21" height="12" font="15">936.</text>
<text top="574" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref932">Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart</a></text>
<text top="587" left="477" width="131" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref932">disease and stroke statistics</a></text>
<text top="584" left="607" width="192" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref932">–2013 update: a report from the Amer-</a></text>
<text top="600" left="477" width="240" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref932">ican Heart Association. Circulation 2013;127:143</a></text>
<text top="598" left="717" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref932">–52</a></text>
<text top="600" left="734" width="3" height="12" font="15">.</text>
<text top="614" left="450" width="21" height="12" font="15">937.</text>
<text top="614" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref933">Hagler MA, Hadley TM, Zhang H, et al. TGF-beta signalling and</a></text>
<text top="627" left="477" width="143" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref933">reactive oxygen species drive</a></text>
<text top="625" left="626" width="173" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref933">ﬁbrosis and matrix remodelling in</a></text>
<text top="641" left="477" width="267" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref933">myxomatous mitral valves. Cardiovasc Res 2013;99:175</a></text>
<text top="638" left="744" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref933">–84</a></text>
<text top="641" left="762" width="3" height="12" font="15"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref933">.</a></text>
<text top="654" left="450" width="21" height="12" font="15">938.</text>
<text top="654" left="477" width="209" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref934">Miller JD, Weiss RM, Heistad DD. Calci</a></text>
<text top="652" left="686" width="114" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref934">ﬁc aortic valve stenosis:</a></text>
<text top="668" left="477" width="293" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref934">methods, models, and mechanisms. Circ Res 2011;108:1392</a></text>
<text top="665" left="769" width="24" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref934">–412</a></text>
<text top="668" left="793" width="3" height="12" font="15">.</text>
<text top="681" left="450" width="21" height="12" font="15">939.</text>
<text top="681" left="477" width="323" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref935">Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associa-</a></text>
<text top="695" left="477" width="114" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref935">tions with valvular calci</a></text>
<text top="692" left="591" width="209" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref935">ﬁcation and aortic stenosis. N Engl J Med</a></text>
<text top="708" left="477" width="66" height="12" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref935">2013;368:503</a></text>
<text top="705" left="542" width="18" height="16" font="22"><a href="http://refhub.elsevier.com/S0735-1097(14)01279-0/sref935">–12</a></text>
<text top="708" left="560" width="3" height="12" font="15">.</text>
<text top="735" left="450" width="220" height="12" font="15">Key Words: ACC/AHA Practice Guidelines</text>
<text top="736" left="674" width="8" height="10" font="28">-</text>
<text top="735" left="687" width="72" height="12" font="15">anticoagulation</text>
<text top="748" left="450" width="35" height="12" font="15">therapy</text>
<text top="749" left="489" width="8" height="10" font="28">-</text>
<text top="748" left="502" width="92" height="12" font="15">aortic regurgitation</text>
<text top="749" left="598" width="8" height="10" font="28">-</text>
<text top="748" left="611" width="67" height="12" font="15">aortic stenosis</text>
<text top="749" left="682" width="8" height="10" font="28">-</text>
<text top="748" left="695" width="70" height="12" font="15">bicuspid aortic</text>
<text top="762" left="450" width="23" height="12" font="15">valve</text>
<text top="763" left="477" width="8" height="10" font="28">-</text>
<text top="762" left="490" width="71" height="12" font="15">cardiac surgery</text>
<text top="763" left="565" width="8" height="10" font="28">-</text>
<text top="762" left="578" width="55" height="12" font="15">heart valves</text>
<text top="763" left="638" width="8" height="10" font="28">-</text>
<text top="762" left="650" width="101" height="12" font="15">infective endocarditis</text>
<text top="763" left="756" width="8" height="10" font="28">-</text>
<text top="762" left="769" width="28" height="12" font="15">mitral</text>
<text top="775" left="450" width="37" height="12" font="15">stenosis</text>
<text top="776" left="491" width="8" height="10" font="28">-</text>
<text top="775" left="504" width="93" height="12" font="15">mitral regurgitation</text>
<text top="776" left="601" width="8" height="10" font="28">-</text>
<text top="775" left="614" width="78" height="12" font="15">prosthetic valves</text>
<text top="776" left="697" width="8" height="10" font="28">-</text>
<text top="775" left="709" width="45" height="12" font="15">pulmonic</text>
<text top="789" left="450" width="61" height="12" font="15">regurgitation</text>
<text top="789" left="515" width="8" height="10" font="28">-</text>
<text top="789" left="528" width="85" height="12" font="15">pulmonic stenosis</text>
<text top="789" left="618" width="8" height="10" font="28">-</text>
<text top="789" left="630" width="118" height="12" font="15">transcatheter aortic valve</text>
<text top="802" left="450" width="57" height="12" font="15">replacement</text>
<text top="803" left="512" width="8" height="10" font="28">-</text>
<text top="802" left="524" width="82" height="12" font="15">tricuspid stenosis</text>
<text top="803" left="611" width="8" height="10" font="28">-</text>
<text top="802" left="623" width="106" height="12" font="15">tricuspid regurgitation</text>
<text top="803" left="734" width="8" height="10" font="28">-</text>
<text top="802" left="747" width="36" height="12" font="15">valvular</text>
<text top="816" left="450" width="64" height="12" font="15">heart disease.</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e177</text>
</page>
<page number="122" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="627" height="17" font="17">Appendix 1. Author Relationships With Industry and Other Entities (Relevant)d</text>
<text top="122" left="64" width="683" height="14" font="17">2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease</text>
<text top="204" left="64" width="86" height="8" font="14">Committee Member</text>
<text top="204" left="194" width="53" height="8" font="14">Employment</text>
<text top="204" left="293" width="47" height="8" font="14">Consultant</text>
<text top="191" left="354" width="35" height="8" font="14">Speaker</text>
<text top="189" left="389" width="8" height="13" font="14">’s</text>
<text top="204" left="360" width="30" height="8" font="14">Bureau</text>
<text top="179" left="417" width="50" height="8" font="14">Ownership/</text>
<text top="191" left="414" width="55" height="8" font="14">Partnership/</text>
<text top="204" left="423" width="37" height="8" font="14">Principal</text>
<text top="191" left="489" width="37" height="8" font="14">Personal</text>
<text top="204" left="487" width="40" height="8" font="14">Research</text>
<text top="153" left="544" width="55" height="8" font="14">Institutional,</text>
<text top="166" left="539" width="64" height="8" font="14">Organizational,</text>
<text top="179" left="554" width="35" height="8" font="14">or Other</text>
<text top="191" left="552" width="38" height="8" font="14">Financial</text>
<text top="204" left="556" width="22" height="8" font="14">Bene</text>
<text top="201" left="577" width="9" height="13" font="14">ﬁt</text>
<text top="191" left="629" width="28" height="8" font="14">Expert</text>
<text top="204" left="626" width="35" height="8" font="14">Witness</text>
<text top="191" left="706" width="70" height="8" font="14">Voting Recusals</text>
<text top="204" left="716" width="45" height="8" font="14">by <a href="e57.full.html#123">Section</a></text>
<text top="204" left="761" width="6" height="8" font="27"><a href="e57.full.html#123">*</a></text>
<text top="220" left="64" width="77" height="8" font="14">Rick A. Nishimura,</text>
<text top="233" left="77" width="35" height="8" font="14">Co-Chair</text>
<text top="220" left="162" width="85" height="8" font="14">Mayo Clinic, Division</text>
<text top="233" left="174" width="72" height="8" font="14">of Cardiovascular</text>
<text top="246" left="174" width="80" height="10" font="14">DiseasedJudd and</text>
<text top="258" left="174" width="88" height="8" font="14">Mary Morris Leighton</text>
<text top="271" left="174" width="91" height="8" font="14">Professor of Medicine</text>
<text top="220" left="305" width="22" height="8" font="14">None</text>
<text top="220" left="365" width="22" height="8" font="14">None</text>
<text top="220" left="431" width="22" height="8" font="14">None</text>
<text top="220" left="496" width="22" height="8" font="14">None</text>
<text top="219" left="539" width="4" height="11" font="18"></text>
<text top="221" left="550" width="22" height="8" font="14">None</text>
<text top="220" left="632" width="22" height="8" font="14">None</text>
<text top="220" left="730" width="22" height="8" font="14">None</text>
<text top="287" left="64" width="76" height="8" font="14">Catherine M. Otto,</text>
<text top="299" left="77" width="35" height="8" font="14">Co-Chair</text>
<text top="287" left="162" width="105" height="8" font="14">University of Washington,</text>
<text top="299" left="174" width="99" height="10" font="14">Division of Cardiologyd</text>
<text top="312" left="174" width="91" height="8" font="14">Professor of Medicine</text>
<text top="287" left="305" width="22" height="8" font="14">None</text>
<text top="287" left="365" width="22" height="8" font="14">None</text>
<text top="287" left="431" width="22" height="8" font="14">None</text>
<text top="287" left="496" width="22" height="8" font="14">None</text>
<text top="286" left="539" width="4" height="11" font="18"></text>
<text top="287" left="550" width="22" height="8" font="14">None</text>
<text top="287" left="632" width="22" height="8" font="14">None</text>
<text top="287" left="730" width="22" height="8" font="14">None</text>
<text top="327" left="64" width="70" height="8" font="14">Robert O. Bonow</text>
<text top="327" left="162" width="98" height="8" font="14">Northwestern University</text>
<text top="340" left="174" width="73" height="10" font="14">Medical Schoold</text>
<text top="353" left="174" width="96" height="8" font="14">Goldberg Distinguished</text>
<text top="365" left="174" width="39" height="8" font="14">Professor</text>
<text top="327" left="305" width="22" height="8" font="14">None</text>
<text top="327" left="365" width="22" height="8" font="14">None</text>
<text top="327" left="431" width="22" height="8" font="14">None</text>
<text top="327" left="496" width="22" height="8" font="14">None</text>
<text top="326" left="539" width="4" height="11" font="18"></text>
<text top="328" left="550" width="22" height="8" font="14">None</text>
<text top="327" left="632" width="22" height="8" font="14">None</text>
<text top="327" left="730" width="22" height="8" font="14">None</text>
<text top="381" left="64" width="76" height="8" font="14">Blase A. Carabello</text>
<text top="381" left="162" width="86" height="10" font="14">VA Medical Centerd</text>
<text top="394" left="174" width="93" height="8" font="14">Professor of Medicine,</text>
<text top="406" left="174" width="71" height="8" font="14">Baylor College of</text>
<text top="419" left="174" width="37" height="8" font="14">Medicine</text>
<text top="381" left="305" width="22" height="8" font="14">None</text>
<text top="381" left="365" width="22" height="8" font="14">None</text>
<text top="381" left="431" width="22" height="8" font="14">None</text>
<text top="381" left="496" width="22" height="8" font="14">None</text>
<text top="380" left="539" width="4" height="11" font="18"></text>
<text top="381" left="550" width="35" height="8" font="14">Edwards</text>
<text top="392" left="550" width="50" height="8" font="14">Lifesciences</text>
<text top="404" left="550" width="31" height="8" font="14"><a href="e57.full.html#123">(DSMB)</a></text>
<text top="401" left="581" width="4" height="13" font="27"><a href="e57.full.html#123">y</a></text>
<text top="413" left="539" width="4" height="11" font="18"></text>
<text top="415" left="550" width="41" height="8" font="14">Medtronic</text>
<text top="412" left="591" width="4" height="13" font="27"><a href="e57.full.html#123">y</a></text>
<text top="381" left="632" width="22" height="8" font="14">None</text>
<text top="381" left="695" width="104" height="8" font="14">2.4.2, 3.2.3, 3.2.4, 4.3.3,</text>
<text top="394" left="695" width="86" height="8" font="14">5.1.3, 6.2.3, 7.3.1.1,</text>
<text top="406" left="695" width="78" height="8" font="14">7.3.3, 7.4.3, 8.2.3,</text>
<text top="419" left="695" width="95" height="8" font="14">11.1.1, 11.1.2, 11.2.2,</text>
<text top="432" left="695" width="87" height="8" font="14">11.3.2, 11.4, 11.6.1,</text>
<text top="444" left="695" width="95" height="8" font="14">11.6.2, 11.6.3, 11.7.3,</text>
<text top="457" left="695" width="95" height="8" font="14">11.8.3, 12.2.1, 12.2.3,</text>
<text top="470" left="695" width="87" height="8" font="14">13.1, 13.1.2, 13.1.3,</text>
<text top="482" left="695" width="95" height="8" font="14">13.2.1, 13.2.3, 13.3.1,</text>
<text top="495" left="695" width="104" height="8" font="14">13.3.2, 14.1, and 14.2.2.</text>
<text top="511" left="64" width="67" height="8" font="14">John P. Erwin III</text>
<text top="511" left="162" width="104" height="8" font="14">Scott and White Hospital</text>
<text top="523" left="174" width="77" height="10" font="14">and ClinicdSenior</text>
<text top="536" left="174" width="74" height="8" font="14">Staff Cardiologist,</text>
<text top="549" left="174" width="82" height="8" font="14">Associate Professor</text>
<text top="561" left="174" width="48" height="8" font="14">of Medicine</text>
<text top="511" left="305" width="22" height="8" font="14">None</text>
<text top="511" left="365" width="22" height="8" font="14">None</text>
<text top="511" left="431" width="22" height="8" font="14">None</text>
<text top="511" left="496" width="22" height="8" font="14">None</text>
<text top="510" left="539" width="4" height="11" font="18"></text>
<text top="511" left="550" width="22" height="8" font="14">None</text>
<text top="511" left="632" width="22" height="8" font="14">None</text>
<text top="511" left="730" width="22" height="8" font="14">None</text>
<text top="577" left="64" width="71" height="8" font="14">Robert A. Guyton</text>
<text top="577" left="162" width="81" height="10" font="14">Emory Clinic, Inc.d</text>
<text top="589" left="174" width="84" height="8" font="14">Professor and Chief,</text>
<text top="602" left="174" width="43" height="8" font="14">Division of</text>
<text top="615" left="174" width="59" height="8" font="14">Cardiothoracic</text>
<text top="628" left="174" width="31" height="8" font="14">Surgery</text>
<text top="576" left="290" width="4" height="11" font="18"></text>
<text top="577" left="301" width="41" height="8" font="14">Medtronic</text>
<text top="577" left="365" width="22" height="8" font="14">None</text>
<text top="577" left="431" width="22" height="8" font="14">None</text>
<text top="577" left="496" width="22" height="8" font="14">None</text>
<text top="576" left="539" width="4" height="11" font="18"></text>
<text top="577" left="550" width="22" height="8" font="14">None</text>
<text top="576" left="615" width="4" height="11" font="18"></text>
<text top="577" left="626" width="45" height="8" font="14">Defendant,</text>
<text top="588" left="626" width="31" height="8" font="14">Cardiac</text>
<text top="600" left="626" width="33" height="8" font="14">Surgery,</text>
<text top="611" left="626" width="23" height="8" font="14">2013</text>
<text top="577" left="695" width="104" height="8" font="14">2.4.2, 3.2.3, 3.2.4, 4.3.3,</text>
<text top="589" left="695" width="86" height="8" font="14">5.1.3, 6.2.3, 7.3.1.1,</text>
<text top="602" left="695" width="78" height="8" font="14">7.3.3, 7.4.3, 8.2.3,</text>
<text top="615" left="695" width="95" height="8" font="14">11.1.1, 11.1.2, 11.2.2,</text>
<text top="628" left="695" width="87" height="8" font="14">11.3.2, 11.4, 11.6.1,</text>
<text top="640" left="695" width="95" height="8" font="14">11.6.2, 11.6.3, 11.7.3,</text>
<text top="653" left="695" width="95" height="8" font="14">11.8.3, 12.2.1, 12.2.3,</text>
<text top="666" left="695" width="87" height="8" font="14">13.1, 13.1.2, 13.1.3,</text>
<text top="678" left="695" width="95" height="8" font="14">13.2.1, 13.2.3, 13.3.1,</text>
<text top="691" left="695" width="104" height="8" font="14">13.3.2, 14.1, and 14.2.2.</text>
<text top="706" left="64" width="49" height="8" font="14">Patrick T. O</text>
<text top="704" left="113" width="22" height="13" font="14">’Gara</text>
<text top="706" left="162" width="89" height="8" font="14">Brigham and Women</text>
<text top="704" left="251" width="7" height="13" font="14">’s</text>
<text top="719" left="174" width="82" height="10" font="14">HospitaldProfessor</text>
<text top="732" left="174" width="86" height="8" font="14">of Medicine; Harvard</text>
<text top="745" left="174" width="73" height="10" font="14">Medical Schoold</text>
<text top="757" left="174" width="76" height="8" font="14">Director of Clinical</text>
<text top="770" left="174" width="43" height="8" font="14">Cardiology</text>
<text top="706" left="305" width="22" height="8" font="14">None</text>
<text top="706" left="365" width="22" height="8" font="14">None</text>
<text top="706" left="431" width="22" height="8" font="14">None</text>
<text top="706" left="496" width="22" height="8" font="14">None</text>
<text top="706" left="539" width="4" height="11" font="18"></text>
<text top="707" left="550" width="22" height="8" font="14">None</text>
<text top="706" left="632" width="22" height="8" font="14">None</text>
<text top="706" left="730" width="22" height="8" font="14">None</text>
<text top="785" left="64" width="57" height="8" font="14">Carlos E. Ruiz</text>
<text top="785" left="162" width="85" height="8" font="14">Lenox Hill Heart and</text>
<text top="798" left="174" width="83" height="8" font="14">Vascular Institute of</text>
<text top="811" left="174" width="88" height="10" font="14">New YorkdProfessor</text>
<text top="823" left="174" width="89" height="8" font="14">and Chief, Division of</text>
<text top="836" left="174" width="82" height="8" font="14">Pediatric Cardiology</text>
<text top="785" left="305" width="22" height="8" font="14">None</text>
<text top="785" left="365" width="22" height="8" font="14">None</text>
<text top="785" left="431" width="22" height="8" font="14">None</text>
<text top="785" left="496" width="22" height="8" font="14">None</text>
<text top="784" left="539" width="4" height="11" font="18"></text>
<text top="786" left="550" width="22" height="8" font="14">None</text>
<text top="785" left="632" width="22" height="8" font="14">None</text>
<text top="785" left="730" width="22" height="8" font="14">None</text>
<text top="852" left="64" width="78" height="8" font="14">Nikolaos J. Skubas</text>
<text top="852" left="162" width="88" height="8" font="14">Weill Cornell Medical</text>
<text top="864" left="174" width="79" height="10" font="14">CollegedAssociate</text>
<text top="877" left="174" width="50" height="8" font="14">Professor of</text>
<text top="890" left="174" width="81" height="8" font="14">Anesthesiology and</text>
<text top="902" left="174" width="78" height="8" font="14">Director of Cardiac</text>
<text top="915" left="174" width="45" height="8" font="14">Anesthesia</text>
<text top="852" left="305" width="22" height="8" font="14">None</text>
<text top="852" left="365" width="22" height="8" font="14">None</text>
<text top="852" left="431" width="22" height="8" font="14">None</text>
<text top="852" left="496" width="22" height="8" font="14">None</text>
<text top="851" left="539" width="4" height="11" font="18"></text>
<text top="852" left="550" width="22" height="8" font="14">None</text>
<text top="852" left="632" width="22" height="8" font="14">None</text>
<text top="852" left="730" width="22" height="8" font="14">None</text>
<text top="932" left="697" width="102" height="7" font="18">Continued on the next page</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e178</text>
</page>
<page number="123" position="absolute" top="0" left="0" height="1160" width="864">
<text top="709" left="64" width="647" height="17" font="17">Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant)d</text>
<text top="729" left="64" width="683" height="14" font="17">2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease</text>
<text top="107" left="64" width="180" height="14" font="17">Appendix 1. Continued</text>
<text top="197" left="64" width="86" height="8" font="14">Committee Member</text>
<text top="197" left="194" width="53" height="8" font="14">Employment</text>
<text top="197" left="293" width="47" height="8" font="14">Consultant</text>
<text top="184" left="354" width="35" height="8" font="14">Speaker</text>
<text top="181" left="389" width="8" height="13" font="14">’s</text>
<text top="197" left="360" width="30" height="8" font="14">Bureau</text>
<text top="171" left="417" width="50" height="8" font="14">Ownership/</text>
<text top="184" left="414" width="55" height="8" font="14">Partnership/</text>
<text top="197" left="423" width="37" height="8" font="14">Principal</text>
<text top="184" left="489" width="37" height="8" font="14">Personal</text>
<text top="197" left="487" width="40" height="8" font="14">Research</text>
<text top="146" left="544" width="55" height="8" font="14">Institutional,</text>
<text top="158" left="539" width="64" height="8" font="14">Organizational,</text>
<text top="171" left="554" width="35" height="8" font="14">or Other</text>
<text top="184" left="552" width="38" height="8" font="14">Financial</text>
<text top="197" left="556" width="22" height="8" font="14">Bene</text>
<text top="194" left="577" width="9" height="13" font="14">ﬁt</text>
<text top="184" left="629" width="28" height="8" font="14">Expert</text>
<text top="197" left="626" width="35" height="8" font="14">Witness</text>
<text top="184" left="706" width="70" height="8" font="14">Voting Recusals</text>
<text top="197" left="716" width="45" height="8" font="14">by <a href="e57.full.html#123">Section</a></text>
<text top="197" left="761" width="6" height="8" font="27"><a href="e57.full.html#123">*</a></text>
<text top="213" left="64" width="50" height="8" font="14">Paul Sorajja</text>
<text top="213" left="162" width="97" height="10" font="14">Mayo ClinicdAssociate</text>
<text top="226" left="174" width="91" height="8" font="14">Professor of Medicine</text>
<text top="213" left="305" width="22" height="8" font="14">None</text>
<text top="213" left="365" width="22" height="8" font="14">None</text>
<text top="212" left="409" width="4" height="11" font="18"></text>
<text top="213" left="419" width="46" height="8" font="14">Intellectual</text>
<text top="224" left="419" width="45" height="8" font="14">property in</text>
<text top="236" left="419" width="40" height="8" font="14">patent on</text>
<text top="247" left="419" width="56" height="8" font="14">percutaneous</text>
<text top="258" left="419" width="41" height="8" font="14">closure of</text>
<text top="269" left="419" width="50" height="8" font="14">paravalvular</text>
<text top="280" left="419" width="41" height="8" font="14">prosthetic</text>
<text top="292" left="419" width="52" height="8" font="14">regurgitation</text>
<text top="213" left="496" width="22" height="8" font="14">None</text>
<text top="212" left="539" width="4" height="11" font="18"></text>
<text top="213" left="550" width="22" height="8" font="14">None</text>
<text top="213" left="632" width="22" height="8" font="14">None</text>
<text top="213" left="730" width="22" height="8" font="14">None</text>
<text top="307" left="64" width="80" height="8" font="14">Thoralf M. Sundt III</text>
<text top="307" left="162" width="97" height="8" font="14">Massachusetts General</text>
<text top="320" left="174" width="67" height="10" font="14">HospitaldChief,</text>
<text top="332" left="174" width="66" height="8" font="14">Division Cardiac</text>
<text top="345" left="174" width="31" height="8" font="14">Surgery</text>
<text top="306" left="290" width="4" height="11" font="18"></text>
<text top="307" left="301" width="33" height="8" font="14">St. Jude</text>
<text top="319" left="301" width="32" height="8" font="14">Medical</text>
<text top="307" left="365" width="22" height="8" font="14">None</text>
<text top="307" left="431" width="22" height="8" font="14">None</text>
<text top="307" left="496" width="22" height="8" font="14">None</text>
<text top="306" left="539" width="4" height="11" font="18"></text>
<text top="307" left="550" width="22" height="8" font="14">None</text>
<text top="306" left="615" width="4" height="11" font="18"></text>
<text top="307" left="626" width="24" height="8" font="14">AATS,</text>
<text top="319" left="626" width="38" height="8" font="14">Secretary-</text>
<text top="330" left="626" width="19" height="8" font="14">Elect</text>
<text top="307" left="695" width="104" height="8" font="14">2.4.2, 3.2.3, 3.2.4, 4.3.3,</text>
<text top="320" left="695" width="86" height="8" font="14">5.1.3, 6.2.3, 7.3.1.1,</text>
<text top="332" left="695" width="78" height="8" font="14">7.3.3, 7.4.3, 8.2.3,</text>
<text top="345" left="695" width="95" height="8" font="14">11.1.1, 11.1.2, 11.2.2,</text>
<text top="358" left="695" width="87" height="8" font="14">11.3.2, 11.4, 11.6.1,</text>
<text top="371" left="695" width="95" height="8" font="14">11.6.2, 11.6.3, 11.7.3,</text>
<text top="383" left="695" width="95" height="8" font="14">11.8.3, 12.2.1, 12.2.3,</text>
<text top="396" left="695" width="87" height="8" font="14">13.1, 13.1.2, 13.1.3,</text>
<text top="409" left="695" width="95" height="8" font="14">13.2.1, 13.2.3, 13.3.1,</text>
<text top="421" left="695" width="104" height="8" font="14">13.3.2, 14.1, and 14.2.2.</text>
<text top="437" left="64" width="74" height="8" font="14">James D. Thomas</text>
<text top="437" left="162" width="75" height="10" font="14">Cleveland Clinicd</text>
<text top="449" left="174" width="50" height="8" font="14">Professor of</text>
<text top="462" left="174" width="56" height="8" font="14">Medicine and</text>
<text top="475" left="174" width="46" height="8" font="14">Biomedical</text>
<text top="488" left="174" width="48" height="8" font="14">Engineering</text>
<text top="437" left="305" width="22" height="8" font="14">None</text>
<text top="437" left="365" width="22" height="8" font="14">None</text>
<text top="437" left="431" width="22" height="8" font="14">None</text>
<text top="437" left="496" width="22" height="8" font="14">None</text>
<text top="436" left="539" width="4" height="11" font="18"></text>
<text top="437" left="550" width="22" height="8" font="14">None</text>
<text top="437" left="632" width="22" height="8" font="14">None</text>
<text top="437" left="730" width="22" height="8" font="14">None</text>
<text top="510" left="64" width="735" height="8" font="18">This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in</text>
<text top="522" left="64" width="571" height="8" font="18">conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily re</text>
<text top="519" left="635" width="165" height="11" font="18">ﬂect relationships with industry at the time of</text>
<text top="534" left="64" width="174" height="8" font="18">publication. A person is deemed to have a signi</text>
<text top="531" left="238" width="561" height="11" font="18">ﬁcant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $10,000 of</text>
<text top="545" left="64" width="476" height="8" font="18">the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person</text>
<text top="543" left="540" width="259" height="11" font="18">’s gross income for the previous year. Relationships that exist with no</text>
<text top="555" left="64" width="486" height="11" font="18">ﬁnancial beneﬁt are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.</text>
<text top="569" left="64" width="735" height="9" font="18">According to the ACC/AHA, a person has a relevant relationship IF: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in</text>
<text top="581" left="64" width="735" height="9" font="18">the document; or b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the</text>
<text top="594" left="64" width="735" height="9" font="18">document; or c) The person or a member of the person’s household, has a reasonable potential for ﬁnancial, professional or other personal gain or loss as a result of the issues/content addressed in the</text>
<text top="605" left="64" width="39" height="9" font="18">document.</text>
<text top="617" left="64" width="396" height="8" font="18">*Writing committee members are required to recuse themselves from voting on sections to which their speci</text>
<text top="615" left="461" width="339" height="11" font="18">ﬁc relationships with industry and other entities may apply. Section numbers pertain to those</text>
<text top="629" left="64" width="89" height="8" font="18">in the full-text guideline.</text>
<text top="639" left="64" width="78" height="11" font="18"><a href="e57.full.html#123">y</a>No ﬁnancial beneﬁt.</text>
<text top="653" left="73" width="451" height="8" font="18">AATS indicates American Association of Thoracic Surgery; DSMB, data safety monitoring board; and VA, Veterans Affairs.</text>
<text top="806" left="64" width="33" height="7" font="18">Reviewer</text>
<text top="806" left="150" width="55" height="7" font="18">Representation</text>
<text top="806" left="243" width="45" height="7" font="18">Employment</text>
<text top="806" left="332" width="40" height="7" font="18">Consultant</text>
<text top="795" left="409" width="30" height="7" font="18">Speaker</text>
<text top="793" left="439" width="6" height="11" font="18">’s</text>
<text top="806" left="414" width="26" height="7" font="18">Bureau</text>
<text top="784" left="479" width="43" height="7" font="18">Ownership/</text>
<text top="795" left="477" width="46" height="7" font="18">Partnership/</text>
<text top="806" left="485" width="31" height="7" font="18">Principal</text>
<text top="795" left="567" width="31" height="7" font="18">Personal</text>
<text top="806" left="566" width="34" height="7" font="18">Research</text>
<text top="761" left="650" width="46" height="7" font="18">Institutional,</text>
<text top="772" left="646" width="54" height="7" font="18">Organizational,</text>
<text top="784" left="658" width="30" height="7" font="18">or Other</text>
<text top="795" left="657" width="32" height="7" font="18">Financial</text>
<text top="806" left="660" width="18" height="7" font="18">Bene</text>
<text top="804" left="679" width="8" height="11" font="18">ﬁt</text>
<text top="795" left="750" width="24" height="7" font="18">Expert</text>
<text top="806" left="748" width="29" height="7" font="18">Witness</text>
<text top="821" left="64" width="40" height="7" font="18">Blair D. Erb</text>
<text top="821" left="142" width="8" height="7" font="18">Of</text>
<text top="819" left="150" width="59" height="11" font="18">ﬁcial Reviewerd</text>
<text top="832" left="154" width="38" height="7" font="18">ACC Board</text>
<text top="843" left="154" width="39" height="7" font="18">of Trustees</text>
<text top="821" left="225" width="33" height="7" font="18">Bozeman</text>
<text top="832" left="238" width="38" height="7" font="18">Deaconess</text>
<text top="843" left="238" width="36" height="7" font="18">Cardiology</text>
<text top="854" left="238" width="49" height="8" font="18">Consultantsd</text>
<text top="866" left="238" width="33" height="7" font="18">Physician</text>
<text top="821" left="317" width="18" height="7" font="18">None</text>
<text top="821" left="398" width="18" height="7" font="18">None</text>
<text top="821" left="468" width="18" height="7" font="18">None</text>
<text top="821" left="544" width="18" height="7" font="18">None</text>
<text top="820" left="633" width="45" height="11" font="18"> Medtronic</text>
<text top="821" left="725" width="18" height="7" font="18">None</text>
<text top="880" left="64" width="27" height="7" font="18">Mario J.</text>
<text top="891" left="77" width="22" height="7" font="18">Garcia</text>
<text top="880" left="142" width="8" height="7" font="18">Of</text>
<text top="877" left="150" width="59" height="11" font="18">ﬁcial Reviewerd</text>
<text top="891" left="154" width="15" height="7" font="18">AHA</text>
<text top="880" left="225" width="22" height="7" font="18">Monte</text>
<text top="877" left="247" width="16" height="11" font="18">ﬁore</text>
<text top="891" left="238" width="55" height="7" font="18">Medical Center-</text>
<text top="902" left="238" width="51" height="7" font="18">Albert Einstein</text>
<text top="913" left="238" width="35" height="7" font="18">College of</text>
<text top="924" left="238" width="40" height="8" font="18">Medicined</text>
<text top="936" left="238" width="50" height="7" font="18">Chief, Division</text>
<text top="947" left="238" width="46" height="7" font="18">of Cardiology</text>
<text top="880" left="317" width="18" height="7" font="18">None</text>
<text top="880" left="398" width="18" height="7" font="18">None</text>
<text top="880" left="468" width="18" height="7" font="18">None</text>
<text top="880" left="544" width="18" height="7" font="18">None</text>
<text top="879" left="633" width="45" height="11" font="18"> <a href="e57.full.html#128">Medtronic</a></text>
<text top="879" left="678" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="890" left="633" width="30" height="11" font="18"> Pﬁzer</text>
<text top="880" left="725" width="18" height="7" font="18">None</text>
<text top="961" left="64" width="45" height="7" font="18">Smadar Kort</text>
<text top="961" left="142" width="8" height="7" font="18">Of</text>
<text top="958" left="150" width="59" height="11" font="18">ﬁcial Reviewerd</text>
<text top="972" left="154" width="38" height="7" font="18">ACC Board</text>
<text top="983" left="154" width="45" height="7" font="18">of Governors</text>
<text top="961" left="225" width="79" height="7" font="18">Stony Brook University</text>
<text top="972" left="238" width="61" height="8" font="18">Medical Centerd</text>
<text top="983" left="238" width="61" height="7" font="18">Clinical Professor</text>
<text top="994" left="238" width="43" height="7" font="18">of Medicine;</text>
<text top="1006" left="238" width="29" height="7" font="18">Director,</text>
<text top="1017" left="238" width="62" height="7" font="18">Echocardiography</text>
<text top="1028" left="238" width="39" height="7" font="18">Laboratory;</text>
<text top="1039" left="238" width="29" height="7" font="18">Director,</text>
<text top="1050" left="238" width="51" height="7" font="18">Cardiovascular</text>
<text top="1062" left="238" width="28" height="7" font="18">Imaging</text>
<text top="961" left="317" width="18" height="7" font="18">None</text>
<text top="961" left="398" width="18" height="7" font="18">None</text>
<text top="961" left="468" width="18" height="7" font="18">None</text>
<text top="961" left="544" width="18" height="7" font="18">None</text>
<text top="960" left="633" width="30" height="11" font="18"> Pﬁzer</text>
<text top="961" left="725" width="18" height="7" font="18">None</text>
<text top="1076" left="697" width="102" height="7" font="18">Continued on the next page</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e179</text>
</page>
<page number="124" position="absolute" top="0" left="0" height="1160" width="864">
<text top="107" left="64" width="180" height="14" font="17">Appendix 2. Continued</text>
<text top="190" left="64" width="33" height="7" font="18">Reviewer</text>
<text top="190" left="150" width="55" height="7" font="18">Representation</text>
<text top="190" left="243" width="45" height="7" font="18">Employment</text>
<text top="190" left="332" width="40" height="7" font="18">Consultant</text>
<text top="179" left="409" width="30" height="7" font="18">Speaker</text>
<text top="177" left="439" width="6" height="11" font="18">’s</text>
<text top="190" left="414" width="26" height="7" font="18">Bureau</text>
<text top="168" left="479" width="43" height="7" font="18">Ownership/</text>
<text top="179" left="477" width="46" height="7" font="18">Partnership/</text>
<text top="190" left="485" width="31" height="7" font="18">Principal</text>
<text top="179" left="567" width="31" height="7" font="18">Personal</text>
<text top="190" left="566" width="34" height="7" font="18">Research</text>
<text top="145" left="650" width="46" height="7" font="18">Institutional,</text>
<text top="157" left="646" width="54" height="7" font="18">Organizational,</text>
<text top="168" left="658" width="30" height="7" font="18">or Other</text>
<text top="179" left="657" width="32" height="7" font="18">Financial</text>
<text top="190" left="660" width="18" height="7" font="18">Bene</text>
<text top="188" left="679" width="8" height="11" font="18">ﬁt</text>
<text top="179" left="750" width="24" height="7" font="18">Expert</text>
<text top="190" left="748" width="29" height="7" font="18">Witness</text>
<text top="205" left="64" width="62" height="7" font="18">Richard J. Kovacs</text>
<text top="205" left="142" width="8" height="7" font="18">Of</text>
<text top="203" left="150" width="59" height="11" font="18">ﬁcial Reviewerd</text>
<text top="216" left="154" width="33" height="7" font="18">ACC/AHA</text>
<text top="227" left="154" width="38" height="7" font="18">Task Force</text>
<text top="239" left="154" width="40" height="7" font="18">on Practice</text>
<text top="250" left="154" width="36" height="7" font="18">Guidelines</text>
<text top="205" left="225" width="70" height="8" font="18">Indiana Universityd</text>
<text top="216" left="238" width="55" height="7" font="18">Clinical Director</text>
<text top="227" left="238" width="49" height="7" font="18">and Professor</text>
<text top="239" left="238" width="35" height="7" font="18">of Clinical</text>
<text top="250" left="238" width="33" height="7" font="18">Medicine,</text>
<text top="261" left="238" width="30" height="7" font="18">Krannert</text>
<text top="272" left="238" width="38" height="7" font="18">Institute of</text>
<text top="283" left="238" width="38" height="7" font="18">Cardiology;</text>
<text top="295" left="238" width="67" height="7" font="18">Associate Dean for</text>
<text top="306" left="238" width="60" height="7" font="18">Clinical Research</text>
<text top="204" left="317" width="49" height="11" font="18"> Biomedical</text>
<text top="218" left="328" width="29" height="7" font="18">Systems</text>
<text top="227" left="317" width="34" height="11" font="18"> Insight</text>
<text top="240" left="328" width="58" height="7" font="18">Pharmaceuticals</text>
<text top="249" left="317" width="50" height="11" font="18"> Theravance</text>
<text top="252" left="368" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="205" left="398" width="18" height="7" font="18">None</text>
<text top="205" left="468" width="18" height="7" font="18">None</text>
<text top="205" left="544" width="18" height="7" font="18">None</text>
<text top="204" left="633" width="28" height="11" font="18"> Cook</text>
<text top="218" left="644" width="46" height="7" font="18">Incorporated-</text>
<text top="229" left="644" width="15" height="7" font="18">Med</text>
<text top="240" left="644" width="28" height="7" font="18"><a href="e57.full.html#128">Institute</a></text>
<text top="240" left="672" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="249" left="633" width="35" height="11" font="18"> Eli <a href="e57.full.html#128">Lilly</a></text>
<text top="252" left="668" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="263" left="644" width="26" height="7" font="18">(DSMB)</text>
<text top="205" left="725" width="18" height="7" font="18">None</text>
<text top="320" left="64" width="57" height="7" font="18">David H. Adams</text>
<text top="320" left="142" width="50" height="7" font="18">Organizational</text>
<text top="331" left="154" width="40" height="8" font="18">Reviewerd</text>
<text top="342" left="154" width="18" height="7" font="18">AATS</text>
<text top="320" left="225" width="57" height="7" font="18">The Mount Sinai</text>
<text top="331" left="238" width="61" height="8" font="18">Medical Centerd</text>
<text top="342" left="238" width="57" height="7" font="18">Marie-Josée and</text>
<text top="353" left="238" width="54" height="7" font="18">Henry R. Kravis</text>
<text top="365" left="238" width="35" height="7" font="18">Professor;</text>
<text top="376" left="238" width="36" height="7" font="18">Chairman,</text>
<text top="387" left="238" width="51" height="7" font="18">Department of</text>
<text top="398" left="238" width="50" height="7" font="18">Cardiothoracic</text>
<text top="409" left="238" width="26" height="7" font="18">Surgery</text>
<text top="320" left="317" width="18" height="7" font="18">None</text>
<text top="320" left="398" width="18" height="7" font="18">None</text>
<text top="320" left="468" width="18" height="7" font="18">None</text>
<text top="320" left="544" width="18" height="7" font="18">None</text>
<text top="319" left="633" width="36" height="11" font="18"> Edward</text>
<text top="333" left="644" width="43" height="7" font="18"><a href="e57.full.html#128">Lifesciences</a></text>
<text top="333" left="686" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="342" left="633" width="45" height="11" font="18"> Medtronic</text>
<text top="320" left="725" width="18" height="7" font="18">None</text>
<text top="423" left="64" width="64" height="7" font="18">Howard Herrmann</text>
<text top="423" left="142" width="50" height="7" font="18">Organizational</text>
<text top="434" left="154" width="40" height="8" font="18">Reviewerd</text>
<text top="446" left="154" width="16" height="7" font="18">SCAI</text>
<text top="423" left="225" width="43" height="7" font="18">University of</text>
<text top="434" left="238" width="46" height="7" font="18">Pennsylvania</text>
<text top="446" left="238" width="68" height="7" font="18">Perelman School of</text>
<text top="457" left="238" width="40" height="8" font="18">Medicined</text>
<text top="468" left="238" width="42" height="7" font="18">Professor of</text>
<text top="479" left="238" width="66" height="7" font="18">Medicine; Director,</text>
<text top="490" left="238" width="48" height="7" font="18">Interventional</text>
<text top="502" left="238" width="36" height="7" font="18">Cardiology</text>
<text top="513" left="238" width="30" height="7" font="18">Program</text>
<text top="423" left="317" width="35" height="11" font="18"> Paieon</text>
<text top="434" left="317" width="41" height="11" font="18"> Siemens</text>
<text top="447" left="328" width="27" height="7" font="18">Medical</text>
<text top="456" left="317" width="38" height="11" font="18"> St. Jude</text>
<text top="470" left="328" width="27" height="7" font="18">Medical</text>
<text top="423" left="398" width="18" height="7" font="18">None</text>
<text top="423" left="468" width="32" height="11" font="18"> Micro-</text>
<text top="436" left="478" width="48" height="7" font="18">Interventional</text>
<text top="447" left="478" width="27" height="7" font="18"><a href="e57.full.html#128">Devices</a></text>
<text top="447" left="505" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="423" left="544" width="33" height="11" font="18"> Abbott</text>
<text top="436" left="555" width="30" height="7" font="18"><a href="e57.full.html#128">Vascular</a></text>
<text top="436" left="584" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="445" left="544" width="36" height="11" font="18"> Edward</text>
<text top="459" left="555" width="43" height="7" font="18"><a href="e57.full.html#128">Lifesciences</a></text>
<text top="459" left="598" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="468" left="544" width="45" height="11" font="18"> Medtronic</text>
<text top="468" left="590" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="479" left="544" width="41" height="11" font="18"> Siemens</text>
<text top="492" left="555" width="27" height="7" font="18"><a href="e57.full.html#128">Medical</a></text>
<text top="492" left="582" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="501" left="544" width="38" height="11" font="18"> St. Jude</text>
<text top="515" left="555" width="27" height="7" font="18">Medical</text>
<text top="524" left="544" width="57" height="11" font="18"> WL Gore and</text>
<text top="537" left="555" width="37" height="7" font="18">Associates</text>
<text top="423" left="633" width="29" height="11" font="18"> None</text>
<text top="423" left="725" width="18" height="7" font="18">None</text>
<text top="551" left="64" width="57" height="7" font="18">Sunil V. Mankad</text>
<text top="551" left="142" width="50" height="7" font="18">Organizational</text>
<text top="562" left="154" width="40" height="8" font="18">Reviewerd</text>
<text top="573" left="154" width="14" height="7" font="18">ASE</text>
<text top="551" left="225" width="48" height="8" font="18">Mayo Clinicd</text>
<text top="562" left="238" width="68" height="7" font="18">Associate Professor</text>
<text top="573" left="238" width="41" height="7" font="18">of Medicine</text>
<text top="551" left="317" width="18" height="7" font="18">None</text>
<text top="551" left="398" width="18" height="7" font="18">None</text>
<text top="551" left="468" width="18" height="7" font="18">None</text>
<text top="551" left="544" width="18" height="7" font="18">None</text>
<text top="550" left="633" width="29" height="11" font="18"> None</text>
<text top="551" left="725" width="18" height="7" font="18">None</text>
<text top="587" left="64" width="60" height="7" font="18">Patrick McCarthy</text>
<text top="587" left="142" width="50" height="7" font="18">Organizational</text>
<text top="599" left="154" width="40" height="8" font="18">Reviewerd</text>
<text top="610" left="154" width="13" height="7" font="18">STS</text>
<text top="587" left="225" width="47" height="7" font="18">Northwestern</text>
<text top="599" left="238" width="68" height="7" font="18">University, Feinberg</text>
<text top="610" left="238" width="33" height="7" font="18">School of</text>
<text top="621" left="238" width="40" height="8" font="18">Medicined</text>
<text top="632" left="238" width="60" height="7" font="18">Surgical Director,</text>
<text top="643" left="238" width="23" height="7" font="18">Bluhm</text>
<text top="655" left="238" width="51" height="7" font="18">Cardiovascular</text>
<text top="666" left="238" width="28" height="7" font="18">Institute</text>
<text top="587" left="317" width="33" height="11" font="18"> Abbott</text>
<text top="600" left="328" width="30" height="7" font="18"><a href="e57.full.html#128">Vascular</a></text>
<text top="600" left="357" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="609" left="317" width="33" height="11" font="18"> Baxter</text>
<text top="620" left="317" width="36" height="11" font="18"> Edward</text>
<text top="634" left="328" width="43" height="7" font="18"><a href="e57.full.html#128">Lifesciences</a></text>
<text top="634" left="370" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="587" left="398" width="18" height="7" font="18">None</text>
<text top="587" left="468" width="41" height="11" font="18"> Cardious</text>
<text top="598" left="468" width="36" height="11" font="18"> Edward</text>
<text top="612" left="478" width="43" height="7" font="18">Lifesciences</text>
<text top="612" left="521" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="620" left="468" width="41" height="11" font="18"> MiCardia</text>
<text top="587" left="544" width="18" height="7" font="18">None</text>
<text top="587" left="633" width="50" height="11" font="18"> Direct Flow</text>
<text top="587" left="725" width="18" height="7" font="18">None</text>
<text top="680" left="64" width="37" height="7" font="18">Stanton K.</text>
<text top="691" left="77" width="29" height="7" font="18">Shernan</text>
<text top="680" left="142" width="50" height="7" font="18">Organizational</text>
<text top="691" left="154" width="40" height="8" font="18">Reviewerd</text>
<text top="702" left="154" width="14" height="7" font="18">SCA</text>
<text top="680" left="225" width="75" height="7" font="18">Brigham and Women</text>
<text top="677" left="300" width="6" height="11" font="18">’s</text>
<text top="691" left="238" width="28" height="7" font="18">Hospital</text>
<text top="680" left="317" width="18" height="7" font="18">None</text>
<text top="679" left="398" width="34" height="11" font="18"> Philips</text>
<text top="693" left="408" width="38" height="7" font="18">Healthcare</text>
<text top="680" left="468" width="18" height="7" font="18">None</text>
<text top="680" left="544" width="18" height="7" font="18">None</text>
<text top="679" left="633" width="40" height="11" font="18"> National</text>
<text top="693" left="644" width="30" height="7" font="18">Board of</text>
<text top="704" left="644" width="62" height="7" font="18">Echocardiography</text>
<text top="715" left="644" width="8" height="7" font="18">Of</text>
<text top="713" left="651" width="15" height="11" font="18">ﬁ<a href="e57.full.html#128">cer</a></text>
<text top="713" left="666" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="679" left="725" width="49" height="11" font="18"> Defendant,</text>
<text top="693" left="736" width="64" height="7" font="18">Echocardiography,</text>
<text top="704" left="736" width="19" height="7" font="18">2012</text>
<text top="729" left="64" width="33" height="7" font="18">Mouaz H.</text>
<text top="740" left="77" width="32" height="7" font="18">Al-Mallah</text>
<text top="729" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="740" left="154" width="47" height="7" font="18">Prevention of</text>
<text top="751" left="154" width="51" height="7" font="18">Cardiovascular</text>
<text top="763" left="154" width="28" height="7" font="18">Disease</text>
<text top="774" left="154" width="39" height="7" font="18">Committee</text>
<text top="729" left="225" width="54" height="7" font="18">King Abdul-Aziz</text>
<text top="740" left="238" width="26" height="7" font="18">Cardiac</text>
<text top="751" left="238" width="31" height="8" font="18">Centerd</text>
<text top="763" left="238" width="68" height="7" font="18">Associate Professor</text>
<text top="774" left="238" width="41" height="7" font="18">of Medicine</text>
<text top="729" left="317" width="34" height="11" font="18"> Bracco</text>
<text top="729" left="398" width="18" height="7" font="18">None</text>
<text top="729" left="468" width="18" height="7" font="18">None</text>
<text top="729" left="544" width="18" height="7" font="18">None</text>
<text top="729" left="633" width="29" height="11" font="18"> None</text>
<text top="729" left="725" width="18" height="7" font="18">None</text>
<text top="788" left="64" width="56" height="7" font="18">Nancy M. Albert</text>
<text top="788" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="799" left="154" width="52" height="7" font="18">ACC/AHA Task</text>
<text top="810" left="154" width="30" height="7" font="18">Force on</text>
<text top="821" left="154" width="28" height="7" font="18">Practice</text>
<text top="833" left="154" width="36" height="7" font="18">Guidelines</text>
<text top="788" left="225" width="55" height="7" font="18">Cleveland Clinic</text>
<text top="799" left="238" width="47" height="8" font="18">Foundationd</text>
<text top="810" left="238" width="62" height="7" font="18">Senior Director of</text>
<text top="821" left="238" width="62" height="7" font="18">Nursing Research</text>
<text top="833" left="238" width="41" height="7" font="18">and Clinical</text>
<text top="844" left="238" width="68" height="7" font="18">Nursing Specialists,</text>
<text top="855" left="238" width="68" height="7" font="18">Kaufman Center for</text>
<text top="866" left="238" width="45" height="7" font="18">Heart Failure</text>
<text top="787" left="317" width="45" height="11" font="18"> Medtronic</text>
<text top="788" left="398" width="18" height="7" font="18">None</text>
<text top="788" left="468" width="18" height="7" font="18">None</text>
<text top="788" left="544" width="18" height="7" font="18">None</text>
<text top="787" left="633" width="29" height="11" font="18"> None</text>
<text top="788" left="725" width="18" height="7" font="18">None</text>
<text top="880" left="64" width="66" height="7" font="18">Jeffrey L. Anderson</text>
<text top="880" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="891" left="154" width="52" height="7" font="18">ACC/AHA Task</text>
<text top="902" left="154" width="30" height="7" font="18">Force on</text>
<text top="914" left="154" width="28" height="7" font="18">Practice</text>
<text top="925" left="154" width="36" height="7" font="18">Guidelines</text>
<text top="880" left="225" width="79" height="7" font="18">Intermountain Medical</text>
<text top="891" left="238" width="31" height="8" font="18">Centerd</text>
<text top="902" left="238" width="54" height="7" font="18">Associate Chief</text>
<text top="914" left="238" width="46" height="7" font="18">of Cardiology</text>
<text top="880" left="317" width="59" height="11" font="18"> Sanoﬁ-aventis</text>
<text top="880" left="398" width="18" height="7" font="18">None</text>
<text top="880" left="468" width="18" height="7" font="18">None</text>
<text top="880" left="544" width="68" height="11" font="18"> GlaxoSmithKline</text>
<text top="880" left="633" width="29" height="11" font="18"> None</text>
<text top="880" left="725" width="18" height="7" font="18">None</text>
<text top="939" left="64" width="33" height="7" font="18">Robert H.</text>
<text top="950" left="77" width="34" height="7" font="18">Beekman</text>
<text top="939" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="950" left="154" width="58" height="7" font="18">Adult Congenital</text>
<text top="961" left="154" width="47" height="7" font="18">and Pediatric</text>
<text top="972" left="154" width="36" height="7" font="18">Cardiology</text>
<text top="984" left="154" width="26" height="7" font="18">Section</text>
<text top="939" left="225" width="66" height="7" font="18">Cincinnati Children</text>
<text top="936" left="291" width="6" height="11" font="18">’s</text>
<text top="950" left="238" width="58" height="7" font="18">Hospital Medical</text>
<text top="961" left="238" width="68" height="8" font="18">CenterdDivision of</text>
<text top="972" left="238" width="36" height="7" font="18">Cardiology</text>
<text top="938" left="317" width="38" height="11" font="18"> St. Jude</text>
<text top="952" left="328" width="27" height="7" font="18">Medical</text>
<text top="939" left="398" width="18" height="7" font="18">None</text>
<text top="939" left="468" width="18" height="7" font="18">None</text>
<text top="939" left="544" width="18" height="7" font="18">None</text>
<text top="938" left="633" width="29" height="11" font="18"> None</text>
<text top="939" left="725" width="18" height="7" font="18">None</text>
<text top="998" left="697" width="102" height="7" font="18">Continued on the next page</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e180</text>
</page>
<page number="125" position="absolute" top="0" left="0" height="1160" width="864">
<text top="107" left="64" width="180" height="14" font="17">Appendix 2. Continued</text>
<text top="190" left="64" width="33" height="7" font="18">Reviewer</text>
<text top="190" left="150" width="55" height="7" font="18">Representation</text>
<text top="190" left="243" width="45" height="7" font="18">Employment</text>
<text top="190" left="332" width="40" height="7" font="18">Consultant</text>
<text top="179" left="409" width="30" height="7" font="18">Speaker</text>
<text top="177" left="439" width="6" height="11" font="18">’s</text>
<text top="190" left="414" width="26" height="7" font="18">Bureau</text>
<text top="168" left="479" width="43" height="7" font="18">Ownership/</text>
<text top="179" left="477" width="46" height="7" font="18">Partnership/</text>
<text top="190" left="485" width="31" height="7" font="18">Principal</text>
<text top="179" left="567" width="31" height="7" font="18">Personal</text>
<text top="190" left="566" width="34" height="7" font="18">Research</text>
<text top="145" left="650" width="46" height="7" font="18">Institutional,</text>
<text top="157" left="646" width="54" height="7" font="18">Organizational,</text>
<text top="168" left="658" width="30" height="7" font="18">or Other</text>
<text top="179" left="657" width="32" height="7" font="18">Financial</text>
<text top="190" left="660" width="18" height="7" font="18">Bene</text>
<text top="188" left="679" width="8" height="11" font="18">ﬁt</text>
<text top="179" left="750" width="24" height="7" font="18">Expert</text>
<text top="190" left="748" width="29" height="7" font="18">Witness</text>
<text top="205" left="64" width="51" height="7" font="18">Vera A. Bittner</text>
<text top="205" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="216" left="154" width="47" height="7" font="18">Prevention of</text>
<text top="227" left="154" width="51" height="7" font="18">Cardiovascular</text>
<text top="239" left="154" width="28" height="7" font="18">Disease</text>
<text top="250" left="154" width="39" height="7" font="18">Committee</text>
<text top="205" left="225" width="77" height="7" font="18">University of Alabama</text>
<text top="216" left="238" width="61" height="8" font="18">at Birminghamd</text>
<text top="227" left="238" width="42" height="7" font="18">Professor of</text>
<text top="239" left="238" width="66" height="7" font="18">Medicine; Director,</text>
<text top="250" left="238" width="26" height="7" font="18">Cardiac</text>
<text top="261" left="238" width="49" height="7" font="18">Rehabilitation</text>
<text top="204" left="317" width="39" height="11" font="18"> Novartis</text>
<text top="205" left="398" width="18" height="7" font="18">None</text>
<text top="205" left="468" width="18" height="7" font="18">None</text>
<text top="204" left="544" width="35" height="11" font="18"> Amgen</text>
<text top="216" left="544" width="54" height="11" font="18"> <a href="e57.full.html#128">AstraZeneca</a></text>
<text top="216" left="598" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="227" left="544" width="35" height="11" font="18"> Eli <a href="e57.full.html#128">Lilly</a></text>
<text top="227" left="579" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="238" left="544" width="68" height="11" font="18"> GlaxoSmithKline</text>
<text top="240" left="613" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="249" left="544" width="69" height="11" font="18"> NIH/Joint <a href="e57.full.html#128">Abbott</a></text>
<text top="252" left="613" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="260" left="544" width="59" height="11" font="18"> Sanoﬁ-aventis</text>
<text top="260" left="604" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="272" left="544" width="68" height="11" font="18"> Schering <a href="e57.full.html#128">Plough</a></text>
<text top="272" left="612" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="204" left="633" width="30" height="11" font="18"> Pﬁzer</text>
<text top="205" left="725" width="18" height="7" font="18">None</text>
<text top="288" left="64" width="56" height="7" font="18">Biykem Bozkurt</text>
<text top="288" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="299" left="154" width="52" height="7" font="18">ACC/AHA Task</text>
<text top="310" left="154" width="30" height="7" font="18">Force on</text>
<text top="322" left="154" width="28" height="7" font="18">Practice</text>
<text top="333" left="154" width="36" height="7" font="18">Guidelines</text>
<text top="288" left="225" width="81" height="7" font="18">Michael E. DeBakey VA</text>
<text top="299" left="238" width="61" height="8" font="18">Medical Centerd</text>
<text top="310" left="238" width="61" height="7" font="18">Mary and Gordon</text>
<text top="322" left="238" width="52" height="7" font="18">Cain Chair and</text>
<text top="333" left="238" width="42" height="7" font="18">Professor of</text>
<text top="344" left="238" width="31" height="7" font="18">Medicine</text>
<text top="288" left="317" width="18" height="7" font="18">None</text>
<text top="288" left="398" width="18" height="7" font="18">None</text>
<text top="288" left="468" width="18" height="7" font="18">None</text>
<text top="287" left="544" width="32" height="11" font="18"> Forest</text>
<text top="301" left="555" width="67" height="8" font="18">Pharmaceuticalsd</text>
<text top="312" left="555" width="7" height="7" font="18">PI</text>
<text top="312" left="562" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="287" left="633" width="35" height="11" font="18"> Amgen</text>
<text top="299" left="633" width="40" height="11" font="18"> Corthera</text>
<text top="310" left="633" width="39" height="11" font="18"> Novartis</text>
<text top="288" left="725" width="18" height="7" font="18">None</text>
<text top="358" left="64" width="24" height="7" font="18">Joseph</text>
<text top="369" left="77" width="34" height="7" font="18">Cleveland</text>
<text top="358" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="369" left="154" width="46" height="7" font="18">Heart Failure</text>
<text top="380" left="154" width="52" height="7" font="18">and Transplant</text>
<text top="391" left="154" width="25" height="7" font="18">Council</text>
<text top="358" left="225" width="77" height="7" font="18">University of Colorado</text>
<text top="369" left="238" width="61" height="7" font="18">Anschutz Medical</text>
<text top="380" left="238" width="31" height="8" font="18">Centerd</text>
<text top="391" left="238" width="42" height="7" font="18">Professor of</text>
<text top="403" left="238" width="59" height="7" font="18">Surgery; Surgical</text>
<text top="414" left="238" width="58" height="7" font="18">Director, Cardiac</text>
<text top="425" left="238" width="54" height="7" font="18">Transplantation</text>
<text top="436" left="238" width="56" height="7" font="18">and Mechanical</text>
<text top="447" left="238" width="67" height="7" font="18">Circulatory Support</text>
<text top="357" left="317" width="28" height="11" font="18"> Sorin</text>
<text top="358" left="398" width="18" height="7" font="18">None</text>
<text top="358" left="468" width="18" height="7" font="18">None</text>
<text top="357" left="544" width="46" height="11" font="18"> Heartware</text>
<text top="357" left="633" width="29" height="11" font="18"> None</text>
<text top="358" left="725" width="18" height="7" font="18">None</text>
<text top="461" left="64" width="64" height="7" font="18">Salvatore P. Costa</text>
<text top="461" left="142" width="62" height="7" font="18">Content Reviewer</text>
<text top="461" left="225" width="57" height="7" font="18">Geisel School of</text>
<text top="473" left="238" width="41" height="7" font="18">Medicine at</text>
<text top="484" left="238" width="46" height="8" font="18">Dartmouthd</text>
<text top="495" left="238" width="68" height="7" font="18">Associate Professor</text>
<text top="506" left="238" width="7" height="7" font="18">of</text>
<text top="517" left="238" width="33" height="7" font="18">Medicine;</text>
<text top="529" left="238" width="40" height="7" font="18">Dartmouth-</text>
<text top="540" left="238" width="64" height="7" font="18">Hitchcock Medical</text>
<text top="551" left="238" width="61" height="7" font="18">Center Section of</text>
<text top="562" left="238" width="45" height="8" font="18">Cardiologyd</text>
<text top="573" left="238" width="59" height="7" font="18">Medical Director,</text>
<text top="585" left="238" width="62" height="7" font="18">Echocardiography</text>
<text top="596" left="238" width="13" height="7" font="18">Lab</text>
<text top="461" left="317" width="18" height="7" font="18">None</text>
<text top="461" left="398" width="18" height="7" font="18">None</text>
<text top="461" left="468" width="18" height="7" font="18">None</text>
<text top="461" left="544" width="40" height="11" font="18"> Edwards</text>
<text top="474" left="555" width="43" height="7" font="18">Lifesciences</text>
<text top="486" left="555" width="48" height="7" font="18">(PARTNERS 2</text>
<text top="497" left="555" width="44" height="8" font="18">Trial)d<a href="e57.full.html#128">Co-PI</a></text>
<text top="494" left="598" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="461" left="633" width="29" height="11" font="18"> None</text>
<text top="461" left="725" width="18" height="7" font="18">None</text>
<text top="610" left="64" width="44" height="7" font="18">Lesley Curtis</text>
<text top="610" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="621" left="154" width="33" height="7" font="18">ACC/AHA</text>
<text top="632" left="154" width="38" height="7" font="18">Task Force</text>
<text top="643" left="154" width="40" height="7" font="18">on Practice</text>
<text top="655" left="154" width="36" height="7" font="18">Guidelines</text>
<text top="610" left="225" width="81" height="7" font="18">Duke University School</text>
<text top="621" left="238" width="49" height="8" font="18">of Medicined</text>
<text top="632" left="238" width="68" height="7" font="18">Associate Professor</text>
<text top="643" left="238" width="40" height="7" font="18">in Medicine</text>
<text top="610" left="317" width="18" height="7" font="18">None</text>
<text top="610" left="398" width="18" height="7" font="18">None</text>
<text top="610" left="468" width="18" height="7" font="18">None</text>
<text top="609" left="544" width="61" height="11" font="18"> GE <a href="e57.full.html#128">Healthcare</a></text>
<text top="612" left="605" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="620" left="544" width="68" height="11" font="18"> GlaxoSmithKline</text>
<text top="623" left="613" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="632" left="544" width="55" height="11" font="18"> Johnson and</text>
<text top="645" left="555" width="28" height="7" font="18"><a href="e57.full.html#128">Johnson</a></text>
<text top="645" left="583" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="609" left="633" width="29" height="11" font="18"> None</text>
<text top="610" left="725" width="18" height="7" font="18">None</text>
<text top="668" left="64" width="48" height="7" font="18">Larry S. Dean</text>
<text top="668" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="680" left="154" width="41" height="7" font="18">Intervention</text>
<text top="691" left="154" width="25" height="7" font="18">Council</text>
<text top="668" left="225" width="43" height="7" font="18">University of</text>
<text top="680" left="238" width="67" height="7" font="18">Washington School</text>
<text top="691" left="238" width="49" height="8" font="18">of Medicined</text>
<text top="702" left="238" width="42" height="7" font="18">Professor of</text>
<text top="713" left="238" width="47" height="7" font="18">Medicine and</text>
<text top="725" left="238" width="60" height="7" font="18">Surgery; Director,</text>
<text top="736" left="238" width="46" height="7" font="18">UW Medicine</text>
<text top="747" left="238" width="52" height="7" font="18">Regional Heart</text>
<text top="758" left="238" width="23" height="7" font="18">Center</text>
<text top="668" left="317" width="34" height="11" font="18"> Philips</text>
<text top="681" left="328" width="27" height="7" font="18">Medical</text>
<text top="668" left="398" width="36" height="11" font="18"> Daiichi-</text>
<text top="681" left="408" width="26" height="7" font="18">Sankyo</text>
<text top="690" left="398" width="35" height="11" font="18"> Eli Lilly</text>
<text top="668" left="468" width="43" height="11" font="18"> Emageon</text>
<text top="668" left="544" width="40" height="11" font="18"> Edwards</text>
<text top="681" left="555" width="43" height="7" font="18"><a href="e57.full.html#128">Lifesciences</a></text>
<text top="681" left="598" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="668" left="633" width="29" height="11" font="18"> None</text>
<text top="668" left="725" width="18" height="7" font="18">None</text>
<text top="772" left="64" width="64" height="7" font="18">Jeanne M. DeCara</text>
<text top="772" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="783" left="154" width="37" height="7" font="18">Council on</text>
<text top="795" left="154" width="56" height="7" font="18">Clinical Practice</text>
<text top="772" left="225" width="43" height="7" font="18">University of</text>
<text top="783" left="238" width="28" height="7" font="18">Chicago</text>
<text top="795" left="238" width="40" height="8" font="18">Medicined</text>
<text top="806" left="238" width="68" height="7" font="18">Associate Professor</text>
<text top="817" left="238" width="43" height="7" font="18">of Medicine,</text>
<text top="828" left="238" width="35" height="7" font="18">Section of</text>
<text top="839" left="238" width="36" height="7" font="18">Cardiology</text>
<text top="772" left="317" width="18" height="7" font="18">None</text>
<text top="772" left="398" width="18" height="7" font="18">None</text>
<text top="772" left="468" width="18" height="7" font="18">None</text>
<text top="772" left="544" width="18" height="7" font="18">None</text>
<text top="772" left="633" width="29" height="11" font="18"> None</text>
<text top="772" left="725" width="18" height="7" font="18">None</text>
<text top="853" left="64" width="48" height="7" font="18">Susan Farkas</text>
<text top="853" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="864" left="154" width="47" height="7" font="18">ACC Board of</text>
<text top="876" left="154" width="35" height="7" font="18">Governors</text>
<text top="853" left="225" width="57" height="7" font="18">Sanford Medical</text>
<text top="864" left="238" width="53" height="8" font="18">Center Fargod</text>
<text top="876" left="238" width="41" height="7" font="18">Cardiologist</text>
<text top="853" left="317" width="18" height="7" font="18">None</text>
<text top="853" left="398" width="18" height="7" font="18">None</text>
<text top="853" left="468" width="18" height="7" font="18">None</text>
<text top="853" left="544" width="18" height="7" font="18">None</text>
<text top="853" left="633" width="29" height="11" font="18"> None</text>
<text top="853" left="725" width="18" height="7" font="18">None</text>
<text top="890" left="64" width="60" height="7" font="18">Frederico Gentile</text>
<text top="890" left="142" width="62" height="7" font="18">Content Reviewer</text>
<text top="890" left="225" width="51" height="7" font="18">Centro Medico</text>
<text top="901" left="238" width="41" height="7" font="18">Diagnostico</text>
<text top="890" left="317" width="18" height="7" font="18">None</text>
<text top="890" left="398" width="18" height="7" font="18">None</text>
<text top="890" left="468" width="18" height="7" font="18">None</text>
<text top="890" left="544" width="18" height="7" font="18">None</text>
<text top="889" left="633" width="29" height="11" font="18"> None</text>
<text top="890" left="725" width="18" height="7" font="18">None</text>
<text top="915" left="64" width="44" height="7" font="18">Linda Gillam</text>
<text top="915" left="142" width="62" height="7" font="18">Content Reviewer</text>
<text top="915" left="225" width="69" height="7" font="18">Morristown Medical</text>
<text top="926" left="238" width="31" height="8" font="18">Centerd</text>
<text top="937" left="238" width="42" height="7" font="18">Professor of</text>
<text top="948" left="238" width="38" height="7" font="18">Cardiology;</text>
<text top="959" left="238" width="37" height="7" font="18">Vice Chair,</text>
<text top="971" left="238" width="51" height="7" font="18">Cardiovascular</text>
<text top="982" left="238" width="31" height="7" font="18">Medicine</text>
<text top="915" left="317" width="18" height="7" font="18">None</text>
<text top="915" left="398" width="18" height="7" font="18">None</text>
<text top="915" left="468" width="18" height="7" font="18">None</text>
<text top="914" left="544" width="40" height="11" font="18"> Edwards</text>
<text top="928" left="555" width="43" height="7" font="18"><a href="e57.full.html#128">Lifesciences</a></text>
<text top="925" left="597" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="914" left="633" width="40" height="11" font="18"> Edwards</text>
<text top="928" left="644" width="43" height="7" font="18"><a href="e57.full.html#128">Lifesciences</a></text>
<text top="925" left="686" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="915" left="725" width="18" height="7" font="18">None</text>
<text top="993" left="697" width="102" height="7" font="18">Continued on the next page</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e181</text>
</page>
<page number="126" position="absolute" top="0" left="0" height="1160" width="864">
<text top="107" left="64" width="180" height="14" font="17">Appendix 2. Continued</text>
<text top="190" left="64" width="33" height="7" font="18">Reviewer</text>
<text top="190" left="150" width="55" height="7" font="18">Representation</text>
<text top="190" left="243" width="45" height="7" font="18">Employment</text>
<text top="190" left="332" width="40" height="7" font="18">Consultant</text>
<text top="179" left="409" width="30" height="7" font="18">Speaker</text>
<text top="177" left="439" width="6" height="11" font="18">’s</text>
<text top="190" left="414" width="26" height="7" font="18">Bureau</text>
<text top="168" left="479" width="43" height="7" font="18">Ownership/</text>
<text top="179" left="477" width="46" height="7" font="18">Partnership/</text>
<text top="190" left="485" width="31" height="7" font="18">Principal</text>
<text top="179" left="567" width="31" height="7" font="18">Personal</text>
<text top="190" left="566" width="34" height="7" font="18">Research</text>
<text top="145" left="650" width="46" height="7" font="18">Institutional,</text>
<text top="157" left="646" width="54" height="7" font="18">Organizational,</text>
<text top="168" left="658" width="30" height="7" font="18">or Other</text>
<text top="179" left="657" width="32" height="7" font="18">Financial</text>
<text top="190" left="660" width="18" height="7" font="18">Bene</text>
<text top="188" left="679" width="8" height="11" font="18">ﬁt</text>
<text top="179" left="750" width="24" height="7" font="18">Expert</text>
<text top="190" left="748" width="29" height="7" font="18">Witness</text>
<text top="205" left="64" width="63" height="7" font="18">Charles Hogue, Jr.</text>
<text top="205" left="142" width="62" height="7" font="18">Content Reviewer</text>
<text top="205" left="225" width="51" height="7" font="18">Johns Hopkins</text>
<text top="216" left="238" width="68" height="7" font="18">University School of</text>
<text top="227" left="238" width="40" height="8" font="18">Medicined</text>
<text top="239" left="238" width="42" height="7" font="18">Professor of</text>
<text top="250" left="238" width="61" height="7" font="18">Anesthesiology &amp;</text>
<text top="261" left="238" width="43" height="7" font="18">Critical Care</text>
<text top="272" left="238" width="33" height="7" font="18">Medicine;</text>
<text top="283" left="238" width="59" height="7" font="18">Chief, Division of</text>
<text top="295" left="238" width="59" height="7" font="18">Adult Anesthesia</text>
<text top="205" left="317" width="18" height="7" font="18">None</text>
<text top="205" left="398" width="18" height="7" font="18">None</text>
<text top="205" left="468" width="18" height="7" font="18">None</text>
<text top="205" left="544" width="18" height="7" font="18">None</text>
<text top="204" left="633" width="61" height="11" font="18"> Merck (DSMB)</text>
<text top="204" left="725" width="49" height="11" font="18"> Defendant,</text>
<text top="218" left="736" width="33" height="7" font="18">Operative</text>
<text top="229" left="736" width="32" height="7" font="18">Mortality,</text>
<text top="240" left="736" width="19" height="7" font="18">2012</text>
<text top="309" left="64" width="53" height="7" font="18">Pei-Hsiu Huang</text>
<text top="309" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="320" left="154" width="57" height="7" font="18">Content Lifelong</text>
<text top="331" left="154" width="30" height="7" font="18">Learning</text>
<text top="342" left="154" width="33" height="7" font="18">Oversight</text>
<text top="353" left="154" width="39" height="7" font="18">Committee</text>
<text top="365" left="154" width="46" height="7" font="18">(Educational)</text>
<text top="309" left="225" width="51" height="7" font="18">Sutter Medical</text>
<text top="320" left="238" width="31" height="8" font="18">Centerd</text>
<text top="331" left="238" width="48" height="7" font="18">Interventional</text>
<text top="342" left="238" width="41" height="7" font="18">Cardiologist</text>
<text top="309" left="317" width="18" height="7" font="18">None</text>
<text top="309" left="398" width="18" height="7" font="18">None</text>
<text top="309" left="468" width="18" height="7" font="18">None</text>
<text top="308" left="544" width="68" height="11" font="18"> St. Jude Medical</text>
<text top="319" left="544" width="69" height="11" font="18"> Boston Scientiﬁc</text>
<text top="330" left="544" width="66" height="11" font="18"> Abbott Vascular</text>
<text top="308" left="633" width="29" height="11" font="18"> None</text>
<text top="309" left="725" width="18" height="7" font="18">None</text>
<text top="378" left="64" width="48" height="7" font="18">Judy W. Hung</text>
<text top="378" left="142" width="62" height="7" font="18">Content Reviewer</text>
<text top="378" left="225" width="57" height="7" font="18">Harvard Medical</text>
<text top="390" left="238" width="32" height="8" font="18">Schoold</text>
<text top="401" left="238" width="68" height="7" font="18">Associate Professor</text>
<text top="412" left="238" width="43" height="7" font="18">of Medicine;</text>
<text top="423" left="238" width="52" height="7" font="18">Massachusetts</text>
<text top="434" left="238" width="66" height="8" font="18">General Hospitald</text>
<text top="446" left="238" width="66" height="7" font="18">Associate Director,</text>
<text top="457" left="238" width="62" height="7" font="18">Echocardiography</text>
<text top="378" left="317" width="18" height="7" font="18">None</text>
<text top="378" left="398" width="18" height="7" font="18">None</text>
<text top="378" left="468" width="18" height="7" font="18">None</text>
<text top="378" left="544" width="18" height="7" font="18">None</text>
<text top="378" left="633" width="29" height="11" font="18"> None</text>
<text top="378" left="725" width="18" height="7" font="18">None</text>
<text top="471" left="64" width="45" height="7" font="18">Bernard Iung</text>
<text top="471" left="142" width="62" height="7" font="18">Content Reviewer</text>
<text top="471" left="225" width="61" height="8" font="18">Bichat Hospitald</text>
<text top="482" left="238" width="42" height="7" font="18">Professor of</text>
<text top="493" left="238" width="36" height="7" font="18">Cardiology</text>
<text top="470" left="317" width="33" height="11" font="18"> Abbott</text>
<text top="481" left="317" width="49" height="11" font="18"> Boehringer</text>
<text top="495" left="328" width="35" height="7" font="18">Ingelheim</text>
<text top="504" left="317" width="40" height="11" font="18"> Edwards</text>
<text top="517" left="328" width="43" height="7" font="18">Lifesciences</text>
<text top="526" left="317" width="36" height="11" font="18"> Valtech</text>
<text top="471" left="398" width="18" height="7" font="18">None</text>
<text top="471" left="468" width="18" height="7" font="18">None</text>
<text top="471" left="544" width="18" height="7" font="18">None</text>
<text top="470" left="633" width="49" height="11" font="18"> Archives of</text>
<text top="484" left="644" width="51" height="7" font="18">Cardiovascular</text>
<text top="495" left="644" width="28" height="7" font="18">Disease</text>
<text top="506" left="644" width="61" height="7" font="18">(Associate Editor)</text>
<text top="504" left="705" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="515" left="633" width="49" height="11" font="18"> Boehringer</text>
<text top="529" left="644" width="35" height="7" font="18"><a href="e57.full.html#128">Ingelheim</a></text>
<text top="526" left="678" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="471" left="725" width="18" height="7" font="18">None</text>
<text top="543" left="64" width="18" height="7" font="18">Amar</text>
<text top="554" left="77" width="49" height="7" font="18">Krishnaswamy</text>
<text top="543" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="554" left="154" width="57" height="7" font="18">Content Lifelong</text>
<text top="565" left="154" width="30" height="7" font="18">Learning</text>
<text top="576" left="154" width="33" height="7" font="18">Oversight</text>
<text top="587" left="154" width="39" height="7" font="18">Committee</text>
<text top="599" left="154" width="46" height="7" font="18">(Educational)</text>
<text top="543" left="225" width="64" height="8" font="18">Cleveland Clinicd</text>
<text top="554" left="238" width="55" height="7" font="18">Associate Staff,</text>
<text top="565" left="238" width="39" height="7" font="18">Robert and</text>
<text top="576" left="238" width="62" height="7" font="18">Suzanne Tomsich</text>
<text top="587" left="238" width="51" height="7" font="18">Department of</text>
<text top="599" left="238" width="51" height="7" font="18">Cardiovascular</text>
<text top="610" left="238" width="31" height="7" font="18">Medicine</text>
<text top="543" left="317" width="18" height="7" font="18">None</text>
<text top="543" left="398" width="18" height="7" font="18">None</text>
<text top="543" left="468" width="18" height="7" font="18">None</text>
<text top="543" left="544" width="18" height="7" font="18">None</text>
<text top="543" left="633" width="18" height="7" font="18">None</text>
<text top="543" left="725" width="18" height="7" font="18">None</text>
<text top="624" left="64" width="49" height="7" font="18">David Lanfear</text>
<text top="624" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="635" left="154" width="46" height="7" font="18">Heart Failure</text>
<text top="646" left="154" width="52" height="7" font="18">and Transplant</text>
<text top="657" left="154" width="25" height="7" font="18">Council</text>
<text top="624" left="225" width="78" height="8" font="18">Henry Ford Hospitald</text>
<text top="635" left="238" width="32" height="7" font="18">Assistant</text>
<text top="646" left="238" width="57" height="7" font="18">Professor, Heart</text>
<text top="657" left="238" width="45" height="7" font="18">and Vascular</text>
<text top="668" left="238" width="52" height="7" font="18">Institute in the</text>
<text top="680" left="238" width="61" height="7" font="18">Center for Health</text>
<text top="691" left="238" width="64" height="7" font="18">Services Research</text>
<text top="623" left="317" width="41" height="11" font="18"> Thoratec</text>
<text top="624" left="398" width="18" height="7" font="18">None</text>
<text top="624" left="468" width="18" height="7" font="18">None</text>
<text top="623" left="544" width="35" height="11" font="18"> Amgen</text>
<text top="625" left="580" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="634" left="544" width="46" height="11" font="18"> Biocontrol</text>
<text top="637" left="590" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="646" left="544" width="55" height="11" font="18"> CardioRentis</text>
<text top="623" left="633" width="29" height="11" font="18"> None</text>
<text top="624" left="725" width="18" height="7" font="18">None</text>
<text top="705" left="64" width="51" height="7" font="18">Richard Lange</text>
<text top="705" left="142" width="62" height="7" font="18">Content Reviewer</text>
<text top="705" left="225" width="66" height="7" font="18">University of Texas</text>
<text top="716" left="238" width="53" height="7" font="18">Health Science</text>
<text top="727" left="238" width="49" height="7" font="18">Center at San</text>
<text top="738" left="238" width="35" height="8" font="18">Antoniod</text>
<text top="750" left="238" width="33" height="7" font="18">Professor</text>
<text top="761" left="238" width="41" height="7" font="18">of Medicine</text>
<text top="705" left="317" width="18" height="7" font="18">None</text>
<text top="705" left="398" width="18" height="7" font="18">None</text>
<text top="705" left="468" width="18" height="7" font="18">None</text>
<text top="705" left="544" width="18" height="7" font="18">None</text>
<text top="704" left="633" width="29" height="11" font="18"> None</text>
<text top="705" left="725" width="18" height="7" font="18">None</text>
<text top="775" left="64" width="36" height="7" font="18">M. Regina</text>
<text top="786" left="77" width="24" height="7" font="18">Lantin-</text>
<text top="797" left="77" width="31" height="7" font="18">Hermoso</text>
<text top="775" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="786" left="154" width="58" height="7" font="18">Adult Congenital</text>
<text top="797" left="154" width="47" height="7" font="18">and Pediatric</text>
<text top="808" left="154" width="36" height="7" font="18">Cardiology</text>
<text top="820" left="154" width="26" height="7" font="18">Section</text>
<text top="775" left="225" width="51" height="7" font="18">Texas Children</text>
<text top="772" left="276" width="6" height="11" font="18">’s</text>
<text top="786" left="238" width="50" height="7" font="18">Hospital Heart</text>
<text top="797" left="238" width="31" height="8" font="18">Centerd</text>
<text top="808" left="238" width="68" height="7" font="18">Associate Professor</text>
<text top="820" left="238" width="46" height="7" font="18">of Pediatrics,</text>
<text top="831" left="238" width="35" height="7" font="18">Section of</text>
<text top="842" left="238" width="68" height="7" font="18">Cardiology; Medical</text>
<text top="853" left="238" width="68" height="7" font="18">Director, Cardiology</text>
<text top="864" left="238" width="22" height="7" font="18">Clinics</text>
<text top="775" left="317" width="18" height="7" font="18">None</text>
<text top="775" left="398" width="18" height="7" font="18">None</text>
<text top="775" left="468" width="18" height="7" font="18">None</text>
<text top="775" left="544" width="18" height="7" font="18">None</text>
<text top="774" left="633" width="29" height="11" font="18"> None</text>
<text top="775" left="725" width="18" height="7" font="18">None</text>
<text top="878" left="64" width="50" height="7" font="18">D. Craig Miller</text>
<text top="878" left="142" width="62" height="7" font="18">Content Reviewer</text>
<text top="878" left="225" width="66" height="7" font="18">Stanford University</text>
<text top="890" left="238" width="55" height="7" font="18">Medical Center,</text>
<text top="901" left="238" width="50" height="7" font="18">Cardiothoracic</text>
<text top="912" left="238" width="56" height="8" font="18">Surgery Clinicd</text>
<text top="923" left="238" width="42" height="7" font="18">Professor of</text>
<text top="934" left="238" width="51" height="7" font="18">Cardiovascular</text>
<text top="946" left="238" width="26" height="7" font="18">Surgery</text>
<text top="878" left="317" width="33" height="11" font="18"> Abbott</text>
<text top="891" left="328" width="30" height="7" font="18">Vascular</text>
<text top="900" left="317" width="45" height="11" font="18"> Medtronic</text>
<text top="903" left="363" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="911" left="317" width="45" height="11" font="18"> Medtronic</text>
<text top="925" left="328" width="40" height="7" font="18">Heart Valve</text>
<text top="936" left="328" width="27" height="7" font="18">Division</text>
<text top="945" left="317" width="41" height="11" font="18"> MitraClip</text>
<text top="956" left="317" width="40" height="11" font="18"> Edwards</text>
<text top="970" left="328" width="43" height="7" font="18"><a href="e57.full.html#128">Lifesciences</a></text>
<text top="967" left="370" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="979" left="317" width="38" height="11" font="18"> St. Jude</text>
<text top="992" left="328" width="27" height="7" font="18">Medical</text>
<text top="878" left="398" width="18" height="7" font="18">None</text>
<text top="878" left="468" width="18" height="7" font="18">None</text>
<text top="878" left="544" width="40" height="11" font="18"> Edwards</text>
<text top="891" left="555" width="43" height="7" font="18"><a href="e57.full.html#128">Lifesciences</a></text>
<text top="889" left="598" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="878" left="633" width="29" height="11" font="18"> None</text>
<text top="878" left="725" width="18" height="7" font="18">None</text>
<text top="1006" left="64" width="53" height="7" font="18">Tom C. Nguyen</text>
<text top="1006" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="1017" left="154" width="57" height="7" font="18">Content Lifelong</text>
<text top="1029" left="154" width="30" height="7" font="18">Learning</text>
<text top="1040" left="154" width="33" height="7" font="18">Oversight</text>
<text top="1051" left="154" width="39" height="7" font="18">Committee</text>
<text top="1062" left="154" width="46" height="7" font="18">(Educational)</text>
<text top="1006" left="225" width="66" height="7" font="18">University of Texas</text>
<text top="1017" left="238" width="53" height="7" font="18">Health Science</text>
<text top="1029" left="238" width="32" height="7" font="18">Center at</text>
<text top="1040" left="238" width="37" height="8" font="18">Houstond</text>
<text top="1051" left="238" width="67" height="7" font="18">Assistant Professor</text>
<text top="1062" left="238" width="61" height="7" font="18">of Cardiovascular</text>
<text top="1073" left="238" width="26" height="7" font="18">Surgery</text>
<text top="1006" left="317" width="18" height="7" font="18">None</text>
<text top="1006" left="398" width="18" height="7" font="18">None</text>
<text top="1006" left="468" width="18" height="7" font="18">None</text>
<text top="1006" left="544" width="18" height="7" font="18">None</text>
<text top="1006" left="633" width="29" height="11" font="18"> None</text>
<text top="1006" left="725" width="18" height="7" font="18">None</text>
<text top="1087" left="697" width="102" height="7" font="18">Continued on the next page</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e182</text>
</page>
<page number="127" position="absolute" top="0" left="0" height="1160" width="864">
<text top="107" left="64" width="180" height="14" font="17">Appendix 2. Continued</text>
<text top="190" left="64" width="33" height="7" font="18">Reviewer</text>
<text top="190" left="150" width="55" height="7" font="18">Representation</text>
<text top="190" left="243" width="45" height="7" font="18">Employment</text>
<text top="190" left="332" width="40" height="7" font="18">Consultant</text>
<text top="179" left="409" width="30" height="7" font="18">Speaker</text>
<text top="177" left="439" width="6" height="11" font="18">’s</text>
<text top="190" left="414" width="26" height="7" font="18">Bureau</text>
<text top="168" left="479" width="43" height="7" font="18">Ownership/</text>
<text top="179" left="477" width="46" height="7" font="18">Partnership/</text>
<text top="190" left="485" width="31" height="7" font="18">Principal</text>
<text top="179" left="567" width="31" height="7" font="18">Personal</text>
<text top="190" left="566" width="34" height="7" font="18">Research</text>
<text top="145" left="650" width="46" height="7" font="18">Institutional,</text>
<text top="157" left="646" width="54" height="7" font="18">Organizational,</text>
<text top="168" left="658" width="30" height="7" font="18">or Other</text>
<text top="179" left="657" width="32" height="7" font="18">Financial</text>
<text top="190" left="660" width="18" height="7" font="18">Bene</text>
<text top="188" left="679" width="8" height="11" font="18">ﬁt</text>
<text top="179" left="750" width="24" height="7" font="18">Expert</text>
<text top="190" left="748" width="29" height="7" font="18">Witness</text>
<text top="205" left="64" width="56" height="7" font="18">Philippe Pibarot</text>
<text top="205" left="142" width="62" height="7" font="18">Content Reviewer</text>
<text top="205" left="225" width="63" height="8" font="18">Laval Universityd</text>
<text top="216" left="238" width="35" height="7" font="18">Professor,</text>
<text top="227" left="238" width="42" height="7" font="18">Department</text>
<text top="239" left="238" width="43" height="7" font="18">of Medicine;</text>
<text top="250" left="238" width="43" height="7" font="18">University of</text>
<text top="261" left="238" width="52" height="7" font="18">Cardiology and</text>
<text top="272" left="238" width="53" height="7" font="18">Pneumology of</text>
<text top="283" left="238" width="55" height="8" font="18">QuébecdChair,</text>
<text top="295" left="238" width="62" height="7" font="18">Canada Research</text>
<text top="306" left="238" width="57" height="7" font="18">Chair in Valvular</text>
<text top="317" left="238" width="53" height="7" font="18">Heart Diseases</text>
<text top="205" left="317" width="18" height="7" font="18">None</text>
<text top="205" left="398" width="18" height="7" font="18">None</text>
<text top="205" left="468" width="18" height="7" font="18">None</text>
<text top="204" left="544" width="40" height="11" font="18"> Edwards</text>
<text top="218" left="555" width="43" height="7" font="18"><a href="e57.full.html#128">Lifesciences</a></text>
<text top="218" left="597" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="204" left="633" width="29" height="11" font="18"> None</text>
<text top="205" left="725" width="18" height="7" font="18">None</text>
<text top="331" left="64" width="65" height="7" font="18">Geetha Raghuveer</text>
<text top="331" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="342" left="154" width="47" height="7" font="18">ACC Board of</text>
<text top="353" left="154" width="35" height="7" font="18">Governors</text>
<text top="331" left="225" width="77" height="7" font="18">University of Missouri-</text>
<text top="342" left="238" width="67" height="7" font="18">Kansas City School</text>
<text top="353" left="238" width="49" height="8" font="18">of Medicined</text>
<text top="365" left="238" width="68" height="7" font="18">Associate Professor</text>
<text top="376" left="238" width="46" height="7" font="18">of Pediatrics;</text>
<text top="387" left="238" width="31" height="7" font="18">Pediatric</text>
<text top="398" left="238" width="41" height="7" font="18">Cardiologist</text>
<text top="331" left="317" width="18" height="7" font="18">None</text>
<text top="331" left="398" width="18" height="7" font="18">None</text>
<text top="331" left="468" width="18" height="7" font="18">None</text>
<text top="331" left="544" width="18" height="7" font="18">None</text>
<text top="330" left="633" width="29" height="11" font="18"> None</text>
<text top="331" left="725" width="18" height="7" font="18">None</text>
<text top="412" left="64" width="66" height="7" font="18">Michael J. Reardon</text>
<text top="412" left="142" width="62" height="7" font="18">Content Reviewer</text>
<text top="412" left="225" width="68" height="7" font="18">Methodist DeBakey</text>
<text top="423" left="238" width="60" height="7" font="18">Heart &amp; Vascular</text>
<text top="434" left="238" width="31" height="8" font="18">Centerd</text>
<text top="446" left="238" width="42" height="7" font="18">Professor of</text>
<text top="457" left="238" width="50" height="7" font="18">Cardiothoracic</text>
<text top="468" left="238" width="26" height="7" font="18">Surgery</text>
<text top="412" left="317" width="45" height="11" font="18"> Medtronic</text>
<text top="412" left="398" width="18" height="7" font="18">None</text>
<text top="412" left="468" width="18" height="7" font="18">None</text>
<text top="412" left="544" width="45" height="11" font="18"> Medtronic</text>
<text top="412" left="633" width="29" height="11" font="18"> None</text>
<text top="412" left="725" width="18" height="7" font="18">None</text>
<text top="482" left="64" width="66" height="7" font="18">Raphael Rosenhek</text>
<text top="482" left="142" width="62" height="7" font="18">Content Reviewer</text>
<text top="482" left="225" width="63" height="7" font="18">Medical University</text>
<text top="493" left="238" width="41" height="8" font="18">of Viennad</text>
<text top="504" left="238" width="33" height="7" font="18">Associate</text>
<text top="516" left="238" width="35" height="7" font="18">Professor,</text>
<text top="527" left="238" width="51" height="7" font="18">Department of</text>
<text top="538" left="238" width="36" height="7" font="18">Cardiology</text>
<text top="482" left="317" width="18" height="7" font="18">None</text>
<text top="481" left="398" width="33" height="11" font="18"> Abbott</text>
<text top="493" left="398" width="40" height="11" font="18"> Edwards</text>
<text top="506" left="408" width="43" height="7" font="18">Lifesciences</text>
<text top="482" left="468" width="18" height="7" font="18">None</text>
<text top="482" left="544" width="18" height="7" font="18">None</text>
<text top="481" left="633" width="29" height="11" font="18"> None</text>
<text top="482" left="725" width="18" height="7" font="18">None</text>
<text top="552" left="64" width="61" height="7" font="18">Hartzell V. Schaff</text>
<text top="552" left="142" width="62" height="7" font="18">Content Reviewer</text>
<text top="552" left="225" width="81" height="8" font="18">Mayo ClinicdStuart W.</text>
<text top="563" left="238" width="37" height="7" font="18">Harrington</text>
<text top="574" left="238" width="42" height="7" font="18">Professor of</text>
<text top="586" left="238" width="26" height="7" font="18">Surgery</text>
<text top="552" left="317" width="18" height="7" font="18">None</text>
<text top="552" left="398" width="18" height="7" font="18">None</text>
<text top="552" left="468" width="18" height="7" font="18">None</text>
<text top="552" left="544" width="18" height="7" font="18">None</text>
<text top="551" left="633" width="29" height="11" font="18"> None</text>
<text top="552" left="725" width="18" height="7" font="18">None</text>
<text top="599" left="64" width="52" height="7" font="18">Allan Schwartz</text>
<text top="599" left="142" width="62" height="7" font="18">Content Reviewer</text>
<text top="599" left="225" width="33" height="7" font="18">Columbia</text>
<text top="611" left="238" width="42" height="8" font="18">Universityd</text>
<text top="622" left="238" width="50" height="7" font="18">Chief, Division</text>
<text top="633" left="238" width="46" height="7" font="18">of Cardiology</text>
<text top="599" left="317" width="18" height="7" font="18">None</text>
<text top="599" left="398" width="18" height="7" font="18">None</text>
<text top="599" left="468" width="18" height="7" font="18">None</text>
<text top="599" left="544" width="18" height="7" font="18">None</text>
<text top="599" left="633" width="29" height="11" font="18"> None</text>
<text top="599" left="725" width="18" height="7" font="18">None</text>
<text top="647" left="64" width="56" height="7" font="18">Frank W. Sellke</text>
<text top="647" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="658" left="154" width="52" height="7" font="18">ACC/AHA Task</text>
<text top="669" left="154" width="30" height="7" font="18">Force on</text>
<text top="681" left="154" width="28" height="7" font="18">Practice</text>
<text top="692" left="154" width="36" height="7" font="18">Guidelines</text>
<text top="647" left="225" width="46" height="7" font="18">Rhode Island</text>
<text top="658" left="238" width="56" height="8" font="18">HospitaldChief,</text>
<text top="669" left="238" width="37" height="7" font="18">Division of</text>
<text top="681" left="238" width="50" height="7" font="18">Cardiothoracic</text>
<text top="692" left="238" width="42" height="7" font="18">Surgery and</text>
<text top="703" left="238" width="51" height="7" font="18">Lifespan Heart</text>
<text top="714" left="238" width="23" height="7" font="18">Center</text>
<text top="647" left="317" width="18" height="7" font="18">None</text>
<text top="647" left="398" width="18" height="7" font="18">None</text>
<text top="647" left="468" width="18" height="7" font="18">None</text>
<text top="646" left="544" width="53" height="11" font="18"> CLS Behring</text>
<text top="658" left="544" width="61" height="11" font="18"> The Medicines</text>
<text top="671" left="555" width="33" height="7" font="18">Company</text>
<text top="646" left="633" width="53" height="11" font="18"> CLS Behring</text>
<text top="658" left="633" width="23" height="11" font="18"> The</text>
<text top="671" left="644" width="70" height="7" font="18">Medicines Company</text>
<text top="647" left="725" width="18" height="7" font="18">None</text>
<text top="728" left="64" width="41" height="7" font="18">Dipan Shah</text>
<text top="728" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="739" left="154" width="51" height="7" font="18">Cardiovascular</text>
<text top="751" left="154" width="26" height="7" font="18">Section</text>
<text top="762" left="154" width="38" height="7" font="18">Leadership</text>
<text top="773" left="154" width="25" height="7" font="18">Council</text>
<text top="728" left="225" width="66" height="7" font="18">Houston Methodist</text>
<text top="739" left="238" width="61" height="7" font="18">DeBakey Heart &amp;</text>
<text top="751" left="238" width="30" height="7" font="18">Vascular</text>
<text top="762" left="238" width="60" height="8" font="18">CenterdDirector,</text>
<text top="773" left="238" width="68" height="7" font="18">Cardiovascular MRI</text>
<text top="784" left="238" width="59" height="7" font="18">Laboratory; Weill</text>
<text top="795" left="238" width="54" height="7" font="18">Cornell Medical</text>
<text top="807" left="238" width="34" height="8" font="18">Colleged</text>
<text top="818" left="238" width="67" height="7" font="18">Assistant Professor</text>
<text top="829" left="238" width="41" height="7" font="18">of Medicine</text>
<text top="728" left="317" width="18" height="7" font="18">None</text>
<text top="728" left="398" width="54" height="11" font="18"> AstraZeneca</text>
<text top="730" left="452" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="739" left="398" width="43" height="11" font="18"> Lantheus</text>
<text top="752" left="408" width="27" height="7" font="18">Medical</text>
<text top="764" left="408" width="28" height="7" font="18">Imaging</text>
<text top="728" left="468" width="18" height="7" font="18">None</text>
<text top="728" left="544" width="38" height="11" font="18"> <a href="e57.full.html#128">Astellas</a></text>
<text top="730" left="582" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="739" left="544" width="41" height="11" font="18"> Siemens</text>
<text top="752" left="555" width="27" height="7" font="18">Medical</text>
<text top="764" left="555" width="32" height="7" font="18">Solutions</text>
<text top="764" left="587" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="728" left="633" width="29" height="11" font="18"> None</text>
<text top="728" left="725" width="18" height="7" font="18">None</text>
<text top="843" left="64" width="58" height="7" font="18">Win-Kuang Shen</text>
<text top="843" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="854" left="154" width="52" height="7" font="18">ACC/AHA Task</text>
<text top="865" left="154" width="30" height="7" font="18">Force on</text>
<text top="877" left="154" width="28" height="7" font="18">Practice</text>
<text top="888" left="154" width="36" height="7" font="18">Guidelines</text>
<text top="843" left="225" width="71" height="7" font="18">Mayo Clinic Arizona,</text>
<text top="854" left="238" width="67" height="8" font="18">Phoenix Campusd</text>
<text top="865" left="238" width="42" height="7" font="18">Professor of</text>
<text top="877" left="238" width="33" height="7" font="18">Medicine;</text>
<text top="888" left="238" width="37" height="7" font="18">Consultant</text>
<text top="843" left="317" width="18" height="7" font="18">None</text>
<text top="843" left="398" width="18" height="7" font="18">None</text>
<text top="843" left="468" width="18" height="7" font="18">None</text>
<text top="843" left="544" width="18" height="7" font="18">None</text>
<text top="842" left="633" width="29" height="11" font="18"> None</text>
<text top="843" left="725" width="18" height="7" font="18">None</text>
<text top="902" left="64" width="53" height="7" font="18">Adam Skolnick</text>
<text top="902" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="913" left="154" width="29" height="7" font="18">Geriatric</text>
<text top="924" left="154" width="36" height="7" font="18">Cardiology</text>
<text top="935" left="154" width="26" height="7" font="18">Section</text>
<text top="946" left="154" width="38" height="7" font="18">Leadership</text>
<text top="958" left="154" width="25" height="7" font="18">Council</text>
<text top="902" left="225" width="50" height="7" font="18">NYU School of</text>
<text top="913" left="238" width="40" height="8" font="18">Medicined</text>
<text top="924" left="238" width="67" height="7" font="18">Assistant Professor</text>
<text top="935" left="238" width="63" height="7" font="18">of Medicine, Leon</text>
<text top="947" left="238" width="68" height="7" font="18">H. Charney Division</text>
<text top="958" left="238" width="48" height="7" font="18">of Cardiology;</text>
<text top="969" left="238" width="66" height="7" font="18">Associate Director,</text>
<text top="980" left="238" width="67" height="7" font="18">Health Care Center</text>
<text top="902" left="317" width="18" height="7" font="18">None</text>
<text top="902" left="398" width="18" height="7" font="18">None</text>
<text top="902" left="468" width="18" height="7" font="18">None</text>
<text top="902" left="544" width="18" height="7" font="18">None</text>
<text top="901" left="633" width="29" height="11" font="18"> None</text>
<text top="902" left="725" width="18" height="7" font="18">None</text>
<text top="993" left="697" width="102" height="7" font="18">Continued on the next page</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e183</text>
</page>
<page number="128" position="absolute" top="0" left="0" height="1160" width="864">
<text top="107" left="64" width="180" height="14" font="17">Appendix 2. Continued</text>
<text top="190" left="64" width="33" height="7" font="18">Reviewer</text>
<text top="190" left="150" width="55" height="7" font="18">Representation</text>
<text top="190" left="243" width="45" height="7" font="18">Employment</text>
<text top="190" left="332" width="40" height="7" font="18">Consultant</text>
<text top="179" left="409" width="30" height="7" font="18">Speaker</text>
<text top="177" left="439" width="6" height="11" font="18">’s</text>
<text top="190" left="414" width="26" height="7" font="18">Bureau</text>
<text top="168" left="479" width="43" height="7" font="18">Ownership/</text>
<text top="179" left="477" width="46" height="7" font="18">Partnership/</text>
<text top="190" left="485" width="31" height="7" font="18">Principal</text>
<text top="179" left="567" width="31" height="7" font="18">Personal</text>
<text top="190" left="566" width="34" height="7" font="18">Research</text>
<text top="145" left="650" width="46" height="7" font="18">Institutional,</text>
<text top="157" left="646" width="54" height="7" font="18">Organizational,</text>
<text top="168" left="658" width="30" height="7" font="18">or Other</text>
<text top="179" left="657" width="32" height="7" font="18">Financial</text>
<text top="190" left="660" width="18" height="7" font="18">Bene</text>
<text top="188" left="679" width="8" height="11" font="18">ﬁt</text>
<text top="179" left="750" width="24" height="7" font="18">Expert</text>
<text top="190" left="748" width="29" height="7" font="18">Witness</text>
<text top="205" left="64" width="51" height="7" font="18">Craig R. Smith</text>
<text top="205" left="142" width="62" height="7" font="18">Content Reviewer</text>
<text top="205" left="225" width="69" height="7" font="18">Columbia University</text>
<text top="216" left="238" width="35" height="7" font="18">College of</text>
<text top="227" left="238" width="52" height="7" font="18">Physicians and</text>
<text top="239" left="238" width="41" height="8" font="18">Surgeonsd</text>
<text top="250" left="238" width="42" height="7" font="18">Professor of</text>
<text top="261" left="238" width="51" height="7" font="18">Surgery; Chair,</text>
<text top="272" left="238" width="51" height="7" font="18">Department of</text>
<text top="283" left="238" width="67" height="7" font="18">Surgery; New York-</text>
<text top="295" left="238" width="44" height="7" font="18">Presbyterian</text>
<text top="306" left="238" width="65" height="7" font="18">Hospital/Columbia</text>
<text top="317" left="238" width="63" height="7" font="18">University Medical</text>
<text top="328" left="238" width="31" height="8" font="18">Centerd</text>
<text top="339" left="238" width="57" height="7" font="18">Surgeon-in-Chief</text>
<text top="205" left="317" width="18" height="7" font="18">None</text>
<text top="205" left="398" width="18" height="7" font="18">None</text>
<text top="205" left="468" width="18" height="7" font="18">None</text>
<text top="204" left="544" width="40" height="11" font="18"> Edwards</text>
<text top="218" left="555" width="51" height="8" font="18">Lifesciencesd</text>
<text top="229" left="555" width="7" height="7" font="18">PI</text>
<text top="204" left="633" width="29" height="11" font="18"> None</text>
<text top="205" left="725" width="18" height="7" font="18">None</text>
<text top="353" left="64" width="58" height="7" font="18">Ruth H. Strasser</text>
<text top="353" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="365" left="154" width="12" height="7" font="18">AIG</text>
<text top="353" left="225" width="47" height="7" font="18">Heart Centre,</text>
<text top="365" left="238" width="67" height="7" font="18">University Hospital,</text>
<text top="376" left="238" width="43" height="7" font="18">University of</text>
<text top="387" left="238" width="41" height="7" font="18">Technology,</text>
<text top="398" left="238" width="37" height="8" font="18">Dresdend</text>
<text top="409" left="238" width="67" height="7" font="18">Professor, Director,</text>
<text top="421" left="238" width="65" height="7" font="18">and Chair, Internal</text>
<text top="432" left="238" width="47" height="7" font="18">Medicine and</text>
<text top="443" left="238" width="60" height="7" font="18">Cardiology Clinic;</text>
<text top="454" left="238" width="59" height="7" font="18">Medical Director,</text>
<text top="465" left="238" width="45" height="7" font="18">Heart Centre</text>
<text top="353" left="317" width="18" height="7" font="18">None</text>
<text top="353" left="398" width="18" height="7" font="18">None</text>
<text top="353" left="468" width="18" height="7" font="18">None</text>
<text top="353" left="544" width="18" height="7" font="18">None</text>
<text top="353" left="633" width="34" height="11" font="18"> Abbott</text>
<text top="353" left="667" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="364" left="633" width="54" height="11" font="18"> <a href="e57.full.html#128">AstraZeneca</a></text>
<text top="364" left="687" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="375" left="633" width="30" height="11" font="18"> <a href="e57.full.html#128">Bayer</a></text>
<text top="375" left="663" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="386" left="633" width="48" height="11" font="18"> <a href="e57.full.html#128">Biosensors</a></text>
<text top="386" left="681" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="398" left="633" width="30" height="11" font="18"> Pﬁ<a href="e57.full.html#128">zer</a></text>
<text top="398" left="663" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="353" left="725" width="18" height="7" font="18">None</text>
<text top="479" left="64" width="43" height="7" font="18">Rakesh Suri</text>
<text top="479" left="142" width="62" height="7" font="18">Content Reviewer</text>
<text top="479" left="225" width="48" height="8" font="18">Mayo Clinicd</text>
<text top="490" left="238" width="68" height="7" font="18">Associate Professor</text>
<text top="502" left="238" width="36" height="7" font="18">of Surgery</text>
<text top="479" left="317" width="18" height="7" font="18">None</text>
<text top="479" left="398" width="18" height="7" font="18">None</text>
<text top="479" left="468" width="18" height="7" font="18">None</text>
<text top="479" left="544" width="18" height="7" font="18">None</text>
<text top="479" left="633" width="40" height="11" font="18"> Edwards</text>
<text top="492" left="644" width="43" height="7" font="18"><a href="e57.full.html#128">Lifesciences</a></text>
<text top="490" left="686" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="501" left="633" width="28" height="11" font="18"> Sorin</text>
<text top="501" left="662" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="512" left="633" width="38" height="11" font="18"> St. Jude</text>
<text top="526" left="644" width="27" height="7" font="18">Medical</text>
<text top="524" left="671" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="479" left="725" width="18" height="7" font="18">None</text>
<text top="540" left="64" width="52" height="7" font="18">Vinod Thourani</text>
<text top="540" left="142" width="70" height="8" font="18">Content Reviewerd</text>
<text top="551" left="154" width="57" height="7" font="18">Surgeon Council</text>
<text top="540" left="225" width="58" height="7" font="18">Emory University</text>
<text top="539" left="317" width="36" height="11" font="18"> Edward</text>
<text top="553" left="328" width="43" height="7" font="18">Lifesciences</text>
<text top="562" left="317" width="28" height="11" font="18"> Sorin</text>
<text top="573" left="317" width="38" height="11" font="18"> St. Jude</text>
<text top="587" left="328" width="27" height="7" font="18">Medical</text>
<text top="540" left="398" width="18" height="7" font="18">None</text>
<text top="539" left="468" width="30" height="11" font="18"> Apica</text>
<text top="553" left="478" width="51" height="7" font="18"><a href="e57.full.html#128">Cardiovascular</a></text>
<text top="551" left="529" width="4" height="11" font="26"><a href="e57.full.html#128">y</a></text>
<text top="539" left="544" width="37" height="11" font="18"> Maquet</text>
<text top="539" left="633" width="29" height="11" font="18"> None</text>
<text top="540" left="725" width="18" height="7" font="18">None</text>
<text top="600" left="64" width="50" height="7" font="18">Alec Vahanian</text>
<text top="600" left="142" width="62" height="7" font="18">Content Reviewer</text>
<text top="600" left="225" width="61" height="8" font="18">Hospital Bichatd</text>
<text top="612" left="238" width="53" height="7" font="18">Department de</text>
<text top="623" left="238" width="39" height="7" font="18">Cardiologie</text>
<text top="600" left="317" width="33" height="11" font="18"> Abbott</text>
<text top="613" left="328" width="30" height="7" font="18">Vascular</text>
<text top="622" left="317" width="40" height="11" font="18"> Edwards</text>
<text top="636" left="328" width="43" height="7" font="18">Lifesciences</text>
<text top="645" left="317" width="45" height="11" font="18"> Medtronic</text>
<text top="656" left="317" width="38" height="11" font="18"> St. Jude</text>
<text top="669" left="328" width="27" height="7" font="18">Medical</text>
<text top="678" left="317" width="36" height="11" font="18"> Valtech</text>
<text top="600" left="398" width="18" height="7" font="18">None</text>
<text top="600" left="468" width="18" height="7" font="18">None</text>
<text top="600" left="544" width="18" height="7" font="18">None</text>
<text top="600" left="633" width="29" height="11" font="18"> None</text>
<text top="600" left="725" width="18" height="7" font="18">None</text>
<text top="694" left="64" width="49" height="7" font="18">Andrew Wang</text>
<text top="694" left="142" width="62" height="7" font="18">Content Reviewer</text>
<text top="694" left="225" width="55" height="7" font="18">Duke University</text>
<text top="706" left="238" width="61" height="8" font="18">Medical Centerd</text>
<text top="717" left="238" width="42" height="7" font="18">Professor of</text>
<text top="728" left="238" width="31" height="7" font="18">Medicine</text>
<text top="694" left="317" width="18" height="7" font="18">None</text>
<text top="694" left="398" width="18" height="7" font="18">None</text>
<text top="694" left="468" width="18" height="7" font="18">None</text>
<text top="694" left="544" width="66" height="11" font="18"> Abbott <a href="e57.full.html#128">Vascular</a></text>
<text top="696" left="610" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="705" left="544" width="40" height="11" font="18"> Edwards</text>
<text top="719" left="555" width="43" height="7" font="18"><a href="e57.full.html#128">Lifesciences</a></text>
<text top="719" left="598" width="4" height="7" font="26"><a href="e57.full.html#128">*</a></text>
<text top="694" left="633" width="29" height="11" font="18"> None</text>
<text top="694" left="725" width="49" height="11" font="18"> Defendant,</text>
<text top="708" left="736" width="26" height="7" font="18">Sudden</text>
<text top="719" left="736" width="22" height="7" font="18">death,</text>
<text top="730" left="736" width="19" height="7" font="18">2012</text>
<text top="751" left="64" width="735" height="8" font="18">This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant to this document. It does not necessarily</text>
<text top="763" left="64" width="7" height="8" font="18">re</text>
<text top="761" left="72" width="728" height="11" font="18">ﬂect relationships with industry at the time of publication. A person is deemed to have a signiﬁcant interest in a business if the interest represents ownership of 5% of the voting stock or share of the</text>
<text top="775" left="64" width="118" height="8" font="18">business entity, or ownership of</text>
<text top="773" left="185" width="614" height="11" font="18">$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the</text>
<text top="787" left="64" width="287" height="8" font="18">previous year. A relationship is considered to be modest if it is less than signi</text>
<text top="785" left="351" width="448" height="11" font="18">ﬁcant under the preceding deﬁnition. Relationships that exist with no ﬁnancial beneﬁt are also included for the purpose of</text>
<text top="799" left="64" width="735" height="9" font="18">transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. According to the ACC/AHA, a person has a relevant</text>
<text top="811" left="64" width="735" height="9" font="18">relationship IF: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) The company/entity (with whom</text>
<text top="823" left="64" width="735" height="9" font="18">the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) The person or a member of the person’s</text>
<text top="835" left="64" width="587" height="9" font="18">household, has a reasonable potential for ﬁnancial, professional or other personal gain or loss as a result of the issues/content addressed in the document.</text>
<text top="847" left="64" width="15" height="8" font="18">*No</text>
<text top="844" left="82" width="61" height="11" font="18">ﬁnancial beneﬁt.</text>
<text top="856" left="64" width="91" height="11" font="18"><a href="e57.full.html#128">y</a>Signiﬁcant relationship.</text>
<text top="870" left="72" width="728" height="8" font="18">AATS indicates American Association for Thoracic Surgery; ACC, American College of Cardiology; AHA, American Heart Association; AIG, Association of International Governors; ASE, American Society</text>
<text top="882" left="72" width="728" height="8" font="18">of Echocardiography; DSMB, Data and Safety Monitoring Board; MRI, magnetic resonance imaging; NIH, National Institutes of Health; NYU, New York University; PARTNERS, Placement Of Aortic</text>
<text top="894" left="72" width="728" height="8" font="18">Transcatheter Valves; PI, Principal Investigator; SCA, Society of Cardiovascular Anesthesiologists; SCAI, Society for Cardiovascular Angiography and Interventions; STS, Society of Thoracic Surgeons;</text>
<text top="906" left="72" width="93" height="8" font="18">and VA, Veterans Affairs.</text>
<text top="51" left="118" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="170" width="23" height="16" font="15">et al.</text>
<text top="51" left="690" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="66" left="118" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="65" left="703" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="779" width="20" height="17" font="16">–185</text>
<text top="51" left="64" width="25" height="10" font="15">e184</text>
</page>
<page number="129" position="absolute" top="0" left="0" height="1160" width="864">
<text top="119" left="64" width="208" height="14" font="17">Appendix 3. Abbreviations</text>
<text top="159" left="64" width="13" height="9" font="7">2D</text>
<text top="156" left="81" width="75" height="14" font="7">¼ 2-dimensional</text>
<text top="173" left="64" width="13" height="9" font="7">3D</text>
<text top="170" left="81" width="75" height="14" font="7">¼ 3-dimensional</text>
<text top="188" left="64" width="18" height="9" font="7">ACE</text>
<text top="185" left="85" width="149" height="14" font="7">¼ angiotensin-converting enzyme</text>
<text top="202" left="64" width="11" height="9" font="7">AF</text>
<text top="199" left="79" width="82" height="14" font="7">¼ atrial ﬁbrillation</text>
<text top="216" left="64" width="19" height="9" font="7">ARB</text>
<text top="213" left="87" width="138" height="14" font="7">¼ angiotensin-receptor blocker</text>
<text top="230" left="64" width="22" height="9" font="7">aPTT</text>
<text top="227" left="90" width="179" height="14" font="7">¼ activated partial thromboplastin time</text>
<text top="244" left="64" width="13" height="9" font="7">AR</text>
<text top="241" left="81" width="96" height="14" font="7">¼ aortic regurgitation</text>
<text top="258" left="64" width="12" height="9" font="7">AS</text>
<text top="255" left="80" width="76" height="14" font="7">¼ aortic stenosis</text>
<text top="273" left="64" width="18" height="9" font="7">AVR</text>
<text top="270" left="86" width="122" height="14" font="7">¼ aortic valve replacement</text>
<text top="287" left="64" width="13" height="9" font="7">BP</text>
<text top="284" left="80" width="78" height="14" font="7">¼ blood pressure</text>
<text top="301" left="64" width="25" height="9" font="7">CABG</text>
<text top="298" left="93" width="137" height="14" font="7">¼ coronary artery bypass graft</text>
<text top="315" left="64" width="19" height="9" font="7">CAD</text>
<text top="312" left="87" width="116" height="14" font="7">¼ coronary artery disease</text>
<text top="329" left="64" width="21" height="9" font="7">CMR</text>
<text top="327" left="89" width="138" height="14" font="7">¼ cardiac magnetic resonance</text>
<text top="344" left="64" width="19" height="9" font="7">COR</text>
<text top="341" left="87" width="130" height="14" font="7">¼ Class of Recommendation</text>
<text top="358" left="64" width="11" height="9" font="7">CT</text>
<text top="355" left="79" width="113" height="14" font="7">¼ computed tomography</text>
<text top="372" left="64" width="18" height="9" font="7">ECG</text>
<text top="369" left="86" width="92" height="14" font="7">¼ electrocardiogram</text>
<text top="386" left="64" width="12" height="9" font="7">HF</text>
<text top="383" left="80" width="67" height="14" font="7">¼ heart failure</text>
<text top="401" left="64" width="15" height="9" font="7">HIV</text>
<text top="398" left="83" width="152" height="14" font="7">¼ human immunodeﬁciency virus</text>
<text top="415" left="64" width="8" height="9" font="7">IE</text>
<text top="412" left="76" width="107" height="14" font="7">¼ infective endocarditis</text>
<text top="429" left="64" width="16" height="9" font="7">INR</text>
<text top="426" left="84" width="144" height="14" font="7">¼ international normalized ratio</text>
<text top="443" left="64" width="11" height="9" font="7">LA</text>
<text top="440" left="79" width="59" height="14" font="7">¼ left atrium</text>
<text top="457" left="64" width="29" height="9" font="7">LMWH</text>
<text top="454" left="97" width="143" height="14" font="7">¼ low-molecular-weight heparin</text>
<text top="472" left="64" width="17" height="9" font="7">LOE</text>
<text top="469" left="85" width="90" height="14" font="7">¼ Level of Evidence</text>
<text top="159" left="450" width="11" height="9" font="7">LV</text>
<text top="156" left="464" width="76" height="14" font="7">¼ left ventricular</text>
<text top="173" left="450" width="22" height="9" font="7">LVEF</text>
<text top="170" left="475" width="152" height="14" font="7">¼ left ventricular ejection fraction</text>
<text top="188" left="450" width="29" height="9" font="7">LVESD</text>
<text top="185" left="482" width="181" height="14" font="7">¼ left ventricular end-systolic dimension</text>
<text top="202" left="450" width="11" height="9" font="7">MI</text>
<text top="199" left="464" width="106" height="14" font="7">¼ myocardial infarction</text>
<text top="216" left="450" width="15" height="9" font="7">MR</text>
<text top="213" left="468" width="98" height="14" font="7">¼ mitral regurgitation</text>
<text top="230" left="450" width="14" height="9" font="7">MS</text>
<text top="227" left="467" width="78" height="14" font="7">¼ mitral stenosis</text>
<text top="244" left="450" width="20" height="9" font="7">MVR</text>
<text top="241" left="474" width="123" height="14" font="7">¼ mitral valve replacement</text>
<text top="259" left="450" width="25" height="9" font="7">NYHA</text>
<text top="256" left="479" width="136" height="14" font="7">¼ New York Heart Association</text>
<text top="273" left="450" width="18" height="9" font="7">NVE</text>
<text top="270" left="471" width="122" height="14" font="7">¼ native valve endocarditis</text>
<text top="287" left="450" width="13" height="9" font="7">PR</text>
<text top="284" left="466" width="113" height="14" font="7">¼ pulmonic regurgitation</text>
<text top="301" left="450" width="28" height="9" font="7">PROM</text>
<text top="298" left="481" width="128" height="14" font="7">¼ predicted risk of mortality</text>
<text top="315" left="450" width="17" height="9" font="7">PVE</text>
<text top="312" left="471" width="140" height="14" font="7">¼ prosthetic valve endocarditis</text>
<text top="329" left="450" width="18" height="9" font="7">RCT</text>
<text top="326" left="471" width="132" height="14" font="7">¼ randomized controlled trial</text>
<text top="344" left="450" width="12" height="9" font="7">RV</text>
<text top="341" left="466" width="82" height="14" font="7">¼ right ventricular</text>
<text top="358" left="450" width="24" height="9" font="7">TAVR</text>
<text top="355" left="477" width="185" height="14" font="7">¼ transcatheter aortic valve replacement</text>
<text top="372" left="450" width="12" height="9" font="7">TR</text>
<text top="369" left="465" width="109" height="14" font="7">¼ tricuspid regurgitation</text>
<text top="386" left="450" width="11" height="9" font="7">TS</text>
<text top="383" left="464" width="89" height="14" font="7">¼ tricuspid stenosis</text>
<text top="400" left="450" width="16" height="9" font="7">TEE</text>
<text top="398" left="469" width="168" height="14" font="7">¼ transesophageal echocardiography</text>
<text top="415" left="450" width="16" height="9" font="7">TTE</text>
<text top="412" left="469" width="229" height="14" font="7">¼ transthoracic echocardiography/echocardiogram</text>
<text top="429" left="450" width="18" height="9" font="7">UFH</text>
<text top="426" left="471" width="113" height="14" font="7">¼ unfractionated heparin</text>
<text top="443" left="450" width="19" height="9" font="7">VHD</text>
<text top="440" left="472" width="110" height="14" font="7">¼ valvular heart disease</text>
<text top="457" left="450" width="18" height="9" font="7">VKA</text>
<text top="454" left="471" width="105" height="14" font="7">¼ vitamin K antagonist</text>
<text top="51" left="64" width="110" height="11" font="16">JACC Vol. 63, No. 22, 2014</text>
<text top="51" left="670" width="48" height="10" font="15">Nishimura</text>
<text top="48" left="722" width="23" height="16" font="15">et al.</text>
<text top="66" left="64" width="76" height="11" font="16">June 10, 2014:e57</text>
<text top="62" left="140" width="20" height="17" font="16">–185</text>
<text top="66" left="514" width="232" height="10" font="15">2014 AHA/ACC Valvular Heart Disease Guideline</text>
<text top="51" left="775" width="25" height="10" font="15">e185</text>
</page>
<outline>
<item page="1">2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease</item>
<outline>
<item page="4">Preamble</item>
<outline>
<item page="5">Table 1 Table 1 Applying Classification of Recommendations and Level of Evidence</item>
</outline>
<item page="6">1 1 Introduction</item>
<outline>
<item page="5">1.1 1.1 Methodology and Evidence Review</item>
<item page="6">1.2 1.2 Organization of the Writing Committee</item>
<item page="6">1.3 1.3 Document Review and Approval</item>
<item page="6">1.4 1.4 Scope of the Guideline</item>
</outline>
<item page="7">2 2 General Principles</item>
<outline>
<item page="7">2.1 2.1 Evaluation of the Patient With Suspected VHD</item>
<item page="5">Table 2 Table 2 Associated Guidelines and Statements</item>
<item page="8">2.2 2.2 Definitions of Severity of Valve Disease</item>
<item page="8">2.3 2.3 Diagnosis and Follow-Up</item>
<outline>
<item page="8">2.3.1 2.3.1 Diagnostic Testing–Initial Diagnosis: Recommendation</item>
</outline>
<item page="5">Table 3 Table 3 Stages of Progression of VHD</item>
<outline>
<item page="9">2.3.2 2.3.2 Diagnostic Testing—Changing Signs or Symptoms: Recommendation</item>
<item page="9">2.3.3 2.3.3 Diagnostic Testing—Routine Follow-Up: Recommendation</item>
<item page="9">2.3.4 2.3.4 Diagnostic Testing—Cardiac Catheterization: Recommendation</item>
<item page="9">2.3.5 2.3.5 Diagnostic Testing—Exercise Testing: Recommendation</item>
</outline>
<item page="10">2.4 2.4 Basic Principles of Medical Therapy</item>
<outline>
<item page="10">2.4.1 2.4.1 Secondary Prevention of Rheumatic Fever: Recommendation</item>
</outline>
<item page="5">Table 4 Table 4 Frequency of Echocardiograms in Asymptomatic Patients With VHD and Normal Left Ventricular Function</item>
<outline>
<item page="11">2.4.2 2.4.2 IE Prophylaxis: Recommendations</item>
</outline>
<item page="5">Table 6 Table 6 Duration of Secondary Prophylaxis for Rheumatic Fever</item>
<item page="12">2.5 2.5 Evaluation of Surgical and Interventional Risk</item>
<item page="13">2.6 2.6 The Heart Valve Team and Heart Valve Centers of Excellence: Recommendations</item>
<item page="5">Table 7 Table 7 Risk Assessment Combining STS Risk Estimate, Frailty, Major Organ System Dysfunction, and Procedure-Specifi ...</item>
</outline>
<item page="15">3 3 Aortic Stenosis</item>
<outline>
<item page="15">3.1 3.1 Stages of Valvular AS</item>
<item page="15">3.2 3.2 Aortic Stenosis</item>
<outline>
<item page="15">3.2.1 3.2.1 Diagnosis and Follow-Up</item>
<item page="15">3.2.1.1 3.2.1.1 Diagnostic Testing—Initial Diagnosis: Recommendations</item>
</outline>
<item page="5">Table 8 Table 8 Stages of Valvular AS</item>
<outline>
<item page="17">3.2.1.2 3.2.1.2 Diagnostic Testing—Changing Signs or Symptoms</item>
<item page="17">3.2.1.3 3.2.1.3 Diagnostic Testing—Routine Follow-Up</item>
<item page="17">3.2.1.4 3.2.1.4 Diagnostic Testing—Cardiac Catheterization</item>
<item page="18">3.2.1.5 3.2.1.5 Diagnostic Testing—Exercise Testing: Recommendations</item>
<item page="18">3.2.2 3.2.2 Medical Therapy: Recommendations</item>
<item page="19">3.2.3 3.2.3 Timing of Intervention: Recommendations</item>
</outline>
<item page="5">Table 9 Table 9 Summary of Recommendations for AS: Timing of Intervention</item>
<item page="5">Figure 1 Figure 1 Indications for AVR in Patients With AS</item>
<outline>
<item page="23">3.2.4 3.2.4 Choice of Intervention: Recommendations</item>
</outline>
<item page="5">Table 10 Table 10 Summary of Recommendations for AS: Choice of Surgical or Transcatheter Intervention</item>
</outline>
<item page="26">4 4 Aortic Regurgitation</item>
<outline>
<item page="26">4.1 4.1 Acute AR</item>
<item page="5">Table 11 Table 11 Stages of Chronic AR</item>
<outline>
<item page="27">4.1.1 4.1.1 Diagnosis</item>
<item page="27">4.1.2 4.1.2 Intervention</item>
</outline>
<item page="27">4.2 4.2 Stages of Chronic AR</item>
<item page="27">4.3 4.3 Chronic AR</item>
<outline>
<item page="27">4.3.1 4.3.1 Diagnosis and Follow-Up</item>
<item page="27">4.3.1.1 4.3.1.1 Diagnostic Testing—Initial Diagnosis: Recommendations</item>
</outline>
<item page="5">Figure 2 Figure 2 Indications for AVR for Chronic AR</item>
<outline>
<item page="29">4.3.1.2 4.3.1.2 Diagnostic Testing—Changing Signs or Symptoms</item>
<item page="29">4.3.1.3 4.3.1.3 Diagnostic Testing—Routine Follow-Up</item>
<item page="29">4.3.1.4 4.3.1.4 Diagnostic Testing—Cardiac Catheterization</item>
<item page="29">4.3.1.5 4.3.1.5 Diagnostic Testing—Exercise Testing</item>
<item page="29">4.3.2 4.3.2 Medical Therapy: Recommendations</item>
<item page="30">4.3.3 4.3.3 Timing of Intervention: Recommendations</item>
</outline>
<item page="5">Table 12 Table 12 Summary of Recommendations for AR Intervention</item>
</outline>
<item page="32">5 5 Bicuspid Aortic Valve and Aortopathy</item>
<outline>
<item page="32">5.1 5.1 Bicuspid Aortic Valve</item>
<outline>
<item page="32">5.1.1 5.1.1 Diagnosis and Follow-Up</item>
<item page="32">5.1.1.1 5.1.1.1 Diagnostic Testing—Initial Diagnosis: Recommendations</item>
<item page="33">5.1.1.2 5.1.1.2 Diagnostic Testing—Routine Follow-Up: Recommendation</item>
<item page="33">5.1.2 5.1.2 Medical Therapy</item>
<item page="33">5.1.3 5.1.3 Intervention: Recommendations</item>
</outline>
</outline>
<item page="34">6 6 Mitral Stenosis</item>
<outline>
<item page="34">6.1 6.1 Stages of MS</item>
<item page="34">6.2 6.2 Rheumatic MS</item>
<outline>
<item page="34">6.2.1 6.2.1 Diagnosis and Follow-Up</item>
<item page="34">6.2.1.1 6.2.1.1 Diagnostic Testing—Initial Diagnosis: Recommendations</item>
<item page="35">6.2.1.2 6.2.1.2 Diagnostic Testing—Changing Signs or Symptoms</item>
<item page="35">6.2.1.3 6.2.1.3 Diagnostic Testing—Routine Follow-Up</item>
</outline>
<item page="5">Table 13 Table 13 Stages of MS</item>
<outline>
<item page="36">6.2.1.4 6.2.1.4 Diagnostic Testing—Cardiac Catheterization</item>
</outline>
<item page="5">Figure 3 Figure 3 Indications for Intervention for Rheumatic MS</item>
<outline>
<item page="37">6.2.1.5 6.2.1.5 Diagnostic Testing—Exercise Testing: Recommendation</item>
<item page="37">6.2.2 6.2.2 Medical Therapy: Recommendations</item>
<item page="38">6.2.3 6.2.3 Intervention: Recommendations</item>
</outline>
<item page="5">Table 14 Table 14 Summary of Recommendations for MS Intervention</item>
<item page="40">6.3 6.3 Nonrheumatic MS</item>
</outline>
<item page="41">7 7 Mitral Regurgitation</item>
<outline>
<item page="41">7.1 7.1 Acute MR</item>
<outline>
<item page="41">7.1.1 7.1.1 Diagnosis and Follow-Up</item>
<item page="41">7.1.2 7.1.2 Medical Therapy</item>
<item page="42">7.1.3 7.1.3 Intervention</item>
</outline>
<item page="42">7.2 7.2 Stages of Chronic MR</item>
<item page="42">7.3 7.3 Chronic Primary MR</item>
<outline>
<item page="42">7.3.1 7.3.1 Diagnosis and Follow-Up</item>
<item page="42">7.3.1.1 7.3.1.1 Diagnostic Testing—Initial Diagnosis: Recommendations</item>
</outline>
<item page="5">Table 15 Table 15 Stages of Primary MR</item>
<item page="5">Table 16 Table 16 Stages of Secondary MR</item>
<outline>
<item page="45">7.3.1.2 7.3.1.2 Diagnostic Testing—Changing Signs or Symptoms</item>
<item page="45">7.3.1.3 7.3.1.3 Diagnostic Testing—Routine Follow-Up</item>
<item page="45">7.3.1.4 7.3.1.4 Diagnostic Testing—Cardiac Catheterization</item>
<item page="46">7.3.1.5 7.3.1.5 Diagnostic Testing—Exercise Testing: Recommendations</item>
<item page="46">7.3.2 7.3.2 Medical Therapy: Recommendations</item>
<item page="46">7.3.3 7.3.3 Intervention: Recommendations</item>
</outline>
<item page="5">Table 17 Table 17 Summary of Recommendations for Chronic Primary MR</item>
<item page="50">7.4 7.4 Chronic Secondary MR</item>
<outline>
<item page="50">7.4.1 7.4.1 Diagnosis and Follow-Up: Recommendations</item>
<item page="50">7.4.2 7.4.2 Medical Therapy: Recommendations</item>
<item page="51">7.4.3 7.4.3 Intervention: Recommendations</item>
</outline>
</outline>
<item page="51">8 8 Tricuspid Valve Disease</item>
<outline>
<item page="51">8.1 8.1 Stages of TR</item>
<item page="5">Table 18 Table 18 Summary of Recommendations for Chronic Severe Secondary MR</item>
<item page="52">8.2 8.2 Tricuspid Regurgitation</item>
<outline>
<item page="52">8.2.1 8.2.1 Diagnosis and Follow-Up: Recommendations</item>
</outline>
<item page="5">Figure 4 Figure 4 Indications for Surgery for MR</item>
<item page="5">Table 19 Table 19 Stages of TR</item>
<item page="5">Figure 5 Figure 5 Indications for Surgery</item>
<outline>
<item page="55">8.2.2 8.2.2 Medical Therapy: Recommendations</item>
<item page="55">8.2.3 8.2.3 Intervention: Recommendations</item>
</outline>
<item page="57">8.3 8.3 Stages of Tricuspid Stenosis</item>
<item page="57">8.4 8.4 Tricuspid Stenosis</item>
<outline>
<item page="57">8.4.1 8.4.1 Diagnosis and Follow-Up: Recommendations</item>
<item page="57">8.4.2 8.4.2 Medical Therapy</item>
<item page="57">8.4.3 8.4.3 Intervention: Recommendations</item>
</outline>
<item page="5">Table 20 Table 20 Stages of Severe TS</item>
</outline>
<item page="58">9 9 Pulmonic Valve Disease</item>
<outline>
<item page="58">9.1 9.1 Stages of Pulmonic Regurgitation</item>
<item page="58">9.2 9.2 Stages of Pulmonic Stenosis</item>
</outline>
<item page="58">10 10 Mixed Valve Disease</item>
<outline>
<item page="58">10.1 10.1 Mixed VHD</item>
<outline>
<item page="58">10.1.1 10.1.1 Diagnosis and Follow-Up</item>
</outline>
<item page="5">Table 22 Table 22 Stages of Severe Pulmonic Stenosis</item>
<outline>
<item page="59">10.1.2 10.1.2 Medical Therapy</item>
<item page="59">10.1.3 10.1.3 Timing of Intervention</item>
<item page="59">10.1.4 10.1.4 Choice of Intervention</item>
</outline>
</outline>
<item page="60">11 11 Prosthetic Valves</item>
<outline>
<item page="60">11.1 11.1 Evaluation and Selection of Prosthetic Valves</item>
<outline>
<item page="60">11.1.1 11.1.1 Diagnosis and Follow-Up: Recommendations</item>
<item page="61">11.1.2 11.1.2 Intervention: Recommendations</item>
</outline>
<item page="5">Table 23 Table 23 Summary of Recommendations for Prosthetic Valve Choice</item>
<item page="63">11.2 11.2 Antithrombotic Therapy for Prosthetic Valves</item>
<outline>
<item page="63">11.2.1 11.2.1 Diagnosis and Follow-Up</item>
<item page="64">11.2.2 11.2.2 Medical Therapy: Recommendations</item>
</outline>
<item page="66">11.3 11.3 Bridging Therapy for Prosthetic Valves</item>
<outline>
<item page="66">11.3.1 11.3.1 Diagnosis and Follow-Up</item>
<item page="66">11.3.2 11.3.2 Medical Therapy: Recommendations</item>
</outline>
<item page="67">11.4 11.4 Excessive Anticoagulation and Serious Bleeding With Prosthetic Valves: Recommendation</item>
<item page="68">11.5 11.5 Thromboembolic Events With Prosthetic Valves</item>
<outline>
<item page="68">11.5.1 11.5.1 Diagnosis and Follow-Up</item>
<item page="68">11.5.2 11.5.2 Medical Therapy</item>
</outline>
<item page="5">Figure 6 Figure 6 Anticoagulation for Prosthetic Valves</item>
<outline>
<item page="69">11.5.3 11.5.3 Intervention</item>
</outline>
<item page="69">11.6 11.6 Prosthetic Valve Thrombosis</item>
<outline>
<item page="69">11.6.1 11.6.1 Diagnosis and Follow-Up: Recommendations</item>
<item page="70">11.6.2 11.6.2 Medical Therapy: Recommendations</item>
</outline>
<item page="5">Figure 7 Figure 7 Evaluation and Management of Suspected Prosthetic Valve Thrombosis</item>
<outline>
<item page="71">11.6.3 11.6.3 Intervention: Recommendations</item>
</outline>
<item page="71">11.7 11.7 Prosthetic Valve Stenosis</item>
<outline>
<item page="71">11.7.1 11.7.1 Diagnosis and Follow-Up</item>
<item page="72">11.7.2 11.7.2 Medical Therapy</item>
<item page="72">11.7.3 11.7.3 Intervention: Recommendation</item>
</outline>
<item page="72">11.8 11.8 Prosthetic Valve Regurgitation</item>
<outline>
<item page="72">11.8.1 11.8.1 Diagnosis and Follow-Up</item>
<item page="72">11.8.2 11.8.2 Medical Therapy</item>
<item page="72">11.8.3 11.8.3 Intervention: Recommendations</item>
</outline>
</outline>
<item page="73">12 12 Infective Endocarditis</item>
<outline>
<item page="73">12.1 12.1 IE: Overview</item>
<item page="73">12.2 12.2 Infective Endocarditis</item>
<outline>
<item page="74">12.2.1 12.2.1 Diagnosis and Follow-Up: Recommendations</item>
</outline>
<item page="5">Figure 8 Figure 8 Recommendations for Imaging Studies in NVE and PVE</item>
<item page="5">Table 25 Table 25 Major and Minor Criteria in the Modified Duke Criteria for the Diagnosis of IE</item>
<outline>
<item page="78">12.2.2 12.2.2 Medical Therapy: Recommendations</item>
<item page="79">12.2.3 12.2.3 Intervention: Recommendations</item>
</outline>
<item page="5">Figure 9 Figure 9 Diagnosis and Treatment of IE</item>
</outline>
<item page="83">13 13 Pregnancy and VHD</item>
<outline>
<item page="83">13.1 13.1 Native Valve Stenosis: Recommendations</item>
<outline>
<item page="84">13.1.1 13.1.1 Diagnosis and Follow-Up: Recommendation</item>
<item page="84">13.1.2 13.1.2 Medical Therapy: Recommendations</item>
<item page="85">13.1.3 13.1.3 Intervention: Recommendations</item>
</outline>
<item page="87">13.2 13.2 Native Valve Regurgitation</item>
<outline>
<item page="87">13.2.1 13.2.1 Diagnosis and Follow-Up: Recommendations</item>
<item page="88">13.2.2 13.2.2 Medical Therapy: Recommendation</item>
<item page="88">13.2.3 13.2.3 Intervention: Recommendations</item>
</outline>
<item page="89">13.3 13.3 Prosthetic Valves in Pregnancy</item>
<outline>
<item page="89">13.3.1 13.3.1 Diagnosis and Follow-Up: Recommendations</item>
<item page="90">13.3.2 13.3.2 Medical Therapy: Recommendations</item>
</outline>
<item page="5">Figure 10 Figure 10 Anticoagulation of Pregnant Patients With Mechanical Valves</item>
</outline>
<item page="93">14 14 Surgical Considerations</item>
<outline>
<item page="93">14.1 14.1 Evaluation of Coronary Anatomy: Recommendations</item>
<item page="5">Figure 11 Figure 11 Evaluation and Management of CAD in Patients Undergoing Valve Surgery</item>
<item page="95">14.2 14.2 Concomitant Procedures</item>
<outline>
<item page="95">14.2.1 14.2.1 Intervention for CAD: Recommendation</item>
<item page="95">14.2.2 14.2.2 Intervention for AF: Recommendations</item>
</outline>
</outline>
<item page="96">15 15 Noncardiac Surgery in Patients With VHD</item>
<outline>
<item page="96">15.1 15.1 Diagnosis and Follow-Up</item>
<item page="97">15.2 15.2 Medical Therapy</item>
<item page="97">15.3 15.3 Intervention: Recommendations</item>
</outline>
<item page="98">16 16 Evidence Gaps and Future Directions</item>
<outline>
<item page="99">16.1 16.1 Prevention of Valve Disease—Stage A</item>
<item page="99">16.2 16.2 Medical Therapy to Treat or Prevent Disease Progression—Stage B</item>
<item page="99">16.3 16.3 Optimal Timing of Intervention—Stage C</item>
<item page="99">16.4 16.4 Better Options for Intervention—Stage D</item>
</outline>
<item page="100">Presidents and Staff</item>
<item page="100">References</item>
<item page="122">Appendix 1 Appendix 1 Author Relationships With Industry and Other Entities (Relevant)—2014 AHA/ACC Guideline for the Manag ...</item>
<item page="122">Appendix 1 Appendix 1 </item>
<item page="123">Appendix 2 Appendix 2 Reviewer Relationships With Industry and Other Entities (Relevant)—2014 AHA/ACC Guideline for the Man ...</item>
<item page="122">Appendix 2 Appendix 2 </item>
<item page="129">Appendix 3 Appendix 3 Abbreviations</item>
</outline>
</outline>
</pdf2xml>
